<SEC-DOCUMENT>0001125345-15-000018.txt : 20150605
<SEC-HEADER>0001125345-15-000018.hdr.sgml : 20150605
<ACCEPTANCE-DATETIME>20150605142512
ACCESSION NUMBER:		0001125345-15-000018
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150605
DATE AS OF CHANGE:		20150605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		15915502

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>form10-k_a.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: MacroGenics
    Document created using Disclosure Solutions PROFILE 3.2.0.0
    Copyright 1995 - 2015 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 4pt">UNITED STATES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">Washington, D.C. 20549 </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">FORM 10-K/A</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">(Amendment No. 1) </font>&#160; &#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">(Mark One)</div>

<table id="95d8f366858e4cc8b8ea129afb7be65b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9746;</div>
</td>
<td style="WIDTH: 96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&#160;OF 1934</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">For the fiscal year ended December&#160;31, 2014</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">OR</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="e09668ff74b14f859c3eb8120dedba73" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">For the transition period from&#160;&#160;_______&#160;to________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commission File Number 001-36112 </font>&#160;</div>

<div>
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<div><br>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">MACROGENICS, INC.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-TOP: 3pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">(Exact name of registrant) </font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="da1ef71b74ab416b867d9fc192785f53" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Delaware</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">06-1591613</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(State of organization)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(I.R.S. Employer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Identification Number)</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">9640 Medical Center Drive, Rockville, Maryland 20850</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(Address of principal executive offices and zip code)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 6pt">(301) 251-5172</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(Registrant's telephone number)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">Securities registered pursuant to Section&#160;12(b) of the Act:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="f62cb1b0edb64ef2adf18df51885fe00" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 2px solid">
<div>
<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Title of Each Class</div>

<div>&#160;</div>
</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 2px solid">
<div>
<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Name of Each Exchange on Which Registered</div>

<div>&#160;</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Common stock, par value $0.01 per share</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">The NASDAQ Stock Market LLC</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">Securities registered pursuant to Section&#160;12(g) of the Act: None</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div>
<div style="MARGIN-BOTTOM: 2pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<div><br>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168; </font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9746;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168; </font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9746;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">x </font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">x </font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="dd1cc819132e44258f10d110784b690d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 15.66%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 0.66%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 60.66%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 0.74%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 18.57%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 0.66%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 3.06%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Large&#160;accelerated&#160;filer</div>
</td>
<td style="WIDTH: 0.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 60.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 0.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 18.57%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accelerated&#160;filer</div>
</td>
<td style="WIDTH: 0.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.06%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9746;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 15.66%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 61.31%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 19.31%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 3.71%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 15.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Non-accelerated filer</div>
</td>
<td style="WIDTH: 0.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 60.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 0.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 18.57%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Smaller&#160;reporting&#160;company</div>
</td>
<td style="WIDTH: 0.66%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.06%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168; </font>&#160;&#160;&#160;&#160;No&#160;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9746;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, 2014, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $437,213,185 based on the closing price of the registrant's common stock on the NASDAQ Global Select Market on that date. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">The number of shares of the registrant's common stock outstanding on February&#160;27, 2015 was 29,968,476.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">DOCUMENTS INCORPORATED BY REFERENCE</div>

<div style="MARGIN-BOTTOM: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">None</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXPLANATORY NOTE</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">MacroGenics, Inc. is filing this Amendment No.&#160;1 to Annual Report on Form 10-K/A (this "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Amendment</font>") to amend our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, as filed with the Securities and Exchange Commission (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">SEC</font>") on March&#160;3, 2015 (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Form 10-K</font>"). This Amendment is being filed for the sole purpose of re-filing revised redacted versions of Exhibits 4.3&#160; titled "Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated&#160; December&#160;19, 2014," and 10.25 titled "Collaboration and License Agreement by and between Janssen Biotech, Inc. and the Company, dated December&#160; 19, 2014," reflecting changes to our confidential treatment request with respect to certain portions of the exhibits. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as exhibits hereto.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">No other changes have been made to the Form 10-K or any other exhibits. This Amendment speaks as of the filing date of the Form&#160;10-K and does not reflect events occurring after the original filing date or modify or update those disclosures that may be affected by subsequent events.</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SIGNATURES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment No.&#160;1 to Annual Report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="8f3cfa471bac4158b03f1b318f7d9c79" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 50.05%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">MACROGENICS, INC.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">BY:</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-TOP-COLOR: ; FONT-VARIANT: normal; WIDTH: 46.95%; VERTICAL-ALIGN: bottom; BORDER-LEFT-COLOR: ; FONT-WEIGHT: normal; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: "><u> </u>

<div style="TEXT-ALIGN: left"><u>/s/ Scott Koenig</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Scott Koenig, M.D., Ph.D.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">President and Chief Executive Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Principal Executive Officer)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">BY:</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-TOP-COLOR: ; FONT-VARIANT: normal; WIDTH: 46.95%; VERTICAL-ALIGN: bottom; BORDER-LEFT-COLOR: ; FONT-WEIGHT: normal; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: "><u> </u>

<div style="TEXT-ALIGN: left"><u>/s/ James Karrels</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">James Karrels</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Senior Vice President and Chief Financial Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Principal Financial Officer)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.95%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dated: June 5, 2015</div>
</td>
<td style="WIDTH: 3.09%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.95%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT INDEX</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="ca428edb228f44cc9044510ef5dce662" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 49.12%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 4.02%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 5.42%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 6.96%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: 2px solid" rowspan="2">
<div>
<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Exhibit<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Number</div>

<div>&#160;</div>
</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 49.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exhibit Description</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 31.12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="7">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Incorporated by Reference</div>
</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Filed<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Herewith</div>
</td>
</tr>

<tr>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 4.02%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Form</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">File&#160;No.</div>
</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.42%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exhibit</div>
</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.96%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Filing&#160;Date</div>
</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 50.2%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 6.76%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.08%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 8.24%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.78%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 10.14%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">4.3*</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 49.12%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 4.02%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.42%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.96%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">X</div>
</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 50.2%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 6.76%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.08%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 8.24%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.78%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 10.14%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.25*</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 49.12%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Collaboration and License Agreement by and between Janssen Biotech, Inc. and the Company, dated December 19, 2014.</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 4.02%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.42%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.96%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">X</div>
</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 50.2%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 6.76%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.08%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 8.24%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.78%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 10.14%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">31.1</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 49.12%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Certification of Principal Executive Officer pursuant to Rules&#160;13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 4.02%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.42%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.96%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">X</div>
</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 50.2%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 6.76%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.08%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 8.24%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 9.78%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 10.14%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">31.2</div>
</td>
<td style="WIDTH: 1.08%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 49.12%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Certification of Principal Financial Officer pursuant to Rules&#160;13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</div>
</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 4.02%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.74%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.34%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.42%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 6.96%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 2.82%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 7.32%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">X</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="0f2fc1bfed024a7a89a24feab7aa41e9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">*</div>
</td>
<td style="WIDTH: 98%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Confidential treatment has been requested with respect to certain portions of this exhibit.</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31_1.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: MacroGenics
    Document created using Disclosure Solutions PROFILE 3.2.0.0
    Copyright 1995 - 2015 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 31.1</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">CERTIFICATIONS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">I, Scott Koenig, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">1. I have reviewed this annual report on Form 10-K/A of MacroGenics, Inc.; and</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="55ce011b51824ab0b0817623d9b0b861" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 7%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 46%; VERTICAL-ALIGN: middle">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Date: June 5, 2015</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 47.01%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-TOP-COLOR: ; FONT-VARIANT: normal; WIDTH: 46%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; FONT-WEIGHT: normal; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: "><u> </u>

<div><u> </u>

<div style="TEXT-ALIGN: left"><u>/s/ Scott Koenig</u></div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Scott Koenig, M.D., Ph.D.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">President and CEO and Director</div>
</td>
</tr>

<tr>
<td style="WIDTH: 44.99%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;(Principal Executive Officer)</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31_2.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: MacroGenics
    Document created using Disclosure Solutions PROFILE 3.2.0.0
    Copyright 1995 - 2015 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 31.2</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">CERTIFICATIONS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">I, James Karrels, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">1. I have reviewed this annual report on Form 10-K/A of MacroGenics, Inc.; and</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 12pt">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="c81736293fea4723ab89e906b71608cc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 0.96%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 8.02%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 0.43%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="WIDTH: 45.73%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Date: June 5, 2015</div>
</td>
<td style="WIDTH: 0.96%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 8.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.43%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 45.73%; VERTICAL-ALIGN: top" colspan="2">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 8.98%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 45.9%; VERTICAL-ALIGN: middle" colspan="2">&#160;</td>
<td style="WIDTH: 0.26%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.96%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 8.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.43%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-TOP-COLOR: ; FONT-VARIANT: normal; WIDTH: 45.73%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; FONT-WEIGHT: normal; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " colspan="2"><u> </u>

<div><u> </u>

<div style="TEXT-ALIGN: left"><u>/s/ James Karrels</u></div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.96%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 8.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.43%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 45.73%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">James Karrels</div>
</td>
</tr>

<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.96%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 8.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.43%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 45.73%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Chief Financial Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 44.87%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.96%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 8.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 0.43%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 45.73%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Principal Financial and Accounting Officer)</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>exhibit4_3.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: MacroGenics
    Document created using Disclosure Solutions PROFILE 3.2.0.0
    Copyright 1995 - 2015 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-WEIGHT: bold; TEXT-ALIGN: right">EXHIBIT 4.3<br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">Confidential Materials omitted and filed separately with the Securities and Exchange Commission.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">Triple asterisks denote omissions.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">INVESTOR AGREEMENT</div>
</div>

<div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">By and Between</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">JOHNSON &amp; JOHNSON INNOVATION-JJDC, INC.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">AND</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">MACROGENICS, INC.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Dated as of December 19, 2014</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">TABLE OF CONTENTS</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">
<table id="219cbb4bbd2341679b439f300ec2f02e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: black 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: center">Page</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Definitions</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">1</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">2</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Registration Rights</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">7</div>
</td>
</tr>

<tr style="HEIGHT: 17px">
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Required Registration</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">7</div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.2</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Company Registration</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">9</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.3</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Underwritten Registration; Priority in Underwritten Offering</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">10</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.4</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Revocation of Required Registration</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">11</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.5</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Effective Required Registrations</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.6</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Continuous Effectiveness of Registration Statement</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.7</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Obligations of the Company</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">12</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.8</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Furnish Information</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">15</div>
</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.9</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Expenses</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">15</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.10</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Indemnification</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">16</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.11</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">SEC Reports</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">18</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">2.12</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Assignment of Registration Rights</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">18</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">3</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Restrictions on Beneficial Ownership</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">3.1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Standstill</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">19</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Restrictions on Dispositions</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">4.1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Lock-Up</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">4.2</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Certain Tender Offers</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">20</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">5</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Voting Agreement</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">21</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">5.1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Voting of Securities</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">21</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">5.2</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Certain Extraordinary Matters</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">22</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">5.3</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Quorum</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">22</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Termination of Certain Rights and Obligations</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">23</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">6.1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Termination of Registration Rights Term</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">23</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">6.2</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Termination of Standstill Term</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">23</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">6.3</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Termination of Lock-Up Term</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">23</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">6.4</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Termination of Voting Agreement Term</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">24</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">6.5</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Effect of Termination</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">24</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">7</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Miscellaneous</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">24</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.1</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Governing Law; Submission to Jurisdiction</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">24</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.2</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Waiver</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">25</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.3</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Notices</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">25</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.4</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Entire Agreement</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">25</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.5</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Amendments</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">25</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.6</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Headings; Nouns and Pronouns; Section References</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.7</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Severability</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.8</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Assignment</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.9</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Successors and Assigns</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.10</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Counterparts</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.11</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Third Party Beneficiaries</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr style="HEIGHT: 13px">
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.12</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">No Strict Construction</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.13</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Remedies</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">26</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.14</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Specific Performance</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">27</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.15</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">No Conflicting Agreements</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">27</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.16</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Use of Proceeds</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">27</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.17</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">No Publicity</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">27</div>
</td>
</tr>

<tr>
<td style="WIDTH: 18.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">7.18</div>
</td>
<td style="WIDTH: 65.54%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Limitation of Liability</div>
</td>
<td style="WIDTH: 16.02%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: right">27</div>
</td>
</tr>
</table>
</div>

<div style="margin-bottom: 12pt; font-weight: bold; font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Exhibit A &#8211; Form of Irrevocable Proxy<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Exhibit B &#8211; Notices</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">INVESTOR AGREEMENT</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">THIS INVESTOR AGREEMENT (this "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Agreement</font>") is made as of December 19, 2014, by and among Johnson &amp; Johnson Innovation-JJDC, Inc., a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901 ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Investor</font>") and MacroGenics, Inc. (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company</font>"), a Delaware corporation with its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">WHEREAS, the Stock Purchase Agreement, dated as of December 19, 2014, by and between the Investor and the Company (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Purchase Agreement</font>") provides for the issuance and sale by the Company to the Investor, and the purchase by the Investor, of a number of shares (such shares, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Purchased Shares</font>") of the Company's common stock, par value $0.01 per share (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Common Stock</font>");</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">WHEREAS, as a condition to consummating the transactions contemplated by the Purchase Agreement, the Investor and the Company have agreed upon certain rights and restrictions as set forth herein with respect to the Purchased Shares and other securities of the Company beneficially owned by the Investor and its Affiliates, and it is a condition to the closing under the Purchase Agreement that this Agreement be executed and delivered by the Investor and the Company; and</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">WHEREAS, simultaneously with the execution of the Purchase Agreement, the Company and Janssen Biotech, Inc. ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Janssen</font>"), an Affiliate of the Investor, entered into the Collaboration Agreement.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">NOW, THEREFORE, in consideration of the premises and mutual agreements hereinafter set forth, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Definitions</u></font>.&#160; As used in this Agreement, the following terms shall have the following meanings:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Affiliate</font>" shall mean, with respect to any Person, another Person that controls, is controlled by or is under common control with such Person; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, that with respect to the Investor, "Affiliate" shall mean the Investor's subsidiaries that are wholly-owned directly or indirectly, by the Investor and any Person that wholly-owns, directly or indirectly, the Investor; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided further</u></font>, that with respect to the Investor, the term "Affiliate" shall not include any employee benefit plan of the Investor.&#160; A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.&#160; Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (i) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.&#160; For the purposes of this Agreement, in no event shall the Investor or any of its Affiliates be deemed Affiliates of the Company or any of its Affiliates, nor shall the Company or any of its Affiliates be deemed Affiliates of the Investor or any of its Affiliates.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Agreement</font>" shall have the meaning set forth in the Preamble to this Agreement, including all Exhibits attached hereto.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">beneficial owner</font>," "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">beneficially owns</font>," "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">beneficial ownership</font>" and terms of similar import used in this Agreement shall, with respect to a Person, have the meaning set forth in Rule 13d-3 under the Exchange Act (i) assuming the full conversion into, and exercise and exchange for, shares of Common Stock of all Common Stock Equivalents beneficially owned by such Person and (ii) determined without regard for the number of days in which such Person has the right to acquire such beneficial ownership.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Business Day</font>" shall mean a day other than Saturday, Sunday or any other day that is designated as a J&amp;J holiday in the J&amp;J Universal Calendar (a copy of which for the years 2014 and 2015 is attached as Exhibit E to the Collaboration Agreement and a copy of which prior to the beginning of each such year for succeeding years shall be provided to the Company).</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Change of Control</font>" shall occur if: (a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of the Company, or if the percentage ownership of such person or entity in the voting securities of the Company is increased through stock redemption, cancellation or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of the Company; (b) a merger, consolidation, recapitalization, or reorganization of the Company is consummated, other than any such transaction, which would result in stockholders or equity holders of the Party immediately prior to such transaction, owning at least fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction; (c) the stockholders or equity holders of the Company approve a plan of complete liquidation of the Company, or an agreement for the sale or disposition by the Company of all or substantially all of the Company's assets, other than pursuant to the transaction described above or to an Affiliate; (d) individuals who, as of the date hereof, constitute the Board of Directors of the Company (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Incumbent Board</font>") cease for any reason to constitute at least a majority of the Board of Directors of the Company (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's shareholders, was recommended or approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board of Directors of the Company); or (e) the sale or transfer to a Third Party of (i) all or substantially all of the Company's assets taken as a whole or (ii) a majority of the Company's assets which relate to the Collaboration Agreement, is effected.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">&#160;"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Closing Date</font>" shall have the meaning set forth in the Purchase Agreement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(g)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Collaboration Agreement</font>" shall mean the Collaboration and License Agreement, of even date herewith, between the Janssen and the Company.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(h)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Common Stock</font>" shall have the meaning set forth in the Preamble to this Agreement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Common Stock Equivalents</font>" shall mean any options, warrants or other securities or rights convertible into or exercisable or exchangeable for, whether directly or following conversion into or exercise or exchange for other options, warrants or other securities or rights, shares of Common Stock or any swap, hedge or similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of, or voting or other rights of, the Common Stock.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(j)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company</font>" shall have the meaning set forth in the Preamble to this Agreement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(k)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Demand Request</font>" shall have the meaning set forth in Section 2.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(l)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Disposition</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Dispose of</font>" shall mean any (i) pledge, sale, contract to sell, sale of any option or contract to purchase, purchase of any option or contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any shares of Common Stock, or any Common Stock Equivalents, including, without limitation, any "short sale" or similar arrangement, or (ii) swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of Common Stock, whether any such swap or transaction is to be settled by delivery of securities, in cash or otherwise.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(m)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Exchange Act</font>" shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC promulgated thereunder.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(n)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Existing Registration Rights Agreement</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">" shall mean that certain </font>Fifth Amended and Restated Registration Rights Agreement dated February&#160;3, 2014 by and among the Company, the Founders, and the Investors (as such terms are defined <font style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif">therein).</font></font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(o)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Extraordinary Matter</font>" shall have the meaning set forth in Section 5.2.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(p)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Filing Date</font>" shall mean (i) with respect to any Registration Statement to be filed on Form S-1 (or any applicable successor form), sixty (60) days after receipt by the Company of a Demand Request for such Registration Statement and (ii) with respect to any Registration Statement to be filed on Form S-3 (or any applicable successor form), thirty (30) days after receipt by the Company of a Demand Request for such Registration Statement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(q)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Governmental Authority</font>" shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational organization of which any such country is a member.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(r)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Holders</font>" shall mean (but, in each case, only for so long as such Person remains an Affiliate of the Investor) the Investor and any Permitted Transferee thereof, if any, in accordance with Section 2.12.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(s)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Initiating Holder</font>" shall have the meaning set forth in Section 2.3.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(t)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Interference</font>" shall have the meaning set forth in Section 2.5.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(u)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Investor</font>" shall have the meaning set forth in the Preamble to this Agreement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(v)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">"Irrevocable Proxy</font>" shall have the meaning set forth in Section 5.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(w)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Law</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Laws</font>" shall mean all laws, statutes, rules, regulations, orders, judgments, injunctions and/or ordinances of any Governmental Authority.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(x)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Lock-Up Securities</font>" shall have the meaning set forth in Section 4.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(y)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Lock-Up Term</font>" shall mean the period from and after the date of this Agreement until the occurrence of any event set forth in Section 6.3.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(z)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Modified Clause</font>" shall have the meaning set forth in Section 7.7.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(aa)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Offeror</font>" shall have the meaning set forth in Section 6.2.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(bb)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Other Holders</font>" shall mean any Person having rights to participate in a registration of the Company's securities.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(cc)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Permitted Transferee</font>" shall mean (i) a controlled Affiliate of the Investor that is wholly owned, directly or indirectly, by the Investor, or (ii) a controlling Affiliate of the Investor (or any controlled Affiliate of such controlling Affiliate) that wholly owns, directly or indirectly, the Investor, or the acquiring Person in the case of a Change of Control of the Investor; it being understood that for purposes of this definition "wholly owned" shall mean an Affiliate in which the Investor owns, or an Affiliate that owns, as applicable, directly or indirectly, at least ninety-nine percent (99%) of the outstanding capital stock of such Affiliate or the Investor, as applicable.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(dd)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">"Permitted Transferee Irrevocable Proxy</font>" shall have the meaning set forth in Section 5.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(ee)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Person</font>" shall mean any individual, limited liability company, partnership, firm, corporation, association, trust, unincorporated organization, government or any department or agency thereof or other entity, as well as any syndicate or group that would be deemed to be a Person under Section 13(d)(3) of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(ff)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Prospectus</font>" shall mean the prospectus forming a part of any Registration Statement, as supplemented by any and all prospectus supplements and as amended by any and all amendments (including post-effective amendments) and including all material incorporated by reference or explicitly deemed to be incorporated by reference in such prospectus.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(gg)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Purchase Agreement</font>" shall have the meaning set forth in the Preamble to this Agreement, and shall include all Exhibits attached thereto.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(hh)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Purchased Shares</font>" shall have the meaning set forth in the Preamble to this Agreement, and shall be adjusted for (i) any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization and (ii) any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the Purchased Shares.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(ii)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">registers</font>," "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">registered</font>," and "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">registration</font>" refer to a registration effected by preparing and filing a Registration Statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration Statement or document by the SEC.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(jj)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Registrable Securities</font>" shall mean (i) the Purchased Shares, together with any shares of Common Stock issued in respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization and (ii) any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock described in clause (i) of this definition, excluding in all cases, however, (A) any Registrable Securities if and after they have been transferred to a Permitted Transferee in a transaction in connection with which registration rights granted hereunder are not assigned, (B) any Registrable Securities sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction, or (C) if the Investor and its Affiliates together own less than five percent (5%) of the Shares of Then Outstanding Common Stock, Purchased Shares eligible for resale pursuant to Rule 144(b)(1)(i) under the Securities Act.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(kk)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Registration Expenses</font>" shall mean all expenses incurred by the Company in connection with any Required Registration pursuant to Section 2.1 or the Company's compliance with Section 2.7, including, without limitation, all registration and filing fees, fees and expenses of compliance with securities or blue sky Laws (including reasonable fees and disbursements of counsel in connection with blue sky qualifications of any Registrable Securities), expenses of printing (i) certificates for any Registrable Securities in a form eligible for deposit with the Depository Trust Company or (ii) Prospectuses if the printing of Prospectuses is requested by Holders, messenger and delivery expenses, fees and disbursements of counsel for the Company and its independent certified public accountants (including the expenses of any management review, cold comfort letters or any special audits required by or incident to such performance and compliance), Securities Act liability insurance (if the Company elects to obtain such insurance), the reasonable fees and expenses of any special experts retained by the Company in connection with such registration, fees and expenses of other Persons retained by the Company and the reasonable fees and expenses (such fees and expenses not to exceed [***] for the Holders of Registrable Securities in each Required Registration, selected by the Holders of a majority of the Registrable Securities to be included in such Required Registration.&#160; In addition, the Company will pay its internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Purchased Shares to be registered on each securities exchange, if any, on which equity securities issued by the Company are then listed or the quotation of such securities on any national securities exchange on which equity securities issued by the Company are then quoted.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(ll)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Registration Notice</font>" shall have the meaning set forth in Section 2.2</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(mm)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Registration Rights Term</font>" shall mean the period from and after the expiration of the Lock-Up Term until the occurrence of any event set forth in Section 6.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(nn)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Registration Statement</font>" shall mean any registration statement of the Company under the Securities Act that covers any of the Registrable Securities pursuant to the provisions of this Agreement, including the related Prospectus, all amendments and supplements to such registration statement (including post-effective amendments), and all exhibits and all materials incorporated by reference or explicitly deemed to be incorporated by reference in such Registration Statement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(oo)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Required Period</font>" with respect to a Required Registration shall mean the earlier of (i) the date on which all Registrable Securities covered by such Required Registration are sold pursuant thereto and (ii) [***] following the first day of effectiveness of the Registration Statement for such Required Registration, in each case subject to extension as set forth herein; provided, however, that in no event will the Required Period expire prior to the expiration of the applicable period referred to in Section 4(3) of the Securities Act and Rule 174 promulgated thereunder; provided, further, however, that (i) such [***] to the period</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended, if necessary, to keep the Registration Statement effective until the earlier of (A) such time as all such Registrable Securities registered on such Registration Statement are sold or (B) all such Registrable Securities on such Registration Statement may be sold in any three month period pursuant to Rule 144.</div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(pp)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Required Registration</font>" shall have the meaning set forth in Section 2.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(qq)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">SEC</font>" shall mean the United States Securities and Exchange Commission.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(rr)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Securities Act</font>" shall mean the Securities Act of 1933, as amended, and the rules and regulations of the SEC promulgated thereunder.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(ss)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Selling Expenses</font>" shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(tt)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Shares of Then Outstanding Common Stock</font>" shall mean, at any time, the issued and outstanding shares of Common Stock at such time, as well as all capital stock issued and outstanding as a result of any stock split, stock dividend, or reclassification of Common Stock distributable, on a pro rata basis, to all holders of Common Stock.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(uu)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Standstill Parties</font>" shall have the meaning set forth in Section 3.1.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(vv)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Standstill Term</font>" shall mean the period from and after the date of this Agreement until the occurrence of any event set forth in Section 6.2.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(ww)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party</font>" shall mean any Person (other than a Governmental Authority) other than the Investor, the Company or any of their respective Affiliates.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(xx)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Underwritten Registration</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Underwritten Offering</font>" shall mean a registration in which Registrable Securities are sold to an underwriter for reoffering to the public.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(yy)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Violation</font>" shall have the meaning set forth in Section 2.10(a).</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(zz)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Voting Agreement Term</font>" shall mean the period from and after the date of this Agreement until the occurrence of any event set forth in Section 6.4.</font></div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Registration Rights</u></font>.</font></div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt">&#160;</div>

<div style="TEXT-INDENT: 27pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Required Registration</u></font>.&#160; If, during the Registration Rights Term, the Company receives from any Holder or Holders a written request or requests (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Demand Request</font>") that the Company file a Registration Statement under the Securities Act to effect the registration (a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Required Registration</font>") of Registrable Securities, the Company shall use all reasonable efforts to file a Registration Statement covering such Holders' Registrable Securities as soon as practicable (and by the applicable Filing Date) and shall use all reasonable efforts to, as soon as practicable thereafter, effect the registration of the Registrable Securities to permit or facilitate the sale and distribution in an Underwritten Offering of all or such portion of such Holder's or Holders' Registrable Securities as are specified in such Demand Request, subject however, to the conditions and limitations set forth herein; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the Company shall not be obligated to effect any registration of Registrable Securities upon receipt of a Demand Request pursuant to this Section 2.1 if:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***];</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(i) in the event that the market value of all Registrable Securities outstanding is equal to or greater than [***], the market value of the Registrable Securities proposed to be included in the registration, based on the average closing price during the [***] consecutive trading days period prior to the making of the Demand Request, is less than [***] or (ii) in the event that the market value of all Registrable Securities outstanding is less than [***], the market value of the Registrable Securities proposed to be included in the registration, based on the average closing price during the ten (10) consecutive trading days period prior to the making of the Demand Request, is less than the lesser of (x) [***]or (y) the total market value of Registrable Securities outstanding;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the Company furnishes to the Holders a certificate signed by an authorized officer of the Company stating that (i) within sixty (60) days of receipt of the Demand Request under this Section 2.1, the Company expects to file a registration statement for the public offering of securities for the account of the Company (other than a registration of securities (x) issuable pursuant to an employee stock option, stock purchase or similar plan, (y) issuable pursuant to a merger, exchange offer or a transaction of the type specified in Rule 145(a) under the Securities Act or (z) in which the only securities being registered are securities issuable upon conversion of debt securities which are also being registered), provided, that the Company is actively employing good faith efforts to cause such registration statement to become effective, or (ii) the Company is engaged in a material transaction or has an undisclosed material corporate development, in either case, which would be required to be disclosed in the Registration Statement, and in the good faith judgment of the Company's Board of Directors, such disclosure would be materially detrimental to the Company and its stockholders at such time (in which case, the Company shall disclose the matter as promptly as reasonably practicable and thereafter file the Registration Statement, and each Holder agrees not to disclose any information about such material transaction to Third Parties until such disclosure has occurred or such information has entered the public domain other than through breach of this provision by such Holder), provided, however, that the Company shall have the right to only defer the filing</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">of the Registration Statement pursuant to this subsection [***] in any twelve (12) month period and, such deferral may not exceed a period of more than one hundred and twenty (120) days after receipt of a Demand Request;</div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the Company has, within the twelve (12) month period preceding the date of the Demand Request, already effected one (1) Required Registration for any Holder pursuant to this Section 2.1; or</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">at any time during the period between the Company's receipt of the Demand Request and the completion of the Required Registration, any Holder is in breach of or has failed to cause its Affiliates to comply with the obligations and restrictions of Sections 3, 4 or 5 of this Agreement, the Company has provided notice of such breach to a Holder and such breach or failure is ongoing and has not been remedied; it being understood that (i) a one-time, inadvertent and de minimis breach of Section 4 shall not be deemed to be a breach of the obligations and restrictions under Section 4 for purposes of this Section 2.1(e) and (ii) a de minimis breach of Section 3.1(a) hereof, or an inadvertent breach of Section 3.1(g) hereof arising from informal discussions covering general corporate or other business matters the purpose of which is not intended to effectuate or lead to any of the actions referred to in paragraphs (a) through (e) of Section 3.1, shall not be deemed to be a breach of the obligations and restrictions under Section 3.1 for purposes of this Section 2.1(e).</font></div>

<div>&#160;</div>

<div style="TEXT-INDENT: 27pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Company Registration</u></font>.&#160; Effective from the expiration of the Lock-Up Term until the [***] of such expiration, the<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>Company shall notify the Holders in writing at least ten (10) business days prior to the filing of any registration statement (other than the Company's existing registration statement on Form S-3, SEC File No. 333-200092 and any related Prospectus, amendments or supplements thereto) ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Registration Notice</font>") and will afford each Holder an opportunity, subject to the terms and conditions of this Agreement, to include in such registration statement the number of Registrable Securities then held by such Holder that such Holder wishes to include in such registration statement.&#160; Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by such Holder shall, within five (5) business days after receipt of the Registration Notice, so notify the Company in writing, and in such notification, inform the Company of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not to include Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities (either by the Company or by its stockholders), all upon the terms and conditions set forth herein. Each Holder shall keep confidential and not disclose to any third party (i) its receipt of any Registration Notice and (ii) any information regarding the proposed offering as to which such notice is delivered, except as required by law, regulation or as compelled by subpoena.&#160; If a registration pursuant to this Section 2.2 is an Underwritten Offering, the right of any such Holder to include Registrable Securities in such registration shall be conditioned upon such Holder's participation in such underwriting and the inclusion of such Holder's Registrable Securities in the underwriting to the extent provided herein. The Company and all Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting.&#160; Notwithstanding any other provision of this Section 2 and subject to the prior rights of the parties to the Existing Registration Rights Agreement, if the managing underwriter for the Underwritten Offering determines in good faith that marketing factors require a limitation of the number of shares of Registrable Securities to be included in such Underwritten Offering and advises the Holders of such determination in writing, such Underwritten Offering shall include (i) first, the shares held by the parties to the Existing Registration Rights Agreement, (ii) second, all Registrable Securities of the Holders allocated, if the amount is less than all the Registrable Securities requested to be sold, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">pro rata</font> on the basis of the total number of Registrable Securities held by such Holders; and (ii) third, as many other securities proposed to be included in the Underwritten Offering by the Company and any Other Holders, allocated <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">pro rata</font> among the Company and such Other Holders, on the basis of the amount of securities requested to be included therein by the Company and each such Other Holder so that the total amount of securities to be included in such Underwritten Offering is the full amount that, in the written opinion of such managing underwriter, can be sold without materially and adversely affecting the success of such Underwritten Offering. Notwithstanding the foregoing, the Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration.</font></div>

<div style="TEXT-INDENT: 36pt">&#160;</div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Underwritten Registration; Priority in Underwritten Offering</u></font>.&#160; If, pursuant to Section 2.1, the Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, the Holders shall so advise the Company as a part of their request made pursuant to Section 2.1.&#160; The underwriter(s) will be selected by the Company, subject to approval by a majority in interest of the Holders initiating the Required Registration hereunder (such Holder(s) initiating the registration request, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Initiating Holders</font>"), which approval shall not be unreasonably withheld or delayed.&#160; With respect to any Required Registration of Registrable Securities requested pursuant to Section 2.1 that is an Underwritten Offering, the Company may also (i) propose to sell shares of Common Stock on its own behalf and (ii) provide written notice of such Required Registration to Other Holders (including, without limitation the parties to the Existing Registration Rights Agreement) and permit all such Other Holders who request to be included in the Required Registration to include any or all Company securities held by such Other Holders in such Required Registration on the same terms and conditions as the Registrable Securities. If a registration pursuant to Section 2.1 is an Underwritten Offering, the right of any Holder to include its Registrable Securities in the Underwritten Offering shall be conditioned upon such Holder's participation in such Underwritten Offering and the inclusion of such Holder's Registrable Securities to the extent provided herein.&#160; All Holders requesting the inclusion of their Registrable Securities in such Underwritten Offering shall (together with the Company as provided in Section 2.7(h)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Underwritten Offering.&#160; Notwithstanding any other provision of this Section 2 and subject to the prior rights of the parties to the Existing Registration Rights Agreement, if the managing underwriter for such Underwritten Offering determines in good faith that marketing factors require a limitation of the number of shares of Registrable Securities to be included in such Underwritten Offering and advises the Initiating Holders of such determination in writing, then the Company shall so advise all Holders which requested inclusion of their Registrable Securities in such Underwritten Offering, and such Underwritten Offering shall include (i) first, the shares held by the parties to the Existing Registration Rights Agreement, (ii) second, all Registrable Securities of the Holders allocated, if the amount is less than all the Registrable Securities requested to be sold, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">pro rata</font> on the basis of the total number of Registrable Securities held by such Holders; and (ii) third, as many other securities proposed to be included in the Underwritten Offering by the Company and any Other Holders, allocated <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">pro rata</font> among the Company and such Other Holders, on the basis of the amount of securities requested to be included therein by the Company and each such Other Holder so that the total amount of securities to be included in such Underwritten Offering is the full amount that, in the written opinion of such managing underwriter, can be sold without materially and adversely affecting the success of such Underwritten Offering; provided, however, that the number of shares of Registrable Securities to be included in such Underwritten Offering shall not be reduced unless all other securities (other than those held by the parties to the Existing Registration Rights Agreement) are first entirely excluded from such Underwritten Offering.&#160; In the event the Company advises the Holders of its intent to decrease the total number of Registrable Securities that may be included by the Holders in such Required Registration such that the number of Registrable Securities included in such Required Registration would be less than [***] of all Registrable Securities which the Holders requested be included in such Required Registration, then Holders representing a majority of the Registrable Securities requested to be included in such Required Registration will have the right to withdraw, on behalf of all Holders of all Registrable Securities requested to be so included, such Required Registration, in which case, such Required Registration will not count as a Required Registration for the purposes of Section 2.1(a), and the Company shall bear all Registration Expenses in connection therewith; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>that</u></font>, the right to withdraw a registration and have it not count as a Required Registration may only be exercised once by the Holders (taken collectively).</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Revocation of Required Registration</u></font>.&#160; With respect to one (1) Required Registration only, the Holders of at least a majority of the Registrable Securities to be included in a Registration Statement with respect to such Required Registration may, at any time prior to the effective date of such Registration Statement, on behalf of all Holders of all Registrable Securities requested to be included therein, revoke the request to have Registrable Securities included therein and revoke the request for such Required Registration by providing a written notice to the Company, in which case such Required Registration that has been revoked will be deemed not to have been effected and will not count as a Required Registration for purposes of Section 2.1(i) if, and only if, the Holders of Registrable Securities which had requested inclusion of Registrable Securities in such Required Registration promptly reimburse the Company for all Registration Expenses incurred by the Company in connection with such Required Registration.&#160; Notwithstanding the foregoing sentence, the parties agree and acknowledge that the Holders may revoke any Required Registration (without any obligation to reimburse the Company for Registration Expenses incurred in connection therewith) if such revocation is based on (i) a material adverse change in circumstances with respect to the Company and its subsidiaries, taken as a whole, caused by an act or failure to act by the Company or any of its subsidiaries and not known to any Holder at the time the Required Registration was first made or (ii) the Company's failure to comply in any material respect with its obligations hereunder, and any such revocation based on an event described in (i) or (ii) above shall be exercisable at any time and shall not be counted as the one (1) revocation of a Required Registration permitted by the first sentence of this Section 2.4.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Effective Required Registrations</u></font>.&#160; A Required Registration will not be deemed to be effected for purposes of Section 2.1(a) if the Registration Statement for such Required Registration has (a) not been declared effective by the SEC or (b) become effective in accordance with the Securities Act and the rules and regulations thereunder and not been kept effective for the Required Period.&#160; In addition, if after such Registration Statement has been declared or becomes effective, (i) the offering of Registrable Securities pursuant to such Registration Statement is interfered with by any stop order, injunction, or other order or requirement of the SEC or other governmental agency or court such that the continued offer and sale of Registrable Securities being offered pursuant to such Registration Statement would violate applicable Law and such stop order, injunction or other order or requirement of the SEC or other governmental agency or court does not result from any act or omission of any Holder whose Registrable Securities are registered pursuant to such Registration Statement (an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Interference</font>") and (ii) any such Interference is not cured within sixty (60) days thereof, such Required Registration will be deemed not to have been effected and will not count as a Required Registration.&#160; In the event such Interference occurs and is cured, the Required Period relating to such Registration Statement will be extended by the number of days of such Interference, including the date such Interference is cured.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Continuous Effectiveness of Registration Statement</u></font>.&#160; The Company will use all reasonable efforts to cause each Registration Statement filed pursuant to this Section 2 to be declared effective by the SEC or to become effective under the Securities Act as promptly as practicable and to keep each such Registration Statement that has been declared or becomes effective continuously effective for the Required Period.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Obligations of the Company</u></font>.&#160; Whenever required under Section 2.1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">prepare and file with the SEC a Registration Statement with respect to such Registrable Securities sought to be included therein; provided that at least five (5) Business Days prior to filing any Registration Statement or Prospectus or any amendments or supplements thereto, the Company shall furnish to the Holders of the Registrable Securities covered by such Registration Statement, their counsel and the managing underwriter copies of all such documents proposed to be filed, and any such Holder shall have the opportunity to comment on any information pertaining solely to such Holder and its plan of distribution that is contained therein and the Company shall make the corrections reasonably requested by such Holder or the managing underwriter with respect to such information prior to filing any such Registration Statement or amendment;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">prepare and file with the SEC such amendments and post-effective amendments to any Registration Statement and any Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective for the Required Period, and cause the Prospectus to be supplemented by any required prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the Securities Act, to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such registration statement for the Required Period; provided that at least five (5) Business Days prior to filing any such amendments and post effective amendments or supplements thereto, the Company shall furnish to the Holders of the Registrable Securities covered by such Registration Statement, their counsel and the managing underwriter copies of all such documents proposed to be filed, and any such Holder or managing underwriter shall have the opportunity to comment on any information pertaining solely to such Holder and its plan of distribution that is contained therein and the Company shall make the corrections reasonably requested by such Holder and the managing underwriter with respect to such information prior to filing any such Registration Statement or amendment;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">furnish to the Holders of Registrable Securities covered by such Registration Statement and the managing underwriter such numbers of copies of such Registration Statement, each amendment and supplement thereto, the Prospectus included in such Registration Statement (including each preliminary prospectus or free writing prospectus) in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">notify the Holders of Registrable Securities covered by such Registration Statement, promptly after the Company shall receive notice thereof, of the time when such Registration Statement becomes or is declared effective or when any amendment or supplement or any Prospectus forming a part of such Registration Statement has been filed;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">notify the Holders of Registrable Securities covered by such Registration Statement promptly of any request by the SEC for the amending or supplementing of such Registration Statement or Prospectus or for additional information and promptly deliver to such Holders copies of any comments received from the SEC;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">notify the Holders promptly of any stop order suspending the effectiveness of such Registration Statement or Prospectus or the initiation of any proceedings for that purpose, and use all reasonable efforts to obtain the withdrawal of any such order or the termination of such proceedings;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(g)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">use all reasonable efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other securities or blue sky Laws of such jurisdictions as shall be reasonably requested by the Holders, use all reasonable efforts to keep each such registration or qualification effective, including through new filings, or amendments or renewals, during the Required Period, and notify the Holders of Registrable Securities covered by such Registration Statement of the receipt of any written notification with respect to any suspension of any such qualification; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(h)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">in the event of any Underwritten Offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of the Underwritten Offering pursuant to which such Registrable Securities are being offered;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(i)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">use all reasonable efforts to obtain: (A) at the time of effectiveness of the Registration Statement covering such Registrable Securities, a "cold comfort letter" from the Company's independent certified public accountants covering such matters of the type customarily covered by "cold comfort letters" as the underwriters may reasonably request; and (B) at the time of any underwritten sale pursuant to such Registration Statement, a "bring-down comfort letter," dated as of the date of such sale, from the Company's independent certified public accountants covering such matters of the type customarily covered by "bring-down comfort letters" as the underwriters may reasonably request.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(j)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">promptly notify each Holder of Registrable Securities covered by such Registration Statement at any time when a Prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the Prospectus included in such Registration Statement or any offering memorandum or other offering document includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, and promptly prepare a supplement or amendment to such Prospectus or file any other required document so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus will not contain an untrue statement of material fact or omit to state any fact necessary to make the statements therein not misleading;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(k)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">permit any Holder of Registrable Securities covered by such Registration Statement, which Holder in its reasonable judgment could reasonably be deemed to be an underwriter with respect to the Underwritten Offering pursuant to which such Registrable Securities are being offered, or to be a controlling Person of the Company, to reasonably participate in the preparation of such Registration Statement and to require the insertion therein of information to the extent concerning such Holder, furnished to the Company in writing, which in the reasonable judgment of such Holder and its counsel should be included;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(l)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">in connection with any Underwritten Offering, use all reasonable efforts to obtain an opinion or opinions addressed to the underwriter or underwriters in customary form and scope from counsel for the Company;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(m)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">upon reasonable notice and during normal business hours, subject to the Company receiving customary confidentiality undertakings or agreements from any Holder of Registrable Securities covered by such Registration Statement or other person obtaining access to Company records, documents, properties or other information pursuant to this subsection (m), make available for inspection by a representative of such Holder and any underwriter participating in any disposition of such Registrable Securities and any attorneys or accountants retained by any such Holder or underwriter, relevant financial and other records, pertinent corporate documents and properties of the Company, and use all reasonable efforts to cause the officers, directors and employees of the Company to supply all information reasonably requested by any such representative, underwriter, attorneys or accountants in connection with the Registration Statement;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(n)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">with respect to one (1) Required Registration which includes Registrable Securities the market value of which is at least [***], participate, to the extent requested by the managing underwriter, in efforts extending for no more than three (3) days scheduled by such managing underwriter and reasonably acceptable to the Company's senior management, to sell the Registrable Securities being offered pursuant to such Required Registration (including participating during such period in customary "roadshow" meetings with prospective investors);</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(o)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">use all reasonable efforts to comply with all applicable rules and regulations of the SEC relating to such registration and make generally available to its security holders earning statements satisfying the provisions of Section 11(a) of the Securities Act, provided that the Company will be deemed to have complied with this Section 2.7(o) with respect to such earning statements if it has satisfied the provisions of Rule 158;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(p)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">if requested by the managing underwriter or any selling Holder, promptly incorporate in a prospectus supplement or post-effective amendment such information as the managing underwriter or any selling Holder reasonably requests to be included therein, with respect to the Registrable Securities being sold by such selling Holder, including, without limitation, the purchase price being paid therefor by the underwriters and with respect to any other terms of the Underwritten Offering of Registrable Securities to be sold in such offering, and promptly make all required filings of such prospectus supplement or post-effective amendment;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(q)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">cause the Registrable Securities covered by such Registration Statement to be listed on each securities exchange, if any, on which equity securities issued by the Company are then listed; and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(r)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">reasonably cooperate with each selling Holder and each underwriter participating in the disposition of such Registrable Securities and their respective counsel in connection with filings required to be made with the Financial Industry Regulatory Authority, Inc., if any.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Furnish Information</u></font>.&#160; It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself and the Registrable Securities held by it as shall be reasonably necessary to effect the registration of such Holder's Registrable Securities.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.9</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Expenses</u></font>.&#160; Except as specifically provided herein, all Registration Expenses shall be borne by the Company.&#160; All Selling Expenses incurred in connection with any registration hereunder shall be borne by the Holders of Registrable Securities covered by a Registration Statement, pro rata on the basis of the number of Registrable Securities registered on their behalf in such Registration Statement.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.10</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Indemnification</u></font>.&#160; In the event any Registrable Securities are included in a Registration Statement under this Agreement:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">The Company shall indemnify and hold harmless each Holder including Registrable Securities in any such Registration Statement, any underwriter (as defined in the Securities Act) for such Holder and each Person, if any, who controls such Holder or underwriter within the meaning of Section 15 of the Securities Act or Section 20 of Exchange Act and the officers, directors, owners, agents and employees of such controlling Persons, against any and all losses, claims, damages or liabilities (joint or several) to which they may become subject under any securities Laws including, without limitation, the Securities Act, the Exchange Act, or any other statute or common law of the United States or any other country or political subdivision thereof, or otherwise, including the amount paid in settlement of any litigation commenced or threatened (including any amounts paid pursuant to or in settlement of claims made under the indemnification or contribution provisions of any underwriting or similar agreement entered into by such Holder in connection with any offering or sale of securities covered by this Agreement), and shall promptly reimburse them, as and when incurred, for any legal or other expenses incurred by them in connection with investigating any claims and defending any actions, insofar as any such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Violation</font>"): (i) any untrue statement or alleged untrue statement of a material fact contained in or incorporated by reference into such Registration Statement, including any preliminary prospectus or final prospectus contained therein or any free writing prospectus or any amendments or supplements thereto, or in any offering memorandum or other offering document relating to the offering and sale of such securities, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or (iii) any violation or alleged violation by the Company (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities Law, or any rule or regulation promulgated under any state securities Law; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, the Company shall not be liable in any such case for any such loss, claim, damage, liability or action to the extent that it (A) arises out of or is based upon a Violation which occurs solely in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder; or (B) is caused by such Holder's disposition of Registrable Securities during any period during which such Holder is obligated to discontinue any disposition of Registrable Securities as a result of any stop order suspending the effectiveness of any registration statement or prospectus with respect to Registrable Securities of which such Holder has received written notice.&#160; The Company shall pay, as incurred, any legal or other expenses reasonably incurred by any Person intended to be indemnified pursuant to this Section 2.10(a), in connection with investigating or defending any such loss, claim, damage, liability or action; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the indemnity agreement contained in this Section 2.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without consent of the Company, which consent shall not be unreasonably withheld.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Each Holder including Registrable Securities in a registration statement shall indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and the officers, directors, owners, agents and employees of such controlling Persons, any underwriter, any other Holder selling securities in such registration statement and any controlling Person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing Persons may become subject, under liabilities (or actions in respect thereto) which arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation: (i) arises out of or is based upon a Violation which occurs solely in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder; or (ii) is caused by such Holder's disposition of Registrable Securities during any period during which such Holder is obligated to discontinue any disposition of Registrable Securities as a result of any stop order suspending the effectiveness of any registration statement or prospectus with respect to Registrable Securities of which such Holder has received written notice.&#160; Each such Holder shall pay, as incurred, any legal or other expenses reasonably incurred by any Person intended to be indemnified pursuant to this Section 2.10(b), in connection with investigating or defending any such loss, claim, damage, liability or action; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the indemnity agreement contained in this Section 2.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without consent of the Holder, which consent shall not be unreasonably withheld.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Promptly after receipt by an indemnified party under this Section 2.10 of notice of the commencement of any action (including any action by a Governmental Authority), such indemnified party shall, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding.&#160; The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.10, but the omission so to deliver written notice to the indemnifying party shall not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.10.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">In order to provide for just and equitable contribution to joint liability in any case in which a claim for indemnification is made pursuant to this Section 2.10 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 2.10 provided for indemnification in such case, the Company and each Holder of Registrable Securities shall contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in proportion to the relative fault of the Company, on the one hand, and such Holder, severally, on the other hand; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that in any such case, no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>further</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that in no event shall any contribution under this Section 2.10(d) on the part of any Holder exceed the net proceeds received by such Holder from the sale of Registrable Securities giving rise to such contribution obligation, except in the case of willful misconduct or fraud by such Holder.</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">The obligations of the Company and the Holders under this Section 2.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Agreement and otherwise.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.11</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>SEC Reports</u></font>.&#160; With a view to making available to the Holders the benefits of Rule 144 under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell Registrable Securities of the Company to the public without registration or pursuant to a registration on Form S-3, for so long as any Holder owns Purchased Shares, the Company agrees to:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144; and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">furnish to any Holder, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC (exclusive of Rule 144A) which permits the selling of any Purchased Shares without registration or pursuant to Form S-3.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.12</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Assignment of Registration Rights</u></font>.&#160; The rights to cause the Company to register any Registrable Securities pursuant to this Agreement may be assigned in whole or in part (but only with all restrictions and obligations set forth in this Agreement) by a Holder to a Permitted Transferee which acquires at least 100,000 Registrable Securities (subject to adjustment in the event of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization) from such Holder ; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, (a) such Holder shall, within five (5) days prior to such transfer, furnish to the Company written notice of the name and address of such Permitted Transferee, details of its status as a Permitted Transferee and details of the Registrable Securities with respect to which such registration rights are being assigned, (b) the Permitted Transferee, prior to or simultaneously with such transfer or assignment, shall agree in writing to be subject to and bound by all restrictions and obligations set forth in this Agreement, (c) the Investor shall continue to be bound by all restrictions and obligations set forth in this Agreement and (d) such transfer or assignment shall be effective only if immediately following such transfer or assignment the further disposition of such Registrable Securities by the Permitted Transferee is restricted under the Securities Act and other applicable securities Law.</font></div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Restrictions on Beneficial Ownership</u></font>.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Standstill</u></font>.&#160; During the Standstill Term neither the Investor nor any of its Affiliates (collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Standstill Parties</font>") shall (and the Investor shall cause its Affiliates not to), except as expressly approved or invited in writing by the Company:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">directly or indirectly, acquire beneficial ownership of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents, or make a tender, exchange or other offer to acquire Shares of Then Outstanding Common Stock and/or Common Stock Equivalents; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that notwithstanding the provisions of this Section 3.1(a), if the number of shares constituting Shares of Then Outstanding Common Stock is reduced or if the aggregate ownership of the Standstill Parties is increased as a result of (i) the participation in any offering by the Company of any securities offered pro-rata to all stockholders of the Company or (ii) a repurchase by the Company of Shares of Then Outstanding Common Stock, stock split, stock dividend or a recapitalization of the Company, the Standstill Parties shall not be required to dispose of any of their holdings of Shares of Then Outstanding Common Stock even though such action resulted in the Standstill Parties' beneficial ownership increasing;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">directly or indirectly, seek to have called any meeting of the stockholders of the Company, propose or nominate for election to the Company's Board of Directors any person whose nomination has not been approved by a majority of the Company's Board of Directors or cause to be voted in favor of such person for election to the Company's Board of Directors any Shares of Then Outstanding Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">directly or indirectly, solicit proxies or consents or become a participant in a solicitation (as such terms are defined in Regulation 14A under the Exchange Act) in opposition to the recommendation of a majority of the Company's Board of Directors with respect to any matter, or seek to advise or influence any Person, with respect to voting of any Shares of Then Outstanding Common Stock of the Company;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">deposit any Shares of Then Outstanding Common Stock in a voting trust or subject any Shares of Then Outstanding Common Stock to any arrangement or agreement with respect to the voting of such Shares of Then Outstanding Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">publicly propose (i) any merger, consolidation, business combination, tender or exchange offer, purchase of the Company's assets or businesses, or similar transaction involving the Company or (ii) any recapitalization, restructuring, liquidation or other extraordinary transaction with respect to the Company;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">act in concert with any Third Party to take any action in clauses (a) through (e) above, or form, join or in any way participate in a "partnership, limited partnership, syndicate, or other group" within the meaning of Section 13(d)(3) of the Exchange Act; or</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(g)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">enter into discussions, negotiations, arrangements or agreements with any Person relating to the foregoing actions referred to in (a) through (e) above;</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that [***] would reasonably be expected to require the Company or any third party to be required to [***] or any Affiliate may [***] of the Company [***] by the Investor or its Affiliates shall [***] nothing in the foregoing clause [***] (and not pursuant to the [***] of the Company and its stockholders, and [***] Shares of Then Outstanding Common Stock and/or Common Stock Equivalents.</div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Restrictions on Dispositions</u></font>.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Lock-Up</u></font>.&#160; During the Lock-Up Term, without the prior approval of the Company, the Investor shall not, and shall cause its Affiliates not to, Dispose of (x) any of the Purchased Shares, together with any shares of Common Stock issued in respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization, and (y) any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock described in clause (x) of this sentence (collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Lock-Up Securities</font>"); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the foregoing shall not prohibit the Investor from (A) transferring Lock-Up Securities to a Permitted Transferee or (B) Disposing of any Lock-Up Securities in order to reduce the beneficial ownership of the Standstill Parties to 19.9%, or such lesser percentage as advised in good faith and in writing by the Investor's certified public accountants that would not require the Investor to include in its financial statements its portion of the Company's financial results, of the Shares of Then Outstanding Common Stock.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Certain Tender Offers</u></font>.&#160; Notwithstanding any other provision of this Section 4, this Section 4 shall not prohibit or restrict any Disposition of Shares of Then</font></div>

<div style="MARGIN-BOTTOM: 12pt">Outstanding Common Stock and/or Common Stock Equivalents by the Standstill Parties into (a) a tender offer by a Third Party which is not opposed by the Company's Board of Directors (but only after the Company's filing of a Schedule 14D-9, or any amendment thereto, with the SEC disclosing the recommendation of the Company's Board of Directors with respect to such tender offer) or (b) an issuer tender offer by the Company.</div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Voting Agreement</u></font>.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Voting of Securities</u></font>.&#160; During the Voting Agreement Term, other than as permitted by Section 5.2 with respect to Extraordinary Matters, in any vote or action by written consent of the stockholders of the Company (including, without limitation, with respect to the election of directors), the Investor shall, and shall cause any Permitted Transferees to, vote or execute a written consent with respect to the Purchased Shares, in the sole discretion of the Investor, either (a) in accordance with the recommendation of the Company's Board of Directors or (b) in the case of a meeting of stockholders, if the Investor or a Permitted Transferee has delivered written notice to the Company at any time prior to the vote on any given matter (but in any event not less than five (5) Business Days prior to such vote), setting forth its intent to vote pursuant to this clause (b), in the same proportion as the votes cast by all other holders of all classes of voting securities of the Company (as estimated by the inspector of election immediately prior to the closing of the polls with respect to the vote on any given matter, subject to adjustment for the inspector of election's final tabulation of votes cast). In the event that the Investor or a Permitted Transferee does not deliver timely written notice to the Company as provided in Section 5.1(b), such Person shall be deemed to have elected to vote the Purchased Shares of the Company as to which it is entitled to vote as provided in clause (a) above.&#160; In furtherance of this Section 5.1, the Investor hereby irrevocably appoints the Company and any individuals designated by the Company (such designated individuals to be limited to the Chairman, Chief Executive Officer, General Counsel or Secretary of the Company), and each of them individually, as the attorneys, agents and proxies, with full power of substitution and re-substitution in each of them, for the Investor, and in the name, place and stead of the Investor, to vote (or cause to be voted) in such manner as set forth in this Section 5.1 (but in any case, (i) in accordance with any written instruction from the Investor, properly delivered under this Section 5.1, to vote as contemplated by clause (b) above, and (ii) excluding any matter that is an Extraordinary Matter described in Section 5.2) with respect to the Purchased Shares to which the Investor is or may be entitled to vote at any meeting of the Company held after the date hereof, whether annual or special and whether or not an adjourned meeting (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Irrevocable Proxy</font>").&#160; This Irrevocable Proxy is coupled with an interest, shall be irrevocable and binding on any successor in interest of the Investor and shall not be terminated by operation of law upon the occurrence of any event.&#160; This Irrevocable Proxy shall operate to revoke and render void any prior proxy as to voting securities heretofore granted by the Investor which is inconsistent herewith. &#160;Notwithstanding the foregoing, the Irrevocable Proxy shall be effective if, at any annual or special meeting of the stockholders of the Company and at any adjournments or postponements of any such meetings, the Investor (A) fails to appear or otherwise fails to cause its voting securities of the Company to be counted as present for purposes of calculating a quorum, or (B) fails to vote such voting securities in accordance with this Section 5.1, in each case at least two (2) Business Days prior to the date of such stockholders' meeting. The Irrevocable Proxy shall terminate upon the earlier of the expiration or termination of the Voting Agreement Term.&#160; The Investor shall cause any Permitted Transferee to promptly execute and deliver to the Company an irrevocable proxy, substantially in the form of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit A</u></font> attached hereto, and irrevocably appoint the Company and any individuals designated by the Company, and each of them individually, with full power of substitution and resubstitution, as its attorney, agent and proxy to vote (or cause to be voted) such Purchased Shares of the Company as to which such Permitted Transferee is entitled to vote, in such manner as each such attorney, agent and proxy or his substitute shall in its, his or her sole discretion deem appropriate or desirable with respect to the matters set forth in this Section 5.1 (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Permitted Transferee Irrevocable Proxy</font>").&#160; The Investor acknowledges, and shall cause any Permitted Transferees to acknowledge, that any such proxy executed and delivered shall be coupled with an interest, shall constitute, among other things, an inducement for the Company to enter into this Agreement, shall be irrevocable and binding on any successor in interest of such Permitted Transferee and shall not be terminated by operation of Law upon the occurrence of any event.&#160; Such proxy shall operate to revoke and render void any prior proxy as to any voting securities of the Company heretofore granted by such Permitted Transferee, to the extent it is inconsistent herewith.&#160; The Investor acknowledges and agrees that it shall be a condition to any proposed transfer of voting securities of the Company by the Investor to such Permitted Transferee that such Permitted Transferee execute and deliver to the Company a Permitted Transferee Irrevocable Proxy, and that any purported transfer shall be void and of no force or effect if such Permitted Transferee Irrevocable Proxy is not so executed and delivered at the closing of such transfer.&#160; Such proxy shall terminate upon the earlier of the expiration or termination of the Voting Agreement Term. The Investor acknowledges and agrees that it shall be a condition to any proposed transfer of voting securities of the Company by the Investor to any Permitted Transferee during the Voting Agreement Term that such Permitted Transferee shall agree in writing to be subject to and bound by all restrictions and obligations set forth in this Section 5.1.</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">In the event the Company's stockholders are permitted to act by written consent, the Company and the Investor shall each negotiate in good faith with the other provisions as consistent as possible with the foregoing to govern the voting of the Investor's and its Permitted Transferees' Shares of Then Outstanding Common Stock as closely as practicable to the foregoing.</div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Certain Extraordinary Matters</u></font>.&#160; The Investor and its Permitted Transferees may vote, or execute a written consent with respect to, any or all of the voting securities of the Company as to which they are entitled to vote or execute a written consent, as they may determine in their sole discretion, with respect to the following matters (each such matter being an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Extraordinary Matter</font>"):</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">any transaction which would result in a Change of Control;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">any issuance of Common Stock presented to stockholders for approval (which for avoidance of doubt shall not include the approval of any stock option or similar equity plan); and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">any liquidation or dissolution of the Company.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Quorum</u></font>.&#160; In furtherance of Section 5.1, the Investor shall be, and shall cause each of its Permitted Transferees to be, present in person or represented by proxy at all meetings of stockholders to the extent necessary so that all voting securities of the Company as to which they are entitled to vote shall be counted as present for the purpose of determining the presence of a quorum at such meeting.</font></div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Termination of Certain Rights and Obligations</u></font>.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Termination of Registration Rights Term</u></font>.&#160; Except for Section 2.10, which shall survive until the expiration of any applicable statutes of limitation, Section 2 shall terminate automatically and have no further force or effect upon the earliest to occur of:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the fifth (5th) anniversary of the expiration of the Lock-Up Term;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act; and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">a liquidation or dissolution of the Company.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Termination of Standstill Term</u></font>.&#160; Section 3 shall terminate and have no further force or effect, upon the earliest to occur of:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date sixteen (16) months after of the Closing Date;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">provided that none of the Standstill Parties has materially violated Section 3.1(d) or (f) with respect to any other Person or group (an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Offeror</font>") referred to in this Section 6.2, the date on which an Offeror publicly announces a tender, exchange or other offer for the Company's Common Stock that, if consummated, would result in a Change of Control of the Company;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date that the Company enters into a letter of intent relating to a Change of Control of the Company, announces its intent to do so or announces that it is pursuing a transaction that would result in a Change of Control of the Company;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Standstill Parties together beneficially own less than five percent (5%) of the Shares of Then Outstanding Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act; and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">a liquidation or dissolution of the Company;</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that if Section 3 terminates due to clauses (b) or (c) above and such agreement is abandoned and no other similar transaction has been announced and not abandoned or terminated within ninety (90) days thereafter, the restrictions contained in Section 3 shall again be applicable until otherwise terminated pursuant to this Section 6.2.</div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Termination of Lock-Up Term</u></font>.&#160; Section 4 shall terminate and have no further force or effect upon the earliest to occur of:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date [***] after of the Closing Date;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the expiration or earlier valid termination of the Collaboration Agreement;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the consummation by an Offeror of a Change of Control of the Company, which, in the case of a tender offer, shall be deemed to occur upon the commencement of a tender offer for all outstanding shares of Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Investor and any Permitted Transferees together beneficially own less than [***] of the Shares of Then Outstanding Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">a liquidation or dissolution of the Company; and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Termination of Voting Agreement Term</u></font>.&#160; Section 5 shall terminate and have no further force or effect upon the earliest to occur of:</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(a)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date [***] after the Closing Date;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(b)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the expiration or earlier valid termination of the Collaboration Agreement;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(c)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the consummation by an Offeror of a Change of Control of the Company, which, in the case of a tender offer, shall be deemed to occur upon the commencement of a tender offer for all outstanding shares of Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(d)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Investor and any Permitted Transferees together beneficially own less than [***] of the Shares of Then Outstanding Common Stock;</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(e)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">a liquidation or dissolution of the Company; and</font></div>

<div style="TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">(f)</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Effect of Termination</u></font>.&#160; No termination pursuant to any of Sections 6.1, 6.2, 6.3 or 6.4 shall relieve any of the parties (or the Permitted Transferee, if any) for liability for</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">breach of or default under any of their respective obligations or restrictions under any terminated provision of this Agreement, which breach or default arose out of events or circumstances occurring or existing prior to the date of such termination.</div>

<div style="MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Miscellaneous</u></font>.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal">7.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt"><font style="FONT-WEIGHT: normal">&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Governing Law; Submission to Jurisdiction</u></font>.&#160; This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction.&#160; Any action brought, arising out of, or relating to this Agreement shall be brought in the Court of Chancery of the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of said Court in respect of any claim relating to the validity, interpretation and enforcement of this Agreement, and hereby waives, and agrees not to assert, as a defense in any action, suit or proceeding in which any such claim is made that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in such courts, or that the venue thereof may not be appropriate or that this agreement may not be enforced in or by such courts. The parties hereby consent to and grant the Court of Chancery of the State of Delaware jurisdiction over such parties and over the subject matter of any such claim and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 7.3 or in such other manner as may be permitted by law, shall be valid and sufficient thereof.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Waiver</u></font>.&#160; Waiver by a party of a breach hereunder by another party shall not be construed as a waiver of any subsequent breach of the same or any other provision.&#160; No delay or omission by a party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later exercise of any such right, power or privilege by such party.&#160; No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the party granting the waiver.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Notices</u></font>.&#160; All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent to the address of the relevant party set forth on <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit A</u></font> attached hereto and shall be (a) delivered personally, (b) sent by registered or certified mail, return receipt requested, postage prepaid, (c) sent via a reputable nationwide overnight courier service or (d) sent by facsimile transmission or electronic mail, with a confirmation copy to be sent by registered or certified mail, return receipt requested, postage prepaid.&#160; Any such notice, instruction or communication shall be deemed to have been delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1) Business Day after it is sent via a reputable nationwide overnight courier service or when transmitted with electronic confirmation of receipt, if transmitted by facsimile or electronic mail (if such transmission is made during regular business hours of the recipient on a Business Day; or otherwise, on the next Business Day following such transmission).&#160; Any party may change its address by giving notice to the other parties in the manner provided above.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Entire Agreement</u></font>.&#160; This Agreement, the Purchase Agreement and the Collaboration Agreement contain the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous arrangements or understandings, whether written or oral, with respect hereto and thereto.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Amendments</u></font>.&#160; No provision in this Agreement shall be supplemented, deleted or amended except in a writing executed by an authorized representative of each of the parties hereto.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Headings; Nouns and Pronouns; Section References</u></font>.&#160; Headings in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement.&#160; Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa.&#160; References in this Agreement to a section or subsection shall be deemed to refer to a section or subsection of this Agreement unless otherwise expressly stated.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Severability</u></font>.&#160; If, under applicable Laws, any provision hereof is invalid or unenforceable, or otherwise directly or indirectly affects the validity of any other material provision(s) of this Agreement in any jurisdiction ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Modified Clause</font>"), then, it is mutually agreed that this Agreement shall endure and that the Modified Clause shall be enforced in such jurisdiction to the maximum extent permitted under applicable Laws in such jurisdiction; provided that the parties shall consult and use all reasonable efforts to agree upon, and hereby consent to, any valid and enforceable modification of this Agreement as may be necessary to avoid any unjust enrichment of either party and to match the intent of this Agreement as closely as possible, including the economic benefits and rights contemplated herein.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Assignment</u></font>.&#160; Except for an assignment of this Agreement by the Investor to a Permitted Transferee, neither this Agreement nor any rights or duties of a party hereto may be assigned by such party, in whole or in part, without (a) the prior written consent of the Company in the case of any assignment by the Investor; or (b) the prior written consent of the Investor in the case of an assignment by the Company.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.9</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Successors and Assigns</u></font>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.10</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Counterparts</u></font>.&#160; This Agreement may be executed in counterparts, each of which shall be deemed an original but which together shall constitute one and the same instrument.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.11</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Third Party Beneficiaries</u></font>.&#160; None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party other than any Affiliate of the Investor.&#160; No Third Party with the exception of any Affiliate of the Investor shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against any party hereto.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.12</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>No Strict Construction</u></font>.&#160; This Agreement has been prepared jointly and will not be construed against any party.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.13</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Remedies</u></font>.&#160; The rights, powers and remedies of the parties under this Agreement are cumulative and not exclusive of any other right, power or remedy which such parties may have under any other agreement or Law.&#160; No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other or further assertion or exercise thereof.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.14</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Specific Performance</u></font>.&#160; The Company and the Investor hereby acknowledge and agree that the rights of the parties hereunder are special, unique and of extraordinary character, and that if any party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of this Agreement, such refusal or failure would result in irreparable injury to the Company or the Investor, as the case may be, the exact amount of which would be difficult to ascertain or estimate and the remedies at law for which would not be reasonable or adequate compensation.&#160; Accordingly, if any party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of this Agreement, then, in addition to any other remedy which may be available to any damaged party at law or in equity, such damaged party will be entitled to seek specific performance and injunctive relief, without posting bond or other security, and without the necessity of proving actual or threatened damages, which remedy such damaged party will be entitled to seek in any court of competent jurisdiction.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.15</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>No Conflicting Agreements</u></font>.&#160; The Investor hereby represents and warrants to the Company that neither it nor any of its Affiliates is, as of the date of this Agreement, a party to, and agrees that neither it nor any of its Affiliates shall, on or after the date of this Agreement, enter into any agreement that conflicts with the rights granted to the Company in this Agreement.&#160; The Company hereby represents and warrants to each Holder that it is not, as of the date of this Agreement, a party to, and agrees that it shall not, on or after the date of this Agreement, enter into any agreement or approve any amendment to its Organizational Documents (as defined in the Purchase Agreement) with respect to its securities that conflicts with the rights granted to the Holders in this Agreement.&#160; The Company further represents and warrants that the rights granted to the Holders hereunder do not in any way conflict with the rights granted to any other holder of the Company's securities under any other agreements.</font></div>

<div style="TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.16</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Use of Proceeds</u></font>.&#160; The Company shall use the proceeds from the sale of the Shares hereunder for working capital purposes and shall not use such proceeds for the redemption of any shares of Common Stock (or Common Stock Equivalents) or for the payment of any dividends on shares of Common Stock (or Common Stock Equivalents).</font></div>

<div style="TEXT-INDENT: 27pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal">7.17</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt"><font style="FONT-WEIGHT: normal">&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>No Publicity</u></font>.&#160; The parties hereto agree that the provisions of Section 12.5 of the Collaboration Agreement shall be applicable to the parties to this Agreement with respect to any public disclosures&#160; regarding the proposed transactions contemplated by the Purchase Agreement and the Collaboration Agreement or regarding the parties hereto or their Affiliates (it being understood that the provisions of Section 12.5(a) of the Collaboration Agreement shall be read to apply to disclosures of information relating to this Agreement and the transactions contemplated hereby).</font></div>

<div style="TEXT-INDENT: 27pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal">7.18</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt"><font style="FONT-WEIGHT: normal">&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>Limitation of Liability</u></font>.&#160; IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY'S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;(Signature Page Follows)</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 216pt">JOHNSON &amp; JOHNSON INNOVATION-JJDC, INC.</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table id="66dd3bbc37f14cf780ee980a3025c570" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 216pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">By:</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">/s/Ashish K. Xavier</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 288pt; TEXT-INDENT: -36pt">Name: Ashish K. Xavier</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 288pt; TEXT-INDENT: -36pt">Title: Vice President, Venture Investments</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 216pt">MACROGENICS, INC.</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table id="b4e308b04e8e4df3bc437d8d4e58de0f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 216pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">By:</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">/s/ Scott Koenig, M.D., Ph.D.</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 288pt; TEXT-INDENT: -36pt">Name: Scott Koenig, M.D., Ph.D.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 288pt; TEXT-INDENT: -36pt">Title: President and CEO</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT A</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">FORM OF IRREVOCABLE PROXY</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">In order to secure the performance of the duties of the undersigned pursuant to Section 5.1 of the Investor Agreement, dated as of December 19, 2014 (the "Agreement"), by and between Johnson &amp; Johnson Innovation-JJDC, Inc. and MacroGenics, Inc. (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company</font>"), the undersigned hereby irrevocably appoints the Company and any individual designated by the Company, and each of them individually, as the attorneys, agents and proxies, with full power of substitution and resubstitution in each of them, for the undersigned, and in the name, place and stead of the undersigned, to vote (or cause to be voted) in such manner as set forth in Section 5.1 of the Agreement (but in any case, (i) in accordance with any written instruction from the undersigned, properly delivered under Section 5.1 of the Agreement, to vote as contemplated by Section 5.1(b) of the Agreement and (ii) excluding any matter that is an Extraordinary Matter described in Section 5.2) with respect to all Purchased Shares, which the undersigned is or may be entitled to vote at any meeting of the Company held after the date hereof, whether annual or special and whether or not an adjourned meeting.&#160; This proxy is coupled with an interest, shall be irrevocable and binding on any successor in interest of the undersigned and shall not be terminated by operation of law upon the occurrence of any event.&#160; This proxy shall operate to revoke and render void any prior proxy as to voting securities heretofore granted by the undersigned which is inconsistent herewith.&#160; Notwithstanding the foregoing, this irrevocable proxy shall be effective if, at any annual or special meeting of the stockholders of the Company (or any consent in lieu thereof) and at any adjournments or postponements of any such meetings, the undersigned (A) fails to appear or otherwise fails to cause its voting securities of the Company to be counted as present for purposes of calculating a quorum, or (B) fails to vote such voting securities in accordance with Section 5.1 of the Agreement, in each case at least two (2) Business Days prior to the date of such stockholders' meeting.&#160; This proxy shall terminate upon the earlier of the expiration or termination of the Voting Agreement Term.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 216pt">JOHNSON &amp; JOHNSON INNOVATION-JJDC, INC.</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table id="4d1dc0e0f6e04d939bfef50a4b0348f8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 216pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">By:</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left"></td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 288pt; TEXT-INDENT: -36pt">Name:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 288pt; TEXT-INDENT: -36pt">Title:</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT B</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">NOTICES</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(a)</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">If to the Investor:</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Johnson &amp; Johnson Innovation-JJDC, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">410 George Street</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">New Brunswick, NJ 08901</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Attention: General Manager</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">with a copy to:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Johnson &amp; Johnson Law Department</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">One Johnson &amp; Johnson Plaza</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">New Brunswick, NJ 08534</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Attention: General Counsel</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(b)</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">If to the Company:</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">MacroGenics, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">9640 Medical Center Drive</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Rockville, MD&#160; 20850</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Attention:&#160; CEO</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">with a copy to:</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">Wilmer Cutler Pickering Hale and Dorr <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">LLP</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>60 State Street<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Boston, MA 02109<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Attention:&#160; Steven D. Singer</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>5
<FILENAME>exhibit10-25.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: MacroGenics
    Document created using Disclosure Solutions PROFILE 3.2.0.0
    Copyright 1995 - 2015 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: right; MARGIN-TOP: 12pt">EXHIBIT 10.25</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center; MARGIN-TOP: 12pt">Confidential Materials omitted and filed separately with the Securities and Exchange Commission.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center">Triple asterisks denote omissions.</div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">COLLABORATION AND LICENSE AGREEMENT</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">BY AND BETWEEN</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">MACROGENICS, INC.</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">AND</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">JANSSEN BIOTECH, INC.</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">TABLE OF CONTENTS</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 90pt; MARGIN-RIGHT: 27.35pt; TEXT-INDENT: -90pt">
<table id="f49edd33efdb44a4a64c56edf9d9a47b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 1 DEFINITIONS</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 2 GOVERNANCE</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">24</div>
</td>
</tr>

<tr style="HEIGHT: 19px">
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Joint Steering Committee</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">24</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">2.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Additional Subcommittees and Working Groups</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">27</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">2.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Authority</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">27</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">2.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Alliance Managers</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">27</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">2.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Decision-Making Restrictions</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">28</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 3 LICENSES</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">28</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">3.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">License to Company</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">28</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">3.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Licenses to MacroGenics</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">29</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">3.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Trademark License</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">30</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">3.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">No Implied Licenses</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">30</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 4 DEVELOPMENT</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">30</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Transition of Development Responsibilities</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">30</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Development</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">31</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Decision-Making</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">33</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Compliance with Law</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">33</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Records</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">33</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Cooperation</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">33</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.7</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Progress Reports</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">33</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">4.8</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Subcontracting</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">34</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 5 REGULATORY RESPONSIBILITIES</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">34</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">5.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Initial Data Transfer</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">34</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">5.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Preparation of Regulatory Materials.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">35</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">5.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Adverse Event Reporting and Safety Data Exchange</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">36</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">5.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Recalls and Voluntary Withdrawals</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">37</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">5.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Subcontracting</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">37</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 6 COMMERCIALIZATION</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">37</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Commercialization Activities</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">37</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Trademarks</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">38</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Decision-Making</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">38</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Transparency Reporting</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">38</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Compliance with Law</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">38</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">6.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Subcontracting</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">39</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 7 MANUFACTURING</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">39</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">7.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">General Supply Terms</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">39</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">7.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Transition of Manufacturing Responsibilities</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">40</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">7.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Decision Making</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">40</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">7.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Compliance with Law</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">40</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">7.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Subcontracting</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">41</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 8 MACROGENICS OPTIONS</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">41</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">8.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Generally</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">41</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">8.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Co-Funding Option</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">41</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">8.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Co-Promote Option</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">48</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 9 CONSIDERATION</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">51</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Upfront Payment</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">51</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Reimbursement of Expenses</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">51</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Milestone Payments</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">51</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Company Royalty Obligations</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">56</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Royalty Term</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">59</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Royalty Rate Reductions</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">60</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.7</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Manner of Royalty Payment</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">60</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.8</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Currency</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">61</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.9</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Allocation of N.A. Profit/Loss</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">61</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Third Party Financial Obligations</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">62</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.11</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Taxes</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">63</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.13</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Audit</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">64</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">9.14</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Late Payment</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">64</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 96.37%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 10 INTELLECTUAL PROPERTY MATTERS</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">64</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Ownership of Inventions</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">64</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Disclosure of Inventions</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">65</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Prosecution of Patents</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">65</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Patent Term Extensions in the Territory</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">68</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Infringement of Patents by Third Parties</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">68</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Infringement of Third Party Rights in the Territory</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">71</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">10.7</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Patent Oppositions and Other Proceedings</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">72</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 96.37%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 11 REPRESENTATIONS, WARRANTIES AND COVENANTS</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">73</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">11.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Mutual Representations, Warranties and Covenants</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">73</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">11.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Additional Representations and Warranties of MacroGenics</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">74</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">11.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Additional Representations and Warranties of Company</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">77</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">11.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">No Other Representations or Warranties.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">77</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 12 CONFIDENTIALITY</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">77</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Nondisclosure</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">77</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exceptions</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">78</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Authorized Disclosure</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">78</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Terms of this Agreement</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">79</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Securities Filings</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">81</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.7</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Relationship to Confidentiality Agreement</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">81</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.8</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Equitable Relief</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">81</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">12.9</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Publications</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">81</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 13 TERM AND TERMINATION</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">82</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Term</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">82</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Unilateral Termination by Company</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">82</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Termination for Material Breach</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">82</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Termination by Company for Safety Reasons</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">83</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Termination for Patent Challenge</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">83</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">HSR Filing; Termination Upon HSR</font><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">&#160;</sub><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Denial</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">84</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.7</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Termination for Bankruptcy</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">84</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.8</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Effects of Termination</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">86</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.9</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Remedies</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">90</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">13.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Survival</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">91</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 14 DISPUTE RESOLUTION</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">91</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">14.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exclusive Dispute Resolution Mechanism</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">91</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">14.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Resolution by Executive Officers</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">91</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">14.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Arbitration</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">91</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">14.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Provisional Remedies</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">93</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">14.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Confidentiality</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">93</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 15 INDEMNIFICATION</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">93</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">15.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Indemnification by Company.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">93</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">15.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Indemnification by MacroGenics</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">94</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">15.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Indemnification Procedures</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">94</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">15.4</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Insurance</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">95</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">15.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Limitation of Liability</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">96</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">ARTICLE 16 MISCELLANEOUS</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">96</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">Notices.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">96</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.2</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Governing Law</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">97</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Change of Control of MacroGenics</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">97</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.5</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Designation of Affiliates</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">98</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.6</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Relationship of the Parties</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">98</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.7</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Force Majeure</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">98</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.8</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Entire Agreement; Amendments</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">99</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.9</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Severability</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">99</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.1</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">English Language</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">99</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.11</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Waiver and Non-Exclusion of Remedies</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">99</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.12</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Further Assurance</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">99</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.13</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Headings</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">99</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.14</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Construction</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">100</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 41.68%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">16.15</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 54.69%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Counterparts</font>.</div>
</td>
<td style="WIDTH: 3.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">100</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">LIST OF EXHIBITS</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exhibit A</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#8210;</font>Commercialization Expenses</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exhibit B</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#8210;</font>Global Development Plan</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exhibit C</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#8210;</font>MacroGenics Patents</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exhibit D</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#8210;</font>MGD011</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exhibit E</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">-</font>J &amp; J Universal Calendar</font></div>

<div style="TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Exhibit F</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">-</font>Form of Press Release</font></div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">LIST OF SCHEDULES</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Schedule </font>7.1<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#8210;</font>MacroGenics' Estimated, Non-Binding Manufacturing Costs</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">COLLABORATION AND LICENSE AGREEMENT</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">THIS COLLABORATION AND LICENSE AGREEMENT </font>("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Agreement</font>") is entered into as of December 19, 2014 (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Execution Date</font>"), by and between <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">JANSSEN BIOTECH, INC.</font>, a Pennsylvania corporation, having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (hereinafter "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company</font>") and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MACROGENICS, INC.</font>, a Delaware corporation having its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850 (together with its Affiliates, "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics</font>").&#160; Company and MacroGenics are sometimes referred to herein individually as a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Party</font>" and collectively as the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Parties</font>".</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">WHEREAS</font>, MacroGenics has discovered and is developing a proprietary program that includes a Compound (as defined below) containing CD3 and CD19 specificities and is coded by MacroGenics as MGD011, with various potential human therapeutic uses; </div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">WHEREAS</font>, Company desires to obtain certain license rights in respect of such Compound, all in accordance with the terms and conditions of this Agreement, with MacroGenics retaining certain options to co-promote the Initial Product (as defined below) in the U.S. and to co-fund certain development costs and participate in the profits and losses of the Initial Product, all as set forth in this Agreement; and</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">WHEREAS</font>, MacroGenics and Johnson &amp; Johnson Innovation - JJDC, Inc., an Affiliate (as defined below) of Company, are contemporaneously entering into that certain Stock Purchase Agreement and that certain Investor Agreement, each as of the Execution Date.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">NOW, THEREFORE</font>, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows:</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 1</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> DEFINITIONS</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.1</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Accelerated Approval</font>" means FDA approval of a BLA that (a) includes clinical data from a Phase 2 Trial or Phase 2/3 Trial, but no clinical data from a Phase 3 Trial; (b) has been granted expedited review by the FDA (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, such BLA has been granted a Breakthrough Therapy designation pursuant to Section 506(a) of the FFDCA or a Fast Track designation pursuant to Section 506(b) of the FFDCA); or (c) has been granted orphan drug status pursuant to Section 526 of the FFDCA.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.2</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Acquirer</font>" means any Third Party that is a party to any Change of Control transaction and any of such Third Party's Affiliates.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.3</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Affiliate</font>" means, with respect to a particular Person, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such first Person.&#160; For the purposes of this definition, the word "control" (including, with correlative meaning, the terms "controlled by" or "under the common control with") means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.4</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Alliance Manager</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means the person appointed by each Party from within their respective organization to coordinate and facilitate the communication, interaction and cooperation of the Parties pursuant to this Agreement.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Antitrust Laws</font>" means any law relating to competition that is enforced by (a) the Federal Trade Commission or the Antitrust Division of the U.S. Department of Justice or (b) any equivalent foreign authority, including the European Commission.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.6</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Applicable Law</font>" means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority, including the FFDCA, Prescription Drug Marketing Act of 1987 (21 U.S.C. &#167;&#167;331, 333, 353, 381), the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335(a) et seq.), U.S. Patent Act (35 U.S.C. &#167;1 et seq.), Federal False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), all as amended from time to time, together with any rules, regulations, and compliance guidance promulgated thereunder.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.7</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">BLA</font>" means (a) a Biologics License Application as defined in the Public Health Service Act and the regulations promulgated thereunder, (b) a Marketing Authorization Application in Europe, or (c) any equivalent or comparable application, registration or certification<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>in any other country or region.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.8</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Business Day</font>" means a day other than Saturday, Sunday or any other day that is designated as a J&amp;J holiday in the J&amp;J Universal Calendar (a copy of which for the years 2014 and 2015 is attached as <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit E</u></font> and a copy of which prior to the beginning of each such year for succeeding years shall be provided to MacroGenics).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.9</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Calendar Quarter</font>" means a financial quarter based on a Calendar Year; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the first Calendar Quarter and the last Calendar Quarter may be partial quarters as applicable under the relevant Calendar Year.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.10</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Calendar Year</font>" means a year based on the Johnson &amp; Johnson Universal Calendar; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the first Calendar Year and the last Calendar Year of the applicable period (such as the Royalty Term) may be a partial year as the case may be.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.11</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Centralized Approval Procedure</font>" means, to the extent compulsory or permitted for the Regulatory Approval of a Compound or Product in Iceland, Liechtenstein, Norway or any country in the European Union, the procedure administrated by the EMA which results in a single marketing authorization that is valid in Iceland, Liechtenstein, Norway and all countries in the European Union.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.12</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">CFDA</font>" means the China Food and Drug Administration and any successor agency(ies) or authority having substantially the same function.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.13</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Change of Control</font>" shall occur if: (a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of a Party, or if the percentage ownership of such person or entity in the voting securities of a Party is increased through stock redemption, cancellation or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of a Party; (b) a merger, consolidation, recapitalization, or reorganization of a Party is consummated, other than any such transaction, which would result in stockholders or equity holders of such Party immediately prior to such transaction, owning at least fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction; (c) the stockholders or equity holders of a Party approve a plan of complete liquidation of such Party, or an agreement for the sale or disposition by such Party of all or substantially all of such Party's assets, other than pursuant to the transaction described above or to an Affiliate; (d) individuals who, as of the date hereof, constitute the Board of Directors of a Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Incumbent Board</font>") cease for any reason to constitute at least a majority of the Board of Directors of such Party (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by such Party's shareholders, was recommended or approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board of Directors of such Party); or (e) the sale or transfer to a Third Party of (i) all or substantially all of such Party's assets taken as a whole or (ii) a majority of such Party's assets which relate to this Agreement, is effected.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.14</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Clinical Trials</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means a Phase 1 Trial, Phase 2 Trial, Phase 2/3 Trial, Phase 3 Trial or Phase 4 Trial, as applicable.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.15</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Term</font>" means the time period commencing on the date that Company receives the Co-Funding Option Exercise Notice and concluding on the Co-Funding Termination Date.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.16</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Termination Date</font>" means the last day of the Calendar Quarter during which the Co-Funding Termination Event occurs.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.17</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Termination Event</font>" means the earlier of: (a) the [***] after MacroGenics' receipt of a GDC Late Payment Notice, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that MacroGenics has not paid the entire non-disputed outstanding amount due under the applicable GDC Invoice; (b) Company's receipt of the Co-Funding Opt-Out Notice; (c) if, Net Sales of the Initial Product in the Northern American Territory are less than [***] the last day of such second Calendar Year or (d) [***] after the First Commercial Sale of the Initial Product in the Northern American Territory.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.18</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Combination Product</font>" means (a) a Product that comprises, consists of or incorporates two (2) or more active pharmaceutical ingredients or (b) a package that includes a Product and at least one pharmaceutical product that is not a Product.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.19</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercial FTE</font>" means [***] of work devoted to or in direct support of the Commercialization of a Product (other than Detailing) that is carried out by one or more qualified employees or contractors or consultants of MacroGenics or its Affiliates or Company or its Affiliates, [***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.20</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercial FTE Costs</font>" means, with respect to any period, the Commercial FTE Rate multiplied by the number of Commercial FTEs expended by a Party during such period.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.21</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercial FTE Rate</font>" means a rate of [***]per Commercial FTE per Calendar Year (pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year of the Term); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that such rate shall be increased or decreased annually beginning on January 4, 2016 by the percentage increase or decrease in the [***]&#160; The Commercial FTE Rate is "fully burdened" and covers employee salaries, benefits, travel and other costs not separately accounted for in Commercialization Expenses.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.22</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercialization</font>" means any activities directed to marketing, promoting, distributing, importing, offering to sell and/or selling a Product.&#160; When used as a verb, "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercialize</font>" means to engage in Commercialization activities.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.23</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercially Reasonable Efforts</font>" means, with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective, activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances, it being understood and agreed that, with respect to the Development, Manufacture, seeking and obtaining Regulatory Approval, or Commercialization of a Compound or Product, such efforts and resources shall be consistent with those efforts and resources commonly used by a Party under similar circumstances for similar compounds or products to which it has similar rights, which compound or product, as applicable, is at a similar stage in its development or product life and is of similar market potential, taking into account all commercial, scientific, economic and other factors, including:&#160; (a) issues of efficacy, safety, and expected and actual approved labeling; (b) the expected and actual competitiveness of alternative products sold by Third Parties in the marketplace; (c) the expected and actual product profile of the Compound or Product; (d) the expected and actual patent and other proprietary position of the Compound or Product; (e) the likelihood of Regulatory Approval of the Compound or Product given the regulatory structure involved, including the likelihood of obtaining Regulatory Exclusivity; and (f) the expected and actual profitability and return on investment of the Compound or Product, taking into consideration, among other factors, expected and actual Third Party costs and expenses, the pricing and reimbursement relating to the Product(s), and the</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">payments due to a Party hereunder.&#160; To the extent that the performance of a Party's obligations hereunder is adversely affected by the other Party's failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining whether such first Party has used Commercially Reasonable Efforts to perform its affected obligations.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.24</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Applied Technology</font>" means, with respect to any Reverted Product, (a) any Know-How Controlled by Company as of the Effective Date or during the Term (other than as a result of the licenses granted by MacroGenics to Company under this Agreement) that (i) Company had applied to such Reverted Product prior to termination of this Agreement, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that such Know-How is necessary for the continued Exploitation of such Reverted Product as it exists at the time of such termination or (ii) Company had incorporated into such Reverted Product prior to termination of this Agreement and (b) any Patents Controlled by Company as of the Effective Date or during the Term that Covers the Know-How described in clause (a).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.25</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Inventions</font>" means Inventions Controlled by Company that are necessary or otherwise used to Exploit Compounds or Products in the Field in the Territory.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.26</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Know-How</font>" means all Know-How Controlled by Company, during the Term, used to Exploit Compounds or Products in the Field in the Territory as contemplated by this Agreement, including Company Inventions.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.27</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Patents</font>" means all Patents Controlled by Company, covering Inventions discovered or invented during the Term pursuant to activities under this Agreement that: (a) Cover the composition of matter of, the method of making or using, or the sale or the importation of the Compounds or the Products, to the extent included within a Company Invention; or (b) are otherwise used to Exploit the Compounds or the Products in the Field in the Territory.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.28</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Technology</font>" means, collectively, the Company Patents and the Company Know-How.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.29</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Competitive Infringement</font>" means <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">any infringement or misappropriation that involves the Development, Manufacture, use or Commercialization of a product or product candidate that [***].</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.30</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Compound</font>" means (a)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> MGD011, its derivatives and variants, including molecules that [***] and are specifically claimed in Patents that specifically claim the amino acid sequence of MGD011; and (b) any other DART derived from the DART Platform that binds </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***].</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.31</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Confidential Information</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means, subject to ARTICLE 12, all non-public or proprietary Information disclosed by a Party to the other Party under this Agreement, which may include ideas, inventions, discoveries, concepts, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, development, designs, drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, Regulatory Documentation, Information and submissions pertaining to, or made in association with, filings</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">with any Governmental Authority, data, including pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, without regard as to whether any of the foregoing is marked "confidential" or "proprietary," or disclosed in oral, written, graphic, or electronic form.&#160; Confidential Information shall include: (a) the terms and conditions of this Agreement; and (b) Confidential Information disclosed by either Party pursuant to the Confidential Disclosure Agreement dated [***] (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Prior CDA</font>").</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.32</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Control</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>or<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Controlled</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means, with respect to any Information, Know-How, Patent or other intellectual property right, (a) ownership by a Party or, subject to Section 16.5, any of its Affiliates, of such Information, Know-How, Patent or other intellectual property right, or (b) possession by a Party or, subject to Section </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16.5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">, any of its Affiliates, of the ability (without taking into account any rights granted by one Party to the other Party under the terms of this Agreement) to grant access, a license or a sublicense to such Information, Know-How, Patent or other intellectual property right without violating the terms of any agreement or other arrangement with, or necessitating the consent of, any Third Party, at such time that the Party would be first required under this Agreement to grant the other Party such access, license or sublicense, but excluding, in each case ((a) and (b)), any Information, Know-How, Patent or other intellectual property right that comes into the Control of a Party pursuant to a Change of Control of such Party, except to the extent, and only to the extent that, such Information, Know-How, Patent or other intellectual property right is either (i) actually used by such Party or its Affiliates, or the Acquirer, to Develop, Manufacture or Commercialize the Compounds or Products following the consummation of such Change of Control or (ii) made, conceived or reduced to practice by the Acquirer through the use of, or reference to, any Information, Know-How, Patent or other intellectual property right of such Party.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.33</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Promote Option Deadline</font>" means [***] after Company delivers the Co-Promote Materials relating to such second Indication to MacroGenics in accordance with Section 8.3 (the "[***]").</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.34</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Cover</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">" or "</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Covering</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">" means, with respect to a product, technology, process or method, that, in the absence of ownership of or a license granted under a Valid Claim, the practice or Exploitation of such product, technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue).</font></font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.35</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">CPI</font>" means the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Consumer Price Index-Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-1984=100, published by the U.S. Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the U.S.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.36</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.37</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">DART</font>" means a <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">dual affinity re-targeting molecule consisting of [***]</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.38</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">DART Platform</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means MacroGenics' proprietary platform for generating DARTs</font>.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.39</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Detail</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Detailing</font>" means an interactive face-to-face meeting between a sales representative acting on behalf of the applicable Party and a health care professional having prescribing authority within the target audience that occurs after Regulatory Approval of a Product, during which such Product's attributes (including approved uses, safety, effectiveness, contraindications, side effects warnings and/or other relevant characteristics) are discussed in an effort to increase prescribing preferences of such Product for its approved uses, in a manner consistent with Applicable Law and industry standards and with the quality of similar presentations made by a Party's sales representatives for such Party's other products, if applicable.&#160; Details may include First Position Details or Second Position Details.&#160; Detailing shall not include (a) sample drops made by sales representatives, (b) medical affairs activities or related activities conducted by medical support staff (such as medical science liaisons), (c) activities conducted at conventions, (d) electronic details or (e) activities performed by market development specialists, managed care account directors or other personnel not performing face-to-face sales calls or not specifically trained with respect to a Product.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.40</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development</font>" means all research and non-clinical and clinical drug development activities and processes, including toxicology, pharmacology, project management and other non-clinical efforts, statistical analysis, formulation development, delivery system development, statistical analysis, Manufacturing Development, the performance of clinical trials (including the manufacturing of Product for use in clinical trials), or other activities reasonably necessary in order to obtain, but not maintain, Regulatory Approval of Products in the Field in the Territory.&#160; When used as a verb, "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Develop</font>" means to engage in Development activities.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.41</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development FTE</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means (a) with respect to Company, [***] hours of work devoted to or in direct support of&#160; the Global Development Activities by one or more qualified employees or contractors or consultants of Company or its Affiliates, as measured in accordance with Company's normal time allocation practices, or (b) with respect to MacroGenics, [***] of work devoted to or in direct support of the Global Development Activities, pursuant to Section 4.2(c) or providing assistance to Company pursuant to Section 5.2 or Section 7.2 by one or more qualified employees or contractors or</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">consultants of Company or its Affiliates, as measured in accordance with MacroGenics' normal time allocation practices, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that, in each case ((a) and (b)) such employees or contractors or consultants must be [***]</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.42</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development FTE Costs</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means, with respect to any period, the Development FTE Rate multiplied by the number of Development FTEs expended by a Party during such period.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.43</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development FTE Rate</font>" means a rate of [***] per FTE per Calendar Year (pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year of the Term); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that such rate shall be increased or decreased annually beginning on January 4, 2016 by the [***]&#160; The Development FTE Rate is "fully burdened" and will cover employee salaries and such facilities and equipment and other materials and services, including ordinary laboratory consumables procured from distributors of relevant products as they may use.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.44</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development Transition Date</font>" means the earlier of (a) the IND Clearance Date for the IND for the first Phase 1 Trial of the Initial Product submitted by MacroGenics in accordance with Section 5.2(a), (b) the date on which the JSC determines that Company shall assume responsibility for the preparation and filing of such IND in accordance with Section 4.1(a) or (c) twelve (12) months after the Effective Date.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.45</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.46</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Effective Date</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means the first (1st) Business Day immediately following the date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act with respect to the transactions contemplated hereunder have expired or have been terminated.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.47</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">EMA</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means the European Medicines Agency or any successor agency(ies) or authority having substantially the same function.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.48</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***] and including, in each case, the territories and possessions of each country.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.49</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">European Union</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">EU</font>" means the European Union member states as then-currently constituted; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the EU shall always be deemed to include the [***].&#160; As of the Execution Date, the European Union member states are Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and United Kingdom.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.50</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Executive Officers</font>" means (a) with respect to Company, either (i) prior to the first Regulatory Approval, the Global Head of Research and Development (or his or her designee), and (ii) following the first Regulatory Approval, the president of U.S. oncology commercial operations (or his or her designee) and (b) with respect to MacroGenics, the Chief Executive Officer (or his or her designee)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.51</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Exploit</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">or "</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Exploitation</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">" means to research, make, have made, distribute, import, export, use, have used, sell, have sold, or offer for sale, Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured or otherwise dispose of a Compound or Product.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.52</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">FDA</font>" means the U.S. Food and Drug Administration and any successor agency(ies) or authority having substantially the same function.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.53</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">FFDCA</font>" means the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;301 et seq.), as amended from time to time.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.54</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Field</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means all uses, including the d<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">iagnosis, treatment or prevention of any disease in humans</font>.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.55</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">First Commercial Sale</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means, on a Product-by-Product and country-by-country basis, the first sale for monetary value of such Product under this Agreement by Company, its Affiliates or its sublicensees to an end user for use, consumption or resale of such Product in such country in the Field after Regulatory Approval of such Product has been obtained in such country in the Field, where such sale results in a Net Sale.&#160; Sale of a Product under this Agreement by Company to an Affiliate of Company or a sublicensee of Company shall not constitute a First Commercial Sale unless such Affiliate or such sublicensee is the end user of such Product.&#160; For the avoidance of doubt, the sale of Product for clinical study purposes, early access programs (such as to provide patients with a Product prior to Regulatory Approval pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or any similar uses shall not constitute a First Commercial Sale.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.56</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">First Position Detail</font>" means a Detail in which a Product is Detailed before any other product and a predominant portion of time is devoted to Detailing such Product.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.57</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Force Majeure</font>" means any event beyond the reasonable control of the affected Party, which may include embargoes; war or acts of war, including terrorism; insurrections, riots, or civil unrest; strikes, lockouts or other labor disturbances; epidemics, fire, floods, earthquakes or other acts of nature; acts, omissions or delays in acting by any Governmental Authority (other than delays incident to the ordinary course of drug development); and failure of plant or machinery.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.58</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">FPD</font>" means, with respect to a Clinical Trial, the first patient dosed in such Clinical Trial.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.59</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">FTE</font>" means, collectively, Development FTE, Commercial FTE and Sales Rep FTE.&#160; For clarity, no more than [***] per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year) may</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">be charged for a single individual contributing work factoring into any reimbursable FTE Costs hereunder, regardless of how much additional work time is contributed by such individual during such Calendar Year (or period beginning on the Effective Date and ending on the last day of the first Calendar Year), and any individual contributing less than [***] per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year) shall be deemed a fraction of an FTE on a pro-rata basis.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.60</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">FTE Costs</font>" means, collectively, Development FTE Costs and Commercial FTE Costs.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.61</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GAAP</font>" means generally accepted accounting principles in the U.S., consistently applied.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.62</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Global Development Activities</font>" means the following Development activities relating to the Initial Product:</font></div>

<div>
<table id="fbd3c726740b4f2c90ec8adccb2a3f82" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">performance of any Phase 2 Trial or Pivotal Trial of the Initial Product in accordance with the Global Development Plan;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="16f98af354054024812584c4d7dc377e" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Manufacturing of the Initial Product to conduct such Phase 2 Trial or Pivotal Trial (and associated Manufacturing Development (except to the extent expressly [***] Exhibit A)); and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="115b917e9c934d81ba3e29c9a1c2f9a6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">preparation, filing and maintenance of Regulatory Documentation directly supporting such Phase 2 Trial or Pivotal Trial and obtaining Regulatory Approval of the Initial Product;</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that Global Development Activities shall specifically exclude: [***]</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.63</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Global Development Costs</font>" means all of the following expenses related to Global Development Activities incurred by Company<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>or its Affiliates (or by MacroGenics or its Affiliates pursuant to Section 4.2(c)), regardless of whether such expenses are incurred before or during the Co-Funding Term:</font></div>

<div>
<table id="2d7b3488f4f84fd691169fabbb46cd44" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Third Party Expenses;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="17e19bffe6b34e019f4e7e4571f78e8c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Development FTE Costs; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f67ca620a262401d8065d42b3b27ecdf" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Product Liabilities arising from the conduct of the Global Development Activities before or during the Co-Funding Term (even if such Product Liabilities are not</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">incurred until after the Co-Funding Term), <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that any Product Liabilities for which a Party is obligated to indemnify the other Party pursuant to Section 15.1 or 15.2 because such Product Liabilities are Losses to which such other Party becomes subject as a result of a Claim (or would be Losses if such other Party became subject to such Product Liabilities as a result of a Claim) shall be expressly excluded from this definition of Global Development Costs and shall be the responsibility of such first Party to the extent that such first Party is (or would be) responsible for such Losses pursuant to ARTICLE 15.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">For purposes of clarity, Global Development Costs shall not include [***]</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.64</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Global Development Plan</font>" means the high-level, written plan attached hereto as <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit B</u></font> covering the planned Development of the Compounds and the Products, as amended from time to time in accordance with Section 4.2(b).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.65</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Good Clinical Practices</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GCP</font>" means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guideline adopted by the International Conference on Harmonization ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">ICH</font>"), titled "Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance" (or any successor document), including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA, PMDA, CFDA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.66</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Good Laboratory Practices</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GLP</font>" means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in 21 C.F.R. Part 58 (or any successor statute or regulation), including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA, PMDA, CFDA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable guidelines promulgated under the ICH.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.67</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Good Manufacturing Practices</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GMP</font>" means the then-current good manufacturing practices required by the FDA, as set forth in the FFDCA, as amended, and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical materials, and comparable Applicable Law related to the manufacture and testing of pharmaceutical materials in jurisdictions outside the U.S., including the quality guideline promulgated by the ICH designated ICH Q7A, titled "Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients" and the regulations promulgated thereunder, in each case as they may be updated from time to time.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.68</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Governmental Authority</font>" means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.69</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">HSR Act</font>" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time, and any comparable Applicable Law in jurisdictions outside the U.S. related to the approval of transactions similar to those contemplated under this Agreement.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.70</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">HSR Clearance Date</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means the expiration or termination of all applicable waiting periods and requests for information (and any extensions thereof) under the HSR Act.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.71</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">HSR Filing</font>" means (a) filings by Company and MacroGenics with the U.S. Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, together with all required documentary attachments thereto, or (b) equivalent filings with relevant foreign authorities.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.72</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">IND</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means (a) an Investigational New Drug application as defined in the FFDCA and applicable regulations promulgated thereunder by the FDA; (b) a clinical trial authorization application for a product filed with a Regulatory Authority in any other regulatory jurisdiction outside the U.S., the filing of which (in the case of (a) or (b)) is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction; or (c) documentation issued by a Regulatory Authority that permits the conduct of clinical testing of a product in humans in such jurisdiction.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.73</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">IND Clearance Date</font>" means, with respect to any IND, the date on which the sponsor of such IND is permitted to initiate clinical trials following submission of such IND to the applicable Regulatory Authority.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.74</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Indication</font>" means a [***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.75</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Information</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means information, inventions, discoveries, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, techniques, designs, drawings, correspondence, computer programs, documents, apparatus, results, strategies, Regulatory Documentation, information and submissions pertaining to, or made in association with, filings with any Governmental Authority or patent office, data, including pharmacological, toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, in written, electronic, oral or other tangible or intangible form, now known or hereafter developed, whether or not patentable.</font></font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.76</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Initial Product</font>" means the initial Product Developed hereunder that either (a) contains MGD011 as its sole active pharmaceutical ingredient, or (b) contains a different Compound approved for Development by mutual agreement of the Parties.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.77</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Invention</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means any invention, discovery or development, whether or not patentable, made, conceived or reduced to practice in the course of performance of this Agreement, whether made, conceived or reduced to practice solely by, or on behalf of, MacroGenics, Company, the Parties jointly, or any Affiliate of the same.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.78</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Johnson &amp; Johnson Universal Calendar</font>" means the calendar of a particular period of twelve (12) months that constitutes a financial year for the purposes of Johnson &amp; Johnson, a New Jersey corporation and the ultimate parent company of Company ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Johnson &amp; Johnson</font>"), and its Affiliates.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.79</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Know-How</font>" means all Information and Inventions Controlled by a Party that are necessary or useful to Exploit Compounds and/or Products in the Field in the Territory.&#160; Know-How excludes any Information contained within a Party's published Patents.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.80</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Knowledge</font>" means, as applied to a Party, that such Party shall be deemed to have knowledge of a particular fact or other matter to the extent that a reasonably prudent person with primary responsibility for the applicable subject matter (whether an officer or employee of such Party) knew or should have known of such fact or other matter.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.81</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MAA</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Marketing Authorization Application</font>" means an application for Regulatory Approval in any particular jurisdiction other than the U.S.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.82</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Inventions</font>" means Inventions Controlled by MacroGenics during the Term that are necessary or useful to Exploit Compounds or Products in the Field in the Territory.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.83</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Know-How</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> means all Know-How Controlled by MacroGenics as of the Execution Date or during the Term, including all MacroGenics Inventions.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.84</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Options</font>" mean, individually, the Co-Funding Option and the Co-Promote Option.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.85</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Out-of-Pocket Patent Costs</font>" means all Third Party Expenses incurred by MacroGenics pursuant to the filing, prosecution and maintenance of MacroGenics Patents.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.86</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Patents</font>" means all Patents Controlled by MacroGenics, as of the Execution Date or during the Term that: (a) Cover the composition of matter of, or the method of making or using, the sale or the importation of the Compounds or the Products; or (b) are otherwise necessary or useful to Exploit the Compounds or the Products in the Field in the Territory. The MacroGenics Patents as of the Execution Date include those set forth in <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit C</u></font>.&#160; The MacroGenics Patents include any Patents Covering MacroGenics Inventions.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.87</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Platform Patent</font>" means a MacroGenics Patent that is a Platform Patent.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.88</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Product Patent</font>" means a MacroGenics Patent that is a Product Patent.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.89</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Technology</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means, collectively, the MacroGenics Patents and the MacroGenics Know-How.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.90</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Trademarks</font>" means the trademark DART<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, trademarks which incorporate the acronym "DART", and related logos.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.91</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Major Markets</font>" mean the [***].</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.92</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacture</font>" means all activities and processes related to the manufacturing of a Compound or a Product, or any ingredient thereof, including manufacturing of finished Product for Development and Commercialization, labeling, packaging, in-process and finished Product testing, release of Product or any component or ingredient thereof, including Compound, quality assurance activities related to manufacturing and release of Compound or Product, and ongoing stability tests and regulatory activities related to any of the foregoing.&#160; Where the context so requires, Manufacture shall also include obtaining Product from contract manufacturers.&#160; When used as a verb, to "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacture</font>" means to engage in Manufacturing activities.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.93</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacturing Development</font>" means any of the following with respect to a Compound or Product: [***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.94</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MGD011</font>" means the compound with the chemical structure and amino acid sequence as set forth on <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit D</u></font>.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.95</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">N.A. Profit/Loss</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means the profits or losses resulting from the Commercialization of the Initial Product in the Northern American Territory, which shall be equal to [***]for the Initial Product.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.96</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">&#160;"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Net Sales</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means, with respect to any Product, the gross amounts invoiced by Company or any of its Affiliates or sublicensees for sales of such Product to unaffiliated Third Party purchasers in arms-length transactions, less the following deductions calculated in accordance with GAAP and standard internal policies and procedures and accounting standards consistently applied throughout Johnson &amp; Johnson, to the extent reasonable and customary, and specifically and solely allocated to such Product, whether fixed or variable, and actually taken, paid, accrued, allowed, included, or allocated based on good faith estimates in the gross sales prices with respect to such sales (and consistently applied as set forth below):</font></div>

<div>
<table id="8e32d64ec99b40e6b46d9cece1e673e6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">normal and customary cash, trade or quantity discounts, allowances, and credits allowed, in the form of deductions or fees actually allowed with respect to sales of such Product (to the extent not already reflected in the amount invoiced), excluding commissions for Commercialization of such Product;</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div>
<table id="aad9e41fe3c34ae4adbac8c15620d227" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">charge-back payments, rebates, administrative fees, and discounts (or equivalents thereof) payable to trade customers, managed health care organizations, pharmacy benefit managers (or equivalents thereof), group purchasing organizations, specialty pharmacy providers, federal, state/provincial, local, or other governments, or their agencies or purchasers or reimbursers;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9bdafd3174fe4a608bd362b9291c023b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">retroactive price reductions or credits actually granted upon rejections or returns of such Product, where such adjustments are limited to recalls or damaged goods, billing errors, reserves for returns, and the actual amount of any write-offs for bad debt;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="0e188d2171d8469b96fada84190ace28" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">outbound freight, shipment and insurance costs, to the extent included in the price and separately itemized on the invoice price;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="3cf21d17d52045dfb2d743e34c95f360" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">taxes (other than income taxes assessed against the income arising from the sale of such Product), duties, tariffs, mandated contribution or other governmental charges imposed on the sale of such Product, including customs duties, VAT (but only to the extent that such VAT are not reimbursable or refundable), excise taxes, use taxes and sales taxes, in each case to the extent included in the price and separately itemized on the invoice price;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9e8450458ef043f8ba0455f91cb36442" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">compulsory payments and cash rebates related to sales of such Product payable to a Governmental Authority (or agent thereof) pursuant to Applicable Law by reason of any national or local health insurance program or similar program, including government-levied fees resulting from healthcare reform policies and annual fees paid pursuant to the Patient Protection and Affordable Care Act ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">ACA</font>"), <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that such ACA annual fees shall be reasonably allocable to the Product; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="2f2d1cfc2de640e2a3a18b7f51e740fb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(g)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">amounts payable to patients through co-pay assistance cards or similar forms of rebate directly related to the prescribing of such Product.</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">All of the aforementioned deductions shall be determined, on a country-by-country basis, as incurred in the ordinary course of business in type and amount consistent with Company's or its applicable Affiliate's or sublicensee's (as the case may be) business practices consistently applied across its product lines and accounting standards and verifiable based on the Johnson &amp; Johnson sales reporting system.&#160; All such deductions shall be fairly and equitably allocated to such Product and other products of Company and its Affiliates and sublicensees, such that such Product does not bear a disproportionate portion of such deductions.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Notwithstanding the foregoing, amounts invoiced by Company, its Affiliates, or its sublicensees for the sale of a Product among Company, its Affiliates or its sublicensees for resale shall not be included in the computation of Net Sales hereunder unless such Affiliate or such sublicensee is the end user of such Product and as long as such Product is subsequently resold to a Third Party end user.&#160; In addition, the following shall not be included in the computation of Net Sales: (i) transfer or dispositions of reasonable quantities of samples of a Product at no cost for promotional or educational purposes, (ii) transfers or dispositions of reasonable and customary quantities of a</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Product as free samples or donations, or for patient assistance, testing marketing programs or other similar programs at no cost, and (iii) sales of a Product for clinical study or other scientific testing purposes, early access programs (such as to provide patients with such Product prior to Regulatory Approval pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or any similar use.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">With respect to sales of any Combination Product in a country, the Parties shall determine Net Sales for such Combination Product in such country by mutual agreement based on the relative contribution of the Product and the other active ingredient(s) in the Combination Product.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">With respect to any Product that is sold in combination with services from Company or the selling Affiliate or sublicensee, where the customer receives a specific discount for the bundling of products or services, the Net Sales of such Combination Product or Product shall be determined by the mutual agreement of the Parties.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.97</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Northern American Territory</font>" shall mean the U.S. and Canada, including in each case the territories and possessions of such country.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.98</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Patents</font>" means all: (a) patents, including any utility or design patent; (b) patent applications, including provisionals, substitutions, divisionals, continuations, continuations in-part or renewals; (c) patents of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-issues and re-examinations; (d) other patents or patent applications claiming priority directly or indirectly to (i) any such specified patent or patent application specified in (a) through (c), or (ii) any patent or patent application from which a patent or patent application specified in (a) through (c) claim direct or indirect priority; (e) inventor's certificates; and (f) other rights issued from a Governmental Authority similar to any of the foregoing; in each case of (a) through (f), irrespective of whether such patent, patent application or other right arises in the U.S. or any other jurisdiction in the Territory.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.99</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Person</font>" means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.100</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 1 Trial</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means a clinical trial of the Product that (a) (i) is a first-in-humans trial on subjects who are patients, (ii) is for the purposes of establishing initial safety, tolerability, pharmacokinetic and pharmacodynamic Information for the Product, (iii) exposes subjects to the Product and (iv) is designed to provide the sponsor of the clinical trial with sufficient Information about the Product to initiate a Phase 2 Trial; or (b) meets the definition in 21 C.F.R. &#167;312.21(a) or any of its foreign equivalents.&#160; Solely for purposes of determining which activities are "Global Development Activities" that are included in "Global Development Costs" shared pursuant to Section 8.2 during the Co-Funding Term, any Phase 1/2 Trial included in the Global Development Plan shall be treated as a [***]</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.101</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 1/2 Trial</font>" means a clinical trial of the Product that combines both a Phase 1 Trial and a Phase 2 Trial of such Product into a single protocol, where the Phase 1 Trial portion is performed first to (i) to establish initial safety, tolerability, pharmacokinetic and pharmacodynamic Information for the Product as a monotherapy or in combination with another agent or (ii) determine the Maximum Tolerable Dose ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MTD</font>") of such Product in subjects, and the Phase 2 Trial portion is performed second to further evaluate safety and/or efficacy of such Product as a monotherapy or in combination with another agent in subjects treated with a selected dose.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.102</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 2 Trial</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means a clinical trial of the Product (a) with the endpoint of evaluating its effectiveness for a particular Indication or Indications, its short term tolerance and safety, as well as its pharmacokinetic and pharmacodynamic Information in patients with the Indications under study and is not intended to be pivotal to support Regulatory Approval for the Product; or (b) that meets the definition in 21 C.F.R. &#167;312.21(b) or any of its foreign equivalents</font>.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.103</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 2/3 Trial</font>" means a Phase 2 Trial involving a sufficient number of subjects that, prior to commencement of the trial or at any other defined point in the trial, satisfies both of the following ((a) and (b)):</font></div>

<div>
<table id="c454284248064e30bcb9524611075e78" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">such trial is designed to (i) establish that the Product is safe and efficacious for its intended use, and (ii) define and determine warnings, precautions, and adverse reactions that are associated with the Product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such Product or a similar clinical study prescribed by the FDA; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="853b5dc2fb4c4425860a615010795590" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">such trial is or becomes a registration trial sufficient for filing an application for a Regulatory Approval for such Product in the U.S., as evidenced by (i) an agreement with or statement from the FDA on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA, for such registration trial.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.104</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 3 Trial</font>"<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means a clinical trial of the Product (a) on a sufficient number of patients, which trial (i) is designed to establish that the Product is safe and efficacious for its intended use, (ii)&#160; is designed to define warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed, and (iii) is pivotal to support Regulatory Approval for the Product; or (b) that meets the definition in 21 C.F.R. &#167;312.21(c) or any of its foreign equivalents</font>.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.105</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 4 Trial</font>" means a clinical trial of a Product, possibly including pharmacokinetic studies, which trial (a) is not required to be completed prior to obtaining Regulatory Approval of an Indication; and (b) either (i) is required by the applicable Regulatory Authority as mandatory to be conducted on or after the Regulatory Approval of an Indication, or (ii) is conducted voluntarily to enhance marketing or scientific knowledge of the Product (e.g., providing additional drug profile, safety data or marketing support Information, or supporting expansion of Product labeling).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.106</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Pivotal Trial</font>" means a Phase 2/3 Trial and/or a Phase 3 Trial.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.107</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Platform Claim</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means a Patent claim that Covers [***]</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.108</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Platform Patent</font>" means a Patent that includes a Platform Claim and no Product Claims.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.109</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">PMDA</font>" means the Pharmaceuticals and Medical Devices Agency in Japan and any successor agency(ies) or authority having substantially the same function.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.110</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.111</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.112</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Product</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">any pharmaceutical product, including all forms, presentations, strengths, doses and formulations (including any method of delivery), containing a Compound alone or in combination with other active pharmaceutical ingredients (other than any active pharmaceutical ingredient that is owned or controlled by MacroGenics or any of its Affiliates that is not a Compound), including any </font>Combination Product.&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">For the sake of clarity, all forms, presentations, doses and formulations of a pharmaceutical product containing a Compound shall be considered the same Product for purposes of this Agreement, so long as each form, presentation, dose and formulation contains the same Compound and other active pharmaceutical ingredients (and no other Compounds or other active pharmaceutical ingredients).</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.113</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Product Claim</font>" <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">means a Patent claim that (a) Covers [***]</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.114</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Product Liabilities</font>" means all Losses incurred by Company, its Affiliate or its sublicensee and resulting from or relating to the use of a Compound and/or a Product in a human (including Clinical Trials and/or Commercialization) in the Territory incurred after the Effective Date.&#160; For the avoidance of doubt, Product Liabilities shall include (i) reasonable attorneys' and experts' fees and costs relating to any claim or potential claim against a Party, its Affiliate, or its sublicensee and all losses, damages, fees and costs associated therewith, and (ii) Losses associated with recalls and/or the voluntary or involuntary withdrawal of the Compound and/or the Product</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">(except to the extent a Party is obligated to indemnify the other Party pursuant to Section 15.1 or 15.2 for such Losses) and (iii) fines, penalties, assessments or other financial sanctions levied by any Governmental Authority related to such a claim (except to the extent a Party is obligated to indemnify the other Party for such amounts pursuant to Section 15.1 or 15.2 because such amounts are Losses to which such other Party becomes subject as a result of a Claim (or would be Losses if such other Party became subject to such amounts as a result of a Claim)).</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.115</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Product Patent</font>" means any Patent that does not include a Platform Claim and includes a Product Claim.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.116</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Product Target</font>" means the combination of both the CD3 and CD19 targets. "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">CD3</font>" means [***]&#160; "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">CD19</font>" means [***]</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.117</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Promotional Materials</font>" means all written, printed, graphic, electronic, audio or video presentations of Information, including journal advertisements, sales visual aids, formulary binders, reprints, direct mail, direct-to-consumer advertising, disease awareness materials, internet postings, broadcast advertisements and sales reminder aides (for example, note pads, pens and other such items, if appropriate), which, in each case, are permitted under Applicable Law and intended for use or used by or on behalf of a Party, its Affiliates or its sublicensees in connection with the Commercialization of the Product in the Territory.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.118</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Approval</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means any and all approvals (including supplements, amendments, pre- and post-approvals), licenses, registrations or authorizations of any national, regional, state or local Regulatory Authority, department, bureau, commission, council or other governmental entity, that is necessary to market and/or sell a Product in any country or jurisdiction in the Territory for one or more uses, including any pricing and reimbursement approvals that are necessary to conduct a launch of such Product in such country or jurisdiction (even if such approvals are not legally required to launch such Product in such country or jurisdiction).&#160; [***]</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.119</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Approval Application</font>" means a New Drug Approval Application or Biologics License Application (each, as defined in the FFDCA) in the U.S., or any corresponding application for Regulatory Approval in any country or jurisdiction in the Territory outside the U.S., including, with respect to the European Union, an MAA filed with the EMA pursuant to the Centralized Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the decentralized procedure, mutual recognition or any national approval procedure.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.120</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Regulatory Authority</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">" means any applicable Governmental Authority involved in granting Regulatory Approval in a country or jurisdiction in the Territory, including (a) in the U.S., the FDA and any other applicable Governmental Authority having jurisdiction over a Product; (b) in the EU, the EMA or any other applicable Governmental Authority in the EU having jurisdiction over a Product; (c) in Japan, the PMDA; (d) in China, the CFDA; and (e) in any country or jurisdiction other than the U.S., EU, Japan or China, any applicable Governmental Authority having jurisdiction over a Product.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.121</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Documentation</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means, with respect to any Compound or Product, all regulatory filings and supporting documents created, for, submitted to or received from an applicable governmental agency or Regulatory Authority relating to such Compound or Product, and all data contained therein, including all Regulatory Materials, as well as the contents of any minutes from meetings (whether in person or by audio conference or videoconference) with Regulatory Authorities, registrations and licenses, regulatory drug lists, advertising and promotion documents shared with Regulatory Authorities, adverse event files, complaint files and Manufacturing records.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.122</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Exclusivity</font>" means any exclusive marketing rights or data protection or other exclusivity rights conferred by any Regulatory Authority with respect to a Product in a country or jurisdiction in the Territory, including orphan drug exclusivity, pediatric exclusivity, rights conferred in the U.S. under the Drug Price Competition and Patent Term Restoration Act (21 U.S.C. &#167;355), as amended (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Hatch-Waxman Act</font>"), the ACA or in the European Union under Directive 2001/83/EC, as amended, and Regulation (EC) No. 1901/2006, as amended, or rights similar thereto in other countries or regulatory jurisdictions in the Territory, that prevent such Regulatory Authority from granting any regulatory approval under the Biologics Price Competition and Innovation Act or similar Applicable Law, of a Third Party product that has an amino acid sequence that is the same as or substantially identical to the amino acid sequence of such Product; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, in the event that a Regulatory Authority confers more than one type of exclusivity with respect to a Product in a country or jurisdiction (e.g., the FDA grants both new chemical entity exclusivity and orphan drug exclusivity with respect to such Product), "Regulatory Exclusivity" will be deemed to apply to such Product in such country so long as any Regulatory Exclusivity granted to such Product prevents such Regulatory Authority from granting any regulatory approval under the Biologics Price Competition and Innovation Act, or similar Applicable Law, of a Third Party product that has an amino acid sequence that is the same as or substantially identical to the amino acid sequence of such Product.&#160; Regulatory Exclusivity shall not include exclusivity conferred by a Patent right.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.123</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Materials</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means regulatory applications, submissions, notifications, registrations, Regulatory Approvals or other regulatory submissions, including any written correspondence or meeting minutes, made to, made with, or received from a Regulatory Authority that are necessary or reasonably desirable in order to research Develop, Manufacture, or Commercialize a Product in a particular country or jurisdiction in the Territory.&#160; Regulatory Materials include INDs and Regulatory Approval Applications, and amendments and supplements for any of the foregoing, and applications for pricing and reimbursement approvals.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.124</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Royalty Term</font>" means, [***], the time period beginning with the First Commercial Sale of such Product in such country and continuing until the later of:&#160; (a) the expiration of the last Valid Claim Covering the composition of matter or the method of making or using such Product included in a MacroGenics Patent licensed to Company under the Company License; (b) [***]; or (c) if Regulatory Exclusivity is granted with respect to such Product in such country, the expiration or termination of such Regulatory Exclusivity in such country.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.125</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Second Position Detail</font>" means a Detail in which a Product is Detailed in the second position (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">i.e.</font>, no more than one other product is presented to or discussed with the applicable healthcare professional before such Product) and the second most predominant portion of time is devoted to the Detailing of such Product.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.126</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Tax</font>" or "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Taxes</font>" means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including any interest thereon).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.127</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Territory</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means any country in the world.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.128</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means any Person other than (a) Company, (b) MacroGenics or (c) an Affiliate of either of Company or MacroGenics.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.129</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party Expenses</font>" means out-of-pocket expenses incurred by a Party or any of its Affiliates for services performed by a Third Party on behalf of Company or MacroGenics in the course of such Party's performance of this Agreement. For clarity, such Third Party Expenses will include the costs of any raw materials and resins used for Manufacture of clinical trial material.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.130</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">&#160;"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">U.S.</font>" means the United States of America, including its territories and possessions.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">1.131</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">U.S. Commercialization Plan</font>" means a plan, prepared by Company pursuant to Section 6.1 in the event that MacroGenics exercises the Co-Promote Option, for the coordination of Detailing activities in the U.S.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">1.132</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Valid Claim</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means (a) a claim of an issued and unexpired Patent, to the extent such claim has not been revoked, held invalid or unenforceable by a patent office, court or other Governmental Authority of competent jurisdiction in a final order, from which no further appeal can be taken, and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b) a claim within a</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">patent application that has not been pending for more than [***]from the date of its first priority patent application filing anywhere in the Territory and which claim has not been revoked, cancelled, withdrawn, held invalid or abandoned.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Additional Definitions</u></font>.&#160; Each of the following definitions is set forth in the Section of this Agreement indicated below:</div>

<div><br>
</div>

<table id="930c671128444738805f308c91b213cd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>Definition</u></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>Section</u></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">ACA</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.96</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Advertising and Market Research Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Agreement</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Preamble</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Approval Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Approval Milestone Payment</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Bankruptcy Laws</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.7(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Breaching Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">CD3</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.116</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">CD19</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.116</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Claim</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">15.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Clinical Supply Agreement</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">7.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Approval Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(c)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Approval Milestone Payment</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(c)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Materials</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Option</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Option Deadline</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Option Exercise Notice</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Opt-Out</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(e)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Opt-Out Notice</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(e)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Sales Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(e)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Funding Sales Milestone Payment</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(e)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Commercialization Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Company</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Preamble</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Company Detailing Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Company Indemnitee</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">15.2</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Company License</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">3.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Cooperating Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">12.5(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Promote Materials</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.3(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Promote Option</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Promote Option Exercise Notice</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Co-Promotion Agreement</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.3(c)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Cost Cap</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(d)(iii)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Cost Per PDE</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Cost Variances</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">14.3</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Cure Period</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Development Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Development Milestone Payment</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Disclosing Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">12.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dispute(s)</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">14.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Distribution Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">EAP Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Education Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Execution Date</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Preamble</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">GDC Invoice</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(d)(ii)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">GDC Late Payment Notice</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(d)(ii)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">GDC Repayment Option</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">8.2(e)(iii)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Good Faith Dispute</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.4</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Hatch-Waxman Act</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.122</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">ICH</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.65</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Incumbent Board</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.13</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Indemnifying Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">15.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Indemnitee</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">15.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Infringement Recovery</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.5(d)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Insolvency Event</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.7(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Insolvent Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.7(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Johnson &amp; Johnson</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.78</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Joint Inventions</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Joint Patents</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.3(d)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">JSC</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2.1(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Licensed Patents</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">11.2(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Losses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">15.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">MacroGenics</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Preamble</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">MacroGenics Indemnitee</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">15.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Manufacturing Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Manufacturing Process</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">7.2(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Manufacturing Technology Transfer</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">7.2(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Manufacturing Transition Plan</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">7.2(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Marketing Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Marketing Management Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Medical Affairs Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Milestone Events</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Milestone Payments</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">MTD</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.101</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Non-Insolvent Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.7(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Other Costs</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Other Costs Not Included in Standard</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Party/Parties</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Preamble</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Patent Extension(s)</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.4</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">PDE</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Phase 4 Trial Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Prior CDA</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Protocol</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">14.3(b)(iii)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">PVA</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">5.3(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Quarterly N.A. Profit/Loss Report</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.9(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Recall Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Receiving Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">12.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Requesting Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">12.5(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Reverted Product</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.8(a)(iv)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sales Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(d)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sales Milestone Payment</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.3(d)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sales Rep FTE</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sales Rep FTE Rate</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sales Rep PDE Total</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Selling Costs</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Sole Inventions</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Standard Cost of Goods Manufactured</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Term</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.1</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Terminated Country</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.8</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Terminated Product</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.8</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Terminating Party</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">13.3(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Third Party Obligation</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">9.10(a)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Third Party Obligation Expenses</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Exhibit A</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Third Party Patent Challenge</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">10.7(b)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 50.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Transition Plan</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 49.11%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">4.1(b)</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 2</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> GOVERNANCE</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">2.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Joint Steering</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>&#160;</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Committee</u></font>.</font></div>

<div>
<table id="3551fa6e362a4ec2b279139ed3176321" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Formation and Purpose</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The Parties agree to establish and convene a joint steering committee (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">JSC</font>") within [***] after the Effective Date. The JSC shall consist of representatives from each Party as further described in Section 2.1(d) and operate in accordance with this Section 2.1. The purpose of the JSC shall be to provide a forum for the overall coordination, communication and oversight of the Parties' activities under this Agreement, including the resolution of disputes properly referred to the JSC under this Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="27117f7e25624876ac4838c856b5384c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Responsibilities of the JSC</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The JSC's overall responsibility shall be to:</div>
</td>
</tr>
</table>
</div>

<div>
<table id="3af614bc259749c9951934e07633632e" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">discuss, approve and oversee MacroGenics Development, regulatory and Manufacturing activities with respect to the Initial Product;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="25df75f25f5548f187ffbbf234a3622f" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">discuss, approve and oversee the Transition Plan and Manufacturing Transition Plan;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="fc09bd534ba7483aaae213b29f2b38d1" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">if MacroGenics exercises the Co-Funding Option in accordance with Section 8.2(a), encourage and facilitate communication and information sharing regarding Global Development Activities and Commercialization of the Initial Product in the Northern American Territory, including&#160; review and discussion of Company's then-current Global Development Plan, during the Co-Funding Term;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="94392b882a3745e0aa2666a4b6e212ce" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">coordinate the fulfillment of those rights and obligations arising from MacroGenics' exercise of any of the MacroGenics Options;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="2fc6fb5224864c1b8f2dcef936783666" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">decide matters and resolve disputes referred to the JSC which the JSC has authority to decide or resolve under this Agreement; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="075b0d72add442fbab9fdb889eb3f208" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(vi)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">perform other obligations specifically delegated to it under this Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="30eb7097bcb74524ab44c6d85d51b76f" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">JSC Decisions and Actions</font>.&#160; Actions to be taken by the JSC shall be taken only following [***], with each Party having [***].&#160; If the JSC fails to reach unanimous agreement on a matter before it for decision within [***][***]from the date that the matter is first presented to the JSC in writing, such matter shall be referred to the Executive Officers for discussion and resolution pursuant to Section 14.2.&#160; Any resolution of such matter by the Executive Officers shall be final and binding on the Parties.&#160; If the Executive Officers are not able to resolve the matter within the [***] period specified in Section 14.2, then [***] with respect to such matter, and [***] on such matter shall be final and binding on the Parties, subject to the limitations set forth in Section 2.5.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="d4f39ca494d647d3b6d8d2d23bac720b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">JSC Membership</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>Promptly after the Effective Date, each Party shall designate three (3) such representatives for the JSC.&#160; The JSC may elect to vary the number of representatives from time to time, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that, unless otherwise agreed by the Parties in writing at the JSC, the JSC shall maintain an equal number of representatives from each Party.&#160; Each representative shall have the appropriate level of experience in the subject area of the JSC, and at least one (1) representative shall have sufficient seniority within the applicable Party's organization to have the necessary decision-making authority in order for the JSC to fulfill its responsibilities.&#160; Either Party may designate substitutes for its JSC representatives if one (1) or more of such Party's designated representatives is unable to be present at a meeting.&#160; From time to time each Party may replace its JSC representatives by written notice to the other Party specifying the prior representative(s) and their replacement(s).&#160; Each representative shall be bound by confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="870b8531e9ca4e6ba5803882f7986226" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">JSC Chairperson</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The JSC will have a chairperson, to be designated by Company.&#160; The chairperson shall be responsible for calling and convening meetings, but shall have no special authority over the other members of the JSC, and shall have no additional voting rights.&#160; The chairperson (or its designate) shall: (i) prepare and circulate an agenda reasonably in advance of each upcoming meeting; and (ii) prepare and issue minutes of the JSC meeting within thirty (30) days thereafter.&#160; Such minutes shall not be finalized until each JSC representative reviews and approves such minutes, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that any minutes shall be deemed approved unless a JSC representative objects to the accuracy of such minutes within [***] after the circulation of the minutes.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="fc9023a6a89d473893b5d58111fe4ad9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Meetings</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="92dbce84d6e6465fbe578569e3deae49" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Timing and Frequency</font>.&#160; No later than [***] after the Effective Date, the JSC will hold an in-person meeting to establish the JSC's operating procedures.&#160; The JSC shall meet at least once every Calendar Quarter until the later of the Co-Funding Option Deadline or the final Co-Promote Option Deadline, at which time the JSC shall dissolve; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, (A) in the event MacroGenics exercises the Co-Funding Option, the JSC shall meet at least once every Calendar Quarter until the end of the end of the Co-Funding Term, unless otherwise agreed by the Parties, and (B) in the event that MacroGenics exercises the Co-Promote Option oversight of Co-Promotion activities shall be as specified in the Co-Promotion Agreement. Additional meetings of the JSC may be held with the consent of each Party (such consent not to be unreasonably withheld, delayed or conditioned), as required under this Agreement or to resolve any matter or dispute referred to the JSC in accordance with this Agreement.&#160; In the case of any matter or dispute referred to the JSC, such meeting shall be held within ten [***] following referral to the JSC, or as soon as reasonably possible thereafter.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="73321b0a6b09421b8b5a231e671a6cab" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Meeting Procedures</font>.&#160; Meetings of the JSC shall be effective only if a majority of representatives of each Party are present or participating.&#160; Other than the initial meeting, the JSC may meet either (i) in person at either Party's facilities or at such locations as the Parties may otherwise agree, at least</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">&#160;twice every Calendar Year; or (ii) by audio or video teleconference.&#160; Each Party shall be responsible for all of its own expenses incurred in connection with its representatives' participation in the JSC meeting, including all travel and lodging.&#160; All other Third Party expenses incurred by the JSC in furtherance of a JSC meeting, such as expenses associated with off-site meetings, shall be shared equally by the Parties.</div>

<div>
<table id="f947dd89a07c448bbbd5022dfa82c888" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Non-Member Participation</font>.&#160; Additional non-members of the JSC having relevant experience may from time to time be invited to participate in a JSC meeting, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that such participants shall have no voting rights or powers.&#160; Non-member participants who are not employees of a Party or its Affiliates shall only be allowed to attend if: (i) the other Party's representatives have consented to the attendance (such consent not to be unreasonably withheld, delayed or conditioned); and (ii) such non-member participant is subject to confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">2.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Additional Subcommittees and Working Groups</u></font>.&#160; The JSC may establish other subcommittees or working groups, as needed to further the purposes of this Agreement, including any responsibilities assigned to the JSC under this Agreement; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the JSC shall not delegate its dispute resolution authority.&#160; In particular, if MacroGenics exercises the Co-Funding Option, the Parties contemplate establishment of a Joint Development Committee to facilitate communication regarding Global Development Activities during the Co-Funding Term and a Joint Marketing Committee to facilitate communication and information sharing regarding the Commercialization of the Initial Product in the Northern American Territory. The purpose, scope and procedures of any such subcommittee or working group shall be mutually agreed in writing by the JSC.&#160; Actions to be taken by any subcommittee or working group shall be taken only following unanimous vote, with each Party having one (1) vote.&#160; If any subcommittee or working group fails to reach unanimous agreement on a matter before it for decision relating to the Development or Commercialization of Products for a period in excess of [***]from the date that the matter is first presented to such subcommittee or working group in writing, such matter shall be referred to the JSC for resolution pursuant to Section 2.1(c).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">2.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Authority</u></font>.&#160; The Parties agree that it shall be conclusively presumed that, unless otherwise explicitly stated, each voting member of the JSC, or each subcommittee or working group established by the JSC, has the authority and approval of such member's respective senior management in casting his or her vote. The JSC, and each subcommittee or working group established by the JSC, shall each have only the powers assigned expressly to the JSC in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend or modify the Global Development Plan or the U.S. Commercialization Plan or to amend, modify or waive compliance with this Agreement.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">2.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Alliance Managers</u></font>.&#160; Promptly following the Effective Date, each Party shall designate in writing an Alliance Manager to serve as the primary point of contact for the Parties regarding all collaboration activities contemplated under this Agreement.&#160; Each Alliance Manager shall facilitate communication and coordination of the Parties' activities under this Agreement relating to the Compounds and the Products.&#160; The Alliance Managers shall not be a member of the JSC.&#160; The Alliance Managers shall be allowed to attend, as a non-voting observer, meetings of the JSC, as well as any subcommittee or working group established by the JSC of which the Alliance Manager is not a member.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">2.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Decision-Making Restrictions</u></font>.&#160; Notwithstanding anything to the contrary in this Agreement, to the extent that [***] with respect to any matter pursuant to Section 2.1(c), [***] shall not [***]:&#160; (i) expand [***] or [***] or [***]or [***], under this Agreement; (ii) determine that [***], or [***], under this Agreement; (iii[***]that is expressly stated to [***] or [***] or the [***] or [***] and; (iv) resolve any dispute regarding whether a [***] or the [***].</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 3</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> LICENSES</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">3.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>License to Company</u></font>.&#160; Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Company an exclusive (even as to MacroGenics), royalty-bearing, non-transferable (except in accordance with Section 16.4) license, with the right to grant sublicenses as provided in Section 3.1(a), under the MacroGenics Technology, to Exploit the Compounds and the Products in the Field in the Territory (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company License</font>").</font></div>

<div>
<table id="76e9d01e056842e0b65db4cc7e3a122b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sublicensing</font>. Company shall have the right to grant sublicenses of the rights granted to Company under this Section 3.1 to:&#160; (i) its Affiliates through multiple tiers; and (ii) Third Parties through multiple tiers subject to the conditions in this subsection (a) provided below.&#160; Any sublicenses to Third Parties [***] that include [***] may only be granted with MacroGenics' prior consent, not to be unreasonably withheld, conditioned or delayed, unless such sublicense is: (A) in connection with, and only to the extent necessary or useful to enable, a Third Party to perform services for the Company, its Affiliate or sublicensee in the course of its performance of its Development, Manufacturing and Commercialization rights and obligations under this Agreement; and (B) to one or more Third Party distributors only to the extent reasonably necessary or useful, to enable such Third Party distributors to Commercialize Products in such</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">countries.&#160; Company shall identify each Third Party sublicensee to MacroGenics for which Company has [***]&#160; Each sublicense shall refer to and be subordinate to this Agreement and, except to the extent the Parties may otherwise agree in writing, any sublicense must be consistent in all material respects with the terms and conditions of this Agreement.&#160; Company shall remain responsible for the performance of this Agreement and the performance of its sublicensees hereunder.&#160; Company shall provide to MacroGenics copies of all sublicenses which grant the right to directly [***] to a Third Party in a jurisdiction in the Territory, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company shall have the right to redact commercially sensitive information from such copies.&#160; Information regarding the scope of the license grants, territory and/or term of each such sublicense shall not be considered commercially sensitive.</div>

<div>
<table id="83462795495c48d49e7fb509793e815c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Termination of License</font>.&#160; Company shall have the right to terminate the Company License with respect to one or more of the MacroGenics Patents included in the Company License, by providing [***] prior written notice to MacroGenics specifying the MacroGenics Patent(s) to be subject to such termination.&#160; Upon the effectiveness of such termination, (i) the Company License will no longer extend to such MacroGenics Patent(s); (ii) such MacroGenics Patent(s) shall no longer be subject to the provisions of ARTICLE 10, and MacroGenics shall have the sole right to prosecute, maintain, enforce and defend such MacroGenics Patent(s) at MacroGenics' sole expense; and (iii) no claims of such MacroGenics Patent(s) shall be considered a Valid Claim for purposes of Section 9.5 or Section 9.6.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">3.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Licenses to MacroGenics</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Subject to the terms and conditions of this Agreement:</font></div>

<div>
<table id="f1a9f57659894c18968f0e3ad2da476d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company hereby grants back to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section 16.4), non-sublicensable sublicense under the Company License for use with the Compounds and the Products in the Field in the Territory, solely to the extent necessary for MacroGenics to exercise its rights and perform its obligations under this Agreement, including any rights or obligations that arise in the event MacroGenics elects to exercise any of the MacroGenics Options.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="5fbff633208a45888ba8f2adb4e4c766" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company hereby grants back to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section 16.4), non-sublicensable license under (i) the Company Technology, (ii) any Know-How Controlled by Company, as of the Execution Date or during the Term, that is incorporated into the embodiment of a Product Developed hereunder, and (iii) any Patent Controlled by Company, as of the Execution Date or during the Term, that Covers technology incorporated into the embodiment of a Product Developed hereunder, in each case ((i), (ii) and (iii)), for use with the Compounds and the</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">Products in the Field in the Territory, solely to the extent necessary for MacroGenics to exercise its rights and perform its obligations under this Agreement, including any rights or obligations that arise in the event MacroGenics elects to exercise any of the MacroGenics Options.</div>

<div>
<table id="005044128b614ff9965157ebb45ff738" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company hereby grants back to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section 16.4), non-sublicensable license under the Company License to [***], <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that MacroGenics shall not [***] without the prior written consent of Company.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="556d39e3b53a494d846298963728278a" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company hereby grants to MacroGenics a non-exclusive, fully-paid, royalty-free, non-transferable (except in accordance with Section 16.4) license, with the right to sublicense, under any Platform Patent Controlled by Company by virtue of the use of the MacroGenics Know-How or exercise of the Company License and that claims technology applied to a Product, [***]</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">3.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Trademark License</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>MacroGenics hereby grants Company a non-exclusive license to use the MacroGenics Trademarks in connection with the Development and Commercialization of the Products, subject to customary and reasonable quality control procedures to be mutually agreed upon by the Parties prior to the launch of any Products.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">3.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>No Implied Licenses</u></font>.&#160; All licenses and rights are granted only as expressly provided in this Agreement and no license or other right is or shall be created or granted under this Agreement by implication, estoppel, or otherwise.&#160; All rights not expressly granted by a Party under this Agreement are reserved by such Party and may not be used by the other Party for any purpose.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 4</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> DEVELOPMENT</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Transition of Development Responsibilities</u></font>.</font></div>

<div>
<table id="910a0e4ca4524fe4a19062840295a2ea" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the period beginning on the Effective Date and ending on the Development Transition Date, MacroGenics shall use diligent efforts to perform (i) all Development activities necessary to <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>, other than <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>, and (ii) any Development activities assigned to MacroGenics in the Transition Plan;&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, in the event that MacroGenics does not</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>&#160; after the Effective Date, upon Company's request, the JSC shall discuss and determine whether Company should assume responsibility for the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>.&#160; If the JSC determines that Company should assume responsibility for the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>, then, promptly following such determination, MacroGenics shall transfer to Company all Information Controlled by MacroGenics that is reasonably necessary for Company to <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> and provide reasonable assistance to Company with respect to the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>.&#160;&#160; </div>

<div>
<table id="58d3a71958ed443fb11c4972776aced9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">[***] following the Development Transition Date, MacroGenics shall transfer to Company, and Company shall cooperate in good faith to support MacroGenics' transfer of, all activities and responsibilities related to the Compounds and the Products in accordance with a transition plan to be approved by the JSC promptly after the Effective Date (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Transition Plan</font>").&#160; The Transition Plan shall be designed to effect an efficient transfer from MacroGenics to Company of all Compound and Product-related Development, Manufacturing, regulatory and other related responsibilities and documentation, as well as all Information Controlled by MacroGenics that is reasonably necessary or useful for Company's Exploitation of the Compounds and the Products (including copies or tangible embodiments thereof), and may be updated and amended by the JSC as necessary to effect such transfer.&#160;&#160; The Transition Plan shall include an itemized list of deliverables and the dates by which such deliverables are expected to be provided by MacroGenics to Company.&#160; Any dispute between the Parties regarding the conduct of the activities set forth in the Transition Plan shall be referred to the JSC for resolution.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="02b44673185241278069e84919398cc9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">MacroGenics shall report on the status of any activities conducted pursuant to this Section 4.1 at each meeting of the JSC or as otherwise requested by Company.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Development</u></font>.</font></div>

<div>
<table id="bfa11570afef4a6d91e8ec3e47c9ef58" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Development</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Activities</font>.&#160; Except for Development activities to be undertaken prior to the Development Transition Date by MacroGenics pursuant to Section 4.1, Company shall be solely responsible for and have sole authority with respect to, at its own expense (subject to MacroGenics' exercise of the Co-Funding Option), all Development of the Compounds and the Products.&#160; Company shall use Commercially Reasonable Efforts to Develop, and to seek Regulatory Approval for, [***]&#160; In addition, Company shall use Commercially Reasonable Efforts to [***]</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div>
<table id="4a9b6915d5ea4f49a75ea21e58d9e1dc" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Global Development Plan</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Except with respect to [***] as specified below, Company shall use Commercially Reasonable Efforts to conduct the Development of the Products for the Territory in accordance with the Global Development Plan, at its own expense (subject to MacroGenics' sharing of expenses upon its exercise of the Co-Funding Option).&#160; Company shall have the right to make amendments to the Global Development Plan, which shall be consistent with Company's Development obligations set forth in Section 4.2(a), and each amended Global Development Plan shall include all material Development activities anticipated to be required to obtain Regulatory Approval for Products in [***], as well as timelines regarding such activities, including the plans and timelines for preparing the necessary Regulatory Materials.&#160; The Global Development Plan shall include any Development activities with respect to [***] that Company elects to conduct, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company shall have no obligation to conduct Development or to seek Regulatory Approval for Products in [***].&#160; Beginning with the delivery of the Co-Funding Materials and continuing through the Co-Funding Option Deadline (if MacroGenics does not exercise the Co-Funding Option) and the Co-Funding Termination Date (if MacroGenics exercises the Co-Funding Option), Company shall update the Global Development Plan to include a then-current, non-binding budget for any Global Development Costs.&#160; During the Co-Funding Term, Company shall update and amend, as appropriate, the then-current Global Development Plan and shall submit such updates and/or amendments for review to the JSC.&#160; While the Global Development Plan shall not require the approval of the JSC, Company shall review and consider all comments to the Global Development Plan received from MacroGenics at the JSC in good faith.&#160; Company will consider including, in the Global Development Plan, Clinical Trials using the Initial Product [***] or other products, to the extent that Company reasonably determines that such Clinical Trials are feasible from a medical, scientific, regulatory and commercial perspective.&#160; The Parties acknowledge and agree that Company's ability to conduct such Clinical Trials may be subject to [***] and that Company shall have no obligation to conduct such Clinical Trials unless the conduct of such Clinical Trials is [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="d1ac8171508f4c93be46d714f897dbbb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Development</font>.&#160; In the event that MacroGenics, at any time during the Co-Funding Term, wishes to conduct a Clinical Trial of the Initial Product that is consistent with, but not currently included in, the Global Development Plan, it shall submit a written proposal for the conduct of such Clinical Trial to the JSC for approval, together with a draft protocol, clinical plan and budget.&#160; The JSC shall consider such proposal in good faith.&#160; If the JSC approves such proposal, then: (i) such Clinical Trial shall be deemed to be a Global Development Activity and shall become part of the Global Development Plan; (ii) the costs associated with such Clinical Trial shall be Global Development Costs and shared in accordance with</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">Section 8.2; (iii) upon Company's request, the Parties shall enter into a clinical trial agreement governing the conduct of such Clinical Trial, which agreement shall account for necessary regulatory and other considerations and shall be consistent with the terms of this Agreement; (iv) MacroGenics' agreement with the sites at which such Clinical Trial is conducted shall be consistent with Company's form of clinical trial site agreement and with the terms of this Agreement; (v) the Parties shall amend the PVA as necessary to provide for the sharing of information and data relating to such Clinical Trial; and (vi) MacroGenics shall use Commercially Reasonable Efforts to conduct such Clinical Trial in accordance with the Global Development Plan.&#160; If the JSC does not approve such proposal, the JSC shall inform MacroGenics as to the reasons for such determination and, if the JSC has any specific suggestions for revisions to the protocol that may address the reasons underlying such JSC determination, such suggestions and MacroGenics may submit a revised proposal to JSC.&#160; MacroGenics shall not conduct any Clinical Trial of the Initial Product without the express approval thereof by the JSC.</div>

<div>
<table id="5a1dbb91f121442fac5754bee147486f" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Clinical Trial Registries</font>.&#160; For all Clinical Trials in the Field in the Territory, Company shall be responsible, in accordance with Applicable Law, for registering in the appropriate clinical trial registry and posting the results of such Clinical Trials.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Decision-Making</u></font>.&#160; Company shall have sole authority with respect to the Development of the Compounds and the Products in the Field in the Territory in accordance with this Agreement.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Compliance with Law</u></font>.&#160; Each Party shall conduct all Development activities related to Compound and Products in all material respects in a good scientific manner and in compliance in all material respects with all Applicable Law, including applicable national and international (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, ICH, GCP, GLP, and GMP) guidelines.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Records</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Company shall prepare and maintain, or shall cause to be prepared and maintained, complete and accurate written records, accounts, notes, reports and data with respect to Development activities conducted pursuant to this Agreement (including the Global Development Plan) in conformity with Applicable Law and Company's standard practices, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that in no case shall such records be maintained for less than [***] following the Calendar Year to which such records pertain (or any longer period required by Applicable Law).</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Cooperation</u></font>.&#160; Upon reasonable advance notice, at the request of the JSC, each Party agrees to make its employees and consultants reasonably available at their respective places of employment to consult with the other Party on issues arising in connection with the Global Development Plan.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Progress Reports</u></font>.&#160; No later than [***] and [***], Company shall provide to MacroGenics in writing (or, if the JSC has not yet been dissolved pursuant to Section 2.1(f)(i), to the JSC verbally) a report detailing Company's efforts and progress during the [***] to such date, as applicable, to Exploit each Compound and Product.&#160; Each such report shall describe, among other matters:&#160; (a) material Development activities completed since the last report, including the object and parameters of the Development, when initiated, when completed and a summary of all material results; (b) material Development activities planned to be undertaken before the next report, including the type and object of any Clinical Trials to be conducted and their projected starting and completion dates; and (c) material changes in Company's Development and Commercialization plans.&#160; In addition, Company shall reasonably respond to reasonable requests by MacroGenics for information regarding Company's Development and Commercialization activities for such Compounds and Products, to the extent such information is necessary to assess Company's compliance with its obligations hereunder.&#160; In addition, if MacroGenics does not exercise the Co-Funding Option or MacroGenics exercises the Co-Funding Opt-Out in accordance with Section 8.2(e), at the request of MacroGenics, the Parties shall meet to discuss Development and Commercialization progress at either Party's facilities (or such other location as may be agreed upon by the Parties) on a semi-annual basis.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">4.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Subcontracting</u></font>.&#160; Company may subcontract the performance of any Development activities conducted in accordance with this Agreement to any of its Affiliates or any Third Party, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and shall remain responsible for the performance of such subcontracted activities in accordance with this Agreement.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> REGULATORY RESPONSIBILITIES</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">5.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Initial Data Transfer</u></font>.</font></div>

<div>
<table id="32a3283053df4aa8a734bba8e909dc31" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Within [***] after the Development Transition Date, MacroGenics shall deliver to Company electronic copies (unless otherwise required by Applicable Law) of all Regulatory Materials relating to the Products in the Field in the Territory which are Controlled by MacroGenics.&#160; Upon the completion of such transfer, MacroGenics shall, and hereby does, assign to Company all such Regulatory Materials and shall promptly (and in any case within [***] take all steps reasonably necessary to effectuate the assignment of all INDs, Regulatory Approval Applications and Regulatory Approvals included in such Regulatory Materials, including submitting to any applicable Regulatory Authority a letter or other necessary documentation (with copy to Company) notifying the Regulatory Authority of the assignment.&#160; In the event that any such IND, Regulatory Approval Application or Regulatory Approval cannot be</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">transferred within such [***] period, MacroGenics shall take all actions reasonably requested by Company with respect to the maintenance or transfer of such IND, Regulatory Approval Application or Regulatory Approval.</div>

<div>
<table id="604cb3a4bbf144afba46b4d42d3eee0d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Within [***]after the Development Transition Date, MacroGenics shall make available to Company separate electronic copies of all remaining Regulatory Documentation, including the study reports from all non-clinical trials and clinical trials, in each case, whether completed prior to the Development Transition Date or then in-progress, that are Controlled by MacroGenics (to the extent not previously provided to Company).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="782b964d7d2042228cc62b62e98ee1df" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Notwithstanding Section 5.1(a) and Section 5.1(b), from time to time after the Development Transition Date, to the extent not done so already, MacroGenics shall, and shall cause its Affiliates to, without additional compensation, disclose and make available to Company, in whatever form Company may reasonably request, as soon as reasonably practicable after the earlier of the development, making, conception or reduction to practice, all Regulatory Documentation and other Information Controlled by MacroGenics, which in each case is reasonably necessary or useful for Company's Exploitation of the Compounds and the Products, including copies or tangible embodiments thereof.&#160; For clarity, MacroGenics will have the right, unless otherwise required by Applicable Law, to retain original copies of the foregoing subject to ARTICLE 12.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">5.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><u>Preparation of Regulatory Materials.</u></font></div>

<div>
<table id="99221d6b411045bb83127a6b81c59a94" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">By MacroGenics</font>.&#160; During the period beginning on the Effective Date and ending on the Development Transition Date, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>, in consultation with <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>, shall (i) <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]as soon as possible after the Effective Date, </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>provided</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> that </font>Company shall <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>and provide a <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> and (ii) take all actions necessary to maintain all Regulatory Materials relating to the Products in the Field in the Territory which are Controlled by MacroGenics.</font></div>
</td>
</tr>
</table>
</div>

<div>
<table id="cf493ea0f2f6464d8894cae44bf551ec" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">By Company</font>.&#160; Except for the activities to be undertaken prior to the Development Transition Date by MacroGenics pursuant to Section 5.2(a), Company shall, with respect to the Products in the Field in the Territory, have the sole right and sole authority, at its own expense (subject to MacroGenics' exercise of the Co-Funding Option), to: (i) develop and implement the overall regulatory strategy with respect to obtaining Regulatory Approval of Products in the Field in the Territory; (ii) prepare, obtain, and maintain all Regulatory Documentation, including all INDs, Regulatory Approval Applications and Regulatory Approvals; and (iii) conduct communications with the relevant Regulatory Authorities. The regulatory strategy</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">for the Territory shall be consistent with the Global Development Plan and the terms of this Agreement.&#160; All Regulatory Materials (including all Regulatory Approvals) generated with respect to the Products under this Agreement shall be owned by, and shall be the sole property and held in the name of, Company or its designee.</div>

<div>
<table id="2ee2c0eabba140ca848d2d555e96bf13" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Assistance</font>. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">MacroGenics shall assist Company as reasonably requested in connection with the preparation and filing of Regulatory Documentation for the Territory, at MacroGenics' sole expense; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>provided</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">, </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><u>however</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">, that Company shall reimburse MacroGenics for FTE Costs and Third Party Expenses incurred by MacroGenics in providing any such assistance later than six (6) months after the Effective Date.</font></div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">5.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Adverse Event Reporting and Safety Data Exchange</u></font>.</font></div>

<div>
<table id="e9d1ca806b3641d6a12467a2105c40b1" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Responsibilities</font>.&#160; Upon the transfer of ownership of the INDs, Regulatory Approval Applications and Regulatory Approvals in accordance with Section 5.1(a), Company will assume responsibility for the monitoring of all clinical experiences, maintaining the global safety database, safety monitoring, pharmacovigilance surveillance, compliance and filing of all required safety reports to all Regulatory Authorities in the Territory with respect to Compounds and Products, including annual safety reports, throughout the Development and Commercialization of each Compound and Product.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c6ac26efe9e641789f664654f2fa5f18" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Safety Information Exchange; Pharmacovigilance Agreement</font>.&#160; In the event MacroGenics exercises the Co-Promote Option, the Parties shall cooperate to develop methods and/or procedures for sharing Information relating to the clinical experiences referred to in Section 5.3(a) with respect to the Initial Product in accordance with safety reporting requirements of the respective Governmental Authorities and as necessary to comply with Applicable Law.&#160; Specific details regarding the management of safety Information, including adverse events reports, related to the Development and the Commercialization of the Initial Product in the Territory, will be delineated in a separate global pharmacovigilance agreement (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">PVA</font>").&#160; The Parties shall meet to discuss the PVA within [***] after MacroGenics exercises the Co-Promote Option and shall agree upon the terms of the PVA as soon as practicable, but in any event no later than the anticipated date of the First Commercial Sale of any Product in the U.S.; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, in the event the Parties do not reach agreement on all terms of the PVA prior to the First Commercial Sale of any Product in the U.S., then the Parties shall enter into an interim PVA prior to the First Commercial Sale of any Product in the U.S. and shall agree upon the terms of the final PVA as soon as practicable thereafter.&#160; In the event of any conflicts or inconsistencies between the PVA and this Agreement, the terms of the PVA shall take precedence for matters relating to pharmacovigilance.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">5.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Recalls and Voluntary Withdrawals</u></font>.&#160; Company shall use reasonable efforts to notify MacroGenics promptly, but in no event later than [***], following its determination that any event, incident, or circumstance related to safety issues or regulatory concerns has occurred that is reasonably likely to result in the need for a recall, market suspension or market withdrawal of a Product in the Territory, and shall include in such notice the reasoning behind such determination and any supporting facts.&#160; Company shall have the sole right to make the final determination of whether to voluntarily implement any such recall, market suspension or market withdrawal in the Territory, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that, prior to the implementation of such a recall, market suspension or market withdrawal, Company shall, to the extent practical, consult with MacroGenics and shall consider MacroGenics' comments in good faith.&#160; For all recalls, market suspensions or market withdrawals undertaken pursuant to this Section 5.4, Company shall be solely responsible for the execution thereof and MacroGenics shall reasonably cooperate in all such recall efforts.&#160; Subject to ARTICLE 15, Company shall be responsible for all costs of conducting any such recall, market suspension, or market withdrawal.&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>For the sake of clarity, during the Co-Funding Term certain [***] associated with recalls and market withdrawals [***]in accordance with Section 9.9.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">5.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Subcontracting</u></font>.&#160; Company may subcontract the performance of any activities conducted in accordance with this ARTICLE 5 to any of its Affiliates or any Third Party, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and shall remain responsible for the performance of such subcontracted activities in accordance with this Agreement.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 6</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> COMMERCIALIZATION</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">6.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Commercialization Activities</u></font>.</font></div>

<div>
<table id="68d2130e5b7647ccb1cabb854b3a407d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Commercialization</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Activities</font>.&#160; Subject to MacroGenics' exercise of the Co-Promote Option, Company shall be solely responsible for and have sole authority with respect to, at its own expense (subject to MacroGenics' sharing of expenses upon its exercise of the Co-Funding Option), all aspects of the Commercialization of the Product in the Field in the Territory, including:&#160; (i) developing and executing a commercial launch and pre-launch plan; (ii) marketing and promotion (including Detailing); (iii) booking sales and distribution and performance of related services; (iv) handling all aspects of order processing, invoicing and collection, inventory and receivables; (v) publications; (vi) providing customer support, including handling medical queries, and performing other related functions; (vii) the review and approval of all Promotional Materials for compliance with Applicable Law, including submission, where appropriate, to the</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">applicable Regulatory Authority and (viii) conforming its practices and procedures in all material respects to Applicable Law relating to the marketing, detailing and promotion of the Products in the Field in the Territory.&#160; Company shall use Commercially Reasonable Efforts to Commercialize Products for which Regulatory Approval is received in the Territory.</div>

<div>
<table id="44710bf21a964252b894fc3b7d768b9e" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Ordering</font>.&#160; MacroGenics shall not accept orders for the purchase of a Product from Third Parties, or make sales of Product to Third Parties in the Field in the Territory for its own account or for Company's account.&#160; If MacroGenics receives any order for a Product in the Field in the Territory, it shall refer such orders to Company for acceptance or rejection.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="8861f0fc999a47ee8c7f160065d1b3d0" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">U.S. Commercialization Plan</font>.&#160; In the event MacroGenics exercises the Co-Promote Option in accordance with Section 8.3(a), Company shall submit the initial U.S. Commercialization Plan to the JSC, or such subcommittee designated by the JSC, [***] for review by the JSC or such subcommittee. Thereafter, Company shall submit an updated U.S. Commercialization Plan to the JSC, or such subcommittee designated by the JSC, at least once each Calendar Year until the termination or expiration of the Co-Promotion Agreement for review by the JSC or such subcommittee.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">6.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Trademarks</u></font>.&#160; Company shall have sole responsibility, at its own expense, for all matters relating to the use of, and shall own, all trademarks used in the sale of Products in the Field in the Territory (but excluding the MacroGenics Trademarks and any trademark that is confusingly similar to a MacroGenics Trademark), including the selection, filing, prosecution, maintenance, defense and enforcement thereof.&#160; Notwithstanding the foregoing, in the event MacroGenics exercises the Co-Funding Option, costs related to Product trademarks in the Northern American Territory shall be treated as a Commercialization Expense.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">6.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Decision-Making</u></font>.&#160; Except with respect to a MacroGenics decision to exercise the Co-Promote Option as set forth in Section 8.3(a) and MacroGenics' right to conduct [***] upon any such exercise, after the Effective Date, Company shall have sole authority with respect to all aspects of Commercialization of Products in the Field in the Territory in accordance with this Agreement, including all decisions regarding pricing, discounts and the terms of sale.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">6.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Transparency Reporting</u></font>.&#160; Company and, in the event it exercises either or both the Co-Funding Option or Co-Promote Option, MacroGenics, shall each be responsible for tracking and reporting transfers of value initiated and controlled by its and its Affiliates' employees, contractors, and agents pursuant to the requirements of the marketing reporting laws or research</font></div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">expense reporting laws of any Governmental Authority in the Territory, including Section 6002 of ACA, commonly referred to as the "Sunshine Act."</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">6.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Compliance with Law</u></font>.&#160; Company and, if MacroGenics exercises the Co-Promote Option, MacroGenics, shall conduct all Commercialization activities related to Compound and Products in compliance in all material respects with all Applicable Law.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">6.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Subcontracting</u></font>.&#160; Company may subcontract the performance of any Commercialization activities conducted in accordance with this Agreement to any of its Affiliates or any Third Party, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and shall remain responsible for the performance of such subcontracted activities in accordance with this Agreement.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 7</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> MANUFACTURING</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">7.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>General Supply Terms</u></font>.&#160; After the Effective Date, except as provided below, Company shall have sole responsibility for and sole authority with respect to, at its own expense (subject to MacroGenics' exercise of the Co-Funding Option), Manufacturing clinical and commercial supplies of the Compounds and the Products for use in the Field in the Territory.&#160; Upon Company's request, (a) MacroGenics shall transfer to Company, at no cost, all nucleotide molecules, cell lines and protein material of Compounds, and all Products in finished form or in process on the Effective Date, in MacroGenics' inventory on the Effective Date, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that MacroGenics may retain reasonable quantities of such materials for [***] of such inventory; and (b) MacroGenics shall use Commercially Reasonable Efforts to Manufacture, at MacroGenics' facility, and supply to Company (i) [***]; (ii) [***];<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>and (iii) based on a timeline reasonably acceptable to MacroGenics, in its sole discretion, clinical supplies of Compound for use in other [***], in each case ((i), (ii) and (iii)), at a cost equal to [***] incurred by MacroGenics in connection with such Manufacture [***] with respect to new clinical supplies Manufactured after the Execution Date [***].&#160; A non-binding estimate of such costs are set forth on <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Schedule </u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7.1</font>.&#160; MacroGenics shall not be obligated to [***] in fulfilling any such Company request pursuant to clause (b) of this Section 7.1, unless otherwise agreed by the Parties.&#160; MacroGenics shall continue to conduct and complete any [***] that are being conducted as of the Execution Date with respect to [***] through the [***] of the Execution Date, and Company shall reimburse MacroGenics for any reasonable Third Party Expenses and Development FTE Costs</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">incurred by MacroGenics after the Execution Date in conducting such [***].&#160; Promptly after the Effective Date, the Parties shall enter into good faith negotiations to conclude a clinical supply agreement (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Clinical Supply Agreement</font>") and a related quality agreement within [***] after the Execution Date, which Clinical Supply Agreement shall include specifications and procedures for delivery and acceptance of Products.&#160; Such quality agreement will reflect the findings of any supply qualification audits conducted by Company of MacroGenics and any critical sub-suppliers.&#160; Company shall not have the right to [***] to be negotiated under the Clinical Supply Agreement.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">7.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Transition of Manufacturing Responsibilities</u></font>.</font></div>

<div>
<table id="9a8db2da24dd4a2d827ff017bf8f2ff9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Subject to the JSC's approval of a Manufacturing transition plan (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacturing Transition Plan</font>"), MacroGenics shall effect a transfer to Company or its designee (which designee may be an Affiliate or a Third Party manufacturer, and which Third Party manufacturer may be a backup manufacturer or a second manufacturer of a Compound or a Product) of all MacroGenics Know-How and rights under Third Party agreements relating to the then-current process for the Manufacture of Compound and Product (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacturing Process</font>") and to facilitate implementation of the Manufacturing Process at facilities designated by Company (such transfer and implementation, as more fully described in this Section 7.2(a), the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacturing Technology Transfer</font>").&#160; MacroGenics shall provide all reasonable assistance requested by Company to enable Company (or its Affiliate or designated Third Party manufacturer, as applicable) to implement the Manufacturing Process at the facilities designated by Company.&#160; Company shall reimburse MacroGenics' personnel costs at the Development FTE Rate and reimburse Third Party Expenses incurred by MacroGenics in providing any such assistance.&#160; &#160; </div>
</td>
</tr>
</table>
</div>

<div>
<table id="b5ab682b79cf4e6eb742a15cd6c156a2" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Without limitation to the foregoing, in connection with the Manufacturing Technology Transfer, MacroGenics shall cause all appropriate employees and representatives of MacroGenics and its Affiliates to meet with employees or representatives of Company (or its Affiliate or designated Third Party manufacturer, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the working up and use of the Manufacturing Process and with the training of the personnel of Company (or its Affiliate or designated Third Party manufacturer, as applicable) to the extent reasonably necessary or useful to enable Company (or its Affiliate or designated Third Party manufacturer, as applicable) to use and practice the Manufacturing Process.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic">7.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Decision Making</u></font>.&#160; Company shall have sole authority with respect to the all aspects of Manufacturing of Compound and Product in the Field in the Territory, including CMC development.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">7.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Compliance with Law</u></font>.&#160; Each Party shall conduct all Manufacturing activities related to Compound and Products in compliance in all material respects with all Applicable Law, including applicable national and international (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, ICH, GCP, GLP, and GMP) guidelines.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">7.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Subcontracting</u></font>.&#160; Company may subcontract the performance of any Manufacturing activities conducted in accordance with this Agreement to any of its Affiliates or any Third Party, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company shall oversee the performance of any subcontracted activities in a manner that would be reasonably expected to result in their successful and timely completion and shall remain responsible for the performance of such subcontracted activities in accordance with this Agreement.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 8</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> MACROGENICS OPTIONS</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">8.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Generally</u></font>.&#160; Subject to the terms of this Agreement, MacroGenics may, at its discretion, exercise the Co-Promote Option and the Co-Funding Option.&#160; MacroGenics' exercise(s) of the Co-Promote Option and the Co-Funding Option are separate and independent of each other, such that MacroGenics may exercise: only the Co-Promote Option; only the Co-Funding Option; both the Co-Promote Option and the Co-Funding Option; or neither.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">8.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Co-Funding Option</u></font>.</font></div>

<div>
<table id="784aa58745764bf99912d29467b04693" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Option Grant and Exercise</font>.&#160; Company hereby grants MacroGenics an option to fund [***] of the Global Development Costs and share [***] of the N.A. Profit/Loss (in lieu of royalties on Net Sales of the Initial Product in the Northern American Territory), as further described in this Section 8.2 (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Option</font>").&#160; MacroGenics may, at its discretion, exercise the Co-Funding Option by delivering written notice thereof to Company (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Option Exercise Notice</font>") at any time before the date that is [***] (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Option Deadline</font>").&#160; Company shall promptly provide written notice to MacroGenics of the occurrence of [***]&#160; The Co-Funding Option shall be deemed to be exercised on the date that Company receives the Co-Funding Option Exercise Notice.&#160; If the Co-Funding Option Deadline passes without Company receiving a Co-Funding Option Exercise Notice, the Co-Funding Option shall immediately and permanently expire on the day after the Co-Funding Option Deadline.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="1964509ca93f48aca9024c5f8bf7df99" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Materials</font>.&#160; No later than [***], Company shall deliver to MacroGenics: (i) a projected timeline for the Global Development Activities; (ii) a summary of</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">[***]; (iii) a [***] that are included in the Global Development Plan, which [***] of the Global Development Activities and an annual basis thereafter; (iv) a then-current, non-binding [***], which shall be on an [***], and (v) a then-current, [***](the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Materials</font>").&#160; After delivery of the Co-Funding Materials, but prior to the Co-Funding Option Deadline, upon MacroGenics' reasonable request and with reasonable notice, Company shall promptly make available to MacroGenics (i) during normal business hours its employees and consultants who performed the activities on behalf of Company in preparation of the Co-Funding Materials to answer MacroGenics' questions about the Co-Funding Materials; and (ii) any additional Information in Company's possession relating to the Initial Product that may be reasonably useful in evaluating the Co-Funding Materials.&#160; MacroGenics acknowledges and agrees that nothing in the Co-Funding Materials will be deemed to be a representation or warranty, either express or implied, that Company will be able to successfully Develop or Commercialize the Initial Product in the Northern American Territory or, if Commercialized, that it will achieve any particular sales level of the Initial Product in the Northern American Territory.</div>

<div>
<table id="66fdf1f9ff5d493e89e7743df48dba46" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Terms of Co-Funding</font>.&#160; During the Co-Funding Term:&#160; (1) MacroGenics shall be responsible for [***] of the Global Development Costs; (2) the N.A. Profit/Loss shall be allocated between the Parties as provided in Section 9.9; (3) Section 9.3(c) shall apply in lieu of Section 9.3(b); (4) Section 9.3(e) shall apply in lieu of Section 9.3(d) and (3) royalties with respect to Net Sales of the Products shall be payable only under Section 9.4(b) (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">i.e.</font> no royalties shall be payable with respect to Net Sales of the Initial Product in the Northern American Territory).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="144fc5b4416848ba8f47741ab708a038" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Invoicing and Payment of Global Development Costs</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="5bda678a85c440a8accb753411b40570" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company shall provide to MacroGenics, no later than [***] before the first day of each Calendar Year during the Co-Funding Term, a rolling, non-binding annual forecast of Global Development Costs that Company expects to incur during the [***](the "[***]"), with the [***]&#160; In addition, Company shall provide to MacroGenics, no later than [***] before the first day of each Calendar Year during the Co-Funding Term, [***]The first Calendar Year in each [***] shall be referred to as the [***]&#160; The [***] shall be consistent with the Global Development Plan and with Company's internal budget for the relevant periods.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div>
<table id="b9c67077f1cf47c8ad38c1b6970205c6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Except with respect to the Calendar Quarter in which the Co-Funding Option is exercised, within thirty (30) days after the end of each Calendar Quarter during the Co-Funding Term (including the Calendar Quarter in which the Co-Funding Termination Date occurs, if any), (A) Company will provide a written report and invoice to MacroGenics setting forth in reasonable detail the Global Development Costs incurred by Company during such Calendar Quarter and (B) MacroGenics will provide a written report and invoice to Company setting forth in reasonable detail the Global Development Costs incurred by Company pursuant to Section 4.2(c) during such Calendar Quarter&#160; and Company's share of such Global Development Costs (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GDC Invoice</font>").&#160; The GDC Invoice for the first Calendar Quarter during the Co-Funding Term shall also include all Global Development Costs incurred by Company prior to such Calendar Quarter (i.e. Global Development Costs relating to Global Development Activities incurred prior to the exercise of the Co-Funding Option).&#160; Within sixty (60) days after the receipt of each GDC Invoice, MacroGenics, to the extent the amounts set forth in such GDC Invoice are not in reasonable dispute and after netting out Company's share of any GDC Invoice provided by MacroGenics for such Calendar Quarter, shall pay the GDC Invoice in full, subject to the Cost Cap provisions set forth in Section 8.2(d)(iii).&#160; If MacroGenics fails to pay to Company the total amount set forth in a GDC Invoice within [***] from the date of such GDC Invoice , Company shall so notify MacroGenics in writing (a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GDC Late Payment Notice</font>").&#160; MacroGenics shall notify Company of any amount reasonably disputed in a GDC Invoice, including the basis for such dispute.&#160; Company shall notify MacroGenics of any amount reasonably disputed in a GDC Invoice provided by MacroGenics, including the basis for such dispute. Disputes with respect to the amounts set forth in a GDC Invoice that are not resolved by the Parties within [***] after such dispute is first raised shall be referred to the JSC for attempted resolution; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that such dispute shall not be subject to Company's final decision-making authority under Section 2.1(c).&#160; If the JSC does not resolve such dispute within [***], the provisions of ARTICLE 14 shall apply.&#160; The audit rights set forth in Section 9.13 shall apply to any payment made pursuant to this Section 8.1(d)(ii).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="3408a607997747f5955ab64876d2c232" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Notwithstanding Section 8.2(d)(ii), during any Calendar Year in which Global Development Costs to be paid by MacroGenics [***], MacroGenics may elect to [***] by providing written notice of such election to Company within [***] after receipt of the first GDC Invoice for such Calendar Year that [***]&#160; Following Company's receipt of a [***] during any Calendar Year, MacroGenics shall not be obligated to [***]</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">Any [***] that have not been paid or deducted from payments due hereunder at the end of any Calendar Quarter shall be carried forward to the next Calendar Quarter; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that all [***]shall be paid by MacroGenics or deducted within [***] during which such [***] were incurred.&#160; [***] that are carried forward from one Calendar Year to a subsequent Calendar Year [***]for purposes of determining whether [***]&#160; As used above, [***] means (a) with respect to [***] during the period beginning [***] and ending [***] for the period beginning [***] and ending [***] that become due and payable&#160; pursuant to [***] during such Calendar Year, and (b) for each [***] thereafter [***] during such Calendar Year. For example, if the [***] that became due and payable pursuant [***] during the applicable Calendar Year).</div>

<div>
<table id="98983efa1297470faa6049733fb47824" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Notwithstanding subsection (ii), during any [***] in which Global Development Costs are greater than [***] of the [***] for such Calendar Year [***], Company shall [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="049705c9d0374407acbca2b5eb434bc9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Upon the request of either Party, the finance teams of the Parties will meet and attempt to agree in good faith on changes to the processes for reporting, calculating and invoicing Global Development Costs (including [***] and [***] pursuant to this Section 8.2(d) to reflect any process improvements identified with respect thereto.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="e093f57f544c47d590f1480c3278174a" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Opt-Out</font>.&#160; Notwithstanding the foregoing, at any time during the Co-Funding Term after MacroGenics has paid at least a cumulative total of [***] in Global Development Costs pursuant to Section 8.2(d), MacroGenics may, in its discretion, elect to cease funding [***] of the Global Development Costs and sharing [***] of the</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">N.A. Profit/Loss (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Opt-Out</font>") by providing written notice of such election to Company (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Opt-Out Notice</font>") on or before [***] of the applicable Calendar Year.&#160; If MacroGenics delivers a Co-Funding Opt-Out Notice in accordance with this Section 8.2(e), then the following provisions shall apply beginning on the Co-Funding Termination Date and for the remainder of the Term:</div>

<div>
<table id="23207149f8cc455ebb19959ebb3b3652" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">MacroGenics' obligation to fund [***] of Global Development Costs shall terminate on the Co-Funding Termination Date and MacroGenics shall have no obligation to fund any Global Development Costs (including Global Development Costs incurred by MacroGenics in performing Clinical Trials in accordance with Section 4.2(c)) incurred after the Co-Funding Termination Date (but, for clarity, MacroGenics shall be responsible for paying any and all invoiced Global Development Costs incurred on or prior to the Co-Funding Termination Date);</div>
</td>
</tr>
</table>
</div>

<div>
<table id="95d9c12ca71047b9bfcd3b2658153434" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">the sharing of N.A. Profit/Loss pursuant to Section 9.9 shall terminate on the Co-Funding Termination Date;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="cab7d7bd13ad466a8d3fcedf018b36f7" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">if MacroGenics exercises the Co-Funding Opt-Out [***]then MacroGenics may elect (in the Co-Funding Opt-Out Notice) to be reimbursed for the Global Development Costs paid by MacroGenics prior to the Co-Funding Termination Date (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">GDC Repayment Option</font>"), in which case (A) Company shall pay to MacroGenics, in [***]the Global Development Costs previously funded by MacroGenics, with the [***]to be made within [***] after the Co-Funding Termination Date and the [***] to be made on or before the last day of the next [***] immediately following the payment of the [***], <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company's obligation to make any such payments shall terminate as of the effective date of the termination of this Agreement by Company pursuant to Section 13.3, and (B) beginning with the first Calendar Quarter after the Co-Funding Termination Date, royalties with respect to Net Sales of the Products shall be payable under Section 9.4(c)(ii); and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="24140221ed074e67b1168c5750e1766e" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">if (x) MacroGenics exercises the Co-Funding Opt-Out [***] or (y) MacroGenics exercises the Co-Funding Opt-Out prior to the [***] but does not elect the GDC Repayment Option in the Co-Funding Opt-Out Notice, then, in each case ((x) and (y)), beginning with the first Calendar Quarter after the Co-Funding Termination Date, royalties with respect to Net Sales of the Products shall be payable under Section 9.4(c)(i).</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div>
<table id="4211430497534ad89084df4120d8bd73" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Termination of Co-Funding Term due to Failure to Pay Global Development Costs</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font> If MacroGenics fails to pay the entire non-disputed, outstanding invoiced amount set forth in a GDC Invoice within [***] after receiving a GDC Late Payment Notice (and MacroGenics has not delivered [***] in accordance with Section 8.2(d)(iii)), then the following provisions shall apply beginning on the Co-Funding Termination Date and for the remainder of the Term:</div>
</td>
</tr>
</table>
</div>

<div>
<table id="17f301f4ce4848e3b7d3252e0c157327" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">MacroGenics' obligation to fund [***] of Global Development Costs shall terminate on the Co-Funding Termination Date (except with respect to Global Development Costs incurred on or prior to the Co-Funding Termination Date), and MacroGenics shall have no obligation to fund any Global Development Costs incurred after the Co-Funding Termination Date (but, for clarity, MacroGenics shall be responsible for paying any and all invoiced Global Development Costs incurred on or prior to the Co-Funding Termination Date);</div>
</td>
</tr>
</table>
</div>

<div>
<table id="faf28ade68f34b8dbf54ca9461e25186" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">the sharing of N.A. Profit/Loss pursuant to Section 9.9 shall terminate on the Co-Funding Termination Date;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="faf604e119e844f1b4a99ea317b6d536" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">beginning with the first Calendar Quarter after the Co-Funding Termination Date, royalties with respect to Net Sales of the Products shall be payable under Section 9.4(c)(ii); and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="73f87ba0ad40483c8f6cb4821de4b849" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company may setoff against any amounts that are then owed to MacroGenics or that subsequently become due to MacroGenics pursuant to<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>this Agreement the amount of any such non-disputed, outstanding invoiced Global Development Costs and any other Global Development Costs MacroGenics subsequently becomes obligated to pay pursuant to Section 8.2(d).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="8202c517579b422db3842f3ca028a98a" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(g)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Expiration of Co-Funding Term</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font> If the Co-Funding Termination Event is the result of the application of subsection (c) or (d) of Section 1.17, then the following provisions shall apply beginning on the Co-Funding Termination Date and for the remainder of the Term:</div>
</td>
</tr>
</table>
</div>

<div>
<table id="83f74d1685dc4277b22354ec9170110b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">MacroGenics' obligation to fund [***] of Global Development Costs shall terminate on the Co-Funding Termination Date (except with respect to Global Development Costs incurred on or prior to the Co-Funding Termination Date), and MacroGenics shall have no obligation to fund any Global Development Costs incurred after the Co-Funding Termination Date (but, for clarity, MacroGenics shall be responsible for paying any and all invoiced</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">Global Development Costs incurred on or prior to the Co-Funding Termination Date);</div>

<div>
<table id="2b78666919b047b89f96dcb1d7b95d10" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">the sharing of N.A. Profit/Loss pursuant to Section 9.9 shall terminate on the Co-Funding Termination Date; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="906d3beb0e0b4c8c94ee6492adead04c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company shall have no obligation to make any payments to MacroGenics' hereunder with respect to Net Sales of the Initial Product in the Northern American Territory beginning with the first Calendar Quarter after the Co-Funding Termination Date.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="de465d1d35ad4ec9bdc9f07301682729" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(h)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Change of Control</font>.&#160; In the event of the occurrence of a Change of Control of MacroGenics before or during the Co-Funding Term, the following provisions shall apply until the end of the Co-Funding Term.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="e6c02584e4f748939f0340677813ce33" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Upon the consummation of a Change of Control of MacroGenics, MacroGenics shall have no further right to [***] pursuant to Section 8.2(d)(iii). Commencing within thirty (30) Business Days after such Change of Control, MacroGenics shall reimburse Company for all outstanding [***]under Section 8.2(d)(iii) that have not previously been recouped by Company as set forth therein, [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="2954dc9558f84bd883c8e9b9e67b8f8c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Upon the consummation of a Change of Control of MacroGenics, (A) the JSC shall be dissolved (except to the extent necessary to perform the activities described in clause (B) of this sentence), and (B) prior to dissolution, the JSC shall establish reasonable procedures to protect the secrecy of Company's and MacroGenics' competitively sensitive Confidential Information with respect to such other products, including, for example, limiting access to such information and requiring each Party's representatives on the JSC and any employees performing activities in connection with this Agreement to sign individual confidentiality agreements agreeing to comply with the confidentiality provisions of this Agreement.&#160; It is understood that such procedures shall not be established or required in any way that would diminish any of MacroGenics' rights under this Agreement to information regarding Products, diminish MacroGenics' operational responsibilities under this Agreement in any meaningful way, or otherwise impair MacroGenics' rights with respect to Compounds or Products.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="3b51711d8a0f42c880f969e480e3dd87" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Decision-Making</font>.&#160; For clarity, MacroGenics' exercise of the Co-Funding Option shall not alter either Party's respective rights with respect to the Development of Compounds or Products, including Company's decision making rights as set forth in Section 4.3.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">8.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Co-Promote&#160; Option</u></font>.</font></div>

<div>
<table id="babc353181ce423c8afa19ccb675022c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Option Grant and Exercise</font>.&#160; Company hereby grants MacroGenics an option to co-promote the Initial Product in the U.S. for all approved Indications, as further described in this Section 8.3 (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Promote Option</font>").&#160; MacroGenics may, at its discretion, exercise the Co-Promote Option by delivering written notice thereof to Company (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Promote Option Exercise Notice</font>") at any time before the [***](in the case of the [***] or the [***] (in the case of the Indication planned for [***]); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that MacroGenics shall only have the right to exercise the Co-Promote Option with respect to the [***] if Company obtains, or seeks to obtain, an [***]&#160; For purposes of clarity: (a) if MacroGenics does not exercise the Co-Promote Option [***] and Company has not obtained, or is not seeking to obtain, an [***], then the Co-Promote Option shall expire upon the [***], and (b) if MacroGenics does not exercise the Co-Promote Option prior to the [***] and Company has obtained, or is seeking to obtain, an [***]for the [***], then the Co-Promote Option shall remain exercisable until the expiration of the [***]&#160; Furthermore, once MacroGenics exercises the Co-Promote Option, such exercise shall [***].&#160; Notwithstanding the foregoing, in the event of the occurrence of a Change of Control of MacroGenics prior to MacroGenics' exercise of the Co-Promote Option, Company may terminate the Co-Promote Option upon immediate written notice to MacroGenics within [***]of the consummation of such Change of Control, if, after such Change of Control, MacroGenics or the Acquirer or its Affiliates would be conducting Clinical Trials or Commercializing any product that would directly compete in the Field with the Initial Product, whether through the same mechanism of action (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, [***]) or for treatment of the same Indication as the Initial Product with such competitive product in the U.S. and, upon receipt of such notice by MacroGenics, this Section 8.3 shall be of no further force or effect.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="4ef67fa7221448c189e7e936ce6d1405" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Promote Materials</font>.&#160; With respect to [***], Company shall deliver to MacroGenics (i) a non-binding [***]</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">and (ii) a summary of the key terms of the Co-Promotion Agreement (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Promote Materials</font>"); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that Company shall not be obligated to deliver the Co-Promote Materials for the [***] for which the [***] unless Company obtains, or seeks to obtain, an Accelerated [***]&#160; After delivery of the Co-Promote Materials, but prior to the applicable Co-Promote Option Deadline, upon MacroGenics' reasonable request and with reasonable notice, Company shall promptly make available to MacroGenics (x) during normal business hours its employees and consultants who performed the activities on behalf of Company in preparation of the Co-Promote Materials to answer MacroGenics' questions about the Co-Promote Materials, and (y) any additional Information in Company's possession relating to the Initial Product that may be reasonably useful in evaluating the Co-Promote Materials.</div>

<div>
<table id="47b6f3de1ce04f90bd30a31833660278" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Terms of Co-Promote</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">.&#160; Promptly following Company's receipt of the Co-Promote Option Exercise Notice in accordance with Section </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8.3</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(a)</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">, the Parties shall enter into good faith negotiations for a separate co-promotion agreement with respect to the co-promotion of the Initial Product in the U.S. (the "</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Co-Promotion Agreement</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">").&#160; </font>In addition to such usual and customary terms that are typically found within contract sales force agreements, including with respect to the diligence obligations of MacroGenics, the Co-Promotion Agreement shall include<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> the terms set forth below in this Section 8.3(c).</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">&#160; MacroGenics shall commit in the Co-Promotion Agreement to employ a number of sales representatives sufficient to provide [***] of the Details for the Initial Product in the U.S.&#160; For the sake of clarity, MacroGenics' exercise of the Co-Promote Option shall have no affect on Company's authority with respect to Commercialization of the Products under Section </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6.3</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> and MacroGenics shall have no right to Detail the Initial Product in the U.S. unless and until the Parties execute the Co-Promotion Agreement.</font></div>
</td>
</tr>
</table>
</div>

<div>
<table id="28a47432a48a4791b2f5a4b9c8d5739e" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">MacroGenics' Detailing Percentage</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Unless otherwise agreed by the Parties, MacroGenics shall contribute [***] of the total Details for the Initial Product in the U.S. for each Calendar Year, as set forth in the U.S. Commercialization Plan; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, if Company increases the total number of Details in a given Calendar Year, MacroGenics shall have the right, but not the obligation, to increase its total sales force efforts within [***] of receipt of notice from Company in order to maintain the agreed-upon percentage of Details assigned to MacroGenics.&#160; Company will have the right to allocate the planned Details for the Initial Product in the U.S. for each Calendar Year between the Parties, which allocation shall be set forth in Company's call plan for such Calendar Year.&#160; The Parties may agree to treat electronic detailing, such as live video conferencing, as a form of Detail, in which event the Parties shall mutually agree upon the costs of such electronic details and such costs shall be deemed to be Commercialization Expenses during the Co-Funding Term.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c38c809766f643b08526bbfe8b1571ee" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Fee for Detail</font>.&#160; Company shall reimburse MacroGenics for the Details of the Initial Product in the U.S. performed by MacroGenics at a Cost Per PDE as measured and approved by the JSC prior to the First Commercial Sale of the Initial Product in the Northern American Territory.&#160; For clarity, Company shall not pay or be responsible for any costs associated with MacroGenics' Detailing of the Initial Product other than the Cost Per PDE agreed upon by the Parties and, in the event the Parties agree to treat electronic details as a form of Detail, such electronic details shall not be reimbursed at the Cost Per PDE, but instead shall be reimbursed at the cost mutually agreed upon by the Parties as described in Section 8.3(c)(i).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="284f8a5a12074f0c925170cdabcdd073" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Audit Right</font>. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>Each Party shall have the right to audit the other Party's records regarding performance under the Co-Promotion Agreement, solely for the purpose of determining the other Party's compliance with the Co-Promotion Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="31a24ce6df0e487faa0df295682e580c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Termination of Co-Promotion Agreement</font>.&#160; MacroGenics may terminate the Co-Promotion Agreement by [***] prior written notice to Company.&#160; Company may terminate the Co-Promotion Agreement immediately if (1)&#160; MacroGenics fails to contribute at least [***] of the Details for the Initial Product in the Northern American Territory that MacroGenics is obligated to provide under the U.S. Commercialization Plan and fails to remedy such shortfall within [***] after receiving written notice of such shortfall from Company or (2)&#160; MacroGenics materially breaches the Co-Promotion Agreement and fails to cure such breach within [***] after receiving written notice of such breach from Company.&#160; The Co-Promotion Agreement shall be subordinate to and coterminous with this Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="6e781a66d2404a619669e3f79fe8bec9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Promotional Materials and Samples</font>.&#160; Except for MacroGenics Trademarks, Company shall remain solely responsible for the production of product labeling and Promotional Materials for the Initial Product, the training and testing materials for all sales representatives (including those acting on behalf of MacroGenics) who Detail the Initial Product, and restrictions with respect to the ability of such sales representatives to Detail other products.&#160; MacroGenics' sales representatives for the Initial Product shall only use Promotional Materials provided by Company, without alteration, and shall use all such Promotional Materials.&#160; Company will provide to MacroGenics, at Company's expense, reasonable quantities of Promotional Materials and product samples and/or sample vouchers for the Initial Product to support MacroGenics' Detailing of the Initial Product in the U.S..&#160; Company shall not use the MacroGenics Trademarks in any of the Promotional Materials without MacroGenics' written consent (such consent not to be unreasonably withheld, delayed or conditioned).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="58d88d9b08ce4775be42bd0d33652859" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(vi)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Training and Related MacroGenics Sales Force Issues</font>.&#160; Company will be responsible for designing and providing training materials for the representatives (including those acting on behalf of MacroGenics) who Detail the Initial Product. Company shall provide training to MacroGenics' sales representatives who Detail the Initial Product, at MacroGenics' expense.&#160; Company will ship training materials to MacroGenics as reasonably required for MacroGenics' ongoing training needs at MacroGenics' expense.&#160; MacroGenics shall compensate its sales representatives who Detail the Initial Product in the U.S. using a sales compensation structure similar to that used by Company with respect to its sales representatives who Detail the Initial Product in the U.S.&#160; Each sales representative who Details in the Initial Product in the U.S. on behalf of MacroGenics shall be an employee of MacroGenics or its Affiliate.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="6e4e3fa466104ccf94df3d9d408fc41b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(vii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Compliance</font>.&#160; MacroGenics' sales representatives performing Details of the Initial Product in the U.S. shall comply with Applicable Law and all of Company's reasonable instructions, quality standards, policies and guidelines which relate to the Commercialization of the Initial Product and of which MacroGenics has been given sufficient written notice by Company to appropriately train such sales representatives.&#160; MacroGenics shall establish a compliance program and appoint a compliance officer to ensure that MacroGenics' Detailing of the Initial Product is in compliance with Applicable Law and such Company instructions, quality standards, policies and guidelines.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ce9dee8a128b4967aee74cf294e779cb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(viii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Governance</font>.&#160; The Parties shall establish a committee to oversee and facilitate communication between the Parties with respect to the Detailing of the Initial Product in the U.S.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9f4b210244c0474f92269ea63b0d8d55" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(ix)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Change of Control</font>.&#160; In the event of the occurrence of a Change of Control of MacroGenics during the Term, Company may terminate the Co-Promotion Agreement upon immediate written notice to MacroGenics within [***] of the consummation of such Change of Control if, after such Change of Control, MacroGenics or the Acquirer would be Developing or Commercializing, or assisting a Third Party or its Affiliates to conduct any Pivotal Trial or Commercialize, any product that would directly compete in the Field with the Initial Product, whether through the same mechanism of action (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, binds to the Product Target) or for treatment of the same Indication as the Initial Product with such competitive product in the U.S.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 9</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> CONSIDERATION</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Upfront Payment</u></font>.&#160; Within [***] after the Effective Date, Company shall pay to MacroGenics Fifty Million Dollars ($50,000,000) as a one-time, non-refundable, non-creditable upfront payment.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Reimbursement of Expenses</u></font>.&#160; Company shall reimburse MacroGenics for FTE Costs and Third Party Expenses incurred by MacroGenics in providing assistance pursuant to Section 5.2(c) and 7.2(a) of this Agreement as contemplated thereby.&#160; Company shall also reimburse MacroGenics Out-of-Pocket Patent Costs incurred pursuant to Section 10.3(b).&#160; Company shall reimburse such FTE Costs, Third Party Expenses and MacroGenics Out-of-Pocket Patent Costs within sixty (60) days after receipt of an invoice issued by MacroGenics describing such costs in reasonable detail and providing appropriate supporting documentation.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Milestone Payments</u></font>.&#160; Company will notify MacroGenics within [***]</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">following the achievement by Company, its Affiliate or sublicensee of each Development Milestone, each Approval Milestone or Co-Funding Approval Milestone, as applicable, and each Sales Milestone or Co-Funding Sales Milestone, as applicable (collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Milestone Events</font>").&#160; Within [***] after achievement of each Milestone Event, Company shall remit the applicable Development Milestone Payment, Approval Milestone Payment or Co-Funding Approval Milestone Payment, as applicable, or Sales Milestone Payment or Co-Funding Sales Milestone Payment, as applicable (collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Milestone Payments</font>") to MacroGenics.&#160; Each Milestone Payment by Company pursuant to this Section 9.3 shall be payable only once.&#160; For the sake of clarity, if Development of a first Product is discontinued prior to the time at which a Milestone Payment pursuant to this Section 9.3 is made with respect to such Product, then the achievement by a subsequent Product of any Milestone Event for which the Development of such first Product did not result in the achievement of a Milestone Payment under this Section 9.3 shall be deemed to be the first achievement of such milestone event under this Section 9.3.&#160;&#160; In addition, if for any reason the [***] Development Milestone does not occur prior to the occurrence of the first [***] Development Milestone, then the [***] Development Milestone shall be deemed to occur concurrently with the occurrence of the [***] Development Milestone (e.g., if Development Milestone [***] occurs with respect to an Indication and Development Milestone [***] has not previously occurred with respect to such Indication or any other Indication, then Development Milestone [***]will be deemed to occur concurrently with Development Milestone [***] and Development Milestone Payments [***] and [***] shall become due and payable in accordance with this Section 9.3).&#160; Similarly, if for any reason a [***] Development Milestone does not occur with respect to an Indication prior to the occurrence of a [***] Trial Development Milestone with respect to such Indication, then a [***] Trial Development Milestone shall be deemed to occur concurrently with the occurrence of such [***] Development Milestone, but only if at least one of the [***] Development Milestones has not yet occurred with respect to another Indication (e.g. if (a) Development Milestone [***] occurs with respect to an Indication (other than [***]) and none of Development Milestone [***]have occurred with respect to such Indication or any other Indication, then Development Milestone [***] will be deemed to occur concurrently with Development Milestone [***] and Development Milestone Payments [***] and [***] shall become due and payable in accordance with this Section 9.3 or (b) if Development Milestone [***] occurs with respect to [***] and Development Milestone [***] has not yet occurred with respect to [***], then Development Milestone [***] will be deemed to occur concurrently with Development Milestone [***] and Development Milestone Payments [***] and [***] shall become due and payable in accordance with this Section 9.3).</div>

<div>
<table id="37157f8804bb4597a0162fa9da3c24bb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development Milestones</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The following payments (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development Milestone Payment</font>") shall be made on a one-time basis with respect to the first Product to achieve the corresponding milestone event (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Development Milestone</font>"):</div>
</td>
</tr>
</table>
</div>

<table id="2a8130cad91744df80fffe41950a9ac0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Development Milestone</div>
</td>
<td style="WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Development Milestone Payment (USD)</div>
</td>
</tr>
</table>

<table id="26f46b8a7f24408ca90086f4710db674" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]Trial Development Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">FPD in a Phase 1 Trial for any Indication</font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***] Trial Development Milestones</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]</font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]</font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">[***] <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***] with respect to which Development Milestone [***] was achieved<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> 1</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> with respect to which Development Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> was achieved or the Indication with respect to which Development Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>was achieved<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> 1</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>Development Milestones</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">7.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">8.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>respect to which Development Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>was achieved<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> 2</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 74.18%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">9.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> with respect to which Development Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> was achieved or the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> with respect to which Development Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> was achieved<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> 2</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 25.82%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: justify; MARGIN-LEFT: 45.35pt"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">The Development Milestone </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Payment for this Development Milestone, when achieved, will be due regardless of whether </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">.</font></font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: justify">
<table id="5e9ce501d5514683a99bfc73ef9c6cc5" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: auto; VERTICAL-ALIGN: top; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">The Development Milestone </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Payment for this Development Milestone, when achieved, will be due regardless of whether </font>[***]</td>
</tr>
</table>
</div>

<div>
<table id="e64a4563ddab40de8d7b3a292ddd2a43" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Approval Milestones</font>.&#160; The following payments (each, an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Approval Milestone Payment</font>") shall be made on a one-time basis with respect to the first ghgh Product to achieve corresponding milestone event (each, an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Approval Milestone</font>"), if and only if the Co-Funding Term is not in effect when such Approval Milestone is achieved.</div>
</td>
</tr>
</table>
</div>

<table id="d8323073e89d4ebba21da79aa0c857e6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Approval Milestone</div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Approval Milestone Payment (USD)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">1.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">2.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></font></div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">3.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> with respect to which Approval Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> was achieved<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> 1</sup></font></div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">4.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font></div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">5.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font>&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></font></div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 70.55%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">6.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> with respect to which Approval Milestone <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">[***]</font> was achieved <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></font></div>
</td>
<td style="WIDTH: 29.45%; VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: justify; MARGIN-LEFT: 45.35pt"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">The Approval Milestone Payment for this Approval Milestone, when achieved, will be due regardless of whether </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">.</font></font></div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 45pt"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">The Approval Milestone Payment for this Approval Milestone, when achieved, will be due regardless of whether </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">.</font></font></div>

<div><br>
</div>

<div>
<table id="8b5f80b063c9402cb0fa751b25bafd38" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Regulatory Approval Milestones during Co-Funding Term</font>.&#160; The following payments (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Approval Milestone Payment</font>") shall be made on a one-time basis with respect to the first Product to achieve corresponding milestone event (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Approval Milestone</font>"), if and only if such Co-Funding Approval Milestone is achieved during the Co-Funding Term.&#160; For the sake of clarity, this Section 9.3(c) shall only apply during the Co-Funding Term.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<table id="30962972b5db4244a6745b3e7a07e37a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center">Co-Funding Approval Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center">Co-Funding <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Approval Milestone</font></div>
</td>
</tr>
</table>

<table id="42f88858e582414aa26b0528158b99ea" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 15px">
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">&#160;</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Payment (USD)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]</font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***] <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="TEXT-INDENT: 18pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***] respect to which Approval Milestone [***] was achieved <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: justify; MARGIN-LEFT: 45.35pt; MARGIN-TOP: 6pt"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-STYLE: italic">The Co-Funding Approval Milestone Payment for this Co-Funding Approval Milestone, when achieved, will be due regardless of whether </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]</font></font></div>

<div>
<table id="1c402b5218424d07a9fec18363d03195" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Annual Net Sales Milestones</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>The milestone payments set forth in this Section 9.3(d) (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sales Milestone Payment</font>") shall each be payable to MacroGenics one-time only, upon the first time during the Term that the total aggregate Net Sales of Products in any Calendar Year by Company, its Affiliates and its sublicensees in the Territory during the applicable Royalty Term for the Products in the applicable country exceed the amounts set forth in the following table (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sales Milestone</font>"), if and only if the Co-Funding Term is not in effect when such Sales Milestone is achieved.</div>
</td>
</tr>
</table>
</div>

<table id="e317a3121fc6462eb5a53569bd75865e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 100%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Annual Aggregate Worldwide Net Sales Milestones</font></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center">Sales Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Sales Milestone Payment (USD)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 69.83%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 30.17%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 6pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">If more than one Sales Milestone described in this Section 9.3(d) is achieved during the same Calendar Year, Company shall pay MacroGenics each Sales Milestone Payment that corresponds to such Sales Milestones.&#160; For purposes of clarity, only one Milestone Payment shall be owed on the first occasion that aggregate annual</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">Net Sales of the Products exceeds [***] or [***] under Section 9.3(d) and Section 9.3(e).</div>

<div>
<table id="25f25f0543d6459cae2eb67e9cc69196" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Annual Net Sales Milestones during the Co-Funding Term</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>The milestone payments set forth in this Section 9.3(e) (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Sales Milestone Payment</font>") shall each be payable to MacroGenics one-time only, upon the first time during the Co-Funding Term that the total aggregate Net Sales of the Products by Company, its Affiliates and its sublicensees in the Territory during the applicable Royalty Term for the Products in the applicable country, excluding Net Sales of the Initial Product in the Northern American Territory during the Co-Funding Term, exceed the amounts set forth in the following table (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Co-Funding Sales Milestone</font>"), if and only if such Co-Funding Sales Milestone is achieved during the Co-Funding Term.</div>
</td>
</tr>
</table>
</div>

<table id="849472f7f3f84269a8ce1e9940e71dc5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 100%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">Annual Aggregate Net Sales Milestones in the Territory (excluding only Net Sales in Northern American Territory with respect to the Initial Product)</font></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.22%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: center">Co-Funding Sales Milestone</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.78%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; FONT-STYLE: italic; TEXT-ALIGN: center">Co-Funding Sales Milestone Payment (USD)</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.22%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.78%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.22%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.78%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.22%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Upon the first occasion that aggregate annual Net Sales of the Products exceeds [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.78%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">If more than one Co-Funding Sales Milestone described in this Section 9.3(e) is achieved during the same Calendar Year, Company shall pay MacroGenics each Co-Funding Sales Milestone Payment that corresponds to such Co-Funding Sales Milestones.&#160; For purposes of clarity, only one Milestone Payment shall be owed on the first occasion that aggregate annual Net Sales of the Products exceeds [***] under Section 9.3(d) and Section 9.3(e).</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Company Royalty Obligations</u></font>.&#160; As further consideration for the rights granted hereunder, Company shall pay to MacroGenics royalties on the aggregate annual Net Sales of each Product at the rates set forth in this Section 9.4, in each case, subject to Section 9.5, Section 9.6 and Section 9.10 below.</font></div>

<div>
<table id="df1ea6d27dee4bdca5526660435d573f" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Royalties if no Co-Funding</font>.&#160; In the event that MacroGenics does not exercise the Co-Funding Option prior to the Co-Funding Option Deadline in accordance with Section 8.2(a), then Company shall pay to MacroGenics, with respect to Net Sales of each Product in each country in the Territory during the applicable Royalty Term for such Product in such country, royalties at the following rates:</div>
</td>
</tr>
</table>
</div>

<table id="706bff3fe09644d99a3e9e30bdd3526a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Annual Net Sales</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Royalty Rate</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product greater than [***] and less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product greater than [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div>
<table id="8015add83066429c940ecb4281507555" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Royalties during Co-Funding Term</font>.&#160; In the event that MacroGenics exercises the Co-Funding Option prior to the Co-Funding Option Deadline in accordance with Section 8.2(a), then Company shall pay to MacroGenics during the Co-Funding Term royalties at the rates set forth below in this Section 9.4(b).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c61fdbf2e66849c4a404517b16fa9206" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Initial Product</font>.&#160; With respect to Net Sales of the Initial Product in each country in the Territory during the applicable Royalty Term for the Initial Product in such country, excluding Net Sales of the Initial Product in the Northern American Territory, royalties at the following royalty rates:</div>
</td>
</tr>
</table>
</div>

<table id="fcfe7690ea6242b1b24b9810f8c24a9a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Annual Net Sales of the Initial Product</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Royalty Rate</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of the Initial Product (excluding Net Sales of the Initial Product in the Northern American Territory) less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of the Initial Product (excluding Net Sales of the Initial Product in the Northern American Territory) greater than [***] and less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of the Initial Product (excluding Net Sales of the Initial Product in the Northern American Territory) greater than [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">For the avoidance of doubt, the aggregate annual Net Sales of the Initial Product in the Northern American Territory during the Co-Funding Term shall be excluded from the calculation of the royalty thresholds set forth above and on royalties payable to MacroGenics pursuant to this Section 9.4(b)(i).</div>

<div>
<table id="612436edc1094e9ca80227671ab9e4a4" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Products other than Initial Product</font>.&#160; With respect to Net Sales of any Product other than the Initial Product in each country in the Territory during the applicable Royalty Term for such Product in such country, royalties at the following royalty rates:</div>
</td>
</tr>
</table>
</div>

<table id="ec9e02f1aa98494a80d18cbce87d944a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Annual Net Sales of any Product other than Initial Product</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Royalty Rate</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of</div>

<div style="TEXT-ALIGN: left">&#160;</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">such Product less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Initial Product greater than [***] and less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product&#160; greater than [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div>
<table id="610834e9e41348548c9031b214bb189d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Royalties after Co-Funding Term</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="83867abdb30b46c1ad47fb391697ef83" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">MacroGenics exercises Co-Funding Opt-Out and does not elect GDC Repayment Option</font>.&#160; In the event that MacroGenics exercises the Co-Funding Option in accordance with Section 8.2(a), but MacroGenics thereafter exercises the Co-Funding Opt-Out in accordance with Section 8.2(e) and does not elect the GDC Repayment Option, then Company shall pay MacroGenics during any part of the Term after the Co-Funding Term (x) with respect to Net Sales of the Initial Product in the Northern American Territory, royalties at the rates set forth in the second column of the following table and (y) with respect to (1) Net Sales of the Initial Product in any country outside the Northern American Territory and (2) Net Sales of any Product other than the Initial Product in any country in the Territory, royalties at the rates set forth in the third column of the following table, in each case ((x) and (y)) during the applicable Royalty Term for such Product in such country:</div>
</td>
</tr>
</table>
</div>

<table id="af7ca5ae1a19426da3807198bdd3805f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 40.96%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Annual Net Sales</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 32.15%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(a) Royalty Rate for Northern American Territory Net Sales of the Initial Product</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 26.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(b) Royalty Rate for (i) outside Northern American Territory Net Sales of the Initial Product and (b) Territory Net Sales of each Product other than the Initial Product</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 40.96%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 32.15%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 26.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 40.96%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product greater than [***]and less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 32.15%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 26.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 40.96%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product greater than [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 32.15%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 26.89%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div>
<table id="c982ceb29ffb4793963b171ffb04e69b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">MacroGenics exercises Co-Funding Opt-Out and elects GDC Repayment Option; Termination of Co-Funding for Cause</font>.&#160; In the event that MacroGenics exercises the Co-Funding Option in accordance with Section 8.2(a) and (x) MacroGenics thereafter exercises the Co-Funding Opt-Out in accordance with Section 8.2(e) and elects the GDC Repayment Option or (y) the Co-Funding Term is thereafter terminated pursuant to Section 8.2(f), then, in each case ((x) and (y)), during any part of the Term after the Co-Funding Term, Company shall pay to MacroGenics, with respect to Net Sales of each Product in each country in the Territory during the applicable Royalty Term for such Product in such country, royalties at the following rates:</div>
</td>
</tr>
</table>
</div>

<table id="913baf2cffd143fb8e7a82e9edfa7f66" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Annual Net Sales</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Royalty Rate</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product greater than [***]and less than or equal to [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 70.61%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On the portion of worldwide annual Net Sales of such Product greater than [***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 29.39%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div>
<table id="cf1a6b4f67fd43d6993cf31cd4991808" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Examples of Royalty Calculation for Initial Product</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>By way of example, if global aggregate annual Net Sales of the Initial Product is [***], MacroGenics did not exercise the Co-Funding Option and no royalty rate reduction under Section 9.6 or 9.10 applies, then the royalty payable by Company to MacroGenics for the Initial Product for such Calendar Year, subject to other applicable reductions, would be as follows:</div>
</td>
</tr>
</table>
</div>

<table id="894a2e090bb3491896588b51e66c8f33" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 12px">
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Global Net Sales</div>
</td>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Royalty Tier</div>
</td>
<td style="WIDTH: 28.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Royalty Due</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
<td style="WIDTH: 28.43%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
<td style="WIDTH: 28.43%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>
</td>
<td style="WIDTH: 28.43%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">Total Royalty Due</div>
</td>
<td style="WIDTH: 35.79%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">=</div>
</td>
<td style="WIDTH: 28.43%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div>
<table id="929a41d040cf4204a1c590290271b8e3" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">No Multiple Royalties</font>.&#160; For each Net Sale of a Product, only one royalty under Section 9.4(a), 9.4(b)(i), 9.4(b)(ii), 9.4(c)(i) or 9.4(c)(ii) shall be payable.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Royalty Term</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Royalties under Section 9.4 shall be payable on Net Sales on a Product-by-Product and country-by-country basis beginning upon the First Commercial Sale of the relevant Product in the relevant country in the Territory until the expiration of the Royalty Term for such Product in such country.&#160; Following the expiration of the Royalty Term with respect to a Product in a country of the Territory, subject to the terms and conditions of this Agreement, Company shall have a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the MacroGenics Technology to Exploit such Product in the Field in such country of the Territory.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Royalty Rate Reductions</u></font>.&#160; The royalty rates set forth in Section 9.4 shall be subject to reduction as follows:</font></div>

<div>
<table id="1f1f525bb7b646debccaec7e7a6e091b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">the royalty rates shall be reduced by [***], on a country-by-country basis and Product-by-Product basis, in each country in which, at any given time, both (i) no Valid Claim of MacroGenics Patents [***] of the applicable Product in such country, and (ii) either (x) [***] Product in such country [***]or (y) [***] Product in such country;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="a800850902af4423bb2adc3f29a49092" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">the royalty rates shall be reduced by [***], on a country-by-country and Product-by-Product basis, in each country in which, at any given time, (i) no [***] of the applicable Product in such country, and (ii) there is [***] Product in such country and [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="2e99281706ba4753a5c2bc029ad62614" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">in the event that the royalty rate reduction in Section 9.6(b) applies to a Product in a country [***]for such Product in such country [***], the reductions set forth in Section 9.6(a) shall thereafter apply to such Product in such country;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="fb239dee99f54c81b0ca28180a1b2906" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">in the event that Company does not [***] in a country in which [***] and MacroGenics does not elect to [***] in accordance with Section 10.3(b) which would have been at its sole expense, the requirements set forth in clause (i) of Sections 9.6(a) and 9.6(b) shall not be deemed to have been satisfied, and there shall be no reduction in the applicable royalty rates until the global expiration date of the family of such [***]; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="e6b7303e2af044ddbd2870d9f0f61e28" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">in no event shall the cumulative effect of all reductions available to Company under this Agreement decrease the royalty rate to [***] of the otherwise applicable rates.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Manner of Royalty Payment</u></font>.&#160; Within [***] following the end of each Calendar Quarter after the First Commercial Sale of a Product in the Territory (but excluding a First Commercial Sale in the Northern American Territory that occurs during the Co-Funding Term), Company shall provide MacroGenics with a report setting forth, on a Product-by-Product and country-by-country basis (excluding any country in the Northern American Territory during the Co-Funding Term), the Net Sales of such Product in such country, a reasonably detailed</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">statement of the [***]) and a calculation of the royalty payment due with respect to such Net Sales.&#160; Such report shall also include the exchange rates and other methodology used in converting Net Sales into U.S. Dollars from the currencies in which such sales were made for purposes of calculating the appropriate royalty rate and the royalty payment due, and the application of the reductions, if any, made in accordance with the terms of Section 9.6 or Section 9.10.&#160; Company shall pay all amounts due to MacroGenics pursuant to Section 9.4 with respect to Net Sales by Company, its Affiliates and their respective sublicensees for such Calendar Quarter in U.S. Dollars at the time the submission of such quarterly report is due.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Currency</u></font>.&#160; All payments under this Agreement shall be payable in U.S. Dollars.&#160; With respect to sales of a Product invoiced and Commercialization Expenses incurred in a currency other than U.S. Dollars, such amounts and the amounts payable hereunder shall be expressed in their U.S. Dollars equivalent calculated using the Currency Hedge Rates described below.&#160; For each Calendar Year during which royalties become due under Section 9.4, Company shall provide MacroGenics: (a) the [***] to be used for the [***] of each country in the Territory in which any royalty-bearing Net Sales are expected to occur; and (b) the details of each such [***], in each case ((a) and (b)), in writing no later than [***] after the [***](s) are available from [***] or its Affiliates, which is customarily at the [***]&#160; Each Currency Hedge Rate will remain constant throughout the upcoming Calendar Year.&#160; Company shall use the [***] to convert Net Sales to U.S. Dollars for the purpose of calculating royalty payments and N.A. Profit/Loss hereunder.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.9</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Allocation of N.A. Profit/Loss</u></font>.&#160; During the Co-Funding Term, N.A. Profit/Loss for the Initial Product shall be allocated [***] to Company and [***] to MacroGenics. </font></div>

<div>
<table id="ef4b1dcfb4334aaebe923e51a21452e5" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Expense Report</font>.&#160; Within [***] after the end of each Calendar Quarter following the First Commercial Sale of the Initial Product in the Northern American Territory during the Co-Funding Term, each Party shall submit to the other Party a [***] of [***] Party during such Calendar Quarter. Within [***] after the end of each Calendar Quarter following the First Commercial Sale of the Initial Product in the Northern American Territory during the Co-Funding Term, each Party shall submit to the other Party a written report setting forth in reasonable detail the Commercialization Expenses incurred by such Party during such Calendar Quarter, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that the Commercialization Expenses incurred by either Party during the Co-Funding Term before the First Commercial Sale in the Northern American Territory shall be included in the first Commercialization Expense report submitted by the Parties and shall be used to</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div>
<table id="3ed172bf17c3461a98ed47eabd775298" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">determine the allocation of N.A. Profit/Loss between the Parties for such Calendar Quarter.&#160; Each Party shall have the right to review and submit any reasonable objection to the Commercialization Expenses set forth in the other Party's report within [***] following its receipt of the Commercialization Expenses report from the other Party. Disputes with respect to a Commercialization Expense that are not resolved by the Parties within [***] after such dispute is first raised shall be referred to the JSC for attempted resolution; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that such dispute shall [***]&#160; If the JSC does not resolve such dispute [***], the provisions of ARTICLE 14 shall apply. Until the resolution of such dispute pursuant to ARTICLE 14, [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ad46d31d77da40d38e47b031963dadf4" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">N.A. Profit/Loss Reports</font>.&#160; Within [***] after the end of each Calendar Quarter following the First Commercial Sale of the Initial Product in the Northern American Territory, and for the remainder of the Co-Funding Term, Company shall submit to MacroGenics a report setting forth in reasonable detail all [***] (with the detail set forth in Section 9.7, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">mutatis mutandis</font>) and an allocation of profits or losses between the Parties (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Quarterly N.A. Profit/Loss Report</font>").&#160; Company shall pay all amounts due to MacroGenics pursuant to this Section 9.9 at the time of submission of the Quarterly N.A. Profit/Loss Report; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that if the Quarterly N.A. Profit/Loss Report indicates a loss for such Calendar Quarter, MacroGenics shall pay the amount due to Company pursuant to this Section 9.9 within [***] following its receipt of such Quarterly N.A. Profit/Loss Report.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="4d4472aa2d4b449f98c32ce8073cd102" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Financial Report Formats and Timing</font>.&#160; Upon the request of either Party, the finance teams of the Parties will meet and attempt to agree in good faith on alternative financial report formats and timetables to use in lieu of the reports and deadlines described in Section 9.9(a).</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.10</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Third Party Financial Obligations</u></font>.</font></div>

<div>
<table id="3528479118ff4a51b836e0f8883a8f33" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">MacroGenics shall be solely responsible for the payment of any royalties, sublicense revenues, milestones or other payments due by either Party, their Affiliates or sublicensees to Third Parties arising with respect to the [***] (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party Obligation</font>"), (i) to the extent such Third Party Obligation [***], or (ii) to the extent such Third Party Obligation [***].&#160; If MacroGenics fails to pay any amount of a Third Party Obligation related to the DART Platform, a Compound and/or a Product and such</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">payment [***] or the failure to make such payment [***], upon [***] prior notice, Company may elect, in its sole discretion, to make such payment to such Third Party on behalf of MacroGenics.&#160; If Company makes such payment to such Third Party, Company may deduct the amount of such payment from any payments that are owed or that become owed to MacroGenics under this Agreement or, if such deduction is not applicable, MacroGenics shall reimburse Company the amount of such payment within [***] after Company makes such payment.</div>

<div>
<table id="804e9ac2530d4e809d2a874ba131f3d1" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Except for Third Party Obligations set forth in Section 9.10(a), Company shall be responsible for all Third Party Obligations (including any licenses for [***]&#160; Company may credit [***] of any Third Party Obligation resulting from Patents and/or Know-How owned by Third Parties that is paid by Company pursuant to this Section 9.10(b) against any royalties payable to MacroGenics under Section 9.4.&#160; Company shall take such credit during any Calendar Quarter for which royalties are payable hereunder, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that in no event will such credit, together with any reductions under Section 9.6, reduce the royalties payable to MacroGenics for such Calendar Quarter by more than [***]&#160; Any share of such Third Party Obligations that remains uncredited due to the application of such floor may be carried forward to subsequent Calendar Quarters.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.11</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Taxes</u></font>.</font></div>

<div>
<table id="1ad8cb6447ac4e3e834fb3105fc836a1" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company will make all payments to MacroGenics under this Agreement without deduction or withholding for Taxes, except to the extent that any such deduction or withholding is required by Applicable Law in effect at the time of payment.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="12ce3ae1a3314b669c480c44cbda9b6c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Any Tax required to be withheld on amounts payable under this Agreement will be paid by Company on behalf of MacroGenics to the appropriate Governmental Authority, and Company will furnish MacroGenics with proof of payment of such Tax.&#160; Any such Tax required to be withheld will be an expense of and borne by MacroGenics.&#160; If any such Tax is assessed against and paid by Company, then MacroGenics will indemnify and hold harmless Company from and against such Tax.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="5193371677b147c1804c264b62378f07" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company and MacroGenics will cooperate with respect to all documentation required by any taxing authority or reasonably requested by Company to secure a reduction in the rate of applicable withholding Taxes.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="cc3bb81067cf4e688e599068c7932822" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">If Company assigns its rights and obligations hereunder to an Affiliate or Third Party in compliance with Section 16.4 and if such Affiliate or Third Party shall be required by Applicable Law to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings, MacroGenics receives an amount equal to the sum it would have received had no such assignment been made.&#160; The foregoing sentence shall not apply to any additional taxes withheld to the extent MacroGenics may obtain a foreign tax credit therefor.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.12</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Tax Returns</u></font>.</font></div>

<div>
<table id="0cad627339ca4fff9362ba322ae371c6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Parties hereby agree that each Party's share of Global Development Costs, including amounts paid under Section 8.2(d), shall be accounted for by each Party separately for research tax credit and orphan drug credit purposes.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="b7d2492d0d0448d28d15feac1fb0988f" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Parties hereby agree that [***] of any deductions for tax purposes attributable to amounts paid or incurred by MacroGenics pursuant to this Agreement shall be deductible or amortizable solely by MacroGenics, and [***] of any deductions for tax purposes attributable to amounts paid or incurred by Company pursuant to this Agreement shall be deductible or amortizable solely by Company.&#160; All Tax returns reflecting any such amounts shall be filed (and any available elections to effect such intent, including a remedial allocation election, shall be made) consistent with the foregoing.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.13</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Audit</u></font>.&#160; Each Party shall maintain complete and accurate records in the ordinary course of such Party's operations in order to permit the other Party to confirm the accuracy of the calculation of royalties, milestones, profits, losses, Global Development Costs, FTE Costs, Third Party Expenses and other payments under this Agreement.&#160; Upon reasonable prior notice, but not more than [***], such records shall be available during regular business hours for a period of [***] from the end of the Calendar Year to which they pertain for examination by an independent certified public accountant selected by the requesting Party and reasonably acceptable to the other Party for the sole purpose of verifying the accuracy of the financial reports and correctness of the payments furnished by the other Party pursuant to this Agreement.&#160; Any such auditor shall not disclose the other Party's Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the other Party or the amount of payments due by the other Party under this Agreement.&#160; Any amounts shown to be owed but unpaid shall be paid within [***] from the accountant's report, plus interest, as set forth in Section 9.14 from the original due date.&#160; Any amounts shown to have been overpaid shall be refunded within [***] from the accountant's report.&#160; The requesting Party shall bear the full cost of such audit unless such audit discloses an underpayment by the other Party of more than [***] of the amount due (except to the extent caused by improper reporting of the requesting Party), in which case the other Party shall bear the full cost of such audit.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">9.14</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Late Payment</u></font>.&#160; All payments due to a Party hereunder shall be made in U.S. Dollars by wire</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">transfer of immediately available funds into an account designated by the receiving Party.&#160; If a Party does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue on the sum due to such Party until the date of payment at the per annum rate of [***] over the then-current prime rate quoted by [***] or the maximum rate allowable by Applicable Law, whichever is lower.</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 10</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> INTELLECTUAL PROPERTY MATTERS</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Ownership of Inventions</u></font>.&#160; Each Party shall own any Inventions made solely by its (or its Affiliates') own employees, agents, or independent contractors in the course of conducting its activities under this Agreement, together with all intellectual property rights therein ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sole Inventions</font>").&#160; The Parties shall jointly own any Inventions for which the inventors include at least one employee, agent, or independent contractor of each Party (or its respective Affiliates) in the course of performing activities under this Agreement, together with all intellectual property rights therein ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Joint Inventions</font>").&#160; Inventorship shall be determined in accordance with U.S. patent laws.&#160; Subject to any licenses granted under this Agreement, each Party will have the right to practice and Exploit any Joint Inventions without the duty of accounting to any other Party or seeking consent (for licensing, assigning or otherwise exploiting Joint Inventions) from the other Party by reason of the joint ownership thereof; and each Party hereby waives any right such Party may have under the laws of any jurisdiction to require any such approval or accounting and, to the extent there are any Applicable Laws that prohibit such a waiver, each Party will be deemed to have so consented.&#160; In furtherance thereof, at the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no such accounting is required to effect the foregoing regarding Joint Inventions.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Disclosure of Inventions</u></font>.&#160; Each Party shall promptly disclose to the other Party any Invention that is necessary or useful to Exploit Compounds or Products in the Field in the Territory during the Term.&#160; With respect to any Joint Invention, each Party shall promptly disclose to the other Party any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing the Joint Invention, and all Information relating to such Invention to the extent necessary for the use of such Invention in the Development or Commercialization of the Compounds or the Products in the Field and, to the extent patentable, for the preparation, filing and maintenance of any Patent with respect to such Invention.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Prosecution of Patents</u></font>.</font></div>

<div>
<table id="eca22164815d4aca8647f8ebc1a129fa" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Platform Patents</font>.&#160; Except as otherwise provided in this Section 10.3(a), as between the Parties, MacroGenics shall have the sole right and authority to prepare, file, prosecute and maintain the MacroGenics Platform Patents on a worldwide basis at its sole expense.&#160; MacroGenics shall provide Company a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain MacroGenics Platform Patents in the Territory, including by providing Company with a copy of material communications from any patent authority in the Territory regarding any MacroGenics Platform Patent, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses.&#160; MacroGenics shall consider Company's comments regarding such communications and drafts in good faith.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="554bde681c474c8ea0d88a8ac36b0923" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Product Patents. </font>The Parties shall jointly prepare, file, prosecute and maintain the MacroGenics Product Patents on a worldwide basis through outside counsel selected by Company and acceptable to MacroGenics, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>that</u></font> Company shall reasonably consider utilizing the outside counsel currently prosecuting the MacroGenics Product Patents. Company shall reimburse MacroGenics for MacroGenics Out-of-Pocket Patent Costs incurred in the filing, prosecution and maintenance of MacroGenics Product Patents.&#160; The Parties shall use good faith efforts to agree upon the Patent strategy with respect to the MacroGenics Product Patents, including the scope of protection to be sought in such Patents and the countries in which such Patents are to be maintained.&#160; If the Parties disagree with respect to the preparation, filing, prosecution or maintenance of any MacroGenics Product Patent, such disagreement shall be [***], and such [***] provide a potential resolution for the dispute; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that if such disagreement relates to whether or not [***], then such disagreement shall [***] and the Party that desires to file or maintain such [***] right to file or maintain [***]&#160; If the Parties agree with such potential resolution, such resolution shall be final and binding.&#160; If the Parties do not agree with such potential resolution, [***] with respect to the disputed matter.&#160; Each Party shall have access to copies of all documents relating to the preparation, filing, prosecution and maintenance of the MacroGenics Product Patents and shall be permitted to access such documents in a timely manner.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="2820d99a24df4f6693f7447feed201a9" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Patents</font>.&#160; Company shall have the sole right and authority to prepare, file, prosecute and maintain the Company Patents on a worldwide basis at its own expense.&#160; Company shall provide MacroGenics a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain Company Patents in the Territory, including by providing MacroGenics with a copy of material communications from any patent authority regarding any Company Patent in the Territory, and by providing drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses.&#160; Company shall consider MacroGenics' comments regarding such communications and drafts in good faith.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div>
<table id="1973181c0c5e4dffbba394d7a75c81f4" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Joint Patents</font>.&#160; Except as otherwise provided in this Section 10.3(d), Company shall have the primary right and authority to prepare, file, prosecute and maintain the Patents included in the Joint Inventions ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Joint Patents</font>") on a worldwide basis at its own expense.&#160; Company shall provide MacroGenics with a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain Joint Patents, including by providing MacroGenics with a copy of material communications from any patent authority regarding any Joint Patent, and by providing drafts of any material filings or responses to be made in advance of submitting such filings or responses.&#160; Company shall consider MacroGenics' comments regarding such communications and drafts in good faith.&#160; If Company determines in its discretion to abandon or not maintain any Joint Patent(s) in any country(ies) of the world, then Company shall provide MacroGenics with written notice of such determination within a period of time reasonably necessary to allow MacroGenics to determine its interest in such Joint Patent(s) (which notice from Company shall be given no later than [***] prior to any final deadline for any pending action or response that may be due with respect to such Joint Patent(s) with the applicable patent authority).&#160; If MacroGenics provides written notice expressing its interest in obtaining such Joint Patent(s), Company shall, free of charge, assign and transfer to MacroGenics the ownership of, and interest in, such Joint Patent(s) in such country(ies), at MacroGenics' own expense, and Company shall cooperate with MacroGenics for assignment and transfer of such Joint Patent(s) in such country.&#160; Thereafter, all such assigned and transferred Patents will be deemed MacroGenics Platform Patents and MacroGenics shall have the right to prepare, file, prosecute and maintain such Patents as set forth in Section 10.3(a).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f3da5b97cadc415da62dffe14e239c83" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cooperation in Prosecution</font>.&#160; Each Party shall provide the other Party all reasonable assistance and cooperation in the Patent prosecution efforts provided above in this Section 10.3, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution, as well as further actions as set forth below.&#160; Such assistance and cooperation shall include making a Party's inventors and other scientific advisors reasonably available to assist the other Party's Patent prosecution efforts.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="0f924d2fbe39488593c1fbd17e404cfb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">The Parties shall respectively prepare, file, maintain and prosecute the MacroGenics Patents, the Company Patents and the Joint Patents as set forth in this Section 10.3.&#160; As used herein, "prosecution" of such Patents shall include all communication and other interaction with any patent office or patent authority having jurisdiction over a patent application in connection with pre-grant proceedings.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="bb0ea7fc7b534c62b72fbf41990c689b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">All communications between the Parties relating to the preparation, filing, prosecution or maintenance of the MacroGenics Patents, the Company Patents and the Joint Patents, including copies of any draft or final documents or any communications received from or sent to patent offices or patenting authorities with respect to such Patents, shall be considered Confidential Information of the Party Controlling the relevant Patent and subject to the confidentiality provisions of ARTICLE 12.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="96d03464c42d42979f14a11922aa5a64" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Assignments in the MacroGenics Patents, Joint Patents and Company Patents shall be effected as follows: (i) employees or agents of MacroGenics (or its Affiliates) that are named as inventors on the MacroGenics Patents shall assign their interest in such Patents to MacroGenics or its Affiliate; (ii) employees or agents of Company or MacroGenics (or their respective Affiliates) that are named as inventors on the Joint Patents shall assign their interest in such Patents to their respective employer; and (iii) employees or agents of Company (or its Affiliates) that are named as inventors on the Company Patents shall assign their interests in such Patents to Company or its Affiliate.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Patent Term Extensions in the Territory</u></font>.&#160; Company shall decide for which, if any, of the MacroGenics Product Patents, Joint Patents, Company Patents or other Patents Controlled by Company, its Affiliates or designees the Parties should seek patent term extensions, supplemental protection certificates or their equivalents (each a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Patent Extension</font>" and collectively "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Patent Extensions</font>") in the Territory and Company shall have the right to seek such Patent Extensions.&#160; In the event that the opportunity to seek a Patent Extension, supplemental protection certificate or an equivalent becomes available for a Product in the Territory based on [***] and if Company, its Affiliates or designees do not seek a Patent Extension for [***], subject to the provisions of this Section 10.4, MacroGenics shall have the right, but not the obligation, to [***] and Company shall reasonably cooperate with MacroGenics in [***]&#160; MacroGenics shall not seek any Patent Extension that is reasonably likely to have a material adverse effect on the Commercialization of the Product or if there is a good faith dispute between the Parties as to whether a Patent Extension is being sought for a Patent that does not Cover the applicable Product (a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Good Faith Dispute</font>").<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>In the event that Company does not intend to seek Patent Extensions for any [***], it shall so inform MacroGenics in writing in sufficient time to permit MacroGenics to seek a Patent Extension.&#160; MacroGenics shall not seek any such Patent Extension unless it first engages in good faith discussions with Company regarding Company's reasons for not seeking Patent Extensions and MacroGenics' rationale and plans for seeking Patent Extensions, but, unless a Good Faith Dispute still exists, thereafter shall have the right to seek such Patent Extensions.&#160; The Party that does not apply for a Patent Extension hereunder will cooperate fully with the other Party in making such filings or actions, including making available all required regulatory data and Information and executing any required authorizations to apply for such Patent Extension.&#160; All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks Patent Extension pursuant to this Section 10.4 shall be entirely borne by such Party.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Infringement of Patents by Third Parties</u></font>.</font></div>

<div>
<table id="7fdcf2e2a6cf490c93b301ecd5954683" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Notification</font>.&#160; Each Party shall promptly notify the other Party in writing of any existing, alleged or threatened infringement of any MacroGenics Patent, Joint Patent or Company Patent of which it becomes aware, and shall provide all Information in such Party's possession or control demonstrating such infringement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9b14696367f04434b47999c9e079ea5c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Infringement of MacroGenics Patents or Joint Patents</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ae4fd03ad84d43ebb7a89313062d7287" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company, subject to Section 10.5(b)(ii) through 10.5(b)(vii), shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Third Party engaged in any existing, alleged or threatened infringement of any:&#160; (i) MacroGenics Product Patent or Joint Patent; and (ii) MacroGenics Platform Patent with respect to a Competitive Infringement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="933ca8e6cde44b598c8f95986dfbc8a6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company shall notify MacroGenics of its election to take any action in accordance with Section 10.5(b)(i) within the earlier of:&#160; (i) [***] after the first notice under Section 10.5(a); or (ii) [***] before any time limit set forth in Applicable Law or regulation, including the time limits set forth under the Hatch-Waxman Act.&#160; Notwithstanding the foregoing sentence, Company shall not initiate any such suit or take such other action with respect to any MacroGenics Product Patent or Joint Patent without first consulting with MacroGenics and giving good faith consideration to any reasonable objection from MacroGenics regarding Company's proposed course of action, and Company shall not initiate any such suit or take such other action with respect to a MacroGenics Platform Patent without the prior written consent of MacroGenics, such consent not to be unreasonably withheld, delayed or conditioned.&#160; Should MacroGenics reasonably withhold such consent, MacroGenics shall keep Company reasonably informed of any enforcement efforts with respect to the MacroGenics Platform Patents and shall consider Company's comments regarding such enforcement in good faith.&#160; MacroGenics shall cooperate in the prosecution of any suit under this Section 10.5 as may be reasonably requested by Company.&#160; In the event that Company elects not to initiate a lawsuit or take other reasonable action with respect to an infringement described in Section 10.5(b)(i), MacroGenics shall have the right, but not the obligation, to initiate such suit or take such other action, after providing [***] notice to Company and giving good faith consideration to Company's reason(s) for not initiating a suit or taking other action.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="524adfe95e444281ac04265315b1d96c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">If one Party elects to bring suit or take action under this Section 10.5(b) against an infringement, then the other Party shall have the right, prior to commencement of the suit or action, to join any such suit or action.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div>
<table id="759a9a11a56e46e58abfb39b451fef1a" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Each Party shall provide to the Party enforcing any such rights under this Section 10.5(b) reasonable assistance in such enforcement, at such enforcing Party's request and expense, including joining such action as a party plaintiff if required by Applicable Law to pursue such action.&#160; The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party's comments on any such efforts, and shall consult the other Party in any important aspects of such enforcement, including determination of material litigation strategy and filing of important papers to the competent court.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="4aa6192faaeb477d8f1f022a559115fc" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Each Party shall bear all of its own internal costs incurred in connection with its activities under this Section 10.5(b).&#160; In the event that the Parties are joined in suit or action against the infringement or the non-enforcing Party elects to join such suit or action and, in either case, elects to be represented by the same outside counsel as the enforcing Party, then the enforcing Party shall be responsible for all expenses arising from such outside counsel, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that the enforcing Party consents to such joint representation by outside counsel, such consent not to be unreasonably withheld, delayed or conditioned.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="eda17558d19c4a9ea1f4d5a850011beb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(vi)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">The Party not bringing an action with respect to infringement in the Territory under this Section 10.5(b) shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Party bringing such action.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="cdb93b80aa3d43e5a269022ebdb7282d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(vii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Neither Party shall settle any claim, suit or action that it brought under this Section 10.5 involving MacroGenics Product Patents or Joint Patents without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="3023a85ed9624d50b2e5f3d336d3f887" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Infringement of Company Patents</font>.&#160; For any and all infringement of any Company Patent, Company shall have the sole and exclusive right, but not the obligation, to bring, at Company's expense and in its sole control, an appropriate suit or other action against any person or entity engaged in such infringement of the Company Patent.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="540f21f917c54fcb8c324da0d14e0368" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Allocation of Proceeds</font>.&#160; If either Party recovers monetary damages from any Third Party in a suit or action brought under Section 10.5(b), 10.7(a) or 10.7(b) or any royalties, milestones or other payments from a license agreement with a Third Party related to any alleged infringement related to a Product, whether such damages or royalties result from the infringement of MacroGenics Patents, Joint Patents or Company Patents, such recovery ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Infringement Recovery</font>") shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation, action or license negotiations, and any remaining amounts shall be allocated as follows:</div>
</td>
</tr>
</table>
</div>

<div>
<table id="d7229e948902477784657d5023bb46c9" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">with respect to suits or actions brought by Company resulting in an Infringement Recovery relating to the Initial Product in the Northern American Territory during the Co-Funding Term, [***] to Company and [***] to MacroGenics;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="2cbd785842fb4e2c98d41cfaddd952cd" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">with respect to suits or actions brought by Company resulting in an Infringement Recovery relating to (w) the Initial Product outside the Northern American Territory during the Co-Funding Term, (x) the Initial Product in the Northern American Territory after the Co-Funding Term if the Co-Funding Term is terminated, (y) the Initial Product anywhere in the world if MacroGenics does not exercise the Co-Funding Option or (z) any Product other than the Initial Product anywhere in the world, then (1) if the reward is based on lost profits, an amount equal to the royalty that would be payable pursuant to Section 9.4 on the imputed amount of Net Sales of the relevant Product(s) in the country(ies) where such infringement occurred, or (y) if the reward reflects royalty payments, such reward shall be considered Net Sales and subject to the applicable royalty in accordance with Section 9.4; and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="74d4a5235ed74122af09b4fbe1d86a8d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">with respect to suits or actions brought by MacroGenics, the Infringement Recovery shall be retained by MacroGenics.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Infringement of Third Party Rights in the Territory</u></font>.</font></div>

<div>
<table id="b5c87b5cd601433a8dd7ea8381e1d358" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Notice</font>.&#160; If any Product used or sold by either Party, its Affiliates, or sublicensees in the Field becomes the subject of a Third Party's claim or assertion of infringement of a Patent granted by a jurisdiction within the Territory, the Party first having notice of the claim or assertion shall promptly notify the other Party.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="efe012b5bb0941e1afba00ef5b29e1d6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Defense</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="05654c05f1ac4f21bf40029467e8b0d5" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company shall have the first right, but not the obligation, to defend any such Third Party claim or assertion of infringement, other than a [***], of a Patent as described in Section 10.6(a), at Company's expense.&#160; If Company does not commence actions to defend such claim within [***] after it receives notice thereof (or within [***] after it should have given notice thereof to MacroGenics as required by Section 10.6(a)), then, to the extent allowed by Applicable Law, MacroGenics shall have the right, but not the obligation, to control the defense of such claim by counsel of its choice, at MacroGenics' expense.&#160; The non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim or assertion, including if required to conduct such defense, furnishing a power of attorney.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="1844d42b66964ab08f7fe2069e6a5807" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">MacroGenics shall have the first right, but not the obligation, to defend any [***] at MacroGenics' expense.&#160; If MacroGenics does not commence actions to defend or settle such</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">[***] within [***] after it receives notice thereof, then, to the extent allowed by Applicable Law, Company shall have the right, but not the obligation, to control the defense of such claim by counsel of its choice, at MacroGenics' expense.&#160; The non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim or assertion, including if required to conduct such defense, furnishing a power of attorney.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Settlement; Licenses</font>.&#160; MacroGenics shall not enter into any settlement of any claim described in this Section 10.6 that affects Company's rights or interests without Company's prior written consent, such consent not to be unreasonably withheld, delayed or conditioned.&#160; For purposes of clarification, MacroGenics shall not be required to obtain Company's consent to enter into a settlement of a [***] that it elects to settle under Section 10.6(b)(ii), <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company is given prior notice of such proposed settlement with a reasonable amount of time to review and comment and, unless such settlement is likely to detrimentally affect Company's material rights or interest, as communicated to MacroGenics by Company.&#160; Except for a settlement of a [***] that MacroGenics declined to defend or settle under Section 10.6(b)(ii), Company shall not enter into any settlement of any claim described in this Section 10.6 that detrimentally affects MacroGenics' material rights or interests without MacroGenics' written consent, such consent not to be unreasonably withheld, delayed or conditioned.&#160; Each Party shall have the right to decline to defend or to tender defense of any claim described in this Section 10.6 upon reasonable notice to the other Party, including if the other Party fails to agree to a settlement that the declining Party proposes.&#160; In the event that it is determined by any court of competent jurisdiction that the research, Development, Manufacture, or Commercialization of a Product, conducted in accordance with the terms and conditions of this Agreement, infringes, or Company determines reasonably and in good faith that such activities are likely to infringe, any Patent, copyright, trademark, data exclusivity right or trade secret right arising under Applicable Law of any Third Party, Company shall use Commercially Reasonable Efforts to: [***]&#160; To the extent such a license relates to the Commercialization of a Product, the cost of such license shall be considered a Third Party Obligation and allocated between the Parties in accordance with Section 9.10.&#160; In the event that Company decides that neither of the foregoing alternatives is reasonably available or commercially feasible, Company may, at its discretion, terminate this Agreement for the Product affected in accordance with Section 13.2.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">10.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Patent Oppositions and Other Proceedings</u></font>.</font></div>

<div>
<table id="4c972ebecbbe44049afe1bde789cec5a" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party Patent Rights</font>.&#160; If either Party desires to bring an opposition, action for declaratory judgment, nullity action, interference, declaration for</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 72pt">non-infringement, reexamination or other attack upon the validity, title or enforceability of a Patent owned or controlled by a Third Party and having one or more claims that Cover a Product, or the use, sale, offer for sale or importation of a Product (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party's claim or assertion of infringement under Section 10.6, in which case the provisions of Section 10.6 shall govern), such Party shall so notify the other Party and the Parties shall promptly confer to determine whether to bring such action or the manner in which to settle such action.&#160; Company shall have the exclusive right, but not the obligation, to bring, at its own expense and in its sole control, such action in the Territory.&#160; If Company does not bring such an action in the Territory within [***] of notification thereof pursuant to this Section 10.7(a) (or earlier, if required by the nature of the proceeding), then MacroGenics shall have the right, but not the obligation, to bring such action, at MacroGenics' own expense.&#160; The Party not bringing an action under this Section 10.7(a) shall be entitled to separate representation in such proceeding by counsel of its own choice and at its own expense, and shall cooperate fully with the Party bringing such action.&#160; Any awards or amounts received in bringing any such action shall be first allocated to reimburse the initiating Party's expenses in such action, and any remaining amounts shall be allocated between the Parties as provided in Section 10.5(d).</div>

<div>
<table id="e6a2d22016c64402882682bc554d15f6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Parties' Patent Rights</font>.&#160; If any MacroGenics Product Patent or Joint Patent becomes the subject of any proceeding commenced by a Third Party within the Territory in connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof (a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party Patent Challenge</font>") (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, an action for infringement against a Third Party under Section 10.6, in which case the provisions of Section 10.6 shall govern), then the Party responsible for filing, preparing, prosecuting and maintaining such Patent as set forth in Section 10.3 hereof shall control such defense at its own expense.&#160; The controlling Party shall permit the non-controlling Party to participate in the proceeding to the extent permissible under Applicable Law, and to be represented by its own counsel in such proceeding, at the non-controlling Party's expense.&#160; If either Party decides that it does not wish to defend against such action, then the other Party shall have a backup right to assume defense of such Third Party action at its own expense.&#160; Any awards or amounts received in defending any such Third Party action shall be allocated between the Parties as provided in Section 10.5(d).&#160; MacroGenics shall have the sole discretion whether to defend and shall solely control any defense of a Platform Patent which is the subject of a Third Party Patent Challenge, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that MacroGenics shall keep Company reasonably informed regarding such enforcement and shall consider Company's comments regarding such enforcement in good faith.</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 11</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">11.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Mutual Representations, Warranties and Covenants</u></font>.&#160; Each of the Parties hereby represents and warrants to the other Party as of the Execution Date and, as applicable, hereinafter covenants that:</font></div>

<div>
<table id="bec37ce800344e92a4ac6da14f45ed34" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Organization</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="da0d3de2fb014fd2ac9d17ad5ac50dce" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Binding Agreement</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity).</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Authorization</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all necessary corporate action and do not conflict with any agreement, obligation, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law or any order, writ, judgment, injunction, decree, determination, or award of any Governmental Authority presently in effect applicable to such Party.</div>

<div>
<table id="e26f59774de1467b96fc0301ce87b3eb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">No Further Approval</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>It is not aware of any government authorization, consent, approval, license, exemption of or filing or registration with any Governmental Authority under any Applicable Law, currently in effect, necessary for, or in connection with, the transactions contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements (save for Regulatory Approvals and similar authorizations from Governmental Authorities necessary for the Exploitation of the Compounds and Products as contemplated hereunder), except as may be required to obtain clearance of this Agreement under the HSR Act.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="05dc261436d8492b8fe07bd2c5be5539" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">No Inconsistent Obligations</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">11.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Additional Representations and Warranties of MacroGenics</u></font>.&#160; MacroGenics represents and warrants as of the Execution Date and, as applicable, covenants to Company that:</font></div>

<div>
<table id="ea9bdc9c2bd541be816d07fb1cf7ac8b" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">MacroGenics (or its Affiliates) is the sole and exclusive owner of, or otherwise Controls pursuant to an existing Third Party agreement, the MacroGenics Technology and the Regulatory Materials.&#160; MacroGenics has all rights necessary to grant the licenses under the MacroGenics Technology and rights of cross-reference under Regulatory Materials that it grants to Company in this Agreement.&#160; During the Term, MacroGenics shall not, and shall cause its Affiliates not to, grant to any Third Party rights that encumber or conflict with the rights granted to Company hereunder with respect to the MacroGenics Technology or Regulatory Materials.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="cf1eb1b2ed7c4cc184ed37a2406ce479" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The Patents set forth in <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit C</u></font> ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Licensed Patents</font>") represent all Patents that MacroGenics or any of its Affiliates owns or Controls that Cover or disclose any invention necessary or used for the Exploitation of the Compounds or Products in the Territory in the Field as of the Execution Date. &#160;&#160; The Licensed Patents are free and clear of liens, charges or encumbrances other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Company hereunder.&#160; No Third Party has challenged or threatened in writing to challenge the scope, validity or enforceability of any Licensed Patent (including, by way of example, through opposition or the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the U.S. Patent and Trademark Office or any analogous foreign Governmental Authorities).&#160; MacroGenics or its Affiliates have timely paid all filing and renewal fees payable with respect to any Licensed Patents for which MacroGenics controls prosecution and maintenance.&#160; The development of the Licensed Patents has not been funded, in whole or in part, by the U.S. government.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9df45bce4eee40a08b5f25c20fe10910" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">MacroGenics or any of its Affiliates owns or Controls all MacroGenics Know-How necessary or useful for the Exploitation of the Compounds or Products in the Territory in the Field.&#160; The MacroGenics Know-How is free and clear of liens, charges or encumbrances other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Company hereunder.&#160;&#160; MacroGenics and its Affiliates have taken commercially reasonable measures consistent with industry practices to protect the secrecy, confidentiality and value of all MacroGenics Know-How that constitutes trade secrets under Applicable Law (including requiring all employees, consultants and independent contractors to execute binding and enforceable agreements requiring all such employees, consultants and independent contractors to maintain the confidentiality of such MacroGenics Know-How).&#160; The development of the MacroGenics Know-How has not been funded, in whole or in part, by the U.S. government.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div>
<table id="8ae3003ce59643799b0db8d34dcbeccd" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">There is no actual or, to MacroGenics' Knowledge, threatened infringement or misappropriation of the MacroGenics Technology by any Person in the Territory.&#160; MacroGenics has not received any written notice or threat of any material suit, legal claim, action, proceeding or investigation against MacroGenics or any of its Affiliates that relates to the MacroGenics Technology, and no judgment or settlement is owed by MacroGenics or any of its Affiliates in connection with the MacroGenics Technology.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="37e1cceb79a8469b905d7d62fec9a006" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">The MacroGenics Technology collectively constitutes all intellectual property Controlled by MacroGenics that is necessary or useful for the Exploitation of the Compounds and the Products.&#160; To MacroGenics' Knowledge, except as otherwise disclosed by MacroGenics to Company, or discussed by the Parties, during the course of preparing this Agreement, the Exploitation of the Compounds or Products in the Field in the Territory does not and will not infringe or misappropriate the Patents (including any Third Party patent application published as of the Execution Date, when and if the claims thereunder issue in their current form) or other intellectual property or proprietary rights of any Third Party in the Territory.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="7c8fe5f41bb8466e9e0af463570905e8" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">All current and former officers, employees, agents, advisors, consultants, contractors or other representatives of MacroGenics or any of its Affiliates who are inventors of or have otherwise contributed in a material manner to the creation or development of any MacroGenics Technology have executed and delivered to MacroGenics or any such Affiliate a valid and enforceable assignment or other agreement regarding the protection of proprietary Information and the assignment to MacroGenics or any such Affiliate of such person's entire right, title and interest in and to any MacroGenics Technology.&#160; To MacroGenics' Knowledge, no current officer, employee, agent, advisor, consultant or other representative of MacroGenics or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the protection of MacroGenics Patents or other MacroGenics Technology or of any employment contract or any other contractual obligation relating to the relationship of any such Person with MacroGenics or any such Affiliate.&#160; Company shall have no obligation to contribute to any remuneration of any inventor employed or previously employed by MacroGenics or any of its Affiliates in respect of any such inventions, Information and discoveries and intellectual property rights therein that are so assigned to MacroGenics or its Affiliate(s).&#160; MacroGenics will pay all such remuneration due to such inventors with respect to such inventions and other Know-How and intellectual property rights therein.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c047733054ab4a26b9fdd2e851cf77b8" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(g)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">MacroGenics has (i) prepared, maintained and retained all Regulatory Materials for the Compounds and the Products in the Territory pursuant to and in accordance in all material respects with all Applicable Law, including, as applicable, GLP, and such Regulatory Materials do not contain any materially false and misleading statements; (ii) MacroGenics has conducted, and has used Commercially Reasonable Efforts to cause its contractors and consultants to conduct, all studies, tests and pre-clinical trials of the Compounds and the Products conducted prior to, or being conducted on, the Execution Date in accordance with the applicable experimental protocols, procedures and controls pursuant to accepted professional scientific standards, accepted ethical standards and Applicable Law, including, as applicable, GLP; (iii) except as disclosed in writing by MacroGenics to Company prior to the Execution Date, no adverse event involving human subjects has occurred in connection with any study, test or pre-clinical trial of the Compounds or the Products; and (iv) MacroGenics has disclosed to Company all material data and other information in its control generated in the design, approval, undertaking and reporting of any study or pre-clinical trial involving the Compounds or the Products.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9f64c63a5aa646939cca5dc394477be6" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(h)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Neither MacroGenics nor any of its Affiliates has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities in the Territory, and neither MacroGenics nor any of its Affiliates has used, in any capacity, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction.&#160; MacroGenics shall not engage, in any capacity in connection with this Agreement or any ancillary agreements, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction.&#160; MacroGenics shall inform Company in writing promptly if it or any Person engaged by MacroGenics or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to MacroGenics' Knowledge, is threatened, relating to the debarment or conviction of MacroGenics, any of its Affiliates or any such Person performing services hereunder or thereunder.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">11.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Additional Representations and Warranties of Company</u></font>.&#160; Company represents and warrants as of the Execution Date and covenants to MacroGenics that:</font></div>

<div>
<table id="88e068b5c5274cbbab2a99bcb1a83067" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Neither Company nor any of its Affiliates has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities in the Territory, and neither Company nor any of its Affiliates has used, in any capacity, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction.&#160; Company shall not engage, in any capacity in connection with this Agreement or any ancillary agreements, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction.&#160; Company shall inform MacroGenics in writing promptly if it or any Person engaged by Company or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Company's Knowledge, is threatened, relating to the debarment or conviction of Company, any of its Affiliates or any such Person performing services hereunder or thereunder.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c547bc39cb96455cbd3b3048d985be55" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Company is not subject to any agreement with any Third Party which would limit or restrict its ability to perform its obligations under this Agreement in any material respect.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">11.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">No Other Representations or Warranties</font>.&#160; EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 11, THE PARTIES MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, INCLUDING ANY EXPRESS OR IMPLIED WARRANTY OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT OR AS TO THE VALIDITY OF ANY PATENTS.&#160; EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY PRODUCT WILL BE ACHIEVED.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 12</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> CONFIDENTIALITY</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">12.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Nondisclosure</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Each Party agrees that, during the Term and for a period of [***] thereafter, the Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Receiving Party</font>") receiving Confidential Information of the other Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Disclosing Party</font>") shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary Information of similar kind and value, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 12.1 shall not create or imply any rights or licenses not expressly granted under this Agreement).&#160; Notwithstanding anything to the contrary in the foregoing, the obligations of confidentiality and non-use with respect to any trade secret within such Confidential Information shall survive such [***] period for so long as such Confidential Information remains protected as a trade secret under Applicable Law.</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Exceptions</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The obligations in Section 12.1 shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent evidence:</font></div>

<div>
<table id="1e24f300b72542b7b8b50aa43448dd20" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="6dabedb1eb734ec9b79bc6b2d3eaf568" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">is known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, in each case, to the Disclosing Party, prior to disclosure to the Receiving Party or any of its Affiliates by the Disclosing Party;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="10ac296f459644aea0664bec94889997" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that, to the Receiving Party's Knowledge, is not bound by a similar duty of confidentiality or restriction on its use, in each case, to the Disclosing Party;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f2b78347868f487fa111d6bfbeaf3e95" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates in violation of this Agreement, generally known or available, either before or after it is disclosed to the Receiving Party by the Disclosing Party;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f9d07b529bb948acab2228893828be8f" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates without the use of or reference to the Confidential Information belonging to the Disclosing Party; or</div>
</td>
</tr>
</table>
</div>

<div>
<table id="1166296171b74361b5db7c8c657a35e3" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">is the subject of written permission to disclose provided by the Disclosing Party.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Authorized Disclosure</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The Receiving Party may disclose Confidential Information belonging to the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances:</font></div>

<div>
<table id="0ef6a64a70f040ee9771ee69f63f972a" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">filing, prosecuting, maintaining, enforcing or defending Patents as permitted by this Agreement;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="acdaf09eac8f4b1096d00eb88224ee75" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">as reasonably required in generating Regulatory Materials and obtaining Regulatory Approvals;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f815b454d3f34b4caac97e274085d638" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="527982c5b88b4558946b9664faabee3c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">complying with Applicable Law or court or administrative orders;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="27c6a97f996c44e2bb4d829892a9a368" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">complying with any obligation under this Agreement;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="8f310afd270a48d3bb2f31fd6745ca85" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(f)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">in communications with existing or bona fide prospective acquirers, merger partners, financing sources, investment bankers, lenders or investors, and consultants and advisors of the Receiving Party in connection with transactions or bona fide prospective transactions with the foregoing, in each case on a need to know basis and under appropriate confidentiality provisions substantially equivalent to those of this Agreement; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">, </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Third Party receiving such Confidential Information; or</div>
</td>
</tr>
</table>
</div>

<div>
<table id="bb8a0af9b24f49f4b71f2f34b8199131" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(g)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">to its Affiliates, sublicensees or prospective sublicensees, subcontractors or prospective subcontractors, consultants, agents and advisors on&#160; a "need-to-know" basis in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than those set forth in this ARTICLE 12; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 12.3(g) to treat such Confidential Information as required under this ARTICLE 12.</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 36pt">If and whenever any Confidential Information is disclosed in accordance with this Section 12.3, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).&#160; Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party's Confidential Information pursuant to Section 12.3(a) through Section 12.3(e), it will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure and use not less than the same efforts to secure confidential treatment of such information as it would to protect its own confidential information from disclosure.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Terms of this Agreement</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The Parties acknowledge that this Agreement and all of the respective terms of this Agreement shall be treated as Confidential Information of both Parties, subject to the provisions of Sections 12.3(f), 12.3(g) and 12.6.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Publicity</u></font>.</font></div>

<div>
<table id="5ebd6e128216498994d58a2fc1496dbd" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Each Party may, but is not obligated to, make a public announcement of the execution of this Agreement in the form attached as <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit F</u></font> to this Agreement, which shall be issued at a time to be mutually agreed by the Parties, but no later than [***] after the Execution Date.&#160; Except as required to comply with Applicable Law or as set forth in subsection (b), each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned.</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">The Parties acknowledge the importance of supporting each other's efforts to publicly disclose results and significant developments regarding the Products and other activities in connection with this Agreement that may include information that is not otherwise permitted to be disclosed under this ARTICLE 12, and that may be beyond what is required by Applicable Law, but in each case consistent with the need to keep investors informed regarding such Party's business in accordance with customary investor relations,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160; </font>and each Party may request to the right to make such disclosures from time to time.&#160; Such disclosures may include achievement of milestones, significant events in the Development and regulatory process, Commercialization activities and the like.&#160; Except for the initial press release(s) described in subsection (a), whenever a Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Requesting Party</font>") elects to make any such public disclosure, it shall first notify the other Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cooperating Party</font>") of such planned press release or public announcement and provide a draft for review at least [***] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by Applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [***] in advance).&#160; The Requesting Party and Cooperating Party will discuss such proposed public disclosure in good faith. Unless otherwise permitted pursuant to Section 12.6 or required by Applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), the Requesting Party will not issue such press release or make such public announcement without the prior written consent of the Cooperating Party, not to be unreasonably withheld, conditioned or delayed, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that a Party may issue such press release or make such public announcement if: (i) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the Requesting Party, (ii) such press release or public announcement does not materially differ from the previously issued press release or other publicly available information, (iii) such press release or public announcement does not contain the Cooperating Party's name and (iv) the Requesting Party notifies the Cooperating Party reasonably in advance of issuance.&#160; The principles to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts), the need to protect competitively sensitive information regarding the Products and the need to keep investors informed regarding the Requesting Party's business.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Securities Filings</u></font>.&#160; Notwithstanding anything to the contrary in this ARTICLE 12, in the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document that describes or refers to the terms and conditions of this Agreement or any related agreements between the Parties, or requires the filing of this Agreement as an exhibit to such registration, statement or disclosure document, such Party shall notify the other Party of such intention and shall provide the other Party with a copy of relevant portions of the proposed filing at least [***] prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto that refer to the other Party or the terms and conditions of this Agreement or any related Agreements between the Parties.&#160; The Party making such filing shall cooperate in good faith with the other Party to obtain confidential treatment of the terms and conditions of this Agreement or any related Agreements between the Parties that the other Party reasonably requests be kept confidential or otherwise afforded confidential treatment, and shall only disclose Confidential Information that it is advised by outside counsel is legally required to be disclosed.&#160; Each Party acknowledges that the other Party may be required by securities regulators, including the Securities and Exchange Commission, or advised by such other Party's outside counsel that the financial terms, including the milestone amounts and/or royalty rates must be included in such filings.&#160; No notice shall be required under this Section 12.6 if the description of or reference to this Agreement or a related agreement between the Parties contained in the proposed filing has been included in any previous filing made by either Party in accordance with this Section 12.6 or otherwise approved by the other Party.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Relationship to Confidentiality Agreement</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>This Agreement supersedes the Prior CDA; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that all "Confidential Information" disclosed or received by the Parties and their Affiliates thereunder shall be deemed Confidential Information hereunder and shall be subject to the terms and conditions of this Agreement.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">12.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Equitable Relief</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Given the nature of the Confidential Information and the competitive damage that could result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this ARTICLE 12.&#160; In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this ARTICLE 12.</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Publications</u></font>.&#160; Company shall have the right to publish results of all Clinical Trials conducted with respect to a Compound or a Product; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that MacroGenics shall have the right to review all proposed publications prior to submission of such publication, solely for the purposes of identifying any relevant intellectual property or Confidential Information of MacroGenics.&#160; Company shall provide MacroGenics with a copy of the applicable proposed abstract, manuscript, or presentation no less than [***] in the case of abstracts) prior to its intended submission for publication.&#160; MacroGenics shall respond in writing promptly and in no event later than [***] in the case of abstracts) after receipt of the proposed material with any concerns regarding patentability or protection of MacroGenics' Confidential Information.&#160; In the event of concern over patent protection, Company agrees not to submit such</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">publication or to make such presentation that contains such information until MacroGenics is given a reasonable period of time, and in no event less than thirty [***], to seek patent protection for any material in such publication or presentation which it believes is patentable, unless Company reasonably determines that publication of such information is required by Applicable Law.&#160; Subject to Section 12.3, any Confidential Information of MacroGenics shall, if requested by the reviewing Party, be removed by Company from such publication or presentation, except to the extent inclusion of such Confidential Information is required to comply with Johnson &amp; Johnson's clinical trial publication policy.</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 13</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> TERM AND TERMINATION</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Term</u></font>.&#160; This Agreement shall become effective as of the Execution Date and, unless earlier terminated pursuant to this ARTICLE 13, shall continue in full force and effect as long as Company continues to Exploit the Compounds or the Products in accordance with the terms and conditions of this Agreement (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Term</font>").&#160; The provisions of ARTICLE 1 (Definitions), ARTICLE 11 (Representations, Warranties and Covenants), ARTICLE 12 (Confidentiality), ARTICLE 14 (Dispute Resolution), ARTICLE 15 (Indemnification) and ARTICLE 16 (Miscellaneous), and Section 13.3 (Termination for Material Breach) and Section 13.6 (HSR Filing; Termination Upon HSR Denial),<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>shall become effective on the Execution Date; the other provisions of this Agreement shall not become effective until the Effective Date.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><u>Unilateral Termination by Company</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">.&#160; Company shall have the right to terminate this Agreement in its entirety, or on a Product-by-Product basis, at any time after the Execution Date, for any or no reason, upon providing</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">one hundred eighty (180) days' prior written notice to MacroGenics.&#160; Notwithstanding the foregoing, in the event that Company provides such a notice of termination, MacroGenics may, in its sole discretion, reduce the one hundred eighty (180) day notice period to a period determined by MacroGenics by written notice to Company.</font></font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Termination for Material Breach</u></font>.</font></div>

<div>
<table id="e9075bbed1ca4d52b05b7ee284a34264" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Either Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Terminating Party</font>") may terminate this Agreement in its entirety, or on a country-by-country and Product-by-Product basis, in the event the other Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Breaching Party</font>") has materially breached this Agreement, and such material breach has not been cured within [***] after receipt of written notice of such breach by the Breaching Party from the Terminating Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cure Period</font>").&#160; The written notice describing the alleged material breach shall provide sufficient detail to put the Breaching Party on notice of such material breach. Any termination of this Agreement pursuant to this Section 13.3(a) shall become effective at the end of the Cure Period, unless the Breaching Party has cured any such material breach prior to the expiration of such Cure Period (or, if such material breach is reasonably able to be cured within the Cure Period,</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">the Breaching Party has notified the Terminating Party of its plan for curing such and has commenced and sustained its efforts to cure such material breach during the Cure Period).&#160; The right of either Party to terminate this Agreement as provided in this Section 13.3(a) shall not be affected in any way by such Party's waiver of or failure to take action with respect to any previous breach under this Agreement.</div>

<div>
<table id="b3f950f98c1945f297e6c2970eb28d80" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">If the Parties reasonably and in good faith disagree as to whether there has been a material breach or a cure thereof, the Party that disputes whether there has been a material breach or a cure may contest the allegation in accordance with ARTICLE 14.&#160; Notwithstanding anything to the contrary contained in Section 13.3(a), the Cure Period for any material breach that is the subject of a Dispute will run from the date that written notice was first provided to the Breaching Party by the Terminating Party through the resolution of such Dispute pursuant to ARTICLE 14 and for [***] thereafter, and it is understood and acknowledged that, during the pendency of a Dispute pursuant this Section 13.3(b), all of the terms and conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations under this Agreement, except that all payment obligations from one Party to the other Party under this Agreement which are subject to the Dispute shall be tolled until the resolution of such Dispute in accordance with ARTICLE 14.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Termination by Company for Safety Reasons</u></font>.&#160; Company shall have the right to terminate this Agreement, at any time after the Effective Date, with respect to a Product in the Territory at any time upon providing [***] prior written notice to MacroGenics:&#160; (a) if senior executives responsible for Company's pharmacovigilance and clinical science functions determine in good faith that the risk/benefit profile of the Product is such that the Product cannot continue to be Developed or administered to patients safely; or (b) upon the occurrence of serious adverse events related to the use of the Product that cause Company to conclude that the continued use of the Product by patients will result in patients being exposed to a product in which the risks outweigh the benefits.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Termination for Patent Challenge</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.&#160; </font>MacroGenics may terminate this Agreement with respect to a Product (or this Agreement in its entirety if such Product is the only Product for which this Agreement is applicable), if Company directly or indirectly disputes, or assists any Third Party to dispute, the validity of any granted Patent within the MacroGenics Patents in a litigation or other court proceeding with respect to such Product; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, MacroGenics acknowledges and agrees that nothing in this Section 13.5 [***] in this Section 13.5 and, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>further</u></font> that MacroGenics shall not have the right to terminate if Company:</font></div>

<div>
<table id="1296e4f568cd4ff7becb8e6d386be438" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">[***]any [***] in relation to [***]</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div>
<table id="baed9463f69e488b93e36afade8fcf86" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">[***] MacroGenics, its Affiliates, sublicensees, successors or designees [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="b600dcdb05974139a1a84b38550532f4" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">either [***] that [***]</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>HSR Filing</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>; Termination Upon HSR</u></font><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">&#160;</sub><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Denial</u></font>.&#160; If Company and MacroGenics determine that an HSR Filing is necessary, each Party shall, within [***] of the Execution Date (or such later time as may be agreed to in writing by the Parties), file with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice, and/or with equivalent foreign authorities, any HSR Filing required of it under the HSR Act in the reasonable opinion of either Party with respect to the transactions contemplated hereby. Each Party will use reasonable efforts to do, or cause to be done, all things necessary, proper and advisable to, as promptly as practicable, take all actions necessary to make the filings required of such Party or its Affiliates under the HSR Act.&#160; The Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR Filing.&#160; Each Party shall be responsible for its own costs, expenses, and filing fees associated with any HSR Filing; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that Company shall be solely responsible for any fees (other than penalties that may be incurred as a result of actions or omissions on the part of MacroGenics) required to be paid to any governmental agency in connection with making any such HSR Filing. If the Parties make an HSR Filing hereunder, then this Agreement shall terminate (a) at the election of either Party, immediately upon notice to the other Party, if the U.S. Federal Trade Commission or the U.S. Department of Justice, or an equivalent authority in the European Union, seeks a preliminary injunction under the Antitrust Laws against Company and MacroGenics to enjoin the transactions contemplated by this Agreement; or (b) at the election of either Party, immediately upon notice to the other Party, in the event that the HSR Clearance Date shall not have occurred on or prior to [***] after the effective date of the HSR Filing. In the event of such termination, this Agreement shall be of no further force and effect.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Termination for Bankruptcy</u></font>.</font></div>

<div>
<table id="e75ac9f66fc1419a9dd18f8713ff4ff5" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of the type described above (each, an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Insolvency Event</font>"), and such proceeding or action remains un-dismissed or un-stayed for a period of more than [***]</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt; MARGIN-TOP: 12pt">All rights and licenses granted under or pursuant to this Agreement, including, for the avoidance of doubt, the licenses granted to Company pursuant to Section 3.1, are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the U.S. Code and other similar laws in any jurisdiction outside the U.S. (collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Bankruptcy Laws</font>"), licenses of rights to "intellectual property" as defined under the Bankruptcy Laws.&#160; Upon the occurrence of any Insolvency Event with respect to a Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Insolvent Party</font>"), the Insolvent Party agrees that the other Party (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Non-Insolvent Party</font>"), as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Laws.&#160; Further, each Party agrees and acknowledges that all payments hereunder, other than the milestone payments pursuant to Section 9.3, the royalty payments pursuant to Section 9.4, and the payments pursuant to Section 9.9, do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">.&#160; </font>Each Party shall, during the term of this Agreement, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property (MacroGenics Technology in the case of MacroGenics and Company Technology in the case of Company). Each Party agrees and acknowledges that "embodiments" of intellectual property within the meaning of Section 365(n) include, without limitation, laboratory notebooks, cell lines, product samples and inventory, research studies and data, Regulatory Approvals and Regulatory Materials in each case to the extent related to the Compounds and Products. If (i) a case is commenced during the Term by or against a Party under the Bankruptcy Laws, (ii) this Agreement is rejected as provided for under the Bankruptcy Laws, and (iii) the Non-Insolvent Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Insolvent Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall (x) provide to the Non-Insolvent Party immediately upon the Non-Insolvent Party's written request copies of all such intellectual property (including embodiments thereof) held by the Insolvent Party and such successors and assigns, or otherwise available to them, and (y) not interfere with the Non-Insolvent Party's rights under this Agreement, or any related agreements between the Parties, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in the Bankruptcy Laws.&#160; Whenever the Insolvent Party or any of its successors or assigns provides to the Non-Insolvent Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 13.7(b), the Non-Insolvent Party shall have the right to perform the Insolvent Party's obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by the Non-Insolvent Party shall release the Insolvent Party from liability resulting from rejection of the license or the failure to perform such obligations. All rights, powers and remedies of the Non-Insolvent Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws.&#160; In particular, it is the intention and understanding of the Parties to this Agreement that the rights granted to the Parties under this Section 13.7 are essential to the Parties' respective businesses and the Parties acknowledge that damages are not an adequate remedy.&#160; The Parties agree that they intend the following rights to extend to the maximum extent permitted by Applicable Law, and to be enforceable under Section 365(n) of Title 11 of the U.S. Code: (A) the right of access to any intellectual property (including embodiments thereof) of the Insolvent Party, or any Third Party with whom the Insolvent Party contracts to perform an obligation of the Insolvent Party under this Agreement, and, in the case of the Third Party, which is necessary for the Exploitation of Compounds or Products; and (B) the right to contract directly with any Third Party to complete the contracted work upon failure of the Insolvent Party to comply with its applicable obligations.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Effects of Termination</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> All of the following effects of termination are in addition to the other rights and remedies that may be available to either of the Parties under this Agreement and shall not be construed to limit any such rights or remedies.&#160; In the event this Agreement is not terminated in its entirety, but rather is terminated on a Product-by-Product or country-by-country basis with respect to one or more Products as specified herein (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Terminated Product</font>") in one or more country(ies) (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Terminated Country</font>"), then, notwithstanding anything to the contrary contained in Sections 13.8(a) or 13.8(b), the consequences of termination described under this Section 13.8 shall only apply to the Terminated Product in the Terminated Country, and this Agreement shall remain in full force and effect in accordance with its terms with respect to all Products other than the Terminated Products, and in all countries of the Territory other than the Terminated Countries.</font></div>

<div>
<table id="9ca8e7788eb446888e6b5c256e1a74cc" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Consequences of Termination by MacroGenics or Company</font>.&#160; In the event of termination of this Agreement by (i) MacroGenics pursuant to Section 13.3, 13.5, 13.7 or Section 16.7 or (ii) Company pursuant to Section 13.2, Section 13.4 or Section 16.3, the following provisions of this Section 13.8(a) shall apply from and after the effective date of termination (except to the extent otherwise provided in Section 13.8(a)(vi):</div>
</td>
</tr>
</table>
</div>

<div>
<table id="9ad540c798584e4a92b80f25b3550a88" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Without limiting the effect that such termination shall have on any provisions of this Agreement, other than those provisions that this Agreement expressly provides shall survive such termination, all rights and licenses granted</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">herein to Company shall terminate, and Company shall cease any and all Development, Manufacturing, and Commercialization activities with respect to the Products (to the extent such activities were being performed using such rights and licenses) as soon as is reasonably practicable under Applicable Law.</div>

<div>
<table id="3252e5765e94404bb71c19cd5a458ed1" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">All payment obligations hereunder shall terminate, other than those that are accrued and unpaid as of the effective date of such termination and royalties that become due under Section 9.4 with respect to sales of Reverted Products made by Janssen following the effective date of termination pursuant to Section 13.8(a)(vii).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="a679f5c4b41d48fdabb33ff739227c7a" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">MacroGenics shall have a reversion of all rights previously licensed to Company hereunder for which the relevant licenses have terminated on a fully paid-up and royalty-free basis, itself or with or through an Affiliate or Third Party, to Develop, Manufacture and Commercialize the Products at MacroGenics' discretion, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that any Third Party Obligation arising pursuant to Section 9.10(b) is passed through to MacroGenics.&#160; &#160; </div>
</td>
</tr>
</table>
</div>

<div>
<table id="c40638b7997549c7bf10f21b3edd6299" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company hereby grants to MacroGenics, effective as of the effective date of such termination, a non-exclusive, transferable, fully paid-up, royalty-free, sublicenseable license in the Field in the Territory, under the Company Applied Technology and Company's right to Joint Inventions and Joint Patents, solely to Exploit any Product that is in active clinical Development or has been Commercialized by Company at the time of termination (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Reverted Product</font>"); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that MacroGenics shall reimburse Company for any amounts paid by Company to any Third Party in connection with MacroGenics' exercise of such license.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="42ba7f2bfd9947189342a1a6344a7331" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">At MacroGenics' written request, Company shall grant to MacroGenics, effective as of the date of such request, an exclusive, transferable, fully paid-up, royalty free, sublicensable license to use any trademarks owned or Controlled by Company or any of its Affiliates which are solely used in the Commercialization of Reverted Products in the Territory (excluding any Company house marks).</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ddda7132e5a04d67aa9d93a93c3ef607" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(vi)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">The JSC (if then in existence) or a committee formed by the Parties for purposes of effecting transition of responsibilities (if the JSC is not then in existence) shall coordinate the wind-down of Company's efforts under this Agreement and Company, as soon as reasonably practicable after the effective date of such termination, shall provide to MacroGenics, as applicable and to the extent permitted under any applicable Third Party contract, any material Information, including copies of all Clinical Trial data and results, Controlled by Company to the extent solely relating to the Reverted Products, including control of, and all Information relating to, the global safety database.&#160; Company will reasonably cooperate with MacroGenics to provide a transfer of such material</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">Information. Beginning on the date that notice of termination of this Agreement is given by MacroGenics pursuant to Section 13.3, Section 13.7 or Section 16.7 or by Company pursuant to Section 13.2, Section 13.4 or Section 16.3, (A) Company shall have no further obligation to commence or provide funding for any Clinical Trial that has not yet commenced (for purposes of this sentence, "commencement" means the [***]) on or before such date of notice of termination of this Agreement; and (B) at MacroGenics' request, MacroGenics shall have the right, and Company shall cooperate in good faith with MacroGenics to enable MacroGenics, to commence any such Clinical Trial included in the then-current Global Development Plan prior to the effective date of termination of this Agreement; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that such cooperation shall not include any obligation to provide funding for such Clinical Trial.&#160; At MacroGenics' request, Company shall use reasonable efforts to (x) assign to MacroGenics any and all Third Party agreements to which Company or any of its Affiliates are a party that relate exclusively to the Development, Commercialization and Manufacturing activities conducted in connection with Reverted Products prior to such termination (including agreements relating to the sourcing and Manufacture of a Reverted Product or, to the extent the First Commercial Sale of a Reverted Product has occurred, for sale, promotion, distribution, or use of such Reverted Product) or, (y) if such assignment is not permitted under the relevant Third Party agreement: (1) grant to MacroGenics other rights to provide to MacroGenics the benefit of such non-assignable agreement, at MacroGenics' expense, to the extent permitted under the terms of such non-assignable agreement; or (2) to the extent not permitted under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable MacroGenics to receive, at MacroGenics' expense, the benefit of the terms of such non-assignable agreement.&#160; In the event one or more Reverted Products, or any materials relating to such Reverted Products, are Manufactured by Company or its Affiliate, then, upon the written request of MacroGenics, Company shall supply MacroGenics with such Reverted Product(s) and/or materials at [***] and for a transitional period to be mutually agreed upon by the Parties and, if necessary, provide technical assistance reasonably necessary to assist MacroGenics in the start-up of Manufacturing of such Reverted Product(s) and/or materials, and/or obtaining Regulatory Approval of the Reverted Product(s).&#160; In addition to the actions contemplated in this Section 13.8(a)(vi) Company shall take such other actions and execute such other instruments, assignments and documents as reasonably requested by MacroGenics as may be necessary to effect the transfer of rights to such Product(s) hereunder to MacroGenics.</div>

<div>
<table id="1055a91363b54514a6761bac8f0b1263" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(vii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Subject to the payment of all amounts required under Section 13.8(a)(ii), Company shall have the right to sell or otherwise dispose of any inventory of any Reverted Product on hand at the time of such termination or in the process of Manufacturing; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, at MacroGenics' request, Company shall transfer to MacroGenics any Product that has not been sold or used [***] following such termination, at a cost equal to the [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="922e266e867149e89a5762499af5c65d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(viii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 139.5pt">Company shall transfer to MacroGenics any and all Regulatory Materials Controlled by Company on the effective date of termination, to the extent such Regulatory Materials relate solely to any Reverted Products, including any INDs, Regulatory Approval Applications or Regulatory Approvals solely related to any Reverted Products.&#160; Upon MacroGenics' request, Company shall make available to MacroGenics any other relevant Information Controlled by Company on the effective date of termination, to the extent such Information relates to such Regulatory Materials, and shall provide a right of reference to any Regulatory Materials Controlled by Company on the effective date of termination, to the extent such Regulatory Materials are necessary for MacroGenics or its licensees to develop and commercialize Reverted Products and are not transferred to MacroGenics hereunder.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="37c0b79014a44fc09be9f08eac4e6774" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ix)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">MacroGenics shall have the right to assume all preparation, filing, prosecution, maintenance and enforcement activities under ARTICLE 10 with respect to MacroGenics Patents as to which Company has assumed the right and authority to prepare, file, prosecute, maintain or enforce.&#160; Company will cooperate with MacroGenics and provide MacroGenics with reasonable assistance with the preparation, filing, prosecution, maintenance, and enforcement activities with respect to such MacroGenics Patents.&#160; The step-in rights granted to MacroGenics with respect to Joint Patents under Sections 10.3(d), 10.5(b) and 10.7(a) shall remain in effect, and MacroGenics shall have to the right to enforce the Company Patents, solely to the extent a license is granted under this Section 13.8(a), against Third Party infringers.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="fd86ea4008ea4a78b7377e01f6cfb02d" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Consequences of Certain Terminations by Company</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> In the event of termination of this Agreement by Company pursuant to Section 13.3 or Section 13.7, the following provisions of this Section 13.8(b) shall apply from and after the effective date of termination.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="80764da4b8e24397bf3c2390ef8568ea" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Without limiting the effect that such termination shall have on any provisions of this Agreement, other than those provisions that this Agreement expressly provides shall survive such termination, all rights and licenses granted herein to MacroGenics shall terminate (other than the license granted to MacroGenics under Section 3.2(c), which shall survive such termination), and MacroGenics shall cease any and all Development, Manufacturing, and Commercialization activities (including any co-promotion activities) with respect to the Products as soon as is reasonably practicable under Applicable Law.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div>
<table id="158aa220d95e4db79f66e69172f56496" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">All payment obligations hereunder shall continue, including those payment obligations that are accrued and unpaid as of the effective date of such termination, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that Company may pursue remedies under Section 13.9 and offset damages and costs as provided in Section 13.9.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="ad332744d3e24ad4b291351a5e4557d8" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">Company shall thereafter continue to have all rights previously licensed to Company hereunder, itself or with a Third Party or through a Third Party sublicensee, to Develop, Manufacture and Commercialize any and all Products at Company's discretion, in accordance with and subject to the terms and conditions of this Agreement.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="a4ab5f6381fc4f8caf3c5f69153866e6" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">All licenses granted to Company shall continue in full force and effect, in accordance with and subject to the terms and conditions of this Agreement, and all rights of MacroGenics with respect to the Co-Promote Option shall cease.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="1a6f9c83a839403ba2e720e933622327" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 76.5pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 148.5pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 103.5pt">The JSC (if then in existence) or a committee formed by the Parties for purposes of effecting transition of responsibilities (if the JSC is not then in existence) shall coordinate the wind-down of MacroGenics' efforts under this Agreement and MacroGenics, as soon as reasonably practicable after the effective date of such termination, shall provide to Company, as applicable and to the extent permitted under any applicable Third Party contract, any material Information, including copies of all Clinical Trial data and results, Controlled by MacroGenics that relates solely to the Products.&#160; MacroGenics will cooperate with Company to provide a transfer of such material Information.&#160; At Company's request, MacroGenics shall use reasonable efforts to (x) assign to Company any and all Third Party agreements to which MacroGenics or any of its Affiliates are a party that relate exclusively to Development, Commercialization and Manufacture of the Products in the Field in the Territory or (y) if such assignment is not permitted under the relevant Third Party agreement:&#160; (1) grant to Company other rights to provide to Company the benefit of such non-assignable agreement, at Company's expense, to the extent permitted under the terms of such non-assignable agreement; or (2) to the extent not permitted under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable Company to receive, at Company's expense, the benefit of the terms of such non-assignable agreement.&#160; In the event one or more Products, or any materials relating to such Products, are Manufactured by MacroGenics or its Affiliate, then, upon the written request of Company, MacroGenics shall supply Company with such Product(s) and/or materials at [***] and for a transitional period to be mutually agreed upon by the Parties and, if necessary, provide technical assistance reasonably necessary to assist Company in the start-up of Manufacturing of such Product(s) and/or materials, and/or obtaining Regulatory Approval of such Product(s).&#160; In addition to the actions contemplated in this Section 13.8(b), MacroGenics shall take such other actions and execute such other instruments, assignments and documents as reasonably</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 76.5pt">requested by Company as may be necessary to effect the transfer of rights to such Product(s) hereunder to Company.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Remedies</u></font>.&#160; Except as otherwise explicitly set forth in this Agreement, termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor prejudice either Party's right to obtain performance of any obligation.&#160; Each Party shall be free, pursuant to ARTICLE 14, to seek, without restriction as to the number of times it may seek, damages, costs and remedies that may be available to it under Applicable Law or in equity and shall be entitled to offset the amount of any damages and costs obtained against the other Party in a final determination under Section 14.3, against any amounts otherwise due to such other Party under this Agreement.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">13.9</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Survival</u></font>.&#160; In the event of termination or expiration of this Agreement, in addition to the provisions of this Agreement that continue in effect in accordance with their terms, the following provisions of this Agreement shall survive: ARTICLE 1 (Definitions) (as applicable), ARTICLE 12 (Confidentiality), ARTICLE 13 (Term and Termination), ARTICLE 14 (Dispute Resolution), ARTICLE 15 (Indemnification) (solely as to activities arising during the Term or as to any activities conducted in the course of a Party's exercise of a license surviving the Term), ARTICLE 16 (Miscellaneous); Sections 3.2(d), 3.4 (No Implied Licenses), 4.5 (Records), 5.3(a) (Company Responsibilities) (solely with respect to activities undertaken prior to the effective date of expiration or termination of this Agreement), 9.8 (Currency), 9.11 (Taxes), 9.12 (Tax Returns), 9.13 (Audit), 9.14 (Late Payment), 10.1 (Ownership of Inventions), Section 10.2 (Disclosure of Inventions) and 11.4 (No Other Representations or Warranties); and any other provisions of this Agreement that are necessary to interpret or effectuate the intent of the foregoing provisions.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 14</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> DISPUTE RESOLUTION</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">14.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Exclusive Dispute Resolution Mechanism</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The Parties agree that the procedures set forth in this ARTICLE 14 shall be the exclusive mechanism for resolving any dispute, controversy or claim between the Parties that may arise from time to time pursuant to this Agreement relating to either Party's rights or obligations hereunder (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Dispute</font>", and collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Disputes</font>") that is not resolved through good faith negotiation between the Parties.&#160; For the avoidance of doubt, this ARTICLE 14 shall not apply to any decision with respect to which a Party has final decision-making authority hereunder.&#160; Any Dispute, including Disputes that may involve the parent company, subsidiaries, or affiliates under common control of any Party, shall be resolved in accordance with this ARTICLE 14.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">14.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Resolution by Executive Officers</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Except as otherwise provided in this ARTICLE 14, in the event of any Dispute regarding the construction or interpretation of this Agreement or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves.&#160; In the event that such Dispute is not resolved on such basis within [***] (unless otherwise agreed by the Parties), either Party may, by written notice to the other Party, refer the Dispute to the Executive Officers for attempted resolution by good faith negotiation within [***] after such notice is received (unless otherwise agreed by the Parties).&#160; Each Party may, in its discretion, seek resolution of any and all Disputes that are not resolved under this Section 14.2 in accordance with Section 14.3.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">14.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Arbitration</u></font>.&#160; If the Parties fail to resolve the Dispute pursuant to Section 14.2, and a Party desires to pursue resolution of the Dispute, the Dispute shall be submitted by either Party for resolution in arbitration pursuant to the then current [***] except where they conflict with these provisions, in which case these provisions control.&#160; The arbitration will be held in [***] All aspects of the arbitration shall be treated as confidential.</font></div>

<div>
<table id="5e7f46222cd54d76a1473b2a8040fb25" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Arbitrators</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="34665ff95547458189f9bbdd2a39fdbb" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The arbitrators will be chosen from the CPR [***], unless a candidate not on such panel is approved by both Parties.&#160; Each arbitrator shall be a lawyer with at least [***] experience with a law firm or corporate law department of over [***] lawyers or who was a judge of a court of general jurisdiction.&#160; To the extent that the Dispute requires special expertise, the Parties will so inform CPR prior to the beginning of the selection process.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c48beb0e2dc14a119e0c6ac402d01090" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The arbitration tribunal shall consist of [***] arbitrators, of whom each Party shall designate one in accordance with the "screened" appointment procedure provided in CPR Rule 5.4.&#160; The chair will be chosen in accordance with CPR Rule 6.4.&#160; If, however, the aggregate award sought by the Parties is less than [***] and equitable relief is not sought, a single arbitrator shall be chosen in accordance with the CPR Rules.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="66320536435c43c09a4da7f5af6a96a0" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The Parties agree to select the arbitrator(s) within [***] days of initiation of the arbitration.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f0ce6e854d974b718e4091960882bc2c" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Procedures</font>.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="3d9b6118b7804dd0a227f4520c35d9bf" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(i)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The hearing will be concluded within [***] after selection of the arbitrator(s) and the award will be rendered within [***] of the conclusion of the hearing, or of any post&#8209;hearing briefing, which briefing will be completed by both sides within [***] after the conclusion of the hearing.&#160; In the event the Parties cannot agree upon a schedule, then the arbitrator(s) shall set the schedule following the time limits set forth above as closely as practical.</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div>
<table id="7dd677716cb841fc91a7876cd6b61691" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(ii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The hearing will be concluded in [***] or less.&#160; Multiple hearing days will be scheduled consecutively to the greatest extent possible.&#160; A transcript of the testimony adduced at the hearing shall be made and shall be made available to each Party.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="c931d05228094f51a35a16a850a86cb8" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(iii)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The arbitrator(s) shall be guided, but not bound, by the [***] ("<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Protocol</font>").&#160; The Parties will attempt to agree on modes of document disclosure, electronic discovery, witness presentation, etc. within the parameters of the Protocol.&#160; If the Parties cannot agree on discovery and presentation issues, the arbitrator(s) shall decide on presentation modes and provide for discovery within the Protocol, understanding that the Parties contemplate reasonable discovery.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="e5b2d9c259fc4a9999b1fc2b6ac7c5f0" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(iv)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The arbitrator(s) shall decide the merits of any Dispute in accordance with the law governing this Agreement, without application of any principle of conflict oflaws that would result in reference to a different law.&#160; The arbitrator(s) may not apply principles such as "amiable compositeur" or "natural justice and equity."</div>
</td>
</tr>
</table>
</div>

<div>
<table id="55e06c19e1ed49e080f63e4f05010221" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(v)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The arbitrator(s) are expressly empowered to decide dispositive motions in advance of any hearing and shall endeavor to decide such motions as would a United States District Court Judge sitting in the jurisdiction whose substantive law governs.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="7db3ee417ebd4d489a7d5abf9665a008" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 108pt">(vi)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; TEXT-INDENT: 108pt">The arbitrator(s) shall render a written opinion stating the reasons upon which the award is based.&#160; The Parties consent to the jurisdiction of the United States District Court for the district in which the arbitration is held for the enforcement of these provisions and the entry of judgment on any award rendered hereunder.&#160; Should such court for any reason lack jurisdiction, any court with jurisdiction may act in the same fashion.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">14.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Provisional Remedies</u></font>.&#160; Each Party has the right to seek from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">status quo</font>, or preserve the subject matter of the Dispute.&#160; [***] does not apply to this Agreement</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">14.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Confidentiality</u></font>.&#160; Any and all activities conducted under this ARTICLE 14 shall be deemed Confidential Information of each of the Parties, and shall be subject to ARTICLE 12 above.</font></div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 15</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> INDEMNIFICATION</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">15.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Indemnification by Company</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>.</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Company hereby agrees to defend, indemnify and hold harmless MacroGenics and its Affiliates, and each of their respective directors, officers, employees, agents and representatives (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MacroGenics Indemnitee</font>") from and against</font></div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">any and all claims, suits, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and attorneys' fees (collectively, the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Losses</font>"), to which any MacroGenics Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Claim</font>"), to the extent such Losses arise directly or indirectly out of: (a) the practice by Company or its Affiliate or sublicensee of any license granted to it under this Agreement; (b)&#160;the manufacture, use, handling, storage, sale, marketing, export, import or other disposition of any Compound or Product by Company or its Affiliate or sublicensee; (c) the breach by Company of any warranty, representation, covenant or agreement made by Company in this Agreement or, if MacroGenics exercises the Co-Promote Option, the Co-Promotion Agreement; or (d) the gross negligence, illegal conduct or willful misconduct (including to the extent such gross negligence, illegal conduct or willful misconduct gives rise to product liability Claims under any legal theory) of Company or its Affiliate or sublicensee, or any officer, director, employee, agent or representative thereof; except, with respect to each of clauses (a) through (d) above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence, illegal conduct or willful misconduct of any MacroGenics Indemnitee or the breach by MacroGenics ofany warranty, representation, covenant or agreement made by MacroGenics in this Agreement.&#160; Notwithstanding the foregoing, this Section 15.1 shall not apply to any Losses of a MacroGenics Indemnitee that arise during the Co-Funding Term, to the extent such Losses are Commercialization Expenses that are included in MacroGenics' allocation of the N.A. Profit/Loss.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">15.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Indemnification by MacroGenics</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>MacroGenics hereby agrees to defend, indemnify and hold harmless Company and its Affiliates and each of their respective directors, officers, employees, agents and representatives (each, a "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Indemnitee</font>") from and against any and all Losses to which any Company Indemnitee may become subject as a result of any Claim to the extent such Losses arise directly or indirectly out of: (a)&#160;the practice by MacroGenics or its Affiliate or its licensee (other than Company or its Affiliates or sublicensee) of any retained or reverted license right under ARTICLE 3 to Develop, Manufacture or Commercialize any Compound or Product pursuant to the terms of this Agreement or, if MacroGenics exercises its Co-Promote Option, any Co-Promotion Agreement; (b) the manufacture, use, handling, storage, sale or other disposition of any Compound or Product by MacroGenics or its Affiliate or its licensee (other than Company or its Affiliate or sublicensee); (c) the breach by MacroGenics of any warranty, representation, covenant or agreement made by MacroGenics in this Agreement, or, if MacroGenics exercises the Co-Promote Option, the Co-Promotion Agreement; or (d) the gross negligence, illegal conduct, or willful misconduct (including to the extent such gross negligence, illegal conduct or willful misconduct gives rise to product liability Claims under any legal theory) of MacroGenics or its Affiliate or its licensee (other than Company or its Affiliate or sublicensee), or any officer, director, employee, agent or representative thereof; except, with respect to each of clauses (a) through (d) above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence, illegal conduct or willful misconduct of any Company Indemnitee or the breach by Company of any warranty, representation, covenant or agreement made by Company in this Agreement.&#160; Notwithstanding the foregoing, this Section 15.2 shall not apply to any Losses of a Company Indemnitee that arise during the Co-Funding Term, to the extent such Losses are Commercialization Expenses that are included in Company's allocation of N.A. Profit/Loss.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">15.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Indemnification Procedures</u></font>.</font></div>

<div>
<table id="29d3ff11fc204e018e0f7401b3a80fb1" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Notice</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Promptly after a MacroGenics Indemnitee or a Company Indemnitee (each, an "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Indemnitee</font>") receives notice of a pending or threatened Claim, such Indemnitee shall give written notice of the Claim to the Party from whom the Indemnitee is entitled to receive indemnification pursuant to Sections&#160;15.1 or 15.2, as applicable (the "<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Indemnifying Party</font>").&#160; However, an Indemnitee's delay in providing or failure to provide such notice shall not relieve the Indemnifying Party of its indemnification obligations, except to the extent it can demonstrate prejudice due to the delay or lack of notice.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="e21ea80ef58b424585de5623b8a22080" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Defense</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Upon receipt of notice under this Section&#160;15.3 from the Indemnitee, the Indemnifying Party will have the duty to either compromise or defend, at its own expense and by counsel (reasonably satisfactory to Indemnitee) such Claim.&#160; The Indemnifying Party will promptly (and in any event not more than [***] after receipt of the Indemnitee's original notice) notify the Indemnitee in writing that it acknowledges its obligation (which acknowledgment shall not be deemed or construed as an admission of liability, either under this ARTICLE 15 or otherwise) to indemnify the Indemnitee with respect to the Claim pursuant to this ARTICLE 15 and of its intention to compromise or defend such Claim.&#160; Once the Indemnifying Party gives such notice to the Indemnitee, the Indemnifying Party is not liable to the Indemnitee for the fees of other counsel or any other expenses subsequently incurred by the Indemnitee in connection with such defense, other than the Indemnitee's reasonable Third Party expenses related to its investigation and cooperation.&#160; As to all Claims as to which the Indemnifying Party has assumed control under this Section 15.3(b), the Indemnitee shall have the right to employ separate counsel and to participate in the defense of a Claim (as reasonably directed by the Indemnifying Party) at its own expense.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f77a270e85914ccaa902a33929d49e92" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cooperation</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The Indemnitee will cooperate fully with the Indemnifying Party and its legal representatives in the investigation and defense of any Claim.&#160; The Indemnifying Party shall keep the Indemnitee informed on a reasonable and timely basis as to the status of such Claim (to the extent the Indemnitee is not participating in the defense of such Claim) and conduct the defense of such Claim in a prudent manner.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="f46966b61aee427c91dcbe4f2b0e1ce2" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Settlement</font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>If an Indemnifying Party assumes the defense of a Claim, no compromise or settlement of such Claim may be effected by the Indemnifying Party without the Indemnitee's written consent (such consent not to be unreasonably withheld, delayed or conditioned), unless: (1)&#160;there is no finding or admission of any violation of law or any violation of the rights of any Person and no effect on any other claims that may be made against the Indemnitee; (2)&#160;the sole relief provided is monetary damages that are paid in full by the Indemnifying Party; and (3)&#160;the Indemnitee's rights under this Agreement are not adversely affected.&#160; If the Indemnifying Party fails to assume defense of a Claim within a reasonable time, the Indemnitee may settle such Claim on such terms as it deems appropriate with the consent of the Indemnifying Party (such consent not to be unreasonably withheld, delayed or conditioned), and the Indemnifying Party shall be obligated to indemnify the Indemnitee for such settlement as provided in this ARTICLE 15.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="b87045f26570425a9b6dab254433096e" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Product Liability Claims</font>.&#160; Solely for purposes of coordinating the defense of any claims of a Third Party involving or that could result in Product Liabilities included in the definition of Global Development Costs, such claims will be treated as if they were Claims covered by this Section 15.3 and Company shall be deemed to be the "Indemnifying Party" under this Section 15.3 for such claims.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">15.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Insurance</u></font>.&#160; Each Party shall, at its own expense, procure and maintain during the period commencing on the Execution Date through the period of Commercialization and for a period of [***] thereafter, insurance policies, including product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business practices of pr companies similarly situated; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that in no event shall such product liability insurance be written in amounts less than [***] and annual aggregate.&#160; All such insurance shall include worldwide coverage.&#160; Prior to the initiation of any Clinical Trial, the Party responsible for such Clinical Trial shall secure, and maintain in full force and effect, clinical trial insurance as required by Applicable Law in those territories where such Clinical Trial shall be conducted.&#160; Upon request, each Party shall provide the other Party with a certificate of insurance evidencing the coverage required under this Section 15.4.&#160; Such insurance shall not be construed to create a limit of a Party's liability with respect to its indemnification obligations under this ARTICLE 15.&#160; Each Party shall provide the other Party with prompt written notice of cancellation, non-renewal or material change in such insurance that could materially adversely affect the rights of such other Party hereunder, and shall provide such notice within [***] after any such cancellation, non&#8209;renewal or material change.&#160; The Parties acknowledge and agree that Company may meet its obligations under this Section 15.4 through self-insurance.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">15.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Limitation of Liability</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>EXCEPT TO THE EXTENT INCLUDED IN LOSSES RESULTING FROM A THIRD PARTY CLAIM FOR WHICH ONE PARTY IS OBLIGATED TO INDEMNIFY THE OTHER PARTY (OR AN INDEMNITEE OF SUCH OTHER PARTY) PURSUANT TO THIS ARTICLE 15 AND ANY BREACH OF ARTICLE 12 (CONFIDENTIALITY)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">,</font> IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY'S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">ARTICLE 16</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> MISCELLANEOUS</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.1</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Notices</font>.&#160; All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given on the date delivered, if delivered personally, or on the next Business Day after being sent by reputable overnight courier (with delivery tracking provided, signature required and delivery prepaid), in each case, to the Parties at the following addresses, or on the date sent and confirmed by electronic transmission to the telecopier number specified below (or at such other address or telecopier number for a Party as shall be specified by notice given in accordance with this Section&#160;16.1).</font></div>

<div>
<table id="845721eb3e3b47f4bc29bd848b889920" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">If to Company:</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 144pt">Janssen Biotech, Inc.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>800/850 Ridgeview Drive<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Horsham, PA 19044<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Attention:</font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Fax:</font>[***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 144pt">with copies to:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 144pt">Johnson &amp; Johnson Law Department<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>One Johnson &amp; Johnson Plaza<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> New Brunswick, NJ 08933</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: left; MARGIN-LEFT: 144pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Attention:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Fax:</font>[***]</font></div>

<div>
<table id="96f2da982ec44501b963991cfec16648" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">If to MacroGenics:</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 144pt">MacroGenics, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 144pt">9640 Medical Center Drive</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 144pt">Rockville, MD&#160; 20850</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 144pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Attention:&#160; [***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font></font><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 117pt">with copies to:</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 144pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">MacroGenics, Inc.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>9640 Medical Center Drive<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Rockville, MD&#160; 20850<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Attention:</font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font></font><br>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.2</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Governing Law</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of [***], without giving effect to any choice of law principles that would require the application of the laws of a different state.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.3</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Change of Control of MacroGenics</u></font>.</font></div>

<div>
<table id="b5239e989ed745cfa28747c76a9c674d" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">MacroGenics (or its successor) shall provide notice to Company of any Change of Control of MacroGenics within [***] after the date upon which the Change of Control closes or otherwise becomes effective.</div>
</td>
</tr>
</table>
</div>

<div>
<table id="318865515b2d4950a41844342fed2735" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left">On or before the date that is [***] after the date upon which a Change of Control of MacroGenics closes or otherwise becomes effective, Company may terminate this Agreement in its entirety; or, in Company's sole and absolute discretion, Company may require (and MacroGenics, or its successor, shall perform, as applicable) any one or more of the following actions:&#160; (1) the Parties shall dissolve the JSC and after such dissolution Company shall solely have all rights (including all decision-making rights) and shall perform all activities assigned by this Agreement to the JSC; or (2) MacroGenics and its successor shall adopt reasonable written procedures, approved by Company, to prevent disclosure of Company's Confidential Information.</div>
</td>
</tr>
</table>
</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.4</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Assignment</u></font>.&#160; Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party (it being understood that neither a merger in respect of which such Party is a constituent corporation or entity, nor a change in the beneficial ownership of the voting securities of such Party, shall be deemed to be an assignment for purposes of this Section 16.4), except that a Party may make such an assignment without the other Party's consent to (a) an Affiliate or (b) subject to Section 16.3 above, an acquirer of all or substantially all of the property and assets of the Party in a sale of assets or other similar transaction.&#160; Any successor or assignee of rights and/or obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations.&#160; Any permitted assignment shall be binding on the successors of the assigning Party.&#160; Any assignment or attempted assignment by either Party in violation of the terms of this Section 16.4 shall be null, void and of no legal effect.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.5</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Designation of Affiliates</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Each Party may discharge any obligation and exercise any right hereunder through delegation of its obligations or rights to any of its Affiliates.&#160; Each Party hereby guarantees the performance by its Affiliates of such Party's obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.&#160; Any breach by a Party's Affiliate of any of such Party's obligations under this Agreement shall be deemed a breach by such Party, and the other Party may</font></div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">proceed directly against such Party without any obligation to first proceed against such Party's Affiliate.</div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.6</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Relationship of the Parties</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>It is expressly agreed that MacroGenics, on the one hand, and Company, on the other hand, are independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency.&#160; Neither MacroGenics nor Company shall have the authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other, without the prior written consent of the other Party to do so.&#160; All individuals employed by a Party shall be employees of that Party and not of the other Party and all costs and obligations incurred by reason of such employment shall be for the account and expense of such Party.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.7</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Force Majeure</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides notice of such Force Majeure circumstances to the other Party.&#160; Such excuse shall be continued so long as the condition constituting Force Majeure continues and the nonperforming Party takes reasonable efforts to remove the condition.&#160; Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a Force Majeure affecting such Party.&#160; If a Force Majeure persists for more than [***], then the Parties shall discuss in good faith the modification of the Parties' obligations under this Agreement in order to mitigate the delays caused by such Force Majeure.&#160; In the event a Party is prevented from performing its obligations under this Agreement due to Force Majeure for more than [***] according to this Section 16.7, the other Party shall have the right to terminate this Agreement upon [***] notice after the expiration of such period.&#160; A termination under this Section 16.7 by either Party shall be treated as a termination under Section 13.3 above and the corresponding provisions for termination under Section 13.3 shall apply except to the extent the affected Party is prevented from performing due to the Force Majeure.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.8</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Entire Agreement; Amendments</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>This Agreement, including the Exhibits and Schedules hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes, as of the Execution Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, including the Prior CDA.&#160; There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein.&#160; No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.&#160; In the event of any inconsistency between the body of this Agreement and either any Exhibits or Schedules to this Agreement or any subsequent agreements ancillary to this Agreement, unless otherwise express stated to the contrary in such Exhibit, Schedule or ancillary agreement, the terms contained in this Agreement shall control.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.9</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Severability</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.&#160; The Parties shall make good faith efforts to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.10</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>English Language</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>This Agreement shall be written in and executed in, and all other communications under or in connection with this Agreement shall be in, the English language.&#160; Any translation into any other language shall not be an official version hereof or thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.11</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Waiver and Non-Exclusion of Remedies</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.&#160; The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.&#160; The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.12</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Further Assurance</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">16.13</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Headings</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.14</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Construction</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Whenever this Agreement refers to a number of days without using a term otherwise defined herein, such number refers to calendar days.&#160; Except where the context otherwise requires, (a) wherever used, the singular shall include the plural, the plural shall include the singular; (b) the use of any gender shall be applicable to all genders; (c) the terms "including," "include," "includes" or "for example" shall not limit the generality of any description preceding such term and, as used herein, shall have the same meaning as "including, but not limited to," and/or "including, without limitation"; (d) the words "herein", "hereof" and hereunder", and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; (d) the word "or" has the inclusive meaning that is typically associated with the phrase "and/or"; (e) the word "will" means "shall"; (f) if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; (g) "Dollar", "USD" or "$" means U.S. Dollars; (h) references to a particular Person include such Person's successors and assigns to the extent not prohibited by this Agreement; (i) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner; and (j) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein).&#160; The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party.&#160; Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof.</font></div>

<div><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">16.15</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Counterparts</u></font>.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.&#160; This Agreement may be executed by .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were the original signatures.</font></div>

<div><br>
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">SIGNATURE PAGE FOLLOWS</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">IN WITNESS WHEREOF</font>, the Parties have signed this Agreement as of the date(s) set forth below.</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 9pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">Janssen Biotech, Inc.</div>

<div style="margin-bottom: 6pt; text-align: left; font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">By: /s/ Scott White</div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Name:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> Scott White</font></div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Title:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> Vice President, North America Oncology</font></div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Date:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> December 19, 2014</font></div>

<div style="MARGIN-BOTTOM: 9pt"><br>
</div>

<div style="MARGIN-BOTTOM: 9pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left">MacroGenics, Inc.</div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">By:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> /s/Scott Koenig, M.D., Ph.D.</font></div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Name: </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Scott Koenig, M.D., Ph.D.</font></div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Title:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> President and CEO</font></div>

<div style="MARGIN-BOTTOM: 6pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Date: </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">December 19, 2014</font></div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT A</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Commercialization Expenses</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Advertising and Market Research Expenses</font>" means all Third Party Expenses related to: (a) conducting and monitoring professional and consumer appraisals of the [***] in the Northern American Territory, such as market share services (e.g., IMS data), pricing analysis, special research testing and focus groups; and (b) advertising and promotion of the [***] associated with Product advertising.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Commercialization Expenses</font>" means those expenses incurred by either Party (as detailed below) for the purpose of, and directly and specifically attributable to, the Commercialization of the Initial Product in the Northern American Territory, to the extent such expenses are incurred by either Party or for such Party's account and are: [***] <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that any such expenses incurred by MacroGenics shall be deemed to be Commercialization Expenses only to the extent that MacroGenics is permitted to conduct the underlying activity pursuant to the Agreement or the Co-Promotion Agreement or to the extent that the Parties mutually agree that MacroGenics may conduct the underlying activity.&#160; For purposes of clarity, [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Commercialization Expenses shall not include: (a) any Development expenses, including [***] in the Northern American Territory; [***] In addition, there shall be no double counting of any expense (or deduction from Net Sales) that could fall within multiple categories of Commercialization Expenses.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Company Detailing Expenses</font>" means Selling Costs incurred by a Party in performance of Details, where such Selling Costs shall be calculated on the basis of [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cost Per PDE</font>" means the [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Distribution Expenses</font>" means [***] of Net Sales of the Initial Product in the Northern American Territory.&#160; It is understood that such amount shall be deemed to cover all Third Party Expenses and FTE Costs identifiable to the distribution of the Initial Product in the Northern American Territory, [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">EAP Expenses</font>" means Third Party Expenses and FTE Costs to conduct early access programs, named patient programs, and compassionate use programs for the [***] in the Northern American Territory.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Education Expenses</font>" means all Third Party Expenses specifically incurred to educate health care professionals licensed to practice in the Northern American Territory with respect to the [***] in the Northern American Territory through any means not covered in the definition of "Advertising and Marketing Research Expenses", but including [***]</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Manufacturing Expenses</font>" means, with respect to the Initial Product, the reasonable and necessary internal and Third Party invoiced costs, determined in accordance with GAAP and the terms and conditions of this Agreement, incurred in Manufacturing or acquisition of the Initial Product for sale in the Northern American Territory. Manufacturing costs and acquisition costs are comprised of Standard Cost of Goods Manufactured, Cost Variances and Other Costs Not Included in Standard, where:</div>

<div>
<table id="8a7cc57b09ac4fd5a728e74786db4e65" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Standard Cost of Goods Manufactured</font>" are budgeted unit costs established to facilitate inventory evaluation, planning and budgetary control as well as to motivate optimal productivity and efficiency, [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="283a29bfe42f4a6f973a337c010dc4c0" class="DSPFListTable" style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cost Variances</font>" are actual costs of manufacturing versus Standard Cost of Goods Manufactured and include [***]</div>
</td>
</tr>
</table>
</div>

<div>
<table id="6af7d956722942b283ff654882e78e76" class="DSPFListTable" style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 72pt; VERTICAL-ALIGN: top; align: right">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 36pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Other Costs Not Included in Standard</font>" are actual costs of manufacturing which are incurred in the normal course of business but are not included in the Standard Cost of Goods Manufactured including [***]</div>
</td>
</tr>
</table>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt">[***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">For clarity, royalty payments due to MacroGenics under this Agreement shall not be included in Manufacturing Expenses.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Marketing Expenses</font>" means the sum of Marketing Management Expenses, Advertising and Market Research Expenses and Education Expenses.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Marketing Management Expenses</font>" means Commercial FTE Costs of either Party arising from the management of Commercialization activities for the [***] <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that, in each case, such costs may be allocated to the [***] within and across Company's operating units and, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>further</u></font>, that such allocation is made no less favorable to the [***] than to the internal allocation to Company's other products.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Medical Affairs Expenses</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means (a) Third Party Expenses and FTE Costs reasonably necessary and identifiable to the [***] incurred with respect to: medical and scientific information and response [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Other Costs</font>" means including both product costs and administrative costs that are [***] excluding funding allocated to [***] (to the extent such [***]</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">[***] provided that, if either [***] Commercialization of the [***], then the finance teams of the Parties will align on the inclusion and the appropriate allocation methodology for such [***] legal costs directly related to, and specifically attributable to, [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">PDE</font>" means a primary detailing equivalent, [***]; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that, prior to the First Commercial Sale of the Initial Product in the Northern American Territory, the JSC shall determine how to adjust the value of [***]</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">"</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Phase 4 Trial Expenses</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">" means all Third Party Expenses incurred for the Northern American Territory by Company related to a Phase 4 Trial for the Initial Product in the Northern American Territory, including expenses arising from:&#160; (a) the activities related to the performance of the Phase 4 Trial; (b) Manufacturing Expenses for Product used in connection with such Phase 4 Trial; (c) preparation, filing, and maintenance of related Regulatory Documentation; and (d) any Product Liabilities relating to a Product being used in the course of such Phase 4 Trial, </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> that </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and shall be treated as the responsibility of such </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> that Phase 4 Trial Expenses shall not include expenses relating to: </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Phase 4 Trials which address </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> requirements for a </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> in which there are </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> any Phase 4 Trial intended </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160; For purposes of clarity, Phase 4 Trial Expenses shall not include </font>[***]<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> for Phase 4 Trials but shall include the costs for </font>[***]</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Recall Expenses</font>"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>means Third Party Expenses and FTE Costs directly associated with notification, retrieval and return of the Initial Product in the Northern American Territory, destruction of such returned Initial Product, replacement Initial Product and distribution of the replacement Initial Product, in each case that are incurred with respect to a recall conducted in accordance with Section&#160;5.4 of the Agreement, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that the foregoing Recall Expenses are limited to recalls that are not caused by the gross negligence, illegal conduct or willful misconduct of a Party.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sales Rep PDE Total</font>" means the total number of PDEs that one full time equivalent Sales Rep FTE is planned to deliver in a Calendar Year, which number shall be approved by the JSC prior to the beginning of each Calendar Year.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sales Rep FTE</font>" means [***] hours of work devoted to or in direct support of Detailing the Initial Product in the Northern American Territory that is carried</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">out by (a) one or more qualified employees or contractors or consultants of Company or its Affiliates or (b) one or more qualified employees of MacroGenics or its Affiliates, but shall not include personnel performing administrative and corporate functions (including human resources, finance, legal and investor relations).</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Sales Rep FTE Rate</font>" means a rate of [***] per Sales Rep FTE per Calendar Year (prorated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year of the Term); <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>however</u></font>, that such rate shall be increased or decreased annually beginning on January 4, 2016 by the [***]&#160; The Sales Rep FTE Rate is "fully burdened" and covers employee salaries, benefits, travel and other costs.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Selling Costs</font>" means the total number of PDEs delivered by or on behalf of a Party multiplied by the Cost Per PDE.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; TEXT-INDENT: 36pt">"<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Third Party Obligation Expenses</font>" means Third Party Obligations incurred by a Party with respect to the Initial Product for the Northern American Territory, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>provided</u></font> that, with respect to any Third Party Obligation that is not specifically allocated to the Initial Product and/or the Northern American Territory, Company shall use a reasonable method to allocate a portion of such Third Party Obligation to the Initial Product in the Northern American Territory for purposes of determining the Third Party Obligation Expenses.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Nothing in this <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Exhibit A</u></font> is intended to modify or alter MacroGenics' rights or obligations, or to grant additional rights to MacroGenics, to perform Development or Commercialization activities pursuant to the Agreement.</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT B</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Global Development Plan</div>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">[***]</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT C</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">MacroGenics Patents</div>

<div><br>
</div>

<table id="4976a29f4b2149c088bcad468b23bdc8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>Title</u></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Pending Application <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Number</u></font></div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>Foreign Rights</u></div>
</td>
</tr>

<tr style="HEIGHT: 29px">
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>

<div>&#160;</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 37.28%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 28.43%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 34.29%; VERTICAL-ALIGN: middle; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
</tr>
</table>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT D</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">MGD011</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT E</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">J&amp;J Universal Calendar</div>

<div style="TEXT-ALIGN: center"><img style="HEIGHT: 786px; WIDTH: 613px" src="image0.jpg"></div>

<div style="TEXT-ALIGN: center"><img style="HEIGHT: 787px; WIDTH: 620px" src="image1.jpg"></div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">EXHIBIT F</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">Form of Press Release</div>

<div><br>
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center; MARGIN-TOP: 12pt"><img style="HEIGHT: 803px; WIDTH: 620px" src="image2.jpg"></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center; MARGIN-TOP: 12pt"><img style="HEIGHT: 803px; WIDTH: 620px" src="image3.jpg"></div>

<div style="MARGIN-BOTTOM: 12pt; TEXT-ALIGN: center; MARGIN-TOP: 12pt"><img style="HEIGHT: 803px; WIDTH: 620px" src="image4.jpg"></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<hr id="DSPFPageBreak" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; PAGE-BREAK-AFTER: always; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div style="MARGIN-BOTTOM: 12pt; MARGIN-TOP: 12pt"><br>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">SCHEDULE 7.1</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">MacroGenics' Estimated, Non-Binding Manufacturing Costs</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u>Estimated</u></font> fully burdened manufacturing cost for single clinical production lot of MGD011:</div>

<div><br>
</div>

<table id="e4efb90742d541b5b7cab6445887a60d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 16px">
<td style="BORDER-TOP-COLOR: ; WIDTH: 60.36%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 39.64%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 60.36%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 39.64%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 60.36%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 39.64%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP-COLOR: ; WIDTH: 60.36%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
<td style="BORDER-TOP-COLOR: ; WIDTH: 39.64%; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: ; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">This estimate is based on expanded capacity that MacroGenics will be creating over the [***].&#160; Since production under the additional capacity will be a new circumstance, this estimate is still subject to change.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[***]</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`,C`D,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HS
M7-:M=7$7C+2XX#(Z_8;N1H%;`<@Q[<]NY`)]:R-/_MA_$.A7'E74,,J3&^@*
M2;8LIE59G."0W&0!5J&ER>8[S-)FN#L++58="\,W!6^%^;Q!>[G<GRSOW;U)
MP!T[5/:PWT%_=VFZ^G@N(KAC?&.17MR?N@*?E8\\;?3I3Y%W#F.VHKS]AKBZ
M'?6=K;W+M"]OBY'F(]PF[]X`K\A@H[=<\<U/>6NH_P!B:W/87%[YSV)2&V$,
MJD2<X92YR6[8'M1[/S#F.TG@BN86BE4,C#!%<[?>'[^WADDTW6KR(*I81$"3
M/L":AAM;ZT\8:9Y`NA8/82?:=S,R>8"NW.<X/6NIGEC@@>:5@D:*69CT`'6F
MI2AL1.G&>LCQW2_B9+9ZHOVR^O;V(Y4P"U4,3[8->F>'_$']OQ22C3;ZS1,;
M3=1[-^<]/7I7EGPRT^34O'EYK*1E;6`2$-CC<YX7\B37MM;XQ0C/EBM3'!RE
M*GS284445QG6%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`$"V
M5LEX]V(E^T.H1I,?-M';Z>U9ESJ+6R*YFD*-((^+8Y!^G?OTK:IK(&()`.#D
M9'2ACC9/4PX]5+#YY;A6)/!LG[''_P!>E?5Q$\/[R=A(21_HC=NWK6[2%06#
M8&1T-+4OFIWV_'_@&$-6#*&,URF5W%39.2.,XZ=:T(EN9XED2Z`5AD9AP>1W
M!-7J*"9.+V0F.*P]=TF]UV%K`W*VMB_^M,?,D@_N^BC\ZW:*N,G%W1G."FK,
MH:1H]CHE@EE80B*%>?4L?4GN:OT44FVW=C225D%%%%(84444`%%%%`!1110!
MPNK:+K;C5M6U7Q-<6$,`9[.*PG*1HHZ>8"HW'IQ]>:R&\6ZSJ/@_PY"MP;?4
M-6NC;/=(H#;%;:6'8$Y'ZXK(\3^*;+Q/XJ;2]2U(Z?X?LY"'V(S-<,IP?N@_
MAG@#GK6]XC:PN]*\-Z_H,;7&EZ3=C<(8F!6($9.T@'C;^M?41HRA&DJ\-7JM
M-%[KLK]6W9M&,GJ^7S_KY&CHES>Z'X\E\-3ZE=W]G-:"Y@>\??(C9Y&[N.#^
ME8>N^*];O?%.AI!!=:=I3:BL*,7*-=8=0Q('\'/3D'/Y:FC31^)_B4^OV"R/
MIEI9"!+AHV02.2>!D#ID_E1\1/\`D8_!W_80_P#9HZQI*"Q<8S@N9PU\GROI
MWV_X<-XRMM_P/\SJ?$NNQ^']&ENROF3L?+MH1R993]U0/\\5S?POO]3OK#5C
MJUS//<QWI1A+(6V'`RH[`9SP.*M>(]!\1W_BFQU339-*>WLHSY,-\9,+(>K8
M4=<8QSVK&^&']K_;];\W[#]E^VR?:-F_?YW^QVV=>O-<].E267S<6G+1ONM=
MOZW?H5)OF7]=#4^)%]>6-OHIM+N>W,FH(CF&0IN7!X..H]JM?$J\NK#P3=7%
MG<S6\RR1@20N48989Y'-5_B;IU[>:#:75C;M<2V-VEPT:`DE0#G@=>U<MXE\
M;1^-](70-'TJ^:]GD0R"11A`"">03QG')`K7!8=U8T)Q5U&3YMM%=/7Y!)\K
M=^W^9VUUXQT_0ET>TU`7337MNK+(B;QG`Z\[B2?0'.:GT?QCI^M:E<Z:D%[:
M7L"[V@NX?+<KQR!GW'7!YKF]?@$/Q$\&0,`?+B9?Q`_^M4[@#XT,1WTHD_G6
M3PM"5.]G=Q<KW[2:V$G):=K?B/TCQ=I6E>$/[4\S6[RR-V86EO&225"<=?F^
MY],GFNBUCQ+9:,^GI*DT\FH2B*!(`"3GOR1QR.?>N-\!Z5'K?PRO].EQB>>9
M0?[K8&#^!P:I>`X[W7_$EO/J,95?#]K]D4-SF7)&?K@?H*UK82@YU9O[#=_.
M_P`/XZ,7,TM.M_S_`*^XZ^^\?:597MQ;I;:A=I:MMNKBUMS)%`>^]L]O;/2I
MM4\;Z/I5OIES(TTUOJ)/DRP)N``QR1D'OT`)]J\OAMK?0O[8T_6M2U^TOFG<
MP6ME*R1WH88&/E89/<GL16O?:6-/B\`6;V\T`^VLYAGE$CIET;!(51WZ8XK6
M6686,HK5K7YKE;NOGVTZ/4;FTW\SM)O'5A;64$\^GZK%<7$K1P6+VW^D2$8R
M0F>G/<U;T;Q;IVLRW,`CNK*ZM5WS6][%Y4B+_>(]/Q[UB?$*WT>1M/EU5=4M
MO*+&/4K)<K!ZA\<C/'0?CUK%\+:MX@>YU2'3-3N-<TV&R=[>ZN+=D)G_`(5!
M;DG/J?RKEC@J-7"^U@K/S;MOT=FOD[,;;4DCH6^)6CKB9K+51I[/L&H&T/V<
M_P#`LYZ\=*BU?4+I?B?X=MH;N9;2>WD9XDD(23Y7()7H>U>;:K<VNI^#I)KJ
MZU6^U^.7==+/YGEVHW$=/NJ#T'?)/2NYNW1_B3X.>-@R-8,5([C8U=D\#2H.
M\4]JB=_*.C7^>E^B)<VT_P"NIV^MZFFC:)>:DZ[Q;Q%PN?O'L/Q.*\_LM`\9
M>)=-BUR3Q5-933IYL%I"&6,*>5!PP'Y@\=<UW7B32VUKPW?Z=&0))X2J$]-W
M49_$"N"TOXC#PYI%MHFKZ+J":G:QB%(U0;9,<*<DYYQV!KBP$:CH-X:*=2^M
MTG[MO/SW+GTOL=OH<^K6?AH3>)3"MW`C-*\;`@J!G)QQGUQQ7G/A[Q#KD/B'
M3M<U*\N&TG6;F:!(7E8QP\_+@$X'/`]@:U/$_B+5K[P%;6UY8BRU/6)Q;Q0*
MQR4R,D@\KG@8YX-9.K^"O&\?A@6EQJ6G3V%@GFQV\(PXV@_=/E@D]>IYKMPE
M"G&,G7<8N;:^6J?+OU:^XB5VE&/]=CK_`!]?7=G<^'!:W4\`FU)$D$4A7>N1
MP<=1[&NTKR+Q/XCCU'PIX1UN7<WEWBO.%`SN3[V![X./K71Z=\5M"U/4K:P@
MM-166XD6)"\:!02<#.'Z5Q5LOKO#PY(7Y>:_R8U45[OM_F<?9?;-8U36#=^/
MY]'$%Y)''#+=$;EW'H#(O`Z5T3PW.D>`=>N;?Q?+K4FU=ES'.28"",@,';!.
M?45Q%K>^$;76=:7Q)I=W>3-?2&)H&("KN.0<.O>NF35/#=Y\._$EMX<T^ZLX
MHD2259SG<S$`$'>W]WVKV,53GS12B^6\/LQY=UU^(F-N?7NS1\'>)[ZZ\,WV
MF:I-+_:<%DUS!,[$O+"R95MW4D$]?I[UD3ZSJ@^#-G?#4KP7C794W`G;S"-[
M#&[.<58UG1KA_AWH>OZ<2M]86"K(5'+PLF&!]<9)^A-95QQ\"K(_]/I_]#>L
MZ=.C*2J02UJ)-=FN:_R>C!-V2\G^1N:CX:\6>'-,EUFT\87E\UJGFO;W`;:R
MCD_>=@>/;\:ZBZ\5JGP]/B,`*[VH=4SP)#\H'_?5<KJGQ*M?$&C7&CZ)I>HS
MWUU$85#1K@!A@GY6)[U3\1Z9>R:=X9\!V<D?VSR_/N"S'8I`)Y(!XSO[=A7/
M]7J5N18Q)24K[)>XE=WMT[#C)+5=O\K%_P`!ZEK.F^(8]*UV]N+C^TK)+JV:
MXE9BIQDJ-QZXSG_=I/'-Q>2^/K#34\23Z+:2V>]YA.4C4@OR1N49.`.M97B/
M2?&NC_8?$6K:A97BZ9*I06ZA6520#TC7@\#\:TM<M=-\4?$[0DN8OM%C=Z;Y
MH7<5R,.PY4@^E;*%/V_UI--.,K\NJ32Z)I*]K;BNU%Q?E^:N5;6]U'P_XHT>
M"R\9GQ%%>SB*>#S/,V+D#/WVQU)ZCIZ5Z[7E,=C;_#?QQ"[6\;Z-J/R1W,B@
MO;-Z;NN/YCZ&O5@<C(KR\U<9.G..J:^*R5]>J6EUL7!6;3"BBBO(-`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@"MJ%['IVFW5],KM%;0O
M,X098A02<9[\5PG_``N7P[_SY:I_WZC_`/BZZWQ5_P`BAK?_`%X3_P#HMJR?
MAE_R3S2_^VO_`*->O2P\,/'#2KU8.7O);VZ-]GV(;?-9&1_PN7P[_P`^6J?]
M^H__`(NC_A<OAW_GRU3_`+]1_P#Q=>B44OK&"_Y\O_P/_P"U"TNYYW_PN7P[
M_P`^6J?]^H__`(NC_A<OAW_GRU3_`+]1_P#Q=>B44?6,%_SY?_@?_P!J%I=S
MSO\`X7+X=_Y\M4_[]1__`!='_"Y?#O\`SY:I_P!^H_\`XNO1**/K&"_Y\O\`
M\#_^U"TNYYW_`,+E\._\^6J?]^H__BZ/^%R^'?\`GRU3_OU'_P#%UK^'_P#D
MH?C'_MR_]%&NL9E12S$*H&22>`*VK2P5*2C[%O1/XNZ3[>8ES/J>>?\`"Y?#
MO_/EJG_?J/\`^+H_X7+X=_Y\M4_[]1__`!==W9ZA9:C&TEC>6]TBG:S02JX!
M],@U9K)UL'%V=!_^!_\`VH[2[GG?_"Y?#O\`SY:I_P!^H_\`XNC_`(7+X=_Y
M\M4_[]1__%UZ)59=1L6EN(EO;<R6PS.@E7,0ZY89^7\:%6P;VH/_`,#_`/M0
MM+N<)_PN7P[_`,^6J?\`?J/_`.+H_P"%R^'?^?+5/^_4?_Q==_;75O>VZW%K
M/%/"_P!V2)PRGMP1Q4M#KX).SH/_`,#_`/M0M+N>=_\`"Y?#O_/EJG_?J/\`
M^+H_X7+X=_Y\M4_[]1__`!=>@3SPVT#SW$J10H-SR2,%51ZDGI52TUS2-0G\
MBRU6QN9L9\N&X1VQZX!IJIA&N94';_%_]J%I=SBO^%R^'?\`GRU3_OU'_P#%
MT?\`"Y?#O_/EJG_?J/\`^+KT2BI^L8+_`)\O_P`#_P#M0M+N>=_\+E\._P#/
MEJG_`'ZC_P#BZ/\`A<OAW_GRU3_OU'_\77<G5-/6%)C?6HB>7R5<S+AI,XV@
MYY;((QUXJ:.Y@EEEBCFC>2$@2(K`E"1D9';CUJG5P:WH/_P+_P"U"TNYP'_"
MY?#O_/EJG_?J/_XNC_A<OAW_`)\M4_[]1_\`Q=>B4R66."%YII$CB12SN[`*
MH'4DGH*E5\$_^7+_`/`__M0M+N>??\+E\._\^6J?]^H__BZ/^%R^'?\`GRU3
M_OU'_P#%UVEKKVCWUPMO9ZM8W$S9(CAN4=CCKP#FM"JE5PD':5!K_M[_`.U"
MTGU/._\`A<OAW_GRU3_OU'_\71_PN7P[_P`^6J?]^H__`(NO1*J7NJZ=IFS[
M??VMIYF=GGS+'NQUQD\]:4:V#D[1H-O_`!?_`&H6EW.&_P"%R^'?^?+5/^_4
M?_Q='_"Y?#O_`#Y:I_WZC_\`BZ[^VNK>]MUN+6>*>%_NR1.&4]N".*EH=?!)
MV=!_^!__`&H6EW/._P#A<OAW_GRU3_OU'_\`%T?\+E\._P#/EJG_`'ZC_P#B
MZ]$JK#J5A<7<EI#>VTES%_K(4E4NGU4'(H5;!O:@_P#P+_[4+2[G"_\`"Y?#
MO_/EJG_?J/\`^+H_X7+X=_Y\M4_[]1__`!=>B5Y3X?@U2;P-X:BTZ2^1+O[3
M9SO;.5$*O*6\TD?=*A&`;U<#O6BG@G2=3V+T:7Q=T_+R_$+2O:YI?\+E\._\
M^6J?]^H__BZ/^%R^'?\`GRU3_OU'_P#%TU;WQ1'HRW4G]JVUS-<2`QQVOGMO
MC1412I5ML3LC,6`'#`Y7.:CBG\8Q^(="N;B74I+6>6Z6_C%N-L*><JQ*`J8Q
MP#N;+;2Y#8K-5L$W;V+_`/`__M0:DE>Y-_PN7P[_`,^6J?\`?J/_`.+H_P"%
MR^'?^?+5/^_4?_Q='P\_Y&_QO_U_C_T9-7HE=&+^I8>JZ?LF]OM=TGV\Q1YF
MKW/._P#A<OAW_GRU3_OU'_\`%T?\+E\._P#/EJG_`'ZC_P#BZ]$HKF^L8+_G
MR_\`P/\`^U':7<\[_P"%R^'?^?+5/^_4?_Q='_"Y?#O_`#Y:I_WZC_\`BZ]$
MHH^L8+_GR_\`P/\`^U"TNYYW_P`+E\._\^6J?]^H_P#XNC_A<OAW_GRU3_OU
M'_\`%UZ)7)?$W_DGFJ?]LO\`T:E;8>6"K5HTO8M<S2^+N_03YDKW,C_A<OAW
M_GRU3_OU'_\`%T?\+E\._P#/EJG_`'ZC_P#BZ]$JK<ZE864T4-U>VT$LIQ&D
MLJJS_0$\UE&M@Y.RH/\`\"_^U':7<X7_`(7+X=_Y\M4_[]1__%T?\+E\._\`
M/EJG_?J/_P"+KT2BE]8P7_/E_P#@?_VH6EW/._\`A<OAW_GRU3_OU'_\71_P
MN7P[_P`^6J?]^H__`(NN]N[RUL(#/>7,-O""`9)I`B@GIR>*1K^S6ZBM6NX!
M<3+NCA,@WN/4#J1QVJE5P;5U0?\`X%_]J%I=S@_^%R^'?^?+5/\`OU'_`/%T
M?\+E\._\^6J?]^H__BZ]$HJ?K&"_Y\O_`,#_`/M0M+N>=_\`"Y?#O_/EJG_?
MJ/\`^+H_X7+X=_Y\M4_[]1__`!==K=ZYI&GS^1>ZI96TV-WES7"(V/7!-6X)
MX;J!)[>6.:%QE)(V#*P]01UJG4PB7,Z#M_B_^U"TNYY__P`+E\._\^6J?]^H
M_P#XNC_A<OAW_GRU3_OU'_\`%UZ)44EQ!#)%'+-'&\S;8U9@"YQG`'<X%)5\
M$]J#_P#`_P#[4+2[G`?\+E\._P#/EJG_`'ZC_P#BZ/\`A<OAW_GRU3_OU'_\
M77<_VII_ES2?;K79#)Y4K><N(WSC:W/!R1P?6K=#K8-;T'_X%_\`:A:7<\[_
M`.%R^'?^?+5/^_4?_P`71_PN7P[_`,^6J?\`?J/_`.+KT2J-YK6E:=,(;[4[
M*UE*[@D]PJ,1ZX)Z4XU<')VC0;_[>_\`M0M+N<3_`,+E\._\^6J?]^H__BZ/
M^%R^'?\`GRU3_OU'_P#%UW]O<P7ENEQ:SQSPORLD3AE;Z$<&I:3KX).SH/\`
M\#_^U"TNYYW_`,+E\._\^6J?]^H__BZ/^%R^'?\`GRU3_OU'_P#%UZ&S!%+,
M0%`R23P!5"TUW1[^<06>JV-S,02(X;A'8@>P.::JX22;5!Z?WO\`[4+2[G%_
M\+E\._\`/EJG_?J/_P"+H_X7+X=_Y\M4_P"_4?\`\77HE%3]8P7_`#Y?_@?_
M`-J%I=SSO_A<OAW_`)\M4_[]1_\`Q='_``N7P[_SY:I_WZC_`/BZ[R\O[/3H
MA+?7<%K&3@//($!/IDU.CK(BNC!E89#*<@BG[;!VO[!V_P`7_P!J%I=SSS_A
M<OAW_GRU3_OU'_\`%T?\+E\._P#/EJG_`'ZC_P#BZUB,_%TC)&=`QQ_UWK#L
M4\4&YL%E_M7RI;A;*1I';Y%MV#><W/`EVR`M_$&3UK6K+`TW']R]4G\7?Y`E
M*S=R;_A<OAW_`)\M4_[]1_\`Q='_``N7P[_SY:I_WZC_`/BZA2[\77]NL(N]
M7A5CF>7[`D4B2>5*7B3,?^K#",!QDG=@.>V%XKGU>?X2Z5_;JW"ZFE^J3"9-
MO(CDP5X!(QCDY.<Y.15X18+$5XT?9-7MKS7_`$)FY16Y[/1117BFID>*O^10
MUO\`Z\)__1;5D_#+_DGFE_\`;7_T:]:WBK_D4-:_Z\)__1;5YOX/U'QY;^%;
M*+1=%L+G3UW^5+*X#-\[9S^\'\61T[5U2Q"A@G#E;]Y.Z3:V?7OY'5AL%+$-
MR4XQM_-)+\SU^BO//[7^*/\`T+FE_P#?Q?\`X]1_:_Q1_P"A<TO_`+^+_P#'
MJ\[VZ_E?W,Z_[)G_`,_:?_@<3T.BO//[7^*/_0N:7_W\7_X]1_:_Q1_Z%S2_
M^_B__'J/;K^5_<P_LF?_`#]I_P#@<3T.BO//[7^*/_0N:7_W\7_X]1_:_P`4
M?^A<TO\`[^+_`/'J/;K^5_<P_LF?_/VG_P"!Q-;P_P#\E#\8_P#;E_Z*-;/B
M2"WN?#>H074TL,$D+*\D4;.R@]]J@D_X5Y9:Z_XTL/%6N2II-@=0G^S_`&N)
MFRL>$^3;B3NIR>3^%:G_``F?Q`_Z`FE_G_\`;:[*^,2K1FHR5E#HUM%?TA1R
MF:_Y>T__``.)L>!+J^?4[ZUNI=/U*.*&/9JMFJYD'(6-V`Y(';M^-=W7EG_"
M9_$#_H":7^?_`-MH_P"$S^('_0$TO\__`+;66)QT:U1S4&OD*.3SBK>UI_\`
M@<?\SU.O)-1CN$\4:PMNA9=5OO[,F(/W0R1,#^"B3\ZL?\)G\0/^@)I?Y_\`
MVVC_`(3/X@?]`32_S_\`MM:8/,EAI-\C=UV?J$LGG)6]K3_\#C_F=9\/U">"
M[)%&%5Y0![>:U=/7EG_"9_$#_H":7^?_`-MH_P"$S^('_0$TO\__`+;6-?&*
MK5E4Y7JV]GU&LHFE;VM/_P`#C_F>IUS7A'_7>(?^PO-_):Y'_A,_B!_T!-+_
M`#_^VT?\)G\0/^@)I?Y__;:(8Q1A*'*];=&-Y1-_\O:?_@<?\SU.BO+/^$S^
M('_0$TO\_P#[;1_PF?Q`_P"@)I?Y_P#VVLO;K^5_<P_LF?\`S]I_^!Q&ZEI=
MU?:[K6BQJPCLFFU2!L_\M'52@'T;S*ZSP)*]_H]SK$BE7U*Z>?![*,(H_):Y
M7_A,_B!_T!-+_/\`^VT?\)G\0/\`H":7^?\`]MKT*^;>UI>SY&MM;/Y_>[/Y
M$_V-.]_:T_\`P./^?J>IT5Y9_P`)G\0/^@)I?Y__`&VC_A,_B!_T!-+_`#_^
MVUY_MU_*_N97]DS_`.?M/_P.)UWAC_D,^)O^P@/_`$4E=+7EG_"9_$#_`*`F
ME_G_`/;:/^$S^('_`$!-+_/_`.VUI6QBJ2YN5].CZ*PEE$U_R]I_^!Q_S/4Z
MY#Q&MR_CCPVMG-#%-Y=UAYHC(H^5<_*&4_K7-_\`"9_$#_H":7^?_P!MH_X3
M/X@?]`32_P`__MM50QJI3YN5O1K;NFOU!Y1-JWM:?_@<?\ST^$2K`@G='E`^
M=HT*J3[`DX_,U)7EG_"9_$#_`*`FE_G_`/;:/^$S^('_`$!-+_/_`.VUB\0G
M]E_</^R9_P#/VG_X''_,]2/0UYCX<:?3_%5E8VEW::OIS2S&,218NK#.2Q8$
M!ER>#GKZ"H_^$S^('_0$TO\`/_[;1_PF?Q`_Z`FE_G_]MKJP^8*E"<7!OF7;
MUUVOUZ-"ED\VOXM/_P`#C_F>IUQ_PW9D^&VG,B;W59BJYQD^:_&:YS_A,_B!
M_P!`32_S_P#MM4_!^H^/(/"ME%HNB6%SIZ[_`"I97`9OG;.?W@_BR.G:E'$K
MZK./++64>C[2_P`_S#^R9\R?M:?_`(''_,["Q\=+?W-O#'IQ4W'D>26F^^74
M-(,8_P"68(SZ^U:7A+Q/!XMT1=3M[=X4WF-E9@PW+]X`CG`.1R!TZ8P3P5MI
MWC:SDLWM_!FCH]E)+);L)>8VESYA_P!?WR>M3:1%X_T*!X=-\)Z7;QN0643[
M@2%"@\SGG`'UQ7/]8C_*_N8_[)G_`,_:?_@<?Z[&A\//^1O\;_\`7^/_`$9-
M7HE>)>%;[QE!KWB-](TFSN+R2YS?QRN`L4FZ3A?W@XR7[GH/QZK^U_BC_P!"
MYI?_`'\7_P"/5VYCBU/$.7+):1WBU]E$PRB:7\6G_P"!Q_S/0Z*\\_M?XH_]
M"YI?_?Q?_CU']K_%'_H7-+_[^+_\>KA]NOY7]S*_LF?_`#]I_P#@<3T.BO//
M[7^*/_0N:7_W\7_X]1_:_P`4?^A<TO\`[^+_`/'J/;K^5_<P_LF?_/VG_P"!
MQ/0ZY+XF_P#)/-4_[9?^C4K)_M?XH_\`0N:7_P!_%_\`CU8?C#4?'EQX5O8M
M:T6PMM/;9YLL3@LOSKC'[P_Q8'3O73@L4H8FG+ED[26R?<4LHGRO][3_`/`X
M_P"9Z_7FWC?S++79[ZPU&T-PUND=QI=_#E+M`25$>X8<Y/1><]^<55_X3/X@
M?]`32_S_`/MM'_"9_$#_`*`FE_G_`/;:,)F"P]3GY&_*W_`8/*)M6]K3_P#`
MX_YGIMH[R64#R0^2[1J6B_N''3\*FKRS_A,_B!_T!-+_`#_^VT?\)G\0/^@)
MI?Y__;:YWB$W?E?W,:RB:7\6G_X'$ZGX@0)=>&X[>0926]MT8>QD`-<EH!N;
MOQ?HE[>H5GADETX$G.1#"0Q_%F-2?\)G\0/^@)I?Y_\`VVC_`(3/X@?]`32_
MS_\`MM=]#-U2H.C[-N]];/JK=B99-.3O[6G_`.!Q_P`SU.BO+/\`A,_B!_T!
M-+_/_P"VT?\`"9_$#_H":7^?_P!MKS_;K^5_<RO[)G_S]I_^!Q.N\9?ZG1?^
MPO;?S-=+7EG_``F?Q`_Z`FE_G_\`;:/^$S^('_0$TO\`/_[;6LL8I4XPY7I?
MH^H?V1.]_:T__`X_YGJ=<SXY9K70HM4C5F?3;J*ZPO4J&PP_[Y8UR7_"9_$#
M_H":7^?_`-MH_P"$S^('_0$TO\__`+;11QBI5%/E;MY/7R#^R)M6]K3_`/`X
MD=EIUW::QH^F2JQ76&AU&Y(Z"2,O(X_,Q_E7J]>6?\)G\0/^@)I?Y_\`VVC_
M`(3/X@?]`32_S_\`MM;8O,OK#3<&K>3_`*VLOD3')YK_`)>T_P#P./\`F>IU
MS7C?_D#6O_80M?\`T:M<C_PF?Q`_Z`FE_G_]MH_X3/X@?]`32_S_`/MM84<8
MJ513Y6[>3&\HFTU[6G_X''_,]3HKRS_A,_B!_P!`32_S_P#MM'_"9_$#_H":
M7^?_`-MK/VZ_E?W,?]DS_P"?M/\`\#B>EW__`"#KK_KD_P#(USO@&._'A32V
MFN;9[4VP\N-+=E=?JY<@_P#?(KEO^$S^('_0$TO\_P#[;1_PF?Q`_P"@)I?Y
M_P#VVMHXY1I.ERO5I[=K_P"8GE$VT_:T_P#P./EYGJ=%>6?\)G\0/^@)I?Y_
M_;:/^$S^('_0$TO\_P#[;6/MU_*_N8_[)G_S]I_^!Q-[QW$1<Z=>6VLPZ9?P
M"3R3=K^XE4@;E9B-H.!T/)YK:\(W$UUX6L)I[&*RD9#F")-B`9."J]@>N/>N
M'_X3/X@?]`32_P`__MM'_"9_$#_H":7^?_VVNJ>8*5"-%P>G6WKIMY];B_L>
M?-?VM/\`\#C_`)G3?\U?_P"X#_[<5=\0^)9-"E6%-/:ZDE@:2!1+L\QPZ+LZ
M''W\Y]CQ7G5MKGC:[\;FZ@TBP?51IOEF#=A/)\S.[F3KNXZ_AWK6NG^(E]=V
M=W<^%-)DGLG9[=S*/D9E*D_Z[G@D<TL3BE+D]V6D5T81RF>O[VG_`.!Q-^'Q
M_:RZ]IVFBT9DU)YDM)HY0=_E[,G!P,?,_<GY.`2<#+^,O_(H6G_7^G_HN2L2
M/1O&4*V(B\%Z3&+$L;;9<$>7N<2'&)^[*#^8Z$BJ/C^^\976@P)XBTFSL[,7
M*E)('!8R;6P.)&XQN[=JVRW%QIXJG+DD[/I%MDSRBI9_O:?_`('$]MHHHKG/
M-,CQ5_R*&M_]>$__`*+:LGX9?\D\TO\`[:_^C7K6\5?\BAK?_7A/_P"BVK)^
M&7_)/-+_`.VO_HUZ]&/_`"+I?XU_Z2R/MG6T445YQ84444`%%%%`'F4__)0_
M$_\`VZ_^BJNU2G_Y*'XG_P"W7_T55VNO&_Q5_AA_Z1$F.P4445R%!1145S<P
M6=N\]U/'!"@RTDKA57ZD\"@"6BJLFIV$,,$TM];)%.0L+M*H60GH%.>2?:K5
M`!115?[?9_;OL/VN#[7MW^1Y@\S;Z[>N/>@"Q14:3Q2R21QRH[Q$"158$H2,
MX([<<U)0`45A^(AYEUH4!9A%-J&R158C>/(F.#CJ,@'\!5F;3-*MXFEG1(HU
MZN\I4#\2:`-.BN>UNPMK*RMY[9&BE%]9J&5VZ-<1J1UZ$$C\:V[NZCLK.:ZF
MW>7"A=MJDG`&>`.I]J`)J*RHK&\O%$U_=S0EAD6UN^Q8_8L/F8^ISCT%4UU!
M;"ZE\G5H]0MHG"W4+2HTMKG@-E>=N>H;GJ0>,4`=#1110`45!=WMK80&>\N8
M;:$$`R32!%!/N>*F5E=0RL&4C((.010`M%%%`!6G\,O^2>:7_P!M?_1KUD?:
M(?M`M_.C\\IO$6X;MN<9QUQGO6O\,O\`DGFE_P#;7_T:]=</]TG_`(H_E,E_
M%_7D=;1117(4>=_#S_D;_&__`%_C_P!&35Z)7G?P\_Y&_P`;_P#7^/\`T9-7
MHE>CFO\`O3](_P#I*(I_"%%%%><6%%%%`!7)?$W_`))YJG_;+_T:E=;7)?$W
M_DGFJ?\`;+_T:E=>7_[W2_Q1_-$S^%F91117(4%%%%`!115=;^S:]:R6[@-T
MB[F@$@W@>I7KB@"Q14%K>VE\CO:74-PJ,48Q2!PK#J#CH?:IZ`"BBHYIXK>/
MS)Y4B3(&YV`&2<`9/J>*`)****`"BBJUMJ%E>22QVMY;SO"VV58I0Q0^A`/!
M^M`%FBBLZ_N;IKJ&PL2BS2`O+,XR(8^F0.[$\`'C@D],$`T:*Q;RWMK&%'NM
M>N;61R$2>:Y1=S>@4C83[8JUI]U.TTUE>;#<P@,)$&%E0YPP'8Y!!'MZ$4`:
M%%%<[X?LOM_AO2[RYO+YY[BSBED873C+,@).`<#DT`=%164-/LS<&W%_=F<*
M',?VU]P4\9QNSCWJ;1F=M,7?(\C+)(NYVR2!(P&3]`*`+]%%4M1U:STI83=O
M(#,_EQ+%"\K.V"<!4!/0$]*`+'AO_DITG_8&/_HX5Z+7FWA29;CXCF9`X5]%
M)`DC9&_UPZJP!'T(KTFNO%_8_P`*)CU"O._C+_R*%I_U_I_Z+DKT2O._C+_R
M*%I_U_I_Z+DK;*?]]I^HJGPL]$HHHKSBS(\5?\BAK?\`UX3_`/HMJR?AE_R3
MS2_^VO\`Z->M;Q5_R*&M_P#7A/\`^BVK)^&7_)/-+_[:_P#HUZ]&/_(NE_C7
M_I+(^V=;116;<:W;6VO6>CNDIN+J-Y$8`;`%ZY.<Y_"N",)3=HKS^XMNQI45
MS^K^,=,T76[32;E+AIKG;\\:`I'N;:N\YXR?8U/K/B?3]!O].M+[S5-^Y2.1
M0-BD8^\<\#D=C6JPM9\MHOWM5YV$Y)7\C9HK,&N6Q\2'0MDWVH6OVK?@;-N[
M;C.<YS[5IUE*$HVYEOJ.YYE/_P`E#\3_`/;K_P"BJNU2G_Y*'XG_`.W7_P!%
M5=KIQO\`%7^&'_I$28[!1117(4%4-6>&*S$DUI-<*K@CR81*\1[.%Y)(]@3[
M5?HH`\X?3=0BTB%9+&X='LKRUB58BSEY'!C=P!\A8#))``/7'2O0;5'BLX(Y
M3ND6-58^I`YJ:BG?^OZ]0_K^ON"N5U"$W'B:Q%KIUS'+#=&29F@VQ.IC*F7S
M`,%@,*`3G_9Z$=512Z@<WX7TLZ5J&N0K%.L+7*-')-DF7]TN6W'[W.<GUKI*
M**`,37O^0EX=_P"PD?\`TGGJMXUTK^TM#9ECGFFA96BBC)()WKR5'4@9QZ<U
ML:AIEKJD44=TLA\J3S8VBF>)D;!&0R$$<,1U[U3_`.$:L/\`GXU7_P`&UU_\
M<H`/$O\`R"H/^PA9?^E456=:CEDTB?R8S+(FV18UZOM8-M&>YQC\:KKX:TX2
M1NS7\OER+(JS:C<2+N4AE)5G(."`>1VK7H`BM[B*ZMDN('#Q2+N5AW%>=SN=
M6GU)'L[G3O.MIM-TZT:QDC#>:?FD+%0IS][:#P`2>]=PVC0+/)-;37%H\ARX
M@DPK'UVG*Y.>2!D]ZDMM*MK>Y^U'S)[K:5\^=][`'&0.R@X&0``<4+1W#H7:
M***`,K7FA6T4S6MU)DLJ3VUN)GMR5(WA<$]\9"GKSQ2^'()[;PWI\%S;K;RQ
M0*C1*<[<#`_'%:E%`!1110!Q>EZ=K4'CY[V_M8&$]K('N(IG90N\;%&4`!``
M^7/J<]J]'^&7_)/-+_[:_P#HUZS*T_AE_P`D\TO_`+:_^C7KLA_N<U_>C^4R
M7\=_ZZ&KXA2\:WLFLI;E66^@,BP#[\?F*&#<9VXR3C'OQ6Q117'TL5UN>=_#
MS_D;_&__`%_C_P!&35Z)7G?P\_Y&_P`;_P#7^/\`T9-7HE>CFO\`O3](_P#I
M*(I_"%%07MTEC8W%W*&,<$32L%')"C)Q[\5DV_BJQN9-%1(K@'6$=[?*K\H5
M=QW<\<>F:XH4:DUS15U_P+_DBV[&[169_;EM_P`)(="V3?:A:_:M^!LV[MN,
MYSG/M3M#UFWU_2TU"U25(79E`E`#95BIZ$]Q1*C4C'F:TT_';\F*YHUR7Q-_
MY)YJG_;+_P!&I76UR7Q-_P"2>:I_VR_]&I6^7_[W2_Q1_-"G\+,RBBBN0H**
M**`"N.U:VFO-;B33K"XAFC,XE9X`D7SQD"8.!AF)VC&[.,Y`ZUV-%)JX7.6\
M*VUPEY-.UO-;PK96UL4EB,9,D8;=@'J!D#(X/8FNIHHJF[NXDK*P5S7C+2C?
MV-M/''/--;W,)2.,D@?O4W,5'4@`\GH,UTM%);IC"BBB@!&("DD$@#L,UQ_A
M9WO]<N;Z6RN=/2.'[/:6;V4D*I$&SN+%0I8G!V@\#\:[&BA;W![6"LC*VOBE
MWE(`OK:..)B/XHV<E<^XDR![-6O4%W9V]_;F"ZA66(D':W8@Y!'H0>01TH`Q
M_%212Z>\#6=T\LT,D4=Q;6XE,9('RG@E0W0G&/4CBET=Y+B_CWPK&UG9)!-Y
M9R@E;!9`>^T*/^^A[U;;1@T9B;4=0,)&"GGX./\`?`W_`([LU>MK:"S@6"WB
M6*)>BJ,"A`R6L?PIG_A#-#QU_L^#'_?M:V*R;70_L5I#:VVI7T<$$:QQH&0[
M548`Y7/04`8.@:=K5KXUO+K4;6$FXM`9+B*9W0G>=JKE`.!@;<\`9YS72:)_
MR#1_UVF_]&M1_9DW_06O_P`X_P#XBK-G:I96JP(SLJDG<YR22223^)-'2P=6
MR>N>\3VUI,]C+=P:JXA9VCDT_?E&*X&[R_GYR<8X]>*Z&BA@9/P]%^/&%L-4
M)-[_`&#^]SC.?.'7'&?7WKN?%TRP:"S-'JDN9%`CTP2^8Q[9,0+JG<E><#OT
M/+^&_P#DITG_`&!C_P"CA7HM=>-UY/\`"B8:'*:+ILK:Q:7;W.K2>581F26>
M:XCCN)&&W_4N0JD!22-H.7&>:QOC+_R*%I_U_I_Z+DKT2O._C+_R*%I_U_I_
MZ+DK?*G?'4_453X6>B4445YI9D>*O^10UO\`Z\)__1;5D_#+_DGFE_\`;7_T
M:]:WBK_D4-;_`.O"?_T6U9/PR_Y)YI?_`&U_]&O7HQ_Y%TO\:_\`261]LZ+4
M[^/2M,N;^6.62.WC,CK$`6('7`)%<<FJV6O?$70[K3;B.>..PEDEV,"8]V``
MV.AYZ5W9`(((R#U!JM:Z986(D%I8VUN)3F3R8E3>??`YK"A6ITHRNGS-->6J
ML.2OI_6]SRB\36?$@\27MEH37MK?2B.WNQ=I'Y2PG@JIY/(SQBKU_);^-W\&
MBZ'RWD-TDN/X9!'@D>X89%>G6UK;V5NMO:P100I]V.)`JCOP!Q4$.DZ;;O$\
M.GVD;0LS1E(5!0M]XC`X)[XZUW_VI&]XPMRWY6M]8\NNOIM;87([W/._!]U?
M3?$B6UU-3]ML-+-K*_\`STVR`A_Q4@UZA4`LK1;UKT6L(NV38TXC&\KZ;NN/
M:IZX<9B8XB:G%6T2'&/+<\RG_P"2A^)_^W7_`-%5=JE/_P`E#\3_`/;K_P"B
MJNT8W^*O\,/_`$B(1V([B0Q6TL@QE$+#<V!P.Y/2N8\'S31L]C?"5K_[-%<2
M2_;Y+J-PV<$;N$.0>%XQCDUU?48-5[2PL[!76SM(+97;>XAC"!F]3CJ:Y$4]
MBQ1110!R7BR[O$U"WMXO.6V%I-<NT-RT#;D*]&`.2`20I&">O%=-93+<6%O.
MI<K)&K@R##'(SR/6BZLK2^14N[6&X16#*LT8<!AT(SWJ>A;6![A2,H92IS@C
M'!P?SI:*`.;\,6ZM=ZE>Q7-X]MYS6T,4]W+,`(SAF^=CR6R/H![UTE1PP0VT
M?EP11Q)DMM10HR3DG`]22:DH`*Y+QG/=B:SM[.:1)&AGF*+</`#L4$-O49)!
M/W>ASSTKK:KW=C9W\:QWEK!<HK;E6:,.`?7![TFKC3L,TN?[5I-G<;W?S8$?
M<Z[6.0#DCL:MT``#`&`*"<#)JF[NY*5E8#TXKC/#EWJ2Z]%;7+RS+-;323S&
MY$L4CK(H5HP&.P8)&,+R.G&:W4U.\OL/IEE');$\7%Q,8U<>J`*Q8>YP#U&1
MUCL9H[&\\JZTJWT^YNVR9;?#1S/Z%]JG=C^\!GMFDM'<;V-JH+Q;EK25;-XX
M[@KB-Y5+*I]2!U^E3T4`<%8W-[<:)H]K=7UTZW&H7,5Q<+,T<C!#*5&Y2"O*
MCICICI74>&KJXO?#6GW-T2TTD*EF/5O?\>M6WTVPELVLY+*V>U8EFA:)2A).
M22N,9SS]:LJH50J@!0,``<"G<!:YK5Y-2B\7:)B\V6$LSI]GC!!<B)R2Y[\@
M8'X^F.EJ.2"&62.22*-WB):-F4$H2,$@]N"126X=#GM,DU$>-=2@O;SS8_LL
M<D42`A(P7<#CN<`9/]*[CX9?\D\TO_MK_P"C7K($$(N&N!%&)F4(T@4;BHY`
M)ZXY/YUK_#+_`))YI?\`VU_]&O79#_<Y_P"*/Y3)?QW_`*Z&CXBU#4K'[*--
M:R,DCX\F='>2<\81`I&WC)+G(4#H>VY5#4=#TG5WA?4]+LKUH23$US;I(8\X
MSMW`XZ#IZ5?KCZ%=3SOX>?\`(W^-_P#K_'_HR:O1*\[^'G_(W^-_^O\`'_HR
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M=QGH?>K%"VL#W"FR()(V1BP5@02K%3^!'(_"G44`<YX4@#"^OX[B\>WFG:*"
M.XNI)@J1DKD;V/+,"?IBNCJ.&"&VA6&")(HU^ZD:A0/P%24`%<9XWNKR.YAB
ML[F6-H[*XN659VA`V;</E?OD9/R'Y3GDBNSJO=6%G?",7EI!<"-MZ>=&'VMZ
MC/0T=1IV'VLGG6D,H+'?&K99<$Y'<=C4M%%-[DK8:^[8VT@-@X)[&N/\*76H
M_P!J+;7332J]EYTTSW(F223?C?'AB%1AG`XZ=!7957MK&TLC*;6U@@\UM\GE
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MGM$DU(>*]9@O[SSPL,#QQH"L<08R<*/7`&3W_(5TM1K!"D[SK%&LT@"O(%&Y
M@,X!/?&3^=24!U*.L6TMWI<T,5U+:DC)DAP&P.2`>V>F>M</Y^GQ?#O0!=6'
M]I7TUN(K*T.6$DA7J5Z8'7<1QVKT4@,""`0>"#5"?0='NH88KC2;&:.!=L22
M6R,(QZ*".!]*.Z]!W(_`%K<V7C*UM;V;SKF+0`DLF<[F$JYY[UZ#KUW<V6EO
M-:W%I;R!@/,NHVD49[!%(+L>@4$9)_`\3X4@AMOB.8+>)(H8]%*I'&H55'G#
M@`=*[[4-+T_5[;[-J5C;7MON#>5<PK(N1T.&!&:[,:[N#_NHBGH<WIGB+6KC
MQ)!97UG!!;/&L<FU<E;CRA(R;]^20#TV8Q_'GY:ROC+_`,BA:?\`7^G_`*+D
MKMK?1M+L[B.XMM-LX)XX1`DL4"JRQCH@(&0H].E<3\9?^10M/^O]/_1<E;94
MU]>I6[BJ?"ST2BBBO-+,CQ5_R*&M_P#7A/\`^BVK)^&7_)/-+_[:_P#HUZUO
M%7_(H:W_`->$_P#Z+:LGX9?\D\TO_MK_`.C7KT8_\BZ7^-?^DLC[9:FURZ_X
M3*UTT13Q6>'5F:U?$S[=V0^W;M'3KUSGIS2U;7=0L=4N(!<!8[29;J;*+_QZ
M$(".GJSG/7Y*ZN;[.A2>?RE*'"2/@;2W'!/3.0/>JS'2KF]N+5OL<MVT02>(
M[6<Q\X##KMY/7CFLZ=6FFGR725G]^XVCF+?4-;O+R!/.U,JUE#<,MDEJ-AD>
M3[WFC/`"CY?0YYJ7[=J[2ZI<"74_)MWN!&RK:_9UV`[<Y'FGD#\?:MRZTW0;
M\"XN[+3;@1?N1)+%&^S!QLR1Q@\8]:CBL/#=W>&XAM-*FNGRQD2.-G;(&3GJ
M>&'X$>M:^WIN[Y/_`"7_`(/_``WF%G<S(-5U&_TZ6477V.Y9X8EMY!&KJIP=
MP+`@NXR0/NC`&,@ULZ)<R7%BPFEFDFBD:-_.C19%([-L)4D`CE>*M36%E<(R
M3VD$J,GELKQA@5_NG(Z>U/M[:WLX%@M8(X(4X6.)`JK]`.*YJM:G*#48VU_K
M7^O4$FK'F\__`"4/Q/\`]NO_`**J[5*?_DH?B?\`[=?_`$55VJQO\5?X8?\`
MI$0CL<Q%)J"^-+R&\U`BV:P,D4<?RK$-^`W.<MCJ32>$I9KJ:^N8)KN72&V+
M:R7<S2/,PSOD&[D*>,`8'&0!70RV=K,[O+;0R,\9B<N@)9#U4^H]JBL=(TS2
MRYT_3K2T,F-YMX%CW8Z9P.:Y%HK?UN4]RY6?K:WK:3.+"X2WFVDF5DW%5QSM
M'][TSQ6A2,JNI5@&4C!!'!%)JZ&G9G#W4L\_@73[M=5G34(M-%R$%V49\*I:
M0@?-(1Z$[23SZCM+:43VL,J[L.@8;A@\CN.QJ&72M.FB@BEL+62.W(,"/"I$
M6.FT8XQ[5;JV[MDI:(*YB[N-1MO&]KYUTSV+VL[QVL"'^'R^2/XFR3C_`/77
M3U&T$+3I.T49FC!5)"HW*#C(!Z@'`_*IZE'(^$=7O-1\0:P+UKM2R0R1V\UO
M)&L`.[Y?F`&>F3W.2.!795&L$*323)$BRR`!W"@,V.F3WQ4E!)4U-;Q]/E6Q
MFC@G(XD=-VT=R!ZXSCWKC$GU&]\+^'")GF8P-<7.[4GMI)0J?WDR[<MGCC@9
M(KOB`1@C(-4Y=)TV>UBM9=/M9+>$@Q1/"I1".F!C`_"CH5<72[J*]TJTNH5D
M6*:%'02DE@"`1DGDFH=>_P"0)<@G$;`+(<XPA8!S_P!\YK1``&`,`4R6-)HG
MBE0/&ZE65AD$'J#3>Y*T1SMZVH0>,])C^U!;"1952VB&T':@.7]>>@Z"N:_M
M&[FL+R2Z-T+RXM+J:!3<%X_.B?Y`8RN(RK;`I4\]^<5UZV.H64L(BBM+^*'(
MA>X<I-"I&,!MK;O3/RG'7)ZM@T1KB_\`MU];6-O(65WBM5W&5E^Z9)"JEP."
M!@8(SS26@S=J"\6Y:TE6S>..X*XC>52RJ?4@=?I4]%`'"PSROX!\^\N[R>\6
MYEABD6ZDA9Y#,T:9,;`XR1QT`[5V.G6AL-.M[5IYIVB0*TLSEW<]R2>32_8+
M,0K"+2#RED\Q4\L;0^=VX#USSGUJQ3N`5S6KR:E%XNT3%YLL)9G3[/&""Y$3
MDESWY`P/Q],=+4<D$,LD<DD4;O$2T;,H)0D8)![<$BDMPZ'%>'[Z\D\4!I;J
M=[>Z>[5-TS/O\N0`9C/RQ;1D#;][O@UZ9\,O^2>:7_VU_P#1KUB16%G!=RW4
M-I!'<S?ZR9(P'?ZGJ?QK;^&7_)/-+_[:_P#HUZ[(?[G-?WH_E,E_'?\`KH:'
MB?5;S2;2.XLI+8M&?,GAECWLT((#LO[Q2`N020'/(^4YK='(S5:[TZQU`PF]
MLK>Y,$@DB\Z)7\MQT9<C@^XJS7'T*/._AY_R-_C?_K_'_HR:NE\7:O=:1HDL
MEE%*;AT?;*L#2K#A2=S;0<>@SQD\\9KFOAY_R-_C?_K_`!_Z,FKT*2-)HGBE
M17C=2K(PR&!Z@CN*]7,)QACN:2NDHZ?]NHBG\)S^LZQ<6.GZ??0LVR=3&4=-
MN9&C)CR",@[@!CC[W-8PUS6'TV\`NI6GLY(+.1H8XP[S&<JY&X;02FW&>/FK
MK;FZTH00M=W%D(3*%B,KKM\Q3P%SQN!';D$4LMEIDWFVDUM:/]I_>RPO&I\W
M&!N*G[V/EY/M6-.M3A%*5/KV[/\`RT86??\`K^K?B<U<7.M)=6-JLFN[I8YY
M'0"Q\X[3&!S_`*O;\QZ?-DU/::MJ$FNR:;-+-#"EPB_:)4CRQ\E&\GY1C<26
M).,8X'48NMIGA/9]G:QT78C,WEF*+"GG<<8X/[LY_P!P^E:L5A8QP>5%:6ZP
MDJVQ(U"DJ!M..G`5<>F!Z54Z])1LX='TMUWW?W!9F+H][>-J2)=WSS+<QO)$
M%6)H7`8<Q.F&P`1D.#G(P>#57XF_\D\U3_ME_P"C4KH[?3;&TN);BVLK:&>;
M_621Q*K/]2!D_C7.?$W_`))YJG_;+_T:E&&G&>-I.*M[T?+J$OA9F5D>)OMP
MT"[;3[E;:1(V9I=N6"A23M]&Z<GI6O39(TEC:.1%='!5E89!!Z@BO-DKJQHG
M9G&ZO-(/"]I?1ZG.EY;64=PT2714[?EW2%1S(>H`8[23S79(P>-7&<,`1D8-
M5Y=-L)_(\ZRMI/LY!AWQ*?*QTV\<?A5JJ;N2E9(*Y6>[U&S\:LUS<236G]GS
M2Q6ENA/W63''5G.3_(=\]549@A-PMP8HS,JE%D*C<%/)&>N.!Q[4NM_ZV'T.
M4\&ZK>:CJ6M"^>Z,@DC=8I8)(UA!0?(`X&,?KU[UU]1I!#'+)+'$B22D&1U4
M`N0,#)[\5)0!GZVMZVDSBPN$MYMI)E9-Q5<<[1_>],\5R4US?3Z!X?E,DDT:
M:>;N[`U-[:63"+SE/F;J3Z9QDBN\95=2K`,I&""."*JRZ5IT\,$,UA:R16Y!
MA1X5*QXZ;01QCVH[_P!=P);.9+FR@GC#A)(U=0^=P!&1G/.:FHHIO<2V.9N)
M=2B\=6D<EWFSEMIVBMHP0/E\OEO[S9)^@_&J7A+4;JXO83?&Z%Q>6K3E3<&2
M/*N`V4*_NB"<`*<$=>:Z]H(6G2=HHS-&"J2%1N4'&0#U`.!^5,AL;2VGFG@M
M8(IICF61(PK2'_:(Z_C0M/Z]1O4GK#\N[EU#6C;/%#>9BBADD7<%BV`YQ_O-
M+@>HK<K.OM/EENH[VRG6"[1=C;UW)*F<[6'!]<$="3U!(*8')JTMYX(TLS7M
M\VHW,OV:*=+N6,[F<@LVQ@&PH)P<CC%=)I<!M-9O[:,LUNL%N2[L6=I<.K%B
M>IVK%S4?V74FAA@CTO2+;R2S12>895A;G#*FQ><$YY7KU-:=C9)8PLH=I)9'
M,DLK_>D<\9/X``#L`!3`M5S=])J,?C72E:\Q8RK,%MXP1G"`Y<]SGH.@KI*C
M>"&2:.9XD:6//EN5!9,]<'MFD!Q?A:^O)=>4W%S/)#=Q7#Q[IFD#[)0H+(>(
MB`<87@]\&NXJO!86=M<37$%I!%/,<RR1QA6D_P!XCD_C5BCHD'5E'6+:6[TN
M:&*ZEM21DR0X#8')`/;/3/6N&M+<S^&O##3)'=VXL'W6CRHK%]HQ*`Q&=G.2
M.1G(KT*YGM[6VDFNY8HH%'SO*P50/<GBLV<>'3H\$MP-+.EQ;6@>3R_)3T*D
M_*/;%+H_Z[COL1?#.6YG\2:?+>%C</X=4N7ZD^:O)KTG7KNYLM+>:UN+2WD#
M`>9=1M(HSV"*078]`H(R3^!XOPPR/\2F>-E9&T4E2IR"/.'2N\U#2]/U>V^S
M:E8VU[;[@WE7,*R+D=#A@1FNW&ZN#_NHBGH<[8^(=8/B"SL-2LEMQ<HH\M;:
M0X;RM[-YV=A^8,NS&X8SG%9'QE_Y%"T_Z_T_]%R5VUKHNE65RMQ::99V\ZQ"
M!98H%1A&.B`@9VCTZ5Q/QE_Y%"T_Z_T_]%R5ME37UZEZBG\+/1****\TLR/%
M7_(H:W_UX3_^BVK)^&7_`"3S2_\`MK_Z->M;Q5_R*&M_]>$__HMJR?AE_P`D
M\TO_`+:_^C7KT8_\BZ7^-?\`I+(^V;'B#3SJ.GQI'"LLT=Q#*F2!MVR*6(S_
M`+(-9]MIVI#Q0TC1B/3XII)T?`)D+I@_-OSU[%`!CJ>*Z6LW5]3DT\6\<$"3
M3W#E$$DOEJ,*6))P>RG`Q^584:M2WLHJ][_CO^132>YSL&E:U#?W1@BNX5>Z
MED9C=@QR(TP9=B;OE.W<3P,@XYS@5K'0=>M=/DA1)H&>%5)BN%4[A'"N<@]0
M5?G_`!J[;^+[D1Z=#]DCO)KFVR'CE8$S"'S"K?N]BY]F)Y'&*EM_&AN[B&2#
M3S_9<LHC%\[OMS\HQA4.#N8K\Q4<=:]!O%J_N+^OGY:+[MB>:._<QM;>]TJ;
M[$]U?YD+BP"WS!\EUP22V9.#@+\Q'H!R/1***\ZOB/:QBK6:O\QJ-FV>93_\
ME#\3_P#;K_Z*J[56YF9_'OB.(A-L?V;!"*"<Q=R!D_CG%6JK&7]HK_RP_P#2
M4$=CCIK*9?%^I*VH7!>?2G*28_U`+D`(H]/S)I/!&_[3>>2+3[!Y$(5K1BT;
M2_-O;D#YR-I88R#UR:NO=V_B74+BQMM4$*6G*BWG`E:4='QG[BGU&&/4$#G0
MT768-42>#SX)+RT?RKE87#`-ZCV/Z<CJ#7(M%;^MW_F4U=W_`*Z?Y&K6#XOO
M]+T[0))]6B6>#>H2!FP)7_A4Y."/7/&.M;U%)Z@CRZXC5-"L1<W5I<P?8KIK
M9H'#Q)=%P8TC(_B4$JN.>#BO2[7S?L<'G?ZWRUW_`.]CFIJ*IL`KA+F[TR\^
M(<5I8RVMO>VTF^ZN991YLI*$+#&"<D=R!P,>M=W12ZW#I8Y?PI;R6NJ>((9;
MF6YD6[CW32XW,3$A/3@?0=*ZBBB@#%\5WNF:?X>N+C5T\VT7;F+=CS6SPO49
M!/4'C&<\5Q%U>:7:^$;&"ZDTJYO;R6;['']I4VMIN.3SG;B,$8/7/`QFO4:*
M!W*VG+LTRT7[2+G;"@\\'/F<#YL]\]:LT44V[NY*5E8X75+S2[CQ]:V-M+:0
M:A#+'+=74TP$F,?+#$"<DMW`X_$U9T4V"^,I3I6)(9;9_M&P,&BD#C_7;CN+
M')VYP0`<9'3L:*2T&]?P"L[7KFPL]"O+C4R19)&3*%8@D>@P0<GI6C12>PUN
M>:6\MW/X-O&TJ*-[6\FDDEATV>(BQBV#Y!E@`QQDXZ;CCFNT\+.TGA32F:)X
MS]EC&UR,\*.>"1SUK7HJK[_+\";;?/\`$*X7Q!=Z7/XTLM/AEM(-322*6:[G
MF"M&@/$4>3]Y^A"]CSGBNZHI+1ICZ-'$:$T</BZXPFG7=U<S3F:6&W*W%JH/
MRB1F.=I```P!Z9'->E?#+_DGFE_]M?\`T:]9E:_PZG>Y\!:9+((PQ$@(CC6-
M>)''W5`';TYZUUPO]4FO[T?RF2_COZCO&&OW.BQV,=K'<AI[B/S)X[*2=53S
M$#*=BD*S!L`G'?'.!73T45R="CSOX>?\C?XW_P"O\?\`HR:O0W571D895A@C
MVKSSX>?\C?XW_P"O\?\`HR:O1*]'-?\`>GZ1_P#2413^$XJYT/5(-)M[>PM$
M5P;N`K\K+'%*Y*D+O4=`.020/X3VM:_I6I2W5B]E'<R/#9R0K+!<B+9*2FUF
M^8%E^4DCGIT-=-<SK:VLUPX)6)"Y"]2`,URK>*[V"*[GEMK5F2-)([9;EF^0
MH6)!2(DG&,C&!ZXYJJ-7$57S0BG:_P`[_/S!I:(KR:+KC:E)=&-V?]YLE\Y<
MCBY"XYR/]9'CTS['$5_::SIMI-?S75ZL9:8W.;PD"/SDV!?FPA*;QN&,9Y(Q
MQ?E\:2E_(M-(DN+ORQ.(1(<^244B3A2>K;<`$_*<9Z5T.EWZZEIT5TNP%\AE
M0L0K`D$?,JG(((Y4'VJJE;$4[3J05OZ\V*/*]C.\)3O<Z(TS-.T;W$IA,\WF
MMY>\A?GR=PQW!(]SUK/^)O\`R3S5/^V7_HU*ZVN5^(\S0>`M3E0(67RL!T5Q
M_K4[,"#6&%GSXZ$TMY+\QM6BS)KG?&FH:7IVAB758([E6E58;>5PJ2R'.`V3
MC;W.[@8SVKHJR==UB/2[8(+FW@N)LB-[A@L<8[NV2/E&1WY)`[UP,T6YPUXA
MCT>S26\MKMUTY_L$L+[T^UE^%B/=@,`8YP#[UZ;'N\M=_P![`S]:Y2:_TKPK
M);3KJEK]GN0#<K-<KOESTG49^8YZXZCI]T`]6CK(BNC!D895E.01ZBJOH2D.
MK@_M6FW_`,0?L^FW%K:W5JS_`&FX>4&:XD*$")%)RR+]XCH"..]=Y126]Q]#
MF/!]NUK+KL#W$MPZ:@0TLIRSGRX\D_X#@5T]%%-L#!\7W^EZ=H$D^K1+/!O4
M)`S8$K_PJ<G!'KGC'6N,U"YTNW\+Z78SW6F7.HW7FBVF-R/LUF"V2P;.WY/N
MJ1SQ@8YKU&BD@(K88M80)?-P@_>9SOXZ_C4M%%#$E9'"7%WI=U\0XK6SDM8+
MRVDWW=Q),/-E)0@01@G)'<@<#'K5OPY]@7Q1=_V3MDLY;8%S&&!CD#'(FW'<
M9#G.6P<#&.]=A10M!O4*R?$MWIUCX?N[C5@6LD4&1`2"_(PO!&<G`QT/?BM:
MBDQK1GE-\]])\/[H6<<3V,WGSSC39XFCM%P"L/WAQW;:#W`'->G6+M)86[M$
M\3-&I*.1E>.AP2/R-6**J^EB0KA=4O-+N/'UK8VTMI!J$,L<MU=33`28Q\L,
M0)R=W<#C\37=44ENF/HT</X8,<'B2XC5-.N[BX,\MQ<V]N4FMSYF0DK,<G(/
M`POW>XYKN***.B0=;F'XLUBPT/0WO[^".?RW7R(I`/FES\N">F#SGMC-<;!'
M+#::3?3:W:B"6>[ENKJV>.2*":1<JH)ROJO(/4^HKTZB@#$^&LDTOBBR>XM8
M[24Z`-T,:;%3]\.B]OIVKT/Q/=_8]!N)1J?]FOC"7+.B*K=@SNCJJGH25/7U
MQ7*^&YF_X6-)#A-G]DE\[%W9\X#[V,X]LXKT*NO&7?)_A1,-#@=!\1WU]XBL
MX+G56,TBJ'TTQQ*?+^SJ_GX`WC,A*YW;><8S4/QE_P"10M/^O]/_`$7)7HE>
M=_&7_D4+3_K_`$_]%R5OE3OCJ7J*?PL]$HHHKS2S(\5?\BAK?_7A/_Z+:LGX
M9?\`)/-+_P"VO_HUZUO%7_(H:W_UX3_^BVK)^&7_`"3S2_\`MK_Z->O1C_R+
MI?XU_P"DLC[9UM0W5G:WT/DW=M#<19#;)4#C(Z'![U-17GIM.Z+*']C::DOG
MPV-M!<A0J3QP('3"[1@X[#@?E3+;0=,MX+2,V<,SV@_<S31JTBDG)(.."3R<
M8K2HJ_;5+6NQ604445F,\RG_`.2A^)_^W7_T55>^E>_NCI5LS*N`;N9#CRT/
M1`?[S?H.>,BK$_\`R4/Q/_VZ_P#HJH8M$A@,GDW5XGF2-*^)NK,<D_Y[8%=>
M-_BK_##_`-(B3'8Y9(I-0U^>UM;&XTNUL8YHK)%L9(UFE9<&0OMVA?09R>OI
M1H=AJJR>=#`R3V=K"BO<6XA+L,B2#(4;H\`%6^;!.<GD5UO]E_\`3_??]_O_
M`*U']E_]/]]_W^_^M7(M"GJ3V5Y#?VJW$).TY!5AAD8<%2.Q!X(JQ5.QTV&P
MEN)(WE=[A@TAD?.2!C/UQC\A5R@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`K3^&7_)/-+_[:_\`HUZS*T_AE_R3S2_^VO\`Z->NN'^Z
M3_Q1_*9+^)'6T445R%'G?P\_Y&_QO_U_C_T9-7HE>=_#S_D;_&__`%_C_P!&
M35Z)7HYK_O3](_\`I*(I_"%9W]@:-Y8C_LFP\L/Y@7[,F`W][&.O)YK1HK@C
M.4?A=BS-&A6'VBXDEA6=)XD@\F5%,:1IG"*N,8R2><_H*O06\-K`D%O#'#"@
MPD<:A54>@`Z5)13E4E+1L5D%<E\3?^2>:I_VR_\`1J5UM<E\3?\`DGFJ?]LO
M_1J5T9?_`+W2_P`4?S0I_"S$O;R.PM6GD#-CA4499V/`4#U)KF]7-UI.EMJ+
M::=0UFXE4)Y<#3+;'G;]U20J`GD#))/K70WNFVFH&$W49<PL7C(=E*MC&001
MS@D?B:B_L2R]+C_P*E_^*KD92,"#3W.CZ#I$:W-Q:22E[R66W>+(7+D,K`%0
MSXX(Z<5KVW_$FO$L6XL)V_T5NT3=3$?0=U_%>PS8_L2R]+C_`,"I?_BJ9)H&
MG3)LECF=<@X:YD(R#D'[WK3;$C3HHHI#"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`(O#?_)3I/^P,?_1PKT6O.O#?_)3I/^P,?_1PKT6N
MO%_\N_\`"B8]0KSOXR_\BA:?]?Z?^BY*]$KSOXR_\BA:?]?Z?^BY*VRG_?:?
MJ*I\+/1****\XLR/%7_(H:W_`->$_P#Z+:LGX9?\D\TO_MK_`.C7K6\5?\BA
MK7_7A/\`^BVKS?P?IWCRX\*V4NBZW86VGMO\J*5`67YVSG]V?XLGKWKJE7<,
M$X<C?O)W5K;/3?<ZL-A(UVY.K&%OYF_T3/7Z*\\_LCXH_P#0QZ7_`-^U_P#C
M-']D?%'_`*&/2_\`OVO_`,9KSO;O^1_A_F=?]F0_Z"*?WR_^1/0Z*\\_LCXH
M_P#0QZ7_`-^U_P#C-']D?%'_`*&/2_\`OVO_`,9H]N_Y'^'^8?V9#_H(I_?+
M_P"1/0Z*\\_LCXH_]#'I?_?M?_C-']D?%'_H8]+_`._:_P#QFCV[_D?X?YA_
M9D/^@BG]\O\`Y$JS_P#)0_$__;K_`.BJNUQDEEXN'BK6(FU2T.H)Y/VJ7:-L
MF4^3'R=EXZ#\:L?8/&G_`$%[+_O@?_&ZZ<7B7*HG[.2]V/;^5>?7H*.5PM_O
M%/[Y?_(G5T5RGV#QI_T%[+_O@?\`QNC[!XT_Z"]E_P!\#_XW7-[=_P`C_#_,
M?]F0_P"@BG]\O_D3JZ*Y3[!XT_Z"]E_WP/\`XW1]@\:?]!>R_P"^!_\`&Z/;
MO^1_A_F']F0_Z"*?WR_^1.KHKE/L'C3_`*"]E_WP/_C='V#QI_T%[+_O@?\`
MQNCV[_D?X?YA_9D/^@BG]\O_`)$ZNBN4^P>-/^@O9?\`?`_^-T?8/&G_`$%[
M+_O@?_&Z/;O^1_A_F']F0_Z"*?WR_P#D3JZ*Y3[!XT_Z"]E_WP/_`(W1]@\:
M?]!>R_[X'_QNCV[_`)'^'^8?V9#_`*"*?WR_^1.KHKE/L'C3_H+V7_?`_P#C
M='V#QI_T%[+_`+X'_P`;H]N_Y'^'^8?V9#_H(I_?+_Y$ZNBN4^P>-/\`H+V7
M_?`_^-T?8/&G_07LO^^!_P#&Z/;O^1_A_F']F0_Z"*?WR_\`D3JZ*Y3[!XT_
MZ"]E_P!\#_XW1]@\:?\`07LO^^!_\;H]N_Y'^'^8?V9#_H(I_?+_`.1.KHKE
M/L'C3_H+V7_?`_\`C='V#QI_T%[+_O@?_&Z/;O\`D?X?YA_9D/\`H(I_?+_Y
M$ZNBN4^P>-/^@O9?]\#_`.-T?8/&G_07LO\`O@?_`!NCV[_D?X?YA_9D/^@B
MG]\O_D3JZ*Y3[!XT_P"@O9?]\#_XW1]@\:?]!>R_[X'_`,;H]N_Y'^'^8?V9
M#_H(I_?+_P"1.KK3^&7_`"3S2_\`MK_Z->N!^P>-/^@O9?\`?`_^-U<\'Z=X
M\N/"ME+HNMV%MI[;_*BE0%E^=LY_=G^+)Z]ZZ88E_5IQ]G+XH]NTO/\`JS%_
M9<.;_>*?WR_^1/7Z*\\_LCXH_P#0QZ7_`-^U_P#C-']D?%'_`*&/2_\`OVO_
M`,9KF]N_Y'^'^8_[,A_T$4_OE_\`(B?#S_D;_&__`%_C_P!&35Z)7B7A6Q\9
M3Z]XC32-6L[>\CN<7\DJ`K+)NDY7]V>,A^PZC\.J_LCXH_\`0QZ7_P!^U_\`
MC-=V8XESQ#E[.2TCNE_*O,F&5PM_O%/[Y?\`R)Z'17GG]D?%'_H8]+_[]K_\
M9H_LCXH_]#'I?_?M?_C-</MW_(_P_P`RO[,A_P!!%/[Y?_(GH=%>>?V1\4?^
MACTO_OVO_P`9H_LCXH_]#'I?_?M?_C-'MW_(_P`/\P_LR'_013^^7_R)Z'7)
M?$W_`))YJG_;+_T:E9/]D?%'_H8]+_[]K_\`&:P_&&G>/+?PK>RZUK=A<Z>N
MSS8HD`9OG7&/W8_BP>O:NG!8EQQ-.7LY.TEM;OZBEE<.5_[13^^7_P`B;]%<
MI]@\:?\`07LO^^!_\;H^P>-/^@O9?]\#_P"-US>W?\C_``_S'_9D/^@BG]\O
M_D3JZ*Y3[!XT_P"@O9?]\#_XW1]@\:?]!>R_[X'_`,;H]N_Y'^'^8?V9#_H(
MI_?+_P"1.KHKE/L'C3_H+V7_`'P/_C='V#QI_P!!>R_[X'_QNCV[_D?X?YA_
M9D/^@BG]\O\`Y$ZNBN4^P>-/^@O9?]\#_P"-T?8/&G_07LO^^!_\;H]N_P"1
M_A_F']F0_P"@BG]\O_D3JZ*Y3[!XT_Z"]E_WP/\`XW1]@\:?]!>R_P"^!_\`
M&Z/;O^1_A_F']F0_Z"*?WR_^1.KHKE/L'C3_`*"]E_WP/_C='V#QI_T%[+_O
M@?\`QNCV[_D?X?YA_9D/^@BG]\O_`)$ZNBN4^P>-/^@O9?\`?`_^-T?8/&G_
M`$%[+_O@?_&Z/;O^1_A_F']F0_Z"*?WR_P#D3JZ*Y3[!XT_Z"]E_WP/_`(W1
M]@\:?]!>R_[X'_QNCV[_`)'^'^8?V9#_`*"*?WR_^1.KHKE/L'C3_H+V7_?`
M_P#C='V#QI_T%[+_`+X'_P`;H]N_Y'^'^8?V9#_H(I_?+_Y$ZNBN4^P>-/\`
MH+V7_?`_^-T?8/&G_07LO^^!_P#&Z/;O^1_A_F']F0_Z"*?WR_\`D3JZ*Y3[
M!XT_Z"]E_P!\#_XW1]@\:?\`07LO^^!_\;H]N_Y'^'^8?V9#_H(I_?+_`.1.
MKHKE/L'C3_H+V7_?`_\`C='V#QI_T%[+_O@?_&Z/;O\`D?X?YA_9D/\`H(I_
M?+_Y$Z;PW_R4Z3_L#'_T<*]%KQ'2;'QB_C%HK/5K./4_[/+&9D&SR?,`V_ZL
M\[L'I^-=7_9'Q1_Z&/2_^_:__&:Z<3B7+D_=R7NKM_F*.5P_Z"*?WR_^1/0Z
M\[^,O_(H6G_7^G_HN2E_LCXH_P#0QZ7_`-^U_P#C-<KX_L?&5KH,#^(M6L[R
MS-RH2.!`&$FUL'B->,;N_>M<MQ+ABZ<E3D[/9)7_`#%/*X.+_P!HI_?+_P"1
M/;:***P/,,CQ5_R*&M_]>$__`*+:LGX9?\D\TO\`[:_^C7K6\5?\BAK?_7A/
M_P"BVK)^&7_)/-+_`.VO_HUZ]&/_`"+I?XU_Z2R/MG6T445YQ84444`%%%%`
M'F4__)0_$_\`VZ_^BJNU2G_Y*'XG_P"W7_T55VNO&_Q5_AA_Z1$F.P4445R%
M!1110`4444`%%%%`!1110`4444`%%%%`!15"[UFPLY'BDE=Y4`+101/,Z@],
MJ@)'Y5+::C:7Q=;>=7=/OQD%77TRIY'XB@"U1110`4444`%%%%`!6G\,O^2>
M:7_VU_\`1KUF5I_#+_DGFE_]M?\`T:]=</\`=)_XH_E,E_$CK:***Y"CSOX>
M?\C?XW_Z_P`?^C)J]$KSOX>?\C?XW_Z_Q_Z,FKT2O1S7_>GZ1_\`2413^$**
M**\XL****`"N2^)O_)/-4_[9?^C4KK:Y+XF_\D\U3_ME_P"C4KKR_P#WNE_B
MC^:)G\+,RBBBN0H****`"BBB@`HHHH`****`"BBB@`HHHH`***ANKNWLHO-N
M9DB3.T%SC)/0#U/M0!-16;'KVG/($::2$LVQ3<0/"&)Z!2X`/X5I4`%%%%`!
M1110`4444`1>&_\`DITG_8&/_HX5Z+7G7AO_`)*=)_V!C_Z.%>BUUXO_`)=_
MX43'J%>=_&7_`)%"T_Z_T_\`1<E>B5YW\9?^10M/^O\`3_T7)6V4_P"^T_45
M3X6>B4445YQ9D>*O^10UO_KPG_\`1;5D_#+_`))YI?\`VU_]&O6MXJ_Y%#6_
M^O"?_P!%M63\,O\`DGFE_P#;7_T:]>C'_D72_P`:_P#261]LZ/4O^07>?]<'
M_P#037EG@?3?#UPND-)X5U@WV5?^T#'(+?>#D-NWXQQZ5ZQ<P_:+6:#=M\Q&
M3.,XR,53T'2_[$T.STWSO.^S1[/,V[=WOC)Q^=+#XOV.'G!-W;6S:Z/M^03C
MS-?/]#RU[71+CQ7XB.J^&M7U:07I"26,;LJ#'0[77FM3Q;::7'I_A*W_`+&O
MFTXR.?[.56,^"F=N-V=P)YYK>;PAK=OJNHWFE>*/L,=]/YSQ?V>DN#]6;_"I
M]3\+:KJ-KI+'Q#LU+3Y'D^V?8E.\MQ]S.T8''>O2>-I^TIR]IHEWGI[MMK66
MO579/*[O3N8'@P6=MXTG@TRQO]'LGLMQL;\.KS2;OOJ&)X`XZUZ37-:5X8O8
M-:CU;6-;DU2ZAB:*#_1DA6,-U.%ZGWKI:\O,*L*M52B[Z*[UW]6DW\RH)JYY
ME/\`\E#\3_\`;K_Z*J[5*?\`Y*'XG_[=?_157:C&_P`5?X8?^D1''8****Y"
M@JM?374%MNM+5;F8L`$:41J/<M@X`]@3[59K*\0Z7=:SI,EC:7_V(R$"23RR
MY9.Z\,I&>F<],TF",R3Q3=OH,>JV>G6LR%VA:-[PH6D#[`L9$9#@GH3MKIHR
M[1(9%"2%064-D`]QGO6-'H,@M](ADN+=$TZ;S/+MK<QHX"LJ@`NV,;L]3G%;
M=4[""L2\UR>PU:WMI[!5MKB7R891.#)(VTMD1X^[QC);.>V.:VZYQO#=Y)XG
MFU>;48)HW3RHX7M6W01D8(C;S,`GJ6VFD/H/\.>)QX@DG06R1>4B/F.?S-NX
MGY'X&V08Y7G&1S705@Z%X<;1YA+)>?:#';):0A8O+Q$I)&[YCN;GKQ]!6]3=
MN@=2O>S7,%JSVEJ+F;("QF0(.3U+'H!U.`3Z`US@\9EX8_)L8WGQ.TH-SB,+
M"0'V/M^8\\<#/<BMG7M/N]5T>:RL[\V,DN%,XCWD+W`Y&,CC.:RY?"LDVCV>
MG--IZQVV5"KIX*;2,`J&<E7'.&W'D\@TAZ'0VMQ'>6D-S"<QS()$/L1D5!JL
M\MMIDTD!"S$!(V(R`S$*"1[$BI[6WCL[2&VA&(H4$:#V`P*9?6BWUC-:LQ02
M*5#KU4]B/<'!_"F[7T)5[:F,M[_8>I6>DQZ>!;W#[$G-P#+*^TLSE,9(_O,2
M#D]#67?>(8[F.6_%L(9+6WFO+.=)=S311-B16&!@-Z9/4'@BK$RW5S>PIK5U
M)!'!,DXB6V)5G3H4E7C:>I5ANY(SBJMMH7VJ\%O;L\NGHDD.^2W,82%W#N@W
M?ZPM@+D``+GJ:2\QOR.WJ&ZEEAM9)(+=KB55RD2L%+'TR>!4U0W<4TUK)';W
M#6\K#Y954-M/T/!H`YZ7QBEOX>N=3FLF>2&62$16SF5)&0$DJ^T?+P<L0,8/
MX]'!+YUO'+C&]`V,],BL7_A''?1]7M9KP-<ZIN,TR1%45B@3*H6.!@#^+GUK
M:@B\FWCBSNV(%SCK@4]/R#_@_P#`)****0&-I_B"+4==O--BMY56UC5_.D!4
M.2S*=H(Z`J>>_P"M=9\,O^2>:7_VU_\`1KUSD>F>7X@N-5\[/G6R0>5MZ;68
MYSGONZ8[5T?PR_Y)YI?_`&U_]&O79#_<Y_XH_E,E_'_7D;^H:O::6UNES]H9
M[AML:06TDS'U)$:D@#N3@#/6KU87B/PY_;[6A\RT3R&)W3V:S.F<?-$V08Y!
MCA@2.>0>,;M<?0H\[^'G_(W^-_\`K_'_`*,FKT2O._AY_P`C?XW_`.O\?^C)
MJ]"D#-$ZHP1R"%8C.#ZXKT<U_P!Z?I'_`-)1%/X3Q_Q'JEM<>)-2\0+?P+<Z
M-=00VMN9E5Y44GS<*3DY+'\C78WUQ%=?$'PQ<0N&BEL[AT8=P5!%6--\!Z-:
M:*+*\M+6^N6#^;>2VR^8[,2<Y.2.O'/:JX\#3)I&DPPZU)%J6E;EMKY(!]QO
MX60D@C&!U[5VSQ6%G:*E;E3BFUT<;7TZ7U[ZDN,GKW_1W7^1&)6MOB/KETJ;
M_)TA&QZD$D#]*P!I7AZ;PE:^(_$^H7(U"^Y2^#R,87.2JHJY``QTQV[5VNA>
M&WTNZO+Z_P!1DU+4+M526=XEC78N<*JC@#FLT>"]0LP]KH_B6YL-+=B3:&W2
M4ID\A';E1^=13Q5*,N6,[6Y=5=726JV;W[JSZCL][?UH;WA^YM[O0+.6UOI+
MZ'R]JW,JD-)C@D@@'.16+\3?^2>:I_VR_P#1J5O:-I-OH>D6^FVA<PP+M4N<
ML><DG\36#\3?^2>:I_VR_P#1J5QX5Q>/@X;<ZM]X:J&O8S****X#0****`"L
M.[U^>QU:&TN-/`AN&=+=DG#2R%4+$[,<+QC.[.<9`K<KF?\`A&+N37KW4;G4
MH9TN8VA5#:L)((B,;8W\S"^I.WFEJ,L>&_$@\0K.5@B01!&W0S^:OS`G:3@8
M<8^9><9')K>K$T/0'TF:2::[%Q(T$=LFR+RU$<>=N1N.6Y.3Q[`5MU3M?0E7
MZE:^FNH+;=:6JW,Q8`(THC4>Y;!P![`GVKFSXW5K2.:*R5R(9IY\W&%5(GV/
ML;;\YSTX4$=2*V/$.EW6LZ3)8VE_]B,A`DD\LN63NO#*1GIG/3-9UWX4>]TN
MTL)9[!8H$:(K'IXVA2,`Q[F)C<#C.2.3Q216AT<4BS0I*ARCJ&4^H-/ID4:P
MPI$@PB*%4>@%/IO?0E7MJ8L^N3VWB"#3IK$+#<%A%+YX+MM7<7\L#A!TR3G.
M..<TW1O$(U6Y$36ZQ+-#]IMF$N[S(MVW)&!M/3CGKUI]UHMQ>ZI#-<ZAOLX)
MA/%`(0KJX4KC>#RG)."N??'%-T?PZ-*N5E-P)5A@^S6RB/:8X]V[!.3N.<<\
M<#I27F-^1MUA)YLEQ?ZHEN+RXAD-O:0[@@11@-R>`2VXD]<```XYW:P=02]L
M)+EK:29+>Y82"6&'SFMY!C.4ZLC8&<<@D],Y`"*%WXOMCX<^U7&G&X\Z1X#!
M&WF1.%8*S;\8V<]2!GTK9T7?"MW8.[.MI/Y<3,<DQE5=0?INV\\X45@7%M;R
M:#>6$5Q<7=Y?S^>YM[5]N_(/`)PB_+_$WXDUTFDV<UK;R277E_:[F0S3^7RH
M8@``'N`JJN>^,\=*!=2_1110,QM*\0QZMJU_90VTJ1VBH1+("OF[BPR%(SCY
M>O?Z==FL^WTSR-<O=2\[=]IBBC\O;C;LW<YSSG=Z=JT*`ZA67KES?6=FUS:S
M6-O#$C23S72LP4`9`"@C.?7<,>AK4KGO%'ARX\1"SB6^BAM8)/-EMYK<RI.1
M]T-AU.!Z=Z3&O,O>`M0;5?&EMJ#0F%KC0!(8S_#F53BO2K^^ATVS>ZN%G:-,
M9$%N\S?]\H"Q_*O/O":2Q_$79,T;2+HF&:)"BD^<.BDG`]LFN[UBQFU+39;6
M&6WC,@VL+FW$\3J>"KID9!]B*[<;O"W\J(I^86VM:=>74-M;W<<DTMN+E$7J
M8CC#>P.1UKBOC+_R*%I_U_I_Z+DKK+#0OL-SI\WVIY?L=DUI\Z\ODH=V<\?<
MZ>_M7)_&7_D4+3_K_3_T7)6V56^NTK=_\_T)G?E=ST2BBBO--#(\5?\`(H:W
M_P!>$_\`Z+:LGX9?\D\TO_MK_P"C7K6\5?\`(H:W_P!>$_\`Z+:LGX9?\D\T
MO_MK_P"C7KT8_P#(NE_C7_I+(^V;\NK6L6L0:62S74R-(`HR%4?WCVSSCZ&J
MUQXCLK6Y6WD282&\6T.%'#$*0QY^[\RC/J1Q2/X<M#KT6KQO/',KL\BB>0K(
M2NT?+NVC`'IS4&I>&!J%Y?W(O&B:YMA$@$>?*D!!\SKR?E3CC[OO64%AKKF;
MM;7UO_D/4?%XE6ZF6.STN_NLQ"4M&8E`5F95/S2#KL)XSQBI/[?^:Z8:7?&V
MMFD62Y!BV90'.!YF[MC[M9T_@\-<V\L1TR006L5LJWVG^?MV%OF4[UVYW<_0
M4I\)-]MO)P^EYN6E)F;3LW";P1@2^9VSZ=.*U<<)T?X/^OZZAK^1HR>(;5()
M)D@N)40QH"@7#R.0`@)(&X9&>PSUZU?L[HW=N)6MY[=LE6BG4!E(^A(/U!(K
M*B\/-963VFG7200$*1"\`DC##[W!/W6ZD`@YYSR:O:/IO]E6/V<R1MER^(H_
M+C3/\*)D[5]LGO7/55#E?(];^>WY`N;J<#/_`,E#\3_]NO\`Z*J[5*?_`)*'
MXG_[=?\`T55VJQO\5?X8?^D1".PUV98V94+L`2%!`)]N:RM)UF:^U"[L+JT2
MVNK9(Y&6.?S0%?.`3@8;@Y'(Z8)K3G61[>189!'*RD(Y7<%/8XR,_3-8WAG0
M;G0;>:*XO(+MY7\QYUMVCDD<]6<EVW=L8`QBN1%/8W:***`,?Q!K4^B6HN4L
MEG@49E=IQ'CD`*HP2SG/`X'N*UU.Y0<$9&<'M69K.F7>J0-;PZ@+>WEC:*>-
MH!('5N"0<@JP'0Y(YY!K0@A6WMXX4+%8T"`L<G`&.31T!DE%%,EB2:%XG!*.
MI5L$@X/N.10!DZ1XABUC4]1M8(6$5F4"S$\2YSD@8Z`J1GO6S6%HWA>UT/4[
MJZM9I_+FBCB2&2:1Q&%SW9CGVXX[=:W:!:A6+X@U\:(;-`+/S+J4HIN[O[/&
MH"DDEMK>PQCO6U69JVFW%\8VMKJ&!U5T8RVPE!5A@XY!4\=CCU!I,I&C&S-$
MC.%#%02%;<,^QP,C\*=5;3[*/3M.MK*)G:.WB6)6<Y8@#')JS5.U]"5>VH5A
M:/XC&L7\L4,,/V=0Q61+I6D&&V_/'U7."1UR!SCI5Z;6+.*Y:W4S32K]]8(7
MDV=.&*@A3R.#S6%H.FV4>KJ\%XVVT298+.2W:&1%D?+%MQRXR."`!]>M);ZC
MZ'64444`9^LWUSINGR7<$-M*L2EY?M%PT050,Y!"-D^V!4^G3W%UIUO/=6PM
MIY$#/")-^PGMG`S^50ZQIIU:Q6U\\PKYT<CD+G<JN&*]1UQBK]'0`HHHH`Y[
M2_%`U+7I],^RJAC\SE9MTB;&"_O$Q\F[.5Y.1Z5VGPR_Y)YI?_;7_P!&O7&:
M=X9-AJB737IDAA:=H(_+VL#*VYM[9^;GIP/?-=G\,O\`DGFE_P#;7_T:]=D/
M]SG_`(H_E,E_&=!?:K:Z=+;Q3F8R7#;8TAMY)6/3)(120HR,L<`9&35VN=\3
M>%(O$5S97#/;I+:AU5YK83%`Q4EHSD;)!M&U^<<\&NBKCZ%,\[^'G_(W^-_^
MO\?^C)J[?5=4MM&TV:_NRPBB7.%&68^@'<UQ'P\_Y&_QO_U_C_T9-78:[H5M
MKUBT$[2(X1Q%(DCKL9E*YPK#=P>AXZ^M>KF'L_KW[SX;1O;_``HBG\)+=ZM;
MV0A:<.J2QNX?`P-J[B#SUQG\C6>/%EF]F+B.UNY"8XG\H*@<&20QJARP`;<#
MGG`QUJQJ6@QZAIMG9_:'C%M(C!SEV90"K*23GYE)!)SUJA+X15[/5(%N8V^V
MW27"B:#>B*KA_+*[AN4MN[C[U<])87E7.];^>U_\OR'[W]?U_5RZ^O31RP0'
M0]1-S,KNL(:#<%3:"Q/F[<9<=\]>*DCUV"2Y-J+>X%T)1$8<*6!V*Y)PV-JA
MQDYZ\#.1G'E\&M*+;*Z%B#S`(?[(_<G?LYV>;PPV=<]#TJ]:^&1:7LE_'/%'
M>O(A+Q0;4\L(J&/;N/RG;D<\''7'-2CA>71ZV?1[WT^5@]XNZ=K*:E*5CL[N
M.(AC'.ZKY<@!P<%6)'T8`GMT-8GQ-_Y)YJG_`&R_]&I6G8:'-:ZJ;Z>[AE;8
M4W16HB>7)!S*P.'(QQ@+C)]:S/B;_P`D\U3_`+9?^C4JL,J:QM+V>W-'OW\Q
M2ORLS****\XLQ]=UJ?1ECE%BLUN2`[M.$.2P`5%P2SG/3@<=:V*R-;TBYU>%
M[9-0\FTGC,4\1A#DJ>ZMD%6]SD>U:J*$14&<*,#)R:.@=1U&<#)HJ*YMX[NU
MEMI@3%*A1P&*D@C!Y'(_"@#+T3Q!%KESJ"00LL-I*J)*3_K05SN`[#T]1S6S
M6)HGAJWT.^OKBWGG9+G8%CDFD?RPJ@8RS'/3KV''2MN@`K$UWQ`-'N;&V467
MG7;,%-Y=_9T`4#OM;))(`&.];=9.LZ3/J>WR+J*#,3P2>9;"0E'QG:<@J>/4
MCU!XH&C54DJ"P`)'.#D4M16MNEI:0VT98I$@12QR2`,<FI:;W)6VHA(`)/0=
M:Q-#\1#7)Y/)AA^SA`Z/'=*[@$\>8G!0D<CKQW!XK;(!!!Z'K6#I'AI=*OHY
MA<[X;>!K>VB6,KL1F#'<=QW'(&#@?UI+?4;V-^BBHY[B&U@>>XFCAAC&YY)&
M"JH]23TH`S=>U.\TFQ:[MK2VN$0?.LMRT3$D@*J@(V22<<X[5I6[2O;QO/$L
M4S*"\:MN"GN,X&?KBL+5+S3=0>P\S45MXH;I)LR1E4F(SM4,<#[Q![]*Z&A;
M`PHHHH`Y[1O%`U?5KBQ%JB>4')*SAWCVOMQ*N!L8]0,G(KH:Y_2?#)TS4([A
MKSSHX(Y([=!'M8"1P[;VR=YR..!^)YKH*.B#JPK#UK5[NTU"TL+,0))-%+.9
M;A2R8C`RO!')SU[8S@UN5E:UI,FK)`J3P(L;;F2XM5G5O0C)!5AU!!^H-)WZ
M#5NH[P'J*ZOXUM]11"BW.@B3:3]W,J\5Z5?WT.FV;W5PL[1IC(@MWF;_`+Y0
M%C^5>=>"[&'3/'L=C;@B&WT+RTR<G`F7K7?ZQ8S:EILMK#+;QF0;6%S;B>)U
M/!5TR,@^Q%=N-WAR_P`J(I^9!:^)=)O+^.RM[HR32H'0B)]C94.`'QMW;2&V
MYW8YQBN1^,O_`"*%I_U_I_Z+DKH-,\.ZE8:K:S3:M#=6-K`(88)+5O,3Y0"P
MD\S&2?5"<<`CG//_`!E_Y%"T_P"O]/\`T7)6V56^O4K=R9WY6>B4445YIH9'
MBK_D4-;_`.O"?_T6U9/PR_Y)YI?_`&U_]&O6MXJ_Y%#6_P#KPG_]%M63\,O^
M2>:7_P!M?_1KUZ,?^1=+_&O_`$ED?;-7Q(UQ'ID<MO<R0%;F`-Y>`7!E4%2>
MPY[5EVE]._C22T62X=UE?S\S_NUBV90"+=E><?-M&?4]NLJ"[O+6Q@\Z[N(H
M(LA=\KA1D]!D]ZYZ5:T/9\MV[_C8IJYQL&OWB7=W:&YAN5%[*/+!<2P*)P%+
M,&^Z02`,#ICD9`IZ5KNHP6,DHF-Q,(59#<R.R@^5!U&[G)8G_P#6<]E!X@TF
M>*-C?VT3O`+@PRS(KHA&[+#/`QWZ5.^K:;'=K:R:A:+<NP586F4.20#@#.<X
M(_,5U^WM>+I;_P!=A=W<Y6]\5:G8K-%-+IR30,Z[GB<+<D,!M0;\@@')Y;\!
MR.VJC>Z/8ZC<13W43.\7`Q*R@C(.&`(##(!P<BKU<E>I3G&/)&SUN"33?8\R
MG_Y*'XG_`.W7_P!%5=JE/_R4/Q/_`-NO_HJKM5C?XJ_PP_\`2(A'8@O9WM;"
MXN(X6F>*-G6)>KD#.!]:Q/#7B)M8GN+>2:UFDBBCF\RV4A0'W?(<D_,I4@\_
M@.E=`Z"2-D)8!@1E3@CZ'M5'3=)CTYI)/M%Q<SR*J-/<,"Y5<[5X`X&3[G/)
M-<BZE,T*HZO?3Z?ILMQ;6CW4RCY(U(`SZL3T4=ZO5FW5^LCW-FEG=S[1LD:$
M)@;ES_$P[$4G>V@U:^IA3>*K_P#LK3YX8[87$NFMJ,X=&*E5"Y1<-P26ZG.,
M=#75V\RW%M%.HPLB!Q]",URTND02Z?9V8L-8C6UM_LH=##NDB(`9&R<8.T9(
M`/H16_97R32M:?99[=XHU8+*%^Z<@8P3_=-6[=/Z_K0E7LOZ_KJ7JPGUR[7Q
M;#I7V(I:M#(_G/\`>D9=GW`#T^;&3U/TK=JG+IL,VK6VHLT@FMXY(T4$;2'V
MYSQG/RCO4]1F?X?UJ[U>XU)+JS^R?9IE2.)CEPI16^;G&>>@Z5N53M--ALKR
M^N8VD+WDBR2!B,`A0O''3`%7*`*FHW4ME8R3P6LEU*,!8D(&23CDGH!U)]*P
M&\0Z@?!UGKIDT^U5K?S[@S([#..$100>3QDG\#74LH92IZ$8KG;CP;:SV6E6
MJW]]#'IG,&TQ-N8#`9@R$$CMQQ0-6-RRG>YL;>XDB,+RQJ[1MU0D9Q^%0:O-
M+!I4S0/LE;$:/C.PL0H;\,Y_"K<:LD2(TC2,H`+L!EO<X`&?H!4=Y:QWMG-:
MRE@DJ%25."/<'L13>Y*VU,-;^73?$&GZ%:V'EV+HX,\AY=E7=\O.3UY8]3^=
M9^K:E?PSWWVU+82Z?:/J%N\"LI4(>4W-_K`R\,0`!NQZ&K\LC17EG<ZQ;7OV
MBRWK'-9P--'-N&"=J!F4\="!@]S56/1?[2O4E4ZBUKMV^;?X#",L&:)%90^&
MV@$OR!P/9+S&SKJ@O)WMK26:.WDN'1<K%%C<Y]!GBIZ*`.5B\577_")?VE-:
MQ'47DFBBM8V."R,PZ^@"Y)]C]*WM)NY+_1K*\E"B2>!)&"C@$J"<>U4?^$5T
ME]*_L^YM8[J(/*Z-<1H[(TC%B5)'')X^@K0TW3[?2=-M["U3;!`@11@#..YP
M`,GJ:?<3W7S+585_K=W;>)=-TV.RQ:W+LLES(>"0C,%09_V>2>.WTW:IW>FP
MWE[8W4C2![.1I(PI&"2I4YX]":2W'T,C2->FU'6[JWDN(4A262.&$V<J/($.
M"PE9MC<YR%''%=M\,O\`DGFE_P#;7_T:]<Q#H4,>IK?2W5U<-$7,$<[AEA+_
M`'MIQNY]R<#@8KI_AE_R3S2_^VO_`*->NN'^YS_Q0_*9+^/[S9UG67T=(7&E
MWMZDCA"ULT(V$D`9#R*3DG^$&M2JUU8QW<]I+(SC[++YJ*IX9MK+SZXW$_4"
MK-<A1YW\//\`D;_&_P#U_C_T9-7=:E+##IES+<7+6L*QL7G4X,8QR1P>?PKA
M?AY_R-_C?_K_`!_Z,FKT2O2S-VQ;?E'_`-)1%/X3SFXU*W_L_P`U-<E73V6Y
M>V9-09G24*GEQLX8EF.7;82>H&.*U]?UF]TN_P!/D2Y@B9K&5V@G#$3N#'A%
M`(^<Y(!YZG@UU]90\2Z*?-8ZG:)#&54SM.@C9CG@-GKP>*4<1[1IJG=*_GO\
MO^'!K2W]=SDY=7O3JLK"6947S?W/G/M^47?7YL_P+T/88Q@8N-XHU6!6D=;+
MR':9(SY;YA$<J1EW.[Y@`Q8]/N]?3JI=5TZWC,DU_:QQABA9YE`#`9(R3UQS
M]*)8[+6=.VEDN+28`AXI.&YR"K*?4`@@TWB(-ISIZ`EYE7P]J4NJZ<\\LEO*
M5GDB62W4A'56P&&2>O7J:Q_B;_R3S5/^V7_HU*Z6RLK?3[9;>V0K&"6^9BQ)
M)R222222<Y)KFOB;_P`D\U3_`+9?^C4J,)*,L=3<%9<R_-!+X69E9FO:E<:5
MI$UU:V;74RJ2J9PJX!.YCV48^M:=0W=LEY9SVLA8)-&T;%>H!&#BO/E>VAHK
M7U.9O_%%Y;VD$T26^Z/3AJ%R'1CN7CY4P?E/7DYZ#BNJ1@Z*XZ,,BL>Z\,V=
MU!;PM+<(D,`MFV,O[Z+CY'R.AP.F#[UM``#`Z"J=NA"OU_K^M0K`_MV[_P"$
MK?3&L&2T6UDF61N7F92H^4`_=^;'/)/IWWZIOIL+ZQ%J9:3SHH&@501MVL03
MVSGY1WI+<KH4/#FL7>KC4#>6BVKV]T85BSEE78K#<<XW?-VX^O6MNJ=CIL-A
M->2Q-(6NY_/DW$8#;0O''3"BKE-@4=7OI]/TV6XMK1[J91\D:D`9]6)Z*.]8
M5WXAU&'PE9:X'L(5>U6>994=B[D`B-`",9)QDDXXX-=1-$LT$D3$A74J<=<&
ML"X\'VT\>DHFH7T(TM`EOL\IAD#&Y@Z,"V!UQQVI+^OQ`WX7:6".1D*,RABA
MZJ2.E/I%!5%4L6(&"QQD^_%+0Q+8PFUN[_X2Z'2?L7EVKPR/Y\AYD9=GW0#]
MWYL9/4_2ETO4M1DUNZT[4%M@T<2S*84=0,DC:"W^LP,98`#)QBK\VFPSZK;:
MBS2":WBDB0`@*0^W.>,Y^4=Z@L-#AL;PW;7-U=3",Q1O<N&,<9.=H.`3SCEB
M3QUH73^OZZ#>VAJ5S]S-]HU&^N?LSWG]F%(H;5!UF95<MSQ]UTY[#=ZUT%9-
MT9M-OY+Y(9)[29`+A(E+/&R]'51RV1P0.>!@'FA@85YXNN(_`R:B]I;RZA/%
M(PML$Q@(3N+=]H`_$D#C-;6BL+>ZN=,4GRXHHKB)>T:2;AL'L&C;`[`@=JQK
MG2_"]SH*Z9)"]Z41HXF%MYES'O.>/D^0Y/4@`8R>E;VB6#6D#220);M(%5($
MQB&-1A$XXSU)QQECCBGH'8U*P[C6KN+Q59:6MEMM9@^ZXD/WRJAL(`>@SR3]
M!6Y5.XTZ&YU&SOG9Q+:;_+`(P=PP<\4@,C0=?FU74KF.:XA1`\HAM_L<L;LJ
M/MW"1FVN/7:.,BNCK+MM"AM]26^DNKJYDC5U@%PX80JQ!8*<`G.!]XG&,#%:
ME'1!U*6JRWL.G2OI\44ER!\OG,0JCNQQR<#MWKDE\1ZE/H?AY!)<&[U&V>:6
M6UBC,AV*#A0_R#)/?L#CFNXD021LASA@0<5C+X9M8]+L+*"XN86L%V07"%#(
M!C!!RI4Y'7BCH_Z[C)_`-XNH>-+>[6Y6Y$N@[O.6/RPY\X9.W)Q],UZ/J^I+
MI&ESW[V\D\<"[W6-XT(4=3F1E4`#GDBO/O!EC;Z;X_2RM4V00:'L1<YP!,*]
M#U"R:^M?)2\N;-\[EFMRNY3]&!4CV((KLQN\+?RHB'F4+;Q+;W.JV=@+2Y0W
MEK]JAE<QX9<`D%0^\$9')4#/&<UROQE_Y%"T_P"O]/\`T7)746?A>ULKNTEC
MN[QH;10(+61U:-&V;-X^7<"5R,!MO).,\UR_QE_Y%"T_Z_T_]%R5ME5OKU.W
M<4_A9Z)1117FEF1XJ_Y%#6_^O"?_`-%M63\,O^2>:7_VU_\`1KUK>*O^10UO
M_KPG_P#1;5D_#+_DGFE_]M?_`$:]>C'_`)%TO\:_])9'VSK:S=6TR34/LSP7
M"036\A93)%YBD%2I!7([,<'/Y]*TJ*X(3<'S1+.3'A&=);-[C47N[:QCVQVH
MB*[QY)C*\OLYSD$C(R1G%1:7X0NH+6PF:\:WO5;S+F7YFF<9!"%E<*0%4+AE
M8<<5V-%=7U^O:U_P7G_F3R1"BBBN,H\RG_Y*'XG_`.W7_P!%5=JK<B(>/?$9
M1W,A^S>8I0`+^ZXP<\_D/QJU77C'>HO\,/\`TE$QV.8?6-5M_$>H17,<2VD%
M@]Q!`GS,^UL;F..IQT'3ZTOA75KF_DD2\NYI)GMXKE8IH8TPKY^9"AY3(P`P
MW#').13[BQ&N:M)=6LTELMNA@^TQL<RN&SMQT**W7U/&<`YG\.VUG`D^RU-M
M?(1'<QM*S[<9V["Q.(SDE0,#GH#D5R1T6O\`6_\`P"G_`%^'_!-RN?NYKZW7
M6Y-.CB>Y$J8,K85!Y2Y8^N/3O[5T%8QF6VOM2CN+:Z>.=U(,<#N&7RU4\J/8
MTG=K0:W,>>]U.Z\*Z+=0:M<6^HWL<4:"..$K)(X!+,&0\`!C@$=*WK=63795
M=S(RV<0+D`%CN?GCBJB?V5''81KIU^$T_P#X]A]FF_=_*5].>"1SFK5G(;G6
M;BX6">.+[/&@,L3)DAG)QGZBKDU=V)6R-2N<N=3U2'QA#:2>3#ISVTSI_$TA
M0)\S<?*!N(P/3Z5T=5I;"UFO8KR2(-/"CQHQ)X5L;ACH<X'6I*1S7@_6=1U"
MY>/4)W?S+2*YC61$4MN+`LFS_EGP,!OF]:ZZJ&G:+I^E,[64!C+@+S(S[5'1
M5W$[5&3A1@>U7Z;:Z"ZE34I+R*PD:PBBDN>`HE;:HYY)^@YQWKD3K>MOX<T>
M^\VX"S6;S3W%M;"0F8`%%8;2%0_-DX'0<BNX(#*0>A&#66_AS2GM+2U-LPAM
M%V0JLSJ0IZJ2#EE/<'(/>D--%O3;IK[2[2[9-C3PI(5],@'%6J15"J%4`*!@
M`#I2TWOH2KI:G,ZIJ-Y:^)K&TMK]YI+B12;%(5VQP`?/([8+9ST.0.V#UJ+0
M=:OKO5+87$K217T$\ZQ%%`@\N0*%!`R<@\Y)Y';I6M_PCNF_VQ)JJI<)>2E3
M(Z7<JA]O0%0VT@>A&*GM-(L;&[EN;>#9++G<=[$#)R0H)PH)Y(`&3S26FXWJ
M7JKWOF?89C%<I;.%)$SJ&$?O@D"K%5M0T^VU6PFL;R,R6\R[9$#LNX>F5(-)
M[#6YQYUW6SX0U/4+%_M"1/(;:]NE56:%4SYFU5`;Y@0.`",$^_9VKM)9P2.<
MLT:L3ZDBJD6AV$.ES::%GDM)D*/'-<R2?*1C`+,2!CL"*OHBQQK&@PJ@*!Z`
M53L+M\QU<UKFH7MGKEA!:7[23W$J!;!(5(\K/[R1V(+``="".>.:Z6LJ3P[I
MLNKMJI2X6]8*K21W<J!@O0%58`CVQBDMT'1F=9ZA>MXODT]+]KZ%(W>Z`A58
M[4DCRT!'.XC.02?7CI7<_#+_`))YI?\`VU_]&O7+Z=X=TW2KJ6XLDN(WF=I)
M%-W*R,S=6*%BN??%=9\.E@7P%I@MI))(L28:2,(Q_>/G@$]\]_RZ5UP?^R37
M]Z/Y3)?Q_P!>1:\2>)'T"2R2.R^U?:&._P"=AY:#&6^5&_O#EMJ#NPR,[]4-
M2T:PU8Q&]B=_*)V[)GCR#C*MM(W*<#*MD'`R*OUR="CSOX>?\C?XW_Z_Q_Z,
MFKT2O._AY_R-_C?_`*_Q_P"C)J]$KT<U_P!Z?I'_`-)1%/X2*Y@6ZM9K=R0L
MJ%"5Z@$8KFI/"FH26TL1UI$\Y5CE\JV:,,BKM'W9`=V.^<>V.!U5%<E*O4I?
M`_P7ZE6.,7P<TU_<"3`@CM(H8C,,I),`H:4(CA@0J(`=P.0<>IZ?2[.:PTZ*
MVGNGNI$SF5\Y.23CDDX'09)/')-7**JKBJM5<LGH)12V"N2^)O\`R3S5/^V7
M_HU*ZVN5^(XB;P%J8G=TC_=99$#$?O4[$C^=7@';%4G_`'E^:"7PLR:RO$5U
MJ%GHES/IJ1&X1&;?*?EC`4DMC^(\=/>M6J.KSP0Z;*L\33"8>2L"'#2EN-H^
MOKV&3VKCDFUH6K7U,+4;G49M+T5[75[FVOKX11JL<<)1B5W.[!D)X4,<`CM7
M5*"%`+%B!R3WKF;:R;2KS3SJCB:-?EMI`2%M)&&WR_=2,!2V3G//S"NGJFU?
M0E)V5PKF+C5M5@\536T[6]O8+8331`_,24*?.YQP.3P.WZ=/5673K2>\%W+"
M'G$+0!B3C8Q!(QTYP*7_``?R*.>\(:MJ%_)<1:C+(9/(AG1)TC#X<')&SC9D
M<9^;KGM75U1T[1['2O,^QPE"X`):1G.!T4%B<*,G"C@9X%7J;:;T)5^I0UF:
M^M]+FDTZ.)[D#@RMA4'=CZX]._M7*7>NZU'X?TS4!).$;33<R306PD\R<*"%
M?Y2$0C=R-OU'?N)$66-HW&5<%6'J#6;)X=TJ6"T@>U/EVD?E1*)7'R8`V-@_
M,IP,AL@XI+^OQ&7[:8W%K#,5*F1%?:>V1FI:!P,"BF]Q+8YB^U&]MO%=K9V]
M\]RTK%Y;)(5V00!3\[-][<6QCD`YQCO3/#>LWU]>6XNIFE2]LOMBJ44"`[\;
M`0!D8(ZY/!YK5C\.Z;#JTVJ1)<)=S,&E9;N4+(0,#<F[:0!V(Q5BRTBQT^:6
M6U@V/+PQ+LP`SG"@G"C))P,#FDO,;\B[574BZZ=,R7B695<FX=0PC`ZG!XZ9
MZ\>QZ5:JIJ>F6FL:?)8WT1EMI<;T$C)G!SU4@TF-;G'RZ_KO_")OJ%H=T7V@
M^7>7**LCP;E"ML``);)P<`8&<5W?:LX:'8_V8^G.L\MJY!*S7,DAX((^9F+`
M<#C.*T:HE!7-:IJ%Y:^)K&TMK]II+B12;%(5VQP`?/([8W9ST.0.V#UKI:RO
M^$=TW^V)-55+A+R4KYCI=RJ'V]`5#;2!Z8Q2ZCZ,S]+U"]D\57-B+]K^WAB8
MW+^4J1P2EALC0@9)VYR"3T'3I72UEZ7X>T[1I7>P2XCWEF9&NY70ECDG:S%<
MD]\9K4HZ(.IFZZUM'I$TU[?3V=K$`\LL,FQMH_AR.1GI\N#Z&N;L+?5=4\(-
M=/-?0NK326<#W;Q,T1_U?FN`7)`YZ\\9S73ZMHUAKEF+3486E@#A]JRNGS#H
M<J0:@D\-Z9+#%'*ES)Y18I(]Y,T@W=1O+;MIQRN<>U+HQWV$^'=Y_:'BRRN_
M-DE,OAY6,DB!68^:N20.!S7I.KW=U8Z7/=6=JES-$N_RG=UW`=<;$=B<=`%.
M:XCPK;VMMX_\J$&,QZ/L2%8P$5!*N,'/X8Q^-=WJ&G6VIVOV>Z60IN#!HI7B
M=2.ZNA#*?<$5V8U\SA;^5$4U;<RM/\3Q:EJ%C:PVS$7-H;B242`K$V$(CXZM
MA\\=./45S7QE_P"10M/^O]/_`$7)76VWA;0;+48=1MM(LX;Z&/RTN$A`DVX"
MX+=3P`,G-<E\9?\`D4+3_K_3_P!%R5OE5OKU.W<4_A9Z)1117FEF1XJ_Y%#6
M_P#KPG_]%M63\,O^2>:7_P!M?_1KUK>*O^10UO\`Z\)__1;5D_#+_DGFE_\`
M;7_T:]>C'_D72_QK_P!)9'VSK:***\XL****`"BBB@#S*?\`Y*'XG_[=?_15
M0:C/-=7*Z79N4=ANN9@>88SZ?[;=!Z<GL`9Y_P#DH?B?_MU_]%57BT,6[S/#
MJ%[&9I#*^&0Y8^Y7/H!Z``5UXW^*O\,/_2(DQV,&TV1>)9+72[JZ6PLHY%OY
MI)_W,/R_)&BGY05ZD@<#J3FF:?!<0:[?M9W4]U-;112PA[@S"XA<'(+GHS%2
M0!\JG&."PK6B\(:=;WAO(28[IB29T@@#DGK\PCSS5BT\/0V",EG=W%NKL798
M4B0,QZDX3K7(M$4]6:-G=PWUK'<P-NC<<9&"#T(([$'(([$5/5'3],33I+ET
MGGE-PXD?S2,;L8R``,9P,_2KU`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!6G\,O^2>:7_VU_P#1KUF5I_#+_DGFE_\`;7_T:]=</]TG
M_BC^4R7\2.MHHHKD*/._AY_R-_C?_K_'_HR:O1*\[^'G_(W^-_\`K_'_`*,F
MKT2O1S7_`'I^D?\`TE$4_A"BBBO.+"BBB@`KDOB;_P`D\U3_`+9?^C4KK:Y+
MXF_\D\U3_ME_Z-2NO+_][I?XH_FB9_"S)FFCMX7FF=8XHU+.['`4#J37)ZN\
M#V9US59[V"($)9VMNYCD8'@#CYM[G'0@@`#CYL[VKZ;-J<<$<=WY"QRB1U,0
M=9,=`1D<`X/U`JE>Z#=:G$L5_=V5W&K;E2?3DD`/J`3UKC9:.4\1:AJ]MX6L
M=/OTO(Y&5)+N5(9)<J9`!%YB@C=CJ2<G&.=U=II=U+')_9UY(7F5=\$K*5,T
M78D'^)<@-[X/&<"LF@W4=DMDEW9+:K@K`NGH$&#GA<XZ\TZYT;4KLPF75T#0
MR"2-TM0&4CT.[N,@^Q-4(W****0!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`$7AO_`)*=)_V!C_Z.%>BUYUX;_P"2G2?]@8_^CA7HM=>+
M_P"7?^%$QZA7G?QE_P"10M/^O]/_`$7)7HE>=_&7_D4+3_K_`$_]%R5ME/\`
MOM/U%4^%GHE%%%><69'BK_D4-;_Z\)__`$6U9/PR_P"2>:7_`-M?_1KUK>*O
M^10UK_KPG_\`1;5YOX/U'QY;^%;*+1=%L+G3UW^5+*X#-\[9S^\'\61T[5U2
MQ"A@G#E;]Y.Z3:V?7OY'5AL%+$-R4XQM_-)+\SU^BO//[7^*/_0N:7_W\7_X
M]1_:_P`4?^A<TO\`[^+_`/'J\[VZ_E?W,Z_[)G_S]I_^!Q/0Z*\\_M?XH_\`
M0N:7_P!_%_\`CU']K_%'_H7-+_[^+_\`'J/;K^5_<P_LF?\`S]I_^!Q/0Z*\
M\_M?XH_]"YI?_?Q?_CU']K_%'_H7-+_[^+_\>H]NOY7]S#^R9_\`/VG_`.!Q
M*L__`"4/Q/\`]NO_`**J[7&27OBX^*M8E;2[0:@_D_:HMPVQX3Y,?/W7GJ?P
MJQ]O\:?]`BR_[['_`,<KIQ>*4JB?++X8]'TBE_PPHY1.W\6G_P"!Q_S.KHKE
M/M_C3_H$67_?8_\`CE'V_P`:?]`BR_[['_QRN;VZ_E?W,?\`9,_^?M/_`,#B
M=717*?;_`!I_T"++_OL?_'*/M_C3_H$67_?8_P#CE'MU_*_N8?V3/_G[3_\`
M`XG5T5RGV_QI_P!`BR_[['_QRC[?XT_Z!%E_WV/_`(Y1[=?RO[F']DS_`.?M
M/_P.)U=%<I]O\:?]`BR_[['_`,<H^W^-/^@19?\`?8_^.4>W7\K^YA_9,_\`
MG[3_`/`XG5T5RGV_QI_T"++_`+['_P`<H^W^-/\`H$67_?8_^.4>W7\K^YA_
M9,_^?M/_`,#B=717*?;_`!I_T"++_OL?_'*/M_C3_H$67_?8_P#CE'MU_*_N
M8?V3/_G[3_\``XG5T5RGV_QI_P!`BR_[['_QRC[?XT_Z!%E_WV/_`(Y1[=?R
MO[F']DS_`.?M/_P.)U=%<I]O\:?]`BR_[['_`,<H^W^-/^@19?\`?8_^.4>W
M7\K^YA_9,_\`G[3_`/`XG5T5RGV_QI_T"++_`+['_P`<H^W^-/\`H$67_?8_
M^.4>W7\K^YA_9,_^?M/_`,#B=717*?;_`!I_T"++_OL?_'*/M_C3_H$67_?8
M_P#CE'MU_*_N8?V3/_G[3_\``XG5T5RGV_QI_P!`BR_[['_QRC[?XT_Z!%E_
MWV/_`(Y1[=?RO[F']DS_`.?M/_P.)U=:?PR_Y)YI?_;7_P!&O7`_;_&G_0(L
MO^^Q_P#'*N>#]1\>6_A6RBT71;"YT]=_E2RN`S?.V<_O!_%D=.U=,,4OJTX\
MLOBCT?:7^?YB_LB?-_%I_P#@<3U^BO//[7^*/_0N:7_W\7_X]1_:_P`4?^A<
MTO\`[^+_`/'JYO;K^5_<Q_V3/_G[3_\``XB?#S_D;_&__7^/_1DU>B5XEX5O
MO&4&O>(WTC2;.XO)+G-_'*X"Q2;I.%_>#C)?N>@_'JO[7^*/_0N:7_W\7_X]
M7=F.+4\0Y<LEI'>+7V43#*)I?Q:?_@<?\ST.BO//[7^*/_0N:7_W\7_X]1_:
M_P`4?^A<TO\`[^+_`/'JX?;K^5_<RO[)G_S]I_\`@<3T.BO//[7^*/\`T+FE
M_P#?Q?\`X]1_:_Q1_P"A<TO_`+^+_P#'J/;K^5_<P_LF?_/VG_X'$]#KDOB;
M_P`D\U3_`+9?^C4K)_M?XH_]"YI?_?Q?_CU8?C#4?'EQX5O8M:T6PMM/;9YL
ML3@LOSKC'[P_Q8'3O73@L4H8FG+ED[26R?<4LHGRO][3_P#`X_YF_17*?;_&
MG_0(LO\`OL?_`!RC[?XT_P"@19?]]C_XY7-[=?RO[F/^R9_\_:?_`('$ZNBN
M4^W^-/\`H$67_?8_^.4?;_&G_0(LO^^Q_P#'*/;K^5_<P_LF?_/VG_X'$ZNB
MN4^W^-/^@19?]]C_`..4?;_&G_0(LO\`OL?_`!RCVZ_E?W,/[)G_`,_:?_@<
M3JZ*Y3[?XT_Z!%E_WV/_`(Y1]O\`&G_0(LO^^Q_\<H]NOY7]S#^R9_\`/VG_
M`.!Q.KHKE/M_C3_H$67_`'V/_CE'V_QI_P!`BR_[['_QRCVZ_E?W,/[)G_S]
MI_\`@<3JZ*Y3[?XT_P"@19?]]C_XY1]O\:?]`BR_[['_`,<H]NOY7]S#^R9_
M\_:?_@<3JZ*Y3[?XT_Z!%E_WV/\`XY1]O\:?]`BR_P"^Q_\`'*/;K^5_<P_L
MF?\`S]I_^!Q.KHKE/M_C3_H$67_?8_\`CE'V_P`:?]`BR_[['_QRCVZ_E?W,
M/[)G_P`_:?\`X'$ZNBN4^W^-/^@19?\`?8_^.4?;_&G_`$"++_OL?_'*/;K^
M5_<P_LF?_/VG_P"!Q.KHKE/M_C3_`*!%E_WV/_CE'V_QI_T"++_OL?\`QRCV
MZ_E?W,/[)G_S]I_^!Q.KHKE/M_C3_H$67_?8_P#CE'V_QI_T"++_`+['_P`<
MH]NOY7]S#^R9_P#/VG_X'$ZNBN4^W^-/^@19?]]C_P".4?;_`!I_T"++_OL?
M_'*/;K^5_<P_LF?_`#]I_P#@<3IO#?\`R4Z3_L#'_P!'"O1:\1TF^\8IXQ:6
MSTFSDU/^SRIA9QL\GS`=W^L'.[`Z_A75_P!K_%'_`*%S2_\`OXO_`,>KIQ.*
M4N3W9?"NC%'*)_\`/VG_`.!Q_P`ST.O._C+_`,BA:?\`7^G_`*+DI?[7^*/_
M`$+FE_\`?Q?_`(]7*^/[[QE=:#`GB+2;.SLQ<J4D@<%C)M;`XD;C&[MVK7+<
M6J>+IR<9.SZ1;8IY1-Q?[VG_`.!Q_P`SVVBBBL#S#(\5?\BAK?\`UX3_`/HM
MJR?AE_R3S2_^VO\`Z->M;Q5_R*&M_P#7A/\`^BVK)^&7_)/-+_[:_P#HUZ]&
M/_(NE_C7_I+(^V=;1117G%A1110`4444`>93_P#)0_$__;K_`.BJNU2G_P"2
MA^)_^W7_`-%5=KKQO\5?X8?^D1)CL%%%%<A04456OIKJ"VW6EJMS,6`"-*(U
M'N6P<`>P)]J`+-%<M<^-;>V\,IJWV4R2O(T2V\<F0S*Q5B&Q]P8)W8].,G%=
M0#D`^M%@%HHK%N]<GL=8M[6XLD2UN9O(AF^T`N[;2V=@'W>",DY]L<T`;5%8
M?AW7SX@BEG1;$0J<+Y%YYT@Y.-Z[1L)&#C)ZUN4`%%5[V:Y@M6>TM1<S9`6,
MR!!R>I8]`.IP"?0&N=;QK$+*%Q#:K<O)+&5EO!'"/+;:Q$I7D$D`<#)/;F@#
MJJ*CAD:6".1HS&SJ&*$@E<]LC(_*H-4N9+339I80IFP%BW=-[$*N?;)%`"W6
MIV-E(L=U>00R,,JCR`,1ZXIUI?6E_&9+.ZAN$4[2T3A@#Z''>L(7/_".WL%N
MUBIANYTA:]><>=<2L/O;`.0,8.2,`<#`%4M0U&]BU*]NI-.M8)-,MOM,US;W
M32%HQD^4RF-<DJ&(Y.#@_46H/0[*BBH;J26&VDD@@-Q*H^6(,%W'TR>!0!-1
M7*3>,C;V4KRVELD\-Y]DE9[O%NC;-^3+LSC''W?O<>]=#IM[_:.F6M[Y+P^?
M$LGEOU7(S@T[=0+5%%%(`K3^&7_)/-+_`.VO_HUZY/3_`!!%J.NWFFQ6\JK:
MQJ_G2`J')9E.T$=`5//?]:ZSX9?\D\TO_MK_`.C7KKA_ND_\4?RF2_BM_70Z
MVBJ&HZS8:5)`EY*Z--G;MB=\`8RS;0=JC(RS8`R,FK]<A1YW\//^1O\`&_\`
MU_C_`-&35Z)7G?P\_P"1O\;_`/7^/_1DU>B5Z.:_[T_2/_I*(I_"%%%%><6%
M%%%`!7)?$W_DGFJ?]LO_`$:E=;7)?$W_`))YJG_;+_T:E=>7_P"]TO\`%'\T
M3/X69E%%%<A04444`%%%8EQKTMEK,%G=V216]P[I#+]H!=BJEBQ0#A,`\[LY
MZ@4`;=%8GAK7F\0V3786R6(XVBWO//9<\X<;1L.,<9-;=#5@"BJU]-=06VZT
MM5N9BP`1I1&H]RV#@#V!/M7.GQM$UE:R106_VB;S,I-=K''^[?8=LA&&)8@+
MP,]\4`=71348O&K%2I(!*DC(]N*=0`45BW>MW%EK%M:3V*+;W,WD0RFX&]VV
MEL[`/N\8SG/MCFETS5=1N]7NK&ZL+6)+9%+S07;2C<W(3!C7G')^H]:`V-FD
M)`!).`.I-+6!=1R:D]Y,UH+V&VD$5O:,X5)'&-SOGC@DCG.-N0"30!L0WEK<
M.R0W,,K+U"."1^53UP>J>(M/;30;G2[-9(YI8&D^U^6D;QC)$4P7=O.?EP%.
M0>F*Z?0;R>YLY(KKS//MW$;-(NUF!574GMG:P!QQD&@#5HHK&U#6Y].U*WAF
MLE%I/,EO',9QO=V'\,8'*CN20?;%`&S16!H_B9=5NXX6MUA6XB>>V/F[F9%8
M*=PP-IR1QD_6M^@`HJKJ+7JV;'3_`"//R/FG#%5'<[5Y8^V1GU%<Q;^*M0O+
M6QAA2U2^N#<%G>-BBK"<$E-P96;CY2<KGG.,4`=9X;_Y*=)_V!C_`.CA7HM>
M6>`M1&K^-+;4538+G0!)LSG;F5>*]*O[Z'3;-[JX6=HTQD06[S-_WR@+'\J[
M,9HX)_RHF&NQ9KSOXR_\BA:?]?Z?^BY*[&UU_3[V]CM+5YYG>)9@Z6TIB"L,
MC,FW8"1S@G//2N.^,O\`R*%I_P!?Z?\`HN2M<I_WZGZBG\+/1****\XLR/%7
M_(H:W_UX3_\`HMJR?AE_R3S2_P#MK_Z->M;Q5_R*&M_]>$__`*+:LGX9?\D\
MTO\`[:_^C7KT8_\`(NE_C7_I+(^V=;17,>.?$.H>'-(MKG38()KB:Y6`),I(
M.0Q[$<Y`K'\2>/[O3M*T6ZTRWMY7OH1/*)02(T^4=F'.YL?A6='`5JRBX+XF
MTOD.4E'?U._HKG_%>MWND6-HFF0Q3:C>7"P01R@E?4DX(.`!5`>+KB7X<2>(
MHHH1>1Q?/$RG8)`VUAC.<?C40P=6<(S6TG;YO]!W5['7T5PC^(O%FE1Z??:O
M!HLMC=RQQ;+-I1,-_0@-P<>E=W45L/*C9MII]O(2DF>93_\`)0_$_P#VZ_\`
MHJKM4I_^2A^)_P#MU_\`157:TQO\5?X8?^D1".P44$@#).`*KVE_9WZNUG=P
M7*HVQS#('"MZ''0UR%%BLKQ#I=UK.DR6-I?_`&(R$"23RRY9.Z\,I&>F<],U
MJT4`<M?>"[;4=&2TGE6&YB@\B*6S$L,:)D''EB0@]!U)Z5TT48AA2)2Q5%"@
MLQ8\>I/)^IJ*ZO[.Q\O[7=P6_FMLC\V0)O;T&>I]JL4[L+!7.CP[>GQ5)K,N
MHV\R,OEQ0R6I+0)CD(WF8!/<E3GZ5T5%(#%TG0I+"]^U7%VDSI;BVB$,`A41
M@Y&5!(+>X`'H!6U4:7$,DTD*31M+&`9$#`LN>F1VS4E`&;KVGW>JZ/-96=^;
M&27"F<1[R%[@<C&1QG-9G_"+.MA9117%G#<V:20Q/%:,(Q&XPPV&0G/'7=UK
MI:K7NHV.FPB:_O+>UB9MH>>54!/IDGK0`:?9)IVFVUE$SM';Q+$K.<D@#'-&
MH6GVZPFM@YC9U^5P,[&'*M^!P?PJ='26-9(V5T8!E93D$'N#3J;;;U$K6T.&
MRZ>)EUC6]4L[%X5$26U]`0D0Z,T4OF!26_O8)`P"!R*NQ6\=^FH6MC.+R'5)
M_-N;H)^Z6$A5**V<.2JX&.F<GT/657BOK2>ZEM8KJ"2XAQYL22`NF>FX=1^-
M)=AO74L53U2VN;W3+BVL[S['<2IM2XV;S'GN!D<_C5RBAJX)V.6MO"=Q;:78
MVT5]:I/8S&6&1+1MC$J5;S%,A+,=Q.=PYK<TG3DTG2K:PCD:18$"!FZFGWVI
M6&F1K)?WMM:(YVJT\JQ@GT!)J6WN8+RW2XMIXYX7&4DB<,K#V(X-.[8$M%%%
M(#/CTSR_$%QJOG9\ZV2#RMO3:S'.<]]W3':NC^&7_)/-+_[:_P#HUZPXM0LI
M[N6UAO+>2YA_UL*2@NGU`.1^-;GPR_Y)YI?_`&U_]&O79#_<Y_XH_E,E_%_7
MD7_$OAS_`(2&.WC^TK;JA82,!)O:-NJ@I(HYP.&#KP/EXK>Z#%%%<?2Q1YW\
M//\`D;_&_P#U_C_T9-7HE>=_#S_D;_&__7^/_1DU>B5Z.:_[T_2/_I*(I_"%
M%<9JWB?6F\47&AZ%!IQFM8!-(;YV!ER,[8PO?D4FJ^+-7@\,:3?6VG)::A?7
M:6K6]_&X$9;<.V#C(!SZ'I6:P%9\NWO>?=75_D/F5[':45@:4?%HNR=:_L3[
M($/_`!Y^;OW=OO<8ZURMOXP\7-X:'B26WT-M-4DO$IE28@,5.,DKG(]Z(8&=
M1M1DGLM^KO9?@',>DUR7Q-_Y)YJG_;+_`-&I74P3"XMXIE!"R('`/49&:Y;X
MF_\`)/-4_P"V7_HU*6`5L927]Z/YH).\6S,HHJ&ZN[:QMVN+NXBMX5^])*X1
M1]2>*XRB:BH6NK=(8YFN(EBD*A'+C:Q;@`'OGM4U`!7.1^'+T>([K59]1MYU
MG4Q(CVA+P1X^ZC%]HYY)*G-:/B*ZFLO#.K7=N^R>"SFDC?`.UE0D'GW%._LR
M;_H+7_YQ_P#Q%`%;2=$DL+V6\N;I)YF@2W40P>2BQH21\N2-WS'D8'H!6S67
M'9^<TBQ:W=NT3;)`KQ$HV,X/R<'!'YT_P_=37WAK2KRX;=//9Q2R-C&69`2?
MS--NX$?B'2[K6=)DL;2_^Q&0@22>67+)W7AE(STSGIFL^;PJ\ME:QI<6D%Q!
M;R6FZ&T(C\E\9`0N2#P,'<><\5TM5KO4+*P\O[9>6]OYK;(_.E";V]!D\FD,
MDM;=;2TAMD+%(D5%+')(`QR:EHHH;N)*RL<\GA^]'BQ];EU"WG0KLBADM6+0
M)CD(WF8!/<[36EI6FG35NMTWG/<W+W#-MVXW'@=3T``_"K]5[:_L[QY4M;N"
M=X6VRK%(&*'T..A^M"!EBN7UA+BW@O[`7_\`9L-\VZ"_\O<L);&]#R,$G)!)
M'WO4<]12$`@@C(/4&AJX)V.)GT>WT[2K-#J]C"]O'+#$MO:,PE20#<!'YA9I
M."<@GJ>#6_X<TY]/TW$JR*\I#;)'W,BJBHH)]=J`G'&2:O>58:='+<F.VM44
M%I)=JH`.Y)JR""`000>013N%A:YZ7P_>R^+%UI]0MY(HU"0V\MJS>2O\6QA(
M`&;^\5/I70T4NMPZ6,/3?#B6.KRZE+)!).0ZHT5LL)(8@DN1]]OE`S@<#I6Y
M52'5-/N+V2R@O[66ZBSYD"3*SICKE0<BK='1!U*M_!=3V^VRO/LLP8,',0D4
MX[,IQD'V(/O6$OA$P(D]M>JFH^;-+)<-!N1S+]\;-PP.!CYN,#.><]/52_U*
MUTR)9+IV`8X58XVD=CC/"J"3QD\"@"/P381:7X[AL(,F*WT(1J6ZD"51DUZ!
MK%C-J6FRVL,MO&9!M87-N)XG4\%73(R#[$5P?A*Y@O?B(+FVE66&71-Z.IX8
M&8<UZ779C=7"_P#*B8:;'+Z9X0_L[6;:_P#M5O)Y$*Q^9]C"W#X39M:8'+1_
MQ;2"0<?-@`5A_&7_`)%"T_Z_T_\`1<E>B5YW\9?^10M/^O\`3_T7)6V4N^-I
M>HJGPL]$HHHKS2S(\5?\BAK?_7A/_P"BVK)^&7_)/-+_`.VO_HUZUO%7_(H:
MW_UX3_\`HMJR?AE_R3S2_P#MK_Z->O1C_P`BZ7^-?^DLC[9)XUM+B[30Q;V\
MLWEZM!))Y:%MJ#.6..@'K7"S>&M732]>BDLKF06DD5I8*L3$O#Y_F$KZC!'(
M]/:O6GU&QCODL7O+=;QQN2W,JB1ASR%SD]#^5.:]M%8*UU`&,OD@&09,F,[?
M]['..M7AL?5P\%!1\_QO_P``)Q4M_P"M_P"OD<9K>E:SKWC:`V5S)IL.EV^Z
M*[>T\Q7E?@A0V%/RXYYQ6)+HVMZ7H_BO0I([G4%N(UNK>XBM2JRNQ&\`+D`Y
MQ\H]":]$GU[1K9U2XU:PB=ONK)<HI/)'&3Z@CZ@TXZYI"W;6AU6Q%RN=T)N$
MWC`R<KG/`&:JGC:\(QCR>ZDNG9WO>U][^6H<JO<X"3PE%X7O]&US2]':YAPB
M7MKY3321DC_6H#E@0>H'_P"KTT'(!&>?457EU"R@5VFO+>-8T$CEY5`5#T8Y
M/`.#S4EO<07<"3VTT<T+C*R1L&5A[$<&N3$XBKB%&51:K2_XA&*CL>;S_P#)
M0_$__;K_`.BJNU2G_P"2A^)_^W7_`-%5=HQO\5?X8?\`I$1QV(KID2TF>2)I
M45"6C5-Y88Z!>^?2N8\'F6[NK[4KFVN+.:98XTLWM)(5@B3=L7+*`S<G.,@<
M"NJDD2&)I9'5(T!9F8X``ZDU5T_5+/5$=K21FV8W!XV0X/0X8`X/8]#VKD74
MI[%RBBHKBXAM+>2XN)5BAC4L[N<!0.YH`P/%\:7&G2VPL;J6XG@>.*>"W$G)
MQ^[8@$JK8&3P,#[P.*W[;S/LL/FHJ2;!O53D*<<@51F\0Z7!9VMW)<GR+I/,
MB81.<I@'<0!E5`(R3@#/-:0((!!R#T-/5*P;BTR7S/)?R0IEVG8'.%SVS[4^
MJKZC9IJ4>G-.OVR2-I%BZG:,9/MU[TO(#F/"6G:MI_B#6&U&VC!G2%Y+A)G<
M2R?-G;E%XYZ?PX`YKL:JVFHV=]-<Q6LZRO;2>7,%Z*V,XSTZ'M5J@+!7.>*(
MI6GT^XBEOXF@,C(UG:B?]X5PH8%6(')&=O?J*Z"66.")Y975(T!9F8X`'J:S
M9/$>E1V5K>&Y9H;I"\)CA=RRCJVU02`.Y(P*3&BYISW<FFVKWT:QW;1*9D4Y
M"OCD#\:LTV.1)HDDC8.C@,K*<@@]#3+FXBL[66YG;;%$A=SCH`,U3W)6Q+7%
M^&;74;/5XK>XA>3RDG$\LML%$;-)E?+DV@MO'+#<>@Z=*U!=37%_;V][J;6%
MS=*SP6,"J7"CG+L0W/TP,\<XS4%KK\<%X8DU%M0ME;$C20[)(QNV[E8*%D0-
MA20..I)YI+<?0Z>BBD9@JEF("@9)/:@#*\1M=_V+)%9)*TUPZ09B4DHKL%9O
M;`).?:M&WMXK2VBMX$"11*$15'``Z55AUK39])?5(KN-K%`Y:?G;A203],@_
M7M5JVN(KNUBN8'WPRH'1L$94C(.#0!+1156?4K.UO;6RFN$6YNB1#%U9\#)_
M#`ZF@#D-`L;V'Q0KR6MPJQM=^8LD16*`/(&4QOCYRV,GYFQ_L]*],^&7_)/-
M+_[:_P#HUZYZWU>SNK^:R@,[RPL5D;[/((P1C(\S;MSR.,UT/PR_Y)YI?_;7
M_P!&O79#_<Y_XH_E,E_']XOB)-26[OVAEU%K5K%?DMPWR?O!O\O8-V\IG&"6
M]*T_"WFG0D\S[;L\Z7R?MN_SO*\QMF[S/GSMQ][G&,\ULT5QK16*?]?=8\[^
M'G_(W^-_^O\`'_HR:O1*\[^'G_(W^-_^O\?^C)J[V[O;2P@\^]NH;:$'!DFD
M"+GTR:]+-$WBVEVC_P"DHBG\)P7BVU6YUN==<\*7&IV7EK]BN]+B8S*<<K)A
MNF2<=O8]LS4M(UIOA]I-OJMC?7KQZFLDEN@,LRV_S?*2O.<>_<=*]1^U6^(S
M]HBQ*A>/YQ\ZCDD>HY'/O4+ZMIL=M]H?4+18-@D\UIE"["<!LYQ@GC-:4LPJ
MQC",8?"UW\UIVOUMNP<4W<X_PE!H5KJL@TKPGKFES2PLK3WD+B/'!QEG/.0.
MU5O!?@'1I-!L[W5M&8:EO<N+@R*>';&4)QTQVKLCXDT)85F;6M.$3L55S=)M
M8C&0#GJ,C\Q5I=0LGC\Q+RW:,LJ;A*I&Y@"HSGJ001ZY%34QF)M+EYH\UM;N
M^EU:_P`Q*,;6+(X&!7)?$W_DGFJ?]LO_`$:E=);ZC8W=Q-;VUY;S30G$L<<J
MLR?[P!R/QKF_B;_R3S5/^V7_`*-2L,#%K&4D_P":/YHJ7PLS*SM9>&.T1YK6
MXF`?Y9+>`3/`V"!(%P3D>P)YZ8S6C17$]2D<'+H4[>'=`>6TG^U6=U"J0H6(
M1/-&79>S;>23TR>E=Y6=JFN6.C#=>FY5,;B\=I+*@&<<LBD#\36@K!E##.",
MC(Q3OI\Q=3(\6?\`(FZY_P!@^?\`]%M6M(GF1LFYEW`C<IP1]*KZE8IJ>EWE
MA(S)'=0/"S+U`92"1[\U`]O?1QL[ZJ%11EF,"X`I,9F^$],_LI]9MUAECA-\
M6B,N277RT^;)^]DYY]<U;\)_\B;H?_8/@_\`1:U#IU\=6\S['K+.8P"P>SV'
M!Z,`P!*G!P1P>U:NFV4>F:7:6$3,T=K"D*,W4A5`!/OQ3=^HD6:Y+QI/*5@L
M+>PG9[Q'BFOX[)Y_LT)QN`V*3ENPZ<9/2NMJA?ZS8:8\:7<Y1G!8!49\*.K-
MM!VJ,C+'`'K2ZE(M6R+':PHF[8J`+O!!QCOGG-2T`Y&1THH9*V$/0\9]JYC1
M8RWB2:YMM/N+6T^R+"R3P>3Y#*Q(1`!AE.2206&>_:MY]1LTU*/3FG7[9)&T
MBQ=3M&,GVZ]Z99:O8ZA-+#:S%WB^\"C+D9(RI(&X9!&1D<4+>XWM8NT45F7M
M[,;MK.U>.(QQB6XN)!E8E.<`#NQP>O`QD]@0#$\?Z=JNIZ'+#901SVRPN\L/
MF,LCN!\FT*C;L'G&1D@<UT]EYOV&W\]%CE\M=Z*Q8`XY&2!G\A7/O>P1Z-%J
M\?BB<6S'"2S11M'*2=H!4(">?[I!K:TV^>[26.>,175N_ES(,[<X!#*3U4@@
M_F.H-/96"]R[115674K.'4(+"2X07<ZLT<75F"]3[#ZT@.<\/)J%KJ[VR->R
M6;M/+<_:[81"*1GROEL!\X.6S\S=!TZ5UM9]GK>GW]T]M;3EY5!.#&RAP#@E
M20`P!X)4G%:%'1!U"N7\4V,DNI:7>G[8;6`31RBS#F0%U&TC9\W48X]?3-;]
M_?VNF6<EW>3+%`G5CZGH`.Y)["LT^)H&T>TU*"QOKB&YC,JB.-<H@&26)8*O
M';.3VS28T2?#P:@/%]J-5.;[^P?WV<9W><.N._K7?^)P&T&X0_;5W#`DLUF9
MXSV;;"RR,`<9"G)^F:XSPA=17WQ"2[@),,VA^8A(()!E4C@UZ77;C=7#_"B*
M;MJC@?#I\0#Q1`VIB\9&MD3RY%GVQIY2DNS[_)9C(&!4IOYSG`J'XR_\BA:?
M]?Z?^BY*]$KSOXR_\BA:?]?Z?^BY*VRIWQM+U%4^%GHE%%%>:69'BK_D4-;_
M`.O"?_T6U9/PR_Y)YI?_`&U_]&O6MXJ_Y%#6_P#KPG_]%M63\,O^2>:7_P!M
M?_1KUZ,?^1=+_&O_`$ED?;+SV%T/$[744%T@=D+3_:@86C"X*F/(^;/?:?7<
M.E9VL:%J,^IWUQ:P*Z(J7EKF0#==#8,>WRQ@9/\`?/O6_K&H76FVQN+>R2XC
MC1I)6>?RPJJ.@X)+'L,8XY(XS5LM?:\UV>P^RB*&,[5E=G#.VT,0!LV<9.1O
MSQTI4JE=+VL4FDOP5O/^N@W;J8T6EZMIEY;M#'J906$$4C6+6OS2*SE@WG'/
M\75?4U)]AU=9-4@$.J>5</<&-5:U^SG>#MSD^:.2/Q]JTX/%%I,]Q"P,5Q#.
M\.V17"L%D"9#[<$\@X&<9&<=:KV'C"VN;=[BZB6UB2,2,2[.<;(WX`7MYF/P
M_+7GQ+NW37W?\'7Y!;7?;]"&'2+ZSTV2VFM7OW+Q7'GI*D<I88XYX)4@;0<+
MC`SQSL:'%=16+"[B,<C2LP#K&)"#W?R_DW'G...E0MXJT=(5E>XE526R#;2[
MDP<'>NW*<\?,!FMFN6O4JN-JD;7?9_U]PDET/,I_^2A^)_\`MU_]%5=JE/\`
M\E#\3_\`;K_Z*J[1C?XJ_P`,/_2(CCL07D"W5C<6[QB198V0H6VA@1C&>U8'
MAC2+RSO+F\NQ<Q^9!%`D5S)&[J$W=X^,?,`.YQD\UHQ^(=.EU>YTV.4M-:Q&
M69P/D0`X()]1W':I-+U9=4#,EG=P)M5XWGC`65&Z,I!(_`X8=P,UR+NBGV-&
MJ6JV$.I:?)!-`DW&Y$<<;Q]T_G5VJNHZC::38R7E[*(H8QR3U)[`#N3V%)VM
MJ-;Z'(3:!JB:-IL:6IDF&D/ITL0D0>4[A/F))P5&TYQD],`UVEK$;>TAA+;C
M&BH3ZX&*Q[GQ,EOHUMJT>F7UQ:3PK-NB\K*!L8!#."2<]%S6W&YDB1RC(64$
MHV,K[''>KDW=W)5K+^NPZL";1`/&%IJ4%J@C:"9;J4$`LS>6%SSD\*?IBM^L
MMO$&GKK@T=9"]WY32N$&1&%QPQ]2&!Q_]:IZE%7P]HYTB^U=8[5+>TEG1K94
M(P5$2J>!TY!ZUO5D:/XAM=:=DA@N(B(DG3SE4>9&V=KC!.`<'@X/M6O3=^HB
MM?V4&H6CV]S"DT9(;8XR"0<C]0*X^>R\06_@[2-%MK"?YH1%?R6\L7F1(!RJ
M;G`+'IG/'-=C>WUMIUG)=7<RQ0QCYF;]![DGC%9)\661L;*YBM[J7[7`UPD2
M(N]8EQN9LL!QD<`D\\`TAJYKV4206%O#'"T*1QJJQ,02@`Z'!(R/8FJ^M1O)
MI$_EH79-LFP=7"L&*CZ@8_&KD4J3PI-$P:.10RL.X/(I]-WOJ2K6T.=DTZ*Z
M\2:5K5A#')$ZR-/<HP^8%`$]R/I63K5OJ%S-?32VC6;7=E)IP!E$WFR.<1F/
M!RJC)9LA?4YQD7[T6]EJ8M[5]6TR.:=5:XMEC\AI7Y`"R!N23R57&>IS4VBW
M5C<ZH06O;BZ"/Y-U=E<2HK;7,87A>>#\JYXZBDO(;.CJ&ZM8+VUDMKF)989!
MAT;HP]#4U0W5P+6VDG,4LNP9V1(69O8#O0!R'_",:G-X373U>&V:.XN)3;R1
M>8LH+N8Q\KJ!U!Z]<9'%='X?MKJR\/:?:WFS[1#;HCA!@`@8QU/3IG/-4YO%
MVFVFEW5[>K-:M:R&*6WD"F7?MW;0%)!)4YX/UQ@UMQ2":%)5!"NH89Z\T^_R
M%;;YCZP-3T;S?$FDZG;VJ%XYF-S-D!@GE.J]>2,MT'K6_67?:Y%I]XD$]I=^
M4SI&;H(/*5G.%&203DX'R@XSSBDMQ]#*TK2]0M-?9XX;JWMC+-)<M/=^='/N
M.4\M<_(1W^5?3+=:[SX9?\D\TO\`[:_^C7KF(-<BFU06#VEW;NX<PO.@59MA
M`;:,[N,CJ!GJ,UT_PR_Y)YI?_;7_`-&O79#_`'.?^*/Y3)?QFG)I3OXEN+LK
M+]GGL?)9Q.PPV[HN#E>.XQ^=2^&K.?3_``QIEG=(4N(+9(Y%+!L,!SR,YJ]/
M>VEJ)#<74,0CC,K^9(%VH.K'/0>]+:W5O?6L=U:7$5Q;RC='+$X=''J"."*X
MUHK?UU_S*_K\#@?AY_R-_C?_`*_Q_P"C)JZSQ!9M>0VI%K=W*PS^84M+D02#
MY6`(.5SUZ;E_'H>3^'G_`"-_C?\`Z_Q_Z,FKT"X>2*WD>*$S2*I*QA@"Q[#)
MX%>KF,W#&N2[1_\`241#X3GM5TO5+O1=,C4B2^C*QW#APORNA21L^V=WOBLP
M^'M2@L-32.!]RW4*V8@>/>8$F\T%=YV@C<P`;^Z*U9O%+6EG(US9#[8EQY'D
M02[U;&TLP<J/E`;DD=>/2KNI:_:Z3J-O;78=8YH7D\U49]FTJ.0H.!\V2QP!
MBIA4Q,$H**>MU\G?H]O^"'N[]OZ_KT1ASVVM27=C=+%KN8DGC=\V/G?,8R.,
M[-ORG_:R/2I[/2M2CUN7598I9$:="MM,T>X`PQHTORG;O!!!YQC=CKS8D\5H
ME^UL((V5=V9?-;:,"8G(V9_Y8\X!Z\9QS:7Q3I!:5#<L&BW;OW$F"58*0IV_
M.<L!A<GD<<T2EB$N54UM;1=&[AH^I5T>SO8-33?826]M%$ZXF>*15)8'$3K\
M^#SG?CHO%5?B;_R3S5/^V7_HU*Z2QU"VU*W,]J[-&'9#N1D(8'!!#`$$&N;^
M)O\`R3S5/^V7_HU*G#3E/'4N96?-'\_,)?"S,HHJEJNJV>C:?)>WLNR)!T`R
MS'^ZH[D^E><W8LJZO9W-]?Z5$D>ZSCN#-<G</X5)08ZGYL'\*UZR+_Q'8:=I
M5KJ%QY@CNC&L4:J"[%\8XSVSD\]JUZ>V@KWU"H;M));*>.$H)6C94+C*Y(XR
M/2IJRU\0:?)KSZ-'(9+J.%I9-HRJ`$<$_P![Y@<?GVJ6KZ%+34R?"&D7NER3
MFXMY+>(P0Q;9IA*[2("&96#'"<C"\8Y^45U59VD:L=7MA<I875O`ZAHI)_+_
M`'JGN`K$C\0.M:-4VV]24K!7+^*]'NM1=3907!EEMI;9IH9T4*&Q@.KCE,\Y
M7YACCK6]J.HVFDV,EY>RB*&,<D]2>P`[D]A5!O$EL;*RN(+6[N&O(/M$<$**
M9!'@$L1G'&X<`DG/`-(I71J6T)M[6&$MN\M%3<>^!BI::C!T5P"`PR`PP?Q!
MZ4ZF]]25MH<_/HF/%]KJ5M;*L;03K<S`@$NWEA<]SPI^F*J^&]&OK&\MS=1-
M&EE9?8U8NI$YWYWC!R!@#K@Y)XK7.O6/]O+HR.9+PQM(RH`0@&.&/8G<.*98
M:VU[J<U@^EWUK+#&)':8Q%0"<`91VY.#Q[4ET_KO_P`$;VU-:L06UM-JFJ:?
M?1B5;LQW*)(.'5552!ZX9`2/]L>M;=4-7CL#8F?4'$45N?,$V\HT9Z9##D'G
M'OG'>D]@.9D\,W$O@:WLY+%&U*#/E*67*9ER<'./NBM_3BMQKFIWD3%H=D5J
M,?=+QERQ'_?P*?=<=JY\ZI;OIUM>-J.O7EM>)(Z6P$$16-/O,6"HPP.V[)]"
M:ZZQ6V6P@%G&L=L8P8U5=H"D9'':F+0L5@WFC_\`%5Z=J=O:KQYOVF8$`GY`
MJYR<G\*WJS)=>L(M<@T?S"]Y*K.509$8`S\Q[9'04#,C1(-5NO$ESJ>LZ=<V
M\@1H;4>9$T4460?X7+%VP"3C'&*ZJLG3/$%IJDXBACF0.AD@>0`"=`<%EP2<
M`D=0#STK6HZ(.K(;J(3VTB%%<[3M!'?M7,VEC?V?@O3=)N=$%Z#:^3<Q>='F
M-L<<,=K#/4ALCL#71WTUU!;;K.T^U3%@JQF41J,]RQS@#V!/H#7/Q^,/M$44
M5M9)+?M+-$T/GXC7ROOD/MY'(Q\HSGM2Z-?U_6H^S-3P!:W5CXQM;6]G\^ZB
MT`)+)G.YA*N>>_UKO?$]D-0T&XM&TW^T$E&&A40EAZ,HF'EE@<$!N*XCP3?Q
M:IX[AOX,B*XT(2*&Z@&53@UZ-?:A9:9:-=:A=V]I;(0&FN)1&@SP,DG%=N.U
M<+_RHBGIL<YH7AA+;5K/4+O2K**\MM/CB^U1QJ9))"-K9?[QVJJ@9/\`$:Q_
MC+_R*%I_U_I_Z+DKN8]5TZ6^%C'?VKW9B$P@693(8ST;;G.WWZ5PWQE_Y%"T
M_P"O]/\`T7)6V5-O'4_44_A9Z)1117FEF1XJ_P"10UO_`*\)_P#T6U9/PR_Y
M)YI?_;7_`-&O6MXJ_P"10UO_`*\)_P#T6U9/PR_Y)YI?_;7_`-&O7HQ_Y%TO
M\:_])9'VS;U723JC6Y_M"[M?(;>%@\LJQ[%@Z,#CJ/0\^E.CTI5OQ=27=U-L
M8O'%*RE(V(VEAQGD$\9P,\`5H5C>(9[V&"V^RM<I&\I$TEM`)I%&TXPN#P6P
M"<<9[=1RTI3FU33M_7WE-+J,_P"$7M3</(]U=NK3-,D3,NV-V<.Q7Y<\D8Y)
MXSZDU'#X0T^"$Q+-<E2@3EES@*B_W?2-?S-85G<^(!+IFGVJW]M']F$,IFMA
MY<3>1E7!\O\`OX!RYY&"O(IUGK'B*[FL-0?[1]FN9<?8H(<[5!52QD\MEQD,
MV"R<'@]J]!T<2MJB_J_EULW^;(YE:]C0UCPM=W5VS6%R(H;HL+LM)AB"P.`-
MAR.#QE3D]2.*ZNBBO-J5IU(J,NA=E=L\RG_Y*'XG_P"W7_T55VJ4_P#R4/Q/
M_P!NO_HJKM;8W^*O\,/_`$B(H[&)<:$;C6KBY_=I:SV#6K*O#;F8DG&,=^N>
MM5O#7A^YT:XF>4V\<9ACA$=N21*R9S*^5&'8$`CGIU/:R^N7$&M1Z?<:>$%Q
MYGV8K<!I)-@R24QA5/8[CVR!4FC:S-J<UY!<6B6\UJRJXCG$J@L,[20!\P[C
MD#(Y-<BVT_K7_@E/?7^MO\C7J"\MQ=6DD6U"S*0I8<`XP#4]5KZ:Z@MMUI:K
M<S%@`C2B-1[EL'`'L"?:D]59C6YC1:#=KI7AZQ>2`QV#1M=#)(?8A`V\<_/M
M/..E=%7+7/C6WMO#*:M]E,DKR-$MO')D,RL58AL?<&"=V/3C)Q74`Y`/K5-M
MMMDJRT%K'N](EF\06FH0M'%'%;SQR$<.6?9@CC!QM[GTK8K%N]<GL=8M[6XL
MD2UN9O(AF^T`N[;2V=@'W>",DY]L<TBBEX7\.76B3R23&V13`D++;$GSW4DF
M9\J,.<^_U-=/6'X=U\^((I9T6Q$*G"^1>>=(.3C>NT;"1@XR>M;E-W%U(YHE
MFB9&56[C<,X/8UR;^%;P^'M)L-EG)/:P-!)(9I8RN1@E67[P]488;CD8KJ+V
M:Y@M6>TM1<S9`6,R!!R>I8]`.IP"?0&N=;QK$+*%Q#:K<O)+&5EO!'"/+;:Q
M$I7D$D`<#)/;FEY#3:.BL;1+#3[:S0DI!$L:D]P!BK%1PR-+!'(T9C9U#%"0
M2N>V1D?E5;5+J6TLBUN@>XD=8H@1P&8@9/L,Y/L#3=[ZDJUM#$O=+U6Z\6P7
M]VME+I=L1]EB:Z9&C8CYI"OED,W7`W`"I-%\.W&GZC#+,\)@LX98;8HQ+.LC
MAR6!&`1@#@G/7CI5:ZCMM-U.V6_TJ&[6XE6V%]=2J\TKMS\J;3A,CD`KC'"X
M%06MU>:3XA-M#IUO;:?$(UN(K6Z:2-/,;;&50QKL;N0IQCKS@TEY#?GY':53
MU1;]M,N%TMH%OF3$+3DA%/J<`]/I5RH;J26&VDD@@-Q*H^6(,%W'TR>!2>PU
MN<S:^&;E?!]]I<T-JE]<))^_^T--YDCK@R,Q12"<XP`<"NGMHS#:PQ,061`I
MQTX%<S-XR-O92O+:6R3PWGV25GN\6Z-LWY,NS.,<?=^]Q[UT.FWO]HZ9:WOD
MO#Y\2R>6_5<C.#5:O7T%Y>I:KF=3TG5[_P`3VMU+'9SZ3:E7A@:Y=&$G>1@(
MR&([#('?Z=-6-JNMSZ5>0"6Q4V<DT<'G&<!V=S@;4P<X[Y(XZ9I+=!T92TG2
M=73Q+=:KJR6<S.&CMY(KER8(L\($,8&3U+;J[GX9?\D\TO\`[:_^C7KC=+\3
M+J.H1V[6RQ1S^=]F?S=S/Y3;7W+@;>>1R>.N.E=E\,O^2>:7_P!M?_1KUV0_
MW.?^*/Y3)?Q_UY%S5=&NWU"\U#3K;3I+F6S$*K=Y"O('RI?"DD`?4\5=\/V5
MQ8:/'!=PPQ7)=Y)A#,959V8L6W%$Y).?N@#.!4TVL6,-S<6QF,EQ;P^?+##&
MTCJG;Y5!))[`<GTJ6PO[;4[*.[M'9H7R`6C9&!!((*L`000000",5QK;3^MR
MG_7W'"?#S_D;_&__`%_C_P!&35WUU`;FTE@6>6`R*5\V$@.F>X)!&?PK@?AY
M_P`C?XW_`.O\?^C)J]$KTLT=L6VNT?\`TE$4_A,%O"6FW&FBROP;X)_JYKF&
M(R1C@D*0@ZD9)QDY/-6=3T"WU.6-VN+B`)"]NR0%0KQMMW*<J>#M`XP:T+EI
MEM)FMU#3!&,:GH6QP/SKA&O-9BMKJ:`ZR]U,(PDS600[PARK#R6^7<<`[>W+
M=S%#VU9\RG:WZ[^@VDM#HCX2L#,\GFW`+[^`RX&[S<]O^FS?D/?,6H>%8Y+#
M;92N+F-I)(3*^`&>19"<A3C!08.#CN&Z5D3ZGXFEFDM8YF@=+5+UI!;;V4.H
M41;`C,#O$ASM)&!P>175:)/<W.CV\MW'-'.00PG`#G!(R?E7KU^ZIYY`JZOU
MBBE4<TQ1:>R(]`T^YTW33%>3"6YDEDFD8-NY9B<9P,_7`^@Z5C?$W_DGFJ?]
MLO\`T:E=;7)?$W_DGFJ?]LO_`$:E9X.;GC:<GUDOS0Y*T69E4]4L_M^F7-LH
M3S)(G6,N.%8J0#[=:N54U">[M[<-9VB7$I;!$DPB11W9FP3CZ`FN!V:LRU=.
MZ.;U?P=<:CIEFD6HRPW=O;Q0;1L,6%92Q&4+`G;VQG`SQ77("J*I8L0,%CC)
M]^*YEO&EO]ATN>.SFD>_E6/"_<C!DV%B^,$9Z=S[<XZ>J=]_,E66@5BW.C22
M^($OH_(6'['-`RD')=V4YP,9'RG/(-;58ESKMS::S!93Z>!'<N\=NRW`,DC*
MI;.S&`O&,ELYQD"D,K^&]`ET>YGE,%G9PO$D0M;(DQDKG,AR`=QR!WZ<DUT=
M9&DZS-?:A=V%U:);75LD<C+'/YH"OG`)P,-P<CD=,$UKTW?J(@O+<75I)%M0
MLRD*6'`.,`URESX/GETO2X]MI-=6E@;-Q*Q$8)"_O%.TG<I7(X'U%=3?374%
MMNM+5;F8L`$:41J/<M@X`]@3[5S\OBZ5="CU:+3DD@#.LQ-T%4%7V;8SC,C,
M?N\`'N127]?U\Q_U_7W'1VL3V]G##)*TKQQJK2-U<@8R?K4U(IW*#@C(S@]J
M6F]Q+8R9]*=_$MCJ4?E+%##,DHZ,S/LP>G/W>Y]*?H^GSV37\MRT;S75T\VY
M"3\G`0<@=%`J&ZUN>RUFVM+BQ5+:YF\B&;SP7=MI;(C`^[QC.<^V.:--\0Q:
MIKNH:=!"WEV:(?/+<2$E@0!Z`J1G/7/I0O+^NHWY_P!=#9ILD:2)M=589!PP
MR,CD4ZL+4S<W]Q<6\$3S06H3=!'-Y1FD;!VLW9`N"1WW8P<8*8&--X3NIM&T
M^Q;[!=M:K,KP3L?+W.?ED!VD[ESQQW/(ZUU]C!):V%O;RS-/)%&J-*W5R!@D
M_6N'N-3T5+.W0:/H]O<_;)+7<UT+>.)E4EF28)N[@<`')KJM'N;C?/87DB23
MVX1U=7W%XW!VDG`YRKKG'.W/&<!]!=35K*O-*>?7M-OXO*5+?S3-GAF+*%';
MGIWK5K&O];GT[4[>&:R06D\Z6\<QG&]W8?PQ@<J.Y)!]L4NH^A3T?PV]EK1U
M"5+>(1QR11);RR,K!V#9VOQ']W[JY&2372UA:/XC&L7\L4,,/V=0Q61+I6D&
M&V_/'U7."1UR!SCI6[1T0=69'B6UU>]T66UT6:&"ZE(4RRNR;4_BVD*?F[#C
MO6/!X8N[.STUK*TLK>XL4EA$)NG='20#+%_+!W9&?N\],]QTM^;T6I^P&V6<
MD?/<;BBKW.!R2!VR,^HKF%\3:A<^&9M6M[FR3[--)`2;1Y%NF#;5,8\Q<;CQ
M@ENO6EW'V-[P%IPTCQI;:<K[Q;:`(]^,;L2KS7HFLP7ESIDL-DD3R2#:R2SO
M!N4C!`D0%D/^T`?ZUP/@TW9\?H;_`,K[6=#S*(00@;SER!DDX_&O1+^^ATVS
M>ZN%G:-,9$%N\S?]\H"Q_*NW':N%_P"5$4_(Y;1?">H:;KEI=2RP/%#$JM(L
MSC.(A'L$.T(.1GS<[L?+C%9OQE_Y%"T_Z_T_]%R5V%IXBTN^O4M+:Y:21T#J
MPB?8V5W`!\;=VTAMN=V.<8KC_C+_`,BA:?\`7^G_`*+DK;*F_KU*_<4[<K/1
M****\TLR/%7_`"*&M_\`7A/_`.BVK)^&7_)/-+_[:_\`HUZUO%7_`"*&M_\`
M7A/_`.BVK)^&7_)/-+_[:_\`HUZ]&/\`R+I?XU_Z2R/MG6T445YQ8V2-)8VC
MD171P596&00>H(I(HHX8DBB18XT`5408"@=`!3Z*=W:P!1112`\RG_Y*'XG_
M`.W7_P!%5=JE/_R4/Q/_`-NO_HJC4KXV<2+#'YMW,VR"+.-S>I]%'4GT]\"N
MO&_Q5_AA_P"D1)CL<J]AJMAXGO;JVNH-1O)T+.#;E9+6#G:B.7*@DC@%?F()
M)P*V]!LBTLFKRWXO)KJ)(]Z0^4-J9QE<GY\L<]/3`K-@O;[0-3EM[X6\L<T4
MUV\J(X=B@'5SPQ(_@`^4*.2.:K:1K-W:ZK<2W?D_99H(;N=84*K#YN</R3TV
MX<]#PV!AL\BVT*>^O];?\`[>LKQ#I=UK.DR6-I?_`&(R$"23RRY9.Z\,I&>F
M<],UJ@Y&110!RU]X+MM1T9+2>58;F*#R(I;,2PQHF0<>6)"#T'4GI7311B&%
M(E+%44*"S%CQZD\GZFGT4[BL%<Z/#MZ?%4FLRZC;S(R^7%#):DM`F.0C>9@$
M]R5.?I7144AF+I.A26%[]JN+M)G2W%M$(8!"HC!R,J"06]P`/0"MJBB@#-U[
M3[O5='FLK._-C)+A3.(]Y"]P.1C(XSFLS_A%G6PLHHKBSAN;-)(8GBM&$8C<
M88;#(3GCKNZUTM%`%;3[)-.TVVLHF=H[>)8E9SDD`8YJ+5H)IK,/;KNG@D69
M$_O[3DK[9&1GWJ]13;N[L$K*QREMI[ZKXF77H=5MIXHE$<=I-:,7M1_&!^\&
MUSW)7/:I%M%:^N[*VNA<2W-^EW=2(.($780A//)"`8ZX)/&*V;W1=*U*19+_
M`$RSNG485IX%<C\Q5J&"&VB6*")(HUZ(BA0/P%):`]22J>J6US>Z9<6UG>?8
M[B5-J7&S>8\]P,CG\:N44-7!.QRUMX3N+;2[&VBOK5)[&8RPR):-L8E2K>8I
MD)9CN)SN'-;FDZ<FDZ5;6$<C2+`@0,W4U=HIW8!7/7?A^]NO%$.KG4+=H8%"
MPVLUJSB+^\RD2`;STR0<5T-%+K</(PK+PXMMKDFJ32P22_/Y9CM5B?YR,^8P
M^^0``#@<=<GFNP^&7_)/-+_[:_\`HUZS*T_AE_R3S2_^VO\`Z->NN'^YS_Q1
M_*9+^(V;S2II[^6]M[L02M:_9US$'`.[=D@GD=B./J*=H.E?V+I$5CYD;["S
M?NHO+C7))VHF3M49P!DX%:5%<BT5BCSOX>?\C?XW_P"O\?\`HR:O1*\[^'G_
M`"-_C?\`Z_Q_Z,FKT2O1S7_>GZ1_])1%/X0HHHKSBR*.W@BEEECAC228@R.J
M@%R!@9/?BI:**;;>X!7)?$W_`))YJG_;+_T:E=;7)?$W_DGFJ?\`;+_T:E=6
M7_[W2_Q1_-$S^%F96%XML)=1T*2%=2%C"&#3L8C)YB#^#"LI^;@<')Z=ZW:Y
MN^FNM1']HVTUK!8VKEHY+H,8VP#NE*@C<!T49`ZM_=KC?F6KWT([6TEU;2+7
M3+L16-W8S0SM#%#A=BON3:NXX!`QU."#UQ745YYJ7BB]DM=)U.""**X-O)<!
MC$[>8H8*5.#^[C88;<^0,#N,UW5C>QW]HEQ&"N>&1OO(PX*GW!JG?^OZ\B58
MLUS2>'=23Q#=ZM_:EM)),ACA$MFS-;ICA4/F8ZX)^7GV[=+12&87AG0;G0;>
M:*XO(+MY7\QYUMVCDD<]6<EVW=L8`QBMVBBBX&5XATNZUG29+&TO_L1D($DG
MEERR=UX92,],YZ9JI+H%])HT6F1ZA;06_DM;RQ0V6(VC/'R@N2K`=]Q'J*Z"
MB@+D<$*V]O'"A8K&@0%CDX`QR:DHHH!:'._\([>-XIEUB;4()XV7RXX9+9MT
M$>.1&XD`!/=MN:?I'A2ST76)KVSEG$3VZ0)`\\CA`I)ZLQSU&!CC!QU-;]%"
MT`*YC7(9H!?P17W]FQZGMQ?^7N$4H`0@\C!954!L]1CKC/3TC*&4JP!4C!!'
M6AJX)V.6&AOIFA6\0U+3+6*V1T\S[%B,QL.?O2%@W!.[=@YY!J[X:L5@A:=$
ME6+R8K:W,V?,:&(':S`]"2SG'H1TZ5<M]!T:TN?M-MI-A#<9)\V.V16Y]P,U
MHT[A8*YZ7P]>R^*UUI]0MY8HU"0V\MJS>2O\6QA(`&;^\5/I70T4NMPZ6,#3
M?#"Z=J<5PMR&M[995MH5C*E1(P9MS;CNY''`Q[UOT44`9'B32+G7=&DT^VO_
M`+%YI`DD\HON3NO#+C/KGI5<>'96TO3K&2YMHX[*YCF"6UJ8T94Y"X+L1S@Y
MSVZ5OT4+0'J1>&_^2G2?]@8_^CA7;:Q8S:EILMK#+;QF0;6%S;B>)U/!5TR,
M@^Q%<3X;_P"2G2?]@8_^CA7HM=>,UY/\*)CU.7T_P?\`8=9L[XWQ>.UA55CQ
M(&DD"%-[9D*'Y3CA`W`&X@8K#^,O_(H6G_7^G_HN2O1*\[^,O_(H6G_7^G_H
MN2M\I=\;3]15/A9Z)1117FEF1XJ_Y%#6_P#KPG_]%M63\,O^2>:7_P!M?_1K
MUK>*O^10UO\`Z\)__1;5D_#+_DGFE_\`;7_T:]>C'_D72_QK_P!)9'VSK:**
M*\XL****`"BBB@#S*?\`Y*'XG_[=?_159T$&K1ZE<WT]E;2S.3'$?M1`CB!X
M`&S@GJQ[G'8"M&?_`)*'XG_[=?\`T55VNO&_Q5_AA_Z1$F.QS!T:\DO_`+3<
M6QN54N8H9[[<D1<8;:?+W<@D8)('8"I-,TN\TL2[;))VD18BT]X"1&H(5!B,
M<#)ZY//)-='17(496B07]I%-;W4<26Z,/LH64NRH?X2<#@'I[8';)U:**`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"M/X9?\D\TO_MK
M_P"C7K,K3^&7_)/-+_[:_P#HUZZX?[I/_%'\IDOXD=;1117(4>=_#S_D;_&_
M_7^/_1DU>B5YW\//^1O\;_\`7^/_`$9-7HE>CFO^]/TC_P"DHBG\(4445YQ8
M4444`%<E\3?^2>:I_P!LO_1J5UM<E\3?^2>:I_VR_P#1J5UY?_O=+_%'\T3/
MX6<EX@>_=8+6VT^ZN;64G[4UN\2MM'\`WNOWNY';/<Y&7KD$^NZ='82Z#KMO
M`CJ^VWDL@&V]%(:1@5Z<8[5UU%<A1Q5YI\]_&@N=&\0N_DFWF<2V*F>(G)1@
M'P![J%/O6A#-?Q:Q#-:^'K^WAG*QW0DEM]@`&%DPLI.1P#@<CZ`5TM%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!%X;_Y*=)_V
M!C_Z.%>BUYUX;_Y*=)_V!C_Z.%>BUUXO_EW_`(43'J%>=_&7_D4+3_K_`$_]
M%R5Z)7G?QE_Y%"T_Z_T_]%R5ME/^^T_453X6>B4445YQ9D>*O^10UK_KPG_]
M%M7DWACPGXRU/P]:WFD^(/LEC)O\N'[9-'MPY!^51@9()X]:]9\5?\BAK?\`
MUX3_`/HMJR?AE_R3S2_^VO\`Z->MYX2%3!NJV[J26^FS9W8/,ZV$O"FD[]TF
M<G_P@OQ#_P"AK_\`*C<?_$T?\(+\0_\`H:__`"HW'_Q->LT5YWU2'=_>=W^L
M&*_EA_X"CR;_`(07XA_]#7_Y4;C_`.)H_P"$%^(?_0U_^5&X_P#B:]9HH^J0
M[O[P_P!8,5_+#_P%'DW_``@OQ#_Z&O\`\J-Q_P#$T?\`""_$/_H:_P#RHW'_
M`,37K-%'U2'=_>'^L&*_EA_X"CY_?P]XF7Q#JEFVL9OK?ROM,WVF3]YN3*_-
MC)P..>E3_P#",^*_^@W_`.3<O^%=9/\`\E#\3_\`;K_Z*J[73BL#3A-)-_#%
M[]XIBCQ!BK?##_P%'#?\(SXK_P"@W_Y-R_X4?\(SXK_Z#?\`Y-R_X5W-%<WU
M2'=_>/\`U@Q7\L/_``%'#?\`",^*_P#H-_\`DW+_`(4?\(SXK_Z#?_DW+_A7
M<T4?5(=W]X?ZP8K^6'_@*.&_X1GQ7_T&_P#R;E_PH_X1GQ7_`-!O_P`FY?\`
M"NYHH^J0[O[P_P!8,5_+#_P%'#?\(SXK_P"@W_Y-R_X4?\(SXK_Z#?\`Y-R_
MX5W-%'U2'=_>'^L&*_EA_P"`HX;_`(1GQ7_T&_\`R;E_PH_X1GQ7_P!!O_R;
ME_PKN:*/JD.[^\/]8,5_+#_P%'#?\(SXK_Z#?_DW+_A1_P`(SXK_`.@W_P"3
M<O\`A7<T4?5(=W]X?ZP8K^6'_@*.&_X1GQ7_`-!O_P`FY?\`"C_A&?%?_0;_
M`/)N7_"NYHH^J0[O[P_U@Q7\L/\`P%'#?\(SXK_Z#?\`Y-R_X4?\(SXK_P"@
MW_Y-R_X5W-%'U2'=_>'^L&*_EA_X"CAO^$9\5_\`0;_\FY?\*/\`A&?%?_0;
M_P#)N7_"NYHH^J0[O[P_U@Q7\L/_``%'#?\`",^*_P#H-_\`DW+_`(4?\(SX
MK_Z#?_DW+_A7<T4?5(=W]X?ZP8K^6'_@*.&_X1GQ7_T&_P#R;E_PH_X1GQ7_
M`-!O_P`FY?\`"NYHH^J0[O[P_P!8,5_+#_P%'#?\(SXK_P"@W_Y-R_X59\,>
M$_&6I^'K6\TGQ!]DL9-_EP_;)H]N'(/RJ,#)!/'K785I_#+_`))YI?\`VU_]
M&O73'`TWAY3N[J45OW4O\A?ZP8J_PP_\!1R?_""_$/\`Z&O_`,J-Q_\`$T?\
M(+\0_P#H:_\`RHW'_P`37K-%<WU2'=_>/_6#%?RP_P#`4>">'?#?BK4-8URW
MTS6OLUU:7&R\D^U2IYS[G&<J,MRK<GU]ZZ+_`(07XA_]#7_Y4;C_`.)K5^'G
M_(W^-_\`K_'_`*,FKT2NW,,OI4L0X1;VCU[Q3)AQ#BFOAA_X"CR;_A!?B'_T
M-?\`Y4;C_P")H_X07XA_]#7_`.5&X_\`B:]9HKB^J0[O[RO]8,5_+#_P%'DW
M_""_$/\`Z&O_`,J-Q_\`$T?\(+\0_P#H:_\`RHW'_P`37K-%'U2'=_>'^L&*
M_EA_X"CR;_A!?B'_`-#7_P"5&X_^)K(\3^$_&6F>'KJ\U;Q!]KL8]GF0_;)I
M-V7`'RL,'!(//I7N%<E\3?\`DGFJ?]LO_1J5TX/`TZF(IP;=G)+?S%+B#%)/
MW8?^`H\S_P"$9\5_]!O_`,FY?\*/^$9\5_\`0;_\FY?\*[FBN;ZI#N_O'_K!
MBOY8?^`HX;_A&?%?_0;_`/)N7_"C_A&?%?\`T&__`";E_P`*[FBCZI#N_O#_
M`%@Q7\L/_`4<-_PC/BO_`*#?_DW+_A1_PC/BO_H-_P#DW+_A7<T4?5(=W]X?
MZP8K^6'_`("CAO\`A&?%?_0;_P#)N7_"C_A&?%?_`$&__)N7_"NYHH^J0[O[
MP_U@Q7\L/_`4<-_PC/BO_H-_^3<O^%'_``C/BO\`Z#?_`)-R_P"%=S11]4AW
M?WA_K!BOY8?^`HX;_A&?%?\`T&__`";E_P`*/^$9\5_]!O\`\FY?\*[FBCZI
M#N_O#_6#%?RP_P#`4<-_PC/BO_H-_P#DW+_A1_PC/BO_`*#?_DW+_A7<T4?5
M(=W]X?ZP8K^6'_@*.&_X1GQ7_P!!O_R;E_PH_P"$9\5_]!O_`,FY?\*[FBCZ
MI#N_O#_6#%?RP_\``4<-_P`(SXK_`.@W_P"3<O\`A1_PC/BO_H-_^3<O^%=S
M11]4AW?WA_K!BOY8?^`HX;_A&?%?_0;_`/)N7_"C_A&?%?\`T&__`";E_P`*
M[FBCZI#N_O#_`%@Q7\L/_`4<-_PC/BO_`*#?_DW+_A1_PC/BO_H-_P#DW+_A
M7<T4?5(=W]X?ZP8K^6'_`("CAO\`A&?%?_0;_P#)N7_"C_A&?%?_`$&__)N7
M_"NYHH^J0[O[P_U@Q7\L/_`4<'IOAOQ3<^)VL;76O*U`6?G&?[5*O[K>!MW`
M9^]SCI71_P#""_$/_H:__*C<?_$UJ>&_^2G2?]@8_P#HX5Z+73B,#3AR6;UB
MGN)<08K^6'_@*/)O^$%^(?\`T-?_`)4;C_XFN=\9>&_%6C:/#<:YK7VZU:X"
M+']JEEP^UB#AP!T!Y]Z][KSOXR_\BA:?]?Z?^BY*TR[+Z57%0A)NS?<4^(<4
MHM\L/_`4>B4445!XID>*O^10UO\`Z\)__1;5D_#+_DGFE_\`;7_T:]:WBK_D
M4-;_`.O"?_T6U9/PR_Y)YI?_`&U_]&O7HQ_Y%TO\:_\`261]LZVBBBO.+"BB
MB@`HHHH`\RG_`.2A^)_^W7_T55VJ4_\`R4/Q/_VZ_P#HJKM=>-_BK_##_P!(
MB3'8****Y"@JIJ+7JV;&Q\@3`CYIE9@J]SM7ECCH,C/K5NJU]9F]MQ&MS<6S
M!@RRV[[6!'U!!'L01[4,#FIO%=_'X?T^^CL$>6XE6.9^D<0\T(<C.X,<_=[<
MYZ<]=60?#ED='73`TPB$PN&<$;WD#B0D\8Y8<X'TQ6O3=@"D)PI."<#H*6BD
M!A^']:N]7N-22ZL_LGV:94CB8Y<*45OFYQGGH.E;E4[338;*\OKF-I"]Y(LD
M@8C`(4+QQTP!5R@`K'\1ZA=Z5ISWL,]E!!"K/*]RK/G'W555(Y)XSGCT-;%8
M^M^'HM<GLI9;V[MS9N9(UA\LJ7[,0Z,"1V]*3&C1LIWN;&WN)(C"\L:NT;=4
M)&<?A4],C5DB1&D:1E`!=@,M[G``S]`*?5/<E;:A6'8ZGJ)\0S:;?K:@>29X
MS$KKM&[`&YO]9Q@D@#;D`]16O-<06R;IYHXE]78*/UK.L=&MH;X:@+RYO'5&
MCA,T@<1*Q!8*<9.2!]XD\4EN-[&M1110!EZ_JQT?3))HHA-=,"L$.?OM@GGV
M`!)]A5C2;N2_T:RO)0HDG@21@HX!*@G'M3=3T?3]9M_)U"S@N%`(0RQ*Y3(Q
ME<@X-2:;I]OI.FV]A:IM@@0(HP!G'<X`&3U-"ZW![HM4444`<YI&O3:CK=U;
MR7$*0I+)'#";.5'D"'!82LVQN<Y"CCBNV^&7_)/-+_[:_P#HUZYB'0H8]36^
MENKJX:(N8(YW#+"7^]M.-W/N3@<#%=/\,O\`DGFE_P#;7_T:]=</]SG_`(H?
ME,E_']YNOK-I%J4]C)YD;06_VB21T*QA,XX8]?PJ72]1AU;38+^W65(IAN59
M4VL.<<CL>.E5]0T&RU2:5[OSR)8!`RQS-'\H;>"&0A@<CJ#4ND:5;Z+IL=A;
M/.\,98AKB9I7.22<LQ)/6N1;:E/<XGX>?\C?XW_Z_P`?^C)J]$KSOX>?\C?X
MW_Z_Q_Z,FKT2O1S7_>GZ1_\`2413^$****\XL****`"N2^)O_)/-4_[9?^C4
MKK:Y+XF_\D\U3_ME_P"C4KKR_P#WNE_BC^:)G\+,RBBBN0H****`"N8U37M1
MTO68[;RK:Z$R2O%:0*QF"(A8.S9Q@D!<;>XY/2NGK"M_#,=MK5YJ::E?F2[/
M[Y"8L$8P%#;-Z@=L,.:!D7AKQ$VL3W%O)-:S2111S>9;*0H#[OD.2?F4J0>?
MP'2NBK/TW28].:23[1<7,\BJC3W#`N57.U>`.!D^YSR36A3=NA*N5-1:]6S8
MV/D"8$?-,K,%7N=J\L<=!D9]:Y=_%M^^FVTL,5JMQ]DGO)PZL05B8*4`R"C'
M/?.W&"#757UF;VW$:W-Q;,&#++;OM8$?4$$>Q!'M63)X1T][2.!9;B+:)%DD
M1EW3+(=T@;(QACZ`$=L4D5I<V[>9;BVBG4861`X^A&:DI$54144851@#T%+3
M>^A*O;4*P]#UJ[U34M3@N;/[*ELT?E(Y_>$,"<MS@'V[5N53M].AMM1O+U&<
MR7>SS`Q&!M&!CBD,N4444`8_B/4+O2M.>]AGLH((59Y7N59\X^ZJJI')/&<\
M>AK1LIWN;&WN)(C"\L:NT;=4)&<?A6=K?AZ+7)[*66]N[<V;F2-8?+*E^S$.
MC`D=O2M6-62)$:1I&4`%V`RWN<`#/T`H6P/<?1110!AV.IZB?$,VFWZVH'DF
M>,Q*Z[1NP!N;_6<8)(`VY`/45N5EVFA0VNH"]>YNKF5$:.'[0X;R58@L`<9.
M2!]XD\<5J4=$'4*P/%VLW&DZ+/\`V>%;47B=H0>BA1EG/LH_,D#O6_6;J^@Z
M9KMLT.H6<$Q*,B2O$K/'N')4D'!_PI2O;0<;7U%\#S27/C>VGE;=))X?5W;&
M,DR*37H^HZA;Z5IT]]=%A#"NY@J[F/H`.Y)X`[DUYWX+L+?2_'R65K&$@AT/
M8H"@?\MASQQD]37?:QHUGKME]DO?M`C#;U:"XDA96P1G<A![GCI7;CMX<O\`
M*B*6B]XIVGBBWO-5CL8[.\"2`!;E@GE>88Q)Y?WMV[8<_=Q[UR_QE_Y%"T_Z
M_P!/_1<E=+8>$K73M0@NH;V^:.$#9;2R*Z;Q&(O,)*[RVP8Y;'?&:YKXR_\`
M(H6G_7^G_HN2MLJM]>IV[DSOR.YZ)1117FFAD>*O^10UO_KPG_\`1;5D_#+_
M`))YI?\`VU_]&O6MXJ_Y%#6_^O"?_P!%M63\,O\`DGFE_P#;7_T:]>C'_D72
M_P`:_P#261]LZN218HGD=@J("S$]@*\T\/:OJB>(--U>]O;E].UV2>**"20[
M("&_=X!X&0,<>M=QXEL;[4_#M[8:?)%'<7$?EAY6(4*>&Z`GIFN7U'X7Z2NE
M#^Q(%MM6B*/#<R32$;E())&2.<'H*O`RP\:<HUGK+3:]E;??35IZ7V":;5D8
MVN:I8IXWUJWUGQ1K.EPQ"'[-'93R!3E`6X"D#MZ=31JFK:JGP]T>XO\`4;^T
M,FI"-[I&:*9K?YOF..<[1GOG`ZUV^CZ->67B36=4N7@*WZP;5C8DJ40ALY`X
MR>/Z4>*=$N=<BTQ;9XD-K?Q7+^:2,JN<@8!YYKI6,H*I3@UHN6[TZ1UMIWWN
MWJ)IN[]?R.5\.7HD\4V*^']>UG6-/=9!?M?EW2+`^7#,HP<^E>DUS,OAV[M?
M&4>N:5+#'#<+LU"WD8J)/1UP#\P]\=/<UTU<&.JPJRC*&UOG?7>R7Y;6'%--
MGF4__)0_$_\`VZ_^BJNU5N8U7Q[XC<3(S/\`9LH`V4Q%WR,<^Q-6JC&.]1?X
M8?\`I*''8;)(D4;2.P5$!9B>P%4-+U9=4#,EG=P)M5XWGC`65&Z,I!(_`X8=
MP,U;N[=;RSGMG)"31M&Q'H1BL'PUX?N=&N)GE-O'&88X1';DD2LF<ROE1AV!
M`(YZ=3VY%UN4]CI****`,O6=9.BV_P!H;3KRZA`R[VYB^7G`&&=22<\``UI1
MN9(D<HR%E!*-C*^QQWK.U;3Y]0N--"-&+>"Y$\ZOU<*IV@#'][:?PK3HZ`%(
MS!5+'H!DTM-D4O$Z*Q1F4@,.WO2>V@(RM'\0VNM.R0P7$1$23IYRJ/,C;.UQ
M@G`.#P<'VK7KF/"_ARZT2>228VR*8$A9;8D^>ZDDS/E1ASGW^IKIZIVZ!U"L
MS5-<@TN:*%X9YYI$>79"`2L:XW.<D#`R.!DG/`-:=8/B/19M6$'D16S,H=&>
M2:2)T##&04^\/5#PW'(Q4NXU;J;<4J3PI-$P:.10RL.X/(J#4;IK/3YIT0/(
MJXC4G`9SPH/U)%.L;1+#3[:S0DI!$L:D]P!BF:G:O>Z;/!$ZI,RYB9@2%<'*
MDX[9`JG:^A*O;4QX)=(LM=@TR<B\UFX0M+,R!B,#/)/W!Z*/_KU1EU73K::Z
MU#3K>6T:!'N)2%58KV&,[9&`4G)7'!(!X'4&KB-%J>N:=>`PVL]IYOVNVE.V
M4,RA0<8^8<<-T(Z5BKHK277]DQRV]PB6\UIF"0L4AE<,[2<81@HVJ`223G@9
MPEY@SOZBN;F&SMI+BYE2*&-2SNYP%`[DU+371)$*.JLIZAAD4#,,^,-)3PX=
M<D>1+4LZHK)B20J2,*OJ=I/TZXYK;BD$T*2J"%=0PSUYKG5\.7'_``AU[I+F
MW:ZF^T^4^254R,Y'.,CAN<#UKH+:,PVL,3$%D0*<=.!3T#_@DM9ESK]A:ZU:
M:0TA>]N<[409V`*3EO0':<>OYUIUDZCI3W6KZ5>P^4HM9VDFSPS`QLHQQSR1
MUI+<.@Z#7(IM4%@]I=V[N',+SH%6;80&VC.[C(Z@9ZC-=/\`#+_DGFE_]M?_
M`$:]<-I.DZNGB6ZU75DLYF<-';R17+DP19X0(8P,GJ6W5WOPZB2'P%ID<<\<
MZ@28DC#!3F1S_$`>.G3M77!_[))?WH_E,E_'_7D=%/>VEJ)#<74,(BC,LADD
M"[$'5CGH/?I265]::E:)=V%U!=6TF=DT$@=&P<'##@\UBZOX>>^O;ZYABMC]
MJL?L[*[O$9&#9^9T^8#'&X'(]#6CH=I=V6DQ07LFZ92QQY[S[`22%\QP&?`P
M-S#)KD6Q3_K[CC/AY_R-_C?_`*_Q_P"C)J]$KSOX>?\`(W^-_P#K_'_HR:O1
M*]'-?]Z?I'_TE$4_A.$L+74/&=UJ-]-KFHZ?:V]T]M:V]A*(^$X+.<?-D]JB
M'BG5=.\)ZRMQ(EQJ>G7?V*.X*@"0L5"NPZ9^;]*OGP_XBT:_O'\.7NG&SO9F
MG>"_1_W+MU*%>N?0U/!X)@/AB^TN\NWGN;^4W%Q=!<'S200P'8`@<5U.MA[I
MS:<+QLDM4NM]/OUU>HK._GK^MOT&VOA?6;"]L[N#Q/?W#^8#>17C;XG7N$7'
MR'/3G^58_B+0[BW\2:3%#XCU](]3NI!*BWQ`C&TL`@QP.W.>*U[?3/&4U[:)
MJ&L6$5E:N&+V<;>;<`<8<-\H![XK2UG1[C4=:T.]A>)8["=Y)0Y()!7`V\?S
MQ6<<1*G53E.+T>R\G;IWV"VCT-#3;'^S=/BM/M5S=>6#^^NI-\C9.>6[USOQ
M-_Y)YJG_`&R_]&I76UROQ'C67P%J:/,D*GRLNX8@?O4_N@G]*Y,%-O&4Y2_F
M7YE25HM&31117&49VH:M]AN[>UCL;J\N)U9U2W\L;57&22[*,?,*T1TZ8KF_
M$WAZ3694>*VL))/):)+BX+"2V)(/F1X!!(QT^4_[0KH8D,<*(SEV50"QZM[T
M+8'N/ILDB11M([!40%F)[`4ZH;NW6\LY[9R0DT;1L1Z$8I.]M!JU]2II>K+J
M@9DL[N!-JO&\\8"RHW1E()'X'##N!FM&N;\->'[G1KB9Y3;QQF&.$1VY)$K)
MG,KY48=@0".>G4]NDJG:^@M>H5EZSK)T6W^T-IUY=0@9=[<Q?+S@##.I).>`
M`:U*S-6T^?4+C30C1BW@N1/.K]7"J=H`Q_>VG\*0&C&YDB1RC(64$HV,K[''
M>G444`'09K(TKQ#;:O<-##!<1'R_-C:55`E3<5W#!)'(Z-@^U:Q&5(!QD=:Y
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M7K&+78-&\PO>2JS;4&1&`,_,>V1T%:=95YI3SZ]IM_%Y2I;^:9L\,Q90H[<]
M.]`!8:]:ZC>M:QQS(<,T4C@;9E5MK%<$G`/'('7CBM6N;T;P[<:?J,,LSPF"
MSAEAMBC$LZR.')8$84C`'!.>O'2NDHZ(.I4U/48M+L7NI8Y9`N`(X4+,Q/``
M'^16%=>,XK7PE:ZXUC,[W,/FI;QG...=S8P`/7\@:Z69#)!(@QEE(&?I7-MX
M<O#\/%\/^9!]K%JL._<?+W#'?&<?A0O\A]CH/#+;OB6S=,Z*3_Y&%>BNZQHS
MNP5%&69C@`>IKS[PQ$J_$-G,T>\:.5\K#;L>:/FZ8QVZY]JZOQ/I-YK>BR6%
MG=6]N9#^\^T0&5)$P<H0'4X)QW]L'-=6,?P6_E1--=S36Y@>1(UGC9Y$\Q%#
M@EEX^8>HY'/N*X#XR_\`(H6G_7^G_HN2NET[0I[34].OIC:M-!IIM+B2)"ID
M?*$$`Y^4;6ZGC-<U\9?^10M/^O\`3_T7)71E22QU.W?_`#(FVX.YZ)1117FF
MAD>*O^10UO\`Z\)__1;5D_#+_DGFE_\`;7_T:]:WBK_D4-;_`.O"?_T6U9/P
MR_Y)YI?_`&U_]&O7HQ_Y%TO\:_\`261]LZ62^M8KZ&R>91<SJS1Q]V"]3].:
M@EUK3X95BDN`KM<BU`*-_K2-P7IZ$<].>M4)/#TG_"40ZQ'?SD9/FQ/L(`V[
M0J_)NQU.-W<GO575?#5W>ZA?W5O-`GF0J]L'S\MR"OSMQTQ&G3GK64*6';2E
M+I^-]MAZFD?$FF>:L:/=3,5W_N+.:7`W,N250XY5NOI3CX@T\3S19NCY)<22
M"SF,:E02WS[=O&/6L4^&KZVNK=[>..>.*RAMS_Q,Y[4[D+$DB-3O!W=_?UIQ
M\/ZB+G4,11%+EIBLG]J3@+O!`S!MV'KZ^_6M71PO23^]?U_6@7?Y&Y+K>GPK
M(S3L1$$+;(F8_/\`=``!RQX^4<\CCFK%G>P7]N)[=RR9*D,A1E(Z@JP!!]B*
MPX=!N['37L;?[-=0Y255NG?=Y@Y;YP,C)&0W)!XQC&-71[6[M+'R[R3<^\E5
M\YI?+7LN]@&;ZD9YKGJTZ*@W!W=_ZT_I`F]+G`S_`/)0_$__`&Z_^BJNU2G_
M`.2A^)_^W7_T55VJQO\`%7^&'_I$0CL9<7B"PGUBYTR%WEN+:(RRF-=RK@XV
M\=6]A3M+UF/5))XA;7-M-!M+Q7"`-AAE3P3C(['!'<"H3I4Z>(I-1MS!&C69
MA4$'/F%]V2!C(_'-,T;3+VVU&]OKS[-$URJ!H+4DHSKG,AR`=S9`QSPHY-<B
MVU_K4I[FW574=1M-)L9+R]E$4,8Y)ZD]@!W)["K507EN+JTDBVH692%+#@'&
M`:3O;0:M?4S+OQ1IUEX=M];G\U;>X1&BCVCS&W#(&,XSCKSV-;(.1GUKC=0\
M%W-[X:LK-=1>*\M;);8*I4PL?EW'YD+=NHP?UKL(4:.%$:1I&50"[8RWN<`#
M\A5NUW8E7T'UF'7K#^WET5)"]X8VD8(,B,#'#'L3N!Q6G61=:1)+XBL]1B\E
M8HH)HY`<[F9]F#QU^[SSZ5)1-I6K?VLC2I8W4$'/ES3>7ME&2,J%8G''<"M&
MN:\.>'9M'NWE\BRLX?($/D618I*P.?-;<`0V.,98_P"T:Z6F+J5[V^MM.LY+
MJ[F6*&,?,S?H/<D\8K-'B6UDTVQO+>UN[AKV,R0V\:KYI4#))!8#CCOW`&36
MM-$LT3(RJW<;AG![&N1?P?.=$T>!X[.YNK&V:W:.9B(FW`?,#M)R"H(X_+K2
M'H=?%()H4E574.H8!U*L,^H/(/M3ZK:=;266F6MK-.UQ+#$J/*W5R!@D_6K-
M-VOH2KVU,:\U+2)M<M]%N(H[F\D5G"&,.(P!GYB>F1THT[5D;5'TE-'NK)HX
M_-)80^6%S@?<<XS@X!'8TM_IX.N:;J0>"**W,OG%SM+%E"CMST[FI-)L);:Z
MU*[GDCD>\N-Z,ASB,*%5<X]B?Q-)#-2HKFYAL[:2XN94BAC4L[N<!0.Y-2TU
MT21"CJK*>H89%`&&GBRRFTJUO[:WNYUNIGA@B5%5W9=V?O,`!A">2/SXK6L+
MV'4K"WO;<L89T$B;A@X/M7,2>%;QM$M+1ULKHP7DUP]M.Q\F979R`QVGD;P?
MNGD?C70Z-8RZ;HUI93SF>2&,(TA[X_IVIZ:@7JS+G7["UUJTTAI"UY<YVH@S
ML`4G+>@.TX]?SK3K)U'2GNM7TJ\A\I1:SM)-GAF!C91CCD\CK26X=`T_Q#::
MC>?9XHIT#AS#*Z@),$;:^W!SP?4#/;(KJ?AE_P`D\TO_`+:_^C7KA]-\-R6W
MB#^T94MXDB,WE+!+(P?S"#DHW$?3D+D,3GCI7<?#+_DGFE_]M?\`T:]=D/\`
M<Y_XH_E,E_$=/->6UN7$US#'Y<9E?>X&U!U8YZ#WHM+RVO[6.ZL[B&YMY!E)
M87#HP]01P:P-=\,OJ=U?30&*(W-FL+,KM&[LKAAEE&0,#&0<C/%:>A6EW8Z1
M%;WLF^92QQY[S[`22%\Q\,^!@;F&3BN-;%/<XWX>?\C?XW_Z_P`?^C)J[V]O
M;;3K*:\NY5BMX5+.[=`*X+X>?\C?XW_Z_P`?^C)JZKQ+H3:_IC6Z7<L$BJYC
M"[=CL5(&_<K<#/;D=1SBO5S",)8ZTW96C?\`\!1%/X31FO[6!HQ++M\U&="5
M."%&3SVXJE_PDFD_9%N1<LT31I*-D+LQ5VVK\H7.2W&,9J#5]#N-0TNQM8[A
M3+`ZB227^.,J4D^Z!R58XX`SCI6:_A6\%EJD220NT]W');+YKQ;8EE\S8649
M4Y9\$9QQ7/2I8=Q7/+6_Z^G8=Y?U_7]:&RWB33T\K<M^'EW;(_[/N-Y"XR=N
MS./F'.,<U.NLV#G:)6#F58=AB</O90X&TC/W2">..<XP:Y^;P_JDLMI,+:,>
M0LJ&/^W;K<=^P@^;LW?PGY>G0U:L_#]Y:ZK+JH>,7,DB`Q-.\B>5Y:*XW$9W
M93.[&3@`XSQ4J.&4;\SO9]5O?1:>079K6FLV%]=-;V\KF0`D;HG0.`<$HS`!
MP#U*D]16#\3?^2>:I_VR_P#1J5H:5IFHVNH^9+]F@MPC*T=O/(R2DG(81L,1
M8Y^Z3G//2L_XF_\`)/-4_P"V7_HU*K#1A'&TE!Z<T?S%*_*S,JEJNJV>C:?)
M>WLNR)!T`RS'^ZH[D^E7:IZI9_;],N;90GF21.L9<<*Q4@'VZUYLKVT-%:^I
M2N_$<%G8PWK6=[);/`+AY4C7;#'@'+$L/7HN3[5L*P90RG((R#7(ZKH.LWEM
MI-@BV4VFVT2?:H'N7B,[J!@$B-OD&,XXS77+]T9`''0=!5.W0E7LKBUE?\)#
MI[:Y)I$;O+=10M-((UW!`,?*<?Q?,.!_A6K6//I,Y\1QZE;&"-$M)8<,#DR,
MRD$@8R/EYY!I=?Z[#Z$VEZS'JDD\0MKFVF@VEXKA`&PPRIX)QD=C@CN!6E6)
MHVF7MMJ-[?7GV:)KE4#06I)1G7.9#D`[FR!CGA1R:VZ;$C-UG5H]%@@NKA@M
ML92LS%22!L8C&.Y8*!ZYQWJO=^*-.LO#MOK<_FK;W"(T4>T>8VX9`QG&<=>>
MQJ76HVG-A`I'[V=UYZ?ZF7&?QP?PK!U#P7<WOAJRLUU%XKRULEM@JE3"Q^7<
M?F0MVZC!_6A6_+]1G9`Y&?6EID*-'"B-(TC*H!=L9;W.`!^0I](%L9G]O6']
MOKHJ2%[PQM(P09$8&.&/8G<#BG:9JW]J-*8["ZB@1F1;B7RPDA5BIV@,6Z@]
M0*BN-)>3Q)9:E%Y2Q0PS)(.C,S[,'IS]WU]*S]!\.3:7J9N?)L;2)86B:.S+
M8N"6!$C[AD,,$=6ZGFA=`?D=-4%Y<VUI9RSWDB1VZ+F1I.F*GILB)(FUU5EZ
MX89&1R*&!RD5SX>ETRRNK717N%NMSP6D<*[L(?F;82%&/SY'?BNJAD66".1%
M95900KJ5('H0>0?:N,_X15IM*T^$&PO+JR2:)XI)#Y1$C9SG:3E2`1QU';K7
M6Z=;266F6MK-.UQ+#$J/*W5R!@D_6GH+L6:S)=>L8M=@T;S"]Y*K-M09"`#/
MS'MD=!6G65>:4\VOZ;J$7E*EOYIESPS%E"CMST[TAB6FN-=:N^FOI=[;2I%Y
MI>4Q%-N<#E'8C.#@$=C6M69I>GSVEWJ=S<NCR7=SO0J2=L84*JG(]B<>]:='
M1!U*FIZC%I=B]U+'+(%P!'"A9F)X``_R*PSXM>32=*N[?3PT^HQ-*D4D^Q$5
M5W-EPIYQT&.?:NDF0R02(,992!GZ5Q\GA&\;0=$LI4L;PV$+1RVMPQ\F1BN`
MX.TG*\XRO<]*71_UW'H=)X)ODU/QU#?QHZ)<:")%5QA@#*IP:]-=UC1G=@J*
M,LS'``]37E_@6SFT_P`;P6<]RUS+#H(1YF'+D3+S7=>)])O-;T62PL[JWMS(
M?WGVB`RI(F#E"`ZG!.._M@YKMQVCAR_RHBGKN78]5TZ6^%C'?VKWAB$PMUF4
MR&,]&VYSM]^E<-\9?^10M/\`K_3_`-%R5L:5HNLV^M6;WUMI+VEM"H$]O*Z2
M--Y01I&C,9R<#:/WG"^O&,?XR_\`(H6G_7^G_HN2MLJ26.IV[DS;Y'<]$HHH
MKS30R/%7_(H:W_UX3_\`HMJR?AE_R3S2_P#MK_Z->M;Q5_R*&M_]>$__`*+:
MLGX9?\D\TO\`[:_^C7KT8_\`(NE_C7_I+(^V;.N75_9VGGV36JA`2PF1G,C<
M;44`CECQG)QQP<\4[36+^75XXY5MUM)9Y+=8U1O,1D7));=@@D-P`.W-:.HZ
M/9ZI)!)="??`28FAN9(BI(P3\C#M21:-86^H-J"1R?:"#DM,[*"0`2%)V@D`
M9(&36$*E%4^5K6SZ?=U_'Y#:;V,J+Q0V^>*XMI(F6ZDABF\L&.0+*$P/GSNP
M1G.!UQG&*JZ=XQEDM7N+Z$$)$)-EM%EF_=Q,<9;KF0\?X<ZUKHFC7`^WP0LZ
MW/[\,99,'<P?<%)PI)`)P!T`-21^&])BC\M+3"E0N/,?IA1Z^B+^7UK;VF%5
MTXO^OF/74IR>+K>.-V;3K_?#N-Q&%C+0`'&6^?!R?[I/X5T-<YJ_A*+4[I)8
MKC[/&Q)N$"L3+E@3R&'IT8,!U`!YKHZPK^QY8NEOK<2O=WV/,I_^2A^)_P#M
MU_\`157:I3_\E#\3_P#;K_Z*J[58W^*O\,/_`$B(1V,*?Q#)8ZJMK?V:P0R+
M*T,@G#NRQC)9D`^52.AW'MD"I=%UQM5DDAFMEMYEBCG55EW@QR9VDG`P>#D<
MX]36!<:;=V7B*]FDFBU::]C;S81;,LEO:]-JOO*CV&W+D'T)&UX=TM+5#?"\
M2[,T$444B1[!Y2`[`1DY/S')X^@KD6VO]?UH4]]/Z_K4W:K7TUU!;;K2U6YF
M+`!&E$:CW+8.`/8$^U6:RO$.EW6LZ3)8VE_]B,A`DD\LN63NO#*1GIG/3-)@
MC+?QK`FDVEV+.226XG\GRXSN1<2B-FWXQMR>.,G(XZXZFL.70'G\.P:4\]O%
MY,D3*UO;E$`1PP`0N2.!C.[WK<JG8`K%O-<N+'5[>UGL%6WN9?(AE^T`R2-M
M+9"8^[QC);.>V.:VJYP^'K\^*)=9;4K:3*>7!%-:,QMUQR$(D`!)Y)V\]*74
M.A:TS6I[S4[C3KRS2UN8HEGV).)<*Q(`;`&UN.@R/0FMFL#PUH%UH8N?M5]!
M>R7#^9).+9HY9&]68NP(`X``&*WZ;`KWLUS!:L]I:BYFR`L9D"#D]2QZ`=3@
M$^@-8$GBR4:&^IQV$3I!)(ER3=A8T*'!"-MRY8\+\HSWQ6KKVGW>JZ/-96=^
M;&27"F<1[R%[@<C&1QG-44T&^AT:#3K?4+2WB1&B>.*RQ&R$8X4N6##GG<1R
M<@TNC'IH;L3^;"DFUDWJ&VMU&>QJ#4;IK+3YKA$\R1%_=IG&YCPH_$D"GV5J
MEC8V]I&S-'!&L:ESDD`8Y/K4>I6KWFG301,%E(W1LW0.#E<^V0*;M?0E7MJ<
M]-LTO5;5M2TZ&Z>XF6W%]-*&D9W&2(X\':@QR,CIG!ZU5DU:RLM:U`Z7;_9X
M=-A^T7;1\13J"1(`@&-R@$[ASD8]:GM;*75/%0U634;<30H(QIUS;$R6H_BV
MD2`9;GY]I!'3BJDWAO38]4GM-,FGE^UVOV.:#[1)(L$;$EW9F<@9!(5<=>1W
M(2\QOR\O^"=U4-U)+#;2200&XE4?+$&"[CZ9/`J:J>J6US>Z9<6UG>?8[B5-
MJ7&S>8\]P,CG\:3V&MS!G\9"WL)9)H;.*ZBO19.)+W;`&*AB?-*=`#S\N<C%
M=):RO/:12R"(.ZACY,GF)^#8&1[X%8-CX;O-/TBVLX+RQ2:VE\R.06!*MD$$
ML&D+%CDG<&4_AD'7TG3DTG2X+&.1Y%B&-S=22<GZ<GI5:$EVL;5=;GTJ\@$M
MDILY)HX/.,X#L[G`VI@Y`[Y(XZ9K9KGKOP_>W7BB'5SJ%NT,"A8;6:U9Q%_>
M92)`-YZ9(.*2W0^C)-,\1KJFJ2VT$4+0(7&];E3("K;26CZA20<$$YQSBNP^
M&7_)/-+_`.VO_HUZXVR\,K9:I'<I<_Z/`\TD,*QD,&E.7W-N^8>@P,>]=E\,
MO^2>:7_VU_\`1KUV0_W.?^*/Y3)?QF[<:W86T]Q;M,\EQ;Q":6&")YI%4G`.
MU`23[`9J73=2MM6L4O+0RF%RP'FPO$V02#E7`8<@]14%UI<DVH37D-UY,KV9
MMD.S.PDY#]><>GZU;L[6.RLH+6(8CAC6-?H!BN-;:_UO_P``I[_UY'!?#S_D
M;_&__7^/_1DU>@7'G"WD^S",S[3Y8D)"[NV<<XKS_P"'G_(W^-_^O\?^C)J[
MZZMHKVTEMIPQBE4HX5RI(/7D$$?A7I9G;ZV[]H_^DHBG\)S$VO:PD;Q1M8M+
M&MQ*)S`XCG2()D*N_*DLY7.3]TG!S5_4?$3:?=VFZTEFM9;22YE,2@M$%*?,
M<L/E`8YQD],"IF\+Z5)9I:O'=/"F0H:]F)"D`%<[\[2`/ESCVI]YI>E:K=A+
MB-GFM4V%5D=`$?!VG!`8':,@Y'%1[3#-KW797OI]W7_AN@[.QCOXKG&H/$@B
M-NN_Y_*.[Y1<'IOP?]2O<9YZ9XMCQA:!F5[.]&&=(WV)B=U=4*I\V<[G4?-@
M<]>#5X^'M*:1I#:_,V[)\QOXM^>__35_S]AB&_\`#5E=6#P0*()?G,<IW-L+
MN'8XR.I4="".Q%/VF$E))Q:0)/J7M-U%-2MFF6":`I(T3QS`!E93@]"1^M<]
M\3?^2>:I_P!LO_1J5N:)I7]CZ:+4S&9S(\CR$$;F9B3U)/?N2?4FL/XF_P#)
M/-4_[9?^C4I83D^O4^3;F5OO0I7Y7<S*SM;U>/1-,DO)(99BH.R*)<LYP3CV
M&`>3P*T:J:K''+I%Y'-,L$3P.KRMT0$')/TKSY7MH:*U]3%O/%HM8HI/L8*"
MR6^N"TVWRXSQ\ORG>P/;CZ]JZ16#*&4Y!&0:XD:9_;L5GIE\D=O'':[8EN+9
M7DFBP%+HQP8G]1S@,._3ME4*H51@`8`JG;H2K]1:PKWQ%)INJ1P7MFL5K,76
M*43AI&V(7+%`.%P#SNSG'`K=KFE\,73^(+S4;N_M[F*Y0PB-[5M\,1&-B-YF
M!GJ3MYJ=2M"[HNN-JLDD,ULMO,L4<ZJLN\&.3.TDX&#P<CG'J:V*Q]%T-M*E
MEFFN1<3-%'`K"+9B./.T$9.3R<GC/H*V*IVOH2KVU*6I"58HIK>S6ZN(I-T:
MM-Y:J2"I8GG@!CV/7I6&_C6!-)M+L6<DDMQ/Y/EQG<BXE$;-OQC;D\<9.1QU
MQJ>(=+NM9TF2QM+_`.Q&0@22>67+)W7AE(STSGIFH)=`>?P[!I3SV\7DR1,K
M6]N40!'#`!"Y(X&,[O>DO,9N4444`8UUK<]EK%M:3V*I;7,WD0R^>#([;2V1
M&!]WC&2V<]L<T:?K<]QK$FFWEDEM.(?M"*LXE(3=M^?``5O8$CWJN/#U]_PE
M4FM/J-O,I7RX89;1B8$QR$82``D\D[>>E+X=\/WFC7%W/=W]O>RW3%Y9OLK)
M*QSP"QD8;0.`H`Q0O,'Y'05S]['+JC7CM:_;+:W?R8;(R!4G;C<TA/!49Q@@
M_=)P21705R^JI<0Q7^F#4/[-6_??:WWE[EC+8WH3N&')R0<C[W'(I,:W,^\U
M&TDT::]&AVBM8RR1330W0C$)7'^JD"AF8YP``.<@XKI=#O)KFUDBN=YN+:3R
MW9UP7!4,K'MDJPSCC.:Q7TU](\/0V7]LV-K;JK1%([,[9588X4R%C)G."&.2
M>5-:OANPDL=-/F+(C2L"J2-N9$551`3Z[4!/H2:K0DV*QK_6Y].U.WAFLD%I
M/.EO',9QO=V'\,8'*CN20?;%;-<]+X>O9O%8UE]0MY(D4)#;RVK,85_BV,)`
M`S?WBII=1]&6++Q##?\`B*\TJ&%BMM$',^[Y6;<5*@>Q&,YZY':MFL#3?"=G
MI.MMJ%I+<+']G\E8'GE<#YBQ.6<\<],<=>];]'1!U95OS>BU/V`VRSDCY[C<
M45>YP.20.V1GU%<B?&=Y+IMG)!Y.^6]FMY+E+.6>-DC!S(L:-NP2!W..>:Z'
MQ)I%SKNC2:?;7_V+S2!))Y1?<G=>&7&?7/2H8='U.UTRVM+/4K.V,`*!8K']
MRR8X&TR%@1UR'^H-'<9?\&3_`&GQ]'/]HAN/,T/=YT*E4?,PY`).!^)KTB[N
MX+&SFN[J58;>%#))(YP%4#))KS3P-IL6D>.8M/@9FC@T,J&;JW[X9)^IKO=?
MT;^W=-^Q_;KFR^<.)(%C8DCH"'5@1G!Z=AR*Z\;]BW\J)IVZCXM;L)=0AL5>
M;SIHO.B+6TBQNN,_*Y7:3CG:#GVKC/C+_P`BA:?]?Z?^BY*Z&S\,W%MJFGW4
MVI+<)8P"*,M:JDS?(%(,BD`QDC=LV_>P<X`%<]\9?^10M/\`K_3_`-%R5OE5
MOKU.W<B=^1W/1****\TT,CQ5_P`BAK?_`%X3_P#HMJR?AE_R3S2_^VO_`*->
MM;Q5_P`BAK?_`%X3_P#HMJR?AE_R3S2_^VO_`*->O1C_`,BZ7^-?^DLC[9UM
M8_B#2YM4AMEBCMIUBE+O!<DB.0;2!G`/()!'';MUK8HKAIU'3DI1+.$'A"]^
MTV<EZMC]FMK?R9VMU)EFC\@H5($>YB&Y'S8/'RY`ING>%M2E.G:K-Y3:B9/-
MGFN0`57*@#RV1L-L4#(9"#W-=[178\QK6MI_5_\`/\$1R*U@HHHK@+/,I_\`
MDH?B?_MU_P#15+J-^MA`I"^9/*WEP0@X,CD$@#\`23V`)[4D_P#R4/Q/_P!N
MO_HJL5+O5UU:XN[CPY?3LK-%;&.>WVI'GJ,R`Y;&3P.P[<]>-_BK_##_`-(B
M3'8@L;C4M.\0+IMS/93WE^LDSM%$Y:(*/E=R6`V=%"X&/4\FF:)>:A8ZC?RW
M4EK+I#W1B\V"%HA'-QN;:7;Y"V03G[W..2:BT^UU#3=8N]2BT?7Y)+MR\T<L
MUB5;C`&=VX`=ANJ[827=AI?]GKX5U26`[]_FSVI+[R2V?WN.237(MBGN=316
M-X=?41;S6]]8W%M'"X%LUQ+&[O&1T.QFY7IDGD8[YK9H`****`"BBB@`HHHH
M`****`"BBB@"M>:=8ZC'Y=]9V]TG]V>)7'Y$5+#!#;1B.")(HQT5%"C\A4E%
M`!1110`4444`%%%%`!6G\,O^2>:7_P!M?_1KUF5I_#+_`))YI?\`VU_]&O77
M#_=)_P"*/Y3)?Q(ZVBBBN0H\[^'G_(W^-_\`K_'_`*,FKT2O._AY_P`C?XW_
M`.O\?^C)J]$KT<U_WI^D?_2413^$BN8FGM)H4D,;R(RJXZJ2,9_"N)E\':A)
MI\UJMGHT23;0R+\P4A2/,7=$1N).2,=_O9Y/=T5S4,3.C\)35S@'\*W5]=W-
MI,&EMX;:-BKEHT>[**K,KE6W`*@_A()<@]Q77Z)9W%AH]O:W1A,L8(Q`H5`,
MG`&%4<#`R%&?0=*T**JMBYUHJ$MD)02V"N2^)O\`R3S5/^V7_HU*ZVN2^)O_
M`"3S5/\`ME_Z-2GE_P#O=+_%'\T$_A9F5S.K37>IEGM)[.'3;-\S3709DD9>
M2<`C<J$=,C+=_EPU_P`02ZDMG'%IUE-<^<^V9H)$1XX\<E=[*,G@=>,Y[8.%
MK%K<ZOI,.F'PYK-K:PLK!+:>S`(7HI#.P*^V.U<;+13U#Q+/J6FZ>T9@L[HP
M&]6XE@E=5PVU2-O**PR2S9`4\@YKL],O_MUN?,01W,1V3Q`YVMZ@]U(Y![@_
M45RUY:7M_;QQW&A:ZTBQ-!),)[%6FB8\HV&P!P/N@'T-6Y+C5%O+6YLO#%_#
M)&%A<-/;A7AST.)3TZ@X]1W-5H(ZNBBBD`4444`%%%%`!1110`4444`%(R*Z
M%'4,I&"",@TM%`%.UTG3;&1Y+33[2WD<DLT,*H6)[D@5<HHH`****`"BBB@`
MHHHH`B\-_P#)3I/^P,?_`$<*]%KSKPW_`,E.D_[`Q_\`1PKT6NO%_P#+O_"B
M8]0KSOXR_P#(H6G_`%_I_P"BY*]$KSOXR_\`(H6G_7^G_HN2MLI_WVGZBJ?"
MST2BBBO.+,CQ5_R*&M_]>$__`*+:LGX9?\D\TO\`[:_^C7K6\5?\BAK7_7A/
M_P"BVKS?P?\`$O1O#_A6RTN[MK]YX-^YHHT*G<[,,98'H1VKJEB:-/!.G*5I
M.2=O*S.K#9?BL4W*A!R2['K]%>>?\+D\/?\`/GJG_?J/_P"+H_X7)X>_Y\]4
M_P"_4?\`\77G?6:/\QU_V'F/_/IGH=%>>?\`"Y/#W_/GJG_?J/\`^+H_X7)X
M>_Y\]4_[]1__`!='UFC_`#!_8>8_\^F>AT5YY_PN3P]_SYZI_P!^H_\`XNC_
M`(7)X>_Y\]4_[]1__%T?6:/\P?V'F/\`SZ95G_Y*'XG_`.W7_P!%5=KC)/'.
MF/XJUC5!!=^1>^3Y:[%W#8FTY^;'7W-6/^%@:5_S[WO_`'PO_P`573B\90G4
M3C)?#'\(I/\`$4<CS&W\%G5T5RG_``L#2O\`GWO?^^%_^*H_X6!I7_/O>_\`
M?"__`!5<WUFC_,/^P\Q_Y],ZNBN4_P"%@:5_S[WO_?"__%4?\+`TK_GWO?\`
MOA?_`(JCZS1_F#^P\Q_Y],ZNBN4_X6!I7_/O>_\`?"__`!5'_"P-*_Y][W_O
MA?\`XJCZS1_F#^P\Q_Y],ZNBN4_X6!I7_/O>_P#?"_\`Q5'_``L#2O\`GWO?
M^^%_^*H^LT?Y@_L/,?\`GTSJZ*Y3_A8&E?\`/O>_]\+_`/%4?\+`TK_GWO?^
M^%_^*H^LT?Y@_L/,?^?3.KHKE/\`A8&E?\^][_WPO_Q5'_"P-*_Y][W_`+X7
M_P"*H^LT?Y@_L/,?^?3.KHKE/^%@:5_S[WO_`'PO_P`51_PL#2O^?>]_[X7_
M`.*H^LT?Y@_L/,?^?3.KHKE/^%@:5_S[WO\`WPO_`,51_P`+`TK_`)][W_OA
M?_BJ/K-'^8/[#S'_`)],ZNBN4_X6!I7_`#[WO_?"_P#Q5'_"P-*_Y][W_OA?
M_BJ/K-'^8/[#S'_GTSJZ*Y3_`(6!I7_/O>_]\+_\51_PL#2O^?>]_P"^%_\`
MBJ/K-'^8/[#S'_GTSJZ*Y3_A8&E?\^][_P!\+_\`%4?\+`TK_GWO?^^%_P#B
MJ/K-'^8/[#S'_GTSJZT_AE_R3S2_^VO_`*->N!_X6!I7_/O>_P#?"_\`Q57/
M!_Q+T;P_X5LM+N[:_>>#?N:*-"IW.S#&6!Z$=JZ88R@L-.',KN4?P4O\T+^P
M\QYOX+/7Z*\\_P"%R>'O^?/5/^_4?_Q='_"Y/#W_`#YZI_WZC_\`BZYOK-'^
M8?\`8>8_\^F)\//^1O\`&_\`U_C_`-&35Z)7B7A7Q]I6AZ]XCOKFWO'BU.Y\
MZ$1(I91ND/S988/SCIGO75?\+D\/?\^>J?\`?J/_`.+KNS''8>IB'*$TU:/_
M`*2D3#(LQ2_@L]#HKSS_`(7)X>_Y\]4_[]1__%T?\+D\/?\`/GJG_?J/_P"+
MKA^LT?YBO[#S'_GTST.BO//^%R>'O^?/5/\`OU'_`/%T?\+D\/?\^>J?]^H_
M_BZ/K-'^8/[#S'_GTST.N2^)O_)/-4_[9?\`HU*R?^%R>'O^?/5/^_4?_P`7
M6'XP^)>C>(/"M[I=I;7Z3S[-K2QH%&UU8YPQ/0'M73@L90AB:<Y222DOS%+(
M\Q<7^Y9OT5RG_"P-*_Y][W_OA?\`XJC_`(6!I7_/O>_]\+_\57-]9H_S#_L/
M,?\`GTSJZ*Y3_A8&E?\`/O>_]\+_`/%4?\+`TK_GWO?^^%_^*H^LT?Y@_L/,
M?^?3.KHKE/\`A8&E?\^][_WPO_Q5'_"P-*_Y][W_`+X7_P"*H^LT?Y@_L/,?
M^?3.KHKE/^%@:5_S[WO_`'PO_P`51_PL#2O^?>]_[X7_`.*H^LT?Y@_L/,?^
M?3.KHKE/^%@:5_S[WO\`WPO_`,51_P`+`TK_`)][W_OA?_BJ/K-'^8/[#S'_
M`)],ZNBN4_X6!I7_`#[WO_?"_P#Q5'_"P-*_Y][W_OA?_BJ/K-'^8/[#S'_G
MTSJZ*Y3_`(6!I7_/O>_]\+_\51_PL#2O^?>]_P"^%_\`BJ/K-'^8/[#S'_GT
MSJZ*Y3_A8&E?\^][_P!\+_\`%4?\+`TK_GWO?^^%_P#BJ/K-'^8/[#S'_GTS
MJZ*Y3_A8&E?\^][_`-\+_P#%4?\`"P-*_P"?>]_[X7_XJCZS1_F#^P\Q_P"?
M3.KHKE/^%@:5_P`^][_WPO\`\51_PL#2O^?>]_[X7_XJCZS1_F#^P\Q_Y],Z
MNBN4_P"%@:5_S[WO_?"__%4?\+`TK_GWO?\`OA?_`(JCZS1_F#^P\Q_Y],ZN
MBN4_X6!I7_/O>_\`?"__`!5'_"P-*_Y][W_OA?\`XJCZS1_F#^P\Q_Y],Z;P
MW_R4Z3_L#'_T<*]%KQ'2?'NEV'C%M7EM[PVYT\VNU47?N\P-G&[&,#UKJ_\`
MA<GA[_GSU3_OU'_\773B<90ER<LEI%"CD>8_\^6>AUYW\9?^10M/^O\`3_T7
M)2_\+D\/?\^>J?\`?J/_`.+KE?'_`(^TKQ5H,%C8V]Y'+'<K,3.BA<!6'9CS
M\PK7+<=AZ>+ISG-))BGD68N+2HL]MHHHK`\PR/%7_(H:W_UX3_\`HMJR?AE_
MR3S2_P#MK_Z->M;Q5_R*&M_]>$__`*+:LGX9?\D\TO\`[:_^C7KT8_\`(NE_
MC7_I+(^V=;15+5=6L=$L'OM1G\FV0@,^QFP2<#A0356]\4:-I^CV^K75Z([&
MYV^5+Y;'=N&1P!GH/2N.-&I-)QBW?1:=>Q=T:]%4;[6=/TW2CJEY<"*S"JWF
M%2>&QC@#/<=JB;Q#I:Z"-;^TDZ<5W^<L;MQG&=H&>OMQ25&HU=1>KMMU[>OD
M*Z-.BLZ]UW3-/M;6YN;I5ANG5(&52_F,WW0`H).:T:EPE%7:"Z/,I_\`DH?B
M?_MU_P#157:I3_\`)0_$_P#VZ_\`HJKM=.-_BK_##_TB(H[!1117(4%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!6G\,O^2>:7_V
MU_\`1KUF5I_#+_DGFE_]M?\`T:]=</\`=)_XH_E,E_$CK:***Y"CSOX>?\C?
MXW_Z_P`?^C)J]$KSOX>?\C?XW_Z_Q_Z,FKT2O1S7_>GZ1_\`2413^$**SK'7
MM,U*.\>TNA(MF[1W'RL"C+UX(R?J*:/$.D_V(FLF]C33W&5F<%0><=",YSVQ
M7&Z-5.W*^VW5[%71IT5CZ-XJT/Q`[II>H1SR(,LFUD;'KA@"1[U;T[5K'58I
MI;*?S$AE:&0E&7:Z]00P%$Z-6#:G%JV]T":>Q=KDOB;_`,D\U3_ME_Z-2NAT
MS5++6;(7EA-YUNS%0^QE!(.#C('?O7/?$W_DGFJ?]LO_`$:E=&!C*.,IQDK-
M27YH4OA9F4445Q%!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`1>&_\`DITG_8&/_HX5Z+7G7AO_`)*=)_V!C_Z.%>BUUXO_
M`)=_X43'J%>=_&7_`)%"T_Z_T_\`1<E>B5YW\9?^10M/^O\`3_T7)6V4_P"^
MT_453X6>B4445YQ9D>*O^10UO_KPG_\`1;5D_#+_`))YI?\`VU_]&O6MXJ_Y
M%#6_^O"?_P!%M63\,O\`DGFE_P#;7_T:]>C'_D72_P`:_P#261]L/B0H?P?(
MK`%6N8`0>X\P5Y_JBM<:9=:!(K%/#\=W(VX<'+`1=O1B?PKV+4=,L]6M#:WT
M/FP%E?;N*\J<CD$'J*JS>&](N)-1DDLP7U%%2Z(=AY@48'0\?ABML%F-/#TU
M"2=TV_R7Y7^=@E%N5_3];G&^*=2'_%+:6+.[O8U$=[<P6D7F.R(`%^7T+']*
ML?#ZZBG@UCP]<65Q!#%,TD5M>1;'$$F?E*G\?SKL+?1M/M=0^WPV^VZ\A;?S
M"['$:]%`)P*=_9-B-9.K"#%\8?(,H=N4SG!&<'GOC-1+&TG0=%1?>_\`>O?;
M\+B4&K/M;^OS.%\):-(?%MY9W=TUQ:^'CY5C&X^[YF6R?4@<"O1ZIVNE65E?
M7EY;P[+B\96G?<3O*C`X)P./2KE<N,Q/UBIS^2^_K][N_F5&-KGF4_\`R4/Q
M/_VZ_P#HJKM4I_\`DH?B?_MU_P#157:>-_BK_##_`-(B$=@HHHKD*"L_6I?L
M^ERSG41I\<?S27&Q6*J.N-W&?3(/T-:%4=5T>QUNT%KJ$3R0AQ(%65X_F'0Y
M4@\4F".+O/$6O+I%C*LD\<S6UQ<D"*,2%$8>6\H88"E2"P7#9/`KO;>43VT4
MH=7#H&#+T.1U'M6=-X;TRY@ABGBGE$08*\EU*SE6^\K.6W,I[J21QTK550BA
M5`"@8`':J;0"URVIZCJ-MXF@L[&]-W-+EVL1$HCAA"GYG;[VXMC'(!SC'>NI
MK*3PYID>JS:FD=PMU.P:8K=2A9,#`W)NVD8[$8I`9?AC5]0NM0ELM0-RT@M8
MYW^T6XB,<A+!T7@94$<'GO\`,:ZFJ.G:18Z4K+9PF/<`"6D9R%'106)PHR<*
M.!G@5>IMW`K7\5S-9O':7)MI3C$HC#D#/.`>,XZ$Y`]#7'QZ]JEQ96UM]L:*
MZ5;MYI1&A<&$@*CC!7)!&[;QZ$5V%]8VVHVQM[J/?&2&X8J00<@@C!!!Z$'-
M5'\/:7)9QVK6Q\J,E@1*X<EOO98'<V[ODG/?-(:L6M-NFOM+M+MDV-/"DA7T
M)`.*M4BJJ(J*H55&``.`*6F]]"5=+4*Y[1M1U6Y\2:M::@(HXH8XG@AC.[8&
M+\EL<D[0?0=/<Z%QJZ1S206MK<WT\6!)';!?E)[%G95!QSC.<=JK6=W9C56E
MGL;FPU"\41XN<?O`F<`%69,\DX!S^5(?0VJ***`,CQ'=?8M*:Z;4VT^&(YDD
MCB5Y']%3<",DX['T]ZL:+->7&B6<VH1^7=O$K2IC&#[CL?:DU71+#6D@6^CD
M<02>;$8YWC*OV(*$'-7+>!+:!(8S(508!DD:1OQ9B2?Q-"V!DE%%%`'/0W.H
MVGBU+*[OC+;W4,DD2M$B*&5AA4Q\W"GYBQ.>,8Y`[3X9?\D\TO\`[:_^C7KG
M+31-.LKQ[JWM]DK;NLC%4W'+;5)PN3R=H&>]='\,O^2>:7_VU_\`1KUV0_W.
M?^*/Y3)?Q_UY%_5?$;Z9<7T/V!W^S6?VE&,@`F.[:%``+=?;/H#5W0M4?6-'
MAO9+?[/(Y97BRQVE6*G[RJPZ=&52.X!XJ6ZTJRO9))+B$L\D7DLP=E.W.X8P
M>#GG(Y'K3["PM]-M$M;566)23\\C.Q).269B2Q).22237&MM?ZW_`.`4_+^M
M/\SA/AY_R-_C?_K_`!_Z,FKT2O._AY_R-_C?_K_'_HR:O1*]'-?]Z?I'_P!)
M1%/X3QNR\[08]3\10AWM)KZZL[]!SA2WR.![$X_&K>G&+^R_A_\`;]G]F[YO
M,\S[GF<^7GMUZ5Z/'H.F1:==Z>MJ/LMV[O/&68[V?[QR3D?AT[4@\/:3_8B:
M.;&-]/086&3+@<YZDYSSUS77/-*4MT[WW\N5K[U?3Y$^S=[^OXF!XI,'_"7^
M%_L^TZC]J.[9]_R-IW9_V?\`Z]8.O:D_A;6O$EC!D-J]ND]FH'69CY;8]^<_
MA7<:-X5T/P^[OI>GQP2.,,^YG;'IEB2![5-J&@:7JE]9WM[:+-<6;;H'+,-A
MR#T!P>0.N:QI8VA3E&+3E!*WF]>9:7T5]-]KE-2WZCM#TU-'T*RTY,8MX50D
M=SCD_B<FL+XF_P#)/-4_[9?^C4KK:Y+XF_\`)/-4_P"V7_HU*YL%-SQM.4MW
M)?F#5H678S****XBPHHHH`*YBXOKX>+8=.M]2DG\T.UQ#'"@2TBVG:V[!.\M
MC&201GY:Z>LJW\.Z;::G-J,"7$=S._F2D7<NQVQC)3=M/'3CBA;AT*OAI[VX
MDO[B;4[B\LQ,8;?SDB!^0X=LHB]6R![#WK?JO965OI]JMM:Q^7"A)"[B>I)/
M)YZDU8H`S]:E^SZ7+.=1&GQQ_-)<;%8JHZXW<9],@_0UQMYXBUY=(L95DGCF
M:VN+D@11B0HC#RWE##`4J06"X;)X%=IJNCV.MV@M=0B>2$.)`JRO'\PZ'*D'
MBJ\WAO3+F"&*>*>41!@KR74K.5;[RLY;<RGNI)''2A#T-&WE$]M%*'5PZ!@R
M]#D=1[5+2*H10J@!0,`#M2T/<E;',7^HWUOXKM;*UOFN9)B6DLEB4)!"%/SN
MWWMQ;&.0#G&.]1>&]8U*XU3[%J7VDS/:^?*LUOY0AD#;61#@;DY&#\W3J>VO
M'X=TV+5IM4C2X2[G8-*RW<H60@8&Y-VT@#L1BI]/T>PTLN;.$H7XYD9]HZ[5
MW$[5Y/RC`]J%YC>NQ>J"\CN)K22.UN!;S,,++Y8?;ZX!XSCU_(]*GJIJD-E/
MITR:B$^RX#.6;&,'(((Y!!Q@CG/2@$<>FO:K-$MC]LDBNHC=M+(8XS(/*VE$
M?`*9(8$E?PQ78Z;=-?:7:7;)L:>%)"OH2`<5SS6]A/:Q0)X<U66UR9!/Y@1S
MN^\6WRK*<CJ"#D<&NAL+RVO+?-J<+&=C1E2K1D#[I4\@XQQ3Z!U+5<]JUSJ.
MGZU83?;2+"XN%@:,Q((T!!QD_?+LV,$84=QWKH:SVT33GU+[>UO_`*06#D[V
MVE@,!BF=I8#HQ&1ZTNH=&9VC:CJMSXDU:TU`11Q0QQ/!#&=VP,7Y+8Y)V@^@
MZ>YZ&J\=C;Q7TUZD>+B=%21]Q^8+G:,=.YJQ0'4*YKQU+J4'AFZN-/O/LHB0
MM(ZC]X1Q@*?X?<]?3UKI:KWUC;:E92V=W'YEO,NUTW$9'U'-`T+X7)/Q))/_
M`$!?_:RUW.KZDFDZ;-=M$\S(/W<*8W2MV49]?7MU/`KA_#0`^)K@=!HQ`_[_
M``KNM3TG3M:M#::I86U[;D[O+N(@Z@^H!Z'D\UUXV_N6_E1%.RW*%KXB2[U>
MSL([9CY]J;B24.-L380B/W.'S[#'J*Y;XR_\BA:?]?Z?^BY*ZRT\*>']/OX+
M^ST:QM[N"+RHYXH55PFT+C(Y/``Y[5R?QE_Y%"T_Z_T_]%R5OE5OKU.W<F=^
M34]$HHHKS30R/%7_`"*&M_\`7A/_`.BVK)^&7_)/-+_[:_\`HUZUO%7_`"*&
MM_\`7A/_`.BVK)^&7_)/-+_[:_\`HUZ]&/\`R+I?XU_Z2R/MER3Q1!_PET&B
M126W1A,7D`??MW*JKG/3J??`[X@U#Q)=V6HO;>5"5ANE\UB#Q;$)E^O4-)UZ
M84\5MWTVG6LMM<W]Q!`R,5A>:4("S#!`R<$D=JJ3VF@ZAJ5[;2M;37T]L(+F
M$3?O#%R0"H.0/FZ\=1[5%.5&Z;@[6UZZWU8W?N8T?B34[BY@0/%`LMK'<#;I
MD]R2'9\`E&&WY57KU)-3?\)!J)N=0Q)&([9IPL?]F3D'8"1F?=L'3T]NM:4V
MDZ/.PN?.EB\M5MB]O?2P@!6("'8X!()(YYR<4R+3=#NKB5H+IY&GW,\46HRE
M'W`;CL#[>0P/3N#6GM,.[OE?W+^OU[!9W*]OKFH:EIDU[I\414,D:*T3%U/&
M^1ER#C!R%ZD<YYK5T>\DO;`2321/(KE6,<;Q]/5'^9#_`+)S]:2?1-/N0WF0
M')5%W)(RD;?ND$$$,.S#GWJQ9V4%A!Y-NK!2Q8EW9V8GJ2S$DGW)KFJU*,HM
M05G?^M02EU/.I_\`DH?B?_MU_P#157:I3_\`)0_$_P#VZ_\`HJKM5C?XJ_PP
M_P#2(A'8BN;F*SM9;FX<)#"A=V/0`#)-<SX0\2OK][JWF75M(B.C6\,3JQCC
M90>2.ISU]#D5U=5X;*WM[JYN8H]LURRM*VXG<0,#Z<#M7(MRNA8HHHH`YWQ-
M>ZA:S6BVO]H1VH626ZGLXX6**H&,F7('7/`)..!6[;31W%K#-%)YD<B!E?\`
MO`C(-5M0T>QU1HVNXF9HP5#)*\9*GJIVD94X&5.0?2KJ(L:*B*%51@*!@`4+
M8&+4<\GDP22[2VQ2V!WP*DHI/8$<KX4UJYU.13>7,OF7%JETD$L,:@!NIC93
MDJ.F'&[/.<&NJJC9:18Z=-)-:PE'D&TDNS;5Z[5!)VK[#`J]5.P!6%XHDNX;
M"-[+4;BUN7D6"%(EB(DD<@#=O1N!R>,<9K=JO<V5O>26[SQ[VMY?-B^8C:^"
M,\=>">M("2W22*WCCEF::15`:1@`7/<X'`S[56UF[EL-#U"\A3?+;VTDJ)_>
M95)`_2KM(RJZ,C`,K#!![B@"O86D5C80V\/*HO+=W/4L3W).23[UQNGZC>:S
M=7%GJ%RYMKB">2!F1%4M')A7A*_,`O!._G.".*Z*V^WZ/&EF;66^M$^2&6)U
M\Q$[!PY&<<#<"2>XZFJ$.B)<3S"WTR73X)0R3233[F*$Y98D#,(PQZD;?7!X
M-"W!['06$SW&G6L\GWY(4=L>I`)JQ2*H50J@!0,`#M2T`8GB*YU"W6S%HUQ'
M`\I%Q-:P":2,;3MPI5N"V`3@X'IU%GP_J$NJ^'[&^G7;+-$&<`8Y[U/?Z9::
MG'&EU&S>6^]&21HV4XQPRD$<$CKR#5B&&.W@2&&-8XHU"HBC`4#H!0M@'USV
MIZCJMOXITBU011Z=/(R.<[GE(C9L=/E`('N?8=>AJO/8V]S<6UQ-'NEMG+PM
MN(VD@J3QUX)ZT+<.AS>CZU?W6LV_G3,\%ZUTH@**!#Y,@5<$#/(ZY)YZ8KO_
M`(9?\D\TO_MK_P"C7KGK?1["UOI+V&#;/)G)WL0,G+;5)PN3R<`9[UT/PR_Y
M)YI?_;7_`-&O79#_`'.?^*/Y3)?QFAJOB-M,N;R$V)(M[47`EDF"(V6V\GDJ
MHZEB.`#P:M:!K":YI$=]&(OF9D/DR^;&2K%24?`W*<<'`R.U6+C3;6ZEDED6
M199(3`TD4SQL$SG`*D$'/<8/O3[&QM]-M$M;5&6),GYG9V))R2S,26))))))
M)KC6VO\`7]:%/R_K3_,X/X>?\C?XW_Z_Q_Z,FKJ/%7B*/P[I+3[H?M4@86Z3
M/M5F`)Y/IQTZG@#K7+_#S_D;_&__`%_C_P!&35WUW%!/93PW6/L\D;++EMHV
MD8//;BO5Q\H1QUYJZM'3_MU$4_A,G4M=-E9V5Y%Y4UO<QO@KSN;RRZ;2#C!V
MD>^163_PE6I'39Y?+MEGMO)AF*PO(!,TYC<!%;)``R`#DY%;-W=^'KW3K9[J
M^L9+,3*8'-RNPR(<@!L\D$=*DDT;2'^TVIC"O>RBZE5)F1W92OS@@@C!"],<
M_6LH2HPBE.#O?\GK^`:]_P"OZ_4Q9O$&IQR6<(N$S.LSM)_8=T6&PH`/*W[Q
M]X_-TZ"K5GX@NKK69-*`A\Z.1=TK0NBF/RD<X4G.\ECA<\`9.<<R/IF@%T#W
M\WFP[\,=6F\Q0?O#=YF['[H\9Q\A]#6C'H^GK'A8F;=(DV]I79BZJ%#;B<YV
MJ!UYYSG)ISJ8=1MRN]GT2UOO]P693TS4M0FU-K:_$$19698?(D1UPV!AR2LH
MQR2N,<<<UG?$W_DGFJ?]LO\`T:E;MEHFGZ?/YUM"ZL%*H&F=EC!ZA%)(0=.%
M`Z5A?$W_`))YJG_;+_T:E&&E"6-I.&W-'\PE\+,RBBBO.+.;\6W]WIT$4MG?
MO'<N=EM9QPJ[7,I/`)8$[<=<8(ZYKHUW%%+`!L<@>M9E_P"'M.U._BOKE+@7
M4*&..2&ZEB*J>H&QAUK3`P`!GCU-"V![BTUPQC8(P5R/E)&0#]*=39(TFB>*
M1`\;J596&00>HH8&%H5U?#5M2TW4+MKB2W$;QF2-$9E8'+`)QLR"`#\PQSVK
M?JEI^D66EA_LD3*7`!9Y&<X'106)(49.`.!GBKM-B05R7CGQ2="LA;VEW;P7
M\B^8&F91M0$9P#]YCT`^I[5UM07ME;ZC9R6EU'YD$HPZ[B,CZCFD,DAE2:".
M6-U='4,KJ<A@>X-/HZ#%%`+8*YCP[J5Y-J$D&J2ZA%=3+)-#;7,<*IY0?`*;
M!OR`5!WG//2NGK/L=$T_39FEM8"CD;1ND9PBYSM0,2$7/9<"A;@]C0K*O5%Q
MX@T^VD*F)(I;D1G^)U**I^@WG\2I[5JU1U&REN!#/:R+'>6[;HF<':P/#*V.
MQ'Y$`]J`,GQ-JMY:7=G96AN8S/'+*TEND;.`@7@"3Y<?-D]\#`Y-36LJ3:AI
M6H6\PE%[:E971=JR@`,KX.2,$D`9XWFDOMVHP>5?Z#?&2,_+Y%PBYXYVN)%.
MT]#G&>XJWINGRI.MU<QQ1&./R;:WBY6"/C(SCDG`SV&`!ZD6P/<U****`.>T
MDWTOB+4%_M:YN;&T`B:.:.$9F(#'!1%.%4KW/)]JZ&J]K96]D9S;Q[#/*9I#
MN)W.<9//T%6*.B#J%<IXPN;E+G3K6V:Z?S1,SV]I-Y4K[4R&W[EPJG&1D9R.
MO2NKJEJ&DV6J",74;%HR=CQRM&ZYX.&4@X/<9YI,:*GPZN7O/%=E<2W*74DG
MAY6>9!@.?-7)Q7I6KZDFDZ;-=M$\S(/W<*8W2MV49]?7MU/`KA/"D$-K\1OL
M]O&L<,>B;411@*!,N`*[W4])T[6K0VFJ6%M>VY.[R[B(.H/J`>AY/-=N.=W"
MW\J(IZ;F39^)9[K7X=/;3_(MY;=95N)6E&]BF[:G[KRVP.O[P-P?EXKG?C+_
M`,BA:?\`7^G_`*+DKKK/PUI&GW<5S:6AA:)`D:)*XB4!=@(CSLW;1MW8SCC.
M*Y'XR_\`(H6G_7^G_HN2MLJM]>IV[DSOR.YZ)1117FFAD>*O^10UO_KPG_\`
M1;5D_#+_`))YI?\`VU_]&O6MXJ_Y%#6_^O"?_P!%M63\,O\`DGFE_P#;7_T:
M]>C'_D72_P`:_P#261]LTO$27,L4<-MI4EWYRO%+-$8@\,;8W!=[+RW3KQC)
MS@`T['3[V/6X@;&2*WAN)9_M#.A#JZ`!,!BV1G'(Q\O4UT]4=2U-=.2+]Q-<
M2S,5CBA`W'`))^8@8`!/6L*5>?+[**77OU^?_`&U?<YF#2M:AO[HP17<*O=2
MR,QNP8Y$:8,NQ-WRG;N)X&0<<YP*UCH.O6NGR0HDT#/"JDQ7"J=PCA7.0>H*
MOS_C6M'XQ@CBLDNK68W%S:^>HA:,AR(][*J[]XX!Z@#ISS4J>,]-EU*&RB29
MQ*X1)RT:1,<*>"S@L1N`PH)X/%=OM,4K^XN_W?,5X[WW.=UM[W2IOL3W5_F0
MN+`+?,'R77!)+9DX.`OS$>@'(]$HHKAKXCVL8JUFK_,:C9MGFMS/+)X]\1Q/
M*[1Q_9O+0L2%S%DX';-6JI3_`/)0_$__`&Z_^BJNU6,2516_EA_Z2@CL<S!)
MJB^-KJ&:\5XVL3)!``1&G[S`)]6]3^`I_A.2_9]8BU"\:ZFAOBF_&%`\M#A5
M[+DGC^M;_D0_:/M'E)YVW9YFT;MN<XSUQGM1'!#"TC111QM*V^0JH!=L8R?4
MX`Y]JY%HOZ[W*>_]=B2L_6UO6TF<6%PEO-M),K)N*KCG:/[WIGBM"D95=2K`
M,I&""."*35T-.S.#N[V5_".A;;R_EUBZM%%K!#<,AEE*@F1R.2%ZG<<<\@\5
MW4(D6",3,&E"@.1T)QS5*XT'1[Q(4N=)L)UA79$);9&$:^BY'`]A5]55$5$4
M*JC`4#``JV[MDI;"US-S-J$7CFT2>^"V,MK.R0H-H7;Y?S,3U.2?8#\:Z:HV
MMX7G2=H8VF12J2%064'&0#V!P/RJ>I1SGA]V@U^]LQ?SWEL]M%<02/.9PX)8
M%]W123_"ORX&1U('3U7M;"SL?,^R6D%OYK;Y/)C";V]3CJ?>K%-BZE34UO'T
M^5;&:."<CB1TW;1W('KC./>N"U/7=2@^&U@89;[[3/8F66^2*20IM'=U!VLQ
M[DC`R<]*]((!&",@U!]BM/L7V+[+#]EV;/(\L;-OIMZ8]J0TPLIA<6-O,-^'
MC5OG4JW3N#R#]:GI``````!P`*CN+B*TMI+B9ML4:EF/H*;W)6B,"^DU&/QM
MI2M>8L95F"V\8(SA`<N>YST'054\/W4Z:XR7PD>:^-Q+!)'J+SQB-9,;3']Q
M,`J`1GOG'2M1X]7U!HKJ**PLF3)A^U6[3RJ".<X=-A/<`FBQ":?JCI=:;9V]
MQ=GY;RU0`7!`SA^,ANI`).0.O:DM!FW4%XMRUI*MF\<=P5Q&\JEE4^I`Z_2I
MZ*`.`M[W59/#VDVYGGN9+G4+B":9KAH68*92H,B@E`2H^Z.V!76>'KI;W0;.
M=7G<,F-UP07)!P<D`9Z=<<U:?3K&2S:S>RMVM7)+0M$I0DG))7&.3S4Z(D4:
MQQHJ(HPJJ,`#T`IW`=7-:O)J47B[1,7FRPEF=/L\8(+D1.27/?D#`_'TQTM1
MR00RR1R211N\1+1LR@E"1@D'MP2*2W#H<]IEJDGBS4)8+F]\BS`B:*2\ED1Y
M7&XG:S$`!2H&/4^@KO/AU<SW?@+3)KF:2:5A("\C%F.)'`Y/H`!^%8D<$,+2
M-%%'&TK;Y"J@%VQC)]3@#GVK7^&7_)/-+_[:_P#HUZZX)?5)_P"*/Y3)?Q?U
MY"ZMKFLV>HWL=LVGRP(@"XB=C;LQ55:5MP!R6)V``@+G=S6SH-[<WVFE[QH'
MN(IY8)'@0JCE'*Y`))&<=,G'K22>&]"EN[B[DT73GN;E"D\S6J%Y5(P0S8RP
M('0U=M+.UT^UCM;*VAMK>,82&%`B*/0`<"N1;%,X+X>?\C?XW_Z_Q_Z,FKN[
M_)T^X`LQ>'8<6Y*@2_[/S<<^]<)\//\`D;_&_P#U_C_T9-7HE>EFCMBV_*/_
M`*2B*?PG$3Z?J<T,EW_8UPUS<Q7,4T#R0C#R+&%8?O"-@";>N[OCFK>O:5J4
MMS8R645R\D-G)")8+D1;)24VLWS`LORDD<].AKJ9IDMX))I3MCC4NQ]`!DUS
MK^+1!#=W5SI]Q';PB,A7>%'PP)W'=(%(Z8`.>>E*E7K5&I0BM/UTMOYC:6S_
M`*ZF;)HNN-J4ET8W9_WFR7SER.+D+CG(_P!9'CTS['$5_::SIMI-?S75ZL9:
M8W.;PD"/SDV!?FPA*;QN&,9Y(QQL7/C;3+:(MY5U(PYV(B[MFQ7W\L,)AU&3
MT)YQ@FMRPO(]0L8;N+_5RKN'SJ_ZJ2I_`FKGB*].TZD%;\Q14>AE>$IWN=$:
M9FG:-[B4PF>;S6\O>0OSY.X8[@D>YZU2^(\\MMX"U.6"5XI%\K#HQ4C]Z@ZB
MNJKDOB;_`,D\U3_ME_Z-2L<+)5<="5M'):?,&K19F4445PEG&^,;G4;2>6XM
M9)66&S:6&*"Y$924-]]TW`NAX7&&Y[=Z[",LT:EAAB`2/0U%/8VES-#-<6L$
MLL)W1/)&&:,^JD]/PJ>A;6![W"N1O;G5K3Q;.6NO,A.FSRV]K&"%!4I@M_>8
MDGGMT'?/75&8(3<+<&*,S*I02%1N"GDC/7'`X]J/^#^0SF?"EQ<-=S0-<37$
M+65M<[Y93(1)(&W8)/`.`<#@=@*ZJH+:RM;)76UMH8%=B[B*,*&8]2<=3[U/
M3;NR4K(S];6];29Q87"6\VTDRLFXJN.=H_O>F>*Y:\NM6/@G0;R'4&C4K:FX
M;),LI9XQC=G@')SW/YUW#*KJ58!E(P01P14)LK4VJ6IMH3;Q[=D1C&Q=O*X'
M08P,>F*%I^`R>BBBD!S4TFHQ^/+.*6\_T*6VG,=O&"`-OE_,W]YLD_0?C4/A
MN:2ZUN]DL[F\N-*C3RFN+F8N)YPWS%`>%4#CY0`3T'%=,]M!),LSPQM*BE5=
MD!8`]0#Z'`S]*K66BZ5ILK2V&F65K(PVL\%NJ$CT)`H0/5%ZJ]\MT]E(ME+'
M%<$8621=P7GDX[G&:L50O+]XKE+.TA$]VZ[]K-M6-.FYCS@9X``R?P)`P.3B
M>YO/`UK(=6G_`+22":6,&[,32E6/SMM^9MO7'W>@/'3LM.N!=Z9:7(+L)84?
M+KM8Y`/([&L>71[YH4CDM]"N[:([XK1K$QA6ZY#EF`/7G96O87T=];ET1HW1
MC'+$XPT;CJI_3V(((X-/N'8M5S=]+J,7C72P]WBQE68+;Q@C.$!R_P#>.>@[
M?6NDJ-X(9)HYGB1I8\^6Y4%DSUP>V:0''Z!K=YJ'C6\2Y^VPQ/:!H;66VEC6
M(!R,G<H&2!G/O@$XKM*C\B$7!N!$GG%=ADVC<5SG&>N,]JDHZ)`]VRCK%M+=
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M$N0-I/'ED<?>YQ69\9?^10M/^O\`3_T7)7<II>GQWJWJ6-LMVL0A$ZPJ)!&/
MX-V,[?;I7#?&7_D4+3_K_3_T7)6^5-?7J5NY$_@9Z)1117FFAD>*O^10UO\`
MZ\)__1;5D_#+_DGFE_\`;7_T:]:WBK_D4-;_`.O"?_T6U9/PR_Y)YI?_`&U_
M]&O7HQ_Y%TO\:_\`261]LZVJE_IMKJ4:)=1LPC;>A21D93@CAE((X)!YY!JW
M17GQDXN\79EF-'X8TRVE2>T@,<\7,):61D1@FP'9NP?EX/<^M-LO"VGVNFV=
MFX>1;8[L)(\<;ONW%FC5MI^;D`@XK;HK9XFLU9R?W_UW8N5!1116`SS*?_DH
M?B?_`+=?_157:I3_`/)0_$__`&Z_^BJNDX&377C?XJ_PP_\`2(DQV.*O"-*\
M5ZG=WE[+(K:6SC<X01CS,*B=AV&>I-1_#X*DEVD;0RH;>W9Y+9=D8DPVY6&3
MF4?Q-P3QD"MJSO[+7=68_;+>2*W&8;42*6;/_+5EZX[+[$GN,-TC5[".];3+
M?4+6ZM\XMVAF5S&>?W38/!&"5]0"/X>>2.BM_6[_`,QM7=_ZZ?Y'0UG:[;27
M>C7$4=U+;?(2SQ8#%0.5![9]1S6C12:NK%)V=SS&_C'_``B^@R&6W>0Z3LMX
M+@L")=JE7B(4@RCH!P>3@\&O2;7S?LD/G_Z[RUW_`.]CG]:EHJW*]R4K6"N!
MO[O3[OQX+73I+2#4+9M]S<2S#S96*$+!&"<D="0.!CUKOJ*D9Q/@C`NV\@*%
M^P0_;=O_`#]Y;?O_`-O'7//3-=M113;N!B^*[W3-/\/7%QJZ>;:+MS%NQYK9
MX7J,@GJ#QC.>*Y*>TDE^'8F34H?*68RM;V$BM"NZ1=L6X?PH#C`XS[5Z/126
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M6\VULV*85)`I"9_BP2!N/'.*[#PRTC>&=-,L<R2"W4$3-E^!C)/OU_&M6BJN
M(*X7Q!=Z7/XSLM/AEM8-322*6:[GF"M&@.1%'D_>?H0O8\YXKNJ*2W3#I8X;
M2Y=2?XC/+J%C=0M+9R!%:2)DCC$@VD;7)Y[\9RW3`KTSX9?\D\TO_MK_`.C7
MK,K3^&7_`"3S2_\`MK_Z->NR'^YS7:4?RF2_CO\`UT$BUI[CQM>Z7:>(K:66
M*%M]BZQ_N&PNW"@B1SR2QSMP0.#6SX:O+C4/#&F7EW()+B>V221PH&6(Y.!T
MK5HKC6UBCSOX>?\`(W^-_P#K_'_HR:O1*\[^'G_(W^-_^O\`'_HR:O1*]'-?
M]Z?I'_TE$4_A&NBR(R.H9&&&4C@BL;_A$]&V!?L\W!Z_:I=V,8VYW9VXXV],
M8XK;HKBA5J0^"37H78Q(?#5K'J%Q<LQ"O;1VD(A+1O%$G./,#;B2>^1P`/<Z
MEE96^GVJVULA2)22`6+$DG)))))))))-3T43K5)JTG<2205R7Q-_Y)YJG_;+
M_P!&I76UR7Q-_P"2>:I_VR_]&I6^7_[W2_Q1_-"G\+,RL;Q3;277AR]6.ZEM
MPL+NYBX9P%/RY[`G'(YK9K*UO5XM,@5/M%O#/+]Q[APJ1KQEV)(X&1QW)`[Y
MKCDKJQ:=F</J]Y$T&GQRO9SPVVEHRP3$DF?"D(NU@5E9?NL.1S@&O2H6+01L
M49"5!*L<D<=#6#<K8Z?;6,UI?VR71)\EI9E'VS=RRD_Q%NH(Z'!Z9!VK.[BO
MK5+B$DJV001@J0<$$=B#D$>U6W<E*R1/7*-9$?$-3<W#W,=QI\W[J0#8B;XQ
MM"_GDGKGZ5U=%2M[CZ6.8\':?8I!>:K:65O:_;)V")#$J`1(Q51@>N"W_`JZ
M>BB@#.UVVDN]&N(H[J6V^0EGBP&*@<J#VSZCFO/=657\,^'5D:.-1I#&-YUW
M*TFU-JQ\C;,>=K<D<\&O4Z*%I_7K_F.^I#:LS6<+,CHQC4E7.6''0GUJ:BBA
M[DI65CE;NUE3X@6,KWDSB:TN-D9P%A`\L?*!WSDY//Y5G^"TD3572"2UEMTM
M=ES/`6)EF#\-*&4%9",Y!R1QSTKNJ*%I_7K_`)C>JL%<KJUYIUA%XAFUK#6Z
M^4^Q20SQ;0%7@\YD$@QTYP>]=55*]T\73QSQ3/;W47"3(`>#U5@>"I]/RP:3
M&M&>=Q>0^D6TMU+8-ILOVJ18+>17AMIB%\J,$<;AS@#^(\=J[#PZ;EKVY:=P
M66TM$G7N+@*Q?/OM:*KIM];D18WU&SC[/)#:,&/'\.YR`?J&JY9V<-C;B&$-
MC)9F8Y9V)R6)[DFJN38L5PNJ7FEW/CZUL;:6T@U"&6.6ZNII@),8^6&,$Y.[
MN!Q^)KNJ*2W3'T:.6T*VDM?&>N+-=2W,C06[EY,<9,G``X`'3']:ZFBB@.IA
M^+-8L-#T-[^_@CG\MU\B*0#YI<_+@GI@\Y[8S7&/K-MHGAFW8W>E7NM:G<3&
M*?SD\FV:3E_GZ!5!&>>37I]%*P[F1\.[:*S\6V=M!=+=11>'PBSHP99`)5Y!
M':N]\5:M/H^@S7%K%,]PWR1M%:R3^62#\[(@)(&/IT&1G-<IX;_Y*=)_V!C_
M`.CA7HM=F-O+D_PHBGH<KH]Q?:AK5I.NKWS6YL([F>TE@B2,-(,+C]V)`<J[
M'+<<<8-8OQE_Y%"T_P"O]/\`T7)7HE>=_&7_`)%"T_Z_T_\`1<E;Y4T\=3MW
M)FK09Z)1117FFAD>*O\`D4-;_P"O"?\`]%M63\,O^2>:7_VU_P#1KUK>*O\`
MD4-;_P"O"?\`]%M63\,O^2>:7_VU_P#1KUZ,?^1=+_&O_261]LZVBBBO.+"B
MBB@`HHHH`\RG_P"2A^)_^W7_`-%5GW]W!J5\^E_:(4M82/MI+@%LC(B_$$%O
M;COQH3_\E#\3_P#;K_Z*J=K.U=BS6T+,3DDH"377C?XJ_P`,/_2(DQV.'AU&
M"_\`%4H2.2PM;$3+:HMHRBXE9?FD+D!`/0%N3SZ5/X<*2V<FE7%W-+ID5O$(
MI;N-8)4F!.0H`&0N%(;GG^(UU_V&T_Y]8/\`OV*/L-I_SZP?]^Q7(M$4]2GI
M&IBY>:QGEB>]M@"YC8$2(<[9!CUP<CL01Z$ZE11V\$))BAC0G@E5`J6@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K3^&7_)/-+_`.VO
M_HUZS*T_AE_R3S2_^VO_`*->NN'^Z3_Q1_*9+^)'6T445R%'G?P\_P"1O\;_
M`/7^/_1DU>B5YW\//^1O\;_]?X_]&35Z)7HYK_O3](_^DHBG\(4445YQ8444
M4`%<E\3?^2>:I_VR_P#1J5UM<E\3?^2>:I_VR_\`1J5UY?\`[W2_Q1_-$S^%
MF#J6HP:79/=7#?*"%501EV)PJC/<D@5R^L:@NDZ4=0-O#J&L7$BA?+0S+;G!
M`/R@D*@)Y`R23ZUV$D4<J[9(U=<YPPR*B^PVG_/K!_W[%<C*1P=W]AC\)0:?
M;BXN;QX"([@VNWS7W[C$^1NC1FYY"C'\5=)<WEOI5P=36XMQ;R@?;HED!"D#
M'FCZ=&]0`?X>=C[#:?\`/K!_W[%'V&T_Y]8/^_8IW%8G5@RAE(*D9!!X-+2`
M!0```!P`.U+2&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`1>&_P#DITG_`&!C_P"CA7HM>=>&_P#DITG_`&!C_P"CA7HM=>+_`.7?^%$Q
MZA7G?QE_Y%"T_P"O]/\`T7)7HE>=_&7_`)%"T_Z_T_\`1<E;93_OM/U%4^%G
MHE%%%><69'BK_D4-;_Z\)_\`T6U9/PR_Y)YI?_;7_P!&O6MXJ_Y%#6O^O"?_
M`-%M7F_@_P"&FC>(/"MEJEW<WZ3S[]RQ2(%&UV48RI/0#O75*=98)J,+QYEK
M>VMGI:WXG5AJ.%FVZ]5P?E&_ZH]?HKSS_A3?A[_G\U3_`+^Q_P#Q%'_"F_#W
M_/YJG_?V/_XBO.YZW\GX_P#`.OZMEW_00_\`P#_[8]#HKSS_`(4WX>_Y_-4_
M[^Q__$4?\*;\/?\`/YJG_?V/_P"(HYZW\GX_\`/JV7?]!#_\`_\`MCT.BO//
M^%-^'O\`G\U3_O['_P#$4?\`"F_#W_/YJG_?V/\`^(HYZW\GX_\``#ZMEW_0
M0_\`P#_[8JS_`/)0_$__`&Z_^BJNUQDG@;3$\5:QI8GN_(LO)\MMZ[CO3<<_
M+CK["K'_``K_`$K_`)^+W_OM?_B:Z<74KNHN:"7NQZ_W5;IU0HX7+K?[P_\`
MP#_[8ZNBN4_X5_I7_/Q>_P#?:_\`Q-'_``K_`$K_`)^+W_OM?_B:YN>M_)^/
M_`']6R[_`*"'_P"`?_;'5T5RG_"O]*_Y^+W_`+[7_P")H_X5_I7_`#\7O_?:
M_P#Q-'/6_D_'_@!]6R[_`*"'_P"`?_;'5T5RG_"O]*_Y^+W_`+[7_P")H_X5
M_I7_`#\7O_?:_P#Q-'/6_D_'_@!]6R[_`*"'_P"`?_;'5T5RG_"O]*_Y^+W_
M`+[7_P")H_X5_I7_`#\7O_?:_P#Q-'/6_D_'_@!]6R[_`*"'_P"`?_;'5T5R
MG_"O]*_Y^+W_`+[7_P")H_X5_I7_`#\7O_?:_P#Q-'/6_D_'_@!]6R[_`*"'
M_P"`?_;'5T5RG_"O]*_Y^+W_`+[7_P")H_X5_I7_`#\7O_?:_P#Q-'/6_D_'
M_@!]6R[_`*"'_P"`?_;'5T5RG_"O]*_Y^+W_`+[7_P")H_X5_I7_`#\7O_?:
M_P#Q-'/6_D_'_@!]6R[_`*"'_P"`?_;'5T5RG_"O]*_Y^+W_`+[7_P")H_X5
M_I7_`#\7O_?:_P#Q-'/6_D_'_@!]6R[_`*"'_P"`?_;'5T5RG_"O]*_Y^+W_
M`+[7_P")H_X5_I7_`#\7O_?:_P#Q-'/6_D_'_@!]6R[_`*"'_P"`?_;'5T5R
MG_"O]*_Y^+W_`+[7_P")H_X5_I7_`#\7O_?:_P#Q-'/6_D_'_@!]6R[_`*"'
M_P"`?_;'5T5RG_"O]*_Y^+W_`+[7_P")H_X5_I7_`#\7O_?:_P#Q-'/6_D_'
M_@!]6R[_`*"'_P"`?_;'5UI_#+_DGFE_]M?_`$:]<#_PK_2O^?B]_P"^U_\`
MB:N>#_AIHWB#PK9:I=W-^D\^_<L4B!1M=E&,J3T`[UTPJ5_JTUR*W-'KY2\O
M7[A?5<NYO]X?_@'_`-L>OT5YY_PIOP]_S^:I_P!_8_\`XBC_`(4WX>_Y_-4_
M[^Q__$5S<];^3\?^`/ZMEW_00_\`P#_[83X>?\C?XW_Z_P`?^C)J]$KQ+PKX
M!TK7->\1V-S<7B1:9<^3"8G4,PW2#YLJ<GY!TQWKJO\`A3?A[_G\U3_O['_\
M17=F-7$/$-SII.T?M7^RO(F&%RZW^\/_`,`_^V/0Z*\\_P"%-^'O^?S5/^_L
M?_Q%'_"F_#W_`#^:I_W]C_\`B*X>>M_)^/\`P"OJV7?]!#_\`_\`MCT.BO//
M^%-^'O\`G\U3_O['_P#$4?\`"F_#W_/YJG_?V/\`^(HYZW\GX_\``#ZMEW_0
M0_\`P#_[8]#KDOB;_P`D\U3_`+9?^C4K)_X4WX>_Y_-4_P"_L?\`\16'XP^&
MFC>'_"M[JEI<W[SP;-JRR(5.YU4YPH/0GO73@JE=8FFXP3?,NOGZ"EA<NY7_
M`+0__`/_`+8WZ*Y3_A7^E?\`/Q>_]]K_`/$T?\*_TK_GXO?^^U_^)KFYZW\G
MX_\``']6R[_H(?\`X!_]L=717*?\*_TK_GXO?^^U_P#B:/\`A7^E?\_%[_WV
MO_Q-'/6_D_'_`(`?5LN_Z"'_`.`?_;'5T5RG_"O]*_Y^+W_OM?\`XFC_`(5_
MI7_/Q>_]]K_\31SUOY/Q_P"`'U;+O^@A_P#@'_VQU=%<I_PK_2O^?B]_[[7_
M`.)H_P"%?Z5_S\7O_?:__$T<];^3\?\`@!]6R[_H(?\`X!_]L=717*?\*_TK
M_GXO?^^U_P#B:/\`A7^E?\_%[_WVO_Q-'/6_D_'_`(`?5LN_Z"'_`.`?_;'5
MT5RG_"O]*_Y^+W_OM?\`XFC_`(5_I7_/Q>_]]K_\31SUOY/Q_P"`'U;+O^@A
M_P#@'_VQU=%<I_PK_2O^?B]_[[7_`.)H_P"%?Z5_S\7O_?:__$T<];^3\?\`
M@!]6R[_H(?\`X!_]L=717*?\*_TK_GXO?^^U_P#B:/\`A7^E?\_%[_WVO_Q-
M'/6_D_'_`(`?5LN_Z"'_`.`?_;'5T5RG_"O]*_Y^+W_OM?\`XFC_`(5_I7_/
MQ>_]]K_\31SUOY/Q_P"`'U;+O^@A_P#@'_VQU=%<I_PK_2O^?B]_[[7_`.)H
M_P"%?Z5_S\7O_?:__$T<];^3\?\`@!]6R[_H(?\`X!_]L=717*?\*_TK_GXO
M?^^U_P#B:/\`A7^E?\_%[_WVO_Q-'/6_D_'_`(`?5LN_Z"'_`.`?_;'5T5RG
M_"O]*_Y^+W_OM?\`XFC_`(5_I7_/Q>_]]K_\31SUOY/Q_P"`'U;+O^@A_P#@
M'_VQTWAO_DITG_8&/_HX5Z+7B.D^`M+O_&+:1+<7@MQIYNMRNN_=Y@7&=N,8
M/I75_P#"F_#W_/YJG_?V/_XBNG$U*[Y.:"7NKK_P!1PN7?\`00__``#_`.V/
M0Z\[^,O_`"*%I_U_I_Z+DI?^%-^'O^?S5/\`O['_`/$5ROC_`,`Z5X5T&"^L
M;B\DEDN5A(G=2N"K'LHY^45KEM7$1Q=-PIIN^W-;\;"GA<NY7?$/_P``_P#M
MCVVBBBL#S#(\5?\`(H:W_P!>$_\`Z+:LGX9?\D\TO_MK_P"C7K6\5?\`(H:W
M_P!>$_\`Z+:LGX9?\D\TO_MK_P"C7KT8_P#(NE_C7_I+(^V=;5.75+*#5+?3
M9)MMY<(SQ1[3\RKU.<8'XFI+Z^M]-L9KV[D\NWA7?(^TM@>N!DUR=W/%>?$K
MP]/;N)(VL)I0P_NL.#7/AZ'M+N5[)/[TKCD[+[OS1TMMK>GW>ERZE!<;[.'?
MODV,,;,[N",\8/:J[^)]'CM].GDO0L6HL%M69&`D)Z=OEZ]\5RGAZ>)/AEK:
M/(JM";Q)`3]TDM@'\Q67J&DIJWAWP+ID[,BW$;+N'!4F+(/X'%=\<!1]I*,V
MTE)KY*+?Z"<G;3S_``/2FU6R35TTIIL7LD)G6+:>4!QG.,=?>KE>7^&M2N[[
MXBVEOJ*%=0L-.DM;G/1F5^&'KD$'\:]0KCQF&^K2C#NK_GMY#C*]_P"NAYE/
M_P`E#\3_`/;K_P"BJNU2G_Y*'XG_`.W7_P!%5=I8W^*O\,/_`$B(1V"BBBN0
MH*QEUVYE+F#P_J<T:NR"1'MP&VL5)&Z4'&1W`K9KGQ+]G\,RSG41I\<<TS27
M&Q6*J)6SC=QGTR#]#0W8"Q_;-_\`]"SJO_?RU_\`CU7=/OOM]NTAMIK9U<HT
M4Q4LI'^ZS#\C7&MXCUAK&PCE-W!)+;3W1F2"(R&-'`0NCX4?*P9@,'L,5U&@
MS+<6<TZ2+(LD[.'48#`@'(%.P7-6BBN8OK^]B\66MA;:B\[3L6EM$A39;P;3
M\[-@MNW8QS@]-O>EUL!T]%<_X>:^FOM1DDU6YO+**3[/")TB!+K]]LHB\9^7
M'L:Z"@`HJEJSM%IDT@OUL%0;GN60-L4=2-W&<="<_0]*XR;Q!K;:-920RW7F
M3"YECVQ1+/+$GW'<.`H4Y&[`!Y&!1<=CT"BJVGW'VO3;6Y\Q)/-B5]\8(5L@
M'(SVJS3:L[$IW5PHKF=4U"]M?$UC:6M\TTMQ(";%(5VQP`?/([8+`YZ'(';!
MZU!H6LZG)KD=CJ(N/-F@EEDCDM_+2%D=0!&V!O4ANN6^O:DM1O0ZVBBH;I)Y
M;61+:<03,N$E9-X4^N,C-`$U%<5%K&IR^7I;7TL=TVHR6SSF.,S1HL9D7<`#
M'N.!R!C!]:Z/P_?RZIH%C>SJ!+-$&?`P,]R*=M+@:5%%<]KEUJ&G:A97:WI6
MQDN(X9(_*38H8X)8GYR22`-N`._%+K8.AT-:?PR_Y)YI?_;7_P!&O7%Z;J.J
M3>+=0LKT11V\=NDD$49W$`NXW,V.I"@XZ"NT^&7_`"3S2_\`MK_Z->NR'^YS
M_P`4?RF2])V_KH=;16!=:YJ4&KS6,6CQRCR6DMV^V`,^,<NNW")DX#9)^4_+
M5_1-1DU;2HKR6W6!W+`JDGF(<,1N5L#<IQD'`R".*X^ERCB_AY_R-_C?_K_'
M_HR:O1*\[^'G_(W^-_\`K_'_`*,FKT2O1S7_`'I^D?\`TE$4_A.9N/B#X6M;
MZ2RGU41W$4AB=3!)A6!P1G;CKWSBM+4_$6DZ/IL.H7UXJ6DS!8Y45I`Q()&-
MH/8=:P/!HA,'B@7(0P?VO<>9O^[MPN<^U<C)]I_X5UX<^S;=_P#;0^R^=G;C
M>^S/?;].U=,<!0G4Y%=6:3U6MTWIIIMY@Y-7^?X'H>D>,_#^O7OV/3=0\^XV
M%]GDR+P.IRR@=Z2]\:^'-.U+^S[O5H8[D'#+AB%/HS`8!^IHTS_A+-\_]L?V
M/Y7E'ROL/F[]_;._C'6L3P=_9'_"N&_M+RO*_>_VCYW7?N.[?WST]^E8?5Z'
MO2LVDTK)IN[OK?E7;:WS"[V.Y1U=%=&#*PR&!R"*Y/XF_P#)/-4_[9?^C4KI
M-/-H=.MS8&,V?EKY/E?=V8XQ[8KF_B;_`,D\U3_ME_Z-2L<"K8RFO[R_,<OA
M9F4445Q%!1110`445RE]K,^G^)UA.I&>!4>>\A$2B.T@"DABV-V\L!U.",\#
MK0!U=%<IX0\2OK][JWF75M(B.C6\,3JQCC90>2.ISU]#D5U=`!16?K4OV?2Y
M9SJ(T^./YI+C8K%5'7&[C/ID'Z&N7;6-<DTC3)Y%U.*)EFFN+BV@A\P0J?D+
MB0;5)4AB`,\'`H`[BBHK::.XM89HI/,CD0,K_P!X$9!J6AZ`G<**YB^U&]MO
M%=K9V]\]RTK%Y;)(5V00!3\[-][<6QCD`YQCO47A?7;G4[J-KNXF4W=N;B*W
MEAC"X#`'RV4[L#(!#C)/(XH6H/0ZRLU-<MI462."]=&&59;60@CU'%:58EH7
M7PA;LEXEF5MU)N'4,(P.IP>.F>O'L>E#!%O^V(?^?6__`/`23_"K-G>17T'G
M0[]NYD(="I!!P00>>HKCAJ>J7?AH7D.J7L,DMT8+!S#"&N0Q`1W5HR`.I^4+
MD"NDT!)(]/DCEE,TBW$P:1@`7.\Y.!P,^U.P%G4+[[!;K(+::Y=G"+%"5#,3
M_O,H_,U2_MF__P"A9U7_`+^6O_QZK.J?\N7_`%])_6LC5-0O+7Q-8VEM?M-)
M<2*38I"NV.`#YY';[V<]#D#M@]:76P=+EUM=N8@'G\/ZG#%D!I&>V(7)QD@2
MDX^@-;->?VVMZA>RW$5W<,T$\<CPAT0(^R8*#%M^;;CKOYR1CBO0*.EPZV"B
MLW76MH](FFO;Z>SM8@'EEADV-M'\.1R,]/EP?0UQUI/K-QIMC/=C4X],D:X>
M/RGD-PHR/(\PK\Q&,\G(Z;J5QV.^\-_\E.D_[`Q_]'"O1:\E^&][/J7BBQO;
MG!GF\/*[D#&295R:],U?4DTG39KMHGF9!^[A3&Z5NRC/KZ]NIX%=N-]UPO\`
MRHB&NQ>KSOXR_P#(H6G_`%_I_P"BY*WK'Q8]YXCBTO[!LADA5_M'F,<.4#[/
MN;.AZ;]_?9M^:L'XR_\`(H6G_7^G_HN2MLI36.I7[DS=X,]$HHHKS30R/%7_
M`"*&M_\`7A/_`.BVK)^&7_)/-+_[:_\`HUZUO%7_`"*&M_\`7A/_`.BVK)^&
M7_)/-+_[:_\`HUZ]&/\`R+I?XU_Z2R/MG530QW$$D,R+)%(I5T89#`]0:RM'
M\+:)H,TLVF:?';RR\,X9F./0%B<#V'%7#J=L-2_L\><UQM#';`[(H.2-S@;5
MZ'J:9+K6GPRK%)<!7:Y%J`4;_6D;@O3T(YZ<]:Y8^W47"-[/IKJ4[=3.O/`_
MAK4-2.H76DQ27+-N9MS`,?4J#@_B.:U)]*L;FXLIY;<&2R8M;D,5$9(QT!P>
M/6JI\2:9YJQH]U,Q7?\`N+.:7`W,N250XY5NOI3CX@T\3S19NCY)<22"SF,:
ME02WS[=O&/6M)?6Y6YN;3;?1"]VY(-$TT:V=9%J!J!C\HS!CROH1G'XXS6A6
M?+K>GPK(S3L1$$+;(F8_/]T``'+'CY1SR..:L6=[!?VXGMW+)DJ0R%&4CJ"K
M`$'V(K&:JM*4[V6FOY#NCSJ?_DH?B?\`[=?_`$55VJ4__)0_$_\`VZ_^BJNU
MMC?XJ_PP_P#2(BCL%%(S*BEF(50,DD\`5G:/KMEKL=S+8,SQ03&$R$8#G`.5
M]1R.>]<A1I5R\UA%?:7_`&=J>CW\T27+RCRI0@)\QF4Y60'N#7444`<Y+9VD
M]I';3:/JTB1YVL]R6?!Z@N9=Q4]P3BM+1XGBMIMUNUN&F9DC;&0O&.A([4FJ
MZPNDH'>SNYXPC22/`@*Q(O5F+$#\!DGL#5^.1)HDEC.Y'4,I]0:`'UE1^'=-
MAU>;5(DN$NYF#2LMW*%<@8&Y-VT@#L16K2$X4DYX&>!FCS#R(+*QMM/@,%K'
MY<9=I"-Q.68EF.3ZDFK%9FF:W%J=Q/;BUN[::%5D,=R@4E&SM;`)QG!X.",<
M@5IT`4M5TFRUJQ:RU")I;=B&9!(R9(.1RI!ZU7D\.:;-;102I<2+$6V.]W*T
M@#=1O+;MI[C./:M6L_6M9M-`TJ;4+TMY,8^Z@RS'T`[F@-R]'&D,21QJ$1`%
M55&``.@IU-1Q)&KC.&`(S4=W=165E/=S';%!&TCGT51D_P`J&"\C/?0-+CU:
M76")XKN0J9)%O)45MO0,H;:0/0C%3Z?I6G63O/91`&3/S>8S@`G)"Y)"@GG"
MX&:KV>DQSK'>:I$EQ>N-Q$@WK#G^%`>!CIGJ>]9L9BFFN[O1=+FM);=W!G'E
MI!=,AVLC*K9.<8#%>,=>Q$#[G4U#=VD%]:R6US$LL,@PR-WIUO,ES;13QYV2
MH'7/H1D5)0!E_P#"/:8;(VI@DV&3S2_GR>:7QC=YF[?G'&<]..E:$$$5M;QP
M01K'%&H5$48"@=!5;4=2CTZ.+=%+/-,_EPP18WR-@G`W$#H">2.E3VMP+JUC
MG$<L8D7.R5"CK[$'H:`)JSYM$TZXU`7TMOF<%23O8*Q7[I90=K$=B02.U:%%
M`%=;&W34)+Y8\7,D:Q,^X\JI)`QTZDUM_#+_`))YI?\`VU_]&O7+0:XTNM?V
M7)I=]!)L:3S7,13:#C/RN2,GID`_D:ZGX9?\D\TO_MK_`.C7KKA_N<_\4?RF
M2_B_KR-"Y\'Z->7%_/-'>%K]=MRJZA<*CC`'W`X4<`<@#]:U+"QATVRCM+=I
MS%'G:9YWF?\`%W)8_B:BEUK2H+BXMYM3LHYK:/SIXWG4-$G]Y@3E5]SQ5BUN
MK>^M8[JTN(KBWE&Z.6)PZ./4$<$5R+;0HX'X>?\`(W^-_P#K_'_HR:O1*\[^
M'G_(W^-_^O\`'_HR:NZOM0M].A66Y,F'<(JQQ/(S,<G`502>`>W:O2S2+EBV
MDKNT?_241#X3#N/A]X6NKZ2]GTH27$LAE=C/)AF)R3C=CKVQBM+4_#NDZQIL
M.GWUFKVD+!HXD9HPI`(&-I'8]*M2:A:P^5YLAC\U&D3>C#A1DYR."!V/-4_^
M$DTG[(MR+EFB:-)1LA=F*NVU?E"YR6XQC-8>UQ<^5WD[;;Z>A6FY6TGP5X>T
M*^%[ING^1<!2H?SI&X/7AF(HOO!/AO4M1_M"[TJ&2Y)RS990Q]64'!_$59;Q
M)IZ>5N6_#R[MD?\`9]QO(7&3MV9Q\PYQCFIUUFP<[1*P<RK#L,3A][*'`VD9
M^Z03QQSG&#3=3&<WM&Y7[ZWMZBM&UBZB+&BHBA44855&`!Z5RGQ-_P"2>:I_
MVR_]&I6]::S87UTUO;RN9`"1NB=`X!P2C,`'`/4J3U%8/Q-_Y)YJG_;+_P!&
MI3P491QE)25GS1_-!+X69E%%5-0O38VXD6TN;IF8*L=N@+$^Y)``]R0*XBBW
M16%)XLL([2UNECN)(IX?M#%4'[F($`N^2.`3VR?05N@@C(Z&BP!65;^'=-M-
M4FU&!+B.YG?S)2+N78[8QDINVGCIQQ6K2,RHI9B%4#))/`%&VH$$-E;V]U<W
M,4>V:Y96E;<3N(&!].!VJQ6;H^NV6NQW,M@S/%!,83(1@.<`Y7U'(Y[UI4`4
M=5T>QUNT%KJ$3R0AQ(%65X_F'0Y4@\5!+X=TV>&&*9+B01!@KO=RERK=59RV
MYE/'RDD<=*U:S=5UA=)0.]G=SQA&DD>!`5B1>K,6('X#)/8&@>K-%$6-%1%"
MJHP%`P`*6F1R)-$DL9W(ZAE/J#3Z!+R,J/P[IL.KS:I$EPEW,P:5ENY0KD#`
MW)NVD`=B,5/::/86-W)=6\!65P0279@H)R0H)PH)Y(7&35ZLS3M;BU"\EM/L
MMW;31H)`MQ&%+H20&`R2.0>&P?:A`^YIUR/VG2KOPY'H^K6.JO&(U2:--/NP
M"1VW(G(R.QP:ZZLJ\9K_`%3^S%E:.&*)9[GRV*LP8D(N1R`=CYQSP!W-`&1%
M?^'8_L]N(=9D:VE\^)9K2^E9&P1GYE)Q@GCI6SH;^;822^7-&LES,ZB:)HVP
M7."58`C\15+6X_#NA:'+=7VFVPM8<,$2!2Q;MM_VL\Y_'-6],>2VNWL'DDD@
M,2S6SR'+!.C(3U.TXY/9AZ9H`FU593#;O%`\QBG1V1,9P.N,D"LG[!9_VQ)J
MJZ/JZ7DI4R.ET5#[>@*B7:0/0C%=+10!RSZ;;QK,UEH=[%/-\H9W4H@+!FV@
MN0@)&3M`S74UG:?J_P#:-S.D5C=)!$[Q_:7\ORW96VD*`Q;KGDJ!Q6C0'4H:
MMHUAKEF+3486E@#A]JRNGS#H<J0:A?PYILL,,<J7,GDL6C=[N9I!G@C>6W;3
MW7./:M6L?7=>CT801X@,T^XI]HG$,:A1DEGP<=0.G4B@-S1\,1I%\2FCC4(B
M:+M55&``)EP!7=ZGI.G:U:&TU2PMKVW)W>7<1!U!]0#T/)YKS_PA.]S\0EGD
MA,+R:'N,9=6VDS+QE20?J*]*=UC1G=@J*,LS'``]377C/L7_`)43#R,RT\-Z
M387<-S:6GDM#&(XT25Q&@"[01'G;NVC;NQG'&<5R'QE_Y%"T_P"O]/\`T7)7
M<QZGI\U[]BBOK9[ORQ-Y"S*7V'HVW.=OOTKAOC+_`,BA:?\`7^G_`*+DK?*6
M_KU._<4_A9Z)1117FEF1XJ_Y%#6_^O"?_P!%M63\,O\`DGFE_P#;7_T:]:WB
MK_D4-;_Z\)__`$6U9/PR_P"2>:7_`-M?_1KUZ,?^1=+_`!K_`-)9'VS0DT61
M_$8U`6UDHWJ_VL%O/P%V^7@@C:>N01_NYYJIJOAJ[O=0O[JWF@3S(5>V#Y^6
MY!7YVXZ8C3ISUK4URZO[.T\^R:U4("6$R,YD;C:B@$<L>,Y...#GBA9>*HK_
M`,5-I$;VP6.%]_[T&3SE*Y4#/0`GMS@]ARJ4L0U[2'1?@K#=EN5#X:OK:ZMW
MMXXYXXK*&W/_`!,Y[4[D+$DB-3O!W=_?UIQ\/ZB+G4,11%+EIBLG]J3@+O!`
MS!MV'KZ^_6IXO%#;YXKBVDB9;J2&*;RP8Y`LH3`^?.[!&<X'7&<8JKIWC&62
MU>XOH00D0DV6T66;]W$QQENN9#Q_ASM_M33=OQ?^=OZU"R3]/T+<.@W=CIKV
M-O\`9KJ'*2JMT[[O,'+?.!D9(R&Y(/&,8QJZ/:W=I8^7>2;GWDJOG-+Y:]EW
ML`S?4C/-9LGBZWCC=FTZ_P!\.XW$86,M``<9;Y\')_ND_A70UR5Y5N6U1;L2
M2O9=#S*?_DH?B?\`[=?_`$55VJ4__)0_$_\`VZ_^BJNT8W^*O\,/_2(CCL(R
MAE*L`5(P01P:R]'TR73KG5'<Q[+J[\Z()GY5V*N#QP?E/2M*63RH7D",^Q2V
MU>IQV%8GAOQ(/$*SE8(D$01MT,_FK\P)VDX&'&/F7G&1R:Y%UL4S>HHHH`YO
MQ3I6K:P;6UM1:OINXM=P2W#0M/CHNY4;"^OKTKH8P5B12BH0H&U3D#V'M6+K
M?B(Z1<"%+43%+9[N4O+Y86)"`VW@[FYZ<#W%;44BS0I*ARCJ&4^H-"V![CZ1
MMVT[2`V."1D9I:Q)/$D">(QI`@E.(9))+A@512H4[1D?-PPSCI0`FD:9?P:O
M=:C>_9(GGB6-X[0DI*RD_O6R`0Q&!CG`'4UN5B:'X@.KRF.2U$!>!+J'$N_?
M$Y(4G@;6XY'(Y')K;INX=0KG?%?AJ3Q#8NL-[+!.L,D<2?)Y3%AC+91CTXR,
M'!/K6QJ-_'IME)=2I*ZK@!(D+,Q)P``/4UA3^,8K?PU8ZL;&9Y+Q%=+=#G:"
M0"6?&`!D?7M2'>VIT-I"]O9PPR2M*\:!6D;&6('7@`?D!3-0LX]1TVZL9<^7
M<PO"^/1@0?YU9HH>I*T1FZ7J:W*_9;DB+481MF@)P21_$OJAZ@_UR*YA=,DT
MG6&^R0Z?#>2QRHD-FS%KDNP(DF!&55.>2S=<`C(!V-2U#3;W7[;0;O2TO1(&
M9Y)X0T:$*&`&X?,<8Z=*32+N&RU?^QET:UTWS(GGB2V=3\JL`2ZJH"DYR,%L
M\]#0M]!F[;0+:VD-NI)6)%0$]P!BI:*@O+J*QM);F;?Y<:[B$0LQ]@!R30!F
M>(=$_M=+1UB@G>UE,@@N#B.4%2I5C@\?-GH>E6]%L9M-T>VLYY_.EB3#/^/0
M>PZ#Z5EQ>)KBZ\-KJ\&FJO[R19$N;D1+"J,P+.V#C[O0`\GTYK:T^[_M#3;:
M\$3Q>?$LGEO]Y<C.#3LU<"S116->>(8[;Q#8Z.MM+))<L0\N"$C^1F`SCYB=
MO0=._;*`FT[3Y[?5-4O;AHV:ZE3RMO)6)5`"GC^]N/XUTWPR_P"2>:7_`-M?
M_1KUR<'B&*Y\43:+#"S>3`9'N,_+N!`*`8YQD9.?:NL^&7_)/-+_`.VO_HUZ
M[(?[G-_WH_E,E_'_`%Y$LFFZX?$-U>)9Z2MNJ-]D<7#JY9@H8R*(_O$+C<'.
M`!P:T_#FFSZ3HL=I<%/,#NY5)6E";F+;=[`,^,_>89/4U(FNZ=)JLNF+.WVJ
M($L#$X3@`D!R-I(!!(!R`>15FQO[74[&*]LIEFMIANCD7HP]17&MBC@_AY_R
M-_C?_K_'_HR:NOUW33J4%NOV*RO1%+O,%X6"'Y2,Y`(R,]U/X'D<A\//^1O\
M;_\`7^/_`$9-7H%QYPMY/LPC,^T^6)"0N[MG'.*]3,9.&-;7:/\`Z2B(?"86
MHZ!<W>B:=9)<JTULR+++)GYTVE)/Q*L<>^*HOX5O!9:I$DD+M/=QR6R^:\6V
M)9?,V%E&5.6?!&<<5;;6=4@TMYVBM;ADO4M_/0-'&Z,ZJ6526.06*]>HS[59
MU?7GTG4H(FM99[9K:6>5HE!:,(4^8Y8?*`QR!D],"IA/$IJ$;/5O[K,++?\`
MKL9<WA_5)9;286T8\A94,?\`;MUN._80?-V;OX3\O3H:M6?A^\M=5EU4/&+F
M21`8FG>1/*\M%<;B,[LIG=C)P`<9XKOXKG&H/$@B-NN_Y_*.[Y1<'IOP?]2O
M<9YZ9XMCQA:!F5[.]&&=(WV)B=U=4*I\V<[G4?-@<]>#5S^M6Y;;KSV;OU?_
M``07*R72M,U&UU'S)?LT%N$96CMYY&24DY#"-AB+'/W2<YYZ5G_$W_DGFJ?]
MLO\`T:E=#INHIJ5LTRP30%)&B>.8`,K*<'H2/UKGOB;_`,D\U3_ME_Z-2L\+
M*4L=2Y]^:/YA+X69E4M4CO);39:16<VXXEAN\A)$((*Y`./Q4^F*NT5YQ9QD
MOA"^_L^.V2YAD,MF]E.TC,/+C9]PV8!SM!*@''&.1TKL44(BH.BC`K(U[5=0
MTJ..6UL+:Z1W6,+)=-$[.QP%4"-@?J2.];"[BH+`!L<@'.*=]!6U%I&4,I5@
M"I&"".#2TR63RH7D",^Q2VU>IQV%)[#1FZ/IDNG7.J.YCV75WYT03/RKL5<'
MC@_*>E:M8/AOQ(/$*SE8(D$01MT,_FK\P)VDX&'&/F7G&1R:WJ;OLQ(*YOQ3
MI6K:P;6UM1:OINXM=P2W#0M/CHNY4;"^OKTKI*PM;\1'2+@0I:B8I;/=REY?
M+"Q(0&V\'<W/3@>XI=2C:C!6)%**A"@;5.0/8>U/ID4BS0I*ARCJ&4^H-/H9
M*V`YQQUK"TW2]0CUN;4KTVD3/#Y+K:9Q<$'B1@1D$#@#+=>M2'Q%%_PDR:,E
MO*3Y3N\[`JBE=IVC(^;AADCI3-&\0C5;D1-;K$LT/VFV82[O,BW;<D8&T]..
M>O6A=QO;4W*Q[V0:5JYU*;Y;*:`17$I;B$H258CLIWL"W;"]NFQ5>^O(K"SD
MN9E=D0?=C0LS$G```ZDDT`8'BW0TU[27FCU0VQ2WD6,ET\@[A@EB58CCC(P0
M"?6K6AF2[F^UEI7MX8%MH)I5"F?'+R#`'RDA0.!G:2."*PWU30;?1K3Q!_PC
M%M]MN6)14MT+IAMI9I`O&,C\\#-=S3Z6"]PHHK'F\01Q^)+;1DMI7>4,7F(V
MHA"[@!Q\QP>W2D!1TCPY-I^N&\$%C:1*LJO]D+9NB[!@T@8<%><?,W4]!Q73
M5C6FMSR:Y_9=W9+;R/"T\6V<2-L5@OS@#"YR",%N_2MFCH@ZA6)K>D37E[8Z
MA:)!)=6GF*L<[%5977!^8!B".#T/I5_5+R:QT^2>WM'NIA@+$A`R?4D]`.I-
M82ZYJ]SX0LM:@2T1GM_/N`89)2.,A413DY/<GCKS2>UQK<T_A]IAT;QC;:<9
M3*;?0MA?U_?#]*[[Q/I-YK>BR6%G=6]N9#^\^T0&5)$P<H0'4X)QW]L'-<1X
M)NFOO'4-VZHK3:")"L;AU!,JG`8=1[UZ)J.HVVE6;75T91&&5<10O*[$G``1
M`6)R>PKMQRNX)_RHBF^J.;TWPSJ=KKMC<S7,7V:"-7F6*3Y99Q#Y181F/<HQ
MCGS&''W03FLKXR_\BA:?]?Z?^BY*Z^W\1Z9=:FNG1R7`NF0,%DM94`RH;:69
M0`^T@["=P':N0^,O_(H6G_7^G_HN2MLJ;>.IW[DS2478]$HHHKS30R/%7_(H
M:W_UX3_^BVK)^&7_`"3S2_\`MK_Z->M;Q5_R*&M_]>$__HMJR?AE_P`D\TO_
M`+:_^C7KT8_\BZ7^-?\`I+(^V;VHZ/9ZI)!)="??`28FAN9(BI(P3\C#M5C[
M+`+F.Z*DS11M&KEB2%)!(]_NCGKQ4]8_B#2YM4AMEBCMIUBE+O!<DB.0;2!G
M`/()!'';MUKDIR<FH2E9?U^95D):Z)HUP/M\$+.MS^_#&63!W,'W!2<*20"<
M`=`#4D?AO28H_+2TPI4+CS'Z84>OHB_E]:YD>$+W[39R7JV/V:VM_)G:W4F6
M:/R"A4@1[F(;D?-@\?+D"FZ=X6U*4Z=JLWE-J)D\V>:Y`!5<J`/+9&PVQ0,A
MD(/<UWN"W5?^M;=?+\5H3=VV-K5_"46IW22Q7'V>-B3<(%8F7+`GD,/3HP8#
MJ`#S71T45YTZTYQ49.Z6Q5E>YYE/_P`E#\3_`/;K_P"BJNU2G_Y*'XG_`.W7
M_P!%5=K?&_Q5_AA_Z1$4=B*Y@6ZM9K=F95E0H2IP0",<5DZ'H#Z3-)--=BXD
M:".V39%Y:B./.W(W'+<G)X]@*CAUZY?Q)=V$UGY%I!:F99'^_)AL$@`\+Z=S
M3?"NMW&LVK2W4\/G&-)/LZ6<D#1!LXSO8[P>S``<&N1=U_6__!*?;^NG_`.A
MHHJCJ]]/I^FRW%M:/=3*/DC4@#/JQ/11WI-V&E<IZ_H']NK%&\T"Q*K*ZRVJ
MRG##&Y&."C@9P>1ST-:\4:PPI$@PB*%4>@%<E-XMN1IVDLOV>*ZN['[9(SP2
M21J!MR,)\P&6^\<A0,G-=;"_FP1R94[E#90Y7GT/<5336A-[V'UFW>D+=ZS:
MW[2X6""6$Q;?O!]O.<\8V^G>M*L&36KS_A+(M(6S\JV>&5Q<2\EV79]T`_=&
M[G/4_2EOH4A^B>'_`.R)C(]R)RENEK#B/9LB3)`/)W-SR>!P.!6W6'HEYJMU
MJ-_'=SV<]K;,(ED@MGB+2=6'+MD#('USZ5N4V[B$==Z,N<9&*PO^$;_XI"'0
M/M?^KC1//\OKM(.=N?;UK3U&ZELK&2>"UDNI1@+$A`R2<<D]`.I/I7+7/BW4
M$\.Z1?I%`LUY`\T@$$DP!5<[0BG<`?[Y.%[]:5QV;.THJ&TF-Q9P3L%!DC5R
M%;<!D9X/<>]0ZK<2VNF32P8\[`2,L,@.Q"J3[9(IM69*=U<H:F;+^W=/N)K^
M.*:T60^1C<S!QC/!R`/I5'POIYAU'4+W^V;+4Y9W/GNEN5F0_P`*$^8=J@=%
MVCKFI(KR72_$-EHUO8D6TPD:6[E/SSR!`V1ZGGDGZ"L)O$QN)I+V46Z7MI:S
M782!2)84B8;X)<GYMRG/08.#CH:2WT&]CT*BBH;HW`M9#:"(W&/D\XD)GWQS
M0!DVVB7MAI26ECJ:QR+/+*7DM@Z.'9FVE=P/&[J&'3\*T-*TZ/2=*MK")W=(
M$VAG/)KF[?Q1?W4:6T#V;W,E\]I%>"%_(<)&79@F_/4%?O=1G/:NAT74?[6T
M:TO]@0SQABH.<'N/SI@7ZS[_`$S[;J.FW?G;/L4K2;=N=^4*XSGCKGO6A6!K
M6KWVEZC9A3:-!<SQP1V^UFFE+'YF!R`H4<]#D#J*2WL'0++PE9:=KZ:G:RW"
M*L+Q^0UQ*ZEF;<6^9R,=>,8R<]:[+X9?\D\TO_MK_P"C7KC].UN[O?$M]ITM
ME]G@@A62(O\`?DR[+NX.`#MX'7OWQ78?#+_DGFE_]M?_`$:]=D/]SG_BC^4R
M7\?]>1/?>&M1U/4[R6ZUI5LIXO*ACAM,36ZG!(5V9D.XCG,9R#CI6KH>EOHV
MD0V#WDMXT98^=*BJS98GHH`XSC@51U+Q;:Z3-=K>65['#;0O*+AE18Y=@!8*
M2P/&X?,P"Y_BZUI:1J<>L:5!J$431QSKN56DCDXSUW1LR'/7AC7&MBGN<1\/
M/^1O\;_]?X_]&35WUU;17MI+;3AC%*I1PKE20>O(((_"N!^'G_(W^-_^O\?^
MC)J]$KTLT;6+;7:/_I*(I_"9\.BV,%A]A59GMPZN%EN))""I!7!9B0`5'`.*
MCO=-TO5[W;<QM)/;)M($CI\KX.TX(#`[1D'(XJ_<Q-/:30I(8WD1E5QU4D8S
M^%<3+X.U"33YK5;/1HDFVAD7Y@I"D>8NZ(C<2<D8[_>SR<L/[[<I5.5_Y[]>
MPWI96.G/A[2FD:0VOS-NR?,;^+?GO_TU?\_88AO_``U975@\$"B"7YS'*=S;
M"[AV.,CJ5'0@CL17-/X5NKZ[N;28-+;PVT;%7+1H]V45697*MN`5!_"02Y![
MBNOT2SN+#1[>UNC"98P1B!0J`9.`,*HX&!D*,^@Z5=5RI)3C5N]-/EZBB_(3
M1-*_L?31:F8S.9'D>0@C<S,2>I)[]R3ZDUA_$W_DGFJ?]LO_`$:E=;7)?$W_
M`))YJG_;+_T:E1@IRGC:<I;N2_-#DK19F445F:]J5QI6D375K9M=3*I*IG"K
M@$[F/91CZUPMV5RTKNQ)>Z;]MU'3KIIMJ64CR>7MSO8J5'.>,9/:K]<MJWBF
M>PT73YX((Y;VY2&212#LC1BH9CSGJV`,]?H:ZFJ:L2G?4*BN8%NK6:W9F594
M*$J<$`C'%2USYU^Z'BF33I++R;)+62832?>D*%02H!X7YN_)_G+L]&4K[DNA
MZ`^DS23378N)&@CMDV1>6HCCSMR-QRW)R>/8"MNN>\*ZW<:S:M+=3P^<8TD^
MSI9R0-$&SC.]CO![,`!P:Z&JE>^I*MT"L77]`_MU8HWF@6)59766U64X88W(
MQP4<#.#R.>AJYJ]]/I^FRW%M:/=3*/DC4@#/JQ/11WKG9O%MR-.TEE^SQ75W
M8_;)&>"22-0-N1A/F`RWWCD*!DYI;E'6Q1K#"D2#"(H51Z`4^F0OYL$<F5.Y
M0V4.5Y]#W%/IO<E;:&=<:6+C7+/4C+@6\,L7E[<[M^WG.>,;?3O571_#HTJY
M64W`E6&#[-;*(]ICCW;L$Y.XYQSQP.E-?6[O_A+8=)%GY=J\,C^?)UD9=GW0
M#]T;NIZGZ4:1>:M<:S?6]U<64]I:A4,D%L\3&4\E>9&!`!&?<^U)#?F;M5+Z
M_BL@BE9)9I<B*&(9=R.N.P'N2`/6K=8?GR0ZAK%V+26XN(3'!#$A&60JK<9/
M`+.V2?[OL*3V`R6TO4(O"`T>2RE:,$9EB*.X&_>24W`<>S$^F>E=9:74%[;)
M<6\@>)NAQCIP00>00>"#R*X^?Q?J2>']-OA#;I/<I,\@6&28#9G"A5(;!QRY
MX'<<UN:/*[ZG>$1JL,T%O<G8^Y?-<.&`/T1#GOFGW$;59]WIGVK5M/O_`#MO
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MQ`'S2,JCKU+"NW';PO\`RHBGMH9FF>%+C3M3@F_M-9;.%A*(3;D2&40B'/F;
M\;=HSMVYSWK"^,O_`"*%I_U_I_Z+DKL;;6[>YO[>Q\FXCGFM?M0#*"JKE1C>
MI*L?F'W21[],\=\9?^10M/\`K_3_`-%R5ME5_KM*_<F=N5GHE%%%>::&1XJ_
MY%#6_P#KPG_]%M63\,O^2>:7_P!M?_1KUK>*O^10UO\`Z\)__1;5D_#+_DGF
ME_\`;7_T:]>C'_D72_QK_P!)9'VSK:***\XL****`"BBB@#S*?\`Y*'XG_[=
M?_157:I3_P#)0_$__;K_`.BJNUUXW^*O\,/_`$B),=BD^EP/JC:@7E$S6_V8
MA6P`N<Y&.0??-0Z=HL6GW4MTUS<W=S(BQ>=<,I81KDA?E`XR3R<D]R:RQJ%]
M_P`)<=.M]1-T"CR7">0HBM%Q^[Y'S%B>Q;D9.!4GAK4;N]OM1C-X]_90%$2[
M>-$#R\^8J;0`5'R^ISD9-<BVT*9T=,FB6:"2)B0KJ5..N#3ZS]:E^SZ7+.=1
M&GQQ_-)<;%8JHZXW<9],@_0TG:VHUOH5)?"]G)I]G:+/<1?9;?[*LJ%=[1$`
M,IRI&#@9P`?3%:\$$=M;QV\*!(HD"(H[`#`%<A+?Z^_@Y-76YE@EA22388(P
M\J!OD:3=PHV<L%`;TQTKKX)5GMXY4975T#!EZ$$=15.^MR>Q)5.7389M6MM1
M9I!-;QR1HH(VD/MSGCK\H[U<KEM1U6YL?%%O;IJ)F5\R3VHB41V]N%.7=OO;
MMW3D`],=Z749NZ;IL.EVK00-(RO+),S2$$EG8L>@'<U<KD?"GBAM?UK5$-W;
M/;JL<EK#$ZLR(<Y+8YS]W([9`KKJ;"]Q&4,I4]",5A-X4L_[/L;2*YNHC9PM
M!',C+O,;`!E.5(YP.V?3%:.K.T6F32"_6P5!N>Y9`VQ1U(W<9QT)S]#TKE!J
M^N7.BZ?-&-3\N2:9WN(((1*UNH.QF$@V*3E3P,G'`I=QZG9VUM%9VL-M`@2&
M%`B*.P`P!4=_:"^L)[4R-&9$(610"4/9AGC(.#^%+87,5YIUM<P3&:*6)724
M@`N".IP!S^%6*;O?4E6MH<\US;/J%G/J_FV=]8A\9!$,F\8)#XP>G3(([BJ?
M]G1:C<O#;/>7D,JM%+<W8S'%`Q!>)"0"^[IGYL#OP`9]4U&\M?$UC:6U^\TE
MQ(I-BD*[8X`/GD=L%LYZ'(';!ZU!X=UZZU'4T-U<3(MTDK0V\D,80['V_(RG
M=D#[P<<DY&`*2U&^QUM5-4L%U33+BQ>XG@2=-C20,`X!ZX)!QZ=*MU7O?,^P
MS&*Y2V<*2)G4,(_?!(%)[:C6YE1>%X8=,M[);^\_T5]UM,%A5X?E*X4+&%(P
M3U!ZUK65G#I]E#:6ZE884"("<\"N0BU:^N/#%[J`U.^6&*X*V-PL<*R7:G"K
MD-&5P7)`(`XQ76Z=%=0:=;Q7MR;FZ5`)9BH7>W<X``%4[DEFL2;PVDOB(:VN
MHWL=P$$8C`B9`@Y*C<A(SW((/O6W7-:YJ%[9ZY806E^TD]Q*@6P2)2/*S^\D
M=B"P`'0@CGCFDMT/HS93384UB;4PTGG2P)`RDC;M4DC'&<_,>];_`,,O^2>:
M7_VU_P#1KUYWHFN:C=>)/)N;DM:3M<K%N1!&_EN`/*Q\_`SNW]3]WBO1/AE_
MR3S2_P#MK_Z->NR'^YS_`,4?RF2_C_KR+\GAEGU6]U#^V]45KI-@C4Q;80,8
M\L^7N&",X+$$DY!K3TVP73;,6ZS2SMN9WEEV[Y&8DECM`&23V`'M6)J_BJYT
M:\NDGTL-;QPF2%XYR\DARH&8U0E5+-@$%F)!^6M?1M1;5=*AO'C2.1\AXU+_
M`",#@CYT1@1CH5!]JXUMH4SBOAY_R-_C?_K_`!_Z,FKT2O._AY_R-_C?_K_'
M_HR:O1*]'-?]Z?I'_P!)1%/X0HHHKSBPHHHH`*Y+XF_\D\U3_ME_Z-2NMKDO
MB;_R3S5/^V7_`*-2NO+_`/>Z7^*/YHF?PLS*AN[9+RSGM9"P2:-HV*]0",'%
M35F:]<?9-*DN7U/^SH8CNEG6-6;;Z+NR,DX['Z5QNUM2U>^A5O\`PCHVIV$-
MK=V<4C0QQQI<-$AE"H00-Q7H<<_4UN(BQHJ(H55&`H&`!7&SZSXACT71+AHD
M@^T7$*W,DH'F%6D"A=F,`E3DGMT'MV=4[[^9*L%49M+@GU1-09Y1,EN]N`K8
M&UB"3ZY^4<@U>KF+B_OT\6PZ?:ZB;@R!WG@\A?+M8MIVL3][<6QU;!&>!UI=
M1]#4T[18M/NI;IKFYN[F1%B\ZX92PC7)"_*!QDGDY)[DUIUSGAK4;N]OM1C-
MX]_90%$2[>-$#R\^8J;0`5'R^ISD9-='38#)HEF@DB8D*ZE3CK@UCR^%[.33
M[.T6>XB^RV_V594*[VB(`93E2,'`S@`^F*MZU+]GTN6<ZB-/CC^:2XV*Q51U
MQNXSZ9!^AKG);_7W\')JZW,L$L*22;#!&'E0-\C2;N%&SE@H#>F.E+N/6Z.O
M@@CMK>.WA0)%$@1%'8`8`J2HX)5GMXY4975T#!EZ$$=14E-WOJ2K6T*<NFPS
M:M;:BS2":WCDC101M(?;G/&<_*.]&GZ=#IL<ZPM(WGSO.[.03N8Y/0#@=!]*
MQ+[4KNU\5VMI%J#3^82\UHL2!+>W"G+NWWMV[IR`>F.]5O#/BS^W_$NHPI>6
MSV8@CDM(8W4L!N8,6QSDX4D=@1WH6NPWYG85SE]<W37KWVDV5Q)/'N@D5@HB
MG"D\$YRI!SAL'J>#71UB0EUT:_9+Q+,K<SDW#J&$8$AR<'CIGKQ['I4O8$<Y
M/IEX=-M+6ST;4H)[=7C6=KB'[DA^<'@[@?H#P.1UKI/#-O!9V#VL<<J30L%F
M\U`ISL7&`"0%"[0!D\#G)YKGDUG6[O2K2:`ZF]J]S*WVN&"`2O;*ORLPD`09
M)SP,D#@5T6@W,5XUY<P3&:*5HG24@`N#"G)P!S^%5_7]?UW%<T;R\6RB5VCD
MD+.$5(P"23]2!67<-]IU&SOGTS4A+:;_`"P/*P=PP<_-5W5/^7+_`*^D_K61
MJFHWEKXFL;2VOWFDN)%)L4A7;'`!\\CM@MG/0Y`[8/6EU'TN.MA'I]VU]<6^
MK2D`QI)=-&X@1F!(!!R1G'7)XKI*X*WUZZU&.0W5Q,BW2.T-O)#&$.R4+\C*
M=V0/O!QR3D8`KO:?1!U,O7]#A\1:6VGW%S<P0LP9S`R@MCG!W`@CVQVJ&3PX
MDMK;QOJ%X9K?<(KE1$KJC#!3"H%VX_V?Y"K&NM;1Z1-->WT]G:Q`/++#)L;:
M/X<CD9Z?+@^AKDEDN[CP6EW<_;X[F>Y,6FHU[-&X21PL?F%6!;`Y^;)Q278?
M9G9^$+2&Q^(*VENFR&'0_+1?0"90*]!U&R>_M?*CO;JRD#!EFMBN]2/9E92/
M8@BO/?!MJ;+Q^EL9I9S%H>TRS.6=R)EY)/)-=SX@U2XT?27N[6QDO9@ZJL*+
M(>I`)/EH[8`YX4UV8W>%_P"5$0V'6NB6MG<6<T32YM+5K6,%@05)4DGCK\@_
M6N-^,O\`R*%I_P!?Z?\`HN2NDLO$%Y<ZI9VTFGP"WNH?,2>&[\PY"ABVPH#Y
M>3MW$@Y_A`.:YOXR_P#(H6G_`%_I_P"BY*VRF_UVEZ_YDS^%GHE%%%>::&1X
MJ_Y%#6_^O"?_`-%M63\,O^2>:7_VU_\`1KUK>*O^10UO_KPG_P#1;5D_#+_D
MGFE_]M?_`$:]>C'_`)%TO\:_])9'VSK:***\XL****`"BBB@#S*?_DH?B?\`
M[=?_`$55VJ4__)0_$_\`VZ_^BJBU*[F,B:=9-B[F&3)C(@3NY]^P'<^P-=>-
M_BK_``P_](B3'8P)?#T%QJ5\FBR7%H2S/>3_`&J5DFE8?<V;L=/O$`$#`4@]
M-7PQ9:?96!CL(KBW,9\J6UENI)1`P_A`=B`.<@C&00:P((I+?5[FR\/WEUY5
MG#*+NYNK@O"DA7*(`>-P/S,V,_WB2:CT234H-6NKJ*&Y=8;6!YXY;@3M.&W[
MBK!FYXW*,]"1@9&.1;%/<[^J.JZ/8ZW:"UU")Y(0XD"K*\?S#H<J0>*M03Q7
M5O'/!(LD4BAD=3P0:DH`R9?#>F3Q0QS13R^4&56DNI6<J3DJS%LLI_NL2/:M
M55"J%4`*!@`#I2T4`%94?AW38=7FU2)+A+N9@TK+=RA7(&!N3=M(`[$5JT4`
M5XK*WAO9[R./$]P%65]Q^8+G''0=3TJQ110!2U72;+6K%K+4(FEMV(9D$C)D
M@Y'*D'K5=_#NG2V\4,BW+B(DH[7DQD`/4;]VXJ?[I./:M6B@!D44<$*0Q(J1
MHH5$48"@=`*?110!E?\`".Z;_;$FK*EPEY*5,CI=RJ'V]`5#;2!Z$8J:WT:P
MM;][V&`K.X(R9&(7)RVU2<+D\G`&>]7Z*`"JVH:?;:K836-Y&9+>9=LB!V7<
M/3*D&K-%`&9'X?TZ.R2SV3R6Z2I*J374LFUD(*X+,2`"!QT]JTZ**+@%94GA
MW39=8;52EPMZP56DCNY4#!>@*JP!'MC%:M%`&?:Z)IUG?/>6]OLF?<?]8Q5=
MQRVU2=JY/)P!GO71_#+_`))YI?\`VU_]&O696G\,O^2>:7_VU_\`1KUUP_W2
M?^*/Y3)?Q&HWA;27O[R]:.Z,MZ,3C[;-L;@`'9OV@C`P0`1VK0L+"WTVT2UM
M598E)/SR,[$DY)9F)+$DY)))-6:*Y"CSOX>?\C?XW_Z_Q_Z,FKT2O._AY_R-
M_C?_`*_Q_P"C)J]$KT<U_P!Z?I'_`-)1%/X0HHHKSBPHHHH`*Y+XF_\`)/-4
M_P"V7_HU*ZVN2^)O_)/-4_[9?^C4KKR__>Z7^*/YHF?PLS*Q/$UE9:A906]U
M;O<S&8-:PI.\69!T8E""`O))[8XYQ6K=7,-G:R7,[[8HURQQG\AW/M7-:MY,
M&FOK&L2W<$TA5([>VE*R;3]V%2O.YC@G:1D@<X%<;+18M;!;9;?1]6FEO$\P
M3VEQ-(Q9G4[]K'.25(R,GE1CG:2>CKS+6WU==,LX;V>9;BWT][N91<LK0D2#
M:P*_ZUU'&UL`GG-=YI5_)<(UM=8%["!Y@`P'4_=<#L#CIV(([573^OZZ$_U_
M7WFC6.OA?2DO+J[1+I)KLEI]E[,JR$C'*A\=.G'':MBBD,SM)T.QT.'R+!9X
MX<!1&]S)(J@?W0[$+U[8K1HHH`HZKH]CK=H+74(GDA#B0*LKQ_,.ARI!XJO+
MX;TR>*&.:*>7R@RJTEU*SE2<E68MEE/]UB1[5K44`(JA5"J`%`P`!TI:**`,
MJ/P[IL.KS:I$EPEW,P:5ENY0KD#`W)NVD`=B*NI8VT=_+?+'BYEC6-WW'E5)
M(&.G\1_.K%%`!7-3P6=WIU[I>J6-[+!+<R,RQQ2X92Y8?,G;IWKI:*`.8-EH
MS6\<+V>L,L1)1F-T7`(`*[R=VTX'RYQ[5I:,BK)>M%;206YD01(\1C^58U'`
M/;C'X5JT4`9^K;EBMY%CDD$=PCL(T+''/.!S65]ET<:Q)JJV6KI>2%3(Z?:5
M#[>@*@[2!Z$8KI:*`.6N+73B9Y;/3KX7<WR@M#+M7+`MM#?*F2,G&,]ZZFBB
M@"AJVC6&N68M-1A:6`.'VK*Z?,.ARI!IHT.Q\FWB=9Y5MYA/$9[F21E<=#N9
MB3UZ$XK1HH`B\-_\E.D_[`Q_]'"NZU'3;;5+7[/=+)L#!@T4SQ.I'0JZ$,I^
MAKA?#?\`R4Z3_L#'_P!'"O1:Z\7_`,N_\*)CU,>S\,:5I^J'4;6.YBN"BQD"
M\F\LJJ[0#'OV'`]O?K7)_&7_`)%"T_Z_T_\`1<E>B5YW\9?^10M/^O\`3_T7
M)6V4_P"^T_453X6>B4445YQ9D>*O^10UO_KPG_\`1;5D_#+_`))YI?\`VU_]
M&O6MXK(7P=K9)``T^<DGM^[:N6^'/B+1+7P%IL-QK.GPRKYNY)+I%8?O7/()
MKTZ<)3R^2BK^^O\`TED-^^>@45D?\)5X=_Z#VE_^!D?^-'_"5>'?^@]I?_@9
M'_C7%]7K?RO[F5=&O161_P`)5X=_Z#VE_P#@9'_C1_PE7AW_`*#VE_\`@9'_
M`(T?5ZW\K^YA=&O161_PE7AW_H/:7_X&1_XT?\)5X=_Z#VE_^!D?^-'U>M_*
M_N871Q,__)0_$_\`VZ_^BJJ6^E:A;37,L>I1,\\A=GDMLMC^%<AAPHX'^))I
MLVL:8?'?B*X&HV9@E^S>7)YZ[7Q%@X.<'!JW_;>D_P#04LO_``(3_&NK&4*K
MJ*T7\,.G]U$Q:L9T7AI;>\-Y#'I,=TQ),R:8H<D]?F#9YJS:Z5=V,1BL[BPM
MXRQ8I#8[`2>IP'ZU8_MO2?\`H*67_@0G^-']MZ3_`-!2R_\``A/\:Y?J];^5
M_<RKH;I>G3:>USON5E2:3S!&D6Q48_>QR>IY^N?6M&J']MZ3_P!!2R_\"$_Q
MH_MO2?\`H*67_@0G^-'U>M_*_N871?HJA_;>D_\`04LO_`A/\:/[;TG_`*"E
ME_X$)_C1]7K?RO[F%T7Z*H?VWI/_`$%++_P(3_&C^V])_P"@I9?^!"?XT?5Z
MW\K^YA=%^BJ']MZ3_P!!2R_\"$_QH_MO2?\`H*67_@0G^-'U>M_*_N871?HJ
MA_;>D_\`04LO_`A/\:/[;TG_`*"EE_X$)_C1]7K?RO[F%T7Z*H?VWI/_`$%+
M+_P(3_&C^V])_P"@I9?^!"?XT?5ZW\K^YA=%^BJ']MZ3_P!!2R_\"$_QH_MO
M2?\`H*67_@0G^-'U>M_*_N871?HJA_;>D_\`04LO_`A/\:/[;TG_`*"EE_X$
M)_C1]7K?RO[F%T7Z*H?VWI/_`$%++_P(3_&C^V])_P"@I9?^!"?XT?5ZW\K^
MYA=%^BJ']MZ3_P!!2R_\"$_QH_MO2?\`H*67_@0G^-'U>M_*_N871?K3^&7_
M`"3S2_\`MK_Z->N=_MO2?^@I9?\`@0G^-:/P[U_1K+P)IMO=ZO86\Z>;NCEN
M41ES*Y&03GH175"A5^JS7*_BCT\IDW7,COJ*R/\`A*O#O_0>TO\`\#(_\:/^
M$J\._P#0>TO_`,#(_P#&N7ZO6_E?W,JZ.2^'G_(W^-_^O\?^C)J]$KRSP%KN
MD6WBGQE-/JMC%%-?9B>2X15D&^4_*2>>HZ>HKO/^$J\._P#0>TO_`,#(_P#&
MO0S2A5>*;47M'I_=1$&N4UZ*R/\`A*O#O_0>TO\`\#(_\:/^$J\._P#0>TO_
M`,#(_P#&O/\`J];^5_<R[HUZ*R/^$J\._P#0>TO_`,#(_P#&C_A*O#O_`$'M
M+_\``R/_`!H^KUOY7]S"Z->N2^)O_)/-4_[9?^C4K6_X2KP[_P!![2__``,C
M_P`:YCXB:_HU[X$U*WM-7L+B=_*VQQ7*.S8E0G`!ST!KJP%"JL52;B_B73S1
M,FN5F7J6FSWUS:RQW:Q+;L7$3Q;U9^S'D=.<>_/4#%>]T6?4XEBOY-.NXU;<
MJ3Z>)`#Z@%NM6_[;TG_H*67_`($)_C1_;>D_]!2R_P#`A/\`&N7ZO5_D?W,J
MZ*'_``CI\FWAQI?E6[;H$_LU=L1]5&[Y3]*G?2[Z6_M;N74(M]NQYCMMI9#]
MY"=QX/'X@'M5C^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNB_15
M#^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNB_15#^V])_Z"EE_X
M$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNB_15#^V])_Z"EE_X$)_C1_;>D_\`
M04LO_`A/\:/J];^5_<PNB_15#^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J
M];^5_<PNB_15#^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNB_15
M#^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNB_15#^V])_Z"EE_X
M$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNB_15#^V])_Z"EE_X$)_C1_;>D_\`
M04LO_`A/\:/J];^5_<PNB_15#^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J
M];^5_<PNB_15#^V])_Z"EE_X$)_C1_;>D_\`04LO_`A/\:/J];^5_<PNBUX;
M_P"2G2?]@8_^CA7HM>6:!K6E0_$1[J74[..W.DF/S6G4)N\T';G.,XYQ7>?\
M)5X=_P"@]I?_`(&1_P"-=6*H57R6B_A70F+6IKUYW\9?^10M/^O]/_1<E=;_
M`,)5X=_Z#VE_^!D?^-<)\6-:TK4?"UK#8ZG974JWJ,4@G5V`V.,X!Z<C\ZVR
MJC5CC:;<7OV%4:Y6>I4445Y)H4]6TV'6=&OM+N&D6"]MY+>1HR`P5U*DC((S
M@^AKRO\`X9Q\'_\`02US_O\`P_\`QJO8**`/'_\`AG'P?_T$M<_[_P`/_P`:
MH_X9Q\'_`/02US_O_#_\:KV"F3-(D$C11^9(JDJF[;N/89[4`>1?\,X^#_\`
MH):Y_P!_X?\`XU1_PSCX/_Z"6N?]_P"'_P"-5VESXT:PNVL[_3&M[@10NO[X
M,C.[8:,,!]Y0=W^T,XZ&IK7Q+J-V('BTJW$-_$7TYWO"/-PN[$H$9\O*Y(QO
MZ<X-`=+G"_\`#./@_P#Z"6N?]_X?_C5'_#./@_\`Z"6N?]_X?_C5=*_CG68[
M3393X>MFDODDE1(;FYG"(I0<^5:L026[@`8Z\XKH==UU]%T.;4)+>",QRQQ_
MZ7<B&+YF5=QD`;:HW=2N>.E'F%M;'G/_``SCX/\`^@EKG_?^'_XU1_PSCX/_
M`.@EKG_?^'_XU78Q>/K5;'3KF[M1MO;G[*DMI=12PE]^U2C,R-(I/0JAZ'.,
M4[_A8.G,L30V&H3AHWDD\M(_W.P*65@7!W`NHP,\FBP'&?\`#./@_P#Z"6N?
M]_X?_C5'_#./@_\`Z"6N?]_X?_C5=W;>+TNM6M+`:?/#)-(8I4G=0\#A7;!"
M[E/"#HV/F]J9+X]TB"]GM)(KL20*S/\`NP1\ID#`<\D>43CT*^M`6.'_`.&<
M?!__`$$M<_[_`,/_`,:H_P"&<?!__02US_O_``__`!JNKU3XC6^F64TK:+J/
MG6\<DES#(8E^S*FPDN0YSD2(1LW'GMS6O>>++*Q\/VVLS071M[B,R1HBJSD>
M6S@8#8R0O&#U(HZ7!:NQY[_PSCX/_P"@EKG_`'_A_P#C5'_#./@__H):Y_W_
M`(?_`(U79/\`$C0(]0L[1Y71KH_(SO&N!N*@[2^Y@64CY5;&.<#FJD/Q2T6[
MEL%M(WF%Y=_9%V31,0Q7<A^5BO/H64CN,\4[,3:6YS'_``SCX/\`^@EKG_?^
M'_XU1_PSCX/_`.@EKG_?^'_XU7H>H^*+?3=5-C+8WKA8P[W$:H8TR'*J<L&R
M=C=`1TR1FJESXYL;>5HUL-0G95W/Y2(=J[8F).7'03+TYZX!XREKL,X?_AG'
MP?\`]!+7/^_\/_QJC_AG'P?_`-!+7/\`O_#_`/&J[6/QU;-=JDVFWL%OM7S9
MI-G^CN97BV2`-_?3`*[LY[#FJ]K\2](O[;S["UO+P!V#K;-#*454W[SMD/&/
MX?O=BH-`/1V.2_X9Q\'_`/02US_O_#_\:H_X9Q\'_P#02US_`+_P_P#QJO0$
M\6VTWA^TU>"SN9TNI5BC@@E@D?<21]X2&/C'/S?KQ6'_`,+1TVYB673;4W4*
M3[;J0W40$$(1W,IVLQ^ZC80@-QR%XR`M3F_^&<?!_P#T$M<_[_P__&J/^&<?
M!_\`T$M<_P"_\/\`\:KN-$\=:?X@N;6#3K:XF,WF^8Z20.D&S;G>RR$'.]<;
M-W7G&#1:>-(I9TAN-,O829S"\O[MHXLS-%&6(?/SLI'R@X[X'-.S`X?_`(9Q
M\'_]!+7/^_\`#_\`&J/^&<?!_P#T$M<_[_P__&J[35O&\>DW>KVSV)>6QCC>
M$><!]I+`%@./EVY!/7@U*_C6V5F1-*U*61GVVZ(L>;D!BI9,N,`$8^;;Z].:
M0/0X;_AG'P?_`-!+7/\`O_#_`/&J/^&<?!__`$$M<_[_`,/_`,:KME\<6\]W
M:1VNF7DL-PN3.Q1%!\DS;!EOO;=O7"\_>X(I=-\>:7J;V\<4-RDMPY2-"T3[
MF5PC@,CLIVY#'!/'OD4[.]@VU.(_X9Q\'_\`02US_O\`P_\`QJC_`(9Q\'_]
M!+7/^_\`#_\`&J[.3QNUMJ\EG<:-=B%)I(S.CQD*JM&N\C=G:3)_O#'W?2Q9
M^-+.[=E:POX,/$J&41XD$DK1*PVN>-RGK@X[4EK:W4'I?R.$_P"&<?!__02U
MS_O_``__`!JC_AG'P?\`]!+7/^_\/_QJO1+C7+JWU];%M.46A*H+F2?8SL1G
MY%*[6`Z'YPW^R:R&^(=KYL@33+LI;22I=D2P.8MD>\'Y)"#GIC.1W`H6H/0Y
M+_AG'P?_`-!+7/\`O_#_`/&J/^&<?!__`$$M<_[_`,/_`,:KN9_&]K%J5Q8P
MZ7J5U+`0K&%8L%V8JJC=(#DD'G&`!R158?$*SCCL?M.FW<<E[!)+%&DD+,2B
MLQ3:7#[L+UV[<D#-'2X6UL<?_P`,X^#_`/H):Y_W_A_^-4?\,X^#_P#H):Y_
MW_A_^-5Z*?$]H^E)J%G;W-ZDLWD6\=N$W3MWVEF"XX;DD?=-9T?C*>YL=:O[
M;1I6L["W26"1ID#7+%-Y79_"`".2><GCBBP+4XO_`(9Q\'_]!+7/^_\`#_\`
M&J/^&<?!_P#T$M<_[_P__&JZYOB)8VL%W+J5A<V8@>14,DL02;;+Y1"L7`4Y
M*YW;0,]3UK0D\6VS:9I^H6<7VBWO4+HWF`8`*CMD'[W8XXH>BN'6QP/_``SC
MX/\`^@EKG_?^'_XU1_PSCX/_`.@EKG_?^'_XU76S_$K2+335O;RUO+17*>4E
MRT,9D5U+!P6D"XPK<$AN.`>,ZVH^*['3[C382DDO]H*7@D#QHF,`CEV&2<_=
M4,W4XXH>@=;'GG_#./@__H):Y_W_`(?_`(U1_P`,X^#_`/H):Y_W_A_^-5V-
MKX_MY].BN)-(U%)FC$LD"B-BD>P.9<[P"@!'^T?[N>*?)\0M'CFGB\F\=X8F
ME(6-?F"F3<!\W4"(G'H5]:;5G8%JKHXO_AG'P?\`]!+7/^_\/_QJC_AG'P?_
M`-!+7/\`O_#_`/&J]#'B>+^QIM1?3K]&AG6W:T98_.WLRJH&'V\[U/WNA_"J
M<?CFQ:.YD>UN46!)69?E+@QH6D4C.`P((X)!(ZXI`M=CB/\`AG'P?_T$M<_[
M_P`/_P`:H_X9Q\'_`/02US_O_#_\:KT"R\66NHC5EM;6<RZ:#NC=X@TA`)X7
M?N4''!<*#U&1S69;_$.V6">74]-NK&.&/=YK/&48^7&Y3.[AOW@Z_+QG=UP`
M<E_PSCX/_P"@EKG_`'_A_P#C5'_#./@__H):Y_W_`(?_`(U7>IXK74/#4.L:
M+9_;1-+Y81IAMC()#%WB$@P".JAAT[<T#QC9I!OGMY1(J1LXB9)%^??C#`\_
MZMO3J/?`]-P."_X9Q\'_`/02US_O_#_\:H_X9Q\'_P#02US_`+_P_P#QJNPN
MO'\,.G2W$>BZDUQ$'9[9Q&I155&WL0Q`4B1.F6Y^[P<2-\0-*BO;NUN8;B!K
M214F8O"ZJ&#E6)21MH.P@`X;++QS3LT&YQ?_``SCX/\`^@EKG_?^'_XU1_PS
MCX/_`.@EKG_?^'_XU7HM_P")8-/FMXI+&]?S(TDD9%3%N';:N_+#JW'R[NAS
M@<UDR^-+VW\-66L3Z#)&UUYS_9Q<HQC1(W=2S=,L$'`!QGOBD"5]CD/^&<?!
M_P#T$M<_[_P__&J/^&<?!_\`T$M<_P"_\/\`\:KL)?B/H]H]K#?13V=Q/,86
MAGDA5HR-O)S)\P^=3A-S<].#C0U'Q=9:5J,MK=VUVD,*%I+L*ODJ1&TFW[V[
M.U6/W<<=>11L"UT1Y_\`\,X^#_\`H):Y_P!_X?\`XU1_PSCX/_Z"6N?]_P"'
M_P"-5V-K\1=)OK:VEM+:ZG>YE:"*.%H9,RJ`Q3>DA3.T[_O8P#W&*M-XK>/2
MM%O)-/96U)8R8VE`,6]D7MD'[^>O:G8-W8X3_AG'P?\`]!+7/^_\/_QJC_AG
M'P?_`-!+7/\`O_#_`/&JZV?XE:1:::M[>6MY:*Y3RDN6AC,BNI8."T@7&%;@
MD-QP#QG?U75)[;P_)JFFV\%YLA\]4EG,*LF-Q(8(W..@Q^(I/3<-W8\S_P"&
M<?!__02US_O_``__`!JC_AG'P?\`]!+7/^_\/_QJNU7QC-:WMO:ZMI1@\V&*
M5YK6X$T4/F.ZJ&+*C<[1R%/+>@S4NE>.M(UG2+S4;(R2QVKJC1QO'(S%L;,;
M'(RV1P2".X%-H+ZV.%_X9Q\'_P#02US_`+_P_P#QJC_AG'P?_P!!+7/^_P##
M_P#&J[B]\;6VGM9QW.FWD$MVK[$G>%&5U#'8R[RY^Z?F567D'.*JP_$G1[FX
MN+6VAN+F[@*KY%O)"SR,7"$`;P5PS`9<+GJ,CFDM79`]-6<C_P`,X^#_`/H)
M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5VK^.83/8QV^E7TB7!"O(QC18F,3R;
M#EOOX7V7G[U6-$\96FOW,,-G8W9WK(9)-\+)#L;:0S+(0<GILW>^*`>BNS@O
M^&<?!_\`T$M<_P"_\/\`\:H_X9Q\'_\`02US_O\`P_\`QJNPD^(^DP7L-I<6
MUS!)/</!#YTD"^9M<Q[E!DW$%P1P,]R`.:H0?%&UM[6*77M/_LN2>3]S%]LB
M<^5@'>Q8J,X8?(A=N>`><"U`Y[_AG'P?_P!!+7/^_P##_P#&J/\`AG'P?_T$
MM<_[_P`/_P`:KMKGQLD,L9CT?4GM6ED4W'EKM=$21BR#=EN8R,8![XP03-)X
MM23PM;ZY8V,EPDTT<8A6>%F`9PI.Y7*<9[,:`.#_`.&<?!__`$$M<_[_`,/_
M`,:H_P"&<?!__02US_O_``__`!JNI/Q.TFUTF"]U*UN+&278?)FEA4[60/N5
MF<!A@]/OG^[GBNV1UD174Y5AD$=Q3::$G<\@_P"&<?!__02US_O_``__`!JI
M[/\`9Y\'VE[!<_;=9F\F19/+DGCVO@YP=L8.#[$'W%>LT4)M.Z&%%%%(`JM?
M:A9:7:-=ZA>6]I;)@--<2B-!G@9).*LUFZYIUWJFG&VL[\V3LPW2!6.Y>Z_*
MRL,^H8$''TI._0:MU'/KVCQE@^K6*E8!<L#<H,1'_EH>?N_[72D.OZ,)$C.K
M6`=X?M"K]I3+1?WP,\K[]*Y>W^'T]I90VD.KP^7!Y,L9DL5=O.C5%#%BV=A$
M:Y48/7YL<4^\\`SWT,L$NK1+#,/,D$=BJ-YVQD#*0V`F&^Y@G_:Y.:=K_P!?
MU_7W+^OZ_K_@ZVIKX5N[D6^I7.GM<33QLL<ER%=I8CE=HW9R#Z?C5'2;[P5%
M/'J5EJ5LC7/R0&:];9\V/EB5VVKDD9"`<XSS3[?P=*&EFN]1CFN99DF9TM=@
M!6992`-Q(!VXZGUYJ&+P*P5Q-J,<C&U>V4BVQM#;`&Y8\@(/KGMTI+97#N7?
M[+\-:I+'8VUZWGZ8K1>58ZI+%)"I()5_*D#=0.&J5]4\-26TGF:K;26\;_:'
ME>\+1QM$RCERV%PVWY<CGMUK-\/Z'J$&LZE]JB>*P$3V]LSI&KNK2,Y.4D?=
M]X\D*?5<Y)1/!%VBQR?VM;?:8%18&&GJJ#84*%U#9<XC`/S#VVX`H73^OZZ"
ME?7^OZZE_44\*:GJ<,UY?VCW<4`N$47Y3,2L'60HK@,H(R&((%4]+TWPQY$%
MM-J&FWMUJ(N94,,P07"S,&D,:!CD?*O()(V]>M4I/AS*[2*NN2Q0RP[94BC>
M/?)G.3MD`V@\CC>.@<#BI[3P/>Z;=VM[9:LB3PQ,)%VS[9W+.PW%IF8J6?D/
MO(_A*Y--67]?UY#N[?U_7<U!IOAK1;VP26:&"\+G[-]IO&,LKD$'EVW2-\Y'
M.3R/055BL/!-YJMW<12Z9/>R2RQW`6[#'S'C"NI7=@,4CZ8X"D^M2ZUH-]K&
MKV3^=##;+:O%=-Y6\MEXVVH=P*D[?O<].F<5B:EX%U";[5++J,]]=7LUNGFI
MF/[/&CL2WS2$?<=E(0#)/W1DFA=/ZZ_TP3W+WE^`[<7%E)?VC;(&-R\U^SE8
MV,9)DD9SUQ'C<<X`QQ5Z1/!\GAZ&VDN].;2;61)HRUX/+C9<2*=V[H`0V,XP
M1VJD_@J^2ZGFLM:BM5(E6`+9D,BR2K(RLRR*6&00"NT@'KD9.9!\/)1)=VHN
M9(XDM(88;B4;EEE#[S)M#[P<*B[MRMP2".#1NOZ_K_@@E9O^NW]>AO&P\):/
M8V%^;NWL;**,16\W]HM%#*IR0K'>%E')(W;NIJN]AX(:WE@FU"VDBT]_-<3:
MJ[_9">/XI#Y8!7`'`!'&*M:EX:U"_P##5MI"ZY,C(NRYG*N6G4J01D2!@><@
MECTYW<U4C\#O;V5M';ZA$MS;EW25[3<I<S"4%EW#(&,8R#WR*.K$_A3ZEV\O
M_"SV]OJ=[=VZ6]\RI%<32,D<A4/CDX`X+]<9SWXJI%I_@S2FN8(YH3-&%2XC
M^V232J)/+1=PW%@#LC`)[#ZU9_X1('1M,T][M#]B$N7$&`^^-TX7/RXWYZGI
MBJ/_``@DK%4?5$,$3AX5%KAPQ>-WW-O^8$QC'`QGG=@4MF[#72XLW_""KJ45
MS/>6J7/E_:BLEXZJ$):4/(A;:!EV8;QP3QT&+4%EX1_L_P"2]MY[/8Q!EU)I
MD5)%((4LY"J54X`P``<51/@74(I(VLM=BM_)7]VWV(E]Q1$;+"0$J1&.!@C)
M^;IBG%\/I%NTM3/(8(K":)KJ10ZS2/(S(2K.6)17D!+'G?P<YPW;5(2;?O2W
M.ITO3-$DTFV_LYENK(2_:8IENFGWO_>,A8E_Q)K%>7PEIUS<Z5-%J6+97N)$
MF@O)((D\M@Q5F!14VE@`IVYX`S6]H.FWNDZ>EI=ZC]M"+P[(^[.23\SNQ*X*
M@`DGCECGB/5-!_M)]1;[3Y?VS3S9?ZO.S.[YNO/WNGMUH>^FQ4;=?Z_K4JZ;
M+X7M%L;FTU:"7S2]M:S3:DTYD)(+1JSN2QRHXZC&.*KVEKX,N]5MYK._L[B[
M>1Y8DBU(N)6#EF^0/A]K$D`@A23C%5;WX?K=ZDMVNHE5,V]X<3(K)B,%?W<J
M9.8P<MN'/W3UJ2R\!BRU32[L:@9$LH(HGB/G*)&C!"L`LH0'YC]Y7_"FNC)U
MLRSJMOX,N-4N&U.YTW[?;1O+,);L*\*,@C9B-PV@K@9X'XU+I=AX5FOYY=,G
MMKBY1EG=8KTR^5NRP(7<0BMN+8``.<\U5U3P;=:MK4E]<:RQAP5A@,3$1J=N
M1_K-IY7@[0>2"3Q5G1?":Z1KU_J7VMITN#(8XW:8F+S'WN/FE,>,_P!U%/')
M-2O,;*5IHW@W5X);B"&4PP0[&WRW$*>7Y90.%8@$%`0)`#D#ACCB"S;PK%?V
ME]'J$5I;Z>[LJZ@)(Y&FF&T2"2<@LK`,`0"&.3DXK2TWP?%:6>K6US<^:FH1
M^05B\Q5BBPP"J'D<C&\]"%Z845'<^&M:O(XVN->MGGB)6+_B7_NU0HR-E?,R
M7(;[P8#@?+C(+;UN@>NX^:+P@=5N$GOK+[=</LDA>_.XLY7Y0F_Y23&O``R5
M/J:AEA\#J$U"34+!(].D2,R_VEMCC</O57^?:2&)(#9/)QU-/C\$6\21HER"
M(U959H06Y>)@2<]1Y0'X^U4+?P9JLFF,DFKK9S2J(F2&!EQ#ER49DD!+9D)W
MJ5Z#@\Y6UK=`6M[]34GC\)76M232W]HUZH626`:@0IR`JN\0?:3RH#%<_=P>
ME1KX8\*Q0PVJQNZ3R/`@^V32;R$=60MN/`4,,$X&!W`Q2D\$BS\/S6R,U[*+
M=XPD2+&\A,,<8PS-@$>6#DG^5:9\)6=WHVC:?JD<%['8D23)<PK*L[^6RDD'
MC.YBV<4]-D)-O5F>+3P/;6DZ?:40W$;2N&O9?M#K"[,77+>9E6W'<O/O35M/
M!MG=6WV2Z@M]0+-%:)-<2O\`O$WQES$7&['S`L>HXW=*CE^'>;%]/@U&&"R>
M/:T:V8W*09"FPA@%4>9@K@YQP5R:G;P/<+?&>#5HXT:X-PV;,-('W2,NUMW`
M'FD$$'..V2*3V_K8:VOU)M-M_"L_A6STB#5;*ZL[:/Y9;6]$9!3&YU:-@5P6
M&<'C=CO5VW3PNVB7Z6MU9'32#!=M%=#8F%"%2P;Y2``.H/XUSZ^!;N&^LFFO
M);R234/MEW=#*J%$04QD/([$,R(<`X&.P`!O0^$K_3O"E]I<6H?;'F=?(5HR
M$B4$<!6<CMD@%5[!5Z4WU8;6)TL_"%VB0Q7$+AHFFCECO7RRR.9"Z2AN3NB9
ML@Y&T]!5T#P[?+]C^VP73Z?$"ZF],DD2'!!<[BW.T'+=:QYO`EU(_P!H36(H
M[Q\F1_L9*$MYV\JF_C_7G')QM&=V:OZ#X5GT74+J8ZJTUM-'M6W6-D4-QEB-
MY7/'!55.#\Q8X-)ZW7]7!VO<H6]SX%U.U5(-2@B%O;QR!DOWMY(X43*L'#AM
MH63D@XYP36A>'PCK;K<W&HV-Q]BA69F34,*L1PRM)M?#)D!@6R,C-9I^'SOI
MK6LNJ(9&X,BVN!C[-Y`&-Y]`W7VHO?AXMY>ZC/\`VE(GVD^9#\]P#"Y=7/W9
M@NTE%^ZJ-_M=Z<K7!&E+H/A>XT^UF""2U<11P26]S(1(NW8J@HWS*5X(Y!'7
M-5K73?"&HWMQ/%9,EU<2RP2B6*:!B[Q*'&U@,9C08.!QDCJ:MQ>'Y;#2=(M8
M'\U[*Y\V0J7._<'#-^]=VX,A;EFZ5':>'+JSF1GGAG>:^6YFD@@$"C:I^8KN
M.78XW,,9ST%'5O\`KH+9*W];CM5C\/WUEJ6G'5;.`I+'=7P%T-T01E)+?,#'
MD1@9XQUK/O;3X?\`V)+:\U+3XX6B\\;]5*&2-@4WEO,!96S@DDAB><FFW7@F
MZU:34&NKX6R//)):"*-E="71MS.D@+`^6O`VD<\],#?#]QIKP0:FL4[+%B7R
MYFPZ-(Q;<9O-&3*3Q(",=2"127PJ_E_7R*V>GG_7S-*U3PCI=SJ+PWUE%(4!
MNU>_W")'.1\K-B,,3G@`$G/)JLMOX)BMX+87MFXFB:>!?[0:225-@4NGSEF^
M6,<C/W<CFF)X'F,T?VG5A<10RK+'OMAYC,9(W<R-NPV3'Q@#&>^!3;SP/=7<
MT"G6V6S@=Y$MQ"P`=F<D\2!2,/CYE)RH((Y%#V$K&E?P^'HM+M+&_OF2,@RV
MIEOY1<MA224D+^:3M)Z'."1TK/2T\"W45C>+>V31N1;6[_VBP61QNPI&_P">
M3YVZY;YCZFKFK>%I=1,0BOXH4^SK;S"2T64LJG<I3<<(<]3@\=,$`BA<>`GD
M:;R=3CC6>,P3*UKN_=&**-@OS#:Y\H$-R!G!!IJS;N"Z%FXT_P`'ZK(89IH?
M.97D:,7CQ2,B@1N2`P)3]VH.?E^4'KS5&^TCPC%H<=Y#J%I#I=U<0^;=23M<
M1.B2&145F<K&N[//0#(P.,32^`FECNK<ZFHM;DR.X%J/-#L&`*R;LJ`&Z``D
MC[P!(-^P\*FTTBTLI;M99(;P7<DF)6$C9/\`SUED8=NK'ITI7>_];_Y"UM_7
M;_,74W\+7FH17%Y>6TEW:P"X$<=T=QBR"&:-&^=<X(R",\BH+R;PA=6UEH]U
M=PA,ND%O]H='P%D1B<$-MVB0$MQ^E48OA[)';):'5D-LB`@"UP_FB'R=V[?]
MS;SMQG/\6.*D?P-="\$UMK*0*)Y+D'[&&D65DD0%6+X``DZ8.2O49INRV*5^
M8NP0^$K^5-1L]1MW;?YPGM-290^-J')1P&7*H"IRN<<9HU2_\(?V1<ZY>WMG
M-I\<G[Z>.8RIOVF+;A"<G#%=H'?IFL=/`EQ'J5AYUS)=9NIKJZN@,+AD0"/$
MCNYS(B..H`3'IG9TKPK/8:`^ESZHUP#/'+&VQML:HRD(H9V('R^N!G@`8%'0
ME:,KK!X+\N"234[>7['/Y,<ESJKR/#*Q#;-SR%E8[0-I.<9&,9%7;B#PO:);
MZ;=W=K&=.A$\<,]Z0\4:L"'.YL[05')XXQ52Q\&26VI6=W-J*2BSD7R$2VV?
MNU$H"L=QW-F4G=QTZ<DTR_\`!=Q<>(;K5[/5FMI9AOC#"9O*EV!-P43+&05&
M#\F[DX8<870K1,DD@\'36EH$O[<(\(-J]KJ+K(\<0(S&T;AF`!8':>>^:TX;
M[0K[0+FXCU&"XTMU<3SM=ED4$?,&<M\N`>F1CVK`LO`$UE"T*:NCI,&^T&6U
M\UV)>1U*N[L5P9&R3N)&,$'FKTW@U9=%U#3UOFC-U)!(DB*R>6T21J/NN&P3
M&#PRGG`/>F];@OB1)>7'@XM'->:EIB^9!$Z-)?*H:*-BZ,/FP5!).>_?-+&O
MA>UL[O1UOTECPK36K7[SO$K$!<`L61<E<;<`<8Q5:R\#Q6J0A[F-V387/ENV
MX@2Y.9)';DS$\L<8]^*ECX*NQ-,EQ>QK;12J;<+;X=B(XD+E@_0["-I&0><G
MBCJU_3(=]&6H-%\%2W&(+BVDFB<P.JZD[$R#<Q#C?\TF"Y);+8+9/6K%O%X2
M@%Y<P:C;B&V=)KD?VDS0V[`AE8H7V1DGG.!GOFLC4O`]T]A]G6Y-P[2PPP20
M1K";>!9&9F<ECO;:SJ2H&=PX')I__"N%6'4(X]3D3SI%DMF#W.8,2>9M.)P,
M;O\`GF(S[TE??^OZ_JY4D7=2T'P<\5M<WVQ;>9"(I/MDBPL-C?-D-MSM+8<\
MXZ'I5FT_X1K0]/75[*0RV\XV)/!)+>--N.?EP79R2,Y&3P3ZT3>$DFT73-.-
MRJK9-N8['<2<$'[[LV#GNS5+<Z%?C0IM/TS5([.66YEF:9K8N-CR,Y0`.I'W
ML;@P/<8/0>FP+5>\9\%UX1DU"W%O<3QR0JUPDT4EQ%"0W[TAY!A&X8OL8G`.
M<`5,MGX5D32)X97B-X5%@\-S-$\H";L95@2NU,D'@X&:?I_A>ZL]4AN'O[4V
ML;"7[-!9F/\`>^2(<JQD;";1D+@G/\1J*#P4\$VBS)K=VK:9'''Y2Q1>7*%#
M#H5+*3NYPW0#N`0]+Z!T98OO"WAZ&&YN[BPGD7+2NL33RGD,&"HA)P=[911@
MDDXS6=8W_@R[TF#24N9X;>\D\R$7K7-O).X93E9)=KN<E<$$YZ=C78PB40(L
M[H\H4!V1"JD]R`2<#VR?K7,OX.#VEG`;T9MK0VP;R>N9$?=][C_5XQ[^U+K;
MH#VNMQLMMX-C0`ZC:VYMI8[7?%J;1/'(J[5B+*X(.!C:3SCD&M^#5M-N;2:Z
MM]0M9K:`LLLR3JR1E?O!F!P".^>E<MI_P^2RNA*VH-(J3^8F[SF;9LD4(=\K
M*,&4G**H]N:N:)X1N-#T.^L;?5&^TSJ%BN\3.T8"[4R))7R1_LE1Z`4='W_4
M+)-);&F/%'A\Q12C7=,,<J/)&_VN/#JOWF!SR!@Y/:M*WN(+NWCN+::.:"10
MT<D;!E8'H01P17%I\/7_`+/NH)=7=YIQN\X+*"K^:)<[O-+XW+C&\''\7>NH
MT/2QHVCV]AO$AC!+.#(0S$EB?WCNW))ZL?K3TL'4T****0!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5SGC
M1+F31$2WGO(,SKYDEI!/*VW!X(@=)<$X&5/U&,UT=%`TSB_#<\\_B6;>FN6S
M);8FBO5N&A=_E_U;,OE@)R,@[G)).<9.4-6\<F344%M<;88CY+/;!=Y0^6Q!
M"G.X_O%PIX`P".*])HH>HD>:P:KXU>ZTF.0/Y$D9,DGD3#S/G8$2?Z("K!`N
M,^2,GN.!6T75?&<.B^'TOXM6:Y$VR\3[-RZX38"[1,0-I)8MM^;<#(N`#ZG1
M5)V$]3A/%.J^)+?7_)T6/43"MO)Y@%L'ASY3E&0^4<MO"@@R#M\A!S5759_%
M$"BS-[J\@6<B.>"Q4M/S&=KE$^10&DPPVYVX)/0^BT5*T'+5'%^(YI_^$DCB
MM&UZ.X6W9A)!!,]M]U\(`H$9<G!)=AC`P1FH]&AU-='TP)/J;+'J*AWD2X1K
MB(CEG2=GE10<C!;'&>A%=Q10M/Z\[@]3B=>N-<B\37$=@^IF*2V0)%';%H&X
MDWMYFT[7'RX`8$G'![92OXJC+O$=4601R["\;N`VZYV_*W!X\K@_[/M7I=%-
M.UP>JL>>:AJ?B/2[BUAGO]0,:W20QS_8D(N=UPJD2D1[4^0C:1MR2>N*GUN_
MUV'Q0YC.LM:P%V6"SL\QM']G8AP^PAG\S(VDGHOR]">QGTO3[J]M[VXL;::Z
MML^1/)"K/%GKM8C*_A5NDMK`SS:SUCQ@$LH9&N7:Y-PH::W42J(_WB-M,<>=
MZ_)]U<''0Y-:FEWNNW?A&"6X74?MR7L:L\L11Y$#C)VB*,A<9&"@Z'EA\Q[`
MVUN;I;HP1&X5#&)M@WA2<E<]<9`X]JEHZ`<=:2ZM!X7U!M:N-7NW$,<@:VM@
MEP=R*62,1J#PV1TR/7(S6/8'4#?Z62^ON3Y1MPZ7:QHOG/YJS;P-VV/:`THR
M<`CDUZ313OK<7V>4X/59?$MKH]S#9VVKWKF_D)GB,0E6(%2H`9D^5N1E0>`?
M7([B&99E+*KKABI#H5.1]>H]QP>U244EHK#ZW"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@##^SRW^N:@CWUW%'"(@B0R;0,J
M2>U3_P!B?]1/4O\`P(_^M18_\A[5O^V/_H)K5H`QK..6S\0/:_;+F>%K42;9
MWW8;=C(X]*TWN[:,3E[B)1;KNF+.!Y8QG+>@QSS5#_F:_P#MQ_\`9ZP-?\-:
MMJ3^(I+34KZU6ZM1'#;P?9]EPPC(PQD1F')QP5_K0-*[LSII]:TJUO8+*XU.
MRANK@9A@DN%5Y/\`=4G)_"K*75O()BD\3"%BLN'!\L@`D-Z'!!Y]:XVYTO4X
M;36=,71/MG]JDE;P2QA(\QJH$NYMWRD<;%;@#I4VF0:KI\^LZ=+H][-'=SL\
M=^)8/*(,*+E@9-X)*G^'O0]GZ?TB5T-T^)=!%_'8'6]-%Y*%,=O]J3S'##*X
M7.3D<CUJ^UU;I<K;-/$MPR&18BXW%1@%@.N`2.?<5P":1K*Z3JFB-H<[_P!H
M0PHEX9H?)A(MXXR6_>;\JRD_*IZ#GO5N?0O$3^)/^$@C:V)@G2*.T>(^=);K
ME6Q+YNP!MS/@KU"Y((XII7L"^&YV2WMHZV[+=0LMQ_J")!B7C/R^O`)X["IZ
MP=-T3[)XAO[QD;R./L:E@5CW_-+M';+`$Y_"MZI&'09-85O>:IK:BYL)8+/3
M6YAE>(R2W"_WP,@(I[9W$CGBM34;=[O3+NVC?9)-"\:M_=)4@&JV@7T5_HMM
M)&GE,B".6`XW0.HPR-CN#Q_+B@"E<W&M:*'N[B2'4=/09E$<)CGB7^)Q@D2`
M==H"G`.-QP*VFN8$M#=/-&MN$\PRLP"A<9W$],8YS4&JZE;:3ITMW=-^[4!0
MO4R,>%11W9B0`!U)K&31KR#X9)H?^MOH]'%IPP&^00[.IXY/K2>PXI-I,U=/
MU[1]7CEDTW5K"]2'_6-;7*2!/J5)Q^-68KVTF6W:*Z@D6X7?`4D!$JXSE?48
MYR*Y34/"VI'2W@@U*ZO+Z\C6TDN;U8MMM!U<;8A%N!QC@[N1R!3(]!UFW\*W
M^EGRFO+61IM+N;11"`2-P"JSMLVDLN"2"O'3BJ_K^OZ[DG53ZII]M937L]_:
MQ6L+%99Y)E5(R#@AF)P#GCGO5(^+/#BV"WY\0:4+)I/*%P;R/RR^,[=V<9QV
MJMK>A._A1-)TH/$4EM]C(R[T"RHS/E\@L`"W(.3V-8^M^'-1M&L;NPNM:O[P
M7?F7-S`;,7&T1.BX$BK%@;@/NYYI#Z7.@E\7>&H+6"ZF\0Z3';W&[R97O8PD
MNTX;:=V#@\''2M%+^SD3>EW`R^4)MRR`CRST;_=X//2N2DT?7M4N+"YBU#5M
M*GALKB)KBX6S>5G9T*B145D((4GY,=.2#5;_`(1G49-.CB33Q#Y=I;JT$TZN
MLKQSF1T+#LP[X`^89`Y`?]?F']?D=7%XCT*?39=1BUK3I+&$XEN4ND,2'T9L
MX'4=35C3]3T_5K;[3IM];7MODKYMM,LBY';*DBN/U2PU?59)]4BT*XM61+=!
M9O+!YUQLN$D)RKE`%56"Y?\`B/3ON:+;WDVMZAJ]S82:<MS#%$MM,Z-(2A?+
MMY;,O.X`8)X'/I0M@-^BBBD`5G:QJ;:=:H((A/>W#^5:P9QO<^I[*!EB>P![
MX%7+FYAL[66YN95B@B0O(['`51R2:R=(M9;R[;7;^'9<2H8[6)AS;P$@X/HS
M$!F^BC^')`$TJZO;&]_LC5[C[3.ZF6WNR@03C^-<#@,I/3NI!Y(:MRJ.K::F
MJ67E>88IHV$L$ZCYHI!T8?R([@D'@TS1]2?4+9UN8A!?6[>5=0@YV/Z@]U(P
M0?0^N10!+_:NG"&[F_M"U\JS8K<OYRX@(&2'.?E('/-,NM;TFRN+>WN]4LK>
M>Y_U$<MPB-+_`+H)RWX5P-WX.U=[G78H[,-9ZS+-)<@RK@E"3%QG^/(4^R\X
MK8?3=2LEU6U_L(ZD-410)A+$$BQ$J;)=[`[002-@;J>,]4G=7&UK8ZUK^S3[
M1NNX%^S8\_,@'E9&?F_N\<\]JH)XK\.27_V!/$&E->;S']G%Y&9-PZKMSG/M
M7'WO@_68;'69;(":_N(XK4F20`7D0@C0D\\,K!B,^XZ-FNO>QN3K]U<B/]R^
MGK"K;ARX9SC'7H13EIM_6@EK^!H&_LUACE-W`(Y$,B.9!AE`R6![C'.?2G_:
M;?,(\^+,_P#JOG'[SC/R^O'/':N#B\)ZW!I&G1R:A?7KQZ9+`]M.;<)`[0A0
MJE$4GGC)9OZUK;-2U/PA-9G1K[3M0M;93:-/+`2TZK\I0I(X&&`^]@$'N,TW
MNUV_X(1N[>?_``#IXIX9M_E2I)Y;%'V,#M8=0?0^U1?VC8_86OOMEO\`8U!9
MKCS5\L`<$[LXXP:RKS3;NT\)-INC+LNI$$2RL03&SGYY6R1N(RS'G)-<];^&
MM9TNS^Q&WM;^UL[N*^@AMD%O'(,$-$$>1L,&Q("S8+'J*5M0Z7.P77=(?2SJ
MB:K8MIPSF[%PAB&.#\^<?K22Z[I$&EIJ<VJV,>GOC;=/<((FSTP^<'\ZYZ>U
MU&XNK?61X;$9@NS,UD98OM$N8MGF$AO+WCC`+_=[@\4&UU*+4+37%\.Y$9G!
MT^&6+SU,A3$I)81E_E8'YNAX)[G4#J8;ZSN!"8;J"43H9(=D@/F*,99<=1R.
M1ZBB*_LYY1%%=P22$,P1)`3A6VL<>@/!]#Q7(VNF:KI=Y#K":3)-NEN6;3K>
M6(/"LIC(P694)S&2P#=7.">\-OX6U,7%O?B-(-0MX)I('\P%5DDF9S$V.JE6
M`..,\CD"A]/ZZ,/Z_$Z.Z\7>&K*1$N_$.DV[N@D19;V-2RGHPRW(/K6@FHV4
MLZPQWEN\KE@J+*I8X`)P,]@P)^H]:YS3=(U&+1_!\4]MLFL&5KM/,4^5_H\B
M'G/S?,P'&:I7'A6^O/$?VPH8/*GN9[:Y#*?+=A`$.,Y(.QP1Z9!QD5324K>H
M/I;^M_\`+\3J[K6M*L;+[9>:G9V]J&*>?-.J)N!P1N)QG((QZU9CN()K9;B*
M:-X&7>LJL"I7U!Z8KB;'3-<L+*ROKC3));Q([N.2"SFA,D#RS;Q)&92$/'J1
MQC@\BKD.A:K+X%GTZ[\M[R25I5CD$:;T\W>$D\I0F6'#%1CD]:G^OZ_,$;]I
MKVCW\!GL]6L;B$2B$R0W".OF'@)D'[QR..M2:CJ^FZ/"LVIZA:643-M5[F98
MU)]`6(YKE-5BU;4HTO8?"DMO)!<6CF)IK?[1,L<NX@$2;-H&<9<$DG@=[DKZ
MF-8CUW_A'+R??:FV^QF6W$\!#D[AF3RRK#&</GY5X]'_`%^`=3<O-;TG3D@>
M^U2RM5N#B$SW"()3Z+D\_A4-[XFT#3;P6E_KFFVMTP!$,]W&CD'H=I.>:Y;^
MP]4T^QA6+3;N2XD252]A-;D0I)*T@A=)L*8P"!E<GK@#@T?8_$=EK1G%MK`1
MX+<2)HYL!;LRKA@1<'>!G@;<<>]"$SOJ*.U%(84444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!0N=$TZ\N6N)[8-,P`9
MPQ!('3H:A_X1S2?^?3_R(_\`C110!8L])L;"5Y;6W6.1UVLV221Z<FKM%%`!
M1110`4444`%%%%`!6#KVDV?ERZG&LL%ZJ\S6\[Q%\`@;]A&\#MNSBBB@!NA:
M7:2I#J<Z27%X.4EN)GE\O(P=@8D)D$_=Q70444`%%%%`!1110`4444`%%%%`
M!1110!7OK&UU*T>UO(5F@<@LC=#@Y'Z@52_X1S2?^?3_`,B/_C110`?\(YI/
M_/I_Y$?_`!J:QT73M-N9;BTM4BFF54DD!)9E7.`2>PR?S-%%`%^BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
*HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`,,`C0#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HK
M$O\`7OL&N_8IO*CMAI\MY).Y/R;&4<^V&)_"LQ/%-_#?>1<VJO%+8S7<$OEF
M'/E[>"I8GG<.3@^U4H-BYD==17*6/B/47FT9;B&VE&K6CW$2Q!D,;*BOM)).
M<[L9X^E%KXBU2;3+W_0T?6((T<Z=Y;1M'N.#RQQ(!@X*X!QCBGR,7,CJZ*Y)
MO%C>58PPLD]S=3R0LXM91Y)1=S!HN6W=.,CUSBG3>(M6BCT^&2RC@N+S4#:+
M)*K;2FQG$@3((SC&TGCFCD8<R-^^-^BJ]BL,A7[T4I*[A[,.A_"L>X\37MD<
M77AS4B>WV<QR@_\`CPJWHNJW%[>:I8W21^=I\ZQ&2($+(&C5P<$G'WL8R>E9
M'Q.MK>;P+?23*-T.QXV[AMP''X$C\:NFDYJ$EN8U>91<XO8W='UD:O"\AL+Z
MR*'!2\BV$^XP2"/QK3SFO%/AAX&T7Q!I=UJ.L6'VADN#'#ND95P%!/`(SR>]
M>R6EG;V%I%:VL*0P1+M2-!@*/045X1A-QB]BZ,W."DR>BBBL34****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`RI-$BGUF74KEA/FU-JD!0;1&Q!;.?O
M$D#VP*J+965NX(T;$C1M$H:1#\A'*KENAQT'I6^0""",@U1ETBQF$:O;1E(V
M+*FWC)&*=V"4;ZE2.&WD2T9-)4K;QE+<[DPB$`$+@],`5%'::?")X_[+2,2`
M&9MZY('W<G.<9SCTJ]_8.DCII]O_`-^Q2'0=,:4NUE"<J$P5&,"E>1?+3[O[
MO^"5#86@M1:_V$AA5S*`-GW_`.\.<[O?K4T-E`6MD;2MJPR>;&SLK>6^"-W4
MG../QJ<:'I8;<+"W!SG.P5H4[LEJ/0KQ6EO;33SQ1(DD[!I7`Y<@``G\`!^%
M<=XGTW4O&D\>E0*]II$3AY[F1<&4CLBGJ/?I^7/<TF*JG4<'S+<RJ4_:+E>Q
M2TC2K71-+@T^RCV6\*X4=SZD^Y/-7J**EMMW9:22L@HHHI#"BBB@`HHHH`*Q
M/$NK:EI=K`NE:9)?7EQ*(D^5C'%G^)R.@Z>GUK;K&\3^([7PQHTFH7(WMG9%
M$#@R.>@_Q-;X:+E5BE'F?;N!EZ1XFU./Q%-H/B&"SCNQ;_:8YK-F\MD[@AN0
M>OY5DCQ[J_V)/$+:?9CPX]SY`^=OM`7=M\P_PXSVZ_SI?#7A[5;R/4_$NM,1
MJ>H6KQV\(_Y8QD<#'8]..W?DFN>,T9^!,=L&!G:X\D1_Q;_.+;<>N.:]R&'P
MTJEE%/6$7:]E>_,U]VYC=VW[_@CO/%_C.S\,:<Q1TFU&2/=;V_7/^TV.BC!^
MN*E_X2*:/P`/$$J1"X-B+C8`=F\KD#KG&2.]5?%.EVL?@_4KR2WC-\FF&#SB
M,L%`Z`]N2>E4MNDR?";3XM;NIK6PDM(%DEA!+`\$=%/<#M7%3I4)4:;46WSV
M?5OR2+3=TWV_R+OAZ\\9:B+&]U"/1(]/N(Q(Z1"43!2N1P25STK:\0:A+I/A
M[4-0@5&EMX&D02`E20.^"*X.XTZQ\+^,O#8\-R.HU`E;F(3-()HN,.<D]BQ_
M"NS\81O+X.UA$4LQM),`?[II5Z5-UZ4DERRZ6MI>VJN_ON%.^S&VVLW,W@==
M;9(A<FP-SM`.S=LW8QG.,^]1>'/$J:AX6T_5=5GM+26[)4`OY:%MQ`"[CUP.
MF:YNP\5:&/A8('U.V6Y33FMS`9!YF_85P%ZGFL#4[8GX6>$H)0RB2^7.#@X8
MN1^AKHCE\97A-<MYV3MTL]OP(Y[13\G^AZW!J5A=7,EM;WMM-/%_K(HY59D^
MH!R*S;/6O+.HR:KJ>C+;P7)BC:"?'ECLLI8X#^PKE-2TNQT?XI>&5TVUBM%E
MBE6185"AL*W7'4^]1:'I*:Y:>.=-;&9M0D"$CHP)*G\P*Q6#HJGS\SY6HO;5
M7E9_D7=WMY_HST2ZO[.QB26\NX+>-V"JTT@0,3T`)ZFF7.JZ=9W$=O=7]K!-
M)_JXY9E5F^@)R:\LT"^E\8:OX;TJ=7VZ-$TUXKCK(AVJ#[\+^9JG9Z;J6MW/
MB>1X_#[.MU(MQ-JN_P`V!>0"C#A5'8^U:K*81;C5G9K?YNR_S^:)51O^NI[#
M<ZA96<D4=U>6\$DQ(B664*7QUP">?PJ(ZUI0LA>G4[(6A.T3FX7RR?3=G%>7
MZGISR?\`"!:?J%W;7X\Z2-I;>0R1R(&7`#<9&W`-;?BWPS'+JVE+HIT59[97
M*:3=A0DH8\L(^_?\NO%9?4*"<(RGOS:VTT;7XV^0^=]NB.]MKNVO8%GM+B*>
M%NDD3AE/XCBJ\&M:5=79M;?4[.:Y&<PQSJSC'7@'->>Z%J^GZ;IWB:VU'P__
M`&=/;QJ]]#9W#&.0MQA0&Q'U_A/3Z5AZA%LG\)7=OHVF:3!-=Q-`+>;S)W4E
M>7;`R/KDY-7#*E*<HMM+H].U^^ORZ:^0G4LKGI.FZ_=7GC;6-%DCA%M911O&
MRJ=Y+`$Y.<=_05;\3>(;;PSHSW]PC2-N"10J<&1ST'^?2N?T/_DJ_B;_`*]X
M/_05IGQ/1XM.TG43&TEO8ZA'+.`,X7U_I^-9K#4I8NG3:T:C\_=3_%E7:YO+
M_(IMXR\::<\5YJWA9!ILKA0("3*H)XSACS[%1D^E==XFUT:#X8NM5"@ND8\I
M)`1EVX4$=>IYJG>^/O#-E8I='58)E<@".!P\G/<J.1COFN6^)>JO=WNC:19V
M5Q?G<+Z:UB1M[H.@(P2,_-GCBM*>'>)KTU*CR*[ONDTM>OW7\Q7Y4W>YTG@C
MQ1=^(;:\BU.WBMM1M)0LL4:D`*1E3@D^_?M4NC>(;O4/&&N:1-'`MO8>7Y3(
MI#G<,G<<X_("N(T?Q#>1?$R*^OM%N='@U5!;NEP&`=P/E8$JO?:/Q]ZUM%U.
MPTWXE^*FO[ZVM5?R@AGE5`WR]LGFM,1@5&51J&\$TEK9W2=K?/Y$J3MOU.J\
M7ZS<>'_"]YJ=HD3S0[-JR@E3E@.<$'OZUR<&O?$ZYMXYX?#NEM%*@=&W@9!&
M1_RVK1\?:G8:E\/=6:POK:Z5/*#F"57"_O%ZX/%<KIVD@V5I(?BIY`\M&-N;
MK&S@?+_KNW3I58&A3CA>:I%<W,U[T9/HOY=OF.;=U8Z37O'EUX?\8:=IEU!;
MBQF@1[B3!WQEB02#G&`0.WK6OJOB*[L?&>B:/#'`UM?K(TCL"7&T$C:0<=O0
MUS6L6EKJ_P`6;2UFVS6MSI+*2IR&4A^0?U!K)L+JZ'Q$\.:/?[C>:49K9I"/
M]8FPE&_%<54<'1G",E'50;?W.S^37XH3DUS?+]#>O_%?C&;Q3JFE:!I6GW<5
MBR!C+\K`,,C),B@]^E:_A3Q9>:M?7>D:S8"QU:U4.\:G*NIQR.3ZCN>HYK(T
M35-/TSXC>+#?WUK:"1H-AGF5-V%.<9/-&G:A:ZO\5[S4K&5);&RTWRYKA#E"
MV<]>_?\`[Y-15HPE"4/9))034E>][+Y.[=AMN[UZDGC'Q[?:!KR6-A:0W$,$
M2SWK.K$HK,!Q@C!Y'7/45TOB'6GTWPE=:Q8B*5DA$L7F`E6!(QG!'8^M>46V
MLZA?S>(KV/POJ&IPZSNB2XB5P(XQD`#"')''?M6S8:J]_P#!G5;*XRMUIR?9
MI$8890&&W([<<?\``:UJY;&"I>ZO=E%2UWO:]^UG=`IWG_7]:EI/%GQ#_LM=
M6;P_IKZ?Y0G+HW)CQG('FDCCV_"N]T+5H]=T.TU.)"BW$>[83G:>A'X$&O';
M_0M:TOPII>IW&N:G=Z)<11_:K:&9D,,;`8`!)4CMT`Z<5['H26$>A6*:60;$
M0KY)SG*X[^_K7/FE*A&DI4TMVKQ32TZ.[W%!NZOV-"BBBO#-@HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K(_X2KP[_T'M+_\#(_\:UZ\
M?^&?@_0?$'ARXN]4L/M$Z7;1JWG.F%"(<85@.I-=^$P]&=*=6LVE&VUNM^]N
MQ,FTTD>D_P#"5>'?^@]I?_@9'_C1_P`)5X=_Z#VE_P#@9'_C63_PK+P?_P!`
MC_R9F_\`BZ/^%9>#_P#H$?\`DS-_\75<N7?S3^Z/^8O?-;_A*O#O_0>TO_P,
MC_QH_P"$J\._]![2_P#P,C_QK)_X5EX/_P"@1_Y,S?\`Q='_``K+P?\`]`C_
M`,F9O_BZ.7+OYI_='_,/?-;_`(2KP[_T'M+_`/`R/_&C_A*O#O\`T'M+_P#`
MR/\`QK)_X5EX/_Z!'_DS-_\`%T?\*R\'_P#0(_\`)F;_`.+HY<N_FG]T?\P]
M\UO^$J\._P#0>TO_`,#(_P#&C_A*O#O_`$'M+_\``R/_`!KA_`O@7PWK/@VP
MO[_3O.NI?,WOY\BYQ(P'`8#H!71?\*R\'_\`0(_\F9O_`(NM*U'`4JDJ<I3O
M%M;1Z?,2<VKFM_PE7AW_`*#VE_\`@9'_`(T?\)5X=_Z#VE_^!D?^-9/_``K+
MP?\`]`C_`,F9O_BZ/^%9>#_^@1_Y,S?_`!=9\N7?S3^Z/^8_?-;_`(2KP[_T
M'M+_`/`R/_&C_A*O#O\`T'M+_P#`R/\`QK)_X5EX/_Z!'_DS-_\`%T?\*R\'
M_P#0(_\`)F;_`.+HY<N_FG]T?\P]\UO^$J\._P#0>TO_`,#(_P#&C_A*O#O_
M`$'M+_\``R/_`!K)_P"%9>#_`/H$?^3,W_Q='_"LO!__`$"/_)F;_P"+HY<N
M_FG]T?\`,/?-;_A*O#O_`$'M+_\``R/_`!H_X2KP[_T'M+_\#(_\:R?^%9>#
M_P#H$?\`DS-_\71_PK+P?_T"/_)F;_XNCER[^:?W1_S#WS6_X2KP[_T'M+_\
M#(_\:RM;E\#^(EA75=4TNX6$DQC^T0F,XS]UQGI2?\*R\'_]`C_R9F_^+H_X
M5EX/_P"@1_Y,S?\`Q=7"6!IRYH3J)]TE_P#)![_D5M)M/AYH5\+W3;[2X+@*
M5#_VENX/7AG(J00_#U=8_M876B"]W;_,^V)C=UW;=VW.>^,U+_PK+P?_`-`C
M_P`F9O\`XNC_`(5EX/\`^@1_Y,S?_%UH\3AG)R=6I=Z=-NWQ"Y7:UD7[W7?"
MVHV4UG=:WI<EO,A21/MJ#(/49#9J)-4\'II*Z5_:ND-8K&(A"]XC#:.@Y8YJ
MK_PK+P?_`-`C_P`F9O\`XNC_`(5EX/\`^@1_Y,S?_%UDI8%*RG.V^RW[_$/W
M_(CTA/`&@W#W&FWNCP3.,&3[<K$#T!9C@?2MH^*?#I&#KVED'_I\C_QK)_X5
MEX/_`.@1_P"3,W_Q='_"LO!__0(_\F9O_BZ=2>"J2YISJ-^:3_\`;@2DMDB@
M^D?#*2\-VTNB^86W8%\`F?\`<#[?TK5U&]\%ZM!;P7NJZ5)%;2++"BWRH$9>
M!]UAT].E0_\`"LO!_P#T"/\`R9F_^+H_X5EX/_Z!'_DS-_\`%UI+$8633E5J
M-K;;3T]X5I=D6+G4/!MWJMIJ<^KZ6]Y:`B"3[>HV9Z\!L'\11I^I>#M+ENY;
M/5]+B>[E,TY^WJV]SWY8X_"J_P#PK+P?_P!`C_R9F_\`BZ/^%9>#_P#H$?\`
MDS-_\74<^"<>7GJ6]%Z_S=Q^]Y$MA>>"M+OKR]LM4TF*XO&WSN+Y3O.2>A;`
MY)Z8JGJ=M\/-8OA>WUWHTMQD$N+Y5W8_O!6`;IWS4_\`PK+P?_T"/_)F;_XN
MC_A67@__`*!'_DS-_P#%U4:^$C+G52HGWTO_`.E"M+LB2XNO!-U/I\TNIZ3O
MT\YM=E\JB+IT`8#L.M)K%QX'\01)'JFHZ/<!/NDWB*R_1@P(_.O-M-T'2CX3
MT6Y?2K6XO=26>&)YIIANN1+MC!"N!MVAB<#.%SGK5N&Q\+R637L?AF">W`DF
M/^GS1,L42Q^;CYFWR!W8!?E'R\D=[G]4HU7#VE2\&UI;376VOS_$$I-7LM3O
M-/D\":7ITUA9WVBQVLP(E0W:-Y@_VB6)/XU0ATGX:VZ!8KC2$VRB4,-1^<,.
MF&WYQ[9Q7):5IOAZ^\76>DW/A6VM[>]MVG@D74;AB`K2#D\#<0@(3T#'<<8J
MQ\,_!^@^(/#EQ=ZI8?:)TNVC5O.=,*$0XPK`=2:UINA*E.O&K4LFK[7=[K^;
MRZB=[\MD=W!J7@ZVU:YU2'5]+6\NE59I/MZG<%X'!;`Z=A5N;Q)X9N(7AFUK
M2)(G!5T>ZC(8'L1FLS_A67@__H$?^3,W_P`71_PK+P?_`-`C_P`F9O\`XNN-
MO`2=W.?W+I_V\5[_`)%.TT[X;6-^+VWGT59P=REKY653G.0I8@?@.*TDO_!L
M>MR:RNK:7_:$D?E-,;]3\O'`!;`Z#H*A_P"%9>#_`/H$?^3,W_Q='_"LO!__
M`$"/_)F;_P"+K25?"3=Y5*CTMTV[?%L*TNR)M5O?!FMK`NHZMI<WV>02Q$7Z
MH5;URK`UF:CIGPXU6_FOKV\TN6YF.7?^T]N3C'0.!VJ[_P`*R\'_`/0(_P#)
MF;_XNC_A67@__H$?^3,W_P`73IU\+3^"K45NUE_[<#4GND5;>R^'=KI=UIL-
M]I:VEV5,T?\`:6=Q4Y')?(_`U2_X1SX6_P#/?2__``:M_P#'*J?\(+X;_P"%
MC_V3_9W^@_V1]I\KSY/]9YVW=G=GIQC.*Z+_`(5EX/\`^@1_Y,S?_%UO.O1I
M-/VU7WM>GX^]N))O2R'QW'@B+4[?4DU32Q=VT`MXI/[07Y8P"`,;L'J>2,TL
M]SX)N-<@UF75-*.H0+MCF%^HP.1T#8/4]14?_"LO!_\`T"/_`"9F_P#BZ/\`
MA67@_P#Z!'_DS-_\77-[7!WO[2IM;9;=OBV':5K612U'3/AQJM_-?7MYI<MS
M,<N_]I[<G&.@<#M5^UG\#6.DS:7:ZCH\-G,A25([U`7!&#EMVXG'?.:;_P`*
MR\'_`/0(_P#)F;_XNC_A67@__H$?^3,W_P`752Q&%E%1=6HTMEI_\D%I7O9%
MS3M9\):3816-CK&E0VT0PB"]0XYSU+9/)K/9?`3G4B=1TO\`XF6/M8&H@"3G
M/3?QSZ8J3_A67@__`*!'_DS-_P#%T?\`"LO!_P#T"/\`R9F_^+J55P<6Y*I4
MN]]%KU_F[ZA:5K61;&K>$!I(TO\`M?239"'R!$UZA&S&,9+9Z4W2M3\(:)8+
M9:?K.FQ6RDE4.H*^,]<%F)JM_P`*R\'_`/0(_P#)F;_XNC_A67@__H$?^3,W
M_P`74N>!:<7.I9Z[+?O\06EV1K?\)5X=_P"@]I?_`(&1_P"-'_"5>'?^@]I?
M_@9'_C63_P`*R\'_`/0(_P#)F;_XNC_A67@__H$?^3,W_P`74<N7?S3^Z/\`
MF/WS6_X2KP[_`-![2_\`P,C_`,:/^$J\._\`0>TO_P`#(_\`&LG_`(5EX/\`
M^@1_Y,S?_%T?\*R\'_\`0(_\F9O_`(NCER[^:?W1_P`P]\UO^$J\._\`0>TO
M_P`#(_\`&C_A*O#O_0>TO_P,C_QK)_X5EX/_`.@1_P"3,W_Q='_"LO!__0(_
M\F9O_BZ.7+OYI_='_,/?-;_A*O#O_0>TO_P,C_QH_P"$J\._]![2_P#P,C_Q
MK)_X5EX/_P"@1_Y,S?\`Q='_``K+P?\`]`C_`,F9O_BZ.7+OYI_='_,/?-;_
M`(2KP[_T'M+_`/`R/_&C_A*O#O\`T'M+_P#`R/\`QK)_X5EX/_Z!'_DS-_\`
M%T?\*R\'_P#0(_\`)F;_`.+HY<N_FG]T?\P]\UO^$J\._P#0>TO_`,#(_P#&
MC_A*O#O_`$'M+_\``R/_`!K)_P"%9>#_`/H$?^3,W_Q='_"LO!__`$"/_)F;
M_P"+HY<N_FG]T?\`,/?-;_A*O#O_`$'M+_\``R/_`!H_X2KP[_T'M+_\#(_\
M:R?^%9>#_P#H$?\`DS-_\71_PK+P?_T"/_)F;_XNCER[^:?W1_S#WS6_X2KP
M[_T'M+_\#(_\:/\`A*O#O_0>TO\`\#(_\:\X?PAHD6K>,DCTI)ETN&WEM87F
MEP,Q%V&0P)R1W-4XK#PNUQ+_`,2*UDB$<M["$NIP9+0#;&VXO@%G[\C';O6E
M6C@*<N5RGLGLNJOW[?DQ7G:YZG_PE7AW_H/:7_X&1_XU-:Z_HU[<+;VFKV%Q
M.^=L<5RCLV!DX`.>@->.:W#H>EP7;+X-MBVGO"+W;J=Q+R\NS;$`!OX!Y.W!
M_A.*V;+2=.TCXM>&X],MDMX9[`SLD<S2KN9)LD,W)&`/3Z4Z>&P=:,G2E*Z3
M>J5M%?HV#E*+LSUNBBBO)-`KSOX-?\BA=_\`7^__`*+CKT2O'_AGXD_L;PY<
M6_\`8NLWVZ[9_,L;7S4'R(,$Y'/'3W%=E.M"&#JQD]6X_A<UI8:K7E^[5['L
M%%<E_P`)U_U*GBC_`,%W_P!E1_PG7_4J>*/_``7?_95YWMH=SI_LW%?R_BO\
MSK:*Y+_A.O\`J5/%'_@N_P#LJ/\`A.O^I4\4?^"[_P"RH]M#N']FXK^7\5_F
M=;17)?\`"=?]2IXH_P#!=_\`94?\)U_U*GBC_P`%W_V5'MH=P_LW%?R_BO\`
M,/AE_P`D\TO_`+:_^C7JUXS_`+8&CQR:1%).T<ZO<00RF.26(9RJLO(.<=.:
MXWP3XWMM'\(6-A)H^L7#1>9F6VM@\;9D8\'<,]<?6M34/&NCZI'&EWX:\1-Y
M3[XW2VV.C>JLK@@_0UZ%;&48XZ=2]US-[>;]"8Y9BN6W+^*_S-_P9JL.JZ&7
MB>^W0S-%)'?-NEB8<["V`2!D8)Y]:Z*N!L?'.DZ;;^1:>&_$*(6+MFUW,S'J
M68N22?4FK/\`PLFS_P"A?\0_^`8_^*KEKXFC.K*4-$QQRS%):Q_%?YG0>)I9
M8/"VJS0R/'*EI(R.C$,I"G!!'0UYL==U66UT>P&I70GL+E/MD@E8-*KRH(PQ
MSD@JQ_*NCN_'^FWUG-:7/ASQ"\$R&.1?L@&5(P1D/FLX^(?#1>1_^$2U_=(8
M6<BV/)B_U?\`RT[?KWS79@LQPU&'+45W>^WR_*_SL3/*\7):1_%?YGIE%<5_
MPLFS_P"A?\0_^`8_^*H_X639_P#0O^(?_`,?_%5YOMH=R_[-Q7\OXK_,M^-H
M"EE;7<5S>PS-=V\!,%W+&I1I`"-JL!D@GG&:Z6WMTM;=(8VD9$Z&65I&_%F)
M)_$UPU]XYTG4H4AN_#7B&2-)%E4?9,893E3P_8BK/_"R;/\`Z%_Q#_X!C_XJ
MMYXR$J4:=]F_TM^HO[,Q7-?E_%?YG:UR_B_5)-"FTO53,ZVL<LD5Q&'(5PT;
M%<CH3N48SZU2_P"%DV?_`$+_`(A_\`Q_\55/4_&NC:Q9-9W_`(8\036[,&*&
MTQR#D<AP>M&'Q5&%12J:QZ^CT&\MQ5OA_%?YE70[_5_[1T[0;^^N'O&NTO9'
M,K!C"8=Y3UV[^,=.,5Z77GO_``F>B_VP-6_X1?7_`+<(?($OV3^#.<8WXZ]\
M9J[_`,+)L_\`H7_$/_@&/_BJTQ>.HUY*45;37UZDQRO%K>/XK_,[6N1UZS'_
M``EFB1+=:A''>O-YZ1W\R*VV/(P`X"\^F*@_X639_P#0O^(?_`,?_%56G\<Z
M3<WEK=S>&O$+3VI8PO\`9,;=PP>`^#QZUGA\9"E-ROT:^].WXC>68IKX?Q7^
M9WJJ%4*,X`P,G)_,TM<5_P`+)L_^A?\`$/\`X!C_`.*H_P"%DV?_`$+_`(A_
M\`Q_\56'MH=Q_P!FXK^7\5_F7/'=Q<6^E:?]GDN5,FHP1NMM*8WD4DY4,",9
M^HK8T>`0VC8MK^W+-DQWMT9W_/S'P/8&N1OO'&D:DD*7?AKQ#(L,RSQC[+C#
MKRIX?]*M?\+)L_\`H7_$/_@&/_BJZ98VFZ$:2\[[B>68J]^7\5_F=K17%?\`
M"R;/_H7_`!#_`.`8_P#BJ/\`A9-G_P!"_P"(?_`,?_%5S>VAW'_9N*_E_%?Y
ME#3]4U+3O&26>OIJ<4EQ<NMO<QSEK6=6SM0H<JN!C&W#>M>B5YK;^)?#MI=I
M<0>%O$2M&[/&GD,8XV/5EC,FU3R>0!U/K6K_`,+)L_\`H7_$/_@&/_BJZ\7C
M:%:47#3373]-?S)668M-^[^*_P`P^'D5NWPZTB>:V29K8S2Q90,RMYD@RN>A
MP2/QI'\0^%;F"/.BB:.W:*[A4VD9`>4%]R9.-XSEB.>>]8W@7Q7_`&9X-L+/
M_A']>N_+\S]]:V?F1MF1CPV><9P?<&H8ET>%+-5\,>,\VAN"C&SR3YP((;GD
M*"`OI@4L=B*<L35E%_:=OO8XY;BN5)Q_%?YG=Z*^A:Y86FKZ?96YC9089#;!
M67&3\IQV+-R#CDX/-<K\&O\`D4+O_K_?_P!%QT_P_KEIX:TE-,L/"_BTVL;$
MQK)8`[,\D#!'&<G\36!\,_$G]C>'+BW_`+%UF^W7;/YEC:^:@^1!@G(YXZ>X
MK:EB:*PE:*>[C^I/]FXNZ;C^*_S/8**Y+_A.O^I4\4?^"[_[*C_A.O\`J5/%
M'_@N_P#LJ\_VT.Y?]FXK^7\5_F=;17)?\)U_U*GBC_P7?_94?\)U_P!2IXH_
M\%W_`-E1[:'</[-Q7\OXK_,ZVBN2_P"$Z_ZE3Q1_X+O_`+*C_A.O^I4\4?\`
M@N_^RH]M#N']FXK^7\5_F'_-7_\`N`_^W%=5,)#!((2HE*G86Z`XXS7F$GC&
M.'XB_P!IRZ'K<:G2?L_V=K0";_6[M^W=]WMG/6MN3XBV$L3QR>'=?>-P596L
ME((/4'YJZ\3B*3<+/:*%'+<5_+^*_P`RKX0U2^AU\:5KD>J6VIM$W^NG,MO<
MD<EUW?=/LAVUZ#7F]AXIT#3)UFM?#'B0.B>7&9(6D$:_W4#2$(.G"XZ"M/\`
MX639_P#0O^(?_`,?_%48S&4*U3GIZ?Y_C^8HY9BUO'\5_F=K7E][KNHV/B/Q
M!!]MN2MXYL[)2[%89L1[=O.%SYC'_@-;?_"R;/\`Z%_Q#_X!C_XJLMO$_AU[
MK[4WA37S-]I%WN-L?]:%VAOO^G;I[56"QV'HN3J*Z:[>=PEEF+:TC^*_S.F\
M"S7$_A"S>ZN);B;=(K2RN69L2,!DGGM71UP-AXYTG2[-+2S\->(8H$)*K]DW
M8R23R7)ZDU9_X639_P#0O^(?_`,?_%5AB,52J593CLVV..68I*W+^*_S.NN[
M6.\MS#*TRJ2#F&9XF_[Z0@_K7/>`XVD\.PWLUS=SW$K2*[3W4DHPLC`8#,0.
M`.@JE_PLFS_Z%_Q#_P"`8_\`BJK6'CG2=+LTM+/PUXAB@0DJOV3=C))/)<GJ
M33CC(*C*G?=K];_I]P/+,4W\/XK_`#.^JEK$$USHM]#;RO%.\#B.1&*LK8."
M".1S7+_\+)L_^A?\0_\`@&/_`(JC_A9-G_T+_B'_`,`Q_P#%5E'$0C)23V*6
M6XK^7\5_F<^GB^],D7B)KF7^S8[<6<D.\[#.8#(6QTSOPN>M>B:!#/!X?T^.
MZEDFN!;H99)'+,S$9.2>>M<&?$'AEM);2SX1U_[$TOG&+[,?OYSG/F9Z^];'
M_"R;,#_D7_$/_@&/_BJ[L9C\-5BHTE;_`"6WSU=_D9QRO%I_#^*_S[':UA>+
MH=WAJ_N5FN89K:VDDB>"YDBPP4D$[2,].^:Q_P#A9-G_`-"_XA_\`Q_\54-W
MX_TV^LYK2Y\.>(7@F0QR+]D`RI&",A\UR4<33IU(SOLRUEN*_E_%?YG4:!;K
M!HMJPDN)&EB21VGN'E)8J,\N20/8<5IUP\/Q$L+>".&+P]XA6.-0BC[&#@`8
M'\=/_P"%DV?_`$+_`(A_\`Q_\54U,1"<G*^XHY9BDDN7\5_F=G(2(G(Z[37%
M>`3->Z58WEU#K$DQ1R;N>_9X9#N(_P!7YI[>J#I3C\2+)@0?#_B'!X/^AC_X
MJJVG^.=)TJPBLK+PUXABMX@0B?9-V,G/4N3U-;4\;3A1E#JVN^VM_P`UY`\L
MQ3:]W\5_F=]17%?\+)L_^A?\0_\`@&/_`(JC_A9-G_T+_B'_`,`Q_P#%5S>V
MAW'_`&;BOY?Q7^8WQQ<:Q8WMO=Q6]]<:0L++,+"X:*6*3/\`K/E^\`.Q!7KF
MNJTB\BO]'L[N"626*6%6624`.W'5L<9]<5PM_P"*]"U*X%Q<^&?$GG>7Y1DB
MA:)F3^ZQ20;E]CD5?A^(>G6\$<$/AS7XXHU"HBV2@*!T`^:NNKC:$Z$(+XEU
MM_7WZ$_V9B^:_+^*_P`RSH2J_P`0/&:.H96%D"I&01Y)JU>:MH6G7ZZ?+IH#
MAHK`;;=-JQ2#*CVBR-I]^U<GHGB]$\7^)+^/0M<G6[^RXBAM-TD6V,CYQN^7
M/4>HJQJE_I^KWEW=7'ACQBLMS9&R8QV>T(N2=Z\\.">#4XS$4Y5$T_LQ_""_
MX8<<LQ5OA_%=_7YFUX>U/PIK$TFEZ=I4,+0112"`V:!1'Q)&?ERH&7RH..=Q
M`X-8^HP16WQK\.001)%#'IS*D<:A54!9\``=!4.F76FZ1K;ZM:>%_&"W#P+;
MNIL1M9%1%4'G/&S(YZEO6JXU;^V/C-H5Q_9]_8[;1T\J^A\IS\LQR!D\<]?8
MUT9?B*2E-7WA)?.Q%7+\3&/,XZ+S7S/5:***XSE"O._@U_R*%W_U_O\`^BXZ
M]$KSOX-?\BA=_P#7^_\`Z+CKT</_`+E6]8?^W$/XD>B4445YQ84444`%%%%`
M'D7@W_D5++_@?_H;5NUA>#?^14LO^!_^AM6[77F'^]U?\4OS9,/A04445R%!
M115:34+*&\CLY;RW2ZE&8X6E4._T7.30!9HJO#?6EQ<S6T-U!)/#CS8DD!:/
M/3<!R/QJQ0`45'/<0VL#SW$T<,*#+R2,%51ZDGI4#ZII\=I%=O?VJVTQ`CF:
M90CD],'.#GVH`MT444`%%5X[^SEO)+2.[@>YB&9(5D!=![KU%213Q3;_`"I4
MDV,4?8P.UAU!]#[4`2445R>KW.JW/BF32M.U&YMG^Q0S1B-(BBY>4.[ET8G&
MU`%!&2?J0`=917-3:5J\<,<1\9W*7<ORQE[:VVNP&3A=F3P"<9H\.7>HG6M3
MT_4+NXG:V@MV(G6/Y79I<E61%W*0J$9''(]:`.EHK*\13W%OI(-K</;RR75M
M#YJ*I95>=$;`8$9PQZ@U!/IUQ:P//<>+-1AA09>21;154>I)AXH`W**Y35$O
M;?PS?ZM8>*K^X$-I+/"P2U>-RJDCD0\C([&NKH`***KQW]G+>26D=W`]S$,R
M0K("Z#W7J*`-OX9?\D\TO_MK_P"C7KK:Y+X9?\D\TO\`[:_^C7KK:Z\P_P![
MJ_XI?FR8?"@KSOX-?\BA=_\`7^__`*+CKT2O._@U_P`BA=_]?[_^BXZVP_\`
MN5;UA_[<)_$CT2BBBO.+"BBB@`HHHH`\Z\2?\E.C_P"P,/\`T<:EJ+Q)_P`E
M.C_[`P_]'&I:Z\7_`,N_\*)CU"BBBN0H***ANKNVL;=KB[N(;>%?O23.$4?B
M>*`)J*JMJ5@KVZ->VP:Y_P!0IE7,O^[S\WX5:H`***K1ZC8S23QQ7MN[V_\`
MKE6528O][GC\:`+-%0VMW;7MNMQ:7$5Q"_W9(G#J?H1Q4U`!114;3Q+,D+2H
M)7!*(6&Y@.I`[XR/SH`DHHJ"\NH[*TDN)<E4'11DL3P`!ZDD`?6@">BL6:2]
MBMGO-3U6WTR'.0JA-L8/9G?@GZ`#MSU,EK?SQ7$$%W)#<0W(_P!&NX1A7."=
MK#)YP,@@X.#TXR`:U%%<]%%J&I:MJX&MWMK%;72PQ101P%0OD1.>7C8DY=N]
M`'0T5S\%J]U/-!;^,;Z:6$XECC^R,T9]&`AX_&K&A277GZM:W5[+=_9;P11R
MS*BMM,,3X.Q5'5V[4`;%%%1SSPVT+37$L<42\L\C!5'U)H`G\"?\C7XJ_P"W
M3_T!J[VN"\!_\C7XJ_[=/_0&KO:Z\;_%7^&'_I$28[!7G>L?\ERT#_KP;_T&
M>O1*\[UC_DN6@?\`7@W_`*#/6V6_%4_P3_(4^AZ)1117G%A7G?P:_P"10N_^
MO]__`$7'7HE>=_!K_D4+O_K_`'_]%QUZ.'_W*MZP_P#;B'\2/1***S;C6[:V
MUZST=TE-Q=1O(C`#8`O7)SG/X5P1A*;M%>?W%MV-*BN?U#QCIFF>([;1)TN#
M<3E`)$0&-"Y(4,<Y!./2I[_Q/I^F^(+'1KKS$N+U28GP-F<X`)SG)/3BM?JM
M;3W7JKKT[B<DC9HK-MM;MKK7;[2$247%FB/(S`;"'&1@YS^@K2K*<)0=I+S^
M\9Y%X-_Y%2R_X'_Z&U;M87@W_D5++_@?_H;5NUTYA_O=7_%+\V3#X4%%%%<A
M05QVN2->^*+;318W,%JLL4]S>QV,C^>ZG*1AU4@`'!+$X'3UKL:*%NF'0XO0
M]-NX/$D(C%PMG:?:@1/:F,_O'#`;\D29.2"O0#GFNTHHHZ`4M5>&.Q+SV<MW
M&KJQ2*(2LI!X<*>NT\\`GC@&N*CL+ZWL+>22SN9+;%]&BB!FED,I!1W0#*D_
M-G@`9YP*]"HHMI8:=BII<,UMI%G!<-NFC@1)#ZL%`-6Z**;=W<E*RL<G);?;
M/$\'V:QN[9(UN([@M#Y2IO'^MC<##.Q`[D@=0#5OPEIYTRTU&V$$D,8OY3$'
M!RR\8;)ZY]>]=#126@WJ%8$5S#%X_O+=SB2;3;8QDCKMDGR,^O.<>Q]*WZP]
M6\,Q:M>O='4;VU=XXXV%OY7\!<JP+(Q5AYC<J10!6U?2=WB[0]2CBGE=9G61
MLLR1)Y3]NBY)'/<X]JFL)XKCQQK'E.&\BRM8I,?WM\Y_0&G/X?OI(FA;Q1K'
MEE=ORK;AO^^A%FIM%\/PZ++-)'=W-PTL:19F$8VJA=AC8B\DR,23DG-'2P=1
M/$O_`""H/^PA9?\`I5%3O$=V;'19;A=,DU*5"IBMTA,A+Y^4X`)`!YSCC%6M
M3T]-4L3:O-+!^\CE66';N5D=74C<".JCJ#5/^QK_`/Z&;5?^_=K_`/&:`,3[
M.T'PQUHR22R3RVEW-,TEN\'[QE8MA'`(7GCBNSK!N_#EQ?6<]I<^(]5>">-H
MI$V6PW*PP1D0Y'!K>IL`KEDC,OB^TEM=.N(5@\];@2P>7&N[GS48##LQ`[DX
MZ@&NIHI=;AT-/X9?\D\TO_MK_P"C7K6UM+QIM+>UEN55;Q/.2$<,ASG=QG`^
MH'K63\,O^2>:7_VU_P#1KUUM=>8?[Y4_Q/\`,F/PV\@KSOX-?\BA=_\`7^__
M`*+CKT2O._@U_P`BA=_]?[_^BXZVP_\`N5;UA_[<)_$CT2BBLW7=:MO#VD2Z
ME=I*\,14,L0!;D@#J0._K7!"$IR4(J[99I45G1:U;3:]+HZI*+B.W6Y+$#9M
M)P!G.<_A6?=>,=.M(-9FDANBND.B3A57+%L8V_-SU[XK2.'JR=E'M^.B^^XN
M9'0T4U'#QJXSA@",TZL1GG7B3_DIT?\`V!A_Z.-2U%XD_P"2G1_]@8?^CC4M
M=>+_`.7?^%$QZA1117(4%8?BJ^ET_2TFMM->^N_-"P!;=I1$QR/,(4$@`9Z#
M/;O6Y10QH\VET2XBLX+?3I+YY[JU2-Y9M/<*S+*7R"<&$@L3\PP1C'->DCIS
M113;$%<#J=C<W]S>?V9IMS!']B>*2*6`1",^8K;8\#:^\;B2"W;D=#WU%+K<
M.EC#\.1R[]4NFCEB@NKOS8$EC,;!=B*258`C)4]16Y110`5S4VE&+Q[9:C''
M.XEMIQ+*Q+*G^K"J.RC@G'<YKI:*%H[@%9FNL(K&.X="T5O<12R`=D##+?1?
MO?\``:TZ#R,&@#"\4W\ECI*7%IISW]T9`+?9`THB8@_O#M!(`&>G)Z=ZJ6,,
M=KHFBZ;'+-+.\ZR;I86B<[6WR,48`JO;D?Q`=ZT_[%,`V6&HW=E#@@0Q['1<
M]U#JVW'8#CVJQ9:9!92R3!I9KB7AYYFW.1Z#LH]@`.^*$#+M8^C?\A3Q#_V$
M$_\`26"MBL>30I?MUW=6NLZA:?:I!+)%"L#+N"*F1OC8]$7O0!G:9&7\5BXM
MM.N+:V2U>*5)X/*6%MX("8&&W<DD%N@Y'0Z.C?\`(5\0_P#803_TE@H_L:__
M`.AFU7_OW:__`!FK.F:8--%T3=W%U+<S>=++/L#%MBH.$50!A%[4=+!UN7ZX
M[Q_INK:EIA2SMXKBUC3>T(E=9&DR-I"JAW`#)QD<\]J[&B@!/AZ9#XD\3&55
M63;9[E5MP!\ML@'`S^0K6\92LKZ?'&VM)*[G9)I\4[QQ'(^>7RE);`SA6^4Y
M.1QD9O@3_D:_%7_;I_Z`U=[79C?XR?\`=A_Z1$F'PV]3"\/::;2ZU.YWZ@(Y
M9RD45W=S3`*O&X"1CMW,6/RX&-M<QK'_`"7+0/\`KP;_`-!GKT2O.]8_Y+EH
M'_7@W_H,]:Y;\53_``2_])%/]3T2BBBO.+"O._@U_P`BA=_]?[_^BXZ]$KSO
MX-?\BA=_]?[_`/HN.O1P_P#N5;UA_P"W$/XD=SJ=_'I6F7-_+'+)';QF1UB`
M+$#K@$BN-75K'7?B'HEWI]S'-%%I\LDNU@?+#=`V.AYZ5WA`(((R#U!JK;:7
MIUFLJVMA:P+-GS1%"JA\^N!S^-88>M3I1E=/F::^]6')7T_K>YY)<#7->T_7
M=3L]">XAOKD3V]\+I$,2PG"X0\G@'\ZT[V*'QUK.CON$<ESHSRQN/^64RN.1
M]&!%>G06T%K;K;V\,<,*#"QQH%51Z`#BH+;2=.LWC>UT^U@:-2J-%"JE03D@
M8'`)YKO>:QWC"S5^6W:UM;OR6UEY$\C_`*];G!^`-0NM2\8:]-?Q&*\2""&=
M3_?0%6/XD9_&O2*@BLK2&ZFNHK6&.XFQYLJ1@.^.FX]3^-3UP8RO&O5YXJRL
ME;T5BHJQY%X-_P"14LO^!_\`H;5NUA>#?^14LO\`@?\`Z&U;M/,/][J_XI?F
MPA\*,GQ#J$^GZ66M89WGE81JT4#S>5GJY5`3@#GIUP*K>"[R2^\(Z?--+/+*
M8\/).K!F()Y^;D_6M^HX8(;:%88(DBB085(U"J/H!7(NI1)1110!R&CW4Z>(
MW-Z)'-[-<"V>+47FC54.-IB'R)P.O)SD'!KKZK1:?907<MU#9V\=S-_K9DB`
M=_J0,G\:LT=$@ZL*Y?Q7<7HO;&T@$GD21S22&.Y:W)9`"!O4$C@L<8Y(&>,U
MU%07=E:W\/DWEM#<19#;)HPZY'0X-`T1:3<K>Z/9W2-*RS0(X:8`.<@'YL`#
M/TJY2````#`'0"EIO5DK1#)HUF@DB<N%=2"4<HP'L000?<&L#PC#NL[C4%N+
MN2&[E8P1W%U)-LC4E5QO).3@L?J/2NB(!&",@U'#!%;0I#!$D42#")&H55'H
M`.E)#)***S)]3F>\>STZU%Q+%CSI))-D46<?*3@DM@YP!]2,C(!S.M7UY%XL
M9H[F=;:VFM(W"S,-GF,00(A\L@;C);E>V:[FL*Z#VUS'J.HZ39W'D`XNH%WR
MPCN0"N<>NTY]JVT=9(UD1@R,`593D$'O1TL'6XZL;Q,;D:0/LLI0F>,.JS")
MY$+`%$<D88]!R/J*V:BN+>"[@>"YACFA<8>.10RL/<'@T`9'A6YN;G2)/M(D
MS%<S11^:^]MBN0,MDY(Z9R<XZFMRF111P1)%#&D<:#:J(H`4>@`Z4^FP.;\2
M2:C#J6CO#>>39M>Q1R1("&D))R&/]W`''?O5+3;Z\?Q%"[RS%KB\NX)H3*2B
M1Q_<(3.%/3D#G=SVKK98(9]GG1))Y;!TWJ#M8="/0^],2SM8[M[M+:%;F10K
MS",!V`Z`MU(I+3^O0'K_`%ZFU\,O^2>:7_VU_P#1KUI:YJ&I6=W8QZ>UFWFO
MAH)49I91D`[<$!``22YR!@#'-9OPR_Y)YI?_`&U_]&O6]?:)I.J7$%QJ&EV5
MW-;G,,EQ;I(T?.?E)&1R!TKKQ_\`OE3_`!2_-DQ^$OUYW\&O^10N_P#K_?\`
M]%QUZ)7G?P:_Y%"[_P"O]_\`T7'6V'_W*MZP_P#;A/XD>B5YQXW\2Z=K/A?4
M]*@=HM02\2V%K,5$CL)%^95!)*^]>CU5;3+![Y;YK&V:[48$YB7S!_P+&:PP
ME:G1J*I-7:LUZHJ2;5D<E+?VNC_$V234;B*UAN-+18Y9F"(65^1N/&:YS498
MKSPQX\U"V<26T]W&L<J_=?:5SCUZUZC>Z=8ZC&L=]9V]TBG(6>)7`/K@BAM.
ML6L/L+6=N;/`7[.8E\O`Z#;C%=5+'TX<LN5W7*GVM%I_?H2HV?X_A8IZ=K^C
M7?D6UMJUA/<,@"Q17*,QP.>`<UJUG6WA_1;*X6XM=(L()D^[)%;(K+VX(&>E
M:-<%5TW+]W>WF.*:5F>=>)/^2G1_]@8?^CC4M1>)/^2G1_\`8&'_`*.-2UMB
M_P#EW_A01Z@>!FN0\+W,ZZEY5]YCW-Y%)=1RIJ+W,1C\SIM^XF-P`VYR!UKK
MZK6VGV5G)+):VEO!),VZ5HH@I<^K$#D_6N1;E/8LT444`<9XHU"[@UB4$W*6
M5I9K<[K>Y,39WD,0`I$A`"_(W')]J[)3N4$9Y&>14-Q8VEX\3W-K!.T+;XC+
M&&*-ZC/0_2IZ.E@>]PJO?)"]C,)WD2$(2[12M&P`YX92"/P-6*;)&DL;1R(K
MHX*LK#((/4$4GL-;F)X2@==#CNI)KF0WA^T*MQ</*8T;[J@N2>%QGGKFMVFH
MB11K'&BHB@*JJ,``=@*=5/?0E!7#-?7@\;%Q=3_95U!;0@3-QF#=L\G[NW/S
M>9][MC'-=S5?[!9F^%\;2#[6%V"?RQYFWTW=<4EH[CZ6+%%%5+Z_2R6,>6\T
M\IVQ0QXW.>_7@`=R>!0!F^)_M1@LE@>3RVN0LT,-P()9EVM\J,67G.#@,"0#
M4WABZN;WP[:3W>?.8,"2<E@&(!SWR`#FF7<.HWUH8[S2M+N8F(+6TLI<$9]2
MF"?;'7OWJ_IU[#>0$1QM"\)\N2!P`T38!P0..A!&."#0M@9;KFM7DU*+Q;HF
M+S98RRNGV>,$%R(G)+GOR!@?CZ8Z6HY((99(Y)(HW>(EHV902A(P2#VX)%`=
M#D?#E]>2ZQ:F6::3[9;W$MPCREEC=)0JA0>%X)&!C..>:[*H(;*UMYYIX;:&
M.:<@RR)&`TA'3<1R?QJ>CH@ZE34UO'T^5;&:."<CB1TW;1W('KC./>N,DN]7
M;P)H5['J+H";?[0Y),LI:1!C=G@8)SZ\#UKOB`1@C(-5_L-I]E2U^RP?9TQL
MA\L;%P<C`Z#!&10M']PRWX$_Y&OQ5_VZ?^@-70^(M0U*Q^R_V:UD9)'(\F='
M>2<\81`I&WC)+G(4#H>W/>!/^1K\5?\`;I_Z`U==J.AZ3J[POJ>EV5ZT))B:
MYMTD,><9V[@<=!T]*Z\;_%C_`(8?^D1(CL_F9/A?7=1U:[OH]0ABB1-LMJ43
M:7B9G`;[[9'R]2$/7*#@G`UC_DN6@?\`7@W_`*#/7=VNG6-B\[V=G;V[SOYD
MS0Q*AD;^\V!R?<UPFL?\ERT#_KP;_P!!GK;+?BJ?X)?D*?ZGHE%%%><6%>=_
M!K_D4+O_`*_W_P#1<=>B5YW\&O\`D4+O_K_?_P!%QUZ.'_W*MZP_]N(?Q(WK
MB\U7_A-K.%[:YCT\ATC*/'LE^3)=OFW<'@#'OSGC+U?4[ZPU*^<3W'D:5,+R
M10S'S(I-H"GU`_>G';:*Z[4=3M]+ACEN!(1)*D2B-"QRS!1GT'/4U%;ZS#<:
MH]@(9E9=^V5@NR0H0&`P<\%AU`]LTJ55I*?L]$K>MGJ_6S_7H-HX];A[75[>
MVU+48A(EK;%OM.MRVI+'=N*HO$G/KCL*@CU,BPU.1;^)KY%N-BKK<KS9#G`\
M@_*O`Z@\5V,/B33;BSDN(9TD,1Q+"LB>9&<D?,-W'3@=31!XDTZ6%II9EM85
MZR7,B(.W^U[UO[>?6F^G5_EY]B.7S,*\NV^S-_:6HFSNQ<DW$,EW);PXVG8J
MRK]Q3P=W\1!!YX'2Z--]HT>UES,=R=9F#,<<9S@9SV..1@TX:OIAD@C&HVAD
MG4/"OGKF13P"HSR#[5=KBKU>:"BXV_KH6EJ>1>#?^14LO^!_^AM6S.CR02)%
M*8I&4A9``=I['!ZXK&\&_P#(J67_``/_`-#:MVGF'^]U?\4OS80^%'%:5I\K
M^'-<M$U"Z0I?S[YPP,C@`9&[MGU'3MBMWPI_R*.C_P#7G%_Z"*E_X2#2C9RW
M:78D@CF-N6C1G)DSC:H`)8Y],U<LKVWU"U2YM9/,A?.#@@Y!P00>001@@\BN
M5;?=^"'U^_\`,GKEM:MI%\9>'[IKJ5HVG=$@X")^Y<D^Y/J>G;O74U5GU*SM
M;VULIKA%N;HD0Q=6?`R?PP.II+<?0X_0KO2[_P`<W3Z5):P1VXECF_?`SWDI
M())!.XHN."?7CBNZJA::SI]]=R6MM/OE3/\``P5L'#;6(PV#P=I.#UJ_1T0=
M64]4MI+O3I88KJ6V9AS)%C=CN!GID<9[9KARFFR_#G2([Z:**Y-D?LKW"LR;
M\=N0OF?W<\YY&>:[R]OK?3[5KFZDV1J0,A2Q))P```223P`!FJ;^(M+CLH[M
MKAO*D9E&(7+`K][<N-RX[Y`QWQ1T8T[%K37>72[222*2)VA0M'*<LIP."?6K
M5(K*Z*ZL&5AD$'@BEIO5DK1'(/'>6/C2_GA::_N7TUI(8695`_>?*BYP`/<]
M:9X$-VMSKT=Y#<K/]L5Y'G9"2YC3(^5FQ[=L$<]<=%#K>GW&H-8QSDSJ67F-
M@K%?O!7(VL1W`)(J:QU&SU*.62RG69(I&B=DZ!AU&>_X4HZ+Y?K<;W^?Z%JN
M%\06[7'@/4MEU-`UO)<-<QIP97WL<,>NWD'`ZC':NZK#UDVFGW"7OVV>SN)3
MM(@A,WGX'\484DX'<8(`ZXH&C`UEHH/%<-Y*NFW<R);QP6<]N6GP6.YXF)`&
M,Y)`;A>=M=/X>S_8D)R/+9I&AP,#RB[&/_QS;67+>V-Y/!:W^LFXAF"$1V]N
MRPR!_NB1QD`-V!8;NF#73@```#`'0"GT)`Y*D`X..#Z5YV]O>6MIXB@2YDN6
M74;;[3--_%&5C,A(&,+@G(&.*]$)"J68X`&2362GBC1Y+>6=;IO+C"D[H7!<
M,<*4!7+@G@%<Y[4EO_7<H@\(R1OHS+##"D*3R+&]OD0RKG[\8+-M4]@#@=JW
MJKV5];:C:K<VLGF1,2,[2I!!P00>00>"#R*L4V)'+^*;:0ZEHER;J41+?PH+
M<<(2=V6/<GH`.@I+#2]-G\;WUY#I]K%)8*(_,CA56>60;G9B.IVE1SZGUK9O
M=;T_3[E+>ZG*2,`W$;,$!.`6(!"@GC+$"I6U*S75$TPSK]L>(S+$`<[`0"?0
M<FE'3\0>_P!QO?#+_DGFE_\`;7_T:]3^+-4ETZ73?LVI&VG>=?\`1CL`NDW`
M,J[D)9\=%5D/4YXQ4'PR_P"2>:7_`-M?_1KUUM=>/_WRI_B?YLF/P_(*\[^#
M7_(H7?\`U_O_`.BXZ]$KSOX-?\BA=_\`7^__`*+CK;#_`.Y5O6'_`+<)_$C=
M\4WNJV]WIZVEO<_8Q<0F66%XQO)D`\LY8$#'H.<@<#-,\2&^;5(]/M+JYA;4
MK<I&\;D>4T9+%A_=)!QGO@5TMS<1VEM)<2[O+C7<=JEC^`')-9:>);21K4K!
M<&.>.&1I<+MB\TXC#?-G)/'R@X[XJ*-25HN,/AO\WTOZ/[]AO??^D<D^K2WE
MII^H7-WY,-[+,PCN=3DLD4*J(!O3GJK''?)-3:?J$#Z]*DFHVK*LL*PJWB&;
M.#%&<(G28%B>3C<2<UUIU[3UO;NR:=%NK89,+R(K.-@?*@GI@]3@=:A@\36$
M]Q)#AXO*)WR2LBJ`&D4G.[D?NV/';!]<='MI.+M3:5N[V;NOPT\Q<MEN<U87
MUU-X?C?5=1GLYGM(##)YCE6BRN]V9>=Q/#-_`&!SU)Z3PS<K<Z=+Y<CRQI,5
M5_M1N488!^24@%UYQD\YR.U6O[=TC[.+C^U;'R"_EB3[0FTMUVYSC/M5]6#*
M&4@J1D$'@US8BMS1:<+7?R_(:7F>=^)/^2G1_P#8&'_HXU+47B3_`)*='_V!
MA_Z.-2U.+_Y=_P"%!'J<I>0M;^/K*XN+R5XI+.Y(1CM2%1Y?3'XDD\_E5/P/
M<Z=?ZEJ%YI+VL%B46.*UCE#2OM)S-*,D@MG`+<D#FNLEU.RAU!+"2Y1;IXVE
M$9/.Q<98^@Y[TS3]7L=5#_8YB^P`G=&R94]&&X#*G!PPR#C@URK^OO*9>K&\
M4VTEUX<O5CNI;<+"[N8N&<!3\N>P)QR.:V:JW^HVVFPK+=.RJS!$5(VD9V/9
M54$D\'H.U3)75AQ=G<XK5_[/_L72&R#JT5M;O!&0WF2*""5A).`Y[D9..HQB
MN_'3IBLQO$.E*+9OM65N1F-A&Q`&<98@?(,\?-CGCK6G5-W^\E*R2"N)@CU'
M3M?\2&T:;4;]K:W:,.RC!9I.@)"A5';(SCU.:[:LZTUW3;VXD@@N,NBECNC9
M58`X)5B`&`/!*DXI#,7P#YJZ3?1317*M'?S`O<,A9SNYSM8\YZ]O3-=75:PU
M"TU2T6[L9UFMV9E61<X)!(./Q!YJS38'+>.+:633;:<74J1174&84P%D)F0`
ML>O'/'O[51E:.'QX\[)IUY=23QQ)`;<_:H(]G^L5F/"@DYP".?O9XKJ-1UFP
MTIHUO)F1G!8!8F<A1U8[0=JC(RQP!ZTU==TUM1%BMQF<D*,1MLW$;@N_&W=C
MG;G..U"_K\`>QHUDW"EM?9/,\J:2Q9;:3:#M.[YR`?K&<>PK6JEJEM:7%F7N
MW,20'SEG5]C1$?Q`]N,Y[$9!R#28(X7R)H-$N(#<+):KK<BWDU[\Z&/;]Z09
M&5W;<C(';@5N>$)8YV+0V_D*ELJ.%)*-B2385R2<%<D#/"LO;%._ME'LG?\`
MM^58PPCXTYA<Y897"%>21D@A"#BMS25LO[/CEL'\R&;]YYN<F0GJQ)Y)_P#U
M4UM;T_(76_K^9=KEM:MI!XR\/W+74K1M/(B0<!$_<OD^Y/J>G;O74UGSZWI]
MM?K933E9V*C_`%;%5+?=#,!M4GL"1GM26XWL8WA_3-./B/5M2M=/MK;R)/L<
M9AA5,X`9V.!R2QQ_P&NIJJFI6<FIRZ<DZM=Q1B62(`Y52<`D]/PJU1T0=64]
M4MI+O3I88KJ6V9AS)%C=CN!GID<9[9KS*^57\*>'UD>-%&ERF-[A=RM)\NU8
M^1B8\[6Y(YX->HWM];Z?:M<W4FR-2!D*6)).```"22>``,U2?Q'IB6\$_FSN
ML[LD:16LKR;E^\"BJ6!&.<@8H7]?U\QIV-+X<LS>(/$;,CHQCLB5<Y8?NVX)
M]:V/&>M#27T^-?$$&EW$[D0Q2^4%G8$??:3H@!.0N&.1@@\',\!$-XI\4L,X
M(M#R,'_5M7?5V8[^,G_=A_Z1$SA\-O4Y+PAK5]J6IZK;7-R;I+9E#2!X'1)"
MS!D0Q'A0`IP_SC//45D:Q_R7+0/^O!O_`$&>O1*\[UC_`)+EH'_7@W_H,]:Y
M;\53_!+\@G^IZ)1117G%A7G?P:_Y%"[_`.O]_P#T7'7HE>=_!K_D4+O_`*_W
M_P#1<=>CA_\`<JWK#_VXA_$CN=3L?[1LOL_F>7^]CDW;<_<=7Q^.W'XU0LM`
M^R:Y-J7GQ-YA<_+!ME;<0<2/GYPN,*,#`]:VJPO$TU]';PI:FZ2*0.)'M;?S
MGSM^52,'"D\$XXXY'6N:A*I+]U%V3_K]"[)[E-/"$FP)+J",J!EBV6^W`9]Y
MW?-\QST/'ZU+!X3$,UN[7@<0RK)M,/7!4^O^S6,;[Q"D\<%DM[#%%;$,+B`"
M-76,,N&\L<,01DN<9/`.*L:9JNO7.I:?=3FX:SOAY@M8X,"!&+;=[^60WR[2
M1O4CT/2O0G#%<K?.N_Y^7J8WBUJ@'A[4K76+:W@0/8^?%<23E4ZH6.!\VY>,
M#`4YSG(Y%=K117G5L1.M;FZ&JBD[GD7@W_D5++_@?_H;5M30QW$$D$J[HY%*
M.I[@\$5B^#?^14LO^!_^AM5W5]1DL+4"VMVN;V;*V]NI`+MZDD@!0.23].I`
MK3,/][J_XI?FQ0^%')/IYBMKK188E$W]I?;$M(9!&[6X8$>6P("-QP,@X';K
M73>&K*YT_0XK>Z78X>1E3(+(I<E0Q!.YL$9.3D]SUKF)]2CL]"U"*\B@BU6S
MGA=Y_M8V^?)@*YD*C;@<%<$!>.174Z#JYU:QWR^0MS&=LJP2^8A_NNK8&58<
M@_4=0:Y5M;^MAVU-6L#4]&\WQ)I.I6]JA>.9C<S9`8)Y3JO7DC+=!ZUOT4AG
M):3H5U;^(H[@Q7%O9VOV@1QR3I(A\Q@?W>T!L<$G?R#P,BNMHHHZ6`S=>GU.
MWT>9]'LQ=7Y`6)"RJ!G^([B!QUQGFN8CT&^MK"TF@LKR6X$5S%/'<2Q"1Y)L
M$RG#E<9'0'('8UW-%%AW*NFVK6.EVEHS[V@A2,MZD`#-6J**;=W<E*RL<C'9
MZEJOBJ:;6=,N4L(EDALU62(Q;6&&=\/NW,.`-O`-:GAO3)-+@OX6@6"-[V22
M%%(QY9QMQCITZ5M44EH-ZA6!XK;67L8[71[6:3[0VRXFA>,/#'W*AV4%CT'/
M'6M^BBUP3L<5+8:C-?Z3IPT:]BT&Q6)U5982SR+C:)/WF=J\$XSDC\^UHHIW
M`:[,L;,J%V`)"@C)]N:Y#1DUU);_`%;4=&N6U.<*@A^T1+&D()PD95SEL$G+
M;<GN*[&BD!C^&K&YT_2?(N(_+S-(\<3,&>-&8D!V!.YN>3D_4]:V***`.5\4
M0ZMJ-_:Z?'IUS+HQQ)=26\D0>4@\1_.ZD+QDGOT%16GAW5K7QO%JCW-O<6[Q
MS>;+Y!5E#%-D?^L.<!>"!C@Y&3FNOHH6G]=P>II_#+_DGFE_]M?_`$:]3^*K
M#6[Z[TO^SH+::S@N8IIE>[:%\K(IS@(0P"[N"1SZX%0?#+_DGFE_]M?_`$:]
M=;79C_\`?*C[2?YDQ^"WD%>=_!K_`)%"[_Z_W_\`1<=>B5YW\&O^10N_^O\`
M?_T7'6N'_P!RK>L/_;A/XD>A.N^-ESC<",USG_")9FTTO?,8;.&&-XPK+YAB
M.5;AP.O9@V.V.M=+6?K<MW#I,TEB)/.!7F--[JNX;F5><L%R0,'D=#TKEH5*
MD9<L':Y32>YF7WAB2]OKR4WR)!<N)#&+?+JPB\L?/NZ=21CVR.<UI/!7F+<C
M^T,><''^IZ;C,?[W_3;_`,=]^,P7NN6L4"6<>JEVNVD9I+0!98VF.2P\HD-M
MYQE.N1TQ0^J>)VCDE$TY6TG^RM';P!FNF3.YPRQ.$SE1@@#(/*UZ:IXI*T:B
MMM]VBZ?UU$Y(M:[X<U".66;2XUG:YCD@=2B;8U:*-.C,/^>8.X9QTVM78V\9
MAMHHB<E$"DCV%.0ED5BI4D9(/44ZO,JXB=2$82Z#21YUXD_Y*='_`-@8?^CC
M4M1>)/\`DIT?_8&'_HXTL\\5K;R7$\BQPQ*7=W.`JCDDFM,7_P`N_P#"A1ZG
M+ZU9V6G>([;5IXHHK6:&:&YE)P7=P@4'OC:IY`PH!)P*=X7T:\L[Z2ZN$N88
MUM8[6**>:.0@*S'Y2@`*@$`$_,><U#_:UPFN07>JV`BM+IC;V0DE'F(I0L6,
M>.X'))!'`V]27>%M?2:466(192@-8NEP)&0$9$,@ZJV/F`/\/&<BN5>7]?U<
MI^?]?U8ZZL;Q+-K$>DE-$M6GNY6"%@R`Q*>K@.R@D=AGK6S12!'!MX9O$L_L
MUG9W2Q75G':L9YH]\++(SM(^&(.=Q/RD\]O3O!P,444[A8*X_3M.OM7UJ]NO
M$6DSHCQM!;QO)$T*0Y!P=KEBS8!.1CC%=A126]PZ&-X7L)],T06MQ$(G$\S!
M`0<*TC%>G'0BMFBBAL#F?%T>KWL<&G6-E<2V-QD7LUO)$)`G]Q0[K][N>PJO
M]FU2\\56OVK2KJ'2+#:;01RPE2^W&^3]YN^7)``!]:ZZBA:`]0J&[DFALYI+
M>`SS*A,<08+O;'`R>!GWJ:B@#C='@UB"QO;O4-(O)M1O7'VM1<Q1D)@@+"5<
M\+_M,IY)SGBM_P`/6=SI^@VMI=;!+$I7:G\*Y.T>Y`P">YK3HIW`*Y36H-6U
M+Q':V\FG7+:+;NDV^&2+][*#D%PSA@BG!P`22*ZNBEUN'0Y'0_#VJZ7XKN+R
MYN;>X@FML23K`4:20N3@YD;D#'.,8P!C%==111TL'6YFZ]/J=OH\SZ/9BZOR
M`L2%E4#/\1W$#CKC/-<M_8%Y'IMF8K'5C>(L^93?1Q.)Y"#YCA'PRY'0,<#C
M:>W=T4!<9\.5G3Q!XD6Y=7G"60D91@,WEMDC\:W/&>ESZK:6L-OI8NYDE$D,
MX\K-M(""K'S.0AYW%#O';KD9/@3_`)&OQ5_VZ?\`H#5WM=F._C)_W8?^D1)A
MI&WJ<AX-T>YTR\O7FTG[!OC1)9,Q_P"ES!Y"TV$8]0R\MACW'%96L?\`)<M`
M_P"O!O\`T&>O1*\[UC_DN6@?]>#?^@SUKEOQ5/\`!+\A3[^9Z)1117G%A7G?
MP:_Y%"[_`.O]_P#T7'7HE>=_!K_D4+O_`*_W_P#1<=>CA_\`<JWK#_VXA_$C
MT2BBBO.+(YX(;F!X+B))87&'CD4,K#T(/6G@!5"J``!@`=J6BG=VL`4444@/
M'?"UPEIX*M[B0,8XDE=@BEC@.QX`Y)]A45O=QSP7-[+>BWU*YB*1%HBXM5_A
M4#C)!Y//)]@*M>#?^14LO^!_^AM6[77F'^]U?\4OS9,/A1Q.EV,>FZ.;,:Q:
M23B99Q<'3G)>0'):0,[;B?4%2.V*EACL])M5N;.\,U_&\DLG[ME6<.Q9DQS@
M9.5Y.#WY.>QHKEN416MPEW:Q7,0<1RH'4.I5@".X/(/M4M%%(`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#3^&7_)/-+_`.VO_HUZZVN2
M^&7_`"3S2_\`MK_Z->NMKKS#_>ZO^*7YLF'PH*\[^#7_`"*%W_U_O_Z+CKT2
MO._@U_R*%W_U_O\`^BXZVP_^Y5O6'_MPG\2/1****\XL*B@MX+6$0V\,<,0R
M0D:A5&>3P*EHIW=K`%%%%(#SKQ)_R4Z/_L##_P!'&L.ZU"WO=7>VN7:.SLW&
MY6C;]_*,$=N47CZM_N\[GB3_`)*='_V!A_Z.-2UUXO\`Y=_X43'J<:;:*3Q1
M+J\^KV]Q$Z>5'!+92$P1D8(1M^`3W.TTVRTK2;<%)]1,L4=LMK;JD+H8T5MR
MDG)RX.,-QTZ5VE%<BT*>IEZ)J37T,T,N6GMFV/($*K*,9#KGU'4=CD>A.I11
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`_P)_R-?BK_
M`+=/_0&KO:X+P)_R-?BK_MT_]`:N]KKQO\5?X8?^D1)CL%>=ZQ_R7+0/^O!O
M_09Z]$KSO6/^2Y:!_P!>#?\`H,];9;\53_!/\A3Z'HE%%%><6%>6_"?6M*T[
MPM=0WVIV=K*UZ[!)YU1B-B#.">G!_*O4J\M^$^BZ5J/A:ZFOM,L[J5;UU#SP
M*[`;$.,D=.3^==E/VGU.KR6M>-[_`#M8UI>PYOWU_*UOU.\_X2GP]_T'M+_\
M#(_\:/\`A*?#W_0>TO\`\#(_\:/^$6\/?]`'2_\`P#C_`,*/^$6\/?\`0!TO
M_P``X_\`"O._>^1T_P"P_P!_\`_X2GP]_P!![2__``,C_P`:/^$I\/?]![2_
M_`R/_&C_`(1;P]_T`=+_`/`./_"C_A%O#W_0!TO_`,`X_P#"C][Y!_L/]_\`
M`/\`A*?#W_0>TO\`\#(_\:/^$I\/?]![2_\`P,C_`,:/^$6\/?\`0!TO_P``
MX_\`"C_A%O#W_0!TO_P#C_PH_>^0?[#_`'_P/+?">J:?;>&;.*>^M8I%WY1Y
ME4CYV/0FMK^V]*_Z"=E_X$+_`(UB^$]+T^Y\,V<L]C:RR-OR[PJQ/SL.I%;7
M]BZ5_P!`RR_\!U_PKJQWMOK53FM?F??N3'ZCRKX_P#^V]*_Z"=E_X$+_`(T?
MVWI7_03LO_`A?\:/[%TK_H&67_@.O^%']BZ5_P!`RR_\!U_PKE_>^17^P_W_
M`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`
M0,LO_`=?\*/WOD'^P_W_`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=
M*_Z!EE_X#K_A1_8NE?\`0,LO_`=?\*/WOD'^P_W_`,`_MO2O^@G9?^!"_P"-
M']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`0,LO_`=?\*/WOD'^P_W_
M`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`
M0,LO_`=?\*/WOD'^P_W_`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=
M*_Z!EE_X#K_A1_8NE?\`0,LO_`=?\*/WOD'^P_W_`,`_MO2O^@G9?^!"_P"-
M']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`0,LO_`=?\*/WOD'^P_W_
M`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`
M0,LO_`=?\*/WOD'^P_W_`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=
M*_Z!EE_X#K_A1_8NE?\`0,LO_`=?\*/WOD'^P_W_`,`_MO2O^@G9?^!"_P"-
M']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`0,LO_`=?\*/WOD'^P_W_
M`,`_MO2O^@G9?^!"_P"-']MZ5_T$[+_P(7_&C^Q=*_Z!EE_X#K_A1_8NE?\`
M0,LO_`=?\*/WOD'^P_W_`,#0^'>OZ-9>!--M[O5K"WG3S=T<MRB,N97(R"<]
M"*ZC_A*?#W_0>TO_`,#(_P#&N7^'>@:->^!--N+O2;"XG?S=TDMLCLV)7`R2
M,]`*ZC_A%O#W_0!TO_P#C_PKJQWMOK53FM?F??N3'ZCRKX_P#_A*?#W_`$'M
M+_\``R/_`!K@_A/K6E:=X6NH;[4[.UE:]=@D\ZHQ&Q!G!/3@_E7>?\(MX>_Z
M`.E_^`<?^%<'\)]%TK4?"UU-?:99W4JWKJ'G@5V`V(<9(Z<G\ZUH>W^IU;6M
M>/?S!_4>9?'^!WG_``E/A[_H/:7_`.!D?^-'_"4^'O\`H/:7_P"!D?\`C1_P
MBWA[_H`Z7_X!Q_X4?\(MX>_Z`.E_^`<?^%<'[WR*_P!A_O\`X!_PE/A[_H/:
M7_X&1_XT?\)3X>_Z#VE_^!D?^-'_``BWA[_H`Z7_`.`<?^%'_"+>'O\`H`Z7
M_P"`<?\`A1^]\@_V'^_^`?\`"4^'O^@]I?\`X&1_XT?\)3X>_P"@]I?_`(&1
M_P"-'_"+>'O^@#I?_@''_A1_PBWA[_H`Z7_X!Q_X4?O?(/\`8?[_`.!P6OZS
MI<WQ$2ZBU*SDMQI(C\U9U*;O-)VYSC..<5+_`&WI7_03LO\`P(7_`!J+7]&T
MN'XB):Q:;9QVYTD2>4L"A-WFD;L8QG'&:E_L72O^@99?^`Z_X5U8KVWN7M\*
M[DQ^HZ_'^`?VWI7_`$$[+_P(7_&C^V]*_P"@G9?^!"_XT?V+I7_0,LO_``'7
M_"C^Q=*_Z!EE_P"`Z_X5R_O?(K_8?[_X!_;>E?\`03LO_`A?\:/[;TK_`*"=
ME_X$+_C1_8NE?]`RR_\``=?\*/[%TK_H&67_`(#K_A1^]\@_V'^_^`?VWI7_
M`$$[+_P(7_&C^V]*_P"@G9?^!"_XT?V+I7_0,LO_``'7_"C^Q=*_Z!EE_P"`
MZ_X4?O?(/]A_O_@']MZ5_P!!.R_\"%_QH_MO2O\`H)V7_@0O^-']BZ5_T#++
M_P`!U_PH_L72O^@99?\`@.O^%'[WR#_8?[_X!_;>E?\`03LO_`A?\:/[;TK_
M`*"=E_X$+_C1_8NE?]`RR_\``=?\*/[%TK_H&67_`(#K_A1^]\@_V'^_^`?V
MWI7_`$$[+_P(7_&C^V]*_P"@G9?^!"_XT?V+I7_0,LO_``'7_"C^Q=*_Z!EE
M_P"`Z_X4?O?(/]A_O_@']MZ5_P!!.R_\"%_QH_MO2O\`H)V7_@0O^-']BZ5_
MT#++_P`!U_PH_L72O^@99?\`@.O^%'[WR#_8?[_X!_;>E?\`03LO_`A?\:/[
M;TK_`*"=E_X$+_C1_8NE?]`RR_\``=?\*/[%TK_H&67_`(#K_A1^]\@_V'^_
M^`?VWI7_`$$[+_P(7_&C^V]*_P"@G9?^!"_XT?V+I7_0,LO_``'7_"C^Q=*_
MZ!EE_P"`Z_X4?O?(/]A_O_@']MZ5_P!!.R_\"%_QH_MO2O\`H)V7_@0O^-']
MBZ5_T#++_P`!U_PH_L72O^@99?\`@.O^%'[WR#_8?[_X!_;>E?\`03LO_`A?
M\:/[;TK_`*"=E_X$+_C1_8NE?]`RR_\``=?\*/[%TK_H&67_`(#K_A1^]\@_
MV'^_^`[P7K>DVOB;Q++<:I90QS?9?*>2X10^$8'!)YQWQ7;?\)3X>_Z#VE_^
M!D?^-<3X+T32;KQ-XEBN-+LIHX?LOE));HP3*,3@$<9[XKMO^$6\/?\`0!TO
M_P``X_\`"NK&>V]HN:WPQ[_RHF/U&WV_P#_A*?#W_0>TO_P,C_QKB;N_L]1^
M-F@S6-W!=1+9.I>"0.H.V8XR._(_.NV_X1;P]_T`=+_\`X_\*XF[L+/3OC9H
M,-C:06L363L4@C"*3MF&<#OP/RK;+_;<\[6^"7?:VI-7ZGR^[S7Z;'IE%%%<
MARA7G?P:_P"10N_^O]__`$7'7HE>=_!K_D4+O_K_`'_]%QUZ.'_W*MZP_P#;
MB'\2/1**ANY6@LIYD`+1QLX!Z9`S7(>']3\:ZS:V&HNOA];"XVNZ@3"4)GG'
M)&[&>^*Y:>'E4@YW22[E-V.UHKA;/6_&6LWVJ+I::"MO97DEL/M0F#G:>#\I
M(Z$>E6M5UGQ/;:EHVDV::0=0NX)))VF$OE!DQG:0<XY[BMG@*BER<ROOOMI?
M7Y"<DK_UY'845S7A[6]5N=8U#1]9ALQ>6B))YMDS&-E;/'S<@UTM<]:E*E+E
ME_5]1IW/(O!O_(J67_`__0VK=K"\&_\`(J67_`__`$-JW:VS#_>ZO^*7YL4/
MA04445R%!115:34+*&\CLY;RW2ZE&8X6E4._T7.30!9HJ!+ZTDNY+1+J!KF,
M!GA60%U!Z$KU%3T`%%1SW$-K`\]Q-'#"@R\DC!54>I)Z52FU_1K:"&>?5K"*
M&<$Q227**L@'4J2>?PH`T:*9%+'/"DT,B21.H9'1@58'H01U%/H`**K)J-C)
M=R6B7ENUS$-TD(E4N@]2N<BEM+^SU"(RV5W!<QAMI>&0.`?3([T`6***P;[5
M2[3_`/$RM],L(G,+7DK)N>3H0F_Y1@\9(.2",<4`;U%<^\MSITR1Q:XNHW#K
MYBV=V85DE4=?+**O/U!'TZC;M;F.\M8KF$DQRJ'7(P<'U'8T`2T453CU73I8
M9YH]0M7BMR1,ZS*5B(Z[CGC\:`+E%1P3PW,"3V\J2PR#<DD;!E8>H(ZU)0`4
M57GO[.VGA@N+N"*:8XBCDD"M(?\`9!Z_A4GGQ>?Y'FIYVW?Y>X;MN<9QUQGO
M0!K_``R_Y)YI?_;7_P!&O76UR7PR_P"2>:7_`-M?_1KUUM=>8?[W5_Q2_-DP
M^%!7G?P:_P"10N_^O]__`$7'7HE>=_!K_D4+O_K_`'_]%QUMA_\`<JWK#_VX
M3^)'HE%%<1IOC2^N_%XLIK:!=(N)YK:TG4-O>2,#.3G&#SCBN6CAZE92</LJ
MY3:2NSMZ*Q+/6+BX\7ZGI+I$+>U@BD1@#N);.<G..WI60OC66WLO$%U>6Z/_
M`&??&TMHH00TIX"@Y)Y)/4?E5QP=63M%:Z?^3;?F%U_7WG945R,>I>-;:ZM9
M+[2-.GLYY`C1V<C^;`#W8M\IQWQ775G6HNE:[3OV=P3N>=>)/^2G1_\`8&'_
M`*.-2U%XD_Y*='_V!A_Z.-2UKB_^7?\`A0H]0HHHKD*"BBH;J[MK&W:XN[B&
MWA7[TDSA%'XGB@":BLZX\0:+:-&MSJ]A"TBAT$ERBEE/0C)Y'O6B#D9%`!11
M52/5-/EDN(X[ZU=[;F=5F4F+_>Y^7\:`+=%06EY:W]NMQ9W,-Q"W22%PZG\1
MQ4]`!15:[U"RL/+^V7EO;^:VR/SI0F]O09/)I1?69O?L0NH#=A=Y@\P;]OKM
MZX]Z`+%%%9M[?3&]&GV1C$XC$LTLG*P1DD`XR,DD-@<#Y23TP0#2HKG%EQ9R
MZE!XO6:!"07G^SM;J?0E%4CT^]6KI>HC4;9F952:)MDJ*VY0<`@J>ZD$$'T/
MK0!>HHJN]_9Q7D=G)=P)=2C,<+2`.X]0O4T`6**C6>%IW@65#,@#/&&&Y0<X
M)';.#^524`%%%1S3Q6\?F3RI$F0-SL`,DX`R?4\4`3^!/^1K\5?]NG_H#5WM
M<%X$_P"1K\5?]NG_`*`U=[77C?XJ_P`,/_2(DQV"O.]8_P"2Y:!_UX-_Z#/7
MHE>=ZQ_R7+0/^O!O_09ZVRWXJG^"?Y"GT/1****\XL*\[^#7_(H7?_7^_P#Z
M+CKT2O._@U_R*%W_`-?[_P#HN.O1P_\`N5;UA_[<0_B1W>H*SZ;=(BEF:%P`
M!DDX-<?X*\$Z19Z7I>J3Z7)#JZ1[W:1Y%96Y'*$X'';%=LTT22I$TB+))G8A
M8`MCK@=\5']MM-Z)]J@W/(8D'F#+.,Y4>I&#Q[5A3Q%6G2E3A=*6]K^>GH-I
M.USR5=)TQ-:UM]=\'Z]J$LNH2O!-:V\FPQD\<AE!YR?QK3\365I>W7AN>?PU
MK%SI,5I(C6D4#F6+[H0-AL@\=VKOI->T>&6.*75K!))`"B-<H"P)P,#//-":
M]H\D\D":M8M-'G?&+E"RXZY&>,5Z#S"NY1GR/1=WVMIV^1+BM?/_`#N<EX(L
M&MM>O9M,TC4-)T1X%!M[]2':<'[RAB2!M]Z[VJESJ>GV:R-=7UM`L9`<RS*H
M4GH#D\9JRCI)&LD;*Z,,JRG((]17G8JK.O/VDE;^N[W944EH>2>#?^14LO\`
M@?\`Z&U;M87@W_D5++_@?_H;5NU68?[W5_Q2_-A#X4%%17%Q#:6\EQ<2K%#&
MI9W<X"@=S26EU#?6D-U;OO@F021M@C*D9!P>:Y"B:N.UR1KWQ1;:<+&Y@M5E
MBGN;V.QD?SW4Y2,.JD``X)8G`Z>M=C10MTPZ'%Z%::E::\D,\3R[9;IY9);<
M!(U=RR-')MR2PP"-QZ=!BNTK/M=;T^\OGLX)RTR[NL;*K;3AMK$;6P>#@G'>
MM"CH@ZLR?$=V;'19;A=,DU*5"IBMTA,A+Y^4X`)`!YSCC%8%O:7+>%[6Q7[3
M/)J-Z?MTAM9(=JLQ>3Y64%5P-H)'>NUJCJ.L6.DB,WLQ3S,E0L;.<#DG"@D*
M.Y/`[T+0-RZJJB*BJ%51@`#@"EIJ.LB*Z,&5AE2#P13J`.`N_/U;6K^./2IX
M(+2*X2U@:RD1;R5U(9VDVA0IZ#G)//I6KX.MKF"2^>5;EHW6$+/=P^5(S*F&
M7;M4;5P,''.3R>M=552SU*SU"2Y2TG65K64PS;0<*X`)&>_4=*$#UU+=<1JE
M_+9:4+&UTZ2;45N983,MH\PM5<D^:0JD_,K`X'4DCL:[>J=WIEO=S)<$R17$
M8PLT+E&QZ'LPYZ$$9YI-7!'#2Z6VGFWBL9KR.V'V.>26ZLV4;(<9;S"1LPH.
M48`Y/'>NTT*)X])C,@=3*\DP5Q@H'=G"D=L!@/PK/E73X=4@LK^[U#4+KB5(
MWA:1$RV%9A$@08(X+=,9]ZZ&JO="M9C7_P!6V4W\'Y1W]N:X&>SN+BYN;FQT
MVZBLU^QEXI;8QN@BERT2(``RA>?EW9/`)X`]`J&ZNH;*V>XN)`D2=6QG]!R3
M["DG9W'NK&7X9AFBTV9Y8WC6>[FFB21"K*C.2N5/(]<'GFMJJUC?VVHVWVBU
MD+Q[BIW(596'!!5@""/0BK-`>9R_BN+[0OV>WTZXDO7\MHY4@#1S;7W>6[@$
MJH//.T>A/(I]GI1L_'5Q=I%.RW%EF29R6&_S/N@G@8'0>E=+68FOV#ZJNF_Z
M4MTY;8LEG,BMMZD,5"D>^<<CUH6_W@]4=-\,O^2>:7_VU_\`1KT[Q8EZVJZ0
MUM)?>6CL3!;Q3[)FRN`\D,B[,`'_`%@9#DY[4WX9?\D\TO\`[:_^C7KK:Z\?
M_OE1_P!Z7YLF/P?(*\[^#7_(H7?_`%_O_P"BXZ]$KSOX-?\`(H7?_7^__HN.
MML/_`+E6]8?^W"?Q([+7[JYLM`OKBS@EGNEA;R8XD+L7/`X'/4UYU<^"?$>F
M>%;.:#5C<R:>ZWD.GI9*&$F<L`X.YCR?K7JDLT4(4RR)&&8("[`98G`'U)J.
M:^M+<2F>Z@B\I0\F^0+L4D@$YZ`D'\JC"XRI0CRTXIZW>E[]+>6[VUU'**EN
M<9->7VB^*Y==.BZC>66I6<2E;2'?+"Z_PLAP1P:IP^&]6U'PSJUR+7[+?W6J
M?VE:V\Q`(VD%5;T)P>#7<W6LZ78Y^UZE9V^&V'S9U3#8!QR>N"#]"*C7Q!HK
MSQP+J]@TTFW9&+E"S;N1@9YSD8K:.+K**E"GKIKKJH[?\$7*NK_JUC@];N-=
M\1W4`TVQ\4:9J"!$D4R^39@!OF.X'YCR>1UP.*],'2JS:E8I$)6O;98VB\X.
M95`,?'S9S]WD<].:EMKJWO8%GM9XIX6^[)$X93]".*Y\16=2$4H<JC^OG\AI
M6=[GG_B3_DIT?_8&'_HXU+47B3_DIT?_`&!A_P"CC4M+%_\`+O\`PH(]0HHK
M/L-;T_4Y7BM)R[*N[YHV0,N<;E+`!ESW7(KD*-"L/Q5?2Z?I:36VFO?7?FA8
M`MNTHB8Y'F$*"0`,]!GMWK<HH8T<A9V#FS\/Z4JW,]F&>XNII;=XMS(=P#*P
M&T%VR`>RUU]9][K>G:?=1VUU<;)9`"`$9@H)P"Q`PH)X!;&36A3O<5K!7F\\
M=QK9U:2/2KJV$5M);65DUC)$&4NI>0L5"EB0"%![>YKTBBEUN!SOA.&>.'49
M)4N"DUV9(YKF+RI9AL4%F3:NWD$#Y1P.G<]%56PU&TU.%YK*=9HTD:)F4'&Y
M3@CWY[U:IL25CDO&D\I6"PM["=GO$>*:_CLGG^S0G&X#8I.6[#IQD]*IPZ5<
M1^([>*R^UBV2]6[<SVA7CR=A(ES@@\#9@,#G/%=S5$ZO9C5/[-!G:Y`!8);R
M,B9SC<X7:O0]2*2T&]2]6+-)'#JNH07%J9Q<6RR1QX4^>%#!D`8@$CC@\?-]
M:VJKWEC;W\(CN(]P!W*P8JR'U5AR#[B@#BEM[G[>^HPV=W_9RW\-PP>V992H
MB9"HB"@E4.S&!SSUZUJ>"(IEL)I)%95W>4H(Q]UF/Z;@OU0BKU[:06=LTNH:
MKJ$EMD*(MW+'LH\M0[$^F3FM'3IK.XT^&2P*?9=NV,(NT`#C&.V,8QVHZ`]R
MU7+:_&9]4M8[73K@W274$K/Y'[F=5/):0`XV`D@$CGH#74T4=;ATL<UHFD_V
M;XLUETBG\F>&!O.E+-YCYDW?,>N,CCL,5TM9EKKUA>:B;"+[4MR$,FR:SFB^
M4'&<NH!&?>M.CH'4*YKQEI1O[&VGCCGFFM[F$I'&20/WJ;F*CJ0`>3T&:Z6L
M_4M:T_23&+V<QEP6`6-G(4=6.T':HR,L<`9ZT+=,#3\"?\C7XJ_[=/\`T!JU
MO&9N/LMJ+-=1^UB4/"UH)BI8$?(_EL``PS\T@9!@Y[`Y'@)@_BGQ2RD%2+,@
MCO\`NVKOJ[,;_%C_`(8?^D1)CM]YC:,EZFI:V+J6YDB^UJ;<S#@(8D)"8`&T
M-N''?.><URFL?\ERT#_KP;_T&>O1*\[UC_DN6@?]>#?^@SUKEOQ5/\$O_20G
MT/1****\XH*\[^#7_(H7?_7^_P#Z+CKT2O._@U_R*%W_`-?[_P#HN.O1P_\`
MN5;UA_[<0_B1T,VBZB?&-MJWVF&6W4,FTPD-"FW[H._!RW.=OUZ#&?JVAZK)
M?ZC=6<*N862YL`9`-TIV;UZ\<1GD_P#/0UT.MW]SIUG'-;0QR9GBC<R,0%5G
M520!U/-4+'7Y;CQ"^GRR6O+3`6Z#]]"$(`9_F.0X.1P./6BE5K\JJ))I*WR6
MO3^K>;&TNI0ATO4M*U*-;:/4S:K;6\6;,VNQRF0=_FG=W_A]34"Z;K1TJ_T_
MR=3!E$XC#M:?9P6<LI&#YG?OZ\U>C\6.UANEM9(+D[C&7C!CF`<J2N'R`#C.
M<=<@&BU\62>6IN+9YI'?9'#:QC+$[0.6<`<M_P#7K:^(W<(WT_#J0U%=1'TV
M^M(%B^R7%U)!<-*E[;2Q+,Q=2-Q5_E+#)!!XQ@CT&[I,4\&E6\=S'''*J_,D
M:@`<\<#C..N.,YQ6=#XKM9W@$=G>%97CC9]J;8G<X"M\V<^X!'O6]7'B)U+<
MM2-OZ_K0M)7T/(O!O_(J67_`_P#T-JW:PO!O_(J67_`__0VK=HS#_>ZO^*7Y
ML(?"BEJMA#J6GR030)-QN1''&\?=/YU%X?M9K'PYIMI<ILGAMHXY%R#A@H!&
M1Q4NIZE%I=JLTD4LI>18HXX@-SNQP`,D`<]R0*=INH1:I8I=PK(BL64K(,,K
M*2"#CC@@]"17(MF4]T6Z***`.5TR#5KOQ9/J&KZ=<P)"'AL0)(C$D9QECARQ
M=L#^'`%=563I_B&TU&\^SQ13H'#F&5U`28(VU]N#G@^H&>V16M1T0=0K&\1Q
MW5UITEE#I\EW%<1LCF*X$;(?X202,KZ\_@<UHWM];:=9R75W,L4,8^9F_0>Y
M)XQ66?%-G_9=E?1V]U*MW$9HXD5=XC`RS$%@,`8Z$GGC-)ZH:NF:EA'/#IUM
M%<LCW"1*LC(,*6`YP/3-6*9#*D\,<T3!HY%#*P[@\BGU3WU)6VA7OH9[BQGA
MMK@6\[H52;9OV$]\9&<?6L#PAH=_H<NJQ71@,$DZM"8HRN\"-06Y=B,D=#SD
M$YYK2C\0Z;+J]SIJ39EM83+/)QY<8!P06]1W]*ET?6K37+:6YLB[0QS-%N9<
M;B,<CVYXI+NNJ_4;[&A117)ZMK%I%:3:GJUS/%I\<K16UK`Y5YRI(+'!!;D'
M`SMVC)Z\`#]6TO4'\0?;-/ANDG<PJ+H7>(%16)=7BR,Y!8#AN3_#74URNI/;
MZ==1&TCU"T<E$%T"3;;G("JZLWS9.`2H)&>HKH=/N_MUA%<%/+9@0Z9SL8'#
M+^!!%'0"S61XDTV;5-)$-N6\R.>*<*K;2^QPQ4'L2!P?6M<D`9)P!6);>*+&
M^M[V:PCN;Q;6582+>/=YK$`C9SC'/WC@=\XYH`F\/PWT&GNM]YH)F<PQS2>9
M)''GY5=LMN(]<GZFM6J>F:C#JMBMU"DB*69&20`,K*2K`X)'!!Y!(]ZN4V`5
MDV=I<GQ%J-]<Q[8]D<%J=P.4`W,<`\98]_[HI^HZ]8Z9>V=E/(3<W<@CCB09
M(S_$?1?>E.N6?_"0KH@+M>&`SMM'RJH(&"?4YZ?_`%J2\@\CI?AE_P`D\TO_
M`+:_^C7I/%>BW^H:[I%Y;0M<1VI)5-D#)')N4AW$H+`8!&8_G&>.II?AE_R3
MS2_^VO\`Z->MZ^UO2=+N((-0U2RM)K@XACN+A(VD.<?*"03R1T]:[,?_`+Y4
M?]Z7YLF.L+>1?KSOX-?\BA=_]?[_`/HN.O1*\[^#7_(H7?\`U_O_`.BXZUP_
M^Y5O6'_MPG\2.@\2:+J6I7MC<VES"8[::)Q!)"3@B0%I,[U'"]L'C..M+KVB
M3:IJENHB5K&>)HKTE@,!?FCX[_,36W?&Y6T<VCP)+Q\\X)1!GDD#&<#/&1]1
M7-1>(M59XW=+188W@28>4P:82RM&KI\WR#`5L'=UQGO2H3K2BG"WNZ+Y_P#!
MV\]QRLG?O^A3@TK7(+33KF6&\6^+S-=&Q>W+@D*J_P"M.T@A!TYJU8VVL0:O
M<2O#K(AN)HW.&LMC#RD4F3G<#E3G9QQQ5VY\3-:7^I6\]M((;=PD5RB!D!,0
M<!AN!)SGH`.@R,U2B\82I/<FZ1!;P;S^ZB)9@K3#NV`<1#\<^O&]\1.+?)'5
M?@]?P_`.5):$6G:%J%AHBVUS9-?2200,V)DCDB:,KB,'H0N,KV)W9(SD[^A1
M7<=M.;R)HVDF+KYJQB5A@<R>7\A;(/3MCO5)O&%LJ29T[4/.B#/)!LCWJBHK
ME_OXQAUX!SSTK?BD$T*2J"%=0PSUYKFQ-2LXOVD4K_UIJ"MT//?$G_)3H_\`
ML##_`-'&I:B\2?\`)3H_^P,/_1QJ6HQ?_+O_``H(]1"2%)`)('0=ZY?PY!JL
M^M7FJ:WI]S;74B>5"#)$T,40;(5=KDECU)('2NH9@BEF.`!DFLO2M?M=7?;#
M%/%NC$T)E"CSHR<!UP3Q['!]JY%N4]C5HHJEJNJV>C:?)>WLNR)!T`RS'^ZH
M[D^E#=@,SQ-;:AJ$2V5K8EP622*Y$X"QR*V?WB$C<O?C=D]A@&N@&<<]:Q9_
M$UG`+9C%<,DT*3NRA<01N<*S\^O'&>A[5M4;:!>X52U:TN+_`$N>UM;H6LLJ
M[1,4+[1WX!!Y&1U&*NUCP>)]*N;G48DN1LT]0UQ.V!&,[N`W?&TY_+UHW&NY
M6\(:5?:/I]W;7@@4&[D>%88]@V$\'&YN#V'4=\UT-4='U:VUO34O[02"%V95
M\Q=I.UBIX_"KU-WZB"N6DTO4$\4/=6D-U%YMPDDMPUWN@>((%*>5D8;CCY3Z
M[NU:VKZ]8:(L'VN0^9/(L<42#+L2P&<>@R,FDEUR*#5([*6TNXUDD$*7+(!$
MTA7=M'.X\#J!CMG-);W![&I1167J5S*UPMG%/]F01F:YN,C,<8/09X!///8*
M?:@"#Q+IDVH6]G)`)G-K<B9HH9/+>1=K*0K9&#\W!R/J*LZ##?P:/#'J+EK@
M%OO-N95W':&.3DA<`G)R1WK$M[K1KW2I+O3[75+L+.;=7AE?S78?Q;RXPONQ
M`_,5I>'M4:^AV/(\RF-)H)W4*TD;9`W`<;@00<<'@]Z%L#U-NBBLRYU^PM=:
MM-(:0O>W.=J(,[`%)RWH#M./7\Z`(])L[E-2U6]O(]LD\X2'Y@?W*J`O3IR6
M/XUKUG0:W9W.N7.D0EVN+:)9)2!\HR>F?7_&M&CH@ZA7)^+]&OM4GA:WMGN(
MQ;30@13"-DD?;M9\L-T?!RO.>/E-=)>WUMIUG)=7<RQ0QCYF;]![DGC%9@\2
MPS6.G7-I87ET=00O##&(PX4#)+;G`';OWH&G8V?AVLB>(O$J2E3(J60<J,`G
MRVS@>E;?C/2Y]5M+6*WTH7<R2B2*<>5FWD!!4GS.0AYW%#O';KD9'@(D^*?%
M)*E21:<'J/W;5VEYJ=AISP)>WUM;-</Y<(GE5#(W]U<GD^PKLQW\9/\`NP_]
M)B1#2-O4Y[PCI\MK?ZK<2Z#-I'GNH"&2)TFP6_>$I(Q9SG)9@#C:.<9K&UC_
M`)+EH'_7@W_H,]=U9ZG8:BTZV-];730.8YA!*KF-Q_"V#P?8UPNL?\ERT#_K
MP;_T&>M<M^*I_@E_Z2*?ZGHE%%%><6%>=_!K_D4+O_K_`'_]%QUZ)7G?P:_Y
M%"[_`.O]_P#T7'7HX?\`W*MZP_\`;B'\2.^N;6&\A\F=-\>Y7QDCE6##I[@5
M!#IEE:7<U[&A223+.6E8J,\L0I.U<XR2`,]ZNUA>);6_NH85M([F6/YQ)';7
M`A<DK\A))&5!ZC//H>E<E&\GR<UDRR:#PYHXC9HK<LDOS`^>[#!.[Y<MP"3G
MC`-2QZ#ID+QO';8:-@ZGS&X/'O["N2NK/78',S//IMK!:LLD[7A,>5C!1L>9
M@#<`"`@^I!-6M*M?$#ZCIVI3F[D%R/-N(GF(A@#%CM4"0'(!48,;#CJ.:[IT
MI\O-[;\?PWM_2,KW6J-*3PE$=:M[R*X\JUA9'^SA6R64D@YW8/)[J3V!`XKH
MZ**\^I6G4MSN]C2R3N>1>#?^14LO^!_^AM6[6%X-_P"14LO^!_\`H;5LSR&&
M"241O(44ML099L=A[UOF'^]U?\4OS8H?"C-\0Z7+JVFK;Q"%]LR2M#/_`*N8
M*<[&X/!^A^AI_A_39M)T>.TF=&96=@L?W(PS$A%X'RJ#@<#IT'2L3_A*=0_X
M1Z\O9+6."[CO_LD<7EO-MRRCYE0Y8@$G"^G%=!I%V;[38YS<Q7#$D-)%"T(R
M"01L8EE(Z$$YR*Y5L46Y98[>&2::1(XHU+N[L`JJ.223T`K*_P"$L\-_]#!I
M7_@;'_C1XL_Y$W7/^P?/_P"BVJ*_UN[MO$NFZ;'98M;EV62YD/!(1F"H`?\`
M9Y)X[?1`<_IMQX?MO$']HRZ[H,21&;RE@U'<'\P@Y*,V(^G(7(8G/'2NZBEC
MN(8YH9$DBD4.CHP*LIY!!'4&N=T?Q'+JNK-&&MUMF:54C:*19/W;%<AS\CYP
M25&"O'7-7?"?_(FZ'_V#X/\`T6M'1!U9J31+-$R,JMW&X9P>QKE4\+W\&CZ5
M%$]JUY:6<EI)O=@A#@`L#MSD;0<8&?45T>HW4ME8R3P6LEU*,!8D(&23CDGH
M!U)]*Y]]<U:;PA8:Q;2645S/&N8'MGD$DCD!54B1=O)[Y_2C=,:;1T=A:+8:
M?;6:$LL$2Q@GN`,58J.W\X6\8N3&T^T>88P0I;O@$DX_&I*;U9*T6AD?V0?^
M$D>_VP_97LS`T>.2Q?<21C&#3]%TV731?B5HS]HO))TV$\*V,`\=>*SY/$5Z
MNM:C:?8%B@MK)[B)IGVF5E;&<]%3W//>I/"^MW6L1W/VH1[HBA5E@>`D,N[E
M');`Z!NC=J2VT_K7_,;WU[_I_D=!7):M;AM'OM"N'A@FF$BV5Q<'$;AR3MW8
MX89QCJ0`?IUM87BS5[G1]#FN;6P%VX4D[_\`5H`,DOSDCV'4^G6@:,77?MI\
M16<TBV5_9VP5K73X[IEF>7NY4(0V.V6"CJ2.W5Z5:-8Z='#)M\TL\LNWIO=B
M[8]MS&N:N/$*:/K7V1(+*U@\R"/R1%MEG$A`WH00-JDX/!^HKL:?0D"`1@C(
M-8$&DZA83:O-9"R)NIXY(8I=VS8L:J5.!\N=IP0#CT/2MXYVG:`3CC-<?)XH
MU&VN;RQF-C-=1M!&)((W\N&25]H1LMEB!\V1MSZ"DM[(KH;N@:;+I6F?9YFC
MR97D6*(YCA5CD1IP/E';@?05J5F:'J,NHV,C3A!/!/);R&,$*S(Q&0"20#UQ
MDX]36G38C*UC2GU"2PDA\I7M[N.:1FX)1<\#`]ZS+;PI-9^*XM5BU*>2#;,9
M4E\LL6<J<`A`2OR]SD;5`XS5GQ)J]]HR1W,36GD%DC6%U9I;B1FQL3!`7CG/
MS?0=:?::U=W/BJXTR2R\BVCMS(CR'YY"'VY`!X7T[GK2COIY_D$O/R_,Z_X9
M?\D\TO\`[:_^C7K>U"REO;BR&Y!;13>;,AZO@'8/P;!_X"*P?AE_R3S2_P#M
MK_Z->M36?$MGH=]I]I<QRL]])Y<90H`#D#^)@6/S#Y5#-U.,`UUX_P#WRK_B
M?YLF/P_(V:\[^#7_`"*%W_U_O_Z+CKT2O._@U_R*%W_U_O\`^BXZVP_^Y5O6
M'_MPG\2.ZU#3K;5+-K2[5WA8@E4D9"<'(Y4@]:J#P[IHGAF9+AY(=NUI+N5]
MVUBR[LL=^"21NSCM6K6?K<5Y-I,R6._SB5XCDV,R[AN56XVDKD`Y&">HZUR4
MJD[J"E9/ST*:3W(GT/2;V[GO&B\V60E92)WVE@NPY4';N`R,XR.:1O#6D.)`
MUID2A@_[Q^<[\]_^FC_G["N8;3/$*16\=K9WD.VY,P<WVXA#,25<"4`G9CDA
M^I''6H([77[ZU>YMKR[NUMYS;VRPW)$<Z)N_>2'S8R22<$@G[O1J]!496TK:
M+3?[NMA.7D=#K?A*+5>;>X^R,^X3-M9BX**G9EQPHX.5/=37011K%$D:_=10
MHSZ"E3=L7>`&QR`<X-.KSIUJDXJ$G=+8:2W/.O$G_)3H_P#L##_T<:EJ+Q)_
MR4Z/_L##_P!'&I:VQ?\`R[_PH4>HA&01QSZUS>@>&Y--U)[V:.WB983!'';S
M2.FTMNR`_P!P<#"#('//-33Z_<P^*$TYK(QV?V>64SOUD*!3\@!Z?-C)ZGZ4
MSPUK\^M%GE:W"20I/'&L4D<B!NQW<./]M>,Y&.*Y%W7];_\`!*>UF=%5/5+/
M[?IES;*$\R2)UC+CA6*D`^W6KE9FO:E<:5I$UU:V;74RJ2J9PJX!.YCV48^M
M*5K:CC>^ABW7A6ZFACB22WVS64-E=%F8%5C.=R<?,3DC!QV/M76C@8KF;W5-
M9-GI,UC/8++?B-1!+:N^6(W.VX2#"A<GH>G7FNF&<<]:MWZD*UE;L%8]KHYA
MU[4+QD@-K<PPQI&!R"A<G(QC^(5L5R<GBF_1]>+:>D"Z?;I+`DS89\EQEL'`
MSMX'7\3@24;'A_39M*TK[+.T;/YTLF8R2,/(S#J!V(K4K&\.:K<:K:7#7(CW
MPSF+<L+PEA@')C<ED//0GWZ&MFFQ(R?$&E/JVGK#!Y2S":)P\G&%616(R`3R
M%_E6>VDZO<>,5U*\CLY["WXLT%RZM#D89RGEX9ST^\,"K/B76[O1H;=K6R\[
MS9HTDE?[D:LZKSSDL=W`]B>U4CXIFC\3?V?-]G2,W?V5;<J?.P4W"7.<;"1M
MQM_'M1'R_K8;V.JK)U!DLM16\N5!L9H?(G=AE8\'*EO]D[F!/;CWK6J.?S/L
M\GDJC2[3L60X4GMD@'C\*0&!%IU[8Z=?F+^S9X[F\DG:.X9A&\+#[I;!VG\&
M'\Z9X2M9DA\QI?-MHHA!;R;<!QN9B5]4&55<@9V$]"*Q(;FW-U+8II^C27@O
MDMTNHK(B!92K._R;N67;R0PR2.E=CHFHG5=(@O&14=MRNJ]`RL5./;(H6WW?
MD#W_`*[FA63J6DR7>KZ7>0^4@M9GDF)X9@8V08XY.2.M:U8&M:O?:7J-F%-H
MT%S/'!';[6::4L?F8'("A1ST.0.HH6]@Z%?1_"LVC^(9+U-2GGM6M_+VS>7O
M9R[,2=J#(YSG.<DYKIZPM(UN[U'7=2LKBR^RPVR1M$'/[QPQ<;FP<`';P.OK
MZ#=HZ!U9'-$LT3(RJW<;AG![&N0D\(W+:%I5F]KIEU<6EJUN9)V?]RS8_>1G
M:02,=U!]&'?JK]KI;-S9M;K,,8>XSL4=R0.3@9XR,^HZURS^*=0/A@ZRDFGI
M!"TBF1XWQ=%6VH(EW9&_L26QZ&@:N=?\.87M_$'B2&25IGC2R5I&ZN1&PR?K
M73>)]-U'5K)+2R^SB-V_>-+,\;1D$%7&T$.!@YC8`-QDC'/-_#UVE\2>)I&0
MHS+9L4/528VXKK=:UN+0X;>:>VGEBEF6$O$T8V%C@9#,I;)/10Q]J[,=?VR_
MPP_])B9PMR_>5M'TS4+;6=1O[XVX-RL:`0S/)OV;OFPX_=\'[BD@')SDFN8U
MC_DN6@?]>#?^@SUVMCJ]KJ-[?6MOO9K-Q'(Q7"EB,_*>^.A]P1V-<5K'_)<M
M`_Z\&_\`09ZURWXJG^"7Y!/]3T2BBBO.+"O._@U_R*%W_P!?[_\`HN.O1*\[
M^#7_`"*%W_U_O_Z+CKT</_N5;UA_[<0_B1Z)1117G%A1110`4444`>1>#?\`
MD5++_@?_`*&U;C,%4LQ`4#))/`K#\&_\BI9?\#_]#:C4/,UR:XT^!Q'9P#%Q
M,RY623M'C(RHX+<C/"_WL=>8?[W5_P`4OS9,/A1DBWNHH;F_M[BY@TF>Z:=C
M&0)D!_Y;#@@KD?<(/R\\GBNFTO3[;3;(0VS,ZNS2M*Q!,C,<ECC`Y)[`#TKF
MK#5KBXTW5)6UMTTVUD54U.2",%P!^\"``*0#P"0>_6I/"=W=V>FVD6H)(EK=
MLWV1Y%"LGS'8C@<+N7!`X`.5P/E%<JV*-;Q9_P`B;KG_`&#Y_P#T6U4[O6O"
MMY>V-U)XBTT/9R-)&%O8L$E2ISSZ$UTE%(#D;>Z\'VVIK>IXBT\^6TCQ0F]A
MV1,_WV7OD^Y(],5K>$_^1-T/_L'P?^BUK8HH`1E#*5/0C%9,7AVTBT_2[(23
MF'39%DBRPRQ4$#=QSUSQCD"M>B@`HHHH`S;O1+.^O)[BX\Q_/M#:21[L*4)R
M??/XT:7HL&E/-*LTUQ/,%5Y9RN[:HPJ_*`,#)[9]2:TJ*`"JFIZ?%JVF7%A.
MSK%<(48QD!@#Z9!JW10!F3Z+%<WL<\MS=-$A1OLQ<&(LARK8QD$'T(![@UIT
M44`-=2\;*&9"P(W+U'N*YZP\'6MAIDFGKJ%]-`[B53+Y6Y)`VX2;E0$MD#[V
M:Z.B@"IIVGQ:9:"WB=WRS.\DA!9W8Y9C@`9)/8`5;HHH`Q-1\-QZAK=MJO\`
M:-[!/;(4B6,1,BYZD!T;!/3/7%7_`.SH?[8_M/=)Y_D?9]N1MV[MV>G7/O5R
MB@#3^&7_`"3S2_\`MK_Z->MC5-"AU6YAFDN;B$QC8ZQ%<2ID-L;<I(&5!RI!
MXZUC_#+_`))YI?\`VU_]&O76UUYA_OE7_%+\V3'X4@KSOX-?\BA=_P#7^_\`
MZ+CKT2O._@U_R*%W_P!?[_\`HN.ML/\`[E6]8?\`MPG\2/1****\XL****`"
MBBB@#SKQ)_R4Z/\`[`P_]'&I:B\2?\E.C_[`P_\`1QJOJ5\UG"BPQB6[F;9!
M%G&YO4^B@<D^GOBNO%_\N_\`"B8]3+UF*2XURU?3E274+:%]RRG]TL3D9#8Y
MW-LP/3DX.,%WAW3+"("^MFG++']F6*?;FU53S$,`=#ZDGISC%9D9N]*\2VUA
M;:DUY=7<AFO(1`@5$V8,CM][.X`+R!@``<9J.TFU'2/$VH&YN7NE6&*6=/*5
M6D4Y!E14[+@#!RQ`.<X6N5?U_7]=2F=M4-W;)>6<]K(6"31M&Q7J`1@XJ2.1
M)8UDC8.C@,K*<@@]"*=2:OH"=C.CT6VCN-.F#RDZ?"T,()&""`,GCKA?;J:T
M:**&[@E8*RKKP]97LU_+.96^W11Q2*&P%"$E2O&0<G]!6K10!0TO2HM+2<K+
M+/-<2>9-/-MWR-@`9V@#@`#@"K]%%`%/4]-AU6S^S3M(J>8DF4(!RC!AU!XR
M*A;1HI-46]EN;J4(_FQV[N#'&^W;N48R.">,XYSC/-:5%`!4-W;_`&JSFM_.
MEA\U"GF1$!UR,9!(//X5-10]0.>LO"5O8Z5%I\>H7IC@<26[D1!X6&>01&`2
M<G.X-FMFQLH=.LHK2`'RXQ@;CDGN2?<GFK%%%P"L2;PVDOB(:VNHWL=P$$8C
M`B9`@Y*C<A(SW((/O6W11UN!3ATV&'5;K45:0S7,<<;J2-H";L8X_P!H]ZN4
M44`9VN:/%KNE2Z=/<7$$,N-[6[`,0#G'((P>_%9MQX0CN3I[2:OJ&[3R3`0E
MN`">`=OE;<@<#CBNCHH`7P""OBCQ0I8L0+,%CC)_=MSQ76:SHL>M1+#+>7<$
M6"DL<#J%F0XRC!@>#CJ,,.<$9-<KX$_Y&OQ5_P!NG_H#5WM=>-_BK_##_P!(
MB3#;[S'T7PUI^@37,E@UWBX"ADGNY)E7;G&W>QQU/2N3UC_DN6@?]>#?^@SU
MZ)7G>L?\ERT#_KP;_P!!GK;+?BJ?X)?D*?3U/1****\XL*\[^#7_`"*%W_U_
MO_Z+CKT2O._@U_R*%W_U_O\`^BXZ]'#_`.Y5O6'_`+<0_B1Z)1117G%A1110
M`4444`>/>%8WE\%VT<<K0NZR*LB@$H2[<C/%3#091I1TW[>WV5HS&RB+!(/7
M+`YR><G.>:;X-_Y%2R_X'_Z&U;M=>8?[W5_Q2_-DP^%')GP):G3!IK7MTUFK
M*RQ--*0A7[NW+_*!Z#CIZ5H?V!-_9K:>VIS26[`@^:#(_7.=[,6R#T.>.,5N
M45R7*(K>-X;:.*29IG10K2,`"Y'<X[U+110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110!I_#+_DGFE_\`;7_T:]=;7)?#+_DGFE_]M?\`
MT:]=;77F'^]U?\4OS9,/A05YW\&O^10N_P#K_?\`]%QUZ)7G?P:_Y%"[_P"O
M]_\`T7'6V'_W*MZP_P#;A/XD>B4445YQ84444`%%%%`'G7B3_DIT?_8&'_HX
MUE_V;J2ZO<WZW5H[2`1Q"2%CY48_A&'QR>2<<\>@K4\2?\E.C_[`P_\`1QJ6
MNO%_\N_\*)CU.97PQ*FJ3ZDDD"W-P09B'N`LF!@;D\W:1CL1BI].T*YTHN;-
MK)"P"Y9)7VJ.BKND.U1V48`]*WZ*Y"C,T?3[G3DGBEGB>!GWPQQQE1%G[RC)
M/&>0.V2.F,:=%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`#_`G_`"-?BK_MT_\`0&KO:X+P)_R-?BK_`+=/_0&KO:Z\;_%7^&'_`*1$
MF.P5YWK'_)<M`_Z\&_\`09Z]$KSO6/\`DN6@?]>#?^@SUMEOQ5/\$_R%/H>B
M4445YQ85X_\`#/\`X2K_`(1RX_L/^QOLOVMMWV[S=^_8F<;.,8Q^M>P5YW\&
MO^10N_\`K_?_`-%QUV4Z?/@ZLKM6<=OGN:TJ_LI?"G?NKFO_`,7#_P"I7_\`
M)BC_`(N'_P!2O_Y,5UM%>=[+S9T_7O\`IW#[CDO^+A_]2O\`^3%'_%P_^I7_
M`/)BNMHH]EYL/KW_`$[A]QR7_%P_^I7_`/)BC_BX?_4K_P#DQ76T4>R\V'U[
M_IW#[CPSPU_PD'_"/VOV'^S/LWS[//\`,W_?.<XXZYK6_P"*K_Z@O_D6CP;_
M`,BI9?\``_\`T-JW:ZL=1Y<547,_B?7S)CCO=7[N'W&%_P`57_U!?_(M'_%5
M_P#4%_\`(M;M%<OLO-E?7O\`IW#[C"_XJO\`Z@O_`)%H_P"*K_Z@O_D6MVBC
MV7FP^O?].X?<87_%5_\`4%_\BT?\57_U!?\`R+6[11[+S8?7O^G</N,+_BJ_
M^H+_`.1:/^*K_P"H+_Y%K=HH]EYL/KW_`$[A]QA?\57_`-07_P`BT?\`%5_]
M07_R+6[11[+S8?7O^G</N,+_`(JO_J"_^1:/^*K_`.H+_P"1:W:*/9>;#Z]_
MT[A]QA?\57_U!?\`R+1_Q5?_`%!?_(M;M075[;6,8DNKB.%2=H+L!D^@]3[4
M>R\V'U[_`*=P^XR?^*K_`.H+_P"1:/\`BJ_^H+_Y%K1@U6PN9Q!%=1F8C<(R
M<,1Z@'DBKE'LO-A]>_Z=P^XPO^*K_P"H+_Y%H_XJO_J"_P#D6MVBCV7FP^O?
M].X?<87_`!5?_4%_\BT?\57_`-07_P`BUNT4>R\V'U[_`*=P^XPO^*K_`.H+
M_P"1:/\`BJ_^H+_Y%K=HH]EYL/KW_3N'W%#P+_PF7_"&V']D_P!@_8?WGE_:
M_.\S_6-G.WCKGIVQ71?\7#_ZE?\`\F*/AE_R3S2_^VO_`*->NMKJQU'EQ51<
MS^)]?,F..]U?NX?<<E_Q</\`ZE?_`,F*XSX9_P#"5?\`".7']A_V-]E^UMN^
MW>;OW[$SC9QC&/UKV"O._@U_R*%W_P!?[_\`HN.M:%"^#JRYGHX]?4'CO>7[
MN'W&O_Q</_J5_P#R8H_XN'_U*_\`Y,5UM%<'LO-E?7O^G</N.2_XN'_U*_\`
MY,4?\7#_`.I7_P#)BNMHH]EYL/KW_3N'W')?\7#_`.I7_P#)BC_BX?\`U*__
M`),5UM%'LO-A]>_Z=P^X\>UO_A*?^$Z3[5_8_P#:']F#'E>;Y7E>:?7G=N_#
M%2?\57_U!?\`R+6QXD_Y*='_`-@8?^CC4M=6*HVY/>?PKJ3'';_NX?<87_%5
M_P#4%_\`(M'_`!5?_4%_\BUNT5R^R\V5]>_Z=P^XPO\`BJ_^H+_Y%H_XJO\`
MZ@O_`)%K=HH]EYL/KW_3N'W&%_Q5?_4%_P#(M'_%5_\`4%_\BUNT4>R\V'U[
M_IW#[C"_XJO_`*@O_D6C_BJ_^H+_`.1:W:*/9>;#Z]_T[A]QA?\`%5_]07_R
M+1_Q5?\`U!?_`"+6[11[+S8?7O\`IW#[C"_XJO\`Z@O_`)%H_P"*K_Z@O_D6
MMVBCV7FP^O?].X?<87_%5_\`4%_\BT?\57_U!?\`R+6[02`,DX`H]EYL/KW_
M`$[A]QA?\57_`-07_P`BT?\`%5_]07_R+6A#K&F7-RUM!J-I+.IPT23JS#Z@
M'-7:/9>;#Z]_T[A]QA?\57_U!?\`R+1_Q5?_`%!?_(M;M%'LO-A]>_Z=P^XP
MO^*K_P"H+_Y%H_XJO_J"_P#D6MVBCV7FP^O?].X?<87_`!5?_4%_\BT?\57_
M`-07_P`BUNT4>R\V'U[_`*=P^XQ/"?\`PEG_``D'B#^SO[%^T_Z/]I^T>;L^
MXVS9MYZ9SFNN_P"+A_\`4K_^3%9_@3_D:_%7_;I_Z`U=[75C*-JB7,_ACU_N
MHF..T_AP^XY+_BX?_4K_`/DQ7+C^V?\`A<VA?VY]@^U?9'V_8=^S9MFQG?SG
M.?TKU6O.]8_Y+EH'_7@W_H,];9?1O.?O/2$NOD35QG-'E]G'7R/1****Y#E"
MO._@U_R*%W_U_O\`^BXZ]$KSOX-?\BA=_P#7^_\`Z+CKT</_`+E6]8?^W$/X
MD>B4445YQ84444`%%%%`'D7@W_D5++_@?_H;5NUA>#?^14LO^!_^AM6[77F'
M^]U?\4OS9,/A04445R%!6!K6KWVEZC9A3:-!<SQP1V^UFFE+'YF!R`H4<]#D
M#J*WZQ)O#:2^(AK:ZC>QW`01B,")D"#DJ-R$C/<@@^]"W0=&-MM3U)?$QTV]
M2U\F2%YHC$K@J`P`&YN)"0<D*!M[YR#6[65;Z%##J:WTEU=7#Q[_`"$G<,(=
M_P![:<;N<?Q$X'`P*U:.B#J5K]KI;-S9M;K,,8>XSL4=R0.3@9XR,^HZUREQ
MXUGA\(R:C###<7N9A!M5ECE2,G,N"<A,#UZD#/-='KFCQ:[I4NG3W%Q!#+C>
MUNP#$`YQR",'OQ5*Z\):;J&D?V?J"B\VQF*.XE@A$L2G^X50!<=L"A#[&W"Y
MDAC<XRR@G%/J*WMXK2VBMX(UCBB4(B*```.G`J6F]]"5MJ<U=Z_>:=KOV2Z:
MTDC>&:<10(YDAC09#NV<')XQM'/<U8\,:M<ZK9&2\N(&N0J,\$=I);M%N&<$
M2,2P]&``.*2T\+16>I7UZFIZ@S7S$SJQC&<C``8('4+VPW%7=-T>+3IYK@W$
M]U=3*J//<%=Y5<[5^4`8&3VSSR326VHWOH:-<K/+<P6,^O\`GV,4FZ7=/=JS
MB"%20J(H(Y.`3R.3WP!755R.M^'9;B>%2]ZVGQW!ND2T,1:.0G)W+(I#KDDC
MN">AXPF-%2;Q`VM/;6EQ!;VRE+=IDN(Y-RR2#(VR*,1,O&TL.3QQ75:-<R76
MEQO,V^5'DAD?&-S1NR$X]RI/XUSU_I#ZJR_98[[SG$8FFNHTCBD,9RC2+M#,
M0><(%!Z$@5U-G:I96<5LA9EC7&YNK'N3[D\U3L(F.=IV@$XXS7+V^LZI+=ZE
M8R76FI-9Q)-)<);N\4).28V&\%B`,YRO7[HKIW4O&RAF0L"-R]1[BN>LO!UM
M9:+>:2-1OY;6[1E?S/*W`M]YMP0$L?5LTAFAH%SJ%YH\-UJ7DB:;+J(HFC`0
M_=R&8D'')Y[XK3IJ(L<:HHPJ@`?2G4WOH2MC`\2:O?:,D=S$UIY!9(UA=6:6
MXD9L;$P0%XYS\WT'6JUAXCO+KQ.^G21PB#S)8P!&X*[,8(D)VN3GE5&5[U=U
M'PW'J&MVVJ_VC>P3VR%(EC$3(N>I`=&P3TSUQ3[?PW9VVIB]62=MDDDT<#%2
MD<C_`'V'&[)R>I(YX`I+S\QOR_K^OZ['5_#+_DGFE_\`;7_T:];&IZ[!I5U!
M!+;W$GF#>\D87;"F0NYMS`XRP&%!/M6/\,O^2>:7_P!M?_1KUK:UX<L]>FLI
M+PDK:2>8J"*)MQ_WF0LO_`"I]ZZ\?_OE7_%+\V3'X#7KSOX-?\BA=_\`7^__
M`*+CKT2O._@U_P`BA=_]?[_^BXZVP_\`N5;UA_[<)_$CT2BBBO.+"BBB@`HH
MHH`\Z\2?\E.C_P"P,/\`T<:EJ+Q)_P`E.C_[`P_]'&I:Z\7_`,N_\*)CU"BB
MBN0H*HZK-=06+2VLUI!L.Z2:Z#%(T`R3@$9/MD?6KU96OZ%#XAL$L[BYN8(E
MD60B`I\^.@8,K`C/.,=J3&C!E\:7']DZ3/!:HUS=RQ><&!"QQ-($#XSD;OX0
M??KBNSK!OO"&E:I;PIJ$*75Q&R'[7)!%YK!6R%)"`;>Q``XK=``````'``JM
M+?,D6N1O/$VH:;>:C;W`LYW@LI+H);HY\D@X17.?F+9SP%Z'KUKKJY_3O"D>
MFB\6+5=2<7C,\I9HPV\_Q;U0-D=N<8[4NI1;T#4)=0LG>>ZAFF1]KK':26YC
M.`=K)(Q;/.<G&01Q6K5#3-*BTW[0XFEGN+AP\T\VW?(0`!G:`!@`#@"K]-B1
MA^)M4O='T]KZ"6SC@A4L_GJS-(W&V-`",%NF<G''!JG;>)Y[O71:J(((4F$$
MD<T4FXN4#G$@^0$;L!3R<$YJ_K'AV+6;ZRNWO[NWDLR6B6'RRNX_Q%71@2.Q
M[4K^'+234$O'EF;$JSO%\NR255VB0_+G<`.Q`]J2\P?D;%8U[!)J>H3P,J20
M6L09()&(2:5LXWX!RH`''/4G'`K9K%U:TN4FGGMA.T-U"(+A;=@)8^N)$W<9
M`8Y'7@8R1@I[#6YBOJ,U[IFK6\\FDM%IA`EF^PN\)^7+1JGF`[E..0W?H#6M
MX6DU)+$V>K,C742I("N>$<9"G)))4AADD\`5DVVGZ9:Z!_8T4VM75NS(8X#9
MA'!5MV"?*4#)')<_CS72Z;:SQ&XN;LC[1<N&9%.5B4#"H#WQR2?4GMBJ$7ZP
M-:U>^TO4;,*;1H+F>.".WVLTTI8_,P.0%"CGH<@=16_6)-X;27Q$-;&HWL=P
M$$8C`B9`@Y*C<A(SW((/O26Z#H4M`\1WFJ:S+:3I`(MLK+LC=2NR39@,3B4'
MJ2N`O0]:ZBL?3O#=GIMZ+F*2>3RU=((Y"I6!7;<P7`!Y('4GVQ6Q1T0=65K]
MKI;-S9M;K,,8>XSL4=R0.3@9XR,^HZUQDGCB[6PBN?\`0TCV3R+<21L([ORV
MP%B&[*EADC);IT/6NKUS1XM=TJ73I[BX@AEQO:W8!B`<XY!&#WXJJ_AQ9;**
MTEU._:%$:)U!C198SCY&54"XP,`@!AZT(9M?#R9;CQ'XEG3.V1+-QGT,;&NM
MUK6XM#A@FGMIY8I9EA+Q-&-A8X&0S*6R3T4,?:N4\`JJ>*?%"*`%468`'8>6
MU=9K&BIK42Q2WEW!%@I+'`R[9D.,HP93P<=1AAS@C)KLQUO;+_##_P!(B1#X
M=?,AT'Q+:>(9;Y;.-PEG,86D,L+!F!(/".S+TZ.%/(XKE-8_Y+EH'_7@W_H,
M]=EINC+IUS/<&]N[N24!%-RRGRT!)"`A02`6/+9/O7&ZQ_R7+0/^O!O_`$&>
MM<M^*I_@E^0I_J>B4445YQ85YW\&O^10N_\`K_?_`-%QUZ)7G?P:_P"10N_^
MO]__`$7'7HX?_<JWK#_VXA_$C7^(LM['X<A2PNYK6>:\BB$L,A1AN)'4$<5Q
MOB7Q+JEUX/TA;2_N+>\BMWFO)(I2KDQL(L$@YY8FO1/%&CW&MV%K!;/$C0WD
M4[&0D`JAR0,`\UR]W\/;R1?$_D7%OG4RHM`[MB)?,\QPW!QD^F:[,OKX:%.'
MM;74K_?9?K?Y!)-RT_K74M^+9M1U*[TK0-+OI[6ZE@DNI98)"K!50A02.<%C
M^E4-8\0W-Y\)(=3BNY[>[!BBFEB<HZN'"OR.><'\ZU)/`5MK&NWM_P"(8HKJ
M,I'%:1QS2+Y:*.<XV\D\]ZSYO`%]#I.L:1ITMK'I]S=17%HDDCDQX(WAN#Z#
M')Z<U5&IA$J<'+6+BWIIJ]=>NZZ?9(:E:_E;\/\`,HZ3?Q/X@TP>&?$>N:P&
MFVWL=Z7>)(L'))9`%/''^<^HUS.J>';O_A);'7M'EABN5_=7D<K%5N(OP!^8
M=N/3TKIJ\_'5:=7DE#MY7O?K9+Y:;%P33=SR+P;_`,BI9?\``_\`T-JW:PO!
MO_(J67_`_P#T-JW:SS#_`'NK_BE^;'#X45=1U&TTFQDO+V410QCDGJ3V`'<G
ML*73[V/4M.MKZ%76*XB65`XP0",C/O3KRW%U:21;4+,I"EAP#C`-5]$LI--T
M*PL9F1I;>W2)RA)4D*`<9[5R+9E/H7Z***`,N#7(IM4%@]I=V[N',+SH%6;8
M0&VC.[C(Z@9ZC-:E<SI.DZNGB6ZU75DLYF<-';R17+DP19X0(8P,GJ6W5TU'
M1!U"L[5M732(!-):74Z!6=S`@(C51DLQ)`'TSD]@:T:R=>L[W4+,VMO#8S02
MJR2QW6X8_NLI`(R#S@CGCD8I/R&K7U-.*19HDE3)5U#+D8X-/J"R@>UL+>WE
MF:>2*-4:5NKD#!)^M3U3M?0E7MJ%9NDZY9ZTUX+,NRVDY@=R,!F`!ROJ.>M6
M[VU^VV,]J9I81,A0R0D!USW!(.#^%8WAKP]/H,^I;[QIX;B56A4A!M4(J\A4
M4`\8XXP!WS276X^AT%%%!.!DT`9TVK^7JZZ=%8W5Q)L6222+RPD2L2`6W,#_
M``G@`GBM&N7U7P])J6M+>V\5@C;HC]N#-]HA"-DJHP00PR."O!.0U=11T#J%
M5K^^ATZT:XFW%0RJJJ,L[,<*H]R2!5FLO7])_MG2_LP*ATECF0/]UBC!L'V.
M,?C0!;L;LWMMYIMKBV8,5:*X3:RD?0D$>X)!]:LUE>'],FTK3W@F\I=\SR)!
M"<QP*3PB'`X'T'7I6K0`5DKKC'6TTN32KZ-W5W69C$8]J_Q':Y8`DC&0#S]:
MUJS+/3YXM<U*_G:-A.(XX`I)*QJ.0>.,L6/'M0MPZ'3?#+_DGFE_]M?_`$:]
M=)<ZC8V23/=WMO`L""25I9541H20&;)X&0>3Z5S?PR_Y)YI?_;7_`-&O4NK^
M'+JXU*^O[%+0231VA5)&*>9)#,7.\A3@$;1G!/'3BNO,/]\J_P"*7YL4/A.C
MMKFWO;:.YM9XI[>5=T<L3AE<>H(X(K@/@U_R*%W_`-?[_P#HN.NST*SN+#28
MX;ORA<%Y))%A8LBEW9MJD@$@;L9P.G05QGP:_P"10N_^O]__`$7'6]#_`'*M
MZP_]N)?Q(]$KR/4]6OTUW5$U/Q#?Z-J27!&G1N66S>//&["D'CN:]<KA+_PQ
MXJDAO],@U2QN]+O'8[]0$DD\"MU5.H.!TS^E/+*E.$I>T:5[;^NO1KU74<U=
M&=XNU1(O$.C1ZKK][IME+8&2:73)W"M)G@C:#D'UQTIM[?6D/P[UF^T'Q+K%
M^5DC4W%S.^^)MRY"DJI&0W.*U;CPIKFGW^CW.@SZ>YT^Q^R'[>7&[WP@_K5C
M4]'\4Z_X7U'3=4?1TN)C'Y#6IE"C#`MNW`GMQ@5W1K4$J24E9-7U7\W:U]O,
MA)\UW_6A@:%J<+>*-,B\/>(M9UB*1F%]'>EW2--O!RRC!S7J%(HVHH/88I:\
MC%XB->2:5K+R;?K9+\BH1:W/.O$G_)3H_P#L##_T<:EJ+Q)_R4Z/_L##_P!'
M&I:>+_Y=_P"%#CU,J77H(-62PEM;N,2,42X:,")G"[R!SD\`\XV\8SGBETG7
MK;5W=(8IXB(UE3S0!YD;9VNN">#@]<'U`JGJ.CZAJ>KP22FTCMH'+)<1;A.4
M*D-$001@DY)##H/E[TWP]H-UIEP);IX3Y-I'90^4Q.Y$).]L@8)ST&<8ZFN5
M;:E/R_K^D=%534+TV-N)%M+FZ9F"K';H"Q/N20`/<D"K=8?B/5/L44-K'%'<
M37`<FV>VFE$L0P'_`-6C[>77DJ1SC'-2QH4^+-*VZ9B1VDU)E$$07Y@#_$P[
M#/&?RS6W7!(8(],TBWVZ@\UG=)+([:3=#Y%+$(I\KD#=@9].U=79Z[8WUX+2
M(7:3F-I52XLYH=RJ5!(+J`<%EZ>M43U-*HKFYAL[:2XN94BAC4L[N<!0.Y-2
MTUT21"CJK*>H89%(93T?5K;6]-2_M!((79E7S%VD[6*GC\*O5E^']-FTK2OL
ML[1L_G2R9C)(P\C,.H'8BM2F_(`K+EUR*#5([*6TNXUDD$*7+(!$TA7=M'.X
M\#J!CMG-:E<RVDZO<>,5U*\CLY["WXLT%RZM#D89RGEX9ST^\,"DMPZ'3444
M4`5-0O38VXD6TN;IF8*L=N@+$^Y)``]R0*=I]]#J>GP7MON\F9`Z[A@XJ'5!
M<RV_DV:64S,<2P79(61".1D`X_%3].])HEA+I>CV]G--YKQ`C(Z`$DA1[`'`
M]A0@9H444AY&,X]Z`,^#6[.YURYTB$NUQ;1+)*0/E&3TSZ_XUHUS&C^%9M'\
M0R7J:E//:M;^7MF\O>SEV8D[4&1SG.<Y)S73T=$#W85GZEJO]GS6T"65S>3W
M!;9%;[`0%&22790!T[]ZT*Y[Q)H+ZP\+QV>GW#)')&KW18-"6Q\Z8!&1CI@'
MT8=P:.C\!$GQ3XI)4J2+3@]1^[:NTO-3L-.>!+V^MK9KA_+A$\JH9&_NKD\G
MV%<-\.87M_$'B2&25IGC2R5I&ZN1&PR?K73>)]-U'5K)+.R-N(W;]ZTLSQM&
M005<;00X&#F-AAN,D8Y[,=_&7^&'_I$2(?#]YJ6NHV-]+<16E[;W$EN^R=(I
M5<Q-Z,`>#[&N$UC_`)+EH'_7@W_H,]=!X5T&_P!#-U%<W!DMS@1`W<LY8Y8E
M\/Q'G(&Q<KQGO7/ZQ_R7+0/^O!O_`$&>M<M^*I_@E^0I_J>B4445YQ85YW\&
MO^10N_\`K_?_`-%QUZ)7G?P:_P"10N_^O]__`$7'7HX?_<JWK#_VXA_$CJVU
MUO\`A)/[*6W3RE"AYV9Q\Q4L%&$*9QC@N#STJ"X\4+;7\=J]KS]J:"5O,XC4
M;=K].<F1!CWZ\5HR:6LNHB[>ZN60,'%L6!C#@8##(W#CL#COC-5+_P`+V&HO
MJ+S/.K7\:1R%'`V;.C+QPW`YY^Z*R@\-=<RTLN^_7_/Y#=^AG1^,&ENK:$Q:
M;;&:&*8+>:CY3D29P%7RSN/'J.3BB/QEOCO)2FF$6PE)A34=T^$8K\T?E_*.
M,]3C-:K:&5O3<VNI7EINC2-HX5B*L$SC[Z,1U/0BH?\`A&E-K/9OJE\]E-O#
M6["':-Y).#Y>[J3U-:\V$?V>W5_,GWR.?Q*PLUO+:VA>UDE*17$]QY<14`DN
MS!6VKD$`\Y]JV;.=KJSAG:,1M(H8J'#@?0C@CWJC)H:;W>TOKRR+R>9BW==H
M8C#?*RE>>X(//(P22;MC9Q6%G':PEBB`\L<DDG))^I)KFJNBX>XM?G_PW]="
ME>^IY5X-_P"14LO^!_\`H;5NUA>#?^14LO\`@?\`Z&U;M7F'^]U?\4OS80^%
M&3XBU.?2M,%Q;A#(TT<671I-NY@,A%PSD9^Z.33]`U&75=&ANYU19&+*P0$#
MY6(S@\J>/NGD=#TJ;4],BU2V2*622)HY%EBEB(#1N.C#((_,$4NF:;!I5D+6
M`LR[F=G<C<[,268X`&22>@`KD6S*>Y<HHHH`Y71_%,U]K@L+C[.K2^<!`BD2
MVYC8`"0D\[@=PX7\>M=56;;:-%;ZBUZ]S=7$@WB)9W#"$.06"\9P2!U)QC`P
M*TJ.B#J5-1NI;*QDG@M9+J48"Q(0,DG')/0#J3Z5SB^*+^XT?2984M4O+NTD
MNY-Z,R!4`)4`,#D[@,Y./0UUK*&4J>A&*Q#X6L_[+LK&.XNHQ:1&&.5&7>4(
MPRG*XP0!T`/IBCHQJW4U+"[6_P!/MKQ`56>)9`#V!&:L4R&)((8X8E"QQJ%5
M1V`X%/INU]"5>VIS\>O7;>([RQ?3W2V@M6FC[RS$-CY1G`![9Y/M4_AS5KK5
M[6ZEO+9+:2&Z>$1*<E0N,9/<\\XXJ[_9T/\`;']I[G\[R/(VY&W;NW9Z9SGW
MHL-.AT[[3Y+.WVB=IWWD'#-U`P.G%)>?]:_Y#>^G]:?YERN(\0WUR-'N]6ET
M_P"W1J\BV]M+CR(HT./,D&?G+$9'L0..37;US5[;PQV%[HVIB:/3KDOY5U&,
MA5<EBK'!VD$G!(QC'.<T`BAKL1TV^LI;**PM)+F6*"(6T1%Q(2>3D$+M4$G:
MP8$9Z5U&EWC7VG13R*JRY:.55.0LBL5<#Z,IKF)X]/N]:76=&U6ZO[[RQ#%#
M:M#)"%'4%RC>6#_$=P)[<X%=1IMG]@T^.W9E:0;GD91@,[$LQQ[L2?QI]!%H
MG"DX)P.@KF].UO5]5CU58[."TN+:=(XDN-S%5**Q+A3RV#]T$>F>]=+64VA0
M[K^2*ZNX);V5)FDBD"E&50HV\=/E&0V0>_%(H7P_J4VJZ0ES<*BS;W1@BE?N
ML1DJ>5)QG:>1G!K4JGINFPZ7:M#"SN7D:621\;I'8Y+'``R?8`5<IL1AZUK5
MWIVI:;:P66^*YN$CEN'/RJ&)X7G);CZ"HHO$4ESXP728(4-D()6:<YRTB,H*
MKVP-V#[\=JU;_3H=1^R^<SK]FG6=-A`RRYP#QTYJDGA;1HM<BU>&Q@ANHU<9
MBA10Q8C+'`R6X/.>Y]:4?/S_`"!^1UGPR_Y)YI?_`&U_]&O6T^NVL=]?6ACN
M3)90+/*5@8AE;=C;CEC\IZ#^M8OPR_Y)YI?_`&U_]&O70'3(3J5Q?;I/-GMU
MMV&1M"J6((XZ_.?TKKS&_P!;JV_FE^;%3MRJ_D2V%Y'J.G6U["&$5Q$LJ!Q@
M@,,C/OS7!_!K_D4+O_K_`'_]%QUWEA9QZ=IUM8PLS16\2Q(7.20H`&<=^*X/
MX-?\BA=_]?[_`/HN.MZ-OJ=>W>'_`+<1K=7.JU?76TS4;.T2V603*SR2.SA8
ME!49.U&QUZMM''6FZSX@?26N$6R-Q(D"2PHLF#*2Q5EZ<8X.>>M7=0TM=0==
M]U<QQ%2DL,;#9*I[,"#CZK@^]%WI%M>ZE9WTV_S;0.(U!^4[Q@[AW]JYX2H+
MEYEWOO\`+_+TUW+UNS&N_&`A9/+CL4ADE:..>\OO(C8*B,3G8W.6(Q_LT6WB
MTW&J?8O^).I#1KSJGSR;D5\QKY?SCYL`Y&<=JM0>%H+*RLK:QO[VU^Q^9Y<J
M&-F(<Y(.]"#^52P:#+;W4DZ:UJ'[YUDF0K!ME8*J\_N\C(49P1[8K=O"6:2[
M]7WT?W$^]U*EKXK-]I)O[.Q\Z-(H_,Q+PLK[?DR%/"ALLV./0\XUM)OVU*R^
MT,D`^8J&M[@31MCNK`#(^H!XZ54B\-6MM:Q06ES=VWEP)#OAD"LVS!5CQ@L.
M>V#D@@BKNGZ>FGQR@32SRS2>9+-+MW.V`,X4`#@`<`=*QK/#N+]FNNF]_P#(
M>IPWB3_DIT?_`&!A_P"CC4M1>)/^2G1_]@8?^CC4M&+_`.7?^%!'J(Q"J6/0
M#)KG/#GB*;6YRS/;B&6'SHHA%(DBKG'5OED'J5Q@\8/6NDK(T_P[9Z=>BZB>
M5RD;101N5VP(QW%5P`<$@=2:Y%OJ4]C7K'N?^1RTS_L'W?\`Z,MJV*P=5N!8
M^)=-NY8+MX!9W,3/;VLDVUF>`@$(I(R%;KZ4`+KUYJUI<6B:;<60:YE6)(9[
M9W)/)9MPD&`%!/0]/>I;C/\`PF.F9Z_V?=_^C+:J<^J:5<:G:7[Q:SYEJKK&
MHTJYV_/C)/[K.>/7N:?!>IJ7BRRFM[>]6*&QN4=Y[*:%0S/`5&749)VMT]*.
M@'0U0UN_DTS1+R^B1'D@B+JKG`./\].]7ZK:A80:G836=R&,4HPVTX([@@^N
M:&!G^'-5N-5M+AKD1[X9S%N6%X2PP#DQN2R'GH3[]#6S5#2]*BTM)RLLL\UQ
M)YDT\VW?(V`!G:`.``.`*OTV)!7*GQ3-'XF_L^;[.D9N_LJVY4^=@IN$N<XV
M$C;C;^/:NJK-;1HI-46]EN;J4(_FQV[N#'&^W;N48R.">,XYSC/-);CZ&E6-
MJTD]Q=?8XS,+>.`W%QY!Q+(,X6-?3.&R00>`.^1LUF7RSVE_'J,,331^7Y5Q
M$@R^W.591WP2<CJ0>.1@@'*6\T%SIHA.AZ;:7<VIO9Q*T&\1$`MN8@@EN#R"
M.3U[UM^$]2GN[3R9V9P$WQ.Q).`S(RDGDX9>"><,,Y()-9SX=$4T*:NR73W+
M7JK&RM<1R'C*Q[2?;!4]:T=`T]K;?.8Y88?+6&WAE(WA`22[>C,S$D>@'0Y%
M"V_KL'7^N_\`D;=85_K=W;>)=-TV.R_T6Y=EDN9#P2$9@J#/7Y>2>.WTW:IW
M>FPWE[8W4C2![.1I(PI&"2I4YX]":%N'0SM(UN[U'7=2LKBR^RPVR1M$'/[Q
MPQ<;FP<`';P.OKZ#=JG#IL,.JW6HJTAFN8XXW4D;0$W8QQ_M'O5R@.I4U&ZE
MLK&2>"UDNI1@+$A`R2<<D]`.I/I7.3>)-27P?9Z]NT^!6M_-F61'8NY^[&@!
M&"3QDDXXX-=:RAE*GH1BN<E\&6KQ:3''J-_"NEKBWV^4PSTW,'0@MZ''%`SH
M_AZ[2^)/$TC(49ELV*'JI,;<5UNM:W%H<,$T]M/+%+,L)>)HQL+'`R&=2V2>
MBAC[5RG@$%?%'BA2Q8@68+'&3^[;GBNLUC14UF)8I;R[@BP4ECA9=LR'&48,
MIX..HPPYP1DUV8[^,O\`##_TB)$/A^\32]9?4KR\MI-+O;)K4J&:X:(J^>1@
MQR-VP<'!PP]:X_6/^2Y:!_UX-_Z#/7=V5C%8K,(V=C-,TSLY!.6/3Z`8`]@*
MX36/^2Y:!_UX-_Z#/6N6_%4_P2_])%/]3T2BBBO.+"O._@U_R*%W_P!?[_\`
MHN.O1*\[^#7_`"*%W_U_O_Z+CKT</_N5;UA_[<0_B1T/BU+2:""&XL+BYDDW
M+'+':R3I;Y`S(0@/S#^$XSGN!DU7T6Q%OXEN;E(KEI92_GR7-DL>U>-FV3;E
ML@#(W'W"GBNKJCJ>JVNE0"2X9LMG8B1LY;`R>%!(`[GH.]94Z\W3]C%-WN4X
MW9QUL-7^P/:"*\EB!;?'/9A1$WF'`C.W+`J<DY...1G%26%OK$/DPVZ7%IYL
MH5YA;`LJDIGEE..`>O%=%_PDVG1+%]J>6W=XA)\]O)LY`)P^W:V,\X/J>QJ:
M#Q!IMUJ4FGV\TDMS&Q60)!(50@D?,P7:.01R>U=,J]6S?LM-]M/RL9M*2O<Y
MF+6=734+.WN;NY2;SH(FB^RKMD1F.YG;;\K''`!''('<=S5=K"S>]2]>T@:[
M1=J3F,%U'H&Z@<FK%<6(JPJ6Y8V+2:9Y%X-_Y%2R_P"!_P#H;5LSM(D$C0QB
M255)1"VW<>PSVK&\&_\`(J67_`__`$-JW:O,/][J_P"*7YL(?"CC8M5U^?P]
M?L`\NI)J/V919QH3&FY<[=_RG`)Y;\:Z#0KQ+W2UD6XN)W1WCD-RJ"175B"K
M;`%R#QQQ]>M.?0].DMYH#`0DTQN'*R,K>8?X@P.5/T(JS9V=O86RV]M'LC4D
MXR222<DDGDDGDD\FN1;%$]<]J>HZK;^*=(M4$4>G3R,CG.YY2(V;'3Y0"![G
MV'7H:KSV-O<W%M<31[I;9R\+;B-I(*D\=>">M"W#H<UHFO7-_K*_:+B:**>2
MXBB@>&/RV,;E<*P.\,`,G<"#GC&*ZVJ,6CV,&H-?1P$7#9YWL54G[Q52=JD]
MR`">]7J.@=2IJ4EY%82-81127/`42MM4<\D_0<X[UR[:CJ5UX)TJ_35;B#4;
ME$C3R8XMLLKD`;@R'`')XQQFNR(#*0>A&#5&/1=/BMK&V2WQ#8L'MUWM\A`(
M!Z\\$]<T+_(9;MTDBMXXY9FFD50&D8`%SW.!P,^U2444".4N=9U:VUS5([A[
M:VM8-.>XMU/S`%6(#N1SSC[H[>]3>$]2OKTWD&H2S&:(1.J7"QB4*ZYR?+^7
M:3G'?CFMJ;3+.>ZDN9H%>62`V[EB2&C)R5(Z4W3]*L]+5UM(F7S"-S/(TC''
M`&6).`.@Z#M0M%K_`%J#WT_K1%VL#QA?ZIIOA^XN=+$2R1HSO-(<^6H'9<?,
M3TYX[^U;]8^HS1:FESI26+WL;+LN/WGEQKG^$OUS[*#COB@$9&J:UJFGZRI<
M7`MC-;QPQI;AHI5D(5V9\?*P)X&1]#VZ^N>DBM8=4BO=3TQH'.U1<).7AR.%
MWC@9&>&*\>HKH:?00ASM.#@XX)%<+_;VIQR7L$&HR7L*S6]J;[R$58YGDVN(
MP!@A01][=@]2:[ET$D;(V=K`@X)!_,5D6?A72+"Q>RMX)Q:N,>2]W*ZK@Y!4
M,QVG/.5P<TEN/H/\/7MQ>6$PN7,DMO<RVYE*@&0(Q`8@8&<=<`#-:U06=G;V
M%JMM;)LB7)`+%B23DDDY))/))Y-3T,#FO%&H7FGRVIL[]Q<S,L=M81PJQG?/
MS%B<D(%ZXVX]3TJ6TU#5'\97%C="**S%J9(8D.XGY]NYCCJ?0=*MWGAW3;_4
MTU&=+@7B1^6LL-W+$0N<X^1@,9J[]BM_[0^W>7_I/E>3OW'[F<XQTZT+I\P>
MNWD;?PR_Y)YI?_;7_P!&O6E=:Y=)J.H6%KIAEFM;>*:,RW"QI+O9ER3SM5=I
M).">#A3QG-^&7_)/-+_[:_\`HUZVM2\/Z;JZW*WD,C?:8DAE,<\D99$8LHRC
M`CECTZYYKKS#_>ZO^*7YL4+<JOY$NCW[ZII-O>R0>0TJDE`^\=2,JV!E3C(.
M!D$<"N)^#7_(H7?_`%_O_P"BXZ[VSM(K"TCM86F:.,84S3/*_P"+N2Q_$UP7
MP:_Y%"[_`.O]_P#T7'6]"WU*O;O#_P!N)UYE<[+7FMETB4W=E/>PY7-O#&TA
MD.1@%5ZKZ]L>M<M!I^JK>:#+;PA]-@N25C/FPF(L)-V8VCR%7.U<D<`?WLCN
MZ@N[N"QM7N;E]D28R<$GDX``')).``.36%#$2A'DBKW_`%5MNY35SD;_`/M2
M'7-7%HEXRSL"(3:!X)%^S@%MY4\A@`%SSTP><9Z6^KVDU[<6UE.)L2-&WV;=
M\V^Y8%01UR4Z?WAZUU4/B>P>!9IA/%&\[0HQMY2N0^P;CMPA)[-BG'Q5H_FV
M\2W,DDMPBR11Q6\CLRG.#A5)'W3G/3'-=:K5HQY?9=D].P-HYO4M5UO2UN(;
MC4+L*B2217`M$9W811L`5"8\L,SY;`Q@`L._<6K.]I"[\NT:EN.^*9=6%G?B
M,7EI!<"-MZ":,/M;U&1P:L5Q5JT*D(I1LUOL)*QYUXD_Y*='_P!@8?\`HXU+
M47B3_DIT?_8&'_HXU+58O_EW_A01ZG/2ZCJJ^-+:P80Q6$MO,T8'S-(R[/F;
MT`+$8![<]J-&N=0CUV^TS4+TW#1PQS1%XD0MDD,5"]$R``&RW7)(Q6Q-I]K<
M7D5W+"'FBC>-&).`K8W#'0YP.M0Z=HUAI1<V<!0L`N6D9]JCHJ[B=JCLHP!Z
M5RHIE^LKQ%=:A9Z)<SZ:D1N$1FWRGY8P%)+8_B/'3WK5J.>".YMY()EW12J4
M=<XR",'I4R3:T&K7U.'UOQF]A::/;QW]M#=RK;37;RL@/ENR@X![GYB2!P`>
MG%=V""`000>015272[*>QALI(=UO"8VC3<1@H05YSG@@5<JVU^)*3L@KD#K&
MO?:O$<3PKYUO:I)96UNH<J6W@9./F)P"1T'3W/7U2FTBPN);J26W#M=QK%,2
MQ^95SM&,\8R>14C*7AR\>XM[B&XN+V6\MY`DZ7BPAXR5!`_=#;@@Y')Z]:VJ
MJV&G6NFQ-';(PWMN=Y)&D=STRS,2QX`')[5:IL$<]XKU'5-.M;>33Q$D1GB6
M:9SE@&D5=JKCJ<GGMBJ?]O7+^)Y89+B:WM(;U;,+Y,;1.2@8!B2'#$G@CY>.
M>M=+>V-OJ%OY%U'YD6]7V[B/F4A@>/<"H9-'L9=16_>`FX4A@=[;2P&`Q7.T
ML!P"1D4EIO\`UM_P0>Q>J.=I$@D:&,22JI*(6V[CV&>U255OK^&PB5I`[N[;
M(XHQEY&]%'^0`,G`H`YB'5-2D\.:I=ZCJ$EM<6=W*N;)(^0,`1CS$8$9.,XR
M?TKI-)BO8-*MTU&Y-S>!`992JKECR1A0!QTZ=JRGL7:SFB?00;>>?[3+$+S]
MXSY#9QTSD#C=BMFROH+^$R0EOE8HZ,NUD8=58=C1T^X/^"6:Y[4]1U2W\4Z1
M:H(HM.GD9'.=SRD1LV.GR@8'N?8=>AJO/8VUS<6UQ-'NEMG+PMN(VD@J3QUX
M)ZT!T.6\.:WJ%[KABN[AF@GCF>$.B!'V2;08MOS;<==_.2,<5V-9]GHFG:?=
MO<VUOLE<$<R,P4$Y(52<*">3M`R:T*.B#JRIJ4EY%82-81127/`42MM4<\D_
M0<X[UQDNOZX/#>FZB99PK:>]Q)-!;!Q).,$(_P`I"(1GGY?]X=^](#*0>A&#
M66WAO26M[6W-J?*M4,<2B5Q\AZJW/S*<#(;(.*%_7XCT-/X=3&X\0^))BI4R
M)9/M/;,;&NK\0ZO<:)9QWD5G'<0"15G+2LAC0G&X81AQWW%5`ZL*YCP'QXK\
M5`?].G_H#5UVI:+8:NT+7L+N8L[=DKQY!QE6VD;E.!E3D'`R*[,=_&7^&'_I
M$2(?#KYE#P[XD?7;F_B>R^SK;N/+;>Q\U"6`8;D7/W>J[EYX8G('-:Q_R7+0
M/^O!O_09Z[73]&L=+EFEM(G1IL;MTKN`!G"J&)VJ,GY5P.3Q7%:Q_P`ERT#_
M`*\&_P#09ZURWXJG^"7Y"G^IZ)1117G%A7G?P:_Y%"[_`.O]_P#T7'7HE>=_
M!K_D4+O_`*_W_P#1<=>CA_\`<JWK#_VXA_$CT2L_5-)CU01%KBXMY(]P$D!4
M':PPR_,",$>V>."*T**X(3<'S1W+.7G\&6H>2YB>2YG$+Q117+J$PR;"I8(7
MV]\9.#TQ4MEX0M+4:4SS2-)IZ#:0B?._)9BY7?R220&`/<5T=%;O&5G'E<OZ
M_ILGDB%%%%<Q1Y%X-_Y%2R_X'_Z&U:FHRVT.FW4MXY2U2)C*P8KA<<\CD<>E
M9?@W_D5++_@?_H;5H:KJD&D6$EW/R%X5`>7/H/RSGH`"3P*Z\Q_WNK_BE^;%
M3V1Y[8ZOX?B\.ZGJ5PEC_9TTT?V;289EXP,+YJ@X!<\L#Q@<YYKL_"">7X9M
M1]JMKG)=MUK('B3+$[%([+G;^%9*W-@]F^KB\8:PLB_.T$H8EA\L(C*[S&1T
M`!S]X<UT>CZM;ZUIZ7=OD9.V2-OO1N.JD>H_^O7+?<"_7"^(+O2Y_&EEI\,M
MI!J:212S7<\P5HT!XBCR?O/T(7L><\5W5%):-,?1HX[3O[/7QSOTO#^9#,MV
MJ!A)')N!W3;CDYY"9`P,XR#QV-%%'1(.MS%\5WNF:?X>N+C5T\VT7;F+=CS6
MSPO49!/4'C&<\5P^I'4#\.9(K58Y[.1)YKB33IXFCMQG*P@[A\HSSMSTP!S7
MJ5%"'?8KV+M)86[M$\3-&I*.1E>.AP2/R-6***;=V2E96///MVG7?B^__LF:
MTMY;2.<3R-)NFNYBI^4*,NR)UX!Y&`.*U?`WV>"&XLK2+3Y888XO].L(?+29
MB""K<DEUQR2?XN@KKJ*2T5AO5B-G:=N,XXS7`ZO?:39>"](2^A@N+NY0+#'>
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MQ.B8&UI6S\T9Q\@P,9&"<5Z!126GXC>II_#+_DGFE_\`;7_T:]2ZEJES;:KK
M$%SJ@L[.*Q@EAFCC53`SO(I9F97&/E&6*[0.2.":B^&7_)/-+_[:_P#HUZZV
MNO,/][J_XI?FQ0?NKY&1X7O;C4/#=E<W4HFG92&E&TK)@D;E*@`J<9!``((.
M!G%<E\&O^10N_P#K_?\`]%QUZ)7G?P:_Y%"[_P"O]_\`T7'6]!WP5?UA_P"W
M$[21Z)574+&/4K)[:5G0$JRO&<,C*0RL,\9!`/((JU17G1DXNZW+.:E\%64[
M1M->WLI23S3O,9W/O+[ON?*<D_=QQP:AB\%V\]A=PWA$375V]Q(L`20`'A5!
MD0D8'.5"D$G%=7172L;72MS"Y4(BA$5!G"C`R<FEHHKE&>=>)/\`DIT?_8&'
M_HXU+47B3_DIT?\`V!A_Z.-2,RHC.[!549))P`*Z\7_R[_PHF/4X*_N]/N_'
M@M=.DM(-0MFWW-Q+,/-E8H0L$8)R1T)`X&/6K'@C`NV\@*%^P0_;=O\`S]Y;
M?O\`]O'7//3-2MJ5CK^HLL]U/`(VQ8".-^'QN$A;&W>1]U"2=O)'S$#6T+Q%
M#JSR6<B31:A;J#-');21`C.`XWJ.&QD#K^5<JT5BF;=<[XTU#2].T,2ZK!'<
MJTJK#;RN%260YP&R<;>YW<#&>U=%14M7&G8X#[%*FF>%IFU9;J-+R)-ELX:`
ML68D@C[P'"CGC%=_1157_,FP5YI;:IX<EU+6+])K:#2K:WDCGC2?]_>-N!+L
M`VX@'Y5)Z[O2O2Z*0SEO`C12Z1<7,$EFL,]P9([2TD5TM5(&$^7@-QN('=C7
M4T44V[B1Q7C^\TN-;2RN!:_VC=!DMI+N4)%;#C=*<G`(['KG@=Z28:<OBO2I
M+*47&H+*$NL;O.=#%@/DG_4C@X`VEB#G(Y[:BA.PWJ%8>I2VD6IW$FH/LMX]
M/=@VXJ0N[]X01R#C9R.>16Y52^L4O40^8\,T1W131XW(?QX(/<'@U+V&MSS[
M2[J:\T/49]`MXQ:WDBK]DL)XO,M(0IR[`N`)'^N1UY(K;\",&T^R*QR1L=,M
M_-5F!!(+!&X)&2,^^`,]*WC#K90)]ML1SS+]F;.,_P!W?C..^<>W:K&GZ?'I
M\#(KR2RR-OFFE(+RMZG&!V'````P`*J^_P`OP$6ZX7Q!=Z7/XSLM/AEM(-32
M2*6:[GF"M&@.1%'D_>?H0O8\YXKNJ*2T:8=&CA_#!C@\27$:IIUW<7!GEN+F
MWMRDUN?,R$E9CDY!X&%^[W'-=Q111T2#K<Q?%=[IFG^'KBXU=/-M%VYBW8\U
ML\+U&03U!XQG/%<*X9=(L7GGTN;3VBN95C5_,MXYBRE(4*L,.%RJD'@YP*]4
MHH'<B^&SM)KGB)VB>)FBLB8W.63]TW!/<BM[QGJLNEVEJ]MJ9M+DR@I$=@%R
M`1F,;T;<Y!^5%*,W8C!K)\"?\C7XJ_[=/_0&KO:[,<_WR?\`=A_Z3$B"M&WJ
M<EX0UJ^U+4]5MKFX:Y2V90S[X'1)"S!D0Q'A0`O#_.,\]161K'_)<M`_Z\&_
M]!GKT2O.]8_Y+EH'_7@W_H,]:Y;\53_!+\A3_4]$HHHKSBPKSOX-?\BA=_\`
M7^__`*+CKT2O._@U_P`BA=_]?[_^BXZ]'#_[E6]8?^W$/XD>B4445YQ84444
M`%%%%`'COA:XAM/!5O<W$BQPQ)*[NQP%4.Q)J&'58)5GUF6XMI;D1M]BLC<(
MI1<<`DG`=NY[#`[$FUX.`/A.R!&0?,_]#:MOR8O^>2?]\BNO,/\`>ZO^*7YL
MF'PH\ZM#Y^G3WNH^9_;,ES'<,R7ULI0KD`0_.RD*"1A\9R:T-,6'0=/CO(M1
MMI+CS)'NX#<(QEC9V8#(./,7=P>AY'<$=KY,7_/)/^^11Y,7_/)/^^17+<H;
M;7,-Y:Q7-O(LL,JAT=3D,#T-2T@``P!@#L*6D`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110!I_#+_DGFE_]M?_`$:]=;7)?#+_`))YI?\`
MVU_]&O76UUYA_O=7_%+\V3#X4%>=_!K_`)%"[_Z_W_\`1<=>B5YW\&O^10N_
M^O\`?_T7'6V'_P!RK>L/_;A/XD>B4445YQ84444`%%%%`'G7B3_DIT?_`&!A
M_P"CC65/C7;Q[1<_V;;OBX;H)Y!_RS'JH_B[$_+_`'A6KXD_Y*='_P!@8?\`
MHXUG2>%_#\LK22:%ICR.2S,UI&2Q/4DXZUUXO_EW_A1,>IESP:K?^,H7O-.N
M5TFR;=:M%)%L>0@@R2?/NP,D`!3ZT^UTC4%AN=3V+%K#74LB!W^62/.%C8C.
M%**OT/..HJ__`,(GX;_Z%_2O_`*/_"C_`(1/PW_T+^E?^`4?^%<BT13+]C>Q
MZA:K/&&7DJ\;C#1L."K#U!JS5>RL+/3H#!8VD%K"6W&.",(N?7`[U8H`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`?X$_Y&OQ5_VZ?^@-
M7>UP7@3_`)&OQ5_VZ?\`H#5WM=>-_BK_``P_](B3'8*\[UC_`)+EH'_7@W_H
M,]>B5YWK'_)<M`_Z\&_]!GK;+?BJ?X)_D*?0]$HHHKSBPKQ_X9ZIKMEX<N(]
M+\._VE`;MF:;[:D.UMB?+M89Z`'/O7L%>=_!K_D4+O\`Z_W_`/1<==E.G*6#
MJM2:LXZ*VN^]TWIY6\S6E6A3E[U-2OWYM/\`P&2_&YK_`/"0>+_^A'_\JT7^
M%'_"0>+_`/H1_P#RK1?X5UM%>=[.7\S_``_R.GZW1_Y\0^^?_P`F<E_PD'B_
M_H1__*M%_A1_PD'B_P#Z$?\`\JT7^%=;11[.7\S_``_R#ZW1_P"?$/OG_P#)
MG)?\)!XO_P"A'_\`*M%_A1_PD'B__H1__*M%_A76T4>SE_,_P_R#ZW1_Y\0^
M^?\`\F>&>&K_`%>#P_:QVNB?:81OVR_:D3=\YSP>1SQ^%:W]J:]_T+?_`)/1
M_P"%'@W_`)%2R_X'_P"AM6[75CJ4UBJB<V_>?;OZ$QQ='E7[B'WS_P#DS"_M
M37O^A;_\GH_\*/[4U[_H6_\`R>C_`,*W:*Y?9R_F?X?Y%?6Z/_/B'WS_`/DS
M"_M37O\`H6__`">C_P`*/[4U[_H6_P#R>C_PK=HH]G+^9_A_D'UNC_SXA]\_
M_DS"_M37O^A;_P#)Z/\`PH_M37O^A;_\GH_\*W:*/9R_F?X?Y!];H_\`/B'W
MS_\`DS"_M37O^A;_`/)Z/_"C^U->_P"A;_\`)Z/_``K=HH]G+^9_A_D'UNC_
M`,^(??/_`.3,+^U->_Z%O_R>C_PH_M37O^A;_P#)Z/\`PK=HH]G+^9_A_D'U
MNC_SXA]\_P#Y,PO[4U[_`*%O_P`GH_\`"C^U->_Z%O\`\GH_\*W:*/9R_F?X
M?Y!];H_\^(??/_Y,PO[4U[_H6_\`R>C_`,*/[4U[_H6__)Z/_"MVBCV<OYG^
M'^0?6Z/_`#XA]\__`),PO[4U[_H6_P#R>C_PH_M37O\`H6__`">C_P`*W:*/
M9R_F?X?Y!];H_P#/B'WS_P#DS"_M37O^A;_\GH_\*/[4U[_H6_\`R>C_`,*W
M:*/9R_F?X?Y!];H_\^(??/\`^3,+^U->_P"A;_\`)Z/_``H_M37O^A;_`/)Z
M/_"MVBCV<OYG^'^0?6Z/_/B'WS_^3,+^U->_Z%O_`,GH_P#"C^U->_Z%O_R>
MC_PK=HH]G+^9_A_D'UNC_P`^(??/_P"3*'@76/$=KX-L(;#PK]NM5\S9<?VA
M'%O_`'C$_*1D8.1^%=%_PD'B_P#Z$?\`\JT7^%'PR_Y)YI?_`&U_]&O76UU8
MZE-8JHG-OWGV[^A,<71Y5^XA]\__`),Y+_A(/%__`$(__E6B_P`*XSX9ZIKM
MEX<N(]+\._VE`;MF:;[:D.UMB?+M89Z`'/O7L%>=_!K_`)%"[_Z_W_\`1<=:
MT*4W@ZK]H]XZ>[KOY7!XNCS+_9X??/\`^3-?_A(/%_\`T(__`)5HO\*/^$@\
M7_\`0C_^5:+_``KK:*X/9R_F?X?Y%?6Z/_/B'WS_`/DSDO\`A(/%_P#T(_\`
MY5HO\*/^$@\7_P#0C_\`E6B_PKK:*/9R_F?X?Y!];H_\^(??/_Y,Y+_A(/%_
M_0C_`/E6B_PH_P"$@\7_`/0C_P#E6B_PKK:*/9R_F?X?Y!];H_\`/B'WS_\`
MDSQ[6]3UV7QTD\_AWR;O^S`@M?MJ-E/-)W[P,=>,=>]2?VIKW_0M_P#D]'_A
M6QXD_P"2G1_]@8?^CC4M=6*I37)>;?NKM_D3'%T=?W$/OG_\F87]J:]_T+?_
M`)/1_P"%']J:]_T+?_D]'_A6[17+[.7\S_#_`"*^MT?^?$/OG_\`)F%_:FO?
M]"W_`.3T?^%']J:]_P!"W_Y/1_X5NT4>SE_,_P`/\@^MT?\`GQ#[Y_\`R9A?
MVIKW_0M_^3T?^%']J:]_T+?_`)/1_P"%;M%'LY?S/\/\@^MT?^?$/OG_`/)F
M%_:FO?\`0M_^3T?^%']J:]_T+?\`Y/1_X5NT4>SE_,_P_P`@^MT?^?$/OG_\
MF87]J:]_T+?_`)/1_P"%']J:]_T+?_D]'_A6[11[.7\S_#_(/K='_GQ#[Y__
M`"9A?VIKW_0M_P#D]'_A1_:FO?\`0M_^3T?^%;M%'LY?S/\`#_(/K='_`)\0
M^^?_`,F87]J:]_T+?_D]'_A1_:FO?]"W_P"3T?\`A6[11[.7\S_#_(/K='_G
MQ#[Y_P#R9A?VIKW_`$+?_D]'_A1_:FO?]"W_`.3T?^%;M%'LY?S/\/\`(/K=
M'_GQ#[Y__)F%_:FO?]"W_P"3T?\`A1_:FO?]"W_Y/1_X5NT4>SE_,_P_R#ZW
M1_Y\0^^?_P`F87]J:]_T+?\`Y/1_X4?VIKW_`$+?_D]'_A6[11[.7\S_``_R
M#ZW1_P"?$/OG_P#)F%_:FO?]"W_Y/1_X4?VIKW_0M_\`D]'_`(5NT4>SE_,_
MP_R#ZW1_Y\0^^?\`\F8GA/5=?M_$'B"2S\-?:YI?L_GQ?;HX_)PC;>2,-D9/
M'3%==_PD'B__`*$?_P`JT7^%9_@3_D:_%7_;I_Z`U=[75C*4U45YM^['M_*O
M(F.+HV_@0^^?_P`F<E_PD'B__H1__*M%_A7+B\U*]^,VA2ZII7]FSBT=5A^T
M+-N7;-\VY>.I(Q[5ZK7G>L?\ERT#_KP;_P!!GK;+Z4W.=IM>Y+MKIMMU^_LR
M:N*I.-E0BO.\]//X[?>>B4445R'*%>=_!K_D4+O_`*_W_P#1<=>B5YW\&O\`
MD4+O_K_?_P!%QUZ.'_W*MZP_]N(?Q(]$HHHKSBPHHHH`****`/(O!O\`R*EE
M_P`#_P#0VK=K"\&_\BI9?\#_`/0VK=KKS#_>ZO\`BE^;)A\*"BBBN0H*QM0U
MJ?3]6M+5K%6M[F18DE\\!V8Y)VICD*!DDD8[9K9K'U+1KG4[I!)J&+$2QS&#
MR1O#(0PVN",`D#.0?8BA;H'L1:?XC%]J@MC;!()C,+:82Y,AB;:^5P-O/3DY
M'I6[6%I_AQ;'4UN?M(>"$S&WB\O!0RMN?+9^;GIP,#UK=HZ`]RM?SW%M9O+:
MVPN9A@+&9!&.O4L>@'4\$\<`U@3>,XH/#T&IFQDDDF<JL43;D(5]I??C&SH0
M2!G(XK?OH;F>V*6EU]EFR"LAC#C@]"IZ@]\$'T(K);PUO\/7.F-=_O+F8SRS
M"/Y=Y<.=JYX''3)^IH0/8WZ***`(YYDMX))Y21'&I=B`3@#D\"L[0M:&N6MQ
M<+:R6XBN'A"2_>.W')';.>E:M4-+TS^S1>?OO,^TW3W'W<;=V..O/3K0MP>V
MA?HHHH`QM5UN?2KR`2V*FSEFC@\XS@.SN<#:F#D#ODCCIFMFN>N_#][=>*(=
M7.H6[0P*%AM9K5G$7]YE(D`WGID@XKH:.@=0JM?SW%M9O+:VPN9A@+&9!&.O
M4L>@'4\$\<`U9JM?0W,]L4M+K[+-D%9#&''!Z%3U![X(/H10!!HFJ?VQI45\
M(A'O+#`?>IPQ&5;`RIQD'`R.U:%9^CZ9_9=H\33>=)+,\\KA=JEV.3M7)VCV
MR?K6A38!6,OB&&3Q4-#BA9R(&EDGW?*K*5^3'<X8$^F16S7/P>$K*U\10ZM;
M2W$?EK+NA,\K*SR$$MR^`.#QC!R#V%);ZAT.S^&7_)/-+_[:_P#HUZZ%=5L&
MO;JS%U&;BUC66=,_ZM3G!8]!T-<]\,O^2>:7_P!M?_1KUHZIX;_M.[O)CJ%Q
M;"YMX8"8%3<OENS]7#*0=V""O3/K77F'^]U?\4OS8H6Y34L;VVU*Q@O;.42V
MTZ"2*0`@,I&0>:X/X-?\BA=_]?[_`/HN.NUT336TC1;33WNI+MK>,)YTBJI?
M\%``KBO@U_R*%W_U_O\`^BXZWH6^I5[=X?\`MQ+^)'HE%%%>:6%%%%`!1110
M!YUXD_Y*='_V!A_Z.-2U%XD_Y*='_P!@8?\`HXU+77B_^7?^%$QZA1117(4%
M5-0GN[>W#6=HEQ*6P1),(D4=V9L$X^@)JW6/XDT>ZUS2_L-M?BS5W!F)B+^8
MG=.&4@'O@]*3&O,R'\=Q[+!TLT*W2!@'N`K.?,V%8AC]X<\_P\$&NOKE[GPC
M)=(J->P1*]LEK.D%L50QJVY?+&\^6>V<M]*Z@#`QZ56A.H5S%[XMDTRYFAO]
M.$3B$S0JEP'8J'5!O&,)DL#P6XSZ8KIZY:Q\+7]L^IR7&J6UQ-?@[YVL?W@_
MNK\TC*4`R-NT=>M+J,V-)U0ZDERDD217-K,89TCD\Q0V`W#8&1AAV%:-9>AZ
M+%HMM,B>3OGD\R3R(O*C!VA0%3)VC"CC)K4INPD8_B#6I]$M1<I9+/`HS*[3
MB/'(`51@EG.>!P/<5"/$H.LBT^R@6WV@6AG,OS"8IOQLQTQQG/7MWJUK.F7>
MJ0-;PZ@+>WEC:*>-H!('5N"0<@JP'0Y(YY!JE#X62#4HYDNB;1)EN?)9,L91
M'Y8._/3`SC&<\Y[4+S&]CH:***0&=K>KQZ)IDEY)#+,5!V11+EG."<>PP#R>
M!5JQN?MEA;W6S9YT2R;<YQD9QFDO[7[;I]S:;]GGQ-'NQG;D8SBEL;;['86]
MKOW^3$L>[&,X&,XH74'T)Z***`,:TUN>37/[+N[);>1X6GBVSB1MBL%^<`87
M.01@MWZ5LUSVA>'[W2M2O+R[U"WO9+MBSR?9627_`&5#>80%`Z`+70T=$'4*
MQ_$&M3Z):BY2R6>!1F5VG$>.0`JC!+.<\#@>XK8K+UG3+O5(&MX=0%O;RQM%
M/&T`D#JW!(.058#H<D<\@T#7F:W@([O%/BDX(R+,X/;]VU=K?:C::9`DUY.L
M,;RI"I;^)W8*JCW)(KA_A["MOXC\30H6*QI9H"QR<"-AR:Z3Q%X;;7VM'75;
MNQ:V<,!"D3*_S*>0ZGGY<`@C&3U'%=F._C+_``P_](B1#X=2YIFNZ?J\MQ%9
M2R.]N0'$D$D>020&7<HW*2K89<@X/-<9K'_)<M`_Z\&_]!GKI]`T"YTB>9[B
M_CN4\I(+=$MS'Y<:LQ`8EFW-\W7@<=*YC6/^2Y:!_P!>#?\`H,]:Y;\53_!+
M\A3_`%/1****\XL*\[^#7_(H7?\`U_O_`.BXZ]$KSOX-?\BA=_\`7^__`*+C
MKT</_N5;UA_[<0_B1Z&2%4L3@`9)->>^'_%6KW?B6UEO;A6T;5FN$L8Q&H\L
MQMQE@,G(!ZGO76>*$U";PU?0:5"9;V:,Q1J'"XW<$Y)`X!)KCM1^'-S8Z+;2
M:3J>IW5_8O'+;VL]RODA@1G:"`%[]ZO`QP_LY*LTG+17Z:;^6K6ODPG>UHA?
M:UJDWB36[8^,[318;.15AAGMX6+@H"<%L'K]>M17/BW6;OP_X:N1J<.DR7\\
MD5Q=-"C)M7@/A^`#C/4=:W=*\,1W&OZY?ZUHUK(MU+$]N;A(Y2`$`8#KCFI_
M%&@2:MJ?A\)8Q3V-K<,UPCA=BIMP/E/4>P!KJ5?"JI&#BM$G>T;?!MMK=][Z
MHGWFF_4S_#NM:B?%0TJ3Q!:Z_;26S3-<00HGD,"``=A(.<_6NYKD=(T.^\-^
M*[B/3[</H%ZOF%591]EE]@3G:?09QGVKKJ\['.G*HI4[6:6UE]Z5DGY?,J*:
MO<\B\&_\BI9?\#_]#:MVL+P;_P`BI9?\#_\`0VK=J<P_WNK_`(I?FQP^%%:^
MOK?3;-[JZ<I"F`2J%CDD``!02221P!3[6YCO+=9XEE5&Z"6%HF_%6`(_$5G^
M(K(W^EB(6]Q<!9HY&BM[CR9&"L#PW'/'JOU%.T""^M]*6/4&<R^8Y19'WND9
M8[%9LG<P&`3D_4]:Y%L4S4HHHH`H1:S83ZBUA'/FX7/R[&"MM^\%;&UB,\@$
MD=ZOUR6B:/JNF:PJ!IA:+).\TCS;HY5=RR!4W?*P).3M&?4]NMHZ!U"J&IZQ
M::1%YMY]H$>TL7BM990H'4L44[?QQ5^LG7K2YOX+2TACWP272&Z^8#$0^8]^
M<D`8'K0!I03QW-O'/$6,<BAU+*5.#R.#R/QJ2BB@!DTT=O"\TSJD4:EG=C@*
M!U)JKIVK66JI(UI*S>60'5XFC89&0=K`'!'0XP:=JD,]SI-Y!;&,3R0ND?F#
M*[B"!D>E8OA32[O3C>&:"6WAD$02.XF$TFY5VL=^YOE/&!GCT'2A=0?0Z6L6
M&`ZW-)<W3RBRCE:."W5RJOM)4N^/O9(.`>,8.,UM5D:=<I8SOI=TXCD$C-;E
MN!-&Q+#:>Y7.".O&>AH`I7B:7;WGV/3KHV&I#&QHD8Q!CRJR`?)\WH2&(^Z0
M>:VM.NS?6$5PR>6[`ATSG8X.&7/?!!'X5R/B:S,>M*Z+<1"YG@EQ'/&5N'C(
M.WRR-^_"X&WY<<MC%=7I-H]EIL<4@42LSRRA3D!W8NV#Z;F-"VN'4NUG'7=,
M\N\D%VK+9N(YRBEMKG&%&!\QY`P,\G'6M`@,I!Z$8-<8?#-Q;1ZI'9VBQ0B_
MMKFVB1E`D2,1Y`YX.5(YQS^="WU_K49UMG>6]_:K<VS[XFR`2I4@@X((.""#
MP0>14]9/AZRN+.PF-RACEN+F6X,18$QAV)"DC(SCK@D9K6H8BK=ZE9V$EO'=
M7"1R7,@BA4]78]@*%U*S?4WTY;A&O$C$KQ#DJI.`3Z5EZ]HWVV^TR]M[57N8
M;N(R2Y`*Q*23U[9/046VC?9/%\M];VJQVTMH1)(I'S2F3)SWSCO0O/S_`"!^
M7E^9V/PR_P"2>:7_`-M?_1KUUM<E\,O^2>:7_P!M?_1KTW7]`N;R[UMTMKB>
MWO;&WB*QSQ[G*R.751+N0?*1PP"MG!/)-=>8?[W5_P`4OS8H*\5\CKZ\[^#7
M_(H7?_7^_P#Z+CKK_#=I+8>'[2UEMTMVB4J(E2--BY.T$1_(&QC.WY<YQQ7(
M?!K_`)%"[_Z_W_\`1<=;T%;!5_6'_MQ/VD=_<SI:VLUQ)GRXD+MCT`R:XFQD
M\9:YI:Z]:ZK:6B2J9+?3C:AU9.=H>3.X$CTKMKF!+JUFMY/]7*C(V/0C!KB;
M&+QGHFEKH-KI5G=I$ICM]1-T$55YQNCQN)`]/UJ<'R\DN7EYKKXK6MK>U].W
MGV'+IV)7\87FIZ-H0TJ.*'4=8=D!E&Y8`F?,;'?&.!5ZRL?%T%Q<V=UK%O=6
M\EN3%?\`V94DAEZ#]V.&`Z\U0?P==Z7HVA'2I(Y]1T=V<"4E5GWY\Q<]LYXK
M4T>Y\4WVJM/J>GV^F:>L>T6WG+-([_WMR\`?Y]ZWJNDH-X?EY==[7W=K7UVM
MY;W)5]+^1@6<7B^X\47VD-XOP+.**4R?V;%\^_/&.W3UKT*N>L-,O(?'&KZC
M)#BTN+>%(I-P^8KG(QG(_$5T-<F-JJ<HVMLMDEJTK[+O]Q459L\Z\2?\E.C_
M`.P,/_1QJ6HO$G_)3H_^P,/_`$<:EI8O_EW_`(4$>H54AU*SGU&XT^*=7NK9
M5::,`_(&SC)Z=NE6F#%&"D*Q'!(S@UR7AOP]JFC^)+ZXNKB"X@FMXPTZPE&F
MDW.23^\;!&>>,'(`QBN1;E=#KJ***`*%[K%GI]U!;3F<SS@LB0V\DI(!`).Q
M3@<CDXZU?KE_$>F7]SJ*W.GPW?VK[/Y4%S%>;(X6W9S)'D;EZ?WLX^Z.M=.N
M=HW$$XY(H6P/<6HYYXK:"2>>18XHU+.['`4#J:DK,\0Z?+JN@W=E`^R:1/D)
M..000/TH`L:?J=IJD3R6DC,(VV.KQM&R'&<%6`(X(/(Z&K=8OAV#4(8[PWBS
MQPO-NMH;F;S98UVC.YMS9RV2!DX!_`;5-@%9DNO6$&IQZ?*;I+B5_+CS9S;'
M;&<!]NT\>]:=9"VES+XJDO)H_P#18+58[9MPY=F)<XSZ!!R/ZTEN'0UZS]1N
MITDM[.T*K<W).'89$:+]Y\=\9``]6':M"LC5-MGJMCJLN?(ACEMYFQQ&LA1M
MY]@8P">V[)X%`%>^LM-TZV$U_>ZBTCNJB1;F8R._8*D9]ONJN.O'6I='U(RS
M+;-=K=Q2Q&>TN,8:1`0K!AQ\RDKDX'WAQD&F^);*XU&RM/LT3W$<=PLLL<$O
MER.@!_U;Y7:<D<[AQGFJ'A>&X)M(G*F/3H)(79,%2[N"$W`\E%7#'N6ZY!H6
MS!]#JZ**.HQ0!1LM8L-1FDAM9_,=!G[C*&&<$J2,,,\97(J]7)Z%H-U::VEP
M\5Q;VMK#+!%#+,DBX=U8;"H!V_+_`!\Y..@KK*.B#J,EEC@B>65U2-`69F.`
M!ZFLV3Q'I,=E:WC76;>Z7?$ZQ.V5[L0!E5&1EC@#/-7+^R@U"T>WN84FC)#;
M'&02#D?J!7&?\(]JT6A:=$MH7G&E2Z?+$)4'E,^W#$DX*C!SC)Z8!H7]?B-)
M'?>`R#XJ\4D'(/V3!_[9M7?5Y[\.HC;^(/$D);<8TLD)]<1L*V_&%AK>HQV,
M>EP6TUO'<1S3I)=M`Q*R(RXPC!E&&)!([=>A[,=_&2_NP_\`2(D0^'4Z>O.]
M8_Y+EH'_`%X-_P"@SUU>C:=-8ZGK<DB.(KJ[66)GEW[AY2`]22!N##''3CC%
M<IK'_)<M`_Z\&_\`09ZURWXJG^"7_I(3Z'HE%%%><4%>=_!K_D4+O_K_`'_]
M%QUZ)7G?P:_Y%"[_`.O]_P#T7'7HX?\`W*MZP_\`;B'\2.VEU:UBUB#2R6:Z
MF1I`%&0JC^\>V><?0U6D\1V4-W#;.DPDDN6MN@^4J`=QYX4[EQ_O#BD?PY:'
M7HM7C>>.979Y%$\A60E=H^7=M&`/3FJFI>%!?S:G,MZT+WB1^61'GR)%*G>.
M><[$XX^[64%A6TI-VMKZW_+K\AZEBV\2"]DC6STJ_G5HHY2ZF)0BOG;G=(#T
M&>`:%\1@VT]VVEWR6<._,Y,6UMK%3@"3=U!Z@55G\*`ZG'=PC2V6.**)%N]/
M\YH_+S@HV]=O7T[577P7B*\A,FF!;H2JTR:=MN,.Q.#)YG/7TYQ6ML&^O;H_
MF3>9K3^(((R!#:W-RSS&"(1!!YK`$MM+,!@8.22.1@9K2MYA<6\<PCDCWC.R
M5=K+[$>M8\OAZ1;5K.SN;=++=E+2YM!-$H(P5QD';W`!&,GJ,`:>G6?V#3X;
M4RF7RUQO(QGZ#L/0=A7-55'D]QZ_/_ABE>^IY9X-_P"14LO^!_\`H;5LSS);
MP23RDB.-2[$`G`')X%8W@W_D5++_`('_`.AM6[5YA_O=7_%+\V$/A1@V'B"X
MU73+BZLM+?S([EH%BGE$?`Q\S'!*CGH`3[5>T355UG2TO%C"9=T90VX;E8J<
M-QD9'!P.*R[WPQ=3:1J%C::K]F-[=M<22>020C8RG#@\XQG(XS6QI=F^GZ;#
M:.;?]TNU?L\)B0#L`I9B./>N1;?=_P`$HN5C7GB&.V\0V.CK;2R27+$/+@A(
M_D9@,X^8G;T'3OVSLUGW^F?;=1TV[\[9]BE:3;MSORA7&<\=<]Z%N'0K6FMS
MS:_)I=Q8"$B)I499P[;`VT%U`^3=U7DY`.<8Q6S6/#HUS_;,=_>:A]H%N)%M
MU$(C90^,AR#AL8`'`]\GFMBCH@ZE74;^/3;*2ZE25U7`"1(69B3@``>IK$NO
M&$-IX.@U][5B\\/F1VJOEB<9(SCH`"2<=!72.N]&7.,C%<O<>"+2Z\-V^ERW
M,OVBWM&MHKI'=``PY)17`8<#@YZ4#5CIXW\R)'QC<H.*=45K`MK:Q6ZL[+&@
M0%V+$X'<DDG\34M-[Z$J]M3#3Q-!)K5Y8"WD6.TMVF>XD^56*M@A01R!Z]*D
M\.:T^O:<+QDLE5@"JVMY]H*Y&2'^50K#TYI]SHWVG59KXW&WS;(VFSRPV,MG
M=SD'Z$8I-)T>6PNKB\N;I)[F=(XCY47E1A4SMPNX\\G)S^`I+;7^M7_P!O?3
M^M%_P36K"\6:K9Z5HLLEY8&_5@<6QCW*V!D[B00`!W/ZUNUE>(X+>[\/WEK=
M7L5G%/&8S/(1A<_4C/YT`C+74-.TS7EL--TNP29_+$["6.&4[AP$4C]YA1DC
M(P,8STKJ:Y.;2]-UG5)#9ZM;_O/(>[ACPTC>4V4*D,-G(P3@YQQBNLI]`$)"
MJ2>@&36!8>))=7AU!]/L5!M)51?MDK0B12H;<?D8KP>`1^5=!6'/X>>6#78X
M[TQMJO1Q'_J?W83UYZ9[=:7<:MU+6A:C<:MI45[<6J6QE)**DQD#)V;)5>O7
MITQ6E3(8E@@CB7[J*%'T`I]-VOH2KVU,?5?$$>F:C8V(MY9I;J5(RP&$C#$@
M$MC&>#@=:K67B<7?B272/LR*4:1>)PTJ[,?,\>/E5LC:<G/H*TM4TS^TC9?O
MO+^S727'W<[MN>.O'7K6?:>&C;:NEV;TO!%/-<11>7AP\GWMS[OF7T&!]3BD
MO/S_`$_X(WY>7Z_\`[+X9?\`)/-+_P"VO_HUZV[C7M,MI;N&2Z!EM$1YXXU9
MV4.2%&%!)8D<*,D\<<BL3X9?\D\TO_MK_P"C7JWKGA6+7)+YII8BMS!!$(IH
M/,C!BD:0%ER-RDL`5XX!YYXZ\P_WNK_BE^;%3MRJ_D;MM<)=VT=Q&LJI(NY1
M+$T;`>ZL`P/L0#7`?!K_`)%"[_Z_W_\`1<==KHNF_P!D:1;V`='\H'F./RT&
M23A5R=JC.`N3@`#-<5\&O^10N_\`K_?_`-%QUO0M]2KV[P_]N)?Q([74=7M=
M+>U2X+&2ZF6&)$&222!GV`R,GW'J*@U3Q!:Z0+HW$4[?9X4F(C4$N&8KA>>2
M".?J*9J_ARTU>XAN7>:*XB:/#QS2*"JN'V[58#G'7J.O:I=0T5-0U6RO7F*K
M;JZO$%R)0PXR?8\USP6']WFOUO\`I;UV_$IWN0R>(XOM'D6MA>7<AD9`(?+`
M.U58D%W48^<#ZYI\&NR7%W);IH]_^Y=4FD+0[8F*JV#^\R<!AG`/MFLH>"]N
MF:?:&XL[IK1I"S7]EYZR;^^W>,$``9S3[;PD]OJ9O/\`B3,Q>-LG2OGC"HJX
MC;S/D&%X&#C/>MW'"6=I=^C[_JB?>ZET>*;)[$7<<-Q)'Y4<AVJORM)C9&23
MC>=PXS@#DD9&=.RNS>0%WM;BV=6*M%.H#`_4$@CW!(K&L?"[Z7IJ6FGWRPCR
M564-;ATDD7'SE2?XAD,,\C&"",UHZ-I9TJUDB,D3&20R;8(O*B3@#")D[1QG
MJ>23WK&LL/ROV;ZZ;WM^0]3B_$G_`"4Z/_L##_T<:EJ+Q)_R4Z/_`+`P_P#1
MQJ6C%_\`+O\`PH(]3&;Q%#_PDJZ,MO*3Y3R/.P*HI4*=HX^8X89QTI=#U^/7
M9+[RK:6&.VE6-6E!5I`5#!MI&5Z]ZL3Z9Y^NV>I^=M^S0RQ>7M^]OV\YSQC;
MZ=Z+#3/L.H:E=>=O^VS++MVXV815QG//W<]JY%Y_UK_D6S0K.UO5X]$TR2\D
MAEF*@[(HERSG!./88!Y/`K1JO?VOVW3[FTW[//B:/=C.W(QG%*5[:`K7U,>^
M\1SV6FVVI'3T-D\,<LLC7(4J7QA47!+MSWV^Q[5T':N7N_"U[<7>E2+J=N;?
M3HE6.VGM&=&D`QYAQ(O..F<XKJ*IVZ$J^EPK`M/$QU"\U2VLM.GD:R1&CWD1
MF<L6'&[&!E>IZ_EG?K)?1YAJ>HWUO?-!+=PQ1*5B#>64+<\\'.[I@4AC]$U5
MM7LY9FA2-HIFA;RY?,C8KU*M@9';H.0:TZS=(TM].^URS7`GN;N;SIF1"B;M
MH7Y5).!A1W-:5-@8VO>((M#6W!MY9Y9Y%0*@(50752S-C`QN'UHNO$,4'B6R
MT5(6EDN`QDD!PL6%+`'CDG!X].?2K.LZ9_:^GBU\[RL312[MN[[CAL8R.N,5
M0F\)63Z]:ZM%+<1213M/*@N)2LK%=O3?A>W0<@8Z4EY@]M#?J.>6."WDFF.(
MT0L_&>`.>.]24$@#).`*`.$;5=(&@W&H#2H[:-;W[(MM<W1MXCD@;G'W5&"2
M1@]*['36#Z;;LL=M&I0;5M9-\0';:V!D?@*YQ/[.BCG2U\0:<+B34&N4>5$D
M17/&PC=R1R,AE.?Q%;^CZ:FDZ:EHDK2X9G9SQEF8L<#L,DX%"V_KM_F+6_\`
M7<O5C7GB&*U\0V.D+;2R/<,0\V"$C^1F`SCYB=O0=._;.S6??Z7]MU'3;OSM
MGV*5I-FW._*%<9SQUSWH'T*6C^(QK%_+%###]G4,5D2Z5I!AMOSQ]5S@D=<@
M<XZ5NU@:;X873M3BN%N0UO;+*MM"L94J)&#-N;<=W(XX&/>M^GT#J5=1OX]-
MLI+J5)75<`)$A9F).``!ZFL.7Q-?'PW9:S:Z9;R)<QJWDRWA1][$!47$9#$D
M]\5TKKO1ESC(Q6%;>&S;V&AVAO"R:6X<_N\><0C*._'+9[]*2\Q]#>^'Y=O$
MWB<R*$D*V990V0#Y;9&>]=O?:C::9`DUY.L,;RI"I;^)W8*JCW)(KB_`G_(U
M^*O^W3_T!JZ#Q%X;;7WM'35;NQ:V<.HA2)U;YE/(=3S\N`01C)ZCBNS&_P`5
M?X8?^D1(AM]Y<TW7-/U::>*RF9W@(WAHG3()(#+N`W*2"`RY!P>:XS6/^2Y:
M!_UX-_Z#/75:'I.I:?=7UQJ6HVU])<L"LD=HT+JHSA23(P(`/``7N3DDURNL
M?\ERT#_KP;_T&>M<M^*I_@E^0I_J>B4445YQ85YW\&O^10N_^O\`?_T7'7HE
M>=_!K_D4+O\`Z_W_`/1<=>CA_P#<JWK#_P!N(?Q(ZS7Y+J.WC^QW[6\YW"*&
M.-&>>3'RK\P.%ZDX&<<Y&*H:5J&H2ZQ&+F[+I.]TC6VQ0L7E.%!4@;N>^2?O
M#I6Y>Z5IVI[/M]A:W?EYV>?"LFW/7&1QTJO.FBZ*\FHRQ6-G+(-C3E4C:3T7
M=QD\<#/:LJ=2'L_9\MY:]%^>_G^&Q339S\7B>_\`[/"SQJLSAVAGBE5BP60H
M=Z[,+VXYSSR#FEL_$NH!8U,8N[B601HKR+$G)49)"$\9/^%:MM/X8W.L?]E0
MS2JDLL)\I9.<;2XZY^8=?6K*2Z"M\EHDFFB\#'9"IC\P,.N%ZY&/TK>4Z6J]
MEY_UY?,AIM73,R#Q9-/);XT^-8WEB@F)N?F1W)'RC;\RC'7(^G7'3UBR^%]/
MEUF#4B&5X,;(E5`@()((^7<.3G`(!(!(-;5<F(=%V]DK=RE>^IY%X-_Y%2R_
MX'_Z&U;,\AA@DE$;R%%+;$&6;'8>]8W@W_D5++_@?_H;5NDX&35YA_O=7_%+
M\V$/A1R"^*M0.CS74]O;V<BZ@;1GERT=LG]^3!&<=#@@9/6MS0-5_MG24N\+
MNWO&Q3.TE&*DC/8XS^-<^%>.VN;^WNY[?19[DW!N8F`E4D\S`D;3%QT(.5^;
M.*ZJPLH+"S2WM\^6"6W$Y+%B26/N22?QKD6W]=A]2S6!K6KWVEZC9A3:-!<S
MQP1V^UFFE+'YF!R`H4<]#D#J*WZQ)O#:2^(AK:ZC>QW`01B,")D"#DJ-R$C/
M<@@^]"W0^A5TOQ%<WNK112K#]ENVN%MPJD.GDOM.XY(.[D\`8Z<UTM95GH%K
M9:BUY'),Q^?RXF(V1%VW.5XS\QYY)]L5JT=`>Y6OVNELW-FUNLPQA[C.Q1W)
M`Y.!GC(SZCK7+2>+[\>%UU*WLDN7,S1_:%4I`45POF8)SAL\#)^N*Z'7-'BU
MW2I=.GN+B"&7&]K=@&(!SCD$8/?BHWT**;0CI-Q=W$L)P!(5C1@`00`%0*`,
M>E"!FK1110!SDVL:G!XC33/]!F>XCEDBA0.&B51\KR/R,,>,!1CL34^@:M<Z
MA=:C:W#V\[6<BQF>VC9(RQ&63!)Y7N<]^@J*'PFEO>:C=1:OJ*R:@6,W^IR,
MC`VMY>X!>PS@5<T'0X_#]@+*"[N)[=!A%F6,;/7E$7)/<G)H6P/R-6N3N7N8
M[:?Q"TUE"RM)B6\#2+!"I(4(H*_,V`2<@\XYP!765QVKZ&KR16]Y/?QZ?%<M
M=026J+(%=CG;(K*^0&)*G&`#SC`I,:$U"]OK^VT>>[M8(+>\,(`VN)H)''+"
M3@1D9``(.[...E='HUW)>Z7'),RO.C/#,RKM!DC<HQ`[#<IK!O;>*_>-+>YU
M'49AL8PR`+;LZ'*O(=@"X."0F,_W372:?:?8;"&VWF1D'SN1@NQY9OQ))_&J
M=B46#G:=H!..,UR]OXEN;>\U&VU#[-<26D<;'[$C`"5R0(<L3N;ISQUZ"NG=
M2\;*&9"P(W+U'N*P-,\':?I]B]C-))J-H[F0PWT4,@WDY+DA`2W/4DTA]"WX
M:U.YU?08+V[BCBG=G#I'G:NURO?Z5K5GZ-HMEH.GBRL8PD0=G/R@$DG/.`/I
M]`*T*;W$C`\2:O?:,D=S$UIY!9(UA=6:6XD9L;$P0%XYS\WT'6H]/UZ>\\1W
M5G)/!%;QS-%#$UG*&E*J-Q$I;82#N^4`G`JQJ/AN/4-;MM5_M&]@GMD*1+&(
MF1<]2`Z-@GIGKBIAH4/]IQWTUU=3^5(TD,,SADB=@02O&[H3P20,\`4EYC?D
M=1\,O^2>:7_VU_\`1KUKW&O)%>7MG;V%Y=W5I%',T42HF]7)`VM(RJ<;23SC
MWSQ61\,O^2>:7_VU_P#1KUM7FB6]Y-?2O+.CWEH+20QL!M0%SE>.#\YY^E=>
M8?[W5_Q2_-BA;E5_(GTJ_&J:7;WPMIK99TWK%/MW@=L[2PYZ\$]:X?X-?\BA
M=_\`7^__`*+CKT-%5$5%`"J,`#L*\\^#7_(H7?\`U_O_`.BXZWH?[E6]8?\`
MMQ/VE<[C4V*:?(POA9`8W3[0Q49YP&XR>@R#R>AKF%U+68IHS<7LBF![93`T
M48,R2S,F7^7(;9CA<`$&NLN[.UOX#!>6T-Q"2"8YHPZDCIP>*J-I6B6*1W+6
M&GVZVBDQRF%$$(R22#CY1DD_C6%"K3C'EDKOT7_#Z_\`!0Y)O8QKSQ%>6.I:
MK$\2R6L4@CC=90LD;&`.`%VG(R#R3QGH0#5"/Q5?03W<L[O-%#YC+$-BYVO<
M<$[?2-1^&?7.Y'?>&;NY6Z=M,%S<,\,<DICWS@'8=IZL#@#Z8J6:?PS$JF>7
M2$6=0REVC`D5MV",]0<O]<M[UTJ5.*Y72=[+IVW'=&9)XONXA/$^E0BZ@1Y9
M$-YA/+6-'.&V<M^\`QC'!YKJ()/.MXY<8WH&QGID5DZQX8T_6T19@T0#%F\I
M4^?*A>=RGG``####L16RB+&BHHPJC`'H*Y*TJ$H1]FK/KO\`YB5SSOQ)_P`E
M.C_[`P_]'&I:B\2?\E.C_P"P,/\`T<:EJL7_`,N_\*"/4P9=<NT\5Q:6++9:
MM!+)Y\IP9&4(?EYX7YL$GO\`2JWA7Q%>:W-,EU'"H$,<R[(GCQN+#:-Q/F`8
M_P!8ORG/%2:U;RWNMV_]G;6O;:!Q(9?]4L;X^5@.=S;<#!X&2<\`N\,Z78V\
M7VJW>Y>58Q:^7<E2ULJ'_5<`=">IR3P<D8KE6VO];_\``_K>WMI_7]?UY=#6
M9KVI7&E:1-=6MFUU,JDJF<*N`3N8]E&/K6G4-W;)>6<]K(6"31M&Q7J`1@XJ
M97MH"M?4Y*^\8W%B;9YA:PQFSAN6616W7!<X98N>"HY/WNHZ=:[,'(S61+X>
M@FCMH6N[S[-#$D36_F#RYE7IN&.O'5<9Z'(XK7JG;H2K]0KD+WQ1?Z7?7EM<
MK9SO%;&<);J_[@EPJ*[$_-NSG@+C!X/6NOKG;+P?:V<5]"VH7UQ#?%GG2;RL
MLQ_BW*@;([<X'I26X^A=T34;B]^VV]WY37-E/Y,CPH51_E5@0"21PV,9/2M6
MJ6FZ;'IL4JK++/)-(9)9IL;Y&P!D[0!T`'`'2KM-B1A^)M4O='T]KZ"6SC@A
M4L_GJS-(W&V-`",%NF<G''!J./7KR3Q/:::VGM!;RV[R&24_,S*$.%`/0;\$
MGJ?I4^L>'8M9OK*[>_N[>2S):)8?+*[C_$5=&!(['M5Q],BDU.TU!Y)6GMHG
MB7D88-MR2,=?E'3%)>8V7:QM3BEU"_\`L($;P16YF>&0D+,Y.$5B,_)\K9&#
MGCZ'9K'UFRN')N;5IOGA:"=8"!(4/1D)XW*<X!ZY/?%)[#6YEVVKW]U;:G:^
M;I)6P=4FNS"XMU7:2Z[-WS%>`?F`Y[8Q4G@^\EFME!39:SPK<6Z<XC&YE(4'
MD(<*R@DXWD=`*RSH>CGP['I']JZR;6.176W%HGF9!SM91#ELGD[@<XYKI-$L
M[N/S+N^DE:5T6.-9MF](UR1NV`+N))S@8P`.<9-:$FQ6!K6KWVEZC9A3:-!<
MSQP1V^UFFE+'YF!R`H4<]#D#J*WZQ)O#:2^(AK8U&]CN`@C$:B)D"#DJ-R$C
M/<@@^]);H?02QU/43XAFTV_6U`\DSQF)77:-V`-S?ZSC!)`&W(!ZBMRLNTT*
M&UU`7KW-U<RHC1P_:'#>2K$%@#C)R0/O$GCBM2CH@ZE:_:Z6S<V;6ZS#&'N,
M[%'<D#DX&>,C/J.M<E<>-KB/PO\`;H(8;B\:201E598GC1]IFP3D*>,#)Y(Y
M[UTNN:/%KNE2Z=/<7$$,N-[6[`,0#G'((P>_%4;KP?I>H:4+'4$%VRIY<=S+
M!")8U[!2J``#V%"!G0^`CGQ5XI/J+3_T6U=?JNKVNCPPRW/F'SIT@C2-=S%F
M8`<>@SDGL!7'?#^*.#Q-XGBB14C1;-551@*!&V`!74:WX:T_7WMWO&NTDMSF
M-[:[DA/WE8@A6`8$J.H/MBNS&_QE_AA_Z1$F&Q)IFN1:G?ZA9"VG@GL75)!(
MT;`[AD$%&;&1SAL-@@D#(KC]8_Y+EH'_`%X-_P"@SUV.G:+'I]Y<71N[JZEF
M54!N&5C&@)(0$`$C+'EB3SUKCM8_Y+EH'_7@W_H,]:Y;\53_``2_(4_U/1**
M**\XL*\[^#7_`"*%W_U_O_Z+CKT2O._@U_R*%W_U_O\`^BXZ]'#_`.Y5O6'_
M`+<0_B1Z)65K.DRZGY+07*02QATS)#YBE77:PQD<^AS^!K5HKAA.4)<T=RSC
M[WPE<R#S9[V6^C@@>*&U12C$-'MP"9-@(/(.`?4FIM+\*7%E)I]R;X1W$:AK
MQD5]]PY)9MQ#A2N6/5"1V(KJJ*Z'CJ[CR7T]$1R1"BBBN0L\B\&_\BI9?\#_
M`/0VHU5_[5-SIZW!@LH4/VZY4@$<9\L$\9QRV>@P._$7A9)I/!5NEO,L,S)*
M(Y63>$;>V#C(SCTS20:'K$&G?8/M^CR6S`ATDTN1A)N.6+9GY))).>I-=>8?
M[W5_Q2_-BALCGXKN^;1I)+'[8=)N[R"WM3<7#^8T1X=]YRR*QP!Z#D`<5K^$
MKXV]JEA*)%MO-D@MFDD+[&0D-%O(&X#!*DC)'!Y7F6W\-7MK;S6]L?#D,,XQ
M+''HC*L@_P!H";!_&GS:%J\VF_V?]NT>.V``1(M+D3RR#E2N)_E((!!'0BN7
M09TE%16J31VL27,RS3J@$DJIL#MW.W)QGTS4M(`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@#3^&7_`"3S2_\`MK_Z->NMKDOAE_R3S2_^
MVO\`Z->NMKKS#_>ZO^*7YLF'PH*\[^#7_(H7?_7^_P#Z+CKT2O._@U_R*%W_
M`-?[_P#HN.ML/_N5;UA_[<)_$CT2J6JV!U/3WMA+Y3[DD1RNX!E8,,CN,@9&
M1Q5VBN",G&2DMT6<G-X1O9XTBDUD>5Y_VB2-+=E4OYIDR`).G.,-NZ`\&JUM
MX.GDMYY1*UC<O<NT#/EI+>'D*B-'(N.I.,L.<$&NUHKJ6/KI63_!$N*>HB`J
MBJ6+$#!8]32T45QE'G7B3_DIT?\`V!A_Z.-5M2OFM(XXH$$MY.VR"/L3W8^B
M@<D_AU(JSXD_Y*='_P!@8?\`HXUCOI6LKJUS?6^IV(\T!$6>P=S$@_A!$RCK
MR>.3]!CKQ?\`R[_PHF/4Q8H6L_%,=KIMY>7-TC_:-5EDF(A12GW2OW=S'!'&
M0!UP`*K:#/>:?>?:)HY)+F:W%W=>5>O=)-$S8W#C"LO95R"N0"3BMG_A&[[[
M?]OW>'?MF[=]H_L1O,SZ[O.SFI[71]7L3(;.ZT*W,K;Y/)TATWMZG$_)KD13
M_K^OZ_`W8I8YX4FB=7CD4,CJ<A@>A%/K*T73;W34N$NKR">.23S(XX+<Q+%G
M[P`+MP3SUXR?PU:`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`'^!/^1K\5?\`;I_Z`U=[7!>!/^1K\5?]NG_H#5WM=>-_BK_##_TB),=@
MKSO6/^2Y:!_UX-_Z#/7HE>=ZQ_R7+0/^O!O_`$&>MLM^*I_@G^0I]#T2BBBO
M.+"O._@U_P`BA=_]?[_^BXZ]$KQ_X9Z7KM[X<N)-+\1_V;`+ME:'[$DVYMB?
M-N8YZ$#'M793J2C@ZJ46[N.JMIOO=IZ^5_,UI485)>]44;=^;7_P&+_&Q[!1
M7)?\(_XO_P"AX_\`*3%_C1_PC_B__H>/_*3%_C7G>TE_*_P_S.GZI1_Y_P`/
MNG_\@=;17)?\(_XO_P"AX_\`*3%_C1_PC_B__H>/_*3%_C1[27\K_#_,/JE'
M_G_#[I__`"!UM%<E_P`(_P"+_P#H>/\`RDQ?XT?\(_XO_P"AX_\`*3%_C1[2
M7\K_``_S#ZI1_P"?\/NG_P#(''^#?^14LO\`@?\`Z&U;M<9X:L-7G\/VLEKK
M?V:$[]L7V5'V_.<\GD\\_C6M_9>O?]#)_P"2,?\`C75CJLWBJC<&O>?;OZDQ
MPE'E7[^'W3_^0-VBL+^R]>_Z&3_R1C_QH_LO7O\`H9/_`"1C_P`:Y?:2_E?X
M?YE?5*/_`#_A]T__`)`W:*PO[+U[_H9/_)&/_&C^R]>_Z&3_`,D8_P#&CVDO
MY7^'^8?5*/\`S_A]T_\`Y`W:*PO[+U[_`*&3_P`D8_\`&C^R]>_Z&3_R1C_Q
MH]I+^5_A_F'U2C_S_A]T_P#Y`W:*PO[+U[_H9/\`R1C_`,:/[+U[_H9/_)&/
M_&CVDOY7^'^8?5*/_/\`A]T__D#=HK"_LO7O^AD_\D8_\:/[+U[_`*&3_P`D
M8_\`&CVDOY7^'^8?5*/_`#_A]T__`)`W:*PO[+U[_H9/_)&/_&C^R]>_Z&3_
M`,D8_P#&CVDOY7^'^8?5*/\`S_A]T_\`Y`W:*PO[+U[_`*&3_P`D8_\`&C^R
M]>_Z&3_R1C_QH]I+^5_A_F'U2C_S_A]T_P#Y`W:*PO[+U[_H9/\`R1C_`,:/
M[+U[_H9/_)&/_&CVDOY7^'^8?5*/_/\`A]T__D#=HK"_LO7O^AD_\D8_\:/[
M+U[_`*&3_P`D8_\`&CVDOY7^'^8?5*/_`#_A]T__`)`W:*PO[+U[_H9/_)&/
M_&C^R]>_Z&3_`,D8_P#&CVDOY7^'^8?5*/\`S_A]T_\`Y`W:*PO[+U[_`*&3
M_P`D8_\`&C^R]>_Z&3_R1C_QH]I+^5_A_F'U2C_S_A]T_P#Y`[#X9?\`)/-+
M_P"VO_HUZZVO,/`NC^([KP;836'BK[#:MYFRW_L^.79^\8'YB<G)R?QKHO\`
MA'_%_P#T/'_E)B_QKJQU6;Q51N#7O/MW]28X2CRK]_#[I_\`R!UM>=_!K_D4
M+O\`Z_W_`/1<=:__``C_`(O_`.AX_P#*3%_C7&?#/2]=O?#EQ)I?B/\`LV`7
M;*T/V))MS;$^;<QST(&/:M:%6:P=5>S>\=?=TW\[@\)1YE_M$/NG_P#('L%%
M<E_PC_B__H>/_*3%_C1_PC_B_P#Z'C_RDQ?XUP>TE_*_P_S*^J4?^?\`#[I_
M_('6T5R7_"/^+_\`H>/_`"DQ?XT?\(_XO_Z'C_RDQ?XT>TE_*_P_S#ZI1_Y_
MP^Z?_P`@=;17)?\`"/\`B_\`Z'C_`,I,7^-'_"/^+_\`H>/_`"DQ?XT>TE_*
M_P`/\P^J4?\`G_#[I_\`R!C^)/\`DIT?_8&'_HXU+7/:WIFNQ>.D@G\1>==_
MV8'%U]B1<)YI&S8#CKSGKVJ3^R]>_P"AD_\`)&/_`!KJQ56;Y+P:]U=O\R8X
M2CK^_A]T_P#Y`W:*PO[+U[_H9/\`R1C_`,:/[+U[_H9/_)&/_&N7VDOY7^'^
M97U2C_S_`(?=/_Y`W:*PO[+U[_H9/_)&/_&C^R]>_P"AD_\`)&/_`!H]I+^5
M_A_F'U2C_P`_X?=/_P"0-VBL+^R]>_Z&3_R1C_QH_LO7O^AD_P#)&/\`QH]I
M+^5_A_F'U2C_`,_X?=/_`.0-VBL+^R]>_P"AD_\`)&/_`!H_LO7O^AD_\D8_
M\:/:2_E?X?YA]4H_\_X?=/\`^0-VBL+^R]>_Z&3_`,D8_P#&C^R]>_Z&3_R1
MC_QH]I+^5_A_F'U2C_S_`(?=/_Y`W:*PO[+U[_H9/_)&/_&C^R]>_P"AD_\`
M)&/_`!H]I+^5_A_F'U2C_P`_X?=/_P"0-VBL+^R]>_Z&3_R1C_QH_LO7O^AD
M_P#)&/\`QH]I+^5_A_F'U2C_`,_X?=/_`.0-VBL+^R]>_P"AD_\`)&/_`!H_
MLO7O^AD_\D8_\:/:2_E?X?YA]4H_\_X?=/\`^0-VBL+^R]>_Z&3_`,D8_P#&
MC^R]>_Z&3_R1C_QH]I+^5_A_F'U2C_S_`(?=/_Y`W:*PO[+U[_H9/_)&/_&C
M^R]>_P"AD_\`)&/_`!H]I+^5_A_F'U2C_P`_X?=/_P"0-VBL+^R]>_Z&3_R1
MC_QH_LO7O^AD_P#)&/\`QH]I+^5_A_F'U2C_`,_X?=/_`.0.@\"?\C7XJ_[=
M/_0&KO:\D\)Z5K]QX@\01V?B7[)-%]G\^7[#')YV4;;P3A<#(XZYKKO^$?\`
M%_\`T/'_`)28O\:ZL95FZBO!KW8]OY5YDQPE&W\>'W3_`/D#K:\[UC_DN6@?
M]>#?^@SUK_\`"/\`B_\`Z'C_`,I,7^-<N+/4K+XS:%%JFJ_VE.;1V6;[.L.U
M=LWR[5XZ@G/O6V7U9J<[0;]R7;33??I]_9$U<+24;JO%^5IZ^7P6^\]5HHHK
MD.4*\[^#7_(H7?\`U_O_`.BXZ]$KSOX-?\BA=_\`7^__`*+CKT</_N5;UA_[
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M;5NUA>#?^14LO^!_^AM6[6F8?[W5_P`4OS80^%!1117(4%%%9\^MZ?;7ZV4T
MY6=BH_U;%5+?=#,!M4GL"1GM0!H45F0:]83ZF-.4W2W1#,$ELYHP0O!(9E`(
MZ<Y[BM.@`HJO>WUOI]JUS=2;(U(&0I8DDX```)))X``S5&3Q+I,5K%<-<OLE
M+!56"0N-OWMR!=R[>^0,=Z`-:BFQR)-$DD;!T<!E93D$'H:=0`45E_\`"1:4
M+F:!KL(T(?>[HRI\OW@'(VDCN`3CO5FPU*UU.)I+5W8(<,KQM&R\9&58`\CD
M<<T`6Z**I:CJMEI4:/>2LGF$A%2-I&;`R<*H)P!R3CB@"[16<==TT75O;_:@
MSW"JT95&9"&^[E@-HSCC)&>U:-`7"BBF2RQP1/+*ZI&@+,S'``]30`^BH+*\
MM]0LH;RUD\RWF4/&X!&X'OS4]`!116?#K>GW&H-8Q3DSJ67F-@K%?O!7(VL1
MW`)(H`Z/X9?\D\TO_MK_`.C7KK:Y+X9?\D\TO_MK_P"C7KK:Z\P_WNK_`(I?
MFR8?"@KSOX-?\BA=_P#7^_\`Z+CKT2O._@U_R*%W_P!?[_\`HN.ML/\`[E6]
M8?\`MPG\2/1**JZG-);Z3>3Q-MDC@=T.,X(4D5YQ9^.M5G^'NI33S>3KEG''
M*LIC7]Y&[+M<+C'0D=/2L</@JN(CS0MNE]_7T*;LTNYZC17'W^K:SJ6L6NA:
M/=16<WV-;JZO9(A(4!X`53P23ZU"NH>([2\OO#MU>Q7%^]BUS87\<*H6(XVN
MG*YS^E4L#-KXE?>VM[=]K>>][=!*29VU%<)<^++RY\!Z5=6$P75M1ECM4;8#
MMESASM(QV/;O7<H&6-59B[``%B.2?7BLJV&G15Y]VON!23///$G_`"4Z/_L#
M#_T<:EJ+Q)_R4Z/_`+`P_P#1QJ6KQ?\`R[_PH(]0HHHKD*"BBJM_J-MIL*RW
M3LJLP1%2-I&=CV55!)/!Z#M0!:HK*E\1Z3##!,]V/+G&Y&6-F`7.,M@?(`>"
M6P`>*U:`"BBLJ/Q'IDK3)%+-(T2EBJ6TC%P#@E,+^\`/!VYQ0!JT51TW5K/5
MXY7LVE(AD,<@E@>(JPZC#@'O5Z@`HJAJ.LV&E-&MY,R,X+`+$SD*.K':#M49
M&6.`/6F#7M,;418+<YN"0HPC;-Q7<%WXV[MO.W.<<XH`TJ**9--';P233.J1
M1J6=F.`H'4T`/HK('B;26MS,+B3APGEFWD$K$C(Q'MWG(!(P.@)K2M[B*ZMX
MYX'$D4B[E8="*`):**SY];TZWU%+"6XVW#%1C8Q4%ON@L!M4G'`)!/:@#0HJ
MC::O8WUW-:V\Y>6+.X%&4'!P2I(PP!X)&<'BKU`!15>]OK;3K5KFZD\N)2!D
M*6)).``!DDD\`#DU5.OZ6NGQ7S7BK;RR")"RD$N6V[=I&0V>"",CO0!J^!/^
M1K\5?]NG_H#5WM<%X$_Y&OQ5_P!NG_H#5WM=>-_BK_##_P!(B3'8*\[UC_DN
M6@?]>#?^@SUZ)7G>L?\`)<M`_P"O!O\`T&>MLM^*I_@G^0I]#T2BBBO.+"O.
M_@U_R*%W_P!?[_\`HN.O1*\[^#7_`"*%W_U_O_Z+CKT</_N5;UA_[<0_B1T?
MC73+S5O#K6MC#YLYGB?;N"\*X)Y)`Z"N5O?!>JM?^*)(H/,@G@<:>GF(`6E(
M:3'/'(QSBO0Y+ZUBOH;)YE%S.K-''W8+U/TYJ!M:T])XH6N,22SM;HI1N9%&
M2.G'UZ=/6EAL7B*,%"G'3?9^7_R-O2X2BF[OR_"[.1/A'4-9\0+<W]Q?Z;;V
M5E%;VLEE<JCNV/G.1D@9X[9XK0\(:#?^&]3U:Q;SIM+ED6>VN9I59V8CYPV.
M<YQSCM6NGB33)9(TA:ZF,B*X,-G-(H5L[22JD#.#UH7Q'IKB5@UT(XMV^5K.
M81_*<'#E=IY]#5U,1BYP=.4/=:2M9Z6Z^O\`FQ<L5U,_PAI%WI4VNM=6XA%U
MJ4D\.&4[HSC!X/'?@UTU9UQKFGVQ=7ED9DD\HK%`\A+XSM`4$D@<G&<=\5<M
M[B*[MX[B!P\4@W*P[BN3$2J5)>UFK7_R+5CR?P;_`,BI9?\``_\`T-JW:PO!
MO_(J67_`_P#T-JW:O,/][J_XI?FQ0^%!15:^NS96WFBVN+EBP58K=-S,3]2`
M![D@#UI--U"'5+"*\@#B.3.`XP002"#^(/3BN0HM5RNLPZKJ/B2TMY=-N6T6
MW=)M\$D7[Z4'(WAG#!%ZX`))%=510M[ATL9&G6ER-;U6^NX]N]TBMCN!_=*H
M/8\98M[UKUFIKEG+X@DT6,NUU%#YTA`^51D#!/KR#CTK2HZ(.IFZ]/J=OH\S
MZ/9BZOR`L2%E4#/\1W$#CKC/-<E-X<OFTBRB6QOY"HN#<*]Q''.\T@_UA9)-
MNS.<KNZ8X.*[^L_4]4&FFV1;.YNYKF0I'%;[-W"EB2790!@>M(=R?3XIH--M
M8;ED:=(E60QKA2P`S@=A5FFHQ>-69&0D`E6QE?8XR/RIU4W=DI65CBKG3M3U
MO7+UM6TBX-G'%+!8QB>)8B&7!=R'+AFZ#Y?E!K3\,:9>6DUY>7ANE:X$2+'=
M/&T@"`C),?R]^,=ASS6]//';6\D\SA(HU+NQZ``9)JKINIC4E=OL=W;;<%?M
M$8&]3R&4@D?AG([@4EM8;+U9>NBXEL'MHK"6\BG5HY1#<"*101P1DKD>OS#\
M>E:E9+FYU2^FACGDMK*W;8[1\/,^`2`?X5&1R.2<\C'*:N"=CG4\.ZNIAMYT
M60S&RDFN(F54B,!!8;>#S@8P,<G.*[BN2OP=&O(8+*+7!)<2+%%<-=BYB9CS
M@I+*6P!G)`!P.M=%IMXU[9B22+RIE9HY8\Y"NIP<'N.,@^A%5>Z%:VA;JM?V
M4&H6CV]S"DT9(;8XR"0<C]0*LU3U/48M*LFNIDD<;E14C`+,S,%4#)`Y)'4@
M5+5]"D5?#%G<:?X9TZSNH_+GA@5)$R#@CW'%:U4],U*+5;/[3$DD>':-TD`#
M(RDJP."0<$'D$BKE4W=W$%<K:0ZM>^,6O=3TZYBM;;?'8[9(C$`1@R/A]Q9N
M@&W@&NJK)L_$-I>WYM8XYE4O)'%,P`25D.'"\YR#Z@9QQFDMP>QU/PR_Y)YI
M?_;7_P!&O4?B'P_>7MUK3PV\DT-Y9VT97S%8N5E<NJ+(=@.TC`8;"3SD9J3X
M9?\`)/-+_P"VO_HUZZ2XU"RLUF:YO+>!8(_-E,LH41IS\S9/`X/)]#77F'^]
MU?\`%+\V*FVHKY%+PS93:=X<L[2>(Q/$I`C8KN5=QV@[/E!QC(7Y0>%XQ7(_
M!K_D4+O_`*_W_P#1<=>@03PW,$<]O*DL,BADDC8,K`]"".HKS_X-?\BA=_\`
M7^__`*+CK>BV\'7;[P_]N(ZJQW6IPR7&DWD$2[I)('1!G&25(%><Z[X&U2\\
M%:2MG!LUBVMEMKB$2*/,CR"5+9P<$`]?6O1[N_M;`0_:IEC\Z588P>K.QP`*
MAOM:T_35N&N[CRA;QK+*2C':K$JIX'/((XK/"8FO0:=)7UOL]>EOQ+:3W_K^
MK'.W^DZUINLVNO:/;17DOV-;6ZLI)1&7`.058\`CWJ?1M,U>]\2-XAUJWBLG
M2W^S6UG'+YA12<EF8<$_2M:?Q!IUO*8FDGDD#F,I!;2RG<%5CPBGLR\].:(O
M$-A-<_9XQ>M("JM_H,^$+`,`QV84X(/)&,\U3JXAT[>SZ6O9WM^7SM?S)Y5W
M.1T;PCJ=IXYDEN(Q_8EK/-=6;;U.9)`H(QG/'/4=O>O0JS#X@TP0+/\`:28V
MA6<%8V)V,<+P!G+$X`ZGL.*M65];ZA"9;9F*JQ5@\;(RL.Q5@"#]16>*JUZS
M4ZL;65MOZU>[&DDWYG!^)/\`DIT?_8&'_HXU+47B3_DIT?\`V!A_Z.-2TL7_
M`,N_\*"/4***S-,UVQUBZO(+*0R_9&57D`^1B0?NGOC'6N0HTZQO$LVL1Z24
MT2U:>[E8(6#(#$IZN`[*"1V&>M;-%`(X%O#>HVD<$NE0W\4IM%@027**T,JN
MS>9+M?#J=Q)`W?3T[U<[1N()QR169JFMQ:4_[ZTNWA50TMQ&@\N($XR22,_1
M<GVK4IWNA=0KD--BUJ?6K_5=2TNYBNEADBL4\V$Q(F00.')+L0"20`,8KKZA
MNK@6MK).8Y90BYV0H7=O8`=34E%30;*33]#M+><?Z0(PTYSG,C<N<^[$UHU2
MTS4X]4@DD2&:%XI3%+%,!N1AU&5)!ZCH35VJ>KN2MCF?%T>KWL<&G6-E<2V-
MQD7LUO)$)`G]Q0[K][N>PJA%H.H)XHCNDM&CB6Z2993*IB6$0[-ACW?ZW/&[
M!X_BQQ7:UFW.N6=KK=GI#EVN[I69%49"@`G+>F<''TI+0;V-*H;N2:&SFDMX
M#/,J$QQ!@N]L<#)X&?>IJJ:C>&QLVF6,RR%ECBCY^9V(51G!P,D9/89-`'&V
MNCZK-:-J%_INH_VTUTD[R13VZF/"LH$(+,I502,/C.XGK74^'M.ETK0[:SG?
M=*FYF^;."S%L9[XSBL_5+1+6R2ZU.XU2\N&D6-8K&Z>W!9R`%55=!C/]XD]>
M:M6LMW8R6QG^T?9+EO+\NZ96EMW_`(064D,IQCJ2"1R0>'?0#:KGM<MM1O[Z
MTA@LB%@N(YH[OS@8P`?G#QY!SC('#<G.5KH:*76X'*:#HM]9ZI;&XB9(K&">
M%9"ZD3^9(&!`!R,`<Y`Y/?K75UF6.M1:A=-%#:W8B&[R[EHQY4FT[6P021S_
M`'@,]LBM.GT0=2M?RW$-HSVMJ;J0$9B$HC8CO@GC..F2/J*Y&3PQ<R>'(D-D
MIO(KT26Z.RF2&$SJY#-D@M@<G))]3W[>LO6=9.BV_P!H;3KRZA`R[VYB^7G`
M&&=22<\``TD[.XS7\"?\C7XJ_P"W3_T!JUO&%AKFH1V4>E06TT$<\<TZ27;0
M,2LB,N,(P91AB02.W7H<;X?N9/$WB=RC(66S)1L97]VW!QWKO99HH$WS2I&F
M0NYV`&2<`<]R2!79C?XL?\,/_2(D0V^\YSPQ8ZY:ZGJ]QK,%LANGC=)(+MI@
MQ`(P`R+L`&T8_F<DX.L?\ERT#_KP;_T&>NXL]5T[4)[B"RU"UN9K5MD\<,RN
MT3<\,`<J>#P?2N'UC_DN6@?]>#?^@SUKEOQ5/\$OR%/]3T2BBBO.+"O._@U_
MR*%W_P!?[_\`HN.O1*\[^#7_`"*%W_U_O_Z+CKT</_N5;UA_[<0_B1TTGAZ3
M_A*(=8COYR,GS8GV$`;=H5?DW8ZG&[N3WJEJOAB]N[O4[FUN($>4))9[\_NY
M04W%N.A\M.F>]:>OR74=O']COVMYSN$4,<:,\\F/E7Y@<+U)P,XYR,50TK4-
M0EUB,7-V72=[I&MMBA8O*<*"I`W<]\D_>'2BE.MRJJI+16^2U[>7Z#:0S_A'
M;RUU..6UA26W2""%?^)G/;%?+SU5%*OU'6JZ^&=3^Q7UF4B47`F"S#5)V`WL
M6'[DIL4\]NE)%XGO_P"SPL\:K,X=H9XI58L%D*'>NS"]N.<\\@YI;/Q+J`6-
M3&+NXED$:*\BQ)R5&20A/&3_`(5ORXI=M/-]/G;^M3-\J+TFAWMO:+:6R6MS
M;Q2EX?/GDBE4,#G]Z@)#`D_-R2#@X(R=K3H;BWT^&*ZF\Z=5^9\D_AD\G'3)
MZXS6%!XLFGDM\:?&L;RQ03$W/S([DCY1M^91CKD?3KCIZXL1[9)1JK^OZ^\T
M5KZ'D7@W_D5++_@?_H;5NUA>#?\`D5++_@?_`*&U;,\AA@DE$;R%%+;$&6;'
M8>]&8?[W5_Q2_-A#X40:BMX]H5LDM9)"?FCN<A'7NN1G&?7!^E5]!TZ72M(C
MM)I%9E9V"I]V,%B0B]/E4'`X'3H.E8\'B;4)]+DDDMH+:\?4OL,2/EUCY'+X
M(W$#.<$?7O6SH6I/JFF"XD55E622&38"%+(Y4D9['&?QKE6UQW_K^OF:5%%8
M5_K=W;>)=-TV.RQ:W+LLES(>"0C,%09_V>2>.WT0RKIWA6?3?$XU&/4KB:W,
M,BNDWE[F=W#=D&1^.>`.E=/6%IVMW=[XEOM.ELOL\$$*R1%_OR9=EW<'`!V\
M#KW[XK=HZ(&M6%87B+16U;[.RV.GW9B#J%O"PV;@!N4@,,C'=?H16EJ-U+96
M,D\%K)=2C`6)"!DDXY)Z`=2?2L!O$.H'P=9ZZ9-/M5:W\^X,R.PSCA$4$'D\
M9)_`TGL-7Z'0Z=;266FVMK+.UQ)#$J-,W5R!C)^M6:@LIWN;&WN)(C"\L:NT
M;=4)&<?A4]5*]]28VMH5=2LDU+2[JQD8JEQ$T18=1N&,UE>'-$N=)FNI)A;Q
M)*L:K!;$E"5!S(<J/F;(SUZ=31%K>H3^)+O3$L4BCBM3+"T[8,K!MN>,X3\,
M]ZFT+4KV\EO[:_$'G6DH3=%&T8;*@YVL2<9R`V<-C(I+N-]NQLUD6URFFZE/
M8W)\M;B4S6TC<+)NY9,_W@<G'<$8Z'&O6!XOU.;2]`GFATY;T[2664`Q(`,D
MOZCV'4^G6@"3446VURWU:\N(DL[:W>.-"27:5V'1<<G`P,<\XQ5S2(I5M9)Y
MXS%+<RM,T9ZH#PH/N%"Y]\US]S=6.CZ]I=II>DV2232)#<SK"!Y*,K%4!'<X
M)QT`[<BNOHZ!U"LOQ#ILVK:0]I"T>XR(Y27.R4*P)1L`_*P&#P>O0UIDX4G!
M.!T%<B?%E_\`V9K5S)9+;36D\<-O"Z-(WSA,;U0Y)RW1?I0-&UX>TR72=+^S
M2F,$RO(L4)S'"K-D(G`^4?0?05JU0T>\:^T]9GN8KA]Q5FCMW@P0>A1R64CN
M":OTV(*YJT\-R1^)/[1DCMXHH99)8O)ED.\N,<QM\J'DY*_>/)Q5G6M:N].U
M+3;6"RWQ7-PD<MPY^50Q/"\Y+<?056T[Q'+J&NO;J]NEL)I8%C>*19"8\@D2
M?<8Y!^3@@<Y[4EW0/:S.X^&7_)/-+_[:_P#HUZGU7PW-<W^J7EHD"R7-M;K$
M1)Y3>=%(SAV;RW'&4P2K=,$8J#X9?\D\TO\`[:_^C7J[?>+(;"\FMI=,U$NH
M_<$(@%R=Z)A,N,?-(HRVT'.02`:Z\?\`[Y5M_-+\V*%^5?(N^']/N-+T6&UN
MIO.N`SO(X.<L[ECS@9^]C.!GT'2N.^#7_(H7?_7^_P#Z+CKN=,OTU/3X[M(I
M8=Y8-%+C>C*2K*<$C(((X)%<-\&O^10N_P#K_?\`]%QUO1_W*OZP_P#;B/M(
MZ77?#LFK7EK>0W\\,L#QX3Y"@42!F(RA(;CUQP,\5)J^AOJ>JV<V^,6JHZ74
M;#F0=4Q]&R:OZFQ33Y&%\+(#&Z?:&*C/.`W&3T&0>3T-<PNI:S%-&;B]D4P/
M;*8&BC!F269DR_RY#;,<+@`@U%!UIQ3C)+ENE\_E_P`,QRLG?^M`C\+ZI#I^
MG*[PW-U"TK3LM]-:[RV`I#QJ6X"C(J>ST+4[?59+EK>,I+)&_&LW/R`1HARF
MS$A^4G+<GO2WGB*\L=2U6)XEDM8I!'&ZRA9(V,`<`+M.1D'DGC/0@&J$?BJ^
M@GNY9W>:*'S&6(;%SM>XX)V^D:C\,^N>I+%3BWIJN[ZZ]'9?UT'RI(OZ?X:O
M=+T=;*$VER'BC:9+EG(\Y-H^5@,A2`,?W=H(!Z5M:-:WEI:R)>2`LTA9(Q.\
MWE+@?+YC@,W()R1WQVK$D\7W<0GB?2H1=0(\LB&\PGEK&CG#;.6_>`8QC@\U
MU$$GG6\<N,;T#8STR*Y,2Z_+>JE[W]=&"MT//O$G_)3H_P#L##_T<:EJ+Q)_
MR4Z/_L##_P!'&I:C%_\`+O\`PH(]0K*T[2WL=8U.Z_=+!<^4(D3JH1<'(Q@?
MA6J>!7,>&O$5YK%_-!<I"JB+S5V1.FWYRNT%B1*./OK@5R+<I[7.GHHHH`YG
MQ#I.KZMJMF$CLYM(@(DDMI;EXC+*#P6Q&V5'7'<]:Z:N6\0>*9=&U0PM]GB@
MBA2;$RDO<Y8AEC((P5`R>&Z]NM=2#D9HZ`]PJ&[%R;63[&T(N,?(9@2F??!S
M4U<F_BR\BEUOSM/$$=E%$UNDA^=R[,H+8/`)`XZX_(`&KH&F3Z;%=F?R8_M$
MYF6V@8M'!D`$*2%SD@L>!R3]3KUE:)J-Q>_;;>[\IKFRG\F1X4*H_P`JL"`2
M2.&QC)Z5JTV`5S$_A6<^*+75X-3N-JSM-/')Y9ZIM"K\F<=L$\#..:M>)=;N
M]&AMVM;+SO-FC225_N1JSJO/.2QW<#V)[4-K=W_PET&D_8O+M7AD?SY.LC+L
M^Z`?NC=U/4_2DM[H&M#=JAK$<[6/FVT9EF@D698QC,FTY*C/&2,@9[D5?J.>
M0PP22B-Y"BEMB#+-CL/>@#&U*.W\2:7$;6"QOUCF#M;WA95R,@JV`2K#/1E/
M3IW%/3H&6WLM%CG2Z:UN/.NGC;*6X#%TC!QUSM`''RC/'`JJCMKVF7E]>Z9I
M%O<6]S)!))>Q>:(H5`)W8(W'U&0/RYWO#5TM]X=L[E+6.V21,K'&FQ<9."!V
M!'('O0M@W-6BBL*_UN[MO$NFZ;'9?Z+<NRR7,AX)",P5`#_L\D\=OH;Z`4]#
M\+SZ1JZS*T"6T22INC)\RY#MN7S!M&-G(')Z]NE=36'8ZGJ)\0S:;?K:@>29
MXS$KKM&[`&YO]9Q@D@#;D`]16Y3Z(.H5F:MI\^H7&FA&C%O!<B>=7ZN%4[0!
MC^]M/X58U&ZELK&2>"UDNI1@+$A`R2<<D]`.I/I7,7?C&ZM_!UEJ4=O#)J-S
M`)C$,[$7C<QYS@9`Z\DBD@Z':^!/^1K\5?\`;I_Z`U;7BO0=2US[$+*^LX8[
M>99FBNK9I`[*ZL&!5UP0`<9!Z]N",3P$<^*O%)]1:?\`HMJZ_5=7M='@AEN?
M,/G3)!&L:[F+,P`X]!G)/8"NO&_Q8_X8?^DQ)AM]YG>'-'OM*GO?M!C2WD?,
M<4=W-.I)9B7`D_U><CY%)`QUYKF]8_Y+EH'_`%X-_P"@SUUF@^);'Q$;PV!W
M):R^4S^=$^X_1'9EZ='"GVKD]8_Y+EH'_7@W_H,];9;\53_!+_TD4_U/1***
M*\XL*\[^#7_(H7?_`%_O_P"BXZ]$KSOX-?\`(H7?_7^__HN.O1P_^Y5O6'_M
MQ#^)'<WNE:=J>S[?86MWY>=GGPK)MSUQD<=*KSIHNBO)J,L5C9RR#8TY5(VD
M]%W<9/'`SVK3K*UG29=3\EH+E()8PZ9DA\Q2KKM88R.?0Y_`UR4IW:C.342[
M(KVT_AC<ZQ_V5#-*J2RPGREDYQM+CKGYAU]:LI+H*WR6B2::+P,=D*F/S`PZ
MX7KD8_2L.]\)7,@\V>]EOHX('BAM44HQ#1[<`F38"#R#@'U)J;2_"EQ92:?<
MF^$=Q&H:\9%??<.26;<0X4KECU0D=B*ZY1H<O-[1W_7^O(S]ZVJ-"7POI\NL
MP:D0RO!C9$JH$!!)!'R[AR<X!`)`)!K:HHKAG4G.W,[V+LMSR+P;_P`BI9?\
M#_\`0VK=K"\&_P#(J67_``/_`-#:MF?S?(D\@H)MIV%\[=W;..U=&8?[W5_Q
M2_-BA\*,P^'K4VMQ"LLZF:Z-V)`R[HY,@Y7C'&.A!]\U=T^PATVR2UA+%5)8
MLYRS,22S'W))-<I:W$D?A?6YM7O+JZ>SO)COAG>!F*@852C`A<G&,XKI-#L9
M=/T:VMY[B:XG"[I))96D)8\GEB3@=![5R+;[OR'U^\T:IW>FPWE[8W4C2![.
M1I(PI&"2I4YX]":N5S6KR:E%XNT3%YLL)9G3[/&""Y$3DESWY`P/Q],"W'T-
ME--A36)M3#2>=+`D#*2-NU22,<9S\Q[U<KAO#]]>2>*`TMU.]O=/=JFZ9GW^
M7(`,QGY8MHR!M^]WP:[FCH@>[$90RE3T(Q7.W'@VUGLM*M5O[Z&/3.8-IB;<
MP&`S!D()';CBMC4UO'T^5;&:."<CB1TW;1W('KC./>N'-WJ4OA?0[DW=Q*#8
M222".[$4K2``K(26!95YR.>HX-%^O]=1I7T/0(U9(D1I&D90`78#+>YP`,_0
M"GU4TN::YTFSGN%VS20(\B^C%03^M6Z;5G8E.ZN4)](@GU"2]:2=99+8VQ\N
M3;A2<Y!'(;W!INFZ1%ITL\_GSW-S.%$D\Y7>P7A1\H`P,GMGUS7+:A?7<>KZ
MG+HL]Y<_8K>=[R268M$)-F8XD3[N0<$X&<=22:U_#,LPN[ZU,\T]O&D$B/-*
M9#N=,L-Q)..AQVSQ26PWH_Z\CHZQ]=>QO;.XT><W$CW$>UX[5-SJI[G@A>AY
M:M=CA20,X'3UKB[J2UM?"=C=23WCWE]B58K.9HWN[B1<@;AAL#MR``H!X&*&
M-%VYTSP]JFJ6CWNFBVOTF61'FME5IRH("E\$-QS@'/`KJ*X?4+35YKOP[9:O
M?!H)U,4\4.5+2"%F+EAW#`%<8P1GKC'5Z/<R7FBV-S*0TDL".S`8!)4'(^M-
MJQ)=K+;0X=VH/%=7<$M[*DSR12!61E4*-O'3Y1D'(/.>.*TV^X?FV\=?2N#M
M+V$VFJWSZGJ2>'XU1%NWN6,EQ*&.\QGJJGA?DQD_=Q2*.PTW38=+MWCB9Y'E
MD,LLLF-TCGJQP`,_0`5=K&\+B_\`[#C;4%E21W=XXYG+R1QDG8KL>2P&,YYK
M9IL2*=_IT.H_9?.9U^S3K.FP@99<X!XZ<U43P[9IJJWP>4[)6F2#Y?+25AAG
M'&[)!/4XYZ5E^*9I/[0M+73[F\;5Y\>1!%,4BB4-\TL@'!&.,-D'H!FG)*;?
MQ=:-%J,US;7GGQN!<&11*N#LV#Y8PH!&1R2<'UI+_,'_`%_7]?<=Y\,O^2>:
M7_VU_P#1KU:G\(+<7M]=/K6I[KLHP7$!$#(P9#&3%N`4CA22O)R#FJOPR_Y)
MYI?_`&U_]&O5K^U-8_MG4((AI]S;P0LRJF]3"XQM623D$L"3@*"H`ZY!KKS!
MVQE5_P!Z7YBA?E7R-C3-/32]/CM$EEFV%F:68C>[,2S,<`#)))X`'M7#?!K_
M`)%"[_Z_W_\`1<==MHUY)J.AV%]*JK)<6\<KA!P"R@G'MS7$_!K_`)%"[_Z_
MW_\`1<=;T4U@ZZ?>'_MQ%TVFCO;NSM;^`P7EM#<0D@F.:,.I(Z<'BJC:5HEB
MD=RUAI]NMHI,<IA1!",DD@X^49)/XUI52U6P.IZ>]L)?*?<DB.5W`,K!AD=Q
MD#(R.*XJ<W=1<FD:6,Z.^\,W=RMT[:8+FX9X8Y)3'OG`.P[3U8'`'TQ4LT_A
MF)5,\ND(LZAE+M&!(K;L$9Z@Y?ZY;WK,F\(WL\:12:R/*\_[1)&ENRJ7\TR9
M`$G3G&&W=`>#5:V\'3R6\\HE:QN7N7:!GRTEO#R%1&CD7'4G&6'."#7=RX:U
M_:O\?ET_0F\KFWK'AC3];1%F#1`,6;RE3Y\J%YW*><``,,,.Q%;*(L:*BC"J
M,`>@H0%452Q8@8+'J:6N"52<HJ+>BV';J>=>)/\`DIT?_8&'_HXU+47B3_DI
MT?\`V!A_Z.-2UOB_^7?^%"CU$(!!!Z'K61I?ARSTFX$T,D\ACB\B!92I$,><
M[5P`<9]23QUJC<S:C#XYM$EO!]BDM9VCMT^51M\OESW.2?8#\:@\(W$ZS_9[
MX2->3VXN_-74)+J)D9CTS\J'GHN01W-<B[_UU_X)3V.MHHK(\3?;AH%VVGW*
MVTB1LS2[<L%"DG;Z-TY/2DW97&E=V)=0T:/4;A7FNKH0X"R6RN/*E`.1N!!(
MY[J1GH<BM*O/[_5+Y$M7E>[^RVVEPW;20W31.S$X=NA$C#CY6XY.><5WZG<H
M(SR,\BJ:L2G<6LNXT&SNKB_FF,K&^A2&5=V``F<%>,@_-^@K4KDK(WCZ[K]O
MJ]_))"EO#*%MY'B6%29#A2I!!P!DYR?IQ2&=!INFQZ;%*JRRSR32&26:;&^1
ML`9.T`=`!P!TJ[6%X2@==#CNI)KF0WA^T*MQ</*8T;[J@N2>%QGGKFMVF]'8
M2*>IZ;#JMG]FG:14\Q),H0#E&##J#QD42Z;#-JUMJ+-()K>.2-%!&TA]N<\9
MS\H[UC>,9-1@L;::SO/L\"W,(F"`[WS*@`![+@G/KQ[UEM?7@\;%Q=3_`&5=
M06T($S<9@W;/)^[MS\WF?>[8QS1'7^O1?J4]CN:CGGAM;>2>XE2*&-2SR.V%
M4#J23TJ2L75A)<ZQ86:JA'D3W*>9G9YL9C";@.H_>$_50>U(1C7VE:?J>G3V
MRC6EM)KLWDDD4"X=L]-KJ2R9&<;3GWKIM*EBETZ,PWKWBKE3+(JJV1V8*J@$
M=,8&*X^&35I-.DBFOI[IDUB2*=8[@023(%X2(EEVX.#@,.`?QT?#5Q/)+I\T
MS8FO+68S*3DR>7(JI)]=K8)QSE?2A;?=^0/?[_S.LJG=Z;#>7EC=2-('LY&D
MC"D8)*E3GCT)]*N5RFMRROXFL[33;F\?4"\<LL:S$06\`/S%E'!+#(&<G/3&
M*.H=#7M-"AM=0%Z]S=7,J(T</VAPWDJQ!8`XR<D#[Q)XXK4KC?#E]>2ZQ:F6
M::3[9;W$MPCREEC=)0JA0>%X)&!C..>:[*GT0=6(RAE*GH1BL"?P7HMUHD.E
MW%JLRP0B&.XDC1ID4>C%>/P%7=?GM;;1;B>]O)[2V0`O)`^UR,_=!'.3TXYY
MX(KE;E_$$'A6SN)+F6S0WB$Q2.7G\MIE"(SDY^Z3GJ3P,]:2U=AG>_#^*.#Q
M-XGBB14C1;-551@*!&V`!74:WX:T_7WMWO&NTDMSF-[:[DA_B5B"%8!@2HZ@
M^V*YKP)_R-?BK_MT_P#0&K9\6>++;PV+&)KBSCN;N=%5;J81CR]ZAV&3R0&X
M`^O0&NS&ZUH_X8?^D1(AM]Y?TG08-(FFDBN+B7>HCC24KB&,$D(NU1QECRV3
MSUKD-8_Y+EH'_7@W_H,]=5H=SJMQ>:BM]<V5Q;0RB*%[>U>$[@,MG=(^X#(&
M1CD-Q7*ZQ_R7+0/^O!O_`$&>M<M^*I_@E^0I_J>B4445YQ85YW\&O^10N_\`
MK_?_`-%QUZ)7G?P:_P"10N_^O]__`$7'7HX?_<JWK#_VXA_$CT2BBBO.+"BB
MB@`HHHH`\B\&_P#(J67_``/_`-#:MJ::.W@DFF=8XHU+.['`4#J36+X-_P"1
M4LO^!_\`H;5%?S0:K'=3WC[-"LU9G<,1Y[KG)R.=BXX(ZM_NC/7F#MBZO^*7
MYL4-4B-M(DU.*34$B6$LWF6]G(NV.0$@DS+CEGP.2"5P,<YSNV%['?VHE161
M@2DD3?>C<=5/N/\`Z_0UP.B74MUHVHW/A^"(0W<J(EG8S1>9:Q8(,C`L`)&]
M,^F<X-7_``G%/:>%M-U6UMYAMA\NZMR03.@)PXP3\Z]NY&01]W'+89W%1R00
MRR1R211N\1+1LR@E"1@D'MP2*(9HKF".>%UDBD4,CJ<A@>AJ2D!7BL+."[EN
MH;2".YF_UDR1@._U/4_C5BBB@`(!&",@U4?2M.E@@@DL+5X;<AH8VA4K&1T*
MC''X5;HH`****`*$.AZ1;WAO(=+L8KHDDSI;H')/7Y@,\U8M;.ULHC%:6T-O
M&6+%8D"`D]3@=ZGHH`*YVZT!/-V/IUAJ=B&+QP7:`O;ECEMA((*D]N,<\D8`
MZ*B@#`GTJ?48H;-K*UL+&$;1Y9#2A2""L>`!'D'&X$G&0,=1O(BQHJ(H55&`
M`.`*6B@!'19$9'4,K##*1D$5EKX9T!(GB70]-6.3&]!:1@-CID8YK5HH`@L[
M*TT^W%O96L%M""2(X8PBY/L.*GHHH`H7>B:3J%P+B]TNRN9U``DFMT=@!T&2
M,U/'86<-W)=Q6D"7,HQ),L8#N/=NIJQ10!I_#+_DGFE_]M?_`$:];L.A:1;:
MA-J$&E6,5[.");F.W19)`>NY@,G.!UK"^&7_`"3S2_\`MK_Z->NMKKS#_>ZO
M^*7YLF'PH9%%'!"D,,:QQ(H5$1<!0.@`'05Y]\&O^10N_P#K_?\`]%QUZ)7G
M?P:_Y%"[_P"O]_\`T7'6U#_<JWK#_P!N$_B1Z)1117G%A1110`4444`>=>)/
M^2G1_P#8&'_HXU+47B3_`)*='_V!A_Z.-4=2O)6G33+%L7DR[FDQD6\?0N>V
M>R@]3[`UUXO_`)=_X43'J5KZ%-:U`VL2A8K<%+FZ3B0;L$Q(PY7/!8@],#J>
M#1(8-*N)M-:W@BN6S*LT<2I]J7^\V`,N,@-]0>^!S!;0H?&L.GV$EK:2V+>9
M>74T^)I24/[I,G<<YW-CC//4T>&(=,UZZO[K29K:S@0(+2.&0-,'4M^_D7.<
MMG'S<LO7K7*M2GH>ATV2-)8VCD171P596&00>H(JGIE^UY')'/&(;R!MD\6<
MX/9E]5(Y!_`X((%ZD!6ETZQG$`FLK>06Y!A#Q*?*(Z;>./PJS110`5"UI;,\
MSM;Q%ID"2L4&749P&]1R>#ZFIJ*`&HB11K'&BHB@*JJ,``=@*=110!'-!#<Q
M^7/%'*F0VUU##(.0<'N",U']@LS?"^-I!]K"[!/Y8\S;Z;NN*L44`%4]0LFO
M(XVBF,%S"^^&4#(!Q@@CNI!P1_(@&KE%`&%):W$UG+;7/A_3IA(Y=T\P&*1L
M_>8%,Y/!/!_&KFG:=);S27=U(KW,BB,+&"(XD'1$'\SU/'8`#1HH`*H3:'I-
MQ>B]GTNRENP0PG>W1G!'0[B,\5?HH`@ALK6WGFGAMH8YIR#+(D8#2$=-Q')_
M&IZ**`(+RQM-0MS!>VL%S"2"8YHPZY'L>*CBTK3H+,6D-A:QVP8.(4A4(&!R
M#M`QG(!S5NB@!_@3_D:_%7_;I_Z`U=U)%',FR6-9%R#M9<C(.0?P(!KA?`G_
M`"-?BK_MT_\`0&KO:Z\;_%7^&'_I$28[#(H8H5*Q1I&&8N0B@98G)/U)YKS[
M6/\`DN6@?]>#?^@SUZ)7G>L?\ERT#_KP;_T&>MLM^*I_@G^0I]/4]$HHHKSB
MPKSOX-?\BA=_]?[_`/HN.O1*\[^#7_(H7?\`U_O_`.BXZ]'#_P"Y5O6'_MQ#
M^)'HE%%%><6%%%%`!1110!Y#X/`;PE9J1D$2`C_@;5=CT'3(HUCCM%2-`%55
M8@`#L!FJ?@W_`)%2R_X'_P"AM6[77F'^]U?\4OS9,/A10_L73_\`GW_\?;_&
MC^Q=/_Y]_P#Q]O\`&K]%<A1#:VEO8VZV]K$L4*Y(11P,G)_4U-110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!I_#+_DGFE_]M?_`$:]
M=;7)?#+_`))YI?\`VU_]&O76UUYA_O=7_%+\V3#X4%>=_!K_`)%"[_Z_W_\`
M1<=>B5YW\&O^10N_^O\`?_T7'6V'_P!RK>L/_;A/XD>B4445YQ84444`%%%%
M`'G7B3_DIT?_`&!A_P"CC5>72+">YDN9+93-(`'<$@MC@9QZ58\2?\E.C_[`
MP_\`1QJ6NO%_\N_\*)CU*']BZ?\`\^__`(^W^-']BZ?_`,^__C[?XU?HKD**
MEMI=E9W#SV]NJ3.@1GY)*@Y`R>V2?SJW110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`_P`"?\C7XJ_[=/\`T!J[VN"\"?\`(U^*O^W3
M_P!`:N]KKQO\5?X8?^D1)CL%>=ZQ_P`ERT#_`*\&_P#09Z]$KSO6/^2Y:!_U
MX-_Z#/6V6_%4_P`$_P`A3Z'HE%%%><6%>/\`PS\-_P!L^'+BX_MK6;';=LGE
MV-UY2'Y$.2,'GGK["O8*\[^#7_(H7?\`U_O_`.BXZ[*=&$\'5E):IQ_&YK2Q
M-6A+]V[7-?\`X07_`*FOQ1_X,?\`[&C_`(07_J:_%'_@Q_\`L:ZVJ<VJV5OJ
M<&FRS;;NX1I(H]C'<J]3G&!^)K@CAXRTBKG3_:6*_F_!?Y'/?\(+_P!37XH_
M\&/_`-C1_P`(+_U-?BC_`,&/_P!C6Y!KVF7.B-K,5SNT]$=VF\MA@*2&.,9X
MP>U1_P#"2:1YVFPF\`?4DWV@*,/,&,]<<=1P<5?U)W:Y'IZ]-_N%_:>)_G_!
M?Y&/_P`(+_U-?BC_`,&/_P!C1_P@O_4U^*/_``8__8UT*:I92:M+I:39O8HA
M*\>T\(3@'.,?K5RHEAXQW5A_VGB?Y_P7^1X9X:T/[9X?M;C^U-3@W[_W<%QM
M08<C@8]JUO\`A&?^HWK7_@7_`/6H\&_\BI9?\#_]#:MVNC'8>G'%5(I:*3_,
MF.98KE7O?@O\C"_X1G_J-ZU_X%__`%J/^$9_ZC>M?^!?_P!:MVBN7V,.Q7]I
M8K^;\%_D87_",_\`4;UK_P`"_P#ZU'_",_\`4;UK_P`"_P#ZU:.IZ@FEV)NG
MAEG_`'D<2Q0[=S,[JB@;B!U8=2*I_P!LW_\`T+.J_P#?RU_^/4>QAV#^TL5_
M-^"_R(O^$9_ZC>M?^!?_`-:C_A&?^HWK7_@7_P#6ITGB">W,1NM!U.WBDFCA
M\UWMRJL[A%R%E)QEAT!K;H]C#L']I8K^;\%_D87_``C/_4;UK_P+_P#K4?\`
M",_]1O6O_`O_`.M6[11[&'8/[2Q7\WX+_(PO^$9_ZC>M?^!?_P!:C_A&?^HW
MK7_@7_\`6K=HH]C#L']I8K^;\%_D87_",_\`4;UK_P`"_P#ZU'_",_\`4;UK
M_P`"_P#ZU;M%'L8=@_M+%?S?@O\`(PO^$9_ZC>M?^!?_`-:C_A&?^HWK7_@7
M_P#6K=HH]C#L']I8K^;\%_D87_",_P#4;UK_`,"__K4?\(S_`-1O6O\`P+_^
MM6[11[&'8/[2Q7\WX+_(PO\`A&?^HWK7_@7_`/6H_P"$9_ZC>M?^!?\`]:MV
MBCV,.P?VEBOYOP7^1A?\(S_U&]:_\"__`*U'_",_]1O6O_`O_P"M6[11[&'8
M/[2Q7\WX+_(PO^$9_P"HWK7_`(%__6H_X1G_`*C>M?\`@7_]:MVBCV,.P?VE
MBOYOP7^10\"^$_[3\&V%Y_PD&O6GF>9^YM+SRXUQ(PX7'&<9^I-=%_P@O_4U
M^*/_``8__8T?#+_DGFE_]M?_`$:]=;75CL/3CBJD4M%)_F3',L5RKWOP7^1R
M7_""_P#4U^*/_!C_`/8UQGPS\-_VSX<N+C^VM9L=MVR>78W7E(?D0Y(P>>>O
ML*]@KSOX-?\`(H7?_7^__HN.M:&&I/!U9-:IQ_4'F>*YE[WX+_(U_P#A!?\`
MJ:_%'_@Q_P#L:/\`A!?^IK\4?^#'_P"QKK2<#)[5RT/Q&\)W%PL":P@=CM&^
M&1%S[LR@#\37+3P4JJ;IP;MO:[&\SQ*WG^"_R(_^$%_ZFOQ1_P"#'_[&C_A!
M?^IK\4?^#'_[&M/6?%NA^'YXH=4OO(DE3>@\IWR.F?E!I^D>)]&UVWN)].O5
MEBM_]:[(T83C/.X#T-/ZA/D]IR/E[V=OO#^T\3>W/^"_R,G_`(07_J:_%'_@
MQ_\`L:/^$%_ZFOQ1_P"#'_[&K]AXT\.:IJ'V"SU6&2YS@)AEW'_9)`#?@36]
M4U,)[)VJ1:?G=`LSQ+VG^"_R/'M;\-_9O'26/]M:Q+G3!-Y\MUNE_P!:1MW8
M^[WQZU)_PC/_`%&]:_\``O\`^M6QXD_Y*='_`-@8?^CC4M;8K#TUR67V4*.9
M8K7WOP7^1A?\(S_U&]:_\"__`*U'_",_]1O6O_`O_P"M6[17+[&'8K^TL5_-
M^"_R,+_A&?\`J-ZU_P"!?_UJ/^$9_P"HWK7_`(%__6K=HH]C#L']I8K^;\%_
MD87_``C/_4;UK_P+_P#K4?\`",_]1O6O_`O_`.M6[11[&'8/[2Q7\WX+_(PO
M^$9_ZC>M?^!?_P!:C_A&?^HWK7_@7_\`6K=HH]C#L']I8K^;\%_D87_",_\`
M4;UK_P`"_P#ZU'_",_\`4;UK_P`"_P#ZU;M%'L8=@_M+%?S?@O\`(PO^$9_Z
MC>M?^!?_`-:C_A&?^HWK7_@7_P#6K=HH]C#L']I8K^;\%_D87_",_P#4;UK_
M`,"__K4?\(S_`-1O6O\`P+_^M6[6;>:[8V-X;247;SB-962WLYIMJL6`)**0
M,E6Z^E'L8=@_M+%?S?@O\BI_PC/_`%&]:_\``O\`^M1_PC/_`%&]:_\``O\`
M^M4O_"2V'_/OJO\`X*;K_P"-U-9Z[8WUX+2(7:3F-I52XLYH=RJ5!(+J`<%E
MZ>M'L8=@_M+%?S?@O\BI_P`(S_U&]:_\"_\`ZU'_``C/_4;UK_P+_P#K5J7]
M_;Z;:-=73.L2LJ?)&SL69@J@*H)))('`[U0_X26P_P"??5?_``4W7_QNCV,.
MP?VEBOYOP7^1%_PC/_4;UK_P+_\`K4?\(S_U&]:_\"__`*U2CQ-IWF1HZ:A%
MYDB1*TVFW$:[F8*H+,@`R2!R>];%'L8=@_M+%?S?@O\`(PO^$9_ZC>M?^!?_
M`-:C_A&?^HWK7_@7_P#6K=HH]C#L']I8K^;\%_D8GA/PS]N\0>(+?^W-:M_L
M_P!G_>6]WL>7<C'YSCG&./2NN_X07_J:_%'_`(,?_L:S_`G_`"-?BK_MT_\`
M0&KO:ZL9AZ<:B27V8_\`I*)CF6*M\7X+_(Y+_A!?^IK\4?\`@Q_^QKEQI/\`
M8_QFT*W_`+0O[[=:._FWTWFN/EF&`<#CCI[FO5:\[UC_`)+EH'_7@W_H,];9
M?AZ;G.ZVA)_<B:N88F4>5RT?DO\`(]$HHHKD.4*\[^#7_(H7?_7^_P#Z+CKT
M2O._@U_R*%W_`-?[_P#HN.O1P_\`N5;UA_[<0_B1WE]?6^FV,U[=R>7;PKOD
M?:6P/7`R:Y*^GBO?B/H$ULXDC;3YI`1_=8<'\:[*:&.X@DAF19(I%*NC#(8'
MJ#65H_A;1-!FEFTS3X[>67AG#,QQZ`L3@>PXK'#U:5*,I._-9I=M5;^MQR3>
MB_K5,XW19XE^"E\K2*&C@N8W!/1BS8'UY'YU2U31'U9_!^G+(T5PNDN\,G(*
M2*B%3^8%=M<>!O#-UJ3:A/I$+W+-O8[FVL?4KG:?Q%:LFEV4NHVVH/`#=6R,
MD+AB-JMU&,X_,5W_`-HTX3=2G>[<GLM&U9+?57ZZ>A+@WI_6Z?Z'!^"]7EUG
MQY?7%S$8;N/3DAN8R,;95?#?AW_&O2*S[?0]-M-7N=5@M1'>W*A9I0S?.!CM
MG'8=JT*X,;7IUJBE35E9*WHAPBXW/(O!O_(J67_`_P#T-JW:PO!O_(J67_`_
M_0VK=HS#_>ZO^*7YL</A04445R%&/XE_Y!4'_80LO_2J*J6N:A>V>N6$%I?M
M)/<2H%L$A4CRL_O)'8@L`!T((YXYK0\107%QI(%K;O<2QW5M-Y2,H9E2=';!
M8@9PIZD5CR6R2ZPVJGPMKRWK!5:2._B0,%Z`JMR`1[8Q0MT'1F;J.IWCW@BU
M&34(%GU6W6S@ECA6&1$NHN5P/,S@9^8@$'C-=_7%W.FFXFB:V\,:C;S->P3-
M+/<PM'$%G220JHF;;D*<[5R37:4=$'5E+5G:+3)I!?K8*@W/<L@;8HZD;N,X
MZ$Y^AZ5QX\1:O+I^GQYO5:Y%Q,EPD,7G/#&1L)5\(,@Y/`X'&":[#5=)LM:L
M6LM0B:6W8AF02,F2#D<J0>M0OH&GRV26DBW+QHQ96>[E,@SU&\MNP>F,XQ0,
MM:=<K>Z9:W23+,LT2N)57:'R,Y`R<?3-6:9%%'!"D,**D<:A451@*!T`I]-[
MZ$K;4Y8WM\_BQM+@U26<-&[W(CAC"62D?N\$@G>3V8D'K@5;\,27MS#=7<^I
M3WEM),R6OG)&"$4[2V45<Y(/X8JS9^'--L+Z>\MDN(YIW:24?:Y2CL>I*%MI
M/X<=JO65E;Z=916EK'Y<$2[47).!]3R:2V&]R>L7Q/>-8:6;K^TWL40\^5$K
MR2L?NHH8$9)]B3[=:VJR]9TC2]12&XU/>JVC&2.47+P^6>F[*L/SI,:.7;Q!
MK<>HV8NI#`J+:+=(J)Y4;RG#+)GY]W3;LX&?FXKO*YZVM_#.HWT,EO=075S$
MJ%0MZTA<+]QF&X^9CLS9]C70U3:)2$.=IP<''!(KAAK&M,^H16-[/J-O;O$D
MUY';(3&Q;]Z(54?-M7'!#$'^]TKN'021LC9VL"#@D'\Q6-;>$M&L[!K&""X6
MU;&(C>3,$(.X%,O\ASSE<&DMQ]!_AK49M2TMY)S(TD5Q+!OD38SA6(#%<#!Q
MC(P.<\#I6Q4-K:065NMO;Q[(UR0,DDDG)))Y))Y)/)J:FP.?\37.HZ=#'J%M
M>F*VB=!+'Y2%0I8;GD)^;:%Z!,'/J.E33];O9];A+RLUM=75S;"`HN(Q%G#`
M@9R<'.21R,8K;O-$TZ_NUN;FWWRJH4D2,H=0<@.`0'`/.&!%/BTBQAU![^.#
M%P^<G>Q4$]2%S@$X&2!DXYI(&=!\,O\`DGFE_P#;7_T:]7+G7M4AU2ZL8M&B
MD*1&6!C>A<@,%W2_+^[4Y)!!8D(WRY&*I_#+_DGFE_\`;7_T:]7KCP9HEU)?
MO+'>G[><W*KJ-PJ.<@YVB0!3\HZ`<<=*Z\P_WRK_`(I?F*%N5&CH]^^J:3;W
MLD'D-*I)0/O'4C*M@94XR#@9!'`KB?@U_P`BA=_]?[_^BXZ[VSM(K"TCM86F
M:.,84S3/*_XNY+'\37!?!K_D4+O_`*_W_P#1<=;T+?4J]N\/_;B=>97/0G^X
MWTKS[PZ+4_!J07H3R/(N<[^F=[X_'.,5Z&1D8/>N6A^'/A.WN%G31T+J=PWS
M2.N?=68@_B*SPM:E"#C4;6L6K*^U_-6WWU*=]&CDH/[;_MGPG_9WV3^T?[%Y
M^W;]F/?;SG&*V_%?_"0?\*_U'^V?L7F^;'N_L[?M\G<N[.[G/7\*Z'6?"6A^
M()XIM4L?/DB38A\UTP.N/E(IVD>%M%T&&XBTZQ6*.Y`$RL[2!P,]=Q/J:ZY8
M^B^2I;WHM.UE_-?XK_\`MI"@UI_6UB*]/AL0:0;PV8B$J?V?NQC?CY=O^<=/
M:MVL"P\%>'-,U'[?9Z5#'<@Y5MS,%/JH)(7\!6_7FUY4W94VVO/]%=_\$J*:
MW/.O$G_)3H_^P,/_`$<:EJ+Q)_R4Z/\`[`P_]'&I:TQ?_+O_``H(]0HHHKD*
M"LS7KC[)I4ER^I_V=#$=TLZQJS;?1=V1DG'8_2M.J&JZ-8ZW!'#?Q/)'%()4
M"3/&0XZ'*D'BDQHYN?4=>A\.6.L3W+V^W89X6@0`*7Y>7/(^3'RI@@GTZ=F#
MD9'0UE-X;TN1HFEAED:-=FZ2YD8NH.0');]X`3D!LXK5JF2%<:WB.72]6U`W
M.HF]LK2`M<N8TCCAF+`1Q(1W()SN)QP<CI795EZ7X>T[1I7>P2XCWEF9&NY7
M0ECDG:S%<D]\9I=1E#P9K4VMZ7<RW-W;7$\=U(A^SLI55S\H&.HQT)ZUT=5[
M2RM[%95MH]@EE:9_F)R[')//O5B@#G?%M_<:;8I<6^HO!*<I!;10J[W,Q^ZO
MS`_+US@`]\C%5EU34(_$8&HM?VEF7B@B"QP_9Y)63)!)!D.2<`C`^7K6QJ/A
M_3M5N[>[NXY_M%N&$,D5S+$4!ZXV,.M.70M.6_%Z(&,X(;F5RI8#`<J3M+8X
MW$9]Z%Y@S1K#42'Q5JXBD6.0Z;:[79=P4[[G!(R,_G6Y7.:E!<C6]09M'O+Z
MRO;"&W8VTT2$%6F+`[I$(XD7D4GL-;F*GB/4C$\5M=75[;S7J6EO?+%$'<[&
M+^6,!",KM!(QR<YQ6GI5[]OUK1IS<&X?[!>H[M&$;<LUN"&4$@$$8..,CCBL
MS[=HNDVS:4^CZE"BA2(9M6A+0@?=*[KG,?U7%:^DPR2:S82V^CW%C86UE<1A
MII8G#M(\+#&R1R2=C$D_UJM">I>\2_\`(*@_["%E_P"E454M<U"]L]<L(+2_
M:2>XE0+8)"I'E9_>2.Q!8`#H01SQS6AXB@N+C20+6W>XECNK:;RD90S*DZ.V
M"Q`SA3U(K'DMDEUAM5/A;7EO6"JTD=_$@8+T!5;D`CVQBDMT/H4[\WTM[<K_
M`&M<W-C:7]C$T<T<(S,;F)C@HBG"J5[GD^U=S7)W$5S/"+:U\-ZA;&?4;>ZF
MEFF@*C;-&[L<2L?NIT`KK*.B#J4M6=HM,FD%^M@J#<]RR!MBCJ1NXSCH3GZ'
MI7#W/B37?[*MI89K@$PW-PC>3$)'B1AY<DH88"$'Y@H#'C`KN-5TFRUJQ:RU
M")I;=B&9!(R9(.1RI!ZU5E\,Z7/#%%-%/*(MP5I+N5GVMU4L6W,IP,J21QTH
M0S5^'<HG\1>)90ZN'2R8,O0YC;D>U=;K>MIH\=OB!KB:>9(UC1@"%9U5G)]%
MW#]!WKEO`2A/%/BE5`"@68`';]VU=9JOA[1M=\DZKI=I>-"=T33PAFC.0?E)
MY'(&<=<<UV8[^,O\,/\`TB)$/A*7AWQ(^NW5_"]E]F%LX\MM['S4)8!OF1<_
M=ZKN7GAB<@<UK'_)<M`_Z\&_]!GKM=/T:QTN6:6TB=&FQNW2NX`&<*H8G:HR
M?E7`Y/%<5K'_`"7+0/\`KP;_`-!GK7+?BJ?X)?D*?ZGHE%%%><6%>=_!K_D4
M+O\`Z_W_`/1<=>B5YW\&O^10N_\`K_?_`-%QUZ.'_P!RK>L/_;B'\2.O.O6P
M\0C10C-<;`[-YD8"@@G[I<.>G92.139/$=E#=PVSI,))+EK;H/E*@'<>>%.Y
M<?[PXI\FE32:K]I-S&+;S%F,0@`?>J[1\X/*X[$$^^.*H:EX4%_-J<RWK0O>
M)'Y9$>?(D4J=XYYSL3CC[M906&;2D[*R[[_UK\AN_0L6WB07LD:V>E7\ZM%'
M*74Q*$5\[<[I`>@SP#0OB,&VGNVTN^2SAWYG)BVMM8J<`2;NH/4"JL_A0'4X
M[N$:6RQQ11(MWI_G-'Y><%&WKMZ^G:JZ^"\17D)DTP+="56F33MMQAV)P9/,
MYZ^G.*UM@WU[='\R;S-:?Q!!&0(;6YN6>8P1"((/-8`EMI9@,#!R21R,#-:5
MO,+BWCF$<D>\9V2KM9?8CUK'E\/2+:M9V=S;I9;LI:7-H)HE!&"N,@[>X`(Q
MD]1@#3TZS^P:?#:F4R^6N-Y&,_0=AZ#L*YJJH\GN/7Y_\,4KWU/+/!O_`"*E
ME_P/_P!#:MJ9WCA=TB:5U4E8U(!8^@)X_.L7P;_R*EE_P/\`]#:MF='EMY(X
MYFA=E(610"4/J`01^8J\P_WNK_BE^;'#9&!%XJQI]_<75BPFLY1"8K63SP[D
M`[0P`Y&<'(P,'FM?2K[^T](L[_R_+^TPI+LW9V[AG&>]4[+19H3?S7=XL]W>
MHL;O'$8T`4$`A=QYYY.>?:KFDV/]F:19V'F>;]FA2+?MV[MHQG':N7H_E_P1
MERBBBD!C:?X@BU'7;S38K>55M8U?SI`5#DLRG:".@*GGO^M;-9\>F>7X@N-5
M\[/G6R0>5MZ;68YSGONZ8[5H4=`>X5F:SJ-UIEJ;B"SCFBC1I)I);@1+&JC/
M7!))[#&/4BM.L'Q)H%UKPM(X[^&&VAD\R6WFMS*DY'W0V'4X'7'>DQJW4U[.
MY2]LH+J-65)HUD4,,$`C/-3TR)76%%D9&<*`Q1=JD^PR<#VR:?5/?0E7MJ,F
M=XX7=(FE=5)6-2`6/H">/SK-T36)-5^UI-;)!-:R^5)Y4WFINP"0&P.1G!&.
M#ZUHSH\MO)'',T+LI"R*`2A]0""/S%9^EZ5-975U>7=VMS=W(17:.,QIA`0,
M+N///)S^5)#-2LB"VCU/49[RZ42QV\IBMHVY5"O#/C^\3D9[`<8R:UZQ_,DT
M>_N&ECEDL+E_-$D:;O(?`!!`YVG&[/."6S@8H`K>(-2L%U#3M(N+3[5)=RA<
MAMIMP0</GJ#D<8P>#SQ6EI$LS6C07$AEFMI&A>0@9?'1CCC)4@G'<FN;U>PT
M?4M1@O[&:ZGOEN$F:*UGE(EVJ0`<,$C_`-XX[^M=-I=I+:6>+AP]Q*[2RL.F
MYCG`]AP![`4+8'OH7:S]<U5-%T>XOW5&\H#"R2"-220`"Q!P,GK6A534K22]
MLS#%*D4@971Y(1*H*D$94]1QV(/H0>:`$TR\>_T^.Y?[*=^2#:7'GQD=B'VK
MG\JN5GZ1IATRWF5YO.FGF:>5PI5=[==JY.T>V36A0P"L*R\1KJ&MR6,$4+11
MLZ%Q=+YH*'!)BZ[,@@$$\CH!S6[6!!X96#5X[I+D"VBN)+I(%C(;S9`0V7W<
MKR3C'7O0M]0>VAV7PR_Y)YI?_;7_`-&O6LWB72UN[JU$L[SVREG2.TE<L%QN
MV;5/F$9&0F2,C.*R?AE_R3S2_P#MK_Z->K,N@ZS+JE_=OK-FR31^7;(^GEC`
MN0=AS+M93@[OE5CD?,,#'7F'^^5?\4OS8H6Y5\C<LKVWU&RBN[5R\,J[E)4J
M?Q!`(/L1D5P?P:_Y%"[_`.O]_P#T7'7::)IG]CZ1;V'F+)Y0/*)L09).%7)V
MJ,X"Y.``,UQ?P:_Y%"[_`.O]_P#T7'6]"WU*O;O#_P!N)UYE<[#5-?L])NK6
MVG#M+<-A50KD<XS@D%N3T7)Z\4W5/$%KI`NC<13M]GA28B-02X9BN%YY((Y^
MHI-5T1M1N?-CN$AWQ>1.&BWEH]V[Y3D;3GOR/:G:AHJ:AJME>O,56W5U>(+D
M2AAQD^QYK""P_N\WG?\`KSV_$>MV12>(XOM'D6MA>7<AD9`(?+`.U58D%W48
M^<#ZYI\&NR7%W);IH]_^Y=4FD+0[8F*JV#^\R<!AG`/MFLH>"]NF:?:&XL[I
MK1I"S7]EYZR;^^W>,$``9S3[;PD]OJ9O/^),S%XVR=*^>,*BKB-O,^087@8.
M,]ZV<<)9VEWZ/O\`JA>]U+H\4V3V(NXX;B2/RHY#M5?E:3&R,DG&\[AQG`')
M(R,Z=E=F\@+O:W%LZL5:*=0&!^H)!'N"16-8^%WTO34M-/OEA'DJLH:W#I)(
MN/G*D_Q#(89Y&,$$9K1T;2SI5K)$9(F,DADVP1>5$G`&$3)VCC/4\DGO6-98
M?E?LWUTWO;\AZG%^)/\`DIT?_8&'_HXU+47B3_DIT?\`V!A_Z.-2T8O_`)=_
MX4$>IA:CX@ETO48HKJQ"VDTABBE$X,CL$+$B,#[O!&=V<]L<TNA^(?[7E,4E
MND$C6\=U$$F\S=$^<$\##<<CD>YJ$>'KT^*I-9DU&"52OEQ126I+6Z8Y"-YF
M`2>22IS4VA^'4TBYGNGD@DN)4$9:"V6`%02<E5."Y)Y/`.!P*Y5MJ4_(W*I:
MI>7%C9-/;VT<S*?F\V<1)&O4LS$'`&.P)J[52_@O)X5%E>+:RJV[+PB1&'HP
MR#CZ$'CK4L:,)O&*_9K>X2R/EFV2ZN=\NUH8W;:"!@[CP3U'`_"NHKEO^$+B
M2!((KPB-XQ%=;X]QE02&3"\_)RQ'?@X]ZZFJT)ZA4%Y=16-I+<S;_+C7<0B%
MF/L`.2:GHI#,W0=6_MO24OOLSV^Z21/*=LLNURO/OQ6E6?HVF?V1IWV3SO-_
M>R2;MNW[[EL8R>F<5H4WY`%8UUK<]EK-M:7%BJ6US-Y$,WG@N[;2V1&!]WC&
M<Y]L<ULUSR>'[T>+'UN74+>="NR*&2U8M`F.0C>9@$]SM-);AT.AK.U:28BU
MLX':-KN;RVE4X*(%9F(]R%VCT+9[5HU0U2TEN(X)[8`W5K+YT08X#'!4J?JK
M,/8X/:@".[QHNE_\2ZP@9$^\KRB&-%Y)=VP3CUX)_G6;IMS$DFEW]K"UM;:M
ME7MOX5DV-('&.!D(P/KE3UJQ=ZNEQ;H(=0_LNZ1\M'=V^[/JI4D;A[HW;@D5
M7T/3CBR54E%C8EY(GG0J\TK[@6"GE5`=P`>N[T&2(&=+112$9&/6@#'LO$,-
M_P"(KS2H86*VT0<S[OE9MQ4J![$8SGKD=JV:P--\)V>DZVVH6DMPL?V?R5@>
M>5P/F+$Y9SQSTQQU[UOT=$'5A6)KOB`:/<V-LHLO.NV8*;R[^SH`H'?:V220
M`,=ZVZR=9TF?4]OD744&8G@D\RV$A*/C.TY!4\>I'J#Q0-&QX")/BGQ26`!(
ML\X.1_JVKM;[4;33($FO)UAC>5(5+?Q.[!54>Y)%<+\.K=+3Q!XDMHRQ2)+)
M%+')($;#DUTWB+PVVOO:.NJW=DULX<"%(G5_F4\AU//RX!!&,GJ.*[,=_&7^
M&'_I$2(?#J7M.UFQU5YDLY7=H3AM\3ID<@,NX#<IP<,N0<'FN*UC_DN6@?\`
M7@W_`*#/73:#X;.C:A?WCW0E-R0L<:"0)%&"Q"@/(^/O'[NU?11SGF=8_P"2
MY:!_UX-_Z#/6N6_%4_P2_(53]3T2BBBO.+"O._@U_P`BA=_]?[_^BXZ]$KSO
MX-?\BA=_]?[_`/HN.O1P_P#N5;UA_P"W$/XD=#XMO+*V@@CN-4>RN)=RVRBZ
M\A2^!\[MD<+UP3@YQ@G%0Z3>ZM-XLGCOH;A+<VV81OC,14-@/\K$DMUZ#'`[
M9/4U1U/5;72H!)<,V6SL1(V<M@9/"@D`=ST'>L:=:\/91A=N_P#2_IE-7..M
MO$-\]@]NUU#<;2V7B+B2`^80%<[N21R.`,#H1@U)8:QJ:^3%!,CS32B,271>
M0*"4'W0PSU/^-=%_PDVG1+%]J>6W=XA)\]O)LY`)P^W:V,\X/J>QJ:#Q!IMU
MJ4FGV\TDMS&Q60)!(50@D?,P7:.01R>U=4JLK-^QTW_K0S:NKIG/P>*[Y[NS
MAE>PC>26*)H2C;Y0S$-(GS<*,8P0>>_KV=49='L9M234'B8W"8(/FL%)&<$I
MG:2,G!(R*O5Q8BI2G;V<;=RTG<\B\&_\BI9?\#_]#:MVL+P;_P`BI9?\#_\`
M0VK=J\P_WNK_`(I?FPA\*,[7)?L^CW%R;V>S2!#*TL"H6P!T^=6'/TI=#COH
M]'MO[2N6N+QEW2.RJ,$\[?E`''3..<58O;*WU&TDM+J/S(),!TW$9YSVJQ7(
M4%%%%`'':)KFHW7B3R;FY+6D[7*Q;D01OY;@#RL?/P,[M_4_=XKL:S[71-.L
M[Y[RWM]DS[C_`*QBJ[CEMJD[5R>3@#/>M"CH@>["N<\47VIV3P-:M<16OE2N
M\MO;B5O,4`HK#!VH?FR>.G45T=4M0TBRU0Q-=Q,YBSM*R,AP>H.TC*GN#P>X
MI,:MU'Z;=-?:7:7;)L:>%)"OID`XJU2*H50J@!0,``=*6J>^A*NEJ<E>Z[JU
MCK.J^?'$+:VTZ2YMX$^8L58@,Q]\=!T'O5_P_>WDMU>65W</<F%(95F=%4_O
M%)*_*`."..,X/.:U'TZTEO&NY(0TSP^0Q))!CSG;CIUI+#3+33(W2TB*!VW,
M6=G)XP.6).`.`.@[4EMK_6HWOI_6B+=8'C"_U33?#]Q<Z6(EDC1G>:0Y\M0.
MRX^8GISQW]JWZR-8N+2XCDTF6TGOWGC_`'EO!QA"<99B0%'U()P<`XH!%._U
M+58?$NC6RB*/3[AV1V^\\K>6S>GR@$#W/L.O1UAW%S;_`&FSFU/3+BW%L^Z&
MX9@T<;$%?F*L<<'&6&/>MRF)"'(4D#)QP/6N3L=3U6X@UT:E?0:<UI.G[Q%5
MUMXS&K$`MP3R>2",]L<5UM95[X<TK48+N&ZMF>.\D66<"9UWLH`4\$8Q@<#T
MI%*Q'X8O;O4-$CN;OS#O=_)>5`CR19.QF4``$C!X`^E;-5[.SBL;<00M,R`Y
M!FG>5O\`OIR3^M6*;)1S^OZAJEGJ6E1VHBCLYKJ..:0\N^XGY0.PXR3^5(;G
M4;+Q9;6US>F2TO%E**T2*@9<%43'S;L9)+'![8Z5LW5E;WOD_:(]_D2B:/YB
M-KCH>/K5>#1-.M;YKV&WVS,S-]]BJLWWBJD[5)[D`$]Z2T&SH_AE_P`D\TO_
M`+:_^C7J]+XBGM=8N;2\T]8[>.(RQ2QSB21_F"@,F/E+DX3YB3@\#%4?AE_R
M3S2_^VO_`*->M%O"&AR75[//9M<_;6W7$-S/)-!(W&#Y3L8\C:,$+QCBNO,/
M]\J_XI?FQ0^%%_1[]M4T>SOV@,#7$2R&(L&*$C.,CKBN(^#7_(H7?_7^_P#Z
M+CKNM.TZSTG3X;#3[>.WM85VQQ1C"J*X7X-?\BA=_P#7^_\`Z+CK>A;ZE7MW
MA_[<2_B1V6O7-G::1+-?WDEI;`KODBDV,>1\H8<C/3(P?<=:Y"WOKO\`M#3\
M:PLL0,7V>..Y:1IPTK!U#!MLFQ<!BP<X7/RD[J]!J"[NX+&U>YN7V1)C)P2>
M3@``<DDX``Y-84*ZA'D4;M_UV')7.1O]=O++7-7MDN894W#;:L7\T#[.&+J0
MPVJ".<#OU!QG/37;^TFO9_.>7RA(R)+*Y4%7N2.-W(^11SV`]!CJH?$]@\"S
M3">*-YVA1C;RE<A]@W';A"3V;%./BK1_-MXEN9));A%DBCBMY'9E.<'"J2/N
MG.>F.:ZU.2CR^Q;V3^7R'=&#>>*]5L5N(KB738Y80[>>\3B.0B)'6(#?G>=Y
MP<G.T_+796TAFM896`#.@8XZ<BJVHZ18ZL(Q>1,^P$#;(R9!ZJ=I&5.!D'@X
MJZ`%``&`.`!7%6JTIPCR1L^HDF>=^)/^2G1_]@8?^CC4M1>)/^2G1_\`8&'_
M`*.-2U6+_P"7?^%!'J(QVJ6QG`SBN4\+Z[<ZG=1M=W$RF[MS<16\L,87`8`^
M6RG=@9`(<9)Y'%=95&TT>PL;N2ZMX"LK@@DNS!03DA03A03R0N,FN1;E/8O4
M444`<]XA-]]ML(+#5KJUGNI1&(TCA9`JY9W.Y"V<<<'J170CIUS5>2RMY;Z"
M]>/-Q`K)&^X_*&QGCIV%6*.@!69XAO9M.\/WMW;R*DT<9,;,N1N[#'J>@]ZT
MZANK6"]M9+:YB66&0;71NA%#`R/"]_=WD%[%>RR-/;7)CVSJ@E1=JD!_+^0G
MG/R\8QWS6[52PTVUTR%HK5&4.V]V>1I&=NF69B23@`<GM5NFQ(*Y*76-4M?%
M$<%P+@037HMXX?LX\DQ&,D2"3'W]P.1NZ?P]ZZVJ"Z-8)J3:@(/])8[B=[;=
MV-N[;G:&QQNQG'&:2W'T+]1SM(D$C0QB255)1"VW<>PSVJ2J.H:@UJ\-M;Q"
M>\GSY41;:,#&YF/91D9.#U`[T`<S;:UK$]HMO<W"Q7<^K/9F6W12(4"EL+N!
M!Z8RP/6NA\/7TVI:';W-Q_K3N1CC&XJQ7./?&:SV\.W36DT1GL\S3FX95AE3
MYR>H<2;E..X_+M6CHTT1M39K;?9);3$<D&<A>,@J?XE(Y!^N<$$`6W]=@Z_U
MW-*N>U/4=5M_%.D6J"*/3KB1D<YW/*1&S8Z?*`0/<_3KT-5Y[&WN;BVN)H]T
MMLY>%MQ&TD%2>.O!/6A;AT,;1M1U6Y\2:M::@(HXH8XG@AC.[8&+\EL<D[0?
M0=/<]#5>.QMXKZ:]2/%Q.BI(^X_,%SM&.G<U8H#J5-2DO(K"1K"**2YX"B5M
MJCGDGZ#G'>N2GUO4!X+TO5&U1X[V>`;((;=&>[G/W5P0<+UR``<<Y&*[<@,I
M!Z$8-8TOA/1I18CR)T^PQF.V,5W+&8U/4`JP/YT(9L_#TR-XD\3&90LI6S+@
M=`?+;-=+XBUZ?1#9^38^>D\A$LSF58X%'5F:.*3'7^+:O!RPKG/`*A/%'BA1
MG"BS`R23_JV[GK77ZEHMAJSPM>1.[0YV[)GCR#C*MM(W*<#*MD'`R*[,=_&7
M^&'_`*1$B'P_>4M`UZXUB:99[&*V3REGMVCN#)YD3,P!8%5VM\O(Y'(Y-<QK
M'_)<M`_Z\&_]!GKLM,T'3M'FN);**1'N"-Y>>23`!)"J&8[5!9OE7`YZ5QNL
M?\ERT#_KP;_T&>M<M^*I_@E^0I_J>B4445YQ85YW\&O^10N_^O\`?_T7'7HE
M>=_!K_D4+O\`Z_W_`/1<=>CA_P#<JWK#_P!N(?Q(]$K/U328]4$1:XN+>2/<
M!)`5!VL,,OS`C!'MGC@BM"BN"$W!\T=RSEY_!EJ'DN8GDN9Q"\445RZA,,FP
MJ6"%]O?&3@],5+9>$+2U&E,\TC2:>@VD(GSOR68N5W\DDD!@#W%='16[QE9Q
MY7+^OZ;)Y(A1117,4>1>#?\`D5++_@?_`*&U;,Z/)!(D4IBD92%D`!VGL<'K
MBL;P;_R*EE_P/_T-JW"0JEF(``R2>U=>8?[W5_Q2_-DP^%'#:>FHVN@:K:Z>
MEU>3-J<L4DPD3S53C<^7906].>">F!6QX$9F\%Z:&BDCVQ[0'()(R>>"?\:V
M;74+*^@:>TO+>XA4D-)%*KJ".N2#4T4L<\*30R))$ZAD=&R&!Z$$=17(MON*
M_P""/KEM:MI%\9>'[IKJ5HVG=$@X")^Y<D^Y/J>G;O74U6DU"RAO([.6\MTN
MI1F.%I5#O]%SDT+<.AR.A-'#XNN,)IUW=7,TYFEAMRMQ:J#\HD9CG:0``,`>
MF1S7;U6AU"RN+J6UAO+>2XA_UL*2J73Z@'(_&K-'1(.K*>J6TEWITL,5U+;,
MPYDBQNQW`STR.,]LUY^P<^$O#7VAK4:=]C<RF\4M$9<#8"-R\GY@#G@D'KBO
M2)[B&U@>>XFCAA09>21@JJ/4D]*KOJ^FQVL-T^H6BV\Q`BE:90DA/0*<X/X4
M#N)I$C3:-92/!);L\"$Q2,69.!P2>21[\U=HHIMW=R4K*QRD=B!X[O%O)FNX
M[C3B6CF`**ADQL"],8Z^O>IO!=A91:9+J=I9P6W]HR&4)#&$58P2$&!QT&?J
M36Y'J%E+>26<=Y;O=1C+P+*"ZCU*YR*ECN(9GD2*:.1HFV2*K`E&QG!]#@@_
MC26B_KN-[_UV)*X7Q!:-<>!=3N$NY8F\R>6Y6/`,K!BH1CUPN`,=PH[5W58N
MH[=(E:_CU&TLXY7'G1WC;8I&Q@$-D;6/'J#CIGF@$<IKBJ_B^(NJ-(&M%BA=
M<S2J2=YB;/RH`?G&#D#G%=CX>9CHD*L#MC>2.(EL[HUD98SGW0*?QJE=WLDL
ML-CJ&JZ;I_VCI%#<YFF!.`$+;<9Z9`)]"#S6]##';PQPPHJ11J%1%&`H'``I
M]!6'')4@'!QP?2O.WLV@M?$45SJ'FB+4+=YI;PG9,-D9*R;0=J'.#Q@#J,5Z
M+52'5-.N(YY(+^UE2W)$S),K",CKN(/'XTO/^MRC+\'^>-"/FJBQ_:)?LZQD
ME!%O.W:3U7'3VQ6_45O<P7D"3VT\<\+C*R1.&5A[$<&I:;$<+XUO-+;6++3C
M):0ZK*%87=U,$6TB#9++D\.>@QR>_`I=*W_\)9']S^T#=77VPC[Y@_Y9;O\`
M9^[MS[X[UV%QJ%E:3PP7-Y;PS3'$4<DH5I#Z*">?PJ&+7-)GOC8Q:I92788J
M8$N$,F1U&W.<C%)?Y@]3HOAE_P`D\TO_`+:_^C7K*U/Q-,NJZY;6'BJS\RVB
M(DAG:*,6C;T`(PCN``3N=U9`2O``8#5^&7_)/-+_`.VO_HUZZVNO,/\`?*O^
M*7YB@_=7R,KPW=R7OA^TN)9GGD92&F9T;S,$C<&145E.,@A5R"#BN0^#7_(H
M7?\`U_O_`.BXZ]$KSOX-?\BA=_\`7^__`*+CK>AK@J_K#_VXG[2/1*JZA8QZ
ME9/;2LZ`E65XSAD92&5AGC((!Y!%6J*\Z,G%W6Y9S4O@JRG:-IKV]E*2>:=Y
MC.Y]Y?=]SY3DG[N..#4,7@NWGL+N&\(B:ZNWN)%@"2``\*H,B$C`YRH4@DXK
MJZ*Z5C:Z5N87*A$4(BH,X48&3DTM%%<HSSKQ)_R4Z/\`[`P_]'&I:B\2?\E.
MC_[`P_\`1QJ6NO%_\N_\*)CU.4N[=X?B!8SRW4TJ2VEP5B_AB4>7PH'.3R<]
M?RJ/PJ+!->U$:25DL'@B8-%D*C@L"L@)),IZDG!Q@$<<]-_:%E]N^P_;+?[9
MMW?9_-7S-OKMSG%.MKVTO#*+6Z@G\IRDGE2!MC#L<=#[5RK8IZD]8WBFVDNO
M#EZL=U+;A87=S%PS@*?ESV!..1S6S4-U=VUC;M<7=Q#;PK]Z29PBC\3Q4R5U
M8:=F>>^()=2_L?00ME<MI\/V*3?%)&!+(70;2"X.`.G&"2,D8KT<'(!((]CV
MJ+[7;>5%+]HB\N8@1OO&')Z`'OGVJ:K;O?U)2LEZ!7!36D\%_P"+86U!Y)9;
M&+,\ZDA-WF#A4&0H'8#W/<UWM5$U33Y7N$CO[5WMO]>JS*3%_O<_+^-248W@
MYX/L5U!:V]@MO#-MCN=/A$<-S\H)8`$\C[I.3R/P'25!:7EK?VZW%G<PW$+=
M)(7#J?Q'%3TV]24<MXXMI9--MIQ=2I%%=09A3`60F9`"QZ\<\>_M6:[RQ^-V
M:ZA@FN#?*ENG(G$!C'SJP8?NP=VX$$$GU`KLKO4+*P\O[9>6]OYK;(_.E";V
M]!D\FE^WV?V[[#]K@^U[=_D>8/,V^NWKCWI+3^O3_(;U5BQ63<;O[=:,2F&2
MXLRD$N,[65CNP#QGYE..^/:M:JU[:6]Y;[+@$*IWJX;:R$?Q!AT(H`X>."VM
MO"6MK=P1ZB\6I2)";U%EW2L516.1URW:NAT+3K32[YK&PC58;2TCAD90,%\L
MV#[\EC_OCUJ6U'VZU9[7Q(;BV4D--#Y+,,=06`Q^F:T--ALX;&/["RO;N-ZR
M*^_S,\[MW.XGUS1T^[\@_P""6ZY;6K:1?&/A^Z:ZE:-IY$2#@(G[ER3[D^IZ
M=N]:^NWES8Z8);0Q"=[B"!6F0NJ^9*D9)`()P&)ZBJ$D^KPWD=G+XAT)+J49
MCA:Q<._T7[1DT+<.AS_@_CQ/(0%,DD4YG5!B2$^;\HN#GYV(^Z<#`!QD<UZ#
M7(:AK6IV=GJ3P>(-`N;JPMY)Y+5+1M_R*200+@E?3..]=?1T0=64]4MI+O3I
M88KJ6V9AS)%C=CN!GID<9[9KSB>/_BDM"D,MN\ITQTMX+@L")>"KQ$`@RCH!
MP3DX/6O3Y[B&U@>>XFCAA09>21@JJ/4D]*KMJNG):17;ZA:K;2D".8S*$<GH
M`<X-"_K\1W+/PZ\W_A(/$GG_`.N\NRW_`.]Y;9_6MCQGJMWIDFFBVU%+-'D8
MR)YJ))<8QB./?%(K,<G"?*Q['@UF^`_^1K\5?]NG_H#5WM=F.?[Y/^[#_P!(
MB1#2-O4QM&N[RXU/6X+N9)%MKM4A"Q[-J&)&QU.3ECSG\NE<IK'_`"7+0/\`
MKP;_`-!GKT2O.]8_Y+EH'_7@W_H,]:Y;\53_``2_])"?0]$HHHKSB@KSOX-?
M\BA=_P#7^_\`Z+CKT2O._@U_R*%W_P!?[_\`HN.O1P_^Y5O6'_MQ#^)'HE%%
M%><6%%%%`!1110!Y%X-_Y%2R_P"!_P#H;5J7[QQZ=<O-;M<QK&Q:%(]YD&/N
MA>^>F*R_!O\`R*EE_P`#_P#0VJ]J^IC3+(R+$TUP^5@@0$M(V"<`#)X`).!T
M%=>8?[W5_P`4OS8H;(X[25@UVVU:+46G@U&[C69M,$4D!CB0$(F&52X]2.#T
MZ5U?AF*2#PMI4,T;QRI:1*Z.I#*0HR"#T-<_]LMETN4RP7D6MQW$;Y:-/-,\
M@PA`#[0I'R[2PPO!Q70Z!K46N::+A4,4R,8YX2<F.0<$>X]#WKEOO\OZ_$#4
MKCM<D:\\46VG"QN8+598I[F]CL9'\]U.4C#JI``."6)P.GK78T4ENF/H<=I$
MCZAXODG>QN=/MK,2Q6L)L9(Q*6(+RL^T+R1P,Y/6NQHHHZ6#J9/B.[-CHLMP
MNF2:E*A4Q6Z0F0E\_*<`$@`\YQQBN:6U1?"9@G@U">\O!.6NHM/93')(<L@5
MEWHK=,[<8&21Q7=T4=QWLT5M.69=,M%N(DAF$*"2-#D(V!D`^@JS113;N[DI
M65CAO,O=0\3W'V.QDL!9"862S64J1W$[#YI7D";0OH,Y8\^E6_!.GZAILVM0
MWMJ(@UT'$GFL_FL8UW,"47()YSZDC''/744EI]PWJ%<YXOO9[2S@2ST^2XNY
MF,:7"VCSBU4C#.0BD].,#K],UT=%)JX(X2.TN]+O;,Z2^IR.+>UMXXYK/;%)
M$I.\NY7<A`)."4.<<-TKNZ**INX#)2JQ.S*64*25"Y)'ICO7G,=O?:Q;WE\E
MG=6$BO;I%8?89(Q%;1R[L?,H5V/)VC/85Z3126CN'2QC>&1<?V=*;B$INN)&
MC=X1%)*A/#N@5<,>_`^E;-%%`''>+9'N-1@TN.QN4AN%4WFH16,DQ$:MD1*4
M4\D^O"]>IK6M(9;KQ1>W4\,BQ6D:06I=2`=PW.RYZ_PC/^S6W10M`>II_#+_
M`))YI?\`VU_]&O6-K,FHSZGK*:7-KL$BJ%D,]M=/%(OF)N:$+M4!4W`>6P=L
MGN`3L_#+_DGFE_\`;7_T:]=;77C_`/?*K_O2_,4':*^1E^'#<'P_9_:4D64(
M5_>^8&8`D!B)&9P2,'#$L,X)R*X_X-?\BA=_]?[_`/HN.O1*\[^#7_(H7?\`
MU_O_`.BXZWH.^"KOSA_[<2_B1Z)1117FEA1110`4444`>=>)/^2G1_\`8&'_
M`*.-2U%XD_Y*='_V!A_Z.-2UUXO_`)=_X43'J<5?&74O%PLX[*YLK:UD\X7"
MV,F+NX*%0?,"[0J@XR3SP.E3>$;.ZAND:6WF@6#38+242Q%-TREBV,_>`S]X
M9!SUK:GUV.WU);.2RO%5Y/*CN"BB-Y-NX*,G)X'7&W/&:--ULZA?W-F^F7MI
M);JK.9S$5^;H,H[<XYQ_B*Y8Z+^OZZ_D4_Z_KU_4U:P_%5]+I^EI-;::]]=^
M:%@"V[2B)CD>80H)``ST&>W>MRJM_>-90JZ6ES=.S!5BMU!8GW)(4#W)`J6-
M'(?V`J6'AN>'[;=2V]W'N:2%X]H+,7?RR!LR3U(Z8KN:YYO&.GA(72"ZD1T$
MDC*B_N07V?-ELGY@1A=W2NAJO\R>H5Y_#=B>^U#4I]#O1!:020V>F+IDH\Y2
MX)8DIM)9@,#L,D]Z]`K!F\5V=K)*EW:WEMM0O%YL8!G`8*=HSD?,RCY@O7/2
MEU&1^#TE-A=7=UYPO+NX,TZ/;20K&Q4`*H=02``!GN<UT54].U&/48I&6*2&
M6&3RY89=N^-L`X.TD="#P3UJY38D<EXTGE*P6%O83L]XCQ37\=D\_P!FA.-P
M&Q2<MV'3C)Z4DT"MKVE)8Z==*UM.'E:6WV1R(8MOFEP.7`PH!(/7*]"-O6-;
MBT:,2S6EW-$%+R20Q@K$@QEF)('?H,L>P-,'B&T.JBP$<_+B+S]H\OS2N\)U
MW9V\],=LYXHC_7]?U]XV:U5K]XX].N7FMVN8UC8M"D>\R#'W0O?/3%6:RM4N
MIS.+.W:2,"(SSRQ)O=4'`5!SEF.<<'H>^*E[#6YR-K:ZQK&E7]PEOY,]ZZ?:
M;*XCFM1'`JD+$C&,[F/\1`QSCCBNH\(174'A'2H;R#R)H[=%:,DY&!QD$`@^
MH[>]91OM!BTN[N;N/4+)[1@L@FG?SRQ7<H!5SEB.V?J!6SHE]-.I@G=Y/W4<
M\$S@!I(G'&X#C<""#CCH>]5??Y$]A/$O_(*@_P"PA9?^E458VN2->>*+;3A8
MW,%JLL4]S>QV,C^>ZG*1AU4@`'!+$X'3UK3\81S3>'O*MI_L\[WEHL<VP/Y;
M&YCPVT\'!YP>M9O_``COC+_H>_\`RD0_XTENF/H95VFH6NBZ_;(U[)9O8WTM
MS]KMA$(I&#%?+8#YP<MGYFZ#ITKT6O*M1.NWVE^(K9/'!O8["SD:Y0:5$J2@
MJ^4#@YS\I!(Z?45ZK1T0=3)\1W9L=%EN%TR34I4*F*W2$R$OGY3@`D`'G..,
M5QG]FW\5G;7:R7DYDANO.`T]N;B1E;;Y4B$B,X*Y(''<9KTFLW5=8724#O9W
M<\81I)'@0%8D7JS%B!^`R3V!H&7OAN)1KOB(31)%*([+?&GW5/EMD#V%;'C1
M;UI---J]]A)&8Q6T5P5F;C:C/#(ICSS\SADZ[ATSE_#^1)O$WB>6,[D=;-E/
MJ#&U=K?ZKIVE+$VHW]K9K,XCC-Q,L8=C_"-Q&3[5V8[^,G_=A_Z3$SA;E^\Y
M_P`(S-/J&JN&UI8MZA8M3BG!+`MEU,BA0#P`L?`"@X!.*QM8_P"2Y:!_UX-_
MZ#/7=6>IV&HM.MC?6UTT#^7,()5<QL/X6P>#[&N%UC_DN6@?]>#?^@SUKEOQ
M5/\`!+_TD)_J>B4445YQ85YW\&O^10N_^O\`?_T7'7HE>=_!K_D4+O\`Z_W_
M`/1<=>CA_P#<JWK#_P!N(?Q(]$HHHKSBPHHHH`****`/'/"]U#9>"8+JXD$<
M$*2R2.>BJ'8DU0A\1:3,D^JMK>C+J4D+):Q3WT>V!3R%)!."2`6QZ`<X%:O@
MW_D5++_@?_H;5NUUYA_O=7_%+\V3#X4>8VQT]M$F@OM<\.37LUS'<W+OJJR)
M>E3RCY0;%X```8#'YW['4='T33H+B#Q!I$EW!O\`,@BOH]CPEBPB7)'W,_*2
M!Z<`G'?T5RW*(;2ZAOK2&ZMI!)!,@>-QT((R#4U%%(`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@#3^&7_`"3S2_\`MK_Z->NMKDOAE_R3
MS2_^VO\`Z->NMKKS#_>ZO^*7YLF'PH*\[^#7_(H7?_7^_P#Z+CKT2O._@U_R
M*%W_`-?[_P#HN.ML/_N5;UA_[<)_$CT2BBBO.+"BBB@`HHHH`\Z\2?\`)3H_
M^P,/_1QJ6HO$G_)3H_\`L##_`-'&I:Z\7_R[_P`*)CU.5NK#4AXI;6=3^Q/I
M=FI-L#<NI@&/F<IY>&<]!\PP.E6_"F387<DW%W+=RR3HPPR9.4##_<V?A4P'
M]N7HD9=VFVLF8P>D\JG[WNJGIZL,]@:RUU*]FUJYEBTU8KVTB1IX8YQ(9823
MA&P,+*`"RC)'.,_-D<B[%/N=;6/XEM=7OM)-KH\L$,LKA99))"A$?\04A6PQ
MZ9QQ6G;W$5W;QW$#AXI%W*P[BI:`3L<3<^#KJ>.T2&"PMUAMU@C7S6<V3*^[
MS(F*`LQ&,Y"].IKMAP.N:**=PL%<;!X=UBXN-4N=6M],N;F[C,<4AN)&2-`0
M5C";%VCN6#9R`:[*BD!C>'M&;2(;II,":ZF\YU$SRA/E5<;W^9ON]3ZULT44
MV[@8WB+3[_4[-K.V2R>"9"K_`&C<&B;^&1"`02O7&!SCYA6?#X9NHM5C=IXY
M+07:WK2,Q\UI!$(]NW&,'&[.?;'>NIHI+0'J%8VJ22Z?>F^5D2*2W,+32*62
M%P249@"#M^9@3D8X^M;-!`(P1D&@#EX=%G:QUB>Y-C"U]&2D<+[H8WV%3+N*
M@Y;/)Q^)JSX<664+/P;:&UBM87`XE*C+NI[H3@#@9VD]"*O#0=(5]RZ79@AM
M_$*XW9SG&.N><UHT`8_B7_D%0?\`80LO_2J*MBJ&L6$FI:=]GAG2"59H9DD>
M,NH:.19!E01D';CJ.M5OLWB3_H*Z5_X+)/\`X_0!DZ_I3VFG>++X>4MO<:2T
M<:)P0423.1C'\0KKJY[4-)U_4M,NK";5],6*YA>%RFFR!@K`@XS/UYKH:`"N
M;\4Z5JVL&UM;46KZ;N+7<$MPT+3XZ+N5&POKZ]*Z2B@`^'X*^)O$ZE%0A;,;
M5.0/W;<#VKH/$NCWVIS64M@8TE@+`2F[F@:(MCYP$R)`,<QN,'CD=\+P)_R-
M?BK_`+=/_0&KO:[,;_%3_NP_](B3#;[S"T?3-0M]9U&_OC;@W*QH!#,\@?9N
M^;#C]WP?N*2`<G.2:YC6/^2Y:!_UX-_Z#/7HE>=ZQ_R7+0/^O!O_`$&>M<M^
M*I_@E^0I_J>B4445YQ85XY\+_&OA[1?"\\&H:AY,DEV\B+Y,C97:@SPI[J?R
MKV.O/_\`A27P\_Z%[_R=N/\`XY79A\33ITITJD6U*VSMM?R?<EIMW1I_\+-\
M'_\`07_\EIO_`(BC_A9O@_\`Z"__`)+3?_$5F?\`"DOAY_T+W_D[<?\`QRC_
M`(4E\//^A>_\G;C_`..4N?"?R2_\"7_R`6EW-/\`X6;X/_Z"_P#Y+3?_`!%'
M_"S?!_\`T%__`"6F_P#B*S/^%)?#S_H7O_)VX_\`CE'_``I+X>?]"]_Y.W'_
M`,<HY\)_)+_P)?\`R`6EW-/_`(6;X/\`^@O_`.2TW_Q%'_"S?!__`$%__):;
M_P"(K,_X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\`'*.?"?R2_P#`E_\`
M(!:7<XSPUXETC3_#]K:W5WY<R;]R^6YQER1R!CH:UO\`A,M`_P"?_P#\@R?_
M`!-;O_"DOAY_T+W_`).W'_QRC_A27P\_Z%[_`,G;C_XY6M;$86K4E4E3E>3;
M^)=?^W!)22M<PO\`A,M`_P"?_P#\@R?_`!-'_"9:!_S_`/\`Y!D_^)K=_P"%
M)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRLN?"?R2_P#`E_\`(#M+N87_
M``F6@?\`/_\`^09/_B:/^$RT#_G_`/\`R#)_\36[_P`*2^'G_0O?^3MQ_P#'
M*/\`A27P\_Z%[_R=N/\`XY1SX3^27_@2_P#D`M+N87_"9:!_S_\`_D&3_P")
MH_X3+0/^?_\`\@R?_$UN_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\`)VX_
M^.4<^$_DE_X$O_D`M+N87_"9:!_S_P#_`)!D_P#B:/\`A,M`_P"?_P#\@R?_
M`!-;O_"DOAY_T+W_`).W'_QRC_A27P\_Z%[_`,G;C_XY1SX3^27_`($O_D`M
M+N87_"9:!_S_`/\`Y!D_^)H_X3+0/^?_`/\`(,G_`,36[_PI+X>?]"]_Y.W'
M_P`<H_X4E\//^A>_\G;C_P".4<^$_DE_X$O_`)`+2[F%_P`)EH'_`#__`/D&
M3_XFC_A,M`_Y_P#_`,@R?_$UN_\`"DOAY_T+W_D[<?\`QRC_`(4E\//^A>_\
MG;C_`..4<^$_DE_X$O\`Y`+2[F%_PF6@?\__`/Y!D_\`B:/^$RT#_G__`/(,
MG_Q-;O\`PI+X>?\`0O?^3MQ_\<H_X4E\//\`H7O_`"=N/_CE'/A/Y)?^!+_Y
M`+2[F%_PF6@?\_\`_P"09/\`XFC_`(3+0/\`G_\`_(,G_P`36[_PI+X>?]"]
M_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4<^$_DE_P"!+_Y`+2[F%_PF6@?\_P#_
M`.09/_B:/^$RT#_G_P#_`"#)_P#$UN_\*2^'G_0O?^3MQ_\`'*/^%)?#S_H7
MO_)VX_\`CE'/A/Y)?^!+_P"0"TNYA?\`"9:!_P`__P#Y!D_^)H_X3+0/^?\`
M_P#(,G_Q-;O_``I+X>?]"]_Y.W'_`,<H_P"%)?#S_H7O_)VX_P#CE'/A/Y)?
M^!+_`.0"TNYA?\)EH'_/_P#^09/_`(FC_A,M`_Y__P#R#)_\36[_`,*2^'G_
M`$+W_D[<?_'*/^%)?#S_`*%[_P`G;C_XY1SX3^27_@2_^0"TNY0\"^.O#>C>
M#;"PO]1\FZB\S>GD2-C,C$<A2.A%=%_PLWP?_P!!?_R6F_\`B*S/^%)?#S_H
M7O\`R=N/_CE'_"DOAY_T+W_D[<?_`!RM:V(PM6I*I*G*\FW\2Z_]N"2DE:YI
M_P#"S?!__07_`/):;_XBN+^&/C/0-"\-7-KJ5_Y$S7CN%\F1LKM1<Y52.JG\
MJZ'_`(4E\//^A>_\G;C_`..4?\*2^'G_`$+W_D[<?_'*J&*PT*4J2IRM*WVE
MTO\`W/,.65[W-/\`X6;X/_Z"_P#Y+3?_`!%'_"S?!_\`T%__`"6F_P#B*S/^
M%)?#S_H7O_)VX_\`CE'_``I+X>?]"]_Y.W'_`,<K#GPG\DO_``)?_(#M+N:?
M_"S?!_\`T%__`"6F_P#B*/\`A9O@_P#Z"_\`Y+3?_$5F?\*2^'G_`$+W_D[<
M?_'*/^%)?#S_`*%[_P`G;C_XY1SX3^27_@2_^0"TNYI_\+-\'_\`07_\EIO_
M`(BC_A9O@_\`Z"__`)+3?_$5F?\`"DOAY_T+W_D[<?\`QRC_`(4E\//^A>_\
MG;C_`..4<^$_DE_X$O\`Y`+2[G/:WXPT*[\=)J4%]OM!I@@,GDN/G\TMC!7/
M3OC%9VL^,M+G$5E!<S^1/G[1/#&P9$_NKT(9NF1T&>^*[+_A27P\_P"A>_\`
M)VX_^.4?\*2^'G_0O?\`D[<?_'*TJXC#5+7A+16^)?\`R`)274Y2/QSX?A@2
M&$7$<:*%14MR`H'``%9=AXFTR#5#J%]J5S=S+"8(RMD8_D+;LO@D,V1U`4>U
M=_\`\*2^'G_0O?\`D[<?_'*/^%)?#S_H7O\`R=N/_CE9<^&WY)?^!+_Y$/>M
M8XBU\8:1::N1;M.+&Z+/*&B8"&3KN`]&[@?Q<]R:VO\`A,M`_P"?_P#\@R?_
M`!-;O_"DOAY_T+W_`).W'_QRC_A27P\_Z%[_`,G;C_XY34\+UA+_`,"7_P`@
M'O&%_P`)EH'_`#__`/D&3_XFC_A,M`_Y_P#_`,@R?_$UN_\`"DOAY_T+W_D[
M<?\`QRC_`(4E\//^A>_\G;C_`..4<^$_DE_X$O\`Y`+2[F%_PF6@?\__`/Y!
MD_\`B:/^$RT#_G__`/(,G_Q-;O\`PI+X>?\`0O?^3MQ_\<H_X4E\//\`H7O_
M`"=N/_CE'/A/Y)?^!+_Y`+2[F%_PF6@?\_\`_P"09/\`XFC_`(3+0/\`G_\`
M_(,G_P`36[_PI+X>?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.4<^$_DE_P"!
M+_Y`+2[F%_PF6@?\_P#_`.09/_B:/^$RT#_G_P#_`"#)_P#$UN_\*2^'G_0O
M?^3MQ_\`'*/^%)?#S_H7O_)VX_\`CE'/A/Y)?^!+_P"0"TNYA?\`"9:!_P`_
M_P#Y!D_^)H_X3+0/^?\`_P#(,G_Q-;O_``I+X>?]"]_Y.W'_`,<H_P"%)?#S
M_H7O_)VX_P#CE'/A/Y)?^!+_`.0"TNYA?\)EH'_/_P#^09/_`(FC_A,M`_Y_
M_P#R#)_\36[_`,*2^'G_`$+W_D[<?_'*/^%)?#S_`*%[_P`G;C_XY1SX3^27
M_@2_^0"TNYA?\)EH'_/_`/\`D&3_`.)H_P"$RT#_`)__`/R#)_\`$UN_\*2^
M'G_0O?\`D[<?_'*/^%)?#S_H7O\`R=N/_CE'/A/Y)?\`@2_^0"TNYA?\)EH'
M_/\`_P#D&3_XFC_A,M`_Y_\`_P`@R?\`Q-;O_"DOAY_T+W_D[<?_`!RC_A27
MP\_Z%[_R=N/_`(Y1SX3^27_@2_\`D`M+N87_``F6@?\`/_\`^09/_B:/^$RT
M#_G_`/\`R#)_\36[_P`*2^'G_0O?^3MQ_P#'*/\`A27P\_Z%[_R=N/\`XY1S
MX3^27_@2_P#D`M+N8GA/QGX?TSQ!X@NKR_\`+AN_L_D-Y,AW[48-P%R,$CK7
M7?\`"S?!_P#T%_\`R6F_^(K,_P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.
MW'_QRM:N(PM67-*G+9+XET27\GD)*2ZFG_PLWP?_`-!?_P`EIO\`XBN7&NZ;
MX@^,VA7>EW/VB!+1XV;8RX8+,<88`]"*U?\`A27P\_Z%[_R=N/\`XY6KX>^&
MWA'PMJ?]I:-HZ6]YL,8E:>20J#C.`[$`\=1SC([FG2Q6'H\W)!W::UDGNK?R
MK\P<6]V=71117G%A11534[]=+TZ:]>%Y5B7<422-"1]9&51^)%#=@+=17,<L
MMK+'!.8)64A)0H;8>QP>#7,VOCZPO;1;NUT[4Y[=@@62.-&5I6V[8LA\;OF7
MYON<_>ITGCJR@DVW&FZG`NX1%Y8D4"8KN\K&[.X+SG&WT8T6Z?U_7_`"_4QK
M_P`0^(=)U":U9S>1M?0VUO*D"K\XC1G1\=`^20>W(STI$UB_O+&]%AXHFNFC
ML)+J>:&&#=93K@B''ED`'+95P7&WKS6S<^.;6&>:&'3-0G:%F1W18PBL'>-0
M27!^9HR!@'J"<<XCM/'<4C1)<Z3>Q,S1"1U,;)#O"8+G=_><#Y=WKTS@6JM_
M6W],;]V6OW&-/JNJ6?B?3=.G\6Q1Q-;V\KK>WEK;RSEW?(5/LQW\`#"E.W.3
MFMOQ%?:F;;25TRZO)GN'?>^D+;;I`$)!'V@E`N>O.:MV7B^SO+.\NC9WT$=K
M`EP/-1<RQONV,@5CUV]#@\C(%5I/&\<,TD4VBZDDD<8D>$JGF1H-V]F!;;M7
M:.59L[A@&G+[B5N8;^,]=M=1;3O]"N[NVLC)<PK#ADF1%=ER)<G<-VWY%'H3
M@BFCQQK30S7DEQI%E9-,JP-=6TF55H1,@<^:!O8,J@8'/KP*O:I\0_#DNDWB
MWJSK;&8VC*;J&%Y."2>959!@$X;:Q'0'-;OA_P`2Z?KLMU;:?&Z)9E4R[1C<
M,<$(&+J/0LJY'(R*-[_U_7D%T8NC>)M4N=*UF_N%R]I&9EMWC&4`DERO`!)V
MH!]1]:S(/B!JEQIYN9#IE@@F\LSW,<A0$J\B)]Y?F9/)'7[S'KP*ZFY\6V]M
M?7=JVGWI-N619,Q(DSJH<HI:0<A6!RVT=>:HP_$;1Y[6*:*WO':9%>*)%C9I
M-Q=?E(<J<-&5R#C)7G!S0];M`NWJ8%MXV\0OXET477V6'3K^6XBDB%N0;?9*
MB+O8OEF).W(V@%^5.*U-9\::IIWBHZ/!902C>JJ2C[CY@!C.<X_@GS_NC\;4
M/Q`M\VZ76E7D$MQ-/#''YL!;?&SC:5\P,6.S^$%1G[V.:LZ?X[TK4]7M=/M8
MYV^TIOBG9HTC<8!^7<X9R.A"J<$<X&"3?1#>C=SDU^)6M-H\=T+*Q#O<F/>T
MUN$4[0?*;-UA'R=N68-W\OM6IX=\8:K>Z%XFN+Q81=:8]PUO&Z#+(K2;&8J<
M%<J4X`/R'DYK7U'QS9:;K<FD/87DUX%5HHX'@8S9=4X'F97EQRX4<'&<4L7C
M.&YU#3;6WTV\*7DBQO/)M5(6,;2;#@DEL+V&.?O=J%JO4%H]>FIDW/C34M*D
M>VU%].-P#(D;I&Z++(&APJJ7)SME;(R?NYX&15&Z\8^)8=(^V22:8BR6XD4Q
MP.&C+P/*IY9@0#&0>.=W;'.^GCF+[5-:/H]^UR)Y8;=(3&WVK9(4;869<8QD
M[MH&>":;'X]MYKHQ0:=<W`?`@6$KYDI*1MC:V`,"0YRW\!]:$]`LU=/_`(;H
M8LGC_54N=/AACT^[CFD91=QE(XKL!L9B\R<$8&3A?,)QC`SFKGASQ?JE[K]C
MINJ2V#-=627(2UM65LLN_G=,6"@'&0C*2/O*3MJS!\1[`PV[W=C<P--8B]PL
ML+X3"EN`^\;0V260#@XSTK2TGQA8:SK,VF6T,ZR1)Y@DE:-1(N<!D7?O93U#
M;=OOGBFM-'_6XG_7X?U\SEQXV\0C7H+!H].\NZFE6$^6L9VK*\>/GN%+LH3<
M=B-G=C"]31L_''B6U6.PFDM+NZ^R)*;BXCB0L756$GEK,KL@+;,+'VSOZBO0
M/$6J7^D:<MW86-M=D2*CI/=-!@,P4$$1OGDCTXK(;QU%8R7T6L:?):?8\AIX
MYEDA=@B,5#-M(/[P<LH&!G(Y`E-6?]?UN-E?7M?U/1=7$,NK:7;QM:0[I+J!
MA'$Q=@\I'F`[>%7&>"RY;U;J_BV_T^QT'5Y(VCM9(7FO[>.+>S+A%&W/S##.
M#].M+_PM'1#:-=K!<-;*BEI_.MA&'9F41[S*%W91CG.W`^]R,ZNH^,]-T[0K
M'6BDDUA=A666.2)=BMC!(=U+=>B;CZ`T[/\`$+J_]?U_7J<D?'.NV%DRW$NG
MRWL4<K&WDB(EF(>4%EVL!LCV#=P2>Y'&;6K>+];L$^RSWNEV]PDQ0R^0X^T8
M,9V1*SG#A9"3G=G;P!U&M%\1=(?4[.PFAN+6:\?;")Y(%+`L45@OF%B&8$#`
M)&,L%&#6A!XG27Q7-H;1P*R`[,7&9CA0Q9H]ORH<X#9.2#P*%W]?Z^0GM8Y.
MU^(.JW-Y*EO':7MJUQ';PSQ6Y3#2AA&642N<*R;6SM.3]U<<WO$FO:Y8>+UL
MM/U*R1#;K*MM/;ERP$<[,>'!P2BC(QCCKT-^?6VN1!JEWHLDEC%)NL&M[O=+
M)(6\M=T1VJ,EOERS`9R=M/;QY:[E6'2-5G?&'6-(LI)EP8SF0#<#$_3(XZ\B
MD]K_`-;#MK_7];&+<^.]3LDFN[E].2UDCG%I&T+JWFQK&54MOPY;<QP`#A?8
MUJ^(-;FL/$EI%_;2VR,(@EBJ(7N"S$,=KKND`&/]6X*]2#P*M0^-;.X$S1:?
M?%%C:2)W\I%GV[=P4M(`"-R_>VCGKP:IP_$G3)[1;N+3]2>U*,QF18G0,JLY
M7(D.X[48Y7*\=>1E]A(YP_$/59KNXD@O=/>UMA))$?LQ3[0/*=E3`F8AE*'.
M<'@Y5<5H/XZU&YN[^2RO-(BTRV*`74T+N@5Y&02%A(!L`7/H<]0.:ZBY\4V<
M&G6NH)#<36L]R;<-#"\K$#=\ZI&&9AE>PZ'/2L?_`(6-:_V;/>#2[W9%YH+L
MNQ%97=45]V'5G\OIL.W/-%M?P'T]3#L?'VLW$EK:6LUC?74EM(SH;?81*J-(
MO/F`E6`P,1@=?FR,5NWGB^Z7PSINKQR65C'?NSI+>QL46/#-&I`9?G<!0.>I
MZ'@%]UXNAO(DL7TJ]D2Y=K>>2&81K$"SJ!OW*P8A"1C`&>6'&4TWQ_HCP+:P
M6=U"8<PQVZ^5(<H55E4QNRL5!4G!/'N"*6ZM_7G^@KK1_P!?UN4AK&O1^#[K
M5[O5H8)WU)`HEM@J6L/FJAC/S`GOEF/>LY_'GB#3]&LS.EC<W,JPM]H*I"A#
MQ!PC>9,BAB21N!^B'I776_B^VN]`@U:VL+N<3S>1';0R0/(7YX)60H.G.6X[
MXJ"#QUI\S7!^SW'EQ()590"67;$>1D8.9@,<_=//:GW7]:(//^M64_$/B'5M
M/UV."SDB57@A813(&7>_G`Y(YQE5Z'M[FJD?C764\0:9I4]O9N997BFD79$)
MBLSQDQB28,-H0,559#SCCJ=J+QE#>^&KW6+"QGF-JYC^SF6'S&.0.0'.P\_=
M<JPQR!56+Q_`76&;1]029[AX8U0Q,)`K2`N"7'`\MB<X/INZT7LQ]&9VJ^+]
M5'B.]T:TGM8)8[BW2`_9_,PK2(K&3]X#@[C@;%!_A<D'%4?$+5$.^4:>?)&;
MBUCB<S")$WR7`^?_`%?#(!@_-CYC]VM!?BYX7:&.3[1C?(4Q]HM^%X._/F8(
MY'R@E_\`9X-=%JFLW-K]L2PLDNIK2W6=U>1U!#$X`V1NQ.%8X"D]!WX6T=06
MLOZ[G(P>-O$5YI4EU';Z=;RVZS-.LL,C`F)=Y5?G'52@SS@Y//2M+Q-XKO\`
M2M7^Q6LMD,VL<J0.A,\I=G5BAW8P@4,<J>`>G4:T7BF`Z9/?2VT@6&RCO=D3
M"1F1@>!T!8%6'7T]:R?^$\\/6_B"."XAFM=5N56WFBFEB#Q89MBE?,^8DL>8
MPW7D@8IM:V'%Z?UY?H96J?$2]L0;>%]/^U1^9YWG+_JE!AVLP+JHR)&/S,@/
M'(%7?$?B/5([7P_=:;J,%J+]5&VXMN96:2$`!2_'#.<<G&<'N+UM\0[&X*J^
MF:A!(]JMS'%,T`>16("!5$I+$Y7D#`SAB#Q4\'C>UN+T6JZ7J2N#LF9UB"PR
M?/\`NV/F=?W;<C*].>:-MQ+O_7<R+#QMJT_B33=*GMK3$N])G!2/S65W1FC#
MS!\#8"5"2?>ZCN:OXHO-+UG4?*U:*>6))6CTT1JWEHD98.ZX651D??W,AX``
M)R-O1?&5GKDKK!!)$L22F8R21N4:,H"N8V93]_J&.,8Z]*K^/(H[BW631-3B
MMY8S*TLBHI1-T8#XW8*'S`>"6'0KG.!?Y_U^!.FO]?UNC+_X3C5+F[O)]/\`
M[/N=.M9$50D;L]P'=T78X;'\(.<'/;UK,D^(NHVMC=7`U/2[V47($*PVW[J6
M,11,ZHQE7#`N2>7;@X7C`ZJ/QY9R2*O]GWL>Z+SD60+OD1N(V0!B,.<@!BI&
M.0*DMO'6ESZ_;:)+%<6NH3C_`%%P8U>-L$[2N_<>%)W*"G^UR*(Z.S*?5E6W
M\4ZG)H>L7<]O;P2Z=)]F9GC;9Y@;YI#\V3&%9&ZY^]S5?2M8US5KJ[N5U6U-
MK#I\AA6WM?W4\F]U6<$L3MPF0H..>IZU+8>*[*P>XT^'1=1\XW4ZP(DB2&[9
M92KE6=P<CJ=^`!P"<5-%X]MYY%$&G7-PLI(@2$KYDA`0XVM@#ASG+?PGKFIW
M7R_0=^71]'^IS:>.->L=,DO#/8ZE`VU(WCA"[#Y4+&3<9`I0;V)!8=/O@=-^
M3Q)K4_AC2KZT73XKNZ\QI&D`FC*HCME?*E(^;8.CMC/4XH@^(]@8;=[NQN8&
MFL1>X66%\)A2W`?>-H;)+(!P<9Z5I:3XPL-9UB?3;:&=9(HS('D:)1(N<!D7
M?O93U#;=OOGBKEU7]:$I6W.6NOB'J\-]J4<=A:L+55:.W+)YLA+*`H`E,AW[
MCM)C4`@<L#D7[7Q#J<FAZE=MJEG/.E[:+&;6+"I'((<C#,V0=[8)]_PFL_B&
MK6EQ<:EH=]9)"THW+)'*ORAF520PP[*I.`"HX!:K^I>.-,T?^RTU*.6TFU`9
M6&:6%6C&0,M^\PW+#A"QYZ4EM8KX7=G._P#":Z_:Z0;V6.RN$:V9H]L6UT*-
M$K.Y:14(_>EB,H!M^\,\=7H.IR^(/#D<CW$=M>RQ9=K22*0QY)"NN&D3D#(!
M+#MSBJ/_``GMB=3N],CTZ_FOK9P&MX##*S*0QWC;(<#"D[6PW3"DD"K.D^+H
M-16\,]E<68M5DD+RX*R1H[(67!S_``<@@'GOUH;5B;-61S%MK/B&P%I.VLM?
MQO'/+.E[;Q<JEPD0"&)4VG#$Y.X9[>FEHGC+4]1M-?GEL8=VGHSQ0HZ%PPW?
MNW5)';/R@Y*H3G[O%26GQ+TC4(E>QM+V[^8JXMV@D\OE`"660KR9$X!)Y.0,
M'$MSX_M+>TDG_LN_`C@\UVD"*D;_`#@1,0Q.XM&PRH8=.>119V_K^O(([V.?
MU#XAWMNEM';:CI=[([;9'MK9E1U8X$D;/+T4\$*LHSC)7/$]EXWUZ_O;NRA@
ML8I8Y8H4:<(QC+2*FYT2;>P8$L,I&.,9.<UOR^.]-MKGR[JVO+>$R&-+F14\
MI]KA&8?-D*'*KD@9+#&1S5`?%3P[MO"SO&]JH+1R30*Q)8*5(,GR$,0/WFP=
MP2.:$#O8RSX[U(7]N+J^TZTCC5C/`L#-(P%NS^;@MGR]W&!C[I^;J!H>$_%N
MKZ_=W0F:P\BTMR[&*`@S,7<*RE9G55PH.,MG/45KS^,K--+T[4K>WFN[:^7,
M8@92Y)95`'.T_,V,[L<=34EWXCG7P]'JUEIN\$MYL5W.L)B"DA@2H?+;AM`7
M()(YQS2?7[OF-6Z'(?\`"<>)6$=JPTY+B;33="58D0`F(R!E1[C>P4X4@(P/
M7(^[4=KXV\1Z7_9^G77E:K<D3>9/(L,#79661<(OFI@J$!(1)"<CIU/5+XMN
M_.NBVCYMXXIG@*7(\V1HBH=60J`G+<$,WW3["I[/Q+/=:_#I[:?Y%O+;K*MQ
M*THWL4W;4_=>6V!U_>!N#\O%/?;^M_Z^7H%[+7^MCD;KQUJL"O=)J^B3QK`=
MGEP.L;-O3<V7D524#;3\X7/5E.5&IKOB/5%31I].U""W%];(RI-;<N[30+G:
M6X&UVXY.">>AKI_$>IWFC:%=:C9V<%VULC2R137!A!102<$(_/'3`^M8L_CE
M=)GEBUW3C:")`7N+><2P*Q1I-NY@C9VJ>=N/4CC(FOZ^86=[_P!:6,_1O&VK
MWWBBUTFXM;0*?,CE92D9D*%P9(U:;?MRH&T(_7[W&*[^N(7XHZ(]F]VD%PUO
M'&&EE$]MY<;,Y14+^;LR2#R"5]6%:=_XVTVQ\+V_B'9)-I\RAB\<L(V#U.^1
M0W/&%+$GH#1T!;V.DHKCY_B/HUI=QP74-Q;B6Y>WBDFDA02;&V,Z@R;B`QQ@
M#=WVXYKL*72X=;!1110`54U+3+75K/[+>([1;E<>7*T;*RG((92&!!]#5NB@
M#GO^$'\.@$"P8#&`!<2@*>SK\WRN,`!QA@`!GBC_`(0CP]\X^POAT*LHN9<$
MD8+XW8\S'_+3[_O70T4`8UOX5T6UA>**T;8[!GW32,6(=I`22Q).YV/OFEM_
M"^D6L1CBM6P?+)+SR.3Y94IDLQ)P57ZXYK8HHN'F<SHG@Z#3(=2BNI([F.^`
MC,2+(L:1#=A`'D<C[QZ$`<8`J8^"M`,80V<O7+/]KFWR=<[VW;G!W'(8G=WS
M7044`8`\%Z"I=H[6>%V8,'AO)HVCQGA&5P8U^9OE7`Y/'-3V_AG3;.^-Y:"X
MAF:3S'VW+E6ZDKM8D!226(`&3R>:V**`.>D\&:5=7FH75ZLLTEW*)/EGDC\O
M`3!4*V%;*`[UPW09XIG_``A>F&]5WC4VD=K);Q0C?O7S)`\C&3=NR2%QC!'/
M//'244>7]=@.>M_!6B6<ZW%I;2I<(V]7DNII`7W,P=E+_.<LW)YY(S2:5X,T
MK38[%S#ONK1?]9&SQH[%F8L8PVTX9V(SG;G@UT5%%PM<QO\`A%-&_M,ZC]E<
MW1D,H8W$A56)5B0N[:,E5)P.2.:5/"^CQ:A;WR6SK/;X,>)Y-H(#*"4W;2<,
MPR03@UL44;`8MSX4T:['[RUD#!I'5X[B2-U9W#L596!4EAG@^W3BFOX/T)EV
MBR:/IAHIY(V7`4#:58%3A%&1Z>YSN44`<S_P@VD6UI-'ID/V:9X6AC:626:-
M`4"$^67P25`!]<#.<5:L_".CV,L4MO!+')%$D2E+B10`H500H;:&PH!(&2!@
MDCBMRBBX$%W:07UN8+E-\196*Y(Y4AAT]P*I7'AW2KIY7FM=S2NTCGS&!W,J
MJ2,'@X5>G3&1S6I10!C'POI30/$R73%U13*U[,9OD+%2)"^\$;FY!SS3M1\-
M:5JL=O'>PS2B"-HD/VF4,48#(8A@7!P#\V>0#U%:]%`&5%X=TR"XMIX(IX9+
M9=J>5=2H&&2<.`V'&22`P.,G%65TNU75&U'$S7)7:"\[LB#_`&4)VJ3W*@$]
MZN44`<_=^%_#T4=Y=7<1CA96DD>2\D6.#G<SI\V(CD;BR;3D9S4&G+X/>2T@
MT^^L)I)E\RW6.^\QY@N\%Q\Q+\O)EN<DG/-;&M63ZCHUU9QI&[2QE0DDCQJW
ML63YE^HY'7GI6#;:%K?VC2?M<EN8;.0S;OMLTKQ9R-GSKB;Y2`)&VL.>N:%V
M![7+%OX&T:*.Y26*603-\N+B5?*4%2H3#_*P*K\RX)VC)XJS_P`(MIUM820:
M?"D$NYY8WE+RJLC*R[BI8;AAVXR.M<]JW@?4]0\33WT5_!%9R'"`%@\:D!VX
MZ$^;'&?IG\<JU^&VK0'3RUV@6"X,CQ)<0A4/R_O(\68"L=IR`%)W'Y^30M59
MA?EU1WNDZ7IL&BZ7:VC)/;6"JMNZ/D912F>#@]ZKR^#=!GD=Y+)CYF_>HN)`
MK[RS$LH;!.78@D97/&*XN'X<ZU;0)&DNESLFHM>I)/\`,4W>H:-@VW'`P#\Q
M`=,9.OXQ\'ZIXCU5)[8:;'''`429P%F^975E)\MFV_,#PXZ$$'-.[>O5@NQL
M7_A'PU(HEOK8+']PAKJ1$8LQQN&X!CEV`SDC=@=:HR:#X:M-;M[>6\LU,,,U
MPUI<W!DG?>@C:4M(Y;;L4@\>Y-9EU\/YEOXS96NEBTCNHYH59V0V@62-V,8"
M$9?:P(R.W)R:U=>T'5-6U:5?L.E/IIB;:SW,D<K2F-DW.$3)&&*C#C`)/)P`
MNGW@K=>A#]E\'W6G6&FV6MVHANKKSH2FJ,\MTZ_*0DOF;R1P,AB1@"M"X\+>
M%YE+RP1A(&"/MNG10=L8"N`P!X2/Y3W`/7FL^R\-:U#J-C<O)&GEX#L-4N96
MBC#$F,[ABX!!(W.%*Y)&>,1W7@^_G\1:A?1II\27$HD%PKMYTJXC'EN-N`H*
M%A@GDC@<FGT_KR_K^M5K_7]=S8T[1_#C:?=:?I[I+;W*@RK'>O(VW`VX;<65
M0,;0I`';%64\,Z.DUO,+3,ENSM&6E<X+%BV<GG)=NOK7+V/@"<116^I"QN;7
M]SYL1)97"(%((*X(R.]5O#6@W>F>,+6*:S25[6W(FU$12@M^Z11'O=`K*"#C
M:QZG(4YR;C>C=CJH_#6B)+';1R70FMSYR(NI3[XU;C`_>9$9V_<^Y\O3BK-[
MH%K?WDTT[2;)HT1ECD>-U9"Q5E=&#*<.PX__`%\1-\/]4=-0B6UT,I=K''(T
MAWM-M:4F9@\3*)/G4]&^Z1D<$4O^$!U6]BFMU:&7[&\(B6\0K&9/+'G,I>-P
MZEPC9*$$AL8.&`M=PEH[([JY\.V=Q;ZAIR3I$+FR2U2)1_JH5W`<9R>6;GCM
MZ5&^C^&])N[(2W)M+B1C%")-2E1KDG)VME\S'D\-NQGBJ^M^$WUR^L7O4L[B
MVAC"SQ2J<.0D@X7!&,NIP?2B_P!&U>2#1[6*UTVX@AB2.]DFN&CE;:5.$/EM
ME25R0=N<#D4;[_UO_7S!^78:FC>"[\S/%-:S+9H+641Z@Q6`@;!N`?"R`?*&
M/SCIFIX-'\)W+W>BPM;7$Z*/M=M]L:28?>P9/F+9/F-RW)S]*SHO"6HS65W;
MWL>G96.&&U99&D+".1W\Q\H-K8;H,XYYYK3TW2-4T_6[ZZ58!;3R%O+%],PD
MW.#OV."L3*N[A#AR>=O&#=Z@]-OZ_K8OZ?X=TO2W=[6!][JRN\L\DK,"%!R7
M8DYV+R?3ZU7@\'Z%;JXCLC\Z&-B\\C';E3MR6)P-BX'0`8&!Q6[12%9&%%X.
MT&".1$LFPZE3NGD8JO95);*J.P7`7MBIK#PSI6F7*7%E%/#(H(.+N7;(3U:1
M2V)&Y^\P)]ZUZ*!F+<^%-&NQ^\M9`P:1U>.XDC=6=P[%65@5)89X/MTXIK>$
M-":(1K9&-5^Z8IY(V7[O*LK`@_(O(/KZG.Y10#UW.9_X0;2+:TFCTR'[-,\+
M0QM+)+-&@*!"?++X)*@`^N!G.*NZ;X6TG2KF&YM;=DFBA6%3YK[``H7(3.T-
MM4#<!D@8S6S11<+&'+X0T.:1WDLV.^-HV7SY-A#`@DKNQNPS#=C<`<`U=NM&
MLKR>UGE699;;_5O#<21'''RML8;EX'RMD<=*OT4`<[_P@WA[YO\`0Y<L1\WV
MN;(&6.T'?D+\[#:,#!(QCBM&UT'2[-2EO:*B&-XBNXD;&8LPP3C!)/\`+I6C
M10'F9,'AK2X$5!'<2!?N^?=RRE1N5L`NQ(&44XZ#%4W\%Z1-J-Q=3Q.\<L7E
M"'SI%49+EB0&PQ/F-@D97MC-=%11<#F]1\%Z7>07<<42Q&\8?:/,+RKLWAG5
M%+;8RQ&25'7D@FKC^&-*?[4#'<A;EM[HEY,JJV<[D4-B-L\[DP<]ZV**`,^7
M1;">*UCGCDE%J5,323.S`@JP)8G+'*J<DGI4%]X9TO4+6"VGCN%CMYFGB\B[
MFA97)))W(P/5CW[UKT4`9$7AG2H;VXNUAF::XC:*0O<RNNUL;MJLQ"D[1D@`
MG&32CPUI2W1N4AF20Q^7\ES*H'R[-P4-@/M^7>!NQQFM:BC8""\LX+^QFLKE
M/,MYXS'(FXC<I&",CFJ=YX>TJ_=FNK02%V#MEV&2$9`>#_=8C\<]:TZ*`,8>
M%M)^SO"T=U)O18S+)>S/+A6++B0N7!!8D$'(_*GW_AK2]3M+>UO8IYH[=2B%
MKJ7<5(PP9@VYP1UW$YK6HH#S,D>&M+5H&CBGA:"5Y4:&ZEC)+-N8,58;E+<[
M3D>U:U%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%1SSPVMO
M+<7$L<,$2%Y))&"JB@9))/``'>I*Y_QW_P`D\\3?]@JZ_P#134`'_"=^#_\`
MH:]#_P#!C#_\51_PG?@__H:]#_\`!C#_`/%5T%<_X[_Y)YXF_P"P5=?^BFH`
MZ"BJFHZA%IEH+F979#+'%A`"<NX0=3TRPJCJ'B6TT^]DLC!<SW:B/RX854M,
MS[R%7)`SB-B2Q``[T`;-%85KXIMI[VWL9;.\M;V:4Q-;SJFZ(A"X+%6*D$*<
M%2PSQV.%U/Q/#IUX;./3[V]NO,CC6*W\L%BZNPP7=1P(VSDCMUH!.YN45S\O
MB^QM]%N-1N+>\B>VF$$UF45IUD.#MPK$$X(;@D8YS5FZ\1V-GYOF^82L22PA
M0#]I#'`$?/S'<0,<<L.Q!H`UZ*1264$J5)&<'J*6@`HKG;>T_P"$CGN+N_>1
MK".:2&WLPQ5&V,49W`^_D@X!X`P<9YJ4>$=(M8R='M(='G'*2Z?&(1N_VD7"
MN/9@:`-VBLS1]3>_T47=P@2>)I(KA$!P)(V9'VY[;E./8BJ.E^+8=0,/GZ9?
M:='/;&Z@DNS#MDC`!)'ER,1@,#\V.M`'0T5B6/BBQO\`3+74$CN([>>;R"94
M"F%LX&\9X!.,=?O+ZU(_B*V70KC5X[>YEMHF(0(%#3X.T%,L!@GH21GKTYH>
M@&O17+OXS\NX6S;P_JPU%I%066ZV\S!5V#;O.V8Q&W\6>.E3S>)[B*2&$>&M
M7DN7A:9X%>UW1*&V_,3,%.>ORD^^*`.AHKG5\9Z9)`DD,=U*98()H8TC&Z;S
M2X1%!/WOD;.<`#G.,X;)XP2()"VC:G_:+3+#_9_[@2C<KLK9,GEE2(VY#GIC
MK3LT%CI**H:3JT6K02LD,UO-!)Y4]O.`'B?`.#M)!X(.02.>M7Z0!1110`V2
M1(DWR.J+D#+'`R3@#\2<4ZN9:VB\77DINXO,T2V9HX8V/RW4N,-)_NKRJ_[6
M6[*:N:-=S6]Q)HFH2F2[MTWPS-P;F'.`_P#O#A6]\'@,*`-JBJ&M:M!H6B7F
MJW,<LD-I$TKI"H+L!V`)`S^-9DGC;1XSIQ=Y1%?6;WJ3;/DCB5=QWG/!(S@#
M/W3Z4`=%17-3^,[>SM9[B_TG5+-$@>XA$L<9-PB#)V!7.&QSM?:?;@XGN/%4
M"P1RV-A>:D'MA=`6QB4B/."3YCIR,<CK0]-P6IO45B:7XD34GLD?3;ZR>\B>
M>%;DQ'*+L^;]V[8SY@P.O!SCC,FE>([/5[^XL[>.=9($WL9%`!'F21\8)[Q-
M^!'X.S0+57->BLF'Q!:3W,%JD<WVJ61XV@(&^'9]YGYX7E>1G.Y<9S3I->LH
MO$,6B-YGVJ2$RA@!L'7"DY^\0K$#'132`U**PK;Q1!=7"[-/OUL9"PBU!HU\
MARH)/1BX'!^9E"G'!Y&8XO%]JT#W4^GZC:V'DF>*\FB4QS(!G("L77C&`ZJ3
MVS0!T-%<]_PEL,.\7VEZC8OL\R)+A8R9D#*I*['8#!8<,0W/2I=9\5V&A/.M
MW'<D0+`[M%&&`$LAC!ZYX*DGCIZT`;E%<_JGBN'3;>\GBTV^OXK-%DG:U,.%
M0KNW#?(N1@=LGVJ*[\:6NFVIGU+3=0LV58G>)UC=D623RP3Y;L.O)P3Q[\4!
MTN=+16-<^)+.W>:-(I[B9&C2*.`*3.SJ64)D@=`3DD`8ZXJQ::LLUC/=7=G=
M:=]G!,J7:J"H`SG<C,K#'=6/IUH`T:*YQO&$,5G<7ESI&JV]M'`;B.22),3(
M,<KAR5/(X?:>>G!QH:IK2:;)!!':7-]>3AFBM;8)O95QN;+LJ@#(Y+#J,46#
M<TZ*YQO&%N3!%;:9J-U>2>9OM(UC62'RR`^[>ZKQN'"DDY!&1S4C>)I&OFMK
M/0-5O-B1O))'Y$8CWC(!$LJ-D#J-M`7-^BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"L/QG!-=>!?$-O;Q233RZ9<I
M''&I9G8Q,``!R23VK<HH`Y__`(3+2_\`GUUS_P`$-[_\9K'\6>)+34_!NN6%
MG8ZY)=76GSPPI_8=X-SM&P49,6!DD=:[BB@#-UW1XM>TE].GV>3))&SK)&'5
MU5U8J5/4';C\:QO^$%LK.^DO-#%KI4H,<D"6]HJQ+(JR*2Z*5WAEDP1P>!S7
M5T4!N<C-X3U22_@U9-9M/[82;S'E?3V:$J(V0(L8E#`#>QR7)R3]!->>&=3N
M+N/4(M5M(]022&4NUBS1%D21#\GF@X/F$_>XQWKJ**+B22.4;P2M[<)-JFHS
MSN96N9OLKR6N^8HL:LI23<JJ@*[<G.XY)JU9^%DM8M&B:Y$R:3-(]N9(\MY9
M5T1-Q).5#`;N^VNAHIW8WKN%%%%(#G(9YO#5S<6\]K<3:7-,\\-Q;QM,86D?
M<R.JY;&YF(8`J!P=NT9L7'B.-QY.E6MSJ%VP^1$B9(QR!EY&&U0,YQDM@'`/
M2MNB@#-TK2WL-$6REF62=P[SRJN`\LC%G8#/`+,2!G@<5CP^!-*M/#9TBRMK
M2S::&."\N;:U6*2X08W@E2""PR,Y.-V>:ZJB@#F5\&P0:?K6GVUW/]CU2`HR
M7,DERR2%2A?=(Y)!&SY<_P`/7FM/4]&BU/0)-(<HL,D:QD&,,I4$<;>F"!C%
M:=%#UW`Y/6?`FFWEC9VFF6&B6<-O<FX-O/I:S6\A*,OS1JR#/S9SGM49^'VF
M7]O%%K-GI-RD5JUO%';:<(8X<MNW1J6?8?H>>OM7844`<NWA*=Y4NFU11?0P
MVZPS);!55XO,^8INP0PE(*C'?!'&(Y_"NISW,>J-J]G_`&RDR/YQL&\C8BR*
M$$?F[O\`EJQSO//MQ7644[L+_P"1FZ/I<FG)<R7-R+F\NY?.N)5CV*6VJH"K
MD[5`4#&3]:TJ**0!6!XGNKD);Z?!!>>3=DBYN;:)G,48QD#:"0S9P#V&3G(&
M=^B@#%@UFRM;>.W@T[48H8E"(B:?*`J@8``V]*H:U>QZA;QR6MOJ<&H6K^;:
MS'3Y<!NZM\O*,,JP]#D8(!'4T4`8MU;R>*/"+P2Q3:=)?6^'CF3+PD]01GDC
MZUD)X`MSYR37TDD$CS!4";3'"ZN!&#G^$R.0<=P,<5V-%`K(Y2\\*:AJT#Q:
MMK,,XCADBM3%9^64+KM+OESO;;D<;1R>.F+D/A>.VUG4+Z"Z9(KRV,7V;9\D
M;DDLZ\_Q$Y(]<GN:WZ*'KN-:'.3^#M.O_P"QTU."UU"#3;5H!#<VRR*[$(-^
M&R`1L/K][K5+3?!U_H.H&?1M3L(+=HA"UO+IS,%02RR`)ME4+@2E>AZ#Z5V%
M%/F=[B2LK&=;Z5'!KU[JH*F2ZABB("8(V%^=W?.[]*QY_!<5Q?RZHVH70U-K
MM;F.59I1$@7`5?)W[#\F5)(R=Q/%=312\Q]+'.6GAR_MA'8G6%;18MPCM5M=
MLI0@@(\NX@H,]D!X&2><Q#POJ,UA_9M]KK2Z?'"8H5AM_+FZ85I'+,'*\$85
M1D<@UU%%`;G,3^%[W5-[:QJT<\B0O%;&VM/)$>XJ=[`NVYOE'3`Z\4H\,7MU
M,UUJFJ0SW;26WS06ABC"0R&0+M+L<DDY.[TX]>FHH3L'2QS$?@Z.#3M>L8;U
MUM]30QQ(T>1:KLV[5YY4$D@<8''0"K>H^'1J&H)=&ZV!1;C9Y><^5+YG7/?I
M[>];E%%]GV!ZJQRD/@L6<MS+9:@T4GVE;BR#Q;TM<(4V8R-R89N,C`.`1@5/
MH_A"WT^UU5+C[*SZJ,72V=J+:(\$$A,L<D$Y)8DFNDHH#K<Y2Z\,:SJ&DW.G
M7GB&-X6MF@@V66T\X`>7YSYA`'\.P<GCIBPVB:[)+#?/K-@-3@5XHY8].<0F
M)MI*O&9B2<J""'7'H:Z.BG<5D<G<^$;N6S:(7]A/)/*TUX+_`$U9XI7;'S*@
M=2I`50/F/`YR>:I2?#]QJ$5W'/HUV\<4,:S:OI'VN=3&,9$GFKC/7IUKN:*5
9QAVYHHHH`****`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`0B`S$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`I&.%R>@ZTM8&K7
M$M_=C1K)B&8;KF0?\LT]/J:`)M/U"XU+4II(2!IT8\M"5YD?U!]*V:AMK:.U
MMD@A4+&@P`*FH`****`"BFALMM/6G4`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!4%W-)!:RR10F9U4E4!QNJ>D
MQ0!4TW48=2M%GA/LRGJK=P:N5S^HVD^EW1U6P0LA_P"/JW7^,?WA[BM+^U;0
MZ4=0$H-N%W9[_3ZT`0ZSJ9L+=4@7S+N8[(8_4GO]!3M(TW^SK8^8V^XE.^:0
M_P`3?X53TBUEN[A]8O5Q-(,01G_EFG^)K='`H`6BBB@`HHHH`9(A9<KPPY%)
M#()$W=^A'H:DJDS>1?K_`'9AC\10!=HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*.U%(>AH`P=1\1K8W[VK6K.$`
M+,&[&H9=#M_/^V";&G_Z]K;'!?'!^GM56\MQ>>);Z`_QVQQ]<"JYU!Y?#$-H
M#^]:40D=]O7_`.M7B1Q]2$ZGM'=:V^70]!X:,HQY=]+_`#-G2?$(U*\-N+9H
M\J64ENPK5EO+>W<+-/'&Q&0&;%<[I\"VWBQH$'"6^!^0JI?Q_P!JZAJ4NX$6
MT8$7U'7^M.&-K4Z%Y>]*[7;;<4L/"=3W=(V7XG9[AC.>*K#4K-IO*6ZA,G]T
M.*YV[U*5O",+JV'=A$Y!Z8__`%5H6&@V!L;=F@S)M#E\D'/7-=*Q<ZLU&DEL
MF[WZF+H1A%RJ/JU]QIOJ-K%(8Y+F%7'56<`BI8YTE7=&ZNOJIR*XR[FM(/$=
MXUY;^='T"X[X'-.T]IK30-1N8P8TD8+$/3W_`%K"&9R=1Q:5E?UT-7@TH)WW
MM^)U4FIV43['NX5;T+BH]2R]K'+&RDHX8-GC'?FLO2M$LI]&CDFA#R2J6+GJ
M*Q_/F7P5JR*['RAA3[$\UK'&U8N/M(JTDVK?J3]7A)M0;T:3^9>;QI+=7$D6
MD:3/?+&<-(/E%:6C>('U)KB*YL9K*:W`9Q+TP>X/X5C:/-=Z?X&M)M'LUN;A
MVRZ]<Y)R>/2ETKQ!>ZW9ZQ!>P10O;P,"$!R#@Y!S]*J%>2:YI:OI;3[RZE*+
M4N2.BTO?7[CH_P"W=*.`-2M,GI^^6IY-2LH)1%-=0QR-C".X!.>G%>8^'+K3
M!';6MSH7VJ628`7&#QD\=NU7?%E@;WQ5=H@/F1V0E3'7*\TEC9NE[1)/7S&\
M'%5?9MM>>AZ'+>0031Q33(DDIQ&K-@N?84+?6SW+6R7$;3H,M&&^8#W%<!_:
M1U6]\)W+$&7S"DA']X$?SZU=L6\OXC:L^.5@8C\EJUC>9Z+2Z7WJYF\)RIW>
MJ3?XV.NN=6L;)PEU>00L?X7<`_E3I-0M(;<7,ES"L!Z2%QM/XUPW@[2K371?
M:CJ<0NIVEVXDY`XR:?XMT<:=;::]E:F:QM7;?`0649.>>^.U'UFI[)U;:=`>
M&IJK['FUZ]CM[34+2^0O:W,4ZCJ8VSBK5<MX2O-(OH[B?3[-+2X;`FB4]<=#
M74UU49\\%(YZL.2;C^84445J9A1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
MA^Z:6D(H`Q8M/G'B:2^RGDM'M'//053@\/2QZ_\`:3L^RAS(HSSGZ5;B)_X2
MR<9./LR\9XZUN#I7FT\+2K7;6TF_F=3K5*>B>ZL8+Z;>)KMS?1^7M>$JG/.[
M`ZU6L?#$?V?-Z7$[$EO+DP*Z>BMOJ%%RYI*^_IJ1]9J6LGV_`Y:W\/W(M+RS
MF9!"[;X6!S@CID5-:6VOP+%;[H!"A`\PG)V^F*Z.BICE]*%N5M6\QRQ,Y)J5
MG<P8=)F&O75U,J-!,NU><GM4-CHES#:WUC.R_9I>8F#9*^^/RKI**:P%%._K
M^.XOK$[6]/P.6ALM?M+0V<7V=H^0KEN0#5>_@71-&BLVVSO=RXF']]2.0/TK
ML#7).W]M^+T5?FMK,9/ID'^IX_"JI8*G"7-=NRLK]`GB)R5MNI4M=$\3:#YD
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M2OZ'*^&M`N[#4+S4K_R4GN1CRH?NJ,Y-=4.E%%:TJ4:4>6)G4J2J2YI!1116
MA`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%':BB@#"B_P"1NN/^O9<?G6[6
M%%_R-LY_Z=E_G6Z.E<N%VE_B9K6W7H@HHHKJ,@HHHH`**0G%8&I^(TB?[)IZ
MFZO&X`09"_XT`/\`$6L_88/LMO\`->3#:BCG:#W_`,*F\/Z3_9EAB0?Z1*=T
MI]/;\*K:+H3P3F_U!_-O9.>3D)_]>M\#%`"T444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`$'V=!.9A&OF%=I;
M')%3CI11222V`:P)&`VT^M57-_&?D2&=>WS%&_J*N44P,XWU\H_Y!4Q/^S*F
M/YU7DO=:DX@TE$_VIIQC\A6S10!SS:-JNH\:EJ02'_GC;+@'ZFM2PTJSTR/9
M:PA<CECRQ_&KM%`!1110`4444`4Y-6TV*\%G)J%JETQ`$+3*'.>GRYSS4MS>
M6ME`9[JYA@A!P9)7"*/Q-?/OC[1Y-3^)?C*XM5_T_3-,MM0MG"Y(:,Q$XX/\
M.?TK;\2:[!\1KGPCHT:A[66U.LZ@JX(78C`(1SCYMPY]10![3!<P74*S6\T<
MT3C*O&P96'L1UJ3(KQOX<76I67P)LI]*O-,LKA;B4-<ZDQ6*)/,;<WU'8'BK
M'AOXBZ@GBK5M,U;5M+UJPL]+?4?MNF)@+LQN7@D$X-`'KF1ZT;AZUYCX,U?X
M@^*(=.\02RZ/#H]W<$M8M$PD%ODC<'YRW'`/_P!:J7@_Q=XW\2Z]?RNVF1Z#
MI-_+#=2&,B65!DX4#(RH`].O>@#UO</6HY[F"VA::XFCBB09:21@JJ/<GI7C
MB>-O'6L^%M6\:Z7+IEGHMJ[M;V=Q`7DFBCQN);MGG\0>G6LKQ3XAC^(_B#P%
MHSM-!HVK1?:KJ"*7[[AF4H3C^$QL,^Y/84`>QZ9XO\.:S<M;:;KEA=3J<>7%
M.I8]>@SST/2MG(KQ\S>`=.\9:5I?_"$:CIFH#4!'97HLQ#')(C8W!]WSIT['
M@UEZW\7K^75=;_LW6]*TJVTUFBM[:\MFEEO73.2"/NY(`&:`/=,BD:1$1G=@
MJJ,L2>`*\DUGXC^()=,\#WN@6=DEQX@:1)+:Z)9-PV@?,""!DD_E5S0?%'B>
M+QEKOA3Q.]E=2PZ>;NVFMH=J,O?<,]\C@^AH`]!T?6]-\0:9%J6E727-G*2$
ME4$`D'!ZX/45?W`BO#-%\>ZE8_##PY%HNG:?%K6M7TMM;110>7!'AR&;:#C/
M*_F371^(M>\=^"_!VI:AJ3Z;J,PGB2WN;:!@(8V!WO(GL0,8/?GB@#U#(-5+
MS5]-T^18[W4;2VD8;@LTZH2/7!/2N<\`ZI?ZQIT]Y=Z]IFLPLX$$UA$8]G'*
MNIY!Z=:\Q^,3PQ_&#PS)/I#ZO$+/YK"--S3_`#R?*!@Y]?PH`]SM-2L=05FL
MKRWN50X8P2JX4^^#5G(]:\BU?Q(_A'X5KKWAWPS%X>N)KY4DL;FV"DC)7+#C
MJ`,'TJ>+Q1XVT?Q]H>D>(VTM[76X9#$EI$?W,H&=I).2`<<]P30!ZKO7)`8'
M'7':EW#UKPWP/_;]C\3_`!I=7FJ67EV;1RZKLM6_?*$<CRQGY<8/KFL^7XV:
MH;1M=35-(6+[0-F@F%C.8MV.9>@;&3_G%`'T%N%&1ZUY/XG\8>,9/B#9>&O"
MRV`%[IB78:\0D0G+$L2.V%`Q@]:KZ]XX\26GC,>&WU;2-":.UB9+J]MV:*\E
M91OVMG"@,2!F@#V#(K)U'Q3H.CWD-GJ6L65I<S8V133JK'/3@_6IKJZ>PT.>
M]G`DD@MFED$9`W%5R<?4BO(_A%X1T7Q=X=O?$OB.T&K:G?W<BR2WGS[0N,;1
MVZ_H`,8H`]JCFBFB26*19(W`970Y#`]P:JZKJUCHFEW&I:C.(+.W7=+(5)VC
M..@!/>O/];U6_P!#U_1/A[X(M[:TF,!GDGN5:1+>`%N@)R22#W]/7(Y;Q#XO
MU>Z\/>//!_B%[2?4M.M%FCN;5"BRQEHR1M/0C<OY^V:`/6Y?%VAP?V-YE^%_
MMK']G_NW_?9`([<<,O7'6MK<*\1U?_FB_P!8O_1<-:/C?QAXF\/3:M<Q^)_"
M]NMJ=UMIA'F7$J9XW`D$,>>!Z4`>E77B+2K+7;'1;B[":C?*S6T.QCY@4$GD
M#`X!ZFM,$'I7AOB?4=7UCX@_#K4M'BM(]3O=->:-;@DQ1ET)8G&"0H)(]<5N
MZ3\0]9T6\\8V'BDVU[+H,"7"36<?EB0,!A<=LEEY[<T`>K$XI-P]:\7O/&_C
MW0O"VG>--5?2Y-+NYD9],CA*R+%)DKB3GG&#^57M<\8^,;[X@GPWX1?36AGT
M^.]CGNT.(U(R6R.H.0.AZT`>M;@*0NHZL![FO-/&.O\`B71[R;;XH\,:5#%:
MAXH+GYI[APN6^4D8YX&.N:Y+QWKNM^*O@+8ZZ\EG;P3;?ML*QDM(XF"*4.?E
M&021SZ9H`]IO]>TO2[W3[.]O(X;C4)3%:HV<RL!D@?F.OJ/6M#<,XKR+5KS5
MM,U#X=6NK_V5J-U=WI7S_L6#$G[O;LR?E;'4CV]*F7Q5XR\6:EXAF\,3Z=I^
MDZ1(ULK7D)D:XE4$L?\`9'3\QUYH`]7W#UHR*\7O/BUK%Y\/O#VN:/;V8U&[
MU,6%S;R@LA?:>,\%0?E/7@&MO0_$OB[3_BA#X7\42:?/#>V37-M)91%0K#D@
MY.<##CG.<`]Z`/3LXI,BN;\:WNJV&DQS:7J6D:;F4">[U1L)''_LCH6S@8/O
M7)>"?'&K:MK7B32+W4--U0:;;K<6^H6*XC?*\C`)!`/?/8T`>H[AZT;A7@L?
MQ!^)$WPY3QHK:*MC!+LDB$)\R5=^TN><#YB%P,'O75:UXQ\1:QXSTOP[X1:U
MMC/IPU"YN+R$OY:L,J,?B!QGEO:@#O;#Q%I6IZOJ&E6=V);W3BHNHMC#RRV<
M<D8/0],U-/K.F6NIVVFSWUO%?7(+06[R`/(!UP.I[UY=\*WU"3XE>/#JT,$5
M_NMA.D#EH]V&&5)YP>O/K5?QN/\`C(;P4/\`IW_]FEH`]6O]>TO2[W3[.]O(
MX+C4)#%:QMG,K#L/TZ^H]:T-PKSSX@ZB;'QGX$@%I93?:M09#)<0!WBYCYC)
M^Z>>OL*S+7Q+XX\8ZSKS>%)M+LM,TRX^R1?;869KB0?>R1T_+H1[F@#U;<*,
MBO'?$WQ/O(?%]UH5MK6EZ''I\2BXN;V!YO/F(!*HHY`4$\]ZBNOBKK<WPITK
MQ-8V]JFI2:FEC,CC='+@-D@9!7.!].:`/9]P]:-P]:\OTWQ1XRTOXE:;X?\`
M%#:=+;ZK;/+`+*,CRW4%BN2<X&",GKP:I^#O'/B'Q/XH>VN-6TK3FANVCET2
M:`K<^6.ZN3ACWX]#T&*`/7,BC(QFO!M4^,=_/<ZO=Z=K6E:?;6,C1VMA=6[2
M37FS^+<.%W'@#M7LOAO5QX@\,Z=JX@\D7ENLWE;MVW<,XSWH`DU37M)T186U
M34;:S$[^7$9Y`F]O09K1[9KP7XA6<?CSQSKFG>?&D&@Z2PA#OMW7;88`?ECH
M>A]1700_$:[MO@=8>(+5$EOAY=C+)+RD,F[89']1T/U89[T`>L[AZT;AZUY3
MX9\1^++SXBW&AW>NZ/J-C96GVJXDLK;[V[@)NS@,"0>_'Z97A/XA^-+[P_<^
M+-973O\`A'].299DBC*SW,@'R[>H`W,JGIT-`'M>11N%>#:=\8-56]T>XN=7
MTB_34+I89]*MH&26V5\X/F'@[>![_K6GXF^*=TOBW5-)L-;TS1+?2_W1DOK=
MI6NI?X@H'W0,8]_Y`'LV1GK1N'K7C6H_%/79?AUX9\0:5:6J:AJ.H"SF@E&Z
M-R-P..05!*@]>,T]/%'Q('C>Z\&[M$FU"2W2ZCO!&RQVJ?Q97DMUVC/?!H`]
MBW"C<*\<TWXK:KIW@7Q%?:_:P2ZQI-_]A"P_+')(3@9QV!#9/<`=ZC\,?$_4
M9O&&BZ1=ZUI6N1:F&1Q8P-$UHX`(R3PP/(_#/U`/9]P]:0NJC)8#/J:\83QC
M\0M8;Q<=)?2([?0KN95>:(^9(JDX3KCA03D]3@?3&\?ZYK/BKX7^%==^T6L-
MO<742S1>20YN077<#G&SY3Q[T`?0.X>M&1C-9NDQ:G%I<4>K74%U?J"))H(C
M&C')QA23CC%>0R_%37H/AWJ$[O#)XGM=7&G!([<;3SD83.2"%89QUH`]PR/6
ML_2M>TO6TNGTV]CN%M9VMYBN?DD7JO/_`.JN`L_'NJZWK7@>QTLVZ_VG9F]U
M,F/.U%X(4$Y7YE<`^X]*XR[U#4M5^%WC=K.+2["&VU69+I8;789HQMQT.-Y)
MY8^E`'M^N^(M*\-:;_:.KW8MK0.L?F%&;YCT&%!-:88'H>M>!>,HM6B_9ZTT
MZG=V]SO>S:V\F(IY<6P;58D_,1Z\5U-KXI\::-\0=`TGQ*^FR6.M1.8X[*,Y
MA<#.W).3@X&><Y-`'JM%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!QEIX,N(OB7K
M7B6>:WDL=1L$M!;X)?C8#NSP0=I_.L7P%\+)/"$FM37%W#<S74;6]DP+$P09
M8[23ZD@G`[>]>FT4`>2_\*FU3_A6.E^&AJ=I]MT^^-X"R,UO-\S':XZD8;T[
M5;T7X<ZV?%]_KGB*]TN>.^TR33Y;>Q@:-55L#@'J,`YSSS7I]%`'F/A/P3XX
M\,I8:0/$>GOH-I=&0A86-P\6<^7D\`'VZ9/..*VO`O@RY\+6NN07L\%PNI:A
M+=`1YP$<`;3GO7:44`>/I\,/&&FZ#J7A?2O$&F_\(_?2,0+BW<S0H^-RKCC_
M`"3QFMS7_A;'>^'="M=&U*33]4T%0+&^*@DX`R'QC@D`\?D:]$HH`\O/@?QK
MK7B;P]J?B76])DAT:;SD6SMV#2-QG.<#G:.G`]*5?A_XHT'7=5N?#&I:+_9^
MHW!N3;:C:,WDN>NTKV_SCO7I]%`'G^I>"-:U6[\%W=WJ-G)<Z)<-/=LL102D
ME3A%`P,;<<XJQ+X)O9/B5?>)Q=6_V:XTDV*Q?-O#G')XQCBNXHH`\B7X1:G'
M\/\`1-*@U6VAUS1KU[NVNU5BGS/DKZCL>G5171)I'Q%-A=R3>(-':_DFC,40
MM6-NL05@ZG^++%@<_P"SCH>.[HH`X/X?^!K[PMJ6M:IJ-Q8M=:I(A,&GPF."
M(*#]T'N235/QMX#U_6O'FD>*-#O]/@ETZ#RU2\5V!;<QSA>V&]:](HH`\T\2
M>#/&/C#P9<:1K.I:,+MKJ*:&2VBD5`BYR&SDYR:V?$7@Z\UGQKX5UR&Y@CAT
M=I#+&^=S[@!\N..W>NRHH`\ZM?`FNV/C_6]6AO\`37T;6W3[;;S1.TIC"D%5
MP0!G)&?TK,TGX?\`CCPUI[Z1I&MZ%-IR,WV>6]L2TT2MSCCC@DGG/Y<5ZQ10
M!Q7_``AM\?BA:>*VNX&MX=,^Q-'M(=GR3NQT`YK-\=>#?%OBO[=IT6HZ&VCW
M!4PK=VC&>VX&=C#C.03GKSBO1Z*`,[2=+&EZ%9:7YAG2UMDM][CEPJ[<GZXK
MSC3/AUXP\'7FHP^#O$%A#I%VQD2WOXFD:%R,9!`ZCL>AXR#7K%%`'FFJ?#OQ
M`VH:%KVF>(8F\1:=;FWN+B\A)2[4DD[@O0#<<#Z=Q54_"[6+[3O%=UJNJ6<N
MO:]$D.^&,I!$BE<<8W9^7]!UKU7(HS0!Y[>^`-0N3X"VWEJ/^$;*?:,AOWN%
MC'R?]\'KZBN<OOA/XG:/Q#I]CJ^D&PUFZ:XDGN;9FNAGG;NZ`9X_$GOBO9:*
M`/+=5^&WB":Z\*7VE:S9V=[H&GK;AWC9UDD``/']PC(/?!Z58TKX9WMPWBB\
M\3ZC;7-_K\`MY/LD16*%0,*0#R2,*1GT[YKTJB@#R!OA?XNU'0=/\*ZQXAT^
M7P_:3*V^&%A<O&N=JY/`ZX]O?%=9;^#;J#XIS>*Q<0"S?319+``=X8%3GIC'
M%=G10!Y9K/PX\22>*M>U32-4TKR=:B6*5K^W:26!0-I$9Z8Q_(>F:FF^&>H3
M_!F+P2;^V6\C.X7`5C&<2E_KT.*]-HH`\XN/!'B;5;SPE>:MJ.EM/HEXTT@M
MXG16C^0*JYSEOE.2<#D>E5#\/O%>AZKKLGA36M-AT_6':62WO(&)A=LY*8R.
M_4^V1Q7J5%`'EMS\)I8O!WAG0=/OXLZ5J*7T\LZD>:>2P4`>IXSV'6NBO_"-
MW=_%+2?%:7$"VME926SPMGS&+;^1VQ\PKL**`.)^(7@S4/%;:-<Z;>6L5QI=
MU]H6&]C+P2]/O`=QCCZFL[PIX"US2O$.OZSJ]_IT]QJUJ(BEI$T:1L.!@'M@
M#WKT;(]:6@#S&W^&>I0_!B;P2;ZT-Y(Q(N`&\OF82>F>@QTIVI_#W7H==T37
M_#FJ6-KJ=EIZV-TMS&S13JJXSQR?H?0'M7IE%`'`>!/`^L^&?$7B#5M7U:#4
M9M5,;&2.,H<KNSE>@'S8&#VJEX[^'_B'7_&NE>)-!U2RL9]/@\M#<(6.[<QS
MC!!&&[UZ910!YI)X'\6ZM>^%[[7M8TZZNM&U![B1XHBGF1'9A0``-P*MV'45
M77P!XPT+6M<E\)Z]IUII^K3>>8[F%F>!SU*=1GD\GKQZ5ZG10!YI?_#_`,0V
M7BRZU[PWJNF!K^&-+R#4;4NKN@QY@*\Y/)[=>]/\0>!/$7B3P99:9?ZEIO\`
M:$6IK>.\,)CA5%W`(H`SGD<FO2**`..UKPA>:G\1O#_B6*Y@2WTR*9)(FSO8
MNK`%>W<=:YR;X>^+-;\3:)J/B'5-%D72[E9Q<V=HT=S-M.0K'I@X&1T&37JE
M%`'EMM\/_%?AS4=2'AK4]$;2[VY:Y2WU&T9C`S'E5*]L8')[=/7T32K>]M-%
MM8+V>*XO8X0LLJ((T=\<D`=!GVJ]10!YIX>^$6E1Q7]UXJM++5M6O;R2X>?#
M;5#=%&<>YZ#K[5P'C;PA=>!O!]_IKW:'2=2UN*:T9%;9:#YLB88^9=H7`]5S
M7T544MO#<1-%-&DL;_>1U#*?P-`'C'P^UF73_&@\-:1=:+K6F7<4EQ<WNFV0
MMC`<<;]ORD9R`!TW=NE=7X7^',FE_#6^\):K<P3_`&LS9EA4D+OQM(!QR",_
MA7<VUC:62LMK;0P*QRPBC"`GWQ5C(H`\RT7P?X]TBWLM-_MG0);"U=$%P;$F
MX,2D<<_+G:,=_KGFG7W@'Q%I_C#5-<\+ZCI*0ZH0]S9ZC;%U60#[RE><GYCV
M^\>O&/2Z*`/.-<\":_X@T#0+:^U+3S?:?JBWTSQ0F.(H"<(@`[`@9/7'-:T/
MA"[C^+%QXN-Q`;233A:"'!\P-N!SZ8XKL:*`/+?^%337>C>+M.OKZW']M:B;
MZUEB0L8#N)&0<9/../4UIZ#H'CNTO[`:KJF@26<!!G>VLR)Y@%(P21@9."2`
M.E=_10!P7A[P)?:/;^,HY;NV<Z[<S30%`W[L.&`#<?[0Z5D7?PNU6?X4:/X4
MCU&S6^TZZ%SYS*QB?#N<>O\`'Z=J]4HH`S=&AU:/2XUUN>UGU#DR/:(4CZ\`
M`DGI7!?\*LN3\59/$QO8#H\DYNFL@"&,OEE,]"#R2>O<UZ?10!YE\._A?=^#
M?$%]J-_?07B"(V]@L8/[F(N7(P1QU'0]S18_#*_M_!7BW0I;^V\W6KR2XAD5
M6*QAMI`;\NU>FT4`>6:G\//%&M?#6+POJ&IZ49[:6`6TD43J@BC7&&[EC[`"
MNA\1>#KS6?&OA;7(KF".'1VD,L;YW2;@`-N..W>NRHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`KR7XXZOJ6DVWAIM/OKBT,FHC>89"F[`&`<=1STZ5ZR<XX
MKQGXHV>O>,?$^CZ#:>'=02VLM01VU,IN@9&5<MVZ<YY_A]Z`.V\0^.KC1-1N
MK2W\+:SJ,=I$))[F"-5B4$9X9C\V!G..F*HZA\6]$T_PWH6O&TOIK/5W:.-8
MD!DC9>""N>3D$<5RGC!?%=QXLU^"\TSQ+>6$L`BTF/29C';C<N"92".^,@Y[
M\8Q5&W\,:ZG@WX96S:1>">PU8RW<?E'=`GG$[F]!CG-`'?Z!\3;+5]=U#1[_
M`$J^T:[LK8W3I?!5)C&"3P>P(/TSZ4_PQ\0SXJO+;['X<U6/2[DN(=2E51$=
MN[K@DC)4CZUDZKI>J#XWIK$6E3W5C'H+Q!]N(WDRY$>X\`G@<^M<UX3TO5+/
MX@:9+X9\.^(=`TB7>VJVNH'_`$;IQY>2><D^_3&!F@#M],^)4>MZN;;2?#^J
M7FG)>?8WU.-5\E6!`)ZYVC(.<=.:9JWQ0M['4=3MM.T/4M6ATH?Z?<VH7RX"
M`2PRQ&2`#G%<))INKKXXL;_PKX4\0:#?S:A_Q,][#[#+%D[SG.#GKT`YXYQ5
M*3P6=&\1Z_;ZUX2\1ZI9W5V\]I<Z3,=KQN3E756`S]>?PQ0!Z9KGQ3T31;'0
M;\07E]9ZSO\`L[VL89A@#`V$@DDG&/K4WA/XAV_B?7M0T2;2KW2]2LD$CP7F
MT,RDXXP>V1^8KD-0\/WS2_#`Z=X?OK2TL+MWFMW)E:T0LA'F-V[GGZ=JW+?2
M-17X_7>K&RG&G-HPA6Y*'RR^Y3MW=,\'B@"M\5?&VN>&+O1K?1[.[59KR(2W
M"QHT<P.[]PN[/SG&>@^M;FM?$.WT/3M):ZTB_.K:HVVWTE`IGSGG.#@`<=^_
MUQD_&'2]2O\`3-!GTW3;F_-EJT5S-%;)N?8H.2!^E9GB>/77\7>%O'UAX9U"
M>*&"2WN].=%^T0J2P#!0?O$,3[8&<4`=CX5\=VOB74[[29M/O-+U6R`>6SO%
M`?8<88$<$<C\Q7'?%S6-9L_%W@[2M,UB[TZ'4[AH)VMF`)!>-<\]QN-6?!VD
MZGK/Q2U?QK?:/>:5:/;):VT-Y\DK,`H+%1QC`/7N1CIQ4^+VEZM<>+_!NJ:?
MH]]J,&G7#33BTB+L`'C;'IDA3C-`#;W4O$?PY\<Z):7_`(ADUC0M9E\@F^QY
ML#@@%@0.GS#V/(QWKHM5^)]O8:AJ=MI^AZEJT.E#_3[FT"^7`P!+*2Q&2`#G
M%<]+8^(_B-XYT/4K_P`.S:-H6BSM-MO]OFSOP1A/3Y4]ASR:YA_!1T7Q%KUM
MK?A+Q'JMG=7;SVMSI4QVNCGD.JL!GZ\^W2@#U./XE:3-X@T'3889GM]<MS-9
MWN0(R1G*$$Y!XQ]2!4-S\4M%L]0\1P7,4ZP:$$$UPH#++(W`C4?WLY&#Z'M7
M+>*O"^H2?#7PW?\`A[0[NTU+0[A+FVT]W,DR*6Y4XY/\)(ZX&.U8LGP^U_5_
MA/?7=Q82GQ%?ZM_:DUJW[MV`++LRW(X9F')ZCUH`]'T;XAQ:CK]MHNJ:+J&B
MWMW&9;1;P+B<#E@"I."!SS[UQOPZ\1V/AKPQXTUC5IW6VM]<FQCEF/`"J/4G
MBCP;HVF_\)?I-Y%X%\465[%O+7>I7#&&WRC`X+$[LDX`P.N:Q?\`A!?$5_X`
M\2VT6ESK?IXD;4+6"9`OVA`,<;L9&"3[XQ0!Z'I/Q0@N]9TW3M4T#5-&.IKF
MRFNT&R9N,+D="<CK[>M0W7Q:M8]3U;3;+P_JVH7NES.EPEM&"%C3K)NST)X`
MZ\5SNHQ:W\1O%/A/S?"VIZ1;:5,;J]FO%\I3]SY8R.3RO'0\]JR-'U_5=%\:
M_$:*P\.7VK)<W;J'LUW&*7YP@<==IR>1TQ0![+X7\267BSP[::U8!Q!<*3L?
M&Y&!P5..X(KQKQ9XK\3:5\0_$=W:ZM>'3=#GLYI;!6&QX7"AQC'O^I->D?"?
M0=0\-_#O3].U2+R;M6DD>+.2FYR0#CO@USUOX3N]3^)/C]+ZPF33=4L8H(;A
MX\(Y\M02I(P2#S[$4`.^(WB>\GET/1_#>IRVLU[#)J,\]NPW);)$6'.#PQZ'
MU&.]<X_Q!\0_\*Q\(6=I>AO$/B&62V6]FZQJ)2F[@8SRHS]3S4GP]\(>(1I^
MO:GX@LKE;V#2FTG3XI4.YHU0\KGGG@#&!R:A7P'K\OPP\':A9Z<XU_P_</,M
MC<?(9%,Q8@@XYX4^XS0!M6WA;^QM6B>/XK7!UD3)]HMKR\1DE;(+)Y9;(W=O
M3-4Y+G7_`!#\<M=\-1^)]4TVPM[99XEM77Y3LBXP1T.\FL_Q'!?^,M5T&:R^
M'&H:7J:ZE%<W]Y-;*@95Z@R<%AWYQT'6KEPNN>&OCEX@\1Q^%M7U*SGM1#`U
MI!D.VR+^(\8RA!//TH`LZ=XUU_PGJ?BKPWKU_'JEQI5@]]9797$DBA00K#H<
M!@3]",FN;NSXK\/^"M'^(Y\3ZG<7=W+&][:NP>W$+DX^7@#@(,8ZMVKI=-\$
M^(?%-]XM\1Z[8+IMQK&G-9V-HS*TD2D8!8_PG"J/7DY`K%:U\7>)/`.A^`9?
M"VI6,T$\<=W>3)LMC!&3CYN3G[IXZD<=<4`;7QEN_$\'A\ZK9:R+'1M]NL,%
MJ&6>8ORQD?/`&!@#KGFO2O$%OKEUI,<&@WEM:7<CJKW$\9?RXS]YE7H7'!&>
M*\[^,/\`:FI:!_PB^E>&-9NC')#*EU#"'A*KVR#G(Z<BNT'BVZ'AE-8'A77C
M()O)-AY"_:`/[^W=ROXT`<_\$;V^O_".HRZC?7%[<+JLR&:=RQ("IZ]!R>*S
M?CQJ][;^'[/3+>TOO(N;J+S[F%@L;K\W[DG.2Q(SCIP*?\&I-5TBUN]$U+PW
MK%FUQ>37BW,]OMA"D*`I).=W'I6K\9-(U#6/"NG0:98SW<R:K!*Z0H6(0!\L
M<=N1^=`#8_%FE^!]#T/2+30=4^WWV[[-HWF>;<1C))+,S'`_'^1QH:7\2K'4
M-/UYYM-O;+4-$A::ZT^X4"38%W`@]#G_`#Q6)XRT[6=&^*.D^,].T:YU>S6T
M:SNH;9`TD8RV&49R3\WTX(XS6/9>'M:UK4?'WBR;1+VQ_M'3)+.QL[CB=SY0
M4Y0<<[1CW/%`':>"OB1;>-[J1++1M3M[58/-%W<1`1.P(#(I&02"3^1KC_BE
MJOB5/'5KIF@ZQ>6>='FO%B@;B1XR[<C!R2%Q^5=U\,]/N=,^'&B65[:R6US%
M`1)#(NUE.X]1ZUBZUH]_<?'/0-26PFDTV+2Y8IK@1YC5CYGRD],G(_.@"CXA
M\>SZA\,=%N]$N##K&ORQ6MOM8%XY"P$A&`>F",X'45F^$?'][X?\#^)=5\07
M-WJZZ5K#6<;%E\PKE5'/'<YJGX)\`ZS:?$DV^HVTZZ!H$]Q<::[H?+D:4C:!
MGC@<\#J/I55?!GB"[^%_CC3AIEQ'>7&M-=6\,D95IHPR'*#OD`X]:`/5=:\:
MVNBZCX;LI;2>1M=E\J)D(Q$?E^]G_>[>E<%X6U:ZTK7OBA>6]G=W\T6H((X+
M?!;),@R-QP`.I^E5K^7Q-XI\4^!;AO"&I:?8Z7>*)9;@?-G";B5'W4&.&/7G
MIBN@\%Z+J=KXE^(LMS83PQWUWNM7D3:LPQ(,J3U'(_.@#E[+QG?>)?@IJMSX
MH@U7RD4>9J5IY4?G@SA=L?0<<`Y'3-=G<_$>P\.RZ+HQT_5+ZZOM,BN+01*)
M))B?E"-S][@DMTZUP&G:=X@;X%:IX1?POK$6H0#>&>`!9BUPK;4YRQ`R3QV^
ME6]<O=0T#XG^")X-(N;^YM]`5);.'B7&'#X!ZL!DX]J`.CU?QW;>+/A[XTM5
ML;O3=1TVUD2>UN<!URIP>/H?RJ;0?&=MX:^'?A"V-I=:CJE_91BVLK8`R2`+
MEFYX``]:YRRT'Q#J>E_$K6[C1+JS;6X=EE92I^_;:&`ROJ<CCU]JH:OX)U1=
M.\#ZM/H.IW\-GIBV>H65I(8KB+K@C!#$Y8Y'MSC-`'K7A7QG:>*'OK7[)<V&
MI6#A+JRN0-\>1E3D<$$5Q?Q9UV[TSQ9X5LAXBN=$TV[\\7=Q`P&`-N"<@^N/
MQK2^&>EV%C?ZM/8>%];T=9EB$DVK2DO.PW<!23TSUSSGVK.^*VEW5UXR\):A
M_P`(]>:UIUF9S=P6]N)L@[<`@\=?7TH`9\,M=U&^\<Z]IT/B*Y\0:!;VZ/#>
M3KR)3CY0<#U;VXS]>J^)?BR7P9X+NM6MEC:\++#;K+TWMWQWP,G'M7"^&O"%
MQKGQ!U#5U\*S>&O#TFG-8M`W[B68MU8*OW3[CC@=3FMKQ7\([.[\#ZCI6@M<
M+=RR1W$7VN[>0%X]P`^8G&0S#TR1GI0`SP[\/O$T4=EK-WX\U0ZG*4FN8O\`
M66[KD,8PI([8&?TK6U7XH6]CJ&IVVG:%J6K0Z4/]/N;0+Y<!`)9<L1D@`YQ6
M;X?\;>+I+#2]+N/`FIIJ0:.">YF'EVP08#2;L<'`/R]/<]*XEO!1T7Q#KUKK
M?A+Q'JMG=7;SVMUI,QVNCGD.BL`#]>?;&*`.J\;:S:ZUXG^&&I:;.TEG=W[.
MC#*[AF/J/7VJ[\,V9_'OQ%#,Q"ZFF`3G',E9E_X?O7E^&!T[P_?6EI87;O-;
MN3*UHA9"/,;MW//T[5O?#S2=1T_QKX\N;RRGMX+S4$DMI)$(65<R<J>XY'YT
M`8GQ6U+Q(OC/1M'T#5KNR>YL+F41P-CS)(U9U!X/7;BI]5^(=Q>?!VQU73IB
MFN:H8[&!5(WBX+;7(`!]">G<=.*TO$VD:C=?&?P?J,%E/)8VT%PL]PJ$I&2C
M`!CVSQ7)>'/A_J]O\5FLKFUG3PQI-[-J5E(4_=/(X7:HSQ\OL."I]J`-?P%X
MHU?3])\7G69]2UQM&U'[/&D4?FS/@[2%`Z\\^PR:Z71OB(NI>*(/#NHZ!J6D
M7]Q"9X%N@I$BKG/W2<=#U]*X2+2O&FEZ#\0)=$L+RWOKO6C+`P3$CP%FW-%G
MJ<8Z=CQS3O"^EZK<?%O1=671/$UOIT%I+#)<:W(TK[]C=R3M!R,=B<XH`H>'
M;BV3X$^+)=1FOA:C5I%D:T<";!>(84MQWY]LUZ#-X^M]'32=)T[2]3UK4)=.
MCNV@MRK2QP[5`:0D_>)/;^HKA;+PQKJ?`GQ5I3Z1>KJ%QJ;20VQB/F2+OB.X
M#N,`_D:H^(8=;N?'5C9:/#?27UKX;BAGCTR989X<@;A*7!!Z]!SRI'2@#OD^
M+]F/!DGBBYT+4;>Q2Z6V4/LW.22&(Y_A(((]:M:-\4[/5?%5IH4^BZGIKWT)
MFLYKU%03+@D$#.>0#7`ZM'9^(?@S)H7A'2-4^T:;J*1W-C/&7N$D!8NS8X.2
M3]/05VOC/2-1O/B9X#OK:QGFM;-YS<S(A*Q9"XW'MWH`FUKXHG17OIYO">N'
M3+*;R9K]HE1.&"E@"<E<D8/>K&N_$_3M$UK3=+33-0OYM2LUNK3[)&&,FXD*
MN"01G&<]J\L\26/C/6-)U^PU71?%%YJT]TWD&"4C3T@5@P`4'#<`XR">G>NV
MM]$U5?BGX+OFTZY%I:Z#Y%Q,8SMBDV.-K'L>1Q[T`;_AWXG:5KFCZU?W%K<Z
M:=')^UP7.W>@`)S@'U!'U%0:-\1O^$CVHOAK6[.QO+::6WOWC'ELJ@G.0?E)
M'3/?%<C?>"]9UC4OBE;BQGB&I+;M8R.NU9VC);"D\=0!^-;_`(5\1^(+W2+#
M0+KP9J5BT=@\5U=31^7$I2,A0@ZDL<<<8R>O6@"MX.\8Z)X:^%6FWL/]IW<=
MQ<R6]E;W!5[F>4R'Y!CCKG\*Z/2/B-8WMSJ-GJNGWFBWUA:F\DM[P#)@`Y<%
M21@5Y0/`>O/\+?"LKZ)?376DW\\ESIRL89GB=\DJ?O`_*,8YYKJ?"6E:?::K
MJ-]I_@/Q'#.-,F5WU:8XGZ8@4,QR6QU[8]Z`.O\`"_CY_%-W!Y'AS5+;3KE7
M>#4)POEN!TZ$X)P:[(<C->)^"M+U6R^(5HWA[0=?T/P[+%(^HVFIG]R&P=OE
M`D\[L>_7M7M8Z"@!:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Q-%\*Z;H.JZOJ-EYPGU
M:83W.]]PW#/W1V'S&MNB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`*P[GPKIUUXML_$TOG?VC9P-;Q$/A-AW9RO<_,:W**``<"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KD-=^&VA:]K3:Q*]]9Z@Z".
M2>QNFA:11C&['7&*Z^B@#(\.^&=+\*Z8-/TJ`Q0ES(Y9RS2.<99F/))P*UZ*
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHK+A\2:+<:W-HT.IVLFIPKNDM5D!=1QV_$5J`Y%`!117":+X^>]\7:OHVHVL
M-K%;O.;2X5R?.2%MK@@C[PX/!Z'I0!W=%><^%?B:-:EUJ74[)-/T^SB@N()-
MS.[Q3$A-RXSN.`0!_>`YZUO_`/"P/#2Z3<ZE)J#10VTJP31S02),LC<JOEE0
M^2.1QSSZ4`=/17(-\3_"*75M:OJ;K<W./*A:UE#DERF""N00P((/3%6SX[\-
MG75T7^T1]L:<VP_=/Y?G#_EGYF-F_P#V<YH`Z2BO.H?&WB/6YY+SPYH=A-HT
M4SPK-?7A@DNBAPQC&"%&<C+?I713>-M`M-:&DW-Z8[SS$@;,+^4LK`%8S)C8
M&((XSWH`Z.BN33XD^$Y=9.CC50+T7)M&5H7"K*"1M+%=H)((&3SCBJ]CX_TZ
M#19M0UBZMHU_M&6QMUM$ED:4JV``FW<6]0`10!VE%<U:>/?#E]?6UG:WSRS7
M"HRA;>0A-_W0YVX0GH`V.:K:_P");O3O&V@Z1$L(M;ZWNYIGD4EAY2`KC'09
M//!H`ZZBN&T[XE:,FB:5<ZQ>P)>7UN;@QV<4LJK&&*[S\NY4XZL!W]*V+CQO
MX?M=;&D37K)=&5("3"_EK*P!5#)C8&((XSGF@#H:*Y33?B3X3U?4XM.L]5#W
M,KM&BM#(@+KG*;BH&[C.,Y/'K5JP\<>'=3MKRZM;_=:VD;32W#0ND91<AF5B
M`'`(()7-`'0T5RL?Q&\+R6-Q=G4'C6W*+)'+;2I+E_N8C90QW8XP.:N:CXDA
M3P9J&OV"F5;>TFG1)D:,ED4G:RD!E.1@@C-`&]17GEM\19'\%S:C+IR+K45X
M-/.GK(Q!N&("<XR%(.[..F>IJ&U^)5Y?^&?#\UEI"7&O:WYH@M!*5AC$3%7D
M9ST48!QUYH`])HKSG5O&/BK1/"_VR]TC2?[1:]AM(1#=M)#()"1D]&4@X]:D
ME^(MSI,&N1>(-%^R:EI5DMX(H+CS([I#\N4;`(^?@\''O0!Z%17GND^.-=DO
M+W2=2\/QG6(K6.]MH;*X!CFA=@@RS?=*DDGV!Q[V]#\8:CK'PVM?$T>DK/>S
MA\6D,FU!M=ER6;HH"Y)_*@#MZ*P/!NNR^)?!NFZU<11P27<)D9(R2J\D<9Y[
M5R=I\1KQ]!_M!++[?<:IJDMIHEK$/+$L:G`9W)(QPQ)QVZ=Z`/2Z*\WU;Q?X
MST:PTV*ZT+3$U:^U)+*+%RS02*R%@P(^92",'(]QFK]KXWU&:'6K.3P\T>N:
M6R!K);I6C='&5E$A`^08.>./<\4`=S17G/\`PL.^?P1X;U6+3[9M2UZ=;:&-
MYBD,3MN^9CR=H"]N:Z#P?XID\0:5>/>VRVVH:=<O:WD4+&1`Z\Y0]P001^5`
M'345@:5XST'6[FUM].O3<2W4#7$:K$W"*VTEN/EY!&&P>*PKOQEKNHZWJ%GX
M5T*&_M]*F\F]GNKCR?,D'+11#'W@/XCQS0!WE%>=7_C7Q+'XKUK3=+\/VE];
M:3:Q7$R/=&.=MZ;L+PP)&",=^.:J:]\3;VSTC3]=TNQTV32KF!)A'=7FVYG+
M,`8XHUSEE/!]_I0!ZA17+>-/$MQX8\"WOB"VMEDF@2)E@GR!\SJN#CN-U5-(
M\7:E_P`)"N@^)=*ATZ]>S-W#/;W/FPS*IPX!(!##@XYXYH`[2BN`\#>/[GQ7
MJ.H6UYIRV6R(7EAA\FXM69E#GWRO/UK&\.?$[7];BTU)M#L?.UB*X;3VM[HG
M:\61^^0C*J2/O`GZ4`>L45Y9I_CGQM-=:V+K0M*,.B[ENQ;7#ER_EEUV`\$9
MQGIQFK&C^+_$NL:7KQ@BM?M5M;M/9OY9VE@`0IY`*L#\ISD8.<XH`]+HKD)?
M'MA9?#>U\77:2/!+:QRM';J7^=ARN>V&R,G`H'Q)\-)H.GZO/=RQPW\32PQ"
MWD>3:GWR552<*0<MC%`'7T54M-0M=2TV*^L9TGMIX_,BE0Y5@>AKB_#_`,4-
M-N?".G:MK9-K<W44DSPVT$LRQ1K(Z;V*J=J_)U/'6@#OZ*Y75_B/X5T.Z2VO
MM4VRR6RW48BA>4/$V<."@((P"?IS5IO&WA_^T;2Q2_\`.GNT22/R8GD4*^-C
M,R@A0Q(`)(S0!T%%<W!X\\-W,5]-%J!-O8QM)-.89!&54X8JQ7#X.`=I/)%1
M'XB^%UTR[U"34'A@LWCCN1-;R))"7.$W(RA@#V.,4`=316+X?\6:)XI6X.D7
MHG-NP65&1D9<C(.U@#@CH>AK:H`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#SO2_A-I.E_$.;Q
M?%=W32O)),ELV-J2.#N.>I'S-@=L^U>AK]T4`YI:`"O*O$OPQU;5["865_;V
MU\^JW=P)=Q`^RW`VR1D[3\Q&..E>J$XKEHOB#H,_B]O#D=R&N0NT2#[AFW$&
M'/\`>`&?QH`PKOP)K5O/XGDT#48=/;4+*SM=/D5F5H?(&"#@?+D<`CIFLEOA
MGX@E:_OVN]/CU"34+'4;>-YYIT+VZLI621QO(((.?PP*[6Q^(7AS4O$3Z#;7
M<K:@DDD11K>15WIG<-Y&WC![]JDTSQ[X:UC79=&L=226^CW?)L95?;PVQB,-
MCO@GH:`,W1?#FN#QX_BC6GTW>^E_8_*M"YV,)2XP6'(VD`GC)["L:T\`>((2
M-(:[TTZ&-;&JBX`?[20'\SR]N,`[@!N#9QGUKT[=QG!JIJ6I0:3IMQ?W0E^S
MVZ;Y#'&SL!W(502?PH`\KUKX6ZU=:+=>'K4Z)/I;7#W%E=72N+JRWR[W5<`A
MNF,Y7/>M4_#^^CUS5/,MM/U'1]2U%;Z5;B\GA>/[N0(T&QB"N02>>]=#??$'
M0]/O;JTE-R9;9K5'VQ<%K@GRP,GT&3Z?7BMRQU:UU&:]AM_-\RSG,$PDB9,/
M@'C(Y&".1Q0!P!^'>J'2;^U^T67G7/B?^V`^6_U.\,%/R_>X/'3WJ-?A[KEI
M:V,]G<V#:C8:Y<:E%',7$4D<I/RLP&5;!]",UZ?N]C1N]C0!Y]_PB_B:;Q98
M:W(=*L[A6B^W75E/.K7$:CYHFB(VL,\!B<@<UJ:_X7O-6\7Z+J\$D"06-K=P
MR*Y(9C*@5<8&,`CFNM+8ZCI2[N.AH`\MT3P%XI\,RZ3>:7=:3+=PZ2-,N5N?
M,V+B4R"1-HRWWL8..G7FK/\`P@%\FO:F9;;3]1TC4]26_E6XO)XGC^[D"-`4
M8J5R"3SWKK_#WBFP\3K>2:;'<M;VTY@\^2(I',1D$QD_>`((S6SNXS@T`>9V
M'P[U6TT7PY9O<61FTW7'U*=E+8="SD`?+RV&'7TZU';_``[UF;0M>T>>:RTR
MPU&U$<-G932SP1S;BS2`.!Y8/`*KQU->H;N,@&H8[VUFN)[>*XBDGMR!-$C@
MM'D9&X=1D<C-`'G,O@34KVPG-_H>ASWS1PP)))J=TY:-22?G*YC((4J5SWKH
M(O#^KS?#:[T#4+Y+G5+BRGM_M#NSJ"^X*"Q&Y@H91N(R<9JX?&FD"YU&!OM.
M=/NHK2=E@9@))`-N-N3CD`D@"NA+8Z@T`>;Q_#J]7XAVFNFZB.EQQ1S2VA8_
M->)$8UDQMQT.<YSFJNG_``YUK2?#GAH6=YIQUO0Q<H!,KO;3QS,Q9#C##@CG
M'K7J.[V-!?!Z'\J`/)%^&&M)HNI16R:-9W%SJUOJ$5I`SBWC6(?=W;,\GT6M
M*]^'VK^(T\07NOW]K'JFI6?V&U2U#/#:PA@^/F`+%F&3P*])W<XP?RIKS)&C
M.QPJ#+$]A0!P&D^&O%-KJUYX@O!H[ZK_`&;#IUK;Q32B`JK;F9V*[@3V`!QT
M]Z7PIX=\5>&_A^?#S1Z/-<0*R6SBXD".KNS.7^3*D;N,`Y]JZGPWXELO%.F-
MJ.GPW2VOFM'')/"4\T#^-,]5/8^Q]*U]WL:`.5\!:+K'ASPG;:)JPLC]D7RH
M9+21FWKDDEMRC!Y[9KBM%\(:I<^%+#3["7[#K'A35YC;"Z5O+N$+%AO..C(_
M5?\`]7K^[VHW>QYH`\^UOP_XSUV/2[JX&A)>:;JJ7L,$<LHC,:H1AG*Y+$GL
MH`%26'A;Q!:C7-:N)=/N_$>K!81&9)$MK>`9`13M+'@YSCD_B:["_P!7M=,>
MT2Y\T&[G6WB*1,XWMTW$#Y1QU/%0:IXAL](U'2K&Y68S:G.8("B@@,%W?,<\
M#'UH`XBQ\%Z_#\/[+PSJ&E^'-22T;8%N)Y=CIACN#!,JX)QQVSR*W?!/A:?P
MAX=NH?+LGU&ZGDNI4ME,4`=NB+P2%``&<?A7427UM#<06\MQ%'/<%A#$[@-+
M@9.T'DX')Q4V_N0<4`>>^"O`^K^$_$-UJ$E[:3V^IPF2_C5-ICN=[-^Z^7_5
M_,1@XYYJ1/#7BOP_KVN77ARXTJ>SU><7934C(K6\QX8@(/F4C'4CH/QZ?6/%
M6CZ!>:?:ZI=?9Y-0<QVQ*,0S#'!(''+`<^M-U;Q=HFAZMI^EZC>K#>:@X2WB
MVDEB3@9P/E!/`)ZF@#D]1\+>+X_$_B#4M&N=*B&L6]O`9YGD$EN8TVLZJ%()
MY.,GTK.UCX77KZ':Z#I%KH?V:WMDAAU.[1Q>6YWEI&4@$$DDL,%<$GK7JV['
M4&EW>Q_*@#D/%_A>^\0?#FY\-VUVKWDD4,8N;HD!RC(2S8'?:>@[U@ZKX*\5
M:_<7^J:C=:;#J'V%[#38+=Y&AMED`$LC,5!+E<@8'I7IF[V-9.O^*-'\+V2W
M6L7BVZ.VR-<%GD;T51DG\!0!Q6D_#2]\-^)M%U/3M;O+V"VMWM+N/49]V(2H
M"K$`O`!&<$]A4/A#X9ZEX2N?#][;3V*7<$<UOK'EAMMW&SLR$'&2ZY')QT'I
M7?:#XCTSQ+I_V[2IVG@#F-B8V0JP`)!5@"#@C\ZT]WL>*`.9\.>'KO1]?\37
MUQ)"\6JWB3PJA)*J$"D-D=?IFKFO/:Z!X5U2YM[-56.VD;R;>+!D;;@`!1U)
MP.E7I=6M8=7M],D\T7-Q&\L?[IBA"XW?-C`/(XSFKF[V-`'#:9X2N9?@M!X9
M,GDW<^E^23*O^K=UR00/0G'X52_X1+Q5::CHVM6+Z.VHVFDG2KBWFDD\HJ&R
MKJP7)/`R"*]'SQG%)N]C0!R^CZ%J7AGP-:Z3IDEK=:C;I]ZY+)$Y9]S_`'<E
M1RV,#TXKB8_AKXLM?#.F:'!J]J]G'IUQ:7,'VB:*/S979O-`0?O,!\;6P./>
MO7MWL<>M9?B'Q%9>&=(;4[]9FMUD2,^4H9LNP4<9'<T`<=8>`-1M;T3R36;!
M?"T>BK@MD3*.6''"?K[56T_P%KVGW'AUK=]/MI=/M[:WN;^"YF66:-"#)$8]
MNR13C`+8(SGM7I^[G&*CEGCAA>65@D:*69F.`H'4F@#RR;X:ZU?Z7KVF--8:
M78ZA!^[M;2>66'[0)5D\S:X'EYVX(7/WL]A5G5/`&K:WHFHQ3V>EVFIW3VP^
MT+?3W'F1QR!RK&1<C&.,9K>TOXE^'=5BU66&Y;R].#2,0C,985"_O4`&2N6Q
MZY%16GQ8\(7L5])#J$P%E!]HF#VLJD1Y"Y`*\\D=/6@"_I'AVZL/'GB'77DA
M^RZC#;1PQJ3O4QJ0<C&._&#73UB>'?%>D>*K6:XTF>26.%]DGF0O&5.,]&`-
M;1;V-`"T51O]6M=,>S2Y\T&[G6WB*1,XWMTW$#Y1[GBL2R^(&B:AJ-M8VXNF
MFN9KJ&/]SP3;_P"L/7..>.Y]*`.IHJEI>J6VL:;!J%GYC6\R[D+QLC=<<JP!
M'3O5O=[&@!U%-W>U!;'8T`.HI-W/0U1U+5[728[>2[$H6>=+=#'$S_.YPN=H
M.!GN>!0!?HJO#>VUQ--#!<12R0-MF1'#&-L9PP'0X]:FWCT-`#J***`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\JT72/B1%\7KR]U"]9
MO#C/(0#.#$T1'[M4CZJP^7)P.AY.>?5!G'/6EHH`:P)Q7CVCW#Z;\0X]-\*3
MZC-:7%]+-JVEWMH5CL02<R*Y'R[B,J`3FO8B<53MX+(W=Q>VRPF>?:DTT>"7
MV9P"1Z9/TS0!YAI%Y=IX[L;7PI>:M<:5=RW-QJUKJ%H8X;;<Q8E'9`=Q=C@`
MGMVK%\(6UU*/`>A-IUY%J.AWMU+?B:V=$A3+XPY&TYW#&"<U[IM/K1MXZT`>
M+>+="N=1\4^.]0QJFZQTZWETX02R(AG\O[RA>&8$=/<^M0:SI&H:=HNOM9-J
MSRZAX=MKJ4-)(Y-T9<,5]&QR0/7L*]PVX[T;?>@#PGQ!I]_+XAUF1;*Z</=:
M$0PB8[MH.XYQSCOZ5;U+^VH]+\3$1ZF;-O%B_;!")/,-A@;]F/FVG@?+[U[9
MM]Z3;[_2@#P>XTF?4)+2RTS^VH?#,_B2%;8DRI*D1B;SBI;YECW=-U=SX"LK
MRWL?%FD8N1:VVISP:>MPS';$5&-K-R5R3SS7?[?<\TH&!C-`'B'AJZOGU+X>
M:8]OJB7.EM>Q:DTT$JHK^6V`7(PW3(Y/:L+P+:6U_;^%!$^O3ZE=W$\6I[FG
M\AK0AQC?]W;P,8.<[L]J^@X;JVO#,L%Q'-Y4ABE$;AMC`<J<=#@CCWJ'1]%L
M-`TJ'2],@^SV4&[RX@Q;;DECR23U)-`'@OAWP:TL'@^QEBU:VMKS4-0^W;)9
M8\(H(3)_A#``=LY-:>JVMW'JVLV[1:X/$D&HPQZ`T1E,8ME"JOS#]WMQN+[N
M3WYKW!Y8XRHDD12[;5#-C<?0>IJ0#*\'B@#PGQ+H^H%_'>O1-JPU*QO[=M,\
MEY0JDE-S(@X;C([C`KIO!FAV>D_%[Q=(;:\ADF6*2T9_,,4B,H,I#'Y3AR,`
MG(Y`XS7I5K=6][&TEI<131J[(7B<,`RG##([@C%3[?<X]*`/$]6M=134O$KP
MV]VOF>*+!PT<;C?&`-QXZKZ]JLZ,EQ%>^(R]OK1\:^;?FVD82^48]A\G)SY1
M7[NT>N*]CV\8S1M]^*`/G.XL;H>!+V32KZ_2]_LR!;[3DMKL/)-YL>9-S\;P
M<YV=1GM75OH\VB:AXLT>UU'6;+2WTJWE6[7S;AUG+8>1>Y8\;@O;->P[3ZU`
M;JW2X%N9XUF;[L9<;C]!UH`\/;[5)X>\/PR:=+%H,6I7"7S*EVT4^(0(Y0G$
MRH6+?+TW#-=_H.DBZ^&<^G7>H3ZK;31SB*1DEAD$>3M3Y_GRI&`3S@"NX`SS
MFHXGCN(P\4BR(>C(V0?QH`^?=-T673O#?A*'4;>\CT:>VN)KI9$N7"71(5<K
M%\Z_*O`Z#D]35N_L;_[5:PZYK5[/:C2$&FZM]DN]PEW$F0+'\PD'R9W]<"O=
M)+NVBNXK5[B-;B8%HXBX#N!C)`ZD#(S4^T]C0!YE\4/M,'PUTF.:^N9;C[99
MQS7-HICEE.<,R@<@GD@>M<L9(K"R\0+INGZU?>'GU&SCMX[I[I$CW(_G.0/W
MC1@E<C')(ZX%>SZKHEAK=M';ZC!Y\44R3HI8C$BG*G@CH:O[3_>-`'AVCC5S
M8:%%LOQ!!XQ<0J4E4):%=R<-\WE_-QN]>:H>&]/N&U[PC<7EIK;:]%JL_P#;
M,ERDQB5CYFPY/R<CH5XP#7T!L]S3'=(V56<!F^Z"W)QZ4`>8_$/0K.X^(?@O
M5;JWO&@$TD5S-;^8P3"YBSMSMRYZXY&<\"N?@34)=?5Y(=9'C)?$'#D2^0++
M=SD_ZORO+SP.<FO<=O?-&WMGB@#S[XBZ$_B+5]+TY(G82Z?J"K(`<1R;8C&2
M>QW*,9]*X*V@UKQ#%I/BC4["YBOI_$&F6HC:)BT<,*G>[#`P&<EB2/2O?MGO
M1M]S0!XAX<NKZ;XB:1/:Z;?V!>ZO+?44D-S*S($/EF9Y/D)++D;>F!]*Q)+6
M63P'<Q/!XB7Q@9P-3FQ/C_CZ7G/W"=N,;>P:OHK;[FHUEC,IB$JF11DKN&1[
MXH`\>\1Z+8:'X@BTK5(]<F\,II<C6;0//*QO3(2Q+)D[\'@MP,TI@UO1]2\,
M>(O$-O>NXT%K&6[BMC<O8W);*RNG)SM."0#DY%>R;?>E(R,=*`/";O4?$.M:
M=I<^N+<7.BKK-W'/.]C+%YT*Q`0.\<0#X)W=NH&>E7(?#LVJZMX)TZZU/4]0
MTETOR\Z">WS&""D4A;Y\`@CYL$@"O:=O?/-,E>.(*9)50.P4;FQDGH![T`>)
M>%U\1-<:&H_M$SQ:5J<,;3!AAED(A!+<9P!C-4[>UT^7P/#&+C7=/U@&%M5>
MYM[R2&XF!<F*0+SACG+)T&VO=FN(%9P\\8\L9D!<?*/4^GXTZ.5)8Q)'('0]
M'5@0?H:`.2\->)+2VTKPSIEQ975C>:G!(8+1B\AB5!D[F;Y@N,;=WJ!7#_%.
M>Z;7+Z"VTR]^VPV*3V%ZC7+DRAN1$L?R*0`22W7`KUM;73SK+7BQP'4A!Y+2
M<>8(LYQZA<\U;D=($W.ZHO=F.!0!X/KND:E)!XUU^-M7&J65W:/IWE/(`K$1
M[V1!PQZ@\$<5#XPTZXN[_P`2_;K36I]9_M6&2R\M)FA^Q!D(/R_)M'/OG'OC
MZ!VYP<GBC;[F@#A_B;.(-)T_S=-GO;>6]6.;9),(XD(.7D6$;G4=AZX-4?`R
MS3_#35+;6K:]GMDENX1;M$YD:V_A1%;YC\IX!Y[5Z.1Q0!@8H`\I^&^I746L
M7>GV&H7NI^$["S`BO+^V,4EO(&P85)4%PJC!XX([<9@L+*TU?0O$OBCQ,NIV
MT6N7*V\0C@8S6]K&X$>$"DC+#)^7W]Z]6MK&WLXV2VA2)7D>5@@P"[,69OJ2
M23[FIMO/6@#A?AQ?ZY?G6&U"YNKO2(KG9IEW?0^5/*G\19=J\`X`)`[\5YY;
M:!?1V-IJRG61?W'BMK.3;-*`EF[L&`4=%(/WOUKWW;GJ:-OO0!XTFEWND7&E
MZ;9C439VOC/;'O9WVVYB4\D]4W$\GC\<UG>']/OXO$.C2-9W2!+K726,3#;N
M`VG..,]O6O=MOOQZ4NWWH`^?[)&.FZ##XLM]<?2?[!<P"W6<L+WS6SG9R'VX
MP6&.:T_^$?U;7=>T.V\2#4BT7A9I+@1RR('G#G:'93RV"#C/4"O;-I]:"N>]
M`'EKR>)+G]GL/;B\DUQK$*V5/GXWX;WW;,^_XU@W%I=KX,\22>&+^]EM7%OO
MT^VM[F,P@/\`O6C,WS'<F[(7TKW'M2;?<YH`^?92TUUXC30/[6?3--ETNXA@
ME\TRK`'=I`BO\Y&6)P>WL*N7MUJ&I^+;[4+"'5!9S^)M(>$O!+&&A$;AVVD#
M"9ZY'<9KVBWT2PM=8O=6@@"7UZJ)<2[B=X087@G`P/2KVWW-`'AT7@J*34_B
M%8V46I6FJ;A<::X>8*P`5P5;HQW\=2<$BNP^&%W=^);?4O%]XDB'4Y$BMX6)
MVQQ1+M.T=LOO)Y/Z5WTUNEQ!)#)DQR*48!B.",'D<CZBH-+TNST73+?3=/@6
M"TMTV11KGY1]3R?J:`+E%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`#6Z@5XEINOZ\EGIMEHEU9Z?+J?B2]MII!:H5VCG=M_O<
M9[9.,U[<1FLR+PYHT#0-%IEJC03-<1%8@-DK?><>C'N:`/,K#X@Z[IS6MYK=
MY%/I=IJUYI%_,D"H7*+NBEP/NDG*D`XZ=Z(O%?C*^ET335NWMM0O=*EU61H;
M:)_O28BBQ)M`55(R0=Q)KTJ;POH5Q93V4VD6<EK<3FYFA:%2LDIZN1W8^M.U
M3PUH>MQ0Q:II-G>1P<1+/"K"/Z9Z=!0!PM[XE\76E_HDVK,FE6#V\*WIM88[
MG9=/)MVR#=N6)AC#+T)ZFN737_%NA:-XUO4\1_:Y[76TLX/M$((0F1`6QR%4
MJV-H&!@D5Z\_A+P]+=6EU)HMB]Q9HD=M(T"EHD3[JJ>P';TITOA70)Y[J:71
M[)Y;ME:X=H5S*5(*EO7!`/-`'F6I^(O'.FGQ19CQ!9R3^'X8+UI38*/M"R+E
MHL9^4#!P1R<C)K0'B?QAJ7B35GT93+;Z;JBV7]GM'"(Y8@%WL968.'.21@$=
M!@UZ'-H.E7#WKS:?;2/?QK%=LT8)G0#`#^H`J"Y\*>'[S58]4N=&LI=0C962
MY>%3("OW3GKQQ0!Y@/&7B^*6]U=M6M9--M?$K:0EE]D7,D9?;DN.00"N,>^:
MW?AF^NR:YXL75->?48;;5'MTCDC`(88.X<_*N"!M'`()KMCX<T5H)(#I=H8I
M+G[6Z>4,-/G/F'_:SWJ6VT73+/4;G4;:QMX;VZQY\\<85Y<=-Q'6@#Q31]7U
MW0FU_4=/UFQCLE\6202Z=+"&>;S90K-NSD'!!`']ULUTK^,/$4/BZ?P<]VKZ
MF^KQF"X\A1_Q+RAD8XQC<`"F2._M7<-X-\,_;A?G0=.-V)C.)C;KN\PG);..
MN><U"/"\)\=-XIEF#SBR%G#%Y0`0;MS-GJ2>GL*`,'XC21'6O!*!T+KK\!*Y
M&1E7QD5B0>-]?GG365U2U%F?$`TC^QO(7>R%]@(?.[S,?-S@8%>E3>']'N=7
MAU>?3;67485"Q73Q`R(!G&">G4_G4:^%]"363K"Z19+J;'<;L0+YF<8SNQG.
M.]`'CW@;5?$&@:9X>>+4+>32=1UN>P^P_9QN4%W/F&3KNR#QTQBK_A?QGXQF
M@\*ZGJ6K6EU;:Y-<6WV;[*J>5L#;9"PYSE3D=,>_->J1^'-&AAMH8],M$BM9
MS<0(L0`BE.<NH[-R>?>B+PWHD-O9V\6EVB0V3,UM&(AMA+9W%1VSDY^M`'FJ
M>._$>C^#O$-]J\WF:Y80Q2_8Y+9%AB\R0HCQNA(DC[\G/RGFJ_B#QCXK\.P:
MM91:]:ZI<106=S;WJVR*(O-E$;1N%X((Y!'..]>G6'A70-+M;FUL=&L;>WNA
MMGCC@4+*,8PPQR.33(/!_ANUL);"#0[".TED622%(%"NR\J2,<D8XH`P?!^K
MZZWBOQ!X<UN_AU"33DMYDN8X!"3YJDE=HXP".#UYYKR;6+G3W\4:EXBO(91H
M+:N6;4%427D,\`XAR#NBB<\#KP!TKZ'BTVRAU"XOXK:)+NY55FG5`'D"\*&/
M?':L^;P=X;N-3?4I]"TZ6]=MSSO;J68XQDG'I0!8TW5$O_#UGJ,R):_:[=)3
M&T@(0N`=N[H3DX]Z\9\":YJQ\.>&?#.E:M;Z.KZ9=W[7DD*R[V6X=0@#<`=6
M/4X':O9V\/Z0^BC1FTZV;2PH46AC'E8!R!MZ=>:KW/A#PY>V-K8W.AZ?+:V@
M(MX7MU*Q`]=HQQF@#RF+4M=\5^*O!NH6E];Z;J-SH]R9;GR!(N%?!9$)Q\V`
M1GH":DTKQMXR\4OHL5GJUKIK7&AS7URXM%EW/%,\>5!Z%MJY'0`G':O7AH^G
M+=V]TME`+BWB,$,@C`,<9ZJOH/:H+3PSHFGM&UGI5I`8H6MT,<07;$S%F0?[
M)8DX]30!YO9^-O$U]!X;U:YN4LM'N[6$W,MM;)-BY>78%E4MN2-@!AEZ$]:6
M'QOK\TZZR-4M1:#Q!_9!T80*79"^P$/][S.K<X&!^?H`\&^&A/:3C0M/\VS4
M);/Y"YB`)("\<`$D_4U,OA?0DUDZRND62ZF3DW8@7S,XQG=CKCO0!Y>?&7B^
M":^U9M6M9--M?$QTA;(VJ@O&7VY+CD$`KC'OG-='\0G>/Q/X*=3ATOIRI^D+
M5UY\-Z*8)(#I=IY4ES]L=/*&&GSGS#_M9'6K-UI=C?36\MW:Q3R6[%H6D4$Q
MDC!(],CB@#RKPEXN\6S77@^?5]3MKRV\1QW(,"6JQF#RDW!@PY+''(Z<U7\,
M>-?%[P>%=5U75+:\M-:FN(&M%M5C*",,0^\<[LJ1CIC'>O5H?#^D6XL1#IMK
M&-/#"TVQ`>1N&&V?W<CKBDA\.:-;0V,4&F6L<=@[26B+$`(&.<E?0G)_.@#S
M'2_%WBK4K/0;R+7;.63Q''<Q164=L@-G(J,R.IYW!2H#;O[W`IVG?$C4M7T^
M34#?)I]KI>C"74Y6M/-Q>,^P+LX/&QB!E>6&>!7I-AX7T+2]0EU"PTBRM;R7
M.^>&%5=LG)Y'J:=%X;T2"VO+:+2;-(+UBUU&L*XG)ZE^/F_&@#R>]\4^)+[P
MUXTL!K%S')IEE!>07<EM'%<,DB%F0A#A>!P1AAFHK'Q)JGA]M:U*YEMM1U"S
M\,VLZW)@"-(SL=N\CE@N1G)YQVS7K-EX5T#3;>>WLM&L;>&XC\J:..!0LB<_
M*PQR/F/7UIUEX8T+3E=;+2+*!9(?(<1PJ`T>2=A]1DGCWH`\LU[QMXI\.:;J
M2#7;74YCI,&HP7,=JBFW9ID0J0/E*L&.T\GC\:ZWPGJ_B`>,]6\.ZYJ,&H&W
MM(+M)XK<0["^0R`#JHQP3SZUT$'@SPU;:?<V$&A:?':76WSX5MU"R[3E=PQS
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M@NCZ#XC2XC.M7,!EENY;PB6>3:?.#`GY@#GC'&T'MFM;XI3PW7PFUV>"6.:%
M[4,DB,&5AN7!!'!K0O?A_P"'+F&\-KIMMI]Y=HZ/>VD"+,H?ARK8X)!(S[FM
M<:%I?]B+HIL86TU8A"+5EW)L'0$'KTH`\EU+QAXNTZ#Q+J=KJMLNG>'Y[6..
MRDM0QG#B,%6?J!\Q.1S73PZ_K&I_$+6=/37K33+#1Y+1!;20(QN_-`9LLQ#`
M\[1M[XZ]#V$GAO19K>\@ETNT>&]96N8VB!$Q7&TL.^,#'TI+GPWHE[J<.I76
ME6<]]``(KB2%6=`.F"1VS0!?M;NVO81-:W$4\1)`>)PRDC@\CBIJJ:=I=CI%
MHMIIUI#:6RDL(H4"J"3DX`]35N@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`X+3
M/BOH6I>/IO"4,5T+E)'A2X91Y<DB`[E'<=&Y/!Q7>]:QK?PEH%KX@FUZ#2K:
M/5)@0]RJ_,<]3Z`GN0,FMD#`P*`"O)+#QK?Z)XOU@ZW?23Z+/-?K;+)C$$EL
M=VP'&<,G09/(X%>MUQ6M?#/0M=TZ2QO'N2CZF^IEE9-PD?[RC*_</IUXZT`<
MMX+\5>)!=>))M9F-Y)%9V=\EI-(D"6_G`L5WM@*JJ5SGG@]3UT_^%J@6EVAT
MF.?58;^WL(X;6]62":2==R$3;1Q@'/R\$>];FJ_#S1]8?7C</=*NM0P0W"QN
MJB,0_<*<<=!G.:IM\+])EAO1/?ZI-=7<UO<&\:1%EBEA!$;IM4`$*<=,<4`0
MGQUKX\4V_AT>$2]^;=;F?9J"%(8S*4+9(Y&`".A.<8%*GQ%EEO!<)HCG0/[2
M_LQ]1^TC>DN[8',>.$W$#).?;UV='\'6VDZZ=:_M'4;V^>S^R/)=RA]R^89,
M\`8.3@`<`8&*HP_#?2H-3%PE]J/V-;_^T5TTS#[.MQU#XQNZ_-C=C/:@#BV\
M2ZAJ&F?\)9J_BW4="LGNI8;2VL+$SPQ+&^S,QVG)+>N`>@]NDO/B?%9:W=6O
MV".6PLKU+"XN%N@)Q(0N76#;ED!8`D'/!XJUJ/POTF_^W0)J6K6FG:A-YUUI
MUO.OD2/NW$@,I*Y(&=I'05I0^#8;/7;C4].U?4K);NY6ZN;2!HS#-)P"3N0M
M\P`S@CVQ0!SJ?%&[_M*=9?#<BZ5;:P=(EO5NE)\S=M4A"`2,XSSQD=:ATWQW
M=6FEQQP6ESJ>HW^N7-C:Q75TJJH1N<R!>%`Z#:370GX>Z5_9]Q9^?>;)]8_M
MACO7(FW!MHX^YQTZ^]12?#C2FL(X(KS4+>>'4)-2@NXI%$L,KG+`?+@J>F"#
MQ0!#;>.K^7Q;;^'KC0X[.[\J.2=;B^4-\W7R1C$H7O@@X[9XJUXI\77VA^(-
M'T73M$.IW>II*T8^TB((4VYR2#Q@YS[=#3QX$@DO]/N+O6]8O(["5)XH+F5'
M4R(.'+;=V2>2`P'MBM2^\.VE[XETO77>876FI+'"BD;&$@`;=QGMQR*`.3T?
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M(TW=\#/YUH1^#(K/7KC4].U;4K%;JY%U<VD#1F&:3C).Y"PW8Y`(]L4`<5X9
M\<W6E>#M)2X87^J:IJ5['&U[=^5&%C=RQ:0@X`&`!CN*V(OB9+J-OHT6D:$]
MQJFIO<)]EGN1%'%Y'WR9,'=U&,#G/:K\?PWTNWTW3K:UOM0MIM-N)KBUO(G3
MS8S+G>.5*D'..5["K.H>!X=233)9M9U9=2T[>(-2BD19RK_>5OEV$$8'W>PH
M`R?#/B[Q-JWQ`U?1-2T.&SL[2"*3Y;A7>`NN0&(^_N]ONX[TP^.=:L_B#KFE
MZAI<*:'IMD;Q[B.4,Z1A20^.IW8QM`X]370Z=X0MM+\1RZU;7^H&:>VCM[B.
M64.LXC7:KL2-V['?//-)>>#-/OO$-UJ\TUUNO;/[%=VH<>5/'@CYN-P(W'H1
M0!FZ!XYO-4U?3;74=#.G0ZM:-=Z;.+I91*H`)5P`-K[2K8YZ]:YCQ?XBUVQ^
M*<,?V2=])TO2Y=2$,%\(UF"@YDD&.<'Y-G/]X=Q78^'_``'8^'[ZVNQJ.I7[
MVEL;6S6\E5A;1GJJ[5'7`&3G@5>O/"FGZAXC;6KDR22OISZ:\)(\MXG;<V1C
M.?QZ4`<Y?_$O[!9V-Q_96_[5H3ZQM\_&W:JGR_N\]>OZ4NF?$J6>:X36-!GT
MW&DMK$&V=93);KUR!C:W3`_E3H_A3I0C\N;5M8N5&GR:;&)IT(B@?C:OR\8Q
MP>??.!6PW@?29;^*[E,\OEZ0=':)G&QX#US@9W>X-`'(:)XGUG7OB3X>FO+"
M;3+.ZTB:XBA6\$J3(=I5R!C#`'H1Q6YXE\?OX:U-HKFPMGLHY8HY'&H(+DB0
M@!T@`)*@GN5/![8S:T/X>Z?H>J6.HQZCJMU-8V[VMN+J=76.$XP@`4<#'!Z^
MI.!BOK'PSTK6-5U*_DOM1A_M)H7NH(70)(\6-AY4GC`X!Q0!;\7>+;SP]JFB
M:98:,=4N]6>6.)!.(MI10<DD'CG)/8`]:S(OB1+-I-B\>ARKK-YJ$FFII\DX
M55E0?.6DQPH^F3V%6O&7A;4?$7BCPO=6L\MK!I\ERT]S;RA)8M\8"E<@@\CD
M$$8ZTH^&VE_V1:V:W^II<VUZ]_%J*S+]H$S'YC]W;@]"-N*`,B?XH7ZR6-A;
M^%I9M:N+NXLI;#[8J^5+$BN"'(P4*L#GC@'K61>>/O%$D'C:#5-*&GQ:1;1L
MLEE>+YMO(X4A=^#NW`EL[<#&#US7:67P]TJQOM,ODN;V2\L+FXNS-+(K-<2S
M*%=I./0#`7`&*34OAYIFI7>OS/>7\::["D5Y#&Z["4P%=<J2&`&.N.3Q0!0U
M'Q[>V4]U::9HDNJ-I=C#=ZB[7(B9%=<@(-IWMM!8]!QUSQ6=>_%J:&?59K'P
M[)>Z5I<=O/<7JW:KB*5%884CEANZ9['FMW4_ASINI7T]TNHZG9&[MDM+U+69
M56ZC48`<%3SCC*XX-/N/AWH\]IK]J'NHH=;C@BG5'7$2Q*$0)D<<`=<T`7_$
MGBB'P[X=CU;[/)<M-)%%;VZD*99)"`JY/"]<DGTKS[QWXX\1?\(IJVGII3Z7
MJMM<00W1AO0<0RG"O$^T$[B"IX!7(->BZ[X8L?$/A]='O&G6%-C130OMDB=/
MNLI]1BLB;X<:;=:9J%I>7^HW4VH3PSW-Y-(IE<Q$;!PH4*,=`.YH`SO$<]_I
MEG\/[42W=H\FJ6L%S$USYCD",Y1W'W^1R>_6IYOB%<P>(8])?2K1GNI9;>U6
M+4TDE\Y%)5954$1AL=<DC(R.H'2ZWX>M=>N-*FN9)E;3;Q;R$1D`,Z@@!LCI
MS[5@V7PSTK3]7AOX;[42(+Y[^&V9T\M)7!#?PY.0>Y/04`<[HGQ1U=O!UOJ>
ML:5;)>7>I?8;/_21%#*=S;B[8/EA=I!)SG&172:5\2-&N=,:YU>:'2IDNVLF
M228.CRJ`3L<##J000:2+X::7!I2Z=%?ZFD<%[]OLY!(F^TER2?+.WD'<?O!J
MZ"QT9;>R2VOKJ;5F1RZSWZ1LX]OE4#]*`.0F^(>I73>);?3-%@\_1UF4)<7H
M25C'C]X8BN?+(R003G&.,YIFF^/=<?P5I.K7NDZ<EU>Q-)FXU-+>-U`!!48+
M;F!R%`.,')Z9WO\`A![6;6)=2OM2U&^=H9X(XIW0+#'-]Y5*J&QC@;B<5GCX
M8:<MGH\*:MJRR:2LD=K.'CWK$X`,9^3&,#`.,\GF@#&U3XQV]MIUK>:?IL<S
M3:<NH/#=WJV[;&<H$C&#YC95L@8X`ZDXJ[K'Q._LC4[ZU.EQ3)I<<!U#%Z%E
M5I!G$2%?W@48)((Z]*PM4^'/B/2M4C_X1AV,$.GQ6=E,UQ$I@*N[YE5XVW\O
MD%-IP,5VB^"G_M&35H]:U#3]1NXX?[0^PM'Y=S)&N-V'0D=QQCB@"QXI\5G0
M++37L[%K^[U.ZCM;2$R>4K,XSEF(^48![&N#T'QU?Z4-;:_MRVHWOB.2UM[2
M\OML=OB-68&7#`*O;`Y)'O7I'B3PQ9^)K*WBN9KFVFM9UN;>YM7VR0R+T89!
M'0D8(/6L-?AGI4<3^3J&J1W9O_[12]\Y6E2<H$8@LI!#`<@@]>,<4`5M+^)D
M%]=:5'<:<;6&\GN+2:=YP4@N(5W;=V`K*R\JP//I69_PMYVMEGAT1,+9F_EB
MFO1%)Y!=@GE@K\[LJ[MO'!`R373ZSX%MO$'AN'1]4U74KDPS>>EZ61;@'D8R
M%``PQ'`Z4V;P%9K?17FEZGJ.D3I:)9LUDR?O8D^X&#HPR/48]Z`.8@\=1V'B
M+QAKUS-=3:5;:;IUQ;6Y)&T2J2`%/W2S,,_KTJWJ?Q.U#0;74%UCPW]GU*U2
M":*VBO1(MQ%*X3*MM^\K'!&/QK>OO`&D:G+KLEZ]U-_;<$,-R"X`'E#Y&7`X
M;.#W&1TKGO$WPTFN?#=_#8WU[J>K7;VJ-<:A<*&6&*0-M!50!W.<9)[T`+>_
M$_4=+M[Y-0\*S0ZA:3VJ"U%VK>:DY8*58+]X%2".F>,T3?$_5;4:@MSX3=9=
M*N(H]35+Y&$*2X*.IQ\_!Y&!CUK4?X::=.]S+>:IJUY<7%Q;SO-<2H6_<$F-
M1A0-O)SQD^M7KOP+IMW+X@:2:Z!UUH6NMK+\GE`!=G'&<<YS0!C:Q\3X=+UW
M4+4:>D]CILT4%W,+H+.&?'*0[<NJY&2#GKQQ5>R^*5S<7=N\_AR2'2I]6.DK
M>BZ#$S;B%(CP"5XY.>/>NC;P;%%KUSJUAJ^I:>]W*DUU!;-&8IW7C)#(2,C@
MX(JNOP]TI=/MK(3W@BM]7_MA3O7)FW%MIX^[D].OO0!3\&>*O$.N^*?$6FZK
MI5O;6NFS>5'+%,&*MQA#_>R/FW8&.F*>OCRXDU36?)T5GT71IGAOKXW(#HR(
M78K%CYE'`ZYYX'6MO3/#%OI/B'5-8M;JZW:D0\]L[*8MX`&]>,@X&.N.>E9[
M_#[3&U;4+P7FHI:ZB[27NFI/BWG=D*,6&-W(/(W8R!QP*`,_3/B#>7-Q;+J/
MAZ6TAU"P>_TUXKE9C<*HW%"H`VR;2IP,]>M86J_%'7'\"GQ!H^D6`S=11<WH
ME,2LV-LB8!5\\$=MP.3S75:1\/;+2)4E75=6NI+>T:RLVN)E)M(VX/EX4<\#
M!.<8%0R?#73;G3=4M;S4M3NY=2>%YKMVC64&(Y3&U`O!)Z@DYYH`6'QO>-XP
MM_#DVC1VUR88I9_/O55OG7+"$8Q+L.0V".G&:A\0>)I=%\<3QC[3)':>';C4
M6MQ,%BD*/Z;<AN"-V>AZ5IW'@R.]U6POK[6=4N5LI(IH[>1H_+,J*`'X3<"<
M9(!`)[5+J_@ZPUG5[K4KF:Y6:XTN72F6-@%$4AR2,C[W/!Z>U`&/X7^(-UKN
MKV%CJ&@2:9_:5C]NLG-RLN]!C.X``KU!'7(/:H?$'Q-31-;U.SCTZ.YM]*$/
MVU_M8CFS)S^ZC(_>8&">1UK>L/!FGV.I:->QRW)DTBP_L^`,PPT>`,MQRW`Z
M8^E1W?@R%O$%UK&GZMJ>F7%[Y9NTM&CV3E!A2P=&(..."*`,VX^($T?BL>&X
MM':2^F>)[4^=M6:V969IB=OR[=K#;W.!GFL#7/'&L:[\,]<UFQTN73M->UD-
MEJ"W@\T[9`GS(`"A(W8P3C!Z<9ZF\^'FEWVM_P!M3W-Y_:JWB74=VK*'C"#:
M(5^7_5XSD=\Y)S59/ACI<>CWVC1ZGJZZ3=1/$ECYZF*V#N'.P;>N1QN)QD^I
MH`J:5X_OO]*T_4-`:UO[;3HKZ%);Z,++"S!-TCM@1D'D@YXSU/6G/\6G@M)P
MNB)=:A!J5O8M!9WHECE\]&9&CDVC<?EQC`Y[UO:U\.='UZ6[DO);P&ZTZ/3G
M$;J`(TD$BL./O;@/;VJ!/ACI?VC[3/J.I7%PU[:WSRRN@+R6X81\!``N&P0`
M.@Z4`5#\3?LVC:E-J.D_9-2T^_CL)+=KM?)\Q_N,9L8"8Y)QQZ5!%\49I-'A
MN9-+LDN[K4WT^V3^T08'\L9:0S;,!>PP#G(]\2>+?A_<7-G>W&B/))<WNJ0:
MA=0O*J,?+&,1,5*J>A^8,.M/T?P5J^HZ-$GB6]FM[RSOFN=,EM9(S-:(1C:Q
M6,1L3SGY>_K0!TWA#Q-'XIT>2\6V:VEAN'MIX2V\+(N,[6'#+R"&'4&M^J.D
MV4NGV"VTVH75^ZDGS[K;YC9.<':`..G2KU`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`",P4<UYIX:^)T&K:UXEN;^ZAL]&TMMD:26TBR`9`WLQ'4DXV8
MR*]+(!ZBO.+WX<W][H?BJQ^WV\<VJZM_:5J^UF5,%"JN/JF#C-`&P?B=X633
MKF^FO98(K6:."X2>VD22)GY7<A&X`\\XQP:U(O%NDS>&X]?26;^SY3B-C;OO
M<[MH`3&[)88`QS7&ZG\/_$'B"XN=1U2ZTQ+^>YLCY5N)/)6&!BQY(RS,6/4<
M#C-=AXPTK5=9\-7-EHNHG3[Z0H5G#LG`8$KN7D9&1D>M`%G1/$6G>(()I+"2
M0M!)Y4T4T312Q-UPR,`PR.1D5S</C2[FT7QK??9(!+X?GN8H5R=LHCCWJ6[C
MT.*G\$^%M1\/76MW.H26S2:E<).%MY))!&0FT@M)\S?4UBW_`(%\4`^)M/TO
M4=,CTOQ#<F:::97^T0!P%D50!M;(&!DCK0!T_B/Q+)X?\$7'B$61NI(;=)C;
MHVW.[`/.#@#.2?04_P`&ZKJ6LZ+]MU)M)D9W_=2:7<-+$Z8'4L,@YR,4R[LO
M$J>?;:?)I#6*6:1VR7<4C,TH(W>9@XV%01QR"1P<<\]X=\%^(?#,6LW>FOH=
MK?ZG=Q2FUBCD^R01(""%Z'<<D]`*`.PUGQ%8:"(1>"Y>2;=Y45M;23NVW&X[
M4!.!D<UB7?Q1\)6:6;/J+R?;+;[5;^1;R2&2,$@XV@\@JV1U&#Z5+XQT/7M8
MN-*ET>_CABM97:ZM99Y84N5*X4%H_F^4Y..AS7.>%?AIJ6@7>G237EI,MGH]
MQI^5#`EY)VD##(X&UL'OUZT`=/J7C_PWIUC8W,NHAX]0C,EL8(VE+(!DOA02
M%'<GI69X8\<-)\)X?%VN[2R12RSBVCP#MD90%&>^!WK+T[X?:_HD/AB?3K[3
MC?Z592V4XG5S$Z.Q.Y2,'(..#C/J*U=+^'[0_"K_`(0K4+P-NBEB:Y@7^](S
MJ0#]1D?7GO0`[2O$_B2*,ZIXET:ST_1I81)$UO.TL\))`59%Q\Q;(QM'!X-7
MV^(GAN+2+S4Y[N:""RE2&Z2>VD26%GQMW1D;@#G(.,5B2Z#\1+KPS)HSZUI-
MHZV@ABO;43>>[J5PQ/`3*@@XR>>*R9?AAK=WIOB&.>ZL$N-7GL9@HEFE6/R#
M\P9W!9B0`<GN3T%`'8V?Q$\-7UC<W5M>3.+:1(WB%M)YQ9QE,1[=QW#H0.:)
M/B)X:BT@:B]Y*$-R;3R#;R>>)AU0Q8WA@.<8Z$5AZYX&U^[UKQ%J6DZM%92:
MG]B$6V22-ML.0Z,RC*AL]5YXK-MOAOX@LRNH0WFF_P!IQ:TVJ1Q.TKPD/&$9
M&8_/D8.&YSWH`TO"OQ)@OM+U"]U)Y)E_M6XM[%;*RDD>2!-A!**"<X89)QUK
ML(O$FE7'AMO$$%TLNEK`UP9D!/R*"6XZY&#QUR,5P,/P_P#%=E"#;:Q:,TNK
MW.HW<"RS6\5P)57"DI\WRL&.,X((YK2@\,W?ACX*:AH$K+=7,&G7B@VZ,?,W
M;V``ZY^8<>M`%ZS^*?A&^AN)8-1D*P6S79+6TB[XE^\RY7YL8(..]3P_$CPO
M<Z0=4@OI)+7[0+6,K;2%II2,A47;ESCT%<38>!_$NO\`AC3OM<NEVT2>'7L;
M94B=9<RQI_K<CY=N.0,\Y..:ZG6?!^J7&F^%WTNXM$U'071E6X5O)EQ&$897
MD>H.*`,;QA\5[2VTC2Y?#UTADU"Z\@W$]I(ZVP4_/N0`$N./DZX.<5/-\6K+
M2-+@O-4C^T"XU26Q1[&&3:J(V"S;A]X9^Z.O;.#4B>`-6>33[RYO;0W@\0_V
MS>+&&$8&W:(X^.2!CD@9YS4$GPZUA/#,-E;WEB;VV\0G68O,W^4XWE@C$#(/
M/4"@#MM8\3:7H=C;W5]+(J7+K';I'"\DDKL,A51023CMBN/G^*-AIGC*ZM-1
MG,>DC3H;F`K:R-*2Q)9F`&54`#.0,5O^,=`O?$.EVMO#9Z;/+',)6^U2RQ>6
MP4X>)X_F5@>A]*P(O`&LG^V)+O4K>YNK_P`/II9N'W;FF"D,[<?=)/UXH`Z.
M^\>^'M/F19[N0Q,(V:YCMY'@C$F-A>4#:H;<,$GO39?B!X<A\2R>'Y+UEU*-
M@'C\E\+E-^2V-H&.^:X?6/AAXJU+2#I*ZS:-9'3;2T6.6>94MY(0NXK&HVL&
M9?O-R`>G%=3'X)N'U+QM-<7,2P>(88H8C$I,D06$QL2#QU.0!Z4`:VA>--$\
M171M=/GF\_R1<(D]N\)DB/`D3>!N4^HKH*X7P;X/O]$NK-]5M-+D>QLQ:V]W
M;W$\DN``#\K_`"J"!G`[UW5`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`@.>U+7E6B^`/%MC\7K
MSQ)=:X)-)E>1M@E8M*C#Y8BG0!>.?]@>M>J#..>M`"USND>--+UK7=4T:W6>
M.\TYV6031[5<*=I9#GD`\5T5>)>(O#GB>U^TZSH>G3'4VU;4+;:$.6MK@<2\
M=0I&X9[]J`/1O#GCO1O%-[J5MIIG_P!`VEY)H]B2(V<.A/5?E//'2MY;ZV>W
M-PEQ"T`SF42`J/QZ5Y%)X5U30?\`A,(--T`:C"NFZ=!90SIF*Y:(#><`C<0<
ML1QD_6L>3POKLUIJ[Q^'[LZ6VJZ=>G3EM5MA<0HC+,J0!BH^8#*YYP":`/=/
M[0M/E_TF#Y@&7]ZO()P".>0:>;N$7'V<RQ^>1N$6\;R/7'6O*=(\&6&K?$B/
M4KCPC-I^CPZ9NM8;B,(L<XN&;.U3@$@[@O;/2L^V\-ZG_;"13>'+L>(%\1?;
M?[=*CRQ:[]Q_>9RP*97R^G-`'<7?Q-T>#5)[*UL=7U-;:3R[JZT^R::&!AR0
MS#N!UQFNM%[;F=8/.C\YEW"/>-Q'KCK7BUQIOBWP_P"&+GPYI5AKL.I6]Y+)
M8WNG;#;7222YS+GE2%SP>E6KGPO>W'C35#J=CJ27%QK$=S8ZI96"2F*,!`G[
MXG**,$,N",9ZYH`]?6]MGE6%;B$RDD!!(,Y'48Z\52T_7K>_L[BZ>*6SC@N'
M@?[5M3E3C(.2-I['->1+X&O(UU'5X]#G367\7^?%.H/F"T\P$LOHA!;/KWZ"
MGMX9U:+2;![S0;J]L+;Q+=75WIZQAFEA8G8XC)PX[T`>S_;;??$GGQ;I1NC7
M>,N.N5'<?2EFO(+?'G311Y!8;W"\#J>:\DM-#,/CG2[_`$OPG?6\<I@2:WOK
M-&BM(E&0\4P;,3KW49R>*Z#QCX67Q%\1/";WVEF\TFWBNC<EES&K%5*!OJ1T
M[T`=VMW`\BQK-&9&7>J;QDKZ@>GO31J%HR2.+F`K$<2$2+A#[\\5XWX>\$7E
MEIGAR]?09O[5@NKZ&82$@FW,4PC1SGA"?+`],\=:3PEX8U'5->=-4\.G3-/O
M-#DL[V)+$6T)FW@C@,2Y`/#GDX.*`/:#<QB18RZ^8PRJ[ADCU`[BD^UP?:1;
M&:+SR,B+>-V/7'6O+?A':ZA?WM]J6JJ/.TB!=`MSD'B(DR-P<9)V#/\`L]35
M&Y\+WT_C74SJ=EJ2W%QK,=U8ZI9V"2F*(;0@\XG**,8*X(QGKF@#TCP[XLL_
M$.@_VPJFTMC/+"/M#@?<<KDGH,XZ5KS7D$$(EFFBCB.,2.X53^)KQ.'PUKD'
MAGPPMUH]S+:6FI7TU[9?95N&^<OY3&%B`PY/?C=FK4OA:2RM_"<TFB:KK.@6
M;WAFTV>W4RQ-)_J_W!.-JD-CDX#4`>K6NO:7=:K=:9;7T$M]:A6GA5OF0-R/
MK^%.BU_2Y]8FTB*]A?4($#R6ZM\RJ?\`]72O/?!_A>#1?B;J-ZOA>;3[:YL;
M=K*18P4MVV?O49@2`Q.!WR1GZQ:GX3N$^)7B"_T_1GCN+_2&%AJ,2`1Q711P
MS,V?E8\#..<T`>I1W<$TLD<4T4C1G#JC@E#Z$=C22WD$,B)++'&TAPBNX!8^
M@'?\*\J\":%<0:_H-Q;>&KO1&L=,:WU>:=`@O93MVX`/SG<&;=UY`]*N>(=&
M<_$N74-3\+W6N:?<64,-F855Q;2J^6)W$>7U!W#T^M`'I0NX#<FW\V/S@,F/
M>-P'KCK3YIXX`IDD1`S;078#)].>]>*Z-X:U5=4TR*?P[=Q>(;?7)+J[UQE`
MCDMRQ)_>`_.&7:H0C^M7/B9I.KIHMA%KVHC6[:Z\16H@M(K9;=TC/F`QA@?F
M)!`!..GO0!ZR+^U:))1<0^6YPC^8,,?0'OTH:_ME\K-Q"/._U69!^\_W?7KV
MKQ!_!4FJW$<4/A>]L]!G\203?8IDV%(!"5D8J#\B%C^M6O$7A*:'5O$=B/"=
MSJ$=S;6\'A^XMU!2QVKC&_.8L/\`,?4#G@T`>RF^MA*(C/#YA;8$\P;L^F/7
MVIR74,H8Q2QR!&*L48':1V..E>':WX#U&XL/&VH-H\]SKC7-H=.N40AVV^7O
M>+GCHV2*U]=\%WUI9>,K3P[I4D-O>+83)#$VU;C:6,ZISU(`R.Y/O0!Z9J'B
M/1]*TN34[W4;:*RC(5IO,#*"2!CC.3R.E7/M]J/)S<PCSO\`5$R#Y_\`=]?P
MKQ+7/!D^M:#XLFT?PG/IUG+':-9:=-$L;M<(W[R5(P<)^[;;Q][!JSK_`(::
MYU?<_A_4O[#GTB*VL8H-.6>6R()+``MF)QD$')_2@#UO5]832+-+F2VN+A7F
M2';`H+`LVT'!(X&><<^U6OMUKYPA%Q"92Q78)!NR.HQGK7#>--%O[KP5H=C:
M)=7\]M?V32.RCS&5"-SL!T/K7&ZKX&OI(?%FK0Z).VLR>($EL)U4^8(`ZDO&
M<\`Y;)'7\*`/8-2U_2]'EM8M0OH+:2[E$4"R-@NQZ`?EU/%4]%\5V>M7^JVD
M:^3)I]ZUEB5P#,RJ"2H].:Y?XI^'(]:?P[>_V&^J1VFHJ;M((P\AMR#N&,@D
M9QQ7*:IX'O98?%>K1:)<-K+^(8Y;"=5/F>0'0EH^>!C=DCK^%`'M8NX#.;?S
MH_/`W&+>-^/7'6J&I^(;/2=3TJPN5E\W4YFA@9%RH8+N^;TKRZ'PM>R>,;TZ
MK8ZE%>/KS7MKJ=I8I)B'CRU:?.0FT8*XXQ77>/K+4/[2\,ZS9Z?<7\.EWYEN
M(;8!I=C(5RJG&<'M0!TEOK]I<:IJ6GY,<NGO%'*TA"JS2)N4*<\\'\Z34-?M
M[&"UG2&6\CN+I+4-:[7V%CC<W/W0>N,D>E>5Z_H6M>*=.UF[FT*\AAU+6[(Q
MVKC$PMXEV,[`'*Y'/6HK[P?J-GXEO(-+T:>+28_$NEW=LD*?NDC2-A+(H[`'
M&X_2@#URR\0:5J-S>6UG?P3S6;;;A$?F,XSS_C5N.\@F@,\4T4D0SF1'!48Z
M\]*\6U#P3J$)^(EKI&@RV][?A6L;B-0L<D!*&6)6SC+8/RX%27GA2ZO?"OB1
MM$TS4[:6Z%MYNG26264<RQOEC&BL06*@@],Y%`'IVF>*;?5?%&K:)!"<Z=%!
M*;@.&242@D;<>F*JZ9X]TW5];FTZRM-2>&$R(^HFU9;0.GWE\P]Q],5SOP^T
M1M.\9^([ZV\/7&BZ5>P6IM89HU3E=^_Y5)VG/./<>M9MMH=X?'Z+H^CZSI^E
MWD\YURUO-IL9T((W(,D$MG/';TQ0!Z3I_B+2=6TXZA8:A;S6:L4:8/A5(.#G
M.,<T7?B+2;">R@NM0MXI;YMMLK/_`*TXSP?3WZ5X[I7A[4-#\$06*^"_/NDU
MEC?"XL_M`,)+A9(TW@284A1G@9_&H;?P5>_8/#MQJ?AFZN8[/6KGS81`/,2U
M;+1@(#P@8YP#@'/X@'NHO(#<&W$T7G@;C%O&['KCKBE6YB>9H5DC,J`%T#C<
MN>F1U%>/6OA:]?QC=G5;'48[UM>-[;:G:V*2`0\;%:?.0FT8*XXQ6OX(T>;3
M/&^I-#HUW'93^?,]Y?V:QS1R,Z_NUE5OWL9Y(R.,#UH`]0HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"DV@TM%`#=HHV#-.HH`;M&*-HIU%`#=H]Z-@IU%`
M";12;!VIU%`"`8-!4'K2T4`-VBC8*=10!5L-.L]+MA;6%K%;0!BPCB0*N2<D
MX'J3FK)4$YI:*`&[1ZFC:*=10`W8*7:*6B@!NT>IHVCU-.HH`;L%07NG66HB
M$7MK#<""59XO-0-LD7[K#/0CUJS10`W;[FC:*=10`W8*-@IU%`#=HI=OO2T4
M`-VBC:*=10`W:*-@IU%`#=HI<9&*6B@!NP4NT9I:*`&[11L%.HH`;L%+M]Z6
MB@!NP4;`>M.HH`;M%&T4ZB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"DR/44'I7E5EXNU%_%
MUUI\6N&ZO3K;VBZ1);H$6U5OF=9`H(*KEN2<XQC)H`]6S29'K7$PRZ[XF34+
M[3=9_LN&TNYK:UA6W2193$=C--N&<%PW"D<`<Y/%?1_$.J>-O(2QNSI$::=;
M7ES+%&DDADFR0B[P0%`1LG&3G'&*`.^R/6C(]:\WU/Q'K=GXQ;PK%?(U]>V%
MNMK<F`+%#*3-YDI!)R=J+A,G)'89(T;GQ/<>'Y/$L&I3^>VGV<5Y9LRJIE1D
MV8XXR94//3YP.@H`[BBO,-4U[Q%I&F>((IM19KW3O#MM=B3RD^6Y8R[V`QTR
MHP#P,5U6KZE>6WBOPO90S;;>^>X%PFT?/MA++SVP>>*`.EHK@-7O=0N/']UI
M2>(K_2[6*QMY8X[2T27>[O*&+%HVQPB^E=]CY0,Y]Z`%R/6BO.O#GC6[%]X@
M'B&>(6MN]U<6<B(%VP03/$ZG'5AA3[AJE\*>(O$#Z5KT^JP+>WMI=(8[="D'
MEI)%')Y99L#Y=^,GGB@#T"BN.B\?)<:38W,&D7,MY>W4UE%:)+&3YT6[<-^=
MNWY&.[.,"IH?&L4T,*2Z?/%?OJ@TR2T+J2DF-Q;/0J$^?/<=.HH`ZNBO.-/\
M=7VD?#W2]8O[*74D:*5[JX%Q%&RJCD9"L07.!T'I[UM:SXY&EW]W;0:->WRV
M*Q2WDL+(!#%)T;!.6/#<#LI-`'6T5Q6O^+Y,:C::?87K0VDR6T^HQ%=D,QV'
M;MSN(PPRP&!FNIN]2L=-56O;J*W5R0IE<*"1]:`+E%4+;5M/U)918WD%PR+E
MO+<-M],_E7!:#K7B&S\+^'-?OM5.J0:I+;Q7-O-"D;1&=@BM&R`<*Q'RL#D$
M\C%`'IE%<AIWQ`L]2UFWM([21;.\ED@L[PS1GSG0,6_=@[U7",02!G`Z9%1K
M\0$_LY]6DT6]32)`OV*[,D7^E,SA%`7=E=Q/!;`QR<4`=G17'P_$"U_LC4+R
M[L)X;C3YX8;FUBD28@RE0FUE.UL[AQGCI4+_`!!:%)FN]`OK=;*X2WU)S+$R
MVA?:5.0WSC#J3M'`-`';45Y[8>,K[3]9UJ*_L;NXTN+6OLG]H>8FRU#K&$3;
MG<1O?DXXW"M*V^(%I<:Y!9"RE6SN+I[*"\,L9\R==P(\L'>%^1OF([>]`'84
M5@Z'XC?7;NZ6'3)XK*WDD@-W(ZX>:-RC(JYSCC[W3J*RK^\UG3O&VDVT6I&]
M@U"24S6)@11;P*I(D##YN"5!R2&)P,4`=GFBN-L+O6K7QX-(EU(ZG:O9-<W)
M,"1_8VW`1@%>S?-\K9/!.:ZR[262VD2"40RLI"2%-P4]CCO]*`)LT9'K7FTG
MB/6]'@\21&\&IQZ?/:V]K?3QJN)9G571@F`VS>I[?W3SS5[[;X@TR_U?01JB
M7]U'IZ7]M?7D"@H"S(ZLL84-C;E>G7!-`'=T5R-KXENAX`T2_(CN=9U.U@%O
M$WRB:=T#'IT4?,QQT534O@?5+NY\%07FL7HN+B.2X2:Y9`@81S.FX@<#A:`.
MIHK,A\1:-<3)##J=I)*YVHB2@ECZ"N5G\4ZE;?%"32YFC;12D%L%"#='<2J[
MHQ/7!\ME^I6@#O:*X#0?$^IZGX\OHUFCFT62SFDLH(T&XF&58B^XXSN8O[8"
MU;M?B'"UOJ9OM*N+>ZL9((Q;131SF9IB5C565MN2P(P2,4`=I17)3>,+^W-G
M:3>&;Q=6O#*(;(7$1!$>PEO,SM"X?\QC%-OO'D5G/=R#2;R;2;*X^RW>HHR;
M8I<@$!-VY@"P!('KUQ0!UV1ZTM><W_B.>5;O5[OQ-_8.F07TUE;1I:+-YK1$
MJS2D@G!96P%V\#KD\7KSXBV>FR>6T+WMK:K"+V_C>.-5,BJRE8RVYLAU8@`X
M!'6@#N**Y-O&Y_MHV46BWLMK%?C3[B]5DV12MC;\N=Q'S+D@8&X56A\9"$7,
M4-O>ZCJ$FJW-E:VI:)"WEC<V&X`C4#J<GD=:`.UHKE;+QC+?>(%T=-%N$N(H
MT>^$D\2FUW`D?+NS(./O+D?CQ70ZC(\.FW4L9PZ0NRGT(4XH`LT5P5EXYO(?
M#NB#^R[O5]5N=&BU&58"B;EVC>W.!G)&`.N[BM1_&;3W<-OI.BWFHM]GANKD
MH\<?V>.4$KD,PW/@$[1Z=:`.II,CUH/(KS"^UWQ'#X:T_4M.D<ZAJ.NRH+:Z
MP4,*^<%B7(&%98EP1@Y;.:`/4**X73?&,VIZKJ-WIH:]T]=(M;NVMMR1GS&D
MF5P6;&TC8`<GC::<OQ'A?2[>6/2I3J%Q>RV*6;7$2J98^6_>D[,8Z<\G@4`=
MQ17%Z_XQF@@U*TM-)OY);.TWWLT#(39.\9*#&<N1P3M!P,'FKFK>*Y-"OM.M
MI],DFMKIX83=+<1`AY&"#$9.YADC)`[^U`'445RH\:J^HF.+1[V33_MHT\7Z
ME3&9]^QAMSN"@Y&XC&1CTKH;:Z-T)MUM/!Y<K1CS@!OQ_$N"?E/8_I0!9S29
M'K7G?AOQK=B]U]?$$\0M;=[JXLY%C"X@@F:-U..I&%/ONJAHWBCQ1=R/H]W<
M01ZM>ZEY44K6^5LX?LR7#+MXW,H<*-WN3TQ0!ZI17F<_B9X/"7B:?3/%[:K=
M:=9&1&ELU26!_F^9B%"L.,`;?X3US5FR\4:E?ZMH&ES3BVOA<75GJT42#'F)
M"65ER#A3\KKCL<<X-`'H61ZTM><:-K&N^(M0N?#=Q=M:7.BH\6J75N5#7+.K
M+`T>,[<C]XW3#`#ID5UOA+4+G5?"FEW]XC)=3VR-,K=0^/FSP,'.>,4`;5%<
MUXD\6/X;NK;S=+DGLI7C22Y2XC4H7<(,1D[FY89P*MZ]X@&C?9((;*:^O[V1
MH[:UB95+E5+,2S$!5`'7W%`&UD>M%><Z_P"*-0LK^YGG%[811^'9KR6U0QM)
M%*DRKE20RDX)P>001Q6OJWC<Z5?W=K#HM[?+8+%+>RPL@$44G1L$Y8\-P.RD
MT`=?17'7/BX:?KVJV*6][?7:W,%M:VBF-5=WA,AVL<87:"6+$XQQZ5-K/B^]
MT3P_'JMQX?G&U)'NH6NX4:`)DG!+8?(!(V]:`.KHKD['6V;QMJ44MWLT\:99
MW$22L%56=I03GU(5>_:NK5@ZAE(*D9!!X-`"T444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`"'I7*OX*A^SNL=Y*L_]KG5HIC&"8I"<E0/[I&5^A-=43@5S.I?$#P[
MI=OJ4DM]YK:<A>>.&-F/'&U3C:3GCKP>N*`*]SX.O/.U`:5XAO=,LM0<RS6T
M,2-L=OOM&Q&4+=3CN21R:6?P3Y%W:W7A_5)M$F@M%LF\J%)4EB7E`RN,97G#
M=>35E_'GAV+1+;5YK_RK*Y)$;M#)G(ZY`7(QZGCWJ35O''AS0_*_M'588O-C
M$J%59QL/1CM!P#VSC/:@"G=>!X+Z6\N+J_NI;J>VAB2X94$D,L3R.DR$``,#
M)V&,#'K4NL>#H-<U#1[R\NY?.T_;YNU0!=`,K@,.PWHK<>XZ$U=F\7:%;ZK#
MI<VI0I>S;=D1SQN&5#'&%)[`D$Y%4_$OBR#PSJFCI>M''97KS)+*VXE"J;EP
M`#DD\8QWH`-:\'0:S)K;R7<L7]K:>EC(%4'RU4N0P]3^\/Y54N?!^KWAL+B7
MQ5<G4+":22"Z%E"-JNFPILQM/&3GKS6O#XCM+R[TD65S:36NHPRS1/YC!W5`
MO*#&"!NYR01QU[,T_P`9^'M5N9K>QU:VFEB4N54GYE'5ER/G`]5R*`,ZY\*:
MJVM?VK:>)[BTNY+.&UN&%G$XG\LL0V&&%)+MP..:W=.35%GOWOY8VBDN,VD<
M8'[N(*`-QP,DD%O;=CM63-XVT:ZM=4&DZC;W=[8VDESY()P^U2>#CYAD8)!.
M*=X>\;Z-X@TWS[>]A-Q#:I<74*[OW0*Y)!(^8`@C(STH`H7/PYT^ZALTEN[H
M-;:E/?;D.W>LTA>2%L=4)P#_`+HJ;4O`T-_-=SB]ECDGU.+4@#$KH'CC$81E
M/#*0,_7![5HV7C+P_J&GSW]OJ<)M;>18YI)`T?ELV,;@P!&<CD\4QO'/AQ+>
MVG?5(D2YP8=ZLI8%BN[!&0N5;).`,<]10!4T_P`$P6":6!>32-87\]^#Y:J)
M'E5PPP.%&9"1CT%,3PW/+\39=>DC=+."S58E9@5DN&RK2*,\$1@(2>N>^*U;
M7Q9H=ZM\UKJ4$RV"A[DH2=BD$ANGS`X.",CBHH/&GAZYT>XU:/5(?L-N_ERR
M,&4HW&%*D!LG(P,<Y&*`.;D^%=LU@+(:K/Y36/V&4M;QLVSS&?<A(^1OG()'
M4`=P*Z)_#$3W>MW+7$N=5MHK=U"C]V(U8`K[G?W]*)O&_AR#3+?49-4B6VN6
M983M8LY4X8;,;N._''>KZ:]IDDS0I>1/(+47F$.X>220'R.",@_E0!B7'@MY
M+W4GMM9O+6RU&9;FXM41&!E&,D,02`P501[<$5U:@\D]:YRW\=:)=>*)/#L,
M\AOUC61?W3;&W!FP&QU`7//'(P2<@-@\<Z+'I^ERZCJ5E%/?Q+(BPN\B$,<!
M@=H(3/&Y@HH`Z2090CUXKC-%\!2:?#IEI>Z]>:AIVF,C6EHT,<:!D^Z7*C+[
M>HR>H!K</BG1CKXT(WR+J1.!`RL-QQNP&QM)QS@&HO#OB'^T_#']KWPAME22
MX65M^$18I73<2>@PF30!4TCP>=$N4%G?*+%)I)5MVM(RZJ^3Y?F?>V@MD=^V
M2*J+X`QH/]AOK-V^G0+BRC,2%K=@X>-BQ'S["H`SV)SGMJ1^./#DNESZDFJP
M_9('$;NP93N/0!2,DGM@'/:I1XPT!M*&J#5+?[$6*>;D\.`3L(QD-@'Y2,]L
M4`4I_"4E[H]SIUYJ(*33P3*8+2.+9Y3J^,#KN*<Y]>*-0\&07]EX@MFNYD&M
M3QSR,%!,118UP/4'RQ^=7+3QCH%_>VME:ZI;RW-TI:&-2<M@9(Z<-CG:<'VH
MMO&.@7FK+I5OJD$E\ZDK",_-CJ`2,%A_=SGVH`RY_`IN+^Z9M8NETZ\U!-0N
M+)8T`>5=I`WXW!<I&<?[/N:GT[PB^DZ@TME?!+0W;W(MVM(V9=Y)9!)U"EF+
M>HZ9Q5VS\8:%J%S>6]KJ,;S64;23H592J*<%N0-P!'49J.'QSX:G^U>7J]NP
MM"@F(W87<VU3G&"I;C<./>@"[H6C1Z)9W%O'*\HFNY[HEQ@@RR%R/H"V*Q-.
M\)ZII^O76ICQ-/,+J4O-%)9Q$E<$*@?&0J]@/?U-=&FI6LFH3V"3*UU;QI)+
M$,Y16SM)[<[3Q7':#\1[#5+K6KJ:\M+;2M/D,2;XY%D.&VARQ&#N/`0#=0!=
MT'PKJWAQKF4:_-J8DWRM#/;11F>8]&:0#=Z#T`P.U:W]GZM<^%EL+K56BU1[
M<)+?VT0!5\?,RJ>![4Q?&7AY]'?5EU6W-DC>6SY.5?LA7&[<>RXR:LV/B+2M
M2:T6SO$E:[B>:!0&!=$8*YY'&"P!!YYH`Y^V\"RCPS<Z!>ZW<7%FZI]G,=M'
M"UNZ-O#@J/F;<`3NSDCGJ:M/X3NWBU"8ZW,-5OHHX&OOLR'RXES\BH<J`<L3
M[M[#&A/XLT2VGL89=0C$E\%:W4*S%PW0G`^4'U.._I2Q^*]$FUMM&CU&%M00
ME3",GYAU7=C;N']W.?:@#*L_`UB?#=EH>MR'68+%E%JTT8B:-538H^3&<#/)
MY.:O^$O"EAX1TAM/L`Q5YGF9VSEBS$COV&%_#UJ&V\7Z7J>N6]AI=_;79+NL
MX0G*[5)!7L1D8)&1VZU<U;Q7H>A7$5OJFI0VTLHW*K9)"YQN;`^5<Y^8X'!Y
MH`V<5RFL^"+76)=:>2\N(GU..W`>+Y6MW@+%'0^N6S^%7M3\9>'M':-;_5K:
M$R!67DME6Z-P#\O^UT]ZT-1U:RTFPDOM0N([>V3&9'/'/0#N23P`.30!SMSX
M$LKF(0K=W,,0T=M)`C(W!"RGS,]=V5_4U77X=P&UU!)-0E6XN_LS)-;01PB!
M[<DQ.B`8ZG)!SGZ5>3Q;!-I5[J=I<6<EI%=0P0RR2,J$/Y6=Q`)#9D(QCJ`#
MCDUH1>*]#GOKVSCU&$RV2-)<DY"1JOWB7(V\=\'CO0!6A\-SMK.GZK?:I-=7
M-F)PH\I44B54&`!T`V9ZGEC[5GW?@);E[^V75[J+2M0O!>7-D$4[GR"RJYY5
M6(!(]N",U?'CSPTVF/J`U:'[,DHA+%7#%R,@!<;FXR>`>`3V-7K3Q)I%\UDM
MIJ$$QO0YMMC9$FS[P!_O#N#SU]#0!AWO@F=_[4CTO6[G3K352[W=JL$<J%W`
M#NA894D#GJ,DFA/`PLKIYM,U`VPDAACD66UCG.Z)0@=2PX8HJ@]1QG`-:%SX
MX\-V<<;SZM`JRR/&G#')1BC'@<*&!!;[OO5BZ\3Z3;7:V)OH/MLBDQPY)S\N
MX$X!PN._2@"&V\-16O\`:!%Q*WVW4TU%OE`V,OE_*/;]V/S-9[>!T21;JUU*
MXM[Z/4YM1AF$:L%,O#QE3PRD<=C[U;D\;Z)8:-8W^JZE:P?:;>.<>67=65AG
M<OR[BO!Y(''7%/U;QQX;T/RO[1U6&(2QB5"JM("AZ,2H.`>V>O:@"G/X/N;S
M4-.NK[69KG[#.ER@-M&DC.H/R^8!D(2<[?3C-:VGVNIR:!]FUF=)+V59!*\*
M@*H8G"CIG:I`S@9QGO3]4\0Z9HM@E]J%QY-O(0%?RV;)(R.%!/3VJ&Y\5Z)9
MZ9;ZC<:C"MI<Q^9!("6$J\?=`&2>1P!F@"GI?A"#2KC3IDNYG^PZ0-*4,H&Y
M05.\^_R=/>HD\'RVM\MUIFLW-FTEI#:7(6-7$JQ<(PS]QL%AD9'S=,@5>G\8
M^'K;3K*_FU6W6TOAFVDR3Y@[D`#.!GDG@=\5-I>KI<>'X]4NY(8HS&TLDF_"
M*H)^;/I@9S0!<MHKB%K@S71G#REXE*!?*7`^3CKR"<GGFN6TCPK/]@L[&],T
M/]D:S+>V\FY6^THQD9?]T8F(QVVU>L/&.DZA<W4UMJ%LVFVUMYTL[,4\L[B#
MNW8VC`!&1SG-6;#QAH.I"`VFHQ2&>?[/&"K*3)M+;<,`02`2,]<'%`&#<_#*
MPDU#5;NWNYK?[?<6]R(!&K11O$S-C:>"K%F)7IDU8'@=X=$N-,@U;:EU//<7
M'F64;J[2C!PIX4`\C'XYK8N_%VA6%K/<W.I0I%!<&U<X8DR@`E%`&6(!SQGH
M?0U4?Q9;-KFGPQ36[:7=:;<7QNR^`@B:,9ST`PYSGIB@"A_P@'V>.:&PUS4+
M6WNK**SNE"H[2^7'Y:ON8':VW`..N.W6G7G@&&\UN;4#?R(LUU;7;1^0A8/!
MMVJKGD(=H)7US@C)K6L?&7A[4K>XGM-5MWCM@&FR2I12<!B"`=O^UC'O567Q
MQH\^D:A>:7J-E,UB567SG=$3+``D[2<'/!`(/K0!4D\(W=E,S6&IW;64FJ)?
M&Q*IM5FE5Y/G(W%<[FV^I_"NGM(+B'SO/N6N"\K.A*!?+0]$XZX]3R:S[_Q=
MH6F:DFGWFI00W;R+&(VSD,V-N<#"YW#!.`<U%=>-O#UGK*:1/J4:WSRK"L01
MV_>-T7(&`?;/%`&5<_#JPNH;-)+NZ#6VI3WP=#M+K-(7DA;'5"<`_P"Z*L7G
M@>WO+F\O1?7-O?2WRW]O<1*NZWE6)8L#((92%Y!ZYK7N-:CM=:-E-+;)&MD]
MV^7;S`JL`6V[<;!GDYSGMWJ"R\8Z!J#7JVFJ02FQ3S+C&<(G/S9(^9>#R,B@
M#)F\#2W]MK:ZIK5Q=W&K6:63S"!(_*C7<1A5X)R['GUJY>>#K:Y\7V/B6*>2
MWO+6%XF5$!67*E59A_>4,<?7'2K=GXPT"_COI+;5;9X[$;KERQ58UY^8DX!4
MX/S#(..M,L_&OA[4(A);:I"ZF9(""&5@[G"`J0"NX\`D8)XH`S(_!Z:''8ZC
MIKW4^H:?;S)*H*AM2+C)$A/&3)\P/;Z5:\-:/K&BVFCZ>]PGV"RTU8IU.&>6
MX)'.<<!0#WYW>U7=0\6Z)I8N3=WRI]EE6&;;&[E'9=P7Y0>=O/'3O5%_B%X=
M36].TH7;23:C")K>2.)FC8,5"_,!_%N^@P<D<9`*NL>`8=6UB]OFOY8UO'MY
M)8_)1R&A(*['/*@E5R.^#TS6OKF@'5[C3[R&[EL[[3YC+!,BAQ\PVNK*>"K+
MQV/H12Z5XDL]0FN+9[JT^U0O,2D3L1Y<<AC+991R",-C(![G@F&?QOX<MHK&
M2;58$6^C66WR&^9&Z.1CY5_VFP*`*.J>!AJ\4_VS5+F6:?2Y--DE,:9(=PY?
M`X!!&`.F*O2^%XI+S6[@W,H.K6T5O(-HQ&(U<`CU)WG\JZ!2&4,""",C%+0!
MR5_X*2[U>YU:'4;BVOI+N&[AD1%(B>.(Q8P?O*R%@0?7BJVK>`&UF0RW>L3O
M-+8R6-P[VT;;D=RQ*`C$;#<5!&>,=2,UVU%`&%:^&;6'5Y[Z4^>);."T,4L:
ME<1%R&^IWG\JW%544*H"J!@`#@"EHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@!#TKSX^%=<EM]:TVUABTS2KZPNXA;&[,Z&XE8[9%&W,:X9BP!QENG&3Z%10
M!Y_J^D>+M5TRVM0D5O;MI\MM-;17NW;,0%21G"9=,9RO'XUS&L6O]EW>H6-X
ML<@BTBPCELH[GR&OS'NX3Y&+G.%&-IYQ[CV>D*@G)H`\]D\*WTNI:FTNGO>Z
M?J-Y#?B-M0:#RW'E[E=`"#M,888Z]#ZUN>)=+U2?6M"U73;>"Z;399FD@EF\
MK>'CV?*=IY&2>?2NF`Q2]J`/.+?P+J[1Z>+F:VC=H]4-T86)$#W9#*J9^\%.
M1GCI2Q^']?:+13J=M96T&@Z?/&9()C(;AS$8AM&!M7:-QSSGCWKMH-7MYM<N
MM(`<75M!'</D?*4<L%P?7*&M#J*`/*-$\/:WKOAG09GMK2U@L_#DEK;8E+/.
M\\*J"PVC8`%&>O)/I713>'=<MM%M_P"R9+6WU6#14LDF.,>8I0XSM/&`V#C@
MG.*[0#'>L^[UBWLM7T[39@_G:@9%A*KD91=QSZ<4`<._@O6;G3M?61$$NI7=
MC-&D]T9F"PNF_<^WDD(2![XK5\2>%]0U74]=N;80;;WP\^FPEWP?-+2'GCA?
MF'-=I2$GM0!PNL>&_$7VN.\T2:WM[B+15L48OM^<31L0/E(`**X#8."1Q5)?
M"&O()[^-(6NEUJ'4XK>YNFD,B)"(2C28X;&6!P0,`5W,FKVRVMY<0%KO[&S)
M-%:KYD@<`$IM'.[!''O2:?J]OJ-[J-K"'$FGSB";<N!N**XQZ\.*`.6U'0]=
MO-=L=<-LJR+!-:SVUM?-$RQLX9&#@89OE`8<#G@G%5%\+:UIUQ#)H^FV$,,F
MAC3/L\MX[+:L'9@=VW,BX;'8\>]>B55O;Y+$0%U9O.F6%=HZ%CP3[4`<W9:+
MJVG^*OMBPP2V5SI=O9RMYQ5HGB\PYVX^8'?CJ*Q_#/AGQ)X76#RK:PNS/IEK
M:3AYRH@DAW#/W3N0AR>,'(QWS7HW:L^\UBWLM5T[3I5D,VH&00E5RN47<<GM
MQG\J`.2C\/>);GQ987VHS++!9:G-<))]I^4P-&Z1JL04`,`_))['DYXD'@_4
M9OAG>>''EABO)Y+AT?)9!NN&E4'H<$$`^F3UKN:*`.+U'3_$NJOI.I2:?80W
M6F7B3BT^TEA,IC9'^?:`"-Y*\'[O.,\4X_"6KW&H1:G=16D4TWB!-3E@20L(
MHD@,(&['S.<*QX`R3Z5Z!52:^2'4+>S96+W"NRD#@;,9S_WU0!QR>$=233+2
M#_1_-C\2OJCD.>83.[]<<MM8<?AFL7PQI&L:QI.C)';VEM8Z?JM[>BY:0M([
MB6=579MXY<DDD\`>M>EF^MVNI;59HVN88UE>$-\ZJV<$CL"5(_`U'HNIVVMZ
M-9ZK:>9]GNXEFC\P8;!&1D4`<+9>$_$UQ->76JNCW<VA3:>[O=>8))W(.Y1M
M`1..F./PR=@>%$?28+74HX!`NA#3[EAR00%Y!QT&"0>QKL:0\T`<7\-[:]E\
M/OK>I@'4-6D$\C`8S&JA(^O(!50W/]\U5E\)ZS'9R2VXM7NH?$<FKPPR2$)-
M&<@*6Q\K88GH1D"N^`Q2T`>>/X6\0/J\GB/R+(7IU6.[6P,QVM$D#08,F,;\
M,7Z8!&/>M*[T[Q$_B#2=<AL;`SQ6MS;2VYN2JQ^8Z,K;MIW8"?,`!R>*[&J+
MZI;+%>O$_P!I>R!\^&W&^16VAMNT<[B""!WR*`..;PYKUL^E2:=!#;ZE#:VM
MO<7Z7A\MT1B9$:$J0X`+;3URW;',-AX,O[6865Q9_:;:'4)[FUNCJ#!8A)YA
M#F'&"Z^85QG!ZYKT.-_,C5\,-P!PPP1]13J`.(\.Z#KEF?#]O?V6G)%HMN]M
M]IBE+23#8$5@"HV@@`L"3S]*?JFC:];:]K=]I=K97L6K6,=OMGF,9@D0,!G@
M[D(<DXYXQWS6]8Z]%J6LWVGVUK<-'9-Y<UV0HB$N%)C'.XL`P.<8]\UK4`<%
M8^"+JRAO;23[/<0OX=MM)C9A]^2(2`DKV4[E/>MCQ-H^HW]EI,M@(9+O3;V*
M[\F9RJS!592NX`X.&)!P1D"MZ[O+>PMS<74\<$(95+R-M`+$*HS[D@?C55=8
MMVU^31@'^U):K='Y?E*,[)U]<J>*`.8O?#FL:AH&JPM:V-K=WVIV]XL<,I*!
M4:$L6;:,O^[;)QR<5G7G@[7+ZUU;3+1(M+TNZ@E(MWNS.C7!F$BNHV@QJ1NW
M`'&7Z<9/I-5[B]M[5X4N)XXC/((H@[8\QR"0H]3@$X]J`.1NK'Q/>:SH^NOI
MMA'-IYDB:S%T2721%#N'VX!5EPH(Y!.2,U1_X0[7(_#C74#6<7B,:I+JL*JQ
M\J-I,JT1?`)&QCDX'(''%>B44`>;MX$O--:V2S@:]M&T=-/N(5OFMF+H6.XE
M000YD?=Z=16SI7AFZLKW6Y1!!!!>:;:VMO$LI?88XW4J21T&X`'O73W5[;V?
ME&XGBA\Z188_,;&]V^ZH]2?2K%`'#:)X2O[*YT=KM+9X[7PV-+F`;=F7*9`!
M'*X4\_I7):U;#3K[4;2[5&6/2K".6PCN/(:_,>[Y4^1BYSA1C;Z>X]FINP>_
MM[4`<SXAMM?O7TN72V=;4"1KRU%QY$C$J/+^?!X4YR!C.>^,'.TGPCJ-A#X(
MCE,#_P!B12I<L'ZEH2@*\<\GVKL+B\MK+RA<3QPB618HS(P&]VZ*/4GTJS0!
MPD7AK6-)UC3]1TZUL;A([>YLY;624Q*B23>8KJ0I'8`KCITJU<^%;V[^&C>'
M"]M!>&W"`Q@^2&#;@H[[.,?2MW7-<@T*R6XFBEF>25((((0"\TCG"H,D#)]2
M0*T()&E@21XVB9E#&-\;D)'0XXR/:@#A-6\-:[XCL]6>ZM+#3[JZL[=(A#<,
MY:6*4R`.VT?*3@#&2`31+X5O[NRU"YCT];36=]M<VT\^H-<^9-"6958D#:G)
M7CDAV^E=_10!YW_PA>J6NG^&[B)O.O[)YY+Z-+HPF1[CYI65P.2'Z9`!!/2H
M-1\!:AJ&GP6UK!!IR#3KR`QO<M/MEEN(Y02V`6#;&+>F[O7I=%`'EGC'2M:N
M](\1:]JMI;6FS0'LHX()3,SLS!W8G`P`5P!U.23CI5O6/">O^(4UFZFM[&TF
MN+""PM84F+A@DOF,[-M&!R0!BO2*.@H`XZX\,7D]_P"*IF2W:/4WM6M]QS_J
MD4'=QQAAD5RD$JP>*K@/%]IV^)6>+3XKD1R1NRE?/\K825VEG)W@$$M@=*]<
MI"H)SWH`Y+7/#M]J6O7E[;^5Y,V@W&GKN<@^:[`KQC[N!UJK>>$KZ;PR]C''
M;BZ;PXVED[L`R;0`,X^[G/Y]*[<#%9^I:Q!I<^GQW`?_`$ZZ%K$57(#E689]
M!A#S]*`.:U[PC?:EID\-H+6.X-A:Q(SYVM)!-Y@1L<[3C&>VX\57O?"FK>)+
MW5[_`%*.#3I)["*UM$AE\UDDC<RK*S8&,.0`!S@9R,UU^D:O;ZU:2W%L'"Q7
M$MLP=<$/&Y1OPRIQ5^@#SRW\/>*K.PLG62,W%S=7-WJ\-M<^29)7'[O;)M)V
MH`%QP2`.N.9=%\+ZWH3^$W2*VN?[-TZ33[M1.4QO:,^8ORG<!Y9XXZUWU%`'
MF5_X#UN32F6RF@BOI+R_CE8OP;.ZE9FYQ]\#:0#D9S]:NZOX.NEU:_>RLC=Z
M7?:='9O:)?M:[?+#*$.`<HRO@GJ,=#FN_/2H(;L2WD]MY4RM"J$R-&0C[L_=
M;HV,<XZ9%`#[:,0VD,00($15V!L[<#IGO4M%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`C=#7D[>'Y[G5%O)K*^,\WB>:VEE!D!^PD.VWCI$6
MP?0DUZR>128'K0!Y1)ID]K8MIDVGWK>&[7Q%(DMK$CM_H;0@K@#YFB$SY.,C
M`(Z#%,BTB:YBBM+>RU&/P_-XC58+>02+BS^SLLGRGYDB,@/!P,$<8->M<>OZ
MT8'<T`>67>B16+:5IMWI]Y-X7BU"]6:W5'D5-Q!@W*OS&,$OC@@?+GH#5*RT
M]I!IB:[IFIR^%Y+B^,%M-'+(8E+(;?S(QEPNU9,!@<$CIQ7KC2P0O&CRHCRM
MMC5F`+G!.!ZG`)_"I.,]>?K0!Y/KME=?VE=2VFF:F=*-CI2W$*H_FM;++,9(
M^#N9@I7<H);!]ZB?3)3%JUOHMEJ-OH,FIZ;';0JLD8QYF+EHU/S*A5ADC`ZG
MWKUS"_Y-&!Z]?>@#S;4=(M=#TRZT6WT7S]'NM74%)HY98;5#"C%@B<E=X(`!
M`!;)-5_#&G7\*>!5FLKF,6USJ.\/$R^5&PD\L'/*@@J`">F!7J.`!UQ^-&!Z
M_K0!Y7XZBN=3\0R)'HKB\L9K,V5XEO*\DR&56D*.N$C"@,#G)/XBKESX>^W:
M[KVIW-K=FZL]8M7TZ7+C8FV`OL[;2=^['7!!Z5Z3P._ZU%<316\/F2R!$R%W
M$]R<#\R0/QH`\BG\.VFG:/\`$2VL=%GAU2<SFV:*W?\`>0,D9`1@,'+[N`<Y
MS1KFD_\`%0>(+B'2M0D\03:C:R:3<QPR;%`CA#,'^XH!5PV>H&#GBO78IH9B
MXBE1S$Y1PK`[6ZX/H<$<>]2\8H`\CNK"22]NW.FZG_PEK:X!;W:I(%%IYP8$
M2`[!%Y(((S][.1DYJQINGJVK6\EWINK?\)`NLO\`;+GRY#$\!D=H]S?<,>PI
M@#HPZ#FO5,#I4+3PBX6W$B^<4+A,\[00,_3)'YT`><^&[*\;Q=_8):3[+X66
M9H))3N$C3_ZC.#SLB+CJ#S[\6O&FG?:=2\,MK]JU_80SW!N_L=K*456CVIN5
M2S8W$9[?A7<6FG6=E+<RVT*QR74OG3L#S(^`,G\`!^%6N,YS^M`'BU[:W5SX
M.M=)O-`F:#R;V;3GN[:::2$;R+>$*IRLA1E(+GC&*UC:R0Z[X>O+FUNM4OEA
ML86M;BUES:$C]Y-',/E!'5P>NT#(R*]2P/7]:7`]?UH`\?T?2]1BO&N7FF@\
M4++=I*XL9LW3%)-@:8MY?E9*,IP!E5&!6KX*L;6'5-)EM--U6VG%C*NI-=1R
M*C7'[L$L7^](2&^8=1WZ5Z2Q"+G/`'-0_;+06:WCW$2VY0.)F<!=IZ')XP<B
M@#ATT73;7XMWFHR:2XFN;&)K6[6!V7S@91(2XX4[2@YQGBL7PSX3N-,\*Z7=
MZ39W%GKESH5S%*[EA^_*J8]X;H0W`ST&17K.T=,_K5.+4["XU2?3HKR&2\MU
M#30))EXP>A8=LT`>::!IBVVF:I-8&[AN)M$E$UD-/GB+SX^_(SLP:;.1QR<D
M\T:II-O;^&M'TZ7P^)EOK5KR\N9[>:=A=B)1AE4Y\QB3@L0!M([UZQ@'O^M)
MM7K_`%H`\>GBM7D\/V/B>RU"\A3PNKS6J1RRO]H4J`65.2PRP!/<U!/HVJ30
M6L/B8W23IHD'V6Z:UFNVMIU#>85\M@!,"4(SDG`P>"*]<AM=.NKZ/6(!%+<>
M28$N4?=F,L"5!!QC<!^57`%[']:`/,YY+NSU;Q1;-::G<2W_`-A:UDCMG(=5
MC57<MT7!!R"<^QJG<>'[.PG^(J6NBS1:E=6T[6<L5L_[R-K9-P5P,$F3=\N<
MY[5ZS@>I_.FL`!QG\*`/-]'LK7_A)9Y-<TS4)-42YA;3+@12%8[<Q(!M8?*H
M#+)O!P>><Y%3_#^W6RU.]MHK66<-`DTNKRVLMO+<.6;Y)5?[T@')8>O05W<%
MY:7'EK#<Q.TD?FHJN"63^\!Z<CFK&!C_`.O0!X])X833+/Q!=6>B3I$VOHER
M+:-A+-IX$3.J`?,RELD[>OS#U%2/I<OE:M!HMEJ5OH+ZGIT=M"%DC&/,Q<M&
MI^94*L,D8'!/O7KN!1@'O^M`'"^/O"]A)X`%A:Z2LT%E/!)!;PQEC&@E7S-J
MCD_(7X'J:R=2\*:7KGB"4+I5P-+B\.!+'$<D8BD$DF-H.,.!@@$9&?>O4#CU
MZ48'3/ZT`>0ZYI=U>:U=/JTES`WV"VDTV\6RGN'MR$P_E[&`64/SR"2".<#`
MZ'XBZ)8ZDOA^\OM+>_AM=147)2!I&6!D<-E5R2N[9G`[5WN!V/ZTFU>O]:`/
M--0T.\U"_P#%]Y96TPOH+:-=%DD#*(F:V`;R\\!CT)Z\`=JSK2W@T[2]1GTR
MPFN8;NU@CN-+.GW,,:[I,/-)N+,\B@_,JG)"]>]>KSRQ0HK2.%4L$4D]68X`
M_$D"I0!@?XT`>)MX8@E\.?Z5HLLUA:>)DDBC2TD`6S81AVCC.6"$@Y'/<UI^
M)='FNI/$5Y96-]FTM+!M(,:R*8F.0YC']X*%![@5ZT0,]?UHX]?UH`\GU_0[
MK2KK7+'1K.ZCT:06%U<Q1)+()099!/MP=S$JL9958$@'UYF;23#X7FLM,DNI
M;:36K0?9[:TFMT@B9HQ*L88EMA!9F8'`+-TQ7J.%_P`FEP/4_G0!Y/XC\&:9
M:Z>L":-+/IMGK\$PB$3R"*W=(_-V*.2F1R!GO72>,H3)X<TF.VM+J72%NX/M
MUO;HV_[)M(QL'S$`[-RCG`.1U%=GA>N?UHVKU_K0!XS<^%K?5)@L6BW+Z$FO
MVJ6,$\3@)#M`N&5&Y6-F'4X'<5V7C6P3/A^VGLIY_#L<[)?06ZLP"^65BW*O
MS%`Q&>HZ9KM>,T8!YH`\=\:6L=]I`T[3?#MQ&EOIIETJ62VG>82,Y`2/!Q$5
MVALL2<,.``:U];\._P!M:UXFGN[6\D:UM+2739%+KMF"N6:/'!;*H#CGMWKT
MK``.*CAFBG,@C<,8GV.`>5;`.#[\C\Z`/.I['S?$NN27VG7LFO\`VK.BW?EN
MT<<9C`0JX^155@Y<'UY!R!5/P?I:P1^<ANH+Z72I4O+4V$Z---A07FD=B&<'
M=MQU#$CBO5L`#';ZT8'K^M`'&>#1I_A_0-`BNHY(-6UF&/SC(',LUP(=[[\\
M@@*>N,<#TK'^*$<FIF73O[%-PRZ;+-9W9MY9F^T'Y1''LP$?[K;F/?IP:]`A
M:RO+AIHVAFFMV:`N,%HCP63/4=%R/I3Y;B"WDACEF2,S2>7$&;&]L$X'J<`G
M'L:`/.YK8P^-],O6M+C5+MVM8#'-:R@V`\OYY8YON%>[*>^1GM5SQUIVISZK
M#'IZ7;PZU:G2+MHOF%NI<,)2#P`$,PSUR5KO\`__`*Z@-Q`+Q;4S()W0R+'N
M^9E!`)`]`2/S%`'DL]AKU[H=S?75M=%[%K72YXU25WFMHI,SLJ@*SA\H3M/S
M!#@]JT+321;G2(M.,TUK%XCBF\F.REABM4^S.#L#DG9N.2V<;F(KU$A>_P#.
M@CCCKVH`X?1FO=)\$:],-,GN;E;[49H[,@HTZF=RH'&?F!X(_"N6TS1E6Q\2
M6Z";3=-N38&,VFG3B%VRWF+Y1.\J>%<\<=<8KU2WU*QO'C6VO(9C)'YJ".0$
ME,XW?3/&?6I[FYM[54>>9(P[K&I=@,LW``]R>!0!R&DZ5_;WPUGTH:<-($J3
M0PQJ'0*0QV2J&^9`2`X!Y&:P89]6O-$UKQ!JNAS37-P+?3#931OA(DP)9-BY
M9DWN[87[RJ/>O4U.5ZTN!Z_K0!Y#8:/=+X?.GQ6=REC+XHC"Q0PRPJ;1D4.5
M4DLL9R^>>Y]:FUK2)K+6]1@@TR\;0$ETR.Y@MD<AK94F#*H'+*&,>Y5R<9SD
M<5ZQ@>IX]ZCGE@MH6FGE2*->KNP4#\30!Y-]BGM4FN-.L-0B\/VWB"RFM8?*
MD)2)!B9TC.6";^>F#R0,5<U^--5TV:YN8+Y(3J,T\=A=:?-)'=J(5"B14^90
M3RI/?MGBO4-JYSWHPM`%#0W>70]/DELVLG:VC+6KG)@.T90GOCI6C28&<TM`
M!137<*N2<`#)--@FCN((YHG#QR*&1U/#`\@B@"2BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`1NE><V7B2[O/'>E_8]3O9](U&>[@,-Q#"L>84.?+V_O.'7!+<'G
MU%>CG&.:H0:-I-M>O>P:=9Q73,6:9(5#DGJ<XSD]_6@#B]`\07VM>'-!AEUC
M9J%_%=>;)$(_-`3>`P4C'!`[8]:QO#FH:I'X1\&V`\27`DUHD/?2B-WM@(2P
MB3*X)9A@%MQZ]>WIUMHVEV<[3VNFV<$SL7:2*!58D]3D#J<G\ZC_`.$>T46L
MEJ-(L1;R2"9XA;IM9QT8C&,^]`'":?K^I76HZ5:7%[#>BW\07-@+L0)F:-+5
MW#=,!@QP2N,[2.,D5#H.I^)=<;0XG\1/"VM:7)?.\=K$3;%#&H6/(Z'S,DMN
MZ<8SQZ/%I.G016T4-A:QQVK%H$2)0(B002HQ\I()Z>IIT&FV-L8#!96\1MXS
M%"4B"^6AQE5QT!P.!Z"@#SZT\0ZUK]GX3ACU(Z?+JEK=/=7$$2,Q:`H,H&!`
MW'/8X!(]#46D^)=>:W\.ZG>:DLZZ[83NULL"(EO(D1D5D/)/0@@DYSGC&*]%
MBTRP@\CR;&VC^SAEAV1*/+#?>"\<9[XZTL>F6$2VRQV5LBVH*VX6)0(01@A>
M/ER..*`.*LO%-S-X6TZY_M"*6^;PW)J$Z@KN\T)&0Y`Z<EO:L^77?$FCZ#=Z
MO)J0U$W&BIJ$4#VZJMM(67=MV@90!P<,2?E.37?V^A:1:)(EMI=E"DBLKK';
MJH8-]X'`Y!P,CVJR+*T$8C%M"$6+R0NP8$?]W']WVZ4`<SX6?7!=W46I7<MY
M9-#%-;W%P8/-9FW;AB$D>7@*5)YY/)KGKS5K_4Y]2GDUR"V@M=:CT\:6Z)AT
M66/#9^_YC?>';'&#UKT"PT72]+9VT_3K2T9U",8(53*C.`<#H,G`[9HDT72Y
M;XWTFFV;W9`!G:!2YQT^;&>,#\J`/.[O5];676VMKLVMA:ZO<_:YK..`7$<2
M01,"JN,.`2VX\MC;CTHU'Q/J5Q:>(=5LO$*6<6B6\<MM;-!'MNP\"RJTFX;@
M'9MH"XP0>IXKT"Y\/Z+>EC=:38SEG:0^9;HV68`,3D=2%4'UP/2GW&AZ3>7,
M=S<Z99S3Q!1'))`K,H4Y4`D=CR/2@#@[_P`2:XC>)M2CNV2+0[2.:.Q2)=LK
MR6X?#D@MA6.0!@]<DBH;_5M2T)-2OXM<M]<N(=&-Q"_E(&BWR+\Q"<&,?>&>
MP.3WKTI;2U2:>58(EDGQYSA!F3`P-Q[X''/:JUIHVDV,31V>FV=O&ZE66*!5
M#*>H(`Y%`'"76K^)]&T/4;A[]IX\V36EU=B!I,RS!'^6$X,>T@KGDY/-6[RZ
MUG0]?L8M2UR[?2T>"!;B*.!GGFE=AMG7;N4'Y0I0`=<^M=;!X=T2UCDCM](L
M8DD"!U2W0!@ARF>/X3R/0]*DET;2IM06_FTZT>]7!6X>%3(-O3YL9XR<>F:`
M,7Q;J+0O8Z9;:A?6=]>&1X391PLS+&N7R9?D51D>]<WIFL^(/$5GX6M(M8-C
M/J6C27EQ<PP(S&1#&!@,"`#OYX[<8SFO0;[3-.U-8UO[*VNEC;<@GB#[21C(
MSTXXI\=C8PR0O%:V\;PH8XF6,`HI()5?0$@<#T%`'GAUW5]1DBM)-?MM+>WT
M.#4)9&B39=2/N#[MW(C&T9"X/SCD=]'7KV:R^$"7=N8_,2PMBI:-9%Y,8Z,"
M#U[BNLFT?2KG[/Y^G6<OV88@WPJWE=/NY''0=/2II;*SGM/L<UM#);;0ODN@
M*8'0;>F!@?E0!PT>H:_>:S>W<6L>59Z?KJ:>;+R$*RQ-Y>26QNW#S>,$`;><
MYKG-/GUCP_INJO;ZS=S->>)9+!Y7C@_<Y8YE&0J[VP%&X[06&!V/KBV=FGF;
M;:%?-E\Z3"#YW&/F/J>!S["F2:7ILUK/:R6-J]O<.7FB:)2LC$Y+,,8)SSDT
M`<++JOB*TM+#2[_4/LDU[JS62:C((6F2'RBZE@N8Q*S#8./0X)IFE0:@OQ0$
M4OB^[O8H]-5RA6%4E(F="A"KC((Y(P<YZ#BNX70='6QDL5TNR%I*_F20B!=C
M/Q\Q&,$\#GV%.&B:2CVLBZ99J]H"+=A`N80>NTX^7\*`/,_#6MZIK%G:61U^
M+1EMM+^WM)%;PCSB9I5.0PVA%"#.T#[PY'?0T?QI?7:QW.HWD%I')X8CU%E(
M5$68NX+#=SC@<9Q7<3>']#N;>*WGTBPEA@#"*-[="J`_>`&.`>_K4MSH^E7T
MT4MUIUG<2P@K&TL*L4!Z@9'`]J`..;6=6M_$FG2:EJ$T&ES_`&:"V%JL3K/-
M(F66<$;U)/0K@8Q5G7=4OI/%Z:-;:U'H\46G'4/.=$;SV\PKM._^!0,MMP?F
M'([]-_8FD"_6^_LRS^V)@K/Y"[Q@;1AL9X''TXJ6\TK3]0:%KVQMKEH6WQ&:
M)7*'U&1QT'2@#SRQU+4T.G1::]B;D^$S<0-*JB,R[XPIW_>"<],XZ9J-_$.K
M+!8Z/#JFI&]EU)K.]N)XK83VSB'S!$AP(F+<8)SQD8)X'HLFCZ9-&8Y=.M'0
MP&W*M"I'E'JF,?=X''3BH_[`T86)LO[*LOLK2>:8?(787_O8QC=[]:`.`U;7
M=;@T`V4^I7MKKEO!=W>ZT2W;S((F*H\S-E`?N[@G.2<"K8UW5_[0T.]U"_>U
MTJXALE'V)(F$EQ-U296!=5)P%*8`R<^W8GPWH9ABA.CV!CA9FC0VR80L<L1Q
MQD\GUJ0Z#I#7D=X=+LC<Q!1',8%WKM&%P<9&`3CTH`XCPOK'B75[^SU&6=S:
M7%U/!=6DOD+':A-X54P?-,@*J#N[%C@<5?\`".L7[7UU:>(-2D.I&!;E[<B+
M[-'&SE0T,B#)0D8PYW<?B>H70M(2_P#MZZ79K>;S)YX@4/N(P6W8SDCC/I5"
MY\(Z#/8RV":;;6UK,T;3);1K'YH1MP5L#E<CI0!A^.K>]?Q!X4%MKMWID<M[
M)$X@\O;_`*B1MQW*<GY<8.1STS@UD:IXGU>.WUW6X-;2#^RM3%C%I)BC9)EW
M*HW'&\LX)88([<''/I%]I]CJ4`@O[2WNH@P8)/&'`(Z'![U#)HND2Z@E_)IM
MF]XI4K.T"EP5X4[L9R`>/2@#A!JU_J=VUW-KMO'"GB!;`:4Z(`%CN`%*G[_F
M'`?GC:>G>B/7[_4?&%C'INL7[:;J<EY;*L\,*QQO%&?FBP/,RKK@E^#SZBN^
M.C:6U^U\=.M#>,06G,*^8<8Q\V,\8'Y"FQ:-I5M>M>6^FV<=VY+&5(55R3U.
M<9R>]`'(^%/$6J:_K,%K-,J_V98F/5511A[TN4V].`!&[8&/OKU!JOXE\1W<
M'B*,:5J5ZJVFHV=C=VYBA^SDS.N02W[PL4?(V\#CWKK]%T&#1VU"57::XO[M
M[J>9U`))X5>.RJ`!],]2:GDT729K[[;+IMF]WQ^^:!2_'3G&>.WI0!QD6H:_
M=ZS>W<6L>39Z?KJ:>;+[.A6:)O+R2V-V[][Q@@#;SG-)9:EKUYJSWW]K[;.W
MUZ336L?)38\()`.[&[>"5YR!@=">:[M;&T3S-EK"OFRB:3"`;I!C#GU;Y1SU
MX%"6%G&&"6L"AI?/.V,#,G]__>]^M`'FNG>)]8FAT/7&UM)!JNJ_8I-(,,>R
M%"[*0I`#[T`!))/?@9K9\,^)+C4+'1%NM0CDO+K4+R*1"5#O'&TX4;1Z;4Y'
MISUKJH]%TF'46U"/3;-+UB2;A85$A+#!.[&<D#GUI8-'TNWNGN[?3K2*X=R[
M3)`JN6.<DD#.>3S[F@#S[1=>\0_V98>(KG4S>07=I=L^G>0JJ&B4E"K`;LG8
M<Y)R6X`HDU[5]/\`!<>MKXECU"YU"*VD\LPPA+022*K2(!CY5W$?.2,CDCFO
M1H+&SMHXHX+6")(<^4J1A0F>NT#IG)Z57AT#1[>*XBATJRCCN05G1+=0LH.2
M0PQR.3P?4T`<+-JGB2PDMM(O-5>W2]U)+:#4;@0-<)&86<[E3]V&+J%4D=&'
M!KHO"5R8M.U>6ZU"&^,-]*'NH5`#A43D@<;L#G'&0<5K+X<T1+6:U72+$6\Q
M5I8OLZ[7*_=)&.2.WI5RVL[6SA\FUMH8(NNR-`HZ8Z#V`H`X/PGKU]J'B\0_
MVC>WFEWVF-J%N+R*%"!YJJI01\A"K'A^>![U5UG5/$-]XNN[#3=7GM?LU]:P
MI%!'#Y;0L$:0NT@+;P"V-O'W0,G-=]::-I>FLTECIMI:NW#-!"J$C.<<#UKG
M=3\!VVJ7U]+/=LUM?7$4\T/D(7#1[0`DOWE!V+].<8S0!SL>IW5GJ&J6%I>K
M8'5/%<EJ]YM5C"/LJ,-H;Y=S%0HSGD]#TJKJE]J&H/:Z=/K2.^G>*(K2#5!%
M'NQ]F9B2/N%P69>F,CD=J]1FTK39X)X)K"U>&XD\V9'A4K(_'S,,<G@<GT%1
MG0M(?3UL&TNR:R4EEMS`IC!.<G;C&>3S[T`<#;^([RZLI-%.N7SZC'J5S;6]
M[90V^^YCA578L7'EKMWA3CJ5X[@2>&M3N=9UWP7J5ZZR75SX>N9)7"@!F+V^
M3@5W,GA_1I;."SDTFQ>VMR3#";=2D9.<[1C`SD]/6K$>GV43Q/%:0(\*&.)E
MC`*(2"57T!P.!Z"@#D++4;[5/$NJROKPL;;2]16T33A'&5F4HA!<L-V7+$+@
MCIWK(T;Q+K$T?A;5Y-<2Y_MZ[\F;2S"FVW78Y.PKA\H54,6)Y/('2O0I-(TV
M74$OY-/M7O$QMN&A4R#&<?-C/&3^=-AT;2;6^>^@TZSBNW+;ITA57.[[WS`9
MYP,^M`'C_AK4[?1[;3+Z>XEMT3P].@DAC#NK/?*J[0>"=S#KQZU?U&^U2[\.
MZI87^I3&6P\16$$-U=I#YD0+0OE_+PAVLQ/\Z]/.AZ.T)A.EV1B,1A*>0NWR
MR=Q7&/ND\XZ9I1H>D+9268TNR%K(<O#Y"[&/J1C!-`'GW_"0ZM#?R>'?^$@\
MS.L1V(UAHXMZJ]NTNS`&S>&&P''\0XSUE?Q'K5OI>IVL6JQW,UEKEMID.H&%
M<NDGE!BP'REE,C#C'*]J[Q=#TA=..G)I=D+$MO-N(%\LMG.=N,9SSFGQZ3IL
M-G':1V%JEM&XD2%85"*X;<&`QC.[G/KS0!Y]XEUO4-)E,-AKNI7%SI,MI#>B
M2"W$,IFE7[_`8DHW_+,8&![UFZA+J6FP^/KDZ]<77V:[BCBM;J.%XQN6!MVT
MKV#%0.G<@GFO49]$TF[O!>7&FV<UR`!YTD"L^!TY(SQD_G1-HFE7-S+<SZ99
MRSS((Y9'@4LZ@@@,2.1P.#Z4`>?Z]XDU>*'Q3J]MK:6?]A7/D0Z8T4;)<?(A
M'F$_.2Y8A=I'3O5RXU'7[C7-7GM]8-O:Z3JEM;BT%NA6>.182X9B"V?WAVX(
MQWSV[2?1-*NK]+^XTVTEO$VE9WA5G&W[OS$9XR<>F:G%A9@S$6L(,[B24[!^
M\88PS>I&T<GT%`'/>+=1:%['3+;4+ZTOKPR/";*.%F98UR^3+\BJ,CWKF],U
MGQ!XBL_"UI%K!L9]2T:2\N+F&!&8R(8P,!@0`=_/';C&<UZ%?:5I^IJBW]C;
M72QMN03Q!]IQC(STXXIT>GV4,D4D5I`CPH8XF6,`HI()5?0$@<#T%`'GAUW5
M]1DBM)-?MM+>WT.#4)9&B39=2/N#[MW(C&T9"X/SCD=^Y\.'=X8TEN.;*$\=
M/N"I9]&TJX^S_:-.LY?LPQ!YD"MY7^[D<=!T]*N1QI%$D<2*D:`*JJ,``=`!
MZ4`.HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`$/(KSVR\1W$);[9=W3*WBBXLD*
M,N%B578*V0<H`IZ8/3G%>A'I7+GP3:':#=3E1J\FJD<#+NK*4_W<.?>@"O%X
M[8:)/KMYH=U:Z084FM+@S1LUR'950;`?D+%EQDXYY(J*'XBQ?8[HW.ER)>VU
MQ;P-;07"3!C.2L6UU.TDD8(XQ4\?@5?^$?DT*XU>]N--6#R+6-P@,`5@T;9Q
M\S)M4*3V'.<U/)X2ENK06U]JLDR+<VURGEVT46&A</\`PCG<0,Y_#%`%*;Q]
M+::69+S1);74C?\`V!;.:Y14,FP2`^<?E"E3P>YXHUGX@IHTSPRZ6S2VELEU
MJ*F[B3[,C!CA<G]XV%8X7VYYQ6SJ&@37:72V^H-;_:IO,F#6\<JL/*$>W#`C
M'RAOK[<5DP>`4TX6YTS5)K>2.Q2RD>6".8R!,[)#N'#C<WMSR#B@#HKW4G@T
M:2_M;<7#"(21QM*L08'!Y9N%X/>N8M_B$]WIML]MHLDFI7%[+9):"Y39OC!9
MCYWW<8''KTK;U_PZFOZ7!9S7$D;03Q3I*JJ070Y&Y3P5/.1[UR^H^!Y;1--C
M@2XU&W&HSWMX$$(;?(A&51_W>T$GC!(R,=S0!<TGX@S:S%IJVN@3&ZOH6N3$
M;E`L4*RF-G9^AP<'`Y.:?I'Q&L]5U2W@-F8;.\21[.Z-PCF4(I9BT:DM&-H)
M&>O'0G%3^&?#E];RVFJ:M(!?16DMDL$:(JK"TH=-P0!0X55!V_+UQ4VC^$#H
MOE6\&H,^FQ&14M'MHL^6P.$,F-VU<\=\<$F@#-L/B7:WC%Y-/>&"6SEO;-_M
M$<C31QJ&;<JDF,X((SU]B,4Y/B#=S+*MOX8O99Q:KJ$,7GQ#S+4G`D))^5C@
MX3DU:LO!3V6F2:4FJRG3C;2VJ1&VB#B-QM4%P,G8.!TSWS5RU\)6]K<K.MS,
MQ728]*P0,;$)(?\`WN?I0!CZC\3].M#YMK:FZLH;>*ZN[C[0D9BCD7>NU&.Z
M1MO.`.XYSQ5O6/'#Z9J%Y;6^B75\E@L4MY+%(J^5%)T8`\L>&X'9<YJ.W\!#
M3A'_`&7JLMK(+&"SD=K:*7>8EVI+\PX?;QZ'`XXK4E\,0RWFM7)N90VK6\5O
M(,#$80,`5]SO/7TH`S]'\2:SJ/C+6](N=&BALK"1%2Y6X!;#(&7<O?=U&,8Z
M&L*Y\3:C9>/-;NM3MKM-'T6V1E$%XNT[P^TM&/\`6,Y"A<GY<>]=A;^'VM/$
M]]K,%],JWRI]HM2BE&9%VJP;&X<8XSVJO?\`@ZRU.776N9IRFL00PRJC!?+\
MK=M93ZY;//H*`*#>/&T^*_36M$N=/N;2R:_$7G)*)(%8*Q#*>&!/*GVY-7=4
MUG4HO`NLZN]BVG7EM9SS0QO(LI&U"RL<<9Z<=JIW'@+^T8=1_M36;R\N;S3_
M`.SQ.41/*B)!;:JC!9F`))].,"NAU?2EU?0K[29)&CBO+9[9G3&Y0RE21GOS
M0!Q=MXHU6?P:+-[B,>)WO!I@E$8V^:P#^:%`Q@1'?Z?*0>]5]-\2ZIKFC:/;
M/JK6#_V*NJ:CJ$4"O*RDE0$4@@$[6).T]``.>.GMO!5C;>*%UY)9_M`LUMFB
MW?NV8#:)2/[^SY<^E5HO`<5E9:.NG:G=V=]I=K]CBO$5&:2+()5U8%6&1QZ'
MD4`83:S<ZK#H-II'BZZN(KO59+6:]CM4CF54MFD\M@R8SE02=HZU-=^(];MM
M3E\,2W4?VMK^VMDU..(!A#/'(^[R^5$B^4RYZ<@X[5H-X!E\F-XM?O8]234G
MU(WHAB+&1XO*(V%=H&SCI4[^`X9+1B^J7SZJ;N.]_M-BAD\U%*K\N-NS:6&S
M&/F/<YH`SCJNO6ND>*M.BU".;4-%P\5]=0@L\31>:-RK@%QR,X`Z<>MW6-5U
MB/X7?VSI]W#%?QZ6+R2::+?G$6\X7@9)XYX&>E6I_![R:+J5E%JUS#=:I*TE
M[?"-&>0%=NP!@0JA<*`.F/4DTR;P=>3^"_\`A&F\17?EM&8'N?L\6]H"A3RL
M;<8Q_%][WH`TKO6#I/A-M7EAEN3!:"XDCC`WN`H+8]^IK'O/B'I]O/K<,=O+
M<'3;6*X5HCD7!D`(13CK\\?//#@UO:9I4UEHJ:=>WCZCM0QM+/&BET/&TJH"
M]..G/>N<L?AIIUA'HZ+=W4QTV=IO,G(=Y@65E1B>@4QQXQC[@H`S];\::OI6
MMW-KI^F27L@U"SM)(I[A%2(RQAML>`#D\\L2`1Z<4^S\7:O9^)-9@N-)NKJP
MCU*V@:59DQ9^;%#\H'5@'8DD<#.:V=1\$0W]Y?7JW]Q!<W-W;7B.JJ?)D@4*
MN`1R".H/K5J#PM'$-3+W<TDFHW,-S,Y"C#QK&O``QSY8)^IH`;XUU*[TCPQ-
M>V4@CN!<6T8;`.`\Z(W7V8U'J/BV33/%5EI$^F?Z/>3+!%=+=1EMY5F&8OO!
M?E(S5KQ%X>?Q%%;6TFH3VUG',DTT$*)^_P!CJZ@L02H!4?=Q68G@*W37?[1%
M]-L&I'4Q"8TR)BI4@OC<4P6PO;/L*`'6/C:2^U>"W31+H6$MW-8_;C(NT3Q;
M\C;UV_(0&]>,55@^(T<WAZ[UTZ6RZ>DBQ6LGVJ,F5F;:!(,_N<$C.[H,YZ5M
M6/AB&PMXX8[B5@FHS:@"0/OR,[%?H/,/Y"J%OX.N8+ZZU`ZW,^H7$,4#3_98
M0I1&+'<@&&+9P3UQTQ0!'?>.)[**Q@;1U.J74#7!M6OX42.)6`W>:3M.=PP!
MDGGIBH9_B*DEK#/I&BW>I>9IJZH55UC*P$L#UZME>%'6GVOP]@L([%[34)4N
MK7SPTKP1LDJROO9"F,!0V"H7&,8K3A\+A;][VXOYI[B33!ITC&-$#*&9M^%`
M`.6/`XH`9XQU:XL_A[JNK:?,T$Z6+3PR8!*';D'!R*Y,^*+W3;77X)=5U&[M
M]/MK:2.>>&.WNRSR88JK(`R8*C<5'.0,]:[G5M`AU;PK<:!)-(D,]M]F,J@;
M@,8SZ9K`F^'HOXKUM5UN]OKVZMDM!=-%$ABB602!0JJ!G<.2?Z4`2W7CKR)Y
MYCHUT^C07?V*345D3B;S!&?W>=Q4.0I;USQCFL_2_'VHC3=8O]<T06L5E?-9
MPB*Y1C))O"+'R<`Y(RQ(7Z5I2>!(Y9)H#JEX-*FU#^T)+`;=IEW>81OQN"&3
M#X]>X%+-X$AFM]6M3J-S]EO[HWJ1[$S;7&X/O0XYPR@@'(ZB@"O;_$,3V[PK
MI,CZP+I;1+&&YCD5W:,R`B4?+C8I)/48Z&JVI^)-?M?$VC"WT2YDFN-.NI)]
M+%S&`'22(!R_0\$XQR=PX';5F\(3W*0/-K$PNK2Y6YM)H;>.,0L%*L-H&&#*
MS`Y]>,5>MO#IBU>QU2XOY[JZM+>>`M(J@2"5U<D@#C&P``=J`-#2M035=)L]
M0CC>)+J%)A'(,,FX`X/N,XKEKGQ3)HVO^*IKYI)M/TV"Q>.%%&5\PN&(]2<#
M@GM6UIVF:C87L,"W:G2+:Q6".(J"\DN[[Y..`%&,9YW'ICFGJO@NVU9M<,MW
M/'_:\5O'+M"_NQ"21M^N><T`5AXXE@M;P:CH5U::A#<PVT-F)4<W#3?ZO:^0
MOKG/3:>M=#I%Y>WMD)-0TU]/N`Q#0-*LGT(9>"#_`(UFZWX4@UOSW:[N+:=Y
M()H9H2-T$D1)1AD8/WCD'BKEIIM_`\#RZO/.5D=Y@T:`2AAA5X'RA>",'GOG
M-`',^.(-7M;S3;JP\2ZC9QWVHV]DUO$D)1%<X9EW(3GC/)(JE)XEU?PWXFUF
MV:UO];L;*VLFFF\R-6A#!P[[<#<S8!(4`?*>E=GK&B1ZRM@LLLD?V.]BO%VX
M^9HSD`Y[&JTWAB&:]UNY-Q*&U>WB@E``Q&$#`%?<[SU]*`,34O&BZ/K6K6WD
MW%S.MU;VUO#+/'%#O>'S.'(&P$`_>)RV`.M=!JFOC1?#4FLZA:21B%$::!&#
MLNX@$`C@XS^-4[SPH\U[JEU;:D\#:E)&TZ/;QS(52+RPN&'3HWU'ID52U_PK
M.OPRD\-:2)+B2.WB@A,L@#.%=222>,X!-`"'Q\UG!J7]K:'=65Y8FW9K994E
M,D<S^6C*RG&=V01VQU[TZ7QGJ4<CVR>&;B:\M(5N-0ABNXO]&1BVT!B0'8JA
M;`P/>G3^!([V/4&O]5N[J[OGMM]PRHI6."02(BJ``!NSD]3N/M5G5/"3WNIW
MM_9:O=Z=+?VPMKL0JCB15SM8;@=K`,PR/7IF@#*U/QX+S2KN31=-OKJW33UN
M)[N(JK6WFQ%X\(3N9@,,0.@(Z]*V!XG2&?6;5K9V;2+2&X=]X_>^8K'`],;/
MUJ@_P_@A6XATW5;_`$^TNK..SN((2C;EC3RT8,P)4A<`XZ@>O-3ZAX+%[J%]
M<Q:M>6B:A;Q0744*I\XC#!<,02OWCD#K0!*WBB\N=8NK+2]"GOK>SF^SW-T+
MB.,)+M#;0K'+`;ER>V>^*9X'\1:MXCT:2\U32H[(B:2.-HY@XDVR.AX'(QM`
MYZGD<58A\,26>M75]9:K=6]O>7"W5S:*%*O*``2&(RH8*NX#TXQDU-X?\/MX
M?@GMHKZ:>T:9Y88I44>27=G8;@`6&6/7TH`JZ/XHNM;F::UT.X_LIA(+>^,T
M?[XH2/N9RH)!P3[9`S6;;?$6/^S]9N=0TMK=])$+31P7*7`=)3@%67C(P<CZ
M>M31^`DCT:\T0:Q?C2)XYHXK4;`81)SP^,D*22N?7G/%,_X5[!)INKVL^H2L
MVIQV\<KQPQQ!!"<KM51@9SS0!(/',T%M>#4=!NK34(;F&VAL_.1S<--_J]KC
MY?7.>FT]:HMXCO=MW->07]A*-4L;0VPD0^67*`@,05:,[N2,$C.,'INZUX4@
MUKSY&NKBWN'D@FAFBQN@DB)*,`00?O'(.14#>#_/AD%WJMW<S2WUO>O*ZH/G
MA*D*```$.P<=>3S0!0B\6SZOJ6EFVTZ\@TNXOBEO?;U*7"HL@8,H.4!*Y7=U
MQVIUSXWO8]5U#2UT-3=PVLUS:@7T3"41LJD.`<QGYP<'WJUIO@H:9+;)%K%\
MVGV=P]Q;63;-D>X,"I;&Y@-Y(R>/>H-$^'UKHTUNPOIYX[:TFLX4,:(?+D8%
MMS*,LWRCYCZ>I-`%.R^(%Z/#&BW=]HJ)J>JQ^9;VRWD:1R($5VD+L<(OS<*<
MMR![UJR^*(=0^'M[XAMQ<0I':7$A$3+YB-'N5@I(*DAE.#@@\'I5>+P+Y6FZ
M1:C59GFT@[;.>2"-B(=@0Q,N,,"`.>N0#FM>?0GO?"MWHEY>O+]JMY8)+A8D
M1@'!'"J-HP#@?3G-`&+/XZDMIW@@T:[O(;,VZWMR)$'E"94*MCJY^;)QC`&:
MOQ>*Y;G5[F"UTB>;3+2=[>ZU'SD58Y%&6PA.YE'0GUS@'%.B\(V\7]K8N9C_
M`&DL`?(7Y/*0(,?7;SFFP>$C:ZE>2V^J726%[<M=7%CA2K.RD.`V-P5C@D>H
MXQS0!5TWQR][<Z=Y^B75K9ZL"=-N7E1O._=F0;E!RF5!(SGWQ4,/C^6?2++4
MH]`N3#J4L<.G+YR;[AG1FR1_`N4QD]CGVJQIG@@6$VE>=JUY=6ND*ZV%M(%`
MBRI0%B!ERJ$J,]CZU4U'PA>6^@^%='TF>4KI5[$S7)V;TC6.1=^#P3EAQCO0
M!)%X^DN(H[6#0[A];:YFM6TXS(NQHE5G8R'Y=NUT((ZE@,=<+_PGXEAM8K31
MKJ;4I[B>T^Q-(B%)H0"ZE\[=N,G</3WIT7@)+>2WO(-6O%U6*[FNWO6"MYS2
MA5=63&W:51``,8VC!ZU/IO@BVTZYTRY%[<SW-E<7%U)++MS<RS*5=FP,#KP%
MP!B@!MYXON;/Q+;Z/+HXS=$I;R+>QEFD$32;2GWE!VD;C[>M96D_$+4#X6&J
M:QHJ0337C6=I'%=)BXD$DBXR3A`H0Y)/."1V%:-GX"M[36XM1%_.RPW\VH1P
MF*//F2JRL&<#<R@,V!VXZX&#_A`XQI+:<-3N/*BO?MUDS11LUI(79SC(^<'>
MP(;/!Q0!4_X63');6T=OI9DU.>[DM/LINXUC$D:J[`3'Y6^5UP!R>1V-=S&S
M-&K,A1B`2I.=I].*Y>_\)WNHZ1-ILVML(9_,60+90@;74``#'!7!(/7YN<X%
M='96D=A86]G$7,=O$L2%SEB%``R>YXH`GHHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`0G
M`KE?#_C-=:\0:UI,MI]E;3YF2&1I,BX1&*NPXXVMC(_VA75UYK?^`=;FCN)+
M.^M[:ZFU2[9VRQ#65S@2+P`0X`5A[J.:`-CP_P"/8]5M]:N[ZT:RM-/D0QO\
MTC2PNNY'V@9R1@X&>HK2_P"$U\/_`-BKJ_\`:2?8FE,`?RWW&09RFS&[=P>,
M9XK$N?"FMV=SK$FAS06L%U<67E11R&-C;Q1A'C#;3L)`X(ST[55L?!NN::]E
MJ47V66[MM6N;TVLL[L&BG7:1YI&2ZCN1@^U`'3OXQT)$LV.H*?M@4VZK&Y>0
M,2H^4#/4$'(X[XI+;QIX?N]2?3X=5@:Y4LNTAE5BN=P5R-K$8.0I.,'TJO:Z
M/JLOBVVUJ]6TC`TJ2UECA<MMD:57&,CD;1R>,GM6'I_@_7?L'AW1+[["MAHL
MQD:ZBD8R7"JCH@"$?(2')8Y.".*`-;3O$?B#6$BU.PT2T.C3X\@SW9CN)4)X
ME"["H4CD`G)'UK2C\6:+-K;:/%J$;WRL4\L*VW>.J;\;=P[KG/'2N)G\!ZW-
MI^E:5-9:3<MI<L"6FKM.ZS1V\<@;'E[,;MJA?O8/)K4TKPA>Z?J$,-S9QWEI
M;:G+>6T[:C(HC#EVW>3C;O!D9?0@YZT`;\'C#0KC64TB+48WOG9D6,(V"RYW
M+NQMW``G;G.!G%5$\<Z1:Z7;W>IZA:HUQ+,D8MEDD#".0H2!MW8&`&)&`>^,
M$QZ1X8N[*V@2<6YDBUNYU#<#G$<C2D8./O8D`/X\UCZ+X3\1>'+R&^M$L+J1
MK:YMI89)F0)NN9)HW#;3D?O`&&!TXS0!U,GBO21J,FG17)GODB,GDP1.^<+N
MV[@-NXC!VYSR/6I+34Y[/PW;7_B%K>UN!"C793(CC=L`CGH`3BL:WT/6;?Q<
ME]:0V]C9RSO+J!CNF=;S]T%4^45PC[@.0>B]3GB7XF(TGP[U940LQ6/"@$Y_
M>+V%`%^R\8Z#J-G=W=KJ430V9`N&=60Q`]"0P!VGUQ@^M5)/B%X8B2-Y-615
MDSM)AD^Z#@N?E^5,_P`9^7WK'U/PIKNN6OBJXN5L;:[U33X["VACE9U4)O.]
MWVCJ9#P!P`*NZCHFO6VM:O>:5%8W4>J6$=N5N96C\B2,,H/"G<A#DD<'(]Z`
M-;5/&&A:-%')?ZC%&LL8ECV*TA=#GY@$!RO'4<"GR^*M%BGLH&U")I;T1M;K
M$&D,BN2%8;0?ER/O=!W(R*XU-,U70?%&CZ;I4%M?7-GX8-H'N7:*,[9(U!R`
MW<`[?3/-;/A;P==^'=5L9'GAF@M=#AT[S%!#-(LC,3CLN".]`%B+QYHUOI5C
M<ZGJ5HDMTK,HMEDD4J&*EON[@HQ@LP`!J6Q\=:/J'B6\T&!YS=6RJQ?R&\M\
M@DX;&,`#J<`YXS7*Z?X!U?3;:W62*&]6336LKJ"/4)+<9$LCK\RCYE(E(.1Q
M@8K9@\.Z[IVH:G)I:V5JE]ID%O!)YS-]CEBC=5^4K\ZY9>3C@=*`->R\::#J
M$-[+;Z@-ED%:X\V)XS&I)`8AP#M.#R..#4ECXNT34_M)M+]&%M&9I2Z-'B,$
MC>-P&Y<J?F&1Q7'R>"?$%[I?B);EXA=:GI$5C'YUX\Y\Q-Y9BQ484E^`!VZ#
M-7/B#I4][>:+;6!"7.I,VF7>%.39L-\IST^4)QD'[Y'<T`=7<>(M,M=)AU6X
MO$BL9U5XI71AN#*6'!&<D#IC/;K63>>-;.30[75-&EAO(I-1@LI`P92A>58V
M!4X96&[."/3UJOX^AFCT[04LH$>2/6;3RHVR%X)P"0#@>^.*J?\`"(ZO=VU[
M<77V.*[OM<M=1>".1BD<4+1#;NQ\S%8\]`,G'O0!NR>-=!BOKNR:^875JCR2
M1_9Y<E4QNV_+\^,C[N:Y2Y^+FGWT6C)HSM!-J+_.]Y8S.(%"YQM0#>2>,JQ`
MZGBKVD>&/$@\2Z=J>L74<TEFEVCS_:6;S?-(V%(]H$8`49`]>^*-`\*:W8KX
M2BO5M%30?.B=XIV;SD:$HK`%1@Y/3MZT`=!#XQT&XUDZ3%J<!O1(8@A#!6<=
M45R-K,,'*@Y&#Z4@\:>'R+@_VG$%ML>=(58(A)P!NQC.>V<BN:L/"&OQ66B:
M'<?8/[/TK4OMGVQ9&,DR*Q=%\O'RL2Q!.XCCC.:MQ>#]13P78:06MOM$&L+?
M.=QVF,7AFZXZ[3TQUH`UK?QUX<NKBS@AU6)I;Q_+B0QN#O[*V1\C''`;!/:J
M?CGQD/"UO8PQO&EY?S^5%)+;R2I$H!+.RIRV,`;003G/0&JMYX0U*?1_$-JC
MVXEU#6XK^$ES@1JT!.3CAL1-Q].:W?$6D7.JW.A26[1@6.II=R[R1E!'(IQQ
MR<N*`(AXST)-2CTN75(!>DJC`HRIYA`PFXC:&.1\I.>>E7+7Q'I=[JTFEVUV
MLM["&,L:(Q";6VD%L;0<]LY[].:Y*;PCKSV%UH(%A_9UQK']H&],C>8L9F$Y
M7R\<ON&T'=C'/M72>%]&N=&35Q<F(F\U2XNX_+.?D<@KGCKQ0!CMXQUB*XUR
M[_L>"?1])NFMY6AG;[1A45V<(5PP"MT#9.*Z"'Q'I=RER\-Y&PMK>.YE.UL)
M'(I9&/'<`G\*Y6;P_P"*UD\2:=9Q:6ECK-U)*+V6=VDA1XT1AY07!.%./F'7
MVIUQX3UFRNM6@T=+)[*_T^VM$>YF8-$(5=>0%^8D,.<B@#I+KQ3I%EK<.CW-
MYY5].RK&C1/M9FZ+OQMR?3.:/#FM3:U'JAFB2,V>I3V:[,_,J-@$^_-<YJ?A
MGQ'J?B.*:XN8Y+*#5H+R!C<LJI`F"8_*"X+[MQW$GMTQ6MHGAJ:TCU);R:1/
MM&JW%[%]EN'3Y'((#8QD^W(H`;J/C#[!XQL=$^R%K:8K'/>;\+#*X8Q)]6V'
M_OI?6N7U;XM16%[KIB\MH-._T>&!K2??-,0IWE\;50;B-I&3MR#R*U;WP5J6
MHZ7JL\E]Y.K7=U]LA17!A22,CR`6V;^%1`<'^]C@TFH^$M8U#1/%<!-LESK%
MQ!/"OFDJFV.%6!.WUC;''3%`&EI?BZ(P-)J>HV'E16D$\DZ12P?ZR1T#%)!\
MBDJ`,L3G.<#%2OXTTNYTK[?IM[`\27D5K*9TDCVLS*-NW;NW$,-O&#D<XYK-
M\2^$=1U?4]7N+=K?R[R#3HXQ(Q',%RTKYX_NGCU/I5K6_#%Y?S7,EL8%\W5+
M&\R6(RL+(6SQUPG'X4`/T3XA^']=4FWN)H3]K^R*+BW=`TFY@H!(Q\VTX&<]
MB`>*W[34K6^GNH;:99'M)?)G`!^1\!MN>A.".E<1?:->Z7X.\1Q:@MLL4%U<
M:I974;M(WF&5IDRF`00<#@G.371>#-+N--\-6WVY-NH7+/>7@_Z;2L78?AG:
M/910!C^'/&^I:F=)DU'3;2&WU=YEM7MKAG=/+#$^8I48!VGD$@<9ZBM_2?%>
MBZ[<2P:;J$=Q)&-Q"JRAEZ;D)`#K[KD<CU%<5I/PSFTFSTUH$MX;V:&YL]7D
MAD(\Z&7)##(Y93M(R!W]JUO#?A:^M/L,>J6BB6UL6M/ML.J3.0,IQ&A`V!@@
M)YR,`#(H`L>*=?\`$VBWMK]AL-)GL[N[ALX6GN9%D$C\98!"`H.>A)]JT+OQ
M78Z%'90^(;F&TO;A%+")))(58G'W]N`,G@MBFZ_H%Q?VFC06DF19:G;W4C7$
MK,Q1&);YCDD\]ZQ?&/AGQ'K\]_:V]S&VG7$,2VZM<M$L#J^Z0NBJ?,W`+C)X
M]*`.CN?%6C66IMIUS?Q1W2@LZ$-B,!=Y+MC"C;SDD`]!S5*#X@^&+F*[DCU/
M"6BHT_F6\L97<<+PR@DL>`!DGM61XCT6ZM=-\>WTD44T6IVR>1&JER=D.P[A
M]>>O3FL&WTNYUZ\E_L\_;;NUDL[[^T?M[F.XV!T$#.$4HX5V;(!.6&[TH`Z_
M4OB-X>TW3["^:XFGM[VX^SH8;=V9&_BWKC*XR."-QSP#5V+Q58*-0GN[VUBM
M+:>.,2?."N^-7`<,HPQW=!G@COQ6)<^%M0?25:RL+>WO(M:AU-HI;YY?M.P*
M"6D*Y5B!C&"/E'K27/A'5;IM3D;[*C7FM6.HA/,)"I$(=XSMZYC;'KQTH`VD
M\;^'I-(;55U%39K,8"?)DW^8.=GE[=^['.,=.>E7-,\1Z9K.D/JNG7!GLDWY
MD$3+RGWAA@#Q7(^+[.2QU"RN5EBM%GUL3K<@[/*_T79\S[3M+,-O0Y!P<=M;
MPC']J\$SVL%FUJN^YBC+S&19]S,3*K$`E79BW0=>!C%`%&'Q=KUS;^&!:6>F
MSW.MP37A\R5XDCA4(R@':Q+;7`Y`&16DOC-3X?U&]DT^6+4=/E^S3:>S9;[0
M<;$5L88-N0A@.C9QVK`L+37+S3?!NKZ3;65S<Z9936MW!<RM;`2%41L`(<8:
M-N,#M5Z+P?J]Q=1RW]U!&UUJ)U*^:U8C8Z1A(8XPP(8#:I+,.J\`4`2S>-+]
M_".E:E9V%O\`VE>WL=A);7$I5()RQ1PQ`)PK*>V:@O\`QCX@CTC5KVTTO3-^
MBF4:@DMV^UBD:R`Q,J8;()R#@@\&J]]X`OKE[G3Y'M[O1YM7M]2*W+G>P_Y;
MJP"@<D!AC&2QSZF[#X0OK/P?XG\-6@@6RN5N%TK=(3Y:S(<HW'`5RV.O!]:`
M(M1\6^(M/TS3S/86`OKUO,5;61I5\K"G(W!>1DENP&/7C5M_$MQ)JV@Q2QPK
M;ZM!-L4`EUFC&[(/385W'\!US6RFF02Z9;6E[;P3B*-5*R('7(`'&16/JIDF
M\<>'+6#;MMEN+F<;/NIY?EK\V.,LW3(S@^E`#[CQMI-KXNB\,RF<7\D0=6$#
MF/)(`7<!U.<YZ#N0>*GM?&7A^^U0Z9;:I"]WN9%7:P5V'W@C$;7(P<A22,&H
M+_2=2_X3>SUFT2WEM38O93J\I1XPTBOO7@AN%/''UK!TKPGKT-KX9TB\%@ME
MH-SY_P!JCD9GN`BLD8"$?*2');D\CC.:`.LO_$>EZ9J%M87=V$NK@CRXEC9S
MR<`MM!V@GH6P#@^E5%\66%O9WEUJ-[:Q0P7TMHK1;V^9.=I!4$O@'A<\\`FJ
M.OZ'J]SK\5_HT,-K=8AC?4/M;`F(2$O&\.TJXVD[3G(+'ICFG'X/U)9H&9K8
MB/Q/+JQ^<_ZEE<`=/O98<?K0!N6GC/P_?WUK96NIQ2W%T"8D"L,D#)4DC"N!
MSM.&X/%7K36["_@MY[6Y66.XF>")@I&YTW;AR.VQORKED\(:DNF6EOOM_-B\
M2/JKG>>83.\GI][:PX_6I/#WA_7=,DT^SN$L!86-]=7/G)*S22B4RE<+M`7'
MF`'DT`0>'/B=I^JS:9IU['+#JE[`9<10.T0/F;`-V._7/0="<UT-MXNT2\U&
MZT^"]S=VR/))&T+I\JG#%2P`8`X^[GJ*YKPWX1UOP_>:),5LYE@L)K&Y`F8>
M7OG$@=?E^;@8QQ]:;I/A3Q*=4AOM9N8IKB+3KFTDF-TS^=)*RD.J;0(UP@X'
MKWQD@'2V'C+0-3N;F"SU2&5[:$SR\,JB,=7#$`,H[D$XI+7QKX>O+.[NX=4A
M^SVBAIGD5H]JG@-\P&5/0,,@]JQ#X'N+GP?8Z--)!%-'H#Z7+-'SARL6,<<K
ME#5.Z\(ZSJ%FTQL;2WU:-+9UGFU"6Y65H91+Y6&&5C)'7D\]*`.GMO&GA^[L
M)KV+4H_)@DCCE#(ZO&SL%3<A`8;B1C(JWJ'B'3-*AN);V[2);=E20;&9MS#*
MJ%`)8D<X&:Y+5?"FO:V=<OY4L;:[NTLH[:V$S,NVWF\W+R;>K$L.%X`'6KEY
MH&JZBES<:AIEE//+>Q7$$<%_)"UOLC*AQ(%SO!R.``03^(!9F\;6D&M1K))&
MFD/I1U`W3(X9,2JG(QD##9.1QCFM]-3M9-4?3%F5KR.)9WB`/RHQ(!)Z<D'C
MKQ7)V/A759[RUG\23VUZ'T273[Q@>7=Y%;@8&0%&,\'(Z4OPTL;S^Q)]7U!_
M,NK]U5)=I4O;PKY<1P>1N`+X)ZN?6@#N****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@!&.!FJUIJ%I?"8VUS%-Y$K12^6P.QU^\I]Q5E_NFO)+#2K?P[IGBBWM/"A
MDN9M1="ALW,;V;R*%(VC]XJABVQ3G@CB@#UL,I&0P(/0@TAD08RZC/3FO(K+
M0;G^P&T^+3YTL)?%,;"&*WD@0VC(H<A"<I&?FSSW/K576M'T<:_J)O;.*'2=
M,O[)$NC:O+]EC18V,*E>$C.0".V]B<Y&`#V=F`XW`'K4%EJ%IJ-K]HL[B.XB
MW,N^-LC*DJ1^!!'X5YA!H+3>*+B354N(]0&L,?M":;+*9[5R=L?G9V"$HP5A
M@8(.>>3N_#32K31-(NK--)?3[Y;J;[3NMVC$B^=)Y6&/#@(1C!.`10!NMXKL
M/[2-G&MW,$D\F6YAM7>"*7(&QG`P#D@'L.Y&*JZ?X[TC4)UCQ>6J27#6T,]S
M;,D,TBL5(1_NYW*1R1D\#)K(\(:I/X=L8_#=_H^JO?07$B">&T9X;A6<L)?-
M^Z,ALG)R"#WK`A6[U'P/+X-CT74_[0EOY=TTUFR00H;MI/-\Q@`P"X("DDD\
M4`>CQ>(]-G\0S:%#<>9J$,/GRQJI(1<J.6Z9^8<=>:IP^-='GU==.62X#/,U
MO%<-;L()IESNC23&"PVG\N*QI=3"_%N%QINJ>0NGO8FX%A)Y7FM*C`[\8VX!
MRW2LZ#2)/[6T2QTB35)+&UU::]FAO++RX[=?WA.)&4,27<[<$Y#'/%`'I>X*
MN68#ZTI91U8#\:\]^),,FIJFFOH:7D+64\L%R]I)<%;C&U8U"XV,<@AV.!BJ
M-QX9DURXCM]8L+F>"/PO"%WAL)=@N"0?^>H!X/49]Z`/2+V[CT^PN+MP62")
MY2J]2%!)`_*HKW5+73M.-_>S"&W4*2S#)RV`%`')))``'))`%>9:SIDEQ=ZL
M=7T?5KNZ?381H\UM&S&(B$B158'"/OSNW8+`XY'%==XRMKQM)TF^M+5[LZ9?
MPWDUK&N6EC4,K;1W9=VX#U48YQ0!)<>.=/M+#[5<66K1R&=(%M7L769V<D)M
M4]0=IZ&KUKXGT^\L;FYA:X+6I"W%L;=Q/&QZ`QXW<YXP,'GGBN7\3:V=9TW3
M+NTT?6S#8ZO:W$N_3Y%<JK$MM0C<<#';'-/@NI;CQ'J?BDZ7JUM8-816"8M2
M+B0^8S-((OO`+N`Y&>I`Q0!U.B>(+37[>:2T\Z.2WD\JX@N(C'+"^`<,IZ<$
M'TYINF>(8M7U'4+:UMYC;V4AA>[8J(VE7[R`9W<9ZD`>A-8W@FVGBN-><Q7#
M6D][O@N[R-DN+GY0&+`@':I&U>`,?G7'Q^$X]+TR_>#P_*MJ_B-Q>PVT!$D]
M@"=H"CEXPQ4X'4`]1D4`>P[@0#D8/3FJMY?VEE&LMS<Q0QNZ1HSO@,S'"@>Y
M)`KRW^Q9Y1<6VGZ7?0>'YM>M$@M2CQ@0!-L[!.J1,<^@(/O71>//#=A<>%+"
MVBT9+FVT^]M66WA@WF.`2KY@5!R1LR"!VH`ZF'6+>;7;K2/G%Q;P13L2!M99
M"X7!]<H>/I6CN4$#(R>@SUKR_5O"5AK>L:O,VCS?98=`METTB-HS%(IF("#L
MX^3MD9QQFJ^O:-/=>)=6GU(7<4I-M+IE[#ITMS)`@50RQ,C8C;>&W`CD,#D]
M``>L9'J*-R[=VX8]<UQ7Q'=1I&E+*DLD$FKV\<T<():2-MP90!R<C(P.M<K%
MH^SRP^B7X\'OK4C?V>8'.V(P!%<P_>$?G;VQCN#B@#U:YO[6UFMHI[F**2Y<
MI"KL`9&`+8'KP"?PJSN&<$C=C.,UXP?#5M(--OK_`,.7<ND0ZY.T$$UL\LD-
MDT!"CR^65#*,A<<9!P*T=#T::+Q)!<ZB+J#68]6F,MQ%ITK-<Q,7**9]VSR=
MK+Q@8*@8SR0#U;<N<;AG&>M9PUJUELDO+1C>PO,(0;0>9@[]A)]E.<GM@UPN
MC^%HY+B#4[S3ICJ']MWD4DDBMEK1C,H4@_\`++!4@=.0>]9ND>'X[#PC'86>
MB3VFH1Z_;O=A;5EWQK>ED;=C#*L>#D9`'6@#ULR`*W(+*,D`UDV7B73KOPS;
M>('G6VT^>%)A)<$)M#=-WH<G%<'H5K=7/CNRU<Z#_9L\L=ZNH+':2)AB5$8D
ME8XE)VD@J,#/N*=>>'I[[X!V.FW&E23WUM90NML\1,B.I&<*>=VW=QUH`]1#
MKM!W#\Z7<,D9&1U'I7G\6A:?J'BW2Q#I$B:';Z4SV\4MNT44<ZSC9E2!A@"Q
M`([DUD>#])GLM0L+RYCN8]=B%PE\JZ?*OVUPK?ZV<L49,@,A`'8`#I0!Z?>7
M]K86<UW=7,4%O`I:621@%0#N3VJ99%*[MZX/0@\5X9=^';C6[36)XO#(@DN]
M#EDDMHK&2(+>^8&527/[R51N^8`=3CK75WN@6&IWFD6]IHLJZ''I5XRVK6[Q
M1K,'C*;D./FR7(!^H]:`/2LC.,C(ZBC<O/(XX/->0GP_J]KI&D3Z3:W<&LZE
MX>N(]1N&W;WN/*C*>8S='W%P,X(Y'2IK72D@\/>(I-&AO;>:YT-MMC'IDUN/
M/PV&)=FWS9(!P2>!UH`]0O;^UT^RFN[JXB@MX5+2RR-A4`ZDFIU8,H((.>F#
M7E6O>";<>&]<M[#1WDEN]'BE,>TMYEVI?YN>LOS<GJ>*Z/5;5F^&%Y:^%+&:
MT)MRMO;1Q&!P-WSA5;!4D;L=#D\>M`'2ZMJMIH^DW6IWDNVUM8VDE91D@#K@
M#J:HW'B2/3O"TFNZI97-G%$FZ2W.V211NVC[A().0>#WKS/6_#EKJ%CKR:!X
M<O8-+.B%OLTEL\8DO=P:,K&W)D5=P+`=\9-=IXRT5+;X7ZAIFC:>418E\JUM
M(LD?O%8[5'?J:`-_1O$-GK3310K<074`5IK6Z@:*6,-G:2I['!Y&1Q6KD`@$
MC)Z5Y[X7BU&?Q#K=W8"]CM+F*$K=ZU9N)3*"P:-5)0[`NTCH,L<9YH%A;GQQ
MJ$^OZ->7MT+BV;2KJ.!F1(]J@[&!Q'AP[,"0<8^]Q0!Z%N&<9&?3-8&D^+K#
M5[NSMH(YU>[BN)(]Z@`>1*(G!Y_O$8]17$^%=&FM_$%C<ZC]I@UJ.]N%NYDT
MZ7-VI#D;Y]VPQ8*E>`,A1@5;\':9?VVMZ#)/97$216VK"1GC("%[Q60'TW*,
MCU'-`'I)VYP3S]:7(QG(Q]:\L\4:#=WVK>)KW[#=R7$5WIZZ?+&'#(C>4LYB
M(Z97<&([#GI5BZL)]`D\5V>G:";C29C9LEJ8G>$F3<L\@5>7P`K,J]<=B<T`
M=U?:S;V-_IEI)O9M1G:"%D`(#*C/S[80U8L[U;NU$YBEMP690EPFQN"1G'H<
M9'L17E_A[1KNUU'2EBTZ6&RA\2W$T02U:&-(#9E0X1B2B%R<9[GWK!N=&DO+
M,Z;J%A*ZII]_(RS6SRFT+W<VR9$7D/MYR?O`+C&#D`]VRG7<.>G-&5!"Y&3T
M&>M>677AJQU][]DM)KK2T\/6KZ5,BLJ^:!+AH^P?`C]P"/6CQ/:W>J>*H'&A
M%+NRO[#R+Q+.1I)8-RM*XE&%11\RE>3P?6@#U/*@]1D^]))(L:L>6*J6VKRQ
M'L*\YA\-+=:QJ.KW=C<?;[7Q%&UE.=P86_[K=M_Z9G=)G'!YSTINA:=!')?/
MJ.BWI\3M+>K)>F!R&C.\H1)]TH49%"C^+MP30!Z':70NK2"X*21><@<1S+M=
M<C.&'8CN*GR,XR,^E>(Q^'[N2SMX]8AO('31;'^S[A--FN)+1TB`D6/:1Y<P
M<$\C)!'/&!U.G6XL/B+/=1V%QJ#7,MPT]]/92)+9JJC"+(?EDC8\*HY^N*`/
M1J3`S45I<K>6D-PB2(LJ!PLJ%'`(SAE/(/L:FH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`",T=***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*3:/2EHH`3
M`K*F\,Z-<:B]_+81/<.R.[$G#LGW2RYP2.Q(K6HH`3`QBC`QC%+10`F!2X%%
M%`"8%&!2T4`)@48%+10`F!1@>E+10`F!1@>E+10`F!Z4N!110`F!1M'I2T4`
M)@48%+10!5N].L[\0"ZMTE$$RSQ;OX)%Y5A[BK6***`$P,YHP*6B@!,"C:/2
MEHH`3`HP/2EHH`3`(HP,8QQ2T4`)@>E&!2T4`(0#UHQ2T4`)@>E&!2T4`&*.
MU%%`"8&<XYHP*6B@!,#&*6BB@`I-H].E+10`F!69J/AW2=6N%N+ZS2681&'?
MN928SR5.",K['BM2B@!J1I'&L<:*B*`%51@`#H`*7:/2EHH`3`]*,"EHH`3`
MHP#VZ4M%`!C%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!2;A01D8-<"-:U(^"/&]]]LD^U6%QJ"6LF!F
M(1J2@'';WH`[^D+`5Q5]XWO-.1H+;1)]3FM+"&^NV294VQ,&R0"/F;*-\H_,
M=T\1>+;KR]8M=-TNZGALH_+NKZ&55,$CH&7:OWFP&4L1C`/&><`';T5Q6H_$
M2WL-:GM%LA+:6MU':7-Q]I1761]H`2'[S@%UR>.^,XK5T?Q'/K.JWMO#IK)8
MV<TMM)=O,/FF1L;53KC!!W<<\<]:`.@)Q0#D9KS#Q!XN\1O:^.+4Z?'90Z3;
MEK>]AN<R(QC#(2,<ENO;'0YK</CF>PL-0EUK0Y[":U-N(HC.CBX\YBL>'X53
MN!!R<#UH`[.BN=\,^*?^$@6^BDM4M[NQD5)HXKA9X_F7<I611AN.O'!KG],^
M(&J)IFL7^NZ-#;Q6=^UE`(+I6,DGF!%C.<`<D9<D#V%`'H5%<-#\1@UE*7TH
MMJ$=[%9&VM[I)4:2528]LHPI!X!Z8YIVH>/Y]+DN4NM!F_T"*&743%<*WD"7
MA0O3S#N!&!CIGVH`[>BN.F\=G3[367U72)K.YTQ(Y3!YRR>9%*Q6-]PX4;@0
MV?NX)Y%:UOK[KX9EUK5+:.S2&%YY%BG%PNQ03N5U&&X'I0!MDX&32`@].U<#
MJ?CO5[?2[A6\/26=[<6,UWIV^YC=76-06+X'R,H8-MY!QC-,T_5M;T7X23:U
M]B>?4DM6O-MW?F;<"@8R;B.!U/EC'H"*`/0<C.*6O-)O%/B:#Q#8SKH;SS2Z
M+)<S:9#>KL!65<2!B.25.``,_-CMFMC5O'\=@+*.TL%N+BYLEOVCGNDMA%">
MF6;JQ.0%&?NG)'&0#LZ*QFUX3>%DURP@$R36R7,,<\H@RK`$;F/"\'FN>@^(
MDEWI=M);Z/OU&XOI;%+?[8HAWQ@ECYV-N"!QQDGCWH`[JBN&LO']UJ&EZ--;
M:`[WVK+.]O:_:E"J(F`8M)C`&#GH>P[Y#K;XC6UQK$5O]C"V$US):170N49V
MD3=DF$?,J?(WS'VXYH`[>BN*T#XA1:YJ5O;?8!#'>P/<63K=)*TB*`3YB+_J
MB0P(!)[]",5#8_$&]U-;467AF>22_M3=Z>K7<:^=&NT.7)_U>"R@=<Y[<X`.
M[HK@KOXGVR6EM/96`N"]D+ZX2:Z2`PQDL"HW???*.,#CY>HR,W-3\<RV[!-+
MT6?4G_LY-491*(L0-N]027^484=<GICD`[&BN.T_Q3K5]XYN-)&D0#2TM(;E
M;G[2/,59-^&*XYR4QM[8SDYJQK_B^70=9L;233XI;6YEAA,PO4616D<("(C\
MS`$C)SZ^E`'4TA('7O7(MXUN3K36L.A3RV,.HC3KF\69?W4K8VG9U*_,F3QC
M=WJN_BRZU6\LOLFFW,>ER:D+>/4%E4B4H[*X9!RJ$JP!/4C&!D4`=O17-:YX
MJ?2=9L-)M;!;J[NT,BB6Y6!=@8*=K-]Y\L/D'..:DE\4"*_UZU^R,3I%M%<,
MV_\`UOF!S@<<8V?K0!T&10#GI7G=WXMU+1/%7BAI;&>]T:QDMGFE%PJBTC:)
M=Q53RW=B!CVY.*MW7C9-*U+5+58I;JZ.HBVMX;BZCBBXMTE8AR!L0`]]Q)/'
M7``.ZHKC8_'OVS3]/.FZ6UWJ=[+/$EH+A516A.)3YO(*`XP0#NR..N$T'Q1X
MBU+QAJ&E7V@0V=I;10NS_:U>2+>'(R!PV2O;&.^<\`'9T5QI\6:O#XWU33+K
M2[>/1[&S2Z>\%SET0^9\Y7'(.S&T<C&<G(J72?&=Q>ZCIUM?:)/80ZK&TFGS
M&=)?,54WD.%^X=O..1UYH`ZPG%+7(1^(=;G\?W^A/I,`TVWM8YOM0N?G4/Y@
M#%<<Y*8V\$8SDY&,?P;XWU!?#.G2:_IUPD']DO>?VD\RR&<1!=Y90,J2#D<D
MD>E`'H]%<EX;\;#7M2>PFL%M)3;_`&N'9=)/NBW!?GV<(_S#Y>>_)Q5"W\=:
MG:W7BB;6M(BM]+T:3:)H;@.Y.Q&5-N.2V_.>`,@'H30!WE%<-%\1D2RU"6]T
MSR[BR,#-!:W27`=)I/+3#K@;MV<J>G'/-2:AXYO=++0W?A]Q=6]E_:%[''=H
MRP6X9PQ#8&]L)D*!SD\C'(!VM("#TKCSXQEFBU2WNM,N=/ECTQM0M2)D9YH0
M#DC`(1P=O!SU'7FJ0\>W%O:+]ET2[U!;6SM;F]E-P@9(I4!#8Q\[<,2``/E)
MXR!0!WU(2!7+:QXPET;Q+8:9+IT4EM=S1P+.MXGF!WR`?)QN*Y')SZUSZ^--
M<N?#/B*]U32_L*:?=M;QR6-VIDRLBKL^92,C/+8P?04`>E=117&W'CJ2">:X
M&BSOHD%Y]ADU!9DR)?,$1Q%U*!SMSG/7C'-/A\;3SZRMM'HL[6`U!]-EO?.7
MY)EW?P=2O`^;(Y;'-`'7T5SVM>([FQU*WTK2]+.IZE-"UP8O/6%$B5E4L6;/
M4L```>_2L^'QV^H#3$TK1I[BYOXYI%AEE6+RA#*(Y=YY'!/&,Y_6@#L:*YCQ
M'XN_L2_M].M[2*ZOIXFGV37:6R)&I`)+OW)/``/0YQ5&Z^(EO!8:?>QZ;=2P
M:I9^=IY`YGG/2W(`.UB""">"`WI0!VM)D9KC-7\>S:5<ZBHT.:XM])\MM2F2
M=1Y*.BME%/,A`)R..GOBF3>+FT_4M3ACM+N^G.JQV%O"9D"^8UL)!M.!M3UR
M2<DGT%`';T5R-_XRNM+UK2["]TF%%OGAA9DOT:2.63/'EXRR@\;N/7%8:^-=
M<N?#'B.]U32_L,>GW;6\<MC=J9,K(J[?F4C(SRV,'L!0!Z5G-%<9/XZ>WGFN
M!HL[Z)#>_89-06=,B7S!$2(NI0.<9SG.>,<U)#XUGGUE;:/1)VL!J#Z;+?"9
M?DF7./DZE3@?-D<MCF@#KZ3(KG]:\1W-CJ=OI6F:6=2U*:%K@Q?:%A5(E8*6
M+$'J6```/X5R,GB75/$OBOP['86%W%I<T<UQ(GVX02>9#,D;[PH.X(=PV9P^
M[/:@#T_J**YWQ7XCN/#6F"\AL8+M5W,XEO$M\*HS\NX'<3CH*SM1\=SPA!IF
MA3ZA(=-35&03+&5@;=D<YR_'"CKZCN`=G17(W7CJ*VAU/-A(;BU^S&WA\P`W
M0N,",CCCYB5/!QM/7%:/B77KK0M-6[M[&"Z;=AEFO4ME`P3PS`Y/'04`;M%<
M;)XZGN(M/&CZ%-?W5]IJZE'"TZP[8CC(9CGY@64`#KGMC-12?$)[F&W?1-$G
MU%IM-34RK3+#MA8L#R<_/E>!W]1CD`[;<*4'(XKS2]\6.U[J%_;W%[_9TNGZ
M3<V\<;JCJ9[AES\P8#(VAAW`/?FNGM?$UW?ZU<6UAHTEQIMK<-:SWWVA%VRJ
M/F`C/)4$@$Y'.<`@9H`Z0G%)GC->:ZQXXO+[POXJA6V73M0TVP%S'-:WJ7`P
MQ<*0R@88%#Q[CUI_B'QCJ?\`PC6M6T]C-HNJVMO!=0;;A92\3RA=V5&`<@@K
M[]Q0!Z.#FEKB=0^(5MI^M7%HED)+.UNDM+FY^U(KK*^P`)#]YP"ZY/'?&<5V
MU`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`"$9%<E<^!(YY-2BCUG4(--U.5I;NPC*;)&8?/A
MBI90W<`^O3-=:<XXJA'K.GRO:K'?0,UVSI;@.#YK)G<%]2,'/T-`%*3PO:O?
M:C="61#?6"6#(N-L<:;\%??]X>OH*I7G@F*YNM0DAU;4+2#4E3[7!"R[9&5=
M@8$@E<J%!`(!VBKU[XNT#3K1;J]UBS@@:5X!(\@`,B$AE^H((-4]=\<Z3X<=
MY-2N;=+06R3(Z3!I9"[%1B/'*\9W9]?2@"5O"ABU:[O[#4Y[,7DJ33PI%&ZF
M0``LI925+*H!^G&#5[2-$BT=;Y8I9)!>7DMX^_'RM(<D#';BJ\/BC3[BZA,%
MY9O8RVANEN!<#)`<)D+C[N3][/!XQ3[;Q7H5Y9WEY;ZQ926UD2+F1905B/\`
MM&@#/U3P1!J=QK;G4;J&'6;=8;N!`A7*IL5U)&00,<9QQ5W6/"]KK5O=13S3
M1F>*%%>,C,+1.SHZY!^8,V?3BK&C^(M)\00RRZ1J-O?1Q,%D:!MP4GL?>FV_
MB;1+O5!IEOJUI+?%/,%NDH+E?I0!-I6GW-@)A<ZB]YYA!4-#'&(\#L$`Z]3G
M/X5B2^!;:6#5K8ZC=BVU"Z-ZL8"9MKC<K>8C;<Y#*"`<BM.V\4:)?7%Y!::O
M9S2V:E[A(Y0QB4=2<=A4<7B>PO-3MK2PO+*Z$DTL$K)<#<CHF\JJX.\XZC(P
M.:`()/"LETENM_JT]Q]GO8;V("&*,*T?1?E7D$\G//IBFZIX+M-5;6S+=7"?
MVO';QR[-O[L0DE=N1WSSG-7[+Q-HFI:A-I]CJ]G<7D/^LACE5F'X=\>U5[;Q
M7IM_JL=IIU]9W<8$HN)(I@WE,@4X./7)Y]J`'W/ATR:K?ZG;:A/:WEW;PVY=
M$1@BQNS#`8$'.\@Y[=,&HM.\(65CX>O]&E>2Y@U!YWNB^$WF7[X`4`*,<`#I
M5[2==TS789)M*OX+R.-]CO"P8*WH:EMM5LKR*&6WNX98YI'BC9&R'=-VY1[C
M:V?H:`.?C\"1N!_:&L7]^8K"33[9I=@\F.0;6;Y0-SD!1D_W:V'T"VE\+MH$
MKR-:M9?8F<$!RFS9G/KBDL_$VC:AJ3:=9ZK9SWJQB0P1R@OMX.<?B/SJO:^*
MM.U'5(K33;ZSNT`E%P\4H;RF0*<''8[CS[4`,T_PJ+._M[Z?4KF[N8;!K`/(
MJ+F,L&!(4#D;0*9/X01KBPN[2_FM;NTM/L1D$:2":(8P'5@1D'D$8Y)[&KEG
MXIT/44NGLM7LKA+1@L[1S`B/)QR?KWJ:#7+*^TNXU#3[F&\AA#@O"X*ED'*Y
M]:`*FK^&EUK1;2PNKV8RVLL,ZW.Q-S21G(9EQM(/<8QSVKF]2\$26PTU+9;C
M485U">]O`#"KEY$(W!7Q'@'/&,C(QWK>MO%BSV'ABY-FZ-KVW8N\$0YA:7D]
M^%QQ5NU\3Z'?7]U96VK6DUU:`M/$D@+1A3@DCVH`R]"\.WVW1K_5YR+_`$Y;
MB.*-%0*(I2-JOM`7<JJH^7`SFK%EX1&G7$@M-3GCL)+A[AK,Q1LOSY+H&*[@
MA8EL9SSUQ5:^^)'A'3K^&SFUVT\Z23RSL<,(SM+?,>PXQ]2*U?$.OQ>'=';4
M)HGF!DCB2-"J[GD8*H+,0`,D9)Z"@"KHGA:70TAMH-7N)+&!&CBMGBCX0_=4
MN%W':.!S]<TFD>#K31I='>&YGD.E6#V,0?'SHQ0EFP.OR#IZFIO^$C73M'^W
M>)5MM%(?8?-NE=&)&1M;C=^0/!XQ3[KQ=X?L5LWNM:L85O`&MV>=0)%/0CV]
M^E`&39^`(M,2U.FZK=6T\%LUJTIBCD\U"[.I(92,J6;!'J<YK5_X1J)M4EU"
M2[G>XETU=.<D*`5#,V_@?>)8^WM6;J/Q*\*Z3J-[87NKPQW%G$)9%_O9!.U?
M5N.G^T/6MK1->T[Q%I<6HZ7<K<6TO1E['&2I]",\B@"I!X86UUZ+5;>_N(V%
MI':30X0I,D>[822,@Y<]"*HWO@*UO-:N=0-]<(MS=V]Y+`J(098=NS#%=P7Y
M1E<_EDU!9>.KB>]7[7HQMM/FU-],M[M;E9-TJNZ?,F`5!*8&,]><#FMY/$VB
M-K+:.-6LO[24<VOG+O!],>OMUH`@M_#,%N;[9/*?MFI+J+YQ\KKY>%''W?W8
M]^35.T\%1V,\8@U6_%C#>&]AL=R^6CL2S#.W<5W$G!/!-7)O%.G'6(]+L[VT
MN;P7"PW$"2@O""K')`]UQ[9J-/&&E0:2M_JFH6%FA>10?M(="%D*<-@9.1R,
M<'([9H`/$OA@^)K1[*?4IX+&6/RYH(XXVW_,#D,RDJW&,CU]<$0:EX+CU#4;
MZZCU2^M$U""."ZB@*8D$>[;R5)'WCD`\UH7_`(IT+2XK62^UBRMTNL&!I)E`
ME!'!'J/?I6@UU$MJ;DRH8`GF>8#D;<9SD=L4`<SJW@6#5+W4YGU6]AM=4\L7
M]I%L"3*@"@;BNY00,'!Y!-5(/!]QJ.I:IJ5TTFG7#:J+NQ="DCJBP)"=P.05
M<*<KUP1W%:WA?Q7#XFTNYO&MGL3;RE)(;A@&5-H='/H&1@WMR.U4KOXG>#K(
MPAO$%G)YL_D9BD#;#@G+8Z+QU]Q0!;N/"DMR=.N7UBZ74M/DD>&[2.-<I)]Z
M-D"[2N`HZ9^4<YJ73_"YT[6VU./5;R1YK>.&Z24(PN#&&"NQVY!^<],#IQ6Z
M)`\*R(0RL`01W%<[H7C"WUW7=8TE+>2WFTV4Q[I",3@$J67V##!^HH`FN_"T
M-WKLVI&[G5;JT%G=VH"F.>,;\`G&Y3^\;D$55TKP6FG7VFW$^JWU\NEPM#8Q
MSE0(@PVDG:`7;;\H)[>_-5])^(>F:C;:M=7BG3+/3YUC6>Y<`3(XRC@=1N[`
M\XQ6U)XET:+18]9DU6T73)!E+HRCRV]@>YX/'M0!&_AX?\),VMQ7L\3RVZVU
MQ;@*4F12Q7J,@@NW0\U!9^#[&UT.PTAY)+BTM+*2R*R8_>QNH5MV!Z#MZU97
MQ1HCFS5=6LV:]*BV"R@F4MG;M'?.#3;;Q;H%ZUVEIK-C.UHA><1S*3&HZL?8
M8ZT`)H>@7.C".-]8N+R"*`0I'+#$IX(PS,J@LV!CK^O-5+KP7;7EQK?FWEP;
M/65S<VN%VB0(J"16QN!`1<#.,C-&F^(]7U*2WN(_#4Z:5<E3#<O<H)=C=':(
M_=7'.,EO]GTTH_$>D3:RVCQZG:/J2*2UJLH,@QUX]?;K0!F3>$);W2I=/U#6
MKFZA<V[`^3%&0T4@?=\JC)8J`<_ABI]6\)6NL7>I7$UQ,C7^EMID@3&%C)8[
MAD?>^<^W%6;3Q/HM]J#Z?::K:3WB1^:8(Y06"\'./Q'YU5B\9:/'8:;/J.IZ
M?:3:@BM#&+I7#9X^5N-PSWP!0`MUX2M;JY:=[F=2VE/I6%QCRV();I][CZ>U
M16G@RULX;^-+JX87ME!9.3M^5(D95(XZD,<]JTXM?TNXUB;2(=0MI-1A7=);
M+("ZCCJ/Q%/EUC3X!(9;Z!!%.EM)N<?+(^-JGT)W+CZB@#"D\!6DFMR:@;ZX
M"/J$>I-`%3'G(`!\^-VWC[N:6?P+!/9ZU8_VG=K9ZK.;EX0$_=2%E9BIVYY*
M]#G&36G>^(+:VN4MHY[62<7<-K-').$,9DY7L<L1R%XSZUD:%XSFUB_TVV:R
M2+[9!>RE@^=IMYQ%Z=&SGVH`?)X$@DEFB.I7HTN:_P#[0DT\%=C2[MY&[&[8
M7P^W/7VJ_:>%[>T294N)CYVIMJ39QPY.=O3[OZU;FU_2[?4H]/FU&VCO)"P6
M!I`'.U=[<>R\_2DTWQ)HNKV]S/8:K:7,5J2)WCE!6/`SECV&._2@"KJOALW^
MK6VJVFHW&GW\$+V_FPA6#QMSM96!!P0&!]1^%0Z3X-LM&N=,FMKBX8V%M/;K
MYC!C+YSK([L?[Q9<\8')XJQ%XP\/3Z;<:E%K=@]E;OLEG$PVHW7!/J?UIEQX
MLTV&+3[M+ZQ?3KM9'^U&Y``5%R2HP=V._(VC)/2@!VK>&UU'5+34X;M[2]MD
M>+>D:.LD;8)5E8'(!`(Z8-4]0\%0:J('U#4;NXGM;7RK>8[%,4NX-]H4*`!)
MD+VQ@8QR<[4NKV$%P8)KZ".00&Y*NX&(@<%R>FW)'-,TK7--UVU:YTJ_@O(5
M;8SPN&`;T/H:`.4F\$7>K:YXB^WWUS#I>H-;*\<+)_I:)$JN&XW)D@@XQD$U
ML/X-M)-4:_-S.'.IQZGL&W'F)#Y(7I]W;SZY[U>M?$FBWFKSZ3:ZG:RZA!GS
M;9)`77'!R/;-4-3\2W::TVDZ18&^N[58Y[U#(L96)MV`@8C<YVGV'<]!0!7D
M\!6LFM2:A]MN%634(]2:`*F/.0`#YMN[;Q]W-.G\"P3V>M61U*[6SU6<W+P@
M)^ZD9E9BIVYY*]#G&33[OQ-J@\5'1-.T:*Z$=O#<3S2WHA*+(SC`7:=Q&PGK
M4>J^-)-.N[_[/I4EW8:40-3N1,$:#*ASM3&7VHP8\@8/&>:`"3P';R2S1'4[
MT:7-?_VA)8`KL:7=O(W8W!"_S[<]?:K]IX7M[-)E2XF;SM3;4SNQP[')4<?=
M_6KM]K>G:9:+>7M]!;VS+O621PJD8SD'Z5%:^)=&O;^*QM=6LIKJ6+SXX8Y@
MS,G7<`/8YH`@U7PW]OU:VU6UU"XT_4((7M_-A"L'B;DJRL"#@@,#ZC\*@TGP
M;9:-<:9-;3W#&PMI[=?,8,9?-=9'=CC[Q9<\<<FJ%_XWDLY$1+6WEW0ZB^Z.
MXW@&UQ@$@=6SR/X3QS6E9>*()DAENGM;6%]-BU!VDN0&C5_52/NC^]GD\8H`
MB\0>#8-?OTO&O)[:7[))9/L5'#1.06QN!VMQ]X<\U+!X2M;>Y\^.>;(TI-*`
M)!'EJ20W3[W/TJU9>)]$U'3VO[/5K.:U5@CS)*-JDG`!].?6I](UO3->M6NM
M*O[>\@5RC/`X8!AV/OR*`.<U#PF]]XR\.W6UOL&E6[&5VD&)Y%P(E*^JG<^[
M'!K2UWPK%KE_:WWVR:VN+>&6`%$1P4D`W<,#@_*,$?R-:46J6,X#PW43J9VM
MP5;(,JDAD^H*GCVJE_PEWA_[7):?VU8FXBA:>2,3#<L:C+,1[#F@#GW\&7T>
MN:=%INHW5C86>AG3UNXS&TI(=<*0P/\`",[@.H%1R>!)X]<6WTZ\N=-TB/1(
M].66!T:1L2.2OS`D?*P.X=ZL^&?B%INLZ1=:Q>7VFVEDLA6(>>=\:C/^MR,!
MCC.!G@UN-XJT`:C!I[:Q8K>3HKQ0M,`S!AE>/<8(]<T`9MQX`TZ6*2&.>>"%
MK:RM41"#LCM9/,3!(R<G@Y[4Z?P-#*VJ0QZK?P:?JDCRW5G$RA2[J5<JQ&Y0
MV<D9QD?45J/XFT6+5(M+DU6T6_F8K';M*`[$=1CUX-5?#OC/0_%,MU%I%_'<
M26KE)4'!P#C</53V/>@#.B^'MG_9^HVES?W,XO[&.PD8)''MBCSMVA5`!^9N
M?>EG^'\%];ZB-2U:^O;J^@BMC<R;%:.*-@X5550O+9).,G-=C10!S9\*M%J]
MY?V&J3V0O94FGA2*-U+J`"REE)4LJ@'Z<8-=)110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`AZ<5Y9>>"==BU6^N[&.%H]-N?MFAH)`"7ED5YT8'Y5'#*#CHYZUZF<8YJHF
MI:?)C;>6YS.UL/W@YE&<I_O<'CKQ0!PNH>'/$%IH%EH6E@OI_P#9<D$P@DCC
M8W+#[S%\_NSN<D+SFJNK^"]:N]/FAAA@9_\`A';6Q4&4*#/%+O9?8$=#TYKT
M[Y<]J,(/2@#SOQ3X>UOQ"U]<PV"0-<^'Y[$0O.A*S-*K!21Q@@$YZ4OCC35L
MK&[O8XH+999--03Y5`CQSL=Q)X7:&7!((]CTKT/Y<=J1DCD0JZJRD<@C(-`'
M)>!)HBVN1)'*9_[0,EQ<&5)(IY&C3F-D`&``H(QP>O6N4\,Z3J.M:9HT45A#
M;V5GJ][=OJ)E4L_[R=`H0#=N)?J3C"#DYP/4IIK+3+&2:9X;:TA4N['"J@ZD
MTEC<V=[8PW=D\<EM,@DB=!PP/.1]:`/.--\(ZI%HMO876GW#7EEIEU8V]P;V
M(P99`@*J`&^?:I.[[OOUK8;PS?E/!\<<4<*Z;:RQ711@/+9K;RP1CK\W<5V_
MR^U'RY[4`>96_A37KO3/#FDSV%MI_P#8UM/$]^DP?S&,#PJ8POS#=O\`,.<8
M(QR>:LV7A_4Y=/M+?4O#-HBVFC3Z=*([M=UUE4`12`-J-M)R3D$].]>B?+39
M)(HHWED8*B*69CT`')H`YSPC:ZS9QW<&I*ZV4;QI8)/*DDZQA!NWNG!^;..^
M!S65X;TK7-..F6%SI\"6MC?W=P]T+D,9%D,Q7:@&?^6@SG!]C7;?:+<6WVDR
MH("N_P`PMA=N,YSZ8J3Y".WK0!Y]I/@Z]B\+:/8RQ0VU_;P7L4DZL"8C,&`(
M(Y.25)QZ5%:>&M7OM+M;"ZTJTTN2#19]+-Y#<*[DLJ*I4*`=G!;DY![=Z]!B
MNK6:XG@BFC>:W8+*BMRA(##([9!!J7*=!B@#RZ?PGJU]X>OK>32KF/4WT-]/
MB>6^B:('*_NT"@8!VY#$#&,5Z+<0$Z3/:PHH8P-&B#``.W`'M5SY<]LT?+0!
MY_IG@F73[;P1)'911W6F;?[0<2YQ_HSH<<\_.1TJ'2]#\47&KV^H:U&3/%I=
MU:RL9XS&TLC(5\I5`*IA/XN>1Z$GT;"DXXJI>:KIFG2(E]?VEJ\@RBSS*A8=
M.,GGJ/SH`XQ?#VK:?X=\$K;Z?%/=:+L-U;+*J9/V=XVVL?E)W-GWYKH=5L)_
ML%X5MFUA;G"R:==3((BA/S!<KCCW_.MWY3Z4R*6&:-9(I$DC;E61L@_0T`>:
M:;X7UO2M4L=0MM-']G6=Y<"WTB2[$CV\,D:+O5V.W.Y&.S/RAR`>M7[C2M>M
M]1U6]BT&TNAJNF1P"W%R@6UD3<"AW`90^9DE1U7ISFNY>ZM8[J*U>:-9YE9X
MXRP#.%QN('?&X9^M3?)[4`>=6WA/5].,MA'!#<P7'AR#2C=B4*(I8DE&2IY*
MDN,8SWS71>'[&_&A:3%?"YTZXL8HX7@BG1UEVJHRQ`.0<'T.*Z/Y/:CY?:@#
MS73_``3?:1J=KKD%N6U!=:NI;B(W.4>UE=\,`3M5E5E;Y0">0>M.A\-:Y]CL
M]$ETVV,5OKHU%M3,RG?&)O/!V_?\PY\OGC'.<<5Z1\N>U,-Q;K<+;F:,3.I=
M8RPW,HQD@=2!D?F*`.!T'P_K%B-&L+O2+0KI=_+,=2^T`M*CB3YE7&X,=X#`
MG\Z7PYX2U"RU+1Y=0M83#:P:FDN75MIGN0Z8^J9S]<5Z!E?44?(?2@#S^VT3
M6M"NHKFVT:WU&-]#BT_[/]H1/(DBW?+\W&QMP!Q_<'!XJY_PC>I6WPUT_P`+
M0O'),T$5G=3*P"I$>)64,#GY<@#'.1TKM/E/I1\H]*`//M7\'ZQ+/K5O97,<
MEOK.EFVEG;;%Y,R9$9VH!D%6*D\G"CL*EU*SUW4;?1KI/#EO;3:;>V\[6RW4
M>Z55CD5E5A\H52XQDC//`[]YA<]JCAN;:XW^1-%+Y;F-]C!MK#JIQT(]*`*.
MFZO)J%YJ$#6,T"6DBQ"5_NRL5#,%]=I.W/0D<5P5YX-\1`W-UIKP07D^J7J,
M6DZV5R5#."#PZ[5<#KD?@?4/EHPIYP*`//&\/:[I&KW[:)!Y>FS7-HFV"6-9
M3;16^PA-_"D,%'/49Q45AX9US3=*\,2FSBN;C3+^ZFN+/SURRS-)AE8@*74/
MGG&><$5Z1M'I3/,A,C1[T,B`,RY&5!S@D>^#^5`'&0Z!J5YJ^M7T]K!8'4-&
MCM(C'(',,FZ8L,C!_C0DCJ>F<9K'7PCJVMVNB:;J.F6^F6^G:9<V<\\<R2&4
MR0F$>6`,A<?/\V/3'>O0)=9TFWDMXYM2LHWN1F!7G53*#_=!/S?A5F:XMK:W
M>XGFBB@C7<\DC!55?4D\`4`><MH/B.]U+0)+O2?(O=/G@6YU*#4SY$T,?+8A
M!'WN>"O'KBIM'\+7]E?V]M>V5W=0VNKRWL-PEY&(OG+L)&3&_</,*E>?7/05
MZ!;SV]Y;I/;31S0R#*21L&5AZ@C@T>?;_:3;^;'YX3>8]PW;<XSCKC((S0!Q
MGAGPO=Z7I/AR.YM84N[$70F96!*^9NZ$=<_+GZ5F>%_#NO>&D@$FD6U_YVDV
MMFX:Y4"WDBW!E;.<H=Y;*Y^[C'.:]*.W//6E&TT`<7HNEZMIWBB7[+:26>BS
M2W,]S'<7"2AY6?*O$!\R!LLS`\<C'?.;XG\#ZAK7B&[$!C32;V$74QW?,M['
M&\<1"]"#N1CG/,0Z<5Z+\N<<9J.XN+:T@>>YFBAA0?-)*X55[<DT`<'%X9U>
M71=+DN((QJ<FO1:I?J)%PH#8.#T)"*@XZT_PQX8U72]5T>XNH46.V@U))2L@
M.#-=+)'CURH)]J[)=5TUYU@6\@,K3-;A-XSYJKN9/]X+SCTYJ=KBW2Y2W::)
M9W4ND18;F48!('4@9&3[B@#C+_PI?:C+XX7Y(!K,$45I.&&?EAVG..0-W]:S
M+GPIJ>KZ1J4;6$]IJ5SI<=JLES>QR1?*^_R5$8'R]?F(Z-TKTKY?:CY?:@#A
M-:TW7-:ATV]31A8SZ?>13?98[J/?*OELC8;!0;"^5SUV_P`.15:/P;+<WFG>
M9ITL5F;N_DOUNKE)7<3PE-WR\?,3]T=*]$^7VI?E]J`/+XO!.O77A?7(-1DC
M.J21V]I:-Y@(F@MB&3<><&0[MV0<;CU'%=1X:TZ:WU'4KZ[L+RWN+N.`2275
MU'*9-@;Y0$X4+N//?/M6Y>:C9V4MK#<7$<<MW)Y4",V#(V"<#\`:KGQ'H*7G
MV)]:TU;L/Y9@-T@D#?W=N<Y]J`.1T;1O%$OBK2=3UQ<M9I=QS.)8_*)D(">4
MBC(&U!G=SD_6G^.+"]U34H[.T\.QS7LD#BPUI+L0R63\98X`;"DAL`G<,CUK
ML!K>CG4?[-&J61OLX^RBX3S<XS]S.>G/2K_R^U`'`>*_#5SK`:*'0()=5%O%
M#;:\TR*\#<Y?^^"I^88SG/:C4]`UUI?%6GVMK!+:>(-A6\,P'V<-$L,@=>I(
M5=PVYR2`<5WQ*XYQ6>VNZ,L9D.I6?EB))M_G+CRV;:KYS]TMQGI0!E:OH<]S
MJ/A4P1K);:9=F28R$9"B"1%..YW%>GUK$T_PIJ5II7AR+[-"ES9:Y/>7+(X!
M$+M/SD=<ATR/\*[Q+BWEGFACFB>:$@2HK`LF1D;AVR.>:DROM0!YB_@S6R`!
M;Q<?VW_RU'_+RV8?S[^G>C4?!NN3I:O#;V[M:Z/I\)BDF`6:6WG\UXCUX(&,
MXQS7IWR>U'R^U`'G&K^&=9UV77;UM,@M6OO[/@CM7E1FD2&<2.[D?+T8@#)X
M7WQ79Z9IYM-8UBY$2)'=RQR*5QER(U4DCU^4#\*U/E]J7@>E`'":-H^O6=W'
M93:="MI%K=S?F[^T@[XY&E9=J8SGYP#G'MFL/PKIFH:M9:"(M.@BL;#6;R]D
MOS(I:3$LR;`@&<DM@D\84=<X'JQ*YYQ0JH@PJA1Z`4`>?:1X4U*UTCP9;W-O
M%OTJ]FFNUWJP52DP4CU.77IT_"JVI>%]=GL=>T--.MY8M5U07<>I-.N(HV96
M.Y3\Q9-@4`<'(Y&*]$6ZM7NY;19HS<1(KO$&^95;.TD>AP?R-3?)[4`<9:^&
M;E9-6EN+2!I)_$,6H0,6!/EKY7S9[$!7X_QJWX6T[4=*O];M[NR5;>?49KR"
MY256#K(00I7J".^>..*ZCY/:CY<]J`'4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`"'D5Y3;:A/8!FMV7]YXSNHW4J&WKY<C;1D'!RHY'->KG@56^Q60((M(,B8S
MC$0XD/5^GWN3SUYH`\UC\0ZG;>`V\21^(S?7]Y91SM:,L/EVA,B+(Z``$"/<
MP.XD9'..:FFU+Q)I>FW,9U1G62^L8;6YN7@FG59Y-DA81X7;R"O'KUKT"+2M
M,A-PT.GVB&XR)RD"CS<Y)W8'S9R>OK3(-&TBV5DM],LHE9E=ECMU4$H<J3@=
M0>GI0!Q5W_PDEGIUSI\>MRW1M]3\M[DO#%=FV,*R;4++Y9<$\Y`RN>G6LVX\
M1ZSK$[+HFJW*10:3#?63R-;Q?:RP?,D^\`[`54,$`QD\C(KTN[TS3;]=MY86
MMPN_?B:%7&[&W/(ZXXSZ<4RXT72;U(ENM+LIUB3RXQ+;JVQ?[HR.!P.*`.2^
M)-O/=^`T<WLMK(MU9F3[,5VN6FC7N#P"VX>X'4<5EWFH>)EUK4[*RU2?S-&:
MW2);F2W2.X1E4M+/D!B&)91LV@%>/;TJ6WMYH!!+!')$"I$;H"O!!''L0"/I
M5>[TC2K^<2WFG6=Q,%`#S0*[``Y`R1TS0!P5CK'B+4/$<MQ'>,D-OK#V,UG+
M)`D*6X8@';_K3*RX=><'(X(ZV?B'KTUC#=6^FZGJ%IJ-GITNHXM_)$949"F0
MR`DC<,;5YY^E=J^CZ7->B]DTVS>[#!A.T"F0$=#NQG([4Z[TO3[^2.2\L+6X
MDC&$::%7*_0D<=!^5`'%ZM=:UJNN6NDV.LRZ:)=$:_,L$:%C*&"C[P.%^?D=
M3@<BLN^U[4-1%['<>(8=)^QZ+;W@1T39=O(C[V?=SL!`7"D8)Z]J].%K;B42
MB"(2+'Y0?8,A.NW/IQTJ&;2M.N'A>>PM96@7;"7A5C&/1<C@<=J`./\`'%Q;
MP?"#45FECC,NE[$#N`6;8,`9ZGVK+U_7M1CD\5747B$Z:_A^-/LMF$C*7!,*
MN#(&&Y@SDH-I'(XR:]%N=.L+R.)+NRMITA8/$LL2L(V'0KD<$>U-GTO3KRYC
MN;FPM9IX\>7++"K,N#D8)&1@\T`>9M_:K^(_%&L66JRV$EN^G22VRQ(8YLQ)
MN#[@6^Z2``1@\\UJW-[KEQKNL7$&M2P6VDZM;6ZVBQ(4FBD6$N')&2?WAQ@C
M'O7>FSM2TS&VA+38,IV#,F.!N]<>]'V2V!E(MX<RN'D.P?.PQ@GU(P.?84`>
M:ZEXEU?0[C7I[N]DFO!;WDVFVL+126C1PXP<!?,61<C<&."<X]`7NO:EHAOH
MK7Q*VL(WA^ZU022)$3#(@7RRI0`!&RV`<_=X->B0:3IMK<R7-OI]I#<2Y\R6
M.%59\G)R0,G)Y--@T;2K6&:&WTRSABG7;*D<"JL@Y&&`'(Y/7UH`P/#1U6#6
M)HK_`%B74(;FQAO$66-%\EV9@P7:!\GW<`Y(QU-<7XVN8KKQ?JMU+M72;&TA
MT[65!4SM!(3(6C5N0HR`2,DY.WE:]=$42,'6-`P4("%&=OI]*K7.EZ9>7*7%
MUI]K//&!LEE@5F7!R,$C(P>:`,S1-;L]0\)VVJ[H;2TDB)0O,NU$R0F6S@$C
M;P3P3BN'\.WMU)X<\#:##JTFDV]YI3S-<PA/,=HPFV-2X*C(9F/!.%KTLZ5I
M;VDUFVGVAM9W+RPF!=DC$Y)9<8)R,Y/I3I],T^[M8[:XL;::WCQLBDA5D7`P
M,`C`XH`\LMKC4?%.K^%-VLO#,'U:%-0M(D#311NBJR@@J-P"G(!'IUK7BN]>
MU>7P_I']NRVDUWI<\]S=VT*;Y)8GC4$!@0H)8D\>W%>@)96D9@*6L*FW4I#M
MC`\I3@$+Z#@<#TI5L[9)(Y$MH5DC4HC!`"JD@D`]@2!GZ4`>=S:WJT3:%?ZC
MJLL6G&TM/.>Q,6Y[F1MI\V-@3Y;'`&S!'S9]16B\1ZJT=MK/]O\`^D7&N?V8
M^C%(S&D?GF,J!C?O"`/NST[8KT5](TIKF*XDTVS:>(*L<I@4L@7[H!QD8R<?
M6G#2]-&H&_6PM1>DY-P(5\P\8^]C/3CZ4`<1H]_KE[J5KJDNLRM;-K-UISV/
ME((S$C2A#G&[?E`2<XQQBKVO.T/Q!TZ2-MKIH=^RGT(>#FNO2SMHU"QVT*`2
M&4!4`PYSEOJ<GGW-$EM;O*)I((VD5&0.R`D*<9&?0X&1["@#SK2]1UZ+0DUJ
MYUN2Z74/#LFHB!XD5;>=51AY>!G;A\<DY(S4$^N>(-$T"ZUA]7:^:ZT5+](Y
MH5VVTK,H++M`^0"0'!S]WD\UZ6+.T$"PK;0B%8C"J",;1&<#:!_=X''3BE%I
M;*BHMO$%6/R@`@P$_N_3VH`\ROM3UW3KZ^L-)\13:UY&F+JP=DB9\K*N8@4`
M&V2/=@$9&,@FKB^*6U'3K[4DU*^CL=3U*/3M&-DL88[5Y93(-HW,).6[*!@'
MBN\LM,T_34=;&QMK57QO$$*H&QP,X'--.E:8]@M@=/M#9J<K;F%?+!SG(7&.
MO-`'DZ7.IZO%X6EN_$NH6K#6KVR::.2$$K&)]K,=I5FPH7/W3G@9P:TTU[49
M[P:7_:G]GQWOB*]M&O8XXPR+&N4C7*[=S'`R02?>O17TC3)+-;.33K1[56W"
M%H%*`^NW&,TZ32]/FMY+>6PM9(9)/->-H5*L^<[B,8)SWH`\YMM<UF^:TTJ+
M779)-=N-,&HQ1)YDL*6YD##C:7#`KN`QP>*['P[-JB>'"EU.NHWUO//#YTA$
M7F[)652VT$`[0,D#K6O'I]C#';QQ6=NB6Y)@5(E`B)!!*C'R\$]/4U,D<:*1
M&BJ"Q8A1CDG)/U)H`HV]SJS3JMSIUK%"?O.EV7(_#RQG\ZX^*_LO^$J\<W!N
M[<0K96B-)YJ[5;9,-I.<9SQ7H-9YT+1_LLUL=*L3;SOYLT7V=-LC]=S#&"?<
MT`>9:`-(;4/"::P+$V[>$$`%YLV$[HLXW>V:CT:ZM/MNAQZG/O\`##WFH_V:
MUR^8&VE1`"6X*A/.V;O08[5ZC>:+H^HB,WNEV5UY2[8_/MU?8/09'%2W=I8W
MUK]DO+6WN(#C]S-&&4XZ?*1CB@"EI=SH<.;?2I;!1+(S>7:LN&<!2QPO&<%2
M?J*Y+Q/?3:9XM\17]LP2XM?"9GC/HRR2L/U%=A!HFGVMY#<6]NL0MXFB@BB4
M)'$&.6VJ``"<#)]JN26=I.TC36L,C21>3(S1@[TY^4^J\GCIS0!Y[J&K:[X<
MTK4[N36WN_-LK6YC>>%,6C2R^7(X"@?(H(8`YQM.377:%Y=BLEI)XB?5I&D^
M1KAHO,7*AMOR``\?-TS@UK-;VS*RM!$P:/RF!0<I_=^G/2H8-*TRT\K[-I]I
M#Y+%H_+@5=A(P2,#@D<'':@#B_&FNZSIFL-I=C<B.;6+1(M*8J/W=R)`LAZ'
M/R.'YX^0^M9%[XHU75/!VNZY'.8(+>VM8(X7A7"W&Y3.2&!R1O5>O&",9&:]
M3>W@EDBEDAC=X26B9E!*$C!(/;@D<>M1#3;!;62U%C;"WE8O)$(EV.Q.22,8
M)SSF@#S*U(/C2'I_R.%S_P"F^MSQMK-[I.L/):2JGD^'M1NURBG]Y'Y14YQG
M')XS@UV8L+,2B46D`D$IF#B,9WD;2V?[V.,]<<4L]E:W+%I[:&5C&T1,D8;*
M-C<O/8X&1WQ0!Y]<2>)M/LM1E@UFYU"=;&WU.*-H8P00Y,L2@`?(RC`!R1ZF
MJ-SXJU759XKG3K^>'1]5U-K.SN(/*4B..(\HT@V[I)-PR<\(`!G->HK%"KAE
MB0,%"`A?X1VSZ>U0'2---@M@=/M#9J<K;^2OE@YSD+C'7F@#@-0O_$D'AZR>
M[U(PPV\MTU]/9SP&[,,9.QAN!C9@/]8``<XQCI4GA<M=?$;6+L>(+Z:"2TLY
MX;65D595D20CY=N1MZC&/?-=J_A_19((X'T?3VAB+&.,VR%4+<M@8P,]_6K+
M6%FUY'>&T@-U&NQ)C&-ZKZ!NH')H`\\\7?9](UC5=;:;2-5C,$:W.D7Q!G0*
M,@0'G!8'.TKR3G(K2URQT[6O&&E:/%96GF0,-5U!_*7=L4XC0G&<M)@_2,YZ
MX/33Z#I=SK5OJUS86\E[`A2*9XE9EY!!R1G(QP<\9/K5Y(+=+B2=(8UFE`$D
M@0!G`Z`GJ<9/YT`>>>6_AKQ>U]'-H]_;ZQK/E[$B_P!+@=U5&P^3PNT$C;T)
MY%;?BJYU!M=\/Z18ZC+8)J;SI--"JLX"1[QMW`@'C&<'@FNBCTC38;YKZ+3K
M1+MB2TZP*)"3U^;&>:L/;PR313/#&TL1)C=E!*9&#@]LCB@#S7P]KFMW`\*Z
MI>:L]Q'K4D]I-:>4BQ)L21ED7`W;OW6#DX.[H,5R%[>RW_AIKNZ=6FE\)V4D
MC!0H)-V>P``_`5[JEA9QI`D=I`BV[%H56,`1D@@E?0X)Z>IJ/^R=-\KR_P"S
M[3R_+$.WR5QL!R%QC[H/..E`'GVK:[J$?C+4M*CU,6$%SJEK:&Z6./?`K6K2
M<%AC<S`*"V<9X]*B&NZRS'28==:51X@72DU%8H_,:)K8NW0;"ZL",XZCD=J]
M(FTVPN%G6>RMI1.5,P>)6\S;]W=D<XQQGI1'IMA####%96R10/YD2+$H6-N?
MF48X/)Y'J:`,/1(=0N/#E_8W>KW$MU#/<6R7R*BRA0QVGIMW`8&<8R.E<+X<
MO[V'P?X-T]?$MT@UEL3WKO&[VV(BRPH2N`688&[+=1SV]=5(XMP1%7<2S;1C
M)/4_6J8T723;26_]EV7D2R>;)%]G7:[]=Q&,$^]`&#X-U.\U&PU>.XOUOEL;
M^6T@O`J@S(JJ03M^4L"2"1Q\M<EH?B;6)1X>NFU\WLFL:?<2W5GLCVVICBW*
MZ;1N7Y@%.XG)/;I7J<-M;6MLMK;01P0J-J1Q(%5?H!Q69X<\,:=X:TRWM+2"
M,R0P+`UR8E$LJKTWD#F@#EK'Q5//X3L)EU..:_\`^$:DO[@*ZEO-"1D.P'3D
MM5>&]U6XE\/:?<^)KJV_MJSDU"2Z5(E97"QD01;E("_,S<[FPIYKO8-)TNV2
M2.WTZTB20,KK'`JA@V-P.!SG`SZXI\^FZ?>6L=M<6-M-;Q$;(I(595P,#`(P
M,#B@#S74H=2N/$VLWNE>(Y(9K7P]:7"W$,4;+=LK3D%L@C:<'A<9W=>*M>(_
M$ERGB"`Z;J5_']DU"RLKNWS`+<^<RDC##S&8H^<@X'X&O0Q96@9R+6$%XQ"Y
M\L?,@SA3Z@9/'3DU&^DZ;)=B[DT^T>Y&,3-"I<8Z?-C/%`'GE_XCUC1KO7)+
MF]FFOC!>2Z;9PM%):O'#T/`\Q9%R-P8X)SCT&WX/GUA]1E%WJ+7^GS6L=Q%+
M<30-(9"QR4$/`B(QC.><\UU$&DZ;;7,MS;Z?:13RY\R6.%59\G)R0,G)Y-)9
MZ1IFG2-)8Z=:6KLNUF@@5"1UP<#I0!=HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`$;[M<A92Z@GQ/OK.XU&:>T;3$N8H"`J0DRLN`!U.%ZGU[=*Z\C(KG$\&6B>
M*3XA_M+5C>-\IC-V?*V9)V;<?<!)(%`%/Q>M]/J.CV@.J)I$C3?;I-,WB56"
M@Q`E/F"D[N1W`!.#SDV%V-5^&<&HZOK>IQ^2\Z>=#(;>:8K*R1JP49+_`"J-
MHZMD$&NEA\.7;V427FNZC]I#S.\EM+Y:D2-G9@@_*HX7N*KWW@/2[RVTRWBN
M-0L8M,W?9EL[IDPS=6)Y+-U^8\_,?6@#G=:CU^+X=V-_J$^KIKD%D&<V4P2.
M*7'^LF`^]@'YAAAPV!71>)]:O-,^'EQJUG<0R70MHV2=%RA+E1O4'M\V1G/;
MK4EQX-M[JW$$VJZPT9@%O,#>M^_0'/S\=3D@D8)'%27'A>.^DO+6\EWZ-+91
MV46FIE8T5227_P![H`1C`44`8`TDQ>*9/"[ZKJ\FGSZ?]O\`,;4)!-'*DH0X
ME!W;6##*YP-O`Y-1^%]%35/#E]<W.K:TNFW-ZUQ9.=3E#I;H"BMYF=VU\,^,
MXY%=%'X.L4L;ZW>YOII;ZW6UFNI;@F;RE!`4-CC&6/3)+$FK][H5G>^')-"(
MDBL7@%L5AD*L(P,;0W7IQ]*`,'X?QW$?AN:^:ZOIX;VXDN+-;V=Y62WZ1_,V
M3\R@-S_>JEIOCW4I;"/6-1TJ"#1[C2YM1@>&<O*HB"DJZXQE@21@G&.>:[B.
M!8H%A0!8U78JCL`,5E6GA;3;+3+'3XXV>ULK9[6-)6W!HV`#!O7(%`',VOC[
M5I+34I9-)MI9(-/;4(1:S.R;5(S%([(H#X.>,@X-/NOB2L=UJ\%K9>?Y%K%+
MI[;MOVN1PF4&>2`9H>G]X]QBNCTGPY'HXC2+4=1N(8X/(2&YN-Z*N>.V21TR
M23CBL^R^'N@:=;Z7!:V\B1Z9</<0`R9RS-N.[/WAD+@?[*^E`#O%/B2_T)-.
MB@MK7S+MF62ZNF=;6#:`2'95)&[/!(`X.37.76O:]IOB[Q%=:=:6U]9P6MC/
M<QO=,-JD/N\KC!)&3DX&%%=KK6@1ZY;?9YKV^@B:.2*1+:;8)%<`$-P<\=.X
MR:AA\)Z7;K?)#'(B7MK%:2J)#@1Q*50+Z<,>:`,G6?&-SI?BNQTZ(:9<6EQ<
MQ6LB+<-]IC:3(W%0NT`8Z$YQ5:Z\=W]M#JE\=.MOL%G>MIL>Z=A)+<>:J*?N
MD+'AN3R>.E;#^"=+?5'OM]V-]ZFH-`)CY1N%``?;ZX4<9Q[5-)X2TR32]1TY
MEF\F_N7NY&$I#K*S!MR,.5(8`C'3%`'/KX[U1-#OII-*BEO;6YBM_-M_-:U(
MDP1)DIOVKG#84X-;<_B<Z?X)?Q!="UNFCAWE;"8R12,3M4(Y`X)(Y(XY]*L#
MPZWDO&=:U<LTB2"7[2-R[1C`^7&T]QCGO38/">EP^%CX<,+2Z<RNKK+(69RS
M%F8MUW%B6SZT`<;XM\5>*;+0M:TZ:TL;/4TTQ[Z*YM;EV18@P1@,J")`6!'8
MYZC%:.N17OASX2726YBTZ\AB`4V4SNL6Z4<JS_,3AN_>M4^`M*EM[Z.[GO[R
M2]LQ8R3W-R7D6$?PJ<<9/).,D\G-:^L:+:ZYI$^EWF\VTX4.$;:<`@CGZ@4`
M>?:KXAU.[\$_V/'>SPZW"US;WUW!PZ+:J6>3/&TO^ZQQ_P`M>!Z7]4\<WVA>
M'=&O%;3;IFLH)KN*:X9;A]^P$JJJ0/O9RQ`KI&\':.^J:MJ7V<K=ZK;?9;IT
M;&Y,8./0D8R?854N/A]HURK(7O$BEMH+6>*.X(69(?\`5[N.H]1C/>@!\&OZ
MQJ.NWL6FV%FVEZ?=?9;J6>=EE=]BLQ10N,+O'4\\XK(L_&VN:AI^DS0:58+/
MKG.G1R7+X1%C+R-,0IQT&%7/7D\5T(\*6*:Q/J4,UY`US*DUQ!%.5AFD48#,
MOKTS@@':,YQ41\&:8-)TK3XFN85TDJ;*>*;;+%@8^]CD$<$$8(H`YU_$VH:_
MJ-CX>FWZ1<O=W-M?2VDP9F\B-'Q"Q&1O\U3DC(`8=>0RQ\6V&A:7JCVW]O33
MVLEM"+/6F92C3.50AF!;:3DDG=]WBNB_X071_P"RQ9`70D%RUX+P7#"X$[#!
ME\P<[L<>F,#&*1/`VF?9M2AN)KZZDU'R_.N)[DM*/+_U91AC:5))!'>@#'C\
M>:FM@ZRZ9;RWXU"&QC>&1UMIFE4E65F4-A3@-QV.,U._B'494TB/5+%(+W^W
M?L$JVUTXCXC=@XX!92,?*P[^H%;+>%+>81?:[[4+LPW<5W&9Y\[)(_NX``&/
M4=ZL7'ARQN;B&:02[X;X:@N),?O0A3\L'I0!S2^--<DT*Y\16VB03Z.5?[*L
M<KM<'#[`[H$^[U8A<L`.AKI=`U2?4=&CN[J73WD);<]C,9(>/=@"#CJ".*H0
M>";&S5XK*^U.T@\QI(H8+LJD#,P9M@QP"1T.0`S8'-7]+\/6>D:=<64'F2)<
MRR37#S/N>5Y#\S$^_M0!Q\_CK697URSLUT:6:WTZ:^M+BWN'D0!'"D/E`"V#
MD;<@D8Z5T6@ZKJ;^#+?5-9?3HKI[99BZRE(<%05+DCY>O.`0.V:;IW@;2M.7
M:K74Z"Q.G(EQ.7"6QQ^['3C@<]?>I_\`A$;!O"DGARXENKFP>,1#SIRSJHQM
M`;MC:,4`5/!_BF[U^75+:]BLA-8RQKYME(SQ2!T##&]0<CITK/?QOJBWS3C2
M[8Z1#JW]DS2>>1.9#)Y:NJXQMRR9!.>M=)I/A^WT>XO+F*>YGN+QD:>:XEW,
MY4;5[`#`XX':L'3/`B#4+N[U6:64-J\NH06R3MY&2V8V9,#YQU],@'F@"EKG
MBO49;;5F2QB&G:=J,5E+(MV\4SR&6+!7:.%`D&<GGD=*T)/%^HB75M0BT^V.
M@Z1)-%=2O,PN&,2Y=D3;MP#Q@G)QFM2;PEIL]GJ%JZR^5J%ZE]./,.?-4QD8
M/89B7CZTS_A#M-%_=7*M<K%>2F>YLQ.?L\LA4J6*>X/(Z$@$B@"CX5\6W^MZ
MH]G>V-O&'MOM44EI(\B(NX#RY&95&_D?=R#@U%K/B_5;6XUJ;3M,M;C3M"7-
M\TUP4ED/EB0B(!2.%8?>/).*V]&\/)HK1B+4=2GABA\B.&YN/,15R".V21C&
M22<<54U/P1I6J7=[/+)>1)J`07L$%P4CN0O3>/<#:<8R.#0!SOAI]5U7XE:W
M?WL=JUM:)%';D3R;X8Y(PZA4QMY!RQ/0],BGW$MW9>,3<^(FU*WC^UB'3+RT
M8-:>5(5"Q.F"59B`"S#J>&%=E8:+::=J%]>VZ%9;TQ^:-WR_NT"+@=N!65)X
M-@G\0/J-S?ZA/:B1)X["2Z9H%F#%MVP^^T@=`10!D:T;K3O&^CRPWNIPQW5V
M(IY+J7-FT94XA1!P'+$;3@'(.2>AR;>^U>UUS29[^YUFWU&]UF6UN;>9&^QM
M!^\,:Q\;0=H0A@<G#9KL_P#A$;-M0BNYKJ_N%AN#=16TUR7ACE/1@I]#R`3@
M$\5)#X7M4U"WO;BZOKV2V=Y+=;J?>L3-G)`P,G!(!.<#IB@#*UM)M8\;6OAZ
M2]N[6Q&G27K&SF:&1Y!(J*"Z\[0&)P,9/7-<]H5YJ7C&YM=*O]4O(8[?3WE:
M:SE,$DTJ7,L`D<KCC$8;;TRQSGBNPN/"%I<M9S->ZBE[:QO$EXER1,T;_>5F
MQ\PS@C(X(&.E1S^!])<6GV87%@UK:&R0V<QC+0'_`)9MUR,\@]03D&@#-L/&
M%Y!\,;#Q#<VXNKIO*BD56">:QF$6[/09)SZ#-5[CQ]J>EF\T[5-.LDU>*YM[
M>$Q7#&V?SE=E8L5W`*(WR-IS@8ZUM^)?#1U'P:-!TM8K=$>V$2[BJI''*C8!
M'(.U3CWQ3?\`A!=*-O=)))>R7-S/'</>O<DW`>/_`%95_P"':,@`#&"?4T`9
MJ^.=0_L*.X.F1-?MJ:Z8JB1EAE=AE9$9E!V9(!.,\-UXK3U_7]4T#PY;74ME
M!+?2RQPRLA<V\#-G+L0I;RQC&<=QG`YJTWABVGAACO+N^NS#?)?QO/-DK(F-
MH&``%_V<=S5_4]/.HPQQB\N[0QOO#VLNQCP1@\$$<]/8>E`'!7^L^(3XLLKC
M1X].O+A]!DFEB6\;[,Q65>48+\Q/09`QDY-7O$?CVZTC3M/U"VBTUXY;>*XN
M+.:Y87`5RO"!5(XW=6(!K<TOP?I6C/:M9I*AMK)K%-TI;,;.'8G/5BPSGW-5
M;OP!H]X9`S7D<<UO#;3QQW!59DA_U>[CJ,]L9[T`5M4\:7FGZCKI%C`=-T*,
M2WDK2D22!H0Z"-0,9SP22.#QFI_#'BC4-7U*YL;^SMT=(5N$FM'=XMI)'ELS
M*OSC&>.,$5JMX<T]Y]7EDB,O]KJJW:2-E6"IL``[?+5>V\+BVM6MAK.L.AA6
M%2]WEHPIR"#C.X]"QR2.*`-X\UPNF:]>V^C>(+E[VU:XBUNXMK<ZA.4C`#`*
MF0">G0`<UVUQ%Y\$D6]TWJ5WHV&7(QD'L:YV/P+I<>E06*RWNZ"^_M!+HW!,
M_P!HYRY8]202"",8-`&3:>.M3OM'TQ[;3[-]1O[^XT]1Y["`/%O._<5W;,1D
MXQGH*6Y\;:O!8:6)=.L;.\N9)X[F6[G<6L+12;"OF*IP6ZKNP,9[UN6GA#3;
M-;#8;AFLKN6]C:24LS2R!P[,>^=['ZFC4_"=KJEG+9R7=_%:SB99X8)]BRB5
MMSAACZCU`)'>@#-/C.X3Q%?VUQ!:6UA91N[":1Q<7`6,.9(5V[73G'!SP<XX
MK.LOB+?265Y>76G6WDKIDNI0_9I7?RU10WERLRJ`Y##&W(X:NC/A&Q?4[>]G
MGN[@6S,\%M--NAB+1^6<+CIMR,$D?,?6H8?!=G#I4NEF_P!3ET][22R%M+=%
ME2)Q@XXSD#A22<#B@!V@:YK%_J5Q:ZII]K;(;>*[MG@G,FY'+#:V0/F7`SCC
MGBLC4?B&=.NA;S6&UXM8:QNOGXB@VAA.3T'#QG'N1UXKKH-,@MKE)X]V]8%M
MQEN-BDD?CSUK+OO!FCW^JW^I30/]KOK+[#+*KX/EYSE?1NG/^R/2@#(_X2.;
M4+_1VDM2D-SK%U:6[1W#`/''%+\[`<,"4;`Y&-IZBLGX<7MW<:CI"SW4TJOX
M6MI6#R%MS^:XW'/?'&:[6/PQI\,.CPHL@32&W6OS]S&T9+?WB0Q_$YJ/1O">
MFZ%/;S68F#6]BEA'ODW?NE8L,^^2>:`.1O?$.L:%XJ\7WT%O#=:58/:S70FG
M97C0PKO\I0",X^8Y(STJ_)X_N6\0/;6UC!-80WXT^0*[FY9R0ID50NT(I;G+
M9PI/I6MJ?@;2M6U"[NKF2]VWIC-W;)<%8;@(`%#KW&%`]^]6/^$6MTU*XO;:
M]U"U-S.EQ-!;W&V*1UQSMQQN`&[&-W>@#G/&*:O?>._#.F11V<FFR":X:*6>
M2,L\90DG8.=H.5&<$DY[5N:'XEFU;3M-NGM4C-Y>W%LRAB=HB,H!^I\H?F:U
M;C2+:YU>QU24/]IL4E2'#87$@4-D=_NBLS3O!NG:9?0W5O)>'R)I9X(7N6,4
M32;M^U.G.]CSG':@#S[PUKFK6EM8WL'G7\\/ARXN/L[RL?.*70&/][;D`UZ+
MI/B(ZSK=[;VL:-86T$#?:,G+RRKOV@=@$*$YY^8<4:1X0TS0YK6:R6;?:VKV
MD7F2EAY;2>8<^IW#KZ5!X(\,?\(MX>6S<1BYEE>><1DE%+'A%)`)55VJ/IVH
M`Z:BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$/2N9D\<Z5'->(RWABLG:*
M>=;9FC$H<)Y((^](21A0#P:Z>N,N?`TESX?U?3FO8_-N]4?4X',9*QOYBR(K
M#/S`%<'D9S0!;7QUI?\`9T]U+'>P3P3I;M8RVY6Y,K\H@3/)8<CFG7?C2SLH
M;0RV&JM=74+316269:X*J0&RG;&1GM^8JHOA.Y_LV[MFT_P\?M$\4CQFVD*N
M%')8EL[L_=/\/O60GA_Q+IFM>'XK6]CN;JVTR]CEOKJ&1X07EB94^]G@<+DD
MD)^0!O2>/=)\BTFM$OM0%S"+D+96K2M'$21O<?PC((QUR#@<4V_^(6B6-O'.
MANKV.2S6^!L[<R8MSG,IZ84;3G/-4-.\$:KX=6)M#U:W:4Z<ME.;R`D%E=W6
M10I&/FE?Y3P1CGBK6E>!O['E18+[S((]#32E\Q/F)5F;><<8^;I0!I+XKLI=
M<32K:&\NI2$:66"`M%;[UW()&_AR.>G0BN:_X3Z>#4=*.VYU&UNX+XLEE8$R
MF2&=4&%R<`#<"2<'`/&0*TY?"-^^NZ=>PW%C:K:M!YEQ;Q.MQ/'&F#$YW892
M?4<#MGFJEKX*UK2CIUQIFIV/VJS2]C/VBW=D87$_FYP&!!7"CWYZ4`6'\<6R
MZY!-]K3^PY=%.H"3RR7W>:B#`'.3NQMQG/'6MO1/$5OKIN8XH;JUN;8KYUM>
M0F*1`P)5B/0X.#[&N3D^%V[38;$:D&6+2C9B1XN3-YZSB0@'&W<OW?3O73>'
M=$GTJ2[DGM]+A:<1@FQB=6<J#G>6)R.>!VR>M`',Z3X\GGUG7;K4H]1M=/LI
M_L=O:FQ&'D^3:`1EFE8N?D'&W!]:W8_'>D&QN+B<7EK);21Q3VMQ:LLT;2?Z
MO*=]W;&<U3N_!%U-:ZD8-1CBO)=:75[21HMR(ZJBA'&?F'R'.".OM3)?!6H7
MUQ>WU]J,'VRZO[*XVPQ$1QQ6TF]4&3DL?FRQ]1QQ0!O3^([6TT*/5KR&[MHY
M"JK;RP'SR[':J!!DEB<<5DVOC>U:+4KRX%VL44\5O%:&V(N!*R`^5LZEB3GT
MQSG'-:?BC0IM=TZ%+6Z6VN[6ZBO+:1TWIYD9R`PR"5/(."#6+J/@S4=6MII;
MV_LY+_[=#>P`6["%"B;"C#=E@06YR#R#VH`U+/QEIMZ]G&JW4,MU<O:>5-#M
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M.[U&XLX+.WM;&%MJHLH<GDEF)8L>V!QSUH`VIO'=G-IE[)%]KT^ZM)K=98;V
MR82!99%16V9&5;)`.>#DD<8JVOCC2WUN/2U2\+O=-9FX%N3`LZ[OW9?^]A2?
MH16;>^"M3U;^U+G4-2M?MMZ;-$$$!6..*WF$N,$DEF)?G/&1Z5HV'A66TBN$
M:ZC?S=:?4Q\AX5FSLZ]?>@"*P\?:9J6M6NF6UMJ+_:S)]FN_LV+>81_>97SR
MHX&<=Q4.K>+[S2O'NGZ,UO"=+GMXVGN#G?')([I'[;2RA?JPKG_!]AJ%GJNE
M%].>6827?VMKBWFC-D'8L3&['RSN;:,(HR.1P#72:]X,_M_4M0NGO/(2ZTQ+
M./8IWQ2I*TBR`Y[$CCVZT`4Y_'%Q#X\DT]DMQH<%O.)9^3)YT*)(^,?PA9%&
M,9SFG6'B'7+J?3[NYU'P_8PZ@(Y(-+N&(N#"Y&#OW?,^W/`7&>,U+:>!3&=%
M^UW<=S]EM[Q+\F+:;J2YVF1^,8R0WYU1_P"$#U9HM)T^XU#3;FRTRXMWANY;
M(_;/*A<.J%]V.H`R`..V30`V+Q;XBM=+U3Q#="QNM(LK^XADMHH62>.&*5D+
MJQ8J[8`;!"\`XYJ6\\8:O$-1UJ);0:)I=^;*XMFC8SR!75'D5\X&"V0NTY`Z
MC/`O@G6Y;74-&N=5L5T&]O9KF5(K9OM#I)*9&B+EMH!SM)"YQTJQ)X(O97U+
M3VU"%M$U#4!?S1F(^<,D,\0;.-K,HYQD#(]"`#2CUS4CX^?0Y[:".Q^P-=12
M*Y:1R)$4DCHH^8\<GC\*-#US4;_Q1KNF7UM;P1V"P-`(W+LRR;^6/3/R=!TS
MU-5I-!\0MX]375OM,%DD!M/(-O)YGDEU<_-OQORO!QCVHTC0?$-GXQU'5[N^
MTR2UOU1)(H;>17"QAA'ABY&?FYX^F*`*>M>*KZ'XAV&A0I>6]BD'VJYN$M5=
M)!N489F/RQ@$[F'(.*NP>.M.U!6AMTOK::>WDFL9+NU:-+H*FXM&2.0!@X.#
MCM5K4?"_]I^()K^6X"V\VDS::\:K\W[QPQ8'IP`1TK)M/!NKLVE)J>J6DL.D
MVDMO;>1;E6E9T,8=\DXPF.!U.3GM0!!IGC>='TFXU>>*.SG\.)J5PR1'/G%X
MU^4#).=^`HSSC%:\'CO2I"8[B*_L;E9(8VM[RV:.0"5_+C?'=2W&1G'?%8MS
M\-[BYTVPM?[42-[/1HM/200Y_>QRQ2K)@G[NZ(97K@]:NW/@N^UJ76+G6KZV
M-S>V"V,*VL1"0!27#G<<LWF'..!@`<T`:/\`PFVC_P"EA9G>2UU!--DC1<LT
MSE0`O/(^;K_LMZ55@\;6D&DVEQ<-<7LUW/<Q6Z6MF0\S12,I54R3D`=<X(4G
MCI532?`$NGZQI=_-J"S^3'YE\-FW[3=9D;S<#Y1\TSGIG[O/%6-+\%SZ?-H#
MM>QO_9=U>SN!&1Y@G+D`<\8WC/KB@!UQ\1-'ATRTOHHK^Z%S;M="&VMBTL<2
M'#NZY&T!N#[UJ2>)[&+PW!KLHG2VN$C:&-HOWKF3`1`O]YB0`/>N,\0Z'/#J
MUHDJS/:K8WBB2*UFE5WDEW^6PA*MRO')P>PS74KIU[JO@JRM;K2]-@N6AB$U
MC<QF2!,8R@`/8#@\X..M`%JV\2VT]SIEJ]O>VMSJ*3/##<P;&41[=VX=OO#'
M7-86J>.7L-?TD0VMY=V%[97$OD6MJ9)B\;Q@$`=!AFSGV[TEMX-UNT_L2YBU
MBWDO=.:Z4FXB>1!',1A5R^[Y`J@9/(%2GPGK5I+I%WIVJ61O;"SFM7:XMV*2
M^8RL7`5AM(*`XY[B@"W=>/=&MK>UF1KJY6ZMA>1BVMS(1#GYG8?PA?XL].G6
MHIO'6G3V.J-:R7-N]M8/?0SW%FVR:(+GS(P2#(HXR,CJ/4&J5G\/7L;9+>+4
M0ZKH<^EEGBY:25]YDX/3.>/UJ;4/`]Q>Z?;6POHU:'0+C2"QC)!:58UW]>@\
MOI[T`:-OXPL);N2U"7;I;1;KJ^6W(MX6"!V5VS\K;2#CW`S59O&,5WI,-];1
MWMG%)>VT$<EW9'$ZRNJ@H-PX;/WNV<D'I5<>#]137(;Z"?3K=(D99/*A<->#
MRMB+.-V&`;YLXSP`,<DU[7P)?QVTL+WMI!`;ZRNH;.UC<00"!PSA`S'!<CM@
M#`Z\F@#6A\<Z3/J<=F!>+#-.;:"]>U86TTP)&Q).A.0PST..":5?'&EMK,>F
M*EXSO=/9&X%N?)6==W[LOTW84D?AG%95CX'U.VBTK2Y=5MWT;3+_`.V0A8")
MY`&+1HQSMP&8Y('(QTK4L/"TUG%<HUU&_G:T^IC"$85FSLZ]?>@"YK/B6UT6
M:"W>"]N[N=6=+6R@,LA12`S$#H`2.2>_%<O>>.I-3\2Z#8:)_:!L+M&N)+J"
MQ#^8$D1"AW_=4%F#G&Y2`.]=!JV@ZB_B*UUW2;RWCNHK62TEBNHRT;QL0P(*
MD$,&`^HR..M4]!\&2Z+?:/<-?BX-E:744Q,>TRR3RK*S#T`(;`]"*`)[CQA]
MF\<0^&3I&H2-)!YWVN./,8^8#_OD9Y;L>,5F^$_'JZGY%AJ:7*7TLUU&ER;4
MI;R>5(_RJ_0D(H)[<'Z5MWFAWK>,;+7;.Y@54M6L[B&:,DE#(KY4@\-\N.<C
MFJVE>$WL=&L-/GN4E6WN[J=V52-RS&;@<\$>;U]J`)=)\9Z;K&H):0)>1F>,
MRVLMQ;M''=(N-S1$_>`R#VX((S6-XA\7ZKIG_"6+:I;%M*M[.2U\Q#@M*6#!
MN>G`],5:\+^#KCP]/9(Z:5-%9Q/!'<K`XN&3@+R6PIP!NQUP.E&N>"I]6;Q*
M4O8X_P"V(;2-,QD^5Y+,23SSG-`#++QG/J6IZ!!!'%$+N*\6^@;E[>>`(#'G
MMAF/4<C!XJCH7BWQ"F@Z%K>LBQNK#5I(8V^R1-%);-*0L>0S$.NXX)&"-P.#
MBM9O!03Q^GB2UN5AA:"19[7;P\S@+YH]"550?7:*S]&\$ZU#INCZ1J^JV,NE
M:4\4D<5I;,CSM&<IO9G/`8!OE`R1Z4`=K?7D=A87%Y-N\JWC:5]HR=J@DX'<
MX%8G_":Z*+I[<W>&33/[59BO`M^?F^H'.#V(K0T>34;NP,NK6T=O.\LFV)#]
MV+<=F[D_-MQG!QG-<1'\*Y8K%+==5W.MWM\S84(L-NP6XVGG"\`MGJ:`+5M\
M14BU_48+^VOOL(:S,$B6A(MQ/&A`F8="7;'J*UIO&%M87>IQ7#SW4D-ZMK!:
MVMHS2LQA60J!D[^"6+?*`..V2Z3PI(UUXBE6YC5=6:W,:;#^Z\M%7GGG..V*
MI77@R^'B";6['4($NQJ7VR))8B4*-;I`Z-@YR0N0PZ>AH`KZCX_;3=?M?,L]
M0?3YM*DNFMX[)C/$Z2`$LO\`"`N[.?08KH=;UV&S\(R:W!=".$Q1RQS&`R_*
MY7!V94G(;U'6J]OX>OV\00ZO?7T$LPTR2RD6.(H"S2!P1R>`!CU/6EUCPU+J
MG@0^'5N4CE-O%#YQ0E<H5.<9[[:`)X/$UK=:]-I-M;WLS0,8YKF.`F".0`,4
M9^S8(_,5#K?C&PT*[:UG@OKFX6$7#Q6EL966'+`R''105.?J,9JM_P`(S?GQ
ME%K*365I"DKO+]EC=);M"FU4E^;:V#SG'88QSFAK.EZY>>.[MM*:&WCFT1;=
MKJY@:1`3+)D+@@;@"#@T`7(?%CRZ]J7D"2^TR+2[2^MEM(=\DGFM(,J.^0JU
M*GCO2FT>/4#'?)ONVLA;-;'S_M"@GR]G]X[>/J*RY_A]=1QK'IVJB...RL+-
M5D##S8[=GW*Y4@[7#X./2IM/\"3V=M8QF\@#0:VVK.L<9"X9&7RUR<\%NI]*
M`+W_``G6EG2;:_$5_FYGDMH[86Q,YF3=NCV?WOE;VXZTO_"=:8VE6-[!;ZC<
MR7OF"&S@M2UQ^[;;)E/X=IX))QGZBG2>%Y7U33;L72`6FJ37Q78?F$D;IMZ]
M1OSGVJEJ?@J6ZO+&^AEM))[::Z+17$;&.2*:3>5X.0P(7GV/'-`%BX\?Z,EK
M!+;O=7*SP?:=]O;,X@BR1YDN!\J@@CGG@\<&G:GXDN=)^';>(/L[WES'IZW&
MV./(9S'G)`QA,\DCH,U2MO"&KZ?=+=:9>Z99O-8K97,,=FQAC"N[*\2[L@CS
M&R&)!)S6S>:!+=>!KCP]]H42RZ:;+SRO`)CV;L>F><4`8>E^-?L>C62ZC'K-
M]J,L9GE1=-Q+%$6(#NB<*G!`[D#.#S6L/&>ERW5A;V1N;Z2^ACN(OLL!<"%R
M5$K?W5!'.?6JD_AG6+35&U'1M1M(YIM.CL9DNH2Z@Q[BDBX(Z;VRIX/'2G^'
MO!O_``CVIVLT5X9K>VTB+355UP[%'9MY(XYW=*`'^,=4UK1='N=6L)M/2VL8
M6GF2YC=FFQGY`00%SQS@\]JR=0\6ZXR:MJ-C;VT%EH2(][:72$S3YB69P&!P
MFU6P.&RP/2M'Q+H'B#5=7LY[&^TP6%L-XM+VWD=7FSP[;77.WC`/`//7&*UW
MX-U2Y?681JENEEKHC-^HA.]&"+'((CG&UT4#YLE<D\T`79?$6H#QCI&FI;0K
MIFH6TLR3EB97**IQMZ*/G'7).#TK,M?%5[<?$6_T676]+M8+:Y2**QDMV\^X
M0PJY*OO`ZL1]T_=J[J?AW7IO%FE:EI]YI<-CIL;Q102V\C.4<('RP<#/R?+Q
M]<U8U?0=6UJ[A@NKNR72X;Z*[7RX6$Y$;*ZJ26*_>7DXY'8'F@#IZ*KV:W:Q
MO]L>%Y#(Y4PJ5`3)V@Y)YQC)[G/2K%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7/S^*[&+
MQC;^&]LWVF:$R>:!^[5L$A"?[Q56;Z#WK?;[IKS>[\/:_<:9<:S&BC4_[3&J
M1:>Z+YG[L[$C\S=M&81CIU8]^:`.^.IV"ZBNG-?6POF3>ML9E\PKZA<YQP><
M5'#K>D7*2/!J=E*L<HA=DN$8+(3@(<'AB>,=:XF;2;M?$]W+::+?-:7[S-?M
M<"+(!@V@V\@;>K,0%VDX'S'C@G/CT/6UT":RM]&F^QV-[ITUHLJ0QW4Z1.K2
MAMAVL5``!."3GZD`].EO;2!'>:YAC6,X<O(`%.-V#GIQS].:ABUC2[B2VCAU
M*SDDND,ENJ3J3*HZLHS\P]Q7%ZGI6J:[$CSZ,\22Z_:W+V\TB.3;+&BLS`''
M8Y7G\:J)X0NX+2XE@TF..]'BA;N"1`@=;7SER0>R^7O^7T)&.:`.WAUZR6RF
MN[^XMK&**62,M-=1E<(^S<6!P,G'!Y!(!P:FN]<TFP@AGO-4LK:&?_4R37"(
MLG?Y23@\>E<+IGA6^.O:4^H:8KV<-]J\T@DVLJB64&)B,\Y&2/3VK!U;1#;R
MII<MF%A@\.20SQ@1NZ1&1P-GF.%5@H/S`GJ-W04`>O/J%E'8?;GNX%LP@D^T
M-(!'L/1MW3'O20:E870A-O>VTPG0R0^7*K>8@P"RX/(&1R/45S.JVEEKG@O2
M?L]GJ4EJ3;3VZ6R()8P`"I9'^4@#JI!^E9-C;^(K6^\.ZO=Z`7GAL;NVFM[0
MQ1^6SRHT98;L+E4RVTD`DT`=S<ZQIEE'!)=:C:0).0L+2SJHD)Z!23S^%.?5
M-/CU!-/>^MEO9%W);-*HD8>H7.2.#7`V^C7]GJ-K=:CX:_M2*31(;180T;_9
MIT+%T;?P%?<OS#/W.1TJUIVD7MIJ^KPW.@":XN]0>XM]6!C811,GRG<3O!CP
M%"@>F#CH`=I!JNG75S<6UO?VLT]O_KXHYE9HO]X`Y'XU`/$.B'3FU$:QIYL5
M?8UR+E/+#>A;.,^V:\VTKPA)'HT-IJ6CZR;FWTVXLY?LGV:-)=P4,0ZX+L^W
M<I;H2=U69='U.7309M&O3+97<K::T-O;!I%\G`:XB)V-DDJ"`#@`_+S0!U$G
MC:Q/C!-!MI[!_+A\^ZEDO40HI#$!%YWD!"6'&U2#SFM36=<M]+T&]U1&2X6V
MLY+Q8TD&945=V0?0^O3FN1B\-:C=7FKW5UI5G!=WOAZ"W#1JH1;K;,)%4\D`
M;U&?3'7%0G3=<U#PI=63:'<6TB>&GT^-998]TLY0#:`&.!D<$GGVH`[_`/M&
MUCTM;^XGCMK<Q"1GF<*J`C/)/`JI;Z[9/;7EW<W%O;VEO-Y8N))E$;KM5@VX
M\8.ZL'Q'I5[/I_AR1---_%I]S'+>6.Y=TB^4R9`;Y6*LP;!/\/%85SX:OS#9
M3PZ++:VL.L2W+Z;%Y,C".2+:)`K93*MD[>V3CI0!Z1#J%E<-$L-W!*TT?G1!
M)`=Z?WEQU7D<CCFH9-<TF(0^9JEDGVB0Q0[KA!YC@[2J\\D$$8'>N#N]`U+3
M_#MGJ7A[3[M]4L+JZ>.UO#$LDB3E@X&WY%7<4D"\<(!Q5&Z\#SV$DMG)9WM_
MI\NC16:2644#2(Z!Q(H,O*%R^X,#USGD`T`>@)KT`\0:AI<ZB%;*TANGGD<!
M-LA<<YZ8\L\^]78-5TZYLDO+>_M9;5CA9HYE9"1V#`XKS_Q#X<U:YU>YNK;3
M7N[1(-,9K>21,W2P2RM)$<G!;#(>>"1UK,U[2YH(=8U%]$^QV-_JVEQP6+;`
MT^R4*[%0=J[]P7D\@<XH`]2AUC2[BR%[!J-I+:$D"=)U:,XR3\P..`#^5$6L
MZ7-);1Q:E9R272%[=4G4F91U*#/S#W%><MX6U"]N;FZ70Q:6-WKUG<?8&,>5
M@B7;([HIVC=UP,DCK4\7A*[M[2XF@TF..\7Q0MW!(H0.+7SER5/9?+WC'H2,
M<T`>@QZGI\U_)817UL]Y$NZ2W693(@]2N<@<C\ZB;6])$TD']J60FCB,[Q_:
M$W+&.KD9R%]^E<%X8\,W.GZIIXU&QU$W5E?7$@NXDMQ#,&$G[UW'[Q@P?[I)
M.[&>!5WPWX1^RVNCS7FDQ)?0W]Z]P[!2WE2&8+N.?F!4QC'/&.F*`.KT+Q%I
M/B2P^V:3?PW<.<$QMRI]&'53QWJ>#6=+NKFXMK?4K.:>WSY\4<ZLT6.NX`Y7
M\:YSX?:=<Z/X7CTRZTLV5U;,ZN^$VSG>Q#*5/(P1UP>:P-'T;Q!<Z['J>HZ5
M]FN/[,NX+G9%#''YTCH56/82S+A#\S$]1TR:`/1(-5TZ[N)K>VO[6:>``RQQ
MS*S1YZ;@#D?C5:TURUOM4%I9S07,7E.[30S!PK*P4IQWYKAT\%7:>#K6VLK*
M*SU>7PW)8SR[@I\]A$=KLO4DA^>>_-;?AG3V77Q?Q^&6T2$Z>L#@M&-SA@=N
MU"1P,@-W_`4`=/+JFGP7\5C-?VL=Y,,Q6[S*)'^BYR?PHAU73KB]ELH;^UEN
MX1F6!)E:1/JH.1^-<C9Z7<V7BC6&O-`%\][J$=S;:EF,B*/8J@$M\RF,H2`!
MSN&.]8NB^'-2C7PK92^'Q:7NE7C3W^J%DVS`*ZDJP^=S(7#8('0YH`]$.N:0
MHG+:K8@6Z+)-FX3]VK<JS<\`]B:?/J^FVMNMQ<:C:0P.H99))E56!.`02<8)
M(Q]:\[\.^"Y[>3PDVH:-#_HT-]]O,BHWSNR^67Z[CC..N/:DTOPCJ/\`Q*8[
M[2U:&SL=3A5)-C+$SS@P`#/_`#SSCT''%`'H\6H6,UU/;17EO)<0`&:))5+Q
M@]-P!R/QIEKJVF7<,TEIJ%I/'`Q25XIE81D=0Q!X/UKS67P5J@T#0K6PLELK
MQO#]S97\Z%5(F>./:)"#ELN&YYYR:L)X>N)M"UTVVD:G:ZA=:$UHD,B6\46_
M#;4418RP)^\>,8YH`[Z3Q!HT-O)<2ZO8)!'*87D:Y0*L@ZH3G`8>G6F#6[5&
MU![J:"UMK*14:>6YCV$%5;)Y^3[V,-@]^A%<E=:`^G:UHUXOAU-0TZ'37MGM
M84C)@G.P[]C8!W!-A8'/3/%0/I>NV8UAK71T$%[JML[PA(I2EL+:-6,:L0I*
MNNWGL"0#Q0!UMWXDM([G14M7CNX-5G>&.>"560;8W?.1P1\A'!I;/Q3I,T=F
MESJ%C:WMU&CI:/>1-)\W0#:Q#9[$9![5QVB^'-6M8O#WFV+Q_9M;O;R93Y8,
M<4B3["0OR@_.HPO0FJ.BZ+JEK/X-LM2\+7$MOIEI$SSQ"`E;G!4;R6#;8U)/
MRYR3WP*`/1GU_1UENHO[6L?-M%+W,?VE-T*CJ7&<J![U3L_%FF:M96%[I-U#
M>VUW.L.])D4QDJ6^96(.[`^YC=STQFN1TK1=;OO%NGZCK&DQQ-''>QW>(85@
M)<@)M():0$+DEO7M4>E^'=43PEX4TX:,]G>:9?Q_:F)C`.V"5/-!4\C++SU]
MJ`/1+?5=.NKB>V@U"UFN+?\`UT4<RL\?^\`<C\:=;ZKIUW=26MM?VLUS$H:2
M&.96=`>02H.0#D5YUH7AZ^2;PE"?#HL)]'63[?>DQXG/E-'A2O+[V8/R!TYY
MJ[X9T$>&=%\/ZE>Z=':W-AI4ZZA(-NX$A&(8@_,25//-`'9:YJT6A:+?:K<)
M(\-I"TKI&,LP`Z#WK+G\8V,?@Y/$L:7$MO(@,4"H/-9RVT1XS@-NX//!S4/B
MA;OQ+\-=12QLIUN[_3R8K64!)%9ER%8$X##.#S6)_P`(QK`\37EOY`_L)&EU
M.T*RXW74L>PQE?0,9''0?,/2@#KK?Q/H\NF:9?3W]O9IJ4*2VR74RQNX8`@`
M$\GD=*NSZII]K=PVEQ?VL5S.<0PR3*KR?[JDY/X5Y7J_A_Q)=>#K+05TC>J:
M!#;QE(X6876T*Z2.YRB@`$%1SSSTKIK?3;BT\7:K/=^'AJ"7L]M+:7G[MA"B
MHJE6W<IL96<8!SNXYH`ZHZWI*BX+:I9`6Z+).3<)^Z5AD,W/`(Z$U5U+Q)I]
MAIL%]'*;U;IQ%:QV9$C7#D$A4P<'@$YS@`&N&L_"M]8^%?#)ET1;F>SOFGU*
MS&SS)E/FJK'/RN5+JX!/;CFG0>'M9M-0;Q'8:,L/E:O)=1:5YB*[6[P"%R,?
M(LA*EPN<<\G-`'<:3K%W>^:NHZ->:5)$@=OM#QNA!)Z.C$$\9/ID5;M]7TR\
MM/M=MJ-I/;;BGG13JR;AU&X'&:\VG\/Z_J6F^)H+>#68;6YM[8V]MJMZLS22
M+(7E1<LP567:G/'MBII_#$MY:7/V;2=15[F_TZ2XBNT@CC:*.7+A4C..%)W9
M^]QC-`'=/KMD]K:W6GS6U]!<7*6XEAN8]HW'!().&(_NC)/859_M?31>O9-J
M%H+N-#(\!F7S%0=6*YR![UQ^H^&)8Y433-.6.W_X2.UOV6/:J^6J('?&>.0>
M/:LV+P])_86I:-JGA>[N;F2XN9)-2M'B$DR.Y961V(.[#!=K=E.<C@@'HUEJ
M-EJ5L+FPO+>ZMR2HE@E5U)'49!Q4<.L:9<M<+!J-I*UL<3B.=6,7^]@_+T[U
MSNAVNL2^%=6L[B!+"XDDGBL7\M(G*%<))((^%;.>F.`#@'BN=;0KZ?P5;Z=;
M^$EM;NSCM?M*,T*B]$4JF2%6'W@X0G+8'S`'O@`]#AUG2[FQ^W0:E9RVFX)Y
M\<ZM'N)P!N!QG)Q]:K:YKT.C6T,NP3%[RWM617`*&5U0$_3=G'I7":IX<U&_
M'B.]T[P^UE#<#3Q!9DQI).T$_FR/M!V@E2%&3D[>W%:>I6&KZNL]P=(FMS)K
M&GW"122(6,,3QEW.#@$`-\N2>*`.IN-<M8M0AL89X9[EIUAFB292\(968,RC
MD?=[XZU=NK^RT^)I;R[M[:-5+%YI`@`&,G)^H_,5YYX?T"_M+C1X+OPZ5O;#
M4)I;G5A+'B97$AW@@[GW;ER&''X5T7B'1Y=4\4>&IFLUN;&UEN'N0X4JN8B$
MR#U^;&.O-`&\NK::U^M@NH6IO&3S%MQ,OF%?[P7.<>]$6K:=->36<6H6LEU`
M,S0I,I>,>K+G(_&O/++PO<V^NR_;K'49'76C>P75LD`C=6;<I=S^\"J#L*^B
MC''%16_AG4Y/`-QX?&@BUUA;*6&74=T>+E]P)`<?,WF\YW`8SSF@#O9M?LFT
MV2^L+FVOXHYDA8P7484,652"Q.`1NSC.3T')%75U"S,4,OVR`QW#A(7\P8D;
MGA3W/!X'H:\XN/#EU<Z3J#V6DZE#>7']GYBGCMXHP(K@.P58\`LHSECU&`,X
MJY8>%M3B\626TBF/1K!KJ[TZX##'FW';`Y'E[I>O7>#GB@#NK?5-/O+J>UMK
MZUGN+?'G113*SQYZ;@#D?C4AO;0/,ANH0T"AI5,@S&#G!;T!P>OI7GO@KPY/
MIEUH_P!NT[48+VQM9;=Y56W6W8G:"Q9,/)NV[AG)&3GFK&KV&L1:[XG-KH\U
MY'JUE;102I*BHI19`V[)R#\P(`!S[4`=K/JVFVMS%;7&H6L4\K^7'%),JL[<
M':`3DGD<#U%5M:\0Z5X>ABGU;4(;.*:58HS*V-S,<?ESR>@')P*\W\0:;-K6
MO>.=-L]&^VWMU]DBANF*!;0F%?G)8[EQ][Y022*[+QOI,VJ:#;+;V*WTUM>V
MMP82%+.B2JSA=V!DJ#P3STH`W?[:THSVT']IV7G72A[>/[0NZ92,@H,Y88[B
MI[J]M;&V>YO+F&WMT&7EF<(JCW)X%>7:IX<U&\T_Q)8#PR9;K5YHY+"\<Q8M
M8RB*%<YW(8BA.%SU&VNS\5+J;:5;1Z=:+=AKJ-;M3&DCK#SN=%<A2P.WKGC/
M!-`&Q_;&E_8%OO[1M/L;*7%QYZ^65'4[LXP*L6UU;WENEQ:SQSPR#<DD3AE8
M>H(X->;:5X5U#[+X?@O=,!AAUR[O+B*41X2*19C&65?EZLG`Z'Z5VOAO34TC
M2VLH[86\*75PT4:]`C2LRX]B#F@#9HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*;N7'M
M]*4C(Q7E%KKDUYX[L[O3);U?/EOH9[*:_>7F*,[=T'W8AO4%<')&/4T`>H2W
M=O#<6]O(<27!81C:>=HR?TIL]_;6T\<,KE7D1W7Y3]U,;OYBO+-#U%Y8])OK
M/6+_`%'7'L;B:[LK@M(L=TL)&W:0/+(?*[!C(YP<9J;P]>6\\NGW-KK]_?W<
MFDW$UW'<2,_DS[4W$$C]VV<C8,#C..Y`/3[:]M;RVAN+>57BFB$T9Z%D(R#@
M\XYI+.]MM0LX;NUD$D$R!XW`(W`]^:\HT2&"7Q5X2U74]1ODNKKPY$Z.]W(H
MFG!B^3&<-G.2O<\D4W3=5-YI_AN+Q+KNHV.GOH2W:W*7+PF>X#'?ND'+,J`$
M*3SN/![`'L&5^M5;O3=.OY$DO+"VN7C!"--"KE0>N"1Q7F.FG6?$HTJQU35=
M4M&ET&6[=X9#!(TBR[8W;;CG:V2.,\9JMXKUZX?3;=8KN^@U>QT^SG687[0B
MX:1ER5A48F/#;L\"@#U>WU.RNKV\LX9@UQ9LBSI@Y0LH9?S!JI:^(=)N]<N-
M)@O89+R!0SHKCDY(('J5QR!TR,UCZ"/^*Y\:9!P9;3G'_3N*Y_PGJUK8:YI^
MA:'J]OK>D()F(:']_IBA20&8=02=OS`-D]30!UMIXY\,7ZW;6NJQ3+9QM+.R
MHV$0'!/3GGTI++QUX7U%;IK75X)/LD#7,^0RE(AU<@@<"N9\'7!TK5[#0M+U
M]-<TA[::9ML2`V0#93++_>+.,-S\O'>I;6.S\2:)XG\1:C<_9=/U:![*WG;_
M`)8V:!DWC/3<S._IC;]:`.OT7Q'I'B&&6;2;Q+J.)@KLJL,$\CJ!6GN4\_TK
MCO!NH7<FH7^EMJR:U8V<,)BU!(E0;VW!HOD^4E55&]?GY[5SNLS:BVLZQ<QZ
MKJ,#6NNV=A;I%-B-(IE@$AV8PQ_>-@L#CC&*`/3+J]MK(0FXD$?G2K#'D$[G
M;H/QJC#XGT>=;-H[Q2+PS"#*,-QBSY@Z<$;6_(UP4]WJ&E:S+HT&H7TEM:^(
MM/2.2:=GD,<R!GC9R<LF<\'UQ5'3"\=GX39"RLMWK9!&00?W^#0!ZW:W4%[:
MPW5NV^&9!)&^"-RD9!Y]JERO7BO%(M9EFT.2?6=?U2RO+70K.XTP1W#I]HD:
M`%GQ_P`MF,IVD'/;CDDZ]R-8U:36I+O5=2L;O3--L;N..WE,:K.R,9-RCA@2
M@&T\#)XH`].NKVVLA";B01^=*L,?!.YVZ#CUJ?(ZX_2N9\:75S:QZ";:>6+S
M=:M8I/+8C<A8Y4XZ@]Q7-Z>M_=ZM+JSZMJ`DMO$<MBMN)CY)M]Q&PIT/+9W'
M)X`SB@#TK([?RK)NM8T4W,]E=21-+:RP!XWC+;7D/[H].[#@]B.U<UXMNHCX
MJT_3]6U6[TS1I+*:436\[6XEN%92%:1?1`S!<C/OTK#O[J:#Q'J<MG=7.)+C
M0$\XDJ\D;2L&W=.H/(QW/%`'J^1Z?I5>SOK74+<3VL@DC+,H8`CE6*GKZ$$5
MY_HD=]<:C;:Q)JNH-)_;MY8M;M.?):W5YE5=G3C:IW=>,9Q699ZC+>6F@VVM
MZQ?VFEW,NI>==)<O"7E2X811M*.5&P.0,C.T#IQ0!ZUE3V_'%5K'4;/4A.;2
M42>1.]O+@$;9$.&7FO+;K6UNO$VE/I=]J0>WU.TLG\^_<-<PLH)<V^-I0JPR
MYP<YXKJ/!5[;6\^L6L\Z1SW.OWP@C8X:0J03M'?`YH`[3C.,?I1D5Q^K1SZC
M\1;33&O+R&R33&O#%;S-&))4F4+N(Y(PQR._&<UR_A*_U&XO+*]N->CCU"9;
ME=1L9KUY9&D56.U+<J%CV,`>#RHZG.:`/6,CT_2JFHZG9Z3827U]*(;:(KOD
M()VY(4=/<BO%+>[U"7P_J&JQ:Y>B^;P]+-]G.IR222SG:3-''T0`9X'W2V!T
MS74>,=9M=9\+^)387ANK>*SL_F3)3>9FR5/0G@9(STP:`/3N,]/TIJR1MG:R
MG!P<<X/I7E^N:TUQXZM?L4U[;7%MK%O8S1&_<"6-AEB+8?+Y9##YSWSZ"L2S
M%MH,>K6L6JZC;A_$;P:DWVN1I(+0DD2\D[-S;`9.I#=>X`/;<C..]&1Z?I7D
M?V^]*W&GZ;K.HRZ0=>M+&VO#,7?8Z8G193RP#$C=S@]#Q5^_&H:3KT/@^VOK
M]HM5N(+BUGDG=I(K>,9N4\QCG/[M>^?WWMB@#TS*]/Z4N1G_`.M7&>.M1M8?
M[.TRZ>X@%Z\K"X2_:RC3RUW8:1><G/"@<X/I7/:3_:/B*W\(Z=?ZIJ<`N]#F
MGNG@G:*1Y4:(*68<Y&\GMGO0!ZDSHJ,S=%&3Q4=M<PW=K#<PG=%+&LB'&,J1
MD5Y=-J,DLMC;ZWX@U&QC30X+BTGB9D^TW/S"1F`&)6'R?N^0=YX/;>UJ^N[#
MX8:=<6T\UN/*LEN+B%#OA@)02N.#@A,G.#B@#N<@=OTHR.G]*\RU"?3H9=&T
MRV\0:D?#T]U.EU>_;I"1,(T,<7VCJ%)+'[W48SVJGIEWJ&M-H>G-JVIMI=]J
M-_%%=)(T<MQ:QINB/F``GE<;N"1WYH`]8RO^12Y'^17E?ARYU(IX/U:?5-0N
M)]6EN+.[CEF)C\M8Y64A.BL#&OS=3DYSV@\-P7VLMX=BO-<UG;K.CRWEZ8[M
MD)D0Q*FS'^K`#GA<9P,Y[@'K>12$K@Y&1WXKR"'6=3U;3_"T>JZC);VEU8SY
MG^WO9>?<1N%`>503G8"V.`3GKTK5T]]3U/6;""XUF6^%MH4%^K64K)%=7`D<
M!CMP64X'R\`]QTH`]$O;VVT^REO+J01V\*%Y'()VJ.IXJ8%<`CH>G%>1)J4?
M_"MM4U.V\0ZI+X@DT=YKN)KER;>9<!L)_P`LF5\J`,9&>N,U;NM::Z\>V$EE
M<7L$T>L"PN8'U!R'C6)LM]GQM5"=A#DY)(]:`/0;37M+OI(XK>Y5Y)9)HE78
M02T+;9!T['_ZU:61T_I7CUG?BRDA6[N[NWTQKCQ!+=_9Y&0E4F!##:0=PR<'
MJ,\4ND:MI[>$;.!M8O+S^UM0D8S'69(UL<+O6&2?E@0F.!U;/UH`]>\Q`P4L
M`QZ`]3CK4-K?6M[YQMY!)Y,K0R8!&UUZCGTKQ_3TCO+GX?ZMKNI7\<CVUU$T
M[7<D8+HR^6I.1\S#(.>7`&<XJ\NHRW6MO8:SK%_9Z1)JNI(9TN7A^=&C\J+S
M1]U=OF$#(SM_`@'K611P><5Y3I<^HZ^_AS3[G5=4^PWK:D1.DC0RW$$<B^0Q
M<`'E2#D8)'L3GM-%DNAX!B:>ZEGN8[1U:=S\[E01N/OQ0!T.1Z?I6=J/B#2M
M)\[[==+#Y,2S294G:C/L#<#INXKSC0;2]UBXTJSN]=UH1ZIX>74[IH[MD;S\
MH!L(^XHWGY5P#@9SSG(U/6M2UCPN\E[/*XG\,6=Q)&"0AE-UAGV]-Q`'-`'M
M^5)/3WI&>-4+,0%`R6/05Y=:7NH3^+I9;C7$M+Z#6FMVM;B^<![8L=D:6^W:
M2Z$$/DG)/(Q@9NID:A8>*M.GU.[U2\GTV\NDGL+^0Q!8V(6)H1Q&W1<#(<!L
M]Z`/9001D<TG`[?I7D5O>:0LD%I<^)M1M=$M])2ZL[B+4)!YTP9O-S)R7*#8
M`F2`#]T]M"S&K^(6\*Z=JU_J5G+>:)+<7GV>0V\C3*T6TDK@C[Y.!C/?CB@#
MT[(_R*3(]/TKR+4+W4KA].M;[6WLT&A13VMU-J#VBRW(R))'**?,*_(=A(&&
M/![=1XLU&ZL_`NFW1U,QRR7%DEQ>VQV@J[HLCKQT(9B...*`.VX]/TH)'?\`
ME7D<&L6\%OJ6FQZCJ-[HD^J16MA?2:B\01O*WR`W/WM@8$#KR0.]-L]?U/0_
M!FD^)9;FZNHE6\L9(I)'D\QC*_V9R2.>55-Q'(D!-`'KV5R<?RHRN/3\*\LU
M.VU2S:#2I]7U(/9>&I;^5XKAE:6ZC8?,QSDC+-\N<$8'(%5KV]UW2K!+FPU&
M_N;S5/#DE]*)Y#((YD,.7B7HA"R/P!CY5X)Z@'K>0.WZ4C.B#+$*"<?-QR:\
MFDOKJS\/ZI+I?B,3PN=/>%8]0>\FA,EP%>0LZC:&4\+C`*GCFCQ7H<5KI-W:
M7&J:K)8V6M6,J22WLA:&-VC\S+YR0/F8$_=)R,8H`]62*".669(D620CS'5`
M"^!@9/?`J7@UYK-?PV?C73B-9FU"TD:UM;&VMM0?S8=T9.^6/I,C#YB[$D`U
MZ'97EM?VHN+2=)X2S*)$.02K%6'X$$?A0!8P/2C`]***`#`]****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`)P,TP%02P7D]>.33FZ5Y?HGBBYTGQ-X@EUB^EGTZ:
MYO?LRN<^0UL<M&@[[D;(`_N&@#T\;<X`QGGI2@`9P!SR:\Q\,ZOK&F6_B=]4
MU*/[:LEM.B:E(5B@EFB#F(8R0!G`5<]/>KVG^.]5U*PM+:WL[%M:NM0N+)"9
M'6VQ"I9I/N[\8P`N,Y-`'H&T<<#CIQTH*J5P5!`YP17)2Z_X@76['1%LM.6]
MDM/M=U(TKF)$638^SC))RI`.,<YJA:>-]7>+2]5N=+M/[&UA]EF(IV^T)E'=
M3("NWY@AX!XSWH`[O<.N*7:I(.T9'0XZ5Y7:WT(TK1O$.JWWB2:YU1(96NK"
M0_9;;S'4+"4!V@`L%.06///IL:=X[O\`4-<@CAL(7TNXO);)/*\QIXRC.OFO
M\NP)E",9S\PY[4`=[5>WMHK>29HHPAFD,DA'\38`S^0%<CIWBS6]0U6V;^SK
M-=(DU"?3GD$Q,RO&9!OQC&TE,8Z\YK/T3Q1J^H0P:=H=C9F\Q<W4S7US*R+&
M+J2(*IP6)8J3SPH&.F,`'HH55SA0,]<#K2X&,8XKDM$\3:CJGB.\L;J"SLHX
M&=$M96=;IBIQO`("NAY(*D\$9YXJ'Q-XNU'1]2NK:RL[6:.QTW^U+EYY&4F(
M,X9$`!^<[>">!SF@#L@JJ,*`!Z`48'H*XR+QAJ$-U=V^JQ:98EM.&HV<C7#&
M-4R%*S,5&"&9?N]<\=*J:7XXU2X4F[M+.1;?58]/NIK7S-@26-6210X###NJ
MD$=\\"@#OL#T%(<#''Z5SVD^)FOM!U'6YXE2P@EN#`T>29((LC?]6*L1CMBN
M/O/&.J:SX4UQ;FSAABN-#N;RWFM#*?L^(P0DC,H&\[@05_NGV-`'J6U3@E1Q
MTXZ48'IUKSM?'FHQW@M[:QCN;2RFAL[A?WC7,SLL>YD`4J%7S`3N/(4]*O7'
MB+Q+J!U>70K32ULK":6U,EY+()&DC'S.%52-H/`&<G&>,T`=O28'I7*^%M1\
M1:EX!M-1O&TY]4N;1)X&`<1L&0$&08R#DG(7CTK#T+Q=XGN/"WA[[1%IMSK&
MM@FU<L\<0C6/>SRX'WN,;5XYZT`>BL%(^901[BC()^[U]JYK2-<U/6-(U5?L
MMI!J^G7$EHRM(S0/*JJP8$`,%(8<8R.:Y3X>ZEJ%AIGAF.[M[1Y/$3RW$US'
M)(TC[8=^]]W\9(P<<>E`'J.!Z4C*I7#*"/3%<A>>*-7>?2['3;.S:^U$W81K
MEV6.,0.!DX!)R#T'<^E0P>+];U)M.M-.TJU_M%[!;^\AN+@JJ+O*>7&P!RQ9
M6Y/`QWS0!VHVD[MN&QCD<U6;3[:34(;^2!&N8$9(I#R4#8W8]"<#GK6+I>H?
M8/`%G?2306[)8H^Z\DVHK;1@.PSWXX_"H_!WB2]U^/4X[Z.T%Q87(@,EJ7\N
M0&-7!`<!A]['/I0!U/?-136\4\<B/&K+(I5_<'@BN)N_&FL07=[<1:;9OI.G
M:FFG73-,PG<NR!608VX'FIG)YYQ3AXSU?,.J'3;0Z#/J(TY")F^TAC/Y/F$8
MV[=X^[G..<T`;6E^$['2KFUN%ENKE[.$P6GVF7>+=#C(3@=0%&3DX`%;H"XP
M`,?2O--<\7^+I-#O-3TF'2K6UMM1^P[IF=Y79;D0D@`;0IZ<\XR>N*O2>*+S
M2-2UE+BSBEU*--.@"1W$GDR3SLR``-G8H.,D#)[YP*`.^VC=NP-V,9Q1M7).
M!SP>.M<+<^-=8T>+4K;5=-LWU&Q6UD'V29O*F2>8Q+C<,J00<YSZ^U;OA[4M
M7NWU"TUJVM(;NSG5`UH[-'*C(K!ANY'4CGTH`W,*JX"@`=`!TJA)I5J^N)K#
M+(UTEL;9,M\J(6#-@=B2%R?11Z5R,7C?6I[>QU1=.L?[(U.[^Q6>9G\]'9F5
M))!C;M)7E0<@'J<4?"Z'49-*OM4U);1[B]NY=T\+R,\ACED0[]W``QA<?P@9
MH`[WY6^5E!^HIV!GI7D5CXSOO#OPYTJ[@FTZYEBMI9[B"[ED,[QK(P&W:#CI
M@%N/RK>'BC7[+Q1XG>_-@^AZ3:)=&.(-YP0I(PVG&"QV<Y.!QB@#OL#C@<=*
M7MBN(\/^-+Z]NIDU:T@AM_LHNDGM%E=(@6"^4Y9!E_F!^48X/2I[OQ9>_P#"
M46VG6L5G;V4L<;+<WYDC%R7W82(@8W#;RK8)SP*`.NV+LV;1M],<4N!QQTZ5
MY_H/B7Q(?#>K7^LW6AQR0WD]M:N[.B;TE="K<9(X&W'S''/-0Q?$'4YM&MF%
MOID-[+J4VGM<SRNEHK1@MN)(WC<!@`]QS0!Z-@>@XHP/0<5YM;_$'6KG3-)0
MV6G6^J7UM)>/Y_G>3'$L@1<!5+%FSGL,>N:Z6?Q7]E\"?\)-<:?/$WV99C9R
M?*ZNV`$)(XY(&<<>E`'1,%(VE`1Z8IPQG`&./2N#OI]?&O\`A1=96SAE?4Y%
M46$KE'C^RRG#;@#D$#V/'I572_%.L36>GV&BZ?:O>W:WTRF\NI&5!#<E#DG+
M'.X8'09]!B@#T7"@GY1SUXZTNU=V[:,^N*\[O?&LEG=V6HRZ<QGGT-+@0"Y8
M*)9)XHUC(^[C=(,O@D`'M6Q>ZSXATO1BVH/H%OJ3SA(,S2F*5>^%"[RP]!QW
MH`ZL[<XQ^E(RH%P4!'IBO/M+\07'B#6_`^ILOV<WEE?F:*-R4)7RQ^(R,C/3
M-6/$>OZQ=IK]KINGP26.FI]GNY&F*SEWC5\QC&,*KJ3D\\XZ<@'=D`CD`]^:
M"JL,%00>Q%<'?>/+^/7[JWL=/BGL;*\2RG0"1KB5VV99`%V!5\P$[CR%/2IY
M/&]S#,UC):PC44U=K)T#':(%3SC+_P!^L'&3\Q&>^`#M3@#I]*!TZ5YB/'&I
M:YHM[YMA$EG?Z1<7-M);&0M;`1942LRA<L&XVGJ#UZU>T_Q-KDFGVMIH]I9W
M+Z?I5K=7TE[.ZM*9(R0J8!Y(0_,>,GI0!Z!@>E&T>@_*O/[CQWJ]W;M<:+IE
MH\<.DP:Q,+R9E;RI%<^6NT'Y_D/)X_.FZA\0[^%;J\LM,@DL+&UM;NX\Z8K*
MR7`^54`!&X'.2>*`/0MBEMQ4;AWQS0%522%`SUP.M<'>^.=3T=[^QU2QLAJ2
M2VRVH@E=H66=F5"[;=P*F-\X'.!CK3D\;:G'H,US/IL+WD6H0V*E"\<$YE*A
M60NH8`%P#D=5.,T`=SL3`&Q<`Y`Q1D9SBO.-7\2^-(+2SBCATFUOTUJ/3YSN
M=XIE=59"O&54[B#GD8XKH_$%Y-9R>&EGC#S7&IQPR>5,Z*K&*0DC!&X97[K<
M=^HH`Z0JCC!4$`]"*IZKI-MK%M#!=!RD5Q%<+L;'SQN'7\,@5R^F>+-;O]5M
MW_LZS71Y=0GTYI!,QF62,R#?C&-I,>,=><]*D\3^+[W2]7CTG38;1[H6OVR5
M[OS-NS<5"J(U)+$ANN`,=\T`=AL79M*KM],<51U72;75DM4NP[1V]RERJ*V%
M9TY7<.X!P<>H'I7*/XYU(ZKINFII/EW6KPP7%@DQQL0@&=91U5HQD@`<Y'H:
ML6FN:SKUI>WT=G91Z"RW4,;&5_M.8RZ;R,;<%D(QG/(.:`.R`R.1VHP/2O/?
M!&O:Y%H6E1:S#81V3Z(EU;WAN6)^0(#YQ8<$APV1TYZTRU^(=^FE:_<WMO87
M$FE+;2JUD[B.9)21CYP"",=>G(H`]$"(N<*HSUP*7`/4=>M<+=^+]?TBQU!=
M5T_3H[N"YMX8IHYF^SJLW`>0D;@%;(/'/';FJ,'Q`UK^SHTN+73!J%UJ,]I:
MR(TIMF2%<M+D*68$C`VCG/48-`'H^U0=VT9`P"!S2C&.!BN.N->U?4/ASJ>I
M6T"6>IPPSJ#('5,QD@R)D!L$`LN1W&:P_"U]KMCI6F:'I5CI/V^6Q74YY9IY
M?+*2$!>Q8R,0Q/88[YH`].HKA=.\;ZGK]QI,&E:=;1/>69O9?M<I(B5)?+=1
MM'S'.,=!ZU:\;^*KSPU9F:QDTMY88)+F6VNG?S71!GY`@.,X(W-QF@#L**@L
MYS<VD4Y7;YB*^,],C./UJ>@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`0C(KF[OP)H%
M];&"ZM#,AU$ZG\[DXG)R3_NGH5Z8KI&Z5RS>.]+75%L3%?!/M9L7N_LY,$=Q
MN*B-GSU)QCC'S#)!-`%J^\':5J%Q>7$RSK<75Q!=-+',59)80!&R^F`/QJ+_
M`(0;1Q:Q1+]J2:*\:^2Z6=O.69OO-N_VNA'0YZ4V?QMIEO<ZA'(EYY.GEENK
M@0$Q1R#&$SG+.VY<*`2<CU%8GB/XC_8?#FHS66FZE!JUNB$6MW:[6C1VVB4C
M."N01P3S@$4`=59^&["ROH+R,SO<0VK6@>69G+(SAVW9ZDL,YJE8^!='T^ZM
M)H1<F.R=Y+.VDG9H;=GZE$/3&2!UQDXQ7.W?CNZ\.V7^DV^JZE/';VA>"6T2
M*9#+*Z;Y"K;03MP%"]0O/S<==>>(;;3M!CU6\ANH%<(%MWC'G%W("Q[0<;B2
M!C./>@#-/P]T7(1'OX[(3K<?8([QQ;;U;>/W><`;OFP.,U>MO"UI9W[W5K=W
M\"/<FZ:VCN2(3(1\WR^A))*],G.*Q-4\9W=EJWA]DTS4S!?Q77FV'V0&YW)L
MV\9P,98YSC!^E:%YXWLK3P_:ZZECJ=UI]Q`;AI+>VW>3&!DLX)&W`SZ]#0!I
M6GAVPLH4B@60*EY)?#+D_O7+%C],NW%9O_"!:,GD&W-Y;2PI-&)H+ED=DE=I
M'1B.HW,2/3MBIY_%MA!JB:>$NI96B2XD>.+]W#"V<2.Q("K\I]_;K2:+XOL=
M;O%MH;>^MVEA,]JUU;F,7,0QEX\G)`W+U`/S#B@"6V\*65MJ\6I^?>SSP+(E
MN+BX:18%D(+!0>G0#G.`,5)J'AC3M4N+V>Z21I+VP.G3;7(!A)8D#T.6/-9M
MUXPM=,U358;R:>5;:X@MXX8;7+"22+<J@@G>6/3@8)`]ZTM%U^#7=.EO+>"[
MA,,KPRV]Q%LE1TZJ1G&>G0]Z`*^I^#-(U?\`X^XYB1:+9J4F92J+(LBD8Z,&
M12#[54U3P=$?"^O:=8,9;O5U/FS7TS-F0J%#DX."H`P`/X1TK!E^)%[=:5#?
MP:-J-D(M:2RECE@#F>/S'1E0`YW_`"\CL>,GK70)XYT^32TO%M=1,\ER]HNG
MBVS<F5`2R[,XX`R3G&._-`&YINEVVFZ):Z5"NZV@@6`!QG<H&/F]2>_KFLB'
MP3I\.FRZ9]LU*33Y+22S^S27;,B1/P0!Z@<`G.!P*T]*UBVUC2OMMKYBC+H\
M<J[7CD0D,C#LP((/TKEX?%FI/\/?#VN,81>:A/91S#9\N)951L#/'!.*`-K_
M`(1"R2\DN;:[U"T:;RO.2VNF1)#&`%)'K@`$C&0,&E7PAIB:G<7T;7,?VF;S
MY[=)V$,DFTJ7*=,D'GL2`3R*SO&WB.]T)]-CAN;;3[6[D>.?5+N%I8K8@`J"
MH(&7.1DD`8/M736$LDMA!+--;RR.@8R6Y/EMGNN2>#]:`*NBZ%;:#IJ:?:2W
M#VT8VQK/*9#&H``4$]%`'`K+B\!:1!I]K9Q27R)93":R<73;[4XQM1NRXX*G
M((ZU8UKQ3!H-S!'=V.HO;RLB-=Q0;H8B[A%W-G(Y(Z`]15>Z\;Z;9ZP=->"_
MD=+J.TGGBM]T4$DFWRP[9XW;QTS[XH`U-'T&RT.RDM;,2;99&FFDED+R2R-U
M9F/)/3\`!5%O!>E?V;I-E$;J!=)!6SDAN&21`5*D;AR<@X-4[WQI;-J$=A:+
M=AOM\5H;S[.3;O)YBAX@_P#>V[N<8X(SD8J[KFKWT6JV.B:7Y2W]]'++Y\Z%
MD@BCP"^T$;CN=`!D=<]!0!/:>%M,L9]-EMXY%;35F2VW2LVT2D%\Y.6Z#DU7
MF\%Z5--:S*;N&:VB:`207+QM)$6W%'*GE<\^V3C%1WFNWWAO1Q/K-K/J+H6+
MS:7;':L:C)=U9OE[\`GVJ+5/'FE:8D;^5?W9>S6_*VEN7*VYS^\;)&`,<]^>
M`:`-*Z\,:=>>&DT"5)/L$<<<:!96#J(R"A#=<@J#GVJ72M#M=&-Y)`\\LUY*
M)IY9Y2[.^T*#[?*`,#C@50U;Q;:Z,]JUQ9ZC):7'E_Z;%!NAC\Q@J[SG(R2.
M@/6J6K^-+:&YDL+07?FQW45JUV+<M;K*TB`Q;_[VUO3`/&0>*`&67@2&35M2
MO=4EEECGU7[?#;).XA.$0(9$Z%@RD_@O7%7D\#:,EZDX%R84O/MR69G;[.L_
M7>$Z9S\V.@/.,U-+XG@M_$<&BS6.HPM<.8X+IX/W$KA"Y56SG.%;MC@UK7T[
M0:?<S1D;XXF=<],@$T`9<OA/2YM$N](=)?LMU</<OME(<2M)YNY6'((?D>F*
MBF\%:1<P7L=R+BX:]CACFEDG8R$Q9,;ANH<%B<COBN4T[QIK6K:[X6L##>Q)
M=:9#J%U+:VJ,DK.$R"6)VQ#<02/F!Q77:EXIM=.U0:<MKJ%[<!5DF%G;F46Z
M,2`S\\9P>!DX&<4`1?\`"$Z2\-ZDYNKB2]DADGN)IRTK>4P:-=W905S@<<GU
MK;AL8H+JYN4SYMR5:0D\?*,#`[<5S\WCK2X+][=XK[[-'.+634!;$VR3%@NP
MOZ[B!G&,G&<TR;Q]I4-^]J8=0?9<-:>;';%HVN`3^Y!')<@9'&,=2*`)K7P)
MHMI=V\T8N3#:W#75O:-.Q@AE;JRIT&#D@=`22,5L:1I-KHFGBQLPP@$DD@#-
MN.7<NW/U8UA_\)UIO]G07?V?4/-FN'M4LA;YN!.@),93/#8&>N,<YQS2Z?XY
MTO4KVRMH8KY%O"T<5Q+;%(C,H):$L?XQM;CIE2,\4`1-\.-!-K]E7[;'`UK]
MDEC2Z8":+>SA7]<%VYZX)'2M1_"^G2:O-J1\_P`VX@%O<1>:?*G0!@-Z=#@,
M:IV?C73KW4DLXHKWRYG>*WO'@Q!<R)N++&V>3A6YQ@[3@FJ\7Q`TV>Q2[@L]
M4FCN'5+,1VN6O"5+'RAGD*%.6.`/4Y%`&MH_AV#1#&+>^U&6**'R(X;BY:1$
M7((P#W&,9.3CBFZCX8M-5U"*[N[F]=8Y8IEMA<,(=\9RC;/8\^Y`STJE'XF\
MS5HXE2]7=ICWGV%[/$V5D"GG=][)QMQSG.ZL^^\:O<:4MQ8075G<PZO:6-S;
MWL(5T$DD>01DCE)`00>]`&C)X&TEX[B/S+Q4FO!?*JW#`03AR^^/^Z2Q)/;F
MLZ_\$B"739-+3SA;WDUU<+/>/')*\J;6;S5!8'/.!@'/MBEE\>PZ;8/<W-GJ
MFH0_;9K;S[2S4+&RSF)48%^N<`'OUP.E:$OC+38M8-B8;UE6X6UDO5@S;QS-
M@+&7S][+*.`0"0"<YH`AT[PC*UC82:IJ5V^JVC2E+J"X;>L<ASY18_ZQ0-HR
MPY*@\5LS:%9W>@MHU[YMY9O#Y,GVB0N\@]6;J6[YZYK$O?&=L=0CT^T6[#?;
MXK0W?V<_9VD\Q0\0?^]MW=L<$9R,5UN10!@VWA&PMY;.9Y[VYFLYA-#)<W+2
M,&$;1CKVVL?J3DY-/T[PIIFE7-K/:I*'M4N$BW2$@":0229]<L/PKFO"_P`0
M9K_PWJNHZW##;S649NE6$D+);G<(R"Q^\61U^HJ70_&>JCPU<7FM:7<75];7
MTUK-%I4.\)LYR0S=!G&<\XH`VKOP3HE]$(KJ"26,6/V``RG_`%6Y7!_W@RJ0
MW48I)/!=A+]GD>\U)KJWE,L5VUTQE4E/+(STP5X(Q[]>:;<^-+"&STZ>VM[[
M47U&V%U;V]E!OE,6%.]@2-H^9>IZG`S3)/'&EQ7%U&\=Z(K-"]W<&W(CM_D#
MJ&)YW,&&%`)SQ@<4`6['PEI6G-I;6L<B?V7'-':@R$A5E(+YSU/`ZU#?^"=(
MU&^N[J7[5&;U5%U'!<O''.5&%9U4\D#^0SG%4+CXA65O87SOI^HP7]O$LL=C
M>PF%YP[B-"IY&TNRJ3U&>0*DTW5-4AUS[#JGB/P]/-@M/8P`QS0`+D;<N2PZ
M$E@..:`-&;PM:/J=Q?PW=_:R7+1O.EM<F-)&3&&('<@`$C&0,&I3X9TQO$O_
M``D!A_XF/V;[,6S\I3.>5Z9[9].*S+3Q[I5T[_NK^&$VTEU;S3VY1+N)`"[1
M$G)P"#R!D$$9J!O'EE=:;JTEN+ZT>ST]KZ.>XL_EEAPV)8UW#>N1T)4GVSF@
M"_;>#-/M;1[.*[U'["T4L(M#=,8D23J`/8'"Y)V]JCN?`FCW"@*]Y;?Z$MA*
M;:Y:,S0KPJOCJ0.,]<$C/-.A\7VLVHQZ?#:ZA=,"B3W<%L3!`[*&`=L\'#`G
M&<9YQ5C0O$MOXA$DME;7JVH&8KJ:';%<*3]Z,YR1]0#S0!CW'@&VO]<NGEDD
M@TF33K>QCMK2X>+*QF3*,!P4PR@<^OXZMUX,T>[AU"%X72._A@AF2-RH"0Y\
ML*/X<9[5'_PFFCB6QB\YUDO;Z73XE*X(EC)#`\],K@'_`&E]:K-X^TUB%L[3
M4[^1I)56*TM_,8I&^QI.O";P5&>20<`X-`&CJ?A/2]6N+R>Z2;SKN*&)WCE9
M&3RF9XV4CE6#,3D4K^&+6:U^SW=W?7:_:HKL&>X+%7C*LN.P7*@X'7GUIMIX
MJTR_FTB.TE>9=6BEFM9%0A=L>W=NS@J?F`QCJ#65=^,4M=<L97G\K1I-+NKR
M8R)\P,4D2@C'/\1&!UR.]`&QJ?ABPU6&6.X,ZM)<QW8DBE*.DJ!0K*1TP%'Z
MU/=:':WHTT7!E<Z?.MQ`QD.=ZJ5!8_Q<,>M9FC>)&UK7;BW2"\M%@M4=[:\@
M\N169V`;'<$#C![=C64GCHV/B76]/U*"\:UM;^*".[BMLPVZR11D>:^>,NQY
MYP",X%`'2VGAVPLHDCA5PJ7DE\,N3^]<L6/TRYXINI>';74K^"_,]U:W<$;Q
M+-:S&-F1L$JW9AD`C/0\C%43XUTW^V5T_P`N\\MKG[(+WR/]'-QG'E;\\MGC
M@8SQG-7-:\16^B/!`UM>7EW<!C#:V<7F2,JXW-C(``R.21U`ZT`0-X-TN25I
MY3<RW1^SXN9)V,J>3]S:_49RV[^]O;/4TMMX/TRSN9I+=KJ.&5Y)#:K<,(5>
M08=E3L3DG'0%B0,USVI>.C]HDN[&^"Z6=!EU!9#;>8R.DJIG;E2<9(*Y'(ZU
MK:IXZL-*U`VAL=3NRDT5M++:P!HXII-NQ&)(^8[U/&?O"@"])X2TF718M(EB
MD>RBL3IZH9#GR2%!!/7/R+S5<^!])DL]1M[A[RX_M%8DN99KAF=Q$<H,]L>W
M7O6+?>-+JS.DSQ&>]BFUF[L9HH+3]XXC$N$5=QR0R+\V1D`D@=K$OC:.:^T"
MXMYFM]/N7O%OH[F/9)"88RQ#C^`J5.?;VH`T/%'AJ3585FLPC70NK>=UDE:,
M2"(D@!U!*'YCR.>W&:@L?"4US:R#5[RYWI??:[$0W;N]D`NW:LI^9@1NR",8
M;'(%7=&\66>N7KV<=O?6LWD_:(DO+<Q&>+('F*,YVY(ZX(R.*S3X^@M_$.LZ
M;>Z7?VEII<:RR7[H#'@ACSSGG;A<9+$XP.X!T":+#_8]QIDUQ=7,-PLB2//,
M7<A\Y&[MUXQT[5GW7@O2[C[&T<EY:S6EI]BCGM;AHY#!C&QB.H[@]0>1BI-'
M\4VNKWTEA]EU"QODB\\6]];F-WBSMWKR01GCKD=P*ANO&FF6E]?6TJ7833PQ
MO+@0YB@PH8`MGDL",``DG'3(H`N:;X7TK2;JUN+&W,+6MF;*%58[5B+!CQW.
M0#D\U#K/A#3-=O9+JZ-RDDMJ;*;R)VC$T!.2C8ZC)/H>3ZU7A\;::;.^N+R&
M^T]K)$DE@O+<K*4<E495!.[<P*@=<C&*1O&EM'9)/-I>L0W,LQAAL'M/](F8
M+N)50<%0H)+9P,<XH`Z."%;>".%,[(U"+GT`P*EKB[SQ[86ZV-]YMRMJT-T]
MQ;FUS(I@*B0,=PVE"3D`-GG'3G4OO%^EZ?=7EO,\S-:0PRR&./>"96*QHN.6
M=B.`!0!T%%9&A>(+;75N5C@NK6YMG"3VMW&$EB)&5R`2,$<C!K7H`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`0]*\YTWPOJ^HW%_%=SBSTL>(I-0\DVY\Z8)('3:Y.-A8*>F
M<`CO7HYK&O=?L8+V*RAN;>>\,T<<ENLP\R)7.-Q4<X^M`&/=>#&NM'\06)O_
M`"WU341?PRI%GR'7RB@(/WL-$">F0<55U+P3J.N)JL^I:I;_`&V]M(;.,P0$
M1Q1HXD)())8LV>_`..:ZR/6=+EU*33H]1M'OXAF2V693*H]USD5*FH64@;R[
MJ!@LI@;:X.)/[A_VO;K0!S'B#P=+K5WJUS%?I`][;6<<8:(L(WMYFE!/(R"2
M!CCZUKZCI]YJ6ABTG73+BX?9YRW-N7@<`@L`F[/3H<G!YYJMH7BW3M;EEM/M
M%M!J$=Q/#]D:X4RL(I&0N%ZX.W/2ETSQ?IESH,&J:C<6VF)+/+;JMS<*H+1R
M-'P3C.=N<>]`%#2/"-YI]YHES<ZF+A].%V"NQL%9BI5$+,2%0+@`D\8JAK'P
M_O-3MUMAJD)MSI\EDT<\+LL;.Q)F0!@-^&QSGH/<5WQ9`I8D8`R3FL"7Q19.
M]T]A-:WL-O:2SM+%=($#1D`H6SM7KR2>.]`$,/A=1J=_<7$_F6][I<.G21J"
MI`3S,MG/<2?ABJ_A;PK<>'Y;82C295M[<VXN(;0QSR#*[<G<0.%Y`ZG!XZ5L
M77B31=-\A=3U;3[*6>,2)'<72*2OJ,GD>XJA=>-M%TIT&L7UI8>;>R6D.^Y1
MMY3JQP?D'KNZ$@'J*`*5[X,EN]>N-2^VHJS:G9WXC\HG`@3:5SGJW7/:NCL+
M,V<MZY</]IN3,,#[H*J,>_W:EN=2L+*W^T75W;P0;2_F2R!5V@9)R>,8J&77
M=&@GMH)M4L8Y;I0UO&\Z!I1V*@GYASVH`YB+P7>HJV[ZC;FTBUL:M"!`PDYE
M:1D8[L'EL`@"I]9\&MJ=Q'=QSV_VF'4&NXUN(B\;(\8C>-@".H&0PZ'%=,=3
MT];>2X-Y;B&.3R7D,@VJ^[;M)[-N(&/4U3;Q!I4QOH;/4+.ZN[*-GFMXIU9T
MP#PP!R.1B@!=%TY]-TS[++%91_.[;;*$Q1X8D]"3D\\GN>:YJP\$ZI!8:;HM
MWK%M-HNFW"30(EJ5GD$;!HD=]V."!DA03@>^=+0O'F@ZXUI:17UO%J=Q9Q71
MLC*"Z[TW;,]V`'('(&">M7[;Q)IAL-/N+Z]LK*2_53#%)=QMO8]D8'#_`%7-
M`$=_:Z].9!;WNF^4SN##/:,ZM$5&T-\WW@V2>Q!Q@=:3P_HMSH&F:=IB7<4U
MK;0,LNZ(AGD)!!3G"(,L`N#@;0",5I3ZOIMM?P6%Q?VL5Y<`F&WDE59)/]U2
M<GOTHU#5],TF.-]1U"ULTD;8C7$RQAF]!D\F@#DM>\#7>MZQ=73:C#]FG>VD
MC2>)G>V\I@Q6/Y@H#E1GC/)Z\5J+X;D6?6Y/M2_\3.^@NU!0_NQ&L0*]><^5
M^OM6O>ZUI6FQ"6_U&TM8SM(>>94!SG')/?!_*K$]W;6UJ]U//%%;HN]YG8!%
M7U)/`'O0!RMMX5U2SFEMX-7A&E/J?]I")[;,N3*)6C+[L;=VX@XSR!5WQ!H%
MWJ%_8:KI5]'9:K8ETC>:,R121OC>CJ""1PI&",%16I#KFD7-@+^#4[.6S)(%
MPDZF/(!)&X''`!/X4ZTUG2[]8&L]0M+@7"LT)AF5_,"_>VX/.,\XZ4`<CJ_@
M[7-<V-J&LV<[-:RV\D'V5U@0O@"1$W_?4;OO$_>[5HVOA-[6]$_VT,%T./2L
M>7SE2Q\SKT.>E=)#=VMQ&\D,\4D:.R.Z,"%93A@3V(((/IBN>O?&^C+;QS:9
M?V6J$W=O;R1VMTKF,2R",,=N>A;O0!C:GX`O-1O'9]4A>W86FP31,SVY@()$
M7S8`<J">,\GKQB\OA/4H+N_BMM6A33+S4%U%X7MMTH;>KNF[=C:2O7&1FNC_
M`+8TM=3_`+,;4;07[+N%J9E\TCUVYS69HWB[3M4O[NPDN+:WOH+R>V6U>=?,
ME$9QO5>N#_0T`9-MX(NT\46^K7&HPSBWU":]1VB8S,LB,HB+%B`J!N,#L..N
M>H%O=S:7-;W<T+W$JR)YD4950#G;P23P,9YY(/2B+7-)N;ZXL+;4K.:^MP3+
M;1SJTB8Z[E!R*KZ!KL.L^&M/UN1!;17D"2['<'86Q@9^IQ0!F:%X4DT>^TBY
M:\24:?HBZ6RB,C>0R'?UX'R=/>I+C0-3B\27FK:3J4%N+^&*&X2>#S-IC)VN
MA!'.UF&#D9P?:MBWUS2+RSFO+;4[*:U@)$LT<ZLD9'4,P.`?K5&^\9^&].TR
MWU*XUFR%E<RB&&=)59'8MC@CL.Y[#)-`&))X)OWAN-+&K1#19]3_`+1=#;_Z
M0,R><8PV=N#(,YQG''O4\?@V5)H6^W(?+\02:QCRSRK*X\OKU^;K[=*ZB34K
M"+3O[1DO+=+'RQ+]I:0"/8>C;NF/>JDWB70;>UMKF?6=.BM[K_CWE>Y0+-_N
MG.&_"@##A\'R1ZY'J'VU"%UJ75-GEG)#V_D[,YZCKG\,46O@Z6WTO1+,WR,=
M-U:34"WE'$@9ICL`SP1YO7V]ZU5\06Z^(=1TVX"0Q6=I#=M<O(`FV0N,'/3&
MSK[U9/B'1%TI=5;5[`:<QVB[-PGE$YQC?G&<\=:`.;T+P0^A74*QC2YK6">5
MX97M6-RD;AL*'W8W#=C=CD<8YS3H/!EY9:-X8BM-1B%_H(VI+)"3%,K)L<%<
MY&1T(/!]:ZR;4+*VL6OY[N"*T5/,:X>0!`OKNZ8]Z@37-(ET]=0CU.S:R8$B
MY6=3&=H)/S9QP`<_0T`<QK/@W5-7<W+:VD-\^G&S:6*!D!8SI+V;(0A=A&<D
M'K3(/`<L=I=1?:K:)KG5K;4RD$!6-/),?R*"<\B,<^I/%=1)KNCII2ZHVJV2
MZ>WW;HSJ(CDX^]G'6FV^I^?H]U>K$I\AIU50V0WELP!S[[<_C0!R<W@G6HYK
M1[#5[`1V^H76H>3=VCR(TDLC.A(#CE`Q`]R3Z8M1>"Y+77+N]@&E307-\M]B
MZM6DEB?(+[6W8Y(RI(^4GOBMCPYXITOQ%ID-U;7=MYS6T=Q/;+.KO;[U#8<#
MIC/>K=KXAT2^LI[VTU:QGM;?/G3Q7",D6!D[F!P./6@#!MO"NJ6<TEM!J\(T
MIM3_`+1$36V9<F42M&7W8V[MQ!QGD"MW2)=2E@FDU2&&&1KB3R(XSR(=V$W\
MD;B.3CCFIEUC3'TLZHE_:MIX0N;I95,04=3NSC`KG$^(OA^8Z3<6U]:RZ=J!
ME5[MI@BVQ2/?B0-]TD<8.#R*`,ZU^&X@3P^KZF2-.REVBQ?)>1B7SD4@DXVN
M%/?O3KKP#>RS3M'J5N\,UW>7#V\\+F+,^W:Q`89=,'!/'S'IUKK[G7M'L["*
M_NM4LH;.;'E7$DZK&^>F&)P?PJ]YL83S-ZA,;MV>,>N:`..A\(7^F-HMQI6I
M0K=Z=IG]F2&Y@+1S1@*0V`058,H/7'4>]/G\%O>Z9XCL[G4"6UF6.7SDB`,;
MI%&H..A^:/=CT./>NAM-<TC4+:6XLM3L[F")MDDD,ZNJ-Z$@\&J%]XT\-:?I
M5QJ<VLV36MO*()'BE63;(?X,+GYNO'H#Z4`8MUX(O-=EO)_$&IQO+-8+90FQ
MB,0B(=9#+R2=V]%('08QS3X_"6J7?B"QU+6;[39Q:),I:TLC#+/YB>7\[%CT
M4]!W]JWX-=LKJ^B2VGM9K22U:Z6ZCND*D!@O`!R5Y^]TXQUJQ::WI.H6K75E
MJ5G<VZL%:6&974,3@`D'&<XH`X_3?`<^GZ4VF!]):);*:SCNQ9L+C8R[4R=V
M.!C=C[V.U:=WX3EN?#QTL7BJQT1M*\SRSC<R@;\9Z<=/UK?L-6TW5(GFTZ_M
M;N)&*.]O*LBJPZ@D'K5#2?&'AW7!>'3M6M)Q9NRS[9!\@!QN_P!T]FZ&@#/T
MOPYJFCZC=-9ZG!]@O)X[F>.2W)D5PBHX1LXPP1>H)'/6CPYX:N]'U2ZO9[BS
M2*:%4^QV$+0P>8&):786.&.0./3O70:?JFGZM;"YTV]M[R`G'FV\JR+GTR*8
MNL:4VIMIBZA:&_1=[6HF7S0OJ5SG%`'):E\/?MFKZOJ$.H^6;M5EM8C'Q;7.
M8RTN0<G=Y,>1D<`CO4\7@_4-+N;*\T74H([J+3?L$XNH6D24@EQ(,,"&WLQ.
M2<Y_&NGLM9TO4GFCL-1M+IX&VRK!,KF,^C`'BEO]7TW2HC+J-_:V<8&2]Q*L
M8`SCJ3ZG%`'+0^"KK3(/#HTO4XA<:/%/$TES;EUE$V"[85A@AAD#ICCWJ&^^
M'SZC8VMI<ZK_`*G3)[)IDA`9G>2.02`9P,&+[OO77W&KZ9:)&]S?VL*RE1&9
M)54/N.%QD\Y[>M)!K&E7.H3:?;ZC:2WD/^MMXYE:1/JH.10!G:1IFK6^I2:A
MJVH6]U*]LD&R"W,2IM9B6Y8DYS^&.*Q-4\%:AJ%UK$*ZK!#I>KW45Q=1?9B9
ME"*BE4;=@;O+')'&373MXAT11<%M7L%^SHLD^;A!Y2L,AFYX!'0FGW>NZ186
ML-S>:G96]O/CR999U59,]-I)P<^U`'-6O@M]/UF>Y@&E36\FHF^4W-H6GB+-
MN<*V[&=Q)5L<9QS5[Q)X6_M?4]-U.%K4SV8DB:*[B,D<D;XR.""K`JI!]B.]
M7+_Q;H&F:O9:7>ZI:P7EXA>"-Y`-PX`Y[9)P/7!QG%7H-7TRZOY["WU"UFO+
M<9FMXYE:2,?[2@Y%`'':AX!GU&TEB^U65JTNC3:9LM;4I$A>0/O5=W`&,8SU
M[UF:GIVIIXIU6ZMM->ZN6O;1[6&>VE:"9$5!N,BL$4J=YRP8@@=>`.XG\5:%
M;^(H]`FU.VCU22,.D#N`3D@`?[QR"%ZD<U6\-^+]-\00JBW%M#J&Z4-9?:%:
M4!)&3=MZX.W/3O0!E_\`"&7T$=FUEJ5NMS9ZM=:E&TUNS(PF,GR$!@>!*><]
M1TJL/AUY\%NE_J/GN\M]/?%(M@E:YC*,$Y^0#/&<]*[&UUC2[Z[GM+34+2XN
M;?'G113*[QYZ;@#D?C2SZMIEM=16UQ?VL5Q*VR.*2559VQG`!.2<<XH`PO#'
MANYT2XB:X727*6WD&>VM#%-(01@DEB`,#E1WY]JK:[X*N-6U'6F744AM-8M8
M8IE\DF2-XMQ1E.<8RP)!';WKIK75M-OH9IK2_M;B*!BDKQ3*RQL.H8@\$>]9
M&K>+]-M?#-WKNG7%OJD%L5#"UN%8'+A2,C(!YH`;I6A:E'XC;7-8U"WN+E;(
M644=K"8T`W!G8Y)))8#`Z`<<]:@N_!RW]GXIM;FYQ%KDJRJ57F$K%&@SS\W,
M8/;TK?\`[7TP:I_9G]H6G]H%=_V7SE\TKZ[,YQ3!KVC&>Z@&J6)FM$,ES&)T
MW0J.2SC/RCW-`'+OX*N;O1;^PG?2[2:X2`I<V%F4;S8G\Q6?<QRNX#Y>WS<\
MU/JOA;4];%C<W]Y82WUE<^;$AM6,!1DV.A7=DEN6#9^4XZ\YV/$/B"WT3P_?
MZHH2Y-I;&Y,*N`73U'L?6K?]L:8NH1:<]_:I?RKO2U:91*PZY"YR:`.=A\&[
M[C37NA8)!:QWD4MK9VYCCD6XV^YY`!R>Y.>*H6_PZ:/PI?:5/J0GO)KB*>*Z
M>'(7R=@@5DSA@H0`CC.2>IKO\#TI<#TH`P_#ND2Z5]K,D.F1><RL!8V[1YP,
M?,23N/IZ#BMRBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!#TKS;2O#^I6TUE:W/AY'N;36
M9+M]7\V/]Y&[LVX?QDX8*5(_ASS@5Z43@9IN[V-`'EVG^&-76WT'3)M#2.ZT
M_5S>7.K&2,K*BNS;E(^=FDW8((]<FM+3],UNTO[JS.D.;>3Q`^H&[\]-GDL=
MP(7.XMV(P,>]=O-J%M;W4-M-)LEF5W0%3@A,;B3T&,CJ:9-JUE;WUC9R3`37
MV_[,`,B3:NXX(XZ<T`>=6/AK5DO[6V&A+;21>(9M3DU0R1X:`R.VT8.\LRL$
MP1C'4XJO9^$=7LY;.:\L+N:`V][;R16WV=W@+W4DJL!)D8=&4$K@C:,^WK&\
M8S_.H+*_M=2LX;RSF6>VF7?'*G*N/44`<K>^&[ZX\`S:3I]W=VSOI0M(+:Y=
M#Y;>6%&]U&2>,$@D=>U9-UH=]J6G:TUKX5729+K0);)(A+%F28CY4PAQ@=`Q
MZ^V!7H^X'D9(H+<'B@#QK6X(8=5US^T+=WL[9--:[B@\IIBT81ODWG/91A00
M<''S$UM7'AK4TA6Y.D?:VA\42ZCY"M'ODMG##(W''\0."1TKT"33K&:Z2ZDL
M[=[A<;9GB4NN.F"1GK5L-Z@\4`<QX@TF;5]4\,2BR66VM+UIKI)-I$:^1(!D
M'@X<KTSSS7.:]X=U*5_%UJF@1W[:RD:V-WOCVVX\H1[7W?,H0@N-H/7CFO3*
MK6=];W]N)[9F>(LR!BI7E6*G@X/4&@#SIM&F7XA6FB)MDL6\G6[W:W2:)#$N
M1V#L(V')SY;<8Z&DZ+XCN=;AU+5=.,-PNEW=O<%5A6/SI'0J(]AW,N$/+DGD
M=.:]%<01/)=,(XR4`DE(`.T9QD^@R?SICZG:1ZM#ICR$7<T+SQIM/S(I4,<]
M."R_G0!PWA70-0T75=/>ZT;*R:#96;SH8S]GGB63>&YSSN`RN<UA6'@S5;73
M8K;4=+OIXKC08;*1+-K<O"Z!PT69,[=V_(92`"#GL:]@W#'0\=JK:AJ5GI5C
M+>WTRP6T6-\C`X7)`'3W(H`XN72-1M?%MO>:7I=U^_EMDO9+MH9(/)2/!9#G
M>LB\+QP3SCO5K7-/O(_&,>K_`-B?VS9'3&M5A5HRT4H<MTD(&'&U20?X1GBN
MJEU*T@U"VL)9@EU=*[01D<N$QNQ]-P_.J>H^*-$TF]ALK_48(+F496)CD@>K
M8^Z/<X%`'$^'_!%W:RZ7;ZM807%O;Z#-:R`L'1)7E#!!GGA"1D#%=%?VNL6G
M@6SM-,M$>^B@MX7A<(Q"#:)-H8A2P`)&3C(KJZ*`/+H/"FJ2:>\4VG,8Y?%$
M5^T<QBR;8*BEF5?E_A.5%3^)=-/AK1[K7+"RBCN['5FN[*)6VB;SE6-T`&>6
M+'`]0.U>E5%+!'/M$L:2*K!P'4'#`Y!^H/>@#B=4TA-"^#M]ID@\QHM,=9CD
MC?*P)8Y!SRQ)ZUSL&FO>ZE<VUO;O/JK3Z5>7$D8@6$V\4V<@QG`;`=B#U&,"
MO6I(TE0I(BNC`AE89!!Z@BH+33[2P0I:6L%NK'++#&$!.,9X%`'G%SX:U66U
MO=).AH]S<:[]M35S)'L6'SA*&)^_N"CRMN/3G%`\-:M_:5Q;+H8227Q&-3_M
M0R1@)`)`QY!W[BJE,8Z/UQFO4:*`/-](TCQ%<^+=,U/5=/,,EM'>)<,JPK$#
M(0(_+VG>P(7)+<\CIS4K^'=6;X)V_A\69_M-;*&)K?>OWE921NSCH#WKT.B@
M#SWQ/X2N)4U)](T]%1KFQNC;P^6HNA$3N3#?*"!MQN&"5'UJ"]\,SS:)>/::
M1>R7!U>UO6AO/LZM,L9BW^6J85?E3&#C)!]:])HH`YGQ'IZ:MX?M$?3;_*3P
MSK#:-$)(&4Y!(8[&"]UY![9KC]5TWQEJOAP:==Z3$/M&ESQ8M8K<%;AG95$A
M8D(IC*$E/XMW/2O5J*`/+]?\*:S>7=S<06;2)'::81$KI_I!@DD:2+YLKG#*
M1N!4D#\'W7AR002W=KI&N&^%Y)<PLQM,>9]G$8)BR$V'`7&,Y!/&<UZ;10!R
MFIKX@_X0^P2&RMCJ+>0M_!"B,$7CS?*5SM)'\(8XXKF['PGJ?V&PBN-.+1_\
M).^HRQRF/(MRCX9@ORYR5^4=_I7I]%`'G=UX<O;'5--O+?1%O+"TO[Z1[&-D
M!Q-C9*JL=IP=PQD$!SCTKH-"TNXLO!LUA]@2RD8W/E6B2!EC#R.44,.,8(^E
M=)10!YYIOAK4-%\-Z7+IFDVD>M6_A]K1U<+M:?\`='8^#@Y97Y_7FJ-OX8O9
MAKDNH:7J30WAL#$(C;1SEXF8LVU?W8"D@X.<CUKU&B@#G_#46HMX<$6LVD,5
MPS2#RA&BYCW'875<KN*X+`<9)KD?#_A;4%M_!=KJ&AK$NC-,EYYAB96;R2JR
M#!.X%L8/7VKTZB@#S.3PK>6-]HTT%A.UA;07=J;>V$+M;;YMZ.%ERI!4;>,$
M<=LBMB^\.7,_PK;0=,AFM[C[$L,4-Y,I?@C*.ZY7)`*DCCGTKM**`/(?%6FW
M<FF^(];.AC1;5/#KVAC9HP\DA8/TC)&U,$`D\YX&*GUCPIJ>M1:[<V?AZ+3T
MDTV"UMK5GB#3R1R;RPVY4?*=@).3["O4IH([B-HIHTDB<89'`(8>X/6GJNWC
MMVH`\U\5>'=8UZX:YL-)\B-M)\G[--(B!F%U'(83M)'SHC#N/FYJOKGAK5M;
M_P"$@O++03IZ7.G6]G%;,\:O.ZR^8S$*=H`!VY)R<>E>J44`86EZ1%INN:K/
M:V<5O!=+`08P`'*JRG@=,#:*XR?PSJRZ5KVGPZ(C%]9_M"/YXUCO(!*DGD]<
M@D`C#`#->H44`<AX=TVY7Q;K.L-I7]F6ES;V]O%"Q3S)&CWEI&5"0/OA1R3\
MGIBL:ST#54T#5=#;1TCU*=[XQZSYB;29=Y23</WF[YPA&.`IYQ@5Z110!YWI
M6B:A<:[H=PNA?V#'IVF2V\\H,19Y'"@*@7(8+L+988^8<9S2^(4>V\=:&KZ=
M+KLB:7>'RF$09COAPV&VKWQVX)Z\UZ'41@C:X6<QH9%4JKE1N`.,@'TX'Y4`
M>>^%?!]_I>HZ)_:-I`\=GHTD!?<'6&=IPZJN>>%R,@8XJKHWAO58X_"FGSZ$
MEM<:1=M/>:GOC*S@*ZY4CYV,A?<<@8P<UZC10!YEX=\&75K)X1:_TF`?8XK[
M[<6"-B1V7RR?[Q(SSSBH-'\/:QHEQ9W-YX?_`+3MX[*ZM8[57B+6Y^TR21X#
MG:%>,QKP>-H!&!7JE%`'F6G>%=3T:+P8\VEI>-I\%S!=K`R$PF0J4P6(RJX(
MXZ=A3_"/ABZTN[T:/4;#4?M6FF=/M2M;BW?<&!D)7$C;\YPV2">?6O2J*`.1
MOM,N8OB+8:PFE_:;1K!K625-FZ&0RHP9@Q!QM!Y&369H/A&:TTS2VFT^.WU*
M&^OI)+A=N]$E\\*V0><AH_?ITQ7H-%`'G/@SPY<Z;/HHO]-U"*[TZUEMVF!M
MQ;DG:"WR8=]^T,-V2.<\\U'XI\*:AJEQXNEATY9WO+:RBLG8KDE&8R`$GY>,
M9Z9XKTJB@#SGQ%X3U"XN?$::380I:W=E9>5"&6..X>*9VDC('3=&%3)&""!T
M%4M;\.:KK!U^\L=!_L];C3[>TAMF:-7GD67S&<A3M``.W).>#7J=%`'FEMX8
MNX=<G%YI^HS8UQM0@NK=H!&RLVY6=C^\P@.PKDY"C''`-/\`#VJ#P#=^')/#
M\<6I#3+JU;4#)'MGD8$!@P^8^83N.X#&.<UZ710!YOJNEZ[K7AK6(!HDMK)+
MHB6=O'+/&7DD!;(."0O;!)Y]J8OA>[CU^^%[8:C<13:Q%?P7-J;<*5RA`=F_
M>`1[<$`\J..N*]+HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!&Z5Y!<:UKFE
M:PZ2SW;VWAB[DEO'?.+FWG<>5ECPVR-G.,<%%QWKU\\BDV>]`'DFL6&IR:+H
MVGWEU?RS7^E:G<W4:2N"\K*DBH=IQ\I;:%'&,@<'%,L-,TS4[3X?6-G>WK6K
MB;SY(;N3>C_9@63?G<@SQ@$8Z#%>O;><DT;?>@#E]'O8-$\#QSZMJ+F&U\R%
M[NZ8EB!(R*6/4G[HKSB[U!H/AQHNEE+RTU"#P^;RVF%[+;`R8VJBHG^LDSM.
MUN,$>M>W[<?_`%J-O.30!YGJT%YK&HZM')JFI6PL]"M[VW-M.T8%P?-RY"_>
M^X/E/'/2I+G4#;^/0]QJ3W,D\BP6\-O=2*UA^XWL98/N2)U;>><L!]/1]G&,
MTNSZ?E0!XRFK7-MX;OHK;49[J2.6RDU/5H+^:2*2&1CO=,@F%L#YE0':K9'M
MJO)=VOAJYM[+7?.B_MNTMXS:7CW#VT4C1JZ&5QEB=S-DYQN]J]1V\=J-E`&!
MX5L#I7]K:>MW=W-O#>_N#=3-*R(T4;;0S$D@$MU/>N'T:.\\03:-IE]J6II;
MW$.J/,T5R\;LT=X%CRP.<`,<#(X`[<5ZP!@8INSWH`\_\464NJ?!"=;B2ZN;
MI=+$F]78/*ZIU;;][/4@\&J4^B:9K/B3PW9V.HZ@VG?V5>E+FWOI-['S8>#+
MG<0&R<9_A`Z#%>G@87%-V<8S0!Y%J5S?W)TZVU'6)+2+^PHIK2ZFOI+97N1D
M22,4'SLOR'82`<G@]NI\8QW5[\*;L*QO[AK.&1G@3_6D%&9E7T(!.*[7;[T;
M?0T`<')KNF:[XUT74M,O$N;'3K&\FNYT4[(5<1[<DCJ=I^7KP>*I>)]2M-*U
M2XU_0]9CCU*:V@,VFS0&1-2CY$03C(8[B`5.!GYA7I.WWHVGV_*@"M:W\%U<
M3VZ.OVBWV^?%G+1%EW`'MT]*MT@7!ZTM`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`C?=-<
MG'JOB7^U[@W6G)#IL3W3AR,EHXPHB&<_\M"6?..`F,=ZZPC(Q5:^@,]E<0H0
MK21,@)Z`D$4`<?H/CY]2\"W&NWEDL%_;JN^R23[S2!3#@GLX=,?7'44W3_&>
MK:EHFDQ0V-H-?OC<!T:1A;P+!(8Y)"?O%<[0`.26'(ZU#IWP_N;74-`EEO83
M:V=G;17]L$^6XGMT*Q2*<9X+'/\`NKZ4^#P7JFGV6FSV-[9_VI8R7@*3(QM[
MB&XE9S&V.1CY#D`\KW!H`EU'Q'XBL=)MBK:%-?7.H0644T$DCPGS,Y9DSE<'
MMN.?TJ2Z\9WNE-=:=J-A$-8B^SBW$,A,$XFD\I'R1E0'SN&"0.F:QQX`U6WA
MNKBQ30[*Z?5;6^AM($=+9%A7`!PH.6/)P*T+[P;K6L+=ZCJ%_8IK3_9OLJP1
M,;>$02^:JL2=S;GY)XQT'N`:5AKNMB35M+OK*UN=9L8HYT6TD,<,Z2;@IRY)
M3!5@<YZ9'4"H&\7:C_PK"+Q7;Z;%/<-9?:W@\[8B*%+,23R0`.@&2<=.UF'2
M-:AN-6UD-I[:S>QQ00Q.S_9XHH\X4L`&))=VSCN!T%9$'ACQ1#\,'\*>;HQN
M#;FQ6;=+L\@QE2W3._)Z=*`.VM9GGL(+A@%,D2N<=`2,U@:1XTL+R'2XWFDN
M[N]@CE9[*SE,48?[K/P?+5L'&X]C6KHT6I0:)#;ZH+3[7&FQOLI8QX'"X+#/
M3&:X[3?!&L:;!H<=M-86\UC%:PW%_#)()9HHR2\93&UU.<#=TR3Z4`=KJVLV
M^C6@N9X;R92VT):6SSO]=J`G'O21:]ILWA]==CN`=.:W^TB;:1^[QG..O2LO
MQ+I.JZG<:=)8742VT!E^TVDD\D2S[E`0EH_F^4CIT.?85G7FASZ-\';W0BWV
MJXMM&EMP85),C"-@-J]>?2@#3MO'?A^Y6]874D0LXA/(9X'CW0DX$J[@-R?[
M0R*27QWHL,$,A%^S3%S'$EA,TC(I`,FP+G9R/FQ@YXKG;KP?K>OZ??2WUS8P
M33Z)_9EK'&KX4,0Q>0GD'*J,#..>36[J6C:Q'XG77='FL6E?3_L4L-X751AB
MZ.&4$_>8Y!ZCN*`)[GQUX>MH+:;[:TT=S"+B(V\+R[HLD%_E!PJX^8GIWJ&;
MQQI$]CJKV-YMELK)KQ9)[:01O&%)\Q>`9$!'.PUCV/@"[L+5+=+^&4+H-QIA
M=E()EE??NQ_<!S[]*FU+P5?7NGVELEU;JT/AZYTDD[L>9(D:A^GW1Y9]^:`-
MZT\46%WJ"Z;"T\UR$'F2Q6TA@1]H;8TF-JM@@[2<\BJ$/CO2[?0=-O;VY:>:
M]M?M$:V5I*QE48W,J8+8&<G/0=:KVGAC4[7Q);WT#65I;*Q^UF"23?>J(@BB
M1"-NX,,[NN`!W-'AWPA=Z-+X;:>Y@D72M*EL)@F?G9FC((R.G[L]?6@"YJ?Q
M`\/:5:0W4MQ<30RVRW>^VMI)0D+?=D?:#L4\X)QG!]*UK[7=/TS2X]2O96@M
MG*`,\;9!;H"N,@]L=<\5YIK^ES6%[):S0^>J:%#;)`(YQ'?,K/F+,8YZJ,-G
M&[@`9SU7C--0N_"FFF&UV7QU"PE,)!D$3"9"0Q7JJGJ1V%`%^/QWH$FF27S7
M,T213BWDAFMW29)",JIC(W98=..<C%-N?'N@V907,EW$/+668M9RXM5897SC
MM_=Y]&Q61_PANK75])J5[=V:WL^L6M])'"&\M(H!M"J3R6(ZD@"I-7\*ZU.W
MB6VTZ[L!9>(`OG-.'\RW)C6*3:!P^44$9(P>N10!>U[QMIMB9[.VNLWR;%#^
M2S0J[;2J,X&T,P/`)R:V%U_3B]^@E;=87$=M<?(?E=PA4>_$B\CUKEW\)ZS;
M?VK96-WIYTS4+F.Z+7$;F:-@J*R@#Y2"(UPW;)X-32^&]976=7>VNK`6.I7U
MO>.9%<RKY8B5D`''(CX;/&>E`%K6?'^CZ5]N4)?W4EFKA_LUG*Z>8HR8_,"[
M0V.3SP.M:>B>(K36O#T>LB.>TMVC\QA=1-&4&,D_,!E?]H<'M6';>&M9MK/5
M]'2ZL3I=]/=2B9E?SD$X<E=OW3AWSNS]T8QGFKMMH5[<^!)/#NJR6\<CV)L3
M-:;F`4Q[`WS`<]3B@">S\9:5?V=W=6R:@\=L@DQ]@F#2HWW6C4KEP?\`9S3%
M\<:$VD)J1FG2)KAK01O;2"7SU!)C\O&[?QP,9/%9\^D>++O08+*2_L()8#`&
M^RO*@N44GS%9L;D#+@?+D@@\U5T_P5?6MO8JUS;;H=>?5I`K.P",CKL#-R2"
MW4]<4`;1\<:'_9%OJ*RW+K<2O!%`EK(T[2(2'7R@N[*[3GCC%5;/Q9%/_9LQ
MO[4VM]/>!'\MCOBBWD$,.%P%R2W7![U%>>&=335K/5M,GLOM5K<W3B&<,(WC
MGVY&5&0P*J>A!YJG?^!KW5K*RMKR]M5VG4?M,D$3`$7*.H**<\C>,Y/:@#6T
MSQA8ZQK"06,TI@6TEN)%EMWC=E#($D0,`60@M@@'-4]2^)6DV.B7VHI::G+)
M8O&DUJUG)%*OF9VL0RC"G!^8\9&.I%-_L+Q3/9LL^I:=:WD6F26=O/:1N2LC
M>7B0EN@^3[HZ9ZFL]O`6I3Z5XDADNK:&?58+:.("66<(T.3EG?YB&)_#W[@'
M177C?1K&WMY+@7RM-%YQB^PRF2*($@R2*%S&H(ZMBMF;4;>'3FOP7FMQ'YJF
MW0REU(R-H7);/;%<AJ7A74M0U9M5>/3IIKNP^R7EJ]S-''E68H591EAAV#!A
MSVQ6QJ^DZC<>%8M.TRXBL;F,0C]VSK&44C=&&'S*I4%01R,T`)'XXT*327U)
MIYXH8[DVCI-;2)*DV,A"A&[<1C`QSD>M(OCG0VT==266Y*/<-:K`+60SF9<[
MH_*QNW``G&*Q+7P3?Q6H5KBU5CX@CU<JKNX6-0H*;FY9OEZGU[5>U'PQJ#:M
M;:MIL]F+RUOY;E(IPPC>.2)8W!*\AN"00#0!K^']:CU?3[B^%Q');BXE2*11
MM&Q3WSW'.<^AJM8>.=!U*X\F"XG5FC::`S6TD:W"*,LT18`.`.>,T6>AW)\/
M:EIVHSPM+J#W!DDM4*JHEST!SR`>_7K6-;>%-<F?1DU.ZT\1:/9RP0FV#EIW
M>,Q!F#?=`3!(&><\XH`V;#QUX?U&:Y2&\=5M[8W9EEA=(WA'!D1B,.H/!(S5
MK1_$^F:])-#9O.DT:B3R[FW>%FC/`D4.`60D$;AQQ6&W@M[GPG9:'=7,8,6B
M-I<LL8.=Q6,!ESV!C/!]:M^'=#O=/O6N[^TTY;EK5(7GM[B:1W8,21^\^ZG<
M#)Y)H`R=7^(HB@\4VUA8WD5]HL+2+-<VKB%R%W<G`P/3)^8<C(KH--\9:3JE
MI?36WVQFL55IH6LY5EVL"5*H5W,&P<8'.*Q-;\(ZKJ$OBN*WN+(6NO6J(&D+
MAXI%CV#@`@J<`YZ^U:>O:'J5\EX^F7L=K<3Q6T>[<REUCD=G4LO*AE;;D<B@
M"EJ'Q*TFTL;2[BM-3N!/??8'B2SD$D$G&0Z%<@X92%ZMGBNFFUBRMTT]KB1H
M?M\JPVZR(06<J7"D8X.%/7TKC$\$ZG#I4RQ7%FMV==35XHV:1XP%"#RV<_,3
MA3\V/PKHO$>D7>N>'#;0SPV^IQF*XMYL%DBN$8,I]2NX8Y'3J.U`#XO&&B3Q
M1R0W@D#W[Z>`JDGSDSN!'H`I8GICGI2Z/XNTC7;HV]E+/O,?FQ&:W>)9X\@%
MXRP&]1D<C/4>M<QI_P`.A9WWE27(;2OL10Q1\-]J:+RGE`QM&4+'CG+'M6AX
M6\,7NC3V+7L&GR/:V;6OVN.>9I&&5QA'X0$*"P!/(&.*`#4_'5OH7C"^T[4S
M*+**R@N4>"UDE*;FD#LY4'"#:O)QC-:E_P",]$T[4!9SW,A8;/-EC@=XH`_W
M#)(!M0-GC)K(U[PWKEWJ^K76E7&G)%JFFI82_:@^Z(*9/G7;PW$IX..@YJ@W
M@">UFNX[>.QO[*YBMP4OIY8]KQ(D9)5,JRE8U(!Q@YYQ0!I3>*[B'Q)J6G2R
MVT4,&I6=I"SQ.Q<31ABORGALYPQX'>K]OXWT2XN)8(IKABB2/&_V:0)<>6"7
M$3$8D(P<A2>AK+U#P;>77B&[U%;JW6*?5;&]"-NW!($VLO3J>U,\,^#;G0Y]
M-BFM]/N(-.\V."Z,\S2K&5*KA#\BMCAB#@\X`H`WIO&&A6\-K/)?`0W5FU]'
M)L8CR!M^<\<9WJ!GDDX'-6-&\0V&NK,+7SXY8"!+!<P/#*F>5)1P#@X.#T.#
MZ5QB?#68Z=K5G)?1LDJ1PZ42&/V>))C,J/W^_@$@Y*JO<5TWAW2+C3;J\GN;
M.Q@EN%B!>WN)9GD*AL[FD'09X`]30!!'XTL+>R\ZZF>YD>\N+>&*QM)9';RG
M*M\@!8[<#<W3/U%;.HZWI^DZ<M_?3F&V8JN]D/5ONC&,Y)XQC.3BN-N/!FI#
M2FM[<:<]X+R^NK>[>66*2U:9RR%&49X#?,#P<#K6_K&@WFIZ!IMBUVDEQ;75
MI/+.X(\WR9$=C@=VVG\Z`&6_C[0+B>VA6:Y22>80$26DJ>3(?NI*2N(V/8-C
M.1ZU9A\8:-/K/]F1S3>:96@68V[B!I5SF,2D;2XP?E!SP:Q[KPA>SZ5KMHEU
M;A]1UF+48R0V%1&A)5N.O[H_F*KV/@J[L+KRPEC-;Q7\MU;7,D\WFP"3>V1'
M]S>K.0#P".V:`-ZW\8Z3<7E]:'[7!-9P/<.MS:21;XE.&=-P&Y0>X]150^.]
M'N]/U:2PNF66PLFO/,N+641M&`V)%X!D3*GE3SVK$L/`^LJUU-J%];2W4VBR
MZ:\OG2R&65R#YK;ONCC[J\#/':M2\\)W-QX<?35N(%G;0'TO>0<;RH7=Z[<@
M^]`%O4?'.B:*J)J%S+YHA2>7R;:1Q'&W_+1L`[4R.IZ4NK>.=%TC4/L,[7<D
MHD2%VMK225(Y'QL1F4$*QW+@$YY'K5?_`(1>Y^VZK,T\!2]T>'3U!!X=/-RQ
M&/N_O!^1KD]4@NK?Q/JKK8M>S&_LWAL&69%N-BQXD#*-A*D,<MG[@W'``H`V
M-*\?+=:SK<]\US:Z987"VB0MI\@RS/&H<R'^(M)C9C@8;I6]XD\1-IL,8LBK
M3IJ5G:S+(IP%FD53CWVMGZUEWW@^^N-$\0VD5U;"?4=534;<L&*+L,)"OCGD
MQ$9&>M27?AG5]2CE>]N;$3RZG9WNV$/L1(61BF3RQ.T\\=>@H`G\.>+HM0:]
MM]1ECANK::[;.TJAMX9VCWYZ<8&?K71:;J$&JZ;;7]KO\BXC66/>A1BI&1D'
MD<5YMXA\)7\6F6EE;2YOK[5[M&EA0X2TN7=Y06Q\N%P<_P!X`#.>?3K>*."%
M(8D5(XU"(JC`4#@`4`2T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%``3@5G7VJ0VLT,0*R2R31Q&,,-R!S@,1UQ6@>17E^DZ'/#J%JMUX<NCK
M,&L23W&K*%"2Q-(S*Q?.77:RKMQ\I7.!C-`'4:QXT@TNU@Q9EKVYNI+:WMIK
MB*+>4W98ON(5<(2,\YP,`G%2:+XLMM:U#4XK9(Q96#&-KMKA/G=3\WR]0H_O
M'@UR,'A&2ZN-%.H:''.D7B#4)IO/@5@('\\H3G^$DH<>N*K3>#IK70]0-KH:
M1J/$;SRV\-I&6N+,,=JA>`Z`D,%)Q\M`'JGVZU-N+@7$)A*EA)Y@VD#J<YQB
ME^VVWG1PBXB,LB[T0.-S+Z@=2/>O-[;PLDK:3;+I]W-IHUN:>Z@NK188EC-L
MP&V(<"+>%X(Y;/%0IX9FA\4W;7MC>!UU>*XM+NTL$;,&4V()LY1%"[&7CY0<
M9S0!Z:;ZT$OE&YA$FPOL,@SM'4XSTX/-9\/B;3+VQ6\TR==0B,ZP-]G=<J2^
MPD[B.`0?<@<`UR.D>$462WOKO1Q]O&NWCM,Z`N;9S,H!/>,JRX7IR.*SM-\-
MS6OA*/2X/#\EK>P:]!-<.ENJB6(7I=6##[RK'CZ#B@#TTZE8AIE-Y;AH5W2J
M95S&/5N>!]:@L==TK4M,74K._MYK)E#><'`4`^N>GXUYWI>C:AJGC&SO]3\.
M0VNZ*]BU!%L42)MY`0,^29@P4G)XY]ZH6?AN[B\'>&+0^'YH4T^XVZK:_84D
M\Z0QE!-LSB4*<<\G!R`<4`>NO>6T=M]I>:-(-H;S6<!,'H<].<U3CU:#^S[F
M^G(@AMI9D=G;C]VY4G\<?K7`G0C;VV@M)HU_JFBV]U>M<64]H@96D/[MA`3C
MRU^<*/X0PX].DTC1P/`UUIL^E/%&YN@EG<D2D*9'*`DD@\;<<GM0!<\/^)X-
M<T4:M*L-G:N=\/F7*,6C.TJS8X4G<,J>0>O6ML7=N;DVPGC-P%WF+>-X7UQU
MQ7G&D^#T6+P+:W6A1?9(-.E.HPM`OEB<QP@&1>C,2K<G/(JG#X?NR]I;2>')
MO[?CU[[3-J^Q0&@$QD+><.2IC(CV>O&.]`'J7VVVWLGGQ;U0R,N\9"@X+'GI
MD'FGQSQRQK)&ZO&XRK*<@CV(KS"U\'O)J&FS7>B!VDU^^DO'DC!+VQ\XQ!SW
MCSY9"],XXK9TG1M4M?!GB;2;*%K*9KF^CTI.$6-&SY>S'W5R210!V27MK(9O
M+N(G\DD2E9`?+(Z[N>/QIT=W;RPK-%/$\+_=D5P5;Z'\*\PN=&27PM;QZ7X-
MN+3R)+.34K7R$C>\C1R7BZ_O2,;LDX;.,GD5'/X;N;IM8.GZ#-9Z3=:GIHBL
M_+\K<D<G[^3RQ]U2IP>A(4Y%`'J*WUHXA*7,+>=DQ;9`?,QUV\\X]J7[;;>>
ML'GQ><P)6/>-Q`ZX'7C!_*O,I_"#P:=K=Q9Z(([^'7H9-,>*)0T5N'AW&+^Z
MF#+D#&?FJE:Z;_:>KW0M-%EFU*+Q4TO]I[`%A@CE#.OF9R`5#+L'7?\`4T`>
MM?;;;SI(?M$7FQKO=-XW*OJ1U`]ZSK;Q+IFH0V\VF3K?Q2W!MV>!U_=D;@2P
M)!QE".,D]0".:X+PWX9D@U>S&JV-[]OBO;D7-PE@GEW:N)/FDFSEXV##Y3SD
M`8XINB^'+BRL]$LHO#\EK<V7B)I[N5;=55XB;G8X8?>55=1[9`H`]0%[;&<0
M">(S%=PC#C<1G&<=<9!IBZC9/<FV2[@:X!(,0E4N"/;.:X31?"HMY;;5+C2O
M+U&+7;R4W#+^\%NQF"Y/79M*X'3D'%8G@&RLK?6/#=[=V8@O+JPN%LY5LU!N
M,E69I)=Q9G"#`9E4G+9QG%`'HVI>)(-/O5L8;*]U"\V+*\%G&&:*,G`=MQ``
M)!P,Y.#@<5G3>.[2+49K5=)U>5+>WCN+B:.VR(5D!*ADSOS\IR`IQBJ,\FH>
M&?&6K7YT:_U*QU9(71[&(.\,D:["C`L.",,#]:K+J.J:3XPUB^_X1C5KG^T;
M6T$"0HA5702`H[[L+RPYY`YH`Z6\\7Z/:'2<3M<#59$CM6MT+JV\@!BPX"\]
MS4&M>--/T.[F@EM;ZX%K"+B\EM8=Z6D1W8:3G/\`"3@`G`SC%<A?:?J7A_PI
MX2T<:/J-_<65[#?7)L8@Z1A79G3)(R1NP/7':KWBG3I=0&KOI5GKT.J:I81P
M$1HBP2$AMN\MD+LW$-R,C@9H`]!CFCEC22-MR2*&4^H-94NO0Q?:GAB-VD$,
M<P:WD3#AW9<`DA>-AZFL3Q3HVLS>$+RRM)C=GR85%HB!"Z*Z&1`^>=R*XP<?
M>K`U30VN_#_B==%\,W5A%>6]H(;8QJGFNLK%BL8.$P,9Z9Z^]`'IK75NDR0M
M-&LKDA$+@,Q`R0!WXYI(KRWG5VAFCD6-BKE'#!2.H..AK@M4\,7NI:EXWN(;
M0)?3P1QZ7=RJ,J3;[7\MOX<GY21CWK#;PY,^E73Z=HVHQM)!:-=:=]B2TCEB
MCF#R1\'#RE=RYS@C`S0!Z9<>(]%M7M%GU.T3[8Y2W)E7$A`).#TXP>?PZU=%
MW;FY-L)XS.%WF(.-V/7'7'O7G6L:%IMQ)H=_:>"RMC::D[3VPL(P[QF!EW"/
M^[O*\>J[L=#5?1/#EQ;^(()-1M+]=1@U:69KR"Q3%PC;RI>?.3'M<`J>05`Q
M@9H`]$O-5AM[FWME*R32SK"RJXS'N5F!8=<'::2;6],M=4ATN>^@COID+QPL
MX#,`0/YL.._;H:\_\.:'/;7FD"Z\.74>LVNH3/?ZIA0DRL)3O+@YD!RN`0=I
M]*V]<T>+_A8FAZQ)H?VV(6TL#SI;)(T4Q>(Q,V>0``^&[<^M`&YHGB*SUF.8
MQD1317$\#0.XWDQ2,A8#K@E<UIB\MFFDA$\1EB&9(PXW(/4CM7`:'X16UN(-
M3DT@1:HOB"\G-SL`D\ES,`2>I4J5P/IWK)\-^&+BSDM/M=C?QZM;Q745Q+'8
MHJ73,C#=),#F16/S+GOC(&*`/4I-2L8DD>2\MT6-@KEI5`4GH#SP:=+>VL$7
MFS7$4<>`V]Y`!@]#DGW%>;C19]/\(^&;#_A&H)$N+97U5VT];J9+A8A@LC'E
MBVX%CG'3O69!IZZ>?!NG:[H,^HFWT&X6;3UA68^8K0@$J3@XR0#SC=^-`'K'
MV]?[26S$,AW0F83`KMX8#&,[L\YSC'O3XKZUFMVN(KB%X%R6E60%1CKDCCBO
M()/"/B0:':VOV.;[1%X>:!\.&_Y>HY#;[B>28@5QT]ZUH_#EJ^D:Q&MIK5O#
M=26C&"WTR.%%*MGY8>CC_GID'(`ZT`>DF^M19->">-K=4,AE5P5VCDG/3%8_
MASQ&^O>:6TZ:T\J&!V\QPV'D3>8^.Z@KG_>%9_A;5#;VFG:->Z4NGWEPMQ)'
M;V]L(T6&-\!W0$^67#`XYY)%==M`'`ZF@"$7UJ9)8Q<1%X1F50XS&/\`:';\
M:@FU:W6TCN;?_2XWF2(&WD0@%F"YR6`P,Y(SGT!/%>:6=EJFCVNL1Z1X9DO8
MGMBYFU*Q1;B5WG^:-B"//`0LPSUP!GFEL_#E_%IVH1P:7+'#+XBL+J&-;58`
M84,.]Q&O"@;&/KW[T`>DWVIPV3QKE7E>6)#$&&X!W"!L>F35;6O$D&CW=K9"
MSO+Z^NE9XK:SC#,44@,Q+$*`-PZGO@9KB;?1)EU>3[7X;NI-677?M0U1-H4V
MQF#+F3(+*(R%\O'!7..,UT/C:RM+PVC3Z9K$MQ"LCVU_I/$UNX'W<@Y^;I@@
MJ<<T`=&FHVS0VSR/Y#7(!CBG^1R?3:><\]*D^V6PN#;F>+S@N\Q[QN"^N.N/
M>O-=*TS41K#77B[PY)JM]<6UG]FN$B200,H`=2Q/[M@Q+DC@\X/055B\/73_
M`&:TD\.3?V\NN_:)]6,:[7M_.,A;S>I4Q'R]GKQCO0!WY\8^'!8R7IUFS^S1
M3?9WD\P</OV8]?O=^G?IS5C6->L]%T";69=TUK$JMF##%@6"C'.#U]:\TE\(
MH/!^NZ<GA(?;H=6-TA%G'B:#[5O41M_%B+(V\8!([UUWBVP?4_AK=V.EZ9+%
MYL,:PV:1B-D7>ORA1]W`!Z=*`-VTUVUO=1U&TACE\NP(66Z(`A+XRR!L\E1C
M=V&<=<XNI>6TEM]I2>-K?!;S5<%,#J<].*\VO=%U>R\,'PV-*GOK'2[Z"?,0
M7&H69D+M'@GYI`?O`XW8S_%BJ%]X;O9VU6ZTW0IK316U&SD_LT6RC[0D:N)'
M$!(7!9HVP<;O+Z4`>K_;K4VXN/M,/D%2PD\P;2!U.<XQ43ZE&MQ9QQQM-'=;
MMLT;*44!<Y/.2#T&T'\!7GMMX621])MDTZ[FTW^VYI[F"ZM%AB2,VQ`"Q#@1
M;PO!'+9XJ#7M`ETK2;$6UC-!8:<-88F-BGD1O'+LPPR5SD8(!QQQ0!Z9!J5E
M=2-';7=O,Z\LL4JL1]0#5/Q'XBL?"VBR:KJ/G?9HW1#Y*;VRS!1@?4UY[X<E
MTOPG?WU_J%@;74/['MY&BM=/2)98U<C<NUVW2,[*",C.%ZUV?C2RN-1T:QCM
M;=YV74[*5T`S^[6=&8D>@4'-`$OB'QCI7AO0X=7NS-+;SE1$MNF]W!&XD#/0
M*"Q]@:M>(->A\/:4+^6VN+D/-%#'#;A2[O(P50-Q`ZD=37FMYX6\0/H&O:3)
M93/;:58W%IHX1]WVH3'(.,=43;'^>,5UOC5KN[TA(+;2K^XDL;ZQNF$40/FJ
MLJNWE\_,5"G(..HH`W-(\16FKSS6HBN+6^@56FL[J/9*BMT;&2&7.1N4D9!Y
MK7KB+2:^O/$USXKET/4+6UMM,-I#;21K]IN&,@=B$#<`;0!D\Y/3OTUEK%O?
M:K?Z?$)#+8B/SF*?)EP2%![D`<CMD>M`&0/'%A_:MY9S65]!;VET+.34'C7[
M.)CMPN0Q(SO49(`R1S5_1_$5EJLEW"A$4]M=RVIB=AN<QG!91U(KG--\(MJ&
MIZY)J_VU+0ZX;N&TWA8K@+'%M=@!EAN7.,XRHXJIIGA%5U"YU2;2`NHCQ-)<
MQW)0"0P$D9W==FTGCIWQ0!UOB#Q''H`L5-A>7T]].8(8+14+E@C.?O,HQA3W
MJ?2==LM:CF-J9%EMY/+GMYD*2PMU`93R,C!'J#D5S?BFYNY+OP]JD.C:G<1Z
M?J<QFABA!EV^3+&'"YY4DC!ST.:DT,7D6KZQXBNM(N[==3DM;>&UV*TP1,KY
ML@!PHS(<C)("^^*`.SHK.TO5[?5FO/LPDVVERUJ[.N%9U`R5/<`G&?4$=JT:
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`$)P*S+;Q'H]YJ<VF6VIVDVH
M0$K+;),ID0CJ".O%:;=*\QT31;[7;S4%26U@L;3Q1/<R2A2UPS(X(1>R@G@G
M))4D=Z`/3Z*\HNM5UB+P[J&N'6+P;M8DTV4^:J16EJMR4+C*D*V`!O(.`W3@
M8M/+K<?ARXM$\1VH5-12-&DU1#<&$QAFB\_;@2DY89'W>,]Z`/1?MMM]N%B9
MHQ=F(S"'=\Q0$`MCTR0*<+J)KM[4/^^C19&7T5B0#^:G\J\FO_&%W':6U[I.
MH7ZVC:#YH>Z"R2(/M<4;3,`"&*H6.>1@9JS?:I)I%CKLFC>(Y-32%+%&O))$
MD>UB>602$R8*M@$G)!VYYSB@#U:DW<XKRQ[W6;*PCLH_$/F0W&L6EK%(EZMS
M<PQ2J0X9]H&23N7(XX]*J^(-/ECBTB#4?$NIB&S\1M;"[:Y$;)$\3,I=\<LI
M.T,>S$=Z`/7J*Y3Q?J<%II-A9F[O(VU"=+>">VN5A.=I;+2MPH(4]`23@#K7
M)Z1J>JZSI'A"PDUJ\B&HSW\,]S#*OG/'$7*8?'7"*-P&2"?6@#U>J]M>0WEL
MEQ;L)(GSM8=^<5YK_:=[]HT71]7\3W-A;"TN7_M`,D3W,\4VQ59F!!P@+%1U
M[YK1G>^N/@M*^GR-/=/8,P>!=K2+N)<H.H)7=@#GGCF@#K;?Q'HUT]TEOJEG
M,UH";A8YU8Q`#)+8/`%1Z7XJT+7'E32M7LKUX5WR+!,&V+ZG'05SEUK7A'4?
M"5Y%HMWIL\R:5.(([=D:2*/RCQ@<IP!D''2L%M4MK[X8000:KIM['!#8F_AT
M[_6QV@9/.#A69C\@(.`.AH`]&TWQ#I&L3S0Z;J=G=R0'$J03*Y0^^*TZX&ZU
M#1]6\:^%_P#A'[BSN9[<RRW#V;*PCM#$PPQ7@`N8\*>N,CH:K>)=69O$FL6]
M]XCNM$@TW3XKNR$,BQB=COWNVY3Y@#!%V].>G-`';SZWI]OJUOI4EP/MUP"T
M<*JS'`SRV!A1P<%L9P<5.-0M6O7LA<0F[1!(T'F#>%/0[>N*\Y\'VEU?>.VU
M6_O]12\DT.PNKBV,NV,R.)0R,F.%4Y(7L2:J:Y.NC_$?6?$Z[@NE+8+=E%+$
MVDJRK)P.N"$?_@%`'J":A9S7\NGI=0M>1(LDD`<%T4]"5Z@'%/MK2WLQ*+>"
M.+S9&EDV*!O=NK'U)]:\HTZZ31/$EQXDU.-TGO-!N=2N!;J3(J&:/8H#=UC"
MCG'(/%16WB'5-/L?$,<>L79MH9=._P!)FNDO&M(YF(F<2!=O"8/(('7O0!['
M0>E>=7C/&VB:-I?BG4+F"\U.2VN+K[0LDR+]G:0H),=<J#GDC<?PQM1UV]MX
M]8O%\1WD6L:;J2V%EI9=2LT>5";HBNZ1I%W-N_+&*`/2=1\0Z-IES!:ZAJEG
M:3S?ZN*>959_H":=INB:/82?:M.L+2!I%.)((P,ACN.".Q//'6O-Y=:71[+Q
M.SR:+%KB7]S+=1ZSUN;49,(CP067844#IG=QD\QRZUK=_J$SP:G#H\EG#9RV
M=M+>+;VPCDC1F+QE274L70<\;0!@]0#U^H(+VVN9[B&&:.22W?RYE5LF-B`P
M!]#@@_C7GVK3ZK>:]XDE@UN]M$T:>T:W@A8>6P=$9Q(,?,",@#MDFJNI:U?-
MXIO=+N-8N;#39];%K)=1N$:%?L<;I&KD$)OD/7KV'6@#U*BO,M2U7[!J.DSG
MQ+<7FCQ+#'&+6]C%S)(\I0/(FW]\AP!D8^ZQP>37H\%W;W7F?9YXIO*D:*3R
MW#;7'53CH1W%`%34M=TS2'"7]Y'`QC:4!CSL7&3],D#W)`')JU#=P7$DL<4J
M/)"0)%5LE"1D`CL<$'\:S]4\-:3J]U]JOK02RB)8M_F,OR+(LH'![.BG\/2N
M'A\0Z?!;^-]2AO));.YU6&"*YL)T'S/!"@(D/RJ`QP6[<T`>GT5Y)8ZQJ_\`
M8#V:ZS=9/B=-,6Y:=9I5A=%W`28PQ!9L''!QZ5;U1M5TW1I+-_$LK6]IJ$XE
M>:]6WNYH%C$@5)2,$J3SG&0.HH`]0HKS)=?9O$NCWLNL7<FGWBVL5C:PW2+,
MKR1[O]*AQEMWWMP/`[<9JGX:U;6[TP:E/K:B:XAN5OK*:^0E)$1L)%"%!1D8
M<\G@9.<YH`]9HK@O!)U)YM'U&[UN\O5U?1Q=S6\Q4QQR_NCF,`?*,.1COU/-
M-U2[U>7Q+XH:SO;MFT:QBN;.QB8!)IGCDX<8RPR@PN1R30!W]%>/Q:UK-GX8
MU;5;7Q$MVC:.UZ@EODN)1."N'5%5=D?)!7H#@<4Z_P#$%]I,7B)='\2W&J6\
M%C;77VJ9UE$%P\V"@90``4P=GO[T`>O5`UG;O>QWC0QM<1HT:2E1O56()`/H
M<#\A7F>OG5;'6SH47B"]@B@L#=VMS<Z@D)GFWOO+L4.Y4^3Y!@8;OVMWVKW=
MMXET>?4]<66W<6<*V^EWB*?/ER"TD1&9(V.""#PH)QU-`'I%(>!7EWA?5-:U
M'6+:]N=86.:6ZN+>^L)KY,)L#XBB@VY5UVH<Y)*@DYS4>C)JNJ>']-O[KQ#J
M<IUK1II)XED"A)%"%6BP/EXR#USG)H`]2V*S>8``Q&-V.2/K3R<"O'+2Y:Q^
M&WAR6V\3S&R2T^T7\:ZFL=U\L*$I"Q'1#UC./O#GUZ'Q^L>I>#-&OO[0O[2`
MWUC(9%E\I@CRQ_,_&`5!S[$9H`[E-1M9+^:Q293=0QI))%W56)"GZ$JWY5:K
MRG5M.GN?$VM3:;XAO[9K'P]:S07,$JMYY4SE6D./G''T.[Z4[6=5UNY\3ZHL
M.LIITE@UNUG'/>I!`T3JI+R(5)D!;>O7@@8Q0!Z;->VUM/;PS3QQR7#F.%6;
M!D8`L0/4X!/X&EFN8H)8(Y&P\[E(Q_>(4MC\E/Y5SWB.]N+;Q!X5B@F9([G4
M)8YE!XD46\K`'\5!_"N0\.ZO+J$N@ZB_B"6]U6[:>2YTF4KB&589?E50`8MI
MRI!^]UZC-`'JU5=0U"UTNS>\O9E@MH\;Y'Z+D@#/XD5Y;H'B+4+:PC\0:AK<
MD]O)I\T^HVOVQ))A(@&1!"%'EE#N#`Y[9SUK/N[^ZE\*>-+.;4;FZMH(;&6$
MW%ZMR4,C98>8H`[+QSC\:`/;**Y3Q[J,^G:5IQAOVL$N-2@MY[A6`*1/D,<G
M@<<Y/0@&N1CU_%G=Z,^N:E=6TFK-:Z=J*7B0LRI$LCAYR,$!BZ@@$G;B@#U@
MG%)NKRS1]1U;7M,\%V-QK5]!_:-K>-=36[A99/*9-GS8X/J0.>?6LW33-HNG
M:W'8^(+_`.W-XE6R=9K@2/'&\Z)YFTC[S!_O$8/%`'L],EB2:%XI$5XW4JRL
M,A@>H(]*\SU>?5]"L#I8UN]EM7UD6TE]/.J30PO`KJGFE2!F0A=Q'\0'%/:[
MUE-$T?3WUW<]UKC6!N;6Y6:5;<QR'8TF,>:-O)QQP>M`'7R6_A_PEITET;>T
MT^U&P,8X>I!^10`"203P`/I6S!,EQ;QSQDF.10ZD@@D$9'!Y%<#\0='\W3O"
M]NVI:C'Y6K6L`E2?$C;CC>QQRXQD'U)K"U+7;ZVCUF\7Q'>Q:QINI+8V6EEU
M*S)E`FZ(KND,B[FW9^F,4`>OU7O+ZWL+*>\NY%BM[>-I)9&Z(H&23^%<MX:-
M[J7B'7;RYU.[>.PU&6S@M5<"$)LC?+#&6;+G!SP*X^XM8+-?B@KZQ>37"V\^
MVTN+K<&1K1&W[.IP<J#V``H`]7N-1M+2P>^N+B.*T2/S'F=L*J]=Q/I4L2JN
MXJH&X[C@8R?4UY?J']I^'/">NM#KU_<_\2*.[A:X=2T$OS`E"`,`\<=!BM33
M-4FB^(3VU_J\MT]W).EE#:7:M!''&H)6:+&4=?[V3D^F<4`>@T5YAXTU>6'7
MM:@E\2W&DQV.E17MHD,JH99R91@@@EQ\JC8.N?I2C5=>NI]:O6NKP76DZ1;7
ML6GQ#:DEQ)`Y*NN-Q&Y!\OJ30!Z=4#7<*W@M-_[\QF4)_L@@9_,BO*)O$-_I
MD"SZ#XCNM<EN-$N;^=)2LXBE55\MU"J-@+%QMZ?+C'%3RWRV]EKL^D>*9]7D
M3P]/<Q3%U>2&0\@AE`X.`0N/EQ[T`>J)&L8PH"KSP!@<TXM@UYMK/C"0:-?7
M.D:LLS6^F6C2RPD2B#S)=KR]""53<W?[O(K.\366GF+0#%XRU2XM8M:2.6Y-
M^O[G?"[`^8!C/W<9Z;R.]`'K=%108\I-LAD78,.3G</7/>I:`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`0\BFI&D8(157<=QP,9/K]:<W2N1T?Q!J^J)-K,G]
MF6WAY'N$!E=Q,HB9D\QF^Z`2AX[`YSVH`ZHVT1C:/8FQL[EVC#9ZY'O4/]F6
M(@,/V.W\K=N*>2NW/KC'6N"@\?:G!9^(9[M+&[&FV$5_#):Q31+*CEQMQ)R>
M$X8<<U>N/$_B'2H;]-4LM.DNO,M$L?LTCB-S<2&-1)G)&UAR0.>P%`'9I!#G
M`CC^5-@PHX7T^GM31;6\:>2D,2QD;=BH`,>F.F.3^=<!J5[JME::W)JUM:/>
M)-IL>;>61(I`TP4,,$.N-Q^4D\KW!Q5D:UK.MS6%]]DLUT5]7\B+;(WGH8Y7
M3>^?E(8H1M'(R#D\X`.VCL+2%=L5M#&-P;"Q@<CH?K[T^2UAF1DEB1T8Y960
M$-]17"IXOU:Z\3?V787.D7-O>0W+6=PD4VV-HMN-[9VR#YCG9C!%9^D^,/$<
M7@_PX]Y+976J:R"8)S;R[4C6+>S2(F2S<8^4`<YXQ0!Z5+:PSP^3+%')'_<=
M`PX]C2BVB4H1&@V?=PH^7Z>E9?AG4[S5-&6YU"T:VN5D>)U\MD#[6*B158;@
MK`;@#S@URWB_QEK>EZM=6&CP6#2VT$,J17222279D<KB,(1C;CD'DYXX%`'>
M/:P2J@DBC<(V]=R`X/J/0^]/$:KPH`'L,5PA\2W&F^-+Z"2WA^S&_M+.ZF#2
M$@R6^48`L0HWX7``X;)Y'-?_`(3O5KNVTT6=O9Q3:G]IN;>26&:5$M8W548K
M'EF9@RGL`#Z\$`[Z*QM8-_E6\,?F??V1@;_KCKUI(;"UMRQAMX8BPPQ2,+D>
M^*X@^+?$U\+.TT[2K6UU&;3'OY(M1\P!-C["@`P?F)4C.,#KFK/C#7-9A^&W
M]M:1+!9WC103.9`9-BOMR%[9RP&2.F:`.M@M+:U9A;P0P[L;O+0+GTS@4^:S
MM[AD:>"*5D.5,B!MOTSTKSW59?%4'C:U^Q-I<FJ+H,KSB02+;MB9<;5W9ST`
M)/&3]*DO_'>KM,R:5I\+O;6$%Y<0O#-,\S2JS"&(QC"G"X#-W/2@#T+RD$A<
M*-Y`!;')`[9IAMHF+DHI,@PY*CYAZ'UKA+GQ5<:9/XHO(M/4RVT^GQB.25P7
M,RQKALDA<;_X0.G()JUXRU#Q-I'P]N+V&[T^+5H2IFEBB8QA2X'R*Q)!Y'7/
M?VP`=D;>(MN*(3MV9*C[OI]/:F1V5O#$8HX(DC((*)&`"#[5S,FL>(DU^QT(
M+I9NWL_MEU<%9!&%60(P1<YR0RXR>,'KTK)7Q_<P:K?&9["^TI-.N]0@ELHY
M5;;`5^7>WRR9#=5XR/>@#O%M;:!$2.")$C)**J`!#W(';O2_9+=YEN&@B:=1
M@2E`6'T/6O-_%.L:Y8Z!I>L:\MFMNFJ6ERD>FB1I%3YBR'=]\XQR,`\\"NUL
M+^\E\.MJ5R;0RM"T\:6S[XU7&5&[/S'&,L,`]J`-&:PM;@J9[>&5E^Z9(PQ'
MTS2S6-K<.KSV\,KK]UGC#$?3-<"?&NOMIVBR"#3H[C7(C<V@\J:5;>%45CY@
M3YG8EU'&`,GGCFU:^*?$>KSVFG6&G6EEJ1M&NKK^T%E"[1*T2A%&&&_86!;H
M".#G@`[?R(_G.U<OC<=H^;'3/K39+.WE21)(8G60Y=60$,??UZ5P^J>,-=MX
M=;U2TL]/;3-#D,5W#+(_G3,J([[&'RJ!OXR#G':I-2\9:G8R>(+I;6T;3M%<
M1,I+>;/(\:-&`>BJ#(H)P<\X''(!V#65H)HW^S0>9&`$8QC*@=`#VQ5B.)(M
MVQ57<2QVC&2>I/O7+:*VL_\`"4W2:W'9B=;&/9)9LWEN#(_\+<@CI[]>.@S-
M0\9:S;QZIJ]K:6,FBZ7>&SFBD=Q<RE657=3]T`%N`0<@=1G@`[QF&[;QD]JB
M%E;+`8%@B$)SF,1C:?PZ5PO@:UU.;Q7XGU+4VT^:5+U[,311N)E`6-@@9F($
M8!SM_O$FG-XRUB*W\0W%S#8VTMA:7-Q;:=-'(MP1%D*Y).V2-L`Y3IN`SF@#
MN4LX$146&)50Y50@`!'0BDFL;:X&)X(I1G<!)&&P?QKF=8\5SZ3I[W/V:.5O
ML=O+&FXJ&EFE$:@GG"Y89X)`SUJ*[UGQ/IYT_2YDTB36-1N)$MYD$HMTC2,N
MQ92=Q88P`#@YSD4`=7]AMOM'VCR(O/`P)/+&X=NO6D&GV@G:<6T`E;.9/+&X
MYZ\]:XG5_%OB&PO?[+@M+&34+6R6[N]L,\R3%F<*D0094G8>6/&0,-R:LQ>*
MM5E\11VDUG#I]J\2-'!>)()KMVC#E8I.$W*3M*G)^4GI0!V2Q1Q!=JJ`@VJ`
M`,#T'MQ0J(6,JJNY@,L!R<=.:\HU_P`0^(=9\$7P>;3;2X-Q:K<6+13)/!%+
M*J^7("1G)(!8#:R[\>W26&L7>DQZWI/V2PC&A:?;21K:HRQEG5RP`)X4;!@=
M>30!O:IX?TW5=)OM.DA6"*]B:*:2W54?:>O..M:$=E;)"T:0Q!'.64(,$^I'
M<UYCK$TR^-M0599%4>(M)``8X`,(!_/OZUT6G^+=1O-0TO27M(8]2>ZN8[]>
M=L44/\:C/\>^''4?/WZT`=9<VEM<*!<00RA<D>:@;'KUH^PVIE6;[/#YJC"R
M>6-RCV.*XWQ)KFLW4GB'3]*M+22UTRUVW?GNRRRF2(MB,CY5VJ0<MG)XXZU!
MJ'C36+?5KRUTK3H[JWTQX89X1!,\UPS(C'RV4;$PKC[V<\\#J0#N?L%I]H^T
M?9H?//\`RT\L;O3KUJ00QQ(H1%4(,*`H&T>WI7&S^,+^'4;G2/LT!U0:M%9P
M+SM:W=/-\TC/41K)T/5?PJ'PQXSU?7M2L)6TZ,Z7J*.\3103!K4`%E,LC#8V
M[&/EZ$XR>M`'8_V;8R(`UG;,H8L`8E(R>_3K5B2%)4*2*KHPP589!_"O+_!>
MM:]/H&FZ1HJ6+36ME]KN);]I#N5YI51%V\@_NS\QSCC@]M"+QOKFLPVIT.RL
M(I)='CU9Q?.[``LZF,;<<DJ/F[<\'/`!WRVT2#"QHORA.$'W1T'T]J9+86L[
MJ\UO#*RC"L\:L0/;(KS^3QO(ANM9MM.0M+I6EW*1R3/S]HF9=AYVC;G[P7/K
MG`%6[WQ5X@TG3[F'48M*6_34(;1+E-XMU21`PD=,[N#E<`]<'@9H`[HQ*S*S
M*K,IRI(Z'VIJVL".[I%&KN=S,$`+'U)[]37/^%=9U+4M`GU#7!:0F.XG020*
M\<311L5$GSDG!P6SG&"*YZV\>:DAUTW']GWD5EI3:G;2VD4L:NH+C:=Y^8?*
M/F7@T`=\NGVB2M*MM"LCYW.(U#'/7)QWI%M+6&,P1V\"(PY18P`?PKC)?%VN
MZ797]SJEC82'[/;3V2VTC@$S2>6L<A.?NDKE@.03@=JUM`?5_P#A(M236XK1
M;E+6W"R6A;RY5+3<A6R5(Z$$G.,]Z`-;5]%M=;CLTNC)MM;J.[0(0,NAR`<C
MD>HJPUA:M;K;M;0F%3D1F,;1^'2N5M?$NL71U'5Q!9+X?L9;F*1#O-T_D[E9
MP?N_>4@+Z<Y[54M?%NOQ2Z6^J6FFFWUBUEGM?LKONMRD7FA9-WW\CC(V\]J`
M.Y%O$"I$:`ID*0H^7/7'I339VYD:0P1&1R"S;!DXZ9/M7`:?XN\5ZLUM!:VF
MCQW&H:8-5M3*\NV*+*C8^/O,2PY&`.>N.;+^--3U"UT9M&M;1'U+2WU$M>%B
M(@A3<N%Y8G?@=/7VH`[A[>*5'26-'1_O*R@@_7UIL=G;PHB1P1(B-N55C`"G
MU'H:X`_$'4K&PAU;4K&U%A?:1+J5G#;R,TJ>6JL4D8\'(<<@<$$<]:<_C;7M
M-TW5;K4=,AF%I!'<12P0S0Q$M(%,),HR6`.=P&,'I0!Z"\:2;=ZJVTY&1G!]
M?K49M+=KA;AH(C,HPLA0%A^/6N1&K^+)=6.BVZ:*;^UMTNKN5Q*(F61W5$09
MSG"'+'_ODYXK2^(;BUO_`!##:2V%K>+J<4$)NA-,)O\`1XW;$:G)(!Z+@8&3
MW)`.Z5$B+!%4%CN;`QD^OO3&M('D:1X8VD9=C,4&2OH3Z>U>7W7B.YU:U\-:
MU-"B22Z/JLDL"2.J.45!CJ&`)7/7(SUS6U#KGB`7?A:UT]=+:UU"WADEMV25
MIH(1'ND<ONQ@'"C=R2PZ\T`=PUO$X*M&C*5VD%0<CT^GM3$LK:.=IXX(DE8?
M-(L8#-]3U-<#8>)-5>2#3-(M;*.ZO;_4U62Z>5XX_(F`W$;MQW`G@$`$\8`Q
M4&K>/=>M].LVMK73H+Y]+>^DCN-\HFD4E3#$$(.[(X)Z[AC.#0!W(T"Q_MV?
M5W0R7$T,4)5P"JB,N5(&.#ESS]*T!"@=G"@.V-S`#)QTJ+3WN9--M9+Q46Z:
M)6F"*0H<CD`'D#/K5F@""&SM[<L8((HBYR_EH%W?7'6EBM(($V0PQQJ,\(@`
MYZ]*FHH`ACM((H_+BAC2,`C:J`#!ZC%,%A:"W-N+:$0$Y,0C7;GZ8Q5FB@!J
MJ%Z>F.E.HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KGAX*T,271^SR^3=&
M4RVWGOY):5=LC!,[06!.<#N3U-=`_P!TXKB-)^(7VC3=9U#5-$O=.M=,N6A:
M1]C@@.%QA6)W#.2`"/0F@#53P/HBV5[:O%<S)>VRVD[37,CNT2YVKN)R`,GI
MZFK^I>'M,U>WN8+ZV\Z.YC2.0%B.$)9""/NL"Q((YK*U+QH=)T:/5;SP[K,=
MMM=Y_DBW6Z*<;G'F=QS@9..U&L>.['1[VXMFL-1N?LHB>ZDMX0RV\<GW7;)!
MQUX`)X/&*`+8\':-]EN;=HIY!=212SO)<.SR/$P9"6)SP0/RQ21>#-#@U'[;
M';2*XN3=I&)W\I)CU=4SM!/.>.Y]:BD\71R:EJ%E8:5J-^;#<DTMNL>P2A0W
ME?,X.X@CG&.>M<UX3\;7C^'+*[U"RUB_U35"UQ#:1QP\H%4LT6&`6(;@`7.[
M)QW%`'5:;X-T72KN&YM89@UN)%MT>=W2$2'+A%)P`3_(5''X'T2'38=/B2Z2
MWMIQ<6P%U)NMV'`\MLY48)&!Q@FJ[>/=.>WLGL[+4+RXO&F2*TBA`E#Q,%D5
M@Q`4J3SDXXZ],I+\0-.BOFMA8:E(JW36(FC@#(]RI/[H<Y+$`G.-H'4B@#0@
M\/FUU2TN(]2O3;VT<W[B29G\QY&!+.S$Y``PH[9./2L/7?"6I:CK&IW5E=Q0
M"_MHH5G%Q+%+:LF[YE"<2?>)PQ'/'2MBU\5I?:'-J%II.HS7$$[6\VGJB">.
M13RIRP7H0<[N001UK%L_B$VHZYI-E9>']1DMK^&61ICY:F)HY5C<$;N0A)W$
M>V-V:`-R?PGI-_::G!>P-.NJ+&MX7<@R[%"J>/NG@'C'/-2W/AC3+F#3H]DT
M)TX8M9()FC>,;=I&X')!'!!ZUE:/XSLI)KRVNYIR8?MDPGDA5%,<$S(ZC:3D
MK@>Y'/J*2;XAZ?%:1W"Z;J4J"S2^N_+C0_8X'!(:7YO12=J[C@=*`-FU\.:?
M:745T@GDN(K5K02S3O(QC9@Y!+$Y.0.3S4EWH6G7^A/HMS`9+!X1"8RY!V@#
M'/7(P.?:HM6\16FE65M/Y4]W)=N([6WMD#23L5+`*"0.@)))``'-9A\>Z>++
MS6L=16[%V+%K$PCSEN#'YBIC.WE>C`[><YQ0!JVWAZPMKR*[`GDN8[5K02S3
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M`#NV$%4<YW8^4]^*`-FU\/V%I>PWJB>2YBMFM5EFF:1C&S!B"2>3D#D\U1L/
M!&@Z<P\JUD=%MWM4BFG>1$A<Y:-58D!3@<>P':H-&\=6>KW5M;-I]_927$MS
M#&+E$_UD!`D4[6.#DG'KM;TI+_Q@J>`KCQ5IVG7%U&MN\\,)VJ61<X<\\(0-
MWKCMGB@"Q;^"=$MH8(A'<R1V\D3PK-=2/Y?E$E%&XGY1N/'?OVK1L=$L=-TQ
MM-M8FCLSN`AWDA%;.57^ZO)P!P.U<C>>,M3CU'PU*FC:D$U&"Z,VFJD;3,4$
M94@[MH'+')8<'GGBM23Q[8?9+&:ST_4;Z2ZM/MI@@B7?##G!9]S`#G(QG)(.
M,XH`T9?"FE2Z;IEB(YHX]+V?8WBF9)(MJ[!A@<GY>#GKWJ";P7I%Q]G>3[89
MX8Y(1<_;)/->-R2R,^[++D\`].V*2#QC97NI6EEI]K>7IN8(;KS88P$C@ESM
MD8L1@<'CD^W!J&/QQ:K+JD5]IFHZ?)I]H;YUN43]Y`"PWKM8_P!T\'!H`EN_
M`V@7MS--+:R!+AHVN+=)W6&<Q_=+H#AN@ZCG`SG%7I/#>DS1:K#-:++%JK;K
MQ')(D.Q4Z=OE5>F.F>M<[?\`CZV.E:N?L^I:9<6MBU[$\]JK&6'./,1=V#SC
MY6*GD9`K0D\;V$6J_8S:WCVZ7*64M^L:^0EPV`(R=VXG+*,@$`G!(P:`-#2?
M#6FZ+,\]HL[3R1+"\T]P\KLBDE02Q/3)JI<^"-!N[Z:ZFM9#Y\Z7,\`G<0RR
MKT=HP=I/3MS@9SBIM,\3P:OJEU:VEC>-;VTCPM?;5\DRH<,@^;=D'(Y4`XX/
M2F:QXICT34;6WN=+U!K:XECA^VQJAA1Y&VJIRV[J1T4]:`-*QTJTTZ2\DMHR
MC7EP;F?+$[I"JJ3STX4<>U9H\':.9[B6=+FZ:>WEM6%S<R2@12',B*&/`/MZ
M`=`*K/XYLDUD:>NGZC(JWHL);M(088ICC:K'.><CD`@;AG%5KCQE%>ZA:6MC
M;WZ0R:@MLMZ81Y$Y5B)$5LD\;3R0`<'!-`%^/P1H*V5U:26TMQ'=0+;SFXN)
M)6>-22@RQ)&TG@C!%.?P9H\MO''(+J26*=;B.Y>ZD,R.JA00^<CY1C'0CKFJ
MFM>*[K2O%NE:+%H5W>1WT<CFXB9`%VE>@+#.,Y;V(QGG&=H7C:;^V+S3=1L[
MZ1&UF>QM[U(5\E,9*1DYR3@$9QCH"<T`;K^#M);[.T9O()H(&MQ-!=R)(T;'
M)#,#EN><GD$DBG-X2TR2]@NIGO9FMW$D22WDC(CB/RPX4G&[;GGU)/4DU5LO
M&]AJ&HPVL5K>I;W4DD-I?/&ODW,B!BRI\V[HC$$@`[>#TS4T7QM#=VNBVT=O
M?ZC>7UI%=,\<")LB=BOF.-VU0".0"3SQGF@#03P3HHAN(Y4NK@W`@$DEQ=22
M.1"V^,;B<X#<^^3G.:DU+P=HNK7\]Y=P3-)<1K'.J7#HDH7.W<H(!(W'&:CU
MSQA::)=M;?8KV]EB@^U7(M$4BWAR1O<LPX^4X`R3@X'%0WGCS2;.X6W*7$LL
MT,$]FD:C-XLK;1Y62,D$C.<8!!Z4`7Y_"VDW-_)?2V[&XDNH;MF\QAF6$8C.
M,]AVZ'O573O#2V?C'6O$$GE>;?+%#$(P?EC11DMZL3^BK4%SX]T^UU&2W:QU
M%K>"[%G<WJ0@PP2L0%#'.>2R\@'&X9QFI(/'&GW&K16@M+U;:>Y>S@OVC7R)
M9UW913NW'[C<[=ORGF@"?4_!NB:O>SW=W;R&2YB$-R(YWC6=!G`<*0&QDX)J
M2[\*:;=WTM[OO+>>:-(YFM;N2+S0GW=P4C)&<9ZXXZ5C_P#";P:E;6%U:0W]
MM9W%_;VT=R]NA2X+L595RV0`1@MCZ9JY;^.-/N-4AM%M;T6L]RUG!J#(OD2S
MKNRBG=N/W&YV[?E/-`&I+X>TR;Q#!KSVP.I00F!)@Q'R$YP1T/4X],GUJ#3_
M``MIVEW:3V;7<2)))(EN+J0PJSYW83.W&23C&`>F*SM-\?Z;J5U"@M+ZWM9X
M9)H;Z>,+"XC`\P9SD;<]2`#@X)I8?'=H^FRZC/I6K6MGMC:VDFMQ_I6]@J",
M!B=Q)&%8`\T`/;P!X?\`(ABB@N(!%;O:[X+J2-VA9BQ1F!RPR21GIDXJG=>`
M;&]UT2O^YTE=*33TM;65X3A78D':1E"K8P:V]#\10:V;J+[+<V5Y:.J7%I=!
M1)&67<I.TE2"#G@UBVGC6"'2+&9XK_4;F^GNH;>*&W19)&BD8%=N[:``IY)Z
M+DX)Q0!K7'A#1+GS`]GM62*WA*1NRJ$@??$H`/`#>GTJKXF\-G4UMYK,0_:$
MOHKJ59I'19=B,F-R\J<-D$>F#P33YO%:-X'E\2V.GW4X6W:9;5E"2`J2"&R<
M#!!SST!QFN:_X3S4S?:#<G1-3,-]IL\\FGPI&\A93$1(#NP$P[8R03QQG%`'
M3Z%H,UGI-[8ZI<M=QW<TK&%Y'E6*)^/*5G^9E`SU]3C`Q38/`^B6]K<V_E7$
MB7%E_9[F:YD<BWQ@1@D\`9.,>M5[KQ[IT%O;S6]EJ%ZLEDFH2B")<V]NP)#R
M;F&.A^49/!P.*?XPU^2Q\!7FN:1<('$"36\S)N7:S+AMIZ\-F@#3O?#FE:C:
M36EY:B:"6V6U=&8\QJ<@>Q!Y!ZYHTKP]8:/+--:B=IIU1999YWE=PN=N2Q/3
M<:Q?".NW6HZAJEE/?0:C#8>4HOHX/(,CL"64IDYQQ\PX.<=0:T-0\50V>K?V
M;;Z;J&H7$:))<?8XU86Z.2%+98==I.!DX&<4`/B\(Z/#J$UW'!(OG2M/)`)F
M\AI&4JSF/.W)!.>.<YZU!8>!]"TZ:.2&WF8PP/;VZRW#R""-_O+&&)VYZ<<X
MXZ5'8^-M/U#5(+2.UO4M[J5X;2^=%$%RZ;BRH0=W1&()`!QP>F<7PMXCU34=
M5T6"ZNO,CN;?4FE&Q1N,-TL<9XZ$*<>]`'5V/AO2].FM);6!D>TL1I\),C';
M`"#MY/)^4<GFHK7PGH]E'9)!;,JV5F]C!F5CMA?;N7KS]Q>3SQ5'5/'FG:3J
M-U:36E_(MF\:7<\,(9(#(%,>><DL6``4$YZX'-6K'Q3'?P:EY>F:@E[IY`DL
M9$03,&&4*C=MPPS@DCH0<8-`$O\`PBFC&WT^W:TWPZ?:/9VZ.[$"%U5&4\_-
ME5`R:KCP7I)TV73Y7OI[22%(/*FO97"HK!E`RW!!`YZ]JR+SQG+>V6G3V,-S
M8S#7H=-O+>Z1=Z[OO*=I(Z,IR#4*?$2TLM(-PUMJ6J2Q)<W-QY$$:-#!'-(F
M]@7`P"C`8))VY(%`'3:GX6TK5K\7UQ',ESY)MWD@G>(R1$Y*/M(W+GL>F3CK
M45SX/T>YO'O#'/%=-<_:O/AN'1UD\H1$@@\`HH!'3BL_4/B!9:<F6TK5)G2T
MBO;A(858V\+@_,_S8XVD$*2>#C.*OZOXJCT;4+2"XTS4'M;F6*$7T:H84>1M
MJJ<L&ZD=%/6@`'@S0EM+2U2T*P6D$]O"@E;Y8YN)!UYSZGD5'_P@^BC5;34H
MQ>Q7%K#%;Q^5>RHOEQ_=5E#88>QSGO44GCFQ361IRV&HR*MZ+"6[2$&&&8XV
MJQSGG*\@$#<,XIK^.K;9?7$&D:K<6%FLQ:^BB4Q.8L[U7YLG&U@#C!(P#F@#
M1M?"^DV5Y!>06[+-;R7,L9\QCAIVW2\9[D?AVK`U?P=<2:C]HTPPI%_9[6:!
M[J:%X6WLP<-'RW+=">,#'4UT5KXAL[W6!IUL))'^Q)>F4`;`CDA!G.<MAB,#
M^$^U5O\`A*43Q1#H=QI>H6[7)<6UU(J>3,47<P7#%AQGJ!TH`U=-MI;/3+6U
MGN9+J6&%8WN)!\TI``+'W/7\:M5R,7Q!L;BR6[@TS4Y8IY%AL]L2YO)"&)6,
M%L_+L;);`XSDCFKL'BN.]T-]1L=*U"ZFBG:VFL8U0312*<,K;F"\>H8CTH`Z
M&BL[0M:MO$&BVNJ6BRK#<IN595PR\D$'W!!JCXPU*\T;P_)J5G@_99(I;@;-
MQ-N''FX'KLW'/;%`&_17"KXU:/QWJ%A/Y7]BQ6;-#<*P;,T2+)+TYP$E3KZ<
M=:;8^/6LM"M9=5M;J\NQ9KJ&H2642F*RADW,I<EAG"@\#+$+G'-`'>45SGB_
M5Y[#PK_:&FS;9#<6H1]H(*R3QJ>#ZJQ_.H%\=Z?]N2+[#J/V%[K[$FI>2#;M
M/OV;`0=V-WR[MNW/&:`.JHKE(/'>GW%];Q?8M0CL;FY^RVVHO"/(FER5"J0=
MP!((#%0#Z]*@\%>*)-8M(K6<R7=\DMR+B:-5"0*DSK&'/]XJHP!DX&3@4`=E
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`C?=.*XNY\#W%QIGB#2_[446>JW372!K;+PN
MSJ[?-NPP^7C@=?:NT)P,FN;T;QE9ZWJ.J1VWV<6.GLR-=&Z3+,I^8[.R#LQ.
M#0!G^*_`S^)KV[D;4%CANK(6ACFMO-,'S$EXOF`5CG!.#T'I6B_A@O>Z[<F[
M(_M:UAM]HC_U7EJZ[NO.=_3CI6Y%>V\\"3PS120OC9(C@JW;@C@\TQ-4L9;8
MW,=Y;/;CK*LRE!^.<4`8$GA>YG\60ZR]Y;1I#)(X2WM/+EF5DV!)7W?.H^]R
M.N/2JUEX*N=+MO#YT_50EYH]H]GYDMMNCGB;;D%0P*G**00W;'.:ZF?4;.U$
MAN+J"'RU#/YDJKM!.`3GH"012/J=G';"Z>ZMUMRF\3&50A7U!SC'(Y]Z`.;T
MGP5_9=YI-TVH//-9&\DF9H@OGRW+!G88.%`(.!SUZTL?@ORY(G^WG]WKLFL?
MZGKN5AY?7_:^][=*W;W6;:T:.,212SO)$OE+*-P61P@?'7&6IE_XBTC2[^UL
M;_4+>VN;K/DQRN%+X&3].G?J>*`.?N_`\DSW$D>HJ?.U<ZFT,T!>%P8UC\MU
M##<!M#`^N..*32O!%QHTFBRV>J)YFGK<Q2>9:?++'/*)6``8;"",#J,=JZS[
M?;"\%F;B$717>(/,&\KZ[>N*D:>-6*LRA@I8@L,X]?I[T`<1J/PWCO\`219_
MVD\4OV^ZN6F6+[T-PY:6`C/0@@;@<Y4&KNJ^#1>:Y<:I:-8*US:+;RQ7U@+E
M0R$['7Y@00&((Z'CTKIQ>VS>3B>(^<N^+#C]XH&25]1@CD>M-@U&SNK8W%M<
MP30`D&2*5648Z\CB@#*UK0)=433);>[%K>Z;<"X@E$(:,G:4963(X*LPX(QD
M<\5FP^"I/M,5Y<ZD9KTZNNJSNL`5'*Q&)8U7/R@*5Y))./>MB3Q)9KKUAI41
M6=KM;C][%(K+$T.S<K>A^?\`2K-OJ]O<7,T:E/)C6-DN/.0I+O!(VX.>W<#.
M>,\T`8MYX5N&U*SU.QU$07EK=3S*9(-\;QS`;XV7(/\`"N&!'2H)_">K?:KN
MZM-?6*XU"Q2UO7DL@X9DR%D0!AM.&88.1R/2ND&K:>;$WPO;8V@ZW'G+Y8YQ
M][..O%/AU&TN;8W,%U!+;C.94E5D&/<<4`<?<?#I,1_8=3DMFM;6QALW:(2&
M)K5G*,W(#@[\$<=.M4?$/A*_S)J%Q--J%Q>ZE;270M;;Y88(E<(%CW9;#,"3
MNSW[8KT(W4"O(AEC#1KO=2XRJ\\GT'!Y]C63<>*]*L%EDU"YBLX!<1V\4TDJ
M%9F<*5*[22!\P^]CUZ<T`<7?Z%K>H>!&L(;/['>_VIBPEMX!&R0NVUY94)."
M4>7/.3D'@DX[B^T*WO/"USX?C9K>VELFLU91DHA39D9ZD"HK/Q5I]YK-]IOF
MQQR6[Q+&[3+BX\R,."G//![5;UK6K?0M'N=3NUD,%NH+",98Y(`Q^)%`&7:^
M'+Q=0T.^O=1CGFTJ&>'$5N8UE$@0#C<<8V>^<]JHW'@7-Y97D,]I)/;VSVLB
MWMD)XY4+%U.-PVLK$\@\@G/;'5/J-FEZMD]W`MVXRL!E4.P]0N<D<&C^T;/[
M4EK]I@^T."5B\U=Y`R"0N<GH?RH`PK?PL\=U>7#7NQ[O2H=./V:'RA&8_,^=
M!GY?]9PO;`Y-<[/X!NM-\.ZY)%-%>7D^@OIT<5O:^49F"L0[98EI&+')SZ5W
MZZE9O+/&MU;M);\SJ)5)B'JPS\OXTPZMIXL1?&^M19G@7'GKY?7'WLXZ\4`<
M?)X$O-6T^\.J:KFYNM)&F0A+8(MNAPS$C<=S9"]P...M7(O!9M-;NKVU?3FB
MN;U+QEN=/$LL;9!?9)N&-Q&1D':3QZ5TUQJ5G:1"6YN[>&,X(:655!STY/K1
MJ6IV6D:;-J&H7,=O:0(7DE<\`#^9]AR:`,&S\,7$/BL:W)=P*`)E,5I:^29]
M[`J9CN(<H!@'`ZD]\52U/P))J6O3:B^H)Y<EY;7:K);;Y8?)(/EH^[Y48KD@
M#J3ZUTT>N:7):072ZC9_9[AML4AG7;(?0'/)]JN23QPQ/+*RQQHI9W<@!0.I
M)/04`8%KX9-M_:/^EEOMNJIJ7^K^YM\OY.O/^KZ^_3BJ5AX/OM/DBMH]:+:5
M;W[7L5L;8;_F8N4:3/*AF8C@'H#D"N@75H9;FSCM]MQ%=*[+/%*A0;<>^6SG
M^$'&.<<4Z'6=-N)V@@U"TEE0X9(YU9EY`Y`/')`H`S=8T*YU#6=(U6SO5MI]
M/\U-LD'F+(D@4,/O`@_*,'Z\5%9>&#9QW"?:R_G:NVIY\O&-S9V=?U_2M2;6
M;9=+N;ZT:.]2`-E8)DY(_AW%@H/U(K$'CFWFUC4K.SMH[J+3D`FD2\B5VD.S
MY51B,J`XRQ(&05ZT`1:)X).@W,8MI-/:UAGEDC+:>/M"(^[""7=V+?>QDC@^
MM2>&O!G_``CUQ92_;C/]FTF+3,>5MW;'9M_4XSNQCVZUTAO[47GV/[3!]J*[
MQ!Y@\S;Z[>N/>F0ZI8W(E,%[;2B$XE\N96\O_>P>.G>@#G]9\(_VCKIU:![(
M326GV66.]LA<(P!)1@,C:06;V(//05'J'@V>_P!1MM1.J>5>6$42Z>8H-L=L
MRY\UMF[#"0?+CL`/K6Y>^(]'TZQN[VZU*UCMK0E9W$H;RV'\)`R=WMUJO#XI
ML)]=.FQR1LAM$NDNEE4QN&D:,*#GKN7]:`.8MO"FJZE>Z[%=W36>E3ZZ+PP?
M9P9+A46)E*OGY5+H,\9^4],UIZ9X-?2=1,MO)I[6WVU[M/-T\-<(KDLR"7=_
M>8D,1D#BNK%Q$9FA$B>:JAF3<,@'(!QZ'!_*HEU"T>XFMUN8&FA4-+&)5+1C
MU8=1^-`'-6W@O[/X<T/2/MY;^R[Z.\\WRL>;M=GVXSQG=C/M2:7X+.D:CYEL
M^G-;"\>Z3S=/#7$:N22@EW?WF)#$9`XKIQ?VIV;;B$[T\U,2#YDX^8>HY'/O
M38]3L989IH[NW>*`D3.LJE8R.H8YX(]Z`.?L/!<=KX=T_1IKQYH;6.>-W5-A
MD64,#CDX(#^_2JDG@O4+SPR-#U#6DGAMXXEM)!9*"CQ.&1Y%)(?&U01P"`?7
MCJX]2LIK87,5W;O;G.)DE4IQG/.<<8/Y&C^TK+[%]M%W;FTQGS_-7R\9QG=G
M%`%#0])FTK[3YHTX><RL%LK+R`,#!W?,=QS^72LO3?!G]G2:&_VXR?V7<WDX
M'DX\SSRYQUXV[_?..U;MKJ\,]M=W$NV"&VF>)Y)'`7"_Q$]`*S)/'&C&STN^
MM+F*[LM0NEMA/'(`(B8W?+YZ<)R#@C-`%Y=$0^'KK29)V*W"SHT@7!`E+$X'
MJ-WZ5E:/X6N]/O='N[O4DN9-,L)+%1';F,.C&+!/S'D>7^.[MBN@;4[);$7K
M7=NMH1GSS,HCQG&=V<5.LR.BNC!D8;E8$$$>N:`..N/`A^U6UU!/9/-'IZV,
MHOK$3HX7)1P-P*D%FXS@@\]*U==\/R:WX0FT/[2EN\L*()T@^52I4Y"9X&5Z
M9XJ];ZS;W>H-;6[1S1B#SO.CD#*?F*E>.X(]:GAU2QN8DE@O+>6.1_+1XYE8
M,W]T$'D^U`'/Z;X2<:K>:GK]U;ZK=W,,=O@68BB"(S,/D+-ELN>2?3%23>&K
MV'Q!<ZGI&II9+>0107$3VHD`\LG8T?(VD*S#!R.0<<5NS:E9VZ3-/=01+!CS
M2\JJ(\]-V3QGMFJ;Z]`OB&RTE8RYO+26[CF5@5VHR#'X^8"#[4`8FA>#&T&[
MA^S/I[6D-Q)+'OT\&X1'W8C$N[L6^\1DC@^M2:'X._L:^T^Z^W&;[%%>Q[?*
MV[_M$XESUXVXQ[]>*Z.+4;2?SO)N8)?()6;9*K>61U#8/'XT1ZC9RO.L5U`[
M0<3!95/EGT;GC\:`.;U+P9_:$FN/]O,?]J7%G/CRL^5Y!0XZ\[MG7C&>])K'
M@Q]4NM9N(]1:!M2^R#;Y1*J("QVMAAN5]V"..,UT9U2P"%S>VP59?(),RX$G
M]SK][VZT^6^M8+B*WFN8(YYL^5$\@#/C^Z#R:`.3M?`?D6RQ&]C4_P!MIK!$
M-ML0%0H\M5SP/E'//>N;U+PC=Z9=1VZPSZA`EA<B!ULO.C:66=Y3&Z;Q@89!
MR<,!SC%>GG4;07*6S74`GD)V1&5=S8ZX&<G%5=+\1:1K37"Z9J%O=-;R-'*(
MG!*L#@\>GOT-`&1:^&[NX:\O[Z6."\U'2(;&>"!,I`ZB3<5.>1F0@#VJE?\`
M@)[_`%M[U]1C,;W=K=*)+;?)%Y.W]VCEOE1BN2`.I/K77F_M1=BT-Q#]J*[Q
M!Y@\PKZ[>N/>L70?%UMXAU;4K:R2%[6R<Q"X%RK-(X.&P@Y"^C$\T`%IX:^R
MC43]J+?;=534>(\;-OE_)UY_U?7W]J9H?AR]T-S:QZHLNCB>:9+9[8>8!(2Q
M1GSRH9F;H#R`3@<VM,\5Z=JVOZKHMN)A>:8RK,'3"MD=5/<#.#Z<>HJA;_$+
M1+@ZQC[2%TR9(&/E9^T,Y*J(@,ER75E'N*`*OP[\/W&BZ7>3W:3+-=7+>2DP
MP\5M'\D$;8XR$`Z>M-TOP(^G^(+35)=12X:TN+F=7-MB:43`C;)(6.0H.!@#
M@"M:#Q4[6MY/>Z%JNGBVMWN3]HC3#HHSPRL0&/\`=)!X-0:3XWL]0-HEY8WN
ME27L)FM1>JH69<;OE=6*YV\[<YQVH`I?\($H\+Z/I(NXI)]*N//AGGM@\;DE
MMRM&3@@JY'7(X(IUSX-N;BVL5^U:?&;6ZDG^S1V!6UE#+@*\8?YBIP0Q/4=*
MN:?XWLKZ]BB>SO+6VNHVFL;N=%$=VBC)*8)8?+\P#`$CD5<T?Q1I^MZ7=:C;
MK/';6TLD4AGB*-E,;CMZ_IGVH`B\.:!/X=TK2],@O5DM;1)%E#P8:4LV5((/
MRXR>,'/M6MJ%E#J5A<V-P@>"YA:&12,@JPP1^1JGH/B"U\1::;^SCG2'S9(L
M3IL?*,5.5/(Y'?FKG]HV?VX61NK<79&[R/-7S,>NW.:`.+/PX,GABTTJ?5Y9
M[N&Z:>6_>+#S!U*.I`88S&=N<G&!Z5>U7P;]LURXU2T:P5KFT6VEBOK`7"97
M.QU^88P&(*]#QZ5TPU&S:Y%J+J`W!4N(1*-Y4'&<=<9!_*H)=8MTO[>SC>.6
M62;RI%20%H3Y;.-P[9"?K0!5UW1&UK0AIOGB$B6WD\Q8LC,<B/@+G@'9CVS6
M+'X(NHQ!8G6"VCP:G_:4=N+<>;N\SS1&9,XVB0EONYQQFNUHH`XBT\"W-L-,
ML7U@RZ1IU\;VW@^S`2D@ED1I,\JK$GA03P#5GPQX*_X1B]:XM;]F6X:5KR(Q
MX29FD9T<#/RNH;83SN`'3`KKJ*`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!",C!KRE
MO"-Q::;=21^'8Y(E\2O<SVD<<8:YL@3M`'1E#%6"DC[M>KT4`>5W'AN_N-#\
M3BQT22RL[_4;-K6P&V-C'&\0E?8#A`P5CCJ1U%6O%'@JXNM;73=*L5AT/6((
MXM0:`B);?R&+J<#^_N*X&/7.:]*HH`\KMM-U_P#LG[=J.CB>[U&[A@OQ);+.
M\4$,6U76-FP<N&/4X$F<9S3M%\)WIL_!UIJ6D;K6VNK^2[@E1"D:N9&BW*#M
MZE<`9`./2O2H[ZVDOI;)9D-U%&LCQ`_,JL2%)]CM/Y58[4`>8VF@7$6I/'<^
M&9I=237?M:ZHA0+]G,H*_/D,0J$+Y>.-N>PK9\7:.+CQ'X<U5]#_`+2AM)9D
MN0D*2.%:,A.&QE0W/L>:ZVUO;>\>X6WF21K>4PS!3G8X`)4^^"/SJQ0!Y/=>
M'+Z87EDWAUWUN77!=1:QA-JP><)`WF_>&(QY>WU]JZ+QYI&K73V-_H<+27FV
M73Y=KA"D$Z[3)D_W&5&X&>/3-===7UM9>2;F9(A-*L,>XXW.W11[FIE?=TP1
M[&@#R)_!FM?V1JEFEG)*NE0"QTU&?;]IMC<"61022,F)5CSQGD=,5?GT*[NO
M^$LNM'T"72[6YT(VD%OY:PM/<X=@P13@8W!=QQR...:]0HH`\P\3>#]0E'AV
M+0M.BB6WM;@W42XBCF8K#F*1AS^\"LI8<\<G&:;J?A^_U*_U*6'1I8K.[FT8
MK`R*N(HY&\U"`>BJ<$>AXS7H]SJ-M:75I;3RK'+=R&.!6S^\8*6('OA2?PJU
M0!YAX@T&'3KVTL=/TR!8;G7O/BM3$K0R#[)\_P"[)52,J>I7!Y&3C.OX/TK2
M[WP#>:'!%(MNTMW:7:R0K$1(SMO&$)&!NP,,>`.>*ZV^TVRU&$1WUI#<QJP=
M4EC#`,.A&>A]ZS8]:T72[Q-$B>.WECDBA2WBA(56D#L@&!CD1N?PYZT`>;IX
M8\674:W%];3+<ZE&-$O5$F[R[9`BB;Y2`N2LK<9_U@[9K4UKPM=31Z\_]ABY
MB77+&ZMX1&C%X(T@$FP'CHC+CC.,5ZB.E%`'F<OA)=2OO$E])H`1I38/IIDB
M59(Q&B'"X/R[6&"!Z8Y%;WQ"M[V_\+S:5I^G7-W<7SI&IB"[(L.K%G)(P.#R
M,UUU%`'F6M:5K.J^-+:=]%5/L>L6\D5Q%;1_/;+@EVF)W9R2-@QP._-6M/\`
M"C_;)]0N=*Q?IXEDN89RH\SR"2`=V<[-K'CWSC->AT4`>36_AZ46>JZ6-&U1
M=*F@#M=M;1+?^:;@,(]V<3(!ECNSP,<YQ0^AZM=#1[B]T-8["VENX/LT%A$Q
M`8KY=PT!)4$A6!QR-P]:]9HH`\RT[P;'<WNG6UYI=U<Z5%H4T"C4D0NLIF&`
M0"0&VEL$=!TQ71:KHDVH?"R?1OLBRW;:3Y,<,N#B4187D\`AL<]CS75T4`>6
M1Z4L=ZMW=^"I[K3FTE;>WL_LT1:"=68R`IG"^9N7YQ_=YK9/AZXC^%^F:+JJ
M7LMS!%;+-]BVS.'5E/(;AU!'S`YR`>#7=44`>6M8:H;?1[Z\T9;&&RL=5646
MZ"W$:,%$;$(3L9PI/RYP<USD>AE](DMH=.9-=O=!@6W2VM8XEEC29&=BRN27
M^89SMR!TST]T90RE6`*D8((X-4;#1=,TK=_9]A:VF\`-Y$2ID#H..PR?SH`X
MW7_"?D^'_&=IHFE)&NH648AAMU"K)($93@=`<!?2L_5O"$YTSQQ]CT2,7%[=
MPFT,42*TD>R`N%/IN5B1Z@FO4`,#%+0!Y]I>G75AJ.JF3PO]HUDW]U<VVI.J
M;&1@S19DSN&!MC*]OIS6!:>']:GMO$5VFBO:3WOAUK<11VL=L#='>Q154\XW
M`!B>?6O8**`/,]<\#J_A[6+;3-$A$UUH<<0144![A"^.O\8W'YNO/6I9O#(U
MW4KU!I,NF:7<Z"MM&'C2+R9EG=Q\JD@$'#^E>CTCHLB,CJ&5A@@C((H`X?X>
M&YU:PO?$][$([S5I%"C.=D42B-<'T+!VXQG=TK$\(>&IM-OM,;4=.U`:A9"X
M2>2*UB$5R2I!9Y`=T@?J`><D9QBO3[>WBM8(X((TBAB4)'&BA511P``.@%2T
M`>*RZ'J.A^"/$\M_82P&?1VDLG,Q<6$.XD6F2<@J6W9'7I_"*UFTO48+O5]0
MT/PF+.SDL[:S:SF@C/GMYA,DHB#;7*HW&3\Q'<5Z?<VL%Y;R6]S#'-!(I5XY
M%#*P/8@]14@&!B@#RBT\*Z@=&-JVE2?9IO%,5T86B2,&UVH&9HU.`IPV5_,<
MU=U#PP^GW-J8-!-WHEOK$UQ-IT2*P99(0JR+&QP0KECCMS@5Z710!S/A?25@
M\/7=E<:3]EMY;F<I97!60"-F)`/)&".V2`..U<=I?A>63PAX2TB?PVT36.J0
MMJ4<D*!9-L4@,AP?G7.WD]>*]7HH`\PU3PI<6[:<MOIC-I-MJ=X[VD5O',%$
MO*2B-OE*@[A@<C?P.*TYM!O6^$]WH^DQWJW#Q2B.*\VQ2,#*69/EX52N54=E
M('%=Y10!Y;?^'[C4=+UPZ)X:GTA;FPMP('$<?GLDI9XPBL54E!MR<!MPSQ4T
M'A0W>CZV-/M;ZTO7^S7-LMQ:1V\2SPDNFQ$XSD`,2/3J!7IE%`'DLOAO5KI-
M-UJ_TR5FN]0N;K4++R$N'AWJ$A)1^&$:)MXR1O)`ZU:C\,:F+>R@TF&^A"Z+
MJEO%->!8WBFEE0Q@A<A1P=N.B@?2O4**`/(Y='=8%O+'PW)H<%CH%W%?,Z)'
MYKM&`J?*3YFTHS;CQ\P[U!9Z%=W^C276CZ!+99\*S6LDN$1KVXD13&1M/SD;
M6.X_W_K7L$L4<\+PRHLD;J5=&&0P/!!'<4111P0I#$BQQHH5$48"@<``=A0!
MYG-X'B>37$_X1^W,+Z!#':KY2X-UB7?C_;SY>6Z\#FL^;PQJ-Q=7+ZU9:G++
M=6]E)'<VEM%+-&R1HKH)&.8V#JS''!W'G->OT4`>>V_A,S:CJFH7>E!KQ?$4
M5S:3L!O$`\K)4YR%_P!9Q]>*N^"='&BZEKUL^B?8VDU":>*Y2%`DD#$%%5AS
MQ_=QQS7:T4`>3W/AR_E6\L6\.N^MS:Y]ICUC";5@\X2!O-^\,1CR]OK[5U7@
M?P^NC#7';2X;.2?5+AHF6)5+0%@4P1_#Z"NNHH`\KOM!\26-_JFMZ-8%M0&L
M7"1*SA?,MIX8DW@\\+(BMR/X6XYI9O!VJZ=JTLNF6DEQ%I;Z9-;+*X!NQ$DR
M2C<3]_$F[)XSBO4Z*`/,X[77-1U'7Y(;?Q`FGW6D3J+;595P+ES\JQ*&.`%R
M/09%.M;76/$.G^'-,?0;W3H])599[B^**&D6!HU1%5F+`EB2>,`>]>E44`><
M:/8ZM):>$K6YTB[MO^$;A9[IGVGSI$A:%4BP<-NW,V>,``=^+G@NZO[6#7VN
M_#VK6Q>^N-0B66.,&5'.0BX<_/QT.![UW=%`'%_#Y[Y;#4+:^T;4+!S?W%TK
M72J`ZRS.Z@;6/(!&?ZUBWFEZSJ7CFRNYM%6%K/6=XN(K:,![41LJN9L[F8E@
M"O;'3BO3J*`//-$\)M;RVVH3Z4J:E'KUW-]H('F"!S,%)/\`=VLN!].*K>$M
M"N+.X\/I<>&IK;4[%YEU#4LH%F+)("^0<R;FP<D?+GMFO3**`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`$/2O*6O-6N-46<:[J$7G^)9M'\J.0>6EN!(
M_"D'Y\J/FZ@<"O5^M,\F/^XOWMW0=?7ZT`>9'6GM=%O=$O=0U&0IKKZ;:WGV
MT02!1&LH\R<],`E<XR<`=364OB+7(_!^A75AJ=U<ZG(+Z-XCF??:I(RF<]-S
M1@(5;JV<?Q5[`UM"ZLKQ(RL<LI4$$^IIWDQ@@A%!`P.!P/2@#RW6-:O;+^T%
MTS6KB:"+3-(-M<F3?N\VY9&EYX+,N,GO46H3ZII5AXDNHM>U23_A';^!+6.6
M<,)598G993C,@/F,.3P,8Z5ZJ+>$#'EIC`&-HZ#I3O)C(8%%(;[P('/UH`\@
M\1:SF/5K>Z\2W>F7CZ_+:6,HOS!'$GE0LQ<]U0;B!_>8#^*K.IZCJ<NO:A';
M^(DLOL`MFTY[K4A'#+"R(3*Z[3YVYMZY)Z@8QU/J;VEO)_K((WYS\R`\T/:6
MTA4R01.5X7<@./I0!S7C>XN8+71H[>ZGMOM.L6UO(T3[6*.2",UPN@PM:^!&
MM[#Q*T%TVJRQW<-YJ9C<(LTW[N-R"8I'`W9Q\V#ZYKV(QHV-P#8.1D9P:C:S
MMI-V^WB;<<MN0')]3ZT`<>U[=ZO\,(=2\/S:C]I2%;FV\^3,TWEMG8Q'#;PI
M7/.0V>:Q_P#A*%U'0[W6WO-0&GZUJ4=CIAAN?LXCC4$;RY_U89UDR<9^ZN*]
M,6-54`#``P!33;0F(Q&)#$?X"HV_E0!Y9HUY<WJ>#VNKJ6Y:+7[^&.667S6,
M:Q7`3Y\#?\H'S=^M3:)XKN[OPEI`L=1:_P!;CT2YGE@+[V>=57:)/]K=Q@D'
MFO3A#&`N$4;?NX`X[<4+!$F=B*N26.T`9)[_`%H`\Z\&ZH\4S7]UXGM[C39=
M.^TS"YU(3R+)N7,@&U1$@R05Z`XX&*[=-'L/MWV];=?M/F&;S"2?G*!-W7'W
M1CZ9]35L65JI<K;Q`O\`?P@^;Z^M3`8H`4=****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHR!WH`****`"BBB@`HI,CUI<T`%%
M)D>M&1ZT`+11D49!Z4`%%&110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`A.!FO.]6\?W]C\1;?2H[2`Z"EQ#87=TP.]
M+F969`.V,;<\'KU&:]$.<<5Y/=_!IM0TW4IKK6;G^W+VZ>[\R.1EMDD+97,?
M\6``,T`7(OBE::3XK\1V.O23):V5Y'#"\%HSI!&5'S2,HXRQ[_@*Z/6OB%H6
MA7\EI=F[=H`C7<D%NTD=J'^Z96'"YKF-0^'?B2\3Q%!'K&F1VVORQO=!K9G>
M/:J@E#G&3@]1QVP:NZQX"UJYU?Q#)I>KVL%CXABBBODGMRTL85-A,9!`Y7/W
MAU-`&Y=^/]#LK+6KR9Y_)T:6.*[*Q$X+XV[?[P^856\/?$"U\0^+M8\/1Z;>
MVTNG8_>S1D!^F<\?*<GC)^8<BN>USX8:K=VVN:=I&JV=MIFL"!Y4N(&>57B"
MC`8'&TA1V-=/I'AJ_P!*\;:[K`NK>2QU986>$QL)(Y(T"#!S@J1D],]*`,Q_
M&U]:?$V30;N"W&CR21VL%P`P=9VA$@5CG&&Y`[\5B0_%F<:[JTES8Q?V!;6,
M]W:O%DS2B*80ELYVX9B<>F.M;/B?X>W6O+KTD&HK;75[<VMS93`,#;/"@0DD
M>HW=/6J__"JH7>WMY+E!IZ>'CH[HBD/O+A_-!Z?>&<'OUH`M>']=\77FM6BZ
MNWAJ"WND#G3X;IC>0*5W+G/#'IG&.I]*Q+/XA>*HM+O_`!!>Z?I=QH5KJ3VD
M@@:2.XBC5]A<@Y5@,@]16GI_@+6_^$KT/5]7U'2[C^Q_,"3V]D8KBY#)L7S#
MG'`QTJG#\--;ELI=#OM8L_\`A'I]1DOKB*WA83SAGWB,L3@+G&<"@!K_`!'U
MC^TY=16RL)/#,.L?V.P5F^TF3(`E!^[M)(XZXK?M?%&LM\4&\.W=A;6]@=/D
MNH6#EY9-LH0,3T4'DA>3TY[5D'X::C]NFLUU.U'A^;61J[0^01<*XY\L-G;M
MR!VS@5IR^&?$LGQ'C\3+>:2+>.W-D(##)O-N9-Y.=V/,[9Z>U`$FE^)]9N_B
M5?>'[^PMK6TBL/M<`5R\K#S2@9CT&0,[0.,CG-=K7#1>&?$B?$>3Q,UYI)MY
M+<630"&3?Y`D+@YW8\SWZ>U=S0`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%&:1ONG_``KQ[3==7PAXA\0ZK=2N]IJ-_?0^6[<?:83NB12>`74LOU5:
M`/80P)(!!P<'!Z4BR(X8JZL%.#@YP:\4@CNO#UOX@L[JYEA6XU+31JURLIS&
M)T4SL&_A!8[<X'![5TT-OI^B^([O2K?PK;Z89-.NI+:\M[D'ST38&+H`/F.Y
M>6R>#S0!Z+')'*NZ-U=<XRIS0)$+L@=2R]5!Y%>3Z186>A^'?`-[HR1V>I7_
M`-EBN([?`^U1-%F8LG1B`-Q;&1@<]J;H,-NFF^!-:M-HUO5I\7US&<R74;12
M-*9#_%M8*>?ND#&*`/6\C)&1QUHR/7IUKBO`MHELGBBSCFFV)K,J"1Y2\F##
M%SN.3G))IWP[A2UL-;MD=VC@UJZC0R2%V(!`&23DGW-`':4V1UCC9V8*JC))
MZ`5A>*=1:SL8(+:^EM+Z\F$5L8K7[0[MC<0%.!]T$Y)P`#6?X;U6\UKX>-?:
M@RO=&.ZC=A&$W;'=`2HR`2%&0.^:`.LCD66-71E96&593D$=C3Z\Z^'IUNST
MK0H;S4+>YTZYT-)[>);?8]N4$8"[LG<-K\D]QZ5<T3Q-J%_X:\/W<\\1NKW2
MYKN8!`-S*JD$#L,F@#N:*\RTK6?%NLR65LFL65O)J>CKJR2_80WV;E1Y8&[Y
M@=PRQ]#CKQ4U7QYJ4WAJPUC3+LPW$5E;W5[9+9"2(>:P`WR$@J#\V`N3P:`/
M6*0,K$@,"5."`>E<#JVM>(3K>MC3[ZV@M=%GMLP26^\W"2*A<%LY7`+8QW//
M%4-8U;5;>;Q-_9-[#97\>JQVUK''9QNU[(]M&51B<<YR2W4*OM0!Z=4<TJ0H
M9)'5$499F.`!ZD]J\ZU#7/%HU:\T[3,W%SI%O;F2..T0K?RNFXEF9AY:$C`V
MCCGGC%.\0:IJ^HGQ1%;7]C;6.D!;>6UFCR;C?$KEB^<K]_"@#D@YSG@`]'J,
MSPB,2&6,1GHQ88/XURGCBXV2:#9W$KPZ=?:FD%XZDC*[&*(6'16<(I]0<5D>
M*O#F@6S>'=-M].LTM+C6X?/LP@\IAY,V"8^@S@]N<=\4`>C4A90I8L`HY)SP
M*X+3-/M_^$@\3>'K2YG715MX)#%#.0+>9RYDC5QR@*JA*YXW<8S6=IFF7NL_
M"CPA#;P)>0K]GEO;224)]IA"MN7)X/S%6P>#MP>M`'IP8,H92"",@CO2UQ/P
M]`CL]<MXK=[6WAU>6.&V,@D6!=B95".-H)/`X!R.U0>#O$>K:YK-U97=S:O%
MID;12R1+_P`?LA<A9DXX0!&4@?Q;AV%`'>,ZKC<P&XX&3U--$L9D,8D4N!DJ
M#R/PKA=/L=-\2^)?$RZ[#'<W%C=I#;P3]+>#RE*2(/X2Q+G<.>.V*R1H^AW-
MWXZU*[$4,UK<(8-2$FV6%5M(64K)G/!P>203US0!ZB74,JE@&;[HSUILTT<*
MJ9'5`S!1N.,D]`/>O+O$MK)J'@+3]=O[.$:E#9VT]_J(;;<V6`KN8TZ!N3QD
M9SR&'%=)\1Q+)X8LUMY5CF;5;$122+N"M]H3!(XR`>U`'7[U"@LP&3@9XR:=
M7F,^MZG'=KI&HSVNI7%AX@LH/M;6JJ&25=_W.0KKDC</:A_%NO:7HFM7&J3J
MFM6\<=PNF2VH5(4,H3*R*3YB'D9/S<=J`/3J*\RU#Q1XAT&[U'1Y[ZVU&Z$E
MD(;Q+4*8!<.Z$-&&P=NS*Y(SO&?><:UXI1[#1+F=;2[O[V2&#4KFU0.\20^8
M3Y(8J&W90<]%SCF@#T1I%4D%AD#.,]O6H+*_M-0MTGL[N"YA<962&0.K#.."
M#@\@C\*\I\?RZD+/4+(ZA:R3IX<GEFO8K50\P695*9R=@(/(!X(S5[4=7N_!
MMU?@_8[N:RT".99_LB0;G>Y=1D+T09!*@]B>":`/4:9'+'*I:-U<`X)4YK'T
MB#4K:WN8M3UB#4I"-Z/';K"44@\$`G(XR#UZUYQH5A9:/X%\%:KI*1V>L74U
MI&_V<`&[21@)@Z]'^3+9QD;<YXH`]A+*&"DC<>@SUIHEC,AC#J7`R5!Y'X5Y
M7X@U#'BV3Q.#=>5HEY'9KMBD\HVY^6Y8L!LX+CJW_+'\#F:U;D>+_$,ZZ4D9
MDUJSA_MY)!YMCF.`CY>I7..^WYN1@&@#V3[7;$X%Q%G.,;Q4U><'PEX<C^*U
MO&F@Z<J?V3)<[5MEQYHG3#]/O#)YZUN>)[_5(M8T72M+NXK234WFC>X>$2F/
M8F\$*2`3P1SQSGM0!U=%>:V'B7Q!K!T;3(=0M(+JYEOX)[^.W#A_LTBJ'1"<
M`N,\9(&3[4B>*-=DM+?7TU*S6RN=6&F#3C;C=&#<&'=YF[)D&-V,8QV[T`>E
MTA95QN8#)P,GJ:\CT[6/$^GZ2(WUN6^GU#7+FPBG>T1C;^6\V64;@&+;`%4G
M"]!GI6X^H:V+7PXNM6L0NFUX6XDG@3=)$(Y2LH4$B-R!V/'/K0!Z#2%@JEF(
M``R2>U<!X4UKQ#J<VBZE>WMK)8:G'.K6B6^UH6C^ZP?.6SM;.>.>*Z/QC<-;
M>"=>N$CCD:+3YW"2H'1B(R<,IX(]0>M`&YGC(/TIBSQM,T/F+YJ@,4R,@'.#
MCTX/Y5Q6FZQJZ>*;6WU*X^Q6%PHCT^W2T5HKL"(.3Y@.4<?/\I`&%XS5#Q&N
MJ'XBWD^E:I!ITEOX>69Y)K<2A@LTA"G)``]3UH`](I`REBH8%AU&>17EO_"8
M^)M<=IM#M60V]C:W8LUMTD%RTT8DVM(S#8O\(*CJ&.>U7-7UZ_T[Q'KJV*6<
M<QETJW21X`2?/=T)<C!8+G(&>.?6@#T>BO.KS6/$>F6@TVZU2&2[DU;[&-0A
ML@\@B,(E5A".&8'@XZ+D]JT],U;6M+^'=YK6NYGO[:&YN-C0B$LB%O+!4=,J
MH/J-WM0!UPE3S1$742%2P7/)`QDX].1^8J2O-;C5];T:*36KZ]LM5>/0[B^@
M2&+RRI)B.S`)W1],-G/7/K4BZGXUATG5KC)NA#:+>6UQ):)'O<-EX5168LI0
M<-UR>M`'HU1&>-9DB:1%=\[$)&6QUP.^*\WO/&VJ:A<L^BS(-/O+V+3[*X2!
M92I\EI9)`"0&))5`,XR#U.12/>ZN-;\*S:[;$7-M<:@%8JJ-/&MN2KE5)"EA
MU`-`'IU%><Z3XAUYI/#-]=ZG975KXC!Q:);!#:_N&E&Q@Q+XV[6W=SVK.M?&
MOB"TT[2-9O;BUO8-5TVYNQI\<&QH&AA,@VL"2V[&#D=6X]*`/5ZC69&E:+>O
MF*H8KGD`YP?T/Y&O,_\`A*?%6EZ+=:G>".XM9K:&2&ZGMDACAFEE1`H"N2\8
M$A;)(.%Z\UTOA^+4K?Q%JMMJFH6]_-':VVV>*,1L5+2G#H.%/7&.HQ0!T7VZ
MU-^;%;F`W:H)&@$@\P)G&XKUQGC-6:\?T^?5]"O/$%X-5@EN+SQ`NEK--9H!
M$SK%^])!!("\!,XS@^M:]QXF\0:4^IZ2]]9WEY9W>GP1WAM]F1<N5.]`<97K
MQC(Q0!Z2>E1K-&TS0[U\U0&*9&0#G!QZ<'\JX[QPNL:=\,=3EBUITU"UMFD>
M]CA5&DQG(`'"$^HZ8K!U"U\10>,+@V>NP_VC;>'1+)<S62XG(FD*J5!P@[$C
M)]*`/4Z*\UO_`!-XGO=6NX-$A);3[>WF^RI;*XNWE3?AG9QL3^$$`]&Y[5Z/
M'RF<8)ZT`/HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`/K6:V@:0\
M1C;3K=D-W]M(*`_O\Y\S_>SWK1?.PXKS_2_'FKQZ-KVJ:[HT,-MIEX\`^S7(
M=CB15*8(&2-WWL@'T%`':G2=.:2\=[*!VO=HNMR`B;:-HW`]<#BJ.F^$?#VC
MRR2Z?I%K;R21&%F1.=A.2N>PSVKGM3^(5UI3?9[K188[Z&W^UW4#ZE&HBBW,
M%VL1^\<A"=H&/?IFUX@\=?V)8V.HQV$=Q87,23.SWBQ3*K%0-L1!+D!@2,B@
M#6TCPAX=T&=I]*T>SM)F&#)%&`V/0'M^%36OAK1;*YFN+73;>&6;?YC(F,[S
MEOID]<=:Y;3_`!QJ\5KXHO\`6=&@BL=&GD0/;W.YB%5&V;<<G#$[N/3'>I+C
MQ_J%JFH^;X8F$FF(MQ?*+R,B*V8$AP?XGVJQ*#^[][ID`W--\%^&M'-P=.T:
MTMC<1&&8QIC>AZJ?:J3?#WPW'97%G8Z;%I\5RR?:#:KL:558,%)ZX)`SCFJ=
M]\1[:UU>2"*S6:Q@N(K:>X^U(LF^39C9"?F<#S%R>.^,XJQ=^-+B+6+FS@T2
M6>SL[V*SO+L3JOE-)LVLJ8RP'F`MTQ[T`=!J&D6&L0QQ:A:1W"Q2"2/>.4<=
M&!Z@\GI4EKIEC8V`L;6UBAM`"HA1<(`>O'OD_G7.>$O$.N:SJ>M0:GI5M;6]
ME>/;QRPW.\Y"H0A7')PV=W'ICC-0ZAX\>TDO[E-&FFT73[G[+=7RSJ&60%0V
MV(\LJE@"<CH<`]P#JK?3K*TBMX[>WCB2VA\B%5&!''Q\H]!\J_D*I6/A?0=.
M=WLM*M('964M'&`=K?>7/H<=.E<SX,N]:U3Q3XBNM4MI(TM[EK2+;?EXXPJQ
ML$$0`&?F+>9UYQVK%M_$.J0:_/(VK7[+)XB>P,5Q$OV*.`-@+OVY5ST&&)+8
M&,&@#TBVT;3;22"2WLH8W@MOLD15<;(>/D'^SP./:J3>#?#CB$-HUH1#$L*#
M9P$7[JX[@=L]*;J_BBRTNT9H"E]=FX2UCM89EW&9VVJK'.%[Y)]#]*Q=0\>W
MNF/%97.APQ:IY+7$UO+J4:1I$#@,LA'SD\X7`^Z<XXR`=6=)T]I+N1K2(O>%
M3<DKS+M`"[O7``JEJ/A+P]J_F?VAI-K<^9-Y[^8F<R;0F[Z[5`_"N&\6>*+N
M6*ZO]+N[JWMI_"DFH0+G:5?S$*-CLP#$5T?C74=1TR/P]+IR2S7$VJQQ&!)!
M'YRF*3*L3P%R`3Z8H`U;GPAX>NUB6?2;9Q%;BU3Y<8A'1..JCT-2WGAC0]1O
M?MEYI5I/<%!&9)(P25&<`^N,G&>E<]/X_DM]/LQ+I`AU:YGGMQ9SWB1QH83A
MV,I&-O*XXR=PXZD3+X\-UIVCS:;I,EU=ZJTT<-N9U11)%G?E\$;?E;#`<X&!
MS0!T]_IUEJME+97]K%<VLPVR12KN5A[BL@^!O"O]FG3CH5C]D,@F,7E#!<`@
M-ZY&X_F:S])\=MJ=WI1?1YK73]4#I:W4DRDM,@)9"@Y`PCX;/.WH,BLN_P#B
M%J267B&.VT>T_M'3;`WL>S4%FC*`LIW%0,,-N=G?ID4`=<OA;05T1]%32K1=
M-?E[98P$8Y!R<=3D#\J@@\&>&[6P%C;Z1;0VPG%P(XP5`D`V[ACH<<5EIXLU
MCRM.M$T!)];NK9KI[5;U5CCB#*N\R%>Y884`]\GO65<>/(O[2TW7"+N'33I5
M]+/9MC<98IXHPN`<;MQ90<XY]*`.^L]/L]/LTL[.VC@MT&%CC7:!Z_GZU!::
M)I=BUJUK8P0M:0FW@*+CRXR02H]B5'Y5S4_CZXTO[7#K6@RV=Y#;"ZBCCN4E
M22,R+'RXQLPS+NR,`<Y.#5,^,KV]M[I;S3)+"6TU:RLF^R7Z2[VE:,_>V8VX
M=<C&3DC(ZT`=1J?A/P_K5[%>ZEI%I=W,0"I++&"P`.0,]QFHI?!7AB;4_P"T
MIM"L7O!M/FM""?E`"\=.``!]*K:+XGO=:9[JVT1AH[B3[/>M=)NE*$CF/JJD
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M6$,8ECF:&>&]25OW>W.]`,ID-QR:YC0/&T]CHFFSWIO+VY;0[28[YU6)Y)9C
M$"Q*Y4YQN<G`';U`.[C\*Z#'IUU8)I-H+2\.;B+RQB4\8W>N,#'ICBD/A+03
M:/:MI<#1/,MPP8$GS5`"ODG(8``9SVKG[?X@7;6%S+<Z!Y=S%JBZ6D$-XL@D
MF9`P^;:`!EE&?<^F*O+XLU!O#]Q>OHT5O?V]V;66UNK]8HP1CYA*5P0001QS
MF@#5;PQH;0>0=+MC%]E-GLV<>22"4^A(!^M69M(T^XN)+B:SADEEM_LTC.@.
M^+).P^JY)X]ZY>'Q]+?:9H<VFZ*]S>ZQ#-+#;M<JBIY14/N?!XY."!SQQSQ(
MGC>ZO4T^+2M!ENM0N;,7LUM+<+#]GC+;<%B#EMP8``?PG)'%`'0Z9H>EZ/`\
M&G645M&^-PC'7`P`?8`8`["J>D^#?#>AW7VK2]%LK6?&!)'$`P'L>WX5@7OC
M9=)UC58&MYY;G[3;V]O!/=1QQ;W@\P_,1A%`!R26R>GI0OQ(%Q!8QVNF1O?W
M,\T#12WJQPAHBH8)-@AR=PV@`9&>F*`.L31=-CTR335LH?L4H<20;<J^\DMD
M=\DDGZU$_AW1GL;JQ?3K<VUWM\^(KQ)M557/K@*H_`5HHY8`E<''(STKF]?O
M;R?Q%IOAZRNGLS>P3W$]U&%,B1Q[5VQY!`8M(O)!P`>]`&[_`&?9B^2]\B/[
M4D)@6;'S"/(.W/ID`_A63KOABT\0ZEI5Q>E7M[!Y7:W9,B7>FT<YXQUS6+K]
MKJMI-X;T=?$6H`7FH/$]W&(TG,:P2.%)V[2=R#)V\U)%J6N[O$NB_;H6O=-C
MBF@U!X`2T<BL?FC&%W+L8`]#P2.HH`Z:WT32K3[%]GL+>+[#&T5KL0#RE;&X
M+Z9P,_2H%\,Z$-5_M-=+M?MOF&;S0G.\C:7QTW$<9ZUQTNLZE=^'?!GVC4;R
MRM]4LQ/?ZC:Q!I%D\I65<[6";B6YQ_#CO72>!M5N=:\*6E]>7*W,S/-&9TC\
ML2A)64-MXP2%&1@8.>*`+<GA/0)1=A])MB+R199QL^^ZG(;_`'L\Y'-30^'M
M(MX88H["%4AN/M<>1G;-@C?D_P`6">?>LKQCXME\)VJW8L(+JW5&DFWWJ0R!
M5QG8A!+GGIQV]:=XUO;JTT?3YK.9X97U2RCRK8W*\R*RGV()!H`U4T6QM[".
MULH$M5A1UMS$H_<E@<E0>,\FF6>A:?:>'X]#$/FZ>EM]F,4QW;H\8(8GKD9S
M61IWC5-0;2((M/D6ZOOM'GPLXS:>02K[CCGY\*.G4GMBL^Q^(-_J8M19>&99
M)-0M3=V"M>(OFQKM#ER1^[Y90/O9SVYP`=-#X9T6WU,:E%IL"WBDLLVWE25"
MDCT)4`9'84W5/#&A:U,LVIZ9:W4BKL#RID[>?E^G)XZ<U@CQ]+?PV(T/19+^
MYN[$WPB:X6$(JML=2Q!&X-@<9!]AS6/)XUU&77TU/1M-N=1TZ?P_'?FT:=8O
M+'F/EL$'+D#``ZXZ]*`.VU#POH>J3":]TRWED$7D;BN"8\YV''5<]CQ4\VAZ
M7<3R3RV,#RRM$[N5Y9HCF,G_`'3R*Y_4/&\\,MW_`&;HDM_;:?;I<7TOVA(C
M$K)O`13]]MO.,@<CGTFMO%]SJNI"'1M&>\LX_)^TW+W"Q&+S4610$();"NI/
M3KQD\4`6=>\-)K#VLL36\4L%U]I=9[?SHYCL,>'7(S\O0YXP*F\.>'X="TB2
MQ#^<LLTDSC9MC!=LE43G:@Z!>:YS4OB'<?\`"/V]QI>C^;J<\-U)):S3!1:_
M9\B0N<<X;``XSZBG)X\O[?1M&-YI-JNK:E`9TA:_6*'RU"9<R,.,EQA0">?J
M:`.FT_POH6E;OL.DVD&]#&VR,<H<97_=X''3BG:9X<T?1I#)IUA%;L8Q%E,\
M(#D*/09["J>F^,-,U+0K?4T?8TUNUPMJ6!F(7=D*F<M]UL8ZXK*MO'TDOAM-
M;DTE##/<0P6T=O>I*TAE(5=W`"-EE!4],]>*`.@_X1G1/['_`+)&F6PT\2>:
M+<)\H?=NW#T.[G(IUKX=T>R>![?3X4>"1Y8FQDJ[C#MD]R.#7,R_$1[2">WO
MM'^S:Q%=I:?9&O$\HL\9E5O.(`"[`2<C/;!J2'Q_]MTRU-EI37&JW-W+9I9K
M<J(_,B4L[>;C!0`9#`9.1Q0!N6OAG1--NVN['3+:WN"K@2(GW0QRVWTR>3C%
M4?"W@O2?#5A:Q1VT$M[%;"WDO#"%>11UXYQG`R.]<WXG\5:S9:=XADM+2>VU
M.UTB&X>)[E&CM]S3`NF%^9ALSU^8;>%(.9[;Q#)X9F2SO;/4/M$>GPLMHVH"
MZ#R2W+1H/,8`EB2/F)P!@8XS0!U-MX0\/6D<L<&D6J1RPM;O'LRIB)R4P>`I
M/85;TW0]+T=773K""V\P!7,:X+@9QD]3C<>OK2:5>ZC=6#RZGI@L+E&(\E;@
M3*PP""&`'TY`Z&N5LOB!?ZFMJ+'PS+))J%J;NP5KQ%\V-=H<N2/DY90.N<]N
M<`'53:!I-Q9WMI-I]O);WTAENHV0$2N0!N;U/RKS["HX/#6BVULUO%IMNL37
M"W3#;G=*I!#D]2P(')]*YO5?B*+'PQ8^(+;3HY[.>`SS)+>I#+'MX954@^8P
M.1@8''7FK]_XDN9]5U'1[+3G<6EN)+F[,X00K(C%"HQEFRIX&,8SGM0!TMS:
MP7MK+:W4*36\R%)(Y%RK*>H(JC:>'=(L!BUT^&+]P;;(')BW%MF?3+$_C7(^
M'O'JCX?V^LW,4UU:VEC;I->&0!KBZ(5610<=&8`N2!DGT)%B'XB@V5VUQI?^
MF6UQ;P-!:7:3HYG8K'MD``SN&"#C%`'0WWA70M2D62\TRWE=81;ABN"8ASL.
M.J^QK7``&!TKG]5\3R:'X=AU#4K%8KR61(%M$N%*^:[85?,("@=RQQ@`_CCQ
M_$B"*Q-Y?V'DV]O=_9+^:"X%Q';%D#HP91\ZG<JD\;6.#0!W-%<;+XTU3_0K
M:V\,RRZI<V)OS9R72Q^5&&P0S$?>Y7C'4D<8S2VWCQ=2GT]-,TN6:*ZL8M1E
MEEE$8@MV9E8D8)9AM^Z.OJ.X!V-%<-I/Q)@U*YC633FCM[FTDN[1H+A)Y'CC
M4,=\:\QL01@9.>G!I%^(DG_"-1ZS)I4*I=7$<%F%OT9&+C(,KA<0XQ@@YP2!
MWH`[JBN(U?X@/I31P'2X7NTLUO;N-M0C18HR6&$8C]ZQVM@`#IR1D5#K'C6>
M]T[4AI.E7<MI!;K]HO4D"/`TD2R)A.K85U+'(QGC.#@`[VBFKU/UIU`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`#7^Z:Y2?P1;3V>M6)U&\6RU6<W$D/R$1R%E9BIVYY*]#G
M&376,<*3Z5P?AWQ[#JUUKEY=7(M=+L9C"B2V4L94!@OF/(V!R3]S`*]Z`-W4
M?#?VS6/[5M;ZXL+QK<VTC1)&XD3)*Y#@\J2<$?WC6=JG@"UU:YNII]1O5^VP
M007>%CS*(CE2#MRI)Z[<`^E6YO'OA^"WMYGN9P)PS(OV.;?L!P79=N53/\1`
M%37GC7P_8_9_.U&,BXB6>-HE:0&)LXD)4'"<'+'@<9-`%6Z\$V]U!X@MCJ%X
MEGK>YIX!LPDC*JET)7.<(."2.:LW?A.TO#KQ>>X7^VK-+.?:5^151U!7CKAS
MUST%6=*\3Z3K=S<6^GW0FEMU5W'ELN5;.UE+`!E.#\PR.*CE\7:+#K0TE[S%
MWO$1_=/Y:R$`JC28VJQR,*3DY'K0!5B\)&SO9KC3]5N[1+AHGFB5(G#.@52P
M+*2I95`;'IV-65\-VRRZJXFGW:E=Q74HX^5HQ&`%XZ?NQUSU-.A\6:3/K4FD
M)-*M\BNVR2VD17"8W;&90KXR,[2:R;CQS9SW.E?V/(+J&YU&.TFD:%PA5XI'
MS&V`&(*8XSCD'F@#7TW0!I6K:C>V]Y<&+4)C/):N%*+*0JEP<;NB#C..367=
M>`K2[EO8SJ%_'IM]=B\NK!&7RY)`06^;&X*Q`)`/;MS6O;>)M*NX]+DM[H2+
MJA86FU&R^T$MQCY0,').,'`ZD5S6N^.-2TC7=6BCMM.>PTNW@ED2:=HYYVEW
M86/@@ME<`=R0*`.ITK1X-)EU*2*21FO[MKN0/CY6*JN!CMA!6`WP_@>]G>75
M]0DL)[_^T9-/(B\HS;PXYV;L!@#C-;^KWTMIX=O]0B3;+!:R3HL@[JA8`CZC
MFL[3_&6G3^'EU.ZF$31K"EU&J,3'+(J,$`QEL^8N,9R"*`+>N^'[?7M/%M*\
MMM(DR7$-Q;D+)%*ARKC.0<>A!')J@_A*1K^+4AK-Z-11)(I+@QQ-YL;'(0J5
MP`IY7'3)ZY-22>._#L5W+:OJ&)8RR'$+D%U.#&"!AI./N#+8YQ4Y\8:(NB6^
ML->@65PYCB?RWW,XSE-F-V_*L-N,Y&,4`4]5\%6NLI(+V^NWEETIM+DE&P%T
M9E8O]W&[*]N.>E:NIZ+#JDFF/-)*IT^[6[CV8^9E5EP<]L.:YW4?B#IT$>BZ
MA:3B73;R^DM+D^3(98V6-VV^6!O#[E`VD9YZ5J/XWT%-(L]3^V,]O>%A;K%;
MR/)(5)#`1JI;*D'/'&.:`&WOA*"ZG@N8KNXMKN"ZDN8IT5&(\P8="&!!0\<=
M>!SQ4Z^'=UWI%Y=W]S<W.F/,Z2.J+YAD4J0P4`8`.!C'09S4=QXW\/V]A:WO
MV\30W>[R/LT3S.^TX;Y$!;Y3UR..]2IXNT6734OX[S?;O<_9%*QL6,N<;=N,
MY[].G/2@"@G@33UT;2M+:>Z>#36F,9+`,XE21&#$#TE;&,=!45E\/[&WM+FW
MGO+NY2?3/[*.52/;;\X`VJ/FY/S'UHTSXDZ#J.G75ZQO+:*WN&MR)K20-(VY
ME4(-N68[3\HRPZ$`UT>EZM9:S8+>V,WF0DE3E2K*PX*LK`%6'<$`B@#!/@YU
M>QNH]<U!-1LX'MEO`L>Z2%L?(R[=IP0"#C.14)^'6COI]O9-+=M;PV4]H<R_
M,_G2+(\A;KOWH&R.,D\58M_&FF:KK-G8Z9>QRJ[2&4F-EW(JD[D)`#+D8+#(
M[5)!X\\.W-O=3Q7S-%:PFX=S!(`T2_>D3*_O$'&2N0,T`8^N^!KF?3+Z<7UW
MJVJ2V\-JAN'2/]RDBNZK@!=S[>2P()QGCBIM.\,7MU'=6VHO+;:<E];7=C!M
MA$J-$P=MQC&TJS`<<G`//(QO7WBG1]-D=+N]1"ENMRV$9@(V;:IX'5F.`O4\
MX'%9EQXQMYSHTVE,)H[S5%L;A)HWCDBS&[\HP#*WRJ>1R#[T`,7P%;C2KS1_
M[3U#^R;A)D6S#KMA$O4*V-Q`.2H).,GKQ2'P!:2V&JVUS?W4K:G'!%-*$C3:
ML)RFU54*/?BM"#QKH%QJXTN._'VDRF%&:-Q')(,Y19"-K,,'@'/!I+3QMH%]
MJL>FV]^&N92RIF)U1F7J@<C:7']W.:`+VH:/#J6H:7>2O*LFG7#7$04C#,8V
MC(/MAS6;;^#K.WL=+M$GN2FG:@^H1DE<L[&0E6XZ?O6Z>@IH^(/AEMX742Y5
M=RA+>1C+QDB/"_.P[A<D=\5+<^-]`M+*SNWO3)%>Q^=;^1#)*S1C&7*JI(49
M&20,=Z`*>C^`[31KRSGBO;J1+%9UM875`$$QR^2%!8\#!)[?6LK5/AXMMHEO
M#IAN+J2WMK6R\J1T4R0PS>:>2-N\\CGY?:NAU+QSX=TGR_M>HJ`\:3!HHWE`
MB;[LA*@X3_:/'O3+'QKIU_XLO?#L<%XMW:A<R-;.(V)#$_-C`QMZG`;/&:`,
M_3/"][<Q&/4WD@L[;4XKW3X,1>8FP<AS&`I!;)P.<=36AJ/A&WU"\@O8[NXM
M[J"[>ZBD54<!GC$9&U@01@#W!H3QII\WBRY\-)%>"]AB5_,-L_E$D,<;L8``
M7J2`<X!)!JAX/^(&G>(M)M&FF$>I-9?:IXA#(J?+@.48C#`$@'!.,T`7],\&
MV.DMHIMYKAO[(BGBAWE3O$I!;=QU&.,8J-_!D2W-M=V.I7]C=16S6C2Q%"98
MBQ;!#`C*L201R,]ZD/CSP^+(W8O)'A\P11M';2OYS$;OW8"YD``))7(&#5RT
M\4Z-?FP%K>I,;]Y$MPJM\S1@EU/'RD`'(;!H`SKOP/:7-[<WRWMY%>2W$%RD
MRE6,3Q1^6,9!!#*2&!SG)I=3\*7&K:3+IEWKUZUO.LD<RB"$;E?'`^3Y=H!`
M(Y&3U."+&I^-=#TB".:[NI-K^80L5O)*X5#M=BJJ2%!&-QX]ZQ[OXCZ99:Y$
MMU,4TFXTJ._AG6WE9^78$LH4E4"A3D@8H`ZRRLGLY)!]JFDA*HL44@7$050,
M`@9.<9.2>:H:_P"&XM<DM+A;JXL;ZR<O;7EL5\R/<,,N&!!4CJ"/2KUYJ]EI
MVF_VC>7,<-F-I,S'Y0&(`/TY%8\7C[PY+)!&+]@\\JPA'MY%:-V.%$@*_N]Q
MQC=C.1CK0!%>^#IKZTL%?Q#JHO;*Y-S'?8B,FXQF,C:4V!=K'@+WS4J>$!#I
M5]:PZMJ"7M^X>ZU)BCSR$`#'*[57`P`!@9.*LZCXNTC2M4CTZ]EGCN),!2+6
M5HRQ!(7>%V[CCA<Y/`JCHGQ!T;6M*_M!1=6T0NEM<7%LZYD>0QH`<8.2.WW<
M\X-`#M.\*7VDZ-::9:>)=2$5JABC9XH6/E[555^Y_#MX/7DYSQ5JPT*XTF;2
MK/3;GR=)LTE-PCG?)<NW(W$C^\S.6SDGZU:O_$6F:9%-+>W2PI#*(')5CARF
M\*,#DD$8QU)QUJB_CGP_%/;P2WDD<DZ(^'MI%$0?[GFDKB+/;?B@"OXA\#6?
MB"_N[F6\NH/MMFME<K$$.^,,6&"RDJ<L<XZCZ`UL:SHL.LV-O:S22*L%S#<J
M8\9+1.'`.>Q*C-/U36K'1;476HSK!"7V!B"<L02`,#DG!P/7CO69;>.?#]Y=
M6MK!?%IKI_+C5H9%VR8SY;DKA'X/RM@\=*`*FA^&9K/Q?XBUR>/8+QUBM8S)
MNVQ[5,CC^[O?DC_9%6](\(6>C2:.\$UPYTJQ>QAWE?F1BA);`Z_(.F!R:FM?
M%^BWNKG2[>\WW09D'[IQ&[KG<BR$;688.0"2,'T-5F\?>&Q+)'_:&70'A8)&
MWL.J)A?G<=U7)'I0!AP^`KRQUBR@T[4KRTL+;29K3[9$T?G%WF#[<%2.A)!`
MX(%;MEX,T[3I5:U,\:+I:Z6L>X$+$"QSD\ELL>:?/XWT"#3++4#>/)#>J6MU
MA@DDD<#ACL52PVD\Y''>G3^-=!@MK2X%^)TO$+VWV:-YFF`.#M5`2<'KZ=Z`
M*-YX$@N7O#;ZIJ%DE_;1VU['`R8G5!M!Y4[6*_*2,<'UYJS!X0BL=2DN=-O[
MVR@F\DSVL3*4<Q*JJ<D%ERJJIP>0/QJ];>)=*NTTQX+M9%U,M]DVJ27V@EN,
M<`8Y)Q@X'4BN:U[QQJ6CZ[J\4=MISV&EP02R)-.T<\[2[L+'P03E<`=R0*`+
M&G>#]WB/Q3J%]$R0:F/LL$8EW%8B@\QQ_=WMSC_9!JQ%X+$-OI075KPW6EH8
MK>Y:.(L82H4QLNW:R_*IZ9R`<UOW^K6>EZ6VHW\OV>W4*6+@Y!8@`8&2220,
M#O62_CC0H].BO6N)]DTC1QQ"TE,[,OWAY6W?P#GITYH`T;>QDBTX6\E[++<"
M,I]L>-!)DY^;`7;D9XXQQ7):MX$N7M+F6TOKBZU&^O[":XN'\N,JD$BG<H"A
M=P&X\@Y/M@4OB'QU+8)=SZ4;:ZM5T.35(93D[F215V\=B&Y[@BNG'B33!K2:
M-YTCWI`W+'`[I&2-P5W`VJ<<X)!Y'J*`,C_A!+9DDFDU*]DU22]6]_M!MGF*
MZKL4!=NW;L)7&.035FZ\*/>)923:O>&^L;EI[>[1(U*!AM:/:%VE"O&",^]:
M>OZE_8^@7VH^9#%]FA:3?.&*+CNP4%L?09J+_A)--&MKH_G2/>D#<(X'9$.,
MX9P-JG'."0<$>HH`RKGP/:WEMJD=WJ%]-)J5@EC/,Q3=M5G;<.,9S(?8```5
M-K/@VRUR\FNY[BZBFDM8K=&A<*8C%*94D4X^\&YYR..E5M?\:VWASQ7#8ZDW
MEV$FGO<^8D+R.'60`\(#\NTDDXXQUJ[<>++"TOW\^^MA9"PCNU*J[2.'<JI&
M!A@W``'S$]NE`&II]G-9V\B7-_/>2R.6:28*,<`84*``./S)/>LG2?"%GHTF
MC20SW#G2K%[&+?M^=&*$EL#K^['3U-9.I?$?3ETZ#4-.>1[>+5(;*],]K+&8
MP^=V%902P&#@`_K5J^\<6KV6DWVEMY]I<ZF;*YWPNLD8$<C,-A`8,"@X(_G0
M!3;X7Z:;(V<>HWR0R67V";`C)DB\QGZE<J<NPR,9'T!KHX_#]O%J.JWHDF,F
MI0102@XPHC5@"O'7YSU]JE@U_3KF>P@@N5E>_MS=6VQ2=\0"G>3C@?,N,XSF
MHI_%&E6NJC3)KDB\ZM&L;-L7&[<Q`PJX[G`[4`8]O\.]*MM'N=*BFNEM+FVA
MAE4,.9(@H2<<?+)\JY(X)4''%79?"KWEHMOJ&K7=RJ7-O<IF.)-K0N''W5&=
MQ`SG\,4ZS\<>'[Z"ZFAOL1VT8FD:6%XP8\X\Q=P&Y,_Q#(I;7QOX?NX+R>/4
M%2.SVF<S1O$55CA7PP!*$_Q#CWH`NZ]H=OK^F?8YY)8661)H9X<;X9$.5=<@
MC(/J.02*SKGPC'JD<,&L7L^H6J3&8VTD<:1OF,H%8*!D#);_`'CGL,$OCWP]
M!;V\\MU.J3AG13:3;PBG!=EVY5`?XB`/>KDWBC2H-3MM.-R9;FX"L@@B>50&
M^Z6900@;L6(S0!SLW@W5#K]EY&L7T-M;Z/)9&_5HS.S&12%(*G^$?>QG('-;
M6F^$--TF[BFM%E$<6FIIJP.VY?*5BPSGDD[B#S4EMXOT2\U9]-@O-]PC.G^J
M<([)G<JN1M9A@Y4$G@^AJFOQ"\.2I<M;W<MP;>W-R1%;2'S$&`3&=N'P6`.W
M.">:`)-*\*S:/;1VEKK5\+.&)XH(6CB)C4_=^;;D[/X<_CFH;;P?):SWUU%K
M=Y]MOGB-S.88<2+&A4*4V;>=Q).,DXYP,4ME\0-$N_#EIK;FZ@ANB%CA>UD,
MK.5#%50+E\`YRN1P3FK-QXV\/VUM9W$FH*8KQ2T)CC=SM!PS,`,HJGABV`IZ
MXH`S[+P';Z7'9C2M3O+22WL_L;2!8Y/.7<6!8,I&Y69B,8QN(Z5+<>"(YY[Y
MUUC4X$U!$%['$Z`3NJ[-^=N5)`4$+@'`XJRVOR0^!/[>DEMD<60N6DD#&(?+
MG)"Y;'TR:?JGC70=%NOLNH7WE3`IO`B=P@;&&8J"%4Y`W'`H`WE!&<TZD!SF
MEH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`0].*XB[\&ZC<>$O$>DK-;>?J>HRW4+%CM5&D5
M@&XZX4],UVYZ5R\'CK3I=3FLGM[Z!(KPV`NY;?$#SYQL#@G'/`R!R0.IH`34
M=(URW\3WFM:-]@F-Y8):M%=NR>6\;.48%0=RGS&R.#P,&L1/AY?6NE7-A!=V
M[J_AG^QHY'RI,N7.X@`X7YQZFO1,@#)(&.M,\^'R?.\U/*_O[AM_.@#`MM`N
MH/%5EJC/$8(-(-BR@G<7WHV1QC&%-8\?@Z\MM8OB;:VO;"YU1-1C\Z^FC,3%
ME9\QJ-C%6&5Z=L^M;&N^,+/0)[J*Y@GD-OISZBQC`(,:N%8#GKR#70AP45B0
M-W3-`'"Z1X4\01^(-.U'5[V*Y>SCNHWG^TR.9O-(VD1D!8\!5!`Z^O%367A"
M_MO#7@[36EMS-HMS%-<,&.U@D;H0O')RXZXKLQ-$VS$B'?\`<PP^;Z>M'FQF
M1HA(AD`R4##('TH`X/PMHDR^.M;N-O\`Q*].D>'3EV%0KS;99\9Z@-@`C`P2
M.W$?B3P;K6I:YK4]G;Z/);ZK:PVXN+IW$UHR*X\Q`$.2"P(^8<J.:Z?0O$D&
MO6EI/:VMRD5S`TRO(HVKM?85)S][//3H*UX[F"4XCFC<CJ%<&@#%O/#K3:'<
MVJ7$SW<M@UJ));ARC,8]FXKG;[DXS7))X9N4\9^'].4J;6&QM[K5-JG:\UL"
MD)#'@Y9LXQG]TIXP*](\^'R?.\U/*_O[AM_.CS(E3S#(NPC=N+<8]:`.,L?!
M^H6T^E2/-;D6FMWFHR89N8YA-M`X^\/,&?QK+U;0]3TG^SO*2">>X\6/?1`;
MMBH\<N-Y`ROH3@C)%>D--$D?F-(BH>C%@`?QJO'>"2\N;=HI8Q;JK&5P`C[L
M]#GMCG('4=:`.0L/!^J1ZA8ZC=36GVC^VIM4NHXBVU%>!H51"1EB!M))QW]J
MLR>&]5LM:T_5].^Q226S7D<EM*S1JT<\OF`JP!PP*KG@@Y-=;YT2P^:94\O&
M=Y88_.G@@@$'(/0B@#@-,\)>(-#O+/5;>73KF]:.[6\A=GCC#3S>=F-@"2%?
M`Y'(]#3+;1KJ;XGDN(S86L*:E<JD95/M[H8@5SU&P%O4$CGDYU+[Q[%8ZNNE
MR>'?$#W$C2"'R[52LP0C<RG?RO(.>.M;.D:U:ZP;M8MR26MW+:LDA`):,X)7
MVH`Y%O!6M>4J*]HQL]9FU*U87,D9E29I-Z,5&4(60X*DY(YXKI]%T4VFC7UI
M):06;7<TLC"&X>?<7_C9G`)8]ZT;74$N(F=XWM\3/"!/A2Q5B,CDY!QD>W85
M;9U099@H]2<4`<)IWA+6CINEZ3J;Z<++3[.6Q$UN6,TB-'Y:L-PPGRXR.>?I
M4OA[PG=VJVD&KV-G-]GL)+)KI;Z:4LAVC"QN,(K!02,\$`#BNT$L;%0'4EAN
M4`]1ZBHKB\BMX;A]RN\,9D:-6&[`&>E`'G</PZU==$N$GOX9]3ANK9K&0R.J
MM;VW$2.P&Y6(+EBIX9LCO6M_PB=Y+=65PMI:6;0ZS'J$Q^V2W#S*L#1Y+.,[
MLD`#I@=:Z?2-5@UC2K'4(,K'>6Z7,:/@,%8`\CVR*MB>$Q&42QF,=7##`_&@
M#@;#P9KD%GHNBSS:?_9>E:C]L6Y0L9I45BZ+LQA6RQ#'<1@<"J7A71-9U+3]
M$6=+6VTW3M6N[X$[_/D82S!5VD``?.QW9.1MP*]%O;T6=A+=K%)<+&A<1P@,
MS^RY(!_.HX-5L;C49["*[A>\@56E@#?.@;.W(_`_E0!ROA_P;J&E/X6,\ULW
M]DPWD<^QF^8S,I7;Q[<YQ6?9>`]4TV6VN%^SW3&&ZM[F$7LUN"CW$DT95D'/
M^L(8$?3ISZ*9HUE$1D02$9"%ADCZ5E-XGT5+*ZO&U6T%M:RF&>3S!B-P<$'\
M30!AV_A"YC.H@16<,%SH5OIL5NCLZQ/&)01DC)0;U`/4X.15ZQT74[#Q??:B
MOV:2QOK:WCDS(PDB:)7'`QA@=PYR,5T(GB\L/YL>T]&W#!]*<LT;NR)(C,OW
ME#`D?6@#GSH^I0^-KC58/LSV-Y916TP>1EDB,;2,"HP0P/F=R,8JCI'A.]T_
MP_H=C+);F>PTV6TD=2<%G50-IQG&5_E717FL:?8>7]JO8(?-F%NF]QS(>B_6
MI(;])KZ:U\N13&J,LC8V2[@3\ASDXQSQW%`')P^%M7T^S\'RVLEG+>:':?9)
MXI'94E5HT5BC@$@@H",CD$]*JVO@[7K*;3=4273YM2BU&[OKB`NZ1`SH5VHV
M"3MXZ@9YZ5WQFB569I$"H<,2PP/K574]3MM)TNYU*[E"6MM"TTC`9^51DX]>
M.W>@#S+7-.NK&_L8=2N(8F;3+Q)IX_-CCG,DVXQ[E5FQC^$],\9-='I6@WE^
MZ:I)8QZ?#<^'H]/%C*Q9X'RQVMD<J`P'KZBNCT?5#J6EP7MQ;FQ,QPL4DR.>
MO'*DC)'.,YK1:2.+`9U7)`&YL9)Z4`<[KWA^[U7PA%I,3Q+.KVK%G8[3Y4D;
MMVST0X_"LW5?!VH7^G>+K>.:V#ZS=130%F;"JB1*0W'!_=GIGJ*ZF?5K&UO[
M>QGO(8[NY5FAB9@&<+C./ID5:2:-RRB1"R?>`897Z^E`'$:AX5U_4?$*7%Q>
M12VD.K0WL!:YD'EPH!^Z$(&S=G)WDD\U&OA#7%\*G1]]@SVNJ+?VLAE?$P%R
M9RK_`"_(>0,C=7=M<0*&+31@*0&)8<9]:0W$(B$GG1[&.%;<,$_6@#D;CPUK
M.HK#->/8)<#6[?462)G*K%&BJ5!(Y;Y3SP#[57U+P=>3:SK4RVMK?V.JO#,T
M-Q?30!)$55(94!5UPBD9YS[=.N75;)]2ETU;N$WL2+(\&[YE4YP<>^T_E5I)
M4<LJNK,IPP!S@^]`&)XDT6XUA-*6!XE^R:G!>/YA(RJ$D@8'7TK&;P?J']FW
M5N);;S)?$2:JIW-CRA.DF#Q]["GVSWKJEU&.35&LHQN*P";S`05.6*X^N13X
MKP27MQ;&&5/)5#YC`!'W9X4YSD8YR!U%`''Z!X/O-'N+&WGM;:YMK"[EEMKE
MK^;<D;!\$0D;-_SE3@@8)(]*?I'@[4-/E\./+-;,-,N[^>4*S?,)S(4V\=1O
M&<X[]:ZB[UC3[%('NKV"*.XE6&%F<8=SP%'O5PRQ@H#(F7^X-WWOIZT`<'I_
MA+7M$UA=5LFL+B4O?))#+*Z`QS3F9&#!3\P.`PQC&<&K/AWP=?Z+?Z+<3W%O
M+]CM+Q+@Q@KF6XF67Y0?X00PY.>E=DT\2NJ-*@9CA5+#)/M2M+&N[=(HV#+9
M/3ZT`<%X6T65/'FMW!'_`!+-.D>#3E*%0LD^V6?&>P.`",#!([#$?B/P;K6I
MZWK4UI;Z/+;ZK:PVXN+N1Q-:,@8>8@"')!8,/F'*CFO0=\87S#(H4C.XMQCK
MFJESJ^GVMU:VT][!'-=Y^SHSC,F!DX_"@#&U_P`/7U]X?TZVLKF-K_3;B"ZB
M>Z)*3/%V<CD9YY&:IZGH&N:CJ^F:U(EH+BU\^![:*\EB!@DVD$2J`=X*#/&T
M@GT!KJ(+Y93<F2.2!;>4Q%I@%#\`[EY^[SCG'0\59:2-4WLZA<9R3QCUH`\X
MOOA_?W6FS6]K#IUBKZ%/IJVZ32.B2/*'!W%<E<`Y)YR>E;%QH6J0^*AJMDEO
M9VYF62]EAN)&>]B6+:%:';MW[L88'.`/7%=<9HE56:1`KD!26&&STQ3CTH`Y
M;4K'5/%?PZO+*XM8K#4M0LW0P22%EB+9QN(&>F,\<=*CD\/ZJOBZ/4;%;:Q@
M>X5[R:.Y<M>1+%M"O$5VAMV/F!SA1ZXK3T3Q-INO3ZE#I\C/+IUP;:X5XRN'
M!(XSU'!YJA:?$'0;W3;N_AFG:&WNOL@`@8O-(0"HB49+[@<C';GI0!:NM"GG
M\8C5]T)M?[*DLBC9+%FD5LXQC;@&N.\6>&KVQLH;\O'Y45AI]B[Q;RT317`=
MI!@9"@<AA\P]*ZP^,[6+1M0U*\T[5;)+&#SYHKJUV/LY^Z<[6/!X#<<9QFI+
M+Q=IUV98[E+G3+B*%KAX-1B,#")?O.#RI`XR03C(SB@#E=+TNYUJ)X[:"*-+
M3Q!!?O>M,[K>[0N]EW*#N&`N,;?EX/6M^_\`"]S<7EI+&ULL<6N#47!R,Q^2
M4(Z?>).?ZU9TOQ=8:M=2V_E7EFZPFXC-[#Y0FA!P9$R?NC(ZX/(XJ:P\5Z3J
MND76K6]PPL+61XY)9(V3E<9P",GKQQS0!SG@+1I;?5=9O),_9;:5]-TS*%=M
MNDC.V`><;VVY[B-?0&M:X\*S7NH>*FGE1;76K&&T38?G3:DBL3QC^,8_&MG1
M=6M=>TBWU2R:1K><$QETVL0"1R#R.E2VVH),LS21O;B.=H09L+O([KR<@]N_
MM0!YQKOAS4K3P1K,M[IUL]XFB26GVB"\GN'<Y!VHCCY4.,X!SGBK^K^#]>\1
M)J]S=R:=!<W-C!8VT4+NR;4E\QG=BH().0`!QQS7H;,JHS,P50,DDXQ5.TU"
M*Y^U\>6MM,8F9B,'Y5;/T^:@#FM>\+7MWXCN-4MHH;J"\L!9W%M+>RVWW2Q4
MYC!W*=[!@?;'>HIO#&J)JNGW.EV]CIIB%K'/<074F7ACSOA,97:XP=JL3D9S
MQ79O-&D7F-(BH>C%@`?QJNM^#=W,#Q21+;JC&:0`(V[/0Y[8YSCJ.M`'(:!X
M-O='GLK::VMKFVL;J:2VNGOIMT<;A]I$)&S?\^TXP,9/6K>C>$[NPT#0K&>2
MW\^PTZ6SED3)&751E>`<?+[=JZQ;B%D+K-&4&<L&&!CK2M-$L7FM(@CQG>6&
M/SH`X&'P?KBZ9X8\S[)]KT*,VA2*\EB6>`QJA8.JAE?*`XY'4'VFLO"NL:3J
M-O?Z9:Z5#OLY+.XLY)Y72/,SRB17(RY.]MP(&2>#7;S3+#'O8C_9!/WCCH*S
MWUVRM]#BUB^GCL[1XDD+2MPN\#`)_'%`&1J'AJ]N_AI-X;62W%X^G"U#\B+?
MM`STR%S[4D_A>ZGOO$TQ:W,>JV=O!"&R2K1JX);CIEAC&:Z<7$6U7,L>QR`K
M;A@GT'K4M`"*",Y]:6BB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!&^[7C_`/9VI_V[<0P:
M9K)O4\2->0F6`_8#"7&Z0D_*3L+$'KD#'->PGIS3<*!_]>@#CO&NGZO/HI!#
M:E9B^@EN+*V@VR/;*^73[W[PXQQQG!]<5@ZMH5M-=Z/]B\/O#X>CDN4DLY-,
M,L:RMLVS&W!!"G:X!QP3G;SFO4.#47GVP=T,T>Y&"L-XR">@/N>U`'D.I>'M
M2;1)K>TMM4O$_P"$5N;6.2XMRLK2&=2J%>QP.!Z"NZ\;V%QJ/A^TM8()9=U_
M:>:D><^5YJ^9G'(&W=GVS7487'_UZ7"]*`/*)?"36MCJ]Q9:,\5[::]"=+:.
M(YAMM\.[RAT"8,N0!@\YJ?3K"_NOB/INKR:"MA,ES>+>2161CS'L98V>8G][
MNP"`!@9]J]/POY>]02WME`_ES74$;XSM>0`X_&@#QN'2M4TOPPT]U9WMIY/A
M>\A:09C9)&N-RKG!PQ'./2I%\/VT=S?V5MI@M]2N9M,>XLK2Q-NHM5FVR.,,
M<AOFW<\`?C7L,L5IJ-D\<BQ7-K,I5@<,CJ>"/0U!INC:9I"R#3[2*W$F`Y0<
ML`,`9ZX`Z#M0!Q.H:'%HUE<Z58>'H9M(N]65I(FLS<16\9A0EUA'5=ZD8'`)
M)K-T;PQ<SZ;X.T[4](E:QBN;\W=O-%B-(R7:(.N2`N=F%.0,`=J]0EN+6W.)
MIXHSL9\.X'RK]X\]AD9/;-2*8W0,K*RL,@@Y!%`'EQ\/Q6<^C6VJZ!=:CH%M
M:W<$5L(#<>3+YQ:,LG7!C7:K8.,CIG-1:]H>I3ZCJ4UOI=RNG,VEM-;&'S3-
M"BRAX]H/[S8S(64'D`]>A]7POM2.T48#.RJ,@`DXY/04`>7R^'K8>&_LJKJ3
MVZ:L]Q':G17-M_JO]6;?KY.>1T^<UVWAN\E.EV%K<Z1)IL_V*.5X$0^3#GCR
MPW3<,=.PK;PO^31M7_)H`YK5[2YF\?>&KN*WD:WM[>]664+\L981;<GWP<?2
MN;TSPE&NIW&KRZ2Z:FOB:6>.YV$.;<DC.?\`GF03QT[UZ-%+!/"LT,J21.,J
MZ-D$>Q%/.P#)(`')YZ4`>/7>BW4%JUU)HESJ%Y!>:A+;Z=/IYFMYO,NB5;=_
MRR<CD/\`W<]J[;QGI<FK+X?MOLCW%M_:D9O(U!*^3Y4@;?\`[&2H(/!S@UU2
MM'(BLC*RD94@Y!%)(\,*;Y'1%R!N9L"@#RZQ\,3V$&F7UMI,L.HP>))%618S
MOCL3*Z[1Z1>7@`=`,'WJ$:=J-_XQM]4;P^+*X#W\=TT-B4+)Y3+&7FS^]WX4
M@`<9]N?53-;K.L#31B9AD1EQN/X=:=(\42;I75$SC+-@4`>0:9H&OP?#Z]T^
M>PN3K#V%J8K@*=TELNPM:@<!&4!TV9&XG=G))%D^&K)K"ZBBAU*WM9KJUF^Q
MQ:"Z6N55\AH/XU/&\_W@G/2O6,+T_K1A>O\`6@#@]2MM0U'X,7MH-%^Q7TVG
M.B:;;I]PG.%5>W&#CMG%+I>B6NG_`!0U:_DT,J]Y;P/;7R6H*J^V3SLN/NL<
MKG/7BN[PN:,+_DT`>7ZW87^I^-[6Z_L%8I[/6+<)=QV)+R6H`+2&XS@+R5*`
M=O?C,N_!MN/"_C'38/"@%_\`;I+BU9;)0)(=ZL@C?H2%+84<CD5['\N.OZT8
M7'_UZ`.#BT*SO_%^ERIH1CT6VTIV@@FMO+CAG$RE/D(P'`+$<9&2:YRQTO6[
M[4[G4K30QI&IW6BWT<WE61MU2Z=E\L-(3^];Y2=_3OWKU_"_Y-&%]?UH`\@O
M_#.BW>BZ3-:^![B.2UNK.2_66P_>.F2)%P<F0\98C.01R:T=1T6].NZMK.G:
M7.IL5TV[L(A'L,JQ+*)85'][8Q7'8D5Z=M7@#M0%7'2@#RB?P]?OI7A^XU"Q
M:>*[N[B\U6V:S:YVS3#,9DBR"PC'R=]O'!QD;,^A+/\`![4=)6VNKYA:7/V:
M*[M2DF_+F,+&?NX.T(.P"UW^!G_Z]'R_Y-`'EMSX>L-/U&-;_P`*2WNDKI""
MSM[6T\Q8;D,S2C8OW)'W)ACZ'D59\-^&;TZWH_\`PD5BUTUCH5N/,G/FHETL
MC<@G@R!2.>H['FO2,+[5$+BU9V19XBRR>6RAQD/C.T^^.<>E`'%>+-%M)O&_
MAS5[C03J$423QS2QVHF9&^0PENX`(?!Z`GMFL+0].U"Y\2?VI)X?_LZ>XTN\
M2]2&P,(\YG3:K.3^^;"L=W3GWQ7J^%_R::7B5E1G4,WW5+<GZ4`>12>'H[?3
M?!=H^B1S7=Q:O/J-K<0>:)I1$@9Y4)&YPS<,3\N2`.>*]KH%K<Z=X?CA@EO_
M``_%I4EK$[Z4TWDW2R'S':('*.Q&`W/*GD9R?6M1T;3-6\DW]I%.8&+1,WWD
M)&#@CD9%6+:TMK2VBMK:%(8(E"1QQC"JHZ``4`>9V'AP6?B5KB'2[@WMSH5O
M%9:M<6?SI=!)5=Y6P2DA!3.>O3G%9-IX<OT\-3#3+*_L]7DTAX+BW2P:V\YP
M\>\R3%B))"`^TYY#$Y&:]GPO^32X7-`'%>$[&RMM=N[C2]"O=)L);.(".>$Q
M(9`S$[4S\IQC<<#/!YZUD>(]%U"\\0ZXR6%Q);W5SHZ[D4@21K(PFP1V"L=W
ML:]&:ZM1!YS7$0ASCS#(-N?K4J[&4,I!4C((/!%`'EWB'P586]GY5MX=%Q86
MVOP70MH[82;8&2,3>6G]TD<J/0\57U;P^]UKNI2W%G>0QN+632[FVTMII;:(
M*H\N-@?W+!@V1@<'J>@]8S&`S;EPOWCGI]:$:.1%>-@R,,JRG((H`\Y?P<^K
M0^+9Y+%8M7;47?2[N=/F156-T*'LAD!SCKSFLFXT?5=8@MM?U'29ECU'56DO
MM/FM#.\<*QF*`/%D%E4@L0"?O[@.P]=PO0_SI?E_R:`/-(_#@N+'PSIYM;N[
MTQ-5N6N8KFU:%$A*2E5,9Z1;MH4'C&WBJ]YX0LK&]\-22>'&N["QOKV)T%KY
M[1PL9##QR=@8@CL..E>I87_)HVJ/_P!=`'E,^B7)\23RZKHMS>Z%)KEU)/`(
M#*K[H(5BE,?5T!609P<'G'H:5X:NKR70K>_T:X&BR:E?S"RN5)6&V9,PI(N2
M%&X#"'@'%>K86@E0,D@`=230!Y-JGA\Z?IFF+!H]WJ,VG13QVNF7%D;BW<&?
MY/F_Y92!<8<]%]N*]1M;L3R7$/D31F!PA:2,JKY4'*'^(<XSZ@BIT:)T5T96
M5AD,#D$4OR@]J`/(O[%\1Z<LEUI=A<)<:E>7^G7+#Y6ABDN6>*YQCD*"_)[,
M,8SFK8T+4-%U^74[+2KBXL=,U966W1?GEMS91P^9&#]\J0>.IYQSU]2^7U_6
MEPO2@#R>]@UW4_#_`(RMH_\`A(+VSFTU5LX]3MA'(9VWEU10JD@#8.G7-6_$
M%MJ'CK:+'1K^S2TTZ^B6748?(,LLT!B6-5)SCG<6Z<8Z]/1FN[-9#&US")!(
M(RID&=Y&0N/4CD"IL+[4`<+9-=ZGK.AZHVEW]I;Z/ILPG6X@*R/+($7RT7^(
MCRR<C(Y`[U%X-U>:RM/$,MUH>MP[M1GOHT>Q<-)'(PVA1W;U':NW%[8MJ#6`
MNH#>)&)6MQ(/,"$X#%>N,]ZL?+[?G0!QWPRDN(_!=K87>G7]E<6FY9%NX#'N
MW.S`KGJ,$5R.HZ)<H+^ZGT>ZO)H]3U"YM;";3S<6UV&9-A;^XQQ\K]ANZ\BO
M7\+FC"_E[T`<;XQLYKNRT(SZ9+>:=%>*^I6,*^82AC90"@Y=5<J2!G@=#7-7
MF@W#Z?9+%I%W'HB:Q(\NGW%L;@^4T06-S$&RT:M_#GY1CCY<#U57B=G5'5FC
M;:X#9*G`.#[X(/XTJ/$ZAD=64DC(;(]#0!Y3J6A1Q^&=.5+74M0%G+>S06%S
MI#/;RY/RQM%UC49`C;L,U7UW3[Z75Y&N=(9%OIM*C%JR>9#*4BG,D17@2*OI
MD`$`]L'U_:O6JFH:78:K;"WO[:.XA#K(JR#.UAT8>A'J*`/,=)\/Z?=6FD:;
M9V#364.OW9U6W^R&&.(M$[>6Z9.4!,0&200%^E3W_AA[8Z':'36ET*UGOHC;
M/9M=I$6EW1.T602H4,`><;AQW'I5E86>G6PMK."."$$G8@P,DY)/J2><U8PO
MM0!Y+%H822VBU/1M9UBR725ATZ1[<K+!.LCELC/[ER&CVL<8"]16]XKT*75?
MA*MB=-:[O(;2!DMV0-(LBA=V!_>QN''/;O7>X6C:I%`'F-]IFG'6/.N_"5W=
MZ%_9873;6.P)^SRJ[EU\L?ZMV!3:Q`Z'D5VOA"TO[#P=I%IJA8W\-K&D^Y]Y
MW`<Y;O6SM%+0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`(>E><S>)=<M]'\4:]]JCDA
MTNXN;.WL1`,$HX"RN_WC@'D#`P.3GFO1R<#FJD6FV$4-S#':0K%<N[SH(QME
M9_O%AWSW]:`.!FUWQ1I5H\5Y<92\NK2WM=2N[>)#&TKL'/EHY#*JA2I)&2W4
MXIEU<7]BEZEY=66H7*:YIMNT_D*0RL\0RR<A9`#VZ<$8KLXO"7A^"UN+6/1[
M,6]Q&L,L9B!5T7[JD'L,G`[5/%X?T>WMQ;PZ9:1PB5)MBQ`#S$(*L?5@0.>O
M%`'"S^)?$,>DW6IK?+MDU=](@A6V0B`"X,?G,21N;`P`2%R1^-F;6O$VGZ9;
MV=],(+F\U6.PM=1NH8P_EO&7+M&C%-P9611QGY20>A[231=+ETZXT^33[9[.
MY=GF@:,%)&9MS$CN2W/UJ`>&M"6QN+'^R[4VURXDFB:,,)&&,,<]2,#!]A0!
MQMI!KZ_$NSM)_%LEU!'ISS2QK:QHCA9D4HP'`;GEA@CH,9JW\1M!T>YL;&]N
M=*LIKI]4L86FD@5G,9G12A;&=I!(QZ&NH'AS1$>S<:7:A[-BUNPC&8R3N)!]
M2>3ZGFKUS9VM]$D=S!'-&DBRJKKD!U(96^H(!%`'.>)KO_A&-`L;72%M;!;B
M\AL8G\H>5;"1\%MG`.!G`X&2/I6/JNH^(;*^TWP_#K#W-U<+/))J$%E"9?W>
MS$>QF"!OG))Z[1T[UW5]86FI6<MG?6T5S;2C;)%*@96'N#5%O#6AR6<5HVEV
MI@BE,T:^6/ED.<L#UW')YH`\^\1S:G<1:%)K-ND&HMHFKB>-""`PC0=B1R,'
M`/&:OZ!JFJVMUH,-]=/9:3+:VMO8HENDD=VY@#%7?.^-\[L#`7"CKS7;+X>T
M=+>"W73+40V\4D,*>6,(DGWU'H&[^M0#PSHD=V+NWTVVBO$4".=(ANCPFP%<
M\9"@#Z`"@!?$!U%?#U_+H[+_`&BD#/;Y4.&=>0N.^<8_&N&NO%EQKT9U&R\A
M](6^TNWA26%),S22HTK9(/*AU4$=&!Z$5Z%HVDVNAZ1;:99JXM[=-J[VRQYR
M23ZDDG\:2/0M)BM?LL>G6RV_V@7/EB,!?-#;M^/[VX`Y]:`.-/B6_D\=:?'9
M:C//I-UJ$UA)%)9HD:/'$Y;8^=[,'3&<;>OM5K5HM7;XI:-#;Z[/;63V,TSV
MBPH48))""#GNV[KU7MU-=)'X>T2#4CJ$6F6B7AD:3SEB`;>1AFSV)'4]34]Y
MI.G:C<6UQ>64$\UJ^^"1T!:,\'(/;H/RH`\R\%7>N:-X:TB\6[2ZTR:VO&73
MUMPK1M&6=-KC)).&!SZC`K6\.ZKXFOK/[;?-]JT^\TQ[DR/;Q1I#)M4JD85F
M+J0S9W?W1ZXKN;;2["SBMXK:SABCMMWDJB`"/=G./3.3^=5+/PQH>GS--::5
M:0.R/&3'&!\KG+*!V!/)`H`Y'PGJ6KZM<:1917D%G:0:)I]_+'#:H/-,BN#&
M.R)\G89'&,"K=Q#8ZQ\1M0TW78H;B&WL();"TN%#1.&9O-DVG@L&"#/8?6NM
MM-*L+!U>TLX8&6!+<&-`,1)G8G^Z,G`]ZKZQX>T77A$NL:7:7WE9,?VB(/MS
MUQF@#BH]"\.7OCO5(;RTLIK&VT6U6&25@?)7S)PVUR<KTQD'M[4[2[:3Q%\.
M;(7EK9:UJ`2<VHU-\"2(.RQR'`.25$9W8'7.0:ZN[\&>&;Z>":ZT'3II($"1
M%[=3L4$D`<=,DG'O5G4/#VCZM'"E_IEK<+"I2(/&#L4C!`]`1P1TH`Y"TUYM
M&^#MAJ=C<-.\4$-NDUZ/NLTBQ%F&>54DGKR`.>]2W]YKNG76EZ#_`,))#-=Z
ME=2)_:#6D8>!5B+[-@.TLQ`P2.AZ&NU>PLY+`V+VL+6AC\HP%!L*8QMV],8X
MQ5`>&-!73_L']E6GV7S%F\ORAC>N-K?48`![8H`XN'Q)K]V\&DQZE;"Z.MSZ
M2VH);@[D2W,HDV9V[P1M(^[GMVIVD^(M?==`U*]OX)[34-1ETN2T2V"<H95$
MV_).XF')7I\V!TS7<6^BZ1:0VD-M86T4=FYDMU2,`1,0067T)#-S[FG+H^F1
MP6\,=C;B.VG-Q"@C`$<A+$N/0G>W/^T:`/.+#QCKT-IHFMWE_;W4&IK=*VFK
M`J&/R8I'#*X^8DF+!R,?/T'%7+/Q%KUM)H4MUK%IJ$>NV4UP(DME3[*4A\P;
M""=RY^4[L]N>U=+X8\&Z3X:M(%C@@FOHT9&O3"%D=6;<?Z#WP*OV7AK0M-ED
MELM)L[>21#&S1P@?(Q)*^P)).!Q0!RFA:UXA^QV^L7]W%?6M]HC:E'9Q6X1H
MI%"-L4C)8$/CG)R.,=*HV7B/Q6GAN\URX<W-F^C37Z22011I#,J!D2/:[%T.
M6R6Y&T>M>C6]A9VL=NEO;11);Q>3"$4`1Q\?*/0?*O'L*SH/"GAV#SA!H]F@
MEB>%U6(`&-^77'3#=QWH`X3Q+=^*+?PIX@:;Q!@G2X]0@EM[=8GBR7WQ`CG;
M]W#9W#GFO1M*BN+33H8;V_-]<@$O<-&L9?G/W5X&`0.*DETZPFB>*6T@=)(?
ML[(R`AH_[A'IR>*H6GAK3K'4K>]MH3#]EMGMK>%#B.)78,Y`]6(7K_=&.]`'
M%:YJFLZ%XN\4:FFLS36>GZ1%>)I[Q+Y;9\X!<]1@J&)')Z'@"MK2M0U>S\76
M>CW^LV^JQ7NGRWJR+;K$T)5D`"[3@HV\XSS\O4UTUQHVEW-_'J%Q86\EY&AC
M69XP6"G(*Y].3Q[U'IGA_1]':1M-TVVM6=51C%&%)5>B_09X'2@#CI]=\47O
MB34ETI&:'3;^.U-GY,6R6,A"[O(S!U.'8KM&/E'7)JDUT]MXQO51(7$_BRWB
M;S(@^T&P!RN?NMQU'/7UKO;OPWHM_>F]N],MI;D[,RM&-S;#E<^N#R,]*F;1
MM-:X-PUC;F8W`NBYC&?-"[`^?[P7C/I0!YWHVO>*-8DT,'6((1KD%RP(LU8V
MOD$+E>?F9LY.[@=A4L7B2^O8?"=U,ML;IVU&*67R%)+P1R+O3/W-Q3)`[''-
M=_;Z+IEH;0V]A;Q&S5UM]D8'E!^6"^F<#--30M*18%33K95MVD:(",?(9,^8
M1Z;MQSZY-`'%Z-K^L0V,&N:]K$!TR]T4ZB56TP;-AY9XQRZXD[Y.1V%<]K&M
M>))/#7BFUDUR\@ET];*>.=[6*"?;*6!0A#@#A3GKU!XKUC^R--^QI:&QMS;1
MP&V2(QC:(C@%,?W?E''L*KP>&M#MK*YLXM*M$MKE`D\?E#$JC@!O4`'C/2@#
MCM7U+Q3#K!T+3KZ:>ZL]/6Z,Z6D):\D9G&U@S*J(-J@[1GYAR.^AXPO;E?#V
MA+J&;2WO;^VAU3RW.(T<$LI<=%+[4)[ACZYK>F\*Z!<V]O!-I-H\=LC1PJ8Q
M\BM]Y1['N.]7I=-L9]-;3I;2&2R:/RC;L@*%,8VXZ8Q0!P?B_0_#UK;:1:6N
MGV$<-QK5F+FVC1?+=-[?>3[O.3SCGWJYH]M;6WC?6]&TN8Q:3]@BEGAMY,);
M7+LX^4C_`%9*!3@>QXK<3P3X7CTZ33TT#3ELY'$CPBW7:S#H2,<XJ[:^']'L
M=+DTNTTRT@L9599+>.(*C@\'('7-`'G>E:+/J'@*33-.2.:&#Q!.9;66<@7$
M"739C+'/4`=>N*UO!<YTV3Q+';:1-';Q:H(X[&TD21(?W*%MG(4#/51T8D5T
M%OX(\+VD$D-MH-A#'*R.ZQPA<LF=IX[C)Q]:UK*PL]/M5MK*VBMX%Y$<2!1G
MN>.]`'"3:_XIO_$>I#2DD,.G7T=J;$PQ!)$(C+O)(S!P<.Q7:,?*/O4W3O$V
ML77B34M)>^MS%I:W4GVE8Q_IG]Q%!7`,1)#X[A>N378W?AW1+Z_^VW6FVLMT
M=F96C&YMARF?7!Y&>E+-H&FM;K'#901-$)C"ZQC,32@[V7T)W'/KF@#@+;Q9
MX@M[;3[VZU.VNUU?0[C44MT@5/L;QQJZ[2.64[L'=W7\*L/K7B=TT.T34Y#/
MK-L]_P"=;641,"A8R(8U<@'[Y.YB3@'CN.JT'P9HV@Z3'916-M)*;-+2XN/)
M"M<*JX.[V/)(]ZT+O0M)O;2VM;K3[>2&UP;=&0?NL#:-OIQQQ0!Q>I:UXJL]
M*TN]U-AI-K'`TFIW-M#'<-$X<`!D).(RN22F2#QP*L/K&KP^)+ZVU:[-M;SI
M<+IMH+9'AN42/=N\S[P?&25;`ZXS71OX2\.S16\3Z-9/';+LB1H051=V[&/3
M=SCUJ:/PYHL6H2WZ:9:B[EW[YO+&X[_O\_[6.?6@#SRSUKQ'>:)#'I5_:6'V
M'PY9:GL%FI61G1\QXZ(G[O\`A&1D8QBKNJZUXFOO$UQ9:/J$EN+:[M8?)ALD
ME1HG"-([R-]UU5F.WC@+C)-=W#HNF6Z,D-A;QJULMH0L8`,*@A8_]T!C@>YK
MF]4\`0ZIJ%]++=1BWO)X9V'V4&>(QA1B.;.4!V#MQSCK0!9\3:E?IK6BZ'IU
M^FGR:GY[&[,2R,HB53M56XR=PY.>%/'<<[)KOBZYU.^@TJ<7;:4\,12.WB$5
M[N16:1W9\H#D@;.,J>3T'>WVE:?J\*0ZA9PW,<;B1!*N=K#^(>A]Q56X\)^'
MK@QM-H]DWE1+"O[H#$:G*K]`>@H`\]UD#_A.-1!`X\1Z1_Z*KJ/".J:K<ZE=
MV6OW;KJ?E"X.GFW01PQEB`T<B$[T)&/F.[CG%=))H^ES73W$EC;O.\L<[2&,
M9,B#"-GU`X![4S3-`TC12[:;IUM:EU",8HP"5'0?09Z4`>:6%QJ?AFU\:ZTV
MJ)<RQZL+5?/MD55=_(42L5P=JAQ\N0,+V)S5W6_$GB#PXNN:<^KPZA<6FGP7
ML-V;9$>,O/Y91E7Y2,<C@'GO7H?]EZ<8;R$V4!BO&9[E#&")F("DL.Y(`'/I
M5>W\,Z':V5U9PZ5:);78"W$?E#$H`P`WJ`.!GI0!S_B;Q'>Z;#K+Z?/`TEI)
M91HKJ&5&FE"MN`YZ$''^-4+O5_$.D(VDW.KP375QJT%C!J,ELBF*.2+>24&%
M+`JRCMRN<]*["+PYHL%F]I%I5HEN[(SQK$`&*-N4GU(/()J:[TG3=1AN(;NR
MMYX[@J9EDC!#E?ND_3`Q0!C^$_M8EUF.^O(+RXCOA&UQ"H4/B&+!8#@-CJ!Q
MGIZ5R>C:KKNIP:5I.FWUMICW::E,\T5FA"F&[V+A,;>=WS''/)ZG->CV.F6.
MEP&&PM(;:(G<5B0*"<`9..^`.?:H[;2=+LY(9;:RMXGA618V2,`H)&WN!_O,
M,GU-`&#J.OZA8_"U]?)B.HQ::MR^U?D:0*"<#T)S7/7VK>*K)/$B#7+=VT&U
MCU%G-BH-P&5W,)YPJXC(!'S?-UXY]$ETZQGTQM.EM87L6C\HP,@*%/[N/2F2
M:3ITQO#)90/]MB$-UN0'SD`("MZC#$8]S0!P?B?Q;?0W"7.D:A.@M&LQ>6GV
M1'B'GN@`>1L-DJ_&SVSUJS<ZMXAFUS59+348(;+2=4M[9K4VRL;B.01%\MU!
M`D.,8]\]NKG\,Z'<WBW<VE6DEPJJHD:($X7[OUQGCT[5:&F6(:X86D.;F199
MCL'[QUP%8^I&U?R%`'&6_B+5Y?$5OX;>=#J$6HS-=.L:DFR5=\9('`+;XTS@
M<AL=*[U3D5CVN@10^*K[7Y9!+<W-O';1C8!Y429)7/?+$G/L!VK9H`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@!#TKSSP_XFUF#5[ZVN-.DNM-DU^XLUO6N1NA
MR2541X^X",9R.3P*]#/2L2U\,6EHDRQRSD2ZDVI-EA_K"<XZ?=_7WH`Q(_B)
M'+X@6S2RC:Q:_.G"9;I3/YP8J3Y.,B,,"-Q(]<8P3';_`!`O[R:U2U\/%UOW
MGAL6:\5?,EA+"3<,?(@VM@\DX^[TK;MO#!L+^:>QU2]MK>:Z^UR6B",QESRX
M!*E@K'D@'J3C%,L?!MA82:2\4UP3ID]S/#N8'<TY8ONXY`WG&,=NM`&5=^/I
MX?"L>L0Z=9B9'FCNK6ZU!83')$6#HC;3YARIQ@#-,M?%^LW?C*.V73+5=$DT
MJ+4#*]P1,B-G+$!>2"-NWVSGG%6I/AWI[.[Q7U["\JW4<K*4)>.XD,DB_,IQ
MR3@C!`]:O+X/M8]0L[N&ZNHOL]BNGO$&4I/`O(5\C.>3RI'6@#.T_P`9W=_-
MI1N]#:UL-:!_LZX6Y61F_=F0>8@`V9521@M[XK)\,^,M7?PKID5KICZO=6VE
MP7>H3378B;#AB`N0=[D(3S@=,FNAT[P1:Z?/IK'4-0N;?2U=;"WFD4I!N!7/
M`!8JI*C<3@'\:K0_#NSL[5;>PU;4[-38)I\[0R)F>),[2<J<.`6`9<<,:`,W
M4?B?*D2SZ5HJW4'DVDK?:;L6\A%R5$>Q-K;@-P!.>"".<5<?Q9/:ZWJ>G6=E
M/?:C)J0MK>WFN@D?%LDK$-M^10#T^8DG(Z\9U[X.U:SU2\.@PFWS%:Q:=<B6
M-DMEC4)AU<%C@`_=Z@CH>:Z&Y\$V=QJ,NI1WEY;7[7JWR3Q,N8W$2Q%0"""K
M*H!!SU[4`5/$?C34/#>CP7]UI-F'$32W5O)J2I(NT\B(;3YGJ/N]NF>+>C7M
MQ+X[\2VS32-;0P63Q1$Y5"RR;B!VSM&?I4%_\/K/4C,UQJ>HEKJR%C=N70M/
M&&9N25^4Y9ONX&#C'`K<L]%ALM9O]4CDD:>]CACE5B-H$08+CCON.:`.:7Q]
M>2WD<4&@-)'<7DVGVSF[53)<1%]V1CY8\(QW9)XQMZ$VT\87$_AI]0BL;.*_
M@NGL[FUN[\0QQ2(V&'F[2&[$8'.1TJU;>#[&UDLI$FN";34)]1C!8<R3>9N!
MX^Z/,.._`YJ!_`ME]ICNK>]NX+J+4)]0CE&QMKS#:Z[64@KCID9'K0!SUWXN
MFU%/#^L0?:+6WN]*U*>:VBF'+1JF,-C&00<-COT[5(WQ#O+:*TBLM(6Z1?L4
M$KW5^(YB\ZIM8+L.]?G&7XR0W'%;B^`=,CT^PLEGN_*LK6ZM8B7!)6<#>6..
M2,<5@-X/UNPU.Z_L@-%)YML+2^:2)D2*.-$82(REB<(WW<9W#IR:`-IO&=\V
MLO;P:&TNGP:DNFW-W]H`,<C;=K!,<K\Z9.1UXS4J^,)E\;P>'Y;.T\FY:189
MX;Y9)%*)O_>1;?D!&<<GM6C;^&K6W^W;))C]LU!=1DR1Q(NS`''W?W8]^3S6
M?IO@:RTO4[6\AN[MDM)[B>WMW*;$:;._)"AF^\<9)Q0!2TOQ_/>_9[NYT5[;
M1[FWGFBO//#MF$9<,@'`.&V\DG;T%0ZAXJU67P;>ZQ=Z--86C013VLEO?J97
M5V7`;Y2$;#`\;AC(S6Y9>#].LM'L=+W336MHDJ*LK#YUD#!@V`.S'IBJG_""
MP/H$NB3ZOJ=Q9-"MO&LLBDQ(KAAC"\G@#+9.`!0!47XAQOX@6R6RC:R:_;3A
M,+I3/YP8J3Y.,B/<"-Q(]<8P3I>%/%,WB>*:Y%E#;V@;$6+D/,.2")8]H,;>
MV34MKX8-EJ$]Q9ZK>VUO/=?:Y+1/+,9<_?`)4L%8\D`]2>E0V_A`P7EU?MK6
MH2:A/;1VOVLB(.D:,6&`$"DDDY)!_"@#IJ\WT'Q=>VWB3Q"FNWF_31<7;V;;
M0OD+;$>8G`R<JRL/]UJ]&4$=:Y2^^'FC:A`T-PURP.IOJ882`,'<_.F0/N,.
M".N.]`'(Z1XD\3375QIESJ'E7NI:A;K%))$O^@)+;M.R*I')55V@-GGDUH2:
MS'8Z)XIM].\1ZU<WMAI<\ZQZE;E'C<!L2*YC7<,C`ZCBNFO_``5INI7.H7,[
MW*SWD\-RLD<FUK>6)=J/&<<''7.<_2H1X&AE74VO]6U&_FU"P_LYYIS&&2'G
M.T*H&<L3D@\T`8ESJ&K^$+;2IAJ<^K6M];3!DORI>.5('G#!U4$J=A4@].".
M]/TN\U>RO_#S/JT]XWB*UD=TN@ICMYA")5,84`A/O*5SSQSQSLV7@>U@D5]1
MU'4-8,<#V\(OI%VQ1N-K!515&2O&XY..]/T_P7#IZ1XU34)I;:U>TLI9G1FM
M$;J4^7!;`4;F!X4#UR`0^#KO5[_PQ>"YOUGU".^N[9;F6(;?DE9%.Q2!C`'`
M-3^`KZ]U'PG#<ZC<M=7?VBYC>9E"EMD[H.!P.%'`INB^#I-#L+^T@\0:K*+M
MGD\R4Q%H9'8LSIA`,DL3R"/:K7A;PR/"]G+:1ZI?7L#N71;LH?++,S-MVJ.K
M,2<Y]L4`<UI?B76;3Q#J\#Z;)>Z9_;WV3[6;D9M]Z1[5$>,E0S9/(^_QFM63
MQI+;^,8]$GL;9H9O-\J6WO1+-F./>=\07*Y`..3VK4@\-6ML;XI),?MFH+J,
MF2.)%V8`X^[^['YGFLVP\!V6G7UO<PWMYMM9KB:VA)3;$T^[><A<M]XXR3B@
M"QX3\33^*+*2]-G!;VY(,/EW0EDP><2+M'EN.,KSUZUSFB^*]5L=1U".\L7N
M-*;Q!-8K?-<C=$7?;&HCQDH&(7.>-W3`KJ='\,II.I7>HR7UU?7MU%%#)-<;
M`2D>=O"*`3\Q))JD/`EG_:)N&U"_:U;4/[2:R,B^4;C=N#<+NP&P=N<9`H`S
MK'XF6]W?H7M(DTR<S+!.ET))OW2NS,\(&44B-L')/3(&:FT/X@'5IVCDTZ*'
MS;%[ZV\F\6<[%QE90H_=O\R\9;OSQ6G9>$H]/#6\&HW?]F-++(=.81F';(&W
M1YV[MF6)"YX^G%.TSPNVF6B6(UC4+BQCMVMHX)C&=JG`&6"AB5`P,GIUS0!6
M\-^++W7;V!9]%:SLKRR%]97!N`YD3*C#*!\C?.IQD\=<'BJ6M_$2/2=9N[2.
MRCGMM/DCCO'-TJ39<*0(HL$R8#`GD=>,\XZ+2M!MM)M]-AADE9=.L_L41<@E
MD^3EL#K^['ZU4N?#&[5;R_L=4O=/DO0GVA;?RRKLHP'^93ABH"DCJ`/2@"@?
M&=Z^LR6UOH;2V%OJ2Z;<W?V@`QR-MVL$QROSIDY&,\9Q56R\?7=_XFL=-AT>
M$6=Y=7%NLSWF)HS"&WEXMOR_=X!;D$'C-;UOX;M;8WNR28_;-0749,D<2+LP
M!Q]W]V/?DUR^@>&M?TS5[9D3[,JWMQ+>3F2-X[B%V9@JC;O!RR]3QM/7@4`,
MTSQS?MHUA#IFC7&I7LME+>[;F]`;RTE9&R^SYFSM``7OVQFK6J?$J.R.;;3X
MY5AL8K^[$]VL+I&ZE@D:D$R284\#`Z#/-:^C>"M/T26UDMI[ES;V4ED@D93E
M'D\PDX'7/Z4C>$$BN$N-/U.^T^;[$EE(T'EGS53A&(92-ZY."/4T`9>M?$B'
M2[ZXB@LHYX+*&.:\:6Z6*0*Z[@L49!,C!<$C@<@9SG%F_P#'3V$^M2-I9;3M
M&.VZN//`8N8U>-43'.=Z@DD`9[\XOW/A8OJ5QJ%IJU]8W%U`D-PT'ED2E>%D
MPRD!P.,CMCT%/F\)V$\&N0S>;+'K3A[E6(^4B-8P4XXQL![\\T`8T'Q#"V6J
M27^GQK<6*0R".SO%N$E\URD:B3``?<,$'@9!SBM/0=0U*[US48]4T]K":&V@
MS")_-B;+2G<C8&<C`.0#D8]#2S>$_MVDW.FZIJ^H7UO/%&@,AC1HV0[ED5D4
M'?N`.3GE1Q5W2-#.EW-Q<RZC>WUQ<(B/)=,IP$+8VA0`OWSG`H`Y*Q\<Z[&^
MKG4]&M3Y.J#3K..WNLL\S!-J'*@`88L7S[8XYZ;P_P"(+C5+W4-.U#3OL.HV
M`C:9$F$L;+("5*O@$_=.00,8JE>>!+*[EU!OM]_"MY=+>A8I%'D7*[0)4.W(
M/R#@DCD\5J:-X?ATB[O[TW-Q=WM^ZM/<3L,D*"$4!0`J@$X`'<T`9=QXPFM?
M&5KH<EG:-!=2M#'-%?*\RL(S)EX=N5&%(SGT]:H6OBR[U>[T:]?2YK31[F22
M:WNEG#^;&L,A_>(!\F<!E'/3G!&*T;7P+8VFJ1WD=Y=E(KZ:_BMV*;%FE#!R
M3MW$?,V`3QGZ4:=X(M---K''?ZA+969D^S6<LH,42NK*5X&6`#D#))&!B@"A
MIWB74-9U31+E]*ELK"[CEN+63[0'$T?EY`D`^XW(8#GCOD8J%?B-</I.GWW]
MCPQ#56']FK<7RQB10A9VD8KB,#'`^8G(X'(&QI/@R#2)+/R]3U&>&Q1X[2WG
ME4QPQL,;>%!.!P"22`,4#P79Q:+HNG6]U=P/HY4VETC*91A2I#97!#*2",<T
M`92?$1[D:9%::9";J[:57%S>"*$&*3RV$<FTB1B>5&!E>>*U=,\52ZMXGO\`
M2HK&*.VLY&ADDDN@L^\`'(AVYV'/#9Y]*;JG@]]:TM]-U#7-1FM9E9+A-L(\
MU2^['W/EQC:-N,#WYJQ_PBROXBM=8N-0N[F2S:8VL,GEA(?,&TC(4,0!P`2>
MO>@#G=8\1:SHOC;6?L.FR:E96^E6US-#]I$8B&^;<4!!W.0!QP/EY/2M77_&
M,NB:O8VWV.TFM;J6&$O]N59U,K[`1#MRR@D9.1W]*U)_#EM/J6I7SR3"34+)
M;*501@(N_!''7]XWZ5FW'@2QN=4N+TWEXBW%U;WDL"%-K2PA0ASMW8^5<C..
M*`.*U74_$%WK,VD6R/<V=QXCFMV7^T&MF*K;+((@ZJ65<@OD'J-N,&NQ\6:R
MG]DVATW4$,L>K64,OV>8$J&G565L>HR,'WJZG@^QCU-;]9KCS5U)]3`+#;YK
MP^21T^[MY]<]ZT-8T6WUJTAMYVD18KF&Z!CP"6C<.H.1TRHS0!YSK^LZQJ&K
MII&GV\\MK)KLMI.'U,P-(4MQ((U9$W1I_%P2<KCHW'06/Q#CO=:M[6.RC-C<
M7;V4,RW:M,9$W`LT.,K'E&&XG/3CFM:/P=8QZFM^)K@RKJ3ZF`6&WS7A\DCI
M]W;SZY[TZQ\+_P!F73-9:K>PV;73W1L@(S&"V2R@E=P0L2V`>IH`36O$-[::
MI;Z3I.EKJ&HS0/<LDEP($2)6"Y+8.22P``'UQ7-6/BC6[+Q+KB/I4ESIJ:G;
M0R.UT`UIYL,(VJF#N"LV6Y`YXSS74ZIX:CU'4[;4X;V[L+^")X!-:LOSQMU1
M@P(/(#`XR"*2#PM:P)J"B>Y?[=<0W$K2.&.Z)8U&#COY2YSW)H`I7'B^:V\9
MVFA2V=HT%W*88YHKY7F5A&9,O%MRJX4C.>X]:Y;0?$=S:R:;>ZA?7#VL6GZQ
M/<`L6W+#=`*<=RJY`KJ[3P-96>K1WT=Y>%(;Z;4(K<E-BS2A@YSMW$?,V`3Q
MGZ4MKX%TJV6%"T\\4=O=VQCE8%72YD\R0-@>HP/;UH`R+?XEK]EU":\TR./[
M-8'446VO%N,P@@%7*C"2?,/EY!YYXJY+XVU"QM-2?5/#YM;BV,'DH+I6CD69
MBB,SX`0*0=YP0O7)JTW@SSM"N-%N]<U*YL9K,V>R0Q[E4XPVX)DL`,9.>*3Q
M=X=GU/3)C9(9KAWM=T1D";TAE+X!((!.X]<B@#)C^(UTMC<->:/:PWBZD=-@
MC&H`Q22"/S&8RE0%4#O@GL!FGCXC/-;V"6VF0&^N;B:W99KT1VX:(@,$FVD.
M3N!48&1GIBI[#PG?7=M,FH7$]HD%\MUI?EF(S6N%PV65=I#$M\N#PQR3VT-2
M\)S:MI<VG7FO:D]O<))'.NV']XCX^7[GRXQ@$<C)Z\8`.C1RP!(P<=,YI]16
M\*V\$<2#"1H$7)R<`8%2T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`A.!FN=/
MC?0EU9=,:\83M.;;>87\I9LD>6TF-H<XX4G)R/45T1Z5YII>@ZSJ\VHVI%M;
M:9'XFDO7>57\Y_+E#@*N-I5BJ_-GIG@T`=7-XUT.#56TZ2[=95E$#2F!_)64
MG`C,N-@?D<9[BGQ^+](EEOE%Q((K%'>:Y>!U@PAP^V4C:Q4Y!`)Y!K`E\':V
M]G=:*MU8?V5<:M_:!N#O\]4,WGE`F-I/F#`;/W>V:ANO`NIZA'JMH9+/3M/O
M;:8&WM9I)$>Y:4.DI5@`F,?,%Z[CZ`T`=!#XWT.6PNKQKJ6&.UV>8D]M)%)A
MSA"(V`9@QX!`.3D"I?#_`(ACU^?4'MGW6\$B(H:)D="4!975N58'L0*YZY\&
MZM=Q"Y6'3+74X9+2Y24W4]P)I(69MCEQE8_F.,9(R<YKI-$T[4;>ZU*\U(V?
MG7DJ.$M=V%"H%P2W+'CKQVX%`&)H'Q`M+ZYGT^_+K?I?75M&(K:3RY/*=]JA
M\;3(47.W.3Z5O6WB72[PZ6+:Y\TZI"T]IM1OFC4`ECQ\HY'7')`ZUS-OX-UL
M7%M:3W.GC2X-:DU;S$WF9B9&D6/:1M'+8)ST'2CP9HDMOXJUV[8,+"SF>QTQ
M3&4V(S>=-@'MO8*".H3T`H`WM7\9:-H=X;2^N9%E1!)*8[>218$.<-(R@A%.
M#R<=#6)J7Q'ME/B*RTZWN6O-,L7N8IY+9S;R$1NX^;&`OR\'(#9^7-3:MX8U
MQK_Q"^E3Z>8-<MTCD-SO#0.$\LD!00XV<X)'/?%5I_`^IQ0:W8V5S:/9ZGHL
M>G"2<LLD;QQ21JV`"""7!/(QSP:`-K1O&ND:S:3S1W#1&TMTN+GSX7B"QL"0
MZ[@-R?*V",CBEM_'&A7%I=7/VMX8[4*\GVF!X3Y;':L@#@$H3_$.*AU/PDVJ
MZ=>V4TZ(EUI*V#.@^8,-WS>XY_G6+>>"=4U+1;^VG@TR"_N;.*W-TMW/,6*R
M!R/G&53J0.3DT`=;'XBL)-#?66>6"Q0$M)<0/$0H."Q5@#COGTYJC;^.=!N8
M+V87IB2RV-/]H@>(JC'"R`,`2A/\0XIGQ$BDG^'GB"&*-Y)'LI`J(I9F)'0`
M=:Q-5\&ZYXACU>XO;G3H;JZLH+*VCA+E%1)?,+.2,Y)R``.!CDT`;<OCS0X(
M8)9)+Q?.4NL?V"8R+&#@R,@7*IG^(@"FZE\0?#VE11S3WDDT3PI/YEI;23JD
M;_<9B@(4-VSC.#1J6C:W!XEN]:T62PD-W8+:R17A=1&Z,Y1P5!R/WC97CH,&
MO/[[0GT&2XTHQM?+;Z59P16S+-&NI-&6.W,8P3N(`W$XZ<#-`'IW_"4Z9_:W
M]EB29[P#<Z);NWE#9O!<@87(Z9QD\#FJ]KXVT2[M+ZY^T36T=@4^TB[MI(&B
M#\*Q5P#M///L:JGP]JYD\4WEI>QV5WK$<)M7'S-;ND(3YN,'D=LUC2>`=5N=
M,\1Q//:QS:K#:1QAKB6<(822Q9W&XYSQQQ0!N+\0O#I"$W<RDRK&ZO:2J8MQ
MPK2`K\BMD89L`Y%:-OXET^ZUJ72H'FEN8LJ[I;N80PZIYN-FX9Y7.:Q-7\'7
MVH0>-$BN+=3KL426^[=^[VQ!#OX]1VSQ4UEX<U2U\7#48#9V5@\LTEW';S2,
M;PLH5"Z$!588R6!R>E`%F'QG9S>,;CPT+6^%S#&KF;[*_E'.[^+&`,+PQX)X
M'(-/MO&NC71OU$UQ"UC#]HF6YM)(2(LD;P'`W+D'D5#=Z%J__"4WVI6-S;1P
MWVGI:,[%O,@=#(5=1C#<R#@D=*P8O`NMS6NKF]N[9KJ^T(Z9O-Q+-OE.XF1B
MPRH)8_*!Q0!N3_$+0+>T^TO+=LAWD".QF9BBXS*%"Y\KD?/]TYX-23>.]!MX
MK662YFVW,"W0VVLC>5"W223"_NUX/+8Z&N8\7VCQ:SIT4[^5"FC36[2[90DQ
M)3,9:(;L$*3@^HP,U+%X2U"^B&HKI5K#%J.DPV]SI=U>31"!T4A5S&/G3:Q!
M##/'7DT`;$7C^QN]1US3K>&ZBFTN)G-Q/:R>0V$W9R!T_5ARN14LGC_0[&WM
MOM][^^DBADD:&VD9(Q(`5=N#L0D\%L>G4&JQ\+:JE[XB$+6`L]8LTB&6</#(
ML!B``Q@KT.<Y]JCL?!E[:6FL12SVK_;=+L[*/`)"O#&ZECQTRP([\4`:=_XY
MT33=473IYKE[@S);DP6DDL:RMC$9=5*AN0<9SS4^M:W=6E[9Z3IL$4VJ7JR/
M'YS$10H@&Z1\<D9*C`ZENHZUPEQ'-%XOU!_L37<W]N0S0Z>3+'N`1%$Z[1Y9
M*@,V3UV\G.!7:>(M#U2XU33M:T2>V34;)9(C%=EA#-#)C<I*@D$%58$#M0!1
MOM=\56^I:)I4=KHZWMZ)VFD>21HBD00Y3`!4G>>#G&.]6[;Q5>7.C:I*FD'^
MUM,D,-Q9><`@?:&!$A`RA5@V<9P>F>*H7^C>+[G4='U>/^PS?V*W"/`SRK%M
MD$8&&VDD@H>H'4>E6H/#^M66AZN\4VGW.N:K,9IVDWQVZY4(%7&6PJ*`#W(R
M<9H`@;Q;J=[IGAE-,MK-=4UVU-TGVIF\F)5C5V^[\S'YU`''<]L';\.ZW+K>
M@1:C/;"UD+2)+%NWA6C=D;!P,@E<CCH:Y_3_``WK</AC2-+U'2_#U_)IT7DQ
MM)))A0L:JCJ3&2"?FW#CC&#6II7AFYT7P*="L+Y(;P03"*Y2/"Q2N6;<J]E5
MFX'H!0`ZU\:Z+=17\GGW%N+!%DN!=VLD#)&Q(#X=02O!YZ<&BU\<:#=6E_=+
M>/%#8%/M!G@>,J'^XP#`%@W8@'/:N;;P%K%UIGB".YN;5;K4]*BL%)N99_G3
M>2[,XS@ESP!QBMSQ'X7N]62YDL[BWAN<6<L#2J2IEMY6D`?'.TY`R.1S0!;T
M+Q)%KU[?_9')M[=8@$DB:.5';=N5U;!!X!P0.#[U5L]>UK6;AKO2+.Q;28KB
M2W)N)666XV-M9X\`JJA@P&<YV]JO:-I^J0ZCJ-_J9LA)=B()':AB$"!A\S,!
MN//7`],<5D:;H?B?0+BXL=+GTJ71Y+F2>%KHR>=`)&+L@"C#`,21DCK0!3B\
M:ZW!8:EKM]864NAV=]/;O]F9Q<111RM&9"I!#]`2`1QGKTK3U;Q)JFE>(M/M
M_L]A/8WMPELD,4K&Z&X9\W;C&P8Y'ISGM60/!WB2;3]2T">XTJ/1+^]N)Y9H
MS(UPT4LI<IM("J2#MW9..PK5U+P_J^J:I;M(FF6\5M>I-'?0%Q<^2A#"/&/X
ML;6.[!!SCM0!U-P91!)Y&SSMIV;\[=V.,XYQGTKA['7O&4FNZII]XNA"+3((
MYIW@6;<XD5RNW<<9!3G/K7:6OVO?<?:E@5?-(@\IB28\#&[(X;.>G&,5C1^'
M[E=>\1WYEB\O5+6"&)><H460$MQT^<=/0T`9>@?$*QUOPZ)A*(M3CTL7TR26
MTJQ<+\[(2/G16X.TFM6W\6Z>TNGVCS//=W<$4I^RVLKQIO&5+D`^6&YQO(X%
M48O"5W'X7L-,::W-Q;Z#)I;2<X+LD:@CC.W*'WYJF/".L076DR636-I-:Q6<
M-Q?132"2:*(?O(VCV[7!Z*2<C)/7%`'1ZQXDT[0C"M]))YDX8PQ0PO*\NW&=
MJJ"21N!X'3)[55;QOH7V6QN(KQYUOT\RU6W@>1Y0"`V%4$_*3SQQSG%9OB>+
M4_\`A-_#,VF00R31P7H)GW"(9$7#,H.">W'.#2^'O!M[HU_HMS/>03&SM+R.
MX*J5WRW$RRG:/[H(8<G/2@#1A\;:'/JRZ:EXWG-*8$D:!UADE!(,:R$;&8$$
M8![&H8/&FFZCKEEIVG77F-).Z.6A=5E58W+&-B`'VLH!*YQ619>"];AL]'T:
M:[L?[+TO4/M:3IO\^558M&A4C:IRQR<G@#`%6_#OAC7-)BT.PN9]-DL-'9UB
MEC1_.F38Z+G/"'##(&<^HZ4`;]CXAT[4;.RN[:XS!>;_`"69"N[9G=G/3&#U
MKG]1^)VAV6C7.I01W]W'#MVB.SE42AC@,C,H!7_:SCIZBJNF>"M9BTFUT6^N
M[`:?;0W4`D@#F602AP&P>%(#<CGZU-/X8\1ZAX&F\.7=QID92SCMX)8O,(D=
M&&UF!'R@JJ@@;N2>>@H`Z.7Q%86^A+K-S)+;V;`$>=`Z29+;57RR-VXG@#&3
MD53D\9Z7%HZ:H4U!H&=HRBZ?,94(&3NC"[E&.Y&.13-?T75=<T2RVR6<&JV=
MW%>QJ2SP,\;$A2<!L$=P,^U4]9T7Q/JQ@9KFS2$)<)+9QW,T:?,`(F+J-SE?
MFR,`'=[`T`7-0\<Z#IMI;W,UX[QW%N+J'R+=Y6>$C.\!03M`Y)[9&:36/&VC
M:9;C-\OFRVOVB)EB=T5&!V.[`8121C+$54T?P?=:==Z4\T]O+%9Z`-)<`'+O
ME#NQC&W"G\ZJ_P#"(Z[8RW7]FW&F/'?Z7!97`NE<^4\2%`R@??4AFR#CM]*`
M-0>+;>SDG.I7<$<<%C;7#JL3F0-*64>H;<0`%7)SGU%)8^,+2Z@U2_!FEL[5
MXT5(K21IE8J"RM&!OW`GICBLK5/`^IW6H?;[2[M%G@AT\VZRABK2VSR,0^!D
M*1)U'/M5BZ\/>);E9[A;RS@N+B_AN)H;:62)98$CVM$9`-P).#N`&<`8`H`=
M=_$K1K==*>*+4+F+49I(5:&RE)C9-VX,NW.X%2-N,]3T!K5E\8:-#K/]ER7,
M@N!(L+.(',22,`5C:3&T.<C"DYY'K7/6G@O6-/T_26MYK%[VQU6YU`QR22>6
MPF$H*[\%LKYG4@YQSUJ1/!=W;ZO>OY%E>65SJ::@GGW<R&)BRL_[M1L8AAE3
MQVSZT`:OBKQ0?#5UHC2+FUO+MH)PL+228\IV78JY)8LJC&#UJ1_&>D#0;?6H
MWNY[*X+*AM[*61U*DAMR*I*X*D'(&"*GUC1I]1UC0;R*2-4TZ\>>4,3EE,,D
M>![Y<=?>L74_"VMS".*RNX!:%KQI;7SY(%9I7+1N2@R=N3E>`<^PH`UV\7Z/
MY]C%%<2SM>Q)-%]GMY)0(W^X[E0=BGG!;'0^AJSK.O6NA6HN;Q+IHR<8MK62
M=AQDDA`<`>IXKE1X+U>UM]&BT^2RM[JQL[2TDU-)I%E9(S^\0Q@;74@<!CP6
M)["M?Q1HFLZK<VQL+N,6BPS1S6SSR0AW8`(^Z,9;;S\IP#GV%`$E_P".=!TV
MTM[F:[D>.XMA=P^1`\K/">=X"@G:!R3VXS3O$_B-])\&7>NZ>(;@I"DL!DSY
M;AF4`G'.,-FJ&C>#[O3;W2I)KBWECL]`_LIP`<N^Y#NQC[N%/YU9USPQ<ZI\
M/F\.QRP+.UK#`7?.SY"N>V<':>U`#HO$%SI.D-=^)+K369IA'#_9B22>82.$
M"<L7Z\"K_P#PD>FC0?[:EG:"Q`RSS1,C*<[<%"-P;=QC&<UEZEX0C@72I?#=
MKIUA)IU\;M;?RO+BEW(T;@[!P=K<'!Y`S4VN:)JNN>&DMY)[.'5(KF.[B*JS
M0AHY0Z*?XB.`">.Y`[4`-L/&.GW?]K7KW0BTVQCC:1IHFC>)CNW!U8;@>%X(
M[CKFI+;QOH5Q;74YNWMA:*KW"7<#P/&K'"L5<`[2>^,5FZCX5UG6M.UI;NXT
M^VN[UK:2W\A&=$:%]ZAR<%@2`"1CCMQS4UGP;KGB'^V+F]GT^WNKNR@LK>.%
MG=%5)/,9F8@')8D``<#'6@#6'Q"\.E4)NYD)E6-U>TE4Q;CA6D!7]VIR,,V`
M<BK\_BG3;778-'N&N8[J=Q'&[6L@A=R"P428VEL`\9[5C:OX.OM0@\:)'<6Z
MG78HTM]V[]V5B"'?QZCMFH)/"&N7/B.WO+N_AFMK75?ML+-/)N6'856$18V#
M&X_-U./>@#17QOIUM9F2^NEDE>ZN((8[2VE=W\J38RA,%F9>,D#'!(XKH--U
M&UU;3;;4+*42VMS&)(I`"-RGH<&N4TCP;?:?KFG7TEQ;M';76IS.JELD7,@=
M`..H`Y_3-:FCQ:AI<]CH_P!D1K.&U=YKI20JN7^1%'?C<3Z8'K0!T-%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`'IS3!-%E`)$R^=@W?>QZ>M.;[M>1W.A>(-/U
M:::TLKF2U\.W3W>F!3N^UK<2!I(PHY)13*O)_B''`H`]%N_$-G9:S8Z?,P'V
MQ)W6;<-B>5MW!CV/S_F*NM>@:A#:K%(XEB:43+MV``@8/.<G=Q@$<'IQG@8O
M!<9O?!UGJ&FK>VUO;WDM\94\R,7$@1B6SU)8OC([>M9NJ>&M:_LG3[33+*X5
MX-`N[11NP1F6'$>X]"R(P'/Y4`>AZKXBL],BLI2PGCNKV.RW0N"$=\X)]AWK
M4AFCGB62*1)$89#(P(/T->;ZCH>GZII6GVVE>$IK&S;5K.2[@DM1"'09+ED'
M4*#@GO[BNI\/Z4NA6>K6UA8B"'[;+-;0#Y4.Y5/R]@I;/3@4`:=]JUM9Z??7
M:2)-]BA>66.-P6&T$X]CP>M4M$\2VNMWEQ!!'*A@MK>Y+28P4F4LOXC:<UY[
MI>C:G<7FJ:A_8'V"2[\/7$4\,-B+=?M+,"(^N96Z_/W_`!(#GT#6AI>I*-+N
MI$-GHPEMQA6N(X03/$O/)VY&,CKB@#UB.Y@FB66*:-XV.%97!!/L:7[1#M+>
M='@-L)W#[V<8^N>U>6S>'[AYM<U#0-!FT^VMOL=Q86GE>1Y]S`S.Y6+HH9&"
M9(Y/.#BFZ/X<UA=4M[;4;6Z^PW4O]OW1Y)CN2KYAST+!FC(&!]S/6@#U2.XA
ME+K'-&YC.UPK`[3Z'T-8>C^*;?6M2U*&WC'V.P8QM=M,F&=?O@+G(4?WCP>U
M87P_L)-->\LTTIX;-(8"E]<60MKBY8@[EEQ_K&7C+]RQZ]3@?\(B;'3;QX?#
M:FW_`.$D>6ZM8+=0]S8@G:`O&]`Q5@GHIX[4`>KK/`\2S+-&8V&5<,,'\?PI
M5FA,/G+*ABV[MX8;<>N?2O*3X;N;E[I;31)[71+G7[1H[%H_+`@5=DS^7_`C
M'/'&1U'-=/XXT65_#6GVFFV0>QM;V%Y[&"W#B2!<C:(\@,`2K;>X7OTH`ZY;
MB!TC99HV67_5D,,/WX]:IR:UI<>HPZ>=0MUNYE9XXO,&6"D`_J0/7\J\^F\/
M7)\.BQT2"]BOGU@S6=S+:_98]//E@ET3M$0&7;CYB[#O4=KX;A@U3PQ>CPO)
M"T=A<6TCO;K*\%WYB;)';KC<)&$GOGC-`'J*7$+N\:31L\>-ZAAE?J.U"7$$
MDC1QS1M(H!958$@'ID>]>9>"?#[V%YIKW-E>VNH0VDT%WMT\1QW#_*"TLP)\
MW)!9#[GITIFD^$+NT\*Z;-9:<UGXAFT*YMI[AOD?SV5=GF-W.X<$],<<4`>D
M#48FU2.R3$A>.5RZL"%*%`5/O\X_*K$=Q#*KF*:-PA*L58':1U!]#7ET&A23
MZ9=1:!X>O=#NY="FMFDE41*]P?+P,`\OPWS]_4XXJ/X?E.DW4FFZ1J$?FP6C
M7>FIIXM$EB28-(G7$DQ7<I.>1@9H`]3M-2CO+ZYMH_F$,<;B16!5P^[ICTVF
MK+7,"R+$TT8D<D*A898CJ`*Y?P?8P6FI:Q+9:-<:58SF$PQ2QB-6(#!BB`_(
M,XXXYR<<UQ.N:=_:VM^*[:TT6>[UC^U+9;&^1!ML\10L3YF?W>/F)QUSW[`'
MIFE:]::E=7]LI\J>TNWM"CL`7955B5'<8<?K6DMS;M<-;K/$9D&6C#C<![CK
MW%>>6WA**35]6U6XT@_V@/$<4]M<E,2>2!$"5/79CS,CH<&J^FZ?J5Y\0],U
M>XT%;&:*YO%NY(K(1C9L98V:;.9=V%/MGV&0#TH7=L691<1;E`+#>.`1D'\A
M2BX@<QA9HR91NCPX^<>H]:\MLO"<J^"-`ADT9Q?3ZI`=4!C_`'CPB1P?-/4J
M$.,'C!QTI\'A*6UMI+FVT<PWUOXG5K21(@'BL_.4'9_=C\LOP.,9XH`].2XM
MWF>!)XVE3[\:N"R_44HNK=O-Q/$?)_UN''R?[WI^->4VFF:Y?>)H]3BT1-+U
M%K74(YY(;,0JLK8$1:;)\W)7=N[9]Z8NB1CP[I$=MX-NXFMY+9M;B-NJM=HN
MX,O7]\=^V3OD#KSB@#TC6=>MM'TG^TWS/;>;%'F$@Y\R18P1V(!859GU!(KV
M"V5'<R,RNZ%=L.%W?/DYY'3`/7TYKS.Z\/ZA-X?\41Z1I5SIUG=ZC9MI]J(@
MIC$<D8DE6+HJDJ6P0,@9(JQ'HVI>9H"2:/+'=VDE^M_,N76:5X&`FWGEA(2.
MO0G;VH`],CN(9':-)HW=,;U5@2N>F1VJM=ZO86=A<7T][`EK;!C-*7!"8&2#
MCO[=:\ZM?!ES;^%(#IEBUCKEWX:DM[J;[K-<$1$>8>[D[^3SUJO'X6AO-!UV
M&UT>ZBFN]&\M+&73%MH?/&XH>I#3!B/FR>,<T`>F6VJPW=W%%;AIH983,MS&
MRF,@$#;USGG/3'O5N*XAG#&*:.38VUMC`X/H?>O*YM"U"YB8:!H\^F[_``S/
M:1!H1;[+AI4)7'16;#'/?K78^$[?3(8I#IOAN;15:.+S5DMA"9&P>"!]XKW;
MOGJ:`.B%S`9A")HS*1N"!QN(SC./3-'VJWW,OGQ91-[#>/E7U/M[UY#I&G?V
MAJEK)8Z-<'4H/$MS+-JOEA52V2>0,GF9R01\NS].]7%\+SP>$K&>?0GN+@ZP
M\NJP",&:YM1-+L4@\NHS$P3.,+T[$`]36XA:)95FC,;<JX88/XTT75N;?[0)
MXC!C/F;QMQ]>E>0:EIWV.WN)5T:XM-$N_$-FMMIWE[#(@79+MBSA5<Y^7C(/
M(YJ1_#MXT8GBT.:W\/OK;S+I36@EV1&`1B0V^<;?-#/MZX;.*`/7'NK>.(2O
M/$L97<'+@#''.?3D?G67_P`)+IT]G>7.GSK?_9)#%+%;,I8,"`1\Q`XSUSBN
M*L/"\<]_X<M9M/NKO286U%IH[ZU$<:%F0QJ8CP$SG8#T`'2L^3PR;3PUXRTR
MS\-/#>SWS20/#:*JS6YE1D5&'4`9^7M@T`>LBXB$P@:9/.*[@FX;B/7'7%*M
MQ"TSPK+&94`+(&&Y<^H[5Y?:^'ID\5R3W]K>K>IK9N8[VWT\,9868E%-QG(B
M"$*R\=.AZG3\*6$EAXKNE@TJ=K:=)YI=1OK(17"N9>(O-ZRJ1DCT`7GL`#NV
MN;<7"P-/$)F&5C+C<1]/PI?M,'FK%YT?F,"0FX9..O%>9ZWI^I:IXUM;@Z$D
M<EGK%N4NH[(%I+50"9&N,].2I0>GOQ:T_P`+EM0FU6ZTMAJ,7B22:"X9?W@M
MB2,@]?+(9CCISG&:`.XN]3BM;FW@X=YIUA*JPRF59@6'_`35N:XAMU#331Q*
M3M!=@`3Z<UYCX;T66WO=(^U^';R+6[;4)GO]3V`),K"7#E\_O%.5P,':?[M:
MOB;3TG\8076JZ!-K.D_V<T<,:0"<17&\L<H>A9=H#=L=10!W+3PI,D+2QK*X
M)1"PW-CK@=Z1KF!94B::,2.2%0L,L1UP*\FUSP_<SQ^);=_#=S<:S>31G2+]
M8PWD1E$5`)L_NO+96+<CK_%FMF;PM]KUC7M1NM+,MW'J]I-I\[+EE15@+%#V
M7(?..O.<T`>@"X@,:2":,HYVJP888^@/>A;FW<R!9XV,1Q(`X^3Z^E>:OX;U
MEO$LVD0Q&+2K::ZU6RNR/W8FE3:B?5)7E?\`[Y(QC%9>G>'9X?#EX+?3=0M=
M5;0+FW>"/3A"LLVU0"\@)\V3<,J<G@D\9H`]6N]2AM[&ZN8@;HVP.^*!E+DC
M^'D@`_4BK!N(D>..25$DDSL1F`+?0=Z\UUCPC]E\-Z]%H^CM'+?:%'&\<*<S
M3@OU'=_FY)Y/>H-?\.SW/B76)KZUO6\XV\MA>6FGBXEA10H*1R9_=,&5B>F0
MW4]@#U!KF$2+%YT8D;.U-PRV.N![55T[6=/U9IQ87L-P;>1HI1&X)1E."#_G
M%<3!X56?5-4U.[TMC?1>(HY[.X9?G$`\K)4_W.9,CH><U=\"Z-!H>I:_;_V%
M]BE;4)I([A+9522W9@8U5QU`S]WMSTH`ZN_U**Q$8)#R/+%'Y88;@'<(&QZ9
M-61<0F;R/-3S@NXQ[AN`]<>E>9VVBR+JTAO/#MY)K"Z[]I_M1%&UK8S!ES)G
MYE"$+L[%<XXS56'0;K?:0MX>N!XC37OM$^KF,!6MQ,9"WG#JAB(39Z\8[T`>
MG7NIPVMM=2Q@W,ELFYX(&4R?3!(`/U(JP;J!72-IHUD<X5"XR3W`%>0RZ'>K
MH7B?3=-T.YF6ZTV9EO;NQ$5W+,TAQ"S?\MN,G=VP/6MV7PJ+S6-=U"ZTMI+J
M/5K.;3YV3YU15@W%#V7(?..N#G-`'?M>VJ7`MVN85F.,1F0!N>G'6G375O;[
M?/GBBW'"[W"Y/H,UY'865@?%EIJFI6H5?^$BN5M;S[&)'ED)D1(WE+;MH.2O
MRX7:H!XR=CXD6-_JXGTZ/0H[R%M,E-K=?81<.+DY41AB<1<;3O\`\*`.Z&L:
M>^K2:6E[`;Z)%=[?>-X#9QQ_P$U:DNK>&2..6>)'D.$5G`+'V]:X/3-$BLOB
M)_:%QH19KG3+9(KY;96\N=?,$I9^JL5*#)Z\#M6?\0].U/6KN[M8M!2=HH8&
ML;M+(32.Q?+CS2?W.W&??-`'I[R)&C/(ZHBC+,QP`/>D6:)HUD61"C_=8,,'
MZ&N4\;V4MZFCNVG2:EIL%\)+^TC4.9(RC*I*'[X5V5B/0=#7,'P]=RZ'J,-K
MH]Q:Z==>(+66VL=NPI;!HEE.P'Y$;;(V..&Z#-`'J"W5N]O]H6>)H0"3('!7
M`Z\]*3[7;!8F-Q%MF($9WC#D],>OX5YWJGAB+3V2"ST-IM"37!=76GP1@K)$
MUNJ[ECZ,JRD,5']T\&LK5/#:7&H7A.AWEMI<^G[=/6'2UG>S*M)N$:Y_<NQ9
M74X_$$8H`]>R/45'!=6]RA>">*50<$QN&`/IQ6'J::Q::)=7-EB_:.S/DZ?-
M"`TSA>C-GJ>X]ZYGP7HU]9ZEKTMM;#2X;F.T,#C31;H74/YF(<\'D#)/YXH`
M]$::-%+/(B@$`DL!@GH/U'YTU[BWC\PR31KY8!?<X&T'H3Z5YMXJ\+:QJ6N3
M:=;B4V&KPPSW=VC;%BGMU.W(&2`Y\G@$8V'J:SY]$U?4[6QUS5-,D=KS4?,U
M&R:T\YE18?)B+0L>55@S[<G'F9`-`'K+W,$=O]H>:-8<!O,+`+@]#GI6?)K<
M$7B*TTAE8O=6LMU'*I&S:C(#G_OL$?C7GMSX=F&FZ!&EK>76DV][=_:+6YTT
M/L\PGRV%N3_JE^8*.P8'''%6\\,ZLT6@C3+:_N+2UL[Q;B"Z3[.UQ$UQ&QMS
MC[@*@[!QE5`/!-`'KZ.DB*Z,K(PRK*<@CUIU5[$QM9Q-%"T,91=D3)L*#'"[
M>V/3M5B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@!#C'/2DRGM2GD5Y/#XAOW^RZJ/$-S_:T
MVN?V?)HQV&-(O/*E?+V[@1%A]^<_@:`/6/E[57M[ZSN9KF&":-Y;6013*.J,
M5#8/X$'\:YGPRUYJ?B'7KNYU.Z:+3]1ELH+16`BV[(WRPQDMESCG@5RUU?2P
M>,-5T_\`M*73+34=>$-Q>1%5=<6,11`S`A2S8&>O&!UH`]6RO;%&5]J\LM-8
MU3418Z9%KUU):3:[<:='J$002S6Z6Y<$,!M9@ZE=X'8]Z;JNH:I:6>E:5<Z]
M?E0;]'NH)HH)I&AEVQ%Y'PI`!P0#DGGL:`/5<K2_+S7D=Q>^(`-.TN37I(YH
M]%CO$NEOXHTN;@[O,9I&4^9&IV\#LV3VKH]#FU+6/&%W%=ZO((M.M;*X\FR=
M?)FDEC?>2<$E,KD`$=<T`=D+NT>\DLUGB:YC19'B##<JMD`D=@<''T-3?+T&
M*\\\5:[J.EW_`(ODM;ID^PZ';W5NIQA)"\V3^.U:R?&>FZA9^%O$MK<>(M3N
MH8X;2]C=Y%5T+.RNI('W#M#8[8H`]9^3VH#+VKR;4M1U;^U;ZQT[Q&RIIMK%
M-83W.HQ)'<!@=TLQ*DRKO!0XP!M]3FMR]AU;7?%'B+3K77+RQ_L^TMY+1+9E
M53-*C\OD9904!QD#DT`=[E#SQ4-Q?6MJ]NEQ.D;7,ODPACC>^"VT>^%/Y5YC
M'XSFU6TNM1N9]0M;41VVDB.UD6-DOW^:7+,,+M.U-Q''/'(J'3K^[O;'0%O;
MR6Z:V\7/;Q2S2K(Y18Y<`NH`;J><4`>MX'7`J!+NTDN9K5)HFGA"F6(,"R!L
M[21VS@X^AHM[J"[C+6\\<R*[1LT;A@&!P1QW!X([5YMXAU.YT?4_'M_8S"&Z
M@M=,*/@':2SCI]#0!Z>"O;%&4]JYKP[:7NG:MJVG7.K7>I0QF&6%KLJ9$WJ=
MRY`&1E<CCC-<E!XEN+GQQ9W&FWVH2V=W)>Q/9W$\;(6AC/"Q*-T?SKP2<D?6
M@#TV2YMXYX8))%$DQ(C4_P`6!D_I237EK!+'%+*J.ZNZ@^BXW'\,BO+=(UF>
M6+1]63Q`VK:E/87%W+IS[28IUA.555`*`-E"IZGWS4^AZC]HFTV\3Q2^JW%Q
MI%Q=2PN49H)=L>XKM`V*#QL(X(^M`'IMO<V]U:QW5M+'+!*@>.5&RKJ1D$'N
M"*KZ=_9LL;ZAIWV=TOB)FGAP1.=H`;(^]\H`SZ"O+]"WW?BOPKJ5]KM['-=>
M&HI]GVA52:4&(%-N.0V<D#DFG:1KESJEEX>M-6\27.E6\FA+?FZBD2)KB8,0
M^792,*H!*C^]D]!0!ZUE?:EP.M>4:=J6O^*H]+M)M;N]/DN-#EOGEM46-GD6
M78CD$<*0P8@8SQT%>AZ)?_:M*T]9[F*2^DLHIY5#`,=RC+;1V)S[4`75O+1[
MJ2U2XA:XB4,\(<%U!Z$CJ`::FH6,MY/9I=0-<VX5IH1("\8/(+#J,X[UY9J=
M[%X=^(NO>*9`_P!GLKFUM;]D7<1;2VZ\D#GY9!&?S]:Q]0M+FTN]0N[R%_M-
M_IEK?ZLD&XOY#WI,J#^+Y8@$[<*>G2@#V*QU_1=3FEAL-5L;J6(D2)#.KLI'
M7(!HTSQ!HNLE_P"R]5LKQDR&%O.KD8QU`/N/SKC[+7;9_&UAIU@GANYTZ:UG
M:SFT[#3V\:!1AL<*"3CC^[[5SNAWFC7?@[P+!I=U:R>((I[0`6LBF>.,$>>'
MV\A3'NR&X)QWQ0!ZM'K.E3:K+I<6H6KZA$NZ2U653(HXY*]1U'YU82YMI+B2
MWCFC::(`R1JP+)GID=L\UY/H<L%SH'@^"U9&UR/6F-P%_P!<@5Y//\SN/D;!
MW==P[D5M^&+S0(?B)XLM;*]L!YT5LQ2.X4F1P)3*>N21GGTXSB@#O8;JVN&D
M6&:.4Q.4DV,#L;T..AY'%2Y7H.]<#\-[O11+XDL-)N[)HDU:22*&WF5OW7E1
M#<`#RN<_-ZYJAXI\12KXKB73M2OX9;+4;*RN(3<QK"_FNI($1!9\HQ^;(QV^
MZ:`/3?EJ*:YM[;RS,X3S)!$F1U8]!7G\4VKWNM7VH#7;N*+3O$"6*V:[?)DA
M;R]P88R3^]X.>,"J-CJLFIWUA=WGB)OMSZVUM+HS[=L2QR/L"I@,K!0K%CG(
M/N*`/3;:SM;*-X[:".%'D:5E1<`NQ)9C[DDDFDM;ZSOEE-K,DHAF>"3;_#(I
MPRGW!KA?%EI'_P`+(\+3SZU>6$4D5RFU+D1Q[D\L@#(ZMD@CN`,5GZ%;7L&K
MWVIVVL74<9\4SV\MD"OD.C$@Y&,[LD'.>V*`/2[BSM+P1"Y@CE\J598]ZYVN
MO*L/<>M1:AJNFZ3`+C4KZVLXBP4/<2A`2>V37GGA75=;U+6+*^N-557GNY[>
M^L9[R/;'MWXBBA"AE==J$DDG&XG.:T[G4=-T_P")=\WB*YMK>-].A_LR6\=4
MBVAF\X*6XW;MF>^`.U`'<I)%)&LB.CHP#*RG(([$&G94^E><7^IV5SKCV$'B
M,Z'HMIIJWEI)9-'$DS;W#G)4AE3:ORCCYN:R)_$/B"^TK[7/J=S97%IX6366
MBA58_,N%,F-X(/R':,J,9_"@#U[Y:/EQVYKRS5]9UGP_'JFS6+F[DF\/G54:
M<+^YF1E4[`H&$.[E>>GO2'Q$ND7NLVH\1WVK::;.W8W,<T1D@NII"@59<!$4
MC:V#]T'-`'JF4]J7Y:\FL]:U?^P6M%UBZ\S_`(2=-+6Y>5)I5A=5W#>!AB"S
M8..#CTK2DOM1\+VPU"\UJYO=-TO4I;:\,_+-;NBE"Q`Y9'91G`X)Z"@#T)KB
M!;F.W+@32(TB+CDJI`)_`L/SJ3Y/:N,L8]57P$NK7=]#!KSV4TRW-ZV([8RD
M/M;L%7"COC;WI_A#42^C:G$MQ?W=Y83-',+NX2X_>;`VU)$`W+@CL""2,#I0
M!V.5JO<7MG9R6Z7$R1-<R^3"&.-[X+;1[X4_E7EVE:G=WX\-M'XKOKFYUZ.3
M^T;9'3-KB%BS1@+F(I(`G/<\Y-9VE6J7/P^\"V\.NWCS7&JVXDD$ZO):MY$N
M43CY.AX.2,F@#VDE>^*/E]J\NO[_`%BSATO17UF[:"74+RVDOS/'#,^SF&+S
M&4@,03SC+;.V<5;L9M9U+4/#^D7>O.OG6=W/<3Z=,C&7R9T6,>9C&=K8<@<D
M$<4`=OJ6MZ1H[0+J>HVEF;AML7VB54WGC@9Z]1^=6OM%K]F-SYT7V<)YAEW#
M9MZYSTQ[UQOBR[TZQ\>>%9-3N;6WM3!?J7NG54SMBQRW&:YR":"XL-0T?2D:
M?2=6UK98V\+`*UJB*]SY0)4!"RR+P<?/QD4`>G3:OIEOI(U6>^MH]/*+(+EY
M`(]K8VG=TP<C'UJG-XL\-VUC#?3:YIL=I.=L4[7*!'.,X!S@G!S7G%].;;X>
MZYX=$:P7&EZG;"WM[@CY();F.2'=M)^4;BO!/W?PK<T"%S<>,4U>"SBU9=IE
M@MA^X\OR3Y<J`\Y;Y@2><ICH!0!VFEZ[H^MQ22Z5J5I?1Q,%=K:59`I]#CI5
M_*CTKF_`\<:_#K0&150OI=N25`&3Y2\UQOAV?6M;.@0W'B74D_MS2)+VX:(Q
M@QO&8U4194[!^\.>I)`]Z`/5OE]!^50-?6B7\=@TR"ZDC:5(CU9%(#$>P++^
M=>8Z?XCO-?@\-VNJ:Y-I-O=:=-/)=V\BPM<S12!,;V!`^4,Y`]^PK-E\1ZPU
MAINNI*+G4H]"U-HKCR@N]%N8E67;C'^K`?I@^F*`/5HM!T:#4&OXM.M8[MG,
MAE6,!MS#!;ZD<9ZUH_)Z#\J\HGUK5-)TV;'B'?IUQ/9J;Q[R*YGM8Y7823;E
M4*L94*%)!`)8UL2:I'HVL^&K5/$TEWIS7=W%<SW4Z')6$L$=P`"5;D=^W:@#
MN)+VSBOH+.2:-;F='>*,]75,;B/IN'YU/\GM7D^MZY=G^P]9TZ7[7=I8:S+:
MMC=OVE=F!WP`/RJU87FMKI>K/9^)K-XYM/2>VGU#4(I625F(+Y50$C(P!D$!
MORH`].^3/:H+F^M+.2WCN)TB:YE\F$,<;WP6VCWPI_*N6\+7$>K^&-0LTU'5
M3+;SRVDUQ+<I),D@`)\N51A@,C!QZ@CC%<-I5JES\/O`MO#KMX\UQJMN))!.
MKR6K>1+E$X^3H>#DC)H`]IRN>U'R'TKS2[U*6TTRWT&\UK5'O'O[M(+R.YBM
MW,<)W8DE88X5AT&3M)Z`UF:-+-JFO>!M4U37KZ&:ZT5Y'`N%C2617A^7&.=^
M?F'4X&,8H`]>)4C!QBC*]>*Y#59+V]^(-II$>I75I:#3C?/';,%:1TF50I)!
M^4[N<=<"N;\*:SK][<V>J3:FLKW$=Q]LT^>[C.)$4D1PPJH965@`<DG&2<YS
M0!Z=)<V\,\,,CJLDVX1KC[V!D_I1:W5K?6D=S:313V\JAXY8F#*X/0@CJ*\U
M\+ZD=1OO#EY+XE;4+N]MI9[FRDV$VTHCPP4*`4"DE2IZD9Z@U%X6U/6-;;18
MI-5N_P!WX?M]2:.%E4W,WF.,.<?=.,$#&?7B@#U3Y?:CY#Z5X]8>(O$47A^3
M7H=6%U/-I<\\MI-<QRL+A5&!#"J@J$;<&!SVS5CQ);VLOAFVEM_&VI7R?VCI
M\\LPNXQY:R2@;\JN%&/F`/`*YH`]:!!Z4M5M/5$L(%BN6N8UC4+.[AC(,?>)
M'!)ZYJS0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`5`+*U%V;H6T(N3P9O+&_ICKUZ5/10`Q
M(XXRQ1%4NVYMHQN/J??BHY+.UF21);:%UE(:16C!#D="?7H/RJ>B@");6W1(
MD2")5B.8P$`"=N/3J:RM3\/)?ZC;W\%Y/974$<D0>%8V#)(06!#J1U4'ZCO6
MU10!DZ?X<TK3M(M-+CLHI+6U3;$LRB3&>2>>Y/)K2C@BB8M'$B$@*2J@9`Z#
M\*DHH`B>V@D+F2&-_,78^Y`=R^A]1R?SIS0Q.&#QHP==C`J#N7T/MR?SI]%`
M%1]*TZ5(TDT^U=(QA%:%2%'H..*L+%&LC2+&H=P`S`<G'3)I]%`$!LK5H9(6
MMH3%*VZ1#&,.?4CN:5+2VC2-$MXE2,[D4(`%.,9'H<5-10`R.*.)2(XT0%BQ
M"KC))R3]2::]M;R>9O@C;S``^Y`=V.F?7%2T4`(%4,6"@,>IQR:A2RM8YVGC
MMH4F<Y:18P&8^YZU/10!#':6T+L\5O$CNV]F5`"6]3[TD=G:P[O*MH4WDLVV
M,#<3U)^M3T4`0-9VK>3NMH3Y'^JS&/W?^[Z?A39=/LIH8X9;.WDBC^XCQ*57
MZ#'%6:*`&>3%Y@D\M-X78&VC.WT^GM52'2;.#59M2CA`NI8D@,A.<1KDA%_N
MKDDX'<U>HH`B:V@<2AH(V$HQ)E`=_;GUIWE1^;YNQ?,*[=^.<>F?2GT4`5K?
M3[*TD:2VL[>%V&&:.)5)^I`HM]/LK-V>VM+>!G&&,404GZX%6:*`(4M+:.X>
MXCMXEGD&'D5`&;ZGJ:BCTS3XIC-'8VR2G.76%0QSUYQWJW10!6MM.L;-R]K9
MV\#D;2T42J2/3@4YK*T>X%P]K"TX&!(8P6Q]>M3T4`1B"(;L1(-S;VPHY;U/
MOP.?:FBTMA.TXMXA,^-TFP;FQTR>O%344`136T%R%$\$<H1MRB1`VT^HSWI1
M!"H.V)!E]YPHY;U^OO4E%`%8:?9"Z^U"SMQ<9SYWE#?GIUQFG7-E:WJJMU;0
MSJIR!+&&`/XU/10!7GL;2Z5%N+6"81_<$D8;;],]*D>WAD9F>&-BZ>6Q90=R
M^A]O:I**`,S6]"M-=TB[TVX4QQW4#6[R1`!U0]@2.*M)I]G';R0+:P"*0YD0
M1C:Y]2,8-6:*`($L[6.-(TMH5C1@RJJ`!2.A`]:IZWH=KKNER:=<[UMY9$>9
M8\#S0K!MK<=#@`]\=ZTZ*`(VACEA,,D2/&PVE&4%2/3%)!;06L7E6\,<,8.=
ML:!1GZ"I:*`((K*U@GDGAMH8YI/OR)&`S=^3WH2RM(O]7:P)^\\SY8P/G_O?
M7WJ>B@"&:TMKB(Q36\4D;-N*.@()]<'O1%:6T`00V\48C!5-B`;03D@8Z9-3
M44`07-E:7H475K#.%^Z)8PV/IFGB")61EB0,B[$(495>.!Z#@?E4E%`$3VT$
MC,TD$;,P`8L@)(!R,_0\BE^SP^:TODQ^8Z[6?:,L/0GTJ2B@!J(D<:QHBJBC
M:JJ,`#T`IB6T$1C,<,:>6NQ-J`;5]!Z#@?E4M%`%:33[*:!8);2W>%#E8VB!
M4'V&,=S4OD0Y4^3'E5**=HX4]A[<#CVJ2B@"K%IFGP)(D5C;1I*-LBI"H#CT
M/'-.-A9FW2W-I`8$.Y(S&-JGU`Z#K5BB@"/R(=ZOY2;DSM.T9&>N/K5=-*TZ
M-)%33[55D&'"PJ`P]#QS5RB@"."WAMHA%;PQQ1CHD:A0/P%,2RM(O]7:P)^\
M\SY8P/G_`+WU]ZGHH`@FLK2X39/:PRKNW[7C##=Z\]_>E>TMI!&)+>)_*;='
MN0'8?4>AJ:B@!GE1^;YNQ?,"[=^.<>F?2H5T^R2Z-TEI;K<$DF41`.<]><9J
MS10!#':6T3L\=O$CNQ=F5`"S'J3[TL=M!"5,4,:%4"`J@&%';Z>U2T4`5H]/
MLH;AKB*SMTG;.95B`8YZ\XS0FGV4=O);I9VZPR'+QK$H5OJ,8-6:*`&HB11K
M'&JHBC"JHP`/04ZBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
9HHH`****`"BBB@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`0B`S$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`I&.%R>@ZTM8&K7
M$M_=C1K)B&8;KF0?\LT]/J:`)M/U"XU+4II(2!IT8\M"5YD?U!]*V:AMK:.U
MMD@A4+&@P`*FH`****`"BFALMM/6G4`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!4%W-)!:RR10F9U4E4!QNJ>D
MQ0!4TW48=2M%GA/LRGJK=P:N5S^HVD^EW1U6P0LA_P"/JW7^,?WA[BM+^U;0
MZ4=0$H-N%W9[_3ZT`0ZSJ9L+=4@7S+N8[(8_4GO]!3M(TW^SK8^8V^XE.^:0
M_P`3?X53TBUEN[A]8O5Q-(,01G_EFG^)K='`H`6BBB@`HHHH`9(A9<KPPY%)
M#()$W=^A'H:DJDS>1?K_`'9AC\10!=HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*.U%(>AH`P=1\1K8W[VK6K.$`
M+,&[&H9=#M_/^V";&G_Z]K;'!?'!^GM56\MQ>>);Z`_QVQQ]<"JYU!Y?#$-H
M#^]:40D=]O7_`.M7B1Q]2$ZGM'=:V^70]!X:,HQY=]+_`#-G2?$(U*\-N+9H
M\J64ENPK5EO+>W<+-/'&Q&0&;%<[I\"VWBQH$'"6^!^0JI?Q_P!JZAJ4NX$6
MT8$7U'7^M.&-K4Z%Y>]*[7;;<4L/"=3W=(V7XG9[AC.>*K#4K-IO*6ZA,G]T
M.*YV[U*5O",+JV'=A$Y!Z8__`%5H6&@V!L;=F@S)M#E\D'/7-=*Q<ZLU&DEL
MF[WZF+H1A%RJ/JU]QIOJ-K%(8Y+F%7'56<`BI8YTE7=&ZNOJIR*XR[FM(/$=
MXUY;^='T"X[X'-.T]IK30-1N8P8TD8+$/3W_`%K"&9R=1Q:5E?UT-7@TH)WW
MM^)U4FIV43['NX5;T+BH]2R]K'+&RDHX8-GC'?FLO2M$LI]&CDFA#R2J6+GJ
M*Q_/F7P5JR*['RAA3[$\UK'&U8N/M(JTDVK?J3]7A)M0;T:3^9>;QI+=7$D6
MD:3/?+&<-(/E%:6C>('U)KB*YL9K*:W`9Q+TP>X/X5C:/-=Z?X&M)M'LUN;A
MVRZ]<Y)R>/2ETKQ!>ZW9ZQ!>P10O;P,"$!R#@Y!S]*J%>2:YI:OI;3[RZE*+
M4N2.BTO?7[CH_P"W=*.`-2M,GI^^6IY-2LH)1%-=0QR-C".X!.>G%>8^'+K3
M!';6MSH7VJ628`7&#QD\=NU7?%E@;WQ5=H@/F1V0E3'7*\TEC9NE[1)/7S&\
M'%5?9MM>>AZ'+>0031Q33(DDIQ&K-@N?84+?6SW+6R7$;3H,M&&^8#W%<!_:
M1U6]\)W+$&7S"DA']X$?SZU=L6\OXC:L^.5@8C\EJUC>9Z+2Z7WJYF\)RIW>
MJ3?XV.NN=6L;)PEU>00L?X7<`_E3I-0M(;<7,ES"L!Z2%QM/XUPW@[2K371?
M:CJ<0NIVEVXDY`XR:?XMT<:=;::]E:F:QM7;?`0649.>>^.U'UFI[)U;:=`>
M&IJK['FUZ]CM[34+2^0O:W,4ZCJ8VSBK5<MX2O-(OH[B?3[-+2X;`FB4]<=#
M74UU49\\%(YZL.2;C^84445J9A1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
MA^Z:6D(H`Q8M/G'B:2^RGDM'M'//053@\/2QZ_\`:3L^RAS(HSSGZ5;B)_X2
MR<9./LR\9XZUN#I7FT\+2K7;6TF_F=3K5*>B>ZL8+Z;>)KMS?1^7M>$JG/.[
M`ZU6L?#$?V?-Z7$[$EO+DP*Z>BMOJ%%RYI*^_IJ1]9J6LGV_`Y:W\/W(M+RS
MF9!"[;X6!S@CID5-:6VOP+%;[H!"A`\PG)V^F*Z.BICE]*%N5M6\QRQ,Y)J5
MG<P8=)F&O75U,J-!,NU><GM4-CHES#:WUC.R_9I>8F#9*^^/RKI**:P%%._K
M^.XOK$[6]/P.6ALM?M+0V<7V=H^0KEN0#5>_@71-&BLVVSO=RXF']]2.0/TK
ML#7).W]M^+T5?FMK,9/ID'^IX_"JI8*G"7-=NRLK]`GB)R5MNI4M=$\3:#YD
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M2OZ'*^&M`N[#4+S4K_R4GN1CRH?NJ,Y-=4.E%%:TJ4:4>6)G4J2J2YI!1116
MA`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%':BB@#"B_P"1NN/^O9<?G6[6
M%%_R-LY_Z=E_G6Z.E<N%VE_B9K6W7H@HHHKJ,@HHHH`**0G%8&I^(TB?[)IZ
MFZO&X`09"_XT`/\`$6L_88/LMO\`->3#:BCG:#W_`,*F\/Z3_9EAB0?Z1*=T
MI]/;\*K:+H3P3F_U!_-O9.>3D)_]>M\#%`"T444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`$'V=!.9A&OF%=I;
M')%3CI11222V`:P)&`VT^M57-_&?D2&=>WS%&_J*N44P,XWU\H_Y!4Q/^S*F
M/YU7DO=:DX@TE$_VIIQC\A6S10!SS:-JNH\:EJ02'_GC;+@'ZFM2PTJSTR/9
M:PA<CECRQ_&KM%`!1110`C9VG')KC[;QK?3^($T5_"6K071C69R\UN5CB9BO
MF'$AR,@\#)XZ5V-<T+"Z7XE3:B8&^QMH\<`FXP9!,[%?7."#0!NW=_9V$/G7
MEU!;19QOFD"+GTR:1M0LEO$LS=P"ZD7>D)D&]E]0O4C@UR/B73Y7\7:?J-UH
MCZSI:64T!@5$D,,S,K!]C<?,%VY'3/I6!:^&+F+6[@W^EWZ.VJ07=O-:6\#;
M8_D*QF4_,JQA=C`=5'RYS0!UL7C&&75DT_[)*';59=,W[QC>D'G;OH1Q[&M^
MTU"SO5?[+=P7'E-LD\F0/L8=CCH?K7G<WA[4VU>:62PN3;-X@NKIC"P#F![$
MQAE.>"6^4>];/@*QN]-CO;.336M=/A$*VL\]O'#<3X3Y_,"'#;>`&P,Y/7J0
M#JXM3L+B[EM(;VWDN8O]9"DJLZ?50<BHH=;TJYFDA@U.SEEB!,B1SJS(!U)`
M/&.]>8C3=8EU?^VM4T;[$T%EJ(OC!"D"#<OR;9$)=\A2=QR03T[56T.UGTR#
MS+/2(I?$,_AU!;0&TB2&>-6&\L5<Y<[Q][:&P/?`!ZE-KEFVFM?6,T-_$LBQ
MG[/<1XRS!?O%@O&[.,Y],G`JU_:-C]J2T^VV_P!I<$K#YJ[V`R"0N<G&#^1K
MRY/#&J'2/$:0:7,JWE_ITMO&8(X"ZQO'YC;%.%QM)]2!6QIWA9Q=W%_<Z6!?
M+XDDNXIV`W_9R2`0V<[=I/'OTS0!V5UK^D6<-Y+<:E:HMDNZY_>@F$?[0'(S
MV'>IM.U2PU:QCO=/NXKFVD7<LL;9'K^!]CS7G.F^';K[-KFD0:))_9]SITWE
MSZG;Q+.;AG8K&74GS%'WMS<C"\GMI'2+Z[^$<FCZ=I;Z=J!LTA:VD"1&1P%W
M\J2/GPPR>N>:`.Q&LZ6;.2\&I69M8VV/.)UV(WH6S@'D?G4C:G8):+=O?6RV
MS+O68RJ$*^H;.,<CGWKA[R*5]+A32O!RV-K/<Q+>QO90O($"$[EBSM)5MJ9.
M>I(!Q5#1/"E[]D\'VNI:2&MK6ZOY+N&9$*1JYD:+<H.WJ5X&0#]*`/1IM4T^
MVM$NY[ZVBMGQMFDE54;/3#$X-.EU"R@N(;>:[@CGGSY,3R`-)_NCJ?PKSM/#
MLFEWVCM<>'6U'1[6UN[:.S5$E-N[3;T;8YQAD4+GMD9P*JZCX6GEUC4VO=+U
M`0W2VTEJ]A!!(]NJ*J^2LC'*%64G(."&..:`/3_MUH;E;;[5#]H8$K%Y@WD#
M@D#KQWJE9^)=$U"]O+.TU2UEN+-BL\:R#*8`)/N!D9(X!XZ@UC^&=%:TUCQ%
MJ%W8HES/J;M;3NH+M`8X\;6ZA=V[CCG-8K:9J&CZAXRFTSPS#->7C">RE:&/
MRI4,4:O&3D')97.TX!/?F@#O;;4["]@\^TO;:>'=L\R*577=Z9!QGD<5!)K^
MC10PS2:O8)%."8G:Y0+)@X.TYYP?2O,QX7U-]%\310Z7,J7UYI[PQF".`R(C
M1B4[$.%X#>Y'UJ'Q?I&G-K7B*-[!%TBUL+5KCR+:-VA4,[L8@[+LXZA0V<Y/
M/%`'K3:C8I<PVS7ENMQ.-T41E4/(/51G)'TJCI_BC0M52[:QU6TG6T9EG*RC
M]WMZD_[/^UT]ZX*Y\-R7&OZE-=V.HRPW5[;W=I=6=K"7\L"/:GF-\\80H<CC
MY2<=<5)!X8CAT_Q%IUSH-[`)=6-S#<:?!"?,B,BM&!DX91U9".@(P:`/2K>\
MMKJW6XMKB*:!AE9(W#*1Z@CBHK75=.O86FM+^UN(E;8SQ3*ZAO0D'KR.*YG3
M6URW^']R4T6TBU1$F^S6/E+$DH!.S>BMA2PP2`>IKD?^$9U=]$\7"UTN:-K^
M"R6W3[/%;-(R,3)A$.%QGOU]30!ZB=9TL0QS'4K,12R>7'(9UVN_3:#GDY!X
M%7'=(UW.P5<@9)QR>!7FGB7PHI\02%-*E?1Y=,-M"EA9PR&W<,Q?:K_<+AAA
MAW7FM[Q3I5W=_#*73+"&ZFN3;0QI'(P\TX9,[CG&[`.>?6@#HUU;372%UU"T
M99I#'$PF4B1QU5>>3["G?VG8?;Q8?;;;[81N%OYJ^9CUVYS7F^L>#&,/C8V&
MAPK(\<#:08XD7;(L0YB_ND.,YXY%27>EZUJ/C6QN[C1UC-GK`D%Q%;1A7M5C
M95=I<[V8EAE>@QTXH`]%&HV+78M%O+<W+*7$(E4N5!()VYSC(/Y4-?V8M_M'
MVN`0@MF3S!M^7.[G..,'/I@^E</HGA7[/+:ZA<:4J:C'KUW<>?M'F"%S,%)(
M_AVLN!].*;X:T_48+?3=&OM#G$-MJ%[+<SRF,PLDAG*[1DE@PD&>.,X-`&QX
M?\;Z?K>FSZI)-:6>GK-Y<,LMXA+CG!<<>63CA23Q70SZE86L$<]S>VT,,A`2
M22555B>F"3@YKS/3]"U+2O"'A_3?^$=B,;M,^H[+*&::-P6,7RL=O()&[G'`
MXSFDTOP]?Z9#H']L^&VU:VM]"%F;8+'*;>X#$M\K'`#C:NX?W><"@#T&'Q1H
M4^H7MA'JUH;JQ_X^8S*`8^,G.?3OZ=ZTC<0J2&E0$`$@MTR<#\SP*\MU?PM=
M/)XUMK3PX%FU6Q3[%/$D>P$0[7C+9R&+#TP<@UH^(K75O$&A:_\`9]%O+=I[
M.TAMTE9!)*5E=GX#?+@'N?>@#MSK.EB&*8ZE9B*5_+C<SKM=^FT'/)]J=?ZE
M;:?`S331+(58Q1-(%:4J"<+GJ>.U>?>)?":_\)#(T>E22:/+IAMX4L+.&0V[
MAF+!5?[I<,"&'=>:9J/A^X-]>BZ\-W6L0W6D06]A([QF6V=%8,KL6'EL2P;<
MI/*GVH`]%@OHCI\%Y.ZP1RHC9D<``MC`R?<XI\][:VT,LL]S#%'$`9'D<*$S
MTW$]/QKE_%>FWU[\/DL[:U>>ZC^R2&!2`S>7+&[`9.,X4XYZUF:QI\^MPWEQ
M>Z1JMNCZA!-;1Q1Q2N0D6-TD;$J4SD%3DYP>.H`.Q7587OHX$*M!);_:%N5G
M381N```SDYSU`Q[YJ>+4[":":6.^MI([<D3.LJE8R.NXYXQ[UY?J>A^(M2TN
M29M%6VO)/#$]KY-J%14G,RLJ``\':,\'`.>:O>*_#]KI5A?'3M.AM8[R334`
MC0".219VSE.%;`(R&P".IH`]#LM2L-21GL+VVNE0X9H)5<`^^#1!J=A=7,UM
M;WMM-/"<2Q1RJS)_O`'(_&N4\!P6=@WB"TM[9H+U;_S;N+[.D2*S1J55-C,"
MNT`_>)!)Z9K)\*Z7K,GC*SUC4='%C*+&YCO/+MHHHUE>2,A5*DM(,(3N)/X$
MD4`>A3:A96TT,-Q=P0RS-MB220*TA]%!Z_A2B_LS>FR%W`;L+O,`D'F!?7;U
MQ[UQ5QILL?C?5;K4/#AU>&[%M]AN-L;B`(,,A+<QX8E\CKD]^*Q8O#E^1:63
M^'F&L1:]]LEU@[-K0B8R[_,^\<QGR]F/KQ0!Z8=4T];C[.;^U$VPR>69EW;1
MG+8SG`P>?8U)]LMOW/\`I$7[\9B^<?O.,_+Z\<\5PNB^%!!+;WUQI2KJ":]=
MW'GE1O\`(<S!23_=*LHQ].*PW\&^(+BPU;2O)V1:582V.D2$C%RDLF\X_ND1
MJL//J>2":`/4[?4K&[@>>VO;>:%&V-)'*K*K>A(.`>1Q5.^\4:%ING3:A=:M
M:):P2>5)(LH8*_\`=XR=WMUK@IO#\\OAGQ,--TO4[>^O=,2*.W>VAMX]XWD*
M@C(!<%L%NF-N#Q5OQ/X*A?1?$%OH^AP;KFSM&CCC10LDL;OG:#P&V'&>,YZT
M`=O#JT%Q?QPV[)-!);FX6YCG1D(#!<``Y/7J!CCKFI[;4K&\M_M%K>6\\.[;
MYD4H9<YQC(.,YKSCQ/H.HZK.T^D:))!;'1O)%LX2'.+J)V@P#@%XU<>G/.*K
M:QX=OM1C\17&C>'I=-MKC3[>VBM@J0O<2B7>S!%.!A3MR>>#CB@#TY-6TV2T
MENX]0M7MHB1),LRE$(ZY;.!5"_\`$=I;?V0\#+=P:G>"SCE@D#*K%7;=D<$?
M(1QZUS>K:)/I']K#0="MVMKV6T$T2P(Z[!E9'2(D*S*-O!Z^]9ND>'-5MK'2
MD_LZ6-8_%,E^5*(A2W,<@#E5.%^\/E'3-`'H]UJ5A9/$EW>V]N\IVQK-*J%S
MZ#)YZ]J6;4;&VDCCGO+>*21Q&B22JI9CT4`GD\CBO/?B-I>L:V+[3[;1UN8&
MT\BTG2VCD<SLQ#*SN<Q@#:00.YYR`*FU7PH=6U;Q3<7FE"X$UC:BP=P"?,4.
M6V'.5.X)GIG`H`ZO_A*='FN]0LK2_M[B^L%)FMDE4/D+NP"2!]3G`[XJO8^+
M;&XU>XTZY,=G-%';NGG3I^],RDA5P<$C;CC.<C%<W<Z#+#K_`(T,6A%CJEGF
MSNXHH]I)@*NI;.0S/VQSG-8-WX8O_L^HP3>%I+V\O-%LK.QN-L9%K.D95B6)
MRFUF5L@?P'VH`];DU"RBNXK26[@2YF!,<+R`.^.N%/)JMJ>LVNGIL\V*2YRA
M%N)`'VLZINQUP"W7%>;ZWX;U&XMO$EA/X?.H:KJ,T;6&J@(5C4QHH)D/S1^6
MR,W'J,=:MOH-V=4U%+GPU)=7TFLQWMOJJ,F!!OCQ\Y(;Y%!79CD"@#T=;VT,
M*2BZA,<C[$?S`0S$X`![G/&*2ZU"SL8VDN[N"WC49+32!`.<=3[\5Y_8Z7+_
M`,+)DT=8PVE:=,^MJQ(8":<%50\<$/YSC.?O`\8%6/%X@_X3W1OM.C/K$0TR
M\;[(D:/E@\(!VN0#U(]MWUH`ZB37[>+Q&-)=<`V#7WV@N`@17"D'_OH'/2G7
M?BK0+*QBO;C6+);66588YA,K*SD@8!'U&?0<G`KSFV\/^)]%TZR:'28[JY@T
M!K5HG*RH&:Y1C'@L`Q6/=@9P2H&:&\*7CZ-JS'0FF0ZY:7L%N]M#&[PIY(DV
MQCY5)"-QQD=>M`';CQC9W'BZ'0;![6Y8Q":>7[8B[%8,5"+R9#\I)`Q@$'G-
M;D&I6%U'+);WMO,D+%96CE5@A'4,0>#]:\^U7PI<:A?^(KG3-(BLI;S0X8;*
M5XTC:.;]Z&7(^ZVUE4GTP,X%5+S0KF]6_GT?PO)HZ#PY<VC1;$B::XD"^6BA
M3\VS:WS'^]Q0!Z2VL:8D4LK:C:+'"Q21S.H","`03G@@D#!]14RWEJ]R]LES
M$UPBAGB5P74'H2.H%<3/X4B;5_"T:Z-;G3[:TN?M4?E+Y:RLD04LO\3$AN>>
ME4?#/AB\TH>!YQI?V:ZAMIHM5E4*'^:+($C9RV7"GOR!0!Z*]W;1JQDN(D",
M%8LX&TG&`?0G(Q]152_U6*RZ%)762))(Q,BF,.V`S;B..I]3@X!-<-XM\(:E
MK'B.XM+6(KI6L1QS7MP)-OE3VX;R\CJ=Q\KIC'E^M,CT'6-0\.+?WVGL-7O]
M9LKFZ@90"D4,D:\C)&-J,V`<?,:`.GNO'.B#1I]3T^[AU"*WN8[>9;>4;E+3
M"+/T!.<]"!P:VX=3L)[-[N*^MI+9,[YDF4HN.N6S@8KS1_#$_P#PB&O:+'X<
M,=Q+JXERD4:I<VYO!(`"#R%CSP<8Z5?USPNUM)<-INB+-I_]KVMY<6,(55N(
MUBVMM0_*2&V-MXSL]:`.^34;*6WBN([RW>&8A8I%D!5R>@4]"?I534_$FBZ,
M]NFHZG;6S7$ODQB20#+8R0?3`[GCD>HKSQ_#^HK)=ZE9:#-;6/\`;UG>PZ?&
M$63RH0%DD$8.T%C\V,Y(ZU=UG2+O4XK34;KPW),8=>^U/:NL4DIMC#L)`S@Y
M.TE<]N^*`/25974,I!4C((/6EJ*W.85/EF/*CY",;>.GX5+0`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`53O]4LM,L9;V]G6&VB($DAY"Y('./<BK;<J17A\ME9V/@KQY;)J
MEY+>)J,B-;W%V9&5/.CVR;&[G(.XCGB@#V_>H..]*#D9KS'77U3PQ8ZO;6^L
MW\UH+JR,MS=7&9+2&0E92)""5&5'.#MW'`&,UTO@IKE;:_MY=5AOXHKD"$+>
MF[DA4HI*R2$`DY)89Z`@=J`.HW#T-&X9KQ]?$%POA:\UG_A(-0'B)GDCNK#>
M66T03!9"(=IV>7&=P8CGONS4FI:W<Z5;^(8]`\07FH6%K86TZW,TWV@P7#S?
M=$AZY0@[23U]\4`>M/M=2"H*D8((ZBJ=CI.F:46&GV%K:;P`WD0JFX#.!P.@
MR?S->::J=2TNV\7M#X@U9AX=$-Q9B6YW;V:,2,)3C+J3D;3P`>,<4_Q?K,L>
MK^)%?Q#>:?<6%G;W&EVMO/M\ZX=6^79@F0%E0;>GS'UR`#TVWU&SNKR[LX9E
M>XM&59XP.4+*&7/U!S5G<*\?U34+^WU_6`;F2RBN]0L(;^=)OLYC5K3@;\'R
MP9-JYQQGJ.M27VJ:[INEV@TW7/[1OEDO(Q%;3&["V@"[G=OEW2Q$K@]23M_B
MH`]5%_:&\ELQ,GVB*-99(^ZJQ(4GV)4_E4^X5Y#XL9]0T/Q-8P:I>W=A!X:L
M[FV=)V/G']]\Y(^]O`4MZX&:LZA?76DA=+T;6[N^M_$$4<&FW;W#3M!*'VS$
M2'_IFVX<CE#CF@#U7<*HZKK-AHEE]KOYC'%N"*%1G=V/155068]>`#T/I7/>
M-;N2R@T6U-_<6.GW-ZMM>WL3E7C3RVV@R?P;G"*6]^HKB+NW;6KO383K>JW.
MGVWB865C=I=,K/&;9BQ$@QO*N'4/R<;ADYH`]<EU2R@ELHI9@CWSE+=64@NP
M4OCV.T$\^E6MZFN)\;V/VW5/"%D+NZMP^HNIF@DVR@"VESANH)Q@D<\FL35M
M2:QT"ST6[U74GN@]\T=\=0^RED@=@`\@R7;!7"XYP2>E`'J.X5!'?6TMW/:1
MRJUQ;JC2QCJ@;.W/UP?RKRRYU[7K+1-)?[5<R7'B/1[:WMI&)_=7YVJS8Z*2
MCESTYBXY-6];U#4[+6=7L+;5+Q$BGT:VC<R[F1979)",Y^8CDD]P#0!Z?N%4
M;K2-+O+M+RZTZTFN$`"S2PJS+@Y&"1G@\UY]J[7NAV@TIM:U2>U;6O)9VNME
MQY)MQ)L$YY&&YR3D_=XS6QX>L)+OX9W,%QJ]S?33"X+7,-\99%&]MJ"0=PH5
M2!WSZT`=N'4C(Y![BER",UXOX<NK,:5X8TJ?Q-?V>DRZ49Y9TORA%VJQY@\S
M^`(FYA'D=^M=IHFKZG-\*9M5FNY#>K:W4D-U+!\S*K/Y4A0`9RH1N@SGWH`[
M/<*-PKQFVU#4[31=;U2PUJ\DE73K9A:W&IBZDMRTG[^8+R``GW3CJI^7M6@U
MYJ-EI-S':>)!/#)J&GQPF+4?MD\"S2;'+2,HX8$%00<8-`'J^X9IOF+D+W/8
MUYCK#ZCH=@=,&M7SV!UL6\U[<7926&%X%94,Q#%09"!NQGYL9'49<]HKZSX7
MN-6\3.\$5]>6Z7-MJC%8D$99$>7C,G\)/4CCF@#UVVOK6[>=;>59&MY3#*%_
M@<`$J??!'YU-N'Y5Y3<:M=3^(KC3-0UF\LM)FUNZ@>YCG,10K!"T4(D_@4EG
M.!C)&,\D&OXOU]([14TC5]3^T:?:6\T-R^H>4+I9'`5A&!^_.`<D@#\Z`/3)
M?$6DPWCVDEXBSI<1VK(0<B61=R+_`,"'2M+<#7DVN`/XUU.,D@-XATA3@D$9
MA[$=*UO"NHZKJ/B2'2+N[N)&\/6\D.H/D@7,[,5B9AQNS$I?TRX[B@#T/<N<
M&C<*\R\;:AJ=OJGB.:VU2[MET?2(+^VBADVHTQ:49<?Q+A!\IX/?M4.NZAJ?
MAJ^U.QBUC49;:6TL[R>YG?S)+57N#',Z<851&"<8P,9`%`'J>Y>U4Y=8T^"2
M1)KA8S'+'"VX$?/)C8/J<C\Z\PO-9N--DU2RT[Q#?76@PS6$<^HM-Y[V@D=_
M/VS8/11'R<[=_;C%DWIL[.\;2]<N+Z,:[IL"W32;G:,O$&0O_P`M!@D;NX.#
MG%`'H<&N:?<ZO<:7!*TEU;+NFVQL40\?*7QMW<@[<YP0<5/?:C::98RWM].L
M%M$NZ25^`H]Z\LT_2[C24\4ZUI^IZF9-,UTR2P/<O(D\*I$TH9.[%6;!QGY5
M'O7;^";BYU32+C6KF>21-2NI+BU1B<16^=L0`[950WU;GF@"QI7C3PUKE[]C
MTO6+6[N2I;RXFR<#K6YN!KE/!8!O?%N>VNR?^B8:R+F_\_QEK"7VMWEE<Z?/
M`NF6$<QBCN5=%P2F/WH:0LAZXQ_#UH`]"+J`2<\<UD1:KH/B.$6226U]%<6J
M78A>/<LD+,0K8(QC*GZ8KA_!%_J%[=Z?=SZ_'+)=VDIOK*?4/-D,R@9"0[0(
MMC;@0/4=>M<]H37`TW3!::E!I\S^%[%!//,8E(-RP*!\'8S#*A@,@D8H`]FM
MK>PTJT98(;>TMUS(P10B#N6/;ZFF:5K%EK=B+RP>1[=F*J[Q-'NQW`8`D'L1
MP>U<>LUOKGPCU3R9]1$:VURAEEN_,E8Q[LXE'WT)7`/=:SM&L9_-\(Z(FL:I
M'9W.CO>R[;MO,9E\C:N_J$&\\#'''3B@#T[<,9HW+G'>O)-+UR[GN=$O5UV]
MDU^]U8VU_I32;HXH@[>8ODD?($3:=W7H23GF5[O5;G5%G&N:A$9_$TVCF..4
M!$M@'?`4C&_*CY^H'`Q0!ZOD8SVJO9WUMJ%G#>6DJS6\RAXY%Z,#W%<YX,N;
MG[)K6GSW<]RNFZE+:PS7#[Y6C"(XW-W(WD9]`*XC2;G5O$.F6-O-K^I6Y7PO
M%J'FP3E7:XW2*'8]6'3(Z'`ST%`'KMQ=16MK+<S-MBB1I';&<*!DG\JCAU"T
MN+F:VAF5YH%1Y8QU0/DJ3]<'\J\MUW6)+J;6H]3\076F2VVF0R6$$9Q'=!X2
M9&*8_>Y;*X_AQD8/-7=5U34['Q'JU]'>70LM&_LZXGMT<E/L[+*L_P`HZX7#
M],Y04`>C37UK;36T,\JQR7+F.%6ZNP4L0/P4G\*=)=PQ74-L[8FF5F1<=0N,
M_P`Q7F8U;6TTKP_JT<]Q)/JM_=W<5L7+*T1MIG@BP#RN%C.!U//4TWP]>QW,
M^G7%KXCN]3O)])N)[B*5][0S[8]Q&`/+YX\OCIG'6@#U/<M5M0U.STJQDO;Z
M98;:+&^1@<+D@#/XD5Y_I'C.W7PUI=U+J%Q>R6OAUKF_2W??+Y@$.23T\S);
MJ<C)S7.7-[<2^%/&MLU_/=6D,-A)#YM^;P(SMEP)2!GHN0.!^-`'MI('6DW#
M.*Y3X@7\NGZ3IS1W\EA'/J4,$]Q&VTI$^0YR>G'?MU[5R,6N(+*ZTEM8U*ZT
M^;5VMM.U%M0,&42)7<-<XRRARZCKG;C/%`'K.]<@9&3T'>H+2_M;^W%Q:3+-
M"690Z],J2K#\""/PKR#32-0O/A]JNM:S?Q236UU&TS7C1AG1UV*3QDL.#W<*
M,]*(M7U?4!86E[K$]K;R1WTD,[:B;3S9DNY%VM)M)(1`N$X&#WQP`>S;A2%U
MR5R-W7&>WK7G-Q_:>N:EINER^(;B(2>'OMLESI<VQ99PRJ)%(ZH=Y..,\52L
M88S\1;&_O=:NX;RZ\/6\\9DNBL<LN2&79G#*.&*#C))[T`>F1VUO%--/%"B2
MS$&5U4`R8&!D]\#CZ4OD6YNDNFAC,\:%$EVC<JDC(!Z@$@?D*XKX?7_GW%]9
M3ZE-J5]'%#//=)??:;63S,D&+IY><$E,8`(QD5C6FOR7OCVRN+#4+V"WNI;V
M&>WN;[S53RHV`+0=(@&7(YR1]:`/5=R_IFC</I7!_#_4#/<7UE/J4VI7T<4,
M\]TE]]IM9-X.#%T\O."2F,`;<9%8U]?ZLFC>(];35;[?:ZO)88$VV*VM1.N]
MPN"-RJ6^<AB!VP,4`>J[@:-P/(KR=[^[L8(K*;Q.?['N-3CAFNH-1-Q-:1-"
MQVO<%05WR;,'L&P"*M_VV]I8Z9./$$]Q8)XE%N][-)M#6_DMA7;@%=VT9Z,<
M'O0!Z-/?6MM-;PS3*DERYCA5NKL%+8'X`G\*GW"O/TUN:\U3P_):W\KVEUKM
MU$<,0LD2PRD+CNH*@CMP#6(U]JR>#;?6GU>^S>ZHUE=RM=F..VMEGD0%#@^6
M2512^"?F/(X(`/6]PSBH$OK:2UFN5?,4+2*YVG@H2&_(@UY>;^YA&FZ7J?B<
MQZ/->W,;WUIJ!=XML:-%!)<X&&)9V[$@*,]0>M\.R"7P'=2"[:\!:\Q<,FPR
M_O)/F(P,$_2@#I+.]MK^RM[RUE$MO<1K+%(O1U89!'U!J?</Z5XKX9^TW.F:
M1I/A_P`27T]W=Z"S72M<F1-/G14\G``_=_/O0KW`.0:[;P3K-UXGO]0UIWFC
MLU2&SAMF)"I*J[IB5/<.VS)&?D]#0!VM%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`AY%1&WC+%BB;F^\=HY^M2G..*XZ/QC<GQU;Z(1ID]G=/+''):W+/+$R)O/
MF#;M&<$8!)&10!UQB4[LJIW<'(ZBDCMXXEQ%&B#T5<"N(T?QOJNH3Z-/<:7;
M1:;K#20VLD=P6E25$9CO7&-I\M\8)(XS3-+\>:I=G2[F[TJVBL-8M99[%H[@
MM(K1Q[R)%P``P!(P3C@&@#NA`@=GV)N889MHRWU]:1;>)$V+&BJ>=H4`?E7%
M6_C'7KZUTG[-I=@MWK<9N;!);E]L<"HK,TI"GYOG4!5S][KP:G7QE=S^'YKE
M8]-LM2@OGL9(KVZ81&1#AMC*I9L\8&._/2@#L#"IW952&'.1UJA!HUI;ZU>:
MFJLUS>+$LFXY4>6&"E1V/S&N5L/'&JZ[9Z1'H^FV9U*^LWO)5NKAEAB1'$9P
MP4EBS'C@8'6J=EKGB&R\3:\Z6$$^G+JMK%<"2[.^`RPP`B-<8(4MN/3.>!0!
MZ(8$96#(I#?>!4'/UH6WC0`)&B@9`"J!BN(B\?W,_B%;:&QADT\Z@VG$I([7
M(=6*&4KMVB,,"#ELXY]JT?#_`(HN]:UB^MYH+6TA@9U2W>5A=C:^W<T94#:V
M,@J2.10!TXA4=%7ICIV]*H3:'9W&JV.HNI\VQ21;=!@(A?`+8_O8&`?1CZUC
MV_BB\N/&%UI)@M+:VMR4`N972XG(0-OB7;M9.<?>SP<XJ&S\;%_"NFZ[=VHC
MBN=-FU"=$8L4$:AMJ^O!-`'6,BN#&ZJZGJ&&10(45555557[H"C`^E>=^(=5
M\4OI6D74]C96TTVJV;6B6]ZYWARV8Y3L&.,9(R#S77>'=3U'4;*X&J6D5K?6
MUR]O(L,A>-MN"&4D`X((/(S0!L>6#@G!P<CCI3&MXW`#1QL`=PW+GGU^M<:O
MC>[7Q4VF&&PO;:2&XE@.G7#2S9B"G:P*A=S;L8!.#6GX0\07?B&PDN;M;&-L
MJ5AMIG:2($9VRJRJ5<?D:`.@:)3C*J=IR..GTI"B,22BDD\Y'I7$-XBUC7O"
MVK:G'8VL&BRV-U]FF%PQN!M5@&9-H`!VDX!R.*HV?B/6XO!EV-8L(@L?A[[=
M;SV]Z^^4"/#!VP"K_=.Y<XW=<T`=OJFAPZJUI(\\]O/:3>=#-;L%96VE3U!!
M!!(.1WJ31]'M=$LWM[7>?-E>>:21LO+(YRSL?4FN/O/'>H6+71M]+BGL].-K
M'<L]R1*YN%3RPF002&?YBQ''O3[SQ[?Z6;VQU"PM$U:*[AMX%CN&-NRS*S([
M/LW#`CDR`O\`",=10!VQM82A0Q1%2=VTH,9]?K4=]96^H:;<Z=<H6M[B)H9%
M'&588(_(UR">.;\Z%'<G3(GOFU-=,"K(RPRNP^5T9E!*9(R<=FQG%0R^*=0T
M_7+ZQ>RBFU>4V-M&@NY/LWG2I*Q(R/D51&22!EN!UQ0!TVF^&K;3KW[<UQ<W
MEX+86JSW3JS+$#G:,`#DX)/4X%::6L*`A(HU!.<*@'/K5*TN]0BT=KC5X[.V
MNHU8R>7.3#QT.]@"`1ZCBN0M?B)=KI6O7-Y:V,[Z4MO(&T^=GCF24D``NJD$
M8//3D4`=\8592KJK*W4$9!IHMX=GE"*/8.0NP8S]*\_U_P`5>,+'1-0Q8Z9:
M:C9W=HA?SVDC>*9U4;<KG.XE3D=,D=LV+GQ5>:/=:\]U:1F\M(;!9"+MS;(\
MQ=2W(^2-3RS`9(ZC@4`=TT$;J5=$96.2&4$&@V\;,K-&A9?NDJ,CZ>E><Q?$
M75R&M9;32!?27DMO;S+<R&U9(D1GDW!"2,R*H`'7.>E:@\9ZE=V&ABQTN,:A
MJS3Q)'=2-''&T6=S$[=Q0A6(XR05H`[+R4W9VKG.<XJIIFCVVESW\\.]IKZX
M-Q/)(V26P`!_N@``#L!5"RU^YE\%2:W=V0M[J&WEDFMM^X*\>X,`W<94UST_
MCK5XK?3E:QTR"ZU2-KNU$]S)Y<=N`A_>%4)WDN!A1CWH`[QHE8L2JG<,'(ZB
MCR5SG:O(P>.H]/I7%V?C'6=<-M%HNCP+<_9([RZCU"=HMBL[H$7"DDDQL03@
M8QGK43^/[@^(9+:WLH9;&&_&G2`2.;EI,A6=4"[0BLW.6SA2?2@#N%MXTC,:
MQHJ'JH4`'\*/)4*%"H%&,#;TQTKB;WQOJEM<WUPFE6[Z3IVI+I]U*9R)BSE`
MK(N,$#S$SDCOCI5#2O&/BE(+T:A:Z9<7$FL/I=BD,KJ!*,GYSL^XJJ3G[QQC
M`H`[S4M+BU/2[O3Y7DCBNHVCD>$[7PPP<'UQ4]M!%96L5K!&(X84$<:*.%4#
M``^@KBY?'.IVJSV5SI-O_;$%_!8-'%<$P.TR;HV#%00.F<C/7&:O>*VU";PI
M:VMRL275[=6MK="WF95"/*HDV.<'[N0._M0!U*;5)(&,\GC%-:.-I1(8U+J/
ME8KDCZ&N.M8IO%&L:T)-3O;*WTJ\%I;064_E%2L:L9'Q]_)?A6R,+T-9GCG7
MKW3]0B%GJPA&B01W]Y$941KS+X,9&1_RS65L`=2N/2@#T-88DD:18D5VZL%`
M)^II&AB*[6B0J1C!48QZ5Y5XTUS[+XIU.=;[7(HXM(MY;.2Q=A;PR2-*`\P^
MX%/R<L#P#Z5U^E"]M?&]Q#/Y1^UZ5!<7'ER$I]H5F1BBD_*",<XYP/0T`=0(
MU5`@10F,;0O&*<(@,$!>!@<=!7GNM>'5'CS1K5=8UV.WU!+R>>)-4F5=R;"N
MT!OE`WG@<5TNM>*K72K&8VJB[O8YHK9;?=MS)(XC4,V.!EADT`;@@C$AD"()
M#P7"C)_&DV+TV+US]WOZ_6N)U'QAKNEW5OI-U9Z1'JTL;W#.UU)]F$*E0""(
MRVXEB,8XVYSS6/XEUVXU"UCU"%;JQ^T^$M1N3`[%6C<"(KD?WER<'WH`]06-
M>2`!GKCO2"!%Z*HXQPHZ>E<CHGBB^O/$"Z3)%:000QHI-S,ZW%P?+5C)&-NU
MT^;'WL\'.*[/.>E`$1A0LK%%)48&1T^E+Y*X8%5.X8.1U^M244`1^4OR_*OR
M_=XZ?2A840Y5%7)).!CGUJ2B@")8$085$4'.<*.<TBV\2H$6*-5_NA0!4U%`
M&?JVCVNL):+=;\6MU'=1[&Q\Z'(SZCVJTUM"T0B,49C'1"HP/PJ:B@")H$90
MK(I`.0",@'UI&MHG7:\<;+G.TJ",U-10!&(4&,*HP,#`Z"D,"$J2B$K]TE1Q
M]*EHH`BCMXX@1&B)GD[5QF@6\8=G$:!F^\P49/U-2T4`11P)$,1HB`G)VJ!2
M^4N",##=1C@_6I**`(!:PK&T:Q1A&ZJ$`!^HJ*#3H8/M(4;A<2^:ZOR,X4<#
MTPHJY10!&8AN!P.#D9'2D\E"A0HA4]5V\?E4M%`$'V6$1^6(HPF<[0@Q^53!
M0%Q@<]:6B@")8$0N41$9NI5<$U3T;1K70M+AT^SW>3%D[I#EW8DLS,>[$DDG
MU-:-%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`!KF]/\`!.EZ9J-M>0279^RS
M336T#S9CA:;/F;1CON/4G&>*Z2B@#A_"G@5='L=-EU*>:>_L5E\J/[06@A=R
M<LBX&#M./;)QUI?"OP_@TS2M,_M2>>YO[2R-LJFX+PP%EVN8@0,9'&?3@8KM
ML#TI:`.>?P=IK66CV\4MU`^CH([*XAEQ*BA0I4G&&!`&01@XJ!/`>DPVMC';
MRWL,]E/)<1W:3YF:20$2,S,#N+`\Y'IC%=110!S"^!-)@AT]+.:^LY+"*2&&
M>WN")#&Y)9&)SN&3GGH0"*NP>%]/MDO5C\[%Y-%/+ND).Z-45<$\](USG.>:
MVJ*`,*+PM;6^HRW=K?:A;)-<BZDMHIL0M)W^7&0&ZL`0">:6S\+VUIK(U5[R
M_N[I(I(8S<S;Q&CN'8`8'<#KG@`5N44`8;^%[6;6X-5N+R^GDMY7F@@DFS%$
M[)L)5<?W2<`G`R?6JEAX"T:PA6WW7ES;);26B6]S<,\:028W1A>F.`,]?>NG
MHH`YJ#P3I\,-I$]YJ-PEG+#+`)[DOL\HDH.G(YYSR<#G@5N6]C%:O<-$6S<3
M><^3GYL`<>V%%6:*`.7L/`>EZ;)"UM<7ZBV2>.U4S\6ZRG+[./7&"<XP*OZ/
MX<M=&NKR[CN+JYN[P1B:>ZDWLPC4J@X``QD]NI-;-%`'-6W@C3+2"XM8)[Y;
M&99E%G]H/E1"48?8O;O@'(&3@#-6I_"NG7&EG3G\[[.=/;3<!^?)(`//][`'
M-;=%`'.S>"])GBOHW\_;>O;238D[P;?+QZ?<&?6GW_@_3=1NKVZE:Y2YNS`Q
MEBE*M$T.[8R'^$_,<^N<5OT4`8<GABVN(88[N]OKHP7R7\;S2@E9$QM`P``O
M^SCN:BU+P9I6J7EU>3FX6YN'@D$L4I5HGAW;&0_PG#L#Z@UT-%`&1+X<L[K0
M+O1KN2XNK:[619VFE)=]_7GMUX`P!Z50;P-I<MEJ5M<W%]<G44A2YEEGR[+$
M<H`0`!CGH.<UTU%`&-JOAJPUBWO8;HS`7@B\QHY"K*8VW(RGL0W/X5C:YX+\
MZPNI+"62>_G>S:5KJ<KYHMWW`;PIVL<GY@/RKLJ.O6@#C-/\(W5P[W.IWUU"
M\5WY^GI#=&22T78%=?,(^97.25((''6MJ/PW;"XTNXFN;NYN-->5X)IY=S$R
M`AMW'/!P/3`K9HH`H?V/:G1KC2CYGV:X65'^;YL2%BV#_P`"-49_"MC+%I:Q
M3W5M+I:".VG@DPX3:%*L2"&!`&01U`-;M%`'-2>"K&2:.X^WZFMV+<VTMRET
M1)<1$YVR''."3@C!&3@U./"MM'J-Q>6M_J%I]IG2XF@@GVQ.ZXYVX.-V!NP1
MN[UO44`<3:^!8Y]5U.YU:>:2"?5?MT5I%<-Y+@(@0R)CE@RDXZ<+G.*O3^`]
M*N'NV,]^@N+L7RK'<$""XSDR1_W6/.>W)XYKJ**`.;B\$:3'\[O=37#7\>HR
M7$LVZ225/N9/]T#@*``!4_BK29]7T1H+7RC=PSPW4'FL0ADBD5U#8YP=N*W:
M,4`<U>^#[+4=7?54O-3T^ZF5!<"QNVB6?;]W>!U(!(R,'%7[3P[I]F+S"/,;
MM@93.Q<X"!``3T`50/S)R3FM:B@#F[3P1I%G9SVJ_:)(I]/337$TFXF!-^T9
M]1YA&?0#THTCP_)8>))[^5]\<5C!I]HS2EY'C0LS-)QC.Y@/P/K724F!Z4`4
M;K1[:[UBQU23?]IL4E2'#?+B3;NR._W13=8T6SUW3)-/O@[0OA@R.5='4Y5U
M8=&!`(/M6C10!SK>#[4W,%V-1U,7T+.1=BX_>,K``HW&TI\JG;C`(SUR:==>
M#]/OH%CNY[R=ET^;3C+)-EWBEV[RQQRWRCFN@HH`P%\)V?\`:MI?R7=],;-S
M);0R39BA8Q^7E1C^[G@G`R3WK7LK7[%9PVWGS3^4@7S9WWR-CNQ[FK%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%<Y=>-]%L_&5IX5FED&I74?F(`
MGR#@D`GL2%/%`'1T5AZ3XEM-5UC5]/B22-],N%MW:3`$C%0WR\]LULM+&I56
M=59ON@G!/TH`?149GB`8F10%.&RPX^M5;76=.O;Z[L;:\BENK,J+B)&RT989
M&?J*`+U%8$7C#29/%\_AC=,NI11B3#1'8XVAB%;ID`C(..M,L/&VBZEXKN_#
M=K+*]_:QL[GRCY9VD!@&Z$@D`T`=%14:S1NF]'5E]5((I/M$.T,)4*G)!W#'
M'6@"6BH_.C#!=Z[B,A<\D>M<QK?Q"T71-4.F&._O[U%#30Z?:M.8`>A?;]W/
MIU]J`.KHJK::A:WMI;7,,G[JYC$D6X;2P(R.#S^%3>?$#@R+G.,9&<^E`$E%
M9]GK$-Y>ZA:B&XA:Q=4D>:/:CY7=E#_$,=ZN">(JK"12K'"G<,'Z>M`$E%':
MLK2O$6GZQ+J$5M(P?3[M[2<2+M_>*`3CU&#F@#5HJ/SXPF\NH3^\2,?G3P0P
MR.AZ4`+1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"-]VO!M7T#
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M/./[M9">%=:T=XY5T6?4ICX7F>X4HRK-=R7`D9&*[3NY^Z,$A<5[I10!X-%H
M7B*X\/>-[?2M(N;".]L[1K6VAM&LXW=3B<1QDG!(4@\Y88]15T^#])\0^*_#
MD<'@[4M.T!1=?:XIX7@4OY4>TD!LJ"1CMN*D\]3[910!X;/X=U)M7OX7\/ZB
MWB/^WEFT[5UC/DPV8*[1YH.-HC#`IQDGUK0U*VU[PU<>+;>SLM<6?4[Q]1T_
M4=)MEF5V,>!#*"&*@-[<\X([^Q44`>%:MH.L:EJ;S>)K'49)+G2;)+>[MM,:
MZEMIE3,I4QD>4_F$GW^@I?$/@:\O;SQ[J,NF7UWJ44=E_95RJ,&ED6-`\D87
M@ME>2.G(KW2B@#Q+5_#^O3Z;XNVZ7?S1SZK9SR0H"KW<"HOFA>F_W`ZT:OHU
MH=0TV_T+PCJB)'N2+2KS3'-NP:7F0$-_H[YY#'&!C@9KVVB@#%L/$-OJ>N:K
MI5O#.6TTHDMQM'E,[#.Q6S]Y1C(/3(KRFX\'WNJ>)S%?Z/=OI\OBRXN)3Y;!
M6@,*@,2/X"1C/0\BO:8+2"U,GV>&*(2R&201H%W,>K''4GUJ>@#P=?#>HVHL
M8[_0-1O/#EAXCOR^G)"T@^SLH\AEBZM&&W'CCD^M>JZ%J*0-I^BVV@ZI8VPL
M%FC>>/,<(X`A9MQ_>`=N>G6NCHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$/3BO.=!\77
ML'B3Q!'KEX&TT3W;6;;0OD+;$"1#CDY5E8?1J]'KD;WX=Z-J%NT-Q)='.J/J
M8=7"L'<_/'D#[C#@CKCO0!C^%?$6O?9O$D^IR1W$\#07,-O<2"W2`31!_*+D
M?*%!`R0>0:NVGC^6_P!.MOLNDB;5;B]FLH[1+Q3$S1`L[^=C&S`ZXSD]*TM3
M\#V&IW5]=/<W,<]U=6UWN7:1')`H5,`@@C`Y!SUJ-/`=G%%"\.H7T=]#?27Z
M7BLN_P`V08D!7;MV,."N/IB@!9/$VI+J=EI2Z&?[0GMOM4T;7:A($#['.[!W
M8R"`!SGG%4K7Q[-*+&\GT26+1]2<QV-XMRKO(=K."\>!L#!"1R>V<5N6GAN&
MVU:#4Y+R[N;J*R:S+S,#O5G#EC@#G([<`<8K/L/`=E8R:<AO[Z>PTR1Y;*RE
M=3'$Q!`Y`W,%!8*&)P">M`'.VVMR_9=(UO5_%.I6=SJR1306UK:>9:11R,NV
M-CY9^8[@NYF!R>.E:MI\0HKS7H;-+-!97-X]E#.MTK3&52X):$#*IE&^8G/3
MCFI_^%>VJVR:?#K&IQ:.EPDZZ<'C,:E7\P*&*%PN[!QN[#&!6C8>%_[+O7>R
MU6\ALWNGN39A8R@+9+*"5W!"Q+8!ZG\*`,ZP\97=]J\$*Z)(NFRWLUA]M-P"
M5FC+Y^3'W3Y9`.>IZ8YJCI/C*]NK6VL])TR?4KYOM$\JW5ZJ>7$MP\0^?;R2
M5.U<<`<GN>EL?#-I80)%'-.RIJ$NH`L1]^1G8CI]WYSCOP*RX/`%I8O#+I^J
M:A9W$<<T+31.F9(Y96E*D%2/E9V*D`$>]`$VA^*IM<UF^LXK!(K:T=HG>2Z7
MSQ(IP0T.,A2<X;)R,'O5/Q#XL7P]K]X'BN9O)TZ&54\X+#N>=HP6^4E<'EGR
M0%[<<ZEOX62/7[?5[G4KR\FM8Y8K=9@@"+(02"54%L8`&XG\^:EO?#JW.M2:
MO!?W-I>/;1VN^((0$20R=&4]<D'VZ8/-`%G3-0N+O1([RXMX8IV0OY<5R)4/
MIB3`!!XYQWK)\)^*Y/$-YJ5G/9V]O/8B(L;:\6YC=9`Q&'`'/RG(QZ5+#X,T
M^+PC=^'&FN)+6[$WG2$JKDRL68C``').`!@5/HGAF'1;R\O!>7%S<W:11R/(
M$4!8P0H544`<,<T`5+'Q)>ZOJ<Z6>D$Z3%-+:M?&Z4-YD9*L1%C.T,-N<YSV
MQS7+^&?%TT&AVUWJ$MY=26WAB/4IF:8;9,,^3MVYWD+USTQQWKL+#PK'IE_-
M-:ZE?):2W+W366]3'YC@[N<;MI)+;<XSS5"#X>:9;Z;)8K=79C?1O[&+%ESY
M66.[I][YS[>U`%#4?&-\/#^O27ND76G&UT\7L#P7:EY(FW`8;:0CC;R,,!D<
MFM>R\1WVHZU-;V6D&73;6X:UN+YKE599%`W8CQDJ"<$Y!ZX!'6QJ?A2SU73K
MJRFGG2.YL!8,R$9"#/(XZ\_2HX?",%MJ-W/;ZC?16MY.;B>R5U\IY"I#'.-P
M#9R0#C(%`')^(_'-[)I?B;3D@BL[RTTV:[M[FSOUG(V.%^;`&Q\D<<]Z['6/
M$MCHVE7MT\HN9K.#SI+:!PTN./X>H'())'`YK&C^&>FIILMC)J%])$VF-I<>
M?+4QP%@W&%&6R!\QS75WEDUS9R0P7,MI*R@+<0A2Z?3<"/S%`'%7OC'Q*K^'
MS9:+ILHU*YDA=4U,2(VV-V`60)QPI.<'IC'.:T9/&4MOXPCT.>Q@,4PE\J:W
MO5EERD>\[X@,KD9QR>WK3H_`5K#"C1:E>QWBZE)J?VI1&&\YT*-\NW;MVG&,
M>_6F6O@"TT^>*>VOKIS:O<RVD,NP(CSAM^XJH9A\QQDY%`&79_$V25Y)KS2$
M@TY=,DU19X[T2R>4I`"L@4;7)(!&>#GGBMGPWXO;7=3N-/N+.*VN8H%N%\B\
M6Y0QLQ4!F4`*X(Y7GZFL'P]X0U*.UATR_M3!I3Z:UIJ$,KPO]H?`"E&0;ACY
MB2Q_B'&<FNRT?1KG3`HFUF]OD6%8E2X6,=/XB54$L1P230!Q]UXMU31/%/BF
M1[*2]T>Q>UDGD-R%^RQM$NXHF"6[L1Q[9)J^_BV:UUK4]/L[2XOM0DU$6UM;
MRW*I&<6R2LP;;\B`'I\Q)/'7`NZKX$M-5OM0FDU*_BM]3,?VZTB=!'.$`4`G
M;N`(&#@C()J2Z\$6<^HRZC%>WEM>M>K>QS1,O[MA$L14`C!1D4`@YZ]J`*"^
M.IW@ABBT68ZJ]_)IK6;W"A5G2/S#^\P04V\[L9]L\5EW7C#5[[4_#SZ=ITJW
MOVV]L[O36N@J-)''R#)C!4'Y@<9]JT+SP//!-HRZ;>W7F)JDM_?7[R(9B[PN
MF[!&T]47:!C`K5T[P3I^FSZ;<)<W<MQ93SW+2RN"UQ+,I5V?CWXQ@#%`&??^
M-[NT\)6NN+I,*R2+(T]K=WZP-$8]P95)4[VRIP`!5N/Q9/>:KI]AIVEM.UU9
MPW\CR3B,0P2,02>#N88^Z.O/([I?^`[*]F25;Z[@D^SSVLC($.^*9][CYE.T
MY)P1@UI:?X:L]-U2&_ADF,D.G1Z<JL1CRT8D'I][F@#F[+X@7VI-9K:>'I'.
MI1ROIY:\51*8L"3?Q\B@D8/)/H*?J'Q`>U\*6VOV^G0/&T<KW$%QJ"PO&8B0
MZ)E3YC!E8<8!P/6M?2_!EAI+:*89[EO[(CN(X=Y7YQ,06W8';'&,5F2?#/33
M&T<>H7T2RVL]G/M\LF2*65I67)4[3EV&1@X/L#0!<_X2F\N]8:QTC1GO([=8
M6O)7N5B\KS5W`*"#O8+R>0.1SGI1L_B'#>Z[;V:6:?8;F[>RAG6[5IC(A8$M
M"!E4)1AN)STXYK4_X0^&+4Y+ZRU/4+-IXX8[F.%UVS>5@*QR"5;:-I*XR/SJ
M2P\+?V5=LUCJMY#9-=/<_8@L90%LED!*[@A8EL`]30!7TGQ4^LZ-I5]!8[9-
M1$WEPF;A3'NP"V.^WKCC/>N>TKQCK%[I.DWNM6(M//U=[97LKK*NJ^>&WJ5)
MVCR\8!RQP<CI71Z+X+MM$FM&BU*_FALC+]FMY77RXQ(22.%!8\\$DG]:C@\"
MV4,5O;F_O9+2VOVOH('*81F\S<N0N2I\UNISP.:`#2O$VIZGIDFJ'0TM["2U
M^U64LE\G[U2,KY@Q^[R#G.6P,YP>*PKKQE=ZMHN^)%L;JSUVQLYC:W8GC=7D
MB)VN`,@J^",>M;!^']M)X??0I=7U*33EC6*VA9T/V=5D5TQ\OS;2J@;L_*,=
MS4Z^"+,PW"S7MW++<ZA!J,LIV`F2(H5``4`+B-1B@"WX@UZ?2[FQL+"P^W:E
M?&0PPM,(4"H`79G(.`,@<`DDCW(Q;SQQ?VR7\R>'9)(-*C#:H?MB!H&\L2,L
M8QB0A2#G*@Y&,G@;^L^'XM7O-/OEN[BSOK!V:">`C.'`#JRL"&4X'4=AC%9$
M_@"VFCO81K&J)!J,:)J""53]JV@*6)*Y4LH"MMQD#M0!7U'Q^;*[O!#I$US9
MV+P+<SK,JL//">4$0_>)+@')``YR>E2R>-VLM/UN;5-+>VNM(:(S6T<XEWQR
MD!&5L`9/S<=BOH0:NW7@G3KI=34S7$:ZA+:RR!&'R?9]FP+D=#L&<Y[U2\7>
M$9-0TKQ%)IQ>34-6BMHS&[A4'E-D8..#ACU]!0`^W\7:@?[6M;[1HK+4["&.
MX6&2_7R9(W)"DRX^4Y5L@CMWS56W\?27.BV]TFD^9>3:D^EK;17:LC3*K$$2
M8P4.WKCCG@][4_@"TO#//=ZIJ%Q?2SP3+=2E"R>228U"[=FT%F)!')8U9MO!
M-E;Q6JF[NI)(-4;53(Q7,DS*RG(`P%^8\#%`%>Q\8RR7%A#J6F-8-<O<P2,9
MPRPS09)7.!E64,P/'"GBLWQ-XJU:7X5R:_I=H;:>Y164//M>*%FP''R_>(*\
M=MW7CF]XO\)R:OX<FTJR:027=^D[3^;L:W5G'F,OK\FY=O?=6WJ_AVSU?P[+
MH;EX+1XTC'DX!55((`R,?P@4`<S%XHO]&M)K&WT"6Y_L>W634B^I^8T.5+[4
M=QF9MHSD[1R!GTT;7Q;=ZMJ8AT;2'N[&(PBZNI+A8FC\U%D`5"#N(1U)Y'7`
MR:EU7P5;ZE?:C<Q:G?V(U.%8;Z.V==LP48!^925;;\N5QQ[\U)!X/MK'49+G
M3;^]L8)O),UK"X\MS$`JG+`LN555.",@4`&F^*%U&V2;[*8]^J3Z=@29QY;2
M+OZ=]G3WZUCV_P`1%FT&[UJ73U2S65(;95O%,KN[[`DJD`0MDC.XD#GFM:S\
M&6]EJ`N8]2OS"E[+?1VA=?+263=OZ+EAER0"3BJLO@"UO&O)M0U2_NKNXMXH
M%N3Y:/%Y3[T==J@%PW.X@]/2@"I;_$&2XA:WCTI9=8-VMG%;6]ZLD,C-&901
M-@#`53GC((Q@UM^%KZZOX=2EO()K:9;YD,$SAC%A$R`1P5SD@CJ#FH;KPBU]
M'$UUK=^]U;W"W-K<(L2-;N%*G:%3!#`D$,#G)Z5J:/I":/;SQK=7-TT\QFDE
MN7#,6(`/0`8XZ=J`.;M?'<MQ+8W+:-(NBW]V+.TOA<*SNY8JK-%@%4)4\Y)Z
M9`J31_&=WJVI62?V)+%IMY)/!%>_:`W[V+=N!3'"DHP!SDXZ5+:>`;&TFLT%
M_?OIUC=M>6M@[KY4<A.1SC<54DE03P3WXK2TSPU::59V5M#-.RVES-<H7()9
MI#(6!XZ?O6Q]!0!1UGQ-=6FJ2Z9INDS:A-;VHNKHI,L9BC8L%V@_?<[6PO`X
MZCC.&_B\Z*L$DZW=RRZ':3D/.!$6DDV!FRI*\\LY)P.W%=+J7A6*_P!7;4X=
M1O[&XEMQ:W'V610)HP25!R#@@EL,N#\QIG_")117,5U9ZC>6US%8PV"R+L;]
MW&^X9#*02V2#[=,=:`*3^+-2<V-G9Z+!=:M=6[W;0)J"^3'"K!=PEV_-DL,`
M+ZYQ46H^-KNT;49;?0);BSTF,/J4AND1X28Q(RHO.\JI!/('H34UMX`M+!;2
M33]3O[2\MQ.IN8S'F19G+NK*5VXW'<,`8(%.O?`=K=F_1-5U*"VU)(TOX4E4
MBYVJ%))()4LH"L5(R/?F@",^.(R)8ELF-ZNIQ6$<'F_ZQ9%5UESCA?+)8\?P
MD=.:@T'XA0ZYK%G:)9(EMJ(D-E,EVLDC!`6S)&!F,$`D9)[`X-:[>#],/BBT
MUY?-2>VA\I85;]VV%*JY']Y59E!]&(HT7PO_`&$T,-GJMY_9\#.8K)EC**K9
MPF[;NVKG@9XXZB@#!7QE<ZGI^E:B=.N+2QN]2MK>VECNUWREF97WKM.$!7IG
M+#^[5K3?&UWJ%W:DZ%,FEW+W$,=XLX=O-AW[AY8&<'RW`.<DCI6C#X,L(-"T
MG25GN3!IEVEW"Q*[F97+`-QC&6/3%/M_#%OINCP65K-*?LTUQ/$TI'+R^9D-
M@=`93TYX%`&1X<\<W?B#7+>R.D16]M<V37T-PM\)&$>X*`Z!1M;+#(R<8/I5
MO7_%TN@ZU96CV5O-;7$T,+2?;E696D?8"(<9902,G([^E9G@SP_K6C76GQO&
M;2SALO)O(Y&A?SY1@*R%!N`&&)+'^(#&<FM6[\"6-WJ]Q?M>W:+<W<%[-`NS
M:TL.W8<E=V/E7(SCCZT`0'QG>-K3VL&AR2V$&I#3;F\%P`8Y&V[2$QDK\Z9.
M1C/>J[>*;W5;JQ:UTRXCTJ34Q;QWZS@^84=E;=&.50E2`23DCD#(K?M_#5I;
M_;MDLQ^V:BNHODCB1=F`./N_NQ[\GFJ5IX)MK.Y0PZGJ(LXKPWL-CYB^4DC$
MLP^[N*EB3@G`)-`'3]J***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****``
MUSUYXKTP:K%I=I>VL^H"XCBFMQ)EXU8X)P.X].W>N@/2O/M+\.ZW:"RTV?3+
M*2"RU>2]743/\[H[L^0F,A_GVG)Q@<$YH`ZJ/Q3H4VIW&F1:I;27UNK-+`C[
MF7;]X<=2.X'-3?\`"0:1Y5I*=1MQ%>1M+;R&0;9$5=S,#TP%Y)KC?#GA2_TJ
M[TRUOK*XN8].O)Y(+O[>OE[7#XD\O&[<0Y4J<\DG)J@WP]U::UUK3GFC2UAL
MY+/16W?P22^<P<#[O(CC]-J\#U`.IU+QMIG_``B.K:YHMS;:B-/B9V17X)`S
M@]QGL:T9?%6@VNJQZ3<:K:0Z@X&+=Y0&!/(!]">P/)R/6N2O?#6IZGH'B)#I
M<\&I:AIB6RR7.H+*&8;SL&T855+'YN^>@Q46H>%=?GTW7=!CL;62VU74Q=KJ
M#3@>5&S*S;D(W%EV;1C@Y'(Q0!V<OBO0(=6BTJ75K5+^5RB0-(`Q8=OKQ^/:
MJW_"6:7;07=QJ5_8VL<%S+!D3[L["`<\##?,,J,XSU-<2NEZGKESXFTJSL;?
M[/+XD2::_DE&81&(7("8RQ^4`<X^8],<ZVG^%-4@\3V=]-#";>'6=0O6/F`D
M1S1E8R!ZYZCM0!TEYXR\.:?IMKJ-UK%I'9W8W02E\B0>HQV_E4E]X@M8O#1U
MJTGM9;9HUDCEFE,<3*Q`!+8.!SZ5YYK6G?V5JEK9-);:>ATJ^C?_`$A(!)$\
M^[RP[JP^Z<X`!'KVKIM0T^X\1?"J.RTRRDMI+BS@$-M=MM:,*4.UB>X"T`;K
M>*="AU6+2I-5M5OYG*1VY?YBP_AQZ\'ZTMSXJT&SU.'3;C5;6.]FD\I(&?#%
MN./8G(QGK6):>&;E'U:2XM8&:X\01:C`202(U\KYO8C:_'^-'_",W377B*62
MWA;[=JMK=VQ)!.V)8<D^A!1\?_7H`W'\4Z#'K0T=]6M%U$X'V<R#=D]%_P![
MVZU*FOZ5);6ERE]"T-Y(8K=P?]8XR2H]QM;/I@UQ-QX8U^2PO-!%G:FVN-;_
M`+0&I&8?+$9A-RF-Q<$",=L<Y'2I$\):W:Z_J$]F]N+6WCN[C1C(<B.ZN`-P
M9>RJV_'&")#WYH`VKKXC>%;?1[W5%U:*X@LL"98/F<$YV@#WP<=N*G;QCI+M
M8SQW]F=.NH7D6X>4J3M=8QA=O*[FP22,''KQR3>$?$>I:?XD-VK+=:EHT5E&
M;FZ60F5?,+<HH"J2_'X].E;&J>'+WQ-?VLFH6@L[>32;NRG3S5D:)Y&B*$$<
M$C9NSV(%`'27WB+1]+-RM]J-O;M:QI),)'QL#DA?Q)4X'4XJUI^HV>JV,=[8
M7$=Q;2C*21G(->=)X0\12V%OJMZ$?71JBW=Q#!.%#QK$8%".<C(4EQGN2,]Z
M[+PKIITW3[I6LI;1Y[N2=Q-<B9Y"Q&7)'`)]!TH`1O&WAA/M&[7+(?9T5Y09
M1\H(R/K]!S4E[XM\/Z=8VE[=ZO:16UXH:WD:08E4@'*^HY'/3FN8\.>$=2TR
M3PBUS!`/[+AOA<[7!VO*RE2O'.0#DU5T7PYXC\.7<%]'IMO?G[)<VIM_M(0Q
M9N9)8R"1C:RNJD#D8'7&*`.RU'Q9X?TFWCN+_5[2"&50\;M("'4YP1CJ.#R*
M74?%>@:0ULNH:O:6YN@&A\R4#>IZ-_N^YXKE/#G@B]TJXTY+R.UG@@T.:REV
M\KYLDP<J`?X<9&:1=`U_29;QK32[6_2_T>WLMCW`3[/)$A7:<CF,[R?E_N].
M<T`=;>^*-"TV\M;2\U2UAN+K'DQM(,N#P#]">A/!K+MO&VG16M_=ZQ<VVGQV
MNI3V*%W_`-;L.`0.N<'D"LG0?#FN>%KJ2"*SM=3M[BSLK?SVE\L1-#&L3`J0
M25P"XQW.,<YJ.S\.:[I/B0:U%907:B^U!C;^>%?RIV1DD4GC</+P0<'#&@#K
M;KQ5H-EI\5_<:M:):2KOCE\P%7`(!VXZ\D=*9?>,/#VFV=I>7FKVL-M>+NMY
M6?Y9%QG(([<CFN9T'PCJ=CJF@7EW#:KY$FHW%S'$V1`]RZLJ+Q\V/F7(Q^M5
M-6\,^*'T`:'8HJZ:^E2VHAAG2(1SLS`%\J2T>QAPOH>.>`#L;;6FNO%=]HZQ
MIY=O9V]TDRMG=YC2#'X;`<^]2/XHT2/75T1]2MUU-_NVQ;#'C./3..<=:SM'
MT6]LO%5UJ$R(+>32K2U4ALGS(VD+#'I\XYK&NM#\4:CXHM)[T^99V>L?:X7$
MZB,6P1E51'C=Y@+G))['VH`Z8^+_``\-1.G_`-KVOVP([F$/\V%SN_$!2<=<
M"LZP\?:-KNF"]T>[AF5;N.VD6=S%M+R;!V.2<$J._`XS4&C>&;JSM[?S[:#S
MH]=NK_<""1'(TN&SZE7`QZ?2LZW\-ZX/#$&BRV<2M::W'>),)P5FB^UF9B!C
M*D*1P>IH`V/#_C?3-8OI=,FNK:#54N[F!;029=EBD9<X]2J[L>E:MKXJT&^U
M:32K75K2:^C)#0)("V1U`]2.^.E<=;>&->^TVU@]C;06D6OS:NU\MP"S(9'=
M4"``[B&"G)Q@'KTIECX6U]M-\-Z)=6=K!#HLSR/J*S;O.PCHA5,;@6\S<V>A
M7OF@#I'\:Z*VH"*UU*SN(H3)]L>.3<80J%L\=N#S6VNJ6+W<%JEU$T]Q";B)
M%;)>,8RP]OF'/O7&:#X=U5$T&QU71M/2#2K26REN$F#M<*4V#"[>%;`9@3G)
M_&JO@/1Y[M-4N[BZE$4##2-/N('(9K:W=L,&.<Y8D'_<XH`W;[QSI>C>++G2
M-8N[6RB6V@F@EEDP9&D:0$8]!L'/^U6MJGB?1-$N[>UU/4K>TGN3B))6QNYQ
M^')[URFOZ!KIU?6)-.TZWOXM2TB/35FN+D(T;*9,LXVDL/W@/'.5Z54\0>&/
M%5]IS:)%-]HL5LK6&!UG6-?,0CS&E!!9L[05P>_/K0!VZ>)-%DU6XTM-2MS>
MVR&2:'>,QJ.I/;C//I3=.\4:'J\%U-I^J6MQ%:Y\]UD&(P!G))[8!YZ<5Q][
MX5UN]?6M,LHFTW2=2BO#,);H3*\\A^22,`;D!RS,,XYZ>K+CPEJFL:/J4<MA
M+9ZG<Z;';+/<7XFC^5]_E`*!A,Y^8C.&Z4`=9H_B:PUS4I$TRZM[NT6`/YT3
MY(?>RE3Z=`?QK+N?B-HLUIXA32KA+K4-'MYIF@8%1)Y:!C@^F3M)]<U<T2SU
M*37[K5;_`$FUT[SK.*`K%.)'9E9B=Q``P`1CKQZ=*R;_`$#6I!XXLHK2)H=;
MA=[6X\\##FV2((RXR.5SGIB@#>T?Q?H6L64]Q;:K:,MJBO<XE&(`1G+$\8X/
M/3BI;7Q;H%[IKZC;ZM:O9H_EO-OPJMZ'/3\:YW7O"%WJ6DW5O:QPPS/IEM`I
M#!=TD,OF",D#[I^[GMN/%59_"^H:A%/(VERQ74]]ITTTEY?)/YL<,NYA@#`"
MC./[V:`.F;QMX:62Q1M8ME:_`:V#,1Y@)VC&?4\<U/<^*]!LM3BTVYU:UBO9
M9/*2%Y`&+<<>Q.1C/6N6\6:'XHUK4;RUC^?3&EM);4+.J(@1U>42+C<S$I\N
M#CD=,5E7NEZGKNI^--&L+"W:*\U2W$UY+*!Y`6&!B=N,L<#C!ZGMW`/0?^$F
MT3^V_P"QO[3MCJ6,_9@_S^N/KCG'6G_V_I7]G_;Q?1&US(HE!XS'NWC\-C9_
MW37'6OA6_MM7DCNK&XO+0:T=2@F2^5$7<Y?<R8W%D)(QR"`.E6?#>C:[IITZ
MPN;&W6TL;^ZN'N5N-S2B0S%=J8X_U@!R<^F:`+VF^/=(US3K2_TFY@DCFO([
M5UN',3(7)``&#ECC(7OZBM.'Q9X?N+R\M(M7M'GLT,EP@D'[M5^\2>G'?TKD
M=/\`#.NQ^&-#T>>SB1]+U:*=I5N`RRQ+([%@,9'##@\U)8:!JT?@E?#&IZ#;
MWD-M;-`98[T1FY^8;64XRA/+$GH0.N>`#K(/$VBWFB3:Q;ZA%+IT(8R3KG:N
MWKGOQ7.^'/B-IE_X;;7-5U#3K.VDGV0HKL6C!4$(^1RXSSMXK8\,P:U%IUU'
MK+%I/M$GV4/(KR)!@!!(R@`MG)SZ$9)KG-)\.:[H=KX1N5LH;R;2]/DLKJV$
MP4J7"'>C'Y3@I@].&-`'87'B31;738]1FU.U6RD4LD_F`HX'7!'4^PJCKOCC
M0/#J:<^I7HB346Q`P4D;<9WGT7IS[BL#3/"6IV\7AQ[F"V$EOJ]SJ-U%&V4A
M$RRD*I(^;:TBC(';-;?BW3M0O8]'N=-MTN)=/U)+MH6E$?F($=2`QXS\^?P-
M`$&E>.]*N=;O='O+NUMKZ.^:VMH3)\TZ[%96QV)W$8[XXK8C\3:)-K3Z-%J=
ML^HH"6MU?+#'4?4>G6L"S\,W:G5)+FU@,EQK\6HPG<&*HHBR<^HVN/\`]=9^
MD>%+^PO[>VO+&XNK>UU66\M[D7RK&`Y=A(8\;BX\PKMY'?-`'1ZKXVT'1=?L
MM%O[SRKV\4M&I4D#D`9/;)X'T-6G\4Z%'=SVLFJVJ36\;2S*T@'E(K;6+'H,
M-QS6?K^G:DWB?0-6L+1+J.R6XBGC,PC8"4(`PR.<;#D=>:Q+KPAJD_AK7;5%
MC%W/K;:E;J),"95E5U5FQ\N0N.0<<4`=,OC#P\^BOK*:M;-IZ/L><-PK>A'7
M/MBJ-W\1O"UG/I<4FJQLNI*7MY8QN0J,C)(Z<@K]:R/['U^"6:ZT^RN[:2ZO
M(FOS)?QO/<1+&5^1B"J%3M&.XSR#4&F^&->TJR\+SBTBN;G3;N]EN(?M(!*S
MF3!#D8)&X9Z=Z`.PF\5Z!;7YL9]7M(KH!BT3RA2H7KG/2F_\)=X?_L0:S_:]
MK_9I<H+@O\I8'&WUW<'CK7+S^$=2EGN6^SP,LOBB'4^7'-NJ("3[Y4\5%J/A
M/63K]QJMM&65-8^UQ0Q7`B9XGMDA=@2"`P8$X/7GD9H`[&7Q/HD&EQ:G+J=L
MEC*A>.<O\K`#)Q[^W6LN[^(WA6SN-+BDU2-EU)2]O*@W)M&1DGMD@K]:S[;P
MQ=+)X=>/3S;I9ZM<7MREQ<B9_G24;\]"Q9P<#IGVI;CP_J=E?:)>:=802KI^
MH7LKVRS"/]W/OVL"1C^($CWH`Z;5_$.D:!#'+JU_!:+(VU/-;!8]\#J<5SNL
M>/K&#Q)H^BZ?>Z>\E]B5II9&9#&650J;,Y=MQ*DG'RG/:K6L6&K0>,++7M/L
MH[^*.QELY+=IA&R%F#AU+<')4*>AP<\]*S/#'A/4]&O]!EN4M]EK97RW`A;Y
M8Y)YTE"*.X`##/M0!U>K^(=(\/01RZM?P6<;G:AE;!8CK@=347_"5:"=8BT@
M:I;&_F4-'`'Y<%=PQV.1S]*R]8T_5H?%]EKVGV4=_&EC+9R6[3"-D+,'#J6X
M.2H4]#@YYZ5C/H?BN_\`$&GS:BJ&WLM5%U'Y4ZB!+<1E0JIM#%P7/)[#WQ0!
MUL7BK09]7328M5MGOW!*VZO\QQG(^HP>.O%%OXKT"ZOKNR@U>TDN+-"]P@E'
M[M1]XD],#OSQWK"TCPQ=6EM`)X(?.CUVZO\`>""1'(9<,#ZE748]*S(O"^O3
M_#^3PC/9VT+06;PQWZ3Y$[!@4(7&5#X._/3_`&J`.OL_%F@:A8RWMIJMK+:P
MN(Y)0^%1C@#.>F<CGI5[3M2L]6T^._L+A+BUESLE3HV"0?U!K@K[POJ>JZ9J
M&[2I8K^Z6Q5WN[])@ZQ3B1HP`,!5&[!/WL]!7:QZG++KUQIJV4WD00)*UV>$
M+L3^['')``)(XY%`$=QXGT2UUN'19]2@CU*;'EV[-AFSG`],G'`J2T\0Z1?:
MM<:7:ZA!-?6PS-"C99/\Y_"N1U31/$^J>(X7N/WEC;:O!=V["=5B6W3!(*8W
M&3<6Y)QC'XWO#>E:OIFOR)'9M8:&RS2/;272S@SM+N#1X&44@L2"<988'!)`
M.SHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`0G`S2;O8TK=*\?N#KVEZPY6*_DM?"]W)<
M*Q5B+R&XD!"@\ERD;2#`&,A1VY`/7]WL?RK$U;Q;I>BSW4-ZTRO;6T=U)MC+
M?NWD,8(^C#D>E>?WVC7=O'X?L]9=Y=/GM)I[@S><R?;7<2'S/*(Z`L%)XX.`
M#5+7+.^ETVYQ+=ZFQ\-6D8NS;.K3L+HD_*1D-CD@\^M`'M)..V:0MU&#7+^/
M+A%TJTLY[#[3:WERL4TCF3RX!@MO<1_,1D`=ADC)KS]H7A\#Z&^HBYN#:"\D
M31YH;D?:0)CY>UU^9'"X"!L\-TX)`![,N%)PO7G@4[=[5R'C.XC.@Z?:W6F&
M:VOITCG,K2[+8;2VZ3R_F(R-O4#)&37+:))=:5IW@F[OX[Y+6VNK])OW4K%$
M;S!""N"V,;0N?:@#U&>6U,\-O,T/G2!FBCD(W-MQDJ#UQD9QZBI]W'`->37.
ME6%UX@\):SJVFWGELU['(\D4NZ-O-W0JZK]WJW7CU[5'!%*]]:RF+55\8'7-
MEPX,NW[*)RS=_+\GR,8]^G-`'JUK>I=QN\<<RA9&B(EB9"2IP2`1R..#T(Y%
M3[O8UY1::9/JFI:=I^HPWKZ?+?:R\\1,B*X$X,08C!V]P,\XXIND6=_;6OA7
M42-0?4-3TZYCU629Y'+XA+H'!X4A@,<`]1WH`]9W?[)HW\9Q7DFA>&4U&XTN
MUU.+4FM[_P`/+>7ZO/,OFW>4&6.>&`+87C&.G`J]I&J7]K<>#-4UA+]C)HLT
M4Y6WD=FG+0E590#\Q"MU]Z`/3MWL:3=[&O,/[$;Q#=Z38:G%?BR/APRLFYX]
MLX=0N['\:AFX/Y<5FZS:WEW<Q+J]Y-;H-&MWT^ZDCN)##,%;S'`C(!F#%3A@
M2<#'<4`>P[O:J(UBW:5HQ'<,RW7V0E(BP#[=V3C.%Q_$<#/'I7,^,UD;3=#%
MT+N?2&NE75&MU<,T1C8*6"?-M,A3<!VZ\5CV]N\<6CK81ZF+1?$X9?M".'\C
M[.X!;/.SH`6[8SS0!Z9N]C1N]C7C*F[M++7H=*2^U&\E@6XGU:&.>*=X_M`#
MQE'X\T1[R"F#A>`,C,M_&UO9^(O^$134XM)6QMO+"^;C[49@Q,8?YL["N<<<
M<\B@#V!Y`BLQ!PHR:BM+Q+VR@NXE;RYXEE4,.<,,C/OS7FVKZ/IVF^(&TZYM
M]6CTN.P#Z5]B::3%T7<R$%229.8\;^,9[9K+U6SNKB:&+4[B6SB71+9]-G:&
MX;[/*J'S&58B!YH8H<,"3@`=Q0!['OX!P:-_7@UYK-IK7NI^*KV^O;^![."$
M6%^B2'R2]L!))'&/O,3U`!/&.#6OX%=+?1=1AM=,\I+2X94>(RB.\.P$N@ER
MR@D[<9(R#R:`.SWCC@\T;O8UXYHWVB:_UG4+&PGLTO/#]Q+-!&)SLN2P*HYD
M^]*`3]T#J>Q%79-(U'2_#MS>:(-2_M/4-!26Y'F.SO-N4NPW'B7:[],'@8'%
M`'IPOXCJ+6.U_.6$3'CC:6*C\<@TZ&\2>:XB6.8-`X1B\3*&)4-E21AASU'&
M<CJ*XWP?!ID6O7;Z+%J*::UE$4%VDH0.7<L$,G.>A8>OXUEZM#J$DWB*-%O5
M2;Q%8(K1;P?)9(%D*D=%P7R1TYH`[O6M;MM"L1=7,<TF^188H84W22R,<*BC
MCD^Y`J]#,9;>.4Q21EU#;''S+D=#[UY7KO@O3T@M=-2RN9[*'Q)!Y4;22,(H
M9$C,@4YR$SGGL<\TV.PDC\8SF\O'LKVUU2)+.3R;B0FSR@2./!\O:RY5B1P2
MQ/K0!ZO),D,32RL$C12S.QP%`ZDGL*@.HP^;:(@DE6[!,4D2%X\!=V2PX4$=
M"3SVKRVRTFRU?P_JL&I6&IR^*Y[>[2[5_.`9@24'79L_U>S'!QQT-1QVLT'A
MSPLGA:VNX[B.SO=R>7(N+K[&<;@_^W@#/&>E`'KY.1C!IJD(,8P,]A7DEM:Q
MR,L?AB#5AYVB73:HLWG#?.R`1;O,/^MW!^G/X$5>2]_M/PY'#%=ZGIZQ:`D,
MM[]CE.R7=&"`,99A@@XY`/7T`/3]^.H-5;C48;6ZAMY%D+S)(Z[5SP@!/OW&
M*Y/PK)*O@S5(=(TT6DUO+<16F#(8[APORR()>0I8XP>,@\D<U@>'(+3-G-81
M:PMT^EW']H?:4FV_:=J!B2__`"U)S]T\C\*`/4+:Z6ZM8KA$D1)4#J)4*,`1
MGYE/*GV/(J7>/0_E7C^BH]MJ7ABXN([G4;UK2QMQ;2QSI)IY,`WR!ON,G=@W
M.<C/:I_!UO<V^K65[=W4RZV%N$U&V,-P7NY%5OE9F)0*"`5(`!&`/2@#UG?_
M`+)HW"O&M&5Y]0U6^MA=:)#>Z)++<O;Q7$C6TYD4@,'^]*H+?=`[XZ@TYX7.
MC6EE%8&WT2'57AOGB%T8;K,7R2;<^8(]YP1DKN&<D4`>Q[\_PFB1Q'$TA!(4
M9(`R:\=U*&*UTG39GO)M:CLS.UOI?V>ZC$G[\!!$XY#(/D4MD%>>F37K-K>Q
M74UQ"A<R6[A)0R,`"5#<$C#<$<C([=:`,"R^(&C7^J+IL,&K"[8*2DNF3Q[`
MV0&8LH"@X/)P.#6UH^IVNL:3:ZK9[C;7<2RQEEVG!'&1ZUBVL,B_$G7)FC<1
M/I-HJN5.UB))\@'N1D?G7&>&/#=UI7A;2KS1XKNWUJZT*YCD$LC[3/M0Q[E;
MA2#P.!@9%`'K>_GH:R=4\3:7H]Q';W4LS3N`QCMX'F9$)QO<(#M7KR>.#7&_
M#ZUABU03VU[(OGV`>XLWAN`S2[ES)(\I($@Y&!R<D\BKD>K1>%O&>OMK$%VL
M>IR03V=U!;23AT6,(8CL4[2K`G!X^?CO0!W$%S%<V\=Q`PDAD4.CKT92,@BI
M-W3@\UX]KIDO'\0W,]MK*>)?.0Z#L$J%(W1!'M`.Q?F#[]W3G=5W6=,N[C5]
M8OL:B+B+7+.VMI(I)%\NWD6`3;,'&#N?+>W;%`'JF[M@T;N<8/Y5Y%K$!T2;
M4-)C^VP:*FNV(C1&E9C'+%^^5&Y8@G/`/&3CK2)Y,.EW.G?V9=2^&[O5V6RD
MO?M&RWC6)6)VK^\V-()`H)`S@],4`>O;\]`>.M&_D<'FO*-%TJZU/3_`^EZQ
M#?M:O:7HO(G:1,[63RUD/7`QP">P]*CU)=3\/:)I<ME+=O<:M9?V$OF,<K/N
M/DRMGN%\S)P>B]!0!ZWO]OPHW<XP:XCQM:_V=X+T[3+;S3$+JUM/)5F'GQ[@
M"C%<O@@'.W+<=QFN-33(K32([2VE+::^MS?VI;*MR?LVZ/\`<QR#Y9"@^7)X
M7D$Y'-`'M.[_`&31NZ\$XKRZST==1N/#>E7%U<ZAI#?V@)@BS0QA5=#%&2QW
M%5Z*2>=H/-4;_3[EDT.RU6:8Z7'IC)`]R)W`N$<C<_ED'?LV[2W^UCK0!Z_O
MZ<'FD:0(I9N%`R23QBO/K?37U3Q+H,&H37>HV<.AK<&9EDA6>X21-KNO&&PS
M':WJ<CBN?TFT&O:[<3'2)K:'4M+NS?68^T<3>8A1)6?`+\/C:!W[$4`>OPW$
M5Q!'/`ZRPRJ'22-@RLI&001U!%/W>@->(:=IMLNC>&;-K=X=(-@5NXIX[D(N
MH!8RWF!2"/E!P3\N<XYK5U5/(A\/7=S=W6ORVUE"$LY+>XA>X<R`"=&'W7]5
M?/"CIU(!ZI->)!-;Q-',S7#E%*1,RJ0I.6(&%''4XYP.].M[J&[MX[BVE2:&
M1=R21L&5AZ@CJ*Y;QC8_VEJGAJSEADFLY;Z9+E$+!2AMI1\Q7H-V/QQ7`6&E
MZ=;?#31H,3VTD!9]0T^>VN=EW.L7*.5^92"`01\I/8T`>V;O:H;J\2TC1Y(Y
MF#2)&!%$SG+$`$@#@#/)Z`<FN,\5WDW_``JR"[CANM.E86)\I78S0!I8@4SU
M+`$C/6N=BM6B.H)H4&HQZ&-9TK[*CB7&X3+YY0/\VS&W)Z<'WH`]<W8['BDW
M<@8/->/:?BZUVUGL_P"T9=>3Q%<1R2J9?+2R6:0,I)_=[-O;KGWJUX'M9UU[
M3KJ]OI(-8)GCU*%H+@M<N`>&9B4"@@,I&`0`!Z4`>AZ/XBLM<@MIK)+DQW$+
M3([P,%P&VD%L8#9[9SCGI6IOSV/XBO#;6'5[7PN#;PWT4T?AF[V!8W!6;[4"
MO&/OXY'?%=-K6A3:#INN1Z%]O6&=+*XN%$LLA*^8XG*$'=N*`9VG)]J`/3-_
M/0T;O:N-\!VD%FNI0V=Z)K,RQM';1PRI';Y3Y@IDR6W'DX/!R*Y.*W=[JW:2
M'51XN?6_+N2#*%^R><689SY?D^1C&._3F@#TS2]=M]7O+V&UM[GRK20Q&Y=`
M(I'4E75#G)*LI!X'/3-:E<1\-O#]EHNG:I);V+6TLNI74?S%\M$L[B/ACTVD
M8/?WKMZ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@!#R,4FWWI6^Z:\TD\3ZZM[)J']J
MP"TA\0C2/[.:!?WL;2A-V_[V\!LC'&$Y!Y-`'I6WOGGUHV]\FO-9/$NO#3IM
M0;58HDN-9;1H5:W79;`7#)Y[$\LVU2,9"\CCU6Y\5:UHXUO2YM3MKR>RN+"W
MBU&6%4\O[2^UC(JD*2@Y_AX(SZD`]&65))7B5UWH`64'D`],C\#3]I]:\VOM
M2U?0+;7Y3J\%Y?03Z=#]J$2JQ1Y0I$B#Y0V'8<8X(.`:TM>\2WMO>RV-E?P0
MF?5+?3DN657%MOB+L<'@MQ@`]V'7H0#M]N.AHV^YKSFT@UY/B;:6L_C">[A3
M3I)9(UMXE23;,BE&4<!N>6&".@Q6OK>I:E<^+4T"PUA-(2/3OM[W!A25I/G*
M[</P%`!)[\CD=P#K]ON:-OO7G>J^)]1C\36']GZK-+9C4K?3;N'[)&+?>XRP
M#D[RV"&&,@9'O4MEK'B*\U9[P:G$MA!KDFF/9?9U^>($@/O^]O!*],#`[F@#
MNY9$A:-7D53(VU0S8W'DX'J>#0DD<J[HW5U)QN5LCCCJ/>O.M(U;5=<E\/ZO
M=ZK:O:WNHR!=.\I5:WV+*`%8'+$`?-N^HV]*JZ!KVKZBUOI=GJ5EI+10W=\[
M_98]LVV\EC"%>`J@+ER/F.X'(/4`]0A=)X5ECD5T<9#*<@CU!I^WW->4:OXF
MU#3/!EDVCZG+#>:?HT=]/##:QRPLI'REW?!"DJP&WYL`GTJ^+W6M.\6^,K\:
MQ<W4&GV$5U'IIC38Y:.5E08&1@J.1RW?.*`/2-O/4TA!'<UYS9:EXZDTNXGM
MV6_^TV23VTLR00A96=<K$%<AEV,Q!<]54$\FMBRO)]7\#ZDD>LW,EY`)X);J
M6U2.6*1?O*4`V9'3(XH`Z:RU&SU*.1K&[@N$BD,,C0R!PCCJI(Z$>E6=ON:\
MK\--K=KH/@K1;/6O)&JZ<UPUP;.,O"J1PE448P3\Q&YLD@\\XJU%XHUM[:T\
M0?VM;FVN=9&F?V2T"X13<&'[X._S`!O],?P]Z`/2MI/4T;>^>:\UAU_Q+=ZC
M:>7J\,45_JUWI:1_9%80K"92)0<Y9R(\8/R\],CGJO!NIWNHZ7=Q:A,+BZL+
MZ>RDN`@3SO+;`?:.%)!&0.XH`W(G29`\4BNIZ.AR#^52;?<UY#X,N-9O_$6B
M2#6FM;9])EN&L8+>-(6VW(4KM`X+==PY';K76^$M5U:XU&ZLM>O)%U0PBX-@
M88Q'$A8@-%(F=Z'I\QW<<XH`[';[F@KGO7FFI>)M>MYM4U*+5H$MM,UJ/3AI
M[6ZG[2CM&.7^\&`E.,?W.<]GW7B;7(K35M3&IQ10PZN=(@A>!?+BW3J@G=NI
M*JQXR!QSSS0!Z1MSWHV^]>;:EXEU_0#KFG/JL&H3V"V$D5U+`J,IGG\MDD5,
M*<`9&`#@_C3)_$GB#3)=6THZO!?7%I>Z?#'>R6RJ0+EMK*Z)@$KU&,'D9H`]
M(WQ^:8_,4R*`Q7/(!Z''OS^52;?<UYEK6MZMH&M7MHES'<W?V;3K<W[6L0D!
MEFF5G;&T$```*2%!/N<QZ])XL'AV)+O6+NQDBUJTABN1%"LUQ%))&,R*A*KM
M9FX&-P`R,$T`>H[?>EV^]><>*/$>IZ9<JFG:U<S2Z8]G!?H;.+RI&ED1<NQP
M065L@)P.*<^M>))+;6M;AU)/LFD:E+`]@($Q)!%(#(Q<\[O++8P0.!U[@'HF
MWWHV^_%<YX6U:ZUQ=3U(SB33WO'BL`J@`Q1@*7SU(9PQ!YXQBN0NO%/B'3/#
MVMR:CJ3P:[#!%<I9M;1&*%&E";HG7.]#R/F.[CM0!Z?*Z0Q[Y)%100,LV!SQ
MU^M.`SW-</XOUF5++68H9+>9;6?3D$;QI*$,DZAL@Y&<8(STX(K`L=6\0:'X
M?\17[ZY-J$BZVUC&+B%"(,S*AE[<`-]TD*/:@#UC;[T%?<US?AB;7E2_AUHR
M2K#(IMIYEB2652N6W+&2HPV0/45S&E>)M=N+;PUK$FLV\T/B&Y\C^SQ;H/LP
M*.V48'<60H`V[(R>@Z4`>@PZA9W-[<645W!)=6X4S0+("\8;IN`Y&?>K6WMG
MBN$^&5A=VUAJLUSJCWGF:G=IAK>-"&6=PS949.[K@\#H,"H-"UKQ)=G3]9GU
M&*:QN)[RV?3UMU4CRO-",KCDL3%SV^;@4`>A;3CJ:-OOS7F>C:SXNU/2DU23
M45@L[[3I;EKB:&!8K"0*"FP!BS@'<&WCC;VZ5FWFO^(?$GAN/4QJ\FBL=7L;
M;[';H"T09T!9BP!(8MO`/!7:#U(H`]?P?[U(%QWKF];UB_T3PY?RQQR3W-E8
MM(+VX"+#*ZKG)"G(R>P7%<B/$'BK3=-U34)=0N;NU+6<%G+>6,4+1M*^V1V5
M=N0@*]2`3WXH`]3(SWQ2;?>O.I]6\7:;9);75P5DN-5M[.VO;F&+S&252&+1
MQG;E6Z=,X&:;=ZYXEL8[31GU`S7D^J36AU**VCWB-8O,4!&*Q^8<@>G!P#0!
MZ/MSU-&WWK@IM5\4)9Z#87%PEEJ&H7\]F]PT4;MY:I(Z2;`2@<A!D=`2>.,5
M7NO$>IKXIT^*PUFYN+%M2&E7*R6<2Q"41.7*M]\N&4'@;>HH`]!>1(BH>14#
M,%&X@9)Z`>]2;?<UY+I-QJ]KI-M+>ZRVJ>9XJ^RJMW;QL8@MQ(I93C()P,?W
M>BX%:.D>*-<FC\,:S-JUO<VWB"Z$+::(%'V92CM\C@[B5V`-NSR?X>E`'?WN
MF6FHK;B[B\T6\Z7$621MD7E6X/;TJUM]ZX'1M6\0WVI6VH2:I$=/;5KK3GL?
MLZ\I&90K[^N[*#VQVSR9?B#XAO--AN(M(U.YM]0LM/EU"2&*UCD5HUR%,C2?
M=7<I'R_-UH`[G;SG/6JEUIEG=75I>7,8>6R9I(&9B`C%2I.,X)P2.>E<1JVL
M^)+N]U"'2]4AL?L.D0:D`UNL@E=O,RA+=$^3MSSU'=+$ZLWC?Q2\FO3RV<%E
M#*MC)$AC^>.4A1QP%QV^]WS0!V-]:Z9X@@^QW#I,$*3@13%73NC@J01G!P0>
M>?>I]/TJTTN.1+2,IYKF25V<N\C'J69B2QX`Y/0`=J\DM+O51YFL6.KV^ER6
M_A+3[R51:QE)2!,P3:<!$ZC"XZC&,<[-YXMUN]T_7M;L]5@TV+1;6*<6$D"R
M"<O;I-B1CA@"6V+MQR#UZ``])GD2WB,LTBH@^\SG`%2`>YKS/4-:U36;;69_
M[3M+6TL;J&T;3I(P?-#+$Q8OG<&)<[0..,'/47V\1:ROB%?#7VE&U+^U"^]4
M4G^SPAE!(Z`G_59('.>^"0#N))H8I8HI)D224D(K-@N0,G`[G&3Q4NW(Y.:X
M+Q@]YJ.H^$EMWFTFY?5)%26>.-V3_1I>0NXJ<C(&>_:L\>*]2NM%-C'K-P-7
MM[J\B%S9V<3_`&J*W.#(0_R(/F4'!Z]*`/3=I]:-OO7G2^)-<EM?#NJWEZ;'
M2+BQM)I[BV@CE62XE(!20,=R(25"E1W.33]$USQ3JVKQ7J;FL&U&:TGM&CA6
M.WB1G7<'W>8TF54X(`PQXZ&@#OI)$B9%>15+MM7)QDX/`]>`:EP>QKS72-7U
M37)/#^KW6JVK6M]J,@33O+56M]BR@!6!RS`#YMWX8Z5I:M'JK_%/1HK?7[FV
MLWL)YFM5C1D;9)$"#D<[MW7J,<8R:`.MU'2[35;,VE[$)8"Z2%,D?,C!E/'H
MR@_A4MQ/#:Q&6>9(HP1EW8*!DX')]R!^-><Z3XI\47,/]ONCRZ>3=&>S:.)$
MMUC60J%<-YC2;D52"/XF.!@56UZ?4[WX6:A?W^OV]_\`;[&"YCMEMT00%I$/
MR[3ED!./FR>.M`'I5AIMKIL$D-G$(HY)7G=02<N[%F/)[DDU:V^]>?ZCJWB3
MP[IFMK<:M#?W%O<67V6=[94VK-(J,KJN`0#G'?!ZTEYJ_B#1E;2KC6HI[FXU
M:"QAU&2V13#')%O)*#"ELJRCM\RYSTH`[R:6&WV>;,L?F.$3>P&YCT`SU/'2
MI`-PSFO*]1U34)[^/2-0O8]0;2O$FGQI=K$(VDWKO(8+\NX$XXQ]*LZ9XIUQ
MK/P[KDFKVMQ#KLYB_LXP*JVX\N1OE=3N)4H`V<]3P.E`'IH'.2<T$9[UY5HN
MJ^-];MI+ZSU21UETEKJ..6RBCB2Z)!6-#C<Z8W8.>A&2":ZGPKXCF\4:G?7U
MO,/['BB@BA3`.Z9E\R0[N^W<B8!QD-Z4`=8!BEHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`$;[M<[I'@[2].U"ZU%X(;F^FO9KI+B2%=\7F?PJ>O&2,^]=$W*UQ#
M^.;E+XDZ,3I46J?V5-=BY&]9B^Q2(\<IDKDY!&3P0*`.I?1=,DT^>PDL+=K.
MX9GF@,8*2,QW,2.A))S]>:9%X?TB#3[C3XM-M5L[DDSP>4-LI/4L/XB?>N1M
M?$&H6$7B21&M+AXM<D@B34+[[.B)Y4;85BK=R>`.]01>-_$>IZGH/]CZ+8R6
MFJ:6]Z([F\,;Y!C!&X(<;=^.AW9SQCD`[-/#>B1V$UBFE6:VLZA981"NV0#I
MN&.?QH'AS11I\M@-*L_L<NTR0>2NUR,8)&.2,#GVKSWP=XCUJ+1+*1].%]K>
MN2S2Q>;J3>6ZQD[W;*D1`950J`YR#ZXZ$^.)6TJ":+2'.H2ZD^E-:-.H"W"J
MQ_UF,%/EZXSCMGB@#H5\-Z*K6K+I=J&M&+6[>4,Q$G)(/J3R??FI-0T/2M6\
MHZCI]O=&+/EF:,,5R,''U'7UKE-0\=7NFW%VDNA^8FG-;I?M%=#*O,J;%C!`
MW_,^"3M&.?:B\\>W&G0WT-]I$<&I6UU#;B(W>8`LP)CD>7;\B_*P/R\$#L0:
M`.G;PYHK:A_:#:7:&\W*_G>4-VY1@-GU``YJS'I=C$&$=I"H><W+;4`S*>2_
M^][TFFW$MQIT$\\<<<LB!G2*7S44^S8&1[XKA_$6CW8\::);P^)->@@U6:X,
MT45V%5`D1=0@V_*,_6@#L8O#NC07[W\.EV:7COYC3K"H<O@C=G'7D\TV7PSH
M<\<$<ND63I;NTD*M"I",QW,1QQD\GU-<?I'B'6K/7M6MFT^2^TL:Z+,W;W7S
MP;TC"@)CE0S9)R/O\9JW9?$%+[6[>VCLHC8W-Y)90RK=!IS(I8;FA`RL>4(W
M$YY''-`'27'AC0KLPFXTBRE\F,0Q[X5.V,<A/]T>G2K#:-IK:DFHM8VYO43R
MUN#&-X7D;<^G)_.L?4_$%_'KK:1HVDI?W,$"7-R9;H0JB.S!0IVG<QV-QP..
M2.*SK_QS<6C7]['HQFT73KG[)=70N0)0X*JQ6,CYE4L`<L#P<`\9`-Q/!_AR
M*.2./1+%4D38RB$8*A@P&/3<`?J`:OVFE6%A9?8[2TA@M3G,4:`*=W7([YSS
M7)W7CJYM]3FACT5I[6'41I9F%RJLUPP!0!2/NX9<DD8SP#BJ.N>*=2G\-R,E
MFUGK&GZU:6L]K#<Y5RTD9"B3`&UT<=1QDY%`'<Q:3I\!LS%9PH;*,Q6VU`/)
M0@`JOH,*!@>@J%?#FC)J?]IKIEJ+XN9/M`B&_<1M+9]<<9ZXKE9O%MS*8;2_
ML9+'4K?6K6SGAMKO<F)1N1M^WYD(/*X!X[5:T?QC>ZM?V6=$\K2KR2>W2\^T
MAF$L6[=E,<*?+8`YSQT%`'2IHVFQM$R6-NK0SO<1D1@;)7SN<?[1W-D]\FI[
M:SMK,2BV@CB\V1I9-B@;W;JQ]2?6N$NO'>I[];LK;3M.>\M-/EO;=H=0\Y"J
M/M(DPHVL,YV\YP1D=:6R\77<2Z5?:[;FW9M$N=1F6UN"\1CC\IMQ3:#N(8XY
M^7D<YS0!UH\.:*ILRNEV@-D2;8B(#R<G)V^G//UI=.\/Z1HYD;3=.MK0NH5C
M#&%RHZ#Z#/`KG!XVO[9E75]#^Q_:+*>]LS'=";>D2AF63`&UL,.FX>]7?#_B
M6^U>_P#)O-'-E!/:)>VDHN!)YD;'&&&!M894D`D<]:`)M-\':7::O?:I-!!=
M7MQ>M>1320KO@)15VJ?;:>?]HUK-H^FO:75HUC;M;7;,]Q$8P5E9OO%AW)[U
MRVJ>-[FP?5;JWT8W6D:/*8KZY%R$D#!59O+C(^8*'&<D9YQFJ_A>;6=1\?>(
MI]1@58K.46L+1W[LL:F.-PHBVA3G=N+GD$E>0*`-K5/!NEW6@W&D6<$-A#<3
MQ3RF*$'>4=&Y'?(0#GM6C!X=T:VLQ:0:9:1V_G+<>6D0"^8I!#_[P(&#["N+
MTCQ3?V_CK7(-6O2^D/<S0VF4`%LT$4<CC(&3N1RP_P!QN.M)X4\1:Q-+XDN]
M0N4E'D6U];6]U(($MUE$A"%B#M`54R3GG-`'<W6BZ9??:/M=A;S_`&F-89_-
MC#>:BDE5;/4`DD#WJ%?#6B+8W%D-+M?LMPXDFB,8*R,,8+9ZD8'/L*YFS\?7
M%[IP$6EPRZJ^I/IL-O#>!H9'6/S"XEV_="]?ESP0`:O3^)-7AO=-TL:'%_:U
MY!),T1O1Y42QNJL=^W)!#J1\N3G!`YH`UF\+Z"\\<[Z19M+&B1HQA&0J?='X
M=O2I;G2HAIE]:V`CLI+P2,TJ1`XD<<R%>C'///6N:M/',\\EC>-HQ70]0O/L
M=K>+<@RLQ9E5FBP-JDKZDC(R*PUUXRZ1IWB;5?$>LV)U%3+;Q6-KYEK;QE@%
M60"-ANP0"S'J3CH*`/0]&TBUT71++2K1=MM:PK"@/<`8R?<]3]:@M_"V@VEO
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M:09/+7&\@8&?7`XJ.V\.Z-9Z@U_;:9:PWC%B9DB`;+<L<]B<<^M<]KLNK>"O
MAG//8NE]?V%L7>:[E8@GDLW.2V">%)Z8&:BU/QM>Z4UK8S:98+JK6C7EQ%)J
M(2&.,,5&V0IEV.#@!>QR>F0#L;:QM;*-H[6".%'D:5EC7`+L<LQ]R2233(-,
MLK6***WM8HHX7:2-40`([9W,/<[FS]37-?\`"7WFH3VL.@Z-]LDDLH=0F6YN
M1;F**7.Q>ARYVMQP!CDCBLK0/$FLPZM?6]QI[W6F2:_<6:WC77SPDDE0(\?<
M!XZ]3P,4`=8/"/AY6F8:-9`S+(LG[D88/]\8_P!KOZU9N=#TJ\%R+G3[:872
MHL^^('S0GW=WKC)QZ5SMAXPO;_5H8AHA32Y;V>P-W]I!99HM^3LQ]P[",YSG
MMCFF:=XWN;R72KF?13#H^KSB&QNEN0TC$JS*9(\#:&"$C!)Z9`H`W]4T2WO_
M``[<Z*C?9K>:W,"^6/\`5KC`P/3VK+TOP7:6UW?7%]]FNS>VR6DT,=HL,#HN
M3\T8)#,23R>V`*P/#'BG57\-:'86=I_:VKW%K-<2-=77E*L23;`6?:Q).0``
M.W-/OOB;)'I27MAHP9Q9SWD\5[=B':(7:-T0@,)'#(>!C@J<\T`=C;^&M$M1
MB#2[5/WJ3\1C_6)]QOJ.Q[5-=Z+IE_`\%W8P3Q/*)F61`<R#&'_WA@<^U<S!
MXXF-H(Y]+$>JG4(;%;19BRMYBJXD#;<[0A8]/X#TZUJ>(->N=)O--L+'3UO;
MW46D2!'G\I0R+N)9L'`VY/`)X''-`&A;Z#I5I';I;Z?;QK;2M-"%0?NW8$,P
M]"=S9/?)IH\.Z,-2;41IEJ+UG\PSB(;]^`-V?7`'/7BN0M_%%SJOB#PY<+')
M9[HM2AO+-YAL\V$QJ06Z$!@<-Z&J6I?$/6?^$=UR>QT[3?M^F-;LSQWWVB`Q
MRDX(8*,L,8*\=0<\8H`[Q?#NC)<RW*:9:+-+,L[N(@"TBG*N?]H$GGK1;>'=
M&L]0;4+;3+6&\8L3,D0#9;ECGMG`SZUPVIZKKQ\=Z?'JME#!I]EISZC/%;ZE
M)A"CJ&D.U!YFT<!#P<D\5K6?C6^::Q_M#0S:0ZG;23V#I=+*6"1^9B0`#82O
MIN%`'5PZ98P*JQ6L**LS7`"H`!(V2S_4EFR?<U#J&@Z3JT\<^H:;:W4L:E%>
M6(,0I.2/ID`X]JYB+QKJ4VFZ7=QZ$I;69`NFQ->`%U,1D#2';A!A3P-QQCOQ
M18>.KFZ;39[C16@TZ^FDM$G%R'<7*;\H$`Y4F-P&R#P,@9H`ZS^RK#S)G^R0
M[YH1!*VP9>,9PA]5&X\>YIDFB:7+?K?R6%NUXL?E"<QC?LP1MSZ8)'XFLCPG
MXDF\364EZUI;6\!P85CNO-D`/.V5-H\MQQD<_6JZ^+9AXV@T"6VLS#<M*L,T
M%\))5*)O_>1[?D!&<<GM0!JS^$_#UT+<7&B6$OV=%CAWP*=B+]U1QT'85-=^
M'=&U"\6\O-,M;BX3:!)+$&;Y3E?K@\C/2N9TSQW<7HM[RZT=K71[FWGFCO!<
M;V!A&7#)C@'#;<$DA>0*ETC7=4UC7-)DN]*DT^VN+26XMRMP)%D0B/:'``VN
M,YQR,'@]:`.AN/#NC7=^;ZYTNSFNRH4SR0JSD#ISCMV]*ACT&$>+I_$$LGF7
M#6B6<*E,>2@8LV#WW$CZ8%4-<\1ZA8ZRFCZ5I":A>M:&\`DNA"@16VMS@\Y*
MXX[\XQ5&V\=-J<^GKIFF%XKFPBU*:6XF\OR+=F96X`.YAMX4=?4=P#J=2TC3
MM8B6+4K*"[C1MRK,@8*?49Z'WJK+X7T*:UM;632+)H+52MO'Y*[8@>H48X![
M^M<Y;^-M5N$T^7_A'XXX-80G2Y'O0?,;RVD43`+^[#*I((W8[XK-TOXA:N_A
M_19+_3]-_M74X&N(=]_Y$)B4+EV8J=I)<`(`WUQG`!VS^&-#DN(+A])LVEMU
M186,0^0)DH!_NY./3/%._P"$;T7^TCJ/]F6OVPR^<9_+&[S,8W_[V.,]:Y>3
MQI#,FA:I';W:1W6GWUT86FVJ#"JDJZX.[G.#D8ZX.:U/#OB:]U?4/)N]&-E!
M/9I>V<PN!)YD;'&&&!M<94D`D?-UH`U8O#NC07[W\6EV:7DC^8TZPJ'+X(+9
MQG)R>?>IKS2-.U":WFO+*"XEMGWP/)&"T9]5/;H/RKD]1^(26FN7-K%9PRV=
MI=QV=Q(;H+.9'V#]W#C+*I<9.1WQG%37/C&^CUJZM;?1?/L[&^AL[RY^TA60
MR["K*F#N`\P%LD>V>:`-]/#>BQ:C_:,>F6J7GF&;SEC`;>1@M_O$<$]33(O"
MV@00W$,6CV217`Q*BPJ%<;MV"/3<2<>O-<VGCJ]F\3VNFV^D6YM)M0DL#+)>
M[9D:-69F:+:<+A"5R>05/&:AT_QC?/I]C:Z7I4M_?7?VV5%NKT#"PW!1MS[?
M<;0!Z#MF@#MKG3+&\$@N;6&42E#('0'<4.Y"?H>1Z4VZTC3KZ&XAN[*">.X*
MF9)(PPDV],YZXP,?2N-U#XC_`&>*W-OI\)F;3H]1N8KJ\6`QQN#A$X/F2?*W
M`XXZC(I+WXEP6]U)]FL%EL[80&Y,MR([C]ZJN!'#@ER`ZD\CT!.#0!U\.@:1
M;6T=O#IULD,<_P!I1%B&!+G/F?[V>_6H4\,:+#<S75OIUM!=RK(&N(H@KC?]
MX@]B>Y[UBZIXGN_MVNV%KIQ:WTJW9[N[^U>6ZY@\Q/+&TY;/&3@#@\]*SQXY
MOHK(?8=#EOH[*RM;J\>2\`=8Y4SD?+\[C#$]!QG/.*`-'0?!$6BW]E>-=122
M6-JUK"8+40%E..92"?,.%&,X[GJ:V/#6@0>'=%CL8G\UM[S33%`IED=BS,0.
MF2>G88%<WJ?CN]M?$']G6>CV\T*ZA#ISM/>^5+O<!MZQ[#E,'AL\X/I7=KTH
M`6BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`0]*X;2_`\CWMY/JUS<^0=:EU&"RC
MF'DO\VZ-FP-V0<';G&0*[DG`K#A\8:-/K/\`9:3R^<96@64P.(6E7.8Q*1M+
MC!^4'/!H`H3>!;)]3.I07M[;7OVJ>Z66,H=K2QI&Z@,I&,1J1W![U+;>#+*R
M;16LKJ]MVTF$VT)1U/F1,5)1\J<@[%Y&#[U/!XTT2X2-HKEVW0SS,OEMNC6$
MXDWC&4(/&#C)J.T\=^'KQKH)>M&MM`;IGGA>-7A'61"P&]!ZKGJ/6@"&/P18
M6]CI%O:75[;3:2TAM;E'4R`.275@1M93W!'85);>#-.M;.P@66[D:SOSJ1FD
MD#//.0P+2''.=YX&.@J2'QOH<MC<W<D\UM';%/.%U;O"Z*YVH^U@#M)X#8QP
M?2J5C\0M.U'Q,FAQ:=JZ220"599K"6->6(Y#*"HX^\>.V<T`7+[PA8:@^J-+
M+<@ZE/;33;6'RM`5*;>.`=@SU[]*EG\-))JE[J5MJ%[9W5YY(F:'RR"L:N`N
M&4C!WDGW`JEI?C;3Y[;3UEF:ZN[Q=^;*SF9$4NR*SC!,:DJ1EL9VGTJ]#XPT
M:?6?[+2>7SC*T"RF!Q"TJYS&)2-I<8/R@YX-`#M$\/0>'[2SL[.ZNOLEK;F%
M89&4AB6W&0\9W9R/3D\5/>:1!?:MIFI2O*)M.:1HE4C:2Z;#NX]#61XG\5?\
M([X@T6VF1WM+V*Y+K#`\TI=`A78J@D_>;/%6;SQMHUEHMIJ[M=S:?=1>>D]O
M:22JL>,EWVJ=@`]<4`36_ARTMS>E))C]LU!=0DR1Q(-G`XX7]VOZU%8^&1IM
MTS66J7\%FUTUT;)=AB#-DLHRNX(6);:#UJP?%.E_VQ%I<;SS7$BJQ,%N\D<6
MX97>ZC:F1R-Q%&N^)K#P[;K/J"7?DD,S/!:R3+&J]6<H#M`]30!!J'AF&^U=
MM3AO[ZQNI+?[+.UK(!YL>20""#@@EL,,$;CS5*Z\!Z?=S7:M>WZ6%[=+=W-@
MDH\F60<G/&X!B`6`8`D51U_QA?:=J.II:+;R0VT&G31%E/S?:+@Q/GGIM`(]
MZVO^$VT+^UO[-^TRB0S?9EF:W<0--G'E"7&POGC&:`&MX0T]GD<RW.9-635S
M\P_UJA0!T^[A1QU]Z;?>#;"^34@]Q>1-?WL5\\D3J&CEB5`A3([>6IYSS5JW
M\6Z+=S:5%!>*S:JDKV?!'F"/[_7H1Z'T/I567QWH45E:W2RW,R72N\206LDK
MF-&VM)M4$A,_Q'@Y&*`(H_!%@I\V:[O;BZ;4(M0EN9I%WR21\(IP``@'&`!5
MRR\,6-EIMM8QM,\,$\\PWL,L9?,W`D#I^];'X53USQUHVG64HBO!),UG]HCD
M2)I(4#*3&TC@;5#$8&2,U8\1^++;PMIMG=W=I>7'VF>.$+;0,Y4L0,G`]^!U
M)X'-`%33?`>FZ?&(C=7ES&NG-I:),R@);L02HVJ,G@?,>:?;^!]/2&VAN[F\
MOHX+";3@MPR_-!($!4[5'01@`^YJA=?$*STGQ+<6VI>?'8?V?;WD3"SD+Q!V
MD#F4`?(HVIG<!@DUMW_C'1=,U(6-S<2B0;?-D2!VB@W?<\UP-J;NVXB@"A%X
M%LP`+O4M2O?+L9+"W-Q(I\B)QABN%&7(P-S9/RBMBQT:WL&L_*>0_9;-;-`Q
M'*#')XZ_**9X@UEM)CLXH(/M%]?7*VUK$6VJ6(+%F/.%559C@$\51.NW>A6(
MD\4"U$SR".#^S4ED:X8@G:L>"V0`>Y]>*`(K_P`#6&H3:@&O=0AL]2E26]LH
MI`(IV7`.<C<H8`!MI&0!6Q8:1!IU]J5W"93)J,ZSS!B"`RQK&`O'3"#UYJ@?
M'&@C38[\74C1R2M;K&L#F7SE&3$8\;@_^SC-+8>-M"U/4+:RM;F1Y+D'RF,#
MJC,HRR;B,;P,Y7.1@T`4]2\`:-JUG>6UW]I*W6H_VBS*X#+)M5"%..%*K@CT
M)YJ?4_!>G:K/J,TTMS')>FV9FC9?W;6[%HRH((ZGD'(-/T_QSH.IZE#86MS(
M99U8P.T#K',5&65'(VLRCJ`<C!]*=;^-='N&U!"UU;M80FXG6ZM9(3Y0)&]0
MZC<ORGD4`5?^$'LO)8B^OQ>'4/[36\#J)$G*A"0-NW:5&W;C&":T+?P]#!J=
MEJ,EW=W%W:030!YG!WB5U=BV!V*`#&`!QBJD/CW0)UG99YU6!X5=I+:1!B5M
MD;C(&Y&;@,.*UX=7L[B^O[.%G>:P"?:`J$A2R[@H/=L8.!R,CU%`&#:^!-/M
M)K-5O+][&RNFO+:P:0>3%(>1CC<54DE5)(!-13?#VQDMIK&+4]4M])GF\Z33
MHI$\G)?>P&5+*I;D@$>V*-,^).C:AIMS>R6^HVJ0W+6RI+9R;YG#,H5!MRS'
M:<J.5Z'%=!I&NZ?KEJ\]C*S>6_ERQO&R21/C)5T8`J>1P10!0M_#/V+4)I[/
M4[^V@GNOM<EI&4,9<\L!E2P5CR0#U)/%26WANTM$F6.2<B746U)MQ'^L)R0.
M/N^W6JUKX\T*\UB'3();EI)S)Y4WV6002",9<K*1M('J#BGVGCG0;U+F2*XE
M6."!KG?-;O&LL*_>DC+`;U&1DKGJ/6@"NO@:S@GCNK+4-0L[M)+EO/A=,LL[
MF1T(*D%0QR.,@@<U9F\*Q7.I6-W<ZC?SQV,RSV]M(R%4<1[`=VW>>,GEN22:
M+3QQH%W#?S+=R116,:S3//`\8\ML[9%W`;E;:<$9S21^.-#>PGO)9I[9+>1(
MYH[FW>*2,O\`<RC`-ANQQSVH`U-9TNWUS1;S2[S?]GNXFBDV-AL$8X/K64_A
M;-U:7JZOJ,>H6\+V[78\O?/&QR%<;-IVGD<#'/J:6X\:Z3:+9-=1:C!'=[-L
MDMA,JQEFV*)&VX0EN,-CJ/6J]AX^TN\U#6K66WOK1-)+>?<7-LZ1;556)W$8
M!^;@'DCD<&@":?PG'+>QWL>JZE!>?9%LY[B&10UQ&.07RN`P)8AE"D;C5BU\
M,V=HLJ1R3D2ZBVI')'^M)R1T^[^OO4^B^(]/UXS)9F=)80"\-S`\,@5L[6VN
M`=IP<'H<'TJG?>.-!TW4FL+JZD26.589G$#F.!FQM\QP-J;MPQDC-`$UEX;M
M+&".&-YBJ7\M^-Y!)DD+EAT^[\[8_"J%AX&L=/FTX+>W\UGIDCRV5E+(#%`Q
MR!SC<P4%@NXG`)JY+XST2"ZO+>6YD7[$K&ZD\AS'!M[,X&`QR,#.3V%1V_CC
M0I[6ZG>XEM?LBJ]Q'=P/!)&C-M5RK@':3WZ4`5(/`=E8Q:=_9^H:A97%A#+;
MQW$3J7>.1BQ5P5*D!CD<9!`K$U#P/<Z?>0IHMO-+;PZ:UO#(+I!(DYD9S(_F
M*=V6;.0.N>#D5T`^(?ATJI,]TC&58Y%>SE4P[CA6D!7Y%.1AFP#D4Z;Q?8Z?
M=:C'>3&5H+L6T-O:6LLDQ/E+(1M`)<@,6)48`QGF@"C:>%KY_&FGZWJ<J3/9
M:6D+S(<"XN?F#2;.B[5+X/7]X1VJYXDT*]U?7O#]S;3R6T5E).TT\+J)$W1[
M5VA@0<G@@CI4\GB>TAU"^^TW4<5I:V,-VX:%UDC5V<;F)XQ\O3&1@YIL'CO0
M;BTOKA;B=%LF19$EMI$=O,_U>Q2,OO(PN`<]J`*<GP[T6;38+&1[QXHX+J%W
M:7+RFXP97<D?>)&>,#)/%2-X%L)[#5;:[O+ZX;5(8H9YF9%91%GR]@50!C.>
MG-:>@^)K#Q''=/8)=K]EE\F9;FV>%E?&<8<#G!'YBJUGXXT*^U2'3H+F3SIF
M9(G:!UB>1<[HQ(1M+C!^7.>*`'CPQ:O?"\O)[F]F-A)I\AG*XDB=@S;@H'/&
M.,<52LO`UG:O:&74-1O$LK>2VLTN)5(@1QM)&%!9MIV@MG`J9?'V@/:RW4<U
MR\",J*Z6LC":1LX2/"_O&X((7.,<XI__``G6@_V6+];B9@9_LWV=;>0W'G;=
MQC\K&_<!SC'2@"2'PQ90VWA^W26?9H6/LV6&6Q$T7S\<_*QZ8YJ&+P?80Z=I
MUDDUUY=A?/?PL6&XR,9"<\=,RMCZ"DTGQ997J0.]PLBWU_-:V31QG#;06P?0
M@*V<XY&.M6M0\6:5ID,;S/.[RRR0QP6]N\LLC1DA]J*"2!CD]*`&Z1X<BTK4
MKK47OKN]O;F**"2:XV`[(\[1A%49^8DGOFJ>F^"+#2]1M;N&ZO'2SGN+BV@=
MDV1M-G?T7<WWCC).*-!\>:?XAUV]TNTL]14VP4K/+:2)&X*ALY(&WKQG&>HX
MJ_=>*]*M-932G>=[HLJOY-O)(D);[OF.H*IGMDB@"&S\):=9:19:6/.EM;1)
M4596!WK(&#!L`=F/3%,T?PG#HUQ:RKJ6I70M(6M[:.ZF#+'&VWY<`#)&T`,<
MG'&:L1>+-,EUY]&Q=QW@5V3SK62-)0F-_ENP`?&1T-0:;XXT'5KIH+6ZD.+=
MKE97A=(I(UQN9'(VL%)`.#P:`*>L^&KW5O&,=_'?75C:C2Y+5I[215EWM(IQ
MAE/&`3GL0*OV'A/2]+NDEM8Y%CCTY--6$OE/)5BP]\_,><UGCQO8ZC-,=.N,
M10:?/=O]HMI$)5=FR0`@,T9RW*]<<4S4?'VFVND;5NU-^UFDV];>0PH[IN0.
MQ&$W?PAB":`+.F^";+3I]-?[?J%U;Z6'6PMIY`4@W`KQ@`MM4E5W$X!J.R\"
MVVGV^GQVFJ:E&^G;EM)=T;-'"P`,)RF&3@'Y@3E1SQ6G>>*=-T[6;?2[K[4D
MUPZQQR_99/)+MG:GF8V[CCIFLO2/B+I&IVNIW,T%]8P:?,T4DEU:NBMA@HQQ
MRQ)'R?>'I0!;N_"5OJ"6GVV^O;B6VM;FV$SLH9UG`#EL*!D`#&`/QK0T_1;>
MP:T,;2G[)9K9Q[B.4&,$\=?E%9X\<Z*=/:Z+78=9A`;1K207/F$;@HAV[SE<
MMTZ`FME-0ADT\7P6;R3'YN#$P<#&>4QNS[8S0!E/X86/5+R\L=3O[$7LB37$
M,!C*.Z@`L-RDJ6``;!Y`]>:D'ART674Y/,G)U&ZBNIN1P\80`+QP/W:]?>H+
M?QQH<^GWE[)-/:Q64B1W*W=N\+Q%\;=RL`<'<,&B+QQH<NEW&H&6XB2WG%O)
M#+:R)-YK`%4$97<68,,`#G-`'/Z;X<UZRUX30?Z,#JDUS<7'FQO'-;NS-L";
M=X8Y`Z\$9R>E=!I?A&PTBZLKFWDN2]FERD8D8$$3RB5\X'9AQ[>M3^']=BU[
M[?<6\F^WBN!$@:,HZ$1H65@>0P8L"".*BM?&VAWEZ]K#<2EE5V21K=UCFV??
M$;D8D*X.0I/0T`1MX1ACGM[BQU&^L;B&S^Q-)`4)EC'*[@RD94YP<<9/K2GP
MKY=[/=6FL:E:2W21K<F(QD3,@P)"&0X<@`$C&0![55D^(^@&TOY[5KNY-I:F
M["1VLG[^/(&Z,D8=02`2.!U/%2P>/M)ET.QU.2'4(VO1^YM/L4K3O@`MM0+E
ME`/W@,>]`%U_#=H\NNR%Y]VLQK'<8884"/RQLXX^7USS5>U\(:?:0WL4<MR5
MO+."RDW,,A(E95(XZX8YJ1_&FB`V0BN)+AKY%DMTMH7E9U+;2V%!(`/4GIWJ
M>]U=+37[>QDFB5)+2:Y:,QL9&$90$@CY0!NY!Y.1CH:`.5D\-Z_'XBO[JQ'V
M>2XU)+E+T2(T8AP@=&C*EB2JE>".6SD#KZ$OW:Y*3XCZ`;._GM6N[DVEJ;L)
M':R?OX\@;HR1AU!(!89`ZGBI8/'VDR:'8ZE)#J$;7H_<VOV*5IW(`+;4"Y90
M#]X#'O0!U-%4M+U6RUJP2^T^X6>V?(#KD<@X((/(((P0:NT`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`"'IQ7"Z3X+N]*OXD,%C=6<&HR7=O-+<3>9$CEFXC^YO#.PW
M#`QVS7='@4FX^E`'G3^$-3TJV\0ZJ\EM/<ZK8W7]H111G[^&\H0X&?NG:V?O
M$`]<U##X+U;Q)H-J=4GM;94T,65I'$K[@S^6^^7=C&#%&-H_VN>E>E$]L4`D
M#I0!PMSX.U.^TV\BDM]-MKNX^QEKB.YFF+F&82,"7&0O!V@9Y)S6W-H^I)XY
MCURU>U:UDL5L[B.4L'4+(SADP,'[Q&#CI70;C_=S]*-Q.,"@#SJR\"ZSI]II
M<5I+807EHL:/J44LJRF,3-(\>S&UU*M@!CP2Q]*NZ3X+NM+OXE:WL+JS@U&2
M[MYI;F;S(E<LW$?W-X9V`(P,=LUU6E:Q;:S:R7%H'V17$ML^\8(>-RC?AD&K
M,]Y!;-"L\T<1GD$40=L;W()VCU.`3CV-`&7J&CSW?BS1=622,0V$5S'(ASN8
MR!`,=N-ASFN7U?P1KE[IO]G07UO]B?39+,P--)&D<K,?WH"#Y_E;&UL#CW->
M@[N.E0W5Y!96SW-W-'!`GWI)6"J,G`R3[F@#DI/"^JC7K*]LVL[(1/;BZNH9
M9/-NH8TPT;IC8V3P&)R!1XP\+ZUX@FN(K6]B6PN-.>T,$LTD8BE8G]]A/]9\
MIQM;C@>IKL\GTHW'L,T`</J?@J_O9KMX[BW7S[;3H5W;N#;3F5B>.A!P/?K3
M(_!^M+:6^C&ZL?[)@U;^T%F`?SV03>>(RN-H/F'&[/W>V:[2UO%NXFD2*:,+
M(\9$T90DJ2,@'J#C@]",&I]Q]*`/.+OX=:E]KU2\L=0@CN1<";2"04^RAG+R
MJS`$D,S-Q[`<#(K0O/`\D5_87&FQV\D$&FC39;>>>2`,BG*,&C'J6R",'/&*
M[?<?2LV\UVUL=333YED\^2TENUVKD%(RH89]?G6@#DU\':Y9IJ4.F/I,%MJE
MC#;S12+(RVSQP^5B,?Q)@#&[!'7GI70>)M%N]8T."ULY(H[FWNK>Y3SL[&,4
MBOM)'(!VXSBM33=1AU72K34K7<;>Z@2>+>-IVL`1D=C@U'8ZO;ZA>:A:P!_-
MT^<03AA@;BBN,>HPXH`Q)?#E]=:EK-[.]L'U+2(K+RUW,J2+YN3R.5_>#'?@
M\5FWW@F[DU35)XX+"^M=2,,LD-W<S1A)455.53*NI"*1G!!]NG=[CC./SHW<
M=*`,+Q3HEWJ\%C<:;<1V^I:=<BZM7E!,;'!5D<#G:RLP)'(S63<:)XJOK[2M
M6N9-'2^TVX9DMXO-\J2-T*/ER,AL$$87`(YSGCK9[R"U$9N)8XO-D6*/>P7>
M[=%&>I/I21W8EO)[813!H0I+M&0C;L_=;HQ&.<=./6@#D+#P=J<5_8ZA=W=L
MUR-9FU.Z2(,$`>!H0B$\G`VY)QGFG6G@Z^@TG0;-[F`OIVL2ZA(PW89&:8A1
MQ][]Z.O'!KM-Q].:0DD?=-`'E_A3PYKVH^'/#_G30:?;Z>+F6W_=O]H\YQ)&
MA96P%"[V;OGY>E7(?`>M2VNK?;;NV:ZOM#.F>9Y\LVZ4[B96+C(!+'Y0..U>
MB9V^_P!:7<?2@#F-2\/Q3:?>KJ#(;9])%I+L0L^5W'<!U.,Y`ZYJ/X?V-_;>
M%XKW5O\`D+:DYO;P[<?,P&U<=L(%&.V,=*W8=5M;B6.(LT,TCR)'#.IC>3RS
MAF53RR]#D<8(/>DT;5K;6]/6_LPXA9Y(\2+M(9'*-^JF@#D8_!VNVTL4EO<:
M>6L=7FU*TW[_`-ZLQDWI)Q\I"RG!7/(&16_X<T>]TV;5KW498'N]2O/M+I;@
M^7$H18U4$\L=J+DX')/%;^><8K/&K6SZZ^C?.+M+9;HC;\I0LR=?7*T`>8>&
M=.EN9K'3[BS><SI?6]R")8VTU)"VXA6'EX)VKA0!S\N0#6W!X%U/_A'Y]-GB
MTW[2='GTV.^6XG=OG4*OR-D(I`!8`GD#%=IJVJV^B6'VV\W^0LL47R+DAG=4
M''IEA5_<?2@#D=<\'SZQI<]J)XHW:Q@@1R&_UL,GF*3C!VY`Z<]>E5)/!]]<
MPR;K;3[2X>\L;B26.XFF:402!V#%QGUVCW.:ZR]U>VL+[3[2<.)+^9H(2HR-
MP1GY].%-7B2#TH`X7Q)X1UO7-5NV%_"UA++:RP)+-(OV;RF#.HC4;7WE1R>F
M?84_4?!NH:B?%-HT]LMCK96:.3+>;#*L<:J",8*YC!)!!YQ[UU$.KV\VMW6D
MJ'^U6T$<[Y7Y=CE@N#ZY1N*O;CV%`'/>'=&N]/OKB[O;.QBFFMXHWE@N9IG=
MEW$@F0<*"W`YZG-<M<Z!K.NZIXOTN)K>VTV]U*`S3S*_F;%AA)\L?=;.W&2>
M#GK7I6XXZ4G)/0T`<;=>#+RZT;Q)9"\ABFU+4UU"V?:65"OE%5<<?Q1<X['U
MJIK'@S6_$/\`;%U?7%A!=7=E!9010EVC54D$C,S$`DEMP``X&.M=\&SVHW?[
M)H`XW5_!][J$'C*.*X@4Z[%''!NW?NRL00[N/4=J@U'P;J$UWJES!'832W5Y
M]JMI)9I8I+5A;)$&5D&0VY23V(KN2Q':HY[F&UMY;BXD2*&)#)))(VU44#))
M)Z`"@#A[_P`$:K?Z?K$4^HP376H:';Z:T\BD;IH_,W2,`.`2^>*E\=Z9.=+N
M[I5RLC6*,T:,701SEF?Y06X##!7YACC'6NN6_1[Q+=(Y6WP^<LHC/E$9`QOZ
M;N<XZXYJP23V(H`Y3P/Y@35E^QA83>^8MZ&D/VQBB[GQ)\P(P%]/EXK`\*:#
MK6HV&BB[^SVVFZ=JMU>JA1_M$C^;,%!!&`OSL<\Y&WZUWEQJ]M:ZO8Z5+O\`
MM-['*\.%^7]WMW9/;[PJ\I_&@#A[;P;JEAX>\-V]M=6AU#1;IIQY@;RI@_F*
MRY`RORR'!P>1TI@\'Z]'J:Z\EUIYU;^TGO&MV#^1Y;0K!LWXW;@BJ=V,9SQB
MN\W'L*K7U_'86AN)59D#HF%'.68*/U(H`Y.;POKA73;M)M.?4;/5)KXJ0Z0N
M)$=-O&2"-^<\YQ[T]/#6O6NH:;JL-SI\]];?:XYXG5XXI(YY/,^4C<5*E4Z@
MYYKI+W6+>POM/M)P_F7\S00[1D;@C/SZ#"FIY;Q8;JWMVBG9IRP#)&61,#/S
M,.%ST&>IXH`P-'T76=/\3:EJ%S-8S6^I1P/.8PZ.DL<>PA0<@J2`>3D46VC:
MUIOB/5+JQFL7L=3N(KB43AA)"554<*!PP*(,9(P3WKIMQ[C%16UY!>VT=S:3
M1SP2J'CEB8,K@]"".HH`XK2?!^MP:_8:EJE_%=/9I=1M.9I'>?S2-IVL-L>T
M*HPO7\*EM_`\Y\':=H-U<Q`P:3/ITTT:D_ZQ`N5SV&.A]J[7<>PS5&RU>WU"
M\U"U@63S;"<03[EP-Q17&/4;7%`'-KX>\0WEG)#J<VEAAI,VGQFV5\EW"#>2
M>@^7[H!QZFJ4/@WQ!8V.H:?:7>F/;:C;P+,T\;EHI$A6)MH'#*1&I!.""3P:
M[_<?2C)]*`.&U#PCK>H>(TO)[^&6UBU2&^@+S2;HHD`S"(Q\F<[COZ\_E'<^
M"=5N-.UNP^T6?E7.I_VI929D#"7S%D"2`8PN5(RISSGBNOTK6+;6;66XM0^R
M*XEMV#K@AXW*-^&0:O;N<8H`X:;PC=S0S'^Q](\^2X2?S#?7'F!EB*AQ+MW!
M@2`,?PYK6FTC7G\##2TU@C6Q:K&=0VXS(,9;U`/(SUYS71[O:C=GH*`//O\`
MA!-2DL=;1IK:*74KNRG1/.EF$8@9"07<;F)"<>YQ[UK:YX9O[Z\-]83VT5U#
MJ$%]`LRG8Y2,QLKXY&0QP1GH*ZS)]*3=UXZ4`8^BZ?J%M_:$NI-:M->7'FXM
M0P5!Y:)CGDGY3SQGT'2N9T7P->:5!:6<D&GSQV4<\-M>-<3&5$9"J8C(VJV"
M`Q!P><"N^W'THW'TH`Y2V\)W$?AO3]*EGA\RWT-]+DF52?F9(UW#U7Y"<'VK
M._X1'66C\/W$QL7O-+MVLI8X[F:-)82J?,'4!@^Z,'!!&"?K7>;CZ<U!<WBV
MS0*T,[^?*(AY<9;:<$Y;'W5XZGCD>M`'-:#X5N-+URPOC%96T%OI<ED;:U+E
M59IA)E2PR1@'KSDU<U;P_<7_`(DM]2BEB6*+3;FS*MG=NE,9!^@V'-=!N]J-
MW.,4`<G;>$[F/PWI^ER3Q>9;Z(^ER2JI.698UW#_`&?D)_$55L_#?B&TDT&^
M633&O=+M'L)(2T@CEB8)\P;;E6W1CC!&":[=FVKD]JP/#_C#3_$N&T^WU%8F
MC\R.:XLI(HY%SU5F&#0!)X4T6XT+1C;7D\<]U-<374[QJ0@DE<NP7/.T%L#/
M-;E-W'TH#9/2@!U%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"-]WIFO'Y;>^A/B./1(KB
M]U*YL[B4ZJ;>:"=<2C]PV[Y6;;D(5P<(.F0:]AZTA7/<T`>56&@)=Z-K4.@W
M#12-;P75I:K:SP)%<(S.KEI23O;`5@#T49ZU2NH=0UJV@UZ]L[F+3=6U-OM5
MI-#*S16Z1F.`2QH0VP/N8\XRX)R.GL6WU)-&/<YH`\Q72/M6G>&=,,UU?::^
MJ7,<X$,L*+!Y<I6(ACN\L$(HR<$`=C56:W:?Q]IT]KHSV,]EJRVK,D<Q=[1(
MF4.7^YY9R@VC/UZUZQMSW-0O+%'+'"TJ*\A(1"P!;`R<#OQ0!Q.DVT\7@/Q!
M%-+>:<[W^HLL\,#-+&K3N0Z(!EN"",=>U<E=:'I=UI6FFY\.?Z#IVN".6:WM
MY]D\+1'=(L9RZKOV*<9Y7.<5[0>.<FJECJ5CJ37`LKV&Y-O(89O*<-Y;CJIQ
MT//2@#A9+4Q:[XIULZ3=7[:=%"VEP9=`P:V`<1_[1Q@G!/&*Y.?PX+OPMXO@
M@TEGM/+LKFTA@MYDC,HW>:8U<[BP!P?7TS7N.T$8R?SI=O/4T`>-:GIEO+JM
MTD33V&GQVD3Z'<+8W,AM@,AS&JD8D\S)PP)(*]A@/\1V=E?^+-4N=6PMK9:A
M9#[?,LSBW0"-GB&P;51B<?,0078GC%>Q!<=S6/<>%]'N+V6\EM-\TSI)*#*^
MR1D^Z63.UB,#J.PH`\]-G*XL8-;LKZ30WUG5#>1JDA&XRMY#.%^8Q_>P>5SM
M/H:Z3Q%')_PKV!=)M=06U5K<R6ZAQ<BT$B^8H&=^[R\\`[NU=E#+%.I>*59`
M&*DHP(!!P1]0:?L'J:`/*I[#P^NK6<#:3?GP@(9]B+#.8OM>4.[8/FQM#`9&
M-V[')Y=H=GJIDT.2^M[XR#1=37-R&:1%::,PHYY^;R\<$YX/H:]4V^_XT;?<
MT`>&S6]W<Z1H5L=$G@U+3;+2UMK@P3F:09C:7:1A4"`.&#9/!Z<5H:]IH'B7
MQ%<P:;J#^()=3M9-(FCBEV`".$,P;[@7Y7#9Z@<YXKUN.XAEGFACF5Y(2%D5
M6Y0D9`([9!!J?;QC)H`\BO+262\O)!9:I_PEYUO;;7"+(%%KYP92&SL\KR00
M1ZYR,FKK6C6NF>)=7NM'GO[V34Y[%1-YORVCRKR%7DQC)8A1D\\UZAM&.II-
M@XZ\4`>)OX;MYO#0^V:3+-I]IXF1XU2WFPEHPC#LB$E]A(/KW-:NMVTXUO4&
MBLM0;0'?2UN4@CDRUJ$F#``?,0&,>X#G&<C&:]7V^YHV^YXH`\C&G3R+/:Z;
M:ZC'X=EUZTAMH3YJXAV;9RH/S+&23SP.3BI]9T"UTW1I-/!N!I]MJ-Q-!ITU
MO-/!<KY081DIRH#$E>HR.A->J[?<_G2%<#()H`X[65O+CP%8:A:6-S:WMBMO
M?I8(S-(-F"\)[L=FY<'J<9KFM!T_6;C6[/3]02[%K>W2^(96DR/+SO/D-@;0
M0_E':#G@GIQ7J-O/!=Q&2"9)4#%2T;`@,IP1]000:GVC\Z`/&[;0;7_A*-&U
M36-*N9%_M35$>8P2-M/G[K<G'0?>(/2MCP?X9BLIM'UDVMU!J3ZC?QW+%G&Z
M)FG*AE/`7(0CH,G/>O1;BX@M55[B>.%&(4-(X4$GH,GN:GVB@#S+XC6?]K>(
M;:P>%[J'^R[B3RF61UA?<JK,%B!;>,GJ,8R!S63>VCK%;RZ(+R]TQ=`T^-[B
MSC<-/`MR3,$/7<8]QV@[N:]1U'P_INJSQSW<#M,D;1B2.9XVV-U4E",CV-78
M+6&UMH[>WC6&&)0D<<8VJH'0`4`>0ZGI<<FD^)+;0;#4E\/D:>(H424!I5G#
MS-"A^883;DJ!R#CD5,!%:VNLVVG:%<R^&+R]M88TN8IA'$Q5C--L_P!84!$8
MQP-Q)]37KNT9SDTFT>I_.@#RSP[87L5OX20VEPL5OKUZZ@Q.HB@,=QY9PV2J
M89<9/<"I?'"Z?<^,[NVU:"]N[9=$62WM[5)7/G^9(%8!.C8X!/2O3]N#G)JC
M]EL/[;DO%2/^TOLRQ.X;YO*W,5&/3=N_6@#S"7PI/K$MY)KUM>/J-OX9L]DX
M=@RW:B4L5*\-(&QZXS[U-XG6?4/%UNZ:1)%?6-_8I%=+%.TDL)96D=6&$5`"
MRL#GH<XR*]6V\#D\=*7:,8R:`/+M1TNY.C^.M56VNSJT,]Q%I\@#EUC,<;?N
MEZ8+%CD#D_2JVI^%8XD\7Q6]G?".PL8KS2U664@7921FD3GYI-RIGK^ISZR1
MC&"?SJ&"Y@N@Q@F24(Y1BC9VL#@@^X/:@#RKQ?\`:M4U.,G2)5U*S-BUO=+#
M,9)@SJ\I0KA$"C>&SD]>G%6I+2275O$,DUE?GQ6+F==)NMLAC2)HSY)5A\@0
M8.X>IY!)KTV>2.VA:6658HT!+.[`!1[D]*D`XSD_G0!Y/X?TI?[-U0Z=)=)<
M7>B2K+8?8[B-GG(P'D>1B#+DE>#D[B>13KN`^)?!DU@NF7\QB\,F,+-;R1AK
ME0I51N`+.&7_`/7S7JVT'U_.EVB@#R/['=1PG_A$[.[@4>&+B.W40O'BY,J$
MCY\8?.[&?PJ6ZC\/+IEM9:9X>NFT^_E1KV:]@N3'"X1F!=/O,YZ$],E<DUZM
MM]S2[1G.30!YAX4LM1BD\`_:[:Z5K>RU!)C*C9CR4V!L].!P#V%0?$A)]1U"
MX@BTB0WMG##)8W:Q3/)*S2981%,*A7:<ELGD>E>K;>.II-O7D\T`>;:QH1U3
MQ!XFO;B&\:6RGLY=-D1G`0[$+F/'!R5PQ]!BJ=S:>=KNIR:A9:LVN+K$9MIH
MHY&C-EYD>T9'R>6!RPZYYZ\UZKM&,9-,<JA52V-QP.>IH`XOXAV=M>S^'/MU
MK<7&FQ:@SW8@C=]L9AD4%@G.W<R@_7GBN4CM-=&FZ7_95I?0JDNK'2DE1@T4
M30/]G#[N5^8_+O\`85Z\TD:2HCR*K.=J!B`6.,\>IQ4FP>IH`\KT/2M.O-8L
M+?3--U&.QGTV;^W$NUF199&"A%DWGYI-P?)'.#UP:PM*T6&+P]X:LI=.E@TX
M1R1ZK!/:7!3[;M3:TBJ5)&%8`\J#CV(]RV^Y-&WW-`'E,EE"R>'K?Q`=1U?P
M^FGS*LIMIEW7`<%?,C'SCY`0N[^9IT/AF&YU;6]8:QOH[VWU2Q>R=VD#B,1V
MX;C//&Y6/.<$$\5Z;=7-O9Q>;<W$<$>=N^1PHSZ9-2@`J#G\J`/.(=`%WK6H
M:Q<PWHOK/Q%&+23<XQ`?*W!1TV'?(3CKZ\5E06DIO+20V6J+XP.N;;B<"0+]
ME\XN?FSY?E>3@`#C/&,UZZ5SW-1^;&9S!YB^8%W;-PW8]<>E`'E(L6\JQ@UB
MPO7T&36M4:\C2-\%FF8P,X7YBGWCGD9VGT-9SV5Q?1:?I]S8WEQI\CZA/9V5
MX)F:.W#1B%RB@R`KN.W<.`Q'!(KVS;SG)K.U'0=.U6>&>[A=IH0RQR1S/&RA
MNHRA!P?2@#RR:`Z9X?T6V\/WCW5MXAT^+1_M$2E0)E/,V"=RDH9\Y!P44'`%
M=;XRLDC7P_:3VEQ)X<2<QWT5N';"^65BWA?F*!L9[=,UT\6A:9"]@\5G&AT]
M&CM`O`A#``X'3D#&>O7U-:!&>]`'E=]:Z.VI1C4]+U9O#\>EJ^DQB*=C'*KO
MO&%.Y9-ICV;N<<#'(JA=:3K5UI3?VO!J$M_9>%$N(22Y*WRF3:WR\-*.,=3S
M[U['M]S^=(%`Z$T`>1>(;&X\/V>L2Z<EW!'<^&FN;B9G=MUTCJ%8LV</AF]S
MCVIVR+3I-=ET/1+^;1);2WAN8;A)PCW#R$22;3\[;4(+;1SC&<UZ??V=GJEE
M<Z;>(D]O,FR:$MU5NQP<C-6(WB9WB653)&!N0-RH/3([9Q0!Y+8:5=+X=^P1
M6UTEC)XIC5$ACEC4VC(H<J"2RQG+Y.>Y]:U9]%GTJ+3=/TJ&Z6W@\2EX5.YE
MBC-NY'_;,.WTKTG;SG)I=N.YH`\B\)Z>T)AN9KV]L-3;3YX]26.RN#++*%`,
MCNQ92RL&*8'.>!CBMKP%+;Z/;W]L+&7R4EMH_P"T8[6=?MTCC!9HWR58'&YN
MGS<XP<>A[>.IJN]U;I=I:M<1"X==RQ&0!V'J!U(X-`$TO^K;Z''Y5Y;HVD>)
M['X.G[/J-]-=/IB+!8?9TBDMNFY5(`8MMR!DYSTYKU0C-':@#QV]MA#:^('\
M(66J6VG?V&7*&.90UX7#(55^3(%!R0/0'FO4M(TBST>R6VL(/*B+&1@7+$L>
MI))R2:N0S1W"EXY%<*Q4E&!`(."..X-2C@8H`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`$;[M>9-KWB*;4@\.KI%#+X@ET5(#;(RH@#MYF>I<;<#G;CJ":]-/(JF-*T
MX$$65N")S<C$8XE.09/][D\]>:`.!7Q'K/E1:))JJI=G7I-);57A3=L$/FJV
MS&P.<J@XQGG'.*:?$>NAVT>/5XY9H]>321J(@3<8VMS(25'R[U;C@`9'([5W
MTVC:7<V\\$VGVLD-Q()ID:)2)'&,,P[M\HYZ\"B'1M+MX(((-/M8XK>7SH42
M)0(Y#GY@.S?,>>O)H`X,:KXKFUB_BL[N:7^R;R&T:"5+=(YT*QEY96)#@L&<
MKL`&0`,\UT>MW4D/C/PI;((_+N);H/NB4M\L)(VL1E>>N,9Z5K77A_1KZ[^U
MW6EV<]Q\O[V2%68[3E<D]<'D>E6Y+2UEGAN)(8WF@),4C*"R$C!VGMD<<4`>
M=Z!?^(]8LM+OY]?9(-6@N8S#';1YMG0'8Z$CD_*V=V0<\`5E>#I=5CT'PEH-
MOX@DM%U+3Y+P7'V>$R((Q&!#'E<'[S-EMS8!^H]6ATZQMHH8H+6"*.#/E*B`
M!,YS@=LY/YU!-H.D7%C!8S:;:/:6^/)A:%2D6!@;1CC@D<4`<%I_B/7==?1=
M/BU>*!KN748I;ZVMU)E6WD54=`V5!8=>HY..V!M?\13:DKPZND4,NORZ*D!M
MD940!V\W/4N-N!SMQU!KT*+2]/@^RF*SMX_LB&.WV1@>2IP"$_N@X'`]*0:3
MIRD$65N"MP;H8C'$QR#)_O<GGKS0!P4?B'49()M"FUJ]&KPZE<6T5S:6T'F7
M$<2)(68.!&F!*H/KCCK5+1+W6=<\0>#=0N/$%Q;_`&W1GN9X(TC$4C*\.X8(
M_BW<GJ,?+C)KT6X\/Z->!A<Z79S;I3,=\*G,A&TMTZD``GN.*?)H>DS"U$FF
MVC"T;=;`PK^Y/^QQ\OX4`>>:5K&IZGJHT.#5H](\R?4K@W$%M%OD\JZ*!`&&
MW(7+,<$GJ?6I--\0>(/$R:)96^KQ6,M[:7LLEW;VRMO,$XC1E#;@`P.3UXZ>
MM=W<>'=%NX!#<:59RQ+(\H1X5(#OG<W3JV3D]\G-68].L8I()([6!'MXS#"R
MH`8T.,JN.@^4<#T%`%3P_?37OA[39[N2-[R:UCDE*#`9BHW$#L,UQ7BG7]9M
MK_Q,;/6X]/BT.RAO8H6A1_M+,K'RV+<[24`^7G+]>@KM8=#LK?6?[4BCQ<+:
MBTB`X2*+=N*J!TR<9_W1TJF/"6ES^([W6KV"&[EN%@$:3PJP@,6[!4GGDL#_
M`,!%`'"W&M:C;>)]66Q9K:?5+^PMY9HT1FA!LR_RB0A=Q("C<>IZ$\'=.J:U
M'H]KIFHWUY;:Q=7LL-G):1023SQ(-V7!S$C;>6Z=..M=?<Z-I=XMPMSI]K,+
MEE:<21*WF%?NEL]2,#'IBH3X:T)K-;0Z39&W60S",PKM#GJW3J?6@#S^'Q/X
M@G\):)K=YJ,EKIRVKS:A>6D,3R[EDV@M&V?W97).P9STXK0AUOQ/J'B*^DLG
M<6UCJJV3V;+"L7D97=([,WF;RK%EP`#\HYZUV$WAK09_)\[1[!_(&V(-`I"#
M.[`&.!GG'KS3Y_#^C7-\+Z?3+.2[#(WG/"I<E/NG..2.WI0!SGC/4]4TN>"Z
M2]EL-$MX6EO+FUCCEE0AE`W(^28\$Y*`MFLZ'6O$^H^)+V2S=UM['55LGLV6
M$0^1E09'9F$F\JQ9<``_*.:[6^T/2-3GCFO].M+J6,81YHE<J,@XY[9`/U%-
MG\/Z-<W_`-NGTNSDN]R-YS0J7ROW3GU';TH`XS3]:\4:EKTMS!(_V.'5GL9K
M-U@6)(%8KO+%O-,A&&`P`01P1R;>KQ:@_P`5-%2+7KNUM7L)Y6ME5/+;9)$"
MIW#G=NZ]1C@C)KJ9/#^C2Z@-0DTRS:\#K)Y[0J7W+]ULXSD=C4UUI>GWTUO+
M=V5O/);MOA>6,,8V]5)Z'@=/2@#SSPF-7M+D7<.JYTZX\07]O)I_D)C'F3'<
M'QNW;E'?&#C%6O!VL^)]8N=-U2XD>33[]9?M,$JP(EJ0#M6+:?,9@PVL&]S@
M=*[N/3[*%`L5K"BB5I@%0#$C$EG_`-XY.3[FJT/A_1K>_P#M\.F6<=X69_.2
M)0^YN&.?4]SWH`Y8+IVH_$37+3Q!';3?9K:W.GP7BJ4$+`EW0-QGS`03U^51
M]:UYJ=P^HZE8:-KUOI&G:+IT-S#MCCE6X!#\L7_Y9KM5?E(Z_>%=GJ>@:-K?
ME_VKI=E?>5GR_M,"R;,]<9''2DN_#VBZ@83>:593^2FR/S(%;8N0=HXZ9`XZ
M<4`>=7WC#Q!-I<^J07L=H++0+36)+=8`PEED#[HV+<A/E[8/N,<W-:\2:]X9
M_MNWEU)+^6*PM]0MY9+=(Q$6F\MH]J]5.,\G(YY/6O0)M*TZY-P9[*WE-Q$(
M9M\8/F1C.%;U`W'@^IK/\1>&K/Q!I=W:/M@FN8EA:Y2,&0(KAPO/;(Z>]`')
M'Q!J&EW^L:+>^(9;UPMH+2\M[6+STFG9P(@H&S^`$%AP&Y)X-06GB+7YM&M+
M5M29;R7Q%+I#7<L$9D6,*YR57Y-XVCD<>Q[]XGAW1%L9;)=)L5M9G$DD(@4(
MS#&&(QU&!S[5+%HVEP1110Z?:QQPR^=&JQ*`DF,;AZ-@D9ZT`<4_B'5?#D%K
M?:UJBW6G6UU=V5[*T:(6QEH'P`,-\NP@8!+CZU=1/$8\&0ZE$X;Q'>00+-NV
M)Y:F0L50,`N]5D(&[J0,YYSM:]X<M=>TMM,E(BM9;F.>YC5`?."N'*G_`'BH
MR>M:5W866I6QMKZVAN(-P;RY4#+D'(.#W!Z4`8NAWTVJ^$W:SU.:XO0)H%N;
MNW5'292RX=5&WY6&..#CO7#Q?$;5Y0UVBH;8Z=]D$8B+;=5"%BK8&0,X7'/M
MT->JV=C::?;):V5O%;P)]V*)0JK]`*@;1=)9%1M.M"JW'VM5,2X$V<^8./O9
M_BZT`<%%JOBZ?5+R*VNI)9-)NH+22!H[=(IU*QEY968AP6W.5V`#(`YYK/T[
M4+_1M0U"_@U=1;2^*Y+-],,2?O!+(%+;OO[AG=QQA3QWKTJZ\/Z-?7@N[K3+
M.>Y^7][)"K,=IRN2>N#R/2E70='34O[233+-;[)/VD0J),G.3NQG/)_.@#SG
M4]?UBWT#Q-%J][G5%TV:[ALFMX9;41JY4/&P!W+]T%9.<GI1J6I:SHGB#QGJ
M<.L7-P+*RMIHK"1$,0\P2`<8R`GWN",X^8]QZ%#X9T&WBN(H='L(X[E/+F58
M%`D3).T\<C)/'O4\VC:7<7HO9K"UDNA&8A,\2E]A!!7/I@GCW-`&%X6?7EO+
MJ'5+B2ZLS%'+;7%P(%E9F+;@!"Q&S`4@GGD\FL34/$M\_BZR&FZI>-82:K_9
M5Q#);PB%7$;EMC']X6#*#G[M=MI^A:3I+.VG:=:VC.JHQ@B"DJN<+QV&3@>]
M(-"TA=0;4!IEF+QFWF?R5WEN!G.,YP!S[4`<O\.([X:?J4E]KEUJ/_$QNHE2
M<)\FR=U+#:`?FX..@Z``5E/XTU2UU>&TN9$8:7=RIK!5!DPLX6!L=AAPV<_P
MG/6N]&DV=M)>3V%M;VEW=#,EQ%"H9F[,W]X@\\US<W@W6+E;E;CQ+%*+I56Y
M#Z/;GS@.@?CYL=LUU85TE?VEOG?]$_\`A[$ROT,.X\2^)K2RAMYKB/\`M#6[
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MW2+<>6SYW%>."<G..N:GFI1JJI"25K])=?\`MT-;6.8OM5C\5ZGH?B&+/V.U
MU&RMX.2,2N=\WR]B/E3\&JY%XOOXKZXOK:]NK_39])O-1MHKF".,'RBNS9L^
M?:=Q'S\]*VU\'ZRD21+XFC$:2^>J#2+?"R9SO`QPV23FH[7P/J=C*TMGXA@M
MY6!!>+1K=203DC('0GFM'/#O3F5ELM=O_`0M+L5[K4]7TKPK)J:^(8=2N;C[
M(\:F",+$)954E0O)3YCC.3QUIMS=ZQ'J&IZ;_P`).;<Z/9)<M/-;Q%KHOO)+
MC``1=H7"XZ]:L1>!-0MX9(8=>MHXI"I=%T6W`8J<KD8['D>AIU]X(U/4Y%DU
M#Q%!=NB[5:?1K=R!G..1TR`<>U0G0OK*/W/RZ<MN_P!X:]C&L+T^(]0GN=4T
M^PO-3_LVSN+"QO7V0;)$S*R[@W.\L"<$_*H]Z?:Z[>75AH6GZ/;G1XKW[8SK
M8"*4J\4NTI&9<)R=S=,X'`[C7OO!6JZHL:ZAXCANA$<Q^?H]N^SZ9'%-?P-J
M4EG!9OX@@:UMSF&$Z-;[8SZJ,<=3TJW/#M?$O_)K+1KM\]NX694-_P"*M0N+
M/2FU*+3+XZ2]W,\,<<N9$DV`<Y`!R"<9Z8&*JZMXGU"SO8;A);6*:XTBQ+7#
M0KB)IKC8SY/.T`YVDXK9M_!NL6GE_9O$L4/EQF%/+T>W7:A.2HP.A/./6B3P
M;J\JNLGB6)U>$6[!M'MSF(=$/'W?;I6:='FNY1MZ/_Y$>O8@UF77=+T^../7
MIKJW@DE>_O88H/M4"*@8#81M8#))P-V"N!ZZ?B'Q`UEX4AOK&[BWW#VT8N9$
M&(UE=5\UEX['.#BLM_A]=R0)!)K=J\,98JC:+;D#=C=QCO@9]<"K+>#]9=9U
M?Q-$PN$$<P.CVY\Q`"`K<<@`G`/K4\M"\6YIV?9J_P#Y*&O8K23ZL/$%OX:'
MBIE8V\MT][Y$/G,5*`18QMX#%B=N<$?4U[/Q%K6MZ?X;ABU".UFU26[AFN[>
M%6R(=VUT#9`+!/<?-WXJPWP_O7MDMGUVU:!&+I&=%MR%8C!(XZD<?2K:^$M<
M0VQ7Q2B_901;XTB`>2",$+Q\O''%6W0M\4;^C\_[OFON%9F;H.O:W.WAK4;S
M4$FM]7DEMGM5@5%C**[+(&ZY_=G(SCYN@Q7H,;*ZAD(93T(.0:XY/!^LQ1V\
M<?B:-$MF+0*ND6X$1(()7C@D,>GJ:EM_#7B&SMDM[7Q;Y,,:[4CCTJ!54>@`
MZ5C6A2F[QFE\GW?]WT12;['*7U[%X>^*&N>)9Y3'9Q7%K8WSD$JD$D`*L1VQ
M($Y]&/7BHM(O5T3Q%J_B#597LYK_`$1+^X=!YK1&2=UB4#N53RUQTR#VKTU-
M&LY+.:&^M[>[DND5;QY(%_TDJ,`N,8/3IVJ>XTK3[MI6N+*WE::'[/(9(PV^
M/).PYZKDGCWKB&>9V_B/Q#'J,V@3ZQ-%)+JD%HE]=V\`G@5[9I2,)^[W$J%7
M.?O=#TK?GGUE]>T?0(/$182VMQ-<7R6\1D<PRQKMQ@J#\Y5N.QX!Z=(/#FB+
M9R68TFR%M*RM)%Y"[6(.02,<D'H:L0:3I]JT#6]E;Q-`C1PF.,`QJQ!8+CH"
M0"?4B@#SNP\4ZS-!HFN-K$,D>JZI]B;23"FV%"[+\K#Y]ZA03G(Z\"L>&[L8
M/`L&OW.@:5J]XSL=:EO9PES%<>8%*@;&/!R`N1@*,9S7J\6@Z1!J+:C#IEG'
M>LS,;A85#Y888YQG)`Y/>H[CPSH-W?B_N-&L);L,K>>]NA?(Y!SC.10!Q\^L
M^)[WQ)JO]G.ZIIE_%;"R98!%)$1&6>1G82`D,Y7:`,J!SS3K'5?$%WJ[WW]J
MJME;Z[)ICV/D+M>($@-NQNWY*]"!@=":[&Z\/:-?7GVNZTNTGN?E_>R0JS':
M<KDGK@\CTJQ'IME%N\NTA7=,;AMJ`9D/)?\`WO?K0!YMI6L:IJ6I#1+?5XM(
M5YM2N#<0VT6Z3RKHHJ`,-O"Y9C@D]?4UM#5M5M_%]H-1U-DTNX>.WL3:Q1/!
M>.8MQWGET8G<1@[=H'/KTUQX>T:ZA6&XTJSEC61Y55X5(#OG<PXZG)R>^33D
MT#2(]1&H)IEHMX#D3B%=X.W;G./[H`^@Q0!HT444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`(WW37()XNG'CB#07@T][>Y:5(I;>]\R5"B;_P!Y'M`7//1CVKKSG''6N8T_
MP3I^F:A:74%Q>LMG-//;0/(ICB>;/F8PN3G<<9)Q0!F:7X[N[Q;:_O-&6VT:
MYMYYH[I+C>ZF$9;<FW@'#;<$D[>0*FTC6]6U?7-'FO=+^PVMS:37%NT=SYBN
MA$>T.,##C.<#(Y.#6M9^$]-L]*LM-599;:T65$65@=ZR!@P;`&>&-1Z/X2MM
M&GM98K[4KD6D+6]NES<;UBC.WY0,#.-H`)R<<9H`R]9@N]1^(MIIT>KZC8VZ
M:5)<A;28*#()54%@00W#'@C%9LOB+4[SPU)I;ZE%:ZO)JLND_;U(3Y(\EYL$
M@*VP=OXB,#TZ;6?"<6L:O#JBZIJ>GW<4#6XDL953<A8,0=RMW`IUEX/TJPDM
M3##(T5K#)%%#,_F(3(P9Y&W9+.2!\Q)[^IH`XK4O$D^H>%_",MQ>:G;M/>O:
MZC_918S/)%%*&"[`21O0'C/%23R7^L_#&^\0_P!NZG'):6][/8S6USY32QKN
M,9G51@N-N".,8YYS77P^#M-@U1;^(W,;)?&_2$./+64Q&(X&.`5.2,]14B>%
M;)-$U;1_,N/L6IM.TB;Q^Z\[.\1\?*,DD#GDF@!=#M#I/AQ&:^N[QGC$YEO[
MG>02HXWD<+Q^&37.VWQ#E&FZ[<WMC:.VDBWD)T^\\Z.993@88JO(P>V.G-=9
MJ&B6NI^'Y]%N5D:SFM_L[@-ABF,=?6LE_`VGSVNIV]S=7]PVI1PQW$SR*&VQ
M'*!<*`._;G-`&5JGCK4=)E-E<:7IZZA!;?;+J)M0(41EF"K&=F9)"$/&`!TS
MR*WM7\3"P\.V>K0V4DWVN2WCC@=A&V9B%4$]CEAGTYJ74/#J7NJ_VG#>WMC>
M&`V[R6CJ/,3.1N#*02I)P>HR?6IK_0X-3TZULKJ6X=;>:&<2;AO=XF#*6..<
ME>>!^%`')ZG\0+O2;J>UGTRR:;3XHY-0C2].[+C=L@4IF5MN#SM&3CUJ77?'
M5_I^MS6%AI=I,L%S;VKBYNS%*[3%=KH@4[D&[[V1RK<<5O7GAE+C5+K4;;4=
M0T^XNX5AN#:.@$FW[K$,IPP'&X<XX["N=U#POKY\0:I=Z;)]GEN[J":"^6==
ML2JJ*X>(KECA3T/.[MB@!LWC2?3KR^M;>U5YGU>6U274+QEMDV11ORX0^7G=
M\J8QD,<U-%XLUNW\2^(1J-K8+HNE6D=TSPSLTJ(4=N/EPQ.SU&,<9S6M=>#;
M:YBU**._U&VBU*666Z2*1,2>8BHP^93P`@QW&3S3XO!NFP7<DT1N5@FLTLI[
M0N&AFB1&1=P(SD*QZ$>]`&##\1Y5M-0N+[3(`+:P.HH+.[\X>6"`4D;:`LGS
M`X&0>>:EU+QOJ6F3Q6,VF:='J+0->21S:B5C2'=A0&V9:0D-P!@8Z\BM7_A#
M(I=%FT>YU?5KFPELS9^7-*A*H<<A@F2P`QDD\5=O_#T=[J=OJ45W=V5Y#"UO
MYMLRC?&>=K!E(.#R/0DXZF@#F=1\9WVIZ7J']C:-+);PZ:D]V[S>5/"9HBZJ
MB8^9E!!.2/09(Q6EXQUG6M%T33;C1X+2>66[MK>0W,A4`2.JC&`>I.">P.>>
ME2W/@>SNI+B1M0U6-KNV2WO#%<[/M05=H=\#[^.ZXSWXK4UG1(-;TQ;&X:>)
M4ECECD@<*Z/&P96!P1P0.V*`,Q?$&IOXB71ETVV\V&V@NKZ9KHA(4<L"$^7+
MD%#C(48')'2LA/B*;:36%U"TLG2PM%NXVTZ\^T+(&D,81B57:V0/4#/6ND'A
MFT:>]GGDN)Y;VQ2QN#(X^>-=_/`&&/F-D_D!6;%\/M)%K-;7,M[=Q2V":=B>
M0#9"ARH7:HP0><]<T`9]QXHU#1I]3U'7=+^SO:V4.V"&Z$D4K/,57:Q`P<D!
MB0,>XHB^(%RME=F?3();RVN;:`+9W7F02F=MJ;9"HY#?>&...M:Y\%6<MI>0
M7M]J5\UU;I;R37,^7"H2R%<`!6!.<@=0#UJ63PLEU`(;_5-2O46>WG3SG3Y6
MA8,N-J#J0-WKCM0!B+XYU.-'EO-$ACM;*_33]1ECO-_ER.4"F)=H+J/,3.=I
MY.`<5=U#Q=/I_BZQTDP:?-:W5RMKNBO<W$;E&;+1;<!?EQ][/2K\_A'3I[+4
MK1FN1'J%\E_,5<9$JF,C''`S$O'UJ"/P3I\>J?;1/>A1J+:FMOYB^6+AEVEO
MN[L8)X)QR:`.;\0^*]1N_"VIZ@ENMAI]E?QP"[6X/FL\5XB/A`O"%0W?)Y&.
M:TKOQO>QKIS0:9;1KJC/):R7MV8HO)7;MWN%8+(^[*IZ=3GBMEO".GMHD^DE
MK@6T]Z;UR'&[S#,)N#C[NX=,=*JS^!K*329])@OM1M=+G$JM90N@C"2$%E&5
M)`SG&#QN;';`!=U[6YM+BL(K2T6ZU#49O(MH6EV1[MC.2SX.%"J3P"3VKA_$
MWB'7M8CL](BTR&WF76$L-1A_M%T65C#YJJDB+N",""3PP*@8Y-=YJGAVUU2V
ML86:XMWL95EM9[>3:\+*,<$Y!!4E2"""":J6_@O3H?)=I;R6XCU'^TGN)907
MEFV%!NXQM"M@``8`%`&?X]GU>T\.:=!HUZ;"_NKZVM4E&'"[L\'(Y&0!]*Y[
MQ3XSOM1\+:==Z+<S6$RVJZC>;%R4Q(L8A)Z<R%P1C_EF0<=*]#U31X-86S%T
M9!]DNX[N/RSCYT.1GU'M6./`.B"SUNUCCGBCUF=9KG8X&T@[@$X^4;LG'JQH
M`CN/%TUMXTM=%>#3Y;6ZF:%9(;W=/&RQM)EX]N`/E(^]GD5#:^,-1GT"[\1R
M:/%'HB6<EY;2K=;I75!D;TV@+N`)&"<=#BKUMX*L+;4X[U+F](BO9K^*W:1?
M+2:4,';[N2#N;@DXR<4R#P/8V^DW.D)>ZC_9DUO-;):F<%(8Y?O!.,\#A=Q.
MWM0!4_X2C7YKFVL+?0[-M3NH7O$BDOBL<=L"H4NP0_.2V-J@@8ZUF#Q1-XMG
MAMH9;_2K1+"6]NTM"&N79)FA\M"H)P&C<Y49.5QCFNHOO"MM=W=E>0W5[97E
MG`UM'/;2`,T1&"C!@01D`CC@C-51X$TN*ST^&REOK&;3T=8+NWG_`'Q#MND#
M$@A]S<G(//(Q0!A6WC>"QT^"TTZZNM0NI[J6!/[<<VAMQ&B%E=BFXXW+C(+$
MOZ#C17QM=7FGZ(^GZ2LE[JS3Q1PS3^6B/%G<2VTDH0K$$#)&WCGBW!X%LK<1
MR1W^HB^2]>]^W>:IF9W4*P/R[2A55!7&/E'<5H)X=A^U:7=3W=Y<W.FO*\4L
MSJ2YD!4[L``@`X&,8P*`.9O/&QM8=&U34;&YMMUC?7%S;)<9"-!M#*5QA^>A
MXQ^-7=0\5:YHVCF\U30[6"26XCAM]MZ7B0/GYIG"90+C!(!&6'/4UHWG@W2M
M06%+I)I8XHKJ'RR^`Z7!!D!P,]N,8Q3H?#4L%JL*:]K)9=@$SS(S;5!`4@I@
MYW9)(R2!D\4`:VEW$MUIL%Q.L*RR("X@E\V,'_9;`R/?`KB[_P`37>C>*O$6
M4DO8HSIL%M:F0*JO,9$XSP,MMS]*W-#\-R:!-;VUG>2+H]K9^1#:D[F:0ON:
M1SZ]ACCYC[4Z]\(Z??ZA=7LK7(FN9;29]K@#=;L6CP,=,GGU]J`,O_A+M6BM
MEM;C0XDUR74#80VXNB87(B\WS/,*Y"[,_P`.>.!73Z9+>364;ZA:QVUV0?,B
MBE\Q`0<9#8&0>O(!YJAJ7A>SU-_.>6ZAN%NUO(YX9-KQ2J@3*\$8*C!!!!!-
M6['2VM'@8W]]-Y:2*RS2!A*78-N;CJ.@Q@`$C'3`!HXHQ2T4`)BC%+10`F*,
M4M%`"8HQ2T4`)BC%+10`F*,4M%`"8HQ2T4`)BC%+10`F*,4M%`"4M%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`"$X&:Y_4/&_AO2M:AT>^UFT@U"8A4@9CD$]-Q'"Y
M[9(KH#TYKR'PEJVC>')=>T;Q-8R1ZK<:L[E9+1IVNTD;,1!"G<`/?B@#U^BO
M$'UNX?XAVPLAJ-M=1^(#9W2SWD\K2VYR-WEE1$D1)`4CG@?6JNC:A=W=KX*\
M-W=UJG]H07]U;ZLFZ964'S,!I._!&#GMQTH`]FN=>TVU^QF6[CVWEP+:!T!=
M7D.?ERN0#P>N*TE.1FOG[PE;R:9HGAJVM)]06X_X2H1WT#NX\M1YFT$<8!&"
M>Q/-7[:_OY_$*,]]K"^+E\0^5]BW2^1]BW<[D^X(_+R=PYSB@#W.BO!O#D>J
M64'A;6QJ>KR75]K\MI/'-.[1BVW.-NP\8X!R><GKTIWAG7;J[\4Z?)9?VC;1
MW-M?)J%O<WD]Q('128S+O4(CDJ2`E`'N],ED6&%Y7.%12S'T`ZUX58:;J&B?
M#;1O'8U76[G4+62*YO()[N1D:#>4=`GIM(//IG-=_P"#X[Z3X?7&IZ@\S7FJ
M+/?,DC$^6LF2B`$<`+MX`ZYH`VX/&7A^YT>VU:'58'T^YG6WBG&<&5C@*>,J
M<^N*W3D#BOG2YTB_T/2_"MM:VEQ-IFOOIMVZ*F?LUU&$\S@#@,I!Y[J?2MF.
M]O+G7SOOM8'BP>(3$;/?*(?L);G*_<$?EY.X<YQ0![;#<Q7&_P`F6.38Y1]C
M`[6'4''0CTJ:OGFQM9M!\->,;;3)M12Z77Q'=H\DN4LO,_UN1R"PR&=<D@5Z
M7\.6W0:H]MK*:AI9N%^RQ"265K7Y<NADE&Y@201Z9/-`'=T5X7HVHW]QK6GR
M&^U<^+CK4D=_9R-+Y"VF3G<A^14"!<%><GOVC\%QZK8P>!-6.J:Q+<:K>7$%
M['<SN\8B&X*NUN!RH.>O/7I0!ZWXB\8:%X46W;7-1CLUN"PB+([;MN,_=!Z9
M'YUJ6%];:G807UG,DUM.@DBD3HRGH:X#X@VM]=^._`J:=.EO.);S%Q);^<D?
M[D=5R,YY'45S'BZ]NT\0>(;;4]1U>WU*VM[;_A'$L1(B3R;?F*HORMF0`$-G
M`SCI0![?17DOA_0+[Q!XI\5W&IZIJ<4UO((8(([EQ;H\EOAFV\;L,>.F"*XI
M/$_BVVL(=89=1+6=N=`DB\S=ON3&^)B#][#[#N],CF@#Z/H/2OG_`,7W=[X>
M2;2K>35/[9TNRM'MKQ[Z<^=)\ID,40!1APQ8N3WK2EL-;F@^(&N66H:T=1L;
MV>*PMHYF\L*5&YE3N<$X],#'-`'K*^(+)O$TGA\&3^T$M!>%=AV^66V]?7/:
MIO[7L?[:&CFX0:@8/M(@.=QBW;=P[=>*\<\*+,OC2\NO"+SWS2>'XA#)K+S>
M49!.OF)O8;L`$G`SAB1]-R]UD:'\6-*U'Q-+!:.WAPQ320*[Q"4S9VJ<$]CU
M]*`/5J0D@<#->&3ZE?7&N7SF_P!77Q9'KJIIMHC2"![(LN,I]SRS&78GKTI^
MM:C?/XAU[S;W6(?$\&JQ)HMK"9!%);Y4#Y/N,I!<L3SQ^%`'KVCZ[8ZXM\UC
M(TBV5W)9S$H5'F)C<!GJ!G&:ETG5K/6].BO[";SK67<$DV,N2K%2,,`0001S
MZ5XOX<EU&R\7SM?B>+0)/$U]L:VWKB[)7893WB(/';(YJ+P[:ZCKUK\.]/OM
M1UB&&Y@U$WC17$D;R;9"5#MU[8YYQTH`][JIJ6I6>DV,E[J%U#:VL0R\LK!5
M6OGN?7=4N-"T33M2U:5$^R7H$EU>S6Q1TF*12,\:EF*J.`PP>><UZCK5AHUY
M\*+:TU+4YGT[[/;_`/$QMM\Q#`KB7/)(W<DGL>:`.ETCQ3HNNZ8-2TW4H)[,
MR^2)22@W\?+\V#GD<>XK8!)ZU\]ZY)J7B7P.T^KW-Q>6FF:W#%;ZG;0/;_:(
M"0))&0#DK@8;'!Z>]V[UR1/&%G'I+ZI%/;ZU;6QDN+V>9Y[1@`6\HKY:QG<N
M&/S<T`>YQW,4LLD<<L;M&=LBJP)0]<'T-2UX%+87.@S?$S^Q9-375AM-M$7D
M8FW8H7D7/4@$X;)(%-OQ<W5M;PZ)XENFTRYUFQ@,5G<W$DMH6#AF$DH!VL.<
M'(R!0![_`$5X;)IE_;-KS6^JZV%T+6[5-/C-U(P,<CQB16SRX^8]<XQ]<SW-
MSJ-QX]U..YUEM+U9-8C33A-+<!7ML*%01*/+9'R>20<D]*`/:B2!445S%.SB
M&6.0QML<*P)5O0^A]J\,\.1ZI9P^%]:&IZQ)=7WB"2SGBGG=XUMBSC;L/&.`
M<GGGZ8CLM*@TBT\?VD&NWVD78U((DD[3.OD%EVL2OS?.25+@DX_.@#WVBN7^
M'UVM[X1MYD@GA3S)%59KAY\@.1E'<!F0XRN[G!KJ*`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`*3'U_.EHH`3`HV\8Y_.EHH`3`QB
MC`I:*`$P/?\`.C'UI:*`*&LZ/::]I%SI=\)&M;E=DJQR,A9<YQD'.#W]1Q5N
M*"*"%(8D"1QJ%15&`H'``J2B@!,"C:,8I:*`$Q]:"`:6B@!,"C'UI:*`$Q1@
M>_YTM%`";01BC`]_SI:*`$Q1M%+10`F!1BEHH`3'UHVCW_.EHH`3:/?\Z,4M
M%`&!K?@W2-?O!>72W45SY)MWEM+J2!I(B<['*$;ESV/K6M8:?::9806-E"L-
MK;H(XHU)PJCH*LT4`)M%&WCO^=+10`FT8[T8%+10`F![_G1@4M%`"8HVCW_.
MEHH`0#%+110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!2$@=303@9KB[WQ1?P^.H+41Q#0EF73YI"IW_:GC,BG/\`=`VK]7_"@#M:
M*Y?4O'-EINISV+6&H3_998HKJ>"(&.W\W;L+$D$@[QT!(P2<"IAXRL#$I\FX
M$QU3^R_(VC>)LGGKC;M!?.>GOQ0!T5%85[XGAM=?CT:"QO+VZ,:S3"W"8@C9
MBJNVYAD$@_=R>/I69X>\:7NMP:O))X;U"`V$\L2H&C8RE#C8/FX?U'W?<T`=
MA17!W_Q(>&QMI[3PYJ4TS:H--N;9S&KPOA3C[Y!)##&#CKDBM&^\>V&GW,D<
MUA?^3;"/[?<*BF.R:0`JLAW9)^89"AL9'J*`.KHKE+GQ]IUKJ$MJUCJ,BQ7/
MV-YXH`R"X."L0YR68$8P,#(R10OCRS:S5AINH_VBUTUH-+\M/M'FJN\C&[:!
MLPV[=C!'K0!U=%<NWCFP_LVSNHK.]FENYY+6.TCC!E\^/=OC(SC(*MSG;P3G
M%9TOQ$E:\T&.R\.ZE<1ZHTR.#L22%X]P9-I;D@J2><8Y!/2@#N:3(/2L+0?%
M$'B)II+*RNQ8J2(KZ0)Y4^&*G;ABPY'\0%4G\6VVG3ZT]T]S-'9W\-F(TMQE
M7DCC*JN#E\EQR<')QT&:`.KI"0.IK&T?Q$NLZ?>7":;?6UQ:2O#+9W"J)0ZJ
M&P,,5.0RX.<<UQ\GC_4[[P='K2:1>Z?)'JD-N4PDOGH;GRW1`"26P,'('S'@
MGK0!Z3D>M+G/2N.;Q>EU96LJPW^FR_VO%I\\$]NC.&;!VGYB-I#`[E)Q6GX>
M\30^(HGN;.QNX[(_-;W<H3R[E<D93#$CIT8`^U`&]17*7/CVPM=0EMWL;\V\
M%V+.YO5B!@@E8@*&.<\[EY`.-PSBEE\>:?%)?$V5\UO92M;27"Q@JTXD""%!
MG<SDD8P,<]<\4`=517)GQ]816%Q+=6-[;7MO<1VK:?(J><99`#&H(8I\P.0=
MV/7%3R>,8X[RRL!H^I/J%S"+B2S58_,MHMVS>^7P1G/W2QXH`Z6BL?6_$4&A
MK:B2VN;F>[D,5O!;(&>1PI;:,D`<*3DD#CDBLT^.['^T%MFL;]8/M"6<UYL7
MR8;AL`1$ALEMS!25!`)QG@T`=2"#TI:X/2O&TT-G)!<6EYJFI-?7RQP6<:;A
M!#.4#,6*J`!M&2>?>M74/&MK9^'K?7K73K_4=-F@-RTUJB8BB`R68.RGIG@9
M/!H`Z>BN>C\6VUQKPTJSLKNZ9$C>YGB51';"1=R;]S!N1SP#BH=+\<6&JZE;
M6L=I>10WH<V%W,BB*[V#+;,$MC`)!(`(&1GB@#IZ3(/0U@Z]XI3P_/!]ITN_
MEM)&1'O(50Q1%W"*&RP;J1T!ZU@Q>-Y=-\2Z]::C:7TUA;:A%`MY'$ODVJ/%
M&1O;(.-[$Y`.`><"@#O:*Y6?QY86]Y(CV.H&QBN19R:DL0-NDV\)L)SN^\0I
M8+C/&:O6_BBTNHIY(X)SY.HOIQ&!DRJ<9'/W<T`;E)N'K7,>$?%5UXGMKV2X
MT2[T[[/<20J961@^QV4@8).X;?FXQGH3UKG_``_XTO)KO5M1U>UU6"W74TTV
MWMV2'RHRTJQKT8MO!;+$DCTH`](HKD?$_C6707MX[31KK4'?4([*01,B[2RJ
MPQDC)(;`Z#(.2.,Z`\4VHEU2*2VN8Y-,MHKFX1@N<2*Q"C!Y(VD'M]:`-ZBN
M;O?&EC8:E?6DMM=,FGIYE]=*H\JV7R_,4L203D<`*"<]<<&I=&\50:O?36+V
M%]87D<*W"P7B*K20L2`XVL<#((P<$>E`&_17,7OCBPL=3FMGM+R2VMITMKJ_
MC1?(MY7VA48EMQ.70':#C<,XI+;QSIUW?-8Q07)O(C<"Y@*C=;"'J7YX#97;
MC.=P]\`'445R%K\1=)F_>7%K?65J]F]];75S$%CN84`+,F"3P"#A@,Y&,T]/
M'U@D=U]MT_4;&>%(Y4MIXAYLZ2/LC**K'EF^7:<'/:@#K**XG4?'M]97&D1+
MX2U<O?7#P/%)Y2NI6-G&WY]K$@9ZXP&YR,5JW_BI=-UNVTZXTC4!'=2"&&\"
MH8GE*%P@^;=G"GG&,]Z`.AR**\_T_P`>7.JVT,]QIE]I.=973P72.43?O60I
M][Y2-OS'L>FZM8>/-/-\D9L=0%A)=?8TU+R@;=YM^S:"#NQN^7=MVYXS0!U5
M%<O:>.+.\UB&PCT_4!'+<2VBWC1KY/GQ[MT><YSA&YQCMG-6_#_B>'Q'$UQ:
M6-Y'9$;K>[E51'<KDC*88D=.C`&@#=I"0.IK+US7[?0;.&YN8IY1-,MO''`F
MYWD8':H'N1C\:YRX\927TFC?8XKFQG.MKI]_:748$B`PR/M."1R-C`@GM0!W
M%%<Q'XT@&H7]E>:7J%C):6DEZ#<*F)H4.&9=K'OCAL'FJ\?Q$TK[/?7%U::A
M9V]M:K>)+<0@"XA9MJLF"3R<##8/(H`Z^BL_2=3EU.R%Q-IMW8.21Y-ULW_7
MY&8$'ZUC1^.+99=4BOM+U#3Y-/M#>NMRJ?O(`6&]=K'^Z>#@T`=329&<9YKE
MH?'E@8-0FN['4+*.SBCG'VB$9GCD8K&8P"22S#`4X;)''-3:%KTNL:Q?QO:7
M=D;:"$O:7<85HW9I.<@D,"`O()'XYH`Z2BN4NO'MA:ZC);/8Z@;>"[%G<WJQ
M`P02L0%#'.>=R\@'&X9Q3I?'>GQ27W^A7[6]E*UM)<)$"K7`<((4&=S.21C`
MQSU!XH`ZFBN2;X@6$%O<"\T[4;2_A>&/^SYXU$LC2DB(*0Q0[BK<[L#!SBI[
MSQDMFMG$VB:K)J%W"\\=A'&AE"H0&S\VT8W#^+G(QR<4`=-17(2_$32_LEO<
MV5GJ%^DEK]ME$$0!MH,D%Y-S#&"K#`R3M.`<59NO&EJES'!I^GZAJS&".YD-
MA$K"**3.QFW,O)`)"C)QVH`Z:DR!7#:9\1C/H]U?ZCH5]9>7>M901DQL;B7S
M&18U^;`;*\YPH/0FM3Q!XBO-.\"WVNP:5=+=0VKRK:S*F^)@#RX#8VC&3@G@
M<4`=+D'H:6N$TCQ;-9:79VUQIVO:EJ30_:KB-HH3-#$S$!FV,%P<':HRQ`Z9
M!K5A\;V%Y=Z?;:;:WE^U];Q7:-!&`$@=BOF.6(P`1R.O/`/-`'3$@=:`<CBN
M6UKQ9=:7XNTG1(M#N[N*_CD<W$3(`NTKG`+#.,Y;IP1C/.,OPCXXENTMK'5;
M6]\V6>[CCU%HE6WD\J1_ER#G(1>I`!(/.:`.]HKF=(\;6.L:A;VJ6=[;+>1-
M-8SW,85+M%QN9,$D`!E/S`9!XKI0<B@!:***`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@!&!*D"N,G^'\%QH=Q;O=LNK33M=_VBBD;9S)YBN(\[?E.`.^`.<\UV9.!7
M-KXIN;N]D&E:+/?Z?!.UO/=I,B'>I`;RT;[X!)!.1T.,T`'_``BLC7&O3O>@
MOJY@+#RL",QH%]><XS[9[UGKX?GF^*<NKF.5-/M[59%5@`DMVP,9=<=<1`*<
M^H]*Z!_$>CQZP-)?5;(:B>1:F9?,_P"^<YS[4V7Q)HL5ZUG+JUE'<HC2/"TZ
MAE53M8D$]B,?A0!G>(/"USKE_!,+RVMDA:)EE2US<IM?<P27<,*PPI&#QGKF
MJ5QX'O);/6+*/6`EK?WWV]$^SG*.75G1R&&^-L$$<<-UK>_X2;1?[*35/[6L
MOL$BLR7/G#8P7K@^U-N/%>@VFEV^J7&LV,=A<'$-PTRA)#['OT-`&`G@"6+2
MY8(=1AAN6U=-6C:.T"PQNH4;/+W?=POKGFI;CP3.^K7NH13Z8\E\(GG^V:<)
M]LJ`*73+#`*JORG(!&?6MR^\3:+IENEQ?ZM96T$BJZ22S*H=6SM(.>0<'IZ5
M.=:TX1W<OVZV\NS027+>8,1*5W!F]!MYS0!A/X*+R2O]O(\S78]9QY73:JKY
M?7OM^][]*@U#P%]MU.XU);N'[0^I+?1K<6PEC"^0L+QLI/S!@N=W!!QCW[&*
M198U=&#*P!5AT(/>L:/Q1IT>DC4=1O;&SA+RKN-TKIA'*'YN!GID=B<=J`*D
M?A67?HLDD]I&VF7LMV([2T$,;ATD0*%W'&-^<\YQ[TEYX5N9;S3;VUU!(;JP
MO+FY0O!O1EFW;E(W`Y`;@Y[=*T;KQ1H=EIMOJ-UK%C#97`S#.\ZA)!_LG//X
M56L?%-M<W>K17#0V\5E>Q6D<QD^68R1QNF/<F0`>M`%;1?"UUIOB"?5I[RW)
MEMS"T%G:^0CL7W&5QN(9\8&>._K4=WX+:ZFU&3[?M^V:K:ZECRL[/)\KY.O.
M?*Z]L].*WKS6=/T^VN+B\O;>WAMSMF>60*(R0"`2>^"#^-9T/B:.X\IX3:20
M37XM(9?M(42*8]X9?[Y_V1VR>U`&G:V36UU?3[]WVF82X(^[A%3'_CN?QKF8
M?!%S'HJZ2^J(]K#J::A;G[/AUQ<&=D8[L-DG&<#'H:WK7Q'H]]J#:?::K9SW
MBQB5H(Y@7"'!SC/3D?G46F^+-!UB_DL=.UBQN[N,%GA@F#L`#@G`]R*`*^I^
M&#J5PDIN]FS5(-1`V9_U2*NSKWVYS[]*BT#PM<Z1JUSJ$UY;$SP)$T%G:_9X
MBP8EI2NYAO.0,^@[UH7GB?1-/O);.\U>R@NHH3.\,DP#K&!DL1Z8YK.M/B%X
M6N]#BUA=;LXK*1Q'OGD"%7(SL(/1L<XH`PK;PEJFJWNNV]Y=-9Z3/K@O#!]G
M!DN%18F4K)GY5+(,\9^0^M:UUX&2ZT'5=-:\^:]U%]1BE,(80R%PZ@J3AP"H
MR#P035QO&OAZ/Q%!H1U2W_M">)98D#@APV-H![LP(('<<UH6OB#2;[4I].M-
M3LY[ZW&9K>.8,Z?4#ZT`9*^&+Q;"XMO^)$!/+&[1KI0$3*HY#+O^8D\@YXK+
M?X>WCZ)8Z6=9A/V9>+PVA^TQGS3(?*DWY1<80+S@`=:Z)O%WA]/M&[6]/`MD
M62;-PH\M6&03SQFI+SQ/HFG6=M=WNKV,%O=`&WEDG4++GD%3GD=.?>@`U71#
MJ>IZ->^=Y?\`9MTUQLVY\S,3QXSGC[^<\]*QH_!36FMW=]:OIK0W5ZMZ5NK`
M2RQ/D%]DFX?>(R,CY2>*VK_Q)HVEM&NH:K96K2,JHLTRJ6+9QC)[XJK;>,]!
MO/$=UH$.I0'4;4?O(BV,G!)`]2H!SZ<4`8P^'OE7D-[%=6LT\<]V[I>68ECD
MCGE,NW&X$%6QA@>><CFFZO\`#Z?5H8XY-1M%7^S#ITD0L?W4>3DRPINQ&^"1
MW[>E=9I6MZ9KD$DVEZA;7L4;['>WD#A6]#BJB^*-)N9+^VL-2L[J]LHW>6WC
MF!=2N>H'OQ0!EW7@^YNM6TZ[-];1QV4D+!H;7;<2+&N#&TN[E&)R01[>]-\.
M^"W\.S6L<$FG/:6ID$3?V>%N=A!"J9=W;."<98#FKWAKQEI7B73()[:]M/M7
MV6.XN;9)U9K?<H)#?3IFK-KXJT*^MKNXM-8L)X;,,UR\<ZL(@HR2V#P,=Z`,
M+7/`4FM:S=WCZC&(;E[:0++;^8\!A8-B)MV%5BHSQGKSS1J7@6ZU"[U9!K`B
MTS5KJ*YN[=;8&0[%1=JR;N`1&N>#WQ6YK?BG2/#VERZCJ-[''!'&)#@Y9@WW
M=H[YP<4VZ\6Z+9^&9/$4FH0/I2(7%Q$VX/@XPOJ21@#UH`QI?`UU*EQI_P#;
M&-&N-2_M&2W^SCS=QD\TQB3.-IDPV=N<<9J>V\'WEKJ4TB:N/L$FJ-J?V;[,
M-Y=N2A?/W<\C`!]<TES\0]$@GTB47UH=*U&*=Q?-.%1&CV?+[DEB,=B*V+SQ
M/HFG6EM=WNKV,%M=8\B5YE"RY&1M.>1[T`0>']!NM":^B-\EQ9W%U+=11^3M
M>-I'+L"V3N&6XX%9TW@EWTB^M(]0V37&K_VM%*8<B-Q(LBH5S\PRN#R.M;NK
MZU;:+IC7UQN=,JD<<0W/*[$*JJ.Y)('Z]*KV6LWOE7$FLZ9_94<(W^=)<I)$
M5SW8$;3Z@C'/4T`95WX0O[VQ;SM85M0_M*'4DG-J`BM&JJ$V!N5^7USSU-)?
M^#]1N[_4KF'6EMQJ=K#!=@6H8DQAAE"6^4'><@@GT-;=GXDT;4;`WUEJMG/:
M!@C31S*55B<`$YXY]:B@\6Z!<_9/)UK3Y/MC[+8+<*?.;.,+SR<C%`%.Y\(0
MWLGB874[/!KR1QNBKM,06+R^#GD]ZDT#P_=:/*7FDTMR8%B9[33Q;O(P/+,0
MQZ_W0`,U=?Q'H\6IQ:9)JEDM_,Q6.V,P#L1U`'KQ1#XCTB?6I-'AU.SDU*(9
MDM5E!D7`Y^7\:`,23P2R:Y?ZA:R:<8[VXCN72\T\3O'(NT,4?<,;@HX(.T\C
MTI$\'W%C>W^K1ZC)/>WL<ZWH*<7"G/DHHS\GEY`!YR,^O&NOBS06GG@76;`S
M6\/GRH)P62/`.XCL,$&I-1UJ&UBB2%XIKJ8))%`'R7C+HK.,=0-X.?I0!QVB
M^`[S4_#>EQ>(;YMD.B&PCLXX!&T'F1J'WMD[F`50.@XSWJ^_@2ZGTQK66^T^
M"95A:*ZL=-6%Q-$X=9'^8AAD#*<#K72PZ[I<NKRZ3%J%J^H0KNDMEE!D1>.2
MOXC\Z+S7]*TZ]M[*]U*TM[JY!,,,LH5GQZ#O0!E7_AW5]1_L^YEU>W&H6-XU
MU"XM/W0!B:,IMW9/#$YW9R?3BJ`\!2GQ"NJ2:C'((]3.HH7M\S`E2OD^86XC
M&6P`/3TK2TKQ[X9UFUN;JSUBU,-L[)*SR!=N-W)S_"0C$'N!5H>+M`:ZL[4:
MS8^??(KVL?G#,RM]TKZY[>M`&/'X'N$"P'5$:SBUD:M"GV?#JQD:1D+;L$$M
M@'`Q[TV+P-<QQV^GG5\Z-!J7]HI;_9P)L^9YHC,F<;1(2V=N<<9K3TGQOX>U
MNXOX+'5;9WL&87`9PNU5QE\G^#)QNZ9!JQ'XKT&;29=5BUBP?3X6VR7(G78A
MXX)['D?G0!6T[PNUA;QP_:]^S5)]1SY>,^8TC;,9[>9U[XZ5E1>%]<T>2\O]
M-NK%K^ZCB@$,-KY%LIWY>=TWG<Y!/3'0"NATSQ-HNLLBZ9JMG=L^XKY,H;=M
MQNQZXW+GTR*OV=[;:A;BXM)XYX2S*'C;(RI*L,^Q!'X4`<YXXL+[4+/2(].5
MO.BU:VF,@3>(E4G+D9&0.]5T\#2R.MS<ZLTEZ^J_VG/*D(121"T*HBY^4!2O
M)).5]Z2'Q_IUQXNU/2EO--CL]+C)NII;G$A8#+;5QC:G1B2"#VK>UCQ#IF@:
M;=W^HW:106L8EEYRV#D+@>K$$`=S0!S&F?#E[%)_-U**22329-,,L=KL:3>0
M3-(2Q+OD<\C-;1\,S)IMM:P74!D@TY;`-<6WFQL!MR63<,@A<8SWZU=TWQ)I
M&L0PR:?J-O<+-"T\>QP244[6;'H&.#Z&GS^(-*MGMDGU&UC:Z,:VX:0`RE\[
M-H[YP<?2@#-T;PO+I>AZEISW[$WTTTBM;IY:VH=0H6)23M"XR.>I)K%M/AN\
M-EJ,,VHP>9>Z.=*,D%IL]?WK98EG)8D\^E=98:_I.J7UQ96.IVES=6P_?0PR
MAFC^H%&I^(=(T::&'4M4L[.2<XB2>94+_3)_6@#+U?P@-7TZ2T>]>'=:0P(Z
M("4DBD$B/SP1N`RO?%7=*TO4;2^NKW4M22\FGBCB`CMQ$D80N>!DGG?W)Z?A
M4NH>)-&TIXUU#5;*U:1E5!-,J[BW3&?7%+=Z_I-EJ%OIUUJ=G#>W/$-N\RAY
M/H,Y^E`''V_A'5=4O==@NKLV>DSZX+MH/(!>X5%B92LF?E4L@SQGY#ZUJS>"
M/-T74K%=0>.:ZU1M4@G6,?N)=XD0%2<,`5&>F1Z5M2>(='MKI[674[-+A(WE
M>)I@&5$^\Q'8#N:S;OXA>%K/3(=2?6[22SFN!;I+%('&\D9SCI@')]!S0!7;
MPC?SW>H:A=W]C=7E[Y$3QS6&ZW6"(L0@0ODDLS'<3Z<<5D1>%-=TS5]!MM.U
M(EK/3;R*34)[;S$#22QLJ;2V0!SM&3@(!S76+XDLO.G9[JR2QBM(KL71N5P4
M<M@E?X5^7AL\Y/I4EKXBT:[T[^T+75;.:SW;?/692@/H3V/UH`YF+X<)8BS-
MC<VLK0V'V*7^TK);@289G5P,C:0SOP."#CL*TAX6U&UU>34--U:*U>ZM8;>[
M3[(&4F+A7C&[Y#@L-IW#D>E:*^*]!;1FUA=9L3IBML:Z$Z^6&SC&?7VK3M;J
M*\MX[B"5)89%#I)&V593T(/<4`<O;^$KVULK^Q2]L9[.YOGO$AN[#S0N^0R.
MC?.-W)X.!C'>IH/"4D7@"X\,2ZB\SS6LUN;MTSM\S=T4G[J[L`9Z`#-:L_B#
M2;;5X=*GU.SBU"8XBMGE`D?Z+UK+T/Q=_:\-I)+!!;B9+MG#7`W*()O+)"XR
M5/4G^'@<YH`CN/"M_%J+7^D:LEI<2Z>EC-Y]L)5(3.QU&X88;FX)(.1QQ4FA
M>#H?#^H6L]M=2/!;:5'IJ1R+\Q".S;RWJ=W3%71XHTFX34%L=2L+JYL83+-$
MMPHV`#/S'^$>_:A?%&DH^GV]UJ=A!>WT:/#;FY4L^X`C;_>'/![T`1ZOH-S?
M:UI.JVEZEO/I_FJ5DA\Q9$D"AAU&#\HP?TJ'3/"BV&E66GO<F:*WN;F=ODV[
MQ,9<KUXQYO7V]ZDO?%^DPQZK#::A9W.HZ?;RSR6:3`N-BY((ZCL#Z9K5TJ]_
MM+2+*_V>7]J@2;9G.W<H.,_C0!SOAOP?+X=>TC2739;>TC:*.1=/"7#)QL#2
M!NP`!./FZFNL'2EHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!#TXKAM$A\2>
M&C-HT&B1W]@+N66UOOMB1!8Y',F'4C=D,S#(!R,5W)QCFJMY=Q68@,I;$TRP
MK@9^9C@?A0!Y]<>&=;DL;S0SI=NZW&N?;QJAF7"Q><)LE?O[P`(\8Z=\5,GA
M'4#/"\EE`P_X2J34I-S*<VY5PK'U.2O'4?A7H@48I=HH`\KU'3;W2=?TYGT]
M+A;CQ1<75K;+(@#H;-N1GA3N#-@XY&>,YJ>#0?%5I8-%%9B&"_N+ZZN;6TFA
MWP/)CRD+.-I7[VXJ,Y(QD=>^UB_L]'TN?4[[*V]HAE=U3<R`=2!]/2KR[64,
M.01UH`X#2/"5W#<Z.NH6<$L%IX9_LV4,RL!-E`5`]"`W-9>M:!,NJ>'=%A1%
M_M:SAMM5B5N1%:E7W<<8Y:,G_;&/?U/:N*3RHRX?8NX`@-CD`]LT`4-'U,ZH
MMXXM98(X+I[>-I!Q,%QEU_V<Y'_`37&Z1X4U.WD\*_:[6(II]]J,]P#(K;1*
MTIC('<_,O3I7H8`'2C`H`\^@\/ZGHNKZ9?6NCQ7MK!:W=I]D29$,!>8R(Z[O
MEP0`IP<@'OC%17?AC6'M]8DBL8?,EUBQOX;=)E`:.%8-ZJ3@#!C8#..@Z5Z$
MTD*31PM*BRR`E$+?,P'7`[XR*DP*`."O]+UZ\N+?5FTF$R6^L+>'3S<JQDB^
MSB+.X_+O4DM@\?+P>AI(_#VI.--D72[>R$?B'^T9((IE(CB,+*3G@%BS<@=R
M>O6NJU;7+72+FSMI8[B:XO'*0P6\1D<@8W,1V5<C)[9%7WDB$R0[T\UU++'N
M&X@8!('H,CGW%`'G=CX8GTKP9IHOM/A^TV%K??:=I#'$BN<94@MN^7.#FH?A
M^\:ZO8I,7N;Q]"B1+B&:*2*.)&&$8(!AB6X)SD*>>#7H.D:G9ZWI5OJ5C(SV
MTZDHQ4J>"0>/J#5B&TMK8-Y$$4(;EO+0+GZXH`Y"'2M5M?&,LUA8RV^G7=U)
M+J#3SQR12_N@JO&OWU<L%!'3`/M6+8Z3XNL_"^CZ+_9K0P6EG+;7/V>X@WRR
M!0(V#-G$9^;/\73CU[G5?$.EZ+)''?7.R23E(TC>5R,@%MJ@D*,CYCQ6A:SP
M7EK%<V\J2P2J'CD1LJRGH0:`.&T;P]JVCZGX;E:QCFCM]#73+EHY5!@D#1DO
MS]Y<*>G-0^$_"]]I5SHL.HV-Y))I33I'="ZA,.&4CS-H`<EP>0V<$YR>M>BX
M%&T4`><^'/!]]I\GA%KRQ@']FQ7WVOYE;:\K*4(_O$C/(Z51T_P=K>GRV4LE
MK<31"UN[.2&TGA5H%:XDDCV^9QM9&52!@KM7KCCU3:*,"@#SV'P?(1J,;:8@
MM9O#EMIUO%/*DC*Z"3,9;VW)ENAQGM5F?0[X:[X@:;2?MUAJVFQ0$QW"(2R1
MR*R')!!;<`&''.3TKN<"JRW,3ZC+:#/FQQI(W'&UBP'/K\AH`PO"5IK-I!>0
M7Z/':1LB:>MP\;SA`@SYC)P?FSCO@<USVEZ)XHN=8M]0UF#%S'I=U:S,98O+
M,LC(5$2IR$PG5N>1[UZ,[I%&SNRHB@LS,<``=236?+J]E!J&GV;RGS-1WFV*
MC*OM7>>1[<^]`'F\7@WQ#J&AV6EG3K?26L-!GTXW'VA6%S+(JJ,;.0F4W9;G
MY^G4UHZAX=UG7GN9?[%M])(\/7&FQQM,C>9+*%PH*=$39U./O=!S7I&T48%`
M'G>HZ)KVN^']7M9=+BLY)M%6RMTDN5<M*"V=Q7A1R,')Z]JZ+5K.]USP+J5@
M+(6E[=V,T"02NK!692JY9<CT/'K718%&!0!Q4&DZA?:UX4OKO2DMX].M[F*X
MCDDC<QNRQJI&W(.=K=.G?K65_P`(EJ5G=:9-#:3O;)I;Z?)!9S1(T'SEEQYF
M00P(!P01M'7MZ5M%1S2P6\+2SRI%$OWG=@`/Q-`'):KX<O)O`^DVFE0_9[[2
MC;7%K;7$H<;H<?NG<=<C(W#O@]*KZU#XD\2^'Y87\/QV4L%Q!<I;3WJ/]J\N
M17,9V@J`P!&3WZC%=C]KB^WBQ._SC&9?]6VW:"!][&,Y(XSGVJ?:/\F@#S;5
M_#&KZW)K]Y_9,-I]N_L^".V>5"TBPSB21W*_+]UB`,DD+[XJ;5O"6H7-CXQ%
MM:0_:M1O;>:Q<,JMM1(1G/\`"0R/CI^M>B;11@4`>3C3+[7+OQ+IMIID+QR>
M)(Y)=0>51Y"Q"%R,?>)PN!C^^>G.=BSTCQ+=>,=)U+5H?W=C<W;.XDB\KRW5
MDB\M5^?)!&[=WS^'>B-(\[$52QR<#J?6J,.JVTLL,8\W?+-+"O[IB-T9(;)`
MPHX."2,]J`.3\.>$)+31?#]OJ.GP>=;+=QW?*L=LN[(R.N[Y<U#\.+*X-SJ%
M_=.LD=EC1K"4-N$EO`[`OGOEC@^Z<>E=S<7<-O=VMNVX27)81X&1\J[C].!4
MI\BUMV=C'##&"[DD*JCJ2>P]30!Q^B:7JVG>)Y1:V4MIHTTMS/<I<SQR@RL^
M5:'!W*&RS$-P,X%+JNF:JGB]=0T>QE1YI+:.[N))XS!+`I;?F,_,'4$A2O4G
MTS79C:RAE.0>00>M+M%`'FR>&-7:TCTZ33(A##XD_M'S3,A26!IWD^[URH89
M!'7IFK'B#1_$NK:TT7DEM.BU*RN+5HY(DC$4;*\F\$;R^Y3C'&,>^?0<"C:*
M`/.;_P`,:Q<Z;XNTR.S15U"]%_:W(F0+*!Y)\EAU7/EL"2".>_2LW7=/FM'M
MK^6TNK*]N=4LO])OKJ`C<B2\#;\BXW%<L#NW<#."/0]7UZPT2*XEO6E2.WMF
MN9&6%F`C!`)R!C.3TSGOBK[0PW,12:-)(FP2KKD'Z@T`>2W4GV7P?_:NBV\B
MZQ8:Q<6\/G2(1=2W+[9!&R#:R[I`P&.#%@_=-=]HPCT(Z9X7M[:62*UT\,]R
M`=B;2%`/NQW$<_PFMPQVT%N-R11PPC<,@!4QSGT&*D0QRQK)&X='`965L@@]
M"#0!P>K^%M2OHO'B0P1`ZQ#$EDS.!O*PA3G^[\P[U:O=-UG7=)\213Z;'9/?
M:2+.U22X60E\2C+[>%Y=>A/]*[3:*,"@#@%L?$$6K:?JL6A#<-(?3I+=[N-?
M*DWHP9F&1M(!^[D^U6=.\-WR:_!=W,4<:)X>AL/.#!FCF#$L`.O`P<]Z[;`I
M-J_C0!Y]X1\-WVF3:&FHZ=>+/IEM+;+<?:H3``0HW*J@,V_:#\PRO?/6K&L:
M3J\/B'7;NWT>+5H-4TZ.WBWS(GDNFX%&#_P-OW97/W>G-=U@4FT4`>1MHVHV
MFH:AH%MID&J7B^%K+3VD:541#^^0N=_.W(SQS\HX]+C^"]1MVU&RN;6[U&SO
M(;3YK2YBB!:*-$*-O^8`%-X(/\1&`>OIDIMK<&>9HXP=JF1R%ZG"C/U.!]:2
MZGBL[6:YEW>7$AD;8A=L`9.%&23[`9H`XL:/K^GZ;XKGTRW@&IWVI_:+1F*$
MO"5B!Y/`.!)@-QG&:S7\+ZT^GZQ*+-I)IM:M-0AAN)XO,DCB\K<"R_(&/EG`
MZ<CFO28F62,.H(5AD9&#@^W:G[1Z4`><^(/#FM:GK,^K6^GQLHCTV46<LZCS
MF@EE=X2>1GYUP3\N14=YX6U74[W5K]M+AMEO=2TYUM7D0LT5O)EY'Q\N2"?E
MR3A<>U>E8%&T4`<1K'AQO-N)K73+@R?VG]MMY+*>*)XW^SA"Y#_*P)!4@YZY
MQ6MX=U/4I)(M*U2TQ?V]C%+>7$(`@$S$YC7U(`SQQ@BNAVCTH``H`X[3=.U3
M2_$FL"32(;RWU#44NX[XS(/+38JE6!^;*;,KC(.[M@UE:+X4UBSEL&G@1?)L
MM5A?$JG#3W(DC'XJ,^W>O1L#-,EDA@56ED2-68("S`98G`'U).,4`<':>$[J
MW\*Z?:K90I?Q^&Y=.E*LH_>LD>%R.""P8Y_'O1X<T;6-#NYH[C18+N.\2R/G
M^<G[CRXHXW1@>3M*,Z[<@ENW)KO\"LK4]:MM-O[*Q:.XGNKQL1Q6\1<JH(#2
M-Z(I9<GMD4`<'-X=\6ZK=K<:G!NN(K'4;=F\V(1%IAMC\H+\P!"C)?GGZUZ#
MH%K+8^'-,M+A0LT%I%%(H.<,J`$9[\BM#:*!@<"@!:**C,T0F6$R()F4LJ%A
MN(&,D#T&1^8H`DHJCI>JVVKVTEQ:.S1QS20-N7!#QN48?F#5Z@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`0]*\GTMDN-5M);V?5?\`A(EUEDO(&$IB$(D8QY4Y14";
M"K#')QD\BO6#C'/2CC'M0!Y+X8CN;G7K634]2\G5I+JYM]1MI))V>X7#XC"'
M]VJ`;65EXPH`/-5F?Q/+I]_80&]^V^&=.F@$NYMUQ([8213_`!L+=<@_WGZ`
M@5['P*/EH`\?N(8CX(\71:;J`N;:;2EDCLXFGF*.=V7+2_-N8;05[;>@S2:Q
M-,9M:E,^JIXLBU-8=+BB>4*8"5V;4'[LH4#EB1USG%>PY'K1D!>*`/';^X,V
MMZJ;>ZU)_$-OKZ0Z=##)+L6#]TT@*CY-NTRDENG'3BK+6EY<ZJMV]QJBRS>)
MYM.<I/(@%GB1]@`X"E@/FQGT(KTRPTRTTZ2\>VC*->7!N9B6)W2%54GGIPHX
M'I5W*XZT`>.W2WD!71YY;A?#MMK5S:DSW$Z@KY4;PJ\BG>4#-)@DXR%!/%:D
M5I-J$'@_2[C4[F_L;B6]CN9K=Y8A)&H9D0MP^`55<DY;;U.>?305[$<<=:7B
M@#R.;1-.M]<\&7.K-?31P+>6GVJ2:;.4D'DABIZD`_[V.<X%=)XR\F3Q!H]M
MK+W47A^6*?SVADDC0W`VF,2-&00-HD(R0,@5W'%-R@.,@8%`'D&CZ*-8\1>$
M[W4XM1F5O[1,$MQ-*K_9TD5K8MR,':W?EN^<5T'B'2],'Q6\/ZE?13JLEK*B
M2B24)YXDB\I?E.!GYN#P<<YQ7H&5]O6@%3T(_"@#R;PCHEUI^AZ+J6G/>QZI
M<VU[&\,TKF)F^8Q@HQVJ`RC&`.IZU;^'OS:E:3C56,]Q8,U]:2/<22R3@H"[
M^9Q&RG<,#&=W&0*]/XHR/6@#@YM7M?"WC[6;G7#+#!J,%N;*Z$+R+MC4J\65
M4[2&);'^WFN>\0WJ75QXCN;E]8M]4CCC;P[''YT60\8"E(UX+&7<&W#.`,@"
MO7<J.]''YT`>2:Y%J<MSK]Y)/J4=Y8W&FQVIAE=1'YHB6<JJ_*Q(+`D@X]JF
MUQ[OP]IWC>TT^XO8K:V6SNK5WE>1DDD;]YL=B3_"#CG!)]<5ZKQVJCJNEVFM
M:=-I][$9+6;`=0Q7."".1R.0*`/,OM=KIXUZ/3(=3O?#LQM+<F>XN%2.=V82
MOYA_>!0/*W;>YQQS3-,BO)?#VFZ?YUZ+.7Q-+;YBFER;0QR$*KM\_EGCDGOU
MKU[*^O6C*GD$'-`'EUZTO@K28];BEOI[32;RZM'AD=G+PRM^Z!).2%DV`'DX
M)ZUJWFC2:;\.8+6YU7['?ND"7=[)O;S6:3<\;,IW!69W&5(VACC`KK]2TRTU
M6&&&[C,L44R3A`Q`+(=RY`^\`<'!XXJZ/UH`X*V@@U[X47]I%IUS%$]O<1PP
M&>60R%"VUD9L.59@"`>H./:N?T_1M)U*S\`V%JMVUD?/^U;)IE82?9@64L3N
M49XP"!V]J]=^7KQ1Q0!Y'?VUS$F@Z9J5Y.VC+!=1))=7$\8>=)<)YCQX;(C!
MV[B`<'J<5HZ5!<:AKNG"_O;S58+/0H+Q)(VDA2XN%E?#D#!+$?PGUY!KTOY:
M#MQS0!XWH]])-?:UJ-C'/:PW7AZYN98?M,\OE3[@5#F3A9`"W"XQSVQ4,$]^
MUC<7/A>YU2>ZE\/M/J4CO*X^U$H5*[NDFWS\!/\`9XZ5[)=VT%[93VEPN^&>
M-HI%W$95A@C/T--L[:&QLH+2!2L$$:Q1J3G"J,`?D*`/*BC+X/\`%@T74WG2
M33%EAM+:2XD>.0A\OND^8,PP"HZ;>@S5CQM):>*O#'B!K5+NZ@M[2TDCVI*B
MLXDDW%>F_"YSUZ>H%>J94G;D9ZXSS2Y7UH`\G\03S6LP/AF34#IZ:&=AMWE=
M@GVN(2,I8Y+B/S,'[WI78>'DTJ#1KY?#3W,L*DLGG22R+YA0$!#(<GJ,C.,Y
M'7-=,KQL2%=6VG!P<X-..T]>:`/(;.^TNU\*QS2PZM>:Q>Q16^L)/<W*+#(S
MA7>4C_5A7R!LP=N>W-&F1W<WA_3=/,MZ+.;Q-+;?NI9>;0QR$`.WS^6?4GOU
MKU[CUHXH`\KO+=-.72]*U*XU/_A&DO[V.=_-ER,$-`CNIW[!E\<\E5R?6:S:
M]BN/"ZV<FH2@W6J?-<HRO+A9-AE!`YSC&X#/6O3LBC@T`>3>&[B"%](OX6UN
MZU9;6>35;:82L#<K$=P^<81]P95"X!'8\&L=+4:WIWBB.UM;DVEWX?\`M2VL
M=U<2XNLNP4E^?,&5!4<'H1S7N.11\N<4`>*W$5JZ6=K;WSVNBC2Q)8327%TJ
MI=`MYK?*<LZY3"L>F0!6U?7`A\4Z-<W5_+K$QCLX8[:(SP/$[YW3JJX5U;[S
M!QP%ZCH?4,BCB@"G:7UKJ-I/)9SB9$DDA=ESPZ$JP^H((KR_PUHTNIMX=AU&
MXU9H]5T:6XU+-W*GF3(8E3."-N`S8"XS@9SBO5;2UM=/M4MK2&.""/A8T&`,
M_P#UZGX/O0!X=>76KZCX3D%U]LE=O"=RC*RO\[K.JJ2.[[1UZGFMG%W)XTNI
M+[4S9:A!JT2V^]YSNM&*[8XXQ^[(=<@GG!))P:]8X]:.*`/(KVWBO]2\1Z<_
MVC6;F^M[UA<6\UQ&;<1GY(9(\[/O852OWMO(.<FMI?\`8:6^C6E_-J$/AY-(
M$J&.:X1?MPP90Q!W;@N-JGCE@!GBO9L#'-&1ZT`>76-KJ>LP>"M/UU]1*75G
M=M>J9'B>3:8S%YC*00<8/4$GKW%4+^*\9-#L-4OIAIJZ6RP3W4\\8:Y1R"TC
M1X)8(%(#<'+8YKV#BDW*3C(SZ9H`X3Q!<7L7P\TAVOKJZA9K0:E>VR.DCVYQ
MYL@`^9<]\<@$USSF9(=5M=$NM3_L,:GIMO:R>;(VTM)MN!$[9;;AASD@$G%>
MNY7UH^7KQZ9H`XSQA;G1/"%K:V'VR+38KJ%+QH'D>5+4OF0ALE_J1DX)KE;N
MZET_PYXR;0KN_72+7[*-/E>1W"2[OWWE,^6(Y7U&2<=Z]=R/4<51U72[36M/
MFT^^C,EK-@.@8KNP01R.>H%`'C^MZ587FE^((].75+G0;22PGC,LD[`3^;_I
M!7<=QQ$5)'(!Y&"*[K6?M$?P_P!8_LED_LQ-(F^Q/$\K7&1&=O+<YSGG.>E=
MF./O=N]+D>M`'E4FGSZE>:Y=3W.I)+IIL)+$QS2*J,8XS)A1PV[&&SGOT-=5
M\1+I[3PU#(MQ/;J=0M8Y)(&(<1M,JOC'.=I/3FNJRH&20`.<U4U+3+35;:.&
M[C+QQ3QW"`,1AXV#J>/0@4`>6Q75M;V.IV,$-[<^&KO5(K>RENKFXCCA_=[I
M&\P?O/+\Q<#G&X]<9IEMJ.I^'?!6D>(P;N5XEN]/>"0R'<'E?[,QW_-@,L:@
MD$[9.E>P`C'-5-1TVTU/[-]JC,@MKA;B-=Q`WKG:2.^,YP>X!Z@4`>5ZUI>H
M:;9ZK!]KU%[C1=!MKBUD2:0`W>9=TA`/SMP.#D<]*L^(8-0T&\U>STB;43:3
M6-I>W+O-+*X_T@K.R-RP8QC)"\\9`KU88QSVI?EH`\G(FL_".M)I.KO+%]NL
MOL\5H\SFU#R1A]LDF6;<"6[A>>E,\4>&+"TTN^M2M_+I]GK-E.BM<3/Y$;&,
M2X.=Q7&X]3@DD8KUO(H^7IQQ0!YEI$EE;^/K=;:XFU1)V,-LRRW"M80K`"%=
M3\CIZ.?FW/U)Z:>K^'[.\^+.B7DT$[%=/GD,BS2*H=)(=G`..[<=#WSBNZXH
M..]`'D%I;NGA'0=1U&34Q!J5YY>M3":;<(5\U8U(!RB;O+!*@<=3WJ2-;BZ@
MALK6XU0Z#/XC6UMG:60,UK]G82*'/S^7Y@8`YZ=#7K>5SFD)7!+$`#KF@#RF
MQMKNSBTG4TGU)KN'Q&^G*)9Y'1;/S7C"%"<%0@4ACDYP<UJ^(=+TM?BGX?U*
M_CG`>UE195DE"^>LD7E+\IP.-W!X..<XKT+CO1\H]!F@#R_PUH7D7L.L*]]'
M>-XAOHY%\Y_+:(O-@;,[0N0&SCKWYJ'P/]J?7=,N+W5#'JTAGCU.U=YW>>15
M/!5ODC52,J5P"``":]5RIS@@XX-+D4`+12;AZTM`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M"'D8KA?#=A%XJ@EUV_N[O^T$OKB*,0W+Q_8U20H(PH..54$[ASNKNCTKG9_`
M^A7&K3:D]I*L\S[YEBNI4BE;&-SQJP5B1C.1SB@#"N/&&N1P76MQ6^GG1+?4
M?[/:W8.+EL3B$R!\[1\Q^[CH.N3BF2>+]??4<6UMIQM7UB31HEEW[_,7<PE8
M@XVA5QM`R3SD5T3>"]">_:\:R)9KD7C1><_DM.!CS#'G:6[YQUYZU87PQI2L
MC"TPR7[:D#YC?\?#`@OU]&/'2@#ED\7:](EOIJQZ=_;#ZK-I<LI5_(#)$9A(
M%SNQMQ\N>O?'--;QEJSZ(Z"XTNVUNWN[FVDC-M-<)<>3]YHT0AE'*Y))`SCN
M*V-6\$VM_?64T&8(TU)]0NPLKJ\CM"8LJP.5/W3Q@<58_P"$&T!;:UMXK)X5
MMEE5&BN)$<K)_K`S!LONP,[B<X%`&%_PEGB#5(=+BT>WTZ.[O=$75F-T'9%/
MRYC`!'4N,$GC!/-.O/&VI6=I=&6Q@%S<6-K<:6F3B268B,HQSSMD9>F,AATZ
MUU%KX=TVRFMYK>U$;V]G]@APYPD&0=F,_P"R.>O%4;[PE!>Z]X>NR(EM-%60
MQ1X)<L554&?[H`)/J0M`&=KMYJGAF");$0[+NXFN+O4+BV>6&TX#89$(8`G.
M&)P,<]:U]?UZ32_#<%]:K;W-Q=26\%N=Q\IGE=45B1SM^;/'.*MZSH-GKD:Q
M7GVGR]CQLL-S)$&5P`P8*1N!`[T^^T/3=1T,Z/<V<;V/EK&(>0%"XV[2.01@
M8(Y&*`.9?5/%BZM!X?231/[4>WDO'NC!+Y/E*RJ%$>[.[<QS\V,`'O@8\&M3
M:]K&E7\L*V\DFBZI'+%'(63?'-'&2"0,C*DC([UUDG@K1IGBE>&Y^TQL[+="
M\E$WSJ%8&0-N((`&"<<"K-MX6T>S%JMM8)"MI:R6D"HQ`6)R"XZ\DE0<GGWY
M-`'!6GBZ_P!(\)>&OL-U8W"0V&GK>6LL$LDH\WRU!,BG;'PV1N'/XU+-K.M:
M#KOB_5+?[&^DVFIV_P!JBE5S,ZM#`K>600JD`YY!R?3K76#P'X?&Q5LI%C6.
M",QK<2!'$(`B++NPQ4`8)YX'I4MUX*T*]U*2_N+)WFEF2>53._ERR)C:S1YV
ML1@8R.PH`P+GQ?KD4-UK4=OIS:+;:E_9S0,'%PV)Q`9`^=H^8Y"XZ#KDXJ>/
MQ1J<L>MWLMQI=C86-U-80M-'([O.K@(QP1D'.-@&6/0C.*V'\&Z"^H-=M9,7
M:Z%XT7FOY+3@8\PQYV%N^<=>>M33>%](FT^ZLI+4^1=71O)`)6#><6#;PP.5
M((!&",4`<'=>*?%M]IUJ;6ZT^UNX?$*:9-)]CD59E(1E.QVW*/F(89R<#!%;
M&I^)_$,`UVYLX]+:V\/QC[:DRR![EQ"LK^60<1C##&0V3UQC)WV\':*VG2V1
MM9#%+="]=S._F&<8Q)OW;@W`Y!IEWX(T*^FDDN+21C,D:7"BX<+<B/[GF@'#
MX]6SD<&@#(;Q/KMUJ&K_`-EV%M/;Z7"DK6QW&:Z,D`D1$(.%P3R<'/0`=3M>
M%-6NM4TZ5KRZL[BYBE*2+;6\D!B.`=KQN2RMS^1!JT_A_3B=298'C;4@BW+1
M2LA8*NQ<%2"N%&/EQ5./PG;075M-9W-S`B7AO;G]\SO=2;-B[W8DE0/X>G"]
M,4`9FO7GB*+Q_P"'[+3;^SBL+J&=Y89;=F+[-A;)##LPVXQ@YSG@#$\%ZGKE
MA8V1F2RET*>[U!`!O^TQE))G!))VG.PC`'`QSVKN]2T&QU:ZL[JZBD^T6;%H
M)8YFC9-P`894C(.!D'@X%.LM#L=/@MX+:WV16\TD\2[R=KR;BQY/<NW'3F@#
MF/"OBO7=9O+&6ZT^,Z?J-J;E&@M9D^R<*55Y'^60L&ZJ!@J>HYJ6ZBC\2^.-
M2T;4I9196%I!+#:QS/'YS2,Q,A*D$[=BJ.<#)[FMK3?"VFZ1-&]BMS$D6_RX
M?M4AB3><MA"VWKTXX[8I-8\*:3KUS#<WT$OVF%2B3V]Q)!(%/)7<C`D9&<'B
M@#GKW6];LI]7M-&^R26OA^W1[EM2:22:Y)C,FT,#\N%P-Q#')Z<9-/4/'NJI
M%>7UC9V?V&QM;.[FBG+&25;@<(I'"D'.6(/;CO7177@3P[<Y$E@Z+)"L$RQ7
M$B">,-N"R`-\_/\`>R>2.E7+GPKHUVE^LUD-E_'%%<*KLH98L^6``>,9[8H`
MYJ^\7ZYHHUBVO[?3Y[ZS-G+#]GWI&T=Q-Y05LDG<I!Y'48..U/'BG5[5]8TK
M5+K28-4M)+=;:Y2"5HIO.#$*(@Q<N-C\`G/![&M3Q/X4@UVSO?(V17EY]F2:
M9RQ#1PS"0+@'CJPR/6IAX(T(0-&+23>URMV;C[3(9O-085O,W;N!D`9Q@D=S
M0!S]IXQUN]TG24AAL!J5]J5SIQDDCD6)3%YA\S83N'$?W2<Y.,BK$?B_4M-@
MM+C7[>UC@,5XES+`&VK/`S$8))^5T1S@Y((QS706WA;2;-+)8+0J+*X>Z@)E
M8D2N&#L23R2';KGK5+Q'X2@\0:5!I@6-+7^T$O+C?DL0&+ML/8LW&?0M0!4:
MZUJW\,+XE-B+K6I=/B5K&",D*6?<2!DEMH?D`_-M..M6+?4M0U'P7>W-MJ.G
M2ZC&DJ_:(8)$C1EZAHV;>K`=03D'\JW[ZQBU"U:UG,JQLRG,,K1L""",,I!'
M(J"PT*QTRPFLK6%EAG=Y)MTC.TCO]YF8G))SUH`X;P%<WNE:?X1TV2+3RFLV
M<MY-+;PLCL5BB(9R6.Z0ECN;OQTJU%K'B:_\9Z#';7MA#875E-/-;M;LQ.R6
M-6(.[AL-\IZ#G(/%='/X0T>>UTRV:U=8M,C\JT\N=T:--H4KN4@D%0`03SBG
M#PGI"?V:8K1H3IJE+4PSNFQ"02AP?F4[1P<CB@"AI/B.[O[2&:2*%6?6;BP.
MT'_5QO*H/7[WR#/;K6)_PFFNG18-2\C3PM_?G3K*-8I79)%>16DDVG+#$;$(
MHSTYZD=1;^$-%M-2_M&.T9;A;A[E/WSE(Y7!#LJ$[5+;CG`YS4C^%M)DT3^Q
M_LA%D)C.$65@RR%S)O5@=P.\DY!XH`I:1KVH?\([J-_K-FT<E@TN6CA>%;E$
M0/O1'^90<D8)ZJ>:RM!\2>)M67,EI:A;O3VNK:86LZ16TF%*1R,^/,SNSE=O
M"GUKK;'3(-/AEBA>XD65S(YN)WE))`'5B<#CH.*SK3P;I%G9M:VZW:VK6\EL
M(/MLIC2-_O!1N^7V(Y';%`',VWQ!U"^\-7^O06%L(+>:VLTA:3+-<-(JRY92
M1L'F+M..0,\@@47/C37M*GO-&OH;";5DN[:W@N+>*7R2)T=@6C!+Y41/P"=V
M1TY(VM?\%6>H:/<V>GQQVDMQ]DC8Y;88X)%8#:#@':"H(YZ=@*MCP5H0L;JT
M^QLR74R3S2M.YF:1,;&\PG=E<#'/%`&##XH\1W+V>DK9VEMJUS/.BW5S;2I`
M\,2HQD6(D/R9`H!/\+'/0%UO?^*A\1397VH:8FGQZ7'<W$$<#X'SLK%6+9!R
MIY/`7`QD9._)X0TJ=(A,MU)+#<&YBN'NY3+'(5"DJ^[<`0,;1Q[4Y?"6CK=V
MEREJR2VL'V:-EG<;HLYV.,_.,DGYL\D^M`'&S^,==NO[9MK*\TR11I,VH6-[
M#9S*JA'"X^9L294\,O&0.".*C;Q3J>BV6D:EJZ6M]>G0IKL2Q*\6XEK=44C<
M1R7&YL=N`.A[*Q\':)IN?(M'(-J;(+-.\@6W/)B`8G"^U-C\%:%%:QVSV330
MQVTEHB3SO+B%]NY/F)X^1,>F.,4`8.H^+M>\-_VG!K$.FW5Q;Z6^IPR6@>-2
M$<*T;*Q//S##`_A5F;7/%EC;:K'<:?97=Y"MO);?88Y&`25F5BR9+/LVD\8+
M#H!6I'X'T%;2\@:TDF6]MEM)WGN))',*\!`[,2%]@1Z]:TKO1K6]WF42H[B,
M%X9WC;$;%DY4@\%C]<\T`5]#U;[9X>6^NKZQN-@?SKBV5HXEVDYRKDE2,<@G
M@@UR-OXZU2/^W6N'L;R&STAM4M9K:VEA#`%P%_>$[P=HPPP.:[.RT+3M/TJ3
M2[>W_P!$DW^8DCE_,+DERS$DDDDYR>]4K?P3H=O:W%N+65TN+/[!)YMS)(?L
M^,",$MD*,G&/6@##F\5Z_I5C?W&J6VGS,;>VGL5MRZ`--+Y820DDG:2N6`&0
M3QVK7T#^U_\`A(=2CUI;0W"6MN%FM`RI*I:8YVL25(.1C)SC/?%:-YX>TS4+
M66UN[-)H);=;5T<D@Q@Y`Z]0>0>M&E>'[#1I)I;**033JJS2RS/(\FW.W)8D
M\;C0!RE]XNURWGU"]BM]..DZ9JJ:=<1L'\^7>T8#*V=JX\U>"#G!Z<5GVFN7
MFF66M1V%]9Q7SZY?ND5U;RW!=$()VI&00`2,MT&?>NBLO`ED-7U#4=3073SZ
MF;Z!!(XC7"*J[DSM9E(8@D=QZ5=F\&:'-*TK6TB2O)-([Q7$B%C-CS02&Y5M
MHXZ<4`<^?%GB#5(=+BT:WTV.[O=$75F^U!V13P#&,$=2XY)XP>M6?^$JU9M7
MTI98;33=/N8+>0SW,3NMQ)*.8HY%(5&!P`&!W$C%=#:^'],LIK>:WM1&UM9_
M8(MKM\D&0=@&?51SUXJ&7PGI5Q/;2RPSNML86BA-U)Y0,7^K.S=M)'7IUP3T
MH`S_`!MXBO-&M<:9=V$=ZD,ERT%Q;2SO)&@SPL9!49X+'@5FWOBOQ!=/'%HM
MOIR3?V+'J[_:MS`[MV8EP1U('S'IZ'/'3ZKX8TS6;E;F]AD:80O;EHYWC+Q,
M061MI&Y3@<&I(_#VFPS>=':[9/L2V&0Y_P!0N2%QGW//6@#D=8\0ZUJMMKD&
MEVMC]EL+!6NXYV822F6$OB-APNU2.2#D\<=:Z7Q)K,GA[P?/JL,2S/;QQD1L
M<!LLJXSVZU'>^"=!U"5I;BQ):2!;>4),Z+-&HPH<*0'QV)R14_BO0Y/$/A2\
MT>"5(GN%50\@)`PP/..>@H`Y>[\7Z]HBZQ:ZE!IUQ?60LYHFMM\<;I<3>5M8
M,20003N'4$<=JL2:UXK-[?:?;-HS76DVT<][))%*J3E]Y5(P&)0;4Y8EN3TK
M97P;H4<%U`;-Y!=R12SO+.[NYC(,8+DEL*5&!G'7U-/U;PGH^LW<EU>6\AFE
M@^SS-#.\7G19SL?:1N&?7U/K0!@Z?XRU+4M4TEWAM=,TN]M[:6)KJ)W-TTR;
MMD<H(164_+M8$G&1UJ"S\9:VQTS4[JWT_P#L>^O9K`11!Q.CQ^;\^2=I!\EO
MEQQD<UTS^%='DOK:Z:"7_1I(Y(8!.XAC=%VH1%G:"!TX]^M9WASP'9:0(+B\
M47.H03W$T<GF.8T,DC-E8R=H;:0I(&>#ZT`85M\0-:327UN]TV*739=-DOT$
M%M-']GVJ&1'D?Y7+YZJ!C!ZBK'B2\\<6&B6TWV_18+B;4;2(-!;R$!9)%4H0
MS<C)&3QD$X"G!KH[?P;HUM&T$=O,;0K*GV22YD>`+)]X>63MP?3'';%(O@S1
METQ]/:WGD@<1#]Y=2,Z>4<Q[6+97:>1@T`9]AKVM?\)8NF:I]ALXA^ZC1[>1
M6O6$89I(9-VW&2?D.6`4DFJ_C?Q??:#(SZ;<:?(;1$DNK22WEDD*LX4?.AVQ
M`@G!;.?PK=A\*:9!J,%_LNI9[9B\)GNY951BNPL%9B,[>,X[GU-,U+PEHNJW
M4]U>6TC/<(D<X6=T68(24WJ#AMI/&:`,CQ%XA\06VL:I9:)!I[?V;8QW\AN@
MQ,JL9`8Q@@`_NS\QSCT/:KKVM:SJ<7B&WTZWL6T[34$%RLI832EXE<LC?=4*
M''!!W8(XX)ZZ71[":[O+N2`M/>6PM9VWGYXEW87';[[<CGFJ%[X-T'4+N6ZN
M;(F2=$2=5E=%FV\*74'#$=B<GIZ4`/\`$^KWNGMIEEIJ6YOM2N3;PO<@F./$
M;N68+@GA#@9&2>HKC=2\2>+Y;ZRT^VN=+M+RWUI-.NG6%WCN-T'FHP!8%5P>
M5R3D##8SGT#6-%L=<MHH;Z$N(95FB=7*/$Z]&5@05/T]ZSCX+T0Z=]B^QN$%
MU]M\T7#B8S\_O#(#NW<D9ST..E`'*/?^(--\8^*KNP-A+:P3V)NHIP^Y@T2*
MWEX.%P,GG.>E7E\7ZS=>()X[&P2;3K?4O[/>%;69IFPP5Y?-'[M54L3M.3A>
MHSQU(\/:<#?-]F):_P#+^TDR,3)L4*O?C``Z5$_AC36U2:_5;F*>>5)IA#=2
M1I*Z8VEE!VD\#/'.!G-`%+PSJVJZW/?74XLHM/AN9[2..-6,K/%*4WEB<8(!
M^4#WSV'4#I5/3M,M-+@EAM(O+26>2X8;B<N[%F//JQ)JY0`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`'I7$WWQ`<:%K6J:7H=Y>6^G)*4N-\:QRM&2'&-^]0I!)RH)`R,Y&>
MU(R*XV;P))>76I37FI1`7]A<64BVEH(=PE/WW^8AW4<`X'?UH`LW'B^\M/#,
M.LS^&]1.Y&DF@22'="BC)8DN`01R`"3["J]OXXN+GQ<FEQ:-.=-DT^.^6_+H
M`$?)WE2V0HQCUR#QCFH=1\!7>JP6JWFLPS/%9263;[$&/:V`)$0OA9``1NYZ
M]*OQ>#WMM4L;NWU$^5#IB:9<0R0[O/B0D@A@048Y.>M`$%G\0["Y^:2RO+:"
M6UEO+*:8(!=Q1J&<J`Q*\$$;@,@\5'_PL6!TD,.@ZQ-(MN+R.)(DW26QZ3#+
M\`X.%.&..E)I_@*33],;3$O;+[,+2:T21=-19]CKM3=(&YVCV&[O5^S\(+:7
M:3_;6<KHT>DX\O&0A)\SKU.>GZT`5K[XAZ9:;I(+>YO+.&WCN;J\@">7;12+
MN5FRP+';\V%!.,>HJ36/'-MI%]<VO]F:A=BT$;W<MM&K+!')]USD@GOP`3\I
M.*SK?X<&P2/['>V3O]@@LY&O=.6?+1($65<L-IV@`KDC@5MR^%Q)?:]=?;&!
MU>VAMV41_P"J\M7&1SSG?TXZ4`8S?$.2SU?Q#!J>B7-O8Z2R*+D21G>7`V`C
M=QO+#:>@!^8KS75:?J4EWIPN[NQGT\@$O%<LA9`.Y*,RXQSG-8USX5O&UC5[
MZSU.".+5!%Y]M<60F7**%_O#*E1@C'7G-6M!\-#1]&N-.ENC<)<32RMM7RTC
M$G\$:Y.U0.`,T`9T?C^!K$7[:-JB6<^S[!*T:?Z:78!5C`;()R"-V,C)Z"GC
MQ]9QVUTUYIVH6EW:30PSV<D:M*&F.(MNTE6#$8X/6JO_``@E^=#LM);Q$_DZ
M8T;Z<XM%W1-&V8S)SB3:HVX^7(R3S4TG@:2ZFO+N]U4RWMW>VET[I`%1$MW#
MI&JY/^UEB2>?:@"GJ/Q#O+>RM)K;PS?M</J:Z=<VTSQJ\3$*0`=^&+!AM(..
MN2*V=3\6-I%U8QW>C7ZV]T\41N08BD4DC!51AOW$@D`E01S1K/A5]461XK\V
MUQ_:,.H1.8@ZH\:JH4C(W`[?4=?:LR\\`27^L/J%QJB2&2ZM;IMUH"ZM#M^2
M-RWR(Q7)4#N>>:`)?^$RCM)[Z)H;Z_N#JLEC;6\4488NL*R;%Y`VXR=S$=\\
M`5-;>*DU.[\.F-;RT_M"6YC:UEA3(>)6W*YSE<%3@KG/TIT7@M8M934?MS$K
MJ\FJ;/+[O!Y.S.>@'.?PQ5G_`(1<'5]+U`W9S87-U<!-GW_/##&<\;=WXXH`
MH:?\0K"]EC+:??V]C-;RSPWTL8\J01#,@&"6!'/4<X.,U-H7C4:YK0TW^QK^
MSWV8OHYKAHMLD+-M5@%<D9YX([<U'!X2GTGPM::?:7;3SZ?!<"%L>697D5\<
MY^7!;K63X%TK4-+O;>)=.,%DNG)%</<VBPRB92-JHRL=R_?)[`X()).`"+7?
M'6L"U\96L&DW%BVCP%X+XO&PW;`REER3\W4#!XZX/%;D'CJVCL[^74-*U*PD
MLS"/(GC7S)_.)6/8%8@EB",9!'?%,U;P1+J<_B';JIAMM<MEBGB,`8HZIL#*
MV1QC!P1^-7=?\*1Z]:W<,ER8VFB@$;>6'$4D+LZ/M/##+<J>"![T`6-"\1IK
MAO(3:365[9NJ7%K.59HRR[E.4)4@@YX/UJC#X\TN:[TBU"3)-J<\]NB.HS$\
M)*MO&<@%@`#_`+0]:T=$T>?2Q<>:]B1*RE5L[(6ZC`P<X8[B>O/2N?O_`(<0
MW=YK5U%J,D3W[QS6RF/<ME*&5V=1D9+LBD\CD=Z`)XOB!!>)&=.T;4[]V1IF
M2W1,I"'9!(=S#ABC%5^\0.E66\;V<JZ7_9MG=ZC)J=O]JMD@0*3&"H9F+D!<
M;AG/K@9J)O!MS9W*7&AZN;"3^S4TZ026XG4K'GRW&2"&7<W4D'/(JQI?@ZWT
MB\T6:UN9#%I6GR6$<;C)<,8SN)]?W?3'>@"BOC)=5U/38;*UOH[.>]:**]:,
M>3=*BR;PI!)`RN06`W8XS6IX=\3)XFMWN[6PN8[`C=;W4A39<#)&5`8LO3HP
M!YK/TGP9=Z3]BM4UR232["Y>>VM6MU#`,'^5WSE@"^0<#ISFK6@>%IM(UBXU
M*>^AEDGMTA:*UM1;Q,P8DR,H8@N<XSQP*`+4":K%?/)<.9+8&X(C1@2063R@
M.G0!^_>LR+Q[;+::M-J&FWNGOI?DM<0S;';9*<*P*,P/0\9SQ6[KFF-K.BWN
MG+=2VIN86B\^(X>/(^\/<5RH^'"-IFM6C7\,9U6*WB;[+9B*.(0G((3<<DYY
MR:`$U7XB75GHUY=0^&=0%Y:75O!-:W!C0JLI7:^0Q!!S@8Y#8S@9(N7/C!--
MU5A?Q7T!_LZ&?[!Y4;L)))C&JAE8Y<G"X!V]\U>U[PM_;=KJ,7VUH'N_L[(X
MC#>4T+[U."?F!.,CBJ&K>!YM9NGO+G5V2\-I!"DL,`4)+%,9DDVDD$;L#:>P
MZT`2Q>)+B?6])MKBRO\`3);A+HM9SQQ,'\L1D$NK'CYN-I.3D'&*32/'MIJ]
M[90KIVH6\.H0M+87,T:[+K:NY@N#D'&2-P&0,BK/_".7LNLV&K7^J"XGLEN%
M6..W$:$2J@P.21C9GDG)8]!BN8\.^`]3NO#&CQZQJD]M)::9);06\,2QO:R2
MQ[&8N"=Q52<=/6@"_JGQ%GL=(UN5?#M['J&EP)</;7$D6#&Y8!]RN1@%#D=?
M:K5U\0([&-OM.B:@DMO`+F_C#1$V41+89SOP20C,%7)QVJM!\-XUTW5K2>_C
M!U+3H[!FM;00A`@;#XR=S$L2<GVJ>?P/=3ZC)J3W^GS7MQ:BWN6N-,65&92=
MDBJ7RI`8@C)!XS0!TFHFYN]&=M,E"SRJK0OG'!(/?VI(8M0&EWB/(#=,\Y@;
M<.%+-Y?Y#;4=BNIKJ]TMP81IT<,26X5<.[@'>YQT7E0!_LGVK5H`X7Q%J>N>
M'].LKEGDF>35;2'RH0KO+&T:K(@!P,EPQ_7-7!X\MOL:_P#$KOUU,W36?]ED
M1^>)%3><G=LV[,-NW8P1ZUJ>)=!DU^RM8H;W['/:W<=W%+Y0D`=,D94D9&3Z
MUA2?#XSXNY]22?53J)OWGFM%>)LH(C'Y1.-OEJHSG.1G-`#I?%;:C=>&)K!Y
M(8;O49[2\@D4;E,<,I9#U&5=!R#@XZD&J]G\1;:+0K.X:VU#4-MA'>WMPL44
M9MXF!(>1=P&<*3M3)P.*UT\*.6T=Y;JV5M-O);E5MK00QMO21`NT,<8$G7G.
M/>LBT^&W]G0VZVM]9R21Z='8R&]TY9PYCSLD`+#:0&(QD@\9Z4`:USXVL+6'
M57:"X9]/,(\L*,W`FV^48\GHQ;;SC!!S4=OXZLKC5H;06=TEK<736<%^P3RI
M9UW910&W?P/\VW;QUIVI^#(]2\1:3J[7C1FSV?:($3"71CR8B>?EV,S,,9ZD
M5!8^#7T6[>>REL7MUNI+J.-[!3.`^YC&)MW3<Q(8C(''2@#7UB'59G!TZ81C
M[.Z_>`_>%X]IZ?W1)^=6-6COY$@^P2!"&?S,D#(\IPO_`(^4/X4NAC4ET:V&
ML/"^H;<SF`80-GH/H,#/?%:%`'*:EXO30!'9SV5W?WEO:+=7OV8IB"/D%V+,
MN<E6P!DG!P*?%XTAOM2FM-)TV\U)8(5DEF@,:JA>,2(N'8-\RE><8YZ\'!K7
M@\:EKQUBWFM$G>U^RRI=V2W*,`248`D%2I9NAP<\]!3'\(7$VNZ?J,NH6Z_8
MI%=?L]D(I)`(]GELX;F,MEMN/0=LT`9>E>.+O5_#VD:I=:?=:6;S4H;5=HCE
M6;<[+@?-D+Q@G`([`U=C^(=K--''!H^J3&X,D=H5C3%S+&2)$7+<;<'+-A>#
MS267@6:UTC3M+?5_-M=.U".\M_\`1@K;4=GV,=W.=V-V!TZ58T[P4NGRZ(XO
MVD_LJXNYP#$!YOV@N2#SQMW_`(XH`)_&RKX;CUNUT;4+J(>8+F%#$DEJ8\AP
M^YP,@@C`STJO;^.+BY\71Z7'HMP=.DT^.^6_+HH5'S\[*6R%&,>N0>,<U4NO
MAK]H#J-44I)]L#)/:B5%^T2F0NJE@!(N2H;GCM6K%X/>VU6QNX-1Q%#IB:9<
M0R0[O.B0D@A@04/)SUZT`+HOC>SUK4;:U6RN[9+V%I["><)MND7&XJ%8E<!E
M/S`9!XK1O8=5;4P]M,%M=UN2NX=`S^;QCN"GY5S^G^$=0\,Z7LTJ;3KB6UMY
M(K3=8)'*V1B,/*&Y"\9X^;'/-=A9+.EE"MTZ27*QJ)7C7:K/@;B!V&<\4`9N
MKPZK*^=.E"#[.Z\L!^\WQE3T_NB3\ZS=4\=6&DZA<6\EI=2VMFZ)?7D83RK4
MOC:&RP9C\P)"@X!'K75UR5[X+,NNW^IV=Q8H;XQO*EWIZW!210%W(Q8$955&
M#D<9%`%BW\:6=SK7]CI;7(U!9Y8IH2HS"B+N$K<_<8%=I[[AZ'%*S^(^FW30
M236=[9V-U;275K>W"*(ITC7?)C!)&%R?F`R`2*LV_A)K/Q!)K@U*62]GDE%S
ME/EE@(_=P@9^780I##G[W]XU@>&O`5U=^&]$B\0W<GEVFFR6R6`B$9B,L?EO
MO<$EB%)`QCKGF@#7B^(FG^5</?6%_8&.W%W#',BL]Q$SA%*JK'#%F4;6P<L.
M*KZKX[U73QI>WPAJ8DN[W[*\4TD*D?(6&TA]K$X]<#:<X.,J/A]))HTFF7&H
MVH0VZ1I<6FG)#-YB.KI(S`D-@H,K@`U?U#PUJFI6MHUUKB&]L[V.\@E6S`C4
MJA0J4W9(.YCG=U/'`Q0!L7HO9Q9M:GRB)0TZEAG9L;C_`+Z*_E4+1:G_`,(S
MY*RC^U?L@7S-P_UVWDYQCK[4NF+JS7E^VH/!]E\Q5LUC&&VA!N9O]YLD#L*U
MJ`.8N;^\TW4M-M[NXES?:E,D21HCAXQ$[JK$X*C"YXR<@#H35&W^(:7UN\UG
MH>I.LED]Y9.ZHJW:KMW!<MD$%A][&0"1FM_5=$&J:EI%X9S&=-N'G"A<^86B
M>/'M]_/X50TOPDFG:-I.FF\>5-/LWM-X0*9`R@;NIP1CWZT`9^G^/I9_#NDW
MMSH5XNHZF@:VL8GC+3*$5VD5BP`3YARQ!Z#'(J9_B!9O9V4MAIM_?SW<,LL=
MM`B[QY3[)026"C:W'7D],Y%0+X!D_LO0[:;4;>XGT;]W;236(9'@**AC="W)
M.T'<"#D?7.G8>%WM-5TW4)+J!I+*UN+;R[>U$,;"617R%!.W&P#OG.:`*MUX
MZM/L]N;.PU&[\ZR2^D\B$%K:!P=KN"0<\'Y5RQP<#BM"WDOKWP;!+;3$ZA/8
MHR2D@?O#&"">/4^E9W_"&W=M=176G:Y):2FP2PN2;=9/,1"2C+D_*PW/ZCGI
MQ6CI5IJEI=K:/)$=*M;*&")B/WDLJ\,YQT7&!CUR:`+=K'>K%=BY?<[3R&`A
MA\J'[HK*.HW7AS1KK4]>F:2&&.WW>7\Y!VJKD`#^^2?>NGK(\2Z&/$>@7>E-
M<&W6X"@RA=Q7#!NG'I0!AR?$2W@2X:YT358#9N@OPZ1XLT?E9'(?!&""0N2!
MG(&*T;_Q4=-UZTTV?2;SR;N4007H:/RGD*,P7&[?_"1G;BJ^I^"UU&'Q1&;X
MQ_V_'&C'R\^1MC"9'/S9QGM50>`,>(5U-]15U34CJ*!K8&8$J5\KS=W^K&20
M`!CCTH`TK#QE8ZB-%%O!/YNJF8+&P`:#R@?,W\\8;"\<Y(]ZN7<.J/J8>VE"
MVNZW^4D#@,_F]NX*?E7+V.@:G9^(O%>M6D#"5U,&E0SL`H9@'E<=MC28///R
MGUKN;1;A+*!;J1)+D1J)71=JL^.2!V&<\4`34444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`(<XXK'MM6N9+QX[BV\F!$G<RD$`".4H,YXY7YOY5LU3U4_\2F]'_3O)_P"@
MF@#*F\8:1)9ZL=-U&SO;S3K5[A[>.4$\*2,X[<8R*2V\9:,XTJ"[U"UM-0U&
M"*:*T>4;SO&0OY\#UKA-"T'5]<\,Z#,FFV]I;VGAN6V@D\Y6:Z>>%0.`!M`V
MY.[NWXU=E\.>*[B+3["X0&SLY].DBV7$8B5(1&90XQN9]RMCG&,=,'(!W$GB
M?18M5ATJ35;1+^9BD=N9!O9AU&/7@U-J=_<V2PF"W\[S&D#``G:%B=AT]64#
M\:YRU\,W*2:O)<6L#27'B"+4+=B03Y:^5\V>Q`5^/\:Z+1M5?5K::=K.:V1+
MB2&(R\&5%.!(!U`/.,T`++?7*:9:7*V^Z69X%>/!^0.RAC^`)/X51;Q7I^GZ
M1#>ZY>6VFLZEF29MN/FV\`\GM705PGB66ZA^(VBR6>FIJ-PNEWNV!I5C_CA&
M0S#'?'T)^A`.EN?$FCVB6[SZG:1K<[/(S(/WN_A=OKGVI;3Q'H]_JD^F6>J6
MD]];C,L$<H9E]<@>GZ5R?A/PAJ&B:EH[W:0-'::-+:N\9SLF>8/M4'G`&1GV
MJMX>\(ZA8IIEE?VETSZ:EQ##>B]0Q*'1E$@C`#$L#R#T))R:`.JC\5Z=>ZQ#
M8:;?6EXWF.EP(I0QB*H6'3UQBF1>,M'2PTR;4=3T^TFU!%:&,7(=6)X&UL#<
M,_Q8`K#\.:%J]I_PCUO?:/96_P#9%K):M>)<!FF^3:"H`R%8@,<G.3T[U2\+
M^'?$'AI(0VDVM]Y^DVMG(&N5`MY(MP93D'*-O+?+G[N,<YH`ZO0_&>A^([^]
MLM+OTGN+-RDL>,'`QEAZKEL9]0:L0ZI>R:P;1K0K")94\W:>BK&5/IR78?\`
M`:P+5M3\,7^MM)I+W<6H:JL]J\$H)?S!$A4KC*[0KL2>,+UYKN*`,:?5;V/6
M!:)9EH#+$GF[6Z,LA8^G!11_P*E_X2?11J\>DG5;3^T)"RI;>:-Y()!&/7Y3
MQ[5KG[IKRG3]-U#69]1L[;3X/LL?BQ[R:^>09412ARH3&2QVA0>F&//:@#O6
M\5:$LUS"^KV:M;1&6<&4#RT#;<MZ?-QBH?\`A*=,N=,BU#2[VQO()+F.W+BY
M"JI=PN,X/S<\+@9XZ9S7-R^%=63PS+%#:V[WD?B"351;M(%6YC^T-(JEN@)4
MKUSC`JAK6GWL6IW&J7MK#9RZKK6E):V:R*\KK!*"SG;QDJ2<#.`G)H`[ZW\1
MZ1=ZQ-I%OJ=I+J$(/F6R2`NN.H(]1W':LG5OB/X4T:.Z-SK=JTEJP62&)P\@
M).,`#J1W]*Q/#WA:_P!-NM/MKZTNIUT^]N)(;L7L?E`.),2E,;RQ#D%3GDDY
M-0?\(UX@?X=/X6;2[07%M;-''>?:%Q<,LBL"!C*EP"6W8P<=<Y`!W)UB*YT"
M75-+=+R/[.\L!3)$I`.`,>I&*ET^[N+IKKSH3%Y4WEID$;EV*<\^[$?A56PU
M>YN-7%A-I,ULPM?M$TA<,D3%\+'D<%B`6XZ8Y[5LT`<A=>.K;1--74/$*_88
M&CMMORG+22YW*`?[N,GT&:T9_&/AZV%B9]9LHOMZA[7?)@2J2`"/8YIGC?3+
MO6/"UQ:6$:277FP3)&[[0_ERI(5SV)"D<\5S'BS2/%GB*&]M%MS%9W-O"88%
MN(E6*0/F03'!+=%V[>.3]:`.TG\0Z3:Z@FGW&I6T=X^[$#N`WRKO/'H%.<U4
ML/&OAO4TN7LM<LIDM4\R=EE`6)?5B>@KF?$FD3VUA\0M0N+>)X-0M8Q`>I8)
M#M;.""`&]_>L?[!-KZ:U:6DC7NIM'87C72W<3P3K$Y*0[D0*C$!NJGJ#TH`[
M*]^(_A6PT^SOI-8MY+:[N/L\<D1W#<,9)]`,C)]Q6S<ZBXM[*XLT%Q%<S1IN
M4$C8_P#'QVQ@UQ-UX;U.57O[;2[C[<-5L[V07=]&SW*Q#!"E?E7`XYZXKLM+
MU66^U"^M7T^6W6T6(&5CE7D9=S(OKMX!/0Y]C0`Z/4;IO"_]I-:D7?V0S?9\
M'[^W.W'7KQZU#_;\-I;W=QJTD5C##,8TDE;:'`C#DY/_``+_`+YK:KC?B`TB
MMX7:&V%S(-;B*PE@H<B*4@9/`H`UG\6:`FB1ZP^LV0TV1MJ7)E&QFZ8'J>#Q
MUJE>_$#PQIUWIT$^KV__`!,06@D1@R%1GDL.F2"![\5SMCX:UZQUBVU]M.MI
M)'U.[NI=.2=0T231QHK!C\K./+R>GWR`>N2P\,Z[IT^E:M_9UL\RZI>7MQ8Q
M7"CR5G0J%#$`-MXSC'7C-`':_P#"2:/_`&V-&_M2T.I8S]E$H\SUQCUQVZU"
M/%_A\W<MH-:LC<10M/)&)1N6-1EF(]AS7*V?A6^M]6>&[L[J\M5UHZC#-'>Q
MI&-SEPSH1O+)G;CG(`Z=*T?#OAFYTZQT875K"+FTU&\N)&!4D)*9MI!'4D.F
M1_A0!:TSQWH^MZ=:WVD74$\<UW':NL\OE,A8D`8P<MQD+W]15Y?%FCW4VH6E
MAJ=K<W]E$[R6Z299=O7(^O%<GIWAK7(_"^A:3/8Q1R:5J\,[2BX4K+$LCL77
MN.".#S2Z7H7BFYU>WO\`6D)GCTNZM9F-Q&4:61DV^6J@;4PG\7/(]"2`=3:Z
M]<WG@NSUV&TS-<VD-R+<$MC>%)7(&3C/Z5>BOKE]+O+EK?$T+SJD>#\X1F"G
MUY`!_&LGP:]U9:99^'[FRD1]+TVUBFN,YC:;9\T:GOM`4Y''S"NGH`Q[+6BZ
MDZ@J6A::*&'?E?,9XE?:,]\EA_P'UJ;^W=-\MI/MT&Q+H6;'=TG+!1'_`+V2
M!CWJIXOTJ?5_#TT-D$_M"%TN;,N<`31L'3GL"1@^Q-<EH'@G4K#7]/DNTB:Q
M)&IW>U@<:AM=6V\[B/WF<Y(P@%`%R^^(DMI9S7"65K,(](EU(&&YWHQCE$90
M-@9SG.<<'BNPO[N:WBM6AA,OG3QQMP?E5CRW'I7E_P#P@?B#_A'6LC;P^<WA
MZZL`//&/.><.HSZ;>]>EV&IO=ZG?V/V.6.*R\M!<-]R5V7+*O^[\N3T^;V-`
M#(]1NV\,?VD;4K=?9#/]GP<[]N=OKUX]:6SU?S;J2VNMEO,TS1V\;'#3*J*Q
M(!ZXW'IZ5JUROCC1=2U+3+:ZT00G5[&?S+;SFVJ592DBDCG!5B>HY44`:T>O
MZ7+!:3IJ-LT5VS+;N'&)"H8M@^P5B?H:@M/%WA^_MKRXM-:L9H;-6>X:.8$1
MJHR6/M[]*X6/X<7Z6NJZ1!(D>GQ6$T&E3.>0\ZIYF<?,.4/)SG>3VJ]J/A[7
M/$+W,\VDVNEL/#]QIL4?GJ^^68+QE1Q&NSC/][H*`.H\1>)(]%\.ZAJ<'EW,
MMI:&[6'=C>G;GT.#S1K/BO3M'C>![ZT_M(P--#:22@/)A<XQ_G/:N9U/1?$.
MM>'=7MI=-@M)I]&2RMXS=*[-("V=Q`P!R,<GWQTIVJ>']9-SXD@ATJRO[;6#
M%-#<37`7R62-4VL""204W*1QENU`'<:A<S6L$;PQ>:S3Q1D8)PK.%)X]`2?P
MJDNJ7I\,OJ1LR+I87<6^#R1G`QUYQ^M3:?JKW^HZC;_8YHH;.58DN'X6<[06
MVCT4G&>A/2M*@##F\1VFG65S=ZU<0:?;Q73P(\[;`X!X(SU)]J+KQ=X?L4LW
MN=;L(4O%#VY>=0)%/0CV]^E4_$>GZA)X@T+5[&U2\2P:=)K=I`C8D50'4M\N
MY=O0XX8X-8T^E>((-1U6]BT*SNAJVF1V_P!G%RJK:R+N!0EA\R'S"25'5>G.
M:`.R.K62RSQ&\AWP0+<2J&Y2(YPY]CM;GVK+7Q9;0ZOK=M?R06MGID-O,;J2
M0*K"4,<'/3E>/7-<NGAGQ!HZ36MC:6U\)O#UMI?GM<")4DB60$D$$X.\8Q^.
M.M2ZOX6UJ3Q'<:M:6\$Z17&GW$=N\P7[0(4E5UST!!D5AGC*]NM`'8Z-K$&M
MK=2VTD4UK'(JQ31-N613&C9_-B/PIMCJ=Y<:B;>6T,<0$Y$F#_!+L7KZK\U8
M^G7%[HLTK2Z&D<NKZJI6"TD#"-#$N^61@`,C:Q/J>A.:Z_J*`,@:G>?VN+0V
MI$)N&B\W:?NB%7#>GWB5_#UK)U?Q[I-E:2S6E]9W;6U[!;7BK,!Y"R2!"Q/M
MDG\*ZJ3."!SQT]:\QC\+:Z^G0Z5%8&WT:WGLI8;*ZNHYVC*7`>4*PZQA!P&Y
MS[4`=M%XKT&717UF/6;)M-1BC7(E&P,/X2?7VZU-#XATFXTZ+4(-3M9+.:18
MHYED!4NQ`5?J20,>]<YJ_AV_&J1:EIUE!-Y&LKJ!MC($\]3;B)FSTW@Y89_N
M]15"?PSK4^G:M>"RMXKR[URVU)+)9AQ'"T0P7^[O81EO3+=:`.JUKQ$-*:Q6
M)$G:?4H;"5=V#&9!G/U`*G'H:1?%.G7.L0Z987UI=7(G,5S''*&:+]V[=![I
MCV^M8=YHVMZH(;B>R@MY?[>MKXQ"X#[8$C122<#+?*>!^!-5O#NAZMID/A^U
MU#2[)(]#\Y9-168.\JF.0;D4#(W$J6!.<^O6@#J]7U2\L&Q;6GGC[.\G"D_,
M'C4#CU#L?^`U-JM]<V*P&WMS-O9PW!.-L3N.GJ5`_&GZ)J$NJZ-:W\UE+9/.
MF_[/-]]!GC/U&#^-7Z`,.7Q1I5DVGVVIZC:V=]>(C);RR!6);'&#R.>.:D7Q
M-HAUEM'75K,Z@./LWG#?GTQZ^W6L8Z=J^G^,-8O(=,@U"TU06^V1YU0P>6`C
M*P(R5QEQMSSD8&<UCQ>&=<^PVFAR:?;&&#7/[1.IF<'?&)O/!V_>\PY\OTP,
MY[4`=<?%F@KJ+6!U>S%V(WD,/FC=M7.XX]MI]^*SK#Q]H^LZ:+W2+RWN56[C
MMI%ED\HIODV`]#R<$J/XN.F:K:1X:N;2&W,]K")H]>NK_>""1'(TN&SZE748
M]/I6?:^'-:7PQ!HSV4:26FMQW:S"=2LL7VPS$@=00IZ'OTH`ZV/Q/HLNKKI4
M>JVCW[ABMLL@WG!(/'J,'CKQ5JWU6RO(H9;>ZBECFD>*)E;(=UW!E'N-K9_W
M37,:1X:N;.&W:XMH/.BUZZO]X()$4C2X8'U*NHQZ<54T/0]=M8++2KBRAAM;
M6\O)6NUN0S.LOG;"B8S_`,M!G)'M0!U6G>(=%U6^N+*PU2UN;FV_UL<4H9E_
M+WI+S4[RWU,6T5H9(=UN/,P>DC.&_P"^0JG_`(%S7$Z+I%[X:L-/NM3TJ\GD
MT2QGACDCO$>,\*/D11N)DVCJ/E/KUKT>SEDGLH)I8&MY)(U9X6()C)&2I(X)
M'2@":BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`I"%88(R/>@]*\JTF>2_P#B9I^H06$]
ME))<7<-]%YD[-M1"J&7=^[`9E#*%'ISP:`/5%1%`"J``,``=*K37<45_;69#
M>9.KNF!QA<9S_P!]"O,_#VF:A#H^DZW:G4#KES:7D4HFD<K(P5O*#(QP,%%`
MZ=?>K7@M+-M6T>:T;5S<M8RG4?MBS%!<XC#%C(.)"<\`X('3I0!Z4<8X[57M
M+N.[,QC25?*E:)O,C9,LO7&1R/<<'L:X3Q<\<'C&QNY&EU%HA`D6F)Y\;QN\
MA'G1NGRMZLK=D'(SSFP6-UJ>OPZ=>B_.GW.O:FMPH>1`T00,@+#!";E&,$"@
M#U5VP,Y/X5E66N6&H:FEG$)ENFLUO`LT#1L(F8KR&`(.5Y!P:X'PY:WD$?@_
M5I&U!M0O99[6_:>61LPA)2@92<+@HF#@=>^:H:)<WVEZ=%J,^FWM[)'X1@62
M+YU=V\Y]PW8R"`<G'.*`/9.*/E`KQFTBO;7PYXEBTQKJ.V-_I_V4VKS%0&:-
M93$9,M_>R?:NU\6:=)HO@%[305GA@@DC,@B>1Y!!YH,N""7)VENASZ4`=CA?
M2C`->0BTN+;3&B\.:A)/?#48FTJWA6;R+9S$QD$C2YW1LN\MSP3@8-),VE`>
M&[/5IM5_LF33+N2ZCD,HE>X26/.\1\Y#L^,?+G&.,4`>OC;SBC(QFO+/#FG:
MCJ6H>'K77UOV6+1FN62:1TS,DX\KS"I&6"-T/XBJWA"&Y&J6=U>ZI+:ZRR7"
M:E%Y=P\DSA3UW9154@,I48(``]*`/7:J-<0Q7T=HL<@DE1I05B;9P0#EL8!.
M1@$Y//H:\EL8X9-"O].6_D3=):27&KE;HQZ@6)+1R(3NC8@$N4(`W#ITJ2[N
M=6GT?3;C1-/O[)_["O5BMT>1V7$\(#*7PVXH'9,_-@C%`'KXQ@4C1QLRLR*6
M7[I(Y'TKQZ\9;>V\0/X0.JC34T-I3N,S*+PLK(5\S)\S:#D#IP#S6WJ7A^#2
M;36K2TU.\L;2[2SD=YVFG1G,CB13@[@'``8@C&<\4`>D87T%&!Z5R7@W6+`:
M3IMC]G:PEG,ZVML[R/YJQ-AG4N-VPY##=@X85E:Z+27QU=)XA74C:QVT#Z2+
M8S!3)N82%?+.#)N,?7G'MF@#T($8R.E&17D-UYKW=U*1JR^,1K7E6^UI0OV7
MS@1@9\ORO(!)/KG/-:>G:5+/J\NLS/J`OK?Q)+!$3(X7[,6(V;/N[/F)SCKW
MH`]'GG@M[=Y[B6.*&-2SR2,%51ZDG@"J\M_;074L,S-$(H/M$DKH5B5,G),A
M^7(P21G('/2O&[W3XM0\/^*=-2"YUFYDL)+P:DOVA#)()&V1O$WR[P,D;>"%
MZ`8SIZMI5IJ-IK-AI%M=SZ4?"S&TA!FPTXFE88W');=C@]1@=*`/6P8W0$;6
M5AP1R"*BB:SAG-I$8$F"^:84(#;2<;MOID8S[5YGI=YI^C:II<UDE^-)?0YH
M8U2&>3?<F5&*@$$[^N,_AQ4=GI-G!X[TW49[2=+VYT"`VLS^;M-T,J0W\((7
M;D-QWZY-`'JQ"CL*R?[=MO\`A(O[%BBN)KE8Q),\<>8[<')7>V>"VTX`ST[5
MP7@&&5=6T^YFU&2/4I+:1=2M9%N&DGF7;DN7)5-K;L8P"#QQ46L:#-;>(?'&
MJZ/9W0U-;2V>VEA=]Q+B3SBG."VWICH<8P:`/61P.:&56QN4'!R,CH:\KLQ!
M'<ZU_P`(O_:7]CC099)!(9BGVMN4V^9SYFW.0/8'FFWUEJ.@^']&U;2([^:[
MU*U-M>H7>5C<7$2[)F5C@;9%&>@`8@#F@#U;`]*,+TQ7D-NVI:=87YO[:]U"
M/PY9MIB1^8X^T>9*%\TE1N^6%4)*YZMCD4RQMKJ'0=4M+)KI+1O$%FD!MGFP
M(6\E93&SDMMYDR>F<D4`>M7EQ%9V-Q=2Y\N"-I'VC)PHR<?E5?4-1@T[1[G5
M+G>+:V@:XD*C)"*NX\=SCM7F>O:?:6FHZYIURFL0K;6*#01:&9QM,;>9MQD,
MQ?(;?SMQVKK_`!9'J,O@OQ#&$@>V?29UB2)6,I8Q'CT/.>GM0!U,,D4\*31D
M%)%#*<=0>13L+Z5XUJH<V^LF8:NGB6(Q)H/DF4#8T:"/8`=F-X??GWS4VLF=
MKG6I&_M5/%J:FL6E^49=H@++LV@'RRFT/N)XR3GK0!ZAI^JVVIR7J6S.6LKE
MK6<%2,.`K8'MAAS[U9LKN.]MA/&LJJ69<2Q-&V58@\,`>HX/<8(X->;:-'=Q
M?$+4SJ,%T=)DUB5K4HI5%NO*CPTG]X%>$/W00V>2,5M&TF;77T;3-6_M`V4L
M.J/.OFR1Y=;P>5N((/`8E1].PH`]9X;@\T?*?3TKQ3Q!;27]K%97UQ<E;;P_
M;N+J>2?-G(2P,Q$0)8D+EM^/NC!ZX[CQ?!;7/A.PAAU-+:R:6':=LKQ7,80D
M1LT9W!2.=V>H'7."`=?Y]O\`:1;F6/[04,@BW#=M!P6QUQD@9J1F55+,0%`R
M2>@%>2:59:7-XS\.:U=Z+>6`N-)(MTD>=]LZRH(U+?[G.&P,'FJVE0+X@UZ>
M4:9/;PZEI=V;VT$MP2LWF)L60O@!^&P%QWZC%`'L4,T5Q#'-#(DL4BAT=&!5
ME/(((Z@T[@^]>':=8VRZ/X9LFCDATEK$K=QSFZ1%U`+&6#[2"/E!QD[<Y`YK
MH;BPGU,^'[6\O;W4;8:'<32W">;!]HF0Q>6S`88'EB`><_2@#U#Y?SHXKR`V
MVMV>DZ3?:4^H-K.K^'KA[QI9)'+7"Q1LAP>$8,S`8`]*?8)]G\.^)+C1]1E)
MDT5YDLXTN&<3X8B0M+D^8>`5'H#B@#UB>:"U@>>XECAAC4L\DC!54#J23T%2
M<>E>2>(O"<2^%_$$-O!?W+76C1W9A>:23==*7RXYSN.>1T.!Q3\:59^(M(FT
MSS]0M4:"&TL/])C>T+NV^5&Z,O=@_0+C(X!`/6,KU_"H;NY2TM9KF02-'"A=
MA&A=B`,G"CDGV'-</X^75;:\M)=-^U2+J=O)I#B%2RPO(08YB.``OS@G/<8K
M#BAU:Y\.>)&N&O//T71;C2;?YF)FD&\F0<`LQ18>1GG..]`'IEQJME!8WET9
M59;2$S3HO+QKMW\KU!(YP<4BZC;MHZZH@DDM6@%PNR-F9D*[AA0,DX[`9KRZ
MSTBPL=5\8,UE<IJ-SI:R6I82L)0UM^\QU4G>",'D'@5830CHO@^_?3_[026[
M\*L\L;2R/F=4X(!.0_S$8&.@XH`]4B821J^U@K#<`P(/X@TDL]O#Y:R2QQM*
M_EQAF`WM@G`]3@$X]J\OETJ?4KO6[NY;45FTXV$M@R2R*$;RXS)M`X;)7#9S
MWZ5K_$S2=.O!X?O-1M99;>VU-5N'C\S]W"R/DD(<@;@G/;VR:`.OL]4M;S4=
M0T^)F-Q8LBS@K@#>@=<'OP:OY&,YKRN]T"&]\0^*=35+V.>UEL)+&6*21/NQ
MH3@=&S]TY!XXXJ.2&ZD\:WDVH:B]GJ4.K1BV<K<,6M69=L<:J?+VLN58X."6
M)H`]8X/X4<5Q?BNP_M;Q5H&GW"W+:=+!>&YCB=T5RHC*!F4COR!D9Q7/>'H-
M3MO^$/U)'OGU/5+&>/47N9)'#,(BZ;U;Y4PX`'`X)'>@#U7`]*/EZ5XWX>GN
M-,MEU9Y;JXU--.G.I::HN3/>3*%SN9\JA5MVW:!D-QP*BMEO++P]XP.DB>.'
MR[&2U^RM.RB0L?,,9D^8D?+G'H.*`/8+RZCLH#-*LK(&5<11-(?F(4<*"<9/
M)[#)/%6<*.U>9:SHIT+2M<L](^W^0UUITT:>;)(5)F02;223@A<GGU[4[3]*
MEN-6DUF9[\7UOXCE@B/FN%^S%B-FS[NP[B<XZ]Z`/2^U&17CW@ZVM[CQ1HNJ
MWES(EW*]YMDGEG+:@V2$.,>4"J!N%8CGCIQJ^*C:MXEU3^W_`.TA#%I\<FD&
MU,P7S1NWE?+.#)N,>,\X]LT`=M-K=O'K\6CI#<S7+Q^;(T464@0[MID;L&*L
M!C/0UG:IXZT/1-0-C??V@LWF"-2FG3R*[%=P565"&..P/8^E<UX0\._\5L-3
MU6TG&JIHEC+-,\C\W3"59<X.TG@9'0=1C-='XQBD>]\*F-'<)K<;N54G:ODR
M\G'0<]?>@#5TO6[+5[FZAMC)OMA$94EB9"!(@=.#ST/(/(.:U,+UP*\OU/05
MO?%'BS4V6]CNK6>QDLY89'495$+8`X;.-IX/''%0/%=/XUO);_46L]1AU>,6
MSE;ABUJS+MCC53Y95EW*QQP2Q.*`/5]H]*,#TI:*`$P*6BB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`.U1+<022-&DJ,Z?>56!*_4=JD;I7D^BZ)=WVNZA<Z;I]M;
MSQ^)9I+C5BX67RD<%H@!\S;AE<-P`Q/I0!ZLTL<8W.ZJOJ3@4[<OK7F-]K&L
M77AC5-7N;JUEMXM56QALGLT9!LOEC\QB<DM@'V'!'(S5Z3Q5J<.N-X?FN(Q?
M1ZJSR2^4.-.">=OQCT_=;L#G..1R`>@9&,?IBC(KR>7Q%K=\-9@MM<N?LESH
M<VIV5R]C'"Z*KC!CP<E64XRW(X(JS%JGB.#3/#&D1:M<3W6HV+7;WRVD4DN%
M6,B,*Q"D_.26.20#QW`!Z?N%,2:*5`\;JZ'HRG(/XUR5]8ZMXD^'1LM4FCTO
M5;F-5D.[Y-X<84[6Z/@`@'HQ`KG4URXT/2Y=)T_1+/1M5_M."RN!8JLT">8A
M998P=JY(7`5L$%AG.1D`]2W"C<*\Z35_%37&FZ!=W2Z?>7MQ<"/49;>,R20Q
M(C#]V&*!V+D?[J$XYXOG7K^TUR[LKC4[>:"VT`7AG"*BM-YCJ7ZG`PHXSB@#
MMMR^M4196-QJ=OJVT27,4+PQ3*Y(V.5+#C@Y*+^5<S:ZEK&I^*!8QWT=O:6N
MGVM],HMU9IS)O#)D_=4[,\<_2N9\!SZUJ'B#2'.M&"Q?0+>Z;3X;:-(1EV4J
MJC[O(SD<]N@%`'K"21R('1U93T93D&G;A_D5X_H_B+Q)?:78V&C;+>6+3C>A
M+2RBVSN9I5"89E"(-@R5&<L#D=^G36==B\560UF4Z;8W/EPV\$4*2Q7$K1;F
M1I,ED<-OQP%(4=>:`.W\V/?LWKNQG;GG'K0)8V+!6!*G#`'H?>N3D*CXMVQ8
M@?\`$AE&3Q_R\1URFMW&L7'BJ6#3M7_LM/\`A)(K1C;VT>9=UFKAI"?OXP1@
MYXQ_=%`'JXDC+,H=2R?>`/(IV5[5YCJ>NZC8^)-6LK6XCMFFO[2U:[@LEDG`
M-J9"VW'[PY7'.=JDXZ4\ZQXAA\,6<%[J]W#K\_VFY41:=$S-;QL0"RG"*,%"
M<_-EL4`>A_9;;[=]L,*?:1'Y0E*_-MSG;GTSS4R21R+N1U92<94Y%>::'?:]
MK7C#P_=OKKPV]YH$=_-9QPKY3$M&&`SSR23NZCH.*B\/:SJ^K&VT>QU*TT<I
M%=7LDT=G&WF8NY8PH0X``"Y8]22#D<Y`/4=RX]*1Y8XT+R.J*.K,<`?C7F-C
MXG\2>)X-.AL+^TTVXN=(EOWE6W$JL\<OE@*&Z*V03U(`X]:U/',\E]\';JZG
M2-IKBS@DD0<*69D)'/09H`[I)8Y$5T=74\AE.0:9/<P6MO)<7$J0PQ*7DDD8
M*J@=22>`*\KMM3NO#-IXLO;;2(-(NK;[)"NE1$201[S@7`(V@@ASD`*/W?)S
MDAGB.+Q3<Z,MKJ5_-%`FJZ>(;F:S@#S[Y@"&C4E<(VTC^]G!XH`]8@N(+F".
MX@E26&50Z2(<JZD9!!'48I^Y:\PU#Q%K]CI?B#4[;6+2.+PW(+8V4EHG^EE8
MT)9R""F\L=H7`&!UK1OM>UM&\77\5]'':Z`DGE6HMU)F;[,LH+,>0`6XQUYS
MF@#O]P-!P!D]J\SFU?Q6#J\*ZW:K)9:9'JPE^P*<[]Y\@#/W!Y9^;[WS=>*Z
MK4_$,D7@4ZW%"1<3VB26\(^8^;(`$7CD_,P''Y4`=`LB/DJP."02/4=:=N'^
M17D=AJS^!=,UW3+5I/D6VNK-[^-UYF=(9G(;:2JR'><8'S]>>-+Q';>)+:70
M;5?&;F675UA:2*SB5L-$[`.HX(&TX&,'=DYP#0!Z5D?E[5!>7UII]K)=7MS#
M;6\8R\LSA$4>Y/`KF_$>H:C'JNAZ%8ZA'93ZB)F>]>)9&'E*IVJAXW,6]\`'
MCN.+U6YUCQ-::'%+J\4;VWB233FEAM4=)RB2;9BK9&0`05Y&3GL*`/75DC*;
MU8%2-P8=,>N:'EBC3>[JJ\?,QP.>E<;\3;*.7X9ZOYTLF;>T:10CF,.ZKQD`
M\C/..F0*7Q3HLNIZGI5S+IUKJVE6]O.)K.>9442$)LEPPP<`,.>F[(Z4`=BT
ML<94.ZKN;:NXXR?0>],DN[:!@DL\4;'HKN`3^=>*P:7/=>!X]9U#35U'3X]"
M9+9[F[`ELW5Y3O4L.I4IAQS\@QP:V=8T>Y2"P\7W6GZ3JMM8:##]J@U0,9U*
M9E9DRI`<@XYQS0!ZO3&=`VPLNX@D*3R<?Y%16]S]HMXID4@2('VGJ,C.#[UY
MAJ6H[?%__"7'[4(K+45T[?Y;^1]CYCE;=C;_`*YL]>D?KQ0!WFH>&M,U.[DN
MKF*?S)8?(E\NXDC$L><[7"D!AR>OJ16O$L<421QHJ(BA555P`!T`'I7$"]UO
M7M6UK[%X@ATFWTV\^Q+#]D25G.Q#O)8]27^4#CCO65X:U76[+P;X+GN=8>^?
M5KV&.1YHEW+$T,C%-W4G*`[CS0!Z?N'^149GA\X0&1/-*EA&3\Q`."<>F2.:
MXK4?$%Q/!]CL]6E@OI[^XCMC:6B3L\<7WA\WR@#(R2<]JH^'-3N-<\0^#-4O
M=AN;KP_<RR%%P-Q>WS@4`>CY%&X5Y]K'B+6K34?%5S;W"?8_#\*RI:"`,URS
MP!QN;J`K<\<GG)Q3K.^\;)8ZF8XUU!FLUGL9[B**`&8GE%".05VX(+'D\$T`
M=]N6FM<0I*D32HLDF2B$X+8ZX'?%<'I_B.^\_0;3^U9+N675IK*_^T6B0R)M
MMWD\LA>,@A3E>H-9_B*[N=3U#0)K:^$4WVC54@NHE5]@2.100.AX7%`'I^11
MN%>7VE[XIM/A]X>O!JT\\$UHMU?:@MM%+-;1^4K*-C']XN=VYN6Z<5T_B/7+
MFU\,6%_I=Q$\EY<VL,<SQ95EF=5W[?HV['X4`=3E11N%>9_V]XEL[:\O9M5@
MN(='U>/3IHOL:HUZKM$I9F!PA'FC&T8^7GKQ,/$>JW?C*TM]/U:673-1>[MX
MC+9(D<3Q1GF-_O-M=2#N&#S[4`>C`@\"FRS101M)*ZQQH-S,QP`/4FN)\+>)
MM3U_6+2V=XT^PV!_M9$4'_2RYCV#KM`\N1L`YPRYZU1\0ZKJVI/XHC@U*RM;
M+2-ML]I-&#]H#Q*Y8OG*GY\*`.2ISG/`!WUQ?V=G!-/<W4,,-N-TTDCA5C'J
MQ/3\:;'JFGRW4=K%?6SW$D/GI$LJEVC/\8&<E??I7E/C`7VI>*;NS@O(K../
M7=-BREI&S2%X@0SDCY]IS@'Z=J;!)K/AB\\6:B-46]GCU&VL=TEC$H4R)`!*
M<8P%5L;<A3C)ZT`>P[EZYI01VKSF76/%NFV*6UU)MDGU2WL[6]N;>,.Z2J0S
M-&C;<JW3D9P,UN^)+W4]"\,V+07B37[W5M:-<RPC#&218RY08'\6<#'2@#J<
MJ![49!KS,Z_XEL[6\O9M5@N(-'U>/3IXOLBHUZKM$"S-G",/.&-HQ\O.<\6=
M0\2ZA_PE]FFFZG+)ITNI_P!ESPO9((HY/+<MMD/SLX*CMM[4`>A[@:-PZUY/
MIVK^(M(\*WEW+K4NHSW&MOIT3S6Z?Z-_I+H9,9&<C&%)"@D`<<'5FU7Q9:65
MG97$WE7%WJRV,-[<6\8=HFA9RYC0E0RL"!T!P"1UH`]!$D;,RAU++]X`\C/K
M4<US;PLBRS1QLP+*&8`D#DX^@ZUY])JUY9ZQKNF?V@8M0:XLK:WN;;3XWGN9
M/LX=\CA2<!CECA1D#M68FJ7FM0>#[W4)!)=%M6B>3RPA;9'*@)4<`X49QQG-
M`'>Z;X;T:SFM[JTC9EBW/;![AY8XM_4QJ20N0>".Q('!K6N[ZST^TDNKRYAM
MK>,9>69PB*.G)/`KRZQ\2ZEX=\':1!&T;"]\/VG]DHRC/VK"1LGJ1^\C;O@!
MNW%:_C_3M1NO^$3MTU8Q$ZFD,A-K&XDD\J0B0J>.-I^7I\WL*`._61&565@5
M894@\$>M.W"O-[[Q+K=E9^(=3%_;K;Z7?#388&MEV%G,0$SMG.%\W[HP,+UY
MXCU7Q/KWADZU83:E;ZI/9V$%]%<-;K$REYO+*.JG!&!D'@\_C0!Z9N6C</SK
MS&_USQ1ID/B-FUF"?_A'#%.Y-DJM>*R"1HS@X08.`0,]SGOM?$)M371M-DTW
M5IM.=M2M(G:)%8L'F1<<]AG..AZ'@T`=BEQ#(\B)*C/&0'53DJ2,C/IP0?QI
M^X>M>6$:]8^*/%%Y9:Q$#9R:?]I22U4_:_W2!R3_``?+G`7N>N*OZ[XBUI9O
M%-[8:K:V=OX<`_T26W5_M1\D2_.Q(*@[MJ[<<@]>E`'HFX?Y%&0:X"3Q'K-G
MKDEQJ#RPV<D+MIUE%;JZ7FV#S,&09=),A_E(`PHQFIO!FJ>)=1N;2ZU!C<Z=
M?6?V@RF".)()#M*I'M=F=2&;EN1M'/.*`.ZHHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M1ONU7L[.ULUF^RP1P^=*TTFQ<;W;[S'U)]:L'I7#Q>+Y+2VNC#9W-Y<2Z[/I
MD$4MRO+@,5PVT;4^4\<D#UZ4`=2VBZ:;.2T:Q@-M)-Y[P[!M:3?OWD>N_P";
M/K2G3;%]2747M8C>B$P"<J-_EDY*9],\XKFQXSOY;:RMH]"W:W=3W$/V%[H*
MB>2<.YEV_=Y7'RY.X<=2*'_"5_8(M*O=02_@CDGU.6:)I!F)8A(Y5UP=V`N`
M`1C@\CB@#J['PSHNFES9:7:6Y>,Q-Y<8&4)R4_W?;I48\)Z$+*&R72;1;:"3
MS8HU3`C?&-R^AQQQ5*W\1:T^CW6H7FA6]D%B66V$VHH%D#=I&VXC(&"?O#T)
MKGI_B#KMW9:3/I.C63R3ZO)IMRCWN4+JK$"-PO(;&=V.-N,'.0`=N="TPZ-_
M8YT^V.FE-GV5D!CQG.,?7FH5\-:*NG3Z:-+M?L<[^9-"8P5D?@[F]3D#GKP*
MYZ+XB++KL=G]AC^R/>_V<9ENU,PG!*D^3C/EA@1N)'3.,4-XIO=6N[%[;2YX
M]*DU,6\5\LXR[([*VZ/JJ$J0"2<GJ!D4`;S>%="^Q_96TNU,'G_:=I3.)<8W
MYZ[L#&:=/X6T*Z^S>?H]A(+:/R8`T"D)'_=`QT]JQ?%>IZO8>,/#D6DVYNWN
M(;P/:-<"&.3:(R&9B#TYQ@$\_6H[;XB6\EE+=W5C);0IILE\#Y@8L\3F.:$<
M<LKA1D9!W"@#K(M-M8;EKF.WB29XEA:15P3&N=JY]!D\>]5$\-:/%+8RQZ9:
M))8IY=JZQ`&%/[JGL/:J6L^)I=$\,6VJW-CBYG,,?V?S<)%))@?/(1\J`GEL
M?A2V7B2>?5=*TVXLHXIKZRFNV:&X$J)Y;(N`P`W`^8#GCI0!8F\)Z#/;P02:
M19F*W1HX5\O&Q6Y91CL>X[TL7AG18K^.^BTNU6ZCQLE$8RN%"`CT.T!<^@K*
M/B_4+JXMK72-$%[=-9Q7MRCW0B6*.0D*`2#N8[6P.!QR1Q63X?\`$^LPZO?6
MUQITEUILFO7%DMZUR"T.22J^7C[@/&<]3P*`.JU?PQH6NSQ2ZMI-I?2Q`K&\
M\08J.N!4ESX=T>_BN(KK3;699Y5FF#Q@[Y%`57/N``,^U<MXPNM8E\;>'=)M
M[<OITPEGE,=^UNTC1[>NU<X0-G;G#9P<8JWI_CBXNYM,N)=&>#1]6F$-A>"X
M5G<E692\>`5#!21@GMD"@"_K'A"VU&6VGMEM;:>*X6=_,MA+'/MC,8#KD9PI
MP#GBF:=X$T>TTZ.UO+6"^99I9PTD0"QF0Y98U_@3MMZ>N:I:;X[FOETR[FTA
MK;3-2N!;6]T;@,WF8?[R8X!9-HYR<C@4NB?$"/7HM+-K82>;?74L+(S8$,2*
M7$IXSAE,9`('W^O'(!T#^']+DDLI6TZU\RQ`6U;RQF$<<+Z#@<>U0W'A/0;N
MWBMY](LWAA,AC0Q#Y?,)+X]F).?7-8EOX\E.JZK8W5A;*;*QEOD>VOUGWI&V
MTJ^%&QNG'/?TI8_&FJ7`L8[;P\)+S4(VN;2!KU5S:J$)D=MN%8[P`@SR>N,D
M`'2)I=A%/'/'9P)+%!]FC94`*Q<?(/1<@<>U/GTRSN].^P3VL,MF55?(9<IA
M<8&/08%9/AO5X)M(M&O;CR+JYDF*074@67_6N-N,\D=.,]*YOPUXLU9M*M=.
MLK%M7U,M=3RF>Z$*QP+=21H-Q!R?EP!CHO)'&0#MY]&T^ZGN)Y[*"66Y@^S3
M,Z9\R+).QO4<GCW-5;?PQH=HC)#I=JB,\3L-F<M&<QGG^Z>GI6';^/+C5TMO
M[!T.2\D>T6\G2>Y6`PH6=`N<$,Y:-_;CJ,BLN/QRUUXLL9K!+FX75M$AFL=.
M=MFZ0ROEF/(7:H^8\\#C)P*`.SN/#>C7VH#4+K2[26[!0^;)$"Q*<J3ZD=L]
M*L/I%C)'>QO9P,E_G[6"G$^5"'=Z_*`/H*Y:Z\7-I6M:O`+2YNIUO+2SCA-P
MH0R2Q979E1M&<`Y)ZD^U.D\<:A'9VZ2:"(=6FOI+(6\UV$@5D7?GSMO1EY7Y
M<F@#ISI%@6F8V<!:>`6TOR??B&<(?4#<W'N:<^E64EO:V[6D+0VC(T$97*QE
M>%(';';TK"TOQ@UYX#;Q1=:=)"JPR3?98'\YRJ$C@X&2<5C:AXU\2BST*YT_
M1]+E&H7_`-G.S4Q(C#8S*%<(,$[3DD'&W&#G@`[2\T;3]1D$M[8V]Q((GAW2
MQACL?[R\]C@9%5#X4T(Z<VGG2;,VAD$IB,8(+J`%;UR```?05F:KXQN-(\0Z
M=ILUC:/#>316Y=+]?.1Y,@'RMN2H(QG(^E8EE\0=9@L=0N-9TFRC9=4?3K01
MW@"M+D_([,H"JH!)?OCA<X!`.WOM$T_4K>&WO;*">*%@\:NN?+8#`*^A'J*(
MM"TR"TL[6+3[6.WLG$EM$D8"PN`1N4=CAFY]S7-Q^/S)HBWBZ;YEY_:(TPV\
M-PKHTS`%=DN`&0[E^;`QD^G+;;QY=R20M<:&8+4:A_9EW.+I6$-R6"`*N,NF
MXJ-W!YZ=:`.DU;0-+UZWC@U?3[>^AC?>J3IN"MC&0#[$U6/A#0#:VUM_9%H+
M>V1XX8O+^5$<Y90/0GDCO6'I7Q$CU76+>VCLHQ9WDLL-K,MVK2LR!B2\0&8T
M(1L$DGID#-1VOCO5=1L5NK7P\$AN]/>\T^66[&)=FW*N`OR?>R.3D#G'8`Z6
MX\,:+=SK-<:7:2.J)&NZ,8VJ<JN.A`)X':G7OAO1]1O%O+W3+6XN5"@221@G
M"G*Y]<'D9KDK7Q[JT?AKP_<WVDV@U+5T#0@WOE6[+Y:ON:0J=C-NX3GH>>*Z
M[5-2N-/T:2]C@MVF4+B.XNEACR<=9""!^7-`%J.PMX;BXN8H(TGN2IFD48,A
M4;1GZ#BH?[%T[^R3I1L;?^SV0H;;8/+*GD@CW))KD1\1Y)=*TZ:'3(/MM[=7
M%JJ2WH2W5H6*M^_VD'=CY>/FY]*ZK5=2N-/T5[R.&W:=57$=Q="&/)QUD(('
MY<T`(WAW2&U&/4#IMJ;R,*%F\L;AM!"_7&3CT[5#_P`(CH'V%[$:/9"T>;SV
MA$0V^8.C`=C]*3PMX@/B311?FW6W<3RP.B2B50T;E"5<`;@2,@XK!;XA3)I8
MU)M(5+:>Y^Q6;27BKYTX9U;=D81!L8[B<G'3ID`Z*;PMH<]O#;OI-D8879XD
M$(4(S##$8Z9'7UJS%I-A:O;R064$3VT30PE$`\M&()5?0$J./85R!^)#O:6R
MPZ9"=0ENY+1EDO0EJ'C57.)]I!R'7;P,G<.U;3>*66ZUVW:RPVDVD-P3YH(D
M,BN=O3C&SKSG-`&NFGV<<]U,EM$)+O'VAMHS-@;1N]>.*SX?!_A^W@F@BT>T
M6*:(0NFS@Q@Y"X]`><5Q6L>*/$.D>+M5@TR"&]B?5+&V$5S.46,20J2J\'&X
M]^V,X.:[;6M?FT;3;.0V7GW]Y,EM!:I*`#,P)P7(X4!6)..@X&>*`'/X6T)K
M`6#:19M:"8S^68ACS#U?UW'/6K,6BZ;']G\JPM4%J7:`+$`(B^0^T=LY.?K7
MGOBGQ9KE]:1Z3!I36E\NIV]E?QIJ&S*R`,JQRJN<.,@L`"N.G-=G-J[:+<Z%
M8W-L4BOLVYG:??Y,JQ[@I)&6R%8;NO&:`'-X,\.-:+:G1;+[.A8K%Y?RC<`&
MX]"%`(Z<5I3Z?:7%O%;SVT,D43H\:%!M5D(*D#M@@$>F*Y2[\>7,/A.#7[?3
M;4PS>;(D=W?K;LT*YVLN5.YF`SM'KUJ['XKGOM6T_3[#2C.UU907\CRSB,0P
M2,0<\'<PQ]T=>>1W`-EM&TV6*>%K&W:.YG%Q,I08DE!4ASZD%%Y]A45MX;T>
MTU`W]OIEK%=%V?S4C`8,WWB/0G/..M<GH?C*^O--LH=(TB?4KG[-]KN?M=\J
M,D9DD1?GV_.Y\ML#`&!R1WU=-\<0ZK*OV6TD$+Z,NJHTC`,0S,NPCL?EZY[T
M`:FAZ!%HLVIW`D$USJ-VUU/+LVYSPJX]%4`>YR>]/OO#NBZA??;+S2K2XNM@
M3S98@QV\X!]<9./3-9-OXQFO/$T6CV]A%Q#%+/)-="-P)%W`Q(5_>@="01@Y
MJQJ>K_8_%=G;$3MNTVZN=JR@1GRVC^\N,D_-P<\<\'/`!IR:)ILUR]S)86[3
MO-'.TA3DR1C"-GU4=#VI9-%TZ:*]BELH)([XYNE9`1/\H7YAWX`'X5R=KX^U
M741$ECX8:6XNK(:A91O>H@DM^`2YQ\C9887G.>2.<2R^/Y[F.W;0]&;46ETU
M-4*R7`AVPL6!&2#E\KP.AYY'<`W[?PQHMJ,0Z9;+^^2?[N3YB<(V3W';TJ_=
M6-O>QI'=01S(DBRJ'&0'4@JWU!`(KD'^($US!)=Z-HLE_96MG%>W<CW"PO&D
MD?F*JJ0=S;.2,@<@9SG#KGQKJ-T]U%X?T9+TP6D5V\MS="!525"R<;22>&R/
M;KS0!TSZ+ITD-Q"]C;M%<S"XF0H,22@J0Y]2"B\_[(J$>&]'74FU$:9:"\:3
MS3-Y8W;\`;O][``SUKGM.\6ZW)X%TW6KS3M,6\NTC94DU$01.C(&W[F4[2>?
MDYQZT+X[N[ZQT=](T1KN\U6P:^B@>Y$81%*[@S8/]\8P.3Z=:`-]O"^B,M\K
M:59LM_\`\?:F(8G.<Y8=SGG/K2P>'='M=OD:;`NV<7(.W)$H7:'R?X@O&?2N
M<L_%^NZAXOTNRM](MUTR]TQ;YC+<8FC!9`Q(VXRI;;M[]<CI45U=:S=_%N&P
M:V/]F6=DMRFR_:,?,S*9&0+\_(V["<#&>^*`.IN_#FD7[R276FVTLDLB2N[I
M\Q=!M5L]<@<`^E/C\/Z5#':Q1:=:I':[_(58P!%O!#[1VR"<_6N87XAK:WVK
M6^I65O#%864E\)+2]6Y+(C[2K`*-CY(XY[\\5!K'BWQG92Z2J>%[.'[9?+`!
M+J(;>&1V"<+\C?+R>0,`#.>`#H[SPM9W=WH3`)%9Z,YE@M5C&W>$V1D'L%!.
M!ZX]*UKJRMKQK=KB".5K>430EQG8X!`8>AP2/QKDM1\=W-C_`&G<QZ(]QI>D
M/Y>H7*W*JZ.%5F$<9'SA0PR25SVS3[_QQ/93:RZ:-+-8Z-E;J=91N+&-70(F
M"3PXW$D;1SSS0!TATBP,%Y`;*W,5ZS/=1E`5F9@%)8=\@`?A5.+POH=K97%E
M%I5HMO<[3-'Y8(EVXV[O7&!CTQ4N@:I<ZMIB75U!:PN[$!;6[%Q&R]B'`&?I
MBLGQ'XA71-<1I%N'CATB\OG190(V$1C)!7;DM@\'/'/!SP`;<VBZ=<K>K-8V
M\BWX"W89,^>`-H#>O'%/O].M-2LVL[ZUBN+9\;HI5W*<'(_(X-<Q_P`)S=6M
MIJ%QJFA2VBP0PSVJI.LAN%E<HB]`%?=M!&2!N'-1ZIJNNF;PX;ZR_LN:36D@
MDC@NA,DT1AE/)P.,CH1U`H`Z:'0]-MXYHXK"W1)E19%"_?"`*@/K@``?2HKW
MPYHVHWZWE[I=K<7*A1YLD8)(4Y7/K@\C/2LS3O&D5YH.FZO/;&W@NTGDD&_?
MY2Q!B3P.>%K/MO$FI:G?65Q=:3<:?;2V%Q=P%;E7$J;4*[L?=D&<XY`SU/(H
M`Z2+P]I$>J'5(].MEORS/]HV?-N8`,1Z$@`$^@HT_P`-:-I5V+FPTVVMI55E
M5HDQM#'+`#H`2`3CO7)0^.[V'1[4V&B7&I-#I%MJ5RTMVH<0R*3UV_/)\C<8
M`/)XX%6M:\?7>G:M+9V6CQ74<-S;VLKS7HA??,5V%4VDLGSCYLCD-Z4`=S15
M>UGFF:X$MJ\`CE*1EV4^:N`=XP>!DD8//'TJQ0`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`A
M&17.IX-L8WC<3W&4U9]7&2/]:P8%>GW?F/'7WKHF.%)]*X6X^)^C3^']7U+1
MIENI=,8"6*4%`R[PI;/]WDX/Z4`;-[X0MKJX@NX;Z\M+VWN)9XKB!EW+YH`=
M,,"I4X'!'85%+X%TRXM[2"ZFN[F*W^U9$TN3*+A660.<9Z.<8Q5ZU\6^'[W3
M+K4K?5[1[.T;;/-Y@"QGC&<^N1CUSQ5S2M8T[6[%;W3+N*ZMV)4/&>XZ@^A^
MM`&!)X&CN-,@LKK6M2N1;/!);/*R$Q&)B5.-N&)S@E@<@"G'P+:?V>ENFHWR
M7":D=46[4IO$Y!#'&W;M(9N,=ZW8=7T^Y17ANXW5KA[8$'K*I(9/J"K?E52U
M\5:#>ZN-*MM5M9;\H7$"O\Q`Z_B/3K0!6L_"QTZ]DELM7O8+>6Y^U26H$91G
M/+X)7(5SR0#U)QC-0VG@FULKI&AU+419Q7AO8;'S5\J.1B2W;<5))."2`22*
MM1^-/#4K7HCUNR;["NZX;S1M09QG/0\D#CN0.]30^)]$N=(&JPZI;&Q+;//+
MX4-Z'/0_6@"/6_#BZQ?6-\FH7=C=V2R+#+;[,XDV[@0RD'[HKGM5\!0SV?AK
M1[)9?L-A>&>ZGEFR\D?+NK`_?\R0@GMUK1TSXA^&=9UW^Q[#4A-=-&'0A"%?
M.XD`^H"DGIU%65\9:)=V&J3Z9J5E<S:="TLJM*45<`\L<$A>#\P!H`U=0LIK
MR`1P7\]FX<,9(50E@/X2&!&#7/VW@"SL;?3([+4M0MI+"*:%9HV3=(DSAY`?
MEP,L`1M`QVK1E\6Z%9W%M:7NJVD-W<,JI$9.K,%('T.Y<$XSFLMOB)H<S:O;
MV%[`]YIC8E2Y<Q1GE`3OVG@%]O3J,>]`%G_A"K>&6WFL=4U&SFCL4L)9(I%+
M3Q+]W=N4X<9;##!^8U;M?#%I9QS)'-,1+J+:DVXC_6$Y(Z?=_7WJ:?Q-HMIK
M$.CW&J6T>HRX"6[/\W/0'TSVSU[4^T\0Z1?:M<Z7:ZA!-?6PS-"C9*^OMQGG
MTH`2[T2"\UG3]4D=_/L8YHXU&-I$H4-G_OD8K(T_P)9:?+IRC4+^:QTR5I;&
MRED!CA8Y`Y`W-M!8*"3@$]:TQKUM%?:G%=W%I##8O$C/Y_*[U!&\$`)UXY.1
MSQ65J?CW2H?#ZZSIEY:WEFE]#:W$GF;5B#NJL3Z8#;N:`)I?`VG2^"O^$6:>
MZ%HH^2=7`F1M^\,&QP0?;I4MIX,TNSUFYU*$.'GM1:F/C:JA54D'&[<51`22
M?NBIXO%_AZ71'UE-7M3IZ.8VGWX`<?P\\[O;K3I/%OA^'2HM4DU:U6RF4M',
M7X;!`('?()''6@#)T_X?6-A`8?M]Y,HTU]+CW[!Y<#8)QM49;@?,<^]7+CPA
M;R+I+6U_>6=UI<!MH;F!EW-$5"LK!@5(.U3TX(!%7%\4:&^LKHZZI;'467<+
M</\`-TSCZXYQUQ3(?%OA^YU(Z;#J]K)>",R^2KY;:!D_B!SCK0!;TK2HM(TZ
M*RBDEE6(L1).VYSEBQR>YR>M<_%\/[6S,4NG:KJ-E=)'/"9XG0L\<LC2%2&4
MCY6=BIQD>]7O#?C'1?%BW!TB\,QMY"DBE2",,0&^AVDCV]*='XMTN'14U'4[
M^RMHV>50R3%T.R0H<$@$GID8X.1SC-`%%/`-G9I"-(U+4-,9++["[P2*QECR
M6!;>#\X+.0PP?F-)+\.M%8VQB:X@^R6D-K:F-QF#RG+I(I()W`L<YR".".:U
MKSQ-I-GX:;Q"UXDFEK%YWGQ?,&7MCW)X^M<\?B=H2W6F3M>P1Z3?6LTWVF4E
M2DB-&-FW')Q(<XZ;:`-6X\&6-SJ<NH27-SYTM[;7K8*@>9`NU1C'0CK_`$K.
M\2^&9[F^L+BV@DNH5O9+FXB65%;+1!`5W_*0,=#SSQ6Y?^+/#^F16DM[J]I"
MEX`UNS2#]XIZ,,?P\CGI4^MZDFE:)/J`:WVQA2&GF\N/D@<L`<=?0T`4=$TW
M5AX5%EJ5^\5Z0ZK-`$\R!"3L&0NPLJX!.W!(Z52;P%:-%*W]I7JWTFHKJ1O$
M$883!/+&%V[<;<C&.^>M:C^*M!AU:'29-5MEOYG,:6Y?#%AV^O!QZ]JR;_XA
M:+HS*NK7D,)EOI;.+R&,H&SJS\#:1P".<$CK0!(?`=D=4:\-]>;7OX]1>'Y-
MK3HH4,3MW8X^[G&>F*)?`=I(UX4U*^B$][_:,00I_HUSD$NA*YYY!!R,,1WJ
MR_B[3+.VO;O4K^SM[:WN_LJR+*7R=BL-PVC:V&^[S@8.>>(9/'WAR/6K#23J
M2-<7\*S6[*"4<,5"_,.[;N/H>E`%J;PS]L@MH[_4[NZ:VOX[Z-V6-<,GW4PJ
M@;?UYZU&?!UC]DFMA/<;9M5&JL<C/FB19-O3[N5'OCO2-XQTFQL6N]7U&QM$
M^U36R;9R^XQN5/8'<,?,,84\9/6KUYXET2PT^._N=4M4M)5WQS>8"L@XY4CK
MU'2@"GIGA;^QY=EEJMXE@)Y)ELBL91=^<H#MW!`6)`SP?;BI+#PI9:?IFFZ>
MDL[PV%J]K'O899&`!W$#KQVQ6G::E97VG1ZA:W44UG)'YJ3(V5*^N:S]/\7>
M']5L[B[LM6MI8+9E29PV!&6X7=GIGUH`SAX)*^&X]!77M1%BD#6VTI"Q:$J%
M"'*?P@<'KR<YXJ[J7A2SU#2],L1--;KI<L4UHZ%6*M&I5<A@0PP3U'OUJ6T\
M6^'[[3+K4K?5[1[.T;;/-Y@"QGC&<^N1CUSQ1HNO0:[-=R6,T,]G&8_*EB;.
M_<N3GT(/&*`,YO!$?]ARZ1#J]_%;7!N&N<")C.9CER<H0#DDC&,9^E6]2\*6
MFH:9IEBLTUNNF3136LB89E:-2JYW`AA@D'(]^M68/$VB7.KS:5!JEM)?P`F2
M!7RRXZCZCN.HIEGXLT#4+V>SL]6M9[B"+SI(T?)5.,M[@9&<=.]`$NAZ'#H.
MGFT@FFF#323O),069Y&+,3@`<DGH*SCX*L1X?@TE+JZC^SW;7EO<J5\V*4R-
M)D<8_C9<$="15B3QIX:BM+BZ?6K006\@BDDW\;R,A1_>..<#/0^E12>*8)=6
MT"#3Y(+NSU9IU%Q')D+Y<>_C'!Z$$=J`$OO"USJ.FS6-QXAU`Q3B1)0(H,,C
MJ%V@;,#&"0>N6/7C%:;P#9/)-Y&HZC:0SVL-I/#!*H$B1`A,DJ6'#'.",]Z-
M(\>:7<>'-/U+5[NUT^6['$32?[;)D9[94_2M>T\3:'?37L5KJMI*]DN^YVRC
M$2\G<3TQP>>@Q0!FZCX)LM1N[V[-W=PW-S=6]X)(F7]U+`H5"H((QCJ#GK5[
M5_#L6LZ=:VT]W<QSVDJ3P7<3!9$E3(W]-IR"001@@GBG6'BG0M3L9[VRU2VF
MMK=MLTBOPGU]O?I67?\`Q&\+66CW6J#58KBWM9E@E%O\[!VZ#'O@G/3@T`.3
MP-9;S//>WEQ=OJ,6HRW$C+ND>/[B8`P$`XP`/K6GXC\/VOB;1I--NI)H59E=
M)H&VR1,#D,I['M]":L6^L:=<Z0NJQWL1L&0R?:&;:@4=22<8''>N;UGXD^'[
M#PM=ZU8ZA;7H@81K&CX)D;[H/&0."<XZ`XH`LZAX%L+TVQBN)[/R-/;3,0!,
M-;MC*X93M/'!7!J_I_AJTTW4H;Z&64R0Z?%IRJQ!7RT8D'I][FL35?'46B>!
M+;7;NYLIY[DK'"8-ZPR.S8R,C=M`RQ[X4X[5M:1XAL[S3/.GU"SDFAMH[BZ:
MW+>6BN"58;N0IVG&>>*`,JW^'UM80Q+INL:E8RK:-9R30NA:6,NSC(*D!E+M
MA@`1DT^3X?Z<OD)8WM_I\46GC362VE`WP`D@98$@@D\@@\U/:^//#UUK>IZ4
ME^%NM-#&X#J0N%&7(/<+T/TK9_MC3_(6?[7%Y3V_VI6SP8N/G^G(_.@#)NO"
M,=[>V$MQJ5X]O83Q7%O:XC"*\:[5YV[L'J1GD^W%7+WP_;7VK0ZC++*)HK2:
MT`4C:4E*ECTZ_(,?C5>;QOX9@LC>2ZU:+;B9H`^_(9UQN"_WL9'(R.:UIM1L
M;>P:_FNX$LU3S#.T@"!?7=TQ0!DZ9X2L]*N=/G@GN&:QTP:7&'8$&(%3N/'W
MOD'MUXKG(_A_/!JL5I::E>VFE0Z)'IPGAD3S7(D<E3E3CY6'S`#FMIO&=C=W
M&B?V1-!>VNHWDEJ\J,1Y96%Y.GK\@X/8YIZ^-M#MM&LK[5M3L+1KJ%)0$G+H
M0V<%3@$K\IYP.G:@"K/\/M/*SPV%_?Z=:W-I%9W,%M(-LL<:A5Y8$JVP;"00
M2/?FM6R\,6%A=W\UOYBI>6T-JT6[Y4CB5E4+WZ,>I/05(-<MX]1O()[FSCMK
M6UCN6E:?YE5BWS,",*OR\-GGGICFF?'?A==+_M,ZU;?8_-\GS<G[^,XQC/3F
M@"E%X!@AMM)C36+_`,W25>*SF81,T<3($V8*8.`HP<9SWJ_IGA"QTF?29;:6
M?_B5V4EE`KL""CE#EN.2-@_6G1^(EN?%-OI=L(IK:XTTW\=PCYW`2*HQV((8
M'-0VWCC0+CQ)>Z"M]B_LUS(C*0#@,6`/?:%.?ZT`/C\)00:CIM];7MU#-8VO
MV3Y2I$T6Y6VN"#W4<C!JW)H%M+KD^JO)*9IK$6+H#A?+#,V1WSECSFJZ^*M-
MO+ZUM].O;.Y$ER;>4B8@JWEL^%P"&.%Z9&!GGC%5;OQSI$FAZY>:-?6U]<Z5
M:R7$D"N1]U6(S[$J1D4`5K+X<:5;6K6L]S=W=O\`V<VEK'(54+;D@X^11EL@
M?,>:L3>#&NK2VCN=?U6:>TFBFMKEFCW1M&K*#C;M8D.VXD$GCT%:%KXHTBXU
M"WTPWT"ZE-"LWV7=E@"N['UQVZXK6FFBMX9)IY$BBC4N[NP"JHY))/0"@#E;
MSP%:7C7\;:GJ"6>I.DE]:1NH2=E`!.=NY=X"A@I&<=JTT\.I`VL26E]=6T^I
MS+,\L>TF)E1$&S((QA!U!ZFDL_%_A[4(%GM-6MI8VN%M@RM_RU;[J_CV[&G7
M/BO0;.VEN+G5;:*&*5X79FX#H0&7W()`P*`*&F^&;G1[Z+[!J+_9YKV:^U%I
M57?<.R!50!0`J]#QS\HZY)JWKGA:SUZX>:YFG1GT^XT\B,C_`%<VW<>1]X;!
MBG77B_P[9:9:ZG<:Q:)9W0S;R^9D2^NT#DX[^G>I=3\3Z'H]O;SZAJMK!%<\
MPLT@/F#U&.HY'/3D4`5]1\)V&J6,MG=23^7):QVVZ-]K+Y;;T<$=&#8/IQTI
MI\+";[$][JE]>2V=ZEY')*4'S+&4"X50`N&).!DGFH-'\?>'-;DU%;/4E;^S
M]QG9@0NQ0"7![K\V,^QJ*\^)'A6TTN+4CJT<MI+<K:AX@6Q(2,Y'4`!@Q]NF
M:`%T_P`!6%A'%`U]?W-G"DT<-I-(OE(DN=R\`$_>(!))`J33O!<.GB%6U74K
MJ.WMI+2W2XD4B*)@!CA1D@*`&.3BK2^*-/6:XEFO;./3XK.&[%PT^&V2%@"R
MD#`.!@Y)))&!CF6V\5Z!>:8=2@U>T>S5]CR^8`$;T;/W3]:`*5CX+L=/@DBB
MN+AEDTJ'2CN*\11!@K=/O?.<]NG%<_?^&M=7Q%J=WIJ^5<3W,$EM>EXFCCC5
M$5@Z,I?.%;A>NX=.374IXR\.2:(VLKK%J=/63RC-NX#_`-W'7/MCWK6MKB"]
MM8KJWD66&5`\<B]&4]#0`RTMW@:X9[F:<2RF11)MQ$,`;%P!\HQGG)Y/-6:,
M`44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`(QPIKSF]\,ZY/X>\5Z*MI;L+^_>[M9OM`PX>
M1&VLN,J0`<]OSKT8XQS1D?Y%`'#^*/"UYJ$E]=:<D2S_`&BSNHT$@C\]H2V5
M9L';\N,$@\@5K^&M.>P;4IIK*>WFNKE97>>[$[S8C50QQPN`NW'MGO5NQUVW
MO]9O=/MX+A_L9V376P"$2?*3'G.2P#`],8/6M;CKC]*`.%T?1==LKN.TELK4
M646LW-^;D7.6>.0RLH5,<$%P#D_3-/T;PI=6NB:;;W$<$=W;WE[*TJD,56;S
M\$'N<.F?I[5V_'I^E)D9Z?I0!YJ_ASQ'-X.TO1CIUK%/HOD/%)'>!1>-$XP`
M=I*;E!8EAPV.#UJY<>%[N\TRX1-.>*>?6+2\F:\O%F:9(VCW,<<#"IM"]\>]
M=_D>GZ4A(Z`<_2@#D[O3=;A\9:AJ-A#"T-]IL=M'.\H'V>6,RLI9,?,"77IZ
M&N<7PKXFOK;6YM07-Y?>'VTX&:Z5]UP=Q)&T`*F6X'M7?PZO;RRB-8K@EKE[
M;*PE@&4$DL1D*O&`3CG`[UH9&>GZ4`<)'X3OO^*C\Z"W;[>ME]GRP.3#&@.>
M.,,N1^=5];\-:Y=Q^+[&WM()(=7FAN;><W`&"JPJ49<9'^K)STKT3*CKQ297
M&<<?2@#SZZ\*7W]MZNLEG/?:=?W\-\ACOQ"H8&/(=2,_(8PPP3GIQ6AX>TO5
M].\03+':FRT)UGD>WDNQ.#.TNX-'QE%(+$@G&6X'&3V61Z?I29'7'Z4`<#K?
MA34]0?Q1Y44#)J5WI\L`>0?,D)C\S<,<?=.!WJYKOAF[OY+PVL,&VXU2QNVW
M$#>D31[R?4X3'O@5V1(';I[5#9W4=[9PW,<<J)*H8+-$T;C_`'E8`@^QH`XW
M7_#%]<71O=/A7?#JZWRPQRB(S*8%B<[L$!@<L,]<>],L/"]S%K>B7J6'V>*V
MO[RZN?/NQ,[&6,JKY`QDGL.E=YD9Z?I1E<__`%J`//+/PG?6NKO'<V4][:#6
M3J,,RWX1%W.7W-'C)9"2,<@@#I6AX=\-7&G6&BK=06XN;/4+RX=U8$A)3-C!
M[DATS_\`6K?FUNTMM7;3)%F-RMDU[M2,MNC5MIQCJV2..IS6A#*D\$<RHZK(
MH<!T*L,CN#R#[&@#G?"5AJ6DKJ5E>VT:PM?W%U!<),&\Q996<#;C*D!L&L;1
M_"FI6<WA=KB.`C3;W4)[C$F=JS&0QD>I^<9]*[>*[CFN;B!8Y@T!4,S1,JMN
M&?E8C#>^.AXJ?(YP.GM0!SL.B2Q^#+O18UAA>6*ZBC"_<3S&?;T[885DZ)H6
MJ'4_#MUJ5A!"NGZ3-83)YRRY8^2`PXZ$(_\`DUU,&JVLNLW.DKN^U6T$=PXV
M_+L<L%(/KE&JW!=6UR)/(FCE$;F-]C`[7'53CH1Z4`>=S>$-2MY;=X[5[BWD
MT6/39[>VO%@V&/=@`D8*,'(..1M'!KH/$>@W.H?#I]$T^!(YS;PQ1PO+D)M*
M';N[X"]>]=%]JC%\MGY<V\Q&7?Y3>6`"!C=C&[GIG..:KZMJUKI%M%-=;PDM
MQ%;+M7/SR,$7/MDCF@#G+/PS<(^K23P0%KC7XM1@8D$^6OE<^S?*X`_QK.E\
M,ZU;0>?!;0SS0^)Y=56#SPGF0L'4?,1@-\^<'TKT(8[C\Z7CT_2@#SPZ)XJM
M-0O);08M+S4Y[JXAM[E8Y65H8ECP[*<`.C`@<\@^U/T7PUK6A2>$7%M!<_V=
MILFGW82<+L+M$=ZY'S`>6>.O(KO\KZ?I2\8Z?I0!YUIOAW7M"UN+58;&"]^?
M4(VM_M`1E6:X,T;J2,9.`I'49[XQ4VB>$-1T_P#X1'STM3_9T]Y<7:QM\L9F
M#E53(YPSXSQTS74ZIK]GI`EDNTN!%$80T@A8K^]D$:X;H3N(R!R`<]Q6HWL*
M`.=BTW4M.\&W-CI'V:VU%%G-IG!C5C([)GC&,$5REQX/UZ^TKQ2)HSY^J06<
M<*W5TLCDQ,2^YE`4#G@`?EG%>@:-J]IKFCV^IV6\V\ZEEW)@\$@\?4&J:^)[
M"2X>!8KP3)8#4#$;5Q)Y1++@)C=NRI^7&>10!B>)/#-]>7=U>Z;!;&9;NRNU
MA=]@N3`6RC$#C@K@D'H*UO#MG>V][JUW>6%M9->SI*L<,H<G$:J2Y`'SY'/X
M<FMF"\M;F22.*5&EC"^;&#\\>X9`8=02.>:FR/3]*`//?#WA2_TJXT^VO+2>
MYCT^ZGDM[O[>/+"N),2>7C.\ARI'3DG-6M$\*W>G^'M`M98+=;NQTN>TE*L.
M&<+P#W!*Y)KN,KC/]*/EST_2@#@[?P[K&F6/@J:WM;>XFT6S-M=VHE"9+QHK
M.C="5*GKC(8\U'HGA35K75M&U*[BMHF74;Z_NH8I,B#SXR%0'`WD'&3Q7<27
M<:ZA#9;6\V6-Y0<<!5*@_CEQ^M.^V6WF3Q+*KS0(&EB0[G4'.W('/.#CUQ0!
MYOI/@C6;2PCBGBM_,3P_=V`(E!Q-)+N4#CIMZFI]7\#ZEJ6EZ?9Q>1`8O#TF
MGRLKX'G9A95X'*YC<9[9/K7H=M<)=6D-RB2(DJ!PLL91U!&<,IY!]0>11<W"
M6MK-<.DCK$A<K%&7=L#.%4<L?8<F@#@+WPSJ>IZ!XBC.FRPZGJ&FI:K)<Z@L
MP8C>=@P,*JEC@]3NZ#%:/BCPO<ZEI>N0Z=%;I/>6-M%'D[=[Q.[8)`X&"`#_
M`(5V*.LD:N%;##(!7!'U':E^7&<?I0!S/B;3=2\1^#)[5((;6_<QRB"63>A:
M.17V,P[,%P3[]ZYW7?#&O^)&UR_>QMK*:ZL+>RM[<W`=G*2^8SLP&`.2H'.<
M9XZ5Z0"IZ<X]JR]3URWT[4++3Q;W-S=WA)6.WC!*("H:1LD852RY[\C`-`%3
MQCIEUK/AR2RL@C3O<VT@#MM&U)T=N?HIK%U;1==.N^(I-.L[6>#6+."%99;C
M9Y)C#ALK@DY##&./7%=NSA(F8\[`2>*BLKJ.\L8+N,,(YHED4,.0",C/X&@#
MD[C0]6;6_%B)!";+6[95BN3-CRG$)CVLF,]<'([&L_\`L#Q#?>&+FPN+"UMI
M!X>?3(0+K>7E*@9)Q@*<<=>^:[Y+JVDGF@CFC>:$@2QJP+(2,C([9'(J7*YQ
MC]*`.(U/P[J:ZOHNH6<<LB6VGM8SPVURL+1_=8,A(P>5VD<<8/;%27WANYD^
M'VGZ5IUG%;3V36TT=E-/O0^4ZOY328YSMQG'>MZPUVWO]9O=.MX+E_L9V37.
MP"$28!,8.<E@&!Z8P>M:W'3'Z4`<E=V&K:KJFA7\VGPV@LM0DFEC\\.WEFW>
M,$D#!;<W09XQ]*Q/#_@O4;*WABO[>V=1X932G4N&!EWN67_=(8<UZ/N&,_TH
M)4#D?I0!YYJ_@_5K]=4\D6P:?3-/AB$DGRO+;RM(R-C^%@0N?>K>L1>+]3E0
MQ6"V=F\<B3007J+*SE%V,S[2-@.\8'.,'VKN<CT_2CCT_2@#BO#7AK4=*U70
MYKA8?+L?#RZ=*4?/[X/&>!_=PIYJ=M*U2'Q;KMS';126>JV442S><`8GC208
M*XY!+CD5UV1U_I1D8Z8_"@#@U\,ZQ#H'@RUM1;17FCQ?OF+#:DGV22,'I\P\
MQAGVK,3PKXFOK?6Y]07-Y>^'VTX&:Y5]UP=Q)&T`+&2W'TKTBSNX[ZTCN8XY
MD1\X6:)HW'..58`C\:GX-`'!V>F:OHNO+=VULUIIVYI=4;[4)DN0L``9(L%E
MD+*.F.%[Y&-76;.\\7_#Z>V:!M-OKZT#""5\F-^&",0.F0`>.A/%=-E?3GZ5
MF7>N6EAJ2V$RS-.]I+=HL41<LD94,`!R6^=<`#)H`XZZ\,ZEJNGZA%+I+176
MI16MK/<7=^L^R-79G*``<IDE3P2Q!P,53>QU+0=0\%6']GPW-Q97-ZD864*+
ME?*8^:200KL"6(/\6>>:]/1UDC5PI`8!@&7!'U':H8+J*XGN(EBE#6[A"7B*
MAB5!RI(PPYQD=\CM0!YU9>$-<TVYTW4/+W3,+P75O970B-OY\WG#8S##X/RG
MIV(]*O6>@:KH6H:;>Z9H\$ENFCC3VL9+P;K9E8N#O(PZG.&.,\`X/2N^)&",
M?I5"TU:UN=6O],3=]ILEB>4%>,2`E2#W^Z?RH`Y+^R_%6GVWB:'2XK>.>]O!
M>VER)UQRL2M'M93M;"/AB",XJFWA77#IVK2B$-<SZS::C##/=AG=(?*RK.!@
M,?*..PR.:]$@N;>Y1FMY8Y55VC8QD,`RDA@<=P0013?M<?V\V?ER^8(A+O\`
M*;8021C=C&[CIG..:`.#U_PUK>J:S-K%O:VXD$>G3):RSC$LD$DKO$6`X^^,
M-@C(IEYX5UC5;W4]1GL[:W:]U'3G6V,H<^3;2;F9ST+$$_+ST'-=MJFKVNE"
MT^TEQ]JNDM8]JY_>/G;GVR.M7P1@<8[4`<9K?AZ626XFM=.>69M1^V026MV+
M>2%OLZH7R1@DD%2#U!SSTKIM$74DT.R76)(I-2$*_:6B&$,F.<>V:O8'I2T`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`"'I7D,4$S75K+Y&JKXP.M[+B0>:%^R^>6/.
M?+\GR<8QQGMFO7Z*`.$\!^&['2=7\37<-@UO*VIR11N=_P`T.R)N,G!&[/-<
M]I-A*WB1;G5+N6VU>/4ITN?]'N':Y@.\K&#GRQ$4*$$``%0.M>N44`>)QC4K
M'PCX@N;LZC%-'HV[1GFSF*T#957(``F!VYSS@+Z-5_\`<Z=-KLNC:5J-SHDM
MI;PW45P+A5:Y>0B23D&0[4(+[1SC'6O4]2TZUU;3KC3[Z$36MPACEC)(W*>H
MR.:L#Y0%QTXH`\AT_3[L>'CI\45VEC)XHCC181,BFT9%#[-QW+&<OSGN:N7^
MD)I4=KIDT.HOX736)Q=1H97VHT0,8.WYS$)&/3(Z9KU,G%,::.,H'=4+MM7<
M0-Q]!ZGK0!YO8VLZ2^'%MXM2%LNN79/VI'$@B,$P4OGG'W0"W^SWK/TK2Y=+
M\)V>NE]1M]3N/#]T;Z=I6W>8$0HQ#\*RX(7.`*]<J&ZMH;RTFM;B,20S(4D1
MNC*1@B@#SCX?:=8V/B*XDV)9W\VF0$V6+C)&X^9,#*!D,Q48&<;1SS67K4,\
MEUK<C6^J_P#"6C4PFE2Q"4*("R^7M(/EB/8&W9[DYY->F:=X?T_2Y3+:POYI
MB6'S)IGE<1KT0,Y)"^PJW'J5C+J$VGQW<#WD*!Y;=9`713T)7J`?>@#S[5]%
MDU/Q#XGO)UOC+83V<NFO&[J$.R,N4`X.2N&Z\<<5AW5I!>>+KC4+N1DEM]?9
M+>\E,S>854B.W^4>4!YA&,MV`(R37L_:L4>%M)%ZUY]E)E:?[24,SF/SL??\
MO.W=WSCKSUYH`\^\,P!=2\,R6,&K)K#K(?$+3>:%;;$RMYFX[2?-*[<=NG%/
MT30I-:L_!^EZQ#?&R;0I3=1LTD8\T-%LWGCYAEB`?3/:O5QTI:`/$O$-BVH6
MT=CJ#W#1VOAZW)N9_/=K)R7!FVQ@DL0N6WXSM&#UKM_&&QO#&CBT6XFT5KJ`
M7HL]S%K,J?[OS%<^7G'.W/;-;VH^&M+U.ZDN;NW=I)(O)DV3N@ECSG:X4@,/
MKZFM"RDMY;5&M7B>`?*AB(*@#C`QQQC'X4`>:R65O'J-W_8=I>IIZ^&KZ*#=
M')]_S1PI;GDY*CN.G%4X]!FU:UU)[Y-1$MCI&GS6!5Y$*3B(ERH[ME%!ZGMQ
MFO700:6@#RO7H;EO%>K"\AU!]#EU2T%[Y*R8,/V4@?=Y*>:4W;?Q[U3\8)9S
MZ)'I6F:-="WATZXFTVYF6Y+>;N95CC4<AL[64N?ND8&,U[!10!QNA07!\=:A
M/-'+LDT6Q3S'4X9@TVX9]>1D>]<7%H\&A^'/&EOI-A>6FKK?N8C''+N,'G(8
MRAY!X).1D]<]*]FHH`\PUZT'AG5Y4TW2+JZTZ/0Y4-NCRE6:2YC#$L,L2`68
MXRV`<5F6.G3PZ-?6]K:RFS7Q+I[VR1QR[/+#0;V0/EMNX.2<XZGI7L5%`'E_
MAB^L?#^IZQ=7;37-NEJ]W=ZW)#/&Q'FD".1&&"X'0KV7H,C/4^.;A8_#\4,F
MG_;+>[N8X)LF39"AR?,<1_,5!`&!CJ,D#-=!<VL-VGE7$231;E;9(N1E3D''
ML0#^%2R.L4;.[!4498DX``[T`>0V']I^'O"MCXAMK*\G_LZ\OH3:(DF7MI7;
MRMJ-\Q4,(B,Y(4M4?BG3)K3PS9^'Y]/EN+Z#29+F*_\`W[E[QB=R((\#S-YW
M98XY'&,U[#%+'/"DT3J\;J&5U.0P/0@^E/H`\I\16VH7,^I@PW4BO8Z-CY&8
M%Q=DO^(')]NM+IGG7OQ-L-2ATN6RD>YO(KY0)RP14*H96;Y,,5#*%'ISP:]5
M)P,U$]S#'-'"\J++)GRT9@"^.N!WQ0!X_P""+!;*\\.+8V6I1:J&N5UAI(Y5
M008<J#O^7[QBV[??WJ.PL]37PU<EK:]%P?`XB!,;[_-W2_+Z[^1QUKVFB@#R
M+3/"6GS^(/$UD]K<V6H:A:0M9W823@M"-[AONY$@[G((XQ71>`KJZ\07.H^(
M[Z.2)G$>GQQ-P$\H?O2!DCF5G'4\*.>M=TPW*1Z]:K:=IUKI.GPV%C"(;:%=
ML:`DX'U/).>YZT`>8:!YM]X^M-4BTN;3WN8[U=0A`GRK94()6;Y23M8C:!_*
MC1-$U&T\,V&K:>E^/$%YH5RLQED<F2?8ABW*W`8$87I@<5ZS29]C0!YYX,@T
MZ/6K.?2H=6C5]-D-W]L24)YY:+))DY\T\[L'!P*@31=.LOB1XENFT^:.\NK)
M)+*8)(5=BDOFX8?+G[O!]L5Z710!XI-IVHS>&Y;AX=1^U:?X6L)[(`R`QW86
M0%@!UD&%'.2/3FMS5]*FTAO%ECI<5[]EN_#C7!&Z24O=?O%RK$D[R-N0.O!K
MTXG!J-;F%KEK<2)YRH',>X;@I)`./3(/Y4`>7R:++J5YK=W=1W_GV!L)-/97
MD78WE1F3:!P<E<-UX&.*HM9VE[XW;4-2D:,0>(MD=[*9F\P*,);_`"CRP-Y&
M,MGY0",FO8ZQ1X8TG[>UY]E8R-<?:BC3.8_.QC?Y9.W=WSCKSUYH`YSQ?#;3
M^*-.CUZ"ZE\/&TE($(D*"Z#*1O\`+Y^X&VYXSTYK`\/>&_MWB#POJ&L:?>23
MK87<OG7C/YB[+A#;;SG[PC/0\GG.2*];`P*6@#SKQ3#%/XNE36(=5:S&GJVE
MO9+(=MR&?>1Y?_+3!CQN&,9[9KG/%0N+O3;*U32;B/4;#3K-[.YV3&61F*[A
M&$PJE-IW;LGGIQ7LLLL<$+S2NJ1QJ6=V.`H'))/I3'NH([9KEY46!5WF0L-H
M7KG/I0!YF+*Q\.^,_&>HQ:'=7%^T*W-I'&LH^T*8LRA7&5R6!]P>@Z5<^'%H
M;/5]=%O#Y.GR):O`(TF6(N5?S-HEYS]T$^PX%>C56OK^STRSDN[^YAMK:,9>
M:9PB+VY)H`\H/AJ/2](\6W.F6-U;7DFN10120>8',!DMRVWVY<[A[\\59UK2
M-+TW5]0LM0L-2&FVVGH^B+:>>P67+F3:4/\`K=[)C=SCV%>F1:KI\U^;"*]M
MWO!$)C`L@+B,]&QUP?6K=`'CFJZ=K,VFW]Q?)J#ZII_ARSG@9'?*WP$@=QMX
M:08'KU]ZZ_1-,.B>.KZTLX[E=/N=-BN9#*[R!KCS'4MN8G#%<9`Z\&NS!S1G
MGH:`/(O$L$DEUXE>>#53XF6Y5="DM_-PL;(@C\LJ=@&X/OS[YK4N-#>^UW7-
M2N$O?M5AJ]H;!UD<!4*P&0*!P5)+ACWY]*]%M[B&[@2>WE26)QE71@RL/4$5
M(>G%`'BLEJ+GQ`^J,VS4(]6O([*[F,S?:I`LB00DX\H8<#'S=$`(SFM;PG#&
MOB#PX^DP:M%<-:R-KS7/G!7?9M'F>8<%_-R1CG&3T-=U#X5TF"]%VEJ?,$[7
M*J9G:-96ZN(R=H;KR!W-;=`'CF@Z!+KEMI>FZS#J!M!HMQ(RLTD>)Q<$(2?[
MP5B0#]<53\160U62>+59IQ':Z38L]Y/YS&Q)R9&Q&#]Y5^;>0>^<5[:\B1J6
M=@J@9+$X`'K6%=:%H6L:C+).JS7$L*>=&ERZB:+)V[T5L.N01R#G&*`,KQF@
MDL=%5DN9=!>[47XM2Y)@,;!,[/F*;RF<=NO%<YKUD@MP=#M+Y;)/#.K16X*2
M;@Q:/:!N^;G!*CKC&*]0>>"U$22RQQ;V$<88A0S'HH]^.E222QQ%!(ZKO;:N
M3C)]!ZF@#RV;1)=2N];N[F._^T:>;"33W5Y%V-Y49?8!P<E<-U].*;JT$[^)
M=034H+Y_#\NM@7@C$FTI]CC$9.WGR_,SG'&1STKU""]M;E4:"XBE$B;T*.&W
M+TR,=1[U,#F@#QSQIY-WI"V&EZ/>*MMIQFTN>5;DRL[.0$C`^ZR[0WSDG!7C
M`-=KH]O(?'?B=YHI!#/:V*AV4A7^67<`>^,CITS77T4`>-V.D0:3X.\06>EV
M-[9ZH-859/*24/Y!O1L*L>"/+)Y7MR:U-<LX_#VKWMM8Z1-/I:Z-#;B`-*8U
M\RY<.Q*Y8[0VX@<XKU"B@#R#2["ZBT>VMXK6?[+%XO@>W58Y-@@`3YD#Y8)N
MW')..M:6@7=GHGB35KRY:6[B%O<7=UK$D,\;1(DG^JD5OE8@?=*X^5.G()]-
MJ"ZM(;R%H+F*.:%B"8Y%R#@Y&1]0#0`^&59XDE0Y1U#*<=0>E24U1BG4`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`"$X%>>:'KOBG5M7AOHR[6#:C-:7%F\<*1V\2,Z
MY#;O,,GRJ<$`88\=#7H;#*XK,_X1S1_[2.H_V9:?;/,\[SO*&[?C&[/]['&>
MN*`.&L/%NN3W6MVTE_`Z:+:7;I.L8']H,"0C`;0!Y94JVWC=ZC%5KCQEXAT:
MU:[DU&WU)KS0WU1(/LZI]C<-&!C:<M'^\)^;G]V>1SCO;OPSIMQI;6,-K;VP
M6WFMX'CB&8%E&'V>F>"1WQ3='\+:5HNGBUM[*UW/`D%Q*(%!N`JX^?USD\>Y
MH`Y"XUWQ3I%DT=W>9BO+JTM[;4KN&!6B,KL'.R-BI55"[2W4MU.*35K?74\5
M>%K0>,IW9YKF.5X[>%<E8B^'4#:6QQTX&#@'FNRB\*:#!;3VT6D6*V]Q&L4T
M7D+MD1?NJ1Z#)P.V:>WAG19+.*S?2K-K>*0RQQF$$*YSEA[G/6@#CYO$FI77
MC*QBT[5KIM-O+V?3V1[.)8XY(X7+%&/SLRNG<;3S[5CZ'>:K9>'=!N[S5FU4
MS:]-$%NH(V:)4-UG:V,@ML'/;H,#BO2XO#VD0:@VH1:9:)>,YD,ZP@/N/!;/
MJ>Y[T1^'='AG:>+3+2.5IQ<%UA`/FC(W_P"]\S<^Y]:`.*T;Q%KC2>%;VXUN
MWO(?$08M:"W11;8A:3]VRG<=I4*V[/)[=*7P_K7BJ\TW3]6;4+:Z.JZ3-<0V
M4D*QQPSJJE/G'.TY.[)^F!Q79VGAW1["]>\M-,LX+A]P:6*$*QW'+<^YY/J:
M>-&TW[$ED+"V^RI"T"0^4-BQL,,@']TCJ*`,;P=J5Y=07MIJ5_<SZG:N@N8;
MFWCC:W+(&"@Q_*R]P>:XC1Y]6T.+4-FN9EU+Q-)IIN)[:+]RV6)EX`RQVA0I
M.T$CCL?4]/T?3])BDCT^S@M5D;>XB0+N;&,GU.`*;+HFF36=Q9RV%J]M<R&6
M:)H@5D<G)9AW.0#F@#@YO$WB"UFO-&75(;FXM]7M-/743;KDK.F6W(/EW(3V
MQT&1Z]'XEO\`5-"\,V7D7PEOGN[:T:ZFA7YO,D6,N4&!GYLX&.E;$.@Z5;6T
M=M#IUK'#%/\`:418AA9<YW_[V>_6K5U9V][&D=S!',B2+(JR*&`93E6^H(!%
M`'G=]JWB]=9U#2]-O)KFXTB"%UW06ZB^9U+%I2Q78G\.4'\)YSP':OK/B6]\
M5W5AI.I2VPMKRU@$,-K')&T3A&E9W<$AU!;@8&`N,DFNUU#P[I&K3>=J.FVE
MU*$\O?+$&.S.=I]1GMTK!U3P!!JM_?2S7:?9[VXAGD7[,IF0QA1B.7.4!V+V
MXYQUH`9H_B2\NX+87%W&9IM>N[,)A0S0QO*`H'L$7GKQS7.:7JMQ:>"+*QT[
M4;NTU&6XU*Y46MM%*6CCN)=Q8R?*J@E??D8[UZ)%H&D0:B]]#IEG'>._F-.L
M*ARW(W9]<$_G39O#.B7$,,,VDV3Q0L[1HT(PA<DOCTW$G/KGF@#SNVUC7)]<
MTO6WUJ<(_A<:I+81QIY4K#RRR#()&XD_-U&<`XXJ_8^(]=MY="DGURWU%-<L
M9K@Q+;HGV4I#Y@,94Y*Y^4[L]N:[B31-+EDM)'T^U:2R_P"/5O*&81Q]WT'`
M_*F67AS1M/DEEL]*LK>25"CM'"H)4G)7Z$DG'2@#C+7Q-K.E:1H?B?6M62;2
MM2M_,NH?(2-;9GBWQA".3R"O).2R].W06VLW6F_#Y-7\0W9@N3;>=/(L.3"S
MGY5"`<[=RK@]<<]ZMZUX9L]:T&+0\);Z<DD.^!(QM:*-@PBQ_"#M`X[5K7-G
M!>VLMK=0QSV\JE9(I%#*P/8@]10!YJGBKQ%IVD^(TN+QIKK3KRQCAEOK:)'5
M9S&&#K&=N!N)&"#[U)<^)=?TI]7TMM9@O9K2^T^&.^DMT4J+EMK*ZKA?E^\.
MAP1FNKU/P9I=[H4VDVD$-C#/+#+*881\_ER*^".^=N.?6C4?!FEWFCKI=M;6
M]E:_;(;N2.&!=LA1U8AAWW;<'VH`Y1_$OB"SFO-&&KPW=Q!K%K8)J#6R`[9X
M\G<BX4LA/;'09I=3UWQ!;0>)9XO$449\,Q*#%+:QG[:WDK)NDZ%0Q.T!,<@]
M>@[NWT#2;6UBM8--M(H(IA<1QI"`JR@Y#@?WL]^M)=^'M(U"\2\O--M+BY3:
M%EEA#,-IRO/L>1Z&@#C?^$KUEM6&@>>J:C=7\$T#F-<K8NGFN<8YVE)(\D=2
MO?FH+'Q-?:CK<B1ZE<W>CZEI=W=V_P!HM8X@`C(JF/;\Y7#G[_/`KT%]-M)+
M^*^>WA:\B0QQSL@+JIZ@'T/I56T\-Z-82/)::590.ZLK-'"JY5N6'T)YQ0!P
M6E:KJNF>'O",LEW)8Z`FEV(>>"&.7=*X5=DH;YE4_*`R#J3DUW^OZJVD>'=3
MU.%!,]E:RSB//WBBDX_2HSX8T-IK>9M)LC);(D<+&$?NU3[@'H%R<>F:DTG1
MK72;::&W+L9YY+B:20Y,DCG+$]O;&.@%`''6VIZ\-3TS3I/$L5X-:T^:Y6:*
MUC#6A54*M&!D,AW$#?GIU-<YHT&L7^G?#MCXAG:\NA<2I=RPQR/`IM^5&1AC
MP?F;)YKU33_#VD:3(\FG:;:6DCJ$9H80I*@D[>.V23CWHM/#VD6$B26FF6<#
MI(TJ&*$+M=AAF&.A(X-`'#-KWB>X?1M&%Z\=Y):W$L]Y9VT3-.\4HCPBRD*.
M/F.,GG@`5I'5/$M[J7A[2IKN+2[N\TZ2[O3!$DVUXVC!5"<C!WGGGCIZUU%U
MH.EWT<,=UI]K*L+M)$&B'[MFSN*^A.3GUS4EOI&GVAMS;65O$;6(P0%(P/+C
M.,JOH#M'`]!0!@^)K_5O^$@T;1]-U`6`OXKEY9Q"LC)Y0C(VAN,G<1SG@GO@
MCGM+\8ZM!;Z!K6LZE$=/U?3YYYH8[8*MIY<1EWJ>6;Y000?J,=*]#>SMIKJ&
MXD@B>>%66.1E!9`V-P![9P,_2H!H>EK#;0C3[3RK5&2"/R1MB5EVD*.P(."/
M2@#RS5]<\0S^'?%=L=<OU%MI4.H6\\EM##,`YDRG[OHI"KR<,.:V[N'7+/QS
MHD9\57MS&NF7$[Q^1$HN-CQ$J0%QE@V,@9&..IKM+7PWHME;S6]KI5G%#.GE
MRHL(`=,8VGU&.,4#PWHPCLXQI=F$LFWVP\D?N6)R2OISS0!R7@_6O%&JMI^I
M74C3:;J%H\TH>.%%MGP"JQ;6+OR6#;N00.G2J=OJOB^\\'Z7K:ZFYCU",7%U
M]EMH?,LXQ&3^Z5^),G&[.3_=`Z#NK;PYH]G>F\M=,M(;D[_WB1`'YSEOID]?
M6F7/AG1;JQM[.?2K*6UME*P0M""L8(P0H[`CC%`'+^-KRZO?AQ9ZEI>O30+)
M)9R"ZAC"&=))8P"01\N=P;`QTP>"16?J]KK:^-;C^SM?\J^M?#BN]T]K&QN&
M663`88PH)'.T9],5Z'-IME=Z<VGSVMO+9%/+-N\8,94=!MZ8Z?E4<6C:=;#,
M-C;IB#[-\L8'[K).S_=R2<>]`'">)/%VHPR1W&EZE.LED;);ZU6UC,&9W3AG
M;Y\E7X"=.,UI>$8]4'C'Q7]KU^YN[>"]6-+66-`J[H8G!&!D8!*X'!ZGDFNC
MD\.:+<W*W<VE64DZJJK(T()POW>?;)QZ=JL)I%@FIOJ:65NM_(FQ[A8P)&7T
M+=3T'Y4`<?8Z_JMU'JNOOJ\0M+&YN[==(6%/WGD[\#?]_>VW=Z8_A[U2LO$F
MN6TNARSZY;Z@FMV,USY*VZ)]F*0^8#&5.2N?E.[/U'2NZ70M+35&U-;"V%\Q
MR;@1`.3C&<^N.,^G%,LO#FCZ;<23V.EV=M-(I1GBA"DJ3N(^A/.*`.2;7KG4
M_`UL+FZBEN+SPO->7*+M!+F./#8'099O;\JPHM5U.]\+W\4.KVEG9Z186MN;
M.6)2+@26T;%F?[RGYR%Q@97G/0>DVOAK1;%)4M-*LH4E1HY%C@4;E;&Y3['`
MXZ<42^&=$FFBFETFQDDBB$*,T"DK&.BCCH,\>E`$'BC5%TS1R?MDUK<7,R6U
ML\$*RN97/RJJM\I)_P!KBO-KR;7/$-GH<=WK4T4]MXGEL"YM82S;4DVNZX*[
MEP1@?+SGJ!7K-[I]IJ=N;6^MH;F`L&*2J&&0<@X/<&HX=#TNWA@AAT^UCC@E
M\^)5B`"28QO'^U@D9Z\T`>665QK7AN+Q'=Q:O+=33:^FGM)):PCRRZPYFZ*,
MX(4*6"9P?KNMJ_BF";3]#O+\V<U_?R0PZE/!"9C$L'F<QJ3&'+Y4>PS@DUVL
MFCZ=/;W=K+86SP7CE[F)H@5F8@#+CN<`=?05"/"^ABTDM?[*L_(EE69T,0(:
M1<!6/^T`!@^U`'(V\>L'XF:?"WBN6>`:4TLB1PQ"*;9,J$$#(!)/)'(.0,#B
MKFKQZHWQ5T6.'7KFUM'L)Y6M5C0HVR2+*G(YW;NO48X(R:Z;_A'M(S9G^S;3
M=8_\>I$(!@Z?=].0#4MWI&GW\UO-=V5O/+;-O@>2,,T9]5/;H/RH`\S\%W>N
M:-X;TB\6^6[TZ:VO6731;JI1HRSIM<#<2<,#G/48%;_@S5/$VHS6=W?S&YTZ
M^LOM#2/%#&L,GRE5BV,692&;);)&T<C.*Z^#3+.UB@BM[6"*.WSY*H@`CSG.
MWTSDU5LO#NC:;=_:+'3+2VGVLN^*(*0&.6`QT!(R<4`<EXP\47]CJ<ATG4KE
M3I\UI%>6WV6(P_OI%`#NWSY*MP$Z<9H?Q3JL&OGP[+=+]MCU1I9)?*&?[.">
M;NQC_MENQUSCG%===>'M'N[[[;=:9:376%!F>(%OESCGVR<>F:M-IEF^H#4&
MM86O1#Y`N"@W^63DIGKMSSB@#S>W\3ZG=7.K+]OFO=-N=`N-2M/MEG$@`#80
MJJ\LA#='Y/'O34U866KP7\MPUK+-X6LHXY+:W5F$LDS*H1,;>6(`!X'TKT"U
M\-:+9+,MKI5E"LT9BD"0@;D/53_LGTZ4Z?P_I-S$8I]-LY(S`MN5>$$>4IRJ
M?[H/(':@#S.]U'5]4T&*WOM0;[99^+(+.*[G@B#H`%8%D0["P+GIZ"M--=U)
MKZSTV\O(-1DLO$R6)O&MX\R(;9I.@&%=2=I*X/!Z9-=N?#6BMI[Z>=*LC9NV
M]X#"I1FQC<1W.._6I(-!TNUMK>WM]/M8H;:4S0HD0`CD.?G'HWS'GW-`'D6B
M7-[_`,(Q#:V=RMFR^&;VX6XBA0RJ5N>@8C(!&1CWSU`-;47B/6O"OA^QFO-4
M.J+J&D!K'SHT#_;,+MB^4`L"''7)^1C]?0[?1M,M63[/I]K$4B:!2D0&(V.Y
MD^A/./6LVY\&Z9*=)AMX(+6QTZ\^VK:0P@(\H4A#[;2<_@*`*WB35M2T/PUI
MD?VR-;^YN;:QEOI47;&SD!I=O"GH<#@9(^E<_<^)?$&F2ZKI/]JP7MQ9WNGV
M\=Z]NH;_`$ERK!U7"Y7@C&.HSZUZ'>6%KJ%I+:7MO%<V\J[9(I4#*P]"#UJK
M#X>TBWM?LL.FVD<!F%P46(8,H((<^K`@'/7@4`6=/AN;:RB@NKQ[R9!A[AXU
M0R'UPH`'X"K5(#VI:`"BD)Q0#D4`+1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(
MW3BN/@\8W<UO>:N=+5/#MJMQNO?M.93Y)8,WE;?NDH0.<].,5V-<U!X)L(([
MJU^UWS:7<M,SZ<TH\@>:"'`P-VTY8[=V`6)';`!G+XVU"T95U?0Q9_:+*>^M
M/*NQ-N6)0S))\HVMAATW#WJ!?'>LS^;';>&U>X-BNI0H]\JAK9B0-QV\2'!^
M49'3+"M.+P)9`#[7J.I7ICL7L(#<2J3#$XPQ7"C+D8&YLG"BKMMX4L+6X69)
M+@LNF)I8#,,>4I)!Z?>YZ]/:@#!U#XB&")[JRTQKJQ@TZ#5+B9IQ&RV\F[&U
M<'<_RGY>!ZD5--X[DTM-7&N:8;*6QM$OHHXIQ,9HF8H`3@!6WC!'(YSG'-6O
M^$`TK^R[G3_/N_)N-+ATISO7<(8MVT@[?O?,<GITXJ]J7A+3-6N[RXO/-?[7
M8#3Y$W`*(PQ8$<9#`MU]A0!@1_$.2*QU&6[TV)I[(VYV6-X)XW6:3RU`?``<
M'J.@X.>:N)XGU^74&TV#0+:6^M8XY=047^U(A(6V+&Q3YV*KGD*!TS5Z;PDM
MYITECJ&LZG>0MY&/-:,%3$X<'*H,DD#<3G(]*DO?"T%UK,NJ07]_8SW$*PW(
MM90JS*IRN<@X8<C<N#AC0!C?\)/<VT.MR6J6[S6^K/;!=2U+R4($2,=AV'`Y
MX3![G-1Z1XAFUSQ-X8OHO-M[;4=$N+E[8R9&[?#C/8D;CSCO6E+X%L&U0ZG!
M>WUM>_:IKD2Q,AVF6-(W4!E(QB-2.X/>K6F^$M.TB72I;5Y_^)99O90*[@CR
MW*$[N.3\@Y^M`&1KGCF\TF\U<0:-]JLM%\M[^8W(1EC=%?,:X^9@"202.@P2
M34FK>-+VQGU=[+1Q>:?HJ[M0F:Y$;C]V)"(TP=Q"$$Y(ZX&:KS^"GU?Q#XBE
MU&ZN(M+U"2W_`-'MY@!<(D:AEDXR!D8X(R":T]2\#V.I7&HO]NU"V@U,(+^V
M@E`CN-H"\Y!*Y4!3M(R!B@#GQX_U>SU'Q)/J&G6ITC3C"(#%<$2DRJOE@@KC
MYBPR20%SWQFKT/Q`,>CZQ=WMC%YVE^2TJV5T)XI%D;`V2;1EA@Y&...>:TKS
MP+IMY<ZC(;B\CAU"*..>WC=0FZ-0L<B\;E=<`@@]5!Q4USX474-'O-,U+5]1
MO(;I(T)D,:LFPYRNU!R2!DG/3M0!SFN>,_%%CHM\Z:':6NH6=W:QL)+LR1M%
M,Z@,I"C)R2I&..2,XP=.WU^\CU'7UN(8XKRRL[65XIK_`!;*[B0D*Q0;1\O+
M8.>.!BM;5_#%EK5O?PW$MP@O!#N:)P&1HFW(R\=0>><]*I7?@73[];QKF\O9
M+BZ^RL\Y9-P>W8M&X&W;G)Y!&#Z4`<]-XMO-9T_39T5+.X@\2P6$_P!DNO.C
MD7@G:^!N4AP",=<UTNL>(;^WUN/1]&TR._OOLWVN437/D(D>[:.=K98D'`QC
MCDCC*1^"K!8\/<W<LAU1-5>5W7+SJ`!G"X"X4<`"K&J^%X=2U./4XK^^L+Y;
M=K5IK1U!>(\X(8$9!)(.,@F@#BK7Q!J?BWQOH3V]D5TDV)O4B:^:)U9951G9
M4&'*G*A"2I!SQTKHAKOB'_A93Z&MC9'2ELDN#(9V$H!9EW8VXSD8VY[9SSBM
M/2O"6F:+>6=S9"9/LEB;&-"^1L+AR3GDL6&<Y[FIKCP_#-XEAUU+NZ@N8X!;
MND;+LFC#%@&!!/!)Z$=:`.*\%>+=5AT+3?[9L7:PDM[F1=3-QYDC>423O3;D
M94'')/R\XK9\,^.)->U**TFLH8!=6IN[9H+L3E4!7*R@`!'^<8`)Z'TK6L/"
M6G6&EV&G*99;:R65468AMXD#!@W'(^8T[1?#IT1;>&+5]1N+2VB,,5O<,C*J
MDC&2%#$J!@9/3UH`RI);OQ%XKU72UU.ZT^TTD0#%FZK)+*Z[\LQ!^0#``[G.
M<\5!?>+]2TL:D(--.IVFAQC^T[Q[A89&81B0^7'MPQ"D$\J.<#-:NJ^$(-1U
M8:K;:GJ.EWK1"&66QD5?.0'*A@RL#C)P<9Y-5;GP!87`O8QJ6J16^H(B7\*W
M`(NMH`RQ8%@64!6*D9`Q0!2U+X@365W>?9]'>YLK%[=;F7SPCDSJGE!%(Y.Y
MP#D@`<Y/2GR>.+NRCOXK[1]FHVEU;0?9HKD.LBW!VQ,'*@<G(((XP3TQG3N?
M!6F7(U)6>X1=0EMI9`C@!3!MV!>.!\@SU[]*H^*/!S:D;FZL)95N[V[L'G/F
MA0B6\N[*<<-@MZ\@4`-B\8:B;+5(KC3K&TU;3IXXI8;C4`MNPD`96$VW/0]-
MN<U#;>.[N_TG19K'24FOM6>XBB@-V!&KPDAB9-O*$*Q!`STXYJZ/`=CO6Z.H
M:@VHB]%]]N=T:0R!#&`05V[0A*@;?UJUI_@S3M-_L@PS73'2Y+B6$R."7:;=
MO+\<\L2,8H`S;?QV4AAEU;37L(I-.GO&)D#;)(6VRQ=@3W!SS[5)=:[>Z5H!
M\375FP:XM+9?L(=ML$C,V2[8X4>8NYMN0%/'2F>)_!PUBQTG2X03:PZC]HN9
M7DPRQ'>SJ!C#!MVS!XP>^*ZB^LGN[?RH;RXLVWJPE@V[A@YQ\P(P<8/'2@#/
MAUJ<>%IM8NH+</%;O.R6MSYT;!03\KX&00/3O7/IX_NXHII]1T4VT#:5+JUF
MR7(D,L,8!8.,#8^&0X&X<]>*V!X8CTWP;J.C:<SRR7$5R0\[#+RR[B2<```L
MW8`"LW3?`-N='$6J7M[<74FD_P!F-NF!%O&R@2+'A0.3CYCD_*OI0`[_`(2S
M7)IK:PMM!MVU.ZA>[CADOMJ1VP*A6=PA^<EL;5!`QUJ*V\>W6JBTCT?0Y+BZ
M:![BZ@FN%C,*)*T14'!#N61\#@<<D9%;5[X5M[F[LKRWOKRQO+.W:U2>V=<O
M$1RK!E((R`PXX(S5*'P#IMG]B.GWFHV4EK`ULTL-Q\\\;.782%@<DN6;<,$%
MC@B@"'P]XAD;^R=*>!V>71!J#32/\V0RJ5(]?FY.>U.3Q9J-_>Q6NCZ.ETT=
MK;W5Z9+L1"(2@D*F5.]L*3S@=.:L2^"+)C8M#?ZC;/:67V`/#,`TD&5.&)!.
M<J/F&#UYIW_"%VD5TEQ9ZAJ-FYM8K2?R)@//2/[A;(.&`R-RX.&-`%7PEKOB
M#5]3UR'5;&RAMK*]>WBD@G+,"%0A2"HR,-G=D=<8XS4]IXDU'4-8NH[+28WT
MFSN7M;B\DN@CB1!\Q6,KRH/!)(/4@$=='3O#T&EZMJ%];W5SMOY3/+;,RF,2
M$*I<<;@2$`ZXZ\5G3^!=/G?4D%[J$5EJ3O)=64<P$3NZE7/3<-V<D`X)`.*`
M,J#XB2+;:]+>V-H3I-JEX387PN$DC8L,;MHPPV'CW%6G\9ZC907_`/:V@FWN
M89+9;6&*Z$@N?/<I&-V`%(88/4#L34X\`:>UAJ%K<7]_<?;[&.PDD=D#+"@.
MT+M4`$;FYQWK2U?PQ8ZU#<1W+W"&:.)0\4FQHFB9GC=#V8,V<\]!Q0!S%]KF
MI6VC^+;W4K*XL[BSLXV,-O=\'Y7.Z*3;QGCDKG(/'%3:EXHU"]:ZBLM-D.FV
MVH164E\MP!()1+'N/EX_U8R5)SGV(YK7E\&VESI>KV-W?ZA<_P!JQ"*YFEE4
MN``0-N%PO7H!C]::W@FR^W7$\5_J,,%Q=)>26D<P$1F5E;=C&<$J"5S@^E`%
M6\\7W5IXM@T1+/3YDNI'A@>/4`91(L32?O(POR*=N,Y)Y'%8>E_$'6UT*TGU
M73].%[?7<]O:8O?*B;RVDWF1BOR!=@`QDMG.!TKI;7P/I]IJD5['=WA6&^FO
MXK<LOEI-*"'/W=Q'S-@$G&:CB\!V4$<20:CJ$7V>\:\M&5TS;,Q8NJDKRC;V
M!#9R,4`9TOQ"D.EZ9-;Z?"+J^GFM_P#2;KR[9'B)#?O@IR&Q\G`W#TKIM5U*
MXL-&:\B6T\X!=J75T(8LG'!DP?Y<U5OO"[ZCI;6%QKNJ&.19DF8&+,JR=5/[
MO`"CA<`8SWJ34/"UE?Z;IED);BW72YHIK22)@6C:-2JYW`AA@D'([T`85MX]
MNKS2--GMM)CEOK^]GL(X5NQY0EBWY;S-O*$1L<XSCM4R>,=3GATZVM]"#:U=
M"X:2SENPB1+!)Y;GS-ISDD;>.XSCFM&S\&Z?9C3]MQ=R-8WLU^KR."9)90X<
MMQT/F,<#'-+>>$;2YN+:ZBO+VTN[:2=DN+>0!MLS;G0@@@J3@],@J.:`*VG:
MZFG>`YM<U".X18%N)Y8Y.95`D?Y3UY'3TK'UKQMXBTW3-0CET*VM-3739M0M
M<WGFQ>7'MW[R%!WKN!VC(;INKJE\-:?_`,(W+H,WG7%C+&\<@FD+.X<DG+=2
M<L>>M9Z^!K*07']HZAJ.HO+I[:<'N91F.%AA\;5'S-@98Y)VB@#"O=:\3C5_
M";Q:?;F_N[:[,MFE\5@<`1%69]G;/0*<$XZ9-6+OXB2QP:>MOIL"WUQ8_;IX
M+V]$"PIDKM#;3O?<&``';G'%=!:>%X+:YTJZEOKRZN-,CEBADG9<LL@4'=M4
M9P$&,8]\U$WA"V2XM+JROKVRN;:%[<2PE"9(V.[:X92#@Y(XX)/J:`*MCXMN
MM6U:TL]-TLM%+9V]_-+<3>6889MV!MP27&T\<#CKTJW=Z_>)XKAT&RT])Y/(
MCNIYI)]BQPEV0D#!+-\O`X![D5<L-!@L-4DU+[1<SW4MI#:2/,P.]8RQ#'`'
MS$N<]O85(-'MQXA?6P\GVI[1;0KD;-@<N#C&<Y8]Z`.+T[QS.NE:##:VGFS7
MZ22>9J5]L7:LFW:)=GS2<C"X''>K&D^(KD^.?$.B0A[N=;^.3;)(0EK;^1$6
M;..[$X4=223@<UH3>`+*;P]'H']IZBFEB%H9+=7CQ*I?>=Q*9!SQD8X_.K1\
M&:;_`&X^LH\\=^UT+D2JPRO[M8VCZ<HRHN0>_((.*`,/5[C6+KXJ:;IY@1M+
MM[,WB@7[P\B1%:1E5?F*Y(",=I!)XI8_B,;>76%U*SM0MA:"Z1M/O1<B0&0H
M$)VKM<L!Z@9Y-=->^&[&_P!4DO[@REY+"33W0-A3$[`GWSQUS63#\.])%I-;
M75S>WD<E@FG#S75=D*'<@78JX8'G/6@#.UWQ/XRTZUTUET'3H)[G48K8J]^9
M%97Z+D)P<Y!.#CC&[M9U'QKJ5D=3E@T1+FUT:,-J<@NPK(WEB1EB4K\^U2#D
ME<YXYK1G\'1W>GK;7>L:I<2QSPW$-R\J>9$\7W2`%V^N<@YR<]JBO?`EE>M?
M!M2U**+4DC34(HY5"W6T!<M\N5+*`K;2N10!6N?&UPEWJGV72)+BRTN%9[J5
M9?WA#PB1%CCP=S=CD@#WZ5JZ!KD^J:(VI7B6<*KN8&SNOM"%`,YSM4@]<C':
MI(_#5M;RZM-:7-U:S:DL:O)$RYBV($4ID''`[YI=)\.6NE+J/[Z:YDU&8SW4
MDVW+L5"XPH``PH'`H`YNV\67M[<Z3JE[IDEAI4L$U[#,DXE\R(1%AYB@#:V/
MF`^;ZY&*AM?B8TEI<7-QI0*"P:_MTL[H7#F-2HVR@#]VWSJ<#=P&].=S3O`]
MAI_V6,WNH75K:1R06]K<S!XHXG!4IC`W`#@;LD`8S4EEX4DT^P2QM_$.KK;Q
M0&"!2\9,0W`@[BF20!M&[/!/7K0!GCQAJ3VNFQ6^FV-SJNH/+Y,5OJ.ZW\N,
M`LYEV9_B`QM)R?3)%K_A)-4?7K/18]'07CVT=W=^9=`);QL[(V"`=Y!7@8&>
MY%-B\!6$$B7,-_?QZ@M[+??;%=`Y>10KJ5V["A"J-NW^$'KS6G8^';:QU5-2
M6YNIKE;);(O/)N+HKE]Q./O$L<GI[4`>?Z5XDUVXU/2;C1K.:_\`/T:>5[6]
MU#:,K<8#E]O+=AP.O)P*U;OXH0B".XT^SCFA2PBU"X^T78AD".&(2--I,DF%
M/'`Z#/-::?#RQMX+1+'5=5LI+6UDM%E@F0.T3L78'*GG)R",$8%6D\$V=F\;
M:1?7VE[+);$BV=2'C7.PD.K?.N3ANO)H`R]>\67LL.K6NDZ5+=0V=D'O)Q.(
MY8C)&641ICYB`0QY''3)XK7\1Z@=.T;3Y<SGS+ZS@S#-Y9^>5%Y.#E>>1W'&
M1UIE_P"";.^N[RX&HZG;&^@6&]6WG""XVKM#-QD-CC*XR!@UJ:IHMMJUI;VU
MP\JI!<0W*E"`2T3AU[=,J,T`8%CXPO[_`%:"-=%V:9+>SZ>;O[2"ZS1EP3LQ
M]P[,9SG)Z8YKL!T%8]GX;LK&%(HGF*I?RWXW,"?,D9V(Z?=^<X'TYK9'`H`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`$8X4GTKSRZ^)27/A?7=2TVQO+:;2I=A-[:NJ
M,!(JGD@<X)^7[P[UZ&QPI-<%=>#M7N-&\2Z.ES8_9]3O&O+>5MX="TB.5<8Q
M@;2`0>>*`-NW\<Z%<:?>WGGSQ)92)%-'-;2)*&?&P!"NX[LC&!S6CH^N66N6
MTDUHTJF)_+EAGB:*6)L`X9&`*G!!&1T(-8/B;PI/K1O)K>:&.Y\ZUN+;?N"^
M9"6.'*X;!#8R#D5I^'M+DTP7K2V=I;M<3B7_`$>>24O\BKEV<`D\8^@%`%#3
M=;UK7"NHZ9;6!T8S-&@GD<33*K;3*I&54<,0I!)`'(SQ;LO&NA7VI1V$-S+O
MF=HX)I+>18KAESN6.0@*Y&#T/8UEZ1H/B70"VE6%UI;Z&)G:%[A9#<0QL2VS
M`^5L$D`D].M5],\(:S;0>'=+N[NR;2]"N/.AEB5O.G"JR1!@?E7"N=Q!.2!C
M%`&HGQ#\.R$B*XN9&9281':2L;@@?,L6%^<K_$%SCO4UQXYT*"QL[L3SSK>P
MF>WCM[:2621`1N(103\N>>..]9>@>#[W26\,&6ZMW&D0W<<VS/SF9E*[<CMC
MG-9%MH6O:%K^BP:>+2>YBL]39IIUD$`\VY2102HSNP1QWVM]:`.KO?'&AV.F
M6NIM+<S:?<Q^:MU;VLDL:)_>=E4A!]<=#2ZMXWT+1;QK6]N)1(A3S?+MW=8E
M?&UW*@A5).,FN1N_ASK,GA]=$BU6&:S.F_9?WKRQK%,SLSRA$X?(;`#'C:/4
MUTDWABXDO?$D[3P>7JMG!;Q*03L:-7!+<=,N,8]*`-)_%.D1V]Q.TS_N+X:>
MZ")B_GDJ`@&,G.Y3QV.:@G\2Q:.JQZJMP]U-/,(8+6V>:0Q*Y`?:@)VA2F6_
MVAZUAW6B2W7Q4BEC1AIL4*:A=`Q_*UTH>*(@]&.TDD=MBG@]=+Q=H%_K)A?3
M5LHKR&*18+Z262.:U=MN&38/F&`<J>#@=LT`1^._%<WAS3K+[&DQN-0N4MXY
M4M'G$()Y;8OWFP>%R,GZ57?Q7=QWMC;1SP3L^K06$^ZW>-U5[4RG<">&S@\<
M`'!Y!K6US1+G5;71XTN4WV.H6]W*\@/[P1G+8QW-9<WA"\DUZ34%N8/+;78M
M3V_-G8EMY)7I][//IB@"U;>.--AT'3KV]N#/->K(T*65I*QFV-AMD>"W&1GZ
M$]*?>_$'P]9:=;7QGN)X+BU^V+]FMI)2D'_/1PHRB\'EL=#Z50T'P?>:0WAA
MI;F!QI$-W'-L#9D,S*5VY';'.:YSQ!I,]AJ$=O.`8ET22#"13^7=$R,6B)B&
M>F!@_P![Y1R:`.^L/%FEZEJ,=E:"[DD=`S.+23RXR5#['?&U7VD':2",BI]1
M\1Z7I4E['>7(C>RL_MTR[22(<L-P]>5(P.:YS2-!UAM=L-8%M9Z-')^]OK:"
M>1GF!A"K'(N-FY6_C'.%`[FKGBWPD_B'4M+N(YXHXXF,5['(F[[1;%E<Q^Q+
M1KSZ9Y]0";5?&.G6]JIM;R/S&AM[H2-"\D8BEE6-2=O=MQV_3/0&L*[^)*W'
MAC7M1TZQO+>?2I2A-[;.L;A9%4\X'."?EZBDA\`WJ:!J-B][%)<375O]FE<L
M=EK!,LB(3C.[[_'3)&.*FN_!VK3Z+XDT=;FQ%OJEX]Y;RG?O0M(CE7&,8&TC
M(//'2@#I=&\2Z=X@6Z^PM<![5PDT4]N\+KD;E.U@#@CD'O7*77Q+6Y\+Z]J6
MFV-W;SZ5+L/VVU=8W`D53R0.<$_+]X=Z[*"R,.LW]YN7;<I$H`'(*[N3^8_*
MN3NO!VL3Z+XET=;FQ$&IWCWEO*=^]"SJY5AC&!M(R#SQTH`VK?QQH4UA>WGV
MB>)+.1(IHYK:1)0SXV`(1N;=D8P.<UI:3K=EKEK)+:-*IB?RY8IXFBDB;`.&
M1@"IP0>>Q!K!\2^%+C6OM<UO-!'<&6UN+;S-P7S(2QPY7#8(;&0<C\*TO#^E
MR:7]N,EG9V[7$XD/V>>24O\`(HR[.`2W&/H!0!C>'/&-WK*WM_>-I5II]L9!
M-;><WVJSV$C,H(QSC.,#'JU:EOXXT&>UNKA[F:W2V19'%S;21.T;':KHK*"Z
ML>`0#D\5@ZQX(U'Q+=.^J-I=J3:7%M)=V",)K@.-J!]PX4?>*Y/S`8(ILW@O
M5+RS8NFE6VI(EO)'=1S3S^9+#*)0K!^5B+#H"2,GK0!T]IXLTR[%D`+N&2\N
M6M8HKFUDB?S%0R$%6`(^49STHU+Q7I.FPQO/+,6EEDABCB@>221XVVLJJH))
MSGIV!-9NJ:3X@U%]*OR^F)?:=?-<1P[I#$8S"T>TMC.[+DYVXZ#WHM_#.HC4
M]!O;JZM7DL+J\N+CRT90_GA]H4'.,;AG)[4`4[KXAVFFZHME<07EXTFH/:H;
M*RE8P[8@^U^#N?GHO8Y[&M23Q=8V$^I+>W'F?9[M+6*&VMI7F9S$LFS:`2[8
M)/RC`'7D&LJ;PCJT6I-J%G<63SIKDFIQ1S%PI1[?R=K$#(8<G@$5'J'@F^N-
M;GU:&>V:8ZF+R*)WDC5HVMTAD0LGS*WRY!&1QR.:`-Z7QKHL>G6MXLMQ/]J9
MTBMX+:22<LG$@,:C<"AX;(X/6M2]U."PTYKYX[B2,*&"06[R2-GIA%&XGGTK
MC[[PC?2:-!!9V&D6MY"]S+#.ES.&MI),[9$<#<Q.26!P"<5KZSI&L7FB:=:6
MNI#[1;30M=L[M%]K15(=2R<IN)#<>F.AH`?_`,)QH?\`9-OJ7G3^5<2O!%']
MFD\UI4)#1^7C=ORIXQGBAO'.@C2K/45GGDCO"X@BBM9'E8H</^["[AM(.<CC
M%9&D^#+VQ31/,N+8FQU6ZU"4(7(*S+*-JEN3@R#D]0*LS^&]4M]7L=6TJXLC
M/;M>1O#<!@C13R>9P5Y#`JO;!YZ4`7K;7GF\%W.N1/%<%(;B:(I]R0(7V?@0
MHK,T3Q3?C14UGQ#?:/\`898X"/[/20F!I"`/,)8@*-PR>,=36G#H=VO@VYT:
M:>W-U/#<1F6)"B;I"YR%Y(`W=.>E8MGX;\2#PK+H-RN@V\;P0VOGVB.S-&,+
M(6#+@L4SCW-`&[<>--%MX))/-GE*W3V:1P6[R/+*@RX15!+!><D<#!':L6_^
M(MEIGB%4NC-_9<FE)?(T=I*TB?O'5RX`RJ@`9W`8IEKX.U326T9]/N;-_P"Q
MI;B*VCGW+YMK*%X=E'$BE>H!!QSR:TAX?U&XUJXU*]N+1I+C1A82+&K!?,WN
MQ(!S\GS8]:`+^I^+=+TB>UCN_M8CN-FVX2TD>%=[!5W2`;5R2!R>XJ*Z\:Z'
M9ZP-+EGF^T>>ELY2W=DBD?&Q78#"EMPQD\USNK^"M;U.5X3J,$ED?L9A$DTJ
M_9_)*EPL8^5MY0<GD9/H*V5\-W`GUZ0SPXU+4;>\B!!^01K$"#[_`+LXQZB@
M"9O'6B#7(=)5KN2>:X-LDL=I(T+2C.Y1(!MRN#GGC!STJ;3_`!AHVJ:F+"UF
MF,C[O)D>W=(IROWQ&[`*Y'.<$]#7#:7%<P>*$_T%[F8Z[<N;=Q-']E1]X,Z\
M>4?D;\=QY+$UO>&/!ESH-QIL4T-A<0Z=YJ071GF,JQE2JX0_(K8X8@X/8"@#
M4O=:U.\UVZTG08[,R6*1O=SWA;8"_(C4+SNVC))X&5ZY.'7OB^PT9H8-5\U+
MPPB:XBM(9+E8%.<NS*ORID'D@=*JW^B:[8^)KK5_#TVGLM_'&+NVOS(`'C&%
MD0KGG;P1CL#5:Y\/^(HM2U.^L+O3))M4L8[>Y\])$6*5-P5T`SE<.WRD@Y`Y
MH`U+WQSX?L)(TEO2PDB2??%$TB+"^=LK,H(5./O'BEA\;:#-;WUQ]JDBBLMA
MG:>!XL(YPKC<!E#_`'AQP:YZX^']S_8^J:;;7L1CN-!MM)A>4$'=%Y@WL!V(
M<=/>K/BGP9?:]>ZA/!=6\8N=+ALD\S=D.D_F%C@="./K0!?'Q#\.E1NGNHSY
MJQR*]G*I@W'"M)E?D5LC#-@'(J9O%=G92ZK]LN%D6UO$M8X;>WD:4NT2N$"C
M.]B"3\HZ?0UGZOX0O-0M_&4<=U`G]O11QP;@W[O;$$.[CU]*;=>$KB6;5I&M
M]/O%OM2BO(X[B22,Q!(%C!#(,JX9<@CL30!L/XOTL7-G;!;Y[BZ19/*2RE+0
MJQPIE`7,8)!'S8Z'TJFOC6PM([G[9.UQ,+Z:UA@LK2625O+(W#8`2Q4'EA\M
M9/\`PB/B#9ILAOK0ZI;Q0QSZN))!.ZB0M)'M`VR*5(4;CW)ZXJ2V\(ZQIFNG
M6+&YLI)OMEZY@FWJK0W#(WW@"0X:->Q!!-`&S-XYT"*QM;M+J2X2[#_9TMH'
MDDD*$!U"`;LKGD8XP?2MG3=1M=7TRVU&QE\VUN8Q)$^"-RGIP>:Y/1?!U]IN
MI:->W-Y!++;-?3W>Q"H:6Y=7(0'^$$'KSTK5TA-0TR:RTD6R/816KO-=#@"0
MO\B*._&XGCCY?6@!;OQ-9Z7JNH1ZA>0PVMI;6\KYC?<GF.R`LWW2"5``'(P<
M]13(O'&ARZ5<Z@9;F)+:<6\D,MK(DWFL`501E=Q8AA@`<YK-\0^$+S6-1U2Z
MAN;>-;R&PC0/G*FWN#*Q/'<'`]ZGUSPS?7]XU]87%M'=0ZA!?6ZS*=CE(S&R
MN1R,AC@C..*`&W/C6$:CI+Q"1-.N+:]FN1/;O'+&8`A^Z<$'EN".>*VSXBTM
M+)+N6Y\NW:S^W>8ZD`0\?,?S''6L+5?#.J:[=6=Q>W-I$T5K?6SK"&;:)U54
MQG[VT+R3C)Z`5GR>"]9U+07TS4KVPA"Z6EC`;9'?:R,C!V+8R"4'``QZF@"[
M/XY@FAU:ZL[@00V%@+AQ>6DBM$Q9L,Z<.5*C(QU[5J7/C71+/5ETN:>;[3YZ
M6[E+=V2*1\;%=@,+NW#&3S61JGAG7]=TO6HM0N-,BN;_`$T648MQ(51LL2S,
M>2#NX&./?K5Y/#5P)]==IH2-1U"WNXA@_((UA!!]SY1QCU%`$S>.=%77(=)5
MKN2>:X-K')':2-"THSN42`;<K@YYXP<]#3;_`,8VNG^+K/P[)9:A)-=1&030
MVSO&OS*O)`Z?-RW1>,]17'Z5%=0>*(R+![F8Z[<N;=Q-']E1]X,Z\"+[A[#G
M<>2Q-=GJ>E:A)XKTK6K)[4K;036T\4Y8$I(T;%E(!^8>7T/'/6@#.\-^/+74
M+^32K\R)J']H75I$R6T@B?RG?:N_&W?L7<1FM*T\<:!>:@MG%=2J9&9(9Y+>
M1(9F4$L$D8!6(P>A[&J^E^&9["TBADGB9DU>YOP5!^Y*TI"C_:`D'MP:R+#P
M=K<%EH&E7%WI[Z=HDQEAD57\VXVHR1*ZD;5X<[L$YP,8H`Z"'QKHLVFW&H[[
MI+.$H%EDM)5$^\X0Q97]X&.,;<YR*OZ/KEEKEM)-9F4&)_+EAGB:*6)L`X9&
M`*G!!Y'0@UQ!\!ZM)ID]N)K"T2*2UGL+&*:9[>*:(DN<G#*K@XPN,8!ZYSUG
MA_2WTP7S26EI;O<3B3]Q-)*7PJKEV<`D\8^@%`%%O&FG7>M6>FZ?<LTLEX8&
M9H'$<H57WB-R`K%2HS@G%+8^-M/:WM5FF>ZN;B64!;&SF?8BS-'N=<$HN5QN
M/!(..*I:'X7UK2HM+TV2ZT^33-,NWFB=4?SY$(DP#_"I!?DC.<=JSE\#:Q;V
M-K#9S:?!?0O*4U-))5FB62Z:5E"@8==K`;6.,YH`ZV/Q9I4VMMI4+W$DZ.T;
MR);2&%9`,E#)C;NQVS3[?Q/I-SIEIJ2W.RSNK9[J.612H$2@%F;/W<`]ZS=%
MT;6-%NKJU2>RDTJ>^GN@Y5Q.JREG:/'W>';AL]!TSS67H_A/7+#2++3KR32+
MFWL-.GLH8BLA6X+!0IDST7"D%0#UZGI0!M_\)MI']F_;6CU!%:7RHH7L)EFF
M;&[]W&5W.-H)R`>`33K[QKHNG&$7$ET"\(N'"VDK&WB.?GEPO[M>#RV.A]*Y
M]/!VJ+826\D>FSP+<K)96CW<^VP58BH,4N-X)<YQP`,@5&_@;5?,>:>:RU:>
M[TR*UOOM<TT(DF0,`W[O[R$.05([#!Y(H`VM>\;:;8F>SMKHF^38H?R7:%7?
M:51GQM#,#P,Y.:UM7U/^S9]+3SHH_MEZMMB2-FWY1VVKM^Z?EZGC@^HKF7\*
M:W!_:MG:7.FKIVI7,=V_FHYDB<!`Z*!P5(C7#'D<\&M_7]'FU:XT62*6-%L-
M12\DW9^90CK@>^7'Y&@"*W\;:'=:S'I4,\S7$LCPJ_V=_+,J9W1[\;=X"DXS
MG%=#7*:7X:N+"U@BEG@=H]8N-0!4'[DC2$*./O?O!G\:ZN@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@!"<#)K*U'Q)INFZ1=ZF\WG6]I)Y4_D8<H^X*5('<$C(K5;E2#7B\G
MANTL/"?C;3K'1;F'47O7"".WDR]N9D*;&Z,,$G@YX/I0![1GV-&?:O+]>\.2
MZ)8:S;:);72:;)=64]S;Q^9)NBR1,$`.YLA5+!3DC/KBNC\#V4-A::A#:W#2
M6OVD&*%;66"*W&Q<K&)"203EB0<98B@"_-XOTRWLKN\G\Z."TMWN)6V9PBR,
MAP`>3E#^E+9^+M.OK6XDAAO_`#[=%>6S>SD6X56)"GRR,D'!Y&>E4O'VG"3X
M?Z_'96>^XDL9$1((\NQ.3@`<GDDX]37&:[I.KVL7B:UO'N]7OY["U:ROEMMK
M>2)1OAQ&`H(;YN!DAN>E`'KC.%4M@\"J6D:O:ZUHUIJMIO\`LUU$)8]ZX;!'
M<>M<3HL"VOCZ^:.UFU"6[-T\NH26TL+VH5@%A8M\LBGHA7'"CKUJO\*[._LK
M*VBUJSN4O%L(OL<LB,J+;X&Z(+_`ZM][/+94]!@`'6P^,-/N-=FTF&VU&26&
M<V\LZ64A@20*&P9`-HX(_,5O[O8UP_AG2M5C\3>(;XZA=VUD=6D86)MTV3CR
M8P'#E=V,^AQ\OUKD]-@U6ZU:\U/2='DTW4+O1KXRPI#*FR[++Y2R/)\KOD,0
M0`.O8B@#UZXO+:T$9N9HX1+(L4?F,%WNW11GJ3Z5-NXS@UXQJ7AWPW>Z+I5S
M;>'=19H+RTDU(SV\Y?:S$2[@>6?CYB`3@@YJSK]C%+)X@,NF:J^H+!$/#3P1
MRCRU:%501E>$82;BV[!QC.10!Z[N]C^54]0U2#31$9E<^:7"[0/X49SW]$/Z
M5P4FB27>I^*+S5&O[>XM;>%;.\B1Y&@9K8+*\*K]YL\'`)XQ6QX#L[8:9>6H
MT>&V@MKIDCE2&1([G*#,BI)RO4J>2#@\D&@#K;>X2YMH9T!"RHKJ#UP1FI-W
M;!KF?&UE#=^'UM'N9;6`W$0(CMGF210?]7(B8/EG&#@C''-<%-92ZE!H@U'2
M7T[1VT^5;>V>VN)HX)UE;YRJE64LFUDWYQR.#U`/9-WL:HRZO:I9W%S"7NEM
MY#%(EJIE<."`5VKSD9Y':O/;FQMY]4L5\20:IJNG)HT!L9_L\H,ER-WF,47E
M)6!C(W8(Y`/6LD>'[?3/"_C.RL-&NH-2:^;RPEO)E[?SD,>UNC#!)X)/7-`'
MLV>,XHW>QKR.\LI9+R\D^P:G_P`)<=;VV]RJR`"U\X,I#@[!%Y(((]<Y&36E
MIWA]Y=6DUJ>WO!J%OXCE2&4EQ_HI8C:!T\L[B?0GF@#TNLG6=?@T=[.$VUS=
M7=Y(8X+:W4%WP-S'YB``!R<GZ9K`\;P"ZU708M2M+FYT!GF%\D*.RB0J/*,@
M3DIG?Z@'!/:N0TWPLFJZQX<N-0T>[DL?[0OOLXNU?=#:!"T"MDY4;N@;GI0!
MZZ]Y;1W4-L\\:SS!C%&6&YPN-V!WQD9^M5M+UBUU=;MK82?Z+=26DN]<8=#@
MX]O>N0\8:'ILOC[PUJU]I4EQ"J3Q2S1PO)M<;##NVYQSOP3QZUGZ5X80:O=:
MTUG=1ZBGB>8K*-XW0,2#QT\L@Y]">:`/3MV!G!K*U7Q%8:1)'#.+B:XD7>EO
M:P--*5!`+;5!(4$]37GWA/3)X_$5I<ZC-/;ZXMY<)>D64Y:Z&'P&E)\ORL;6
M4@`?*H&*W;R];PUX]U#4=0LKR:PU&RAC@N;:UDN/):,ONC94!*AMX;/0X/>@
M#L[.\@O[2*ZM7\R&5=R-@C(^AY%3;O8UY-XB":GJ6O7>J:3K+S-9QMH&R"4-
M&VTJ=H3[DGF$$[L';@G@</\`$.D:I>_:FO;>\GNK/PJD\+)N(&H+YF&7;PT@
M/3KU]Z`/5MWL:-WL:\A\0V%QX>L]9ETY+NWBN/#37-Q,S.VZ[1UVL6;I)AF]
MSCVIWE16$NNRZ'H5_+HDUI;P7,%Q'.J27#R$22;3\[;48%MHYQC.:`/7-W.,
M4F_V->16&D70\/'3XK2Z2QE\4QJL<,4L2FT9%#E03N6,_/GGN?6M"_L$\%:5
M)K5G%<K;:)J4K);9)#6TR*&1<D94.P8#_9/>@#T47\1U)K':WFK")LXXVEB/
MSXJR#GMBN#;07M/AC]DO+R>VO[B)6N[R&!IY/,DD#NI5?F9"S$$#'RDGBK7A
MF_\`[,\#7=S%HLEI'9O,(;>"*0_:`IX=$;Y@'/13_P#7H`WM/\1:9JNJ:EIU
MG<"6YTYU2Y4#A2P.,'OT(..X(K4W>QKS?1])U?PWK7A^]NK576ZB>ROWMB\C
M-)(QE$D@VC`$F\;CG&_ZFD\)^'3%/HFN36]XFJ->WD-P\A<$P9F$:LIZ*`L>
MWH.A[T`>D[O8TF[GH:\S\&^'GMH_#VL2V]XFJ3Q7,-ZTI?+KSL#@]`-JA>F*
M;X:OKVV\.:)"FD:G/>:7I%P)X9('B#S*JXBW,.6)'!&10!Z#K&K6^AZ/=ZI>
M"3[/:QF638,MM'7`[U7USQ%9>'[2WN+N.ZE%Q,((H[:!I7=R"P`5>3PI_*O*
M4TRX/AWQG_9^ERQ07>B0E(+>UF1&N#YA=0LF2S@%`2`.W'%=WXZT^]OX?#<-
MA)/;S+J\3&XAB$A@`BE^8@@C'0<C'-`'2:9J]EK%H;FQD,D:NT;@H49'4X*L
MK`$$'U%7=WL<UY%<6&I)X?\`L=[#/,8M>?\`MJ86TI%ZC*1'*40@LG,6X*<#
M:1@@<LEM;&U_X1[3;RXN[W1I;Z]$ENEK/&HC$>Y8E3EVC5@"#R./2@#V#//2
MC=[&O'K#3SY.CQ>)--U.7PYY5X;6&6.60Q'SMT`D526!\D84-G!XZU=T;0;K
M5W\-V7B"ROYK)K"]DEBNV<\?:$-NLISRPC;@,<\>HH`].M[VVNXVDMIHYD5V
MC9HV#`,I(9>.X(((]JEW<9((K@OAOH^GZ*-8M8-,DL[T7\_F;H74-#YKF'#'
MAAM(Q@_6L""RF-W:R&PU1?%_]N8N+D+(%-J)RQ^?.SRO)P`.F>,9H`]=W>QK
M#USQ78:#>VMG<6]_<7-S&\D<5E:/.VU"H8D*#@#</SKD]"\/'^T;76YK>[74
MDUV\B\QRX/V7=,%4@\>7C:1VS@]ZT_$NE:GJ/C_17T^_NM.$>G78>[AMTE`)
M>'"'>"HS@GU^7ZT`=C!,L\,<J*X5U#`.I4@$=P>0?8T_<,9P<5Y9XJM!)K6O
MMJ]AJEY<K9Q?V%-;1R$!]FT[#'PLGFG)S@XQV%7M.T2[NM;U6XUFVN)KNRTR
MT-L[EBHN#"ZRLF/E9LA03SV]:`/1L^QJ&ZO+>RM9;FZE2&")2TDCG`4#N:\L
MT'PC%?7.E6VJ6-\UM>^'DN=066251+>909?G[X!;`[>G`QV'AN_N+;X=:5?:
MY%=//'91-<J;=GEW``<H`6+=.V:`-%/%.D/X=37DN2VGR#]U($.Z0[MH"KC<
M22,`8R:FT;7;+7+:2:T\Y&BD\N:&>)HI8FP#AD;D$@@CV(KS/2WN)?AMH)33
M=2:71M5AN;R%K.1)!&)78E%8`O@,#\N:ZS2(-1O/$'B'6K!4MX+MK>&W:[@?
M]Z(D8.X7*D`E\`GKM/;%`&M>^+M(T_\`M(3RR[M.>*.9%B9F9Y0"BH!RQ.1P
M*L:WKUOH=G%-+!<7$L\JP6]O`H,DTA!(49(&<*QY(Z5P%WI^H6'Q'U;Q.]E<
M75G9RVXDMTA=MZM`JF:%1]YT.0>ORE@.>NYX_P##MGKMUX8:YTW[8J:HJ2_(
MQV0M'(6SCHNX)R>^*`.@;Q':17MG:307<4MW=-:1>9"5!=8S(>3U7`(W#(R,
M5K[O8UY5+IVK_P!LO]CMITD7Q'=O;2/&=B`Z>5C?)&`F_`STSQ5;P[IMY#IE
MQ-I4EU;ZW-HLZR6S6<Z-+=`*%>625BI</G'J&)'%`'JSWT::A#9%7\R6)Y5.
M.,*5!_'YQ^M3AL]C7GW@VST^+6K2;2[#5K96TY_M?VN.54,Y:+)._K(>=Q'7
M'4XK/\6:5X@F\07^F::MU]FO"FKQ7*YV1RP(1Y1;^'<ZP'`&<;NO-`'I4UXL
M$UO&8IW\]R@:.,LJ8!.6/\(XQD]R!WJG/XBTV$:>RS>='?W9LX9(<.OF@.2"
M1Z>6P/H17!V=A>ZE>:)JUU9W7_$UUB:>YBD1OW4'V66)%8$`JN`.#T+UC:7X
M5L3H>D:2-%N8I1XB8ZDGDRIF(&Y\LENA7:5&0<8(!ZT`>T[@.M9<WB+3H8]+
ME6;SX=3G6WMI8,.C,59@<CL0AY^E9F@:#:V_AS4=%DM9&T_[3<1QP3%B#$6)
M"C/.WG`]JX+2?#=G-X&\(Z2NCW43+JT/]K1&"6,[Q!('+'CC.T$C@YQWH`]D
MW<]#4-S=P6=K-<W,JQ00H9))'.`B@9)/L!7EVJZ%)9VVF:;]FF/AZ+4KM)8)
M(I9D4-S#N5"&,0.\#D@?+G.,CK=$LX$\`&SNC<ZK9B&>-U>V>-Y8MS_NUC;Y
ML!?E7)R0!ZT`:FC>(['71(;-+M=H#+]HM9(?,0]'7<!N4]B*UMW.,'->/7G]
ML?V3>:=I=QK&H^'8#:2.UY:R"=(B_P"\A7`624!-I(R"`",G.*M3:=]E\.FW
MM&O+K1?[9B-[:6EG/$L-MY?S)&K$NZ%]K-M)^\PQU%`'J^[K[4@8>F/K7FT+
MVFB>)+6XT[3-332#I5S;6T4=M*^9?/4X`.2H(R5W8&/05:TW1VU'Q;I1U*TN
M7M;70K2:-90P1+E9&Y/8N!Z\C-`'9VVK6MR+4$O;S72NT-O<J8Y6"GYCL//&
M1^8]:EL[Q+VW$R0SQ`LR[)HBC<,1G!['&0>XP:\BTOP];A_`FHZUH]S(T<=U
M#/(UO(S1OYFZ$.`,CG>02,4\Z9>RZ5H,&K6TQTLW&HBYBGMYI$$IN&:)I$0A
MMNT-@G(R1QT(`/8L^QI>U>1R67V670+AVO?$$UM#!%#;75C<1,,S,/.1^B,!
MC<'SE47D9&?7*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BD;I7GEEXEO;OQWI9L]3O)]'U
M&>[@\J>"%(@84.?+(_><,I!+<'G':@#T2HGN(HYHX6D42R`E$)Y8#&<?3(_.
MO-M%\0>(SIFG^(KG4A=V]W:7;-IX@50K1*2A5@-V3L.<Y^]P!5SPU=WU[K&@
MW=[K]OJ7V[3I;L1+&B-`6$>0NWK'SCYLG(Z\X`!VUWJNGV#*MY?6UL6&5$TR
MIGZ9-6HW62-9$8,K#*L#D$>HKSWQ):V]U\3[))[32KE1HTI":ECRQ^_3D9!Y
MI;O7M2MO'</AZTOX$TZ:6W<3+&`+0!"?LWW=N9`F5R<@%O\`9H`[VZNH;.W>
MXN)4BA09:21MJJ/<GI4W:O(M4U._USX9:YK5WKJ,EW9W:+I(CC"Q%"0`&^^6
M4`;LGOT'%=,FHW_AFVUQM=U][JU@M8+B*X%JBO"9"Z$!5&"-RK@'/7DF@#MZ
M*\L7Q-XAT[2?$D4E_--=:?>6,4$E]#")%$YC#!Q%\I^^<8Y]ZMZIJFOZ)9W%
MA-KDERYU2"V6]%O&+A89(]QVJ%"%@P/4?=SU(%`'I%(3@5Y5::IXMDN+'1Y]
M5OO-NA=W4=S'!:^=)&DJI$@#80?)\[`9;YNP%=%KFH:['\*KJ^E"Q:P+`//]
ME.[RSQYC(03R%W$$$].*`.MBNX)Y98XI8Y'B;;(J."4/H1V/UJ>O/M7N_#OA
MOPL-7\/+I45WY44=O<*%)V2,BF1L$%PJD,<^G4=:H:OXEUSPT=<L4UI-5:ST
M^WO8[B:%`\;O-LV,$`4J5Y'`.#U[T`>H45Y;J.L>)M*@\3.?$#3CPYY,XW6D
M8:[#()&C<@85<$J"H!'!)-3ZMX@\01ZKJDMKJBPP6>K6NG16YMU=6$ZQ99S]
MXE?,R`".G.<\`'H\TT5O$9)I$C0$#<[!1DG`Y/J2!3P<CIBO--2UG5;/2O$6
MF7EZM_+INI6"I=36\>7CFDB;:4QMRNX@''H>",U-_;'B6&[U:U>]']L2P3RZ
M=9R"+[(8TD"ATD'S!@"N1(?O-Z=`#T%[B.-XT=T5I&VH&8`L<9P/4X!/X5(#
MD9KS&7Q'<6\&DL+NYU&YM-3NX;I;VVB68/':2R>6"B[1T7YDZ@XSU%.L/$.L
MV\NA2R>((M276[">Y>$01J+8I#O!C*\[0WRG=N^N:`/3:*X?P;>Z]=W&EWVI
M:L+NUU;21>_9O(5!;R9CX0@9*XDQ\Q)R,\=*S_$'B'5UG\67MKKD=@GAU%,5
MD88W6X)A60&0M\V&8[!M(Y!Z]*`/2*8\J1C<[!5SC+'`]*\]UC5O$5[J&IQ:
M=JPTX6&D0:DJ"!7WR-YF48L#\G[OMSSU%7OB5:P:KX/M;.Z!\B\U&QBE`.#M
M>=`<>^#0!V4EQ'"F^5UC3(&YV"C).!U]ZEKP_P`2:C/XB\%7ND7F&F\/64[Z
MD<E<W"9B@XXR"`TF?]WITKJ[OQ+>_P#"7Z<=/U.\>P?51I5S;R00B`.(G+A6
M_P!:6!4<_=H`]%J![N"*>*!Y8UFFW>4C,`SXY.!WQ7F\GB'75TR;4WUH0K<:
MRVCQAH8_+M4%PR><<C+/A<<D+R...9=:L=0D\0^$[!/$DDUXEW>(=0$$1EC_
M`'!)4J!LW8XSCH1Q0!W^H:?:ZKI\]C?0B:TN$,<L3$@,IZCBGV]S!<(6MIHY
MD5BA,;A@".QQWK(T.YDF\'JVO74$SHDL5W.P$:.$9D+$=`"%R:\\U.*&+P[X
MM\1:(T>GZ==6D$5O!:XC+HK_`#3LJ_=W!B!T.W)/6@#UJVO;:\0O:SQ3H&*%
MHI`P##J..]5]8M].N;';J@A-K'(DI\Y]J!E8,I)SC@@<'BN7TR'3]-^(LT.D
M1VUMIIT9);I;8*L0<R_NF..`2GF<CJ!ST%;?BFZT6UTU)-9MH+N/S0MO;2HK
MF:4@A556X).3UX`R3@#-`&K->06UL;B>:*.!0"97<*HSWR>*?]HC\GSMZ^5M
MW;]PVX]<],5Y=IVD)87/@G0M5FM;NUE6_D>W9A);^;\K)&H/#;`SA<Y[FJ&J
MPVDOPGU@N_\`H=KJDYTH&4JAB$X"X&?F49<#.<=N@H`]@N+B&U@::>5(HE^\
M[L%4?4GBI`=PR*\E^+NJ+=Z;?:=/!?MIT.GM=1RV\#R07$YRJ!W52JJFTL<D
M<E3VKN-6UV"V\*+?B>[M%N%CC@=;?]\'D(5!Y;C`8D@?-P.]`'1T'I7EUMXC
M\0+HTMJVI2&\7Q&NDK<W$,1D6-U7)94^0L"QQCT&>]6I-6UZUEL?#UQKP2>Y
MU2XM?[5,$8D$:1>8B[2-F\[@,X[=#0!Z#%<Q3AS$ZOL<HVT_=8=0?>DENX()
M(HYI4C:9_+C#-C>V"<#U.`3^%<QX;%Q>>&M20:HAN7N[E/MUHJD;@Q&]5.1G
MCD<C.:XBQ@U&Z\`^`R=>GFNKK5+=TN)421K?,$N5''S8P<%\G)YSTH`]EJI/
MIMI<WUI>SPK)<69<V\A)S&67:V/J.*X"YUGQ%#_9>AG4IWN+B]O+>34((81*
MRQ<QJ`^(P[`\\?P-@=QT^G76O_\`"&R378M?[:2&8()'7RV=2PC+E20,@*6P
M<`D^E`'1U%-<PV[1+-*B-,_EQAF`+M@G`]3@$X]C7G$/B35+2TL[6XU6[;4U
MUJSMK^*[AA!B649**T8VLI'((YI?%-]+JQTM;?5(XO+\4+!#=($<1`6[YQG@
MD$L.<X/KC%`'I0.12UY:=?\`$4FE7"1ZK))9Z7?W4%[J=K'`;AHHT5U=48;"
M!N*OM&?EX'45+-XB\2:KJM\^B73M'I_V9H(2D"174<D:.9)2Y#J#N8#8!@J>
M2>``>FT5YU;:_JUY>/J`UZVAA&N'3#IC1I]Q9@F0WWO,8?-SQM/3O5S3?$MU
M*;B.>_C\[_A));")&VAC$K?<`[X'?KB@#N:*\Z\+:WXGUC4++4I)7:RN;F>&
MZM9!`L=JJ;PH3!\TR`JH(8=V.!Q1H=]XDU;^S[^37BEM?W%Y8M;I;1_NO+\T
M)(K8R6S%DYXYQB@#T,MCM4(OK4W9M!<0_:0N\P^8-X7UV]<>]<)X!?54^&+7
MB:I<:I?O!,]NDX5BCJ7"KD8+98#[Q-8MY;Z&?AGI6IZ:;677Y&MFM;M2#<RW
MA=2P+?>9LE\J>.N1B@#UVBN&O/$MW;:EXM@>_CC6REM([-7VC:9$4D#/WB23
MC.?:J=]XEO6\96+:;J=X]@^K_P!EW%O)!"(`PC<N%/\`K2P*CG[M`'HA..U+
MVKR+7;G7]4\(ZAJS>)KJSC@U?[$EO;11HNU+T1AF8@MNQR<$`X`(ZYU-5U/Q
M1_;%YI&EZC<23:;I\5Q$_EVP^VR'?EI2^W;'E0I\L<9/(X%`'HL\\=M"\TSJ
MD2*7=V.`J@9))]*<CK+&LB,&1@&5E.00>X->=ZC?:OJDOBV&?4/(L]+L>;2*
M-2)3+:;B&<@G:K<C&/<D50T_Q!JUG8Z9X=AN]EUJ"6#Z=(%5FCM6C!F.,8.S
MRY.2#]]/K0!Z;=W]I8('O+F"W1C@--($!/IDU,K;NG3UKA/B'#+<W_A2*'3K
M34)6U*3;:WC;8G_T>7[QVMTZC@\@5SNC:GJB66DZ/ITUSI[7\]_-/';)"SVD
ML<@S;1B4[0!EF[D@9``/`!Z_17GLVJ^(YV\,:9=ZE%I5YJ%O<F\G@6.0JT6P
MJ4SE<D'GJ.3[$9VB>)]:\2MI]A)X@CTUA837<E[##&3=;+AX@P#Y4+M0.<?W
MQ@@=0#U/M2`Y[5YGHOB#Q!XMET:U75AIIN])>]FFM;=&+,DWE@J)`P`8$'H>
M@Q6=H<WB6#P9#<6_B"\NH7O;O[6_[AKFWCCDEYB#C#9*@L&R0.%Q0!Z]17&Z
M[XDEM_"&D7VG:@H74Y[6!-0FC`$:2X_>E#@`X['`!/X5BWGB;6M$T_Q9:_VI
M'J,VBBT:"[DB4,6E;YDD"84XQV`.&_&@#TPU375M/>\-FE[;-=`X\D3*7R.O
MRYS6/X=&K6VIZMI^J:J=26$Q202O"L;J'4Y4A0!]Y3CV/4UQ&E/<:6_C'78_
M#VE7,=CJ&H3I?._^D^8@)"!=AXS@9W=#TH`];HKS_2=7U:VU_1K2?Q!'J\.K
MV$UXX$,:FW*A"ICV?P$L0-V>G4U1L]9\1W'A7PWJ+:V1<^(;J&$XMX]MJC12
M$[!CEOE!RQ(R.F.*`/3J*\SL-?\`$$2Z9J%SJWVBW.N/HTEL;=$$J"1XA*S`
M9WY4,<87J,#K7I8Z#-`"T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`!K.@T'2;:]:]@TV
MTBNV8L9TA4.2>ISC.3GGUK0;[M<E9W&I)\3;ZPN=0:>S;34N8;<1A%AS*R]N
M6.%ZGU[4`=)!IUG:QPQV]K#%'!GRECC"B//7;CIG)Z>M0V>A:5ITK2V.FV=M
M(Q)+0P*A)/7D#OQ7G^F:MJGV#P_XJEU*ZDDU;45M+BQ:3_1EC=W11&O\)7:I
MSR3@YZUT6L:]]NO=&TK1[]5&HW,D<UW"0S1I'&9&5<]&;@9QQSWQ0!M:GX<T
M36GC?5=)L;YHQM0W-NLA4>@R.*E&BZ8J%!86P1I$E*B)0"Z!0C?50JX/;:/2
MN=T4W>B>,W\/MJ5Y?V,VG&]B:]D\R2%ED",-^,L#N!YZ8]^+?C:\N;+2;&6U
MGDA=]4LHF9&P2C3HK+]""0:`--O#NC/-<S-I5B9+H,+AS;KF4-C=NXYS@9SU
MP*M3Z?:7,<L<]M#*DT?E2J\88.G/RG/4<GCW-<I_PE^I/K4L-OHJ2:;;:FNF
MW-S]IPZNVW#JFW!4;TSDCKQG%:7BC7;G0]/2>U&G-*2?DOKPP!@`20N%8LW'
M3%`&C%H&D06S6T.F6:0.RLT:PKM8J<J2,<D$9'I577?#<.LQ0;9%@GANDN0Y
MA617905PZGAA@D>W!'2L/_A,[_48;8:1HOVEWTR'4KE'NA&T4<H;:B<8=_E;
MK@<=1D55/B;4CI'V#3-,:^-GI$$]]*USY<B^9&=HC!'SO\I/)`]\T`;NF>"=
M(LK*2WN;6WO&DNY+QC)`H5)7&"8UZ(,#''7DG))K=MK*WL[6*UM88X+:)0L<
M,:A54#L`.`*\UUWQ1K.DK,-'CCEN(++3&D>ZN6\O;+*R?*FT_,2,%L]#G^$`
MZVH^*KK1]<:.\LF>].G6V+>&\)A::6X,2J,J`/F_C/;MQ0!TMIX7T&P-Q]CT
M73K?[0I2;RK5%\Q3U#8'(Y/'O4D/A[1K:SFM(-*LH[:<@RQ+`H60C&-PQSC`
MQGTKF;CQO?Z7#J46K:/&FH6(M7,=K=>9',D\IC3:S!2""#D$#ZUM^'M6U&_?
M4+?5M/BL[RSF$;+!.98Y%9`X9254]\=.H-`&E+I=A,MT);.W<78`N0T8/G`#
M`#_WN..:1M*T]S(7LK=C)*DSEH@=TBXVN?5AM7![8'I7.>+-:\0:;K6@VVC6
MUA-%?W#Q2?:IF0DB)WV\*=HPN<^H`QSFLFWU_6[#Q7XA6.P%YI<>KV\$DDET
M5:`210CY$P<J"VX\CKQSF@#N9-*L)6F:6SMW:=D>4M&#YC)C86]2N!@GI@55
M'AC0A]HQHUABY!$P^SK^\!;<0W'(W<_7FN:C^(+3>(%M8K*![%M0.F[EN";G
MS`Q4N8MN!&&!&2V>,XQBHO'+ZQ<>)O#6DVD4,MA=RRM+&UY)`961"V"47(51
MAA@\G@C'-`'8V^B:7:)"EOI]K$L$C2Q".%1L=@06''#$$@GJ<FF6GA_1["26
M2STNS@>52DC10*I92<D'`Z$DG%<S:^.+RX>POFTA%T/4KT6=K<I<9FW%F57>
M,J`%)4]&)&1D4MGXUO;E+2_ETF.+2;J_&GI,+G=('WO'N*[<!2ZA1SD[N@H`
M[""RM;585@MXHEAC\J((@`C3CY5]!P./856N]#TF_NTN[S3;2>YCQLEEA5F7
M!R.2.QY'O7+:5\0!JXMD@L-LTVIR6I223;LMU5G$YXR`4`P"!R<9[U%!X_G#
MZXEW:6+C3M/;44?3[TSHZ`L"A)5<-\O;(YH`[5K"U>::9[>%I9HQ%*Y09=!G
M"L>X^8\>YI9[*VNHTCG@CE1'5U5T!"LIRI'N"`1Z5R8\5:[)=VEC#H=L^H7,
M+WHA-\55+4%`-S;,>82V-HR!C[V*T?#&KVQT+2X;JX\N\N8RZPSO^\/S'@^I
M'3\*`-9])L)5NEDLK9Q>8^T@Q`B;`P-_][CCFHQH6DK?M?C3;07C-N,_DKO+
M<#.<9S@#GVK@_"7BG6Y_#VFZ?I]BFIWT-G]JNI;R\,7[LRR(BJ=K%F/EGK@#
M')K2A\=WVKVZSZ#HRW,<=A#?W0NKKR619`Q5$PK!FPAZD#IS0!U[:3I[V4UD
M]C;-:SLS2P&)2DA8Y8LN,$D\GWIMOHVFVOD?9["VB^SLS0[(E'EEOO%?0G//
MK7"7'C)AXMT2ZLTGE&L:'OLK%Y-HDE:1&7>>BX7=D^F0,G`JY)XJNK'4-2MX
MK)KF\?5XM/CCDNCY?F-:K)D9'R(".0`3U/4XH`[.73;.:RDLI;:%[60$20L@
M*."<D$=#DDYJG8>&-!TKSO[/T:PM?/39+Y%LB>8OHV!R/8US<WC74X;*QC?2
MK2#5+BYN+9UN;TI;(T/7][M))8<J-O(!Z8J]:>++A_AU'XJN=,D\U[7[3]BM
MV+G!^Z,X!Z8)XXYZXH`TI_"NC3:+<:/'916MC<X\Z*V01B0#'RG`Z$`*?;@8
MJUJ6A:5K$4<6IZ;:7L<9RBW,*R!3C'&0<<5Q=YXL\4/)X=_LZUT*;^T+J2&7
MR[]Y(VVQNX`;R\KPN3QG(QCG(T]1\7W6G^*K/2E@TZ>WNIQ;`QWQ,Z2%&8%H
M]N`N5QUSSG%`&Z/#>B#38]-&DV(L8W\R.W6W41HW7<%Q@'D\TMYX=T;4;6WM
M;[2K*YM[88ABF@5UCXQ\H(P./2N%L/'NO0:6\NKV6F?:)]3GL+/9=LD>Y&DW
M>8Q3Y54)P1DMZ`\5K)XXN9=%L[F'3%>^N=1;3%B\\B$RA7(=9"N3&=N<[<X[
M$T`=4FD:?'I?]F)96RZ?L,?V41*(MIZKMZ8]JDN["UO[9[:\@BN+=QAXID#J
MWU!KC[+QS?S2V,EUH\4%C/?OI<TZW6]EN59D^5=O,9=2`20>AP*@TGXC-JEU
M`5L(?L=Y#-+:M%<EY5$:ELS+M`C#`<<D]`10!V,6B:7!"D,6GVJ11RB9$6%0
M%D'1^GWO?K3KO2-.O[>2"\L;:XAD<2/'+$&5G&,,0>_`Y]JY?2/%>MZLBNFA
MV\$=[IWV_3G>\)#_`'?DEPOR$[U/&[CWK(TGQYK[>'M!FU"QTT7FJ1^;'<2W
M3Q6Y0!>&;8=DC%N$Z<'G/%`'HMO96UG%Y-K!'!%G/EQ(%7/T%58-!TBU4+;Z
M99Q`3?:`(X%4"7!&\8'#8)Y]ZS?$VHFQAT=L3'[3JEM`1%.4QO)ZD#YE]5XS
M6=!XOU&XUGRXM'0Z8FIOIDMS]H_>+("V'"8P4X4=<Y/3'-`'376CZ=>P^3=6
M-M/$9?.V21`C?_>_WO>ECTG3X=-.FQ65NEBRLK6RQ`1D-G<"O3!R<^N37!:[
MXHUC5?`>N:K:6*6FE&SG:TO4NS]HW(2`Q3:-H)!(PQ(XR*Z.3Q/(EYX@M1:!
MO[)M(+@,9#^],BN<$8XQL]^M`&FOAS14L9+%=*LA:2N'DA\A=C,,8)&.3P.?
M:GOH&D2V7V*33+)K7=N\DP+LSC&=N,9QQFN4UWQ+J-U'JT&GZ:7T^QN$L[B\
M6XVRK+\C$JF.47>,G=GK@&G2>/V/B*2S@LH9+*+4%TYV%S_I!D+!2RQ;?N!F
MY)8<`D=J`.EF\,Z%/:P6LNCV#V\`80Q-;J4C#?>P,<9[^M.N_#VC7\JRWFEV
M4\BJ$5Y8%8A1R!R.@/:N7MO$NHZY>:/=)IAAT>YOV6WN4N<NP191^\3`VAL9
M&">G.*U=5U5K+Q;96NR5LZ9=7'$Y6/\`=M%P4QR?FX;MSZT`7[OPYIMU=B\%
MI;QWIFBE>Y6%?,?8RL`6QGG:!]*G&A:4M])?#3K07DC!FN!"N\D=#NQG/O6#
MX;\4ZEK5Y;_:M(2TLK^Q%]93K<>8S)E?E=<#:V'4\$\>]4EUSQ%<^*O$NES6
M]BNEV5JKI)',PE0.DA4XV\D[1D9&W'!-`'4KX?TA-0_M!-,LUO/,,OGK`H?>
M1@MGU(XS5F'3[2WCCC@MH8DB=I(U2,`(S9W,/0G<V3WR?6O/O#OB;6SX/@35
MM.*H?#WVVWO([TM)-LC4-O.WY'.X,",XSZUI:#XNN=1U6TTM+6&.);6!Y'O+
MMA/)OB5]T8*8E49`+9!R#Q0!UEGI5AIS3-96=O;&=_,E,,83>WJ<=3R:S;SP
M5X:OI)99]$L3-*Q=YTA"2;CU8.N&#>X.:J:YXAU2TUM-'T?2X+V\>T:\!GN?
M)0(K;2"0I.22N..YSC%4;/QU-JUQIZZ9IH,-QI\6ISR7,VSR8&9E8`*#N<;>
M!P#W(XH`Z)?#>D;X99;""XN(HEB%S<())651QN=LDGW)J0:#I(U!M0&FVGVQ
MFW&X\E=Y;CG=C.>!S[5R>B?$.35+B(OIJ&WN[22\M193^?*%10VV5=H"LP8;
M0">015=?B'?/I%K=BQTT/>S!(G-^_DVXV%\7+>7F)^,`8(SW`%`'<-I.GO9S
M6;65L;69F:6`Q+LD+'+%EZ$DG)]ZK3^&-#NHHHKC2+&6.&,Q1*]NI"(>JCCA
M3CITJ'6-;.C>%+G6YX1(+:V^T2112;@<#)`;O['OQ7/:EXWU72[B*PGTW38M
M2:!KR2.74"L:P[L*`VPEI#AN`,#'7D4`=DNF6*BX"VD`%RH2<",?O5"[0&]1
MMXY[51/ART/B*RU<X'V&T:UM8`@"0[B-S#W*JJX[`'U-<;-XT:RUN[U,),8;
MO3=,-M9W$OE!)9Y)OODY"8`&X_[/TK9LO%]S>:%?W+0Z=#>V<XMR9;TK:2DA
M6!24IDC#8^[G<"*`.KEM+>>2&2:&.22!B\3.H)C8@C*GL<$C/H352;P]H]PK
MK-I=G(KS&X8-`IS*1@OT^]COUKCU^(=U-HVG7$6GVB75Y=7%LTDUVRVD;0L5
M.90A/S8^7*C/-2ZI\0WT_4[F"*Q@F@L7BCO!]J/G,SJK8@C"_/M#@DDKGMWH
M`V[SP7I%[>:4[VL`L].CFC2Q\A3"PDV]L<8*YX]36A=>']'O[>&WN]+LYX8%
MV0QR0*RQJ1@A1C@8XP.U4?$6MW6D2Z;;65FEW=ZC.UO`LDWEHK!&?+-@\84]
M`3Z5A+\0)CK?V3[!;-;Q7J:?.4NB9_.)569(]O,:LV"Q(.`3B@#M%L+2.=)X
M[:%)DB\E)%0!ECR#L![+D#CIQ5";PIX?N&D:;1-/D:1R[EK9#N8C!)XY)!.?
MK7/1>-[Y[ZW=](C729M3?2OM`N<RB<.R!MF,;"5QG=GOBFW'CNYM8M3O3I<7
M]GV-XVGJ[76UYKGS511C;A4^;)8GCGC'-`'93:?9W-BUC/:PRVC)L,#Q@QE?
M3;TQ[5!'H6E16,EC%IUHEI*V^2!85V.V0<D8Y/`Y/H*XUOB'=1V$OF:?:?;8
M[M+4S+=,;$!T+AS-LR%`&T_+PV.W-/UCX@3Z;<201V5E++:6D=W>J;TC<&#'
M9!\A\UL*<=!R!0!W2V\2RO*J*)'P'<#EL=,GVR:;!96]L)!!#'$)7,D@1`-[
MGJQ]2>YKC[SQKJ$>H7D=CHPN+33Y+?[9+)<;)`DP0@HF#DJ&)()'`X)-3^&M
M9\0ZEXF\066HVUBEA877DQO#.QD&8T=1@J`00V2<\'C!`S0!OV.A:3IDDDEA
MIMI:O(H5V@A5"RY)P<#IDGCWJ5-+L$@M8%L[<0VC!K>,1@+"0"`5'\.`2./6
MN'GUWQ+<WWC:PN8;&&PT^U?R9H9V\V/=`64_=&2>IY&T\#/6DTSQMJ>E^&_M
M6OZ7LC@TB&]AGBNO-:XSA=KY4;7)*D]1\W6@#N?[*T\1K&+*W"+/]H5?*&!+
MDMO'^UDDYZY-7!P,5S'A;Q/<:U>WME=VUM'/;)'+YEG<&>%E<L`-Q5?G!4Y&
M,<CFNGH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"N;3P=#'XK;Q"-8U8W+#883.OE>
M7DD1[=N=H))`S^-=&W2N4L=8UW7)GOM(AT]=*BN)(`+HOYMSL;:SJR\(-P8`
M$'..V:`+.G>"M,TRZMY(I;M[>UFDGM+267=#;N_!*#&>,M@$D#<<5>UW0+37
M[.."YDN(7AE6:"XMY-DL,@Z,K>N"1SD$$U1F\<:)!JC64DMP%286[W?V9_LZ
MS$@",RXVALD=^]-F\>:%!?26CRW.Z.5K<NMM(R><"1Y08#!D.,A1R1S0!3B\
M%7%KJUS?6WB/46:]C\F[>X"/*%`.WRG`'EX)SC!!YXSS70:KH]MK5I#;W1D"
M0W$5RI1L'?&X=<\=,@9K,_X3G1?[+@OLW>)YGMTM_LS^?YR9S%Y>-V_@\8]^
ME*?&VEMH2:O!#J%U`7:-X[>RDDEA9<[A(@&4*XYS0!<@\.6-O]LV--_IE^NH
M29?_`):KLP!Q]W]VO'UJ/6/#-KK%];7SW-W;7-O#+;K);.%)CDQN4Y!_NCD8
M(QUJI?\`CS0]/M+>Y9[FX6YM1>PK;6SRLT!&?,P!D*!R2>F1ZU._C'15L]2N
MC<L(=/@CN)FV'F.1=T97^]NY`'7(Q0!7/@33$^R?9;K4;,V]DFGDVUR4,T"?
M=5SCMSAA@_,>>:2?P)IDK[HKO4;7?9I93BVN2GVB)!A=_&<@$_,,'DU)-XF7
M1X0=4ANGN+FXD%G:VMLTDSQ#!SL7)X!&2>F16G?ZU9Z;;VL]R9%BN9XX$;8>
M'D.U-PZC)('L30!F7W@G2]06[$LETIN;:WMF:.0`H('+QLO'#!CGT..E)?\`
M@C3=3:22]N+Z:=[6.V\_SMKCRY#(D@(`PX<YSTX'%.N?%-G_`&U#8072)LO3
M:7!DA8JS"!I2JN"`I``))SCIU-,MO'NAW,%U.'NXH;>V>\$D]K)&)H$&6DCW
M`;U`(Y'J/6@`?P/IL\=]]KNKZZGOI('FN)91OQ"X>-!@!54,,X`YW'UJYJ&D
M7$EQYVGWKVKSW4,UT_4M'&/N+Z;L`'/8FF7'C#1+6XOH)KQ5>RL5U"8$=(3G
M##WXZ>X]:73_`!58:IJ;6-K#?,R#]Y,;5Q%&X`)C9\8#C/*]0>.M`$VLZ!;Z
MW]C>2XN;>>SF\^":V<*R,5*'J",%6(Y%-7PU8H^I.&GSJ%S%<S?/_'&$"XXX
M'[M<_C3-8\56&AW=O#>PWPCF9%-S':N\,99@JAY`,+DD#\13K7Q-87VM3Z7;
M1W<KP%DDN%MW,"NOWD\S&W</3-`$<'A>&TOYKFSU+4+:*>Z^UR6D<B^4S_Q<
M%20&/)`(R235R[T:UO=5TW4I6D$^G-(T(5L*2Z%&W#OP:S]8\9:1HUX]I=&Z
M=XHQ+<-!:O*ELASAI64$*.#U[#-8VG>+KC6?B'/I=K]ICTVTA5MPLF9+@NK$
M,9>B+\HVD??R:`-*U\!Z7:7%J4N+YK.SNFN[:Q>;,$4AY!`QG`))`)(!)JPW
M@[2W\)W'AMO/-C.TC,?,_>!GD,A(;'!#'BLK4_'"PZOK6B6^GWZW=C8-<I=/
M;,82VR1ADXP%^3`).&.0.E2Z!X_TG4M*:>[>:TFM[".]N3/;O$A1AR\>X?,N
MX$#'ZT`7(_`VB1WKW*Q28?3_`.SC%N&P1[0N1QG=M`7.>@`J"#P!I<-G=6TE
MW?SK<:9_91:65<I;@$!5PH&1D\D$\\UIZ-XDL=<>>.W2Z@G@"L\%W;M#)M;.
MU]K`':<'!]C67K/C2PM;R33[:67[6EQ#;F7[.QA$C.F8O,QMWE6)QG]:`+U]
MX3L[RZL;M+J^L[JSA-NDUK-L9XCC*-P01D`^H(R"*TM,TZ#2=,M["V:0PP)L
M0R.68CW)Y)]S69=^++"UUM=*FM]02=]PBD-E)Y4S*A<HCXPS;5/`]#69HWQ"
MT[4]"DU:>RU&SC2<VZ1RVKEIGWLBK&`/G8E>0!P3@]*`)8?A[IEI!$EA?ZI9
M.EJUFTMO<`-)$69@&RI&5+-@@`C)YI\G@'2@NRQN;_38VLEL)4LY]HEA7[H;
M(/(&0&&#ACS6MI>M6FN:?)=69E7RV:.2*:(QR12`9VNK<J>0<'L17->#/B!9
MZYI%D;\R07S6!NYG>V>*%PN!(R,>&"DC.#0!J7G@30[WR`\,L:6]DME;I&^!
M"JLKHR]PZE1@Y_.I?^$.TXWWVQY;EI_[0CU$L7'S2I#Y(S@=-O)'K^5)8^-=
M(OUNBGVN+[/;FZQ<6SQ&6`?\M$#`;EZ<CU'K4)\>:/\`94GCAU&;SG*VT<5C
M(SW*@`EXU`RR8(^;I0!2\0^%IIM3TZ[LH'N(HI;F6>,7(B?=*%Y5B#P-O3CJ
M#GC%:FD:5J?_``BD.G:KJLYO]A#W=NRB1?FR`&VX)`PI;'."<#-17'CK0X8;
M62%[J\%S#]H46=K),4BS@NX4':`01SW!]*QE\:2:GX\L-(TM[C^S3:I=M<1V
M+2)<J^<?/T1,#[_][(XQ0!JCP)IRQ#9>Z@ET-0?4?MBRJ)?.=-C'[NW&T[<;
M:>G@?38]3%ZMQ>[5U!M2%OY@\L7#+M+_`'<\@GC..36KJD>J/9?\2B:SBN]P
MP]W$TB;>_"LIS^-<'#XQ\20>$4\0ZG)I9MVU&.U\NUM9-P471AD)RQ)R`2`!
MG..M`'2_\(+IX$HCO=1BW7IOH=DPS;3,Q9S&=N0&W,"#D$$BKK^&H)ULOM=]
M?73V=]]NBDFD7._:RA>%`V@,>`*JQ>.=&DTA[_%ZNRY-F;5K207!G`SY8CQN
M+8(/TK3TW7;'5-+;4+=W$,9995E0H\3+]Y74\JP[@T`4AX0TU;2&V#W'EQ:F
M=47YQGSC(TA!X^[ECQZ=Z;8^$K?3HQ;V^IZD+!?-V61E4Q*K@C:/EW;1GY1G
M`JKI&L:[JT5MK0AT^#1;E!*L,K,+A8CDK*6&5Y7!VX[_`'JET[QUHFH3B&)[
MJ,R1M-;M/:R1+=(HRS1%@`X`YX[&@#2T[0+/3+;3K>!I2EA9_8HM[9S'A!\W
M')^0<_6L4?#^S70CHBZQK`TPPM;_`&;SD*^4V/DR4S@`8!SG!/-+_P`+'\/M
M%(\1OYL1^=&L5C*QGC[R1@+\R#NPX_2K&H>.M#TY(W,EQ<B2V6\46EN\Q\@Y
M_>$*#A1CDGID4`:-_H%EJ%O802^:L=C<Q7,(1L?-']T'/45%;>&;&T298VGQ
M+J+:BV7_`.6I.2.GW?:H+[QEI6G_`&*21;R6TO%C:.]@M7DMP)"%0M(!@9)'
MYBFW7C;1K/6!I<K7)G%PEK(Z6[M'#(^-BNX&%W;AC/6@"M_P@&F?V7=Z4MYJ
M2Z;<I,@LQ./+A$OWMG&?7`)(&3@58U'P7I^I7]W=/=ZA!]LACAN8K>?8DH3=
MMSQGC<>A`/<&K$7BO2YH+25'E)NKUK"./RSO\Y2P=2/1=C$GI@9IVO>);/PY
M;"YO;:_DA"L\DEM:/*L2J,EG*@[1CN?2@"G<^"-.N;Z]N%N]0@CO94FN+:"X
MVQ22+C#D8SDX4$`X.!D&K"^%X8=2NKRTU+4+1;JX2YFMX)%$3.N,G!4D;L#=
M@C/UJOJ_CK0]%D*74EPY6))Y#!;O((H6SB1\#Y4XZFJ\/C6"X\2ZKH:Z?J$4
MEA$'-T]LQA.59LDXX'R\'/S=J`+&G^"=.TVYMY+>[U#[/;7#7%O9M<9AA9@P
M("XY'SG`)..V*TKS0K2^U6+493*)X[6:T4*V%V2%2W;K\@Q6/:>.---MID<C
M7%W<75K#<2R6=E*T<2RCY7?KY8/.`3D#KZT+XUL+5;G[7,]Q*+Z>T@AM+20N
MS1D90+R68`YR,`X)XQ0!L:;H-II=OIL-N92FGV?V.'>V28_DZ\<GY!S]:@D\
M-6CZW=:JMS=Q27<"P7$22#RY54,%)!!.0'/0CM52?QQI$>@0ZS''?W5G+OW&
MVLY)&AV??\Q0,IM((.<57A\<V=QXM30H;*_D22T2Z2]6W;R2CYP<XX7'\1XS
MD=10!I)X6T^/1[?2U:?[/!IS:<A+C=Y3*JG)Q]["#GZU73P99"YTV22^OYH=
M-=)+6VDD4QQLD7E`\+NZ9.,XR2:9:^/-`N/.)GFMX(X'N$N+BW>**:-/OM&S
M##@9&<>HK1LM?AO]*GU!+'4HTA#$PSV;QRM@9^5",MGMCK0!C:QX6NM8\817
MPOKFRLUTR2U:2SF"2EVD4XY!XQGGJ#C%:>G>%-*TJ\BN+2)T$5@FG)"6R@A5
MBP&#U.6/.:Y1OB3]K\,:;KMKI]Y:12ZE#;SQW%LQ+1LS`^7@?.>/X>_%=);^
M,-/N-#?5+:UU*=(YVMY+>*RD:=)`<,K1@;ACO0`[3O"L>E6Z6MKJ^JK:11R1
MPVYF4K$K=,';N^7^').*J_\`""VXEO9QK.K_`&F^18[F?S8]TJ+&452-F.`S
M'.,Y.<U4;XB:<VI:);6ECJ5W!JT+2Q7$-JY"!2`01C.02=W]W`)ZUNZOXCL=
M$DMX)DNI[BXR8[>TMVFD*C&Y]J@G:,C)]Q0`EQX8TZX\)-X:Q*FG&T%F`C_.
M(PH48)SS@=:74/#L%]J=OJ45Y=V5Y#"T'FVKJ"\9YVL&4@@'D<<'..M*?$FG
M";4HB\N[33$+C,9&/,4,N/7@CZ5@0>.H+7Q3J^E:F)E2WOXK>&>*V<QQK)'&
M5\V0#:N78@9Q0!HW?@G3KX3/<75\UQ+;VT'VD3`2J8&9DD5@.),L23W].M27
MGA.'4(HA>:IJ,TT%ZE[;S,\8:&15VC:`FW;@G((/4U)'XNTJ2ZOHLW*PV2N9
M[QK=Q;@IPZB3&TLIR"/4&J\'CO0Y;:ZGFDNK06R+(R75K)$[HQVHZ(1EE9N!
M@=>*`&MX)M#HTFEQZIJD5O,;@W&R5"TYF.7+DJ><DXQC&XU(O@VTMII'T[4-
M1TY9(8H9([65=KB,!5;YE.&V@*2,$@#/2B/QQHTFGW-X3=1K:R0Q7$4MNZ2Q
M/*P5%9",@Y(/T(-7=0\1Z=I<=RUR\FZ"1(O+CB9WDD<91$4`EB?04`3WVCVV
MH7NFW<QD$FGSM/#M;`+%&0Y]1AS5`>&(;?4KF\M-1U"T6ZN$N9[>&11$[KC)
MP5)&[`W8(S3!XUT;^R!J4CW$47G_`&5XI(&$R38R(VCQN#'C`QSN'K65?_$K
M3+>UTV>#3M5NEN[U[)TCLW\R"10=RLN,[N.%ZD9(Z&@!NA>!O)G^T:M<7,AB
MU6YO[>T6?,"EY7:-RN,[@&Z9P#SBMF3P?IDFE:CIS-<"._NWO7=9,/',S!MR
M,!\I#`$>F*L:KXBL=%MK>2Y6Y>6Y.V"V@MWEFD.,D!%!/`Y/I4=EXKTF_GMH
MH)VS<VTEU&S(5&R-@D@.>C*Q`(/(H`1_#LTD+HWB#5\L^XOYD6<;"FW'EXQS
MGIU`-4X/`UA8)`NEW^HZ<8K);$M;2KF2-?NEMRD%ER<-P1DTP_$/01!;SAKQ
MH985N'E6T<I;Q-G:\K`812`2">W/2I]6\<:)HMZ]I=O<F2(IYQBMWD6%7QM=
MR!A5).,GT/I0!9'A>P\W5)&DN&?4_*-P2XZQJ%7'''`&:EM/#]O9:[?:K!<W
M2M?$//;EP8F<*JA\8R#M4#KCVK$3XA:<FM:U8W=CJ-M'I;*KW,ENWEN3C`''
M5B0%'\601UKH].U2/4M/6\2WN[=3G,=U;M%(,>JL,T`9T_A*RGU+5+W[3>1_
MVG!Y%W"D@\M_D*!L$9#!3C@XX'%23>%-,N--73YUDDMUL/L&UGZQ\8.?[PV@
M@CO45AXQTR__`+0'E7UK)I\/GSQ7EH\+B,[L.`P&0=C?E45IX[T&\%ZPGFAC
MM+?[4\L\#QJ\!)`D0D?.N0<$=>U`&GI>DR::S%]5U"^!B2("[=&V[<\_*HRQ
MSR3G.!6E7-Z'XFBUS6[BWMO.CBAMD=X+FW:&5&9F`)5@#@J`1ZUTE`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`AZ5QNG:#XET*XN+/2;[3/[&EN9+B,744C36_F$LR
M+@@,-Q)&?6NR)P,UG7FLV]I/#;AHY9WFCC:)9!N0.<!B.N*`.4E\&:N]K<:,
MM_:#1[C5/[0:0QM]H53+YYC`^[_K!][^[VS5B/P;=I+"YNH<1^(I-8.%/,;*
MX"?[WS=>E=6^HV<5R;:2[@6X"&0Q-*H<*.K8ZX]Z?]K@S"/.C_?#,7SC]YQG
MY?7CGB@#S_4_#^KZ=K]A<V/E3377B&:^5FC<QQ(UF8\2$<CE<9Z9(Z]*>W@;
M6Q:H#J-M*]Q+=W%[;DRQ0M--C:R[3DA,$`-UR>AQCJM6\366F^&]0UN%X[V"
MR1GD%O*K9V]1D<9]JT3?V@NH[5KF%;F1=Z0M(`[#U"]30!S&D>$;C3+S3)7N
M8I8[+0O[*8!""[!D._Z?*>/>LK6?"]Q<:[X6L8E+1"W6/5)%B_=R0P%'0%B/
M^>G`7N&;TX[LZC9K<I;-<P">0D)$95WMCK@9R<4O]H6@G,'VJ#S@A<Q^:-P4
M'!..N`>,T`8/B[0KW7((%L8[%;F%9#%=7#2++;2,`%>-DY'?([X%7=3T#^UO
M"4FBWER\LLELL37.,,9`!B3Z[@&Q5\ZG8K8B]:\MQ:$9$YE7R\9Q][.*=)J%
MI#!Y\MS!'#MW^8\@"[>.<GC'(Y]Z`.,B\!W,NFZ7#J%Y%+<+>75WJ4J*1YS3
MQ2QMLXXP)!C/0*!VJ;PYX1N=,-M'J%MIDRPV3V;W,32^;(IV@8#$A`57Y@">
M<8KH+CQ-HMI?V=C<:G:QW5XADMXVE'[Q1CD'ISD8]>V:NI?VLMW):QW$+W$0
MS)"L@+IGU7.1^-`'G=K\,+J"ULXY-3CED$_EW;["GG60"*D6`.2%B0?-GJW7
M.:WK;PWJ4/C'^U8VLK*S:29[B.T,F;S<H6,R*?E#+U+#DG%=.;R!<;IHAF3R
MQEQR_P#=^OMUJI?ZU'9RK&D?GMB3S-DJ#RRL>_#`G.2,=`>N3QS0!RWB+P;J
M^N:M=2?VA$UE-):R0),TF;;RF#.JH/E.\J.3R,GKQ5VV\.:C#XQ_M6-K.SLV
MDFDN(K3S,WFY0$,BGY=RXR6').*O:#XLM]>N$ABMI8B^FVVH@N0?DFW84^XV
M'/UK8:_M4NTM&N(5N77<D)D&]AZA>I'!H`Y/5O"^MR7^OOI5Y9)!KEND4PN8
MV+0,J>667;PP*=CCGOCBM#P_X9DT+5KZ=9Q);36EG:Q+@AQY"LI+=N=PZ5LQ
M:K83M.L-[;2-;_ZX),I,7^]@_+T/7TJ874)`(D0AD\P$..5_O?3WH`Y?5O#6
MI7>N:I=VMQ:BVU/2Q83+*K;XRHEVLN.""9.<^E1:AX*?4O#L>E3W*+C2%L#(
MJG_6*4*O[KN3IUKIAJ^GM8F^6^M3:#@W`F7RP<X^]G'6DO\`5[#3-+EU.\NH
MH;**/S'F+?+MQG(]<]L=>U`&1X=T6ZTV[N+B[L].CEFAC1Y;5Y7=V7<3DR=%
MR>!SC)YK.3PKK-M/J%M;WUB=+O-3&HGS86,RDR*[QC!VX)4X;J,]#UK6G\8Z
M5#?Z9"+B%[74(9I4O!,OE)Y>S()SWW_F*UI]1L[:&.>XNK>*&0@)))*JJV>F
M">#F@#CH/!VK'Q3:ZI>7\-Q':ZC-=I(S2F1HW1D2+:3L4*'ZCK@=.<PMX'U0
M^'H]+:YLG:QU)K^QD(D4/NDD9EE`.1\LI`*GW]J[34]5M='TZ6^O7*018S@$
MDDD!5`ZDDD`#N35?3-:>_:9;G2K[3FC&X?:U4*RY/(969>W0G(XXH`@T#2I-
M+LKN)[2RMFGN&EQ:L[!LJ!N=FY+<<GT`K(M/!3IX4TO0[RX1TMM+FT^=X@<L
M)$5<KGZ'K750W]I<VZW%O<P30,VU9(Y%92<XQD<=:9'JMA*L#1WMLZW!*PE9
ME(E(ZA>?FQ[4`<A8>#]0BT^ZM[F'2EN9M+DL/MD+2M(S-P#A_NIW*C/-2WG@
MVYD3P[-#);RW&EVGV.5)6D1)4*IN*LG*G=&I&<C!-=:=0LQ<QVQNH!<29V1&
M4;VQUP.IQ2)J-G)>26<=U;O=1C+P+*I=1QU7J.H_.@#C[3PMKFCS_;-&;2+>
M673Q9RVICD\F)D=VC>,]2/WC9!Z^HJUH'@Z;P]?6TD%VDT-MHT6G1^8A#,Z.
MS;SCL=W2ND_M;3]\B?;;7?$GF.OG+E$[,>>![U'J6K0Z=`';:\C,@6+>`S`N
MJ$@=P-XH`LVGVC[%#]K\K[3Y8\WRL[-^.=N><9Z9KDH_!MVGA*RT<W4)FM]5
M6_,@4[2HNC/M'?.#CZUU9O[5;P69N(1<E=XA\P;ROKMZX]Z<;RW59F,\0$'^
MN)<?N^,_-Z<<\]J`.6U_PE<:K-]I@E@$\6HK>PI+O",/)$3JQ7D$C<01TXZ\
MUJZ%HWV#2KFTGM+.`3S2.T=HSE6#]2S-R6/<U:CUBW,5Y-<%+6&VF\HRS3($
M884AL@G`.[&#@^W(S:%U"P4B6,ADW@AQROK]/>@#C=/\+^)+/1V\-R:CITFA
MK`]K',87-T(""`IYV9"G;GV'%-M?".N2MI":G?6)ATBSEMX#;1N&F=XS$'?=
M]T!.PSSGG'%=D=0M`J.;F$)(AD1C(,.H&2PYY`!!S49U6P&G-J'VRW-DJEFN
M!*"@`Z_,.*`.=T'PG=Z3?://)=1.+'0ETMPH.6<,AWC_`&?D/OS7-6'ACQ#I
M.J6^DZ<]KOA\-164EW/%(8BWFR9*X_B&0=I[>E>A6GB#2+[25U6WU&U>P90W
MV@R@*,@$9)^Z>1P<'FKZ2I(BO&RNK`%64Y!'KF@#SBY^'>IM#%I\>IQRZ?#%
M8QVYG,@:`0;2P"*=AWE`23TR>N!71#PS<B77G,\1&I7\%W&"#\@C6($'W/EG
MIZBKNK>*+#2]+FODDCNU@N(H)DMY58QEY%CYYX(+9P?2KRZMI[6;7BWML;5"
M0TXF78,>K9Q0!R-CH4K?%#4+U4==,M4%Q$C1;5-Y,@5V4X^;$:+SV+D>HJ7Q
MCX3U7Q%<3);WT0LI]/>T,$SR*L4C$_O@$.'.TXPWH/>NK&I61M5NOM=O]G92
MRS>:NP@=3G.,>]-EU;3X+1+N:]MH[:3`29YE"-GD88G!H`P/^$5N/MNJS-<1
M%;W1X=.5<'Y73S,L?;]X/RI5\/:C!XAU2\AGMFM-2LHK>575@\;1HZ@KC@@E
MQG/I6^VK:>D,,SWUJL4[;8G,RA9#Z*<\GZ5:W^WZT`<-X?\`"6N>&75;&^L7
MCGL[."Y,L;Y22"-8RR8^\&5>AQ@X.<<5GW/AW6=*\4:3+8^3/+-JVH7H=T?R
MHDDBX5R.A[9]<5U4GC"PATO7M0EBG6'19I(;@!02Q1%<[1GN''7%:[ZA:Q30
M0RW$,<T_^JC>10S_`$!.3^%`'`S>`-:;34M?[4@F$\5TUW$QDBB%Q.Y<RH%/
MS;=S*%;M6M!X4U"TU>QN(KFVDMET>/2KM'5@Y"$G?&1QDY(P>G%=6UW`N-TT
M2Y?RQEQR_P#=^OMUILFH6D,<TDMS#&D!`E9Y`!'D`C=Z<$=?6@#AM+\#7NG:
M='926>B7GV:SEM(9[CSF+H0%4,IR%!4#?@\XXQ71>%=%OM&MKN*\N(VCDN-]
MK;Q.[I:Q[0`BL_)&03Z#.!Q6S%>6\Y`AFBDRBR#8X.5/1N.QQP:B;5+%$@=K
MRV5;@@0,9EQ*3T"\_,?I0!QUCX+U6WT'2=(FN[-HM+U2*[BE17#21+(SD,#T
M8[@..*NZKX:U2XG$EE>1"%KY[F:T=Y(TG1HU4!F3G*LH;T/>NG:^MDG2W>XA
M6>1BJ1-(`S$#)`'4X!!J5ID3;O*KN(4;F`R3V^M`'#Z?X,U32(/"_P!DO+22
M;1TN(9?-1PLB3$$E<'((VC@]<]:T?%WA^_UP0G3UL8;F**18;V5I%GM9&P`\
M93J,`Y4\$X[9KH_MML$=S/$%C<1N2XPK''RGT/(X]Q69H'B:RU^T66)DBG+2
MJULTJF10DC1EL#G!*]?>@#"N?">MG4M6>UU"R^S:H+9IGFA<R@Q*%8#!Q\P7
MKVR>#4.K>#-8U"XURUBO;*/2]:NXKBX+1N9XU18U*K_"2?+')Z9/6M^P\41W
MVL6^FFSEADFL7O06D1@H601E25)&>0>":UK>_M;P2&UN(9Q&Q1_*D#;6'8XZ
M'VH`XJ\\#7FI7>J))+:6&G:A#<QW$5EYG^D-(?DD=6^4.HY)'4D_@R3P1J=U
M9.'&E6NHHEO)'=P^;)OFAD$BA@YR(BP'R@Y&3S6Y>^.=%@TC5[^SNHK]M*5F
MN(()!O\`E`)`]?O#GIGC-;=OJ-G=Q226]U!*D9*R,DJL$(ZAL="*`.,OM`UO
M6X=>M;N6TBNYS92PND+^2#$Y<*3G+<KR>,;NG%2:GX0U;5[>:>\NK$Z@+^&^
MMUC2185V1^648@[CD%_F&.2..,5V5M>VU[`L]I/#<1-D+)#('4X]QQ6*_BV%
MM0DM[33=0O8()C!<W=M$&CAD&,KC.YB,\[0<<YZ4`9G_``B-S)9VL2Q:=9-#
MK46I,+<R.)%0#.YFY,AQC/3`%3:OX8U"Y\N>QGM5N8-874XUF5MC`1^65;'(
M/).172K?VKWCVB7$+7*+N:$2`NH]2O4#D?G33J=B#(#>6X,<?F2#S5^1/[QY
MX'O0!@>)/#=QK-WI&H0FW^U6#.'CE9UCD210'`*_,#E5(//3D5F:KX'N[_PQ
M96=D]GI>H6KS!6M=_E".;<LBC/S9*OG=_>&:[*34K.&W%S+=01VY4.)7E4*5
M..<YQCD<^XI)]4L+5(7N+RVA2;_5-),JA_\`=R>?PH`XR_\``;C4;Z2PMM.G
ML[NUAA-M?-*JH\:[%X3AD*!05(ZCKS6K/X8N);_Q+<^="%U:T@@B4J?W9C5P
M2?;YQC'I703ZC9VI47-U!"S,$422JNYCT`R>IIQOK98I)3<0B*)BLCF080CL
M3V/UH`Y._P#"VHS:OKTT<>E7EAJX@,EM?(_#1J%Q\O!!`R#U!JYINA:Q:^$[
M[39M5(OIS-]FG0LXM`V1&JEOF8)QUKH9[N"U0O/+'$@4L6D<*`!U//84U;ZU
M>=8$N8'F>/S5C60%F3^\!Z>_2@#B]+\%:C;QZTUS<6HGU'2TL!Y;RR?.H?,C
M,YR<F3I[=^M6=1\%2ZCX>BTQKM(V72DL?-1,XD1D8-@]5RG3KS73IJ^GR&81
MWUJYA8+*%G4^62<`-SP<\<]ZL"XC\_R-Z^=MW^7N&[;G&<>F>]`&-H^GZRNJ
MS:CK$]@TCVR0".TC<!2K,2<L<G.[IQCWZUO444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%``:\PTG0+J"]M([KPU,=6M]9DN)]64H%EB9V8-OSN<;65=I'!7/&!7I]%
M`'EUIX9N(_$LKZC9:@]PNM-=1W=O:Q$2QLV5W3'Y@@4A&7VX!%4G\&^(9]/U
M;2A"4BTC3Y;+2)"1BX663><'L1$JQ<^IY()KU2PU&VU*)Y;2598TD>)F7LZ,
M593[@@BK5`'E4WAV6?PMXHCT[2M1ANK[2TB2U>TBMHRWSX550X+C=@MTQMP3
MBHM6\.:A<QZ[9MX=DGUB]U19K+5MJ8CA)0JWFYW)L5-NT<],9S7K"MN)]J3<
M"Q4$''!YZ4`>0S:6^L:IK]O9Z))<:E_PD<;1:GA`MK&GDNPWYW+QNX`Y\SOS
M5_\`X1"XGO4N+G1A)(_BN6>:1U4LUF5DVY.>8]VWY>F>U>F06L%L93!#'&9G
M\R0HH&]\`;CZG`'/L*FH`\EN?"VHPW^/[+D.BV^M731V<5M'*J1R11[)5B;Y
M2H?S>.H+D@5IVWA;S3X/MFTV[GTRUGO7N8]0C3*!@Q3<@.W;NQM'8!>F*]'J
M"YNX;01F9]OFR+$G!.6;H*`/.AX673=3\*3_`/".FYM;$WENZK$DC1*T@,!.
MXYVC!(/\.?>K_A73+C3?%5U';Z3.+"5)Y9;V^MXUG60RY"+(IW2(06;G.`%Y
M[#O`<BD5MW((([$&@#R[Q)X3UNZ\0:C;V$+KIS.-;@G#\?;4CV"/;U.6"/U`
MXQZU)'X<U-YM$U%].E6YN9]0O+Y21F%I8&6-3D]AL7@GIZ5Z>3@9/:J<VIVM
MO>6EI-,BSW>[R$_YZ;1N;'T'-`'(>!]%U'3K^"2\M)(5'AW3;5BV.)8_,WK]
M1N'YU%IFESV?B+5FO?#7VO49M2>YM-39$91$5_=_O"=R[0H3;[C&1DUWXY%+
M0!Y+I.@:U>W^HWDNB+937F@7%M,BVT=N@N78'8-I)<#GYS_4BKR:?>:IX>2S
MOM$UBUMX=#2R<Q>6)GD#)D(NX]-N>>",CZ^F5G:CK=AI=S:6UU,5GNWV0QI&
MSLQR!G"@D*,C+'@9&30!YO)HFKW4&ER7.B!-/L]1N4\B'3XMTL;(HCN7@)VY
M!#@XYPP(`Z5T#>'#/\*+[1+:SN99)+6Z6WAU"-%<2,7*<#Y5`)&W^Z-O3%=S
M10!YY%X>AU34O"#2^&Q#IUG;W8GM[FVC"Q2,L8!*`D9)#8//K63<>$[J"31T
MN-.N)M-ATI[-(DM8[DVKAR<[7)QN7:`PR?E&>M>LT4`<1J^B7[^!=&33(;B>
M[TI[2ZCM[Q@)9_*QE'.<!R,]\;A^-0^(;G5/%'AFXBM_#6I0I%/!++;WAB1K
MJ-)%:2)0'.=R@CG`/2N[=PB%CT')J%+V"33UOD?=;M$)@^#RA&<XZ]*`/,-1
M\.7=]'XAETKP_+86%V=.BBM=BQ&5HYPTLFQ3@#8V,]3M-2ZKX-E2Q\6RV&AQ
MI=B^MY=(:*)%:,(D))B_N882'C&3GK7I=E>0:A907EK(LMO/&LD4B]'5AD$?
M4&IB,B@#Q^72VUC5=>M[31)+C4O^$DC:+4P%"VL:"%V&\G<O&\8`Y\SZUJ:?
MI>L7GQ"TS5KO15M'M[F\%S)%;1QIL*,D;>8"6DW<$YZ$]!@5WMM-IT.I7=A:
M^2EX`MS<1HFTMORH=N.2=A&?]FI[2^MKWSOLTR2^3*T,FPYVNOWE/N*`//O#
M/@E(]*T$ZAHXCO&BNX-0<@!VCD###D')R`N.N.V*G^'EI<W6HWUY?C?_`&3&
M-#M9"=P=8F.^0<`?,=@.!U3'.*]#J&VM;>SA$-M#'#$"6"1J%7))).!ZDDGW
M-`'#P:;<6GQ#:ZLM)N)HKJZ=KNYO;>,B!1$`&@ESNVD@+L.>K'`[Q^+?#>IW
M?B!DL;=GT[74@MM4=&QY2Q2;MQ[G=&63CVSFO0-WS8XY]Z5CB@#RB^\,:G_;
M,UU+ILLNG#7+B5H%MXYLH]O$D<PC8X8*5=?4;L@5-?>&=4M_#6C2>'[:^-TG
MVJPD2ZV12QP7+-E^,A0C!&4`?=`''(KT]7#?=((]13Z`/)H?!ES]BU&QU*UU
M`V6FP#3].:T`:5XFG$FY0Y(8!1$K9QD*XP00*ZS0+"YN_!MY8ZAHUK;!WFCA
MMQ;I$)8^B.\8RJLW4BNMHH`\IT_0YH='\'+<^%97L].1X=2LC!&2TYA11<;,
MXD`(<;NOS9Q6SH6AZM%\/]=L[>U.F75^]Y)I]LS@&U63/EJ=N0N#S@9`S7>,
M<#-`.0#ZT`>8W>AKJ'@6;3K'P=)I\[+8I<1M%&GFA9T+I\I^8*H8[CU!]<U>
MU71+C24U*'1]!MWL;W4;=IXEMDD58O*`>1(B0I(95X^IP37H--W?-CCGIS0!
MY?I/A6];3_#UI>Z23:QZY>7,\$L:!5@=9FC+(IV@99/E'`./2H-3T`6^HZ5H
M]MID3Q1Q:FZ6LD*3(L33`J51V50?F!!W9`XQ@G'K-4;[1]-U/9]OL;:Z\LDI
MYT0?;D8.,],B@#RB/08-0L=+N+2SOKO0I-"2SMG2QBDFA="P<E6X1WR#N7C*
M]>AKU#1F:.UBL3;7J+;6T($UT%S)E>A()RPQ\WN>,UI11I#$L<:JJ(`JJHP%
M`Z`#L*?0!YAJOA34+OPYX["V]]]JO+R9[.&.X94G4Q1@'8&VG)!'/I3/$>@7
M5Q<>*H9O#3ZE=ZE'&NE7@5&$`,2H`7)S'L<,_'8\<UZE10!Y/K?A#7Y]4NK.
MVB?[%A=9CN5DX-_'$(Q'CJV657SD=,>M2W7AK4I=*TG49].ED:XU2:_U.R$*
M3,IE5EC)1SAO+&T8R<<[>E>I$X4GTJ&RO;?4+.*[M)DFMYE#QR(<AE/0B@#R
M^\\.:M9:/;7?AVTO?M,JW>GS)<HL3QQ3N6$@5>%1&&548.UNV,4NN^#3!JES
M;-87EQI3Z3%:6<EI:13R6_EAE95+\QNVX,&&!D<D8KU0-E]OI4!OK?[>;$3(
M;H1"8Q9^8(20&QZ9!%`'&V-A%HNN^)O$6JV+>1;Q6\EK<SJK2;4MP'V'/#$C
M!QC)K6\2V4_B'P=(]E#*EX$CO;2.50KK,A$B*03@'(`.>F:Z-P&3!`(/8CBJ
ME]J=II=C)>7DZ16T1`DE8\+D@#/XD4`>;Z3X7UJ76[0ZC9RI9ZI<IK5^C/O%
MO.A=EA)S@]8!C'_+,\YQ6EX5\)"P71M0FTA8-4CU&]DN)@H$ACD,VTL1U!!C
MQ^%>AT'I0!X]IGA'Q"=&CM$M);.X;PW=V8D9@`DSW&Y5R#U*\UTO@K2$L]4E
MO$T[4+%Y+*.-X9+2*WA4AB<83[SC)^;IC'-=7I>MV&LM<BPF,RV\GENXC8(6
M_P!EB,,.O*DBK^_#`'`R<#)ZT`>6WGAFXBT;Q[IUIX>*7=^TTEG/#"@66-HX
MP$5@<YW!CM/'4U=\0^#3#IVL1:#I20QSQ6,DEO`BJMP(I',D84_*24P.>#D9
MKT>B@#D?!FEQZ=+JDL-O?P"XEC8QW%M';Q@A`/W:)TZ<G')JCX?GU?PPL^@2
M^'K^\5+R>2UO;;R_)DCD=I`7+."K`L01CL.M=Y2,VW'3GU-`'D^F^'-04Z%:
M/X>>+6;36#<WVKE4"RQ!V9F\T'<^\,!MQZY``J72/!<GVKPW)?:&C?Z;J+ZB
MTL:MN0M)Y/F?WA]S`Y`XZ8KTFSU*UOWN4MIED:VF,$P'5)``2I]\$'\:MT`>
M/C3CIFK>';'4M%EN[:*XU<P:>L:./)\U3%M0G!4*1@=L^U07GASQ"?!L&@S>
M'U:-M.NFM]L$=Q)!-)*^R`NQQ&JHR?,/[IP>!GU75+G2]-"ZGJ<EK`MN&"7,
MY`\O</F`)Z9P.!UQ5FQOK;4;1+JSN(KB!QE9(G#*WT(H`X&_\(MJU]K#:AI*
MW,;:!;P6ID`.)QYNX+Z-]SGZ<U%K&E3OX[M=&2/=8ZR\.J7X)!"&V`#`KCHY
M\@=2#M88Y)KTRH#:6_VLW8AC%P8Q$9=@W%`20N>N,DG'O0!SOBO1WU?5O#2M
M9+=645^\EVKJ"@3R)`-P/4;]G'KBN7TSPI>:=IGAR[MM'6'5K?6;AIY%50XM
MB9PH9O[A'E#'88XXKU&B@#R?1O"U[K6JW;ZOH_V"&_T66VO!':QVZI.\BMM7
M:27VX)#GKCW(K=^'8O-4COO$FI1@7=RR6:-G<#'`-A*G`X:3S&X`X(XXKNB`
MPP:CMK:"SMH[:VACA@B4+''&H55`Z``<`4`2T444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`"'IUQ7ENAZCJ][XDBNKC7([>Z&JS6MU87%_A?*!?;'';[?OE0C!LDD
M9YYQ7J1&1BHC:VYF\XPQF7L^P;OSZT`>.VUY=_:8M,^WRV5A<7^JR"2*^^R&
M6=;HX0R;2>%RVWC//7&*U;759KS4HH?$/BR2U^RZ;:W-O-I\XCAO9"6\R0?+
M^]&[8-O3GIS7IK6ENZ;'AC9,[MK*",^OUH-K`?+S$A\OE/E'R_3T_"@#@_`-
ME;67B7Q7$-3NY;M=2D'V6XNR^8RD1\S8>^3C=Z8%8,CR>'KWX@W6GZI?/JL,
MH:&WEN#*?+:*$M,(S]XIEL'!`"@=!7KJPQK(9`B^81@MCDCZT>3&9?-\M?,Q
MC=@9QZ9H`X/PQ>JOC.33=,\07>LZ2VFBZE>>83^7,SC9B3'&Y-QV9[9`%12^
M)#:ZOXEL+C53'=?VM9Q6<!D.\1NL&=B]=I)?)Z<FN_CMX85*Q1I&#R0B@?RI
M?(BW[_+3?C&[:,X],T`>4:AK=S_;&I21^(KQ-5M=>BL[+3$E!26%C&7W18RX
MVM*<GIM&,8J:RU(W^J6=Q>:_<?VJVN/!-I#L-D:)(^P"/&4PFQM_\6<9.1CT
M/3]#LM-N+ZXA5FEO+IKJ1I,$J[*JD+QP,(./K5[R(@[/Y:[VQN;`R<=,F@#R
MK3=7;7O%\"VFIZI%8ZI!?+-`VH[I(BA4*0@'[@@[L<YK+T6[>R^'_A2UL]:N
M5MKR41:A*=0V-;2>4=D(DPQA!8=,=1C(SS[0MM"DC2)$BNQRS!0"3[FD-K;E
M'0PQE7.778,,?4^M`'%-!=ZC\+-6M[G5/MDJQ72I<65T9'VH6V(9`!N8`!6X
MYY]:YNSL+34+7X>6=IK=\Z2K.7N8;S=+&?LH+1J_.T#I@<@>E>N1QQPH$C14
M4=`H`%-2W@C`"1(F"2-J@8)ZT`>67-[JV=!TB]UFY2V:WNE^V?;1:/<S13;5
M#2;6Y"`G'&>22<8J5=8O(-5T"XU?Q%'?+(EG`L>DWP7=-(2#(\6,2Q-P<]@K
M$#K7ITEM!*FR6)'3.=K*",_2D%I;JZN((PZC"L$&0/8T`>9^%-2U>^UVTN[O
M6XTNI;RXM[^PGU`'&W?B*.WV_*RX0YR25!.3FM#Q%IC2?%#2KN.[U`3+I=U,
MD,5RRHS1O"0NT?PMGYAWP/2N\%K`)_/\F/S?[^P;OSZU(45G#$#<!@''(H`\
MJ\.ZQ/+>>%IX/$=]?7VK+(=6LI)`ZP;8F+$)C]SLEVIVSGG--M-8U+1?!6@^
M-+K5K^\CG5&U*&1MZ;7C*H40=,/LX')R23UKU1;>%)&D2)%=_O,%`+?4TODQ
M[-FQ=G3;@8Q]*`/*-,U[6K",VNN7E[(_AVVGN]3:`@O.'13".N>`\F`W7RP3
MTJM#KNIZ?H7B][35KF46D5C-;/+?"\,32,=V),8(QMRO(_.O8?)CW,VT;F&&
M.!D_6F):V\<?EI#&J'JJH`#^%`'F^K/_`&7KTVCWOBK4]/M;73A=V<\T^YKF
M9G??N)'[T+\@\L=FZ=,=+92WG_"(6J_9XS:'25)G\W!SY/\`<V_UKI6AC=E9
MD5F4Y4D9*GVI^U0NP`;<8Q0!Y#I=_$VFZ)8ZIXANM%T^V\-6EY;/;S^0)I-I
M\PEB/GV`)\G3YN0:2+7KV_M!)XD\0WVBW%MH=O>P")Q;^?*P;S'92/G(;8-G
M3GIS7K3VMO(JJ\,;*GW0R@@?2G26\,Q4RQ(Y4Y4LH.#[4`>/C5=3/BFRFU*2
M>RBO='TP:M=0KLD@=C,0#_SS1GRK-U7@<9R--]4U.YA%J-5NX1<^+9]/:2-_
MG6#9(=BG^'&T8/;MS7IK0QONW(IW##9`.1Z'VH\F+^XO7=T'7U^M`'EFIWE]
M81:9I-SK6IR6OV^]BDF2Z$-PZ)S'F8D?=S@C.6Z]L5LQ_P!HQ?"O3U7Q);&^
MD2)9=1EO<K,6<;U6;!P3DJK`'!QBNIU+0H=1O;.]6ZN;2ZM/,$<MN5!(<`,"
M&4@@X4].PJ33-#T_2=)BTRVA!M8\G;)\VYB2S,<]26))]S0!Y;$^G:EXA\&Z
M@^LZO;V^+VW\VXU'(:2-EX$@X<,=PS_&JCTJ[;:N^L>/;-;/4=4AM=0EO;6X
MMWO\LGEQD9$0'[DAERISD\'O7J/V:`HJ&)"BG*J5&`?8=J!;PK(TBQ(KM]Y@
MH!/U-`'BVAW+Z9\/-%@LM9NE2YU`P:E(]_L:T&90J!B#Y.YPH/&>>V<UNP2Z
MI<S:#HDOB)Y(+N]O87GL+SS)1$D>]$:7'+@C!;&<'WKTLVL!#@PQXD.7&T?,
M??UI4MH(E41Q1HJ]`J@8^E`'E6DZMKB:;X9UM-4O+Z]U075L]K*X\EBD4KQ[
M4`&&W1*-V<G<<]L3^$M1U"X@%[_PD*W*W6E2S3PRZ@)I?/7;\R1[%\H*2X8#
MN5':O3Q#&`H"*`O*@`<?2FK:6Z2-(D,:NWWF"`$_4T`>616>HW_A'[5<:[JM
MR=9\-27<T/G<+,%C8>6!]T$.5*CJ.N:KO>1:;X(T"XM_$TTNFPV1N+J&/5=E
MV[!(^(F_B"9(\K(Y9>^*]>$:*`%```P,#&!Z5']BM<*/L\7RG*_NQP?4<4`<
MQXMU:"#1K""26]@.I3I#%+%<BU*':7^>7^`8!Z`DGCO7`VO_`!,T\"ZEJ^NW
M\*FXOH#<_;B@PAE\O+\`L0`N[JP%>T2013(4E170_P`+@$?K2-;PNNUHT*@Y
M"E01GZ4`<9\0KR:TM;*7^UA9640FFNK>*]^RW$ZHH(\I^Y7/*\9W#D5S6L>(
M))H_$%\WB'4M-O-/MH9-(L]^PS[X59"T9'[TM(2A'(!&!CK7J\EM!-M\V*.3
M:<KO4''TS2M;PR2+(\:,Z?=9E!(^AH`\KUK4]:^U:[>+J][:2Z;<:='#!&P$
M:FX$2R[T(.[[QP#P#SBC6=3U;1+O5M&AU:\>QCO;(S7ES<@2V\4ZR;QYNT[%
MWH@!P=N\]."/5C#&<Y13N()R!SCIFD:&)@P9%(88;('S?7UH`YKP<UV-(O(;
MG5(K\0W+I"\=W]H>--BD)))@;G!)/T*UQ'A77[ZXNO#ES;:[=ZI?7]A-+J=D
MTGF1Q;8\H=@'[L[]J^K9/4\UZW';0Q1E(HTC4]0B@#]*I:+HEGH.DVNG62MY
M5M$L2NY!=E7IN..:`/._#FL3RWWA:>#Q'>WU]JJR-JUC)('2#;"Q;Y,?N=DN
MU.V<X.:IZ5=:QX@TNQMY/$&HVQ3PO'J'FP2[7>XWR`.QZL..5Z''/2O75MX8
MY&=(D5W^\RJ`3]?6E$$2C"QJ.-O"CIZ?2@#SG1H;?_A:LMW=:K>)<W&E6D\4
M#W95)V/FAE"?Q*O!`'0DGO1X[US4]+UG6/L5]+#Y&B6\\2@Y59#=%2V/7''T
MKT;R8MZN8U+)]UB!E?IZ4KQ1R'+HK$C!R`<B@#F_#ME<:7JVL:?)JM]?P)Y,
ML1O)/,>/<K!AN[C*Y]L\5YM)9VUEX(\=VZZM>2W::C*C07%V9&11,FV38>YR
M/F/6O;MBYSW/4^M,-O"69C$A9QAB5&2/>@#S77)=5\,V.K6T&M7\]K]KLS)=
M74X,EI#(2LI$A!VC*]<$+N.!Q70>%8;F?3=5L;C6/M4(F\J%X+_[1/;HT:DA
MY<`[]Q+#N`176&)&#!E!##!!'44V*WA@7;#$D:YR0BA1^E`'D7AYG\/_``V\
M,WL6J7L<-QJ\`N'FN24CB\UU9>>%0\9[9JQXHFL]<.F:@^N7<.GQ>)/(%Q!=
M&*-$,!^8-T&&&`W^T<=:]6,$)C\LQH8SU7:,'\*&@B="CQHR'JK*"/RH`\^L
M?$JQWFJ6$^KEKH^(88;6%I2SF`B#H.NP@MST.3ZUG7VHZNFC>(];CU6]WVVK
MR6&T2[8K:U$Z;Y`,$;E4M\Y!P.W%>HB"$.7$:;R,%MHSCL*=Y4>UEVKAL[AC
MKGKF@#C?"=X=/@U/[?K]K<V,4T0@9]0^TR0;P!MDE(&=S$;1[XJI\3+*":3P
MS<W6HW=C;IJR1R2PW1A5%:.3YR>@((`#?[1'>NQN=%TZ\AC@GM(VA299A&!M
M4NIRI('7!P<'C('I5R2..:,I*BNAZJP!!H`\OTJQG_MK5]6M=8OH1#XECA-N
MDN89HV2!6W+W)#_>.>@Q1H>HZO>^(XKFXUN."Z75)K6ZL;B_^7RP7VQQV^WA
M]H1@V22,\\XKU`0Q@8"*,G)P!R?6F?9+?S?-,,9E_P">A4;OSH`XSQ%J%II/
MCW1+[6IDATD6<\=O<3L!%#=$J<L3P"8PP!/N!WK-U+6])U+Q)';+XA?2]!-D
M]VEUI\P@2YN`_P"\_>8PVU-K8!YW$G../2'ACD39(BNOHPR*8UK;NBH\,;(O
MW5*@@?04`>21:QKVJZ;9/>:K?6TJ>'9]3;R3Y+2R128C9AC[I4@D``'CMQ5F
MYU35]+L7NTUB]N9M1\+W&IL)W!6&>)(RIC4`!0?,.0..!WS7JIB0G)4$XVYQ
MV]/I534])M=6TF[TVX4K!=6[V[F/`8(XP<'MQ0!YA'XE329]2E77M3U;36TA
M+B\=)U8VUS)*J+L?A8LAF)7HH7.!BBUU;5(-$U6VAUBZ81:_9V4-P;O[2Z1R
M^2K@2$?-R[]1P>.U>J065O;6PMXXU\L*%(('S8&.?6I%MX40(L:*HZ*%``Q0
M!Y_<-?>%[:>\?6K^[L-&U0&Y^TNTCFTDB3<&(R6V,^\$\X!Z"ND\%F_G\,6M
M]J,LKW-\S7;+(V?*61BR(/0*I4<>YK1UC1[76]*N--NC(+>XP)1&VTNH()4G
MT(&#[$U?5510J@!0,`#H!0`M%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`AZ5PT/
MC>Y:#7[R:RM8H-+AGE6U>=EO#Y1.2T94`*VTD,K$=/?'<GIQ7'ZQX)%W8:K)
M#>7EUJ5QIMS8VS7LP*1"7)(X7IG;R<D``"@"A<>/[W21=G6M'ABS9)>V8MKK
M?O5Y5C5')4;6W2)DC(Y//%20>.[I;#4#=:=!+>6\]O!#]DF8V\[SMM11(Z@@
M@_>XP./6KUOX#TTVLXU![R\N+FT2T>6>X+&%`0VV(\;<,`P/7(!SQ5N?PG;7
MVFW%C?ZAJ5[%,(]K33C?"R<J\94#:P.#GN0*`,O4M4U^V?1(;JQLTU6YO9HH
MEAOI!;MBWD<%_E!(R,;2.",CM7*^&=<N=$\.Z!JNKQ,S:A'=:A/-!>RN952V
M+EY$88+':?E'RC@BO0U\-6PFLIY[J]N9[2Y:ZCEGF#'>T9BQC`&W:3P`.>>I
M-5U\%:-_9^DV#Q2RVNF026\,<DF0\<D9C8/ZY4D4`01:WKL>BW.H:G9:18;H
MTDM#)?MLRW\$K;.&`Q]T'/:L-?%%WKEMX>N6"6TR>)38S_99F:.4+'+D@D`E
M3QP1VK>_X0>Q;3H;.6^U29+=X7MI);G<\!B8E"O&,\]2"2,`]!5BW\':;;QV
MZ!KES!J)U,222Y9[@JRDMQT.X\<4`<=X9\;7&E^"_P#3H9+AX---U:R,Y+7+
M><T?E9/<-Y8Z\AQ@5VVMZY=:1I>GA;2*;5+Z>.UAA\TK$)64L<OC.T!6/3)Q
MC&36-=>`[<R^%[.V0C3='N))W:23,C9^98\8PRE\,<_W!^'1ZWH=IKUE%!=>
M:C0S+/#-"^R2*1>C*>QY(^A(H`Y)]8OX-KZA:207,OB&UM'BANV"#,48W*P^
M\AZ[2!G/(IUGX^N9]'N=1ET^U#-/%;VMB+EEN5DDD$:K.K(/+Y(Y&1UQFMQ?
M".G^3'')+>S,E_'J!DFG+NTR``$D]OE'`P/3%5I/`6F7*W)O;K4KV>>".W^T
M3W'[R)8W+H490,,'.[/)R*`*6H7NLQ:MX4_M9+>SG;4YDE6TN&>*2,6TK#)(
M4XR.A'5<U1D\<W-Q:>)K:>*QD%EI,M_%-IE\[!E&\;=^T%7^7.Y<XSQ72S>$
MK&[C@6^GOKPQ323;IYLEB\31,#@#"[&(P,<\]:JV_@+2X;.ZMFGOYUN-._LL
MM-,"RV^"`BX``QD\XSSS0!E7OCJ]LGNO)TE)[33C:I<.]R5D=KA4\L(",$AG
M^8L1QZFGWOCC4M.CU"VO-*MDU*TNH(B4G=[9(Y@Q261PFY5&QE/R\''8YK:E
M\&:7/%?QN+C;>R6SS8DYS!M\O'''W!GUJ>X\-03:E=ZA#>W]I=71B\U[:0#<
M(PX48((Q\YR/4#TH`M6M\\FB)?7$ED'\G>SPW&Z#..TA`^7WQ7'VOQ"N$TO7
MKJ]M+*=])6WD!TZY:2*9)3@`,RJ<C!]N173)X3TJ+P>?#`BD.FFW:!E,AWE6
MSD[O4DD_6J;>!].FL]2@N;B^N3J4<,=S-+-ERL1R@&``,9].:`*/_"5ZW8O*
MFKZ-;Q&WO;>&=[:X:11#-PL@RH/ROPPQZ_6M&U\4I)HVNZS/;[--TV6=8G0E
MFF2$?._I]Y7`QGI^%3Z]HAO](UM+:))+O4;0P;)G*QDA6"Y(!Q]ZIM+\.V=C
MX3@\/S*+FV6V-O-Y@_UV1AR?]XDD_6@#EM1\4:Q_9]Q9:OIL%D=1TJ[N;*6T
MNC*8PD8)63*KA@''*Y&:S)/$NM?\(+=V6JVT=O<3^&9;VRN8+II';RX@&+G`
MVOET;()Z]>*ZRW\#:;#_`*ZXU"]V6;6,/VNXW^3"PPP3@<D8!8Y.`.:CA^'^
MDQVUS!+/J%R)K%M.5KBXW&"W;JD?'&>.3D_*.>*`,J\\5S:3>W`$+33"PT_$
MEQ=LL"-,\B!WX(101RP!)R!VJ6Q\8ZK=>'KR]FBT.VNHM0>SA,M[(()@AP65
MMF6R<X`%6O$?@U;M8[K3T+W2M:*\<D_EAXH&9E"MM.UOG//X<4EAX0N;@)<:
MI?7<5Q;7DD^G>3<;WM(V0(8][+A@>3R.,X!XS0!E6?C+Q'K&I^$Y-/M-.CLM
M6MIY)XYI7+!HV4/@A>@!ROKG!QBI='\5ZG?0V^GZ)IT5Q>?Z3<S'4+U]J1K<
MR1*`VTEF8J<#HH&/2MZ+P5IEO!H\=K+>VYTDR?9I(Y_F*N<NK$@[@>/?CK40
M\!Z7%Y365UJ%E/&D\7GVUQM=DED:1E)P00&<E>,KV-`%%?&MYJ=EH)T?3(VO
M-8AGDCCNY]B0F(KN#,H)(Y(&!SQVS5C5/$.JGX8W/B"QM8+?44L6N##<.66)
ME!+C('S$8.!T)ZXK4M/"VF6$ND/:Q21+I,,L-JH<XVR;=V[/WB=H.?7-6&T2
MSDT&;19$=[&:%X'4L=Q1P=PS^)H`YNV\2>);AH=/@TK3)]4BLX[R[S=ND01R
MP14.S)=MA/(`'K6D?%]J/`2>*_LTH@>U6X2W)&XEL!4STY)`S^-1'P+9X1DU
M/5X[@6IM)+E+K$DL74*QVX^7)P0`1D\\UJ2>'-+F\-_\(^UH!IGD"W$*DC"#
MI@]01C.>N>:`.9F\1:KH]WJ-_K>EI'/;V<"Q0VMSOBG:28H@#$`J=Q"L2..H
MR*V=$U_4IM=N-#UNPM[>^CMDNU>TG,L3QLQ7&652&!7TIA\$:;-9W=M>SZC?
M?:X$@DDNKIF?:C%D*D8VL&.<CN,G)J[I/AJTTN_N-0-Q>7E]/&D3W%Y+O81K
MT48``&<G@<DDF@#`;QX\,VOW%U:6\-EI23$P/*RWC^7_`!>65P4;LP)X(SW%
M:&F:_JQU^'1];TNVMIKJVDN[=[6Y,JA4*!D?*KAAO7D9!J2Y\&:;?WLEQJ,]
M[J`:*>%8;F;*1I,07"X`..`!DG``I;3P=:VLDDYU#4Y[HV?V**YGN-TD$??8
M<##$@$L02=H]*`-#6=&35[18I+R_M1&WF!K*Z>!B<'@E>H]J\SL6U2T\%^"]
M4M+^_OM3U._MVD6^OW*,3#+D9.=J]R`#G`KUT)MA6/<S87:6)R3QU/O6'!X4
MTZWTO1=/3[1Y&C2I+:@R<[E5E&XXY&&-`&#<^.-0M;.RMYM/LK?6;FXN("L]
MRPMD$)^9]X4L005P,9^;V-+-X[NVT[1IX-.M[>74#*'DU"5XK>,QML*[PA.7
M/*;@`0/7BM^[\+V=T\4RRW5O<073W45Q!)M=6?AAR""I'52".!Z5#?\`A./4
M]+&G76K:N]NT4L,P^T#,Z2')#G;Z<#&,`XH`Q;SQ_-!K5Q;P6-O-:6=W':3@
M3-]HD=]F3&@7!5=X)+$9`)%,\=KJ]WXG\,Z3:QVLFGW4LK2Q2W4D/F.B%L,4
M&<``$<\G@C%;_P#PBEM'>SW-G?ZC9"X,;30VT^V-V3`!P0<$A0"01D#FM"[T
MBWO=4T[49A)Y^GM(T&UL#+KL;([\&@#E[7QM?SOI^H/I4`T+4KT65K,ER3."
M695=XRH4*2O0'(R*6S\::A-#::C/I=O'I5UJ`T]91<$R*_F/'O*[<!?,55'.
M?FR<5?M?`FE6ES:LDM\UK9W+7=M8O/F"*4\Y5<9P"20"2`2<"K+>$=+?PK<>
M'&6=["<REOWGS@NYD)#>S'B@#%TCQ\VM-:PVVGA;B?4WM3'(^"ELJLXF(ZC<
M@&`1U..G-/MO&MQ)XENM,:/39H1:7%U!+9W32D>4R@K)E0`3N_A)Q@UL67A+
M2M/UB/4K:)TECLULD3(V*BX`(&/O8`7.>@`JMIG@72]),/D37[I;VLEG;I+-
MN6&%R"RKQ[+R<G@<T`9MMXPUN^M-*-MI%B+K6HS<V$<MVP5(%169I2$.&^90
M%7/WNO!K4\/:O&NFQ?VB39W=U>W`6VF?<P;SF&T$9!QP!^%/E\':?)I^D6L<
MMY;/I$8BL[B";;*B[`A!.,$$`9R.PK4TS38-'L%M+9I?*#N^9I"[%G8L<L>3
MRQZT`<+H/B#6,2:/IEO#>Z@]]J,^^^N6CCB@2Z9`,A6).3@`=,5?L_&^I:X;
M6WT/2(#?/!)<7,=[=%$A5)FA*AE4[B61\'`&!SUK2/@?3DECN+:YO[2ZCDN'
M%Q;S[7(G8NZ'((*[CD`C@@8IJ^`M*MXK1;":_P!/EMK9[43VMQMDDC<EFWD@
M[CN);/4,2010!RZ^.7NO$^BWUI;S>9JVD/';6$DN$-P)P/F;H``K_-U(X`)(
M%:]_XJFT?6=7C^Q&XFB;3H`@NF$;/.74;5/"`-C)[CKT%:,GP_T!X((!;2K%
M;V?V.%5D/[M0XD#@]?,#*#NJS<^$-/N[N>ZG:Y>:>2TDD;S/O-;MNC/3'4\^
MOM0!C3^,-7L=/*7^F6-MJ?\`:7V#?)=L+09C$BNTFW<`P.T#;G=BM+P_XFO=
M0\%3:]>:<OG1B=EMK)S(91&S*-I8#)8J<>Q%1^)/#D]]<6=U91>:T=_]JGB:
MX,);]R8OD<`XP,''&<=15O1-)U*'P]-9:GJ$S3S/*8Y(Y<R6\;$[4$F/F*C^
M+'\J`.5O?&7B:?1M)O--CT(R7>IPVSHMS(^U7Z(X,8*-G(/&1VS6M>>+[ZQ\
M2Z?IC1:3.EU,MJP@NW::*8QLQ++LP%!4CKG!!Q5R3P+ILT5SYMS?R75Q=0W;
M7AF`E$D0`C((``P!C&.YI;?P-IEO?)=+/?-LO/[0$+S93[05VF3IDDC.1G&6
M/`H`Y[3?&^O6GAR[U'6K73GD.J/I]FL$S*#)YS)AR5X10.&Y)`Y`-7X_'-VN
MASW4NFQ2WD.H0V&V"8^1,TI4*T;LH.W+@'(X(;K6FW@?33:7]J+B_6"[N#=J
MJSX-O,7\S?$<91MQSU/ITJU-X:ANK4V][>W]VOVN*\#32KE7B*LH&%`"Y4$C
M'<^M`'/IXUU>-))KO2+1+:QU%-.U&6*[9B)'*!6B4H"RCS$SG!Y.!Q3K#QY-
M?Z[!!'8P-I\]Y)91M'*S7"LA<>8Z;=JQY0C[V>1ZUN3>$].FL]1M'^T"._OD
MOYMLF#YJF,C:<<#]TO'U]:6T\,0V%XTUG?ZC#"URUT;-9AY.]L[@!C(4DEMH
M.,G-`&#I?C#7M62UN(-&LH[74()C9R/=-D2QCI(`O"MAL8R<#FJ.G>-O$$?@
MG1=2U"STYKK4B/+NFE=+>--F[=,0A\LG!``!7/<5V&F^&['2K+3[2V$QBL/,
M\G>^2=^=V3W^\:HV_@JVL]&32;75=7@LXPR(B7`.V-EV[.5/R@=,\CUH`FU[
M7[C1_#<>H0VD=S-(T2?NW9H8RY`WLRJ3Y8]0OX5S=]K'B"7Q)X?ETJ+3KNZN
M-*NY)(H[YOLK;9(L,'"Y8]AQQN/O77_V)##HUGI5E<W=E!9K&D)MY`'"H,!2
M2#D8ZYZU6TKPCINBRZ?):"??8P30QF23<6$SB21FXY8L,_B:`,M/%>KZF]K;
MZ+H]L]R=/@U"ZCN[HQB-9-VV-2JG<V5;DX''O3M+\;?VO*AM[(I!)HB:JF]_
MF!+,OEG''&WK[U<N/!5A*T3P76H64J67V%I;6XV-)".@;@\C)P1@C)YIEQX%
MT:0P+"UY9116/]GF.UN6C5X`<A&[\$GD$'D\T`85SXGN=/\`%=[/'$UQ)=V&
MF1VMHTI6/SYI)ADG!P,#DXR0OTKH_#%QJ%QJ&L?VG;+;7,<L2-''-YD9_=CY
MD/!VGW`/7(I+[P5I6H/,\WVE9'AMXEDCEVM%Y#,T;H0.&!<\UI:/HL&D?:6C
MGNIY;EP\TMS*9&9@H7//08`X&![4`<Z?%FJRZU+%;Z1#)IMKJBZ9<SFY(D#-
MMPZIC!4;USDYYXZ5$/&NI,L6I+I%N=$GO_[/AE^TD3[S,81(4VXV;QC&=V.:
MZ&'P]96_VS89O]+OUU"3+Y_>C9C'H/W:\?6L^/P-I4=S&XDO3:QWAOTL3/\`
MZ.LW7<%QG`;Y@N<;CG%`$/@;5?$&LV>H2ZW%IZB*\GMXVM78G,<K(005'`P`
M#U(Y.*P]&\1ZOIU_J!N;:&?1F\1RV)N'N6,T322!4VIMQL#,HZYY)QBNSTC0
M+?1)[V2TGNS'=S/.T$DNZ.-W8LY08R,DD]36</`VF#4_MC37SH;TZ@;1K@^0
M;C)(?;CL>0,XR`<<4`9>B^/IM8UFSC2Q@_L^]EEAMWCF9YTV!COE7:%56V'^
M(D%A7>#H*P=/\+P:7<A[/4-1CMEN)+@68F'D`OG*@;<A<DD+G`/2MX8P!F@!
M:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`$)P,USDGCG1XI[U'^U^79,T<\ZVS&-90X3R
M@P'S2$D849)!%=&PR*XNY\#S7/A[5]/:[C$UWJKZG;N4)6-O,61%89R1E<'!
M'6@!=6\;*_AFYOM,26WO;6\MH)K:^@,<D8DEC7YD/3*,2#4Z>-;.V2Z68W%]
M<+?SVT-M8V3F4B,C<-N3D+D9?@'(X[56F\&W=UHE]8^7I=G)<W5K/OMDD;<(
MG1SO+')/R$#T!'6JK^`+I=1_M%)K2:;[?=SF&97"-#.58KE3D."B\].O%`&[
M<>-M%BL["YBDN+M;U#+$EI;O*_EJ0&=E`RH4G!SWXZU)IWB")?!(\07LOF01
MVSW4DD2YW1KDY`'^R*R8?"FJ6%YI>H:7+I=I<VUI)93VZV[_`&?RV?>#&`=P
M(8#J<'GI6I_PCDTG@*?PY/=J9I[*6V>Y6/`W.K`L%SQUSC-`%J[\2:=8VTMQ
M<R/'#%:K>2.5X6(G&3^59\/C[1)(KUYC>6C6:H[17-J\<DB.=J,BD9<,W`QW
MK`\1>']=_P"$+UXW<MO=W#Z.+."WL8'SE<\C))8G(XP,8[]:LWW@O6-9GN]1
MOM3M(]0,=LMEY$#>4GD2^<ID#')R_4`\#UH`UX_'>BFRN[BY^UV369C^TP7=
MLT<L0D;:C%2.03T(S^=7M"\1VGB".Z:V@NX)+67R9X;N`Q21MM##*GL58'\:
MYZ_\&:KJ_P#:MU?7UHE[>FS1%AC;RXHK>82]3RS,2_/;(KJ;6Q>WU+4+HLK+
M=-&RJ!RNU0O/Y4`9W_"8Z='K<NEW4-[9R)'+*LUU;M'#*L>"Y1SP0`0?I5O1
M/$%OK]L]Q;6M[#$"-CW5NT0E4C(=,_>4CO7*Z9X&U:TU6WO[N_M+R:VBNH_-
MF61VN?-^Z9`3@!0%!"\'FMCPGX=OM!DOC/-;K;3>4+>QM-X@MMJD,5#'C<3G
M`X&![F@!Q\=Z./M;!;QHK9S"\JVSLK3;_+\E"!\TF['RC/\`.GKXUTG^R9-0
MF%U;+#.MO-!/`RS12-C:K)UR0RD>NX5E7/@:>?PM-IHNH3=+JLFIV\CHQC#&
M9I`K@$$C#%3@CKD53UW0-1M/#OEVEA8QW,NLV4Z"SCD<866/+RY.6QMR2,84
M>V:`-R/Q]HK:?+=R"\@:*X%K):S6S+.DK#<BF/KEA]W'7(HF\>Z3;S1QS0:A
M'\J&X=K1MEGOQM$S=$)R..W?%9H\%:C<W;ZC?7]LU]-JUM?RK#$PB6.`;51<
MG))'4GOVI=0\$SS:[J=]!#IEU!J+12R17Z2'9(H520%.&!55X/0C.:`-I/&&
MF/=7\>VZ6VL5D,]\T#"V!CX=1)T+*<@CU!J*T\;Z3=6]],Z7EI]B@-U)'=V[
M0NT'/[U5;JO!Y]JQ[SP)=ZG?:F)I[2RT^_@N8IXK%7!N&D(V22*3MWJ!U'))
M/:GIX.U"71M6L[B/2(;F^TQK(W5LDFXLP89.X\)SG:.^>:`)+_XEZ9:Z/JM]
M!I^I3OI\2SF%K9HS+&^[9(I(_P!6=I^;MZ5:C\7V[W<\MQ]HM+:#3/M\EM<V
MC1S1J'=2S$G&,+]W&>^>:76?"<VK:1?6'VI(C=:4+`2;"2K#/S?3GI5._P#"
M.J:LVJ3WEU9I<WVAOI9$*-L5BSD/R<XPXXZ\&@"]!X]T6:&_E87D"V21R,)[
M9T,J2,5C:,$98.PP.Y.*M:%XKM-?^WBWL]1MY+!E2>.ZMC$X8KN"@'J<8./]
MH>M8?C'0[H^&KPQAIB;*WM62&)G?"2AG<`9)^7)P/FXX(."+?@U;F.[UD-:J
M+=IHWCO629'NV*`-N$K%OEPJ@YP>@Z&@#&G^)DEUI<&H6VE:A9I%K"64Z7%J
MS&6,R.A"`<E_E&5'*GCFNAC\=:2^D)?K%?L[W#VJV8M'-R9DR63R^N0`23TQ
MWK-C\%ZFJ):M>VAM8=<&K0D1MYA!E:1T;G&?FP"/3FI]:\&SZC=17L,MN;B#
M4&ND2=6\MHWC6-T;:00<#(8=#C@T`;UIX@L+S1)-71W2UB61IO,0J\1CSO5E
MZAE(((]163I.K:Y=6L&N7@TVUTB:$3M`^X301%2P9I,E6.-I(P`.>3CF]I>A
MK;Z!+IEW:64<<QE$D5F&6,JY.>IR6(/)[G)XK"MO"GB0Z%)X:OM7L9=%-J]F
MLRVS?:FB*E5#$MLR%.,@=J`-*T\>:-=F0%;VV*V[W47VJU>+[1"@RSQ[A\PP
M0?7D<5`?B/H?E32)%J4GEQ^>$CL9"TD'_/91CF/K\WM5-_!^N:EY)U;4;(M:
M:7/8V_V:%@'>50K2/D\#"K\H[YYJ[8^$[FTO$G-W&VW0HM*P%/WT+'?].>G6
M@";4_'FC:8^UQ=W.($NG-I;M,(X&SB5BO1.#S4]]XPTZPO+*&6"]>"\,0BO8
MK9FM\R$!`9!QR2/S%<;#X4U^WOKG1;&:VBB_X1RRTV:\GMW9&V^:K&/!`W`'
M.#_>'XW[GX?7\M]"HU&*2QMY[*2W\_S#)`EN$S&H!V88IDG'\1Z\8`-Z7QSH
M\6M+I9%VTINA9M*MNQBCF/W49^@)XQ]14UOXMTJ\ATN2%IB=1N)+>"/RSO#Q
M[M^X=@NQLGZ>M5[3PU/;?VINN(V^V:PFI+\I^15\KY?K^[//O69HN@3K\1=9
MU!HW33K?_CU1XMH\^94,[)Q\P^1?F]6<9ZB@#6B\3"R?3],O[>[N-6DAC>Y2
MTMS((-W&Z3;PJDAL?[IK3EUJS@U>/3)F9)Y+=[E"1\A1"`W/J-R\>]8?B#PU
MJ.JZS;WEE)96;Q>4/MRJXNE57W.@((#*PXP>!DGGC$GC/PM<>)M/A6SO!9WL
M#.$G()'ER(8Y%X]58X(Y!`-`#+/QKIL[7-\]V8M-CT^&]59+9E<)(SJK9R=V
M[:,*!GIUW#%FR\;:5>2Q0.EY:7,EREM]FN[=HY%=U9DRIZ*P1L'IQBLS5O`7
M]H_VK'%<1PV]SI]I:6R;,^4]O(TB$XQE<E>!C@&F2^#+VYT?4;<+IFGWTQMY
MK:ZLT=BDT3;E9]Y^8!N@[`G.:`-5?'6A/:BX2Y+1F^DL"0N<21ABY/\`LA5+
M%O[O-7=$\06^O6SW%M:WL,((V/=6[1"52,ADS]Y2.]<WIG@&32-42>WN(9+6
M*RV1V\J$J;KR_+,I4<;2N<@8.6;UK3\)^';[09+[[1-;+;3>4+>QM-_DVVU<
M,4W'C<3G`P!@>YH`N2>*K*'Q##HTUM?Q2SL4AN)+9A!(X4N563H3M5C^!I^B
M>);/7S*UC!>?9TP8[F6W9(IU/\4;'AAQ7.V_@G4QXHMM5N]0@N%MM0FNTD;S
M#*R.C(L7)VJ%#=AS@=.<W_#'AK4-&U*YN)I;."TEA5%L-/5U@$NXEI0K'Y2<
M@8'I0!/-XZT:#4FM)/M8B286SWHMG-LDQ.!&9,8W9('IDXS69X*\3WWB76=9
MEGAO+>UMIW@@MYK+RU0*<9,AY+GNO:F2>"M6:VN-(&HVPT6?5/[08^4?M`!E
M\XQC^'_6#[W]WC%;_A_1)=%74Q)*LOVO49[U=H(VK(00I]Q0`V+Q992>(&T6
M2UU""YVR-$\]JR1SA,;O+8_>QD5GQ?$?0IXYI8TOC#'9O?+*;5@DT*8\QHR?
MO;=PSC\,U0T7P1J=EKUEJ5_J,-T]HERAG/F&6X\TC!?<2%V@*,#CK6KH?A>3
M2M)T&QN)HIUTZS>UE.TXEW!1D#T^4\&@#6AURSN=5&G0EY)_LJW9(7Y1&QPN
M3V+8.!_LGTK$UGQI96]T^GVK3?:4N8;8W'V=C`)6=,Q>9C;OVMT_KQ53X<:'
M=:;IMY=WGF^;/.8;831['2TAS'`K+@;3M!./]KUJ1/">L6]SJ%O;:C:#2[S4
MEU%ED@8S*WF*[Q@@@8)4X;&1GOUH`U+GQ;9V6MKI,]EJ2RON6&7[(WE3.J%R
MB/T9MJGCOBLK2OB38ZAHWV^;2M5MI'G:"&V-JSR7#*S@B,`?,0$);^[T)J*#
MP5J8\4VVJW5_!.EMJ$UXDC>8961T95BY;:H0/V'.!P.<UAX!U);2RA^TV$IT
MV_FN;3S$D`DCF:0R))@\-AQ@KW7D'-`'86.O6%_I#:G'*8[9`_FF8%&A*$AU
M<'[I4@@CMBLZW\:Z;/IRWYMM0AMGN(;>)Y[5HQ*96"HR9ZJ21S5G2M)FL-`E
MLOLVG12N92(X(V\G+$D;@3ELY^;UYKF(_`FJKIEW;K>V5LINK.YLK.%)#;6[
M0,&(`)R`Y'(&`,#KS0!K>+/%3:-;V\ML&;R]5M[2Z41%V97`8A`.2V&7&.]/
M'CS21IT=PL.H/<23O;K8+:M]J\Q1N93'U&%^;TP152_\*ZU?V1D?4+'^T1JD
M.I(WD,(1Y:*HC(W9(RO7.<&JMQX*U6XMKV6>32[G4+Z[>[=Y(Y%6V;RA%&82
MIW`JJKD]^>E`&UJ'C?2=-G6*X2].V-);ETM79+1&Z&8XPG0\'D8.12W/C;1[
M75&L)#=%EF6V:=+=C")V*@1>9C&_Y@<?UXK!E\`7BW$TQDT_5'NK*"&Z.I)(
M?,FC0)YAVG!5@!E3W'6I;GP[K6F?V@EI=V\NFWFJ1WQB-NS3JS2QET!!QMX)
MW8R!^=`'30^(K"X^U^69/]$OEL)<I_RU.S`'J/G7FJ</C329]773D%U\\K6\
M=TT#"WDF7.8ED(P6^5NG'RGFL]/"VKV^J7Q@O[0:?=ZK'J;JT#&4E?+S'G.`
M/W><XSS4.D^")](U)"D.F7%I%?R74,DRR&>)7+,0.=NX,Y`;TXQ0!H+X]T>3
M4UL(H[Z5V>6%9$M6,;31ABT0;H7PA.*D\*>+T\5:7/?)I5_9B%W79<1$;]K,
MOR'^(_+R.Q.*9I?ABXT^TBA>XC<QZM/J&0I^[(TC!1[CS!S[&IO"NBW^@6,V
MGW$]O/;+<2RV[QJROB21Y"'R<9&[''I0!EZ9\2;"^TVXO)]+U6T,=TUK%"]J
MS/<.&90L8'5OD)8?P]SWKH-(\0V6MVD\]H)PUNYCGMY8F26)P`=K(><X(^N:
MY=/!>LVTJ/;:A9;K/5IM2LB\3?-YQD\R.3G^[(P!7N`<5O>'M$N]+DU2\OKB
M.:]U*Z^TRB%"L<>$5%5<\\*BY)ZG-`'*S_$M[K2X=0M=*U"T2+6([*=+BU8F
M6,R.C!`.2_R\J.5/'-=&GCK29-)2_6*^+O</:K9"U<W)F3)9/+'.0`23T`[U
MF1^"]354M6O;0VD.N#5H2(V$A!E:1D;G&?FP"*GUKP9-J-S%>PRVQN8-0>ZC
M2=6\MHWC6-T;:00V!D,.AQP:`.ATW6[+5=+_`+0MY"L`W"3S1L:)D)#JX/W2
MI!!],5AV'C.TUO7+.VL?M*0O!+-BXM6C,\8V;9(]PRR\GIZCVJ]8Z!L\,W6D
M3PVELMRLZ.MBK!0)-W/S<EL'))ZFLFU\+^(A806MSK-HC6FGS6-M-:V[+(&9
M55)22W#`+]T<9YS0`:C\2+&QT?5;P:3JQN--B662TFM6B=D;<%?GHF48%NV*
MOW'C>PM;6UDDL-5^T7$;3?8ULG:>.-3M+N@^ZN>YZYXS6!%\/+Z33=<@N;RU
MCEU32X[`M")'PR;_`-XQ=B227.1[=^M7M1\(ZCJ&I6FK3C3)KP6;6=U#()1$
MZABR%"#D$9.0<YSVH`O^*_$W]G>"O[?TV:.2$O;2))M+J\3RH"0!R<JQQCGI
M3H/'&DOIES=O'?PO;7(M6M9;1UN#*RAD18\9)8,"/;TI=4\.3ZCX-M]$C:UM
M9(C:G]S&1$OE2(Y55SD+\F!Z<56\1>$)M9,\T4\*SB]@O+<2JQ3=&A0J^""0
M5+#CID&@"W_PFVCC2/[1D-S&HN/LC0/`PF2;&1&4Z[CQ@=]P]:BF\>Z1;RQQ
MS0ZA'\J&X=K1MMGOQM$S=$)R..H[XJI_PB%S)8VD(33K-H-8BU$K:HY#JF.&
M+')<X^]TX'%1:CX)GEUS4KZ"'3+J#4'CEDBOTD;RY%"J2`IPRE47@XP1UH`T
MY_'.C6^I/9R?:Q&DPMGO!;.;99B0/+,F,;LD#TR<9S6;X+\37WB;6M9EGAO+
M>UMYV@@MYK+RU7:<9,AY+GNO:HY?!6JO;W.D#4K8:-<:I_:+L8C]H`,OG&,'
M.W_6`?-Z<8SS6QI.B:AHT.H+;SVSR7FJR7A,B-A8G<%EX/WMH.#TS0!T=%(,
M]Z6@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!",THX%%%`!1110`4444
M`%(1GO2T4`(!@4M%%`!1110`4444`(1FDV\YSS3J*`"BBB@`HHHH`****`$*
MY.<TM%%``>1BD`Q2T4`%%%%`!1110`4444`%%%%`!1110`4A&:6B@!`,"EHH
MH`****`"BBB@`HHHH`*3;SFEHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`*:[I'&SNRJB@EF8X`'J:=7'?%"62/X?ZHD<=])YR"!ELMN\AS
MM(.X'Y3G!P,\\8ZT`=,-1M6$Q6Z@(A4-*1(/W8(R"W/&1SSVI1?VI,@%U"3&
MX23YQ\C-C"GT)W#`]QZUXG)9ZE'X)\5-=0>(G-[J,%BJ%K7S3$`L0#%1C/)4
M_P#`<8^8U&]MK#::#=P^*9)[_P`1_*(VM/,(A'R%CC!<>5CKC,?IU`/=+>YA
MND9X98Y55RA,;!@&!P0<=P>".U35QOPNMKR#P/;2Z@;DW5U++=2?:/+SEW+9
M&SC#9W<\Y8UV5`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4QXDE7;(@89!P1D9!R*?10!"
MMI;*FQ8(E4OYF`@`W9SN^N><^M(EG:QQB-+>)45F8*J``$YR<>IR<_4U/10`
MR*&*WB2*&-8XT4*J(,!0.@`["GT44`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`49Q2'@5S[-JNJPWMS:7_P!D\J66&VC6)65BA*DR
M;@<Y8'&",#'6@#H,CUHW#UKGK1]3U-)'2]^S-:N8-JQJRRR+C<7R,[2>`%QQ
MW],^VUN[FOC.\[IIUQ;P[EPI:UD=Y$#*V.5W(,[L]0?44`=CN'K1N'K7"R2Z
M^NASW_\`;4X2(.JL(X=Q<3LF"-G3:!^.:T=3&JV.FM$VLS17$MZ(;6XVQ$[&
M`^^"F#MPYZ#H,T`=3D>M&X>M<ZFL7$^BV#PM%]MN9Q:,Y&Y$D7=YAP#SPC8^
MH[4LVGZ\+B.*WU=WM6"[I'CC$J?,"V,+@Y7...*`.AW#UI:YKP__`&I-Y=S<
M:C+=6S"XCD658UVLLNU"-J@_=#9Y]*VK>^6XO+FU6&=6MRH9WC*HV1D;6/#>
M^.AH`MT444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`"'D5DR:(WGRR6M_=VBSMNFBB92K$]2,@E2?4?7K6O10!
MDSZ*7E=K:]N+-91B982#YG&,Y8':V/XAR>_05%%X>2&\DD6YD-I);+;-9%$V
M>6H;`SC=U9CG/.:VZ*`,"3PRO_"/IHT%]=0P*23)\CR,"Q;!+`]SUZ\5-=:#
M]NNK*:\NVN$MD*M#)#&4E)ZLP*\'@=,8_$ULT4`8,'AF&".\B\^3R;B83QQQ
MJD8MW&,&/:!CH.N>_J:N6^G7,(FWZE<S2,FR.1PO[L=L*``3[D5I44`9NC:6
M^DVC6[7DMTI=G4RH@*[B6/W0.Y-3V]DT%[=7)N;B03E3Y4CY2+`Q\@QQGJ?>
MK=%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`!X%1F9%."R@^A84\]*X_4!I>O6&E:B;"V=Y[^*-B\:.V`
MQ!4G\.E`'7>:F]4+`,WW03U^GK3ZPKL2Q>)-(^:-H'\U%C:%<QD(3N5NHR.,
M>E4]:U'5;75;H6MY$D$,5LRQ/`&RTLK1G)R#@8!QZ]\4`=333(JG!(!/3)ZU
MFZ'=7-S;7"W4BRR6]S)!Y@7;O"G@D#O]*S?%5M++=:1):6MK-?)=/Y!N%X4^
M3(<YQGJ`<#N!0!TB.K_=(/XTZN4MFMM.T&V71(C#<7C_`'4@1I7?EGSDJH8?
M-]XX&,8[5/HFI7VJPZE9O.T5Q:2B(3E8V;E0W*J67(SCK^`H`Z2BN?T*36;_
M`$NTOKN]@4SVP)CBAX!(X?)[^W3M[TS2Y]9E@EN;F]BDCMIYXMB0?-.J.RY.
M/NMQQM_7.``='5>VOK6\>1+:YAF:,XD$<@8H?0X/'0USNEZSJLUU9S7,)^RW
MQP-[0JL9VD@(0Y9SP001GOQ@BM&VC2/Q5J'EHJYLK<G`Q_'-0!LT5QNH:_J:
M7]T8)&2V@D:-I([=9X8@N"QD(82*V,_PX&.]=6UU#'Y7FS(GG,$B#'&]L$X'
MJ<`G'M0!/T%,\U<XR`WID9I_45SVLQ6>G:U8:Y+%$NT/;3S;!N56&5.>O!7'
M_`J`-TSQA&<NH51EFSP![T\$$9'(/2N073S9>![ZXMXX+2>XAEO)U$"LA+*6
M\LKW&,#\ZVM0OY+#2XI8PJEVCCWN/DBW<;V]A^%`&M17.O=ZGI27LL][#J$<
M-J)4C"!)0V3UV\;<8P<=C1I.H:H=02VOT8QSQM+&\AA4Y&,A51V++SU[=R<B
M@#H2<#--$J,<*P8]<`YI6`(^;I7#Z=I:N'6PT5;::+5)F2_01HH59VR/E.XC
M;E<$8_*@#NJ*YQ)-:GUW4+*/48DMX1'*CM;@NN[=\F.A7@<]?YU!J.LZNM]>
M?8X'\JPQO'[H))\H8EV=U*KUP0"."<GH`#JJ:\B1@%V"Y.!DXR?2N0U/7M4^
MUS"Q+[(T49@@2Y2,M'O!E`=7`YXV@CH<GD#1U::26/1KJ.:.2WDNH<HT((?<
M>'!/*D=10!NO,D:,[D*BC)9C@`4VWN8+N%9K>6.6)ONO&P93]"*R[Z:ZGU%-
M-MYQ:%H/.,S1A]_.-B@\<=3]1ZUBV&I7%IX;5K58I9KC4;B(/;X**3-)\R[B
M%[8`)`R>_0@'9TA./>N3?4];%F8C*EO=P7=O$6F2-S(DKA?G1'.W&3C!&<#W
MIFJ7&IMH'B*T;4&\^SC!2Y2)58@Q[L8Z>V>M`'8=J*S]/2>'?'<:D+R0X8?N
MT0JI]E['UJW'<0S22QQ2H[PMLD56!*-@'!]#@@_C0!(3@4WS5R`2`3T&>:<>
ME<?;:9IFK:%=/JAC-Z[2+<SNX\RW.XC:"?N`=EZ?7/(!UAGC!P74'_>%/\Q1
MC)QDX&>]<5>V`E\5Z@(]`LKU91:":655W1!F8,P!')V\YSV[XJ]I^F63-=6>
MIHLOV`+%;^>`-D"HN)%]"2&RPYR.V*`.H!S2UE^'YYKG1H)IF+EMVQVZNFX[
M&/U7:?QK4H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`1ONG!Q6`MYX;@CNM;1["-;=FAN+L*%V,#AE8XR#G`_&M]NE>:W]BT
M^E:M?1RH=/,MY)<#G=YZ2,(2/8AN0.ZI[Y`.XN-"TG4)_M5SIUI/*P!\V6$,
MW3CD^U6)]-L[IG:XMH92Z!&+Q@Y4'(!]@>1[UQWB+5;J.XOI;29TG@C+P0F>
M8NV%R'6.,;60G^]D=<XZ5JWM_!/-!+?7LT&ER0(\4T$CQJ\A)W;G7!'&W`)`
M.3U(%`'0P6T-NTK11)&97WOL7&YO4^IX'/M45UIEE>SPSW-K#-+`VZ%W0$QG
MU4GH:Y?59DL/#^G;M;O89S=)Y5S*[*[(9AN+(>&`0_Q#ISQ5FX,5M]F+ZG=K
MHTR&1KK[2Q+2<!5+]54C)XQSQQT(!JWNG:+;P74]Y:V:13D-</)&H$A'0MZG
M/3O5>P3P[J/GQ6,-C+F-4GCCC`(3)VAQC('!P#64)W^TVMWYL]WHMK<;DG<&
M1N8V&[IEE5L8;GJ>3C-.BU*^O9-8N=/AM995@C6*[MM[;_F?Y?F&"5!)XS]X
M#T%`'16ND6%C!)!:6=O!%)PZ11A5;C'(%-L]&T[3&=[&RM[5G^\88PN[ZXKF
MM+OW87L<FII)9?97=VBFG<QN,<^:WW#@_=SGC(`P<MT348XIM`SJMQ/)>V+O
M/]HG9]S`+C@\*00XX`S@YS0!TEK9:6=0N;BWM8%O(WV32+"`P8J&ZX[AA^=+
M'H&DQ7?VN/3;1+C=N\U8@&SZYZ]S^=9GAS5;":^U.SM]2-R!<!H%>9I#L\J,
MG!8DXW;OIS502"YD6.\U&_MM:,ZDP0O)MVA\X5/NLA48+<]3SD4`="^BZ9)<
MBY?3[5IPV\2F%=V[USZU+)8QRWMO=.[EK<-Y:Y^4%A@M]<9'T)]:XG4M2NVU
M>Y5;J;"SM&J)<R03':1A8XRK1R`\C/!YZCMVD]]';RVL<@D\RZD\M%5<D':6
M.?0`#K]/6@"V!@8K*UV^T>VMA!K#0?9YN#'/'N1^1UX(ZX_&M5?NBL#Q=J%I
M9Z2L=Q<)%(\T+(I/)"RH6/X"@"\]OIVNVD9F@AN[9CN0319'<9P?QJ>WTZTM
M+8VUO;110'.8D0!3GKQ6%K]]:SG19(M3EACN;O8'MYROF(5;/3@C.T9/3/!!
MJ"VU"9K'4[>RNYITM;\1.P9I98X"%W%2<LQ!WXZGKCI0!TEKIMG81LEG;0VZ
M,VYEB0*"?4XIEKI%A8RM+:6=O!(YRS1QA2?RK-T4VLE]<3:?J-W=6WE*ACDE
M>2-'!))#.2=V",CM@5K6-]#?PO+#YFU)7B/F1LAW*<'`(&1D=>]`%EEW#%4;
M+1M.TYW:QL;:V+_?,,84MSGG%7Z*`,^+0],AO6O8M/M4NV)8SK$`Y)ZG/7N?
MSI]UI%A?21R7=G!.\?"-+&&*_3-7:*`,^?1-,NI?-N-/M9)<@[VA4G(``.?P
M'Y47NBZ;J,BR7MA:W+H,*TT08@9SWK0HH`IS:58W-K':SVD,MO'C9$\8*K@8
M&!VH72[%(9X4M(%BN"6E01C;(3U)'>KE&:`,P^'M(:V6V;3+,PJ^\1^0NT-Z
MX]?>IX=+LK:YFN8+6".:?_72)&`TG^\>]7**`*EIIEE8!Q9VD$`<Y;RHPN[Z
MXIUE91V,<BH69I)&ED=NK,QR2?T`]``*LT4`(1D8JI)I5A-=I=26=N]PARLK
M1`L#]:N44`4HM)L(;][^.S@6[<8><(-[?4]:?=Z;97[1M=VL$YC.4\V,-M^F
M:M44`-5`O3\J=110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`C?=K+76;9M8&F>7="<JS!VA98SM"D@.>#]X=,]_2M0]*YW4
M;N9?$UC(FEW\L-NDJ/+'&I7+[,8^;..#V[4`="%]S5"_U,:>^&M+N9`N^22)
M`5C7U))&<8Z#)]J=<6=Y-<I+#J4UO$`,PI'&P;GN64GGV-4]=+S6SV/V3495
MG7!DLV1<9_AW$\9[GIB@"U=:I!;6]O*!).UR0($@7<TA(SQ[8YR<`=ZAFUZS
MATI=2"74D+Y&V*W=I`5!+`KC*XVD'.,$8JM-:7T-KI%X\"2W-B/WT%O@;MR;
M6V`XZ<8'%(\=Q8^&;J)K2:>XNGG;RK<!BIE9F`))`XW`$T`;5M*MS;QSH6VR
MH'7/H1D47,J6ML\SAV5!G"*68^P`[UFZ;]IN]`A@5;K3KB.-(RTD:[P0!D@'
M(([5/*;S3=+FD'GZG<("RH`B._MP`/Q_G0`EIJT5S)+$\-Q;7$*[WAG4!MIS
MR""01P>AI-+U4ZI"DZ6-Y;PR1K+')<;`&4\C&UB?SQ5#2I)YKB[GN].O%G>(
M;YI55<C)_=1KD\#KD]2?RCT*UDM;N"*SMM0M+&&$QS1WTQDW$8";,LW3#9Q@
M=.M`&GIVLV^J2SQPQW2&`(6\^%H\ALX(#<GH:TBN1C)KGM/NIV\2WTCZ7?Q0
MW*1(DLD:A04#YSALCJ.U:BV=VEX9FU.9X221;F./:/09"[N/K0!%_:V[4Y;*
M*QO)!#(L<DZ[!&I*AN[`\!AT%17NHV%IJ]JDUO.UU(1#'*L#,B;ST+_=&2OU
MX'M6=>VTAU2>73[/4HK^:56%P92+<X"J2R[L8VKC!7)_*K7B.:;?81P:=>7/
ME744[M`@("J3GJ1S0!>NM5>UNEMH]-O;IO+\PM"J;0,XP2S*,\=*A37HY[&U
MN[>RO9OM*>8L4<8W*OJ<D+Z="2>V:-8-S=Z*8;6"827FV$\`&)7X9CSQM&>E
M1ZO=7MBEO:6%C<O&ZE6N(%5O)`P``I(R3V[#KSTH`T;.ZBO[9+B!V,;YY(*D
M$$@@@\@@@@CVJSMXZUC0W::;X;:Z^PRV_E*Q2VD8>8S;CM!(S\SD@]^6YK7A
M+M"K2*$<@%E#9VG'(SWH`20JB%W<!0.2QP`*AMKP3627,BF`,,D2D<?CT_\`
MUU'JU_96%B\E\8S$WR^6Y7]YGL`Q`-<KI^LZ8/!DUA-Y*21P-&())(?GSG`4
M;L<<5<:;DKVZA<[19T9F570LOW@#DKZ9K,AUS[5JDEI;6XD2*7RI93,@PP`)
MVKDD@9'IWKG=(U'1[&_TH0FVMH_L#1SN)8@`^4P'(;)/RMZ]1ZU+HVJZ%;ZO
M?L\=I;O+=/)'<EH0-NQ1]X-D9(/US[UI[%J^C8KH[`S()?+WIO(W;<\X]<?U
MJC/K=G;W#1.9<(=LDJQ,T<9]&<#"_CTS7*?;-*%J;9C:/JF?^0CY\6TR=I-^
M[<.QVX]JRYK@PRQ6PN;.[\I#&LWVN,(X8.&)RV.K!SGDE5'H:<</?<+G<2>)
M+.*75(I%EC;35#S!E^^I7(*<\^G;FKEMJ4-SI]M>']REPBNBS$*V",@'GK[5
MQNW2Y;BXDDU2W`MYUP6N(_\`3(U@1<?>_P">B*W..5]":@:[M)K73UEFM=\=
ME%&NU[:0[@OS+(9"0N#Z?KTIN@K:!<]#DE6)"[LJJ.I8X`IGVJ'"GS8_G^[\
MX^;Z>M<7;ZI:-H^D-?W%M<_9X#'<VLEU$S-)@#?@MA\8;`[[L]:BU&YT$Z&\
M=M!;AKB[6=8HKB+?'\R%F^\-A*KT4U'L'>S"YW0F1@Q5U(7(8@],=<U%<7]O
M;V9NWD!A&/F3YMQ)P`,=23Q@5R]Q>:";6VEMI;(6X??<V0FB5YA@@;ANPQ!P
M<$\U6:[TV60W5A/8VD,31RK:27$4?G.K9R`&PORY&>_?IFDJ+?<+G4VVL+/?
M)9R6=W;3O&TJB:,`%5(!Y!(S\PXZ^M71/&V\+(A*'#`-G;]?2N0371>:I*Z:
MM%;VQMY%474D"[)#M"[2IW$=2>?2JFD7>GVNI0.;Y5"*RW!:6U2-\J>I7YI.
M<8SSW/<&G08[G<K<Q.RJLD;,R[@%8$D>OTJ-+SS+N6!8R5C529`P*Y)(*^N1
M@$_45P>GWFCVD&F210V\,ZZA(\I62$,L9+X)P_W?F7@>AXXK6M/$&D1^)KR9
M?*ABN(HXS-YD05G5I"6)#9Z,O.*3H--V5Q71U;W$4;JCR(K,/E#,`3]!2F9`
MRH74,_W5+#+?2N+O;W19);Z&_P#L6H_:BPCG6YBPJ$8"DELICU`]^M4M<N+&
M\U*4_:K9X-J1J=T%PLB[3E<,ZO'R>H(!HC0;"YZ(K[N1T]:;+,D0W2.B*.I8
MX%<__P`)%8VFEVFVXT^6;]W')##>QA8P<`D%CR%'/J<57U;5-+>^@GDN[&_M
M$1E:V%Q$2'/1]K-AN,C';/%3[*3>PSI_.3RC)O38!DMNX`^M(;B,(K^8FUAD
M'<,'OP:XO[5HD,$+J;/[#YDLLE@+J-CO<@A]N[;Q@_+VW>U13S:1<!&1[&.R
M-[;R"S>>+*[6.]]N["@@KP.RY[XJO8L+G<K/&YPCHQP#A3G`/2INU<7X<:SC
MU2V2W-MYA2\67R9(R3F960D*<D;0<>@]*[2HG#E=@"BBBH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`",C%-VBG44`%(5!.:6B@!"`1@T;12T4`(
M!CUI:**`$*@T;12T4`)M%!&12T4`)M%)L'O3J*`$VC-+110`TH#UI0,4M%`%
M2]TRPU*-8[^RM[J-6W*D\2N`?4`CK5+_`(1/PY_T`-*_\`X_\*V**I3DE9,+
M&/\`\(GX<_Z%_2O_``#C_P`*/^$3\.?]`#2O_`./_"MBBG[2?=@8_P#PB7AO
M/_(OZ5_X!Q_X4?\`")^'/^@!I7_@''_A6Q11[2?=@8W_``B7ASMH&E_^`<?_
M`,32_P#")^'/^@!I7_@''_A6Q11[2?=@8_\`PB?AS_H`:7_X!Q__`!-'_")^
M'/\`H`:5_P"`<?\`A6Q11[2?=A8Q_P#A$_#@_P"9?TK_`,`X_P#XFC_A$O#G
M_0`TK_P"C_\`B:V**/:3[L+&-_PB7AS_`*`&E_\`@''_`/$TO_")^'/^@!I7
M_@''_A6Q11[2?=BL8_\`PB?AO_H7]*_\`X_\*/\`A$_#G_0`TO\`\`X__B:V
M**/:3[L=C&_X1+PY_P!`#2__``"C_P#B:7_A$_#G_0`TK_P#C_\`B:V**/:3
M[L+&/_PB?AS_`*`&E?\`@''_`/$T?\(GX<_Z`&E_^`<?^%;%%'M)]V%C'_X1
M+PYC_D`:5_X!Q_\`Q-'_``B?AS_H`:7_`.`<?_Q-;%%'M)]V%C.M/#^C:?<?
M:++2K&VFP5\R&W1&P>HR!FM&BBI;;=V`4444@"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`$)P*XZ+4M4N]7O-)AU;;<1W9^<VR8CA55)4=F8EQ]`,
MGW[$C(Q6"OAVX'VN0ZE_I$MU]J@E$`'D-M"D8S\P*C!S[_@`/U#Q%!I4YBNH
MY=D:!Y)V>-0%QRP!8,PZ_=!]*FU#6DTZ>VCEMKF1+IMD<L*!QOVLP7;G=R%/
M.,>I%9][X1^WQW,<M_A+I")F%NAD+%<$JS9*K_LCIV(JU=Z-J%P^GO'JR1-9
M_-G[*&WOM9"?O<##'B@"2YUY+.TBDN;>:&>5BJVTCQJQ(Z_,6V8[YS^M12>)
M[5;*"[AAGN8Y9_L[+`%=HY.FUANYY],^O3FK.I:.NH1Q-YB)<P@A)'B$BX.-
MP*'@@X'N,=>N:DGAVX:RMH(]3V-#=+<EOLR;21T55&`J_F?>@#2TZ_\`MWGA
MH98)8)/+DBEVDJ=H8<J2#D,#P:-6N9[/2KB>UC$DR+\H8$@9.-Q`Y('4@<X!
MQ4>G:=/97VH7$EV)DNY1*L?E!?+PH7&<\\*OZ^M3ZA:/?63V\=U-:NQ4B:'&
MY<,#QGCG&.?6@#%L+NYO1>HFNVUY;+!A9;9566.0YR3U&,8QQV.<U+X?UU[^
MQT]+J&XBN+BU65))44><0J[R`#QR<\@=>*G71KHO+<3ZD9;LPM!%)Y"JL:L0
M3\H^\<@=3]`.<UH?#MS#_90?5"T=C;M;D"`*900!G(/RG`7IZ&@"6#Q);S:B
MEF\4D#R.8XS(\>6<`G&T,67@'J!TI5\0E[V>S73;YKBW<"5%5"`A&0^[=@CV
MSN]JI)X3,<]G*M_M:SF$D(6U1<@`KASU8X8\Y'/.*OV.DWMMJUU>/J0DCN6#
M/#]G"XPNU0&SV&/K0!7/BI?M#P+IMZ[K-)`I`0"1X^6QEN!CG)QZ=>*=<>*;
M6VCAE,4K020K/YI:-`$(SG#,"W'4`&GIX="W:S_:W(%U-<;=@Z2)M*Y]CSG\
M*H_\(8IM!:M?DQM`L,KFV0R'"!,JQSL&`.!WSC&:`.GBE26%)4<,KJ&4CN#T
MI]8S:?>II]C8179S&T8GN$^1BB<\`9Y;`4^Q-;`&*`,?5Y;ZVO\`3IHKLQ6;
M7"PSQ^4K;MW"G)Y'S;1Q_>J.PNM1>ZU2Y,CWEI',8K:!$1&RO#_,2,X;(Y(^
MZ:T]2LEU'3I[1G:/S%PLB]4;J&'T.#^%5X=,FM-'BLK2[V31@?OY(@^XYRQ(
MR.2<GVS0`RPU*/\`X1RUU"XN6,9MUE>65`K$$=2!D9]AGVJ--=VW*Q7=C=V:
MM$\HEF"%-J8SG:Q*G##@X/7TIMAH+6VA_P!E7UT+RW6-8UQ$(R%'K@\GOFI(
M]*FD2:*_U"2\MY(S$(R@CR#U+%?O'W&._%`":;XCL]1NQ;*?*E=2T2O(A,JC
MJ0%8D?0X/MUK7[9K%T_0WM+[SVO%94!"I';1QE@>/G8#+8]L5M8XQ0!Q]SJN
MH6EUJ[_VW`6LY?W-E+$@,B^6K[>"&).X@$=\=>:U[C7C!J(L/[/O7N'B\V$(
MJD2@8!YS\N,_Q;?;--M-`D@UFYOYKJ&<3R^8$:T4,A"A5P^<\!1^M.ETB]?7
MEU&/4A'&J>4(#;`_)D$C=GJ2.O;-`#;OQ/:6<BI(D@94#S!F13"",\AF!)]E
MS_*GW7B"VMYH(H@]TTT8E7R63E&^Z1N8;L\\+D_F*;?^'Q=7C7-O/'"\N/.,
MELLQ.!@%=WW3@8[C@<>L&H^%A?M'NNTE2.&.(17EK'.A*$G?@@8<Y'(P.!QT
MP`3:IJTL>@)?)#>6XE"%CY:>9;AB.61B/H0,GFM"^OTLQ&HCDFGE)$4$6-SX
MZ]2``.Y)'ZBLV]\/33:)%I5IJ+6\*KM=FB$C-SD8R1MY[=,<=JM2Z7<30V\C
M7H&H0;METL(`^;J"F<$$`=^P-`&9INM&UMM3DO9KID@O%BC2Z"K("8T;9D84
M_,QP<XQWQ5@^*;;^S+N]2*20V:[[BWB>-Y%4Y(/#;2"`>A[$=:1?#!9+P75^
M]RUQ,ER&>)?W<JH%R!T*X4?*1QS]:1_#4[Z3?6?]HJCW:"-FBM45$7G.$'<@
M]23T%`%E-;>0W,8L+J.XA@\](9-@,J<@$?-@<CHV#1HFK76IZ?;7%SI\MJ98
M$EW,Z%6+`'C:Q..>]+'I%R-9-_-?B17M5MWA$(7.,G=G.1R3Q4FFZ7/IX6(W
M[RVL48B@A\I5VJ.!N;JQ``&>.^0:`-,=**:#SBG4`%%%%`!12$XH!R*`%HHH
MH`****`"BBB@`HHI`<T`+10>E-W>U`#J**0G!QC-`"T4A.!2;CZ4`.HHH[4`
M%%-W>U*#D9H`6BBB@`HHHH`****`"BBB@`HI#P*`<B@!:***`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`$/2O-K^]U2'3M5L$OKP>?-=7$%P)6W110R,
M'C#]0<A,#T8^AKTEONUBMI^D_P!GW6EM<_NKEY/,4W)WY<Y8`YR,DG@>M`%/
M5_$D^ESW'EQ1RVUJFZ3:DTCD`9(RJ%5./[Q],XS6A<7]Y+=?9-.CA:=(DFE:
MX8A55BP4#;R22K>PQ[TEUX:TV^$RW"3-%.I$L(F<1N2,%BH."WO4TVB6DT4*
ML]P)(4V).D[+*![N#D_C0!C7*W=_>:)]O6YLI9GG2:WM[R15(56*\J1GH#GW
MJ2WU*[M+ZXTB$F[G67%N]Q)C"[%9M[8R=NX>YR/K6A<^';*X^RX>ZA^R@B+R
M+ATQGJ3@\D\\GUJ7^P[$68MD21`KF02)(PD#GJV_.[)Z9STXH`SY=<OK6:.U
MG@MQ<"6#S-LC%6BDD\L,O&0P8]#V'6GOKL\$VH0S0QEX+B."#8Q`<R`%=Y/W
M>3R>?Z5=30[);66!A++YI!>665FD)'W3N/(QQCTJL?#EI;V][]FC\^2Z5?-2
M\E>2.5AC!8$G!X'(]J`(XM6U&'4;BUU"&RC6"T^T>:D[!6)8@`Y'RCCD\U'I
M7B&>[U2.RNX`K31O)&R0S(`%QD$R*N?O#D?E1I7AN.*:ZFN[:U03PK`T,3M(
M&4$G+.P#$\X'IBKD/ARQAO8;T/=/=0Y"S27+NQ4]5.3RO`X]A0!7TBUM['Q#
MJ\-O&(X1'`^P$X!._)_'`IVG6MO8^)]22WC$:26L$C*"<%R\V3CU.!^56+;P
M_;6NH-?)<WS3/C?YET[*P&<`J3C`R<40Z!;0:DU^MS?-,V`P>Z<J0"2`5SC`
MW'CWH`U,Y&17(ZD53Q+=B2/6IT-I#(J6,\FU&+2`G:'`!(5>,=JZ[&!BLJY\
M/VUS?2WC7-_'+*JH_E7;HI5<X&`<8Y/YF@#/ENKMM#T>XE>"X$DMMY\B2,NY
MF=`&0@8(R<D'@CBM"[O[LWK66GPPM/'&LLDD[E416+!>`,DDJWIC%+>:!9WL
M4$+/<PPP;?+CMYVB4;2"IPI[$#'TJ2;1;:>*%6ENEDA78LZ3LLI7T+`Y(^M`
M&5<:_J(GAM8+2V6Y,LD,XEF8K&5C$@*D#Y@5(],9]J9#XHG6R>>ZM%#O#;S0
M1PNSD^<6"JW&21M.<`^PK831+%/LQ"/NMV9U8R'+,RE6+'^(D'O[>E,B\/Z?
M#$(PDC(+=+;#RL?D0DKU/49/S=?>@#/M?$<K6LQN;23S8VC1"L,D<<K2-M4`
MR*"#DC/7`.?:H+&*[B\7R-<06\<\MBS,\$C%)")%`R#R".F?>MB'0;&)9@XF
MN&F0)(]S,TC%020,D\`$D\>M11>&[&&Z^U++>&Y\IH3,URY<H>Q)/8\CT/-`
M$>A3N;*\>X01R1W<PE\N1G4D'DC/('M3(-3U>Y^R7<%E;OI]TR%1YI$J1-R'
M/&#QC@>OM5S3=#MM+DE>WFNV\TEG6:X:0%B<DX8GGWI8="L8+I9XUE&UBZQ>
M:QB5C_$$S@'D]J`,D^)ITU%(VBC>TDN%MT>&.9CEFVJV\H(R,GGG\21S8N+6
M"#QAIUS%'MEG@G$S`GY\"/&1[5+-X5TR==KBXVHZO"JW#A8&!R#&,X7D=JFN
M=`MKO44OI+B^69,A/+NG55!QD``XYP,T`:@(/2L6Z$FH:Y)8R7$T5K#;)*4A
MD,;2LS,,EE(8!=O0'G=S6T!BJ5[I-I?NDDRNLT8(26*0QN@/7!4@T`94,FH:
M?+)I5O.+VZ):Y$MY(0(HF8A0<#+'((XQ_BDNN:D9X;*&UMA>FX^SS+),VQ<Q
M-(K*0,D$+T(!YK1?0K-K>.)3/$T9)6:.9EE)/+9<')SWS3X]%LXQ;[1)NMYC
M.KF0EF<J5)8]6R&(Y_I0!S\?BG5+@V*16-HLEZ(I(PT[81'#XW$#D@IV]:0>
M*M1.G377V.V5A:-=QJ96(*HVU@W'4]1^M;,?AG38I+-T6<-9JJP_OVX"DD`\
M\XW$<]CBI(O#VG0A%6)BBPR0;'<LI1VW%2#U&>GITH`CEU"\75;RR1(,1VJW
M$#L6Y)+`AOQ':JNEZUJ%W+IWVVU@ACO[8SQ"&5G9,*I(8D`'.[MTJU'X;L8I
MI9DDO!-+"87D-W(69.<=3U&3@]J6W\.65M+8O')=YL8S%`&N7("GL1GYNPY]
M!0!'ITLS:[JL<Z('40E6CD8AD._;D'[K<<XZ\5&NJ:K=0K>V%G;S63R*JJ\K
M+*5WA6?I@8&3CVJS;>'[:UOVO8[F^:9\;_,NG96QG`*DXP,G%2'0K+[7]H`E
M7+^88EE81,_7<4SC.>>G7F@#(O\`Q1)8WDA\M)+.*0([1I+(QR0,A@FP8)Y!
M/8\BK#W.MMXFO+:V>Q-K';P.JREPPW-(">!U.W]![U8NO"^F7BRI,LYBD.[R
M5G=8U;.=RJ#@-GG/KSUJQ<Z):W91I&N%94$;-'.R-(H_A<@_,.O7U/K0!6UV
M2>)+,JL;P&[@60%V5AF10I4C@\GD'@CBI+N_N_MK6.GQ0M/'&LLCW#E416+!
M>`,L25;TQ3]0T.VU)8EFFNT6(J56&X>,94AE)P>2"!U]*=/HMO<10JTUTDD2
M[5GCG992/0L#DCZT`9EQKVH*]O##9V_VG[7]DN(Y)B%5C'O5E8+R,8/('7%2
M?VY=QZ9=226R/=V]S]F81;F0L0IW8QNP`PX`)XXJW)X?LI$M%W7"?99?.1DG
M8%G[LYS\QY/7/4TP^&=.=)TE^T2K/<+<L'N'.)!T(.?E[=/04`1>'=>.M).Q
M:U*QA=K0R,2V<YRC*&3ICFM+4;U-/L7N75F"E5"KU9F8*H]LDCFF66E6]BSN
MCS2RN`&EGE,CX'09/;J<>YJU-#'<0/#,BO&XPRL,@B@#(_M+4[:>&*^M[5!<
MN8X&AE9MLFTD*X(&1P?F'ITJKI>N:E=C39KJUMHX;YVC412LS!E5VW<@#:0A
MXZ\CFM*WT*UMY#)YUW*^TJC37#2&,'KMR?E/N.:AA\,6,$=E''->A;*0R0@W
M3G!.0<\_,,$C!]30!L#[M<M:F_M_$&M)I]O"T?FQ2/YTI&XF,$A0,X)ZY/'(
M]ZZD#`QFLA_#6GO=W%R3<B:Y<-,5N'7S`!@(0#]T>GN?6@#,E\6F4H]A;230
MB-)'W0RLS;E#!5V*P#8(^\1U';FG3-='Q3;SZ=;QB6XTXO(+IVCV@.N,J`?F
MY([8]ZU[K0[.Z<,3-#\H1A;RM$'4=`P4C(']:;_8%F+J.XC>YB:.W^S(L<[*
MJQXQ@#.,].>O`H`H7'B&0Z=87-DD>Z[B$NR19)&12!_#&K$]<9X'YTD\UMXB
M\)7-Q<6_,:S#:P9=LD>Y21G##D'&0#5R/PSI\5I!;1M=*L">6KK<N'*?W"V<
ME?8]*%\-6$>G2:?"UU#:R2-(4BN'7&[.X`YR`222/4YH`KW\]TG@.6:UD`NE
MT[>KNQ&#Y><Y'.>X]ZE\/Z:UA:L9(+6.27:Q-NSMOXZDMSGDU.-!M?[&DTII
M;MK61=AW7#E]N`-H;.0,#'YU9L=/2PB,:3W,JDY_?S-(1]">U`"ZC>QZ=82W
M<H8QQ#)"]3V`_,UG#4M1M9H!J5O;)#<2+$A@E9VC=N@;(&<^HZ>E;$L231M'
M*H>-@0RL,@@]C5"UT.UM;A9A)<RLG^K6>=I%C_W0QXXXSZ4`8EE8W=YXHU"Y
MO([.6.VNE6-B\A>-?*1EVC[HY.3[D^U=7SLYZUG6^AV]MJ,M['/>>9-(9)$:
MY<HS8"_=)QT`'X"M+&%Q0!YSJ&H:E;VVN6,=[=C[9/<O;SB1B;<1`F10W\/`
M7:!W)QT-;VH>(;C3?EA2.:*WA5Y?EFE<_+DC*(0IQ_>/<'BM<:%9_8;VS/G&
M*\>1YLRL6R_WMISE1["HI_#>G7(99EG:*1=LL7GN$EXQEU!PQP!R>N!0`R75
M;BXDAM]-CC:>2W6Y8W!(5(V.!]WDDG/Y?2JUWJ^LV=I:32:=!YDET;>2!9CN
M.7*HR,<#!`W<XZUH-H5FUI;V^ZX'V==L4RSL)5'IO!R?QJ.Y\.V5U!;PL]U&
MENV]/*N'0ELYW,0?F.><GUH`C?4-3C:&S-O:OJ$P=UVRL(EC7:"Q)&2<NHP!
MSUR*J7.I7LUQ;Z3.?LES+*@EEMWW`QE)&!4D94L8BN#R,]^*V+C2K>YMHH9'
MFW18\N992)5XQG>.>1U]:C&A6/V1[:1))ED8.\DLC-(S#H=^<Y';GB@#&BOK
M32M1U%UO[^6*WM=S6DXE.TAR-RO(.<D@=3TXXI\7B*_D@NU^Q8GC@>:-S#,D
M0V]4=G0<^F.O/I6M;:'9VQF8B6>29!'))<RM*S(,_+\QZ<GCWJ$^&K$K('DO
M'+QM$&>ZD)C1L9"\_+G`Z>E`$6FZK?7-U;1WEO!$MW:FYB$4K,4`V9#$@9^^
M,8]#4FCRRMJNKQW"(LJ3(,QNS*P*`C@_=..N.*E@T"TM[FTN$ENR]K"8(@UP
MY78>H(S@]!R?[H]*2RT"VL+U[N*XOGED^_YMT[JW&!D$XX%`%1]5U:XB>\TR
MR@N+59#&L<DI663:^UB.,``@X!ZX[9JKJWBJ?3M0DMEBMEP2D?VIWC$K`9XD
M"E`!GH3GCMQ6P^A6+W9N"LJ[FWO$LK".1AT+(#@G\*BE\.:?+<3S_P"DHUP^
M^=8[AU68X`^90<$8`%`&J'4J&#`@\@@TZLZ338Y]1M+A]HCLU;R8E7`#$;=W
MX+D`?[1]JT`,#%`"T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"'IS7.26>G'QO%
M(;6U,GV)Y"QC7=O\Q.<XSFNC(!&#5(Z+I377VIM-LS<;M_G&!=^[KG=C.?>@
M#`U"\U.*\UQHM5V0V%LES'%Y*$[BKDJ6(^[\H[9YZU>N+R>YU"&R2^6P#VZS
MK(JHS3$YRJ[P1A<`G@GYAT[Z3Z/IDKS/)I]H[SC$S-"I,@ZX;CGD#KZ4^33;
M&6T6TDL[=[9``L+1*4&/1<8%`%.ROA9Z(MUJNI6LBH6WW8(CC(WD+[#C`^M:
MP.1D5$]M!)!Y+Q(T6,;&4%<#IQTJ0#`P*`%HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
F****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`0B`S$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`I&.%R>@ZTM8&K7
M$M_=C1K)B&8;KF0?\LT]/J:`)M/U"XU+4II(2!IT8\M"5YD?U!]*V:AMK:.U
MMD@A4+&@P`*FH`****`"BFALMM/6G4`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!4%W-)!:RR10F9U4E4!QNJ>D
MQ0!4TW48=2M%GA/LRGJK=P:N5S^HVD^EW1U6P0LA_P"/JW7^,?WA[BM+^U;0
MZ4=0$H-N%W9[_3ZT`0ZSJ9L+=4@7S+N8[(8_4GO]!3M(TW^SK8^8V^XE.^:0
M_P`3?X53TBUEN[A]8O5Q-(,01G_EFG^)K='`H`6BBB@`HHHH`9(A9<KPPY%)
M#()$W=^A'H:DJDS>1?K_`'9AC\10!=HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*.U%(>AH`P=1\1K8W[VK6K.$`
M+,&[&H9=#M_/^V";&G_Z]K;'!?'!^GM56\MQ>>);Z`_QVQQ]<"JYU!Y?#$-H
M#^]:40D=]O7_`.M7B1Q]2$ZGM'=:V^70]!X:,HQY=]+_`#-G2?$(U*\-N+9H
M\J64ENPK5EO+>W<+-/'&Q&0&;%<[I\"VWBQH$'"6^!^0JI?Q_P!JZAJ4NX$6
MT8$7U'7^M.&-K4Z%Y>]*[7;;<4L/"=3W=(V7XG9[AC.>*K#4K-IO*6ZA,G]T
M.*YV[U*5O",+JV'=A$Y!Z8__`%5H6&@V!L;=F@S)M#E\D'/7-=*Q<ZLU&DEL
MF[WZF+H1A%RJ/JU]QIOJ-K%(8Y+F%7'56<`BI8YTE7=&ZNOJIR*XR[FM(/$=
MXUY;^='T"X[X'-.T]IK30-1N8P8TD8+$/3W_`%K"&9R=1Q:5E?UT-7@TH)WW
MM^)U4FIV43['NX5;T+BH]2R]K'+&RDHX8-GC'?FLO2M$LI]&CDFA#R2J6+GJ
M*Q_/F7P5JR*['RAA3[$\UK'&U8N/M(JTDVK?J3]7A)M0;T:3^9>;QI+=7$D6
MD:3/?+&<-(/E%:6C>('U)KB*YL9K*:W`9Q+TP>X/X5C:/-=Z?X&M)M'LUN;A
MVRZ]<Y)R>/2ETKQ!>ZW9ZQ!>P10O;P,"$!R#@Y!S]*J%>2:YI:OI;3[RZE*+
M4N2.BTO?7[CH_P"W=*.`-2M,GI^^6IY-2LH)1%-=0QR-C".X!.>G%>8^'+K3
M!';6MSH7VJ628`7&#QD\=NU7?%E@;WQ5=H@/F1V0E3'7*\TEC9NE[1)/7S&\
M'%5?9MM>>AZ'+>0031Q33(DDIQ&K-@N?84+?6SW+6R7$;3H,M&&^8#W%<!_:
M1U6]\)W+$&7S"DA']X$?SZU=L6\OXC:L^.5@8C\EJUC>9Z+2Z7WJYF\)RIW>
MJ3?XV.NN=6L;)PEU>00L?X7<`_E3I-0M(;<7,ES"L!Z2%QM/XUPW@[2K371?
M:CJ<0NIVEVXDY`XR:?XMT<:=;::]E:F:QM7;?`0649.>>^.U'UFI[)U;:=`>
M&IJK['FUZ]CM[34+2^0O:W,4ZCJ8VSBK5<MX2O-(OH[B?3[-+2X;`FB4]<=#
M74UU49\\%(YZL.2;C^84445J9A1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
MA^Z:6D(H`Q8M/G'B:2^RGDM'M'//053@\/2QZ_\`:3L^RAS(HSSGZ5;B)_X2
MR<9./LR\9XZUN#I7FT\+2K7;6TF_F=3K5*>B>ZL8+Z;>)KMS?1^7M>$JG/.[
M`ZU6L?#$?V?-Z7$[$EO+DP*Z>BMOJ%%RYI*^_IJ1]9J6LGV_`Y:W\/W(M+RS
MF9!"[;X6!S@CID5-:6VOP+%;[H!"A`\PG)V^F*Z.BICE]*%N5M6\QRQ,Y)J5
MG<P8=)F&O75U,J-!,NU><GM4-CHES#:WUC.R_9I>8F#9*^^/RKI**:P%%._K
M^.XOK$[6]/P.6ALM?M+0V<7V=H^0KEN0#5>_@71-&BLVVSO=RXF']]2.0/TK
ML#7).W]M^+T5?FMK,9/ID'^IX_"JI8*G"7-=NRLK]`GB)R5MNI4M=$\3:#YD
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M2OZ'*^&M`N[#4+S4K_R4GN1CRH?NJ,Y-=4.E%%:TJ4:4>6)G4J2J2YI!1116
MA`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%':BB@#"B_P"1NN/^O9<?G6[6
M%%_R-LY_Z=E_G6Z.E<N%VE_B9K6W7H@HHHKJ,@HHHH`**0G%8&I^(TB?[)IZ
MFZO&X`09"_XT`/\`$6L_88/LMO\`->3#:BCG:#W_`,*F\/Z3_9EAB0?Z1*=T
MI]/;\*K:+H3P3F_U!_-O9.>3D)_]>M\#%`"T444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`$'V=!.9A&OF%=I;
M')%3CI11222V`:P)&`VT^M57-_&?D2&=>WS%&_J*N44P,XWU\H_Y!4Q/^S*F
M/YU7DO=:DX@TE$_VIIQC\A6S10!SS:-JNH\:EJ02'_GC;+@'ZFM2PTJSTR/9
M:PA<CECRQ_&KM%`!1110`ASCCK6.=0OX_$$-A+:0K:S)(T<PF+.VP)U7;A1E
MB.IZ5L,2!D5A7UKK$VNVUY;_`&`06ZNBK(S[V#[<]!CC;0!NY%8^K76J6K33
MP/8Q6,,'F/)<*[-D;BW"D8``'US5JYT;3[RZ2ZN+823IC:Y8@C!R.AJ/5K&2
M^@CMT=%B:9&GW9.Z,'<5&/4@#GC&:`*TVJ7\5CIP>&&&^O``_FD^5"P7<P/<
M^@%2P:A?7FE+<6UK%+<>:T3(TQ2,[6*LP;:3MXR..XI-;TI[]K>5!;3>3N_T
M:[0M"Y./F('1AC@X/4\<Y#K6TO--T=;:U>"6=22OF`I&`6)VJ!DA0#@#G@"@
M"?1KV34='L[V5%1[B%9&122`2,D#VJS<O,MNYMXUDFQ\BLVT$^Y]*R=)TF<:
M!'I6K+:S1Q1I&/(+8<*!R<]#D=JM2Z<]II,UOHODVTY!,1E!9%8]21UH`AL[
MZ_:[N+&ZBMVN8H1*LD+,(VR2`I!R5/'OQS[46-_>G4I+"^6W,GE><&MR2J#.
M-K9YSZ'C.#P,5%I5EJ=EY_VAK/:R`CR][,\O=W8@=>!@#C'TI;/3;Q-5.H79
MLXI"A1EM$(\_IAI">I&.!SC)YH`AT36KC5+J7?=Z;L1Y5-M$Y,Z!7*@MSQTY
MX[UT#'BL)=,OIKVWDN5L8H;>4S(;56#N2",'/`'S$GU(J^NC:?#>F^CM@+EB
M29-QY)Z]\4`5;N_O[.\B:5+7[)+,D*1J[&9BQ`W=AQG)'.`"<TW4]5O;:XGB
MLK:&7[+;BYG,LI7*DL`J\'D[6.3P,#UR&ZAIM]J=TBN;*.&-P\4ZQL;B+D9V
MD\`G'4=N,&IM2TJ>XN7EM;A(OM,/V:X#IG*9)#+_`+0W,.>/FYZ4`0ZAXAAM
MQ;1PSVL<MU%YRO>2^6D:<8)[DG/"CK@\C%375]?0_8;.%;:6^N0Q+,66)0H!
M8]R>2H`]\YXJ*XT=XYX;K3DMFFBMQ:;;L%E,8.1@CD'/Y_E0NBRVMGIXLYU-
MW8AE1Y@=CAAAE('('0CTV@>M`%[2K_\`M'3XKIH_*9MRO'NW!75BK#/<`@\X
M&>M7\YK(:TN-+\/R0:?NFNPK>6S`8\QV)+$=``S$X]!BM*!76%%D?S'"@,^,
M;CCDX[4`4=>NKBQTB6ZM719(F4D.NX,-P!'48Z]:?;ZS93FZ"R.%M69997C9
M8P1UPQ&#CV-8GCN_DM?#S0)IMY?"ZD$+I:P&5E7J20#Z#'U-<H/&5Y%87FG6
MWA77H[%HF2S#:6S-#D<*RYPR@Y_#`KKHX6=6GS17Y$N23/0XM7M;Z<V<$DL5
MT8S(JS6[H=H(&[#`9&2*JZ!K\>HV=NEQ)_IC*P8B)D1V4D$*3P3QD@$XK@M*
M\5SZ;=/,GA7Q-'&0Q\J*TF9)&(ZE7<A!P/N_GZMM/&&IVUMI$;>%=<;[#,\D
MN-/D^92&4;>>N'/7T%:O`5-4E^*\PYT>FKK-FUU]GS,#OV"1H'$9;.-H<C:3
MGCK4=QK^GVMZUG-)*MR%W)&(7)D''W,#Y\9&<9QWKRR?7[N66.5?"^OM/#<1
MSK/+ILC/,58-\_S87ICY0?;%:DOCK4&\01Z@GA'71;I"8=K:<_F8+*2>N,\=
M*/[/J=OQ0<R.Z;Q/I2S-%YLQ=6"8%M(<L5#*H^7DD'('UJ9M=L1'$Z&>994#
MKY-O))A>1D[0<<@]?2O/9?&5PVHM<KX6\2;#?1W04Z:V=HB\MAUZ\9'ZU07Q
M!<>1##)X6\0SJBE1YNFR8C^8G**&`)(QG)ZCKCBCZA/M^*#F1Z7J.MPVT:FW
M>*5FC$H9I-L:QDX#%@#U/``!)-0P^)[/R8VN2ZRO)Y2I"CS!VV[QM*KD@KD@
MX&<'TKS?^W[R/3+"&+PYXC6\M(D@+C36V.J$[3U.&Y/8C)]A5K3?$T]A'9%_
M#/B66:"X#R-_9A`:,1-&J#YNJ@CD@9P<T_[/FEL+G1Z/%XCTN:-GAG>0`!E"
MPN3(#G!48RPR",C/(JU#J=I/;23B1HTBSY@F0QLG&?F#`$<<\UY*?$%YY=HK
M>&?$3B"T6VDB.GNJ2[6."2&R!SGZCN*FLO$;VZ:E%+X6\1B"[:.5/)TQ@8W3
M&.&8Y&5!Y///2D\OJ6T7Y!SH](_MNWO!+:VLLL-X86EC$]JZY48&X!@-PR1W
M[TS1=?MM2M+0N[">:%7SY;+&[;06",1AL<]">GM7&K\0-3=)6N/"FNM((V2+
M9I;@$GNQ+$J.!P,_4U3LO%]Y':Z?9WOAGQ');V(C*/#IC*\C(,#(+8`^G7VI
M?4:O*_=_%#YD>C66HBZU&]A#_+;[!L:)D8$YR>1@@XX(]#0NO:<UQY0F;E_+
M$OE-Y9;^[OQMS^->>VOCG4EU:[N;GPEKI@NE1&6+3Y-ZA0P&,\9.ZF'QE>-I
MXTI_"_B$Z;Y8AWC36\XQ@8VXSMSCC/XXH>`JWV_%!SH]%O=>T_3S)]HDE"Q+
MOE=(7=8AC/S%00O'/-.N-:L;67RGD=GVAV$432;%/=MH.T?6O/6\;7EN]REG
MX6\0BVN9&DD$^E,S(6^]MPV&!]#C'J13O^$ZO;2XG?3O"?B`QW$GFNMSIS@J
M^`,C:>1@#C_'A?4*O\OXH.9'=W/B32K.41S7##,0FWK$[((R<!BP&,9XZ]QZ
MU<M+ZWOHFDA9OE8HRNA1E8=B"`1U'YBO*I_$<OD316WAGQ-^\M?+S+IISYGF
MF3.`?NDL>G2KX\<7T"WYM?#/B..2XNQ/&\FE,X5<(&4C<.?E..>XIO`5;:+7
MU0<R/2+N\@LH/-G8A<X`52S,?0`<D^PJG'K^FR0W$GGM&+=E2598F1E9@"!M
M(SD@C@>M<5J'CMKE[>X@\*>*8[FV8M$7TPLAR,$$;@>1W[?I59O&]U,J7$OA
M;Q"E]%+YL0CTL^6#M*88YW,"">>V>.G,QP-:VL?Q0<R.]?Q#IL5G/=2RR1);
M@&99(75T!.`2A&['OBG6VNV%W="VBDE$I8IM>%TPP&[:<@8;;SCKCFO.+[Q?
M>ZE!,]SX6\0I=>288!%IK&-065B6).2247Z8]ZOZ5XCGO_$=LB^']<MEEU%K
M@2W-@4C16A*$,V>#GG-.6"G&+DU^*#F1Z512*<BEKA*"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
'`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
